In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register.

The following guiding principles have been applied to the disclosure:

- Information will be excluded in order to protect the privacy of patients and all named persons associated with the study
- Patient data listings will be completely removed* to protect patient privacy. Anonymized data from each patient may be made available subject to an approved research proposal. For further information please see the Patient Level Data section of the GSK Clinical Study Register.
- Aggregate data will be included; with any direct reference to individual patients excluded *Complete removal of patient data listings may mean that page numbers are no longer consecutively numbered

GlaxoSmithKline Biologicals, SA

Study detailed title

A Phase III, randomized, open-label, controlled, multi-center study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexaTM vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar[®] and RotarixTM with a booster dose of GSK Biologicals' Infanrix[®] and HiberixTM vaccines at 15-18 months of age.

Abridged Interim Clinical Study Report for Study 117119 (DTPA-HBV-IPV-135)

This abridged report provides all results available at the time of the database freeze (19 June 2015) which include safety data and immunogenicity data against Polyribosyl-Ribitol-Phosphate (PRP) antigen assessed till Visit 4.

Development Phase III

IND Number: BB-IND 006687

EUDRACT Number: 2013-004304-19

Name of Investigational Product: Infanrix hexa™

Indication Studied: Active immunization against diphtheria, tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, poliomyelitis, and invasive disease caused by *Haemophilus influenzae* type B (Hib) in infants.

Study initiation date: 16-April-2014

Study completion date: 31-March-2015 (Visit 4)

Data lock point (Date of

database freeze):

19-June-2015

Date of report: Final: 19-October-2015

Sponsor Signatory: Narcisa Elena Mesaros, MD

Project level Clinical Research and Development Lead,

DTP/Polio Vaccines,

Late Clinical Development,

Vaccine Discovery and Development, GlaxoSmithKline Biologicals, SA.

This study was performed according to the principles of GCP including the archiving of essential documents.

Based on GSK Biologicals' Study Report INS-BIO-CLIN-1010 v05

Copyright 2015 the GlaxoSmithKline group of companies. All rights reserved. Unauthorised copying or use of this information is prohibited.

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

TABLE OF CONTENTS

	PAGE
LIST OF ABBREVIATIONS	5
GLOSSARY OF TERMS	7
TRADEMARKS	9
ABRIDGED INTERIM REPORT BODY	10
TABLES AND FIGURES 1.1. Study Population 1.2. Immunogenicity results 1.3. Safety results	20 24
2. STUDY REPORT AUTHORS /CONTRIBUTING AUTHOR	RS43
3. SERIOUS ADVERSE EVENTS	

LIST OF TABLES

		PAGE
Table 1	Study population Primary Epoch (Primary TVC)	20
Table 2	Number of subjects vaccinated, completed and withdrawn with reasons of withdrawal up to Visit 4 (Primary TVC)	21
Table 3	Number of enrolled subjects by country	22
Table 4	Number of enrolled subjects by age category	22
Table 5	Number of subjects enrolled into the study as well as the number excluded from ATP analyses for Primary Epoch with reasons for exclusion excluded from ATP analyses with reasons for exclusion	23
Table 6	Number and percentage of subjects with an anti-PRP antibody concentration equal to or above 0.15 and 1 µg/ml and GMCs by vaccine group (Primary ATP cohort for immunogenicity)	24
Table 7	Number and percentage of subjects with an anti-PRP antibody concentration equal to or above 0.15 and 1 µg/ml and GMCs by vaccine and lot group (Primary ATP cohort for immunogenicity)	24
Table 8	Number and percentage of subjects with an anti-PRP antibody concentration equal to or above 0.15 and 1 µg/ml and GMCs by vaccine group (Primary TVC)	27
Table 9	Number (%) of subjects reporting solicited local symptoms during the 4-day (Days 0-3) post-vaccination period following each dose and overall (Primary TVC)	28
Table 10	Number (%) of subjects reporting solicited general symptoms during the 4-day (Days 0-3) post-vaccination period following each dose and overall (Primary TVC)	35
Table 11	Number (%) of subjects with adverse events reported during 31-day (Days 0-30) post-vaccination period (Primary TVC)	40
Table 12	Number (%) of subjects with new onset of chronic illness (NOCD) events reported till DBF date (19Jun2015) for Primary Epoch analysis (Primary TVC)	41
Table 13	Number (%) of subjects with serious adverse events reported till DBF date (19Jun2015) for Primary Epoch analysis (Primary TVC)	42

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

LIST OF FIGURES

		PAGE
Figure 1	Reverse cumulative distribution curve (Post dose 3) by vaccine group (Primary ATP cohort for immunogenicity)	25
Figure 2	Reverse cumulative distribution curve (Post dose 3), by vaccine and lot group (Primary ATP cohort for immunogenicity)	26

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

LIST OF ABBREVIATIONS

AE Adverse Event

ATP According-To-Protocol

CBER Center for Biologics Evaluation and Research

CDQA Clinical Development Quality Assurance

CRDL Clinical Research and Development Lead

CI Confidence Interval

D Diphtheria

DBF Data Base Freeze

DTPa-HBV-IPV/Hib Combined diphtheria-tetanus-acellular pertussis-hepatitis

B-inactivated poliovirus and *Haemophilus influenzae* type

b vaccine (Infanrix hexa).

DT Diphtheria Toxoid

eCRF: electronic Case Report Form

FHA Filamentous Haemagglutinin

GCP Good Clinical Practice

GMC Geometric Mean Concentration

GMT Geometric Mean Titer

GSK GlaxoSmithKline

GOC Global Quality Compliance

HBs Recombinant hepatitis B surface antigen

Hib *Haemophilus influenzae (H. influenzae)* type b

ICF Informed Consent Form

IM Intramuscular

IND Investigational New Drug

IRB Institutional Review Board

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

LAR Legally Acceptable Representative

MedDRA: Medical Dictionary for Regulatory Activities

NOCD New-onset Chronic Disease

PRN Pertactin

PRP Polyribosyl-Ribitol-Phosphate

PT Pertussis Toxoid

RCC Reverse Cumulative Curve

SAE Serious Adverse Event

SAP Statistical Analysis Plan

SBIR Central Randomization System on Internet

SOP Standard Operating Procedure

T Tetanus

TT Tetanus Toxoid

TVC Total Vaccinated Cohort

GLOSSARY OF TERMS

According-To-Protocol:

Included all subjects enrolled in the study who met the criteria defined in the protocol for the considered analysis (reactogenicity or immunogenicity).

Adverse event:

Any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also included failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse.

Eligible: Qualified for enrolment into the study based upon strict

adherence to inclusion/exclusion criteria.

Epoch: An epoch is a self-contained set of consecutive timepoints

or a single timepoint from a single protocol. Self-contained means that data collected for all subjects at all timepoints within that epoch allowed to draw a complete conclusion to define or precise the targeted label of the product. Typical examples of epochs are primary vaccinations, boosters, yearly immunogenicity follow-ups, and surveillance periods

for efficacy or safety.

Investigational A pharmaceutical form of an active ingredient or placebo **vaccine/product:** being tested or used as a reference in a clinical trial,

including a product with a marketing authorisation when used in a way different from the approved form, or when used for an unapproved indication, or when used to gain

further information about an approved use.

Medicinal Product)
Legally Acceptable

(Synonym of

Investigational

Representative:

ICH GCP defines Legally Accepted Representative as an individual or juridical or other body authorised under applicable law to consent, on behalf of a prospective subject,

to the subject's participation in the clinical trial.

Randomization: Process of random attribution of treatment to subjects in

order to reduce bias of selection.

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Solicited adverse

event:

Adverse events recorded as endpoints in the clinical study. The presence/occurrence/intensity of these events was actively solicited from the subject or an observer during a specified post-vaccination follow-up period.

Subject:

Term used throughout the protocol to denote an individual who was contacted in order to participate or participates in the clinical study, either as a recipient of the product(s) or as a control.

Total Vaccinated Cohort:

The Total vaccinated cohort included all subjects with at least one study vaccine administration documented.

Treatment:

Term used throughout the clinical study to denote a set of investigational product(s) or marketed product(s) or placebo intended to be administered to a subject, identified by a unique number, according to the study randomization or treatment allocation.

Unsolicited adverse event:

Any adverse event reported in addition to those solicited during the clinical study. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event.

TRADEMARKS

The following trademarks are used in the present report.

In the body of the Study Report, (including the synopsis), the names of the vaccines have been written without the superscript symbol TM or ® and in *italics*.

Trademarks of the GlaxoSmithKline group of companies		
Engerix-B®		
Hiberix™		
Infanrix [®]		
Infanrix hexa™		
Pediarix [®]		
Rotarix®		

Generic description			
Hepatitis B vaccine (recombinant)			
Haemophilus b conjugate vaccine (tetanus toxoid conjugate)			
Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed			
Combined Diphtheria-Tetanus-acellular Pertussis (DTaP), Hepatitis B, Poliovirus and <i>Haemophilus influenzae</i> type b vaccine			
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine			
Rotavirus Vaccine, Live, Oral			

Trademarks not owned by the GlaxoSmithKline group of companies		
ActHIB® (Sanofi Pasteur SA)		
Pentacel® (Sanofi Pasteur SA)		
Prevnar13® (Wyeth Pharmaceuticals Inc.; Marketed by Pfizer Inc.)		

Generic description			
Haemophilus type b conjugate vaccine (tetanus toxoid conjugate)			
Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and Haemophilus b conjugate (tetanus toxoid conjugate)			
Pneumoccocal 13-valent conjugate vaccine (diphtheria CRM ₁₉₇ protein)			

ABRIDGED INTERIM REPORT BODY

Name of company:	Name of finished product:		e of active substance:
GlaxoSmithKline	Infanrix hexa	_	theria toxoid (DT), tetanus
Biologicals, Rixensart,			d (TT), pertussis toxoid (PT),
Belgium			entous haemagglutinin (FHA),
			ctin (PRN), recombinant titis B surface antigen (HBs),
			virus types 1, 2, 3 and
			ribosyl-ribitol-phosphate (PRP).
Study No.: 117119 (DT	 PA_HRV_IPV_135	poryr	ioosyi-noitoi-phosphate (i Ki).
	hase III, randomized, open-label, con	trolled mul	ti-center study to evaluate
immunogenicity and saf	fety of GSK Biologicals' Infanrix her	ca TM vaccino	e when administered to healthy
infants as primary vacci	nation at 2, 4 and 6 months of age, co	n-administer	red with Prevnar® and Rotarix
with a booster dose of C	SSK Biologicals' Infanrix® and Hiber	ix vaccine	es at 15-18 months of age
	y centers: This study was conducted		
the United States of Am		. 0 y 52 m v c.	sugueors at manapre conters in
Ethics: The study proto	col, amendments, the informed conse	ent, and other	er information that required pre-
	and approved by a national IRB.		
Overall this study was to	o be conducted in accordance with et	hical princip	ples that have their origins in the
Declaration of Helsinki,	the principles of "good clinical prac	tice" (GCP)	and all applicable regulatory
requirements.			
During the course of the study, whenever potential issues with regard to the conduct of the study were			
identified, either via site monitoring activities or brought to GlaxoSmithKline (GSK) Biologicals'			
	ight mechanisms, these issues were in	nvestigated	and appropriate corrective
	ns where possible were taken.		
	nt was to be obtained from each subj		
	rior to the performance of any study-s		cedures. Electronic Case report
	ovided for each subject's data to be re		
	history of the subjects, their eligibility		
Consent Form (ICF) sign off was used in order to ensure the subject's entry and/or randomization in the			
	ystem on Internet (SBIR). However,		
enrolled at one site PPD were randomized in the SBIR before the subject's parent(s)/LAR(s) signed			
the ICF. No other study procedure was performed on these subjects before obtaining consent. This			
deviation did not result in elimination of the subjects from the According to Protocol (ATP) analyses.			
Publication (reference): Not published as of 19 October 2015.			
Study period:	16 Amil 2014		Phase: III
Study initiation date: 1			
	: 31-March-2015 (Visit 4)		
Data lock point (Date of	of database freeze): 19-June-2015		

Indication: Active immunization against diphtheria, tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, poliomyelitis, and invasive disease caused by *Haemophilus influenzae* type B (Hib) in infants.

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Name of company:	Name of finished product:	Name of active substance:
GlaxoSmithKline	Infanrix hexa	Diphtheria toxoid (DT), tetanus
Biologicals, Rixensart,		toxoid (TT), pertussis toxoid (PT),
Belgium		filamentous haemagglutinin (FHA),
		pertactin (PRN), recombinant
		hepatitis B surface antigen (HBs),
		poliovirus types 1, 2, 3 and
		polyribosyl-ribitol-phosphate (PRP).

Objectives: This abridged report provides all results available at the time of the database freeze (19 June 2015) which include safety data and immunogenicity data against Polyribosyl-Ribitol-Phosphate (PRP) antigen assessed till Visit 4.Objectives not relevant to this report (i.e. data not available at the time of the database freeze) are presented in square brackets.

Primary:

Epoch 001: Primary vaccination

- [To demonstrate the non-inferiority of *Infanrix hexa* to *Pediarix* co-administered with *ActHIB*, in terms of antibody geometric mean concentrations (GMCs) for pertussis antigens {pertussis toxoid (PT), filamentous hemagglutinin (FHA) and pertactin (PRN)} one month after the third dose of the primary vaccination.
 - Criterion for non-inferiority: Non-inferiority in terms of immune response to pertussis antigens will be demonstrated if, for each of the three antigens, the upper limit of the 95% confidence interval (CI) of the GMC ratio [Pedia divided by Hexa] is ≤ 1.5.]

Secondary:

Epoch 001: Primary vaccination

- To assess the immune response to *Infanrix hexa, Pediarix, ActHIB, Pentacel* and *Engerix-B*, in terms of seroprotection status, seropositivity status and concentrations or titers of antibodies to [diphtheria (D), tetanus (T), hepatitis B surface antigen (HBs), pertussis, poliovirus types 1, 2 and 3] and PRP antigens, one month after the third dose of the primary vaccination.
- To assess the safety and reactogenicity of a 3-dose primary vaccination course of *Infanrix hexa*, of *Pentacel* co-administered with *Engerix-B*, and that of *Pediarix* co-administered with *ActHIB*, in terms of solicited local symptoms.
- To assess the safety and reactogenicity of all study vaccines in terms of solicited general events, unsolicited adverse events (AEs), new-onset chronic diseases (NOCDs) and serious adverse events (SAEs).

Epoch 002 : Booster vaccination

- [To assess the immunogenicity of *Infanrix hexa, Pentacel, Engerix-B, Pediarix* and *ActHIB*, in terms of persistence of the antibodies to D, T, pertussis, HBs, poliovirus types 1, 2 and 3 and PRP antigens, before the booster dose.]
- [To assess the immune response to *Infanrix, Hiberix, ActHIB* and *Pentacel*, in terms of seroprotection status, seropositivity status and antibody concentrations or titers for D, T, pertussis and PRP antigens, and in terms of booster response for pertussis antigens following *Infanrix and Pentacel*, one month after the booster dose.]
- [To assess the safety and reactogenicity of booster doses of *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*.]

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Name of company:	Name of finished product:	Name of active substance:
GlaxoSmithKline	Infanrix hexa	Diphtheria toxoid (DT), tetanus
Biologicals, Rixensart,		toxoid (TT), pertussis toxoid (PT),
Belgium		filamentous haemagglutinin (FHA),
		pertactin (PRN), recombinant
		hepatitis B surface antigen (HBs),
		poliovirus types 1, 2, 3 and
		polyribosyl-ribitol-phosphate (PRP).

Methodology: This is a phase III, open-label, randomized, controlled, multi-center, single-country study with five parallel groups. The subjects were randomized in a [1:1:1]:3:3 ratio to Hexa_1, Hexa_2, Hexa_3, Pedia and Penta groups. The details of the study groups and vaccination schedules are given below:

Epoch 001:

- **Hexa Group:** Subjects in this group received three doses of *Infanrix hexa* (lot A, lot B or lot C as per the group allocation) co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
 - Hexa 1 Group: Subjects received lot A of *Infanrix* hexa,
 - Hexa 2 Group: Subjects received lot B of *Infanrix hexa*,
 - Hexa 3 Group: Subjects received lot C of *Infanrix hexa*.
- **Pedia Group:** Subjects in this group received three doses of *Pediarix* and *ActHIB* co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
- **Penta Group**: Subjects in this group received three doses of *Pentacel* and *Engerix-B** coadministered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
 - *Subjects in the Penta Group who received a dose of hepatitis B vaccine from birth up to 30 days prior to study vaccination should not have received *Engerix-B* at 4 months of age (Visit 2).

Epoch 002:

- **Hexa Group**: Subjects will receive a booster dose of *Infanrix* and *Hiberix* vaccines at 15-18 months of age.
- **Pedia Group**: Subjects will receive a booster dose of *Infanrix* and *ActHIB* vaccines at 15-18 months of age.
- Penta Group: Subjects will receive a booster dose of *Pentacel* vaccine at 15-18 months of age.

The study is open-label for both epochs due to the differences in the number of injections and the appearance of the vaccines administered.

Sampling schedule: One month after the third dose of primary vaccination (Visit 4), a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) was collected.

Study vaccine, dose, mode of administration lot no.:

Vaccination schedule /site:

Three doses of *Infanrix hexa* vaccine (lyophilized Hib vaccine reconstituted with DTPA-HBV-IPV liquid vaccine) were administered at 2, 4 and 6 months of age as an intramuscular (IM) injection in the right thigh.

Vaccine composition /dose /lot number: One dose (0.5 mL) of *Infanrix hexa* contained DT≥30IU; TT≥40IU; PT=25μg; FHA=25μg; PRN=8μg; HBsAg=10μg; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; Aluminium=700μg Al3+ and PRP=10μG; TT~=25μG Aluminum as salts=120 μg. Lot numbers used were:

AHIBC950C (Hib) + AC21VB448C (Pediarix)

AHIBC907D (Hib) + AC21B514A (Pediarix)

AHIBC954A (Hib) + AC21B510B (Pediarix)

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Name of company:	Name of finished product:	Name of active substance:
GlaxoSmithKline	Infanrix hexa	Diphtheria toxoid (DT), tetanus
Biologicals, Rixensart,		toxoid (TT), pertussis toxoid (PT),
Belgium		filamentous haemagglutinin (FHA),
		pertactin (PRN), recombinant
		hepatitis B surface antigen (HBs),
		poliovirus types 1, 2, 3 and
		polyribosyl-ribitol-phosphate (PRP).

Reference vaccine /Comparator, dose and mode of administration, lot no.: Primary Vaccines

Pediarix:

Vaccination schedule /site: Three doses of *Pediarix* were administered at 2, 4 and 6 months of age as an IM injection in the right thigh.

Vaccine composition /dose /lot number: One dose (0.5 mL) of *Pediarix* contained DT≥30IU; TT≥40IU; PT=25μg; FHA=25μg; PRN=8μg; HBsAg=10μg; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; Aluminium=700μg Al3+.

Lot number used for *Pediarix* was AC21VB448C.

ActHIB:

Vaccination schedule /site: Three doses of *ActHIB* were administered at 2, 4 and 6 months of age as an IM injection in the upper left thigh.

Vaccine composition /dose /lot number: One dose (0.5 mL) of *ActHIB* contained Hib=10μg, TT=24μg and NaCl=60mM.

Lot numbers used for *ActHIB* were UH971AA and UH954AB.

Pentacel:

Vaccination schedule /site: Three doses of *Pentacel* were administered at 2, 4 and 6 months of age as an IM injection in right thigh.

Vaccine composition /dose /lot number: One dose (0.5 mL) of Pentacel contained PT=20μg; FHA=20μg; FIM=5μg; PRN=3μg; DT=15Lf; TT=5Lf; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; PRP=10μg, TT=24μg; AlPO₄=330μg Al3+.

Lot numbers used for *Pentacel* were C4574AA, C4517BA, C4507AA and C4557AA.

Engerix-B:

Vaccination schedule /site: Two-three doses of *Engerix-B* were administered at 2, 4 (second dose was not given if subjects had received a dose prior to the study) and 6 months of age as an IM injection in the upper left thigh.

Vaccine composition /dose /lot number: One dose (0.5 mL) of *Engerix-B* contained HBsAg=10μg; Al(OH)₃=250μg Al3+.

Lot number used for *Engerix-B* was AHBVC253A.

Prevnar13:

Vaccination schedule /site: Three doses of *Prevnar13* were administered at 2, 4 and 6 months of age as an IM injection in the lower left thigh.

Vaccine composition /dose /lot number: One dose (0.5 mL) of *Prevnar13* contained PS1=2.2μg CRM197; PS3=2.2μg CRM197; PS4=2.2μg CRM197; PS5=2.2μg CRM197; PS6A=2.2μg CRM197; PS6B=4.4μg CRM197; PS7F=2.2μg CRM197; PS9V=2.2μg CRM197; PS14=2.2μg CRM197; PS18C=2.2μg CRM197; PS19A=2.2μg CRM197; PS19F=2.2μg CRM197; PS23F=2.2μg CRM197; AIPO₄=125μg Al3+.

Lot number used for *Prevnar13* was H39264.

Rotarix

Vaccination schedule /site: Two doses of *Rotarix* were given orally at 2 and 4 months of age. *Vaccine composition /dose /lot number:* One dose (1.0 mL) of Rotarix contained HRV RIX4144= 10^6 . CCID₅₀ (median Cell Culture Infective Dose) and CaCO₃= $60\mu g$.

Lot numbers used for *Rotarix* were AROTA291D (HRV) and AD05VA833A (CaCO3).

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Name of company:	Name of finished product:	Name of active substance:
GlaxoSmithKline	Infanrix hexa	Diphtheria toxoid (DT), tetanus
Biologicals, Rixensart,		toxoid (TT), pertussis toxoid (PT),
Belgium		filamentous haemagglutinin (FHA),
		pertactin (PRN), recombinant
		hepatitis B surface antigen (HBs),
		poliovirus types 1, 2, 3 and
		polyribosyl-ribitol-phosphate (PRP).

Study Population: Healthy males or females between, and including, 6 and 12 weeks of age at the time of the first vaccination were included in the study. The subjects were excluded from the study if they had any previous or intercurrent diphtheria, tetanus, pertussis, polio, hepatitis B, Hib, rotavirus and/or pneumococcal vaccination or disease, with the exception of hepatitis B vaccination at birth. Written informed consent was to be obtained from the parents/LAR(s) of the subject before entry into the study.

Duration of treatment: The intended duration of the study will be approximately 14-17 months for each subject.

Criteria for evaluations: For this abridged report, only the endpoints pertaining to the results for safety and immune response against PRP antigen up to one month after the third dose of primary vaccination were assessed descriptively. Endpoints not relevant to this report are presented within square brackets.

Primary endpoint: Epoch 001 (Primary vaccination)

- [Immunogenicity with respect to pertussis components of the study vaccines *Infanrix hexa* and *Pediarix*
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination.]

Secondary endpoints: **Epoch 001 (Primary vaccination)**

- [Immunogenicity (other parameters) with respect to the pertussis component of the study vaccines *Infanrix hexa, Pentacel* and *Pediarix.*
 - Anti-PT, anti-FHA, anti-PRN seropositivity status, one month after the third dose of the primary vaccination.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination (for *Pentacel* only).]
- Immunogenicity with respect to the other components of the study vaccines *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B*.
 - [Anti-D, anti-T, anti-HBs, anti-poliovirus types 1, 2 and 3] and anti-PRP seroprotection status, anti-PRP antibody concentrations ≥1.0 µg/mL and antibody concentrations/titers, one month after the third dose of the primary vaccination.
- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0-Day 3) after each vaccination (*Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0-Day 3) after each vaccination.
- Unsolicited AEs.
 - Occurrence of unsolicited AEs within 31 days (Day 0-Day 30) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.
- Specific AEs.
 - Occurrence of specific AEs, i.e., NOCDs (e.g. autoimmune disorders, asthma, type I diabetes and allergies) from Day 0 up to six months post primary vaccination.
- SAEs.
 - Occurrence of SAEs from Day 0 up to six months post primary vaccination.

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Name of company:	Name of finished product:	Name of active substance:
GlaxoSmithKline	Infanrix hexa	Diphtheria toxoid (DT), tetanus
Biologicals, Rixensart,		toxoid (TT), pertussis toxoid (PT),
Belgium		filamentous haemagglutinin (FHA),
		pertactin (PRN), recombinant
		hepatitis B surface antigen (HBs),
		poliovirus types 1, 2, 3 and
		polyribosyl-ribitol-phosphate (PRP).

Epoch 002 (Booster vaccination)

- [Immunogenicity with respect to all study vaccines.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-HBs, anti-PRP and anti-poliovirus 1, 2, 3 seroprotection/ seropositivity status, anti-PRP antibody concentrations ≥1.0 µg/mL and antibody concentrations/ titers before the booster dose (Dose 4).]
- [Immunogenicity with respect to the study vaccine *Pentacel*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-PRP seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
 - − Anti-PRP antibody concentrations \ge 1.0 µg/mL one month after the booster dose (Dose 4).
 - Anti-D and anti-T antibody concentrations ≥1.0 IU/mL one month after the booster dose (Dose 4).]
- [Immunogenicity with respect to the study vaccine *Infanrix*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
 - Anti-D and anti-T antibody concentrations ≥1.0 IU/mL one month after the booster dose (Dose 4).]
- [Immunogenicity with respect to the study vaccines ActHIB and Hiberix.
 - Anti-PRP seroprotection status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PRP antibody concentrations ≥1.0 µg/mL one month after the booster dose (Dose 4).]
- [Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0-Day 3) after booster vaccination (*Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0-Day 3) after booster vaccination.]
- [Unsolicited AEs.
 - Occurrence of unsolicited AEs within 31 days (Day 0-Day 30) after booster vaccination, according to the MedDRA classification.]
- [Specific AEs.
 - Occurrence of specific AEs, i.e., NOCDs (e.g. autoimmune disorders, asthma, type I diabetes and allergies) from the booster dose up to one month after the booster vaccination.]
- 「SAEs.
 - Occurrence of SAEs from the booster dose up to one month after the booster vaccination.]

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Name of company:	Name of finished product:	Name of active substance:
GlaxoSmithKline	Infanrix hexa	Diphtheria toxoid (DT), tetanus
Biologicals, Rixensart,		toxoid (TT), pertussis toxoid (PT),
Belgium		filamentous haemagglutinin (FHA),
		pertactin (PRN), recombinant
		hepatitis B surface antigen (HBs),
		poliovirus types 1, 2, 3 and
		polyribosyl-ribitol-phosphate (PRP).

Statistical methods: Analyses were performed as stated in the protocol and Statistical analysis plan (SAP).

For this abridged report, the analyses pertaining to immune response to *Infanrix hexa, ActHIB and Pentacel* in terms of antibody titers against PRP antigens (one month after the third dose of the primary vaccination), and safety and reactogenicity to *Infanrix hexa, Pediarix, ActHIB, Pentacel* and *Engerix-B* in terms of solicited local symptoms, solicited general symptoms, unsolicited AEs, NOCDs and SAEs are described below:

Analysis of demographics

Demographic characteristics (i.e. age {weeks}, gender, geographical ancestry, height in length {cm}, weight {kg} at first dose) and withdrawal status were summarized by group using descriptive statistics. Mean, median and standard error were provided for continuous data such as age.

Analysis of immunogenicity

The primary analysis of immunogenicity was performed on the Primary ATP cohort for immunogenicity. Within group assessment was performed for each group, one month post-dose 3 for each assay for which a serological result was available:

- Seropositivity and seroprotection rates with exact 95% CIs were calculated.
- GMCs/GMTs with 95% CIs were tabulated.

For each antigen, antibody concentration or titer distribution one month post-vaccination were tabulated and displayed using reverse cumulative curves (RCCs).

Analysis of safety

The primary analysis was based on the Primary Total Vaccinated cohort (TVC)

- The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) or 31-day (Days 0-30) follow-up period were tabulated after each vaccine dose and overall (for the Epoch 001) with exact 95% CI.
- The percentage of doses followed by at least one local AE (solicited and unsolicited), by at least one general AE (solicited and unsolicited) and by any AE during the 4-day or 31-day follow-up period were tabulated over the primary vaccination period, with exact 95% CI.
- The percentage of subjects/doses with local AEs (solicited and unsolicited) were calculated at each injection site for *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel and Engerix-B* vaccines, as well as overall (all sites considered).
- The percentage of subjects/doses with each individual solicited local and general AE during the 4-day follow-up period were tabulated for each group as follows:
 - Over the primary doses, the percentage of subjects with the symptom and its exact 95% CI.
 - Over the primary doses, the percentage of doses with the symptom and its exact 95% CI.
 - At each study dose, the percentage of subjects with the symptom and its exact 95% CI.

The exact 95% CIs were calculated assuming independence between doses.

- All computations mentioned above were done for Grade ≥2 (solicited symptoms only) and Grade 3 symptoms, for symptoms considered related to vaccination (general symptoms only), for Grade 3 symptoms considered related to vaccination (general symptoms only) and for symptoms that resulted in a medically-attended visit.
- For fever, analyses were performed by 0.5°C increments.
- The verbatim reports of unsolicited AEs were reviewed by a clinical research development lead (CRDL) and the signs and symptoms were coded according to MedDRA. Every verbatim term was matched with the appropriate Preferred Term. The percentage of subjects/doses with unsolicited AEs occurring within 31 days with exact 95% CI was tabulated by Preferred Term. Similar tabulations were done for Grade 3 unsolicited AEs, for unsolicited AEs considered related to vaccination and for Grade 3 unsolicited AEs considered related to vaccination.

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Name of company:	Name of finished product:	Name of active substance:
GlaxoSmithKline	Infanrix hexa	Diphtheria toxoid (DT), tetanus
Biologicals, Rixensart,		toxoid (TT), pertussis toxoid (PT),
Belgium		filamentous haemagglutinin (FHA),
		pertactin (PRN), recombinant
		hepatitis B surface antigen (HBs),
		poliovirus types 1, 2, 3 and
		polyribosyl-ribitol-phosphate (PRP).

- Subjects who experienced AEs of specific interest (i.e. NOCDs such as autoimmune disorders, asthma, type I diabetes and allergies) from Day 0 up to 6 months after the last primary vaccination were tabulated by Preferred Term.
- Subjects who experienced at least one SAE reported before the database lock for the Epoch 001 analysis with an onset date in the Epoch 001 were reported and the SAE was described in detail.

Data Quality assurance at study level: To ensure that the study procedures conformed across all investigator sites, the protocol, eCRF and safety reporting were reviewed with the investigators and his/her/their personnel responsible for the conduct of the study by the Company representatives prior to study start. A multi-investigator meeting was held prior to the study start.

Adherence to the protocol requirements and verification of data generation accuracy were achieved through monitoring visits to each investigator site. Computer checks and blinded review of subject tabulations were performed to ensure consistency of eCRF completion. All procedures were performed according to methodologies detailed in GlaxoSmithKline Biologicals Standard Operating Procedures (SOPs).

All protocol deviations collected during the study were reviewed by the GSK study team in order to identify important protocol deviations. Consistent with ICH E3 guidance, important deviations are defined as deviations that were likely to affect the interpretation of the results and/or led to exclusion of any subject data from an analysis. Important deviations include, but are not limited to, those related to study inclusion or exclusion criteria, adherence to the protocol, conduct of the study, subject management or subject assessment.

We are communicating in this interim report to Center for Biologics Evaluation and Research (CBER) that, since the data were generated with a PRP serology assay not yet fully validated, there is a possibility, though unlikely, that the PRP immunogenicity results might change.

Independent Audit statement:

This study was subjected to audit by GlaxoSmithKline's R&D Global Quality Compliance (GQC)-Clinical Development Quality Assurance. (CDQA) department.

Study population (TVC):			
Number of subjects	Hexa group	Pedia group	Penta group
Planned, N	195	195	195
Randomized, N (TVC)	195	194	196
Completed, n (%)	178 (91.3)	182 (93.8)	178 (90.8)
Demographics	Hexa group	Pedia group	Penta group
N (TVC)	195	194	196
Females: Males	101:94	80:114	95:101
Mean Age, weeks (SD)	8.5 (1.0)	8.6 (1.1)	8.6 (1.1)
Median Age, weeks (minimum, maximum)	8 (6, 12)	9 (6, 12)	8 (6, 12)
White-Caucasian / European Heritage, n (%)	118 (60.5)	128 (66.0)	115 (58.7)
Other, n (%)	29 (14.9)	27 (13.9)	32 (16.3)
American Indian or Alaskan Native, n (%)	15 (7.7)	15 (7.7)	17 (8.7)

Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age; Pedia group = Subjects who received *Pediarix*, *ActHIB* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age; Penta group = Subjects who received *Pentacel*, *Engerix* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age; N = total number of subjects; n/% = number/percentage of subjects; SD = standard deviation

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Name of company:	Name of finished product:	Name of active substance:
GlaxoSmithKline	Infanrix hexa	Diphtheria toxoid (DT), tetanus
Biologicals, Rixensart,		toxoid (TT), pertussis toxoid (PT),
Belgium		filamentous haemagglutinin (FHA),
		pertactin (PRN), recombinant
		hepatitis B surface antigen (HBs),
		poliovirus types 1, 2, 3 and
		polyribosyl-ribitol-phosphate (PRP).

Summary:

Immunogenicity results:

<u>Primary Objective</u>: The primary objective was not evaluated at the time of this interim analysis. <u>Secondary Objective</u>: Descriptive immunogenicity analysis pertaining to anti-PRP antibody concentrations was performed on the Primary ATP cohort for immunogenicity. Table 1 presents the results of the ATP analysis.

- One month after primary vaccination, 94.0% of the subjects in the Hexa group, 98.7% of the subjects in the Pedia group and 98.7% of the subjects in the Penta group had anti-PRP antibody concentrations
 - $\geq 0.15 \,\mu g/ml$.
- One month after primary vaccination, 55.7% of the subjects in the Hexa group, 94.1% of the subjects in the Pedia group and 82.4% of the subjects in the Penta group had anti-PRP antibody concentrations
 - $\geq 1.0 \,\mu g/ml$.

Table 1: Number and percentage of subjects with anti-PRP antibody concentration equal or above 0.15 μ g/ml and 1.0 μ g/ml and geometric mean concentration (GMC), one month after primary vaccination (Primary ATP cohort for immunogenicity)

					≥ 0.15	μg/m	l		≥1	µg/ml			GMC	;
						95	% CI			95	% CI		9	5% CI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-PRP antibody	Hexa group	PIII(M5)	149	140	94.0	88.8	97.2	83	55.7	47.3	63.8	1.4	1.1	1.7
	Pedia group	PIII(M5)	153	151	98.7	95.4	99.8	144	94.1	89.1	97.3	10.3	8.1	13.1
	Penta group	PIII(M5)	153	151	98.7	95.4	99.8	126	82.4	75.4	88.0	6.5	4.9	8.5

Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age; Pedia group = Subjects who received *Pediarix*, *ActHIB* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age; Penta group = Subjects who received *Pentacel*, *Engerix* and; *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age; GMC = geometric mean antibody concentration calculated on all subjects; N = number of subjects with available results; n/% = number/percentage of subjects with concentration equal to or above specified value; 95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Safety results: The safety analysis was performed on the Primary TVC.

<u>Solicited local symptoms</u>: During the 4-day (Days 0-3) post-vaccination period, injection site pain was the most frequently reported solicited local symptom, reported for 67.9%, 82.0% and 79.8% of the subjects in the Hexa, Pedia and Penta groups, respectively. Pain was also the most frequently reported Grade 3 solicited local symptom, reported for 4.3% of the subjects in the Hexa group, 18.0% of the subjects in the Pedia group and 11.7% of the subjects in the Penta group.

Solicited general symptoms: During the 4-day (Days 0-3) post-vaccination period, irritability/fussiness was the most frequently reported solicited general symptom, reported for 87.7%, 96.3% and 94.1% of the subjects in the Hexa, Pedia and Penta groups, respectively. It was also the most frequently reported Grade 3 solicited general symptom, reported for 9.6%, 18.5% and 16.0% of the subjects in the three groups. Grade 3 fever (> 40.0° C axillary temperature) was reported for 1.1% of the subjects in the Pedia group and for none of the subjects in the Hexa and Penta groups.

<u>Unsolicited symptoms</u>: During the 31-day (Days 0-30) post-vaccination period, at least one unsolicited symptom was reported for 56.9%, 55.7% and 49.0% of the subjects in the Hexa, Pedia and Penta groups, respectively. The most frequently reported unsolicited symptom was upper respiratory tract infection, which was reported for 14.9%, 11.9% and 13.3% of the subjects in the Hexa, Pedia and Penta groups, respectively.

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Name of company:	Name of finished product:	Name of active substance:
GlaxoSmithKline	Infanrix hexa	Diphtheria toxoid (DT), tetanus
Biologicals, Rixensart,		toxoid (TT), pertussis toxoid (PT),
Belgium		filamentous haemagglutinin (FHA),
		pertactin (PRN), recombinant
		hepatitis B surface antigen (HBs),
		poliovirus types 1, 2, 3 and
		polyribosyl-ribitol-phosphate (PRP).

<u>New onset of chronic diseases (NOCD)</u>: At least one NOCD was reported for four subjects (2.1%) in the Hexa group, two subjects (1.0%) in the Pedia group and three subjects (1.5%) in the Penta group up to the data lock point of 19 June 2015. The most frequently reported NOCD was atopic dermatitis, reported for two subjects (1.0%), each, in the Hexa and Penta groups. Bronchial hyperactivity was reported for two subjects (1.0%) in the Hexa group.

Serious adverse events (SAEs): SAEs were reported for seven subjects (3.6%) each in the Hexa and Penta groups and one subject (0.5%) in the Pedia group up to the data lock point of 19 June 2015. Three SAEs were reported in two subjects in the Hexa group that were considered by the investigator to be causally related to the vaccination. Lethargy was reported for one subject (Subject number P). The subject was hospitalized and the event was resolved on the same day. The subject was withdrawn from the study due to this event. A moderate Grade 2 apparent life threatening event and mild Grade 1 leukocytosis was reported for another subject (Subject number P) which led to the hospitalization. Both the events were resolved one day after primary vaccination. No fatal events were reported during the study.

<u>Withdrawals due to AEs /SAEs</u>: One subject in the Hexa group withdrew due to an SAE (lethargy) and one in the Penta group withdrew due to a non-serious AE (seizure). In the context of this interim analysis, withdrawal is defined as subjects not having attended Visit 4.

Conclusions:

- One month post primary vaccination, 94.0% of the subjects in the Hexa group and 98.7% of the subjects in the Pedia and Penta groups, had anti-PRP antibody concentrations $\geq 0.15 \,\mu\text{g/ml}$.
- One month post primary vaccination, 55.7% of the subjects in the Hexa group, 94.1% of the subjects in the Pedia group and 82.4% of the subjects in the Penta group had anti-PRP antibody concentrations
 - $\geq 1 \, \mu g/ml$.
- During the 31-day period following primary vaccination, at least one unsolicited symptom was reported for 111 subjects (56.9%) in the Hexa group, 108 subjects (55.7%) in the Pedia group and 96 subjects (49.0%) in the Penta group.
- During the primary phase of the study (up to the data lock point of 19 June 2015), SAEs were reported for seven subjects each in the Hexa and Penta groups and one subject in the Pedia group. Three SAEs reported for two subjects in the Hexa group (lethargy in one subject and apparent life threatening event along with leukocytosis in the other subject) were considered by the investigator to be causally related to the vaccination. No fatal events were reported during the study.

Date of report: Final:19-October-2015



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexaTM vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar® and Rotarix[™] with a booster dose of GSK Biologicals' Infanrix® and Hiberix[™] vaccines at 15-18 months of age

SAP version

Version 2 (Version 1: 10-Mar-2015)

SAP date

20-May-2015

Scope:

All data pertaining to the above study.

Other author(s):

Detailed Title:

Adhoc reviewers: (Regulatory representative), PPD

(Safety representative)

A Phase III, randomized, open-label, controlled,

Approved by: (Clinical Research and Development

Lead), PPD (Lead Statistician), PPD

(Scientific Writer)



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

TABLE OF CONTENTS

				PAGE
LIS	T OF A	BBREVI	ATIONS	4
1.	DOCU	JMENT H	IISTORY	6
2.	STUD	Y DESIG	SN	6
3.	OBJE	CTIVES.		11
	3.1.		objective	11
		3.1.1.	Epoch 001 (Primary vaccination)	
	3.2.		lary objectives	
		3.2.1. 3.2.2.	Epoch 001 (Primary vaccination) Epoch 002 (Booster vaccination)	
4.	ENDE	PINITS		12
→.	4.1.		endpoint	
		4.1.1.		12
	4.2.		lary endpoints	12
		4.2.1.	_p (· · · · · · · ·) · · · · · · · · · ·	
		4.2.2.	Epoch 002 (Booster vaccination)	13
5.	STUD	Y POPU	LATION	
		5.1.1.	Primary Total vaccinated cohort	
		5.1.2.	Primary ATP cohort for analysis of safety	
		5.1.3. 5.1.4.	Primary ATP cohort for analysis of immunogenicity Booster Total vaccinated cohort	
		5.1. 4 . 5.1.5.	Booster ATP cohort for analysis of safety	
		5.1.6.	Booster ATP cohort for analysis of immunogenicity	
6.	STAT	ISTICAL	METHODS	17
	6.1.		nalysis of the Epoch 001	
		6.1.1.	Analysis of demographics	
		6.1.2.	Analysis of immunogenicity	
			6.1.2.1. Within group assessment	
			6.1.2.2. Between group assessment	18 10
		6.1.3.	Analysis of safety	
	6.2.		nalysis of the Epoch 002	
		6.2.1.	Analysis of demographics/baseline characteristics	
		6.2.2.	Analysis of immunogenicity	
			6.2.2.1. Within group assessment	
			6.2.2.2. Between group assessment	
			0.7.7.3 IIII IIII III II	,,



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

	6.2.3.	Analysis of safety	23
7.	STATISTICAL 7.1. Derive 7.1.1. 7.1.2. 7.1.3. 7.2. Data p	CALCULATIONS	24 24 25 26
8.	8.1. Seque	F ANALYSESnce of analysesical considerations for interim analyses	28
9.	MAJOR CHAN	NGES FROM PLANNED ANALYSES	29
10.	REFERENCE		29



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

LIST OF ABBREVIATIONS

AE Adverse event

ANCOVA Analysis of Co-variance

ANOVA Analysis of Variance

ATP According-To-Protocol

CI Confidence Interval

CSR Clinical Study Report

D Diphtheria

EL.U/ml ELISA unit per milliliter

ELISA Enzyme-linked immunosorbent assay

Eli Type Internal GSK database code for type of elimination code

ESFU Extended Safety Follow-up

FHA Filamentous hemagglutinin

GMC Geometric mean antibody concentration

GMT Geometric mean antibody titer

GSK GlaxoSmithKline

HBs Hepatitis B surface antigen

HHE Hypotonic Hyporesponsive Episode

Hib Haemophilus influenzae (H. influenzae) type b

IU/ml International units per milliliter

LL Lower Limit of the confidence interval

MedDRA Medical Dictionary for Regulatory Activities

NOCD New Onset of Chronic Disease

PRN Pertactin

PRP Polyribosyl-Ribitol-Phosphate: polysaccharide component of the Hib

bacterium capsule

PT Pertussis toxoid: a secreted exotoxin of the *Bordetella pertussis*

bacterium

RCC Reverse Cumulative Curve



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

SAE Serious adverse event

SAP Statistical Analysis Plan

SBIR GSK Biological's Internet Randomization System

SD Standard Deviation

SR Study Report

T Tetanus

TFL Tables Figures and Listing template annexed to SAP

TVC Total Vaccinated cohort

UL Upper Limit of the confidence interval




Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

1. DOCUMENT HISTORY

Date	Description	Protocol Version
10-Mar-2015	Version 1	Protocol Amendment 1 -
		18-SEP-2014
06-May-2015	Version 2. The SAP has been updated to	Protocol Amendment 2
	incorporate the changes in the sequence of	- 17-Apr-2015
	analysis as per the protocol amendment 2	-

The complete statistical analysis plan and results presentation is divided into 2 parts: the first part detailing the analyses to be performed (known as SAP, current document) and a second part, annex (-es) (called TFL) describing the flow and format of tables, figures and listings to be annexed to the SR. For this study, there is only one annex TFL.

2. STUDY DESIGN



FORM-9000026972-01 Statistical Analysis Plan Template Effective date: 01 June 2014 GSK SOP Reference: SOP-9000026972

Form Owner: VVHS Biometrics, PPD



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

N = number of subjects in the study; n = number of subjects in each group; Mo = months

Visit 3 should be conducted at least 8 weeks after Visit 2, with subjects at least 24 weeks of age, in order to comply with US recommendations on hepatitis B dosing

Post-Pri = blood sample collected from subjects, one month after the administration of the third dose in the Epoch 001 Pre-Bst = blood sample collected from subjects, before the administration of the booster dose in the Epoch 002 Post-Bst = blood sample collected from subjects, one month after the administration of booster dose in the Epoch 002 * Engerix-B should not be given at Month 2 (4 months of age) if a dose of hepatitis B vaccine was given at birth up to 30 days prior to study dose 1 to the subject in the Penta Group ESFU = Extended safety follow-up

- Experimental design: Phase III, open-label, randomized, controlled, multi-centric, single-country study with five parallel groups
- Duration of the study: The intended duration of the study per subject is approximately 14-17 months.
 - **Epoch 001:** Primary, starting at Visit 1 (Day 0) and ending at safety follow up contact (i.e. six months following the third dose, Month 10),
 - **Epoch 002:** Booster, starting at Visit 5 (Month 13-16) and ending at Visit 6 (Month 14-17).
- Control: active controls.
 - Epoch 001: Pediarix + ActHIB and Pentacel + Engerix-B
 - Epoch 002: *Infanrix* + *ActHIB* and *Pentacel*.
- Vaccination schedules:

Epoch 001

- **Hexa Group:** Subjects in this group will receive three doses of *Infanrix hexa* (lot A, lot B or lot C as per the group allocation) co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
 - Hexa_1 Group: Subjects will receive lot A of *Infanrix hexa*,
 - Hexa_2 Group: Subjects will receive lot B of *Infanrix hexa*
 - Hexa 3 Group: Subjects will receive lot C of *Infanrix hexa*.
- **Pedia Group:** Subjects in this group will receive three doses of *Pediarix* and *ActHIB* co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
- **Penta Group**: Subjects in this group will receive three doses of *Pentacel* and *Engerix-B** co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

*Subjects in the Penta Group who have received a dose of hepatitis B vaccine from birth up to 30 days prior to study vaccination should not receive Engerix-B at 4 months of age (Visit 2).

Epoch 002

- **Hexa Group**: Subjects will receive a booster dose of *Infanrix* and *Hiberix* vaccines at 15-18 months of age.
- **Pedia Group**: Subjects will receive a booster dose of *Infanrix* and *ActHIB* vaccines at 15-18 months of age.
- **Penta Group**: Subjects will receive a booster dose of *Pentacel* vaccine at 15-18 months of age.

The fourth dose of pneumococcal conjugate vaccine is recommended to be administered at approximately 12-15 months of age. Since the booster dose of the candidate vaccine/active controls will be given in this study at 15-18 months of age, the fourth dose of *Prevnar13* will not be administered as part of the study protocol. Subject's parent(s)/Legally Acceptable Representative(s) (LARs) will be reminded at Visit 3 and Visit 4 to consult their primary health care provider regarding the fourth dose of *Prevnar13* at 12-15 months for their child.

- As the analyses will be performed regardless of the lot of *Infanrix hexa* received, unless otherwise specified, the Hexa_1, Hexa_2 and Hexa_3 groups will be pooled together for the analysis and will be called the Hexa group.
- Treatment allocation: The subjects will be randomized at a [1:1:1]:3:3 ratio to Hexa_1, Hexa_2, Hexa_3, Pedia and Penta groups. This will be done at study entry using GSK Biologicals' central randomization system on internet (SBIR).
- Blinding: The study is open-label for both epochs due to the differences in the
 number of injections and the appearance of the vaccines administered. However, the
 laboratory in charge of the serology testing will be blinded to the treatment, and codes
 will be used to link the subject and study (without any link to the treatment attributed
 to the subject) to each sample.
- Sampling schedule: Blood samples will be drawn from all subjects at the following time points:
 - Post-Pri (Visit 4): One month after the third dose of primary vaccination, a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) will be collected.
 - Pre-Bst (Visit 5): Before the administration of the booster dose, a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) will be collected.



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

- Post-Bst (Visit 6): One month after the booster vaccination, a volume of at least 3.5 mL of whole blood (to provide at least 1.2 mL of serum) will be collected.
- Type of study: Self-contained.

The following group names will be used for the statistical analyses for Epoch 001:

Group order in tables	Group label in tables	Group definition for footnote	Pooled Groups label in tables	Pooled definition for footnote
1	Hexa_1 group	Subjects who received three doses of <i>Infanrix Hexa</i> from lot A and <i>Prevnar 13</i> at 2, 4 and 6 month of age and <i>Rotarix</i> at 2 and 4 months of age	Hexa group	Subjects who received three doses of <i>Infanrix Hexa</i> and <i>Prevnar 13</i> at 2, 4 and 6 month of age and <i>Rotarix</i> at 2 and 4 months of age
2	Hexa_2 group	Subjects who received three doses of <i>Infanrix Hexa</i> from lot B and <i>Prevnar 13</i> at 2, 4 and 6 month of age and <i>Rotarix</i> at 2 and 4 months of age	Hexa group	Subjects who received three doses of <i>Infanrix Hexa</i> and <i>Prevnar 13</i> at 2, 4 and 6 month of age and <i>Rotarix</i> at 2 and 4 months of age
3	Hexa_3 group	Subjects who received three doses of <i>Infanrix Hexa</i> from lot C and <i>Prevnar 13</i> at 2, 4 and 6 month of age and <i>Rotarix</i> at 2 and 4 months of age	Hexa group	Subjects who received three doses of <i>Infanrix Hexa</i> and <i>Prevnar 13</i> at 2, 4 and 6 month of age and <i>Rotarix</i> at 2 and 4 months of age
4	Pedia group	Subjects who received <i>Pediarix</i> , <i>ActHIB</i> and <i>Prevnar 13</i> at 2, 4 and 6 month of age and <i>Rotarix</i> at 2 and 4 months of age	Pedia group	Subjects who received Pediarix, ActHIB and Prevnar 13 at 2, 4 and 6 month of age and Rotarix at 2 and 4 months of age
5	Penta group	Subjects who received <i>Pentacel</i> , <i>Engerix</i> and <i>Prevnar 13</i> at 2, 4 and 6 month of age and <i>Rotarix</i> at 2 and 4 months of age	Penta group	Subjects who received Pentacel, Engerix and Prevnar 13 at 2, 4 and 6 month of age and Rotarix at 2 and 4 months of age

The following group names will be used for the statistical analyses for Epoch 002:

Group	Group label	Group definition for footnote
order in	in tables	
tables		



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

1	Hexa group	Subjects who received a primary dose of <i>Infanrix Hexa</i> and booster dose of <i>Infanrix and Hiberix</i> vaccines at 15-18 months of age
2	Pedia group	Subjects who received a primary dose of <i>Pediarix</i> and booster dose of <i>Infanrix and ActHIB</i> vaccines at 15-18 months of age
3	Penta group	Subjects who received a primary dose of <i>Pentacel</i> and booster dose of <i>Pentacel</i> vaccine at 15-18 months of age



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

3. OBJECTIVES

3.1. Primary objective

3.1.1. Epoch 001 (Primary vaccination)

• To demonstrate the non-inferiority of *Infanrix hexa* to *Pediarix* co-administered with *ActHIB*, in terms of antibody geometric mean concentrations (GMCs) for pertussis antigens [pertussis toxoid (PT), filamentous hemagglutinin (FHA) and pertactin (PRN)] one month after the third dose of the primary vaccination.

Criteria for non-inferiority:

Non-inferiority in terms of immune response to pertussis antigens will be demonstrated if, for each of the three antigens, the upper limit of the 95% confidence interval (CI) on the GMC ratio [Pedia divided by Hexa] is ≤ 1.5 .

3.2. Secondary objectives

3.2.1. Epoch 001 (Primary vaccination)

- To assess the immune response to *Infanrix hexa, Pediarix, ActHIB, Pentacel* and *Engerix-B*, in terms of seroprotection status, seropositivity status and concentrations or titers of antibodies to D, T, HBs, pertussis, poliovirus types 1, 2 and 3 and PRP antigens, one month after the third dose of the primary vaccination.
- To assess the safety and reactogenicity of a 3-dose primary vaccination course of
 Infanrix hexa, of *Pentacel* co-administered with *Engerix-B*, and that of *Pediarix* co administered with *ActHIB*, in terms of solicited local symptoms.
- To assess the safety and reactogenicity of all study vaccines in terms of solicited general events, unsolicited adverse events, new-onset chronic diseases (NOCDs) and serious adverse events.

3.2.2. Epoch 002 (Booster vaccination)

- To assess the immunogenicity of *Infanrix hexa, Pentacel, Engerix-B, Pediarix* and *ActHIB*, in terms of persistence of the antibodies to D, T, pertussis, HBs, poliovirus types 1, 2 and 3 and PRP antigens, before the booster dose.
- To assess the immune response to *Infanrix, Hiberix, ActHIB* and *Pentacel*, in terms of seroprotection status, seropositivity status and antibody concentrations or titers for D, T, pertussis and PRP antigens, and in terms of booster response for pertussis antigens following *Infanrix and Pentacel*, one month after the booster dose.



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

• To assess the safety and reactogenicity of booster doses of *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*.

4. ENDPOINTS

4.1. Primary endpoint

4.1.1. Epoch 001 (Primary vaccination)

- Immunogenicity with respect to pertussis components of the study vaccines *Infanrix* hexa and *Pediarix*.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination.

4.2. Secondary endpoints

4.2.1. Epoch 001 (Primary vaccination)

- Immunogenicity (other parameters) with respect to the pertussis component of the study vaccines *Infanrix hexa*, *Pentacel* and *Pediarix*.
 - Anti-PT, anti-FHA, anti-PRN seropositivity status, one month after the third dose of the primary vaccination.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination (for *Pentacel* only).
- Immunogenicity with respect to the other components of the study vaccines *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B*.
 - Anti-D, anti-T, anti-HBs, anti-poliovirus types 1, 2 and 3 and anti-PRP seroprotection status, anti-PRP antibody concentrations ≥1.0 µg/mL and antibody concentrations/titers, one month after the third dose of the primary vaccination.
- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0 Day 3) after each vaccination (*Infanrix hexa, Pediarix, ActHIB, Pentacel* and *Engerix-B*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0 Day 3) after each vaccination.
- Unsolicited adverse events.



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

- Occurrence of unsolicited AEs within 31 days (Day 0 Day 30) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.
- Specific adverse events.
 - Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies) from Day 0 up to six months post primary vaccination.
- Serious adverse events.
 - Occurrence of serious adverse events from Day 0 up to six months post primary vaccination.

4.2.2. Epoch 002 (Booster vaccination)

- Immunogenicity with respect to all study vaccines.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-HBs, anti-PRP and anti-poliovirus 1, 2, 3 seroprotection/ seropositivity status, anti-PRP antibody concentrations ≥1 μg/mL and antibody concentrations/ titers before the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccine *Pentacel*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-PRP seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
 - Anti-PRP antibody concentrations $\geq 1~\mu g/mL$ one month after the booster dose (Dose 4).
 - Anti-D and anti-T antibody concentrations ≥1 IU/mL one month after the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccine *Infanrix*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
 - Anti-D and anti-T antibody concentrations ≥1 IU/mL one month after the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccines *ActHIB* and *Hiberix*.



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

- Anti-PRP seroprotection status and antibody concentrations, one month after the booster dose (Dose 4).
- Anti-PRP antibody concentrations ≥1 μg/mL one month after the booster dose (Dose 4)
- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0 Day 3) after booster vaccination (*Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0 Day 3) after booster vaccination.
- Unsolicited adverse events.
 - Occurrence of unsolicited AEs within 31 days (Day 0 Day 30) after booster vaccination, according to the MedDRA classification.
- Specific adverse events.
 - Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies) from the booster dose up to one month after the booster vaccination.
- Serious adverse events.
 - Occurrence of serious adverse events from the booster dose up to one month after the booster vaccination.

5. STUDY POPULATION

Six cohorts are defined for the purpose of the analysis:

- Primary Total Vaccinated cohort
- Primary ATP cohort for analysis of safety
- Primary ATP cohort for analysis of immunogenicity
- Booster Total Vaccinated cohort
- Booster ATP cohort for analysis of safety
- Booster ATP cohort for analysis of immunogenicity



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

5.1.1. Primary Total vaccinated cohort

The Primary Total Vaccinated cohort (TVC) will include all vaccinated subjects for whom data are available.

- A safety analysis based on the Primary TVC will include all subjects with at least one vaccine administration documented.
- An immunogenicity analysis based on the Primary TVC will include all vaccinated subjects for whom data concerning at least one immunogenicity endpoint measure is available.

5.1.2. Primary ATP cohort for analysis of safety

The Primary ATP cohort for safety will consist of all subjects from the Primary TVC who complied with the protocol up to the end of Epoch 001, namely all subjects:

- who meet all inclusion criteria and no exclusion criteria for the study
- who have received all planned study vaccines for each completed vaccination visit in Epoch 001;
- for whom administration site of study vaccines is known and is according to protocol;
- who did not receive a product before the blood sampling at Visit 4 (Month 5) leading to elimination from an ATP analysis as listed in Section 6.7.2 of the protocol.

Note that for the purpose of ATP cohort definition, the Epoch 001 ends at Visit 4.

Adherence to the interval related to ESFU phone contact will not be taken into account for inclusion in ATP cohort for safety.

5.1.3. Primary ATP cohort for analysis of immunogenicity

The Primary ATP cohort for immunogenicity will consist of all subjects from the Primary ATP cohort for safety who complied with eligibility criteria and study procedures (see Table 5 of the protocol for the definition of the intervals) up to the post-dose 3 blood sample and had immunogenicity results for the post-dose 3 blood sample. The analysis will be performed per treatment (first dose) actually administered.

More specifically, the analysis post-dose 3 based on the ATP cohort for immunogenicity will include all eligible subjects:

• who receive all the study vaccines up to dose 3 as per the vaccination schedule;



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

- for whom administration site and route of study vaccines up to dose 3 is as per protocol;
- who did not receive a medication/product before the blood sampling at Visit 4 (Month 5) leading to elimination from an ATP analysis as listed in Section 6.7.2 of the protocol
- who did not present with a medical condition before the blood sampling at Visit 4 (Month 5) leading to elimination from an ATP analysis as listed in Section 6.8 of the protocol.
- who comply with the post-dose 3 blood sample schedule, i.e. 21-48 days post-dose 3.
- who were not administered a vaccine not foreseen by the study protocol before the corresponding post-vaccination blood sample.
- who have immunogenicity results post-dose 3.

5.1.4. Booster Total vaccinated cohort

The Booster TVC will include all subjects from primary TVC that received the booster vaccine dose.

- For the Booster-TVC analysis of safety, this will include all subjects with booster vaccine administration documented.
- For the Booster-TVC analysis of immunogenicity, this will include vaccinated subjects for whom data concerning immunogenicity endpoint measures are available.

5.1.5. Booster ATP cohort for analysis of safety

The Booster ATP cohort for safety will consist of all subjects from the Booster TVC who complied with the protocol up to the end of Epoch 002, namely all subjects:

- who meet all inclusion criteria and no exclusion criteria for the study
- who have received the planned booster dose at 15-18 months of age;
- who received 3 doses in Epoch 001;
- for whom administration site of study vaccines is known and is according to protocol;
- who did not receive a product before the blood sampling at Visit 6 (Months 14-17) leading to elimination from an ATP analysis as listed in Section 6.7.2 of the protocol.



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

5.1.6. Booster ATP cohort for analysis of immunogenicity

The Booster ATP cohort for immunogenicity will consist of all subjects from the Booster ATP cohort for safety who complied with eligibility criteria and study procedures (see Table 5 of the protocol for the definition of the intervals) up to the post-dose 4 blood sample and had immunogenicity results for the post-dose 4 blood sample.

More specifically, the analysis pre- and post-dose 4 based on the Booster ATP cohort for immunogenicity will include all eligible subjects:

- who receive all the study vaccines up to dose 4 as per the vaccination schedule;
- for whom administration site and route of the study vaccines up to dose 4 is as per protocol;
- who did not receive a medication/product before the blood sampling at Visit 6 (Months 14-17) leading to elimination from an ATP analysis (see Section 6.7.2 of the protocol);
- who did not present with a medical condition before the blood sampling at Visit 6 (Months 14-17) leading to elimination from an ATP analysis (see Section 6.8 of the protocol);
- who comply with the booster vaccination schedule at 15-18 months of age and with the post-dose 4 blood sample schedule i.e. 21-48 days for post-dose 4;
- who have immunogenicity results post-dose 4.

The list of applicable elimination codes for each cohort can be found in the study specific form FORM-BIO-CLIN-9004-05 Criteria for eliminating subjects from the analyses.

Cohort	Elimination codes	Eli Type
Primary ATP cohort for analysis for safety	1030-2100	PR
Primary ATP cohort for analysis for immunogenicity	1030-2100	PR
Booster ATP cohort for analysis for safety	1030-2100	ВО
Booster ATP cohort for analysis for immunogenicity	1030-2100	ВО

6. STATISTICAL METHODS

6.1. Final analysis of the Epoch 001



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

6.1.1. Analysis of demographics

Demographic characteristics (age [weeks], gender, geographical ancestry, height in length [cm], weight [kg] at first dose, Hep B vaccination history, vaccination history of mother with respect to administration of Tdap vaccine during pregnancy) and withdrawal status will be summarised by group using descriptive statistics:

Frequency tables will be generated for categorical variables such as center;

Mean, median and standard error will be provided for continuous data such as age.

The distribution of subjects enrolled among the study sites will be tabulated as a whole and per group.

6.1.2. Analysis of immunogenicity

The primary analysis will be based on the Primary ATP cohort for immunogenicity. An analysis on the Primary Total Vaccinated cohort will be performed only if, in any vaccine group and at any time point, more than 5% of the vaccinated subjects with immunological data post-dose 3 are excluded from the Primary ATP cohort for immunogenicity.

The following section describes the analyses that will be performed.

6.1.2.1. Within group assessment

For each group, one month post-dose 3 and for each assay for which a serological result is available:

- Seropositivity and seroprotection rates with exact 95% CIs will be calculated.
- GMCs/GMTs with 95% CIs will be tabulated.
- For each antigen, antibody concentration or titer distribution one month post-vaccination will be tabulated and displayed using reverse cumulative curves (RCCs).

All the above within group analysis for Epoch 001 except the reverse cumulative curves will also be performed by gender, by geographical ancestry (the most frequent geographical ancestry versus all other geographical ancestries, namely White Caucasian versus any other geographical ancestry), by Tdap vaccination history of mothers during pregnancy and by Hepatitis B vaccination of the subjects at birth (for anti-HBs antigen).

6.1.2.2. Between group assessment

At one month post-dose 3,



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

- The asymptotic standardized 95% CI for the group difference (Pedia group minus Hexa group and Penta group minus Hexa group) in the seropositivity/ seroprotection rates will be computed for each antigen except for group difference (Penta group minus Hexa group) in the seroprotection/ seropositivity rates for pertussis antigens.
- The 95% CI for each group GMC/GMT ratio (Pedia group divided by Hexa group and Penta group divided by Hexa group) will be computed using an Analysis of Variance (ANOVA) model on the logarithm-transformed concentrations/titers except for GMC ratio (Penta group divided by Hexa group) for pertussis antigens. The ANOVA model will include the vaccine group as fixed effect and the DTP vaccination of the mother during pregnancy as regressor leading to an Analysis of Covariance (ANCOVA) model. For hepatitis B antigen, the hepatitis b at birth vaccine dose status will also be used as regressor leading to an Analysis of Co-variance (ANCOVA) model. The model will include the data from the 2 groups compared. For analysis purpose, we will consider DTP vaccination of the mother during pregnancy as continuous variable.

6.1.2.3. Interpretation of analyses

Except for analyses addressing criteria specified in the primary objective, comparative analyses will be descriptive/ exploratory with the aim to characterise the difference between groups in immunogenicity. These descriptive/exploratory analyses should not be interpreted for formal conclusions since there is no adjustment for multiplicity of endpoints.

6.1.3. Analysis of safety

The primary analysis will be based on the primary Total Vaccinated cohort. If, in any vaccine group and at any time point of the Epoch 001, the percentage of vaccinated subjects excluded from the primary ATP cohort for safety is more than 5%, a second analysis based on the primary ATP cohort for safety will be performed to complement the primary Total Vaccinated cohort analysis.

- The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) or 31-day (Days 0-30) follow-up period will be tabulated after each vaccine dose and overall (for the Epoch 001) with exact 95% CI.
- The percentage of doses followed by at least one local AE (solicited and unsolicited), by at least one general AE (solicited and unsolicited) and by any AE during the 4-day or 31-day follow-up period will be tabulated over the primary vaccination period, with exact 95% CI.



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

- The percentage of subjects/doses with local AEs (solicited and unsolicited) will be calculated at each injection site for *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel and Engerix-B* vaccines, as well as overall (all sites considered) during the 4-day follow-up period will be tabulated over the primary vaccination period, with exact 95% CI..
- The percentage of subjects/doses reporting each individual solicited local and general AE during the 4-day follow-up period will be tabulated for each group as follows:
 - Over the primary doses, the percentage of subjects with the symptom and its exact 95% CI.
 - Over the primary doses, the percentage of doses with the symptom and its exact 95% CI.
 - At each study dose, the percentage of subjects with the symptom and its exact 95% CI.

The exact 95% CIs will be calculated assuming independence between doses.

- All computations mentioned above will be done for Grade ≥2 (solicited symptoms only) and Grade 3 symptoms, for symptoms considered related to vaccination (general symptoms only), for Grade 3 symptoms considered related to vaccination (general symptoms only) and for symptoms that resulted in a medically-attended visit. The percentage of subjects reporting each individual solicited local (any grade, grade 2, grade 3, medical advice) during the 4-day follow-up period will also be tabulated at each injection site for *Infanrix Hexa*, *Pediarix*, *ActHIB*, *Pentacel and Engerix-B* vaccines with exact 95% CI after each vaccine dose and overall where the same row on the table is used for all vaccines given at the same site across the three study groups (e.g. *Infanrix Hexa*, *Pentacel* and *Pediarix* together are in one row and *ActHIB* and *Engerix-B* together are in one row).
- For fever, analyses will be performed by 0.5°C increments.
- The percentage of subjects/doses with concomitant medication, antipyretic medication and prophylactic antipyretic medication during the 4-day and 31-day follow-up period post-vaccination will be tabulated after each dose and over the Epoch 001.
- The verbatim reports of unsolicited AEs will be reviewed by a Clinical Research and Development Lead and the signs and symptoms will be coded according to MedDRA. Every verbatim term will be matched with the appropriate Preferred Term. The percentage of subjects/doses with unsolicited AEs occurring within 31 days with exact 95% CI will be tabulated by Preferred Term. Similar tabulations will be done for Grade 3 unsolicited AEs, for unsolicited AEs considered related to vaccination and for Grade 3 unsolicited AEs considered related to vaccination.
- Subjects who experienced AEs of specific interest (i.e. convulsions, Hypotonic Hyporesponsive Episode) during 31 days with exact 95% CI will be tabulated by



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

Preferred Term. Similar tabulations will be done for AEs considered related to vaccination. Subjects who experienced AEs of specific interest will also be described in detail.

- Subjects who experienced AEs of specific interest (i.e. new onset of chronic disease such as autoimmune disorders, asthma, type I diabetes and allergies) from Day 0 up to 6 months after the last primary vaccination will be tabulated by Preferred Term.
- Subjects who experienced at least one SAE reported before the database lock for the Epoch 001 analysis with an onset date in the Epoch 001 will be reported and the SAE will be described in detail.

All the above safety and reactogenicity analysis for Epoch 001 will also be performed by gender and geographical ancestry (the most frequent geographical ancestry versus all other geographical ancestries, namely White Caucasian versus any other geographical ancestry) except the percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) and 31-day (Days 0-30) follow-up period.

6.2. Final analysis of the Epoch 002

6.2.1. Analysis of demographics/baseline characteristics

Demographic characteristics (age [months] at Visit 5, gender, geographical ancestry, Hep B vaccination history, vaccination history of mother with respect to administration of Tdap vaccine during pregnancy) and withdrawal status will be summarized by group using descriptive statistics:

- Frequency tables will be generated for categorical variables such as race/ethnicity;
- Mean, median and standard error will be provided for continuous data such as age.

The distribution of subjects vaccinated at Visit 5 among the study sites will be tabulated as a whole and per group.

For enrolled subjects that do not participate in the Epoch 002, the reason for not participating will be summarized.

6.2.2. Analysis of immunogenicity

The primary analysis will be based on the booster ATP cohort for immunogenicity. An analysis on the booster Total Vaccinated cohort will be performed only if, in any vaccine group and at any time point of the Epoch 002, more than 5% of the vaccinated subjects with immunological data are excluded from the booster ATP cohort for immunogenicity.



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

The following section describes the analyses that will be performed.

6.2.2.1. Within group assessment

For each group, prior to the booster dose and one month post-booster dose and for each assay, for which a serological result is available:

- Seropositivity and seroprotection rates and booster response rates for pertussis with exact 95% CIs will be calculated.
- GMCs/GMTs with 95% CIs will be tabulated.
- For each antigen, antibody concentration or titer distribution before and one month Post-booster (when available) will be tabulated and displayed using RCCs.

All the above within group analysis for Epoch 002 except the reverse cumulative curves will also be performed by gender, by geographical ancestry (the most frequent geographical ancestry versus all other geographical ancestries, namely White Caucasian versus any other geographical ancestry), by Tdap vaccination history of mothers during pregnancy and Hepatitis B vaccination of the subjects at birth (for anti-HBs antigen).

6.2.2.2. Between group assessment

At pre-booster and at one month post-booster,

- The asymptotic standardized 95% CI for the group difference (Pedia group minus Hexa group and Penta group minus Hexa group) in the seroprotection/ seropositivity rates will be computed for each antigen except for group difference (Penta group minus Hexa group) in the seroprotection/ seropositivity rates for pertussis antigens.
- The 95% CI for each group GMC/GMT ratio (Pedia group divided by Hexa group and Penta group divided by Hexa group) will be computed using an ANOVA model on the logarithm-transformed concentrations/titers except for GMC ratio (Penta group divided by Hexa group) for pertussis antigens. The ANOVA model will include the vaccine group as fixed effect and the DTP vaccination of the mother during pregnancy as regressor leading to an Analysis of Co-variance (ANCOVA). For hepatitis B antigen, the hepatitis B at birth vaccine dose status will also be used as regressor leading to an ANCOVA model. The model will include the data from the 2 groups compared.

6.2.2.3. Interpretation of analyses

In Epoch 002, all comparative analyses will be descriptive/ exploratory with the aim to characterise the difference between groups in immunogenicity. These



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

descriptive/exploratory analyses should not be interpreted for formal conclusions since there is no adjustment for multiplicity of endpoints.

6.2.3. Analysis of safety

The primary analysis for the Epoch 002 will be based on the booster Total Vaccinated cohort and will only look at the booster dose. If, in any vaccine group, the percentage of vaccinated subjects excluded from the booster ATP cohort for safety is more than 5%, a second analysis based on the booster ATP cohort for safety will be performed to complement the booster Total Vaccinated cohort analysis.

- The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) and 31-day (Days 0-30) follow-up period after the booster dose, will be tabulated with exact 95% CI for each group.
- The incidence of local AEs (solicited and unsolicited) will be calculated at each injection site as well as overall (all sites considered) for each group during the 4-day (Days 0-3) follow-up period after the booster dose.
- The percentage of subjects reporting each individual solicited local and general AE during the 4-day follow-up period will be tabulated with its exact 95% CI for each group.
- All computations mentioned above will be done for Grade ≥2 (solicited symptoms only) and Grade 3 symptoms, for symptoms considered related to vaccination (general symptoms only), for Grade 3 symptoms considered related to vaccination (general symptoms only) and for symptoms that resulted in a medically-attended visit. The percentage of subjects reporting each individual solicited local (any grade, grade 2, grade 3, medical advice) during the 4-day follow-up period will also be tabulated at each injection site for *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel* vaccines with exact 95% CI after each vaccine dose and overall where vaccine with same vaccine site is considered together (e.g. *Infanrix* and *Pentacel* together are on one row and *ActHIB* and *Hiberix* together are on one row).
- For fever, analyses will be performed by 0.5°C increments.
- The percentage of subjects with concomitant medication, antipyretic medication and prophylactic antipyretic medication during the 4-day and 31-day follow-up period post-vaccination will be tabulated for each group.
- The verbatim reports of unsolicited AEs will be reviewed by a Clinical Research and Development Lead and the signs and symptoms will be coded according to MedDRA. Every verbatim term will be matched with the appropriate Preferred Term. The percentage of subjects with unsolicited AEs occurring within 31 days following the booster dose with its exact 95% CI will be tabulated by Preferred Term. Similar



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

tabulations will be done for Grade 3 unsolicited AEs, for unsolicited AEs considered related to vaccination and for Grade 3 unsolicited AEs considered related to vaccination.

Additionally,

- Any large injection site reaction (defined as a swelling with a diameter > 50 mm, noticeable diffuse swelling or increase in limb circumference of greater than 50 mm) reported within 4 days (Days 0-3) following the booster dose will be described in detail.
- Subjects who experienced AEs of specific interest (i.e. new onset of chronic disease such as autoimmune disorders, asthma, type I diabetes and allergies) from booster dose up to one month after booster vaccination will be tabulated by Preferred Term.
- Subjects who experienced at least one SAE from the booster dose to study end will be reported and the SAEs will be described in detail.

All the above safety and reactogenicity analysis for Epoch 002 will also be performed by gender and geographical ancestry (the most frequent geographical ancestry versus all other geographical ancestry, namely White Caucasian versus any other geographical ancestry) except percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) and 31-day (Days 0-30) follow-up period after the booster dose.

7. STATISTICAL CALCULATIONS

7.1. Derived and transformed data

7.1.1. Demography

For a given subject and a given demographic variable, missing measurement will not be replaced excepting for age.

Age will be calculated as the number of years between the date of birth and the date of vaccination.

To ensure that the collection of date of birth will not jeopardise the privacy of personally identifiable information, only a partial date of birth (MMYYYY) will be collected.

Therefore, the 15th of the month will be used to replace the missing date. In case the day and the months are missing, the date will be replaced by the June 30th of the year.



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

- **7.1.2. Immunogenicity**A seronegative subject is a subject whose antibody concentration/titer is below the assay cut-off.
- A seropositive subject is a subject whose antibody concentration/titer is greater than or equal to the assay cut-off defined in Table 7 of the protocol.

Note: Due to ongoing re-validation of all assays, these cut-offs may be subject to change.

- A seroprotected subject is a subject whose antibody concentration/titer is greater than or equal to the level defining clinical protection. The following seroprotection thresholds are applicable:
 - Anti-diphtheria antibody concentrations \ge 0.1 IU/mL.
 - Anti-tetanus antibody concentrations $\geq 0.1 \text{ IU/mL}$.
 - Anti-HBs antibody concentrations ≥ 10 mIU/mL.
 - Anti-poliovirus types 1, 2 and 3 antibody titers ≥ 8 .
 - Anti-PRP antibody concentrations $\ge 0.15 \,\mu\text{g/mL}$.
- Other cut-offs to be considered:
 - Anti-PRP antibody concentrations ≥ 1.0 μ g/mL.
 - Anti-diphtheria and anti-tetanus antibody concentrations ≥ 1.0 IU/mL
- Booster responses for anti-PT, anti-FHA and anti-PRN antibodies are defined as:
 - initially seronegative subjects (pre-booster antibody concentration below cut-off:
 5 ELISA EL.U/mL) with an increase of at least four times the cut-off one month after vaccination (post-booster antibody concentration ≥20 EL.U/mL), and
 - initially seropositive subjects with pre-booster antibody concentration
 ≥ 5 EL.U./mL and < 20 EL.U/mL with an increase of at least four times the pre-booster antibody concentration one month after vaccination, and,
 - For initially seropositive subjects with pre-booster antibody concentration ≥ 20 EL.U/mL with an increase of at least two times the pre-booster antibody concentration, one month after vaccination.

Note: Due to ongoing re-validation of pertussis assays, the definition of booster response may be subject to change.

• The GMC/GMT calculations will be performed by taking the anti-log of the mean of the log₁₀ titer/ concentration transformations. Antibody titers/concentrations below the cut-off of the assay will be given an arbitrary value of half the cut-off for the purpose of GMC/GMT calculation.



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

• Handling of missing data - For a given subject and a given immunogenicity measurement, missing or non-evaluable measurements will not be replaced.

7.1.3. Safety/reactogenicity:

- For a given subject and the analysis of solicited symptom within 4 days post-vaccination, missing or non-evaluable measurements will not be replaced. Therefore the analysis of the solicited symptoms based on the Total Vaccinated cohort will include only vaccinated subjects and doses with documented safety data (i.e. symptom screen completed).
- For analysis of unsolicited adverse events, such as serious adverse events or adverse
 events by primary MedDRA term, and for the analysis of concomitant medications,
 all vaccinated subjects will be considered. Subjects who did not report the event or
 the concomitant medication will be considered as subjects without the event or the
 concomitant medication respectively.
- For analysis of convulsion, the adverse event will be identified by using narrow standard MedDRA query.
- For analysis of convulsion, the adverse event will be identified by using narrow standard MedDRA query.
- For analysis of Hypotonic Hyporesponsive Episode (HHE), the adverse event will be identified by using broad standard MedDRA query.
- For analysis of New Onset of Chronic Illness (NOCI), the adverse event will be identified by using narrow standard MedDRA query.
- For summaries reporting both solicited and unsolicited adverse events, all vaccinated subjects will be considered. Subjects for whom the event will not be reported will be considered as subjects without the event.
- Large injection site reactions are defined as either swelling with a diameter of >50 mm or a >50 mm increase in the circumference of any limb when compared to the baseline (pre-vaccination) measurement, or any diffuse swelling that interferes with or prevents everyday activities (for example, active playing, eating, sleeping).
- For the analysis, temperatures by any route will be coded as follows:

Grade	Temperature
0	< 38.0°C
1	≥ 38.0°C - ≤ 39.0°C
2	> 39.0°C - ≤ 40.0°C
3	> 40.0°C



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

• The way the percentage of subjects will be derived will depend on the event analysed (see table below for details). As a result, the N value will differ from one table to another.

Event	N used for deriving % per subject for Vaccination phase
Concomitant vaccination	All subjects with study vaccine administered
Solicited general symptom	All subjects with at least one solicited general symptom documented as either present or absent (i.e. symptom screen completed)
Solicited local symptom	All subjects with at least one solicited local symptom documented as either present or absent (i.e. symptom screen completed)
Unsolicited symptom	All subjects with study vaccine administered
Concomitant medication	All subjects with study vaccine administered

7.2. Data presentation description

The following decimal description from the decision rules will be used for the demography, immunogenicity and safety/ reactogenicity.

Display Table	Parameters	Number of decimal digits
Demographic	Mean, median age	1
characteristics		
Demographic	SD (age)	1
characteristics		
anti-T	GMC	3
anti-D	GMC	3
anti-PT	GMC	1
anti-PHA	GMC	1
anti-PRN	GMC	1
anti-HBs	GMC	1
anti-PRP	GMC	3
anti-Polio 1	GMT	1
anti-Polio 2	GMT	1
anti-Polio 3	GMT	1
Immunogenicity	Ratio of GMT/C	2
Reactogenicity	Mean, Min, Q1, Median, Q3, Max for	1
	duration	
All summaries	% of count, including LL & UL of CI	1

FORM-9000026972-01 Statistical Analysis Plan Template

Effective date: 01 June 2014

GSK SOP Reference: SOP-9000026972 Form Owner: VVHS Biometrics, PPD



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

All summaries	% of difference, including LL & UL of	2
	CI	

7.3. Methodology for computing confidence intervals

- All CI computed will be two-sided 95% CI.
- The exact 95% CIs for a proportion within a group will be based on the method by Clopper [Clopper, 1934*].
- The standardised asymptotic 95% CI for the group difference in proportions will be based on the method 6 described in paper by Newcombe [R Newcombe, 1998, method six**].
- The 95% CI for geometric mean titres/concentrations (GMTs/GMCs) will be obtained within each group separately. The 95% CI for the mean of log-transformed titre/concentration will be first obtained assuming that log-transformed values were normally distributed with unknown variance. The 95% CI for the GMTs/GMCs will be then obtained by exponential-transformation of the 95% CI for the mean of log-transformed titre/concentration.

The GMC/GMT group ratio will be computed using an ANOVA model on the logarithm10 transformation of the concentrations/titres. The ANOVA model will include the vaccine group as fixed effect and the DTP vaccination of the mother during pregnancy as regressor leading to an Analysis of Co-variance (ANCOVA) model. For hepatitis B antigen, the hepatitis B vaccination at birth vaccine dose status will also be used as regressor leading to an Analysis of Co-variance (ANCOVA) model.

8. CONDUCT OF ANALYSES

8.1. Sequence of analyses

The analyses will be performed stepwise:

- 1. A partial analysis of Epoch 001 up to one month after the third primary vaccine dose will be conducted. This analysis will include the final analysis of anti-PRP, solicited and unsolicited symptoms on data as clean as possible. This analysis will be displayed on GSK clinical trial registry as soon as possible.
- 2. The final data analysis of the study covering both the epochs will be conducted at the end of the study. All these analyses will be presented in a final clinical study report.



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

Following analysis folder will be created in SDD and CARS with given analysis ID to perform analysis and archival of statistical reports

Description	Analysis ID (SDD & CARS sub- folder)	Disclosure	TFL reference
Primary Epoch -Anti- PRP and safety	E1_01	CTRS	From TFL Version 1 dated 10-Mar- 2015, following tables will be generated for time point - one month post vaccination dose 3. • Post-Text table section – Table- 29, 34, 35, 38, 39. • CTRS table sections – Table 1-5, 10, 12-15) • Annex table section – Table 3 Please note that the tables from post text section will be generated with output destination 'ANNEX'.
Final	E1_02	CTRS, Clinical Study report, Publication	TFL

8.2. Statistical considerations for interim analyses

All analyses will be conducted on final data and therefore no statistical adjustment for interim analyses is required.

9. MAJOR CHANGES FROM PLANNED ANALYSES

Following are the changed in the SAP from protocol:-

• The analysis of percentage of doses followed by at least one local AE (solicited and unsolicited), by at least one general AE (solicited and unsolicited) and by any AE during the 31-day (Days 0-30) follow-up period will not be tabulated over the primary vaccination period and also over booster vaccination period, with exact 95% CI. Also the same analysis by gender and geographical ancestry will not be performed.

10. REFERENCE

* Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of binomial. *Biometrika*. 1934;26:404-413



Study alias & e-track number(s): DTPA-HBV-IPV-135 (117119)

** Robert G. Newcombe, interval estimation for the difference between independent proportions: comparison of eleven methods, *Statist Med.* 1998; 17, 873-890

1. TABLES AND FIGURES

1.1. Study Population

Table 1 Study population Primary Epoch (Primary TVC)

Number of subjects	Hexa group	Pedia group	Penta group
Planned, N	195	195	195
Randomized, N (TVC)	195	194	196
Completed, n (%)	178 (91.3)	182 (93.8)	178 (90.8)
Demographics	Hexa group	Pedia group	Penta group
N (TVC)	195	194	196
Females: Males	101:94	80:114	95:101
Mean Age, weeks (SD)	8.5 (1.0)	8.6 (1.1)	8.6 (1.1)
Median Age, weeks (minimum, maximum)	8 (6, 12)	9 (6, 12)	8 (6, 12)
White-Caucasian / European Heritage, n (%)	118 (60.5)	128 (66.0)	115 (58.7)
Other, n (%)	29 (14.9)	27 (13.9)	32 (16.3)
American Indian or Alaskan Native, n (%)	15 (7.7)	15 (7.7)	17 (8.7)

Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Pedia group = Subjects who received *Pediarix*, *ActHIB* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Penta group = Subjects who received *Pentacel*, *Engerix* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

N = total number of subjects

n/% = number/percentage of subjects

SD = standard deviation

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Table 2 Number of subjects vaccinated, completed and withdrawn with reasons of withdrawal up to Visit 4 (Primary TVC)

	Hexa group	Pedia group	Penta group	Total
Number of subjects vaccinated	195	194	196	585
Number of subjects completed	178	182	178	538
Number of subjects withdrawn	17	12	18	47
Reasons for withdrawal :				
Subject died	0	0	0	0
Serious Adverse Event	1	0	0	1
Non-Serious Adverse Event	0	0	1	1
Eligibility criteria not fulfilled (inclusion and exclusion	0	0	0	0
criteria)				
Protocol violation	1	0	4	5
Consent withdrawal (not due to an adverse event)	3	6	5	14
Migrated/moved from study area	2	3	0	5
Lost to follow-up (subjects with incomplete vaccination	2	0	2	4
course)				
Lost to follow-up (subjects with complete vaccination	4	0	0	4
course)				
Sponsor study termination	0	0	1	1
Other-loss of Kaiser insurance	0	0	1	1
Other-lost health plan	1	2	0	3
Other-lost health plan at Kaiser	0	1	0	1
Other-lost Kaiser insurance	1	0	0	1
Other-lost Kaiser permanente health insurance	0	0	1	1
Other-parent no show x3	1	0	0	1
Other-refuses blood draws	0	0	1	1
Other-subject was discontinued due to non-compliance	0	0	1	1
Other-terminated by pi due to non-compliance with	1	0	0	1
appointment schedules				
Other-travelling out of country and unable to meet visit	0	0	1	1
window				

Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Pedia group = Subjects who received *Pediarix*, *ActHIB* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Penta group = Subjects who received *Pentacel*, *Engerix* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Vaccinated = number of subjects who were vaccinated in the study

Vaccinated = number of subjects who were vaccinated in the study up to Visit 4

Completed = number of subjects who completed Visit 4

Withdrawn = number of subjects who did not come back for Visit 4

Table 3 Number of enrolled subjects by country

	Hexa group N = 195	Pedia group N = 194	Penta group N = 196	Total N = 585
Country	n	n	n	n
United States	195	194	196	585

Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Pedia group = Subjects who received *Pediarix*, *ActHIB* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Penta group = Subjects who received *Pentacel*, *Engerix* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

N = Number of enrolled subjects

n = number of enrolled subjects included in each group or in total for a given country or for all countries

Table 4 Number of enrolled subjects by age category

	Hexa group N = 195	Pedia group N = 194	Penta group N = 196	Total N = 585
Age category	n	n	n	n
Infants and toddlers (28 days-23 months)	195	194	196	585

Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Pedia group = Subjects who received *Pediarix*, *ActHIB* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Penta group = Subjects who received *Pentacel*, *Engerix* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

N = Number of enrolled subjects

n = number of enrolled subjects included in each group or in total for a given age category or for all age categories

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Table 5 Number of subjects enrolled into the study as well as the number excluded from ATP analyses for Primary Epoch with reasons for exclusion excluded from ATP analyses with reasons for exclusion

	Total			Hex	xa group	Ped	dia group	Penta group	
Title	n	S	%	n	S	n	S	n	s
Primary Total cohort	585			195		194		196	
Primary TVC	585		100	195		194		196	
Administration of vaccine(s) forbidden in the protocol (code 1040)	7	7		1	1	1	1	5	5
Study vaccine dose not administered according to protocol (code 1070)	0	2		0	0	0	0	0	2
ATP cohort for safety	578		98.8	194		193		191	
Underlying medical condition forbidden by the protocol (code 2050)	2	2		0	0	0	0	2	2
Concomitant infection related to the vaccine which may influence immune response (code 2060)	0	2		0	0	0	0	0	2
Non compliance with vaccination schedule (including wrong and unknown dates) (code 2080)	19	20		5	5	8	8	6	7
Non compliance with blood sampling schedule (including wrong and unknown dates (code 2090)	6	9		4	6	2	3	0	0
Essential serological data missing (code 2100)	85	93		31	34	27	27	27	32
Primary ATP cohort for immunogenicity	466		79.7	154		156		156	

Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Pedia group = Subjects who received *Pediarix*, *ActHIB* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Penta group = Subjects who received *Pentacel*, *Engerix* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Note: Subjects may have more than one elimination code assigned

n = number of subjects with the elimination code assigned excluding subjects who have been assigned a lower elimination code number

s = number of subjects with the elimination code assigned

% = percentage of subjects in the considered ATP cohort relative to the TVC

1.2. Immunogenicity results

Table 6 Number and percentage of subjects with an anti-PRP antibody concentration equal to or above 0.15 and 1 μg/ml and GMCs by vaccine group (Primary ATP cohort for immunogenicity)

				≥ 0.15 µg/ml				≥ 1 µg/ml				GMC		
					95% CI		95% CI			95% CI				
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-PRP antibody	Hexa	PIII(M5)	149	140	94.0	88.8	97.2	83	55.7	47.3	63.8	1.4	1.1	1.7
-	Pedia	PIII(M5)	153	151	98.7	95.4	99.8	144	94.1	89.1	97.3	10.3	8.1	13.1
	Penta	PIII(M5)	153	151	98.7	95.4	99.8	126	82.4	75.4	88.0	6.5	4.9	8.5

Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Pedia group = Subjects who received *Pediarix*, *ActHIB* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Penta group = Subjects who received *Pentacel, Engerix* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 7 Number and percentage of subjects with an anti-PRP antibody concentration equal to or above 0.15 and 1 µg/ml and GMCs by vaccine and lot group (Primary ATP cohort for immunogenicity)

					≥ 0.15	5 μg/n	ni		≥1	µg/ml		(GMC	
						959	% CI			95%	% CI		95	% CI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-PRP antibody	Hexa_A	PIII(M5)	53	50	94.3	84.3	98.8	34	64.2	49.8	76.9	1.5	1.0	2.1
•	Hexa_C	PIII(M5)	48	45	93.8	82.8	98.7	25	52.1	37.2	66.7	1.5	0.9	2.3
	Hexa_B	PIII(M5)	48	45	93.8	82.8	98.7	24	50.0	35.2	64.8	1.2	8.0	1.9
	Pedia	PIII(M5)	153	151	98.7	95.4	99.8	144	94.1	89.1	97.3	10.3	8.1	13.1
	Penta	PIII(M5)	153	151	98.7	95.4	99.8	126	82.4	75.4	88.0	6.5	4.9	8.5

Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Pedia group = Subjects who received *Pediarix*, *ActHIB* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Penta group = Subjects who received *Pentacel, Engerix* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age


GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Figure 1 Reverse cumulative distribution curve (Post dose 3) by vaccine group (Primary ATP cohort for immunogenicity)




Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Pedia group = Subjects who received *Pediarix*, *ActHIB* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Penta group = Subjects who received *Pentacel, Engerix* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Figure 2 Reverse cumulative distribution curve (Post dose 3), by vaccine and lot group (Primary ATP cohort for immunogenicity)



Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Pedia group = Subjects who received *Pediarix*, *ActHIB* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Penta group = Subjects who received *Pentacel, Engerix* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Table 8 Number and percentage of subjects with an anti-PRP antibody concentration equal to or above 0.15 and 1 μg/ml and GMCs by vaccine group (Primary TVC)

					≥ 0.15	5 μg/m	ıl		≥1	µg/ml			GMC	
						959	% CI			959	% CI		95	% CI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-PRP antibody	Hexa	PIII(M5)	155	146	94.2	89.3	97.3	87	56.1	47.9	64.1	1.4	1.1	1.7
	Pedia	PIII(M5)	162	160	98.8	95.6	99.9	153	94.4	89.7	97.4	10.5	8.4	13.2
	Penta	PIII(M5)	161	159	98.8	95.6	99.8	134	83.2	76.5	88.6	6.6	5.1	8.6

Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Pedia group = Subjects who received *Pediarix*, *ActHIB* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Penta group = Subjects who received *Pentacel, Engerix* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

1.3. Safety results

Table 9 Number (%) of subjects reporting solicited local symptoms during the 4-day (Days 0-3) post-vaccination period following each dose and overall (Primary TVC)

					Hexa gr	oup				Pedia group				Pe	enta gr	oup	
						95	% CI					% CI				95%	√ CI
Symptom	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
					Dose	1											
Pain	Total	All	185	94	50.8	43.4	58.2	189	128	67.7	60.6	74.3	188	119	63.3	56.0	70.2
		Grade 2 or 3	185	40	21.6	15.9	28.3	189	75	39.7	32.7	47.0	188	56	29.8	23.4	36.9
		Grade 3	185	8	4.3	1.9	8.3	189	24	12.7	8.3	18.3	188	12	6.4	3.3	10.9
		Medical advice	185	1	0.5	0.0	3.0	189	1	0.5	0.0	2.9	188	0	0.0	0.0	1.9
	ActHIB/Engerix B	All						189	123	65.1	57.8	71.9	188	100	53.2	45.8	60.5
		Grade 2 or 3						189	66	34.9	28.1	42.2	188	45	23.9	18.0	30.7
		Grade 3						189	22	11.6	7.4	17.1	188	10	5.3	2.6	9.6
		Medical advice						189	1	0.5	0.0	2.9	188	0	0.0	0.0	1.9
	Hexa/Pediarix/Pentacel	All	185	94	50.8	43.4	58.2	189	113	59.8	52.4	66.8	188	115	61.2	53.8	68.2
		Grade 2 or 3	185	40	21.6	15.9	28.3	189	65	34.4	27.6	41.6	188	51	27.1	20.9	34.1
		Grade 3	185	8	4.3	1.9	8.3	189	17	9.0	5.3	14.0	188	12	6.4	3.3	10.9
		Medical advice	185	1	0.5	0.0	3.0	189	0	0.0	0.0	1.9	188	0	0.0	0.0	1.9
Redness (mm)	Total	All	185	47	25.4	19.3	32.3	189	73	38.6	31.6	46.0	188	67	35.6	28.8	42.9
		>5	185	15	8.1	4.6	13.0	189	27	14.3	9.6	20.1	188	27	14.4	9.7	20.2
		>20	185	3	1.6	0.3	4.7	189	10	5.3	2.6	9.5	188	4	2.1	0.6	5.4
		Medical advice	185	0	0.0	0.0	2.0	189	1	0.5	0.0	2.9	188	0	0.0	0.0	1.9
	ActHIB/Engerix B	All						189	63	33.3	26.7	40.5	188	55	29.3	22.9	36.3
		>5						189	19	10.1	6.2	15.3	188	12	6.4	3.3	10.9
		>20						189	8	4.2	1.8	8.2	188	1	0.5	0.0	2.9
		Medical advice						189	1	0.5	0.0	2.9	188	0	0.0	0.0	1.9
	Hexa/Pediarix/Pentacel	All	185	47	25.4	19.3	32.3	189	56	29.6	23.2	36.7	188	57	30.3	23.8	37.4
		>5	185	15	8.1	4.6	13.0	189	15	7.9	4.5	12.8	188	20	10.6	6.6	16.0
		>20	185	3	1.6	0.3	4.7	189	4	2.1	0.6	5.3	188	3	1.6	0.3	4.6
		Medical advice	185	0	0.0	0.0	2.0	189	0	0.0	0.0	1.9	188	0	0.0	0.0	1.9
Swelling (mm)	Total	All	185	31	16.8	11.7	22.9	189	46	24.3	18.4	31.1	188	53	28.2	21.9	35.2
		>5	185	10	5.4	2.6	9.7	189	18	9.5	5.7	14.6	188	24	12.8	8.4	18.4

117119 (DTPA-HBV-IPV-135)

								1				Ab	riage		<u>erim R</u>		Finai
					Hexa gı					Pedia group				Р	enta gr		
							% CI			T		% CI		_			6 CI
Symptom	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
		>20	185	2	1.1	0.1	3.9	189	7	3.7	1.5	7.5	188	11	5.9	3.0	10.2
		Medical advice	185	0	0.0	0.0	2.0	189	1	0.5	0.0	2.9	188	0	0.0	0.0	1.9
	ActHIB/Engerix B	All						189	41	21.7	16.0	28.3	188	39	20.7	15.2	27.2
		>5						189	14	7.4	4.1	12.1	188	14	7.4	4.1	12.2
		>20						189	6	3.2	1.2	6.8	188	3	1.6	0.3	4.6
		Medical advice						189	1	0.5	0.0	2.9	188	0	0.0	0.0	1.9
	Hexa/Pediarix/Pentacel	All	185	31	16.8	11.7	22.9	189	35	18.5	13.3	24.8	188	45	23.9	18.0	30.7
		>5	185	10	5.4	2.6	9.7	189	14	7.4	4.1	12.1	188	24	12.8	8.4	18.4
		>20	185	2	1.1	0.1	3.9	189	3	1.6	0.3	4.6	188	11	5.9	3.0	10.2
		Medical advice	185	0	0.0	0.0	2.0	189	0	0.0	0.0	1.9	188	0	0.0	0.0	1.9
					Dose												
Pain	Total	All	182	84	46.2	38.8	53.7	184	112	60.9	53.4	68.0	179	93	52.0	44.4	59.5
		Grade 2 or 3	182	25	13.7	9.1	19.6	184	54	29.3	22.9	36.5	179	32	17.9	12.6	24.3
		Grade 3	182	1	0.5	0.0	3.0	184	10	5.4	2.6	9.8	179	6	3.4	1.2	7.2
		Medical advice	182	0	0.0	0.0	2.0	184	0	0.0	0.0	2.0	179	0	0.0	0.0	2.0
	ActHIB/Engerix B	All						184	104	56.5	49.0	63.8	13	6	46.2	19.2	74.9
		Grade 2 or 3						184	47	25.5	19.4	32.5	13	2	15.4	1.9	45.4
		Grade 3						184	9	4.9	2.3	9.1	13	0	0.0	0.0	24.7
		Medical advice						184	0	0.0	0.0	2.0	13	0	0.0	0.0	24.7
	Hexa/Pediarix/Pentacel	All	182	84	46.2	38.8	53.7	184	108	58.7	51.2	65.9	179	93	52.0	44.4	59.5
		Grade 2 or 3	182	25	13.7	9.1	19.6	184	44	23.9	17.9	30.7	179	31	17.3	12.1	23.7
		Grade 3	182	1	0.5	0.0	3.0	184	7	3.8	1.5	7.7	179	6	3.4	1.2	7.2
		Medical advice	182	0	0.0	0.0	2.0	184	0	0.0	0.0	2.0	179	0	0.0	0.0	2.0
Redness (mm)	Total	All	182	57	31.3	24.7	38.6	184	77	41.8	34.6	49.3	179	64	35.8	28.7	43.2
		>5	182	15	8.2	4.7	13.2	184	22	12.0	7.6	17.5	179	16	8.9	5.2	14.1
		>20	182	3	1.6	0.3	4.7	184	3	1.6	0.3	4.7	179	2	1.1	0.1	4.0
		Medical advice	182	0	0.0	0.0	2.0	184	0	0.0	0.0	2.0	179	0	0.0	0.0	2.0
	ActHIB/Engerix B	All						184	66	35.9	28.9	43.3	13	5	38.5	13.9	68.4
		>5						184	17	9.2	5.5	14.4	13	1	7.7	0.2	36.0
		>20						184	1	0.5	0.0	3.0	13	0	0.0	0.0	24.7
		Medical advice						184	0	0.0	0.0	2.0	13	0	0.0	0.0	24.7
	Hexa/Pediarix/Pentacel	All	182	57	31.3	24.7	38.6	184	61	33.2	26.4	40.5	179	64	35.8	28.7	43.2
		>5	182	15	8.2	4.7	13.2	184	12	6.5	3.4	11.1	179	15	8.4	4.8	13.4

117119 (DTPA-HBV-IPV-135)

												ADI	age			eport	<u>-ınaı</u>
					Hexa g			1		Pedia group				Р	enta gr		
							% CI		1			% CI		ı		95%	
Symptom	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
		>20	182	3	1.6	0.3	4.7	184	3	1.6	0.3	4.7	179	2	1.1	0.1	4.0
		Medical advice	182	0	0.0	0.0	2.0	184	0	0.0	0.0	2.0	179	0	0.0	0.0	2.0
Swelling (mm)	Total	All	182	40	22.0	16.2	28.7	184	51	27.7	21.4	34.8	179	44	24.6	18.5	31.6
		>5	182	10	5.5	2.7	9.9	184	16	8.7	5.1	13.7	179	7	3.9	1.6	7.9
		>20	182	2	1.1	0.1	3.9	184	2	1.1	0.1	3.9	179	3	1.7	0.3	4.8
		Medical advice	182	0	0.0	0.0	2.0	184	0	0.0	0.0	2.0	179	0	0.0	0.0	2.0
	ActHIB/Engerix B	All						184	40	21.7	16.0	28.4	13	3	23.1	5.0	53.8
		>5						184	11	6.0	3.0	10.4	13	0	0.0	0.0	24.7
		>20						184	1	0.5	0.0	3.0	13	0	0.0	0.0	24.7
		Medical advice						184	0	0.0	0.0	2.0	13	0	0.0	0.0	24.7
	Hexa/Pediarix/Pentacel	All	182	40	22.0	16.2	28.7	184	40	21.7	16.0	28.4	179	42	23.5	17.5	30.4
		>5	182	10	5.5	2.7	9.9	184	12	6.5	3.4	11.1	179	7	3.9	1.6	7.9
		>20	182	2	1.1	0.1	3.9	184	2	1.1	0.1	3.9	179	3	1.7	0.3	4.8
		Medical advice	182	0	0.0	0.0	2.0	184	0	0.0	0.0	2.0	179	0	0.0	0.0	2.0
	·			•	Dose	3	•	•						•			
Pain	Total	All	172	67	39.0	31.6	46.7	175	98	56.0	48.3	63.5	171	83	48.5	40.8	56.3
		Grade 2 or 3	172	18	10.5	6.3	16.0	175	45	25.7	19.4	32.9	171	28	16.4	11.2	22.8
		Grade 3	172	0	0.0	0.0	2.1	175	8	4.6	2.0	8.8	171	7	4.1	1.7	8.3
		Medical advice	172	0	0.0	0.0	2.1	175	1	0.6	0.0	3.1	171	0	0.0	0.0	2.1
	ActHIB/Engerix B	All						175	93	53.1	45.5	60.7	169	75	44.4	36.8	52.2
		Grade 2 or 3						175	41	23.4	17.4	30.4	169	25	14.8	9.8	21.1
		Grade 3						175	7	4.0	1.6	8.1	169	5	3.0	1.0	6.8
		Medical advice						175	1	0.6	0.0	3.1	169	0	0.0	0.0	2.2
	Hexa/Pediarix/Pentacel	All	172	67	39.0	31.6	46.7	175	90	51.4	43.8	59.0	170	76	44.7	37.1	52.5
		Grade 2 or 3	172	18	10.5	6.3	16.0	175	39	22.3	16.4	29.2	170	20	11.8	7.3	17.6
		Grade 3	172	0	0.0	0.0	2.1	175	7	4.0	1.6	8.1	170	7	4.1	1.7	8.3
		Medical advice	172	0	0.0	0.0	2.1	175	1	0.6	0.0	3.1	170	0	0.0	0.0	2.1
Redness (mm)	Total	All	172	63	36.6	29.4	44.3	175	81	46.3	38.7	54.0	171	65	38.0	30.7	45.7
,		>5	172	7	4.1	1.7	8.2	175	14	8.0	4.4	13.1	171	16	9.4	5.4	14.7
		>20	172	2	1.2	0.1	4.1	175	4	2.3	0.6	5.7	171	2	1.2	0.1	4.2
		Medical advice			0.0	0.0	2.1	175	1	0.6	0.0	3.1	171	0	0.0	0.0	2.1
	ActHIB/Engerix B	All						175	69	39.4	32.1	47.1	169	51	30.2	23.4	37.7
	3.	>5						175	7	4.0	1.6	8.1	169	9	5.3	2.5	9.9
	1					1		1	1.		1	12	1.00		10.0		13.0

117119 (DTPA-HBV-IPV-135)

										D. I'		AD	riage		erim R		Finai
				ŀ	łexa gr					Pedia group				P	enta gr		
	T				1		% CI					% CI			T		% CI
Symptom	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
		>20						175	1	0.6	0.0	3.1	169	2	1.2	0.1	4.2
		Medical advice						175	0	0.0	0.0	2.1	169	0	0.0	0.0	2.2
	Hexa/Pediarix/Pentacel	All	172	63	36.6	29.4	44.3	175	66	37.7	30.5	45.3	170	56	32.9	25.9	40.6
		>5	172	7	4.1	1.7	8.2	175	12	6.9	3.6	11.7	170	11	6.5	3.3	11.3
		>20	172	2	1.2	0.1	4.1	175	3	1.7	0.4	4.9	170	0	0.0	0.0	2.1
		Medical advice	172	0	0.0	0.0	2.1	175	1	0.6	0.0	3.1	170	0	0.0	0.0	2.1
Swelling (mm)	Total	All	172	43	25.0	18.7	32.2	175	53	30.3	23.6	37.7	171	44	25.7	19.4	33.0
		>5	172	7	4.1	1.7	8.2	175	12	6.9	3.6	11.7	171	8	4.7	2.0	9.0
		>20	172	1	0.6	0.0	3.2	175	3	1.7	0.4	4.9	171	0	0.0	0.0	2.1
		Medical advice	172	0	0.0	0.0	2.1	175	1	0.6	0.0	3.1	171	0	0.0	0.0	2.1
	ActHIB/Engerix B	All						175	42	24.0	17.9	31.0	169	37	21.9	15.9	28.9
		>5						175	7	4.0	1.6	8.1	169	7	4.1	1.7	8.3
		>20						175	1	0.6	0.0	3.1	169	0	0.0	0.0	2.2
		Medical advice						175	0	0.0	0.0	2.1	169	0	0.0	0.0	2.2
	Hexa/Pediarix/Pentacel	All	172	43	25.0	18.7	32.2	175	44	25.1	18.9	32.2	170	35	20.6	14.8	27.5
		>5	172	7	4.1	1.7	8.2	175	10	5.7	2.8	10.3	170	4	2.4	0.6	5.9
		>20	172	1	0.6	0.0	3.2	175	3	1.7	0.4	4.9	170	0	0.0	0.0	2.1
		Medical advice	172	0	0.0	0.0	2.1	175	1	0.6	0.0	3.1	170	0	0.0	0.0	2.1
				0	verall/c	lose		•			•		•			•	_
Pain	Total	All	539	245	45.5	41.2	49.8	548	338	61.7	57.5	65.8	538	295	54.8	50.5	59.1
		Grade 2 or 3	539	83	15.4	12.5	18.7	548	174	31.8	27.9	35.8	538	116	21.6	18.2	25.3
		Grade 3	539	9	1.7	0.8	3.1	548	42	7.7	5.6	10.2	538	25	4.6	3.0	6.8
		Medical advice	539	1	0.2	0.0	1.0	548	2	0.4	0.0	1.3	538	0	0.0	0.0	0.7
	ActHIB/Engerix B	All						548	320	58.4	54.1	62.6	370	181	48.9	43.7	54.1
		Grade 2 or 3						548	154	28.1	24.4	32.1	370	72	19.5	15.5	23.9
		Grade 3						548	38	6.9	5.0	9.4	370	15	4.1	2.3	6.6
		Medical advice						548	2	0.4	0.0	1.3	370	0	0.0	0.0	1.0
	Hexa/Pediarix/Pentacel	All	539	245	45.5	41.2	49.8	548	311	56.8	52.5	60.9	537	284	52.9	48.6	57.2
		Grade 2 or 3	539	83	15.4	12.5	18.7	548	148	27.0	23.3	30.9	537	102	19.0	15.8	22.6
		Grade 3	539	9	1.7	0.8	3.1	548	31	5.7	3.9	7.9	537	25	4.7	3.0	6.8
		Medical advice	539	1	0.2	0.0	1.0	548	1	0.2	0.0	1.0	537	0	0.0	0.0	0.7
Redness (mm)	Total	All	539	167	31.0	27.1	35.1	548	231	42.2	38.0	46.4	538	196	36.4	32.4	40.7
` /		>5	539	37	6.9	4.9	9.3	548	63	11.5	8.9	14.5	538	59	11.0	8.5	13.9

117119 (DTPA-HBV-IPV-135)

										D. P.		Ab	ridge		rim R		Final
				ŀ	Hexa gı		0/ 01			Pedia group		0/ 01		Ρ6	enta gr		/ OI
				_	0.4		% CI			104		% CI			0.1	95%	
Symptom	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
		>20	539	8	1.5	0.6	2.9	548	17	3.1	1.8	4.9	538	8	1.5	0.6	2.9
		Medical advice	539	0	0.0	0.0	0.7	548	2	0.4	0.0	1.3	538	0	0.0	0.0	0.7
	ActHIB/Engerix B	All						548	198	36.1	32.1	40.3	370	111	30.0	25.4	35.0
		>5						548	43	7.8	5.7	10.4	370	22	5.9	3.8	8.9
		>20						548	10	1.8	0.9	3.3	370	3	8.0	0.2	2.4
		Medical advice						548	1	0.2	0.0	1.0	370	0	0.0	0.0	1.0
	Hexa/Pediarix/Pentacel	All	539	167	31.0	27.1	35.1	548	183	33.4	29.5	37.5	537	177	33.0	29.0	37.1
		>5	539	37	6.9	4.9	9.3	548	39	7.1	5.1	9.6	537	46	8.6	6.3	11.3
		>20	539	8	1.5	0.6	2.9	548	10	1.8	0.9	3.3	537	5	0.9	0.3	2.2
		Medical advice	539	0	0.0	0.0	0.7	548	1	0.2	0.0	1.0	537	0	0.0	0.0	0.7
Swelling (mm)	Total	All	539	114	21.2	17.8	24.8	548	150	27.4	23.7	31.3	538	141	26.2	22.5	30.1
		>5	539	27	5.0	3.3	7.2	548	46	8.4	6.2	11.0	538	39	7.2	5.2	9.8
		>20	539	5	0.9	0.3	2.2	548	12	2.2	1.1	3.8	538	14	2.6	1.4	4.3
		Medical advice	539	0	0.0	0.0	0.7	548	2	0.4	0.0	1.3	538	0	0.0	0.0	0.7
	ActHIB/Engerix B	All						548	123	22.4	19.0	26.2	370	79	21.4	17.3	25.9
		>5						548	32	5.8	4.0	8.1	370	21	5.7	3.5	8.5
		>20						548	8	1.5	0.6	2.9	370	3	0.8	0.2	2.4
		Medical advice						548	1	0.2	0.0	1.0	370	0	0.0	0.0	1.0
	Hexa/Pediarix/Pentacel	All	539	114	21.2	17.8	24.8	548	119	21.7	18.3	25.4	537	122	22.7	19.2	26.5
		>5	539	27	5.0	3.3	7.2	548	36	6.6	4.6	9.0	537	35	6.5	4.6	8.9
		>20	539	5	0.9	0.3	2.2	548	8	1.5	0.6	2.9	537	14	2.6	1.4	4.3
		Medical advice	539	0	0.0	0.0	0.7	548	1	0.2	0.0	1.0	537	0	0.0	0.0	0.7
				Ov	erall/su	bject			- I	<u> </u>		1	I				II.
Pain	Total	All	187	127	67.9	60.7	74.5	189	155	82.0	75.8	87.2	188	150	79.8	73.3	85.3
		Grade 2 or 3	187	58	31.0	24.5	38.2	189	104	55.0	47.6	62.3	188	88	46.8	39.5	54.2
		Grade 3	187	8	4.3	1.9	8.3	189	34	18.0	12.8	24.2	188	22	11.7	7.5	17.2
		Medical advice	187	1	0.5	0.0	2.9	189	2	1.1	0.1	3.8	188	0	0.0	0.0	1.9
	ActHIB/Engerix B	All						189	148	78.3	71.7	84.0	188	127	67.6	60.4	74.2
		Grade 2 or 3						189	96	50.8	43.4	58.1	188	62	33.0	26.3	40.2
		Grade 3						189	30	15.9	11.0	21.9	188	14	7.4	4.1	12.2
		Medical advice						189	2	1.1	0.1	3.8	188	0	0.0	0.0	1.9
	Hexa/Pediarix/Pentacel	All	187	127	67.9	60.7	74.5	189	151	79.9	73.5	85.4	188	147	78.2	71.6	83.9
		Grade 2 or 3	187	58	31.0	24.5	38.2	189	93	49.2	41.9	56.6	188	80	42.6	35.4	50.0
		0.000 2 01 0	1.01	55	0		55.L	1.55	100		1	00.0	. 50		0	55. 1	30.0

117119 (DTPA-HBV-IPV-135)

Abridged Interim Report Final

					Hexa gr	oup				Pedia group					enta gr		
							% CI					% CI					% CI
Symptom	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
-		Grade 3	187	8	4.3	1.9	8.3	189	27	14.3	9.6	20.1	188	22	11.7	7.5	17.2
		Medical advice	187	1	0.5	0.0	2.9	189	1	0.5	0.0	2.9	188	0	0.0	0.0	1.9
Redness (mm)	Total	All	187	93	49.7	42.4	57.1	189	120	63.5	56.2	70.4	188	106	56.4	49.0	63.6
		>5	187	27	14.4	9.7	20.3	189	49	25.9	19.8	32.8	188	45	23.9	18.0	30.7
		>20	187	7	3.7	1.5	7.6	189	15	7.9	4.5	12.8	188	8	4.3	1.9	8.2
		Medical advice	187	0	0.0	0.0	2.0	189	2	1.1	0.1	3.8	188	0	0.0	0.0	1.9
	ActHIB/Engerix B	All						189	108	57.1	49.8	64.3	188	77	41.0	33.9	48.3
		>5						189	38	20.1	14.6	26.5	188	20	10.6	6.6	16.0
		>20						189	10	5.3	2.6	9.5	188	3	1.6	0.3	4.6
		Medical advice						189	1	0.5	0.0	2.9	188	0	0.0	0.0	1.9
	Hexa/Pediarix/Pentacel	All	187	93	49.7	42.4	57.1	189	98	51.9	44.5	59.2	188	97	51.6	44.2	58.9
		>5	187	27	14.4	9.7	20.3	189	32	16.9	11.9	23.1	188	37	19.7	14.3	26.1
		>20	187	7	3.7	1.5	7.6	189	9	4.8	2.2	8.8	188	5	2.7	0.9	6.1
		Medical advice	187	0	0.0	0.0	2.0	189	1	0.5	0.0	2.9	188	0	0.0	0.0	1.9
Swelling (mm)	Total	All	187	72	38.5	31.5	45.9	189	88	46.6	39.3	53.9	188	81	43.1	35.9	50.5
		>5	187	20	10.7	6.7	16.0	189	34	18.0	12.8	24.2	188	29	15.4	10.6	21.4
		>20	187	4	2.1	0.6	5.4	189	11	5.8	2.9	10.2	188	12	6.4	3.3	10.9
		Medical advice	187	0	0.0	0.0	2.0	189	2	1.1	0.1	3.8	188	0	0.0	0.0	1.9
	ActHIB/Engerix B	All						189	78	41.3	34.2	48.6	188	64	34.0	27.3	41.3
		>5						189	25	13.2	8.7	18.9	188	18	9.6	5.8	14.7
		>20						189	7	3.7	1.5	7.5	188	3	1.6	0.3	4.6
		Medical advice						189	1	0.5	0.0	2.9	188	0	0.0	0.0	1.9
	Hexa/Pediarix/Pentacel	All	187	72	38.5	31.5	45.9	189	70	37.0	30.1	44.3	188	72	38.3	31.3	45.7
		>5	187	20	10.7	6.7	16.0	189	26	13.8	9.2	19.5	188	26	13.8	9.2	19.6
		>20	187	4	2.1	0.6	5.4	189	7	3.7	1.5	7.5	188	12	6.4	3.3	10.9
		Medical advice	187	0	0.0	0.0	2.0	189	1	0.5	0.0	2.9	188	0	0.0	0.0	1.9

Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Pedia group = Subjects who received Pediarix, ActHIB and Prevnar 13 at 2, 4 and 6 month of age and Rotarix at 2 and 4 months of age

Penta group = Subjects who received *Pentacel*, *Engerix* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age For each dose and overall/subject:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the symptom at least once

For Overall/dose:

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

N = number of documented doses

n/% = number/percentage of doses followed by at least one type of symptom 95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit All = all reports of the specified symptom irrespective of intensity grade Grade2*3=Grade 2 or Grade 3

Grade 2 For Pain: Moderate: Moderate: Cries/protests on touch

For Redness/Swelling: >5 mm but ≤ 20 mm

Grade 3 For Pain= Severe: Cries when limb is moved/spontaneously painful.

For Redness/Swelling: >20 mm

117119 (DTPA-HBV-IPV-135)

Table 10 Number (%) of subjects reporting solicited general symptoms during the 4-day (Days 0-3) post-vaccination period following each dose and overall (Primary TVC)

			Н	exa gr	oup			Pedia	group				Pe	enta grou	р	
						% CI				95%						5% CI
										CI						
Symptom	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
						Dose 1										
Drowsiness	All	185	114	61.6	54.2	68.7	189	143	75.7	68.9	81.6	188	149	79.3	72.8	84.8
	Grade 2 or 3	185	36	19.5	14.0	25.9	189	56	29.6	23.2	36.7	188	53	28.2	21.9	35.2
	Grade 3	185	3	1.6	0.3	4.7	189	8	4.2	1.8	8.2	188	12	6.4	3.3	10.9
	Related	185	112	60.5	53.1	67.6	189	136	72.0	65.0	78.2	188	141	75.0	68.2	81.0
	Grade 3 Related	185	3	1.6	0.3	4.7	189	7	3.7	1.5	7.5	188	12	6.4	3.3	10.9
	Medical advice	185	1	0.5	0.0	3.0	189	0	0.0	0.0	1.9	188	0	0.0	0.0	1.9
Irritability / Fussiness	All	185	115	62.2	54.8	69.2	189	165	87.3	81.7	91.7	188	153	81.4	75.1	86.7
	Grade 2 or 3	185	42	22.7	16.9	29.4	189	79	41.8	34.7	49.2	188	68	36.2	29.3	43.5
	Grade 3	185	9	4.9	2.2	9.0	189	17	9.0	5.3	14.0	188	15	8.0	4.5	12.8
	Related	185	113	61.1	53.7	68.1	189	163	86.2	80.5	90.8	188	147	78.2	71.6	83.9
	Grade 3 Related	185	9	4.9	2.2	9.0	189	17	9.0	5.3	14.0	188	15	8.0	4.5	12.8
	Medical advice	185	1	0.5	0.0	3.0	189	0	0.0	0.0	1.9	188	0	0.0	0.0	1.9
Loss Of Appetite	All	185	53	28.6	22.3	35.7	189	76	40.2	33.2	47.6	188	80	42.6	35.4	50.0
	Grade 2 or 3	185	8	4.3	1.9	8.3	189	13	6.9	3.7	11.5	188	26	13.8	9.2	19.6
	Grade 3	185	0	0.0	0.0	2.0	189	1	0.5	0.0	2.9	188	4	2.1	0.6	5.4
	Related	185	48	25.9	19.8	32.9	189	73	38.6	31.6	46.0	188	77	41.0	33.9	48.3
	Grade 3 Related	185	0	0.0	0.0	2.0	189	1	0.5	0.0	2.9	188	4	2.1	0.6	5.4
	Medical advice	185	0	0.0	0.0	2.0	189	0	0.0	0.0	1.9	188	0	0.0	0.0	1.9
Temperature(°C)	All	185	22	11.9	7.6	17.4	189	34	18.0	12.8	24.2	188	29	15.4	10.6	21.4
	>39.0	185	0	0.0	0.0	2.0	189	0	0.0	0.0	1.9	188	2	1.1	0.1	3.8
	>40.0	185	0	0.0	0.0	2.0	189	0	0.0	0.0	1.9	188	0	0.0	0.0	1.9
	Related	185	15	8.1	4.6	13.0	189	31	16.4	11.4	22.5	188	27	14.4	9.7	20.2
	>40.0 Related	185	0	0.0	0.0	2.0	189	0	0.0	0.0	1.9	188	0	0.0	0.0	1.9
	Medical advice	185	0	0.0	0.0	2.0	189	0	0.0	0.0	1.9	188	0	0.0	0.0	1.9
	·				•	Dose 2	2		•	•	•		•			-
Drowsiness	All	182	97	53.3	45.8	60.7	184	132	71.7	64.6	78.1	179	109	60.9	53.3	68.1
10110111333	Grade 2 or 3	182	31	17.0	11.9	23.3	184	43	23.4	17.5	30.2	179	39	21.8	16.0	28.6
	Grade 3	182	8	4.4	1.9	8.5	184	7	3.8	1.5	7.7	179	4	2.2	0.6	5.6

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

				1				D ::						1 -		dged Inte
			Н	lexa gr		۰٬ ۵۱		Pedia	a group				Pe	enta grou		F0/ OI
					95	% CI				95% CI					9	5% CI
Symptom	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
- / ·	Related	182	94	51.6	44.1	59.1	184	126	68.5	61.2	75.1	179	108	60.3	52.8	67.6
	Grade 3 Related	182	7	3.8	1.6	7.8	184	7	3.8	1.5	7.7	179	3	1.7	0.3	4.8
	Medical advice	182	0	0.0	0.0	2.0	184	0	0.0	0.0	2.0	179	0	0.0	0.0	2.0
Irritability / Fussiness	All	182	128	70.3	63.1	76.9	184	147	79.9	73.4	85.4	179	136	76.0	69.0	82.0
•	Grade 2 or 3	182	53	29.1	22.6	36.3	184	70	38.0	31.0	45.5	179	61	34.1	27.2	41.5
	Grade 3	182	6	3.3	1.2	7.0	184	14	7.6	4.2	12.4	179	11	6.1	3.1	10.7
	Related	182	125	68.7	61.4	75.3	184	143	77.7	71.0	83.5	179	133	74.3	67.2	80.5
	Grade 3 Related	182	6	3.3	1.2	7.0	184	13	7.1	3.8	11.8	179	11	6.1	3.1	10.7
	Medical advice	182	0	0.0	0.0	2.0	184	0	0.0	0.0	2.0	179	2	1.1	0.1	4.0
Loss Of Appetite	All	182	56	30.8	24.2	38.0	184	55	29.9	23.4	37.1	179	56	31.3	24.6	38.6
	Grade 2 or 3	182	17	9.3	5.5	14.5	184	15	8.2	4.6	13.1	179	15	8.4	4.8	13.4
	Grade 3	182	1	0.5	0.0	3.0	184	1	0.5	0.0	3.0	179	2	1.1	0.1	4.0
	Related	182	52	28.6	22.1	35.7	184	51	27.7	21.4	34.8	179	55	30.7	24.1	38.0
	Grade 3 Related	182	1	0.5	0.0	3.0	184	1	0.5	0.0	3.0	179	2	1.1	0.1	4.0
	Medical advice	182	0	0.0	0.0	2.0	184	0	0.0	0.0	2.0	179	1	0.6	0.0	3.1
Temperature(°C)	All	182	47	25.8	19.6	32.8	184	36	19.6	14.1	26.0	179	34	19.0	13.5	25.5
	>39.0	182	2	1.1	0.1	3.9	184	3	1.6	0.3	4.7	179	2	1.1	0.1	4.0
	>40.0	182	0	0.0	0.0	2.0	184	0	0.0	0.0	2.0	179	0	0.0	0.0	2.0
	Related	182	37	20.3	14.7	26.9	184	32	17.4	12.2	23.7	179	32	17.9	12.6	24.3
	>40.0 Related	182	0	0.0	0.0	2.0	184	0	0.0	0.0	2.0	179	0	0.0	0.0	2.0
	Medical advice	182	0	0.0	0.0	2.0	184	0	0.0	0.0	2.0	179	0	0.0	0.0	2.0
						Dose 3	3								•	
Drowsiness	All	172	86	50.0	42.3	57.7	175	108	61.7	54.1	68.9	170	88	51.8	44.0	59.5
	Grade 2 or 3	172	24	14.0	9.1	20.0	175	37	21.1	15.3	27.9	170	25	14.7	9.7	20.9
	Grade 3	172	3	1.7	0.4	5.0	175	5	2.9	0.9	6.5	170	9	5.3	2.4	9.8
	Related	172	82	47.7	40.0	55.4	175	106	60.6	52.9	67.9	170	86	50.6	42.8	58.3
	Grade 3 Related	172	3	1.7	0.4	5.0	175	5	2.9	0.9	6.5	170	9	5.3	2.4	9.8
	Medical advice	172	0	0.0	0.0	2.1	175	2	1.1	0.1	4.1	170	1	0.6	0.0	3.2
Irritability / Fussiness	All	172	126	73.3	66.0	79.7	175	135	77.1	70.2	83.1	170	122	71.8	64.4	78.4
-	Grade 2 or 3	172	46	26.7	20.3	34.0	175	58	33.1	26.2	40.6	170	58	34.1	27.0	41.8
	Grade 3	172	6	3.5	1.3	7.4	175	15	8.6	4.9	13.7	170	11	6.5	3.3	11.3
	Related	172	121	70.3	62.9	77.1	175	130	74.3	67.1	80.6	170	120	70.6	63.1	77.3

117119 (DTPA-HBV-IPV-135)

				- W				Dadia					D	mto avou		dged Inter
			П	exa gr		% CI		Peul	a group	95%			Pt	enta grou		5% CI
					95	% CI				CI					9	5% CI
Symptom	Туре	N	n	%	LL	UL	N	n	%	LL.	UL	N	n	%	LL	UL
	Grade 3 Related	172	6	3.5	1.3	7.4	175	13	7.4	4.0	12.4	170	11	6.5	3.3	11.3
	Medical advice	172	0	0.0	0.0	2.1	175	3	1.7	0.4	4.9	170	1	0.6	0.0	3.2
Loss Of Appetite	All	172	46	26.7	20.3	34.0	175	58	33.1	26.2	40.6	170	53	31.2	24.3	38.7
• •	Grade 2 or 3	172	11	6.4	3.2	11.2	175	13	7.4	4.0	12.4	170	15	8.8	5.0	14.1
	Grade 3	172	1	0.6	0.0	3.2	175	2	1.1	0.1	4.1	170	2	1.2	0.1	4.2
	Related	172	44	25.6	19.2	32.8	175	57	32.6	25.7	40.1	170	52	30.6	23.8	38.1
	Grade 3 Related	172	1	0.6	0.0	3.2	175	2	1.1	0.1	4.1	170	2	1.2	0.1	4.2
	Medical advice	172	0	0.0	0.0	2.1	175	1	0.6	0.0	3.1	170	0	0.0	0.0	2.1
Temperature/(Rectal) (°C	All	172	40	23.3	17.2	30.3	175	45	25.7	19.4	32.9	170	37	21.8	15.8	28.7
	>39.0	172	4	2.3	0.6	5.8	175	11	6.3	3.2	11.0	170	7	4.1	1.7	8.3
	>40.0	172	0	0.0	0.0	2.1	175	2	1.1	0.1	4.1	170	0	0.0	0.0	2.1
	Related	172	35	20.3	14.6	27.1	175	39	22.3	16.4	29.2	170	35	20.6	14.8	27.5
	>40.0 Related	172	0	0.0	0.0	2.1	175	2	1.1	0.1	4.1	170	0	0.0	0.0	2.1
	Medical advice	172	1	0.6	0.0	3.2	175	2	1.1	0.1	4.1	170	1	0.6	0.0	3.2
						erall/d										
Drowsiness	All	539	297	55.1	50.8	59.4	548	383	69.9	65.9	73.7	537	346	64.4	60.2	68.5
	Grade 2 or 3	539	91	16.9	13.8	20.3	548	136	24.8	21.3	28.7	537	117	21.8	18.4	25.5
	Grade 3	539	14	2.6	1.4	4.3	548	20	3.6	2.2	5.6	537	25	4.7	3.0	6.8
	Related	539	288	53.4	49.1	57.7	548	368	67.2	63.0	71.1	537	335	62.4	58.1	66.5
	Grade 3 Related	539	13	2.4	1.3	4.1	548	19	3.5	2.1	5.4	537	24	4.5	2.9	6.6
	Medical advice	539	1	0.2	0.0	1.0	548	2	0.4	0.0	1.3	537	1	0.2	0.0	1.0
Irritability / Fussiness	All	539	369	68.5	64.4	72.4	548	447	81.6	78.1	84.7	537	411	76.5	72.7	80.1
	Grade 2 or 3	539	141	26.2	22.5	30.1	548	207	37.8	33.7	42.0	537	187	34.8	30.8	39.0
	Grade 3	539	21	3.9	2.4	5.9	548	46	8.4	6.2	11.0	537	37	6.9	4.9	9.4
	Related	539	359	66.6	62.4	70.6	548	436	79.6	75.9	82.9	537	400	74.5	70.6	78.1
	Grade 3 Related	539	21	3.9	2.4	5.9	548	43	7.8	5.7	10.4	537	37	6.9	4.9	9.4
	Medical advice	539	1	0.2	0.0	1.0	548	3	0.5	0.1	1.6	537	3	0.6	0.1	1.6
Loss Of Appetite	All	539	155	28.8	25.0	32.8	548	189	34.5	30.5	38.6	537	189	35.2	31.2	39.4
	Grade 2 or 3	539	36	6.7	4.7	9.1	548	41	7.5	5.4	10.0	537	56	10.4	8.0	13.3
	Grade 3	539	2	0.4	0.0	1.3	548	4	0.7	0.2	1.9	537	8	1.5	0.6	2.9
	Related	539	144	26.7	23.0	30.7	548	181	33.0	29.1	37.1	537	184	34.3	30.3	38.4
	Grade 3 Related	539	2	0.4	0.0	1.3	548	4	0.7	0.2	1.9	537	8	1.5	0.6	2.9

117119 (DTPA-HBV-IPV-135)

			Н	lexa gr	oup			Pedia	group)			Pe	enta group		agea Inter
				J.		% CI			. J	95%				3		5% CI
										CI						
Symptom	Type	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
	Medical advice	539	0	0.0	0.0	0.7	548	1	0.2	0.0	1.0	537	1	0.2	0.0	1.0
Temperature(°C)	All	539	109	20.2	16.9	23.9	548	115	21.0	17.6	24.6	537	100	18.6	15.4	22.2
	>39.0	539	6	1.1	0.4	2.4	548	14	2.6	1.4	4.2	537	11	2.0	1.0	3.6
I	>40.0	539	0	0.0	0.0	0.7	548	2	0.4	0.0	1.3	537	0	0.0	0.0	0.7
	Related	539	87	16.1	13.1	19.5	548	102	18.6	15.4	22.1	537	94	17.5	14.4	21.0
	>40.0 Related	539	0	0.0	0.0	0.7	548	2	0.4	0.0	1.3	537	0	0.0	0.0	0.7
	Medical advice	539	1	0.2	0.0	1.0	548	2	0.4	0.0	1.3	537	1	0.2	0.0	1.0
						rall/su	bject									
Drowsiness	All	187	148	79.1	72.6	84.7	189	172	91.0	86.0	94.7	188	168	89.4	84.0	93.4
1	Grade 2 or 3	187	67	35.8	29.0	43.2	189	88	46.6	39.3	53.9	188	81	43.1	35.9	50.5
	Grade 3	187	11	5.9	3.0	10.3	189	19	10.1	6.2	15.3	188	22	11.7	7.5	17.2
1	Related	187	145	77.5	70.9	83.3	189	170	89.9	84.7	93.8	188	166	88.3	82.8	92.5
	Grade 3 Related	187	11	5.9	3.0	10.3	189	18	9.5	5.7	14.6	188	21	11.2	7.0	16.6
	Medical advice	187	1	0.5	0.0	2.9	189	2	1.1	0.1	3.8	188	1	0.5	0.0	2.9
Irritability / Fussiness	All	187	164	87.7	82.1	92.0	189	182	96.3	92.5	98.5	188	177	94.1	89.8	97.0
	Grade 2 or 3	187	96	51.3	43.9	58.7	189	128	67.7	60.6	74.3	188	120	63.8	56.5	70.7
1	Grade 3	187	18	9.6	5.8	14.8	189	35	18.5	13.3	24.8	188	30	16.0	11.0	22.0
1	Related	187	161	86.1	80.3	90.7	189	180	95.2	91.2	97.8	188	175	93.1	88.5	96.3
1	Grade 3 Related	187	18	9.6	5.8	14.8	189	34	18.0	12.8	24.2	188	30	16.0	11.0	22.0
	Medical advice	187	1	0.5	0.0	2.9	189	3	1.6	0.3	4.6	188	3	1.6	0.3	4.6
Loss Of Appetite	All	187	95	50.8	43.4	58.2	189	111	58.7	51.4	65.8	188	117	62.2	54.9	69.2
	Grade 2 or 3	187	28	15.0	10.2	20.9	189	32	16.9	11.9	23.1	188	39	20.7	15.2	27.2
	Grade 3	187	2	1.1	0.1	3.8	189	3	1.6	0.3	4.6	188	6	3.2	1.2	6.8
	Related	187	91	48.7	41.3	56.1	189	109	57.7	50.3	64.8	188	116	61.7	54.3	68.7
	Grade 3 Related	187	2	1.1	0.1	3.8	189	3	1.6	0.3	4.6	188	6	3.2	1.2	6.8
	Medical advice	187	0	0.0	0.0	2.0	189	1	0.5	0.0	2.9	188	1	0.5	0.0	2.9
Temperature (°C)	All	187	72	38.5	31.5	45.9	189	78	41.3	34.2	48.6	188	71	37.8	30.8	45.1
. ,	>39.0	187	6	3.2	1.2	6.9	189	14	7.4	4.1	12.1	188	10	5.3	2.6	9.6
	>40.0	187	0	0.0	0.0	2.0	189	2	1.1	0.1	3.8	188	0	0.0	0.0	1.9
	Related	187	61	32.6	26.0	39.8	189	74	39.2	32.2	46.5	188	68	36.2	29.3	43.5
	>40.0 Related	187	0	0.0	0.0	2.0	189	2	1.1	0.1	3.8	188	0	0.0	0.0	1.9
	Medical advice	187	1	0.5	0.0	2.9	189	2	1.1	0.1	3.8	188	1	0.5	0.0	2.9

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Hexa group = Subjects who received three doses of Infanrix Hexa and Prevnar 13 at 2, 4 and 6 month of age and Rotarix at 2 and 4 months of age

Pedia group = Subjects who received Pediarix, ActHIB and Prevnar 13 at 2, 4 and 6 month of age and Rotarix at 2 and 4 months of age

Penta group = Subjects who received Pentacel, Engerix and Prevnar 13 at 2, 4 and 6 month of age and Rotarix at 2 and 4 months of age

For each dose and overall/subject:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the symptom at least once

For Overall/dose:

N = number of documented doses

n/% = number/percentage of doses followed by at least one type of symptom

95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

All = all reports of the specified symptom irrespective of intensity grade

Related = Symptoms which is assessed by the investigator as related to vaccination

Grade 3 For Drowsiness: Severe: Drowsiness that prevents normal activity

For Irritability: Severe: Crying that cannot be comforted/prevents normal activity

For Loss of appetite: Severe: Not eating at all

For Temperature: >40.0 °C

19-OCT-2015 dafda7af3e6c4ed536d0d70018480a46455eaaa5

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Table 11 Number (%) of subjects with adverse events reported during 31-day (Days 0-30) post-vaccination period (Primary TVC)

System Organ Class	Most frequent adverse events-	Hexa group	Pedia	Penta
	On-Therapy (occurring within day 0-	N = 195	group	group
	30 following vaccination)		N = 194	N = 196
	Subjects with any AE(s), n (%)	111 (56.9)	108 (55.7)	96 (49.0)
Infections and infestations	Upper respiratory tract infection	29 (14.9)	23 (11.9)	26 (13.3)
General disorders and administration site	Pyrexia	11 (5.6)	5 (2.6)	15 (7.7)
conditions				
Respiratory, thoracic and mediastinal	Cough	15 (7.7)	7 (3.6)	7 (3.6)
disorders				
Gastrointestinal disorders	Vomiting	9 (4.6)	8 (4.1)	10 (5.1)
Infections and infestations	Otitis media	9 (4.6)	7 (3.6)	9 (4.6)
Gastrointestinal disorders	Diarrhoea	6 (3.1)	5 (2.6)	10 (5.1)
Gastrointestinal disorders	Teething	5 (2.6)	8 (4.1)	8 (4.1)
Infections and infestations	Conjunctivitis	10 (5.1)	8 (4.1)	-
General disorders and administration site	Injection site pain	4 (2.1)	6 (3.1)	7 (3.6)
conditions				
Skin and subcutaneous tissue disorders	Dermatitis diaper	-	-	9 (4.6)
Skin and subcutaneous tissue disorders	Eczema	4 (2.1)	5 (2.6)	-
Gastrointestinal disorders	Gastrooesophageal reflux disease	-	8 (4.1)	-
Gastrointestinal disorders	Constipation	-	-	6 (3.1)
Respiratory, thoracic and mediastinal	Nasal congestion	-	6 (3.1)	-
disorders				
Skin and subcutaneous tissue disorders	Rash	-	-	6 (3.1)
General disorders and administration site	Injection site erythema	4 (2.1)	-	-
conditions				
General disorders and administration site	Injection site swelling	4 (2.1)	-	-
conditions				
Psychiatric disorders	Irritability	4 (2.1)	-	-

Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Pedia group = Subjects who received *Pediarix, ActHIB* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Penta group = Subjects who received *Pentacel, Engerix* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

-: Adverse event absent or not meeting the selected rule(s)

Detail of rule:

Display 10 most frequent primary preferred terms

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Table 12 Number (%) of subjects with new onset of chronic illness (NOCD) events reported till DBF date (19Jun2015) for Primary Epoch analysis (Primary TVC)

System Organ Class	Most frequent adverse events-	Hexa	Pedia	Penta
	On-Therapy (occurring within day 0-	group	group	group
	9999 following vaccination)	N = 195	N = 194	N = 196
	Subjects with any AE(s), n (%)	4 (2.1)	2 (1.0)	3 (1.5)
Skin and subcutaneous tissue disorders	Dermatitis atopic	2 (1.0)	-	2 (1.0)
Respiratory, thoracic and mediastinal	Bronchial hyperreactivity	2 (1.0)	-	-
disorders				
Respiratory, thoracic and mediastinal	Asthma	-	-	1 (0.5)
disorders				
Immune system disorders	Drug hypersensitivity	-	1 (0.5)	-
Immune system disorders	Food allergy	-	-	1 (0.5)
Immune system disorders	Hypersensitivity	-	1 (0.5)	-

Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Pedia group = Subjects who received *Pediarix*, *ActHIB* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Penta group = Subjects who received *Pentacel*, *Engerix* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

-: Adverse event absent or not meeting the selected rule(s)

Detail of rule:

Display 10 most frequent primary preferred terms

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

Table 13 Number (%) of subjects with serious adverse events reported till DBF date (19Jun2015) for Primary Epoch analysis (Primary TVC)

System Organ Class	All SAEs	Hexa	Pedia	Penta
		group N = 195	group N = 194	group N = 196
	Subjects with any SAE(s), n (%) [n assessed by the investigator as related]	7 (3.6) [2]	1 (0.5) [0]	7 (3.6) [0]
Infections and infestations	Gastroenteritis viral	1 (0.5) [0]	1 (0.5) [0]	0 (0.0) [0]
Infections and infestations	Parainfluenzae virus infection	0 (0.0) [0]	0 (0.0) [0]	2 (1.0) [0]
Respiratory, thoracic and mediastinal disorders	Respiratory distress	2 (1.0) [0]	0 (0.0) [0]	0 (0.0) [0]
Infections and infestations	Respiratory syncytial virus bronchiolitis	1 (0.5) [0]	0 (0.0) [0]	1 (0.5) [0]
Respiratory, thoracic and mediastinal disorders	Apparent life threatening event	1 (0.5) [1]	0 (0.0) [0]	0 (0.0) [0]
Respiratory, thoracic and mediastinal disorders	Choking	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Metabolism and nutrition disorders	Dehydration	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Nervous system disorders	Febrile convulsion	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Gastrointestinal disorders	Gastrooesophageal reflux disease	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Respiratory, thoracic and mediastinal disorders	Нурохіа	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Nervous system disorders	Lethargy	1 (0.5) [1]	0 (0.0) [0]	0 (0.0) [0]
Blood and lymphatic system disorders	Leukocytosis	1 (0.5) [1]	0 (0.0) [0]	0 (0.0) [0]
Infections and infestations	Meningitis viral	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
Psychiatric disorders	Mental status changes	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Infections and infestations	Pneumonia	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Infections and infestations	Respiratory syncytial virus infection	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Injury, poisoning and procedural complications	Road traffic accident	0 (0.0) [0]	0 (0.0) [0]	1 (0.5) [0]
Nervous system disorders	Seizure	1 (0.5) [0]	0 (0.0) [0]	0 (0.0) [0]
	Fatal SAEs	Hexa	Pedia	Penta
		group	group	group
	Subjects with fatal SAE(s), n (%) [n	0 (0.0) [0]	0 (0.0) [0]	0 (0.0) [0]
	assessed by the investigator as related]			

Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Pedia group = Subjects who received *Pediarix*, *ActHIB* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Penta group = Subjects who received *Pentacel*, *Engerix* and *Prevnar* 13 at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

Hexa group = Subjects who received three doses of *Infanrix Hexa* and *Prevnar 13* at 2, 4 and 6 month of age and *Rotarix* at 2 and 4 months of age

2. STUDY REPORT AUTHORS /CONTRIBUTING AUTHORS

Scientific Writer: PPD

Lead Statistician: PPD

Project Statistician: PPD

Study Delivery Lead: PPD

Study Delivery Manager: PPD

Synteract HCR, Inc., contractor for GSK Biologicals.

Central Safety Contact: PPD

Clinical Research and Development Lead (CRDL): PPD

Regulatory Affairs representative: PPD

Project CRDL: PPD

3. SERIOUS ADVERSE EVENTS

3.1. SAE Listings

SAE listings were not generated for this interim timepoint.

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

GlaxoSmithKline Biologicals Vaccine Value and Health Science Sponsor Signatory Approval Page

Please note that by signing this page, you take responsibility for the content of the Abridged Interim Study Report.

STUDY TITLE: A Phase III, randomized, open-label, controlled, multi-center study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexaTM vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar[®] and RotarixTM with a booster dose of GSK Biologicals' Infanrix[®] and HiberixTM vaccines at 15-18 months of age.

Study: 117119 (DTPA-HBV-IP)	V-135) Development Phase: III			
I have read this report and confidescribes the conduct and result	irm that to the best of my knowledge it accurately is of the study.			
Name of Sponsor Signatory:	Narcisa Elena Mesaros, MD.			
Title of Sponsor Signatory:	Project level Clinical Research and Development Lead, DTP/Polio Vaccines, Late Clinical Development, Vaccine Discovery and Development, GlaxoSmithKline Biologicals, SA.			
Signature:				
Date:				
For internal use only				
!Ver.!Cre c2fcc169f3911cd6c9ecfe54ch699e25288cddb7				

dafda7af3e6c4ed536d0d70018480a46455eaaa5 1.0 11/3/2015 12:53:28 PM - -

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Abridged Interim Report Final

GlaxoSmithKline Biologicals Vaccine Value and Health Science Sponsor Signatory Approval Page

Please note that by signing this page, you take responsibility for the content of the Abridged Interim Study Report.

STUDY TITLE: A Phase III, randomized, open-label, controlled, multi-center study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexaTM vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar[®] and RotarixTM with a booster dose of GSK Biologicals' Infanrix[®] and HiberixTM vaccines at 15-18 months of age.

Development Phase: III

I have read this report and confirm that to the best of my knowledge it accurately describes the conduct and results of the study.

Name of Sponsor Signatory:

Narcisa Elena Mesaros, MD.

Project level Clinical Research and Development Lead,
DTP/Polio Vaccines,
Late Clinical Development,
Vaccine Discovery and Development,
GlaxoSmithKline Biologicals, SA.

PPD

Signature:

5 NOV 2015

for internal use only
!Ver.!Created On
2fcc169f3911cd6c9ecfe54cb699e25288cddb7 1.0 11/3/2015 12:53:26 PM
lafda7af3e6c4ed536d0d70018480a46455eaaa5 1.0 11/3/2015 12:53:28 PM +

Study: 117119 (DTPA-HBV-IPV-135)

Date:

Annotated Study Book for Study Design: DTPA-HBV-IPV-135 (117119)

Study Design Version: 1.0

Sponsor: GlaxoSmithKline Vaccines

Protocol: DTPA-HBV-IPV-135 (117119)

Generic Drug Name: DTPA-HBV-IPV Vaccine

Trade Drug Name: Infanrix Hexa

A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa™ vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar® and Rotarix™ with a booster dose of GSK Biologicals' Infanrix® and Hiberix™ vaccines at 15-18 months of age.

Generated by Central Designer $^{\mathsf{TM}}$

January 2, 2017 10:31

DT	DTPA-HBV-IPV-135 (117119): SCREENING (Screening) [frmscreening]			
SCI	REENING [sctSCR]			
1. Initials: [hidden] [txtScrSINIT: Not submitted - for internal use] [Initials] [A3]				
2.* Please tick box to confirm CRF creation: [itmCRF_FLG: Not submitted - for internal use]		[itmCRF_FLG: Not submitted - for internal use]		
	Key: [*] = Item is required [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.			

DTP	DTPA-HBV-IPV-135 (117119): ENROLLMENT (Enrollment) [frmenrollment]			
ENRO	ENROLLMENT [sctenrollment]			
1.* Subject Number: [itmPID : Not submitted - for internal use] [Subj Nr] [N9]		[itmPID: Not submitted - for internal use] N9		
1 '	Key: [*] = Item is required [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.			

DTPA	DTPA-HBV-IPV-135 (117119): SUBJECT IDENTIFICATION (Subj ID) [frmpatientidentification]			
SUBJE	SUBJECT IDENTIFICATION [sctPATIENTIDENTIFICATION]			
1.* Subject Number: [itmPID : PID_SCHD.ITMPID] N9				
	Key: [*] = Item is required [♥] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.			

DI	DTPA-HBV-IPV-135 (117119): DEMOGRAPHICS (Demog) [frmDEMOGRAPHY]					
DE	MOGRAPHICS [sctDEMOGRAPHY]					
1.*	Date of birth: [DOB]	[itmDOB_RAW: DEMOG.DOB_RAW] Req/Unk / Req (2013-2018)				
2.	Date of Birth for OCEANS (DO NOT delete) [hidden]	[itmBIRTHDT_HID: Not submitted - for internal use] NReq / NReq / NReq (2013-2018)				
3.* •	Gender: [Gender]	[itmSEX : DEMOG.SEX] Male Female				
4.* •	Ethnicity: [Ethnicity]	[itmETHNIC: DEMOG.ETHNIC] American Hispanic or Latino Not American Hispanic or Latino				
5.* •	Geographic Ancestry: [Geographic Ancestry]	[itmRACE: DEMOG.RACE] African Heritage / African American American Indian or Alaskan Native Asian - Central/South Asian Heritage Asian - East Asian Heritage Asian - Japanese Heritage Asian - South East Asian Heritage Native Hawaiian or Other Pacific Islander White - Arabic / North African Heritage White - Caucasian / European Heritage [itmRACE_OTH: DEMOG.RACE_OTH] Other, Specify: A40				
6.	Weight for OCEANS (Do not delete) [hidden]	[itmWEIGHT_HID: Not submitted - for internal use] XXXX.				
	Please specify subject group: [Please specify subject group:]	[itmSUBSET: CRIT_VAL.VALUE] HEXA GROUP PEDIA GROUP PENTA GROUP				
	 Key: [*] = Item is required [♥] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer. 					

D1	DTPA-HBV-IPV-135 (117119): INFORMED CONSENT (IC) [frmINFORMEDCONSENT]			
DA	TE OF VISIT [sctDATEOFVISIT]			
	Date of visit: [DOV]	[itmACTRDATE: ACTDATES.ACTRDATE] Req / Req (2013-2018)		
IN	FORMED CONSENT [sctINFORMEDCONSENT]			
I ce	ertify that Informed Consent has been obtained prior to any stu	udy procedure.		
2.* •	Informed Consent Date: [IC date]	[itmCONS_DAT: CONSENT.CONS_DAT] Req / Req (2013-2018)		
3.*	Did the subjects' parent(s)/Legally Acceptable Representative(s) agree that subjects' biological sample(s) may be used by GSK Biologicals for future research? (Type 4 tests) [Did the subject's parent(s)/Legally Acceptable Representative(s) agree that subject's biological sample(s) may be used by GSK Biologicals for future research? (Type 4 tests)]	[itmCONS_LAB_Q4: CONS_LAB.CONSLABA] Yes No Not applicable		
4.	Informed consent section number [hidden] [Section number]	[itmINF_NB1_HID: Not submitted - for internal use] N10		
	Key: [♥] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.			

DT	PA-HBV-IPV-135 (117119): GEN	IERAL MEDIC	CAL HISTORY / EXAMINATION (Ge	en med hist) [frmGENERALMEDIC	CALHISTORYEXAMINATION]	
GEN	NERAL MEDICAL HISTORY / EXAMINATION	[sctGENERALMED	DICALHISTORY]			
	Are you aware of any pre-existing conditions symptoms having started before first study to [Are you aware of any pre-existing condition symptoms having started before first study to symptoms.]	vaccination? s, signs or	[itmMED_COND: GENHIST.MED_COND] No Yes -> Please give diagnosis and tick appro	priate Past/Current box in the table I	pelow	
2.	General medical history section number [hide [General medical history section number]	den]	[itmGENMED_NB1_HID : Not submitted - for internal N10	use]		
	MedDR	A SYSTEM ORGA	AN CLASS	Diagnosis	Past / Current?	
3. ✓						
DIA	AGNOSIS Entry [sctDIAGNOSIS]					
Plea	ase report medication(s) as specified in the pr	rotocol and fill in t	he medication section.			
3.1°	* MedDRA SYSTEM ORGAN CLASS: [MedDRA SYSTEM ORGAN CLASS]	1.5	[itmDIAGTERM: DIAGNOS.DIAGTERM] [cIMEDHIST]			
3.2	* Diagnosis: [Diagnosis]	[itmDIAGNOSI : DIAGNOS.DIAGNOSI] A80				
3.3 ³	3* Past / Current? [imDIAGSTAT: DIAGNOS.DIAGSTAT] Past / Current? Past / Current					
3.4	Diagnosis: [hidden] [Diagnosis] [ItmDIAGNOSI_HID: Not submitted - for internal use] A128					
	(ey: [♥] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.					

DT	DTPA-HBV-IPV-135 (117119): DISEASE HISTORY (Dis Hist) [frmdiseasehistory]					
DIS	EASE HISTORY [sctDISEASEHISTORY]					
Plea	se note that If disease history is answered Yes, th	en exclusion criteria 12 needs to be ticked.				
	Has the subject had history of Hib, diphtheria, tetanus, pertussis, pneumococcal, rotavirus, poliovirus and/or hepatitis B diseases? [DTP-Hib-Pn-Rot-Pol-HB disease history?]	[itmDIS_HIST_FLG_X: HIST_DIS.HIST_FLG] Yes -> Please complete table below with appropriate information No Unknown, no information available				
	Disease	Date(s) of diagnosis				
2.						
DIS	EASE DETAILS Entry [sctDISEASEDETAILS]					
2.1*	* Disease: [Disease]	[ItmDIS_HIST_TYP: HIST_DIS.HIST_TYP] DIPHTHERIA PERTUSSIS TETANUS PNEUMOCOCCAL ROTAVIRUS POLIOVIRUS HEPATITIS-B HIB				
2.2 [*]	* Date(s) of diagnosis [Date(s) of diagnosis]	[<i>itmHIST_DAT</i> : HIST_DIS.HIST_DAT] Req/Unk / Req/Unk / Req/Unk (2013-2018)				
1	Key: [*] = Item is required [✔] = Source verification required Note: Source verification critical settings made in Inform will override any settings made in Central Designer					

D	DTPA-HBV-IPV-135 (117119): MOTHERS INFORMED CONSENT (Mot Inf Cons) [frmMOTHER_INF_CON]			
M	OTHERS INFORMED CONSENT [sctMOTH_INF_CON]			
1.* Did the Mother give her consent to collect the Tdap Vaccination History Information ? [Did the Mother give her consent to collect the Tdap Vaccination History Information ?] [ImmOTH_INF_CONS_Q: MOT_CONS.MOTH_CON] No Yes				
2	Mother's Informed Consent date : [Mother's Informed Consent date :]	[itmMOTH_CONS_DAT: MOT_CONS.MCON_DAT] NReq / NReq / NReq (2013-2018)		
- 1	Key: [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.			

DTPA-HBV-IPV-135 (117119): MOTHER'S TDAP VACCINATION HISTORY (Mot Tdap hist) [frmVACC_HISTORY_MOT]						
мот	THERS VACCINATION HISTORY FLAG [sctVACC	_HIST_FLG_MOT]				
Has the mother of the subject received Tdap vaccination during pregnancy before enrolment? [Has the mother of the subject received Tdap vaccination during pregnancy before enrolment?]			Yes	No		
	Vaccine name	Route	Dose number	Da	ite of administration	
2. •						
VAC	CINATION HISTORY DETAILS Entry [sctVACC_	HIST_DET_MOT]				
2.1* •	Vaccine name: (Trade name is preferred) [Vaccine name]	[itmCVACC_TRADNAME: HIST_VAC.TRADNAME] A60				
2.2	Vaccine name: (Trade name is preferred) [hidden] [Vaccine name]	[itmCVACC_TRADNAME_HID: Not submitted - for internal use] A60				
2.3 [*]	Route: [Route]	[itmCVACC_ROUTE: HIS	ST_VAC.MED_ROUT]			
2.4* •	Dose number: [Dose number]	[itmNB_DOSE: HIST_VAC.NB_DOSE] N10				
2.5 [*]	Date of administration: [Date of administration]	[itmCVACC_RDAT_MOT: HIST_VAC.HIST_DAT] Req/Unk / Req/Unk (2013-2018)				
2.6	For GSK - MON: [hidden] [For GSK - MON]	[itmMON_TRANS: HIST	T_VAC.MD_TRANS]			
2.7	For GSK - DM: [hidden] [For GSK - DM]	[itmGSK_MOD_HID: HIST_VAC.GSK_MOD] A60				
Ke	y: [♥] = Source verification required					

Note: Source verification critical settings made in InForm will override any settings made in Central Designer.

DT	PA-HBV-IPV-135 (117119): HEPAT	ITIS B VACCINA	ATION HISTORY (HepB Hist) [frmVA	CC_HISTORY_HEPB]		
VAC	CINATION HISTORY FLAG [sctVACC_HIST_FLG	_HEPB]				
~	Has the subject received any vaccination against enrolment? [Has the subject received any vaccination against enrolment?]		[itmVACC_HIST_FLG_HEPB: HIST_SHT.HIST_F			
	Vaccine name	Route	Dose number	Da	ate of administration	
2. •						
VAC	CCINATION HISTORY DETAILS Entry [sctVACC_	HIST_DET]				
2.1* •	Vaccine name: (Trade name is preferred) [Vaccine name]	[itmCVACC_TRADNAME:	HIST_VAC.TRADNAME]			
2.2	Vaccine name: (Trade name is preferred) [hidden] [Vaccine name]	[itmCVACC_TRADNAME_	HID: Not submitted - for internal use]			
2.3 [*]	Route: [Route]	[itmCVACC_ROUTE: HIS				
2.4* •	Dose number: [Dose number]	[itmNB_DOSE: HIST_V	AC.NB_DOSE]			
2.5 [*]	Date of administration: [Date of administration]	[itmCVACC_RDAT: HIST				
2.6	For GSK - MON: [hidden] [For GSK - MON]	[itmMON_TRANS: HIST] A60	_VAC.MD_TRANS]			
2.7	For GSK - DM: [hidden] [For GSK - DM]	[itmGSK_MOD_HID: HI	ST_VAC.GSK_MOD]			
Ke	y: [✔] = Source verification required					

Note: Source verification critical settings made in InForm will override any settings made in Central Designer.

DT	PA-HBV-IPV-135 (117119): OTHER	VACCINATION	HISTORY (Oth Hist) [frmVACC_HISTOR	кү_отн]	
VAC	CINATION HISTORY FLAG [sctVACC_HIST_FLG	[_ОТН]			
1.*	* Has the subject received any other vaccination before enrolment? [Has the subject received any other vaccination before enrolment?]		[itmVACC_HIST_FLG_OTH: HIST_SHT.HIST_FLG] Yes No Unknown, no information available		
	Vaccine name	Route	Dose number	Da	ite of administration
2. •					
VAC	CINATION HISTORY DETAILS Entry [sctVACC_	HIST_DET]			
2.1* •	Vaccine name: (Trade name is preferred) [Vaccine name]	[itmCVACC_TRADNAME A60	: HIST_VAC.TRADNAME]		
2.2	Vaccine name: (Trade name is preferred) [hidden] [Vaccine name]	[itmCVACC_TRADNAME_A60	_HID : Not submitted - for internal use]		
2.3 [*]	Route: [Route]	[itmCVACC_ROUTE: HI	ST_VAC.MED_ROUT] cj		
2.4 [*] ✓	Dose number: [Dose number]	[itmNB_DOSE: HIST_N	VAC.NB_DOSE]		
2.5 [*]	Date of administration: [Date of administration]	[itmCVACC_RDAT: HIS	T_VAC.HIST_DAT] 'Unk		
2.6	For GSK - MON: [hidden] [For GSK - MON]	[itmMON_TRANS: HIST	T_VAC.MD_TRANS]		
2.7	For GSK - DM: [hidden] [For GSK - DM]	[itmGSK_MOD_HID: H	IST_VAC.GSK_MOD]		
Ke	y: [✔] = Source verification required				

Note: Source verification critical settings made in InForm will override any settings made in Central Designer.

DT	PA-HBV-IPV-135 (117119): PHYSIC	AL EXAMINATION / VITAL SIGNS (VS) [frmVITALSIGNS_US]
HEI	GHT / WEIGHT [sctHEIGHTWEIGHT_US]	
1.*	Height: [Height]	[itmFEET: VS.VSORRES] [itmINCHES: VS.VSORRES] N2
2.	Feet unit: [hidden]	[itmFEET_UNI_HID: VS.VSORRESU]
3.	Inches unit: [hidden]	[itmINCHES_UNI_HID: VS.VSORRESU] [clvSORRESU]
4.* •	Weight: [Weight]	[itmPOUNDS: VS.VSORRES] [itmOUNCES: VS.VSORRES] N3 pounds N2 ounces
5.	Pounds unit: [hidden]	[itmPOUNDS_UNI_HID: VS.VSORRESU] [clvSorresu]
6.	Ounces unit: [hidden]	[itmOUNCES_UNI_HID: VS.VSORRESU] [clvSORRESU]
7.	VSTESTCD [hidden]	[itmVSTESTCD_HID: VS.VSTESTCD] [clvSTESTCD]
8.	VSTEST [hidden]	[itmVSTEST_HID: VS.VSTEST] [cdvSTest]
	y: [✔] = Source verification required the: Source verification critical settings made in InForm	will override any settings made in Central Designer.

DTPA-HBV-IPV-135 (117119): ELIGIBILITY CHECK (Eligibility) [frmeLigibilityCHECK] **ELIGIBILITY CHECK** [sctELIGIBILITYCHECK] [itmELIGIBIL: ELISHEET.ELIGIBIL] Did the subject meet all the entry criteria? [Eligible] Yes No -> Tick all boxes corresponding to violations of any inclusion/exclusion criteria. Do not enter the subject into the study if he/she failed any of the inclusion or exclusion criteria below. [itmINCL CRITERIA: ELIGIBIL.CRIT NR] **INCLUSION CRITERIA** Tick the boxes corresponding to any of the inclusion criteria the subject failed. 1.Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits). 2. A male or female between, and including, 6 and 12 weeks of age at the time of first vaccination. 3. Born full-term (i.e. after a gestation period of 37 weeks to less than 42 completed weeks [259 to 293 days]). 4. Written informed consent obtained from the parent(s)/LAR(s) of the subject 5. Healthy subjects as established by medical history and clinical examination before entering into the study. 6. Infants who have not received a previous dose of hepatitis B vaccine or those who have received only 1 dose of hepatitis B vaccine administered at least 30 days prior to enrolment. [itmEXCL CRITERIA: ELIGIBIL.CRIT NR] **EXCLUSION CRITERIA** Tick the boxes corresponding to any of the exclusion criteria that disqualified the subject from entry. Child in care 8. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccines, or planned use during the study period 9. Chronic administration (defined as more than 14 days in total) of immunosupp. or other immune-modifying drugs since birth. (For corticosteroids, this will mean prednisone > or = 0.5 mg/kg/day, or equivalent). Inhaled and topical steroids are allowed. 10. Planed adm/adm of vac not forseen by prot 30d before dose1 till 30d after dose3 & 30d before/after booster. Inactiv. flu & HepA vac allowed. Rout.admin. of MMR, varicella, pneumo vac allowed 30d after last pri vacc till 30d before Bst&post-bst sampling 11. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device). 12. History of Hib, diphtheria, tetanus, pertussis, pneumococcal, rotavirus, poliovirus and hepatitis B diseases. 13. Previous vaccination against Hib, diphtheria, tetanus, pertussis, pneumococcus, rotavirus and/or poliovirus; more than one previous dose of hepatitis B vaccine. 14. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). 15. Family history of congenital or hereditary immunodeficiency. 16. History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines (including yeast). 17. Hypersensitivity to latex. 18. Major congenital defects or serious chronic illness. 19. History of any neurological disorders including seizures. 20. Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period. 21. History of intussusception or of any uncorrected congenital malformation of the gastrointestinal tract that would predispose the infant to intussusception. 22. History of Severe Combined Immunodeficiency Disease (SCID). 23. Acute disease and/or fever at time of enrol. - Fever: temp>or=38.0°C /100.4°F by any rout. Pref route: rectal for pri & axilary for bst. Sub. with minor illnes (eq: mild diar, mild uper resp.infection) with no fever may be enrol, at discretion of INV 2. Eligibility section number [hidden] [itmELI NB1 HID: Not submitted - for internal use] [Section number] N10 Kev: [✓] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.

DT	PA-HBV-IPV-135 (117119): VACC	INE ADMINISTRATION - DOSE 1 (HEXA GROUP) (vac adm hexa-dose1) [frmVACC_ADMIN_D1_HEXA]		
PRE	-VACC TEMPERATURE [sctPREVACCTEMPERAT	JRE]		
1.*	Pre-vaccination temperature: [Pre-vacc temp]	[itmPRE_TEMP: VS.VSORRES] Temperature (°F)		
2.	Unit: [hidden]	[itmTEMP_UNIT_HID: Not submitted - for internal use] [clvSORRESU]		
3.	VSTEST [hidden]	[itmVSTEST_HID: VS.VSTEST] [clvSTEST]		
4.	VSTESTCD [hidden]	[itmVSTESTCD_HID: VS.VSTESTCD] [clvSTESTCD]		
[sct	/ACC_ADMIN_HEXA]			
Infa	nrix Hexa Vaccine			
5.*	Has Infanrix Hexa Vaccine been administered? [Vaccinated]	[itmV_ADM_HEXA_D1: VACCPROD.V_ADM] Yes -> [itmV_TRT_HEXA: VACC_TRT.V_TRT] Administered treatment number: N10		
6.	P_SITE [hidden]	[itmP_SITE_HEXA_HID: VACCPROD.P_SITE] [c/VACCSITE]		
7.	P_SIDE [hidden]	[itmP_SIDE_HEXA_HID: VACCPROD.P_SIDE] [clVACCSIDE]		
8.	P_ROUTE [hidden]	[itmP_ROUTE_HEXA_HID: VACCPROD.P_ROUTE] [cIMEDROUT_VACC]		
9.	P_CODE [hidden]	[itmP_CODE_HEXA_HID: VACCPROD.P_CODE] [ciprodnames]		
[sct	/ACC_ADMIN_PREVNAR13]			
Prev	nar13 Vaccine			
10.*	Has Prevnar13 Vaccine been administered? [Vaccinated]	[itmV_ADM_PREVNAR13: VACCPROD.V_ADM] Yes - [itmV_TRT_PREVNAR13: VACC_TRT.V_TRT] > Administered treatment number: N10 [itmP_AP_PREVNAR13: VACCPROD.P_AP] Injection Site/Side/Route: According to protocol (Thigh - Lower Left - IM)		

		Not according to protocol -> [itmP_APSITE_PREVNAR13: VACCPROD.P_APSITE] Site:
11.	P_SITE [hidden]	□ No [itmP_SITE_PREVNAR13_HID: VACCPROD.P_SITE] □ [clvACCSITE]
12.	P_SIDE [hidden]	[itmP_SIDE_PREVNAR13_HID: VACCPROD.P_SIDE] [clVACCSIDE]
13.	P_ROUTE [hidden]	[itmP_ROUTE_PREVNAR13_HID: VACCPROD.P_ROUTE] [clMEDROUT_VACC]
14.	P_CODE [hidden]	[itmP_CODE_PREVNAR13_HID: VACCPROD.P_CODE]
[sct\	ACC_ADMIN_ROTARIX]	
Rota	rix Vaccine	
15.* ✓	Has Rotarix Vaccine been administered? [Vaccinated]	[itmV_ADM_ROTARIX: VACCPROD.V_ADM] Yes - [itmV_TRT_ROTARIX: VACC_TRT.V_TRT] > Administered treatment number: N10 [itmP_AP_ROTARIX: VACCPROD.P_AP] According to protocol (Oral) Not according to protocol [itmVADM_COM_ROTARIX: VACCPROD.VADM_COM] If relevant, comment on administration: A200
16.	P_ROUTE [hidden]	[itmP_ROUTE_ROTARIX_HID: VACCPROD.P_ROUTE] [cIMEDROUT_CVACC]
17.	P_CODE [hidden]	[itmP_CODE_ROTARIX_HID: VACCPROD.P_CODE] [clprodnames]
VAC	CINATION DETAILS [sctVACCDETAILS_2VACC_	D1]
18.	Date of administration:	If at least one vaccine administered [itmVACCRDAT: VAC_INFO.VACCRDAT] Req / Req (2013-2018) [itmSAME_DATE: Not submitted - for internal use] Or tick box if date is the same as visit date
19. ✓	If at least one vaccination not done: [Reason for non-admin]	[itmVACC_REAS: VAC_INFO.V_REAS] Please select the major reason for non administration: [itmSAE_CASE: VAC_INFO.SAE_CASE] Serious Adverse Event-> Please complete a SAE Report and specify SAE Report No. [itmAE_NB: VAC_INFO.AE_NB] Non-Serious Adverse Event -> Please complete Non-Serious Adverse Event section and specify AE No. [itmV_OTH: VAC_INFO.V_OTH]

		Other, please specify (e.g.: consent withdrawal, Protocol violation,) A100 [itmDECISION: VAC_INFO.DECISION] Please select who made the decision:InvestigatorSubject's parents / Legally Acceptable Representatives	
20.	Vaccination date (or visit date when same as visit date) [hidden] [Vaccination date (or visit date when same as visit date)]	[itmP_RDAT: Not submitted - for internal use] NReq / NReq / NReq (2013-2018)	
	:: [✔] = Source verification required e: Source verification critical settings made in InFor	m will override any settings made in Central Designer.	

DT	PA-HBV-IPV-135 (117119): VACC	INE ADMINISTRATION - DOSE 1 (PENTA GROUP) (vac adm penta-dose1) [frmVACC_ADMIN_D1_PENTA]
PRE	VACC TEMPERATURE [sctPREVACCTEMPERAT	URE]
1.*	Pre-vaccination temperature: [Pre-vacc temp]	[itmPRE_TEMP: VS.VSORRES] Temperature (°F) XXX.X [itmTEMP_ROUTE: VS.VSLOC] Route: Axillary Oral Rectal (Preferred) Tympanic
2.	Unit: [hidden]	[itmTEMP_UNIT_HID: Not submitted - for internal use] [clvSORRESU]
3.	VSTEST [hidden]	[itmVSTEST_HID: VS.VSTEST] [clVSTEST]
4.	VSTESTCD [hidden]	[itmVSTESTCD_HID: VS.VSTESTCD] [clVSTESTCD]
[sct	/ACC_ADMIN_PENTACEL]	
Pent	acel Vaccine	
5.*	Has Pentacel Vaccine been administered? [Vaccinated]	ItmV_ADM_PENTACEL_D1: VACCPROD.V_ADM Yes -
6.	P_SITE [hidden]	[itmP_SITE_PENTACEL_HID: VACCPROD.P_SITE] [clVACCSITE]
7.	P_SIDE [hidden]	[itmP_SIDE_PENTACEL_HID: VACCPROD.P_SIDE] [clVACCSIDE]
8.	P_ROUTE [hidden]	[itmP_ROUTE_PENTACEL_HID: VACCPROD.P_ROUTE] [cIMEDROUT_VACC]
9.	P_CODE [hidden]	[itmP_CODE_PENTACEL_HID: VACCPROD.P_CODE] [cIPRODNAMES]
[sct	/ACC_ADMIN_ENGERIX_B]	
Enge	rix-B Vaccine	
10.*	Has Engerix-B Vaccine been administered? [Vaccinated]	[itmV_ADM_ENGERIX_B_D1: VACCPROD.V_ADM] Yes - [itmV_TRT_ENGERIX_B: VACC_TRT.V_TRT] > Administered treatment number: N10 [itmP_AP_ENGERIX_B: VACCPROD.P_AP] Injection Site/Side/Route: According to protocol (Thigh - Upper Left - IM) Not according to protocol -> [itmP_APSITE_ENGERIX_B: VACCPROD.P_APSITE]

		Site: Deltoid Thigh Buttock [itmP_APSIDE_ENGERIX_B: VACCPROD.P_APSIDE] Side: Left Right Upper Left Lower Left Upper Right Lower Right [itmP_APROUTE_ENGERIX_B: VACCPROD.P_APROUT] Route: Intramuscular Subcutaneous [itmVADM_COM_ENGERIX_B: VACCPROD.VADM_COM] If relevant, comment on administration: A200
11.	P_SITE [hidden]	□ No [itmP_SITE_ENGERIX_B_HID: VACCPROD.P_SITE] □ [clVACCSITE]
12.	P_SIDE [hidden]	[itmP_SIDE_ENGERIX_B_HID: VACCPROD.P_SIDE] [clvAccSIDE]
13.	P_ROUTE [hidden]	[itmP_ROUTE_ENGERIX_B_HID: VACCPROD.P_ROUTE] [clMEDROUT_VACC]
14.	P_CODE [hidden]	[itmP_CODE_ENGERIX_B_HID: VACCPROD.P_CODE]
[sct\	/ACC_ADMIN_PREVNAR13]	
Prev	nar13 Vaccine	
	Has Prevnar13 Vaccine been administered? [Vaccinated]	Itmv_ADM_PREVNAR13: VACCPROD.V_ADM] Yes - Itmv_TRT_PREVNAR13: VACCPROD.P_AP] Injection Site/Side/Route: According to protocol (Thigh - Lower Left - IM) Not according to protocol -> Itmp_APSITE_PREVNAR13: VACCPROD.P_APSITE] Site:
	P_SITE [hidden]	[itmP_SITE_PREVNAR13_HID: VACCPROD.P_SITE] [clVACCSITE]
17.	P_SIDE [hidden]	[itmP_SIDE_PREVNAR13_HID: VACCPROD.P_SIDE] [clVACCSIDE]
18.	P_ROUTE [hidden]	[itmp_ROUTE_PREVNAR13_HID: VACCPROD.P_ROUTE] [cimedrout_vacc]
19.	P_CODE [hidden]	[itmP_CODE_PREVNAR13_HID: VACCPROD.P_CODE] [clPRODNAMES]
[sct\	/ACC_ADMIN_ROTARIX]	
Rota	rix Vaccine	
20 *	Has Rotarix Vaccine been administered?	[itmV_ADM_ROTARIX: VACCPROD.V_ADM]

•	[Vaccinated]	Yes - [itmV_TRT_ROTARIX: VACC_TRT.V_TRT] > Administered treatment number: N10 [itmP_AP_ROTARIX: VACCPROD.P_AP] According to protocol (Oral) Not according to protocol [itmVADM_COM_ROTARIX: VACCPROD.VADM_COM] If relevant, comment on administration: A200
21.	P_ROUTE [hidden]	[itmP_ROUTE_ROTARIX_HID: VACCPROD.P_ROUTE] [clMEDROUT_cvacc]
22.	P_CODE [hidden]	[itmP_CODE_ROTARIX_HID: VACCPROD.P_CODE]
VAC	CINATION DETAILS [sctVACCDETAILS_2VACC_	D1]
23. ✓	Date of administration:	If at least one vaccine administered [itmVACCRDAT: VAC_INFO.VACCRDAT] Req / Req (2013-2018) [itmSAME_DATE: Not submitted - for internal use] Or tick box if date is the same as visit date
24.	If at least one vaccination not done: [Reason for non-admin]	[itmVACC_REAS: VAC_INFO.V_REAS] Please select the major reason for non administration: [itmSAE_CASE: VAC_INFO.SAE_CASE] Serious Adverse Event-> Please complete a SAE Report and specify SAE Report No. NZ [itmAE_NB: VAC_INFO.AE_NB] Non-Serious Adverse Event -> Please complete Non-Serious Adverse Event section and specify AE No. NZ [itmV_OTH: VAC_INFO.V_OTH] Other, please specify (e.g.: consent withdrawal, Protocol violation,) A100 [itmDECISION: VAC_INFO.DECISION] Please select who made the decision:InvestigatorSubject's parents / Legally Acceptable Representatives
25.	Vaccination date (or visit date when same as visit date) [hidden] [Vaccination date (or visit date when same as visit date)]	[itmP_RDAT: Not submitted - for internal use] NReq / NReq / NReq (2013-2018)
	y: [♥] = Source verification required te: Source verification critical settings made in InFor	m will override any settings made in Central Designer.

Property of GlaxoSmithKline Biologicals

DTI	PA-HBV-IPV-135 (117119): VACC	INE ADMINISTRATION - DOSE 1 (PEDIA GROUP) (vac adm pedia-dose1) [frmVACC_ADMIN_D1_PEDIA]
PRE-	VACC TEMPERATURE [sctPREVACCTEMPERAT	URE]
1.*	Pre-vaccination temperature: [Pre-vacc temp]	[itmPRE_TEMP: VS.VSORRES] Temperature (°F)
2.	Unit: [hidden]	[ItmTEMP_UNIT_HID: Not submitted - for internal use] [IcIVSORRESU]
3.	VSTEST [hidden]	[itmVSTEST_HID: VS.VSTEST] [clVSTEST]
4.	VSTESTCD [hidden]	[itmVSTESTCD_HID: VS.VSTESTCD] [clVSTESTCD]
[sct\	/ACC_ADMIN_PEDIARIX]	
Pedia	arix Vaccine	
5.*	Has Pediarix Vaccine been administered? [Vaccinated]	ItmV_ADM_PEDIARIX_D1: VACCPROD.V_ADM Yes -
6.	P_SITE [hidden]	[itmP_SITE_PEDIARIX_HID: VACCPROD.P_SITE] [clvaccsite]
7.	P_SIDE [hidden]	[itmP_SIDE_PEDIARIX_HID: VACCPROD.P_SIDE] [clVACCSIDE]
8.	P_ROUTE [hidden]	[itmP_ROUTE_PEDIARIX_HID: VACCPROD.P_ROUTE] [cIMEDROUT_VACC]
9.	P_CODE [hidden]	[itmP_CODE_PEDIARIX_HID: VACCPROD.P_CODE] [cIPRODNAMES]
[sct\	/ACC_ADMIN_ACTHIB]	
ActH	ib Vaccine	
10.*	Has ActHib Vaccine been administered? [Vaccinated]	[itmV_ADM_ACTHIB_D1: VACCPROD.V_ADM] Yes - [itmV_TRT_ACTHIB: VACC_TRT.V_TRT] > Administered treatment number: N10 [itmP_AP_ACTHIB: VACCPROD.P_AP] Injection Site/Side/Route: According to protocol (Thigh - Upper Left - IM) Not according to protocol -> [itmP_APSITE_ACTHIR: VACCPROD_P_APSITE]

		Site: Deltoid Thigh Buttock [itmP_APSIDE_ACTHIB: VACCPROD.P_APSIDE] Side: Left Right Upper Left Lower Left Upper Right Lower Right
		[itmP_APROUTE_ACTHIB: VACCPROD.P_APROUT]
		Route: _Intramuscular _Subcutaneous [itmVADM_COM_ACTHIB: VACCPROD.VADM_COM]
		If relevant, comment on administration: A2000
		No
11.	P_SITE [hidden]	[itmP_SITE_ACTHIB_HID: VACCPROD.P_SITE] [cIVACCSITE]
12.	P_SIDE [hidden]	[itmP_SIDE_ACTHIB_HID: VACCPROD.P_SIDE] [clVACCSIDE]
13.	P_ROUTE [hidden]	[itmP_ROUTE_ACTHIB_HID: VACCPROD.P_ROUTE]
14.	P_CODE [hidden]	[itmP_CODE_ACTHIB_HID: VACCPROD.P_CODE] [ciprodnames]
[sct\	/ACC_ADMIN_PREVNAR13]	
Prev	nar13 Vaccine	
15.* ✓	Has Prevnar13 Vaccine been administered? [Vaccinated]	[itmV_ADM_PREVNAR13: VACCPROD.V_ADM] \[\text{Yes} - [itmV_TRT_PREVNAR13: VACC_TRT.V_TRT]} \] > Administered treatment number: \[\text{N10} \]
		[itmP_AP_PREVNAR13: VACCPROD.P_AP] Injection Site/Side/Route: According to protocol (Thigh – Lower Left - IM)
		Not according to protocol -> [itmP_APSITE_PREVNAR13: VACCPROD.P_APSITE] Site: Deltoid Thigh Buttock
		[itmP_APSIDE_PREVNAR13: VACCPROD.P_APSIDE]
		Side: Left Right Upper Left Lower Left Upper Right Lower Right
		[itmP_APROUTE_PREVNAR13: VACCPROD.P_APROUT] Route: Intramuscular Subcutaneous
		[itmVADM_COM_PREVNAR13: VACCPROD.VADM_COM]
		If relevant, comment on administration: $A200$
		No The state of th
	P_SITE [hidden]	[itmP_SITE_PREVNAR13_HID: VACCPROD.P_SITE] [clVACCSITE]
17.	P_SIDE [hidden]	[itmP_SIDE_PREVNAR13_HID: VACCPROD.P_SIDE] [clvACCSIDE]
18.	P_ROUTE [hidden]	[itmP_ROUTE_PREVNAR13_HID: VACCPROD.P_ROUTE] [cIMEDROUT_VACC]
19.	P_CODE [hidden]	[itmP_CODE_PREVNAR13_HID: VACCPROD.P_CODE] [ciprodnames]
[sct\	/ACC_ADMIN_ROTARIX]	
Rota	rix Vaccine	
20 *	Has Rotarix Vaccine been administered?	[itmV_ADM_ROTARIX: VACCPROD.V_ADM]

•	[Vaccinated]	Yes - [itmV_TRT_ROTARIX: VACC_TRT.V_TRT] > Administered treatment number: N10 [itmP_AP_ROTARIX: VACCPROD.P_AP] According to protocol (Oral) Not according to protocol [itmVADM_COM_ROTARIX: VACCPROD.VADM_COM] If relevant, comment on administration: A200
21.	P_ROUTE [hidden]	No [itmP_ROUTE_ROTARIX_HID: VACCPROD.P_ROUTE] [clMEDROUT_CVACC]
22.	P_CODE [hidden]	[itmP_CODE_ROTARIX_HID: VACCPROD.P_CODE] [cIPRODNAMES]
VAC	CINATION DETAILS [sctVACCDETAILS_2VACC_	D1]
23. •	Date of administration:	If at least one vaccine administered [itmVACCRDAT: VAC_INFO.VACCRDAT] Req / Req / Req (2013-2018) [itmSAME_DATE: Not submitted - for internal use] Or tick box if date is the same as visit date
24.	If at least one vaccination not done: [Reason for non-admin]	[itmVACC_REAS: VAC_INFO.V_REAS] Please select the major reason for non administration: [itmSAE_CASE: VAC_INFO.SAE_CASE] Serious Adverse Event-> Please complete a SAE Report and specify SAE Report No. N2 [itmAE_NB: VAC_INFO.AE_NB] Non-Serious Adverse Event -> Please complete Non-Serious Adverse Event section and specify AE No. N2 [itmV_OTH: VAC_INFO.V_OTH] Other, please specify (e.g.: consent withdrawal, Protocol violation,) A100 [itmDECISION: VAC_INFO.DECISION] Please select who made the decision: Investigator Subject's parents / Legally Acceptable Representatives
25.	Vaccination date (or visit date when same as visit date) [hidden] [Vaccination date (or visit date when same as visit date)]	[itmP_RDAT: Not submitted - for internal use] NReq / NReq / NReq (2013-2018)

DTPA-HBV-IPV-135 (117119): LOCAL SIGNS/SYMPTOMS FLAG - HEXA (Loc symp flg Hexa) [frmlocsymptoms_flag_hexa]			
LOCAL SIGNS/SYMPTOMS FLAG - HEXA [sctLOCSYMPTOMS_FLG_HEXA]			
1.*	Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [Local Symp flag for Infanrix Hexa]	[itmLOCSOL_YN_HEXA: SOLSHEET.SOL_YN] Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary No Unknown, no information available	
2.	Solicited symptoms type [hidden] [Solicited symptoms type]	[itmSOL_TYP_HID: Not submitted - for internal use] Generalised Localised	
	Key: [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

	DTPA-HBV-IPV-135 (117119): SOLICITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (INFANRIX HEXA) (Loc symp-Hexa) [frmlOCSYMPTOMS_HEXA]		
	anrix Hexa vaccine injection site. any of these adverse events meets the de	finition of serious, complete a Serious Adverse Event Report.	
RE	DNESS [sctREDNESS]		
1.**		[itmRE_YN:SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_MM_D0:	
2.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clSYMPCODE]	
3.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [clSYMPUNITS]	
sw	VELLING [sctSWELLING]		
4.*		[itmSW_YN: SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_MM_D0: SOLVAL.SYMP_VAL] SOLVAL.SYMP_VAL] (mm): Day 0: Day 1: Day 2: Day 3: N5 [itmSW_ONG: SOLAE.SYMP_ONG] After Day 3: Ongoing? No Yes -> [itmSYMP_MAX_SIZE: SOLAE.SYMP_MAX] Maximum size: N5 [itmERDAT: SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Unk / Req/Unk / Req/Unk (2013-2018) [itmCONT_END: SOLAE.SYMPCONT] Continuing at the end of the study? [itmMED_TYPE: SOLAE.MED_TYPE] Medically attended visit: Emergency Room Hospitalisation Medical Personnel None	
5.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]	
6.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [clsympunits]	
PA	IN [sctPAIN]		
7.* •	Occurred?	[itmPA_YN:SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_INTEN_D0: [itmSYMP_VAL_INTEN_D1: [itmSYMP_VAL_INTEN_D2: [itmSYMP_VAL_INTEN_D3: SOLVAL.SYMP_VAL] Intensity: SOLVAL.SYMP_VAL] Day 0: Day 1: Day 2: Day 3: Colintensity:SOLI Colintensity:SOLI	

		[itmPA_ONG: SOLAE.SYMP_ONG] After Day 3: Ongoing? No Yes -> [itmSYMP_MAX_INTEN: SOLAE.SYMP_MAX] Maximum intensity: [clintensitySol_max]	
		[itmERDAT: SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Unk / Req/Unk / Req/Unk (2013-2018)	
		[itmCONT_END: SOLAE.SYMPCONT] Continuing at the end of the study? [itmMED_TYPE: SOLAE.MED_TYPE] Medically attended visit: Emergency Room Hospitalisation Medical Personnel None	
8.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [cdSympcode]	
1	Key: [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

D	DTPA-HBV-IPV-135 (117119): LOCAL SIGNS/SYMPTOMS FLAG - PEDIARIX (Loc symp flg Pediarix) [frmlocsymptoms_flag_pediarix]			
LO	LOCAL SIGNS/SYMPTOMS FLAG - PEDIARIX [sctLOCSYMPTOMS_FLG_PEDIARIX]			
1.*	Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [Local Symp flag for Pediarix]	[itmLOCSOL_YN_PEDIARIX: SOLSHEET.SOL_YN] Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary No Unknown, no information available		
2.	Solicited symptoms type [hidden] [Solicited symptoms type]	[itmSOL_TYP_HID: Not submitted - for internal use] Generalised Localised		
	Key: [♥] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.			

	DTPA-HBV-IPV-135 (117119): SOLICITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (PEDIARIX) (Loc symp-Pediarix) [frmlOCSYMPTOMS_PEDIARIX]		
	diarix vaccine injection site. The of these adverse events meets the definition	on of serious, complete a Serious Adverse Event Report.	
RE	DNESS [sctREDNESS]		
1.**	Occurred?	Ithms Ithm	
2.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]	
3.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [clsympunits]	
sw	/ELLING [sctSWELLING]		
4.*		[itmSW_YN:SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_MM_DD: SOLVAL.SYMP_VAL] SOLVAL.SYMP_VAL] (mm): Day 0: Day 1: Day 2: Day 3: N5 [itmSV_ONG:SOLAE.SYMP_ONG] After Day 3: Ongoing? No Yes -> [itmSYMP_MAX_SIZE:SOLAE.SYMP_MAX] Maximum size: N5 [itmERDAT:SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Unk	
5.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]	
6.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [clsympunits]	
РА	IN [sctPAIN]		
7.* •	Occurred?	[itmPA_YN:SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_INTEN_D0: [itmSYMP_VAL_INTEN_D1: [itmSYMP_VAL_INTEN_D2: [itmSYMP_VAL_INTEN_D3: SOLVAL.SYMP_VAL] SOLVAL.SYMP_VAL] Day 0: Day 1: Day 2: Day 3:	

		[itmPA_ONG: SOLAE.SYMP_ONG] After Day 3: Ongoing? No Yes -> [itmSYMP_MAX_INTEN: SOLAE.SYMP_MAX] Maximum intensity: [clintensitySol_max]	
		[itmERDAT: SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Unk / Req/Unk / Req/Unk (2013-2018)	
		[itmCONT_END: SOLAE.SYMPCONT] Continuing at the end of the study? [itmMED_TYPE: SOLAE.MED_TYPE] Medically attended visit: Emergency Room Hospitalisation Medical Personnel None	
8.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD]	
	Key: [♥] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

DTPA-HBV-IPV-135 (117119): LOCAL SIGNS/SYMPTOMS FLAG - ACTHIB (Loc symp flg ActHib) [frmlocsymptoms_flag_acthib_d1]			
LC	LOCSYMPTOMS_FLG_ACTHIB [sctLOCSYMPTOMS_FLG_ACTHIB_D1]		
1.*	Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [Local Symp flag for ActHib]	[itmLOCSOL_YN_ACTHIB_D1: SOLSHEET.SOL_YN] Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary No Unknown, no information available	
2.	Solicited symptoms type [hidden] [Solicited symptoms type]	[itmSOL_TYP_HID: Not submitted - for internal use] Generalised Localised	
	Key: [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

DTPA-HBV-IPV-135 (117119): SOLICITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (ACTHIB) (Loc symp-ActHib) [frmlocsymptoms_acthib]		
	Hib vaccine injection site.	e definition of serious, complete a Serious Adverse Event Report.
RE	DNESS [sctREDNESS]	
1.*	Occurred?	
2.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]
3.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [clsympunits]
sv	VELLING [sctSWELLING]	
4.*		Continuing at the end of the study? Continuing at the end of Medical Personnel None None
5.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]
6.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [clsympunits]
PA	IN [sctPAIN]	
7.* •	Occurred?	[itmPA_YN:SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_INTEN_D0: [itmSYMP_VAL_INTEN_D1: [itmSYMP_VAL_INTEN_D2: [itmSYMP_VAL_INTEN_D3: SOLVAL.SYMP_VAL] Day 0: Day 1: Day 2: Day 3: [clintensitySOL]

		After Day 3: Ongoing? No Yes -> [itmSYMP_MAX_INTEN: SOLAE.SYMP_MAX] Maximum intensity: [cIINTENSITYSOL_MAX]			
		[itmERDAT: SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Unk / Req/Unk / Req/Unk (2013-2018)			
		[itmCONT_END: SOLAE.SYMPCONT] Continuing at the end of the study? [itmMED_TYPE: SOLAE.MED_TYPE] Medically attended visit: Emergency Room Hospitalisation Medical Personnel None			
8.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD]			
	Key: [♥] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.				

D.	DTPA-HBV-IPV-135 (117119): LOCAL SIGNS/SYMPTOMS FLAG - PENTACEL (Loc symp flg Pentacel) [frmlocsymptoms_flag_pentacel]			
LC	LOCAL SIGNS/SYMPTOMS FLAG - PENTACEL [sctLOCSYMPTOMS_FLG_PENTACEL]			
1.*	Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [Local Symp flag for Pentacel]	[itmLOCSOL_YN_PENTACEL: SOLSHEET.SOL_YN] Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary No Unknown, no information available		
2.	Solicited symptoms type [hidden] [Solicited symptoms type]	[itmSOL_TYP_HID: Not submitted - for internal use] Generalised Localised		
	Key: [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.			

	TPA-HBV-IPV-135 (117119): S mLOCSYMPTOMS_PENTACEL]	SOLICITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (PENTACEL) (Loc symp-Pentacel)
	ntacel vaccine injection site.	finition of serious, complete a Serious Adverse Event Report.
	DNESS [sctREDNESS]	
1.*		Itms/mp_val_mm_D2:
2.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clSYMPCODE]
3.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [cdSympunits]
sw	/ELLING [sctSWELLING]	
4.* *		[itmSW_N: SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_MM_D0: [itmSYMP_VAL_MM_D1: SOLVAL.SYMP_VAL] SOLVAL.SYMP_VAL] (mm): Day 0: Day 1: Day 2: Day 3: N5 [itmSW_ONG: SOLAE.SYMP_ONG] After Day 3: Ongoing? No Yes -> [itmSYMP_MAX_SIZE: SOLAE.SYMP_MAX] Maximum size: N5 [itmERDAT: SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Unk
5.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]
6.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [clsympunits]
PA	IN [sctPAIN]	
7.* ✓	Occurred?	[itmPA_YN:SOLAE.SYMP_EXP] NO Yes -> [itmSYMP_VAL_INTEN_D0: [itmSYMP_VAL_INTEN_D1: [itmSYMP_VAL_INTEN_D2: [itmSYMP_VAL_INTEN_D3: SOLVAL.SYMP_VAL] SOLVAL.SYMP_VAL] Day 0: Day 1: Day 2: Day 3: [clintensitysol]

		[itmPA_ONG: SOLAE.SYMP_ONG] After Day 3: Ongoing? No Yes -> [itmSYMP_MAX_INTEN: SOLAE.SYMP_MAX] Maximum intensity: [cINTENSITYSOL_MAX]		
		[itmERDAT: SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Unk / Req/Unk / Req/Unk (2013-2018)		
		[itmCONT_END: SOLAE.SYMPCONT] Continuing at the end of the study? [itmMED_TYPE: SOLAE.MED_TYPE] Medically attended visit: Emergency Room Hospitalisation Medical Personnel None		
8.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]		
	Key: [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.			

D.	DTPA-HBV-IPV-135 (117119): LOCAL SIGNS/SYMPTOMS FLAG - ENGERIX B (Loc symp flg Engerix-B) [frmlocsymptoms_flag_engerix_B]			
LO	CAL SIGNS/SYMPTOMS FLAG - ENGERIX B [sctLC	CSYMPTOMS_FLG_ENGERIX_B]		
1.*	Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [Local Symp flag for Engerix-B]	[itmLOCSOL_YN_ENGERIX_B: SOLSHEET.SOL_YN] Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary No Unknown, no information available		
2.	Solicited symptoms type [hidden] [Solicited symptoms type]	[itmSOL_TYP_HID: Not submitted - for internal use] Generalised Localised		
	Key: [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.			

D1	TPA-HBV-IPV-135 (117119): SC mLOCSYMPTOMS_ENGERIX_B]	DLICITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (ENGERIX-B) (Loc symp-Engerix-B)
	gerix-B vaccine injection site. any of these adverse events meets the defir	nition of serious, complete a Serious Adverse Event Report.
RE	DNESS [sctREDNESS]	
1.*	Occurred?	[itmRE_VN:SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_MM_D0: SOLVAL.SYMP_VAL] SOLVAL.SYMP_VAL] (mm): Day 0: Day 1: Day 2: Day 3: N5 [itmRE_ONG:SOLAE.SYMP_ONG] After Day 3: Ongoing? No Yes -> [itmSYMP_MAX_SIZE:SOLAE.SYMP_MAX] Maximum size: N5 [itmERDAT:SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Unk
2.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]
3.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [clsympunits]
sw	VELLING [sctSWELLING]	
4.* *		[itmSW_YN:SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_MM_D0: [itmSYMP_VAL_MM_D1: Size SOLVAL.SYMP_VAL] SOLVAL.SYMP_VAL] Size SOLVAL.SYMP_VAL] SOLVA
5.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]
6.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [clsympunits]
PA	IN [sctPAIN]	
7.* ✓	Occurred?	[itmPA_YN:SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_INTEN_D0: [itmSYMP_VAL_INTEN_D1: [itmSYMP_VAL_INTEN_D2: [itmSYMP_VAL_INTEN_D3: SOLVAL.SYMP_VAL] Day 0: Day 1: SOLVAL.SYMP_VAL] Day 3: [clINTENSITYSOL]

		[itmPA_ONG: SOLAE.SYMP_ONG] After Day 3: Ongoing? No Yes -> [itmSYMP_MAX_INTEN: SOLAE.SYMP_MAX] Maximum intensity: [cINTENSITYSOL_MAX]		
		[itmERDAT: SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Unk / Req/Unk / Req/Unk (2013-2018)		
		[itmCONT_END: SOLAE.SYMPCONT] Continuing at the end of the study? [itmMED_TYPE: SOLAE.MED_TYPE] Medically attended visit: Emergency Room Hospitalisation Medical Personnel None		
8.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]		
	Key: [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.			

DI	DTPA-HBV-IPV-135 (117119): GENERAL SIGNS/SYMPTOMS FLAG (Gen symp flg) [frmGENSYMPTOMS_FLAG]			
GE	GENERAL SIGNS/SYMPTOMS FLAG [sctGENSYMPTOMS_FLG]			
	Has the subject experienced any of the General Solicited signs/symptoms between Day 0 and Day 3?	[itmGENSOL_YN: SOLSHEET.SOL_YN] Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary No Unknown, no information available		
2.	Solicited symptoms type [hidden] [Solicited symptoms type]	[itmSOL_TYP_HID: Not submitted - for internal use] Generalised Localised		
	Key: [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.			

DT	PA-HBV-IPV-135 (117119): SOLIC	CITED ADVERSE EVENTS - GENERAL SIGNS/SYMPTOMS (Gen symp) [frmGENSYMPTOMS]			
Ifan	any of these adverse events meets the definition of serious, complete a Serious Adverse Event Report.				
TEM	PERATURE (°F) [sctTEMPERATURE_SOL]				
Reco	rd temperatures if during the solicited period at	at least one axillary/oral/tympanic/rectal measure is above or equal to 100.4 °F			
1.*	Occurred?	[itmFE_VN:SOLAE.SYMP_EXP] No Not taken Yes -> Day 0: Day 1: Day 2: Day 3: [itmFE_VAL_D0: [itmFE_VAL_D1: [itmFE_VAL_D2: [itmFE_VAL_D3: SOLVAL.SYMP_VAL]] Not			
		Max temperature:			
2.	Unit: [hidden] [Unit]	[itmTEMP_UNIT: Not submitted - for internal use] Fahrenheit			
3.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [cisympcode]			
4.	Threshold for fever based on route and unit [hidden]	[itmFEV_VAL_HID: Not submitted - for internal use] XXXXXXXXXXXXXXXXXXX			
5.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [clsympunits]			
DRO	WSINESS [sctDROWSINESS]				
6.* ✓	Occurred?	[itmDR_YN:SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_INTEN_D0:			

		[itmMED_TYPE: SOLAE.MED_TYPE] Medically attended visit: Emerge	ency Room Hospitalisation Medical I	Personnel None	
7.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD	P]		
IRRI	TABILITY/FUSSINESS [sctIRRITABILITY]				
8.*	Occurred?	[itmCAUSAL: SOLAE.CAUSAL] Is there a reasonable possibility the [itmMED_TYPE: SOLAE.MED_TYPE]	[itmSYMP_VAL_INTEN_D1: SOLVAL.SYMP_VAL] Day 1: [clINTENSITYSOL] [itmSYMP_MAX_INTEN: laximum intensity: [clINTENSITYSOL_M itmERDAT: SOLAE.SYMP_LST] late of last day of sign/symptom: Req/L itmCONT_END: SOLAE.SYMPCONT] continuing at the end of the study? — that the AE may have been caused by the	Jnk / Req/Unk / Req/Unk de investigational product? No	[itmSYMP_VAL_INTEN_D3: SOLVAL.SYMP_VAL] Day 3: [clintensitysolj
9.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD	0]		
LOS	S OF APPETITE [sctLOSSOFAPPETITE]				
10.*	Occurred?	[itmCAUSAL: SOLAE.CAUSAL] Is there a reasonable possibility the [itmMED_TYPE: SOLAE.MED_TYPE] Medically attended visit:Emerge	SOLVAL.SYMP_VAL] Day 1: [clintensitysol] [itmSYMP_MAX_INTEN: laximum intensity: [clintensitysol_m itmERDAT: SOLAE.SYMP_LST] valee of last day of sign/symptom: Req/L itmCONT_END: SOLAE.SYMPCONT] continuing at the end of the study? hat the AE may have been caused by the ency Room Hospitalisation Medical I	Jnk / Req/Unk / Req/Unk de investigational product? No	[itmSYMP_VAL_INTEN_D3: SOLVAL.SYMP_VAL] Day 3: [clintensitysol] (2013-2018)
11.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD	0]		
	y: [♥] = Source verification required te: Source verification critical settings made in InFor	m will override any settings made in Centi	ral Designer.		

	ECK FOR CTURY CONTINUE TO U.S.		
СН	ECK FOR STUDY CONTINUATION [sctSTU	JDYCONTINUATION]	
1.*	Did the subject return for this visit?		
PF	RMANENT DISCONTINUATION [sctPERM_	[itmDECISION: VIS_INFO.DECISION] -> For serious (except death), non-serious adverse events and Other reasons only: Please select who made the decision: Investigator Subject's parents / Legally Acceptable Representatives	
_		מוסיסיו זויסאו זיין	
2.	Study discontinuation:	-> [itmDISCNT: VIS_INFO.DISCNT] Tick box only if permanent discontinuation, i.e. if the subject definitively withdraws from the study In this case, terminate the CRF: Complete Medication, Concomitant Vaccination, (S)AE sections and Study Conclusion.	

DTI	DTPA-HBV-IPV-135 (117119): VACCINE ADMINISTRATION - DOSE 2 (HEXA GROUP) (vac adm hexa-dose2) [frmvAcc_ADMIN_D2_HEXA]			
PRE-	RE-VACC TEMPERATURE [sctPrevacctemperature]			
1.*	Pre-vaccination temperature: [Pre-vacc temp]	[itmPRE_TEMP: VS.VSORRES] Temperature (°F)		
2.	Unit: [hidden]	[itmTEMP_UNIT_HID: Not submitted - for internal use] [clvSORRESU]		
3.	VSTEST [hidden]	[itmVSTEST_HID: VS.VSTEST] [cIVSTEST]		
4.	VSTESTCD [hidden]	[itmVSTESTCD_HID: VS.VSTESTCD] [clVSTESTCD]		
[sct\	/ACC_ADMIN_HEXA]			
Infar	nrix Hexa Vaccine			
5.*	Has Infanrix Hexa Vaccine been administered? [Vaccinated]	[itmV_ADM_HEXA_D1: VACCPROD.V_ADM] Yes - [itmV_TRT_HEXA: VACC_TRT.V_TRT] > Administered treatment number: N10 [itmP_AP_HEXA: VACCPROD.P_AP] Injection Site/Side/Route: According to protocol (Thigh - Right - IM) Not according to protocol -> [itmP_APSITE_HEXA: VACCPROD.P_APSITE] Site: Deltoid Thigh Buttock [itmP_APSIDE_HEXA: VACCPROD.P_APSIDE] Side: Left Right Upper Left Lower Left Upper Right Lower Right [itmP_APROUTE_HEXA: VACCPROD.P_APROUT] Route: Intramuscular Subcutaneous [itmVADM_COM_HEXA: VACCPROD.VADM_COM] If relevant, comment on administration:		
6.	P_SITE [hidden]	[itmP_SITE_HEXA_HID: VACCPROD.P_SITE] [clvaccsite]		
7.	P_SIDE [hidden]	[itmP_SIDE_HEXA_HID: VACCPROD.P_SIDE] [clVACCSIDE]		
8.	P_ROUTE [hidden]	[itmP_ROUTE_HEXA_HID: VACCPROD.P_ROUTE] [cimedrout_vacc]		
9.	P_CODE [hidden]	[itmP_CODE_HEXA_HID: VACCPROD.P_CODE] [clPRODNAMES]		
[sct\	/ACC_ADMIN_PREVNAR13]			
Prev	nar13 Vaccine			
10.*	Has Prevnar13 Vaccine been administered? [Vaccinated]	[itmV_ADM_PREVNAR13: VACCPROD.V_ADM] Yes - [itmV_TRT_PREVNAR13: VACC_TRT.V_TRT] > Administered treatment number: N10 [itmP_AP_PREVNAR13: VACCPROD.P_AP] Injection Site/Side/Route: _According to protocol (Thigh - Lower Left - IM) Not according to protocol -> [itmP_APSITE_PREVNAR13: VACCPROD_P_APSITE]		

		Site: Deltoid Thigh Buttock [itmP_APSIDE_PREVNAR13: VACCPROD.P_APSIDE] Side: Left Right Upper Left Lower Left Upper Right Lower Right [itmP_APROUTE_PREVNAR13: VACCPROD.P_APROUT] Route: Intramuscular Subcutaneous [itmVADM_COM_PREVNAR13: VACCPROD.VADM_COM] If relevant, comment on administration: A200
		No
11.	P_SITE [hidden]	[itmP_SITE_PREVNAR13_HID: VACCPROD.P_SITE] [clVACCSITE]
12.	P_SIDE [hidden]	[itmP_SIDE_PREVNAR13_HID: VACCPROD.P_SIDE] [clVACCSIDE]
13.	P_ROUTE [hidden]	[itmP_ROUTE_PREVNAR13_HID: VACCPROD.P_ROUTE] [clmedrout_vacc]
14.	P_CODE [hidden]	[itmP_CODE_PREVNAR13_HID: VACCPROD.P_CODE]
[sctV	ACC_ADMIN_ROTARIX]	
Rota	rix Vaccine	
15.*	Has Rotarix Vaccine been administered? [Vaccinated]	[itmV_ADM_ROTARIX: VACCPROD.V_ADM] Yes - [itmV_TRT_ROTARIX: VACC_TRT.V_TRT] > Administered treatment number: N10 [itmP_AP_ROTARIX: VACCPROD.P_AP] According to protocol (Oral) Not according to protocol [itmVADM_COM_ROTARIX: VACCPROD.VADM_COM] If relevant, comment on administration: A200
1.0	D DOUTE (hidden)	NO Figure ROUTE ROTABLY MAD MACCEPPOR B. ROUTE 1
16.	P_ROUTE [hidden]	[itmP_ROUTE_ROTARIX_HID: VACCPROD.P_ROUTE] [cIMEDROUT_CVACC]
17.	P_CODE [hidden]	[itmP_CODE_ROTARIX_HID: VACCPROD.P_CODE] [cIPRODNAMES]
VAC	CINATION DETAILS [sctVACCDETAILS_2VACC]	
18.	Date of administration:	If at least one vaccine administered [itmVACCRDAT: VAC_INFO.VACCRDAT] Req / Req (2013-2018) [itmSAME_DATE: Not submitted - for internal use] Or tick box if date is the same as visit date
19.	Vaccination date (or visit date when same as visit date) [hidden] [Vaccination date (or visit date when same as visit date)]	[itmP_RDAT: Not submitted - for internal use] NReq / NReq / NReq (2013-2018)
20.	If at least one vaccination not done: [Reason for non-admin]	[itmVACC_REAS: VAC_INFO.V_REAS] Please select the major reason for non administration: [itmSAE_CASE: VAC_INFO.SAE_CASE] Serious Adverse Event-> Please complete a SAE Report and specify SAE Report No. N2

	Non-Serious Adverse Event [itmAE_NB: VAC_INFO.AE_NB] -> Please complete Non-Serious Adverse Event section and specify AE No. N2	
	[itmSYMP_COD: VAC_INFO.SYMP_COD]	
	or Solicited AE code: [clsympcode]	
	Other, please specify (e.g.: consent withdrawal, Protocol violation,)	
	[itmDECISION: VAC_INFO.DECISION]	
	Please select who made the decision: Investigator Subject's parents / Legally Acceptable Representatives	
Key: [*] = Item is required [♥] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

DTPA-HBV-IPV-135 (117119): VACCINE ADMINISTRATION - DOSE 2 (PEDIA GROUP) (vac adm pedia-dose2) [frmVACC_ADMIN_D2_PEDIA]				
PRE	PRE-VACC TEMPERATURE [sctPREVACCTEMPERATURE]			
1.*	Pre-vaccination temperature: [Pre-vacc temp]	[itmPRE_TEMP: VS.VSORRES] Temperature (°F)		
2.	Unit: [hidden]	[itmTEMP_UNIT_HID: Not submitted - for internal use] [clvSORRESU]		
3.	VSTEST [hidden]	[itmVSTEST_HID: VS.VSTEST] [clVSTEST]		
4.	VSTESTCD [hidden]	[itmVSTESTCD_HID: VS.VSTESTCD] [clVSTESTCD]		
[sct\	/ACC_ADMIN_PEDIARIX]			
Pedi	arix Vaccine			
5.* ✓	Has Pediarix Vaccine been administered? [Vaccinated]	ItmV_ADM_PEDIARIX_D1: VACCPROD.V_ADM Yes -		
6.	P_SITE [hidden]	[itmP_SITE_PEDIARIX_HID: VACCPROD.P_SITE] [clvaccsite]		
7.	P_SIDE [hidden]	[itmP_SIDE_PEDIARIX_HID: VACCPROD.P_SIDE] [clvaccside]		
8.	P_ROUTE [hidden]	[itmP_ROUTE_PEDIARIX_HID: VACCPROD.P_ROUTE] [cIMEDROUT_VACC]		
9.	P_CODE [hidden]	[itmP_CODE_PEDIARIX_HID: VACCPROD.P_CODE] [clPRODNAMES]		
[sct\	/ACC_ADMIN_ACTHIB]			
ActH	ib Vaccine			
10.*	Has ActHib Vaccine been administered? [Vaccinated]	[itmV_ADM_ACTHIB_D1: VACCPROD.V_ADM] Yes - [itmV_TRT_ACTHIB: VACC_TRT.V_TRT] > Administered treatment number: N10 [itmP_AP_ACTHIB: VACCPROD.P_AP] Injection Site/Side/Route: According to protocol (Thigh - Upper Left - IM) Not according to protocol -> ItmP_APSITE ACTHIB: VACCPROD_P_APSITE		

		Site: Deltoid Thigh Buttock [itmP_APSIDE_ACTHIB: VACCPROD.P_APSIDE] Side: Left Right Upper Left Lower Left Upper Right Lower Right	
		[itmP_APROUTE_ACTHIB: VACCPROD.P_APROUT]	
		Route:IntramuscularSubcutaneous [itmVADM_COM_ACTHIB: VACCPROD.VADM_COM]	
		If relevant, comment on administration: A2000	
		No	
11.	P_SITE [hidden]	[itmP_SITE_ACTHIB_HID: VACCPROD.P_SITE] [cIVACCSITE]	
12.	P_SIDE [hidden]	[itmP_SIDE_ACTHIB_HID: VACCPROD.P_SIDE] [clVACCSIDE]	
13.	P_ROUTE [hidden]	[itmP_ROUTE_ACTHIB_HID: VACCPROD.P_ROUTE]	
14.	P_CODE [hidden]	[itmP_CODE_ACTHIB_HID: VACCPROD.P_CODE] [ciprodnames]	
[sct\	/ACC_ADMIN_PREVNAR13]		
Prev	nar13 Vaccine		
15.* ✓	Has Prevnar13 Vaccine been administered? [Vaccinated]	[itmV_ADM_PREVNAR13: VACCPROD.V_ADM] Yes - [itmV_TRT_PREVNAR13: VACC_TRT.V_TRT] > Administered treatment number: N10	
		[itmP_AP_PREVNAR13: VACCPROD.P_AP] Injection Site/Side/Route: According to protocol (Thigh - Lower Left - IM) Not according to protocol -> [itmP_APSITE_PREVNAR13: VACCPROD.P_APSITE]	
		Site: Deltoid Thigh Buttock	
		[itmP_APSIDE_PREVNAR13: VACCPROD.P_APSIDE]	
		Side: Left Right Upper Left Lower Left Upper Right Lower Right	
		[itmP_APROUTE_PREVNAR13: VACCPROD.P_APROUT] Route: Intramuscular Subcutaneous	
		[itmVADM_COM_PREVNAR13: VACCPROD.VADM_COM]	
		If relevant, comment on administration: A200	
		No	
16	P_SITE [hidden]	[itmP_SITE_PREVNAR13_HID: VACCPROD.P_SITE]	
10.	r_stre_imagent	[civaccsite]	
17.	P_SIDE [hidden]	[itmP_SIDE_PREVNAR13_HID: VACCPROD.P_SIDE] [clVACCSIDE]	
18.	P_ROUTE [hidden]	[itmP_ROUTE_PREVNAR13_HID: VACCPROD.P_ROUTE] [cIMEDROUT_VACC]	
19.	P_CODE [hidden]	[itmP_CODE_PREVNAR13_HID: VACCPROD.P_CODE] [ciprodnames]	
[sct\	/ACC_ADMIN_ROTARIX]		
Rota	Rotarix Vaccine		
20 *	Has Rotarix Vaccine been administered?	[itmV_ADM_ROTARIX: VACCPROD.V_ADM]	

[Vaccinated]	Yes - [itmV_TRT_ROTARIX: VACC_TRT.V_TRT] > Administered treatment number: N10
	[itmP_AP_ROTARIX: VACCPROD.P_AP] According to protocol (Oral) Not according to protocol [itmVADM_COM_ROTARIX: VACCPROD.VADM_COM]
	If relevant, comment on administration: $A200$
P_ROUTE [hidden]	[itmP_ROUTE_ROTARIX_HID: VACCPROD.P_ROUTE]
P_CODE [hidden]	[itmP_CODE_ROTARIX_HID: VACCPROD.P_CODE] [clPRODNAMES]
CINATION DETAILS [sctVACCDETAILS_2VACC]	
Date of administration:	If at least one vaccine administered [itmVACCRDAT: VAC_INFO.VACCRDAT] Req / Req (2013-2018) [itmSAME_DATE: Not submitted - for internal use] Or tick box if date is the same as visit date
Vaccination date (or visit date when same as visit date) [hidden] [Vaccination date (or visit date when same as visit date)]	[itmP_RDAT: Not submitted - for internal use] NReq / NReq / NReq (2013-2018)
If at least one vaccination not done: [Reason for non-admin]	[itmVACC_REAS: VAC_INFO.V_REAS] Please select the major reason for non administration: [itmSAE_CASE: VAC_INFO.SAE_CASE] Serious Adverse Event-> Please complete a SAE Report and specify SAE Report No. N2
	Non-Serious Adverse Event [itmAF_NB: VAC_INFO.AE_NB] -> Please complete Non-Serious Adverse Event section and specify AE No. N2 [itmSYMP_COD: VAC_INFO.SYMP_COD] Or Solicited AE code: [clsympcode] [itmV_OTH: VAC_INFO.V_OTH] Other, please specify A100 [itmDECISION: VAC_INFO.DECISION] Please select who made the decision: Investigator Subject's parents / Legally Acceptable Representatives
	P_CODE [hidden] CINATION DETAILS [sctVACCDETAILS_2VACC] Date of administration: Vaccination date (or visit date when same as visit date) [hidden] [Vaccination date (or visit date when same as visit date)] If at least one vaccination not done:

DT	DTPA-HBV-IPV-135 (117119): VACCINE ADMINISTRATION - DOSE 2 (PENTA GROUP) (vac adm penta-dose2) [frmVACC_ADMIN_D2_PENTA] PRE-VACC TEMPERATURE [sctPREVACCTEMPERATURE]		
PRE			
1.* •	Pre-vaccination temperature: [Pre-vacc temp]	[itmPRE_TEMP: VS.VSORRES] Temperature (°F)	
2.	Unit: [hidden]	[itmTEMP_UNIT_HID: Not submitted - for internal use] [clvSorresu]	
3.	VSTEST [hidden]	[itmVSTEST_HID: VS.VSTEST] [clVSTEST]	
4.	VSTESTCD [hidden]	[itmVSTESTCD_HID: VS.VSTESTCD] [clVSTESTCD]	
[sct	/ACC_ADMIN_PENTACEL]		
Pent	acel Vaccine		
5.*	Has Pentacel Vaccine been administered? [Vaccinated]	[itmV_ADM_PENTACEL_D1: VACCPROD.V_ADM] Yes -	
6.	P_SITE [hidden]	[itmP_SITE_PENTACEL_HID: VACCPROD.P_SITE] [clvaccsite]	
7.	P_SIDE [hidden]	[itmP_SIDE_PENTACEL_HID: VACCPROD.P_SIDE] [cIVACCSIDE]	
8.	P_ROUTE [hidden]	[itmP_ROUTE_PENTACEL_HID: VACCPROD.P_ROUTE] [cIMEDROUT_VACC]	
9.	P_CODE [hidden]	[itmP_CODE_PENTACEL_HID: VACCPROD.P_CODE] [cIPRODNAMES]	
[sct	/ACC_ADMIN_ENGERIX_B]		
Enge	erix-B Vaccine (should not be given at Month 2 (4 months of age) if a dose of Hepatitis B vaccine was given at birth up to 30 days prior to study dose 1)	
10.*	Has Engerix-B Vaccine been administered? [Vaccinated]	[itmV_ADM_ENGERIX_B_D1: VACCPROD.V_ADM] Yes - [itmV_TRT_ENGERIX_B: VACC_TRT.V_TRT] > Administered treatment number: N10	

		Site: Deltoid Thigh Buttock [itmP_APSIDE_ENGERIX_B: VACCPROD.P_APSIDE] Side: Left Right Upper Left Lower Left Upper Right Lower Right [itmP_APROUTE_ENGERIX_B: VACCPROD.P_APROUT] Route: Intramuscular Subcutaneous [itmVADM_COM_ENGERIX_B: VACCPROD.VADM_COM] If relevant, comment on administration: A200	
11.	P_SITE [hidden]	[itmP_SITE_ENGERIX_B_HID: VACCPROD.P_SITE]	
		[cIVACCSITE]	
12.	P_SIDE [hidden]	[itmP_SIDE_ENGERIX_B_HID: VACCPROD.P_SIDE] [clVACCSIDE]	
13.	P_ROUTE [hidden]	[itmP_ROUTE_ENGERIX_B_HID: VACCPROD.P_ROUTE] [cimedrout_vacc]	
14.	P_CODE [hidden]	[itmP_CODE_ENGERIX_B_HID: VACCPROD.P_CODE]	
[sct\	/ACC_ADMIN_PREVNAR13]		
Prev	nar13 Vaccine		
	[Vaccinated]	Itmv_ADM_PREVNAR13: VACCPROD.V_ADM] Yes - Itmv_TRT_PREVNAR13: VACCPROD.P_AP] Injection Site/Side/Route: According to protocol (Thigh - Lower Left - IM) Not according to protocol -> Itmp_APSITE_PREVNAR13: VACCPROD.P_APSITE] Site:	
	P_SITE [hidden]	[itmP_SITE_PREVNAR13_HID: VACCPROD.P_SITE] [clVACCSITE]	
17.	P_SIDE [hidden]	[itmP_SIDE_PREVNAR13_HID: VACCPROD.P_SIDE] [clVACCSIDE]	
18.	P_ROUTE [hidden]	[itmp_ROUTE_PREVNAR13_HID: VACCPROD.P_ROUTE] [cimedrout_vacc]	
19.	P_CODE [hidden]	[itmP_CODE_PREVNAR13_HID: VACCPROD.P_CODE] [clprodnames]	
[sct\	[sctVACC_ADMIN_ROTARIX]		
Rota	Rotarix Vaccine		
20 *	Has Rotarix Vaccine been administered?	[itmV_ADM_ROTARIX: VACCPROD.V_ADM]	

•	[Vaccinated]	Yes - [itmV_TRT_ROTARIX: VACC_TRT.V_TRT] > Administered treatment number: N10 [itmP_AP_ROTARIX: VACCPROD.P_AP] According to protocol (Oral) Not according to protocol [itmVADM_COM_ROTARIX: VACCPROD.VADM_COM] If relevant, comment on administration: A200	
		No	
21.	P_ROUTE [hidden]	[itmP_ROUTE_ROTARIX_HID: VACCPROD.P_ROUTE] [cIMEDROUT_CVACC]	
22.	P_CODE [hidden]	[itmP_CODE_ROTARIX_HID: VACCPROD.P_CODE] [clPRODNAMES]	
VAC	CINATION DETAILS [sctVACCDETAILS_2VACC]		
23. ✔	Date of administration:	If at least one vaccine administered [itmVACCRDAT: VAC_INFO.VACCRDAT] Req / Req (2013-2018) [itmSAME_DATE: Not submitted - for internal use] Or tick box if date is the same as visit date	
24.	Vaccination date (or visit date when same as visit date) [hidden] [Vaccination date (or visit date when same as visit date)]	[itmP_RDAT: Not submitted - for internal use] NReq / NReq / NReq (2013-2018)	
25.	If at least one vaccination not done: [Reason for non-admin]	[itmVACC_REAS: VAC_INFO.V_REAS] Please select the major reason for non administration: [itmSAE_CASE: VAC_INFO.SAE_CASE] Serious Adverse Event-> Please complete a SAE Report and specify SAE Report No. N2 Non-Serious Adverse Event [itmAE_NB: VAC_INFO.AE_NB] > Please complete Non-Serious Adverse Event section and specify AE No. N2 [itmSYMP_COD: VAC_INFO.SYMP_COD] Or Solicited AE code: [dSYMPCODE] [itmV_OTH: VAC_INFO.V_OTH] Other, please specify A100 [itmDECISION: VAC_INFO.DECISION] Please select who made the decision: Investigator Subject's parents / Legally Acceptable Representatives	
	Key: [*] = Item is required [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

D.	DTPA-HBV-IPV-135 (117119): LOCAL SIGNS/SYMPTOMS FLAG - ACTHIB (Loc symp flg ActHib) [frmlocsymptoms_flag_acthib_d2]		
LO	LOCAL SIGNS/SYMPTOMS FLAG - ACTHIB [sctLOCSYMPTOMS_FLG_ACTHIB_D2]		
1.*	Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [Local Symp flag for ActHib]	[itmLOCSOL_YN_ACTHIB_D2: SOLSHEET.SOL_YN] Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary No Unknown, no information available	
2.	Solicited symptoms type [hidden] [Solicited symptoms type]	[itmSOL_TYP_HID: Not submitted - for internal use] Generalised Localised	
	Key: [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

DTPA-HBV-IPV-135 (117119): VACCINE ADMINISTRATION - DOSE 3 (HEXA GROUP) (vac adm hexa-dose3) [frmvacc_admin_d3_hexa]			
PRE-	PRE-VACC TEMPERATURE [sctPREVACCTEMPERATURE]		
1.*	Pre-vaccination temperature: [Pre-vacc temp]	[itmPRE_TEMP: VS.VSORRES] Temperature (°F)	
2.	Unit: [hidden]	[itmTEMP_UNIT_HID: Not submitted - for internal use] [clvSORRESU]	
3.	VSTEST [hidden]	[itmVSTEST_HID: VS.VSTEST] [clVSTEST]	
4.	VSTESTCD [hidden]	[itmVSTESTCD_HID: VS.VSTESTCD] [clVSTESTCD]	
[sct\	/ACC_ADMIN_HEXA]		
Infar	nrix Hexa		
5.*	Has Infanrix Hexa Vaccine been administered? [Vaccinated]	[itmV_ADM_HEXA_D1: VACCPROD.V_ADM] Yes -	
6.	P_SITE [hidden]	[itmP_SITE_HEXA_HID: VACCPROD.P_SITE] [clvaccsite]	
7.	P_SIDE [hidden]	[itmP_SIDE_HEXA_HID: VACCPROD.P_SIDE] [clvAccside]	
8.	P_ROUTE [hidden]	[itmP_ROUTE_HEXA_HID: VACCPROD.P_ROUTE] [cimedrout_vacc]	
9.	P_CODE [hidden]	[itmP_CODE_HEXA_HID: VACCPROD.P_CODE] [cIPRODNAMES]	
[sct\	/ACC_ADMIN_PREVNAR13]		
Prev	nar13 Vaccine		
10.*	Has Prevnar13 Vaccine been administered? [Vaccinated]	[itmV_ADM_PREVNAR13: VACCPROD.V_ADM] Yes - [itmV_TRT_PREVNAR13: VACC_TRT.V_TRT] > Administered treatment number: N10 [itmP_AP_PREVNAR13: VACCPROD.P_AP] Injection Site/Side/Route: _According to protocol (Thigh - Lower Left - IM) Not according to protocol -> [itmP_APSITE_PREVNAR13: VACCPROD_P_APSITE]	

		Site: Deltoid Thigh Buttock [itmP_APSIDE_PREVNAR13: VACCPROD.P_APSIDE] Side: Left Right Upper Left Lower Left Upper Right Lower Right [itmP_APROUTE_PREVNAR13: VACCPROD.P_APROUT] Route: Intramuscular Subcutaneous [itmVADM_COM_PREVNAR13: VACCPROD.VADM_COM] If relevant, comment on administration: A200
		No
11.	P_SITE [hidden]	[itmP_SITE_PREVNAR13_HID: VACCPROD.P_SITE] [cdVACCSITE]
12.	P_SIDE [hidden]	[itmP_SIDE_PREVNAR13_HID: VACCPROD.P_SIDE] [cdVACCSIDE]
13.	P_ROUTE [hidden]	[itmP_ROUTE_PREVNAR13_HID: VACCPROD.P_ROUTE] [cIMEDROUT_VACC]
14.	P_CODE [hidden]	[itmP_CODE_PREVNAR13_HID: VACCPROD.P_CODE]
VAC	CINATION DETAILS [sctVACCDETAILS_2VACC]	
15. ✓	Date of administration:	If at least one vaccine administered [itmVACCRDAT: VAC_INFO.VACCRDAT] Req / Req (2013-2018) [itmSAME_DATE: Not submitted - for internal use] Or tick box if date is the same as visit date
16.	Vaccination date (or visit date when same as visit date) [hidden] [Vaccination date (or visit date when same as visit date)]	[itmP_RDAT: Not submitted - for internal use] NReq / NReq / NReq (2013-2018)
17.	If at least one vaccination not done: [Reason for non-admin]	[itmVACC_REAS: VAC_INFO.V_REAS] Please select the major reason for non administration: [itmSAE_CASE: VAC_INFO.SAE_CASE] Serious Adverse Event-> Please complete a SAE Report and specify SAE Report No. N/2 Non-Serious Adverse Event [itmAE_NB: VAC_INFO.AE_NB] -> Please complete Non-Serious Adverse Event section and specify AE No. N/2 [itmSYMP_COD: VAC_INFO.SYMP_COD] or Solicited AE code: [clsyMPCODE] Other, please specify (e.g.: consent withdrawal, Protocol violation,) A100 [itmDECISION: VAC_INFO.DECISION] Please select who made the decision: Investigator Subject's parents (Logally Acceptable Percentable Percentables Subject's parents (Logally Acceptable Percentables Subject's parents (Logally Acceptables
	/: [*] = Item is required [✔] = Source verification	

DTI	DTPA-HBV-IPV-135 (117119): VACCINE ADMINISTRATION - DOSE 3 (PEDIA GROUP) (vac adm pedia-dose3) [frmVACC_ADMIN_D3_PEDIA]		
PRE-	PRE-VACC TEMPERATURE [sctPREVACCTEMPERATURE]		
1.*	Pre-vaccination temperature: [Pre-vacc temp]	[itmPRE_TEMP: VS.VSORRES] Temperature (°F)	
2.	Unit: [hidden]	[itmTEMP_UNIT_HID: Not submitted - for internal use] [clvSORRESU]	
3.	VSTEST [hidden]	[itmVSTEST_HID: VS.VSTEST] [cdvSTest]	
4.	VSTESTCD [hidden]	[itmVSTESTCD_HID: VS.VSTESTCD]	
VAC	CINE ADMINISTRATION - PEDIARIX [sctVACC	_ADMIN_PEDIARIX]	
5.*	Has Pediarix Vaccine been administered? [Vaccinated]	ItimV_ADM_PEDIARIX_DI:VACCPROD.V_ADM Yes -	
6.	P_SITE [hidden]	[itmP_SITE_PEDIARIX_HID: VACCPROD.P_SITE] [clVACCSITE]	
7.	P_SIDE [hidden]	[itmP_SIDE_PEDIARIX_HID: VACCPROD.P_SIDE] [clVACCSIDE]	
8.	P_ROUTE [hidden]	[itmP_ROUTE_PEDIARIX_HID: VACCPROD.P_ROUTE]	
9.	P_CODE [hidden]	[itmP_CODE_PEDIARIX_HID: VACCPROD.P_CODE]	
[sct\	[sctVACC_ADMIN_ACTHIB]		
ActH	ActHib Vaccine		
10.*	Has ActHib Vaccine been administered? [Vaccinated]	[itmV_ADM_ACTHIB_D1: VACCPROD.V_ADM] Yes - [itmV_TRT_ACTHIB: VACC_TRT.V_TRT] > Administered treatment number: N10 [itmP_AP_ACTHIB: VACCPROD.P_AP] Injection Site/Side/Route: According to protocol (Thigh - Upper Left - IM) Not according to protocol -> [itmP_APSITE_ACTHIB: VACCPROD.P_APSITE] Site: Deltoid Thigh Buttock	

		[itmP_APSIDE_ACTHIB: VACCPROD.P_APSIDE] Side:leftRightUpper LeftLower LeftUpper RightLower Right [itmP_APROUTE_ACTHIB: VACCPROD.P_APROUT] Route:IntramuscularSubcutaneous [itmVADM_COM_ACTHIB: VACCPROD.VADM_COM] If relevant, comment on administration:A200	
11.	P_SITE [hidden]	[itmP_SITE_ACTHIB_HID: VACCPROD.P_SITE] [clVACCSITE]	
12.	P_SIDE [hidden]	[itmP_SIDE_ACTHIB_HID: VACCPROD.P_SIDE] [clVACCSIDE]	
13.	P_ROUTE [hidden]	[itmP_ROUTE_ACTHIB_HID: VACCPROD.P_ROUTE]	
14.	P_CODE [hidden]	[itmP_CODE_ACTHIB_HID: VACCPROD.P_CODE]	
[sct\	/ACC_ADMIN_PREVNAR13]		
Previ	nar13 Vaccine		
•	Has Prevnar13 Vaccine been administered? [Vaccinated]	[itmV_ADM_PREVNAR13: VACCPROD.V_ADM] Yes -	
16.	P_SITE [hidden]	[itmP_SITE_PREVNAR13_HID: VACCPROD.P_SITE] [clVACCSITE]	
17.	P_SIDE [hidden]	[itmP_SIDE_PREVNAR13_HID: VACCPROD.P_SIDE] [clVACCSIDE]	
18.	P_ROUTE [hidden]	[itmP_ROUTE_PREVNAR13_HID: VACCPROD.P_ROUTE] [clmedrout_vacc]	
19.	P_CODE [hidden]	[itmP_CODE_PREVNAR13_HID: VACCPROD.P_CODE]	
VAC	CINATION DETAILS [sctVACCDETAILS_2VACC]		
20.	Date of administration:	[itmVACCRDAT: VAC_INFO.VACCRDAT] If at least one vaccine administered Req / Req (2013-2018) [itmSAME_DATE: Not submitted - for internal use]	

		Or tick box if date is the same as visit date
21.	Vaccination date (or visit date when same as visit date) [hidden] [Vaccination date (or visit date when same as visit date)]	[itmP_RDAT: Not submitted - for internal use] NReq / NReq / NReq (2013-2018)
22.	If at least one vaccination not done: [Reason for non-admin]	[itmVACC_REAS: VAC_INFO.V_REAS] Please select the major reason for non administration: [itmSAE_CASE: VAC_INFO.SAE_CASE] Serious Adverse Event-> Please complete a SAE Report and specify SAE Report No. N2 Non-Serious Adverse Event [itmAE_NB: VAC_INFO.AE_NB] -> Please complete Non-Serious Adverse Event section and specify AE No. N2 [itmSYMP_COD: VAC_INFO.SYMP_COD] Solicited AE code: [clsympcode] [itmV_OTH: VAC_INFO.V_OTH] Other, please specify A100 [itmDECISION: VAC_INFO.DECISION] Please select who made the decision: Investigator Subject's parents / Legally Acceptable Representatives
	$r: [*] = \text{Item is required } [\checkmark] = \text{Source verification}$ e: Source verification critical settings made in InFor	required m will override any settings made in Central Designer.

DTI	TPA-HBV-IPV-135 (117119): VACCINE ADMINISTRATION - DOSE 3 (PENTA GROUP) (vac adm penta-dose3) [frmVACC_ADMIN_D3_PENTA]		
PRE-	RE-VACC TEMPERATURE [sctPREVACCTEMPERATURE]		
1.* ✓	Pre-vaccination temperature: [Pre-vacc temp]	[itmPRE_TEMP: VS.VSORRES] Temperature (°F) XXX.X [itmTEMP_ROUTE: VS.VSLOC] Route: Axillary Oral Rectal (Preferred) Tympanic	
2.	Unit: [hidden]	[itmTEMP_UNIT_HID: Not submitted - for internal use] [clvsOrresu]	
3.	VSTEST [hidden]	[itmVSTEST_HID: VS.VSTEST] [clVSTEST]	
4.	VSTESTCD [hidden]	[itmVSTESTCD_HID: VS.VSTESTCD] [clvSTESTCD]	
[sct\	/ACC_ADMIN_PENTACEL]		
Pent	acel Vaccine		
5.* •	Has Pentacel Vaccine been administered? [Vaccinated]	[itmV_ADM_PENTACEL_: VACC_TRT.V_TRT] > Administered treatment number: N10	
6.	P_SITE [hidden]	[itmP_SITE_PENTACEL_HID: VACCPROD.P_SITE] [clvaccsite]	
7.	P_SIDE [hidden]	[itmP_SIDE_PENTACEL_HID: VACCPROD.P_SIDE] [clvaccside]	
8.	P_ROUTE [hidden]	[itmP_ROUTE_PENTACEL_HID: VACCPROD.P_ROUTE] [cIMEDROUT_VACC]	
9.	P_CODE [hidden]	[itmP_CODE_PENTACEL_HID: VACCPROD.P_CODE] [cIPRODNAMES]	
[sct\	/ACC_ADMIN_ENGERIX_B]		
Enge	rix-B Vaccine		
10.*	Has Engerix-B Vaccine been administered? [Vaccinated]	[itmV_ADM_ENGERIX_B_D1: VACCPROD.V_ADM] Yes - [itmV_TRT_ENGERIX_B: VACC_TRT.V_TRT] > Administered treatment number: N10 [itmP_AP_ENGERIX_B: VACCPROD.P_AP] Injection Site/Side/Route: According to protocol (Thigh - Upper Left - IM) Not according to protocol -> [itmP_APSITE_ENGERIX_B: VACCPROD.P_APSITE]	

		Site: Deltoid Thigh Buttock [itmP_APSIDE_ENGERIX_B: VACCPROD.P_APSIDE] Side: Left Right Upper Left Upper Right Lower Right [itmP_APROUTE_ENGERIX_B: VACCPROD.P_APROUT] Route: Intramuscular Subcutaneous [itmVADM_COM_ENGERIX_B: VACCPROD.VADM_COM] If relevant, comment on administration: A200
11.	P_SITE [hidden]	[itmP_SITE_ENGERIX_B_HID: VACCPROD.P_SITE]
12.	P_SIDE [hidden]	[itmP_SIDE_ENGERIX_B_HID: VACCPROD.P_SIDE]
13.	P_ROUTE [hidden]	[itmP_ROUTE_ENGERIX_B_HID: VACCPROD.P_ROUTE]
14.	P_CODE [hidden]	[itmP_CODE_ENGERIX_B_HID: VACCPROD.P_CODE] [clPRODNAMES]
[sct\	/ACC_ADMIN_PREVNAR13]	
Prev	nar13 Vaccine been administered?	
15.*	[Vaccinated]	[itmV_ADM_PREVNAR13: VACCPROD.V_ADM] Yes - [itmV_TRT_PREVNAR13: VACC_TRT.V_TRT] > Administered treatment number: N10
16.	P_SITE [hidden]	[itmP_SITE_PREVNAR13_HID: VACCPROD.P_SITE] [cdVACCSITE]
17.	P_SIDE [hidden]	[itmP_SIDE_PREVNAR13_HID: VACCPROD.P_SIDE] [cdVACCSIDE]
18.	P_ROUTE [hidden]	[itmP_ROUTE_PREVNAR13_HID: VACCPROD.P_ROUTE] [cimedrout_vacc]
19.	P_CODE [hidden]	[itmP_CODE_PREVNAR13_HID: VACCPROD.P_CODE] [clprodnames]
VAC	CINATION DETAILS [sctVACCDETAILS_2VACC]	
20.	Date of administration:	[itmVACCRDAT: VAC_INFO.VACCRDAT] If at least one vaccine administered Req / Req / Req (2013-2018)

	ı	
		[itmSAME_DATE: Not submitted - for internal use]
		Or tick box if date is the same as visit date
		of this box is due to the same as visit date.
21.	Vaccination date (or visit date when same as	[itmP_RDAT: Not submitted - for internal use]
	visit date) [hidden]	NReq / NReq / NReq (2013-2018)
	[Vaccination date (or visit date when same as	
	visit date)]	
22.	If at least one vaccination not done:	[itmVACC REAS: VAC INFO.V REAS]
_ ر	[Reason for non-admin]	Please select the major reason for non administration:
•		[itmSAE_CASE: VAC_INFO.SAE_CASE]
		Serious Adverse Event-> Please complete a SAE Report and specify SAE Report No. N2
		Non-Serious Adverse Event [itmAF_NB: VAC_INFO.AE_NB]
		-> Please complete Non-Serious Adverse Event section and specify AE No. N2
		[itmSYMP_COD: VAC_INFO.SYMP_COD]
		Solicited AE code: [clsympcode]
		[itmV_OTH: VAC_INFO.V_OTH]
		Other, please specify A_{100}
		ALOU
		[itmDECISION: VAC_INFO.DECISION]
		Please select who made the decision: Investigator
		Subject's parents / Legally Acceptable Representatives
	f : [*] = Item is required [\checkmark] = Source verification	·
Not	e: Source verification critical settings made in InFor	m will override any settings made in Central Designer.

D	DTPA-HBV-IPV-135 (117119): LOCAL SIGNS/SYMPTOMS FLAG - ACTHIB (Loc symp flg ActHib) [frmlocsymptoms_flag_acthib_d3]	
L	OCSYMPTOMS_FLG_ACTHIB [sctLOCSYMPTOMS_FL	G_ACTHIB_D3]
1.	* Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [Local Symp flag for ActHib]	[itmLOCSOL_YN_ACTHIB_D3: SOLSHEET.SOL_YN] Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary No Unknown, no information available
2.	Solicited symptoms type [hidden] [Solicited symptoms type]	[itmSOL_TYP_HID: Not submitted - for internal use] Generalised Localised
	Key: [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.	

DTF	DTPA-HBV-IPV-135 (117119): LABORATORY TESTS (Labo tests) [frmLABORATORYTESTS]		
BLO	DD SAMPLE [sctSERUMSAMPLE]		
	Has a blood sample been taken? SER sample taken]	[itmSAMPTAKE_SER: LABSHEET.SAMPTAKE] Yes -> [itmSAMPRDAT_D: LABSHEET.SAMPRDAT] Date of collection: Req / Req (2013-2018) [itmSAME_DATE: Not submitted - for internal use] Or tick box if date is the same as visit date [itmNB_TUBES: LABSHEET.NB_TUBES] Number of tube(s) taken: N2 [itmREQ_NUM: LABSHEET.REQ_NUM] Requisition number: A9	
I I	For GSK: [hidden] Reconciled]	[itmRECONCIL_HID: LABSHEET.RECONCIL] Reconciled (CDR only):0 - Lost in transit1 - Lost in site2 - Lost in GSK3 - Scrapped	
3. E	EVENTTYP [hidden]	[itmEVENTTYP_HID: LABO_CRF.EVENTTYP] [clsystemcd]	
	Key: [♥] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

D1	DTPA-HBV-IPV-135 (117119): INVESTIGATOR SIGNATURE (Inv sign) [INVSIGN_CR]		
IN	VESTIGATOR SIGNATURE [sctINVSIGN]		
1.*	Is this casebook ready to sign? If not, click on the RETURN button below	[INVSIGN: Not submitted - for internal use] Ready to sign	
2.	For Data Managers only: Tick or untick this box to require the investigator to re-sign the case book By ticking or unticking this box you are evoking a change to this form back to an unsigned state. This should be done when significant changes (e.g. those that require medical opinion or other significants situation) occur after the original signature. If the box is already ticked upon arrival on this form, unticking and submitting it accomplishes the same task as ticking and submitting it; that is, the signature will be validated in both [hidden]	[INVSIG2: Not submitted - for internal use]	
1	Key: [♥] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

DT	DTPA-HBV-IPV-135 (117119): ESFU CONTACT (M10) (ESFU contact) [frmPHONECONTACT_DISC]		
ESI	FU CONTACT (M10) [sctPHONECONTACT]		
	ase contact the subject's parent(s) / guardiar SAEs .	n(s) by phone to follow up on the administration of medication or vaccination and to check on the occurrence of intercurrent medical conditions or NOCDs	
1.*	Has safety information been obtained?		
PEI 2.	RMANENT DISCONTINUATION [sctPERM_DI	-> [itmDISCNT: VIS_INFO.DISCNT]	
~		Tick box only if permanent discontinuation, i.e. if the subject definitively withdraws from the study In this case, terminate the CRF: Complete Medication, Concomitant Vaccination, (S)AE sections and Study Conclusion.	

DT	PA-HBV-IPV-135 (117119): CHEC	K FOR STUDY CONTINUATION (BOOSTER EPOCH) (Study Cont) [frmstudycontinuationepoch_disc]
	ECK FOR STUDY CONTINUATION (BOOSTER E	
1.*	Did the subject return for the booster epoch?	
	RMANENT DISCONTINUATION [sctPERM_DISCO	ONTINUATION]
2. •	Study discontinuation:	[itmDISCNT: VIS_INFO.DISCNT] Tick box only if permanent discontinuation, i.e. if the subject definitively withdraws from the study If Yes, please sign off booster epoch
	ey: [*] = Item is required [🗸] = Source verification	n required om will override any settings made in Central Designer.

DT	TPA-HBV-IPV-135 (117119): VACCINE ADMINISTRATION - DOSE 4 (HEXA GROUP) (vac adm hexa-dose4) [frmVACC_ADMIN_D4_HEXA]		
PRE-	E-VACC TEMPERATURE [sctPREVACCTEMPERATURE]		
1.* ✓	Pre-vaccination temperature: [Pre-vacc temp]	[itmPRE_TEMP: VS.VSORRES] Temperature (°F) XXX.X [itmTEMP_ROUTE: VS.VSLOC] Route: Axillary (Preferred) Oral Rectal Tympanic	
2.	Unit: [hidden]	[itmTEMP_UNIT_HID: Not submitted - for internal use] [clVSORRESU]	
3.	VSTEST [hidden]	[itmVSTEST_HID: VS.VSTEST]	
4.	VSTESTCD [hidden]	[itmVSTESTCD_HID: VS.VSTESTCD]	
[sct\	ACC_ADMIN_INFANRIX]		
Infar	rix Vaccine		
5. [*] ✓	Pre vaccination Limb Circumference measurement (Infanrix):	[itmNT_LIMB: VACCPROD.C_N_TAK] [itmCIRC_LIMB: VACCPROD.CIRC_LMB] Not taken	
6. * •	Has Infanrix Vaccine been administered? [Vaccinated]	[itmv_ADM_INFANRIX: VACCPROD.V_ADM] Yes -	
7.	P_SIDE [hidden]	[itmP_SIDE_INFANRIX_HID: VACCPROD.P_SIDE] [clvACCSIDE]	
8.	P_ROUTE [hidden]	[itmP_ROUTE_INFANRIX_HID: VACCPROD.P_ROUTE] [cIMEDROUT_VACC]	
9.	P_CODE [hidden]	[itmP_CODE_INFANRIX_HID: VACCPROD.P_CODE] [clprodnames]	
[sct\	ACC_ADMIN_HIBERIX]		
Hibe	rix Vaccine		
10.* ✓	Pre vaccination Limb Circumference measurement (Hiberix):	[itmNT_LIMB: VACCPROD.C_N_TAK] [itmCIRC_LIMB: VACCPROD.CIRC_LMB] Not taken	

111.*	Has Hiberix Vaccine been administered? [Vaccinated]	Ithmy_nty_Hiberix: VACC_TRT.V_TRT] Yes - Ithmy_nty_Hiberix: VACC_TRT.V_TRT] Administered treatment number: N10
		LNo
12.	P_SIDE [hidden]	[itmP_SIDE_HIBERIX_HID: VACCPROD.P_SIDE] [clvAccside]
13.	P_ROUTE [hidden]	[itmP_ROUTE_HIBERIX_HID: VACCPROD.P_ROUTE]
14.	P_CODE [hidden]	[itmP_CODE_HIBERIX_HID: VACCPROD.P_CODE] [clprodnames]
VAC	INATION DETAILS [sctVACCDETAILS_2VACC]	
15. ✓	Date of administration:	If at least one vaccine administered [itmVACCRDAT: VAC_INFO.VACCRDAT] Req / Req (2013-2018) [itmSAME_DATE: Not submitted - for internal use] Or tick box if date is the same as visit date
16.	Vaccination date (or visit date when same as visit date) [hidden] [Vaccination date (or visit date when same as visit date)]	[itmP_RDAT: Not submitted - for internal use] NReq / NReq / NReq (2013-2018)
	If at least one vaccination not done: [Reason for non-admin] : [*] = Item is required [✓] = Source verification	[ItmVACC_REAS: VAC_INFO.V_REAS] Please select the major reason for non administration: [ItmSAE_CASE: VAC_INFO.SAE_CASE] Serious Adverse Event-> Please complete a SAE Report and specify SAE Report No. N2 Non-Serious Adverse Event [ItmAE_NB: VAC_INFO.AE_NB] -> Please complete Non-Serious Adverse Event section and specify AE No. N2 [ItmSYMP_COD: VAC_INFO.SYMP_COD] or Solicited AE code: [ICSYMPCODE] [ItmV_OTH: VAC_INFO.V_OTH] Other, please specify (e.g.: consent withdrawal, Protocol violation,) A100 [ItmDECISION: VAC_INFO.DECISION] Please select who made the decision: Investigator Subject's parents / Legally Acceptable Representatives

DTF	DTPA-HBV-IPV-135 (117119): VACCINE ADMINISTRATION - DOSE 4 (PEDIA GROUP) (vac adm pedia-dose4) [frmvACC_ADMIN_D4_PEDIA]			
PRE-	E-VACC TEMPERATURE [sctPREVACCTEMPERATURE]			
1.* ✓	Pre-vaccination temperature: [Pre-vacc temp]	[itmPRE_TEMP: VS.VSORRES] Temperature (°F) XXX.X [itmTEMP_ROUTE: VS.VSLOC] Route: Axillary (Preferred) Oral Rectal Tympanic		
2.	Unit: [hidden]	[itmTEMP_UNIT_HID: Not submitted - for internal use] [clvSORRESU]		
3.	VSTEST [hidden]	[itmVSTEST_HID: VS.VSTEST] [clvSTEST]		
4.	VSTESTCD [hidden]	[itmVSTESTCD_HID: VS.VSTESTCD] [clvSTESTCD]		
[sctV	ACC_ADMIN_INFANRIX]			
Infan	rix Vaccine			
5.* ✓	Pre vaccination Limb Circumference measurement (Infanrix):	[itmNT_LIMB: VACCPROD.C_N_TAK] [itmCIRC_LIMB: VACCPROD.CIRC_LMB] Not taken		
6.* •	Has Infanrix Vaccine been administered? [Vaccinated]	[itmV_ADM_INFANRIX: VACCPROD.V_ADM] Yes -		
7.	P_SIDE [hidden]	[itmP_SIDE_INFANRIX_HID: VACCPROD.P_SIDE] [clvACCSIDE]		
8.	P_ROUTE [hidden]	[itmP_ROUTE_INFANRIX_HID: VACCPROD.P_ROUTE] [cIMEDROUT_VACC]		
9.	P_CODE [hidden]	[itmP_CODE_INFANRIX_HID: VACCPROD.P_CODE]		
[sctV	ACC_ADMIN_ACTHIB_BST]			
ActHi	b Vaccine			
10.* ✓	Pre vaccination Limb Circumference measurement (ActHib):	[itmNT_LIMB: VACCPROD.C_N_TAK] [itmCIRC_LIMB: VACCPROD.CIRC_LMB] Not taken		

11.*	Has ActHib Vaccine been administered? [Vaccinated]	[itmV_ADM_ACTHIB_BST: VACCPROD.V_ADM] Yes - [itmV_TRT_ACTHIB: VACC_TRT.V_TRT] > Administered treatment number: N10 [itmP_AP_ACTHIB: VACCPROD.P_AP] Injection Site/Side/Route: [itmP_SITE_ACTHIB_BST: VACCPROD.P_SITE] According to protocol: (Deltoid/Thigh - Left - IM) Deltoid Thigh Not according to protocol -> [itmP_APSITE_ACTHIB: VACCPROD.P_APSITE] Site: Deltoid Thigh Buttock [itmP_APSIDE_ACTHIB_BST: VACCPROD.P_APSIDE] Side: Left Right Upper Left Lower Left Upper Right Lower Right [itmP_APROUTE_ACTHIB: VACCPROD.P_APROUT] Route: Intramuscular Subcutaneous [itmVADM_COM_ACTHIB: VACCPROD.VADM_COM] If relevant, comment on administration: A200		
		No		
12.	P_SIDE [hidden]	[itmP_SIDE_ACTHIB_HID: VACCPROD.P_SIDE]		
13.	P_ROUTE [hidden]	[itmP_ROUTE_ACTHIB_HID: VACCPROD.P_ROUTE]		
14.	P_CODE [hidden]	[itmP_CODE_ACTHIB_HID: VACCPROD.P_CODE]		
VAC	CINATION DETAILS [sctVACCDETAILS_2VACC]			
15.	Date of administration:	If at least one vaccine administered [itmVACCRDAT: VAC_INFO.VACCRDAT] Req / Req (2013-2018) [itmSAME_DATE: Not submitted - for internal use] Or tick box if date is the same as visit date		
16.	Vaccination date (or visit date when same as visit date) [hidden] [Vaccination date (or visit date when same as visit date)]	[itmP_RDAT: Not submitted - for internal use] NReq / NReq / NReq (2013-2018)		
17.	If at least one vaccination not done: [Reason for non-admin]	[itmVACC_REAS: VAC_INFO.V_REAS] Please select the major reason for non administration: [itmSAE_CASE: VAC_INFO.SAE_CASE] Serious Adverse Event-> Please complete a SAE Report and specify SAE Report No. N2 Non-Serious Adverse Event [itmAE_NB: VAC_INFO.AE_NB] -> Please complete Non-Serious Adverse Event section and specify AE No. N2 [itmSYMP_COD: VAC_INFO.SYMP_COD] or Solicited AE code: [clsympcode] [itmV_OTH: VAC_INFO.V_OTH] Other, please specify (e.g.: consent withdrawal, Protocol violation,) A100 [itmDECISION: VAC_INFO.DECISION] Please select who made the decision: Investigator Subject's parents / Legally Acceptable Representatives		
	 : [*] = Item is required [✓] = Source verification e: Source verification critical settings made in InForr 	required n will override any settings made in Central Designer.		

DT	DTPA-HBV-IPV-135 (117119): VACCINE ADMINISTRATION - DOSE 4 (PENTA GROUP) (vac adm penta-dose4) [frmVACC_ADMIN_D4_PENTA]			
PRI	E-VACC TEMPERATURE [sctPREVACCTEMPERAT	TURE]		
1.* •	Pre-vaccination temperature: [Pre-vacc temp]	[itmPRE_TEMP: VS.VSORRES] Temperature (°F) XXX.X [itmTEMP_ROUTE: VS.VSLOC] Route: Axillary (Preferred) Oral Rectal Tympanic		
2.	Unit: [hidden]	[itmTEMP_UNIT_HID: Not submitted - for internal use] [clVSORRESU]		
3.	VSTEST [hidden]	[itmVSTEST_HID: VS.VSTEST] [clVSTEST]		
4.	VSTESTCD [hidden]	[itmVSTESTCD_HID: VS.VSTESTCD] [clVSTESTCD]		
[sc	tVACC_ADMIN_PENTACEL_BST]			
Per	itacel Vaccine			
5.* •	Pre vaccination Limb Circumference measurement (Pentacel):	[itmNT_LIMB: VACCPROD.C_N_TAK] [itmCIRC_LIMB: VACCPROD.CIRC_LMB] Not Taken		
6.*	Has Pentacel Vaccine been administered? [Vaccinated]			

		[itmDECISION: VAC_INFO.DECISION] Please select who made the decision: Investigator Subject's parents / Legally Acceptable Representatives		
7.	P_SIDE [hidden]	[itmP_SIDE_PENTACEL_HID: VACCPROD.P_SIDE]		
8.	P_ROUTE [hidden]	[itmP_ROUTE_PENTACEL_HID: VACCPROD.P_ROUTE] [cimedrout_vacc]		
9.	P_CODE [hidden]	[itmP_CODE_PENTACEL_HID: VACCPROD.P_CODE]		
10.	Vaccination date (or visit date when same as visit date) [hidden] [Vaccination date (or visit date when same as visit date)]	[itmP_RDAT: Not submitted - for internal use] NReq / NReq / NReq (2013-2018)		
	Key: [♥] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.			

D	DTPA-HBV-IPV-135 (117119): LOCAL SIGNS/SYMPTOMS FLAG - INFANRIX (Loc symp flg Infanrix) [frmlocsymptoms_flag_infanrix]				
LO	CAL SIGNS/SYMPTOMS FLAG - INFANRIX [sctLOG	SYMPTOMS_FLG_INFANRIX]			
1.* Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [itmLOCSOL_YW_INFANRIX: SOLSHEET.SOL_YN] Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary No Unknown, no information available		Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary No			
2.	Solicited symptoms type [hidden] [Solicited symptoms type]	[itmSOL_TYP_HID: Not submitted - for internal use] Generalised Localised			
	Key: [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.				

	PA-HBV-IPV-135 (117119): SOLIC mLOCSYMPTOMS_INFANRIX]	ITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (INFANRIX) (Loc symp-Infanrix)
	anrix vaccine injection site. nv of these adverse events meets the definition	of serious, complete a Serious Adverse Event Report.
	DNESS [sctREDNESS]	
1.*	Occurred?	[itmRE_YN:SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_MM_D0: [itmSYMP_VAL_MM_D1: SOLVAL.SYMP_VAL] SOLVAL.SYMP_VAL] (mm): Day 0: Day 1: Day 2: Day 3: N5 [itmRe_ONG: SOLAE.SYMP_ONG] After Day 3: Ongoing? No Yes -> [itmSYMP_MAX_SIZE:SOLAE.SYMP_MAX] Maximum size: N5 [itmRe_DAT:SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Unk
2.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsyMpcode]
3.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [clsympunits]
sw	ELLING [sctSWELLING]	
In	case of large swelling reaction at the injection lim	b, please fill in ALSO the large Swelling Reaction form
4.*	Occurred?	[itmSW_YN: SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_MM_D0:
5.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]
6.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [cdsympunits]
PA	IN [sctPAIN]	
7.* •	Occurred?	[itmPA_YN:SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_INTEN_D0: [itmSYMP_VAL_INTEN_D1: [itmSYMP_VAL_INTEN_D2: [itmSYMP_VAL_INTEN_D3: SOLVAL.SYMP_VAL] Day 0: Day 1: Day 2: Day 3:

		[clintensitysol] [itmPA_ONG: SOLAE.SYMP_ONG] After Day 3: Ongoing? No	[clintensitysol]	[dINTENSITYSOL]	[clintensitysol]
		Yes ->	[itmSYMP_MAX_INTEN: S Maximum intensity: [clintensitySOL_MA		
[itmERDAT: SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Uni		nk	(2013-2018)		
		[itmMED_TYPE: SOLAE.MED_TYPE			
		Medically attended visit:Emer	rgency Room Hospitalisation Medical P	ersonnelNone	
8.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_C	OD]		
1	Key: [♥] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.				

D.	DTPA-HBV-IPV-135 (117119): LOCAL SIGNS/SYMPTOMS FLAG - HIBERIX (Loc symp flg Hiberix) [frmlocsymptoms_flag_hiberix]				
LC	CAL SIGNS/SYMPTOMS FLAG - HIBERIX [sctLOCS	YMPTOMS_FLG_HIBERIX]			
1.* Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [Imalocsol_YN_HIBERIX: SOLSHEET.SOL_YN] Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary No Unknown, no information available		Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary No			
2.	Solicited symptoms type [hidden] [Solicited symptoms type]	[itmSOL_TYP_HID: Not submitted - for internal use] Generalised Localised			
	Key: [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.				

DI	PA-HBV-IPV-135 (117119): SOLIC	ITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (HIBERIX) (Loc symp-Hiberix) [frmlocsymptoms_Hiberix]		
	erix vaccine injection site. ny of these adverse events meets the definition	of serious, complete a Serious Adverse Event Report.		
REI	ONESS [sctREDNESS]			
1.*	Occurred?	[itmRE_YN: SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_MM_D0: SOLVAL.SYMP_VAL_MM_D1: SOLVAL.SYMP_VAL_MM_D2: SOLVAL.SYMP_VAL_MM_D3: SOLVAL.SYMP_VAL] (mm): Day 0: Day 1: Day 2: Day 3: N5 [itmRE_ONG: SOLAE.SYMP_ONG] After Day 3: Ongoing? No Yes -> [itmSYMP_MAX_SIZE: SOLAE.SYMP_MAX] Maximum size: N5 [itmREDAT: SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Unk / Req/Unk / Req/Unk (2013-2018) [itmCONT_END: SOLAE.SYMPCONT] Continuing at the end of the study? Medically attended visit: Emergency Room Hospitalisation Medical Personnel None		
2.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]		
3.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI]		
sw	ELLING [sctSWELLING]			
In	ase of large swelling reaction at the injection lim	b, please fill in ALSO the large Swelling Reaction form		
4.*	Occurred?	Itms// No		
5.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]		
6.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [clsympunits]		
PA	IN [sctPAIN]			
7.*	Occurred?	[itmPA_YN:SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_INTEN_D0: [itmSYMP_VAL_INTEN_D1: [itmSYMP_VAL_INTEN_D2: [itmSYMP_VAL_INTEN_D3: SOLVAL.SYMP_VAL] SOLVAL.SYMP_VAL] Day 0: Day 1: Day 2: Day 3: Idintensitysoli		

		[itmPA_ONG: SOLAE.SYMP_ONG] After Day 3: Ongoing? No Yes -> [itmSYMP_MAX_INTEN: SOLAE.SYMP_MAX] Maximum intensity: [clintensitySOL_MAX]			
		[itmERDAT : SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Unk / Req/Unk / Req/Unk (2013-2018)			
		[itmCONT_END: SOLAE.SYMPCONT] Continuing at the end of the study? [itmMED_TYPE: SOLAE.MED_TYPE] Medically attended visit: Emergency Room Hospitalisation Medical Personnel None			
8.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [cdSympcode]			
	Key: [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.				

D1	DTPA-HBV-IPV-135 (117119): LOCAL SIGNS/SYMPTOMS FLAG - ACTHIB (Loc symp flg ActHib) [frmlocsymptoms_flag_acthib_bst]				
LO	CSYMPTOMS_FLG_ACTHIB [sctLOCSYMPTOMS_FL	G_ACTHIB_BST]			
1.* Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [itmLOCSOL_YW_ACTHIB_BST: SOLSHEET.SOL_YN] Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary No Unknown, no information available		Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary No			
2.	Solicited symptoms type [hidden] [Solicited symptoms type]	[itmSOL_TYP_HID: Not submitted - for internal use] Generalised Localised			
	Key: [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.				

	PA-HBV-IPV-135 (117119): SOLIC nLOCSYMPTOMS_ACTHIB_BST]	ITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (ACTHIB) (Loc symp	-ActHib)
	Hib vaccine injection site. ny of these adverse events meets the definition	of serious, complete a Serious Adverse Event Report.	
REI	ONESS [sctREDNESS]		
1.*	Occurred?	[itmRE_YN:SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_MM_DO: [itmSYMP_VAL_MM_D1: SOLVAL.SYMP_VAL] (mm): Day 0: Day 1: Day 2: N5 [itmRE_ONG:SOLAE.SYMP_ONG] After Day 3: Ongoing? No Yes -> [itmSYMP_MAX_SIZE:SOLAE.SYMP_MAX] Maximum size: N5 [itmREDAT:SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Unk / Req	[itmSYMP_VAL_MM_D3: SOLVAL.SYMP_VAL] Day 3: N5
2.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]	
3.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [clsympunits]	
sw	ELLING [sctSWELLING]		
In	ase of large swelling reaction at the injection lim	o, please fill in ALSO the large Swelling Reaction form	
4.* •	Occurred?	[itmSW_YN:SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_MM_D0: [itmSYMP_VAL_MM_D1: SOLVAL.SYMP_VAL] SOLVAL.SYMP_VAL] (mm): Day 0: Day 1: Day 2: N5 [itmSW_ONG:SOLAE.SYMP_ONG] After Day 3: Ongoing? No Yes -> [itmSYMP_MAX_SIZE:SOLAE.SYMP_MAX] Maximum size: N5 [itmERDAT:SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Unk / Req/Unk	[itmSYMP_VAL_MM_D3: SOLVAL.SYMP_VAL] Day 3: N5
5.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]	
6.	Unit: [hidden]	[itmSYMP_UNI_HID:SOLAE.SYMP_UNI] [clsympunits]	
PA	IN [sctPAIN]		
7.* •	Occurred?	[itmPA_YN:SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_INTEN_D0: [itmSYMP_VAL_INTEN_D1: [itmSYMP_VAL_INTEN_L] Intensity: SOLVAL.SYMP_VAL] SOLVAL.SYMP_VAL] Day 0: Day 1: Day 2:	D2: [itmSYMP_VAL_INTEN_D3: SOLVAL.SYMP_VAL] Day 3:

		[clintensitysol] [itmPA_ONG: SOLAE.SYMP_ONG] After Day 3: Ongoing? No	[clintensitysol]	[clintensitysol]	[clintensitysol]
		Yes ->	[itmSYMP_MAX_INTEN : Maximum intensity: [clintensitySol_m		
			[itmERDAT: SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/U	Jnk / Req/Unk / Req/Unk	(2013-2018)
		[itmMED_TYPE: SOLAE.MED_TYPE: Medically attended visit: _Emer	[itmCONT_END: SOLAE.SYMPCONT] Continuing at the end of the study?] gency Room Hospitalisation Medical	Personnel None	
8.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_CO	OD]		
	rey: [♥] = Source verification required lote: Source verification critical settings made in InFor	m will override any settings made in Ce	entral Designer.		

	TPA-HBV-IPV-135 (117119): SOLIC mLOCSYMPTOMS_PENTACEL_BST]	ITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (PENTACEL) (Loc symp-Pentacel)
	ntacel vaccine injection site.	of serious, complete a Serious Adverse Event Report.
	DNESS [sctREDNESS]	
1.**		Ithms/mp_val_mm_D2:
2.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]
3.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [clsympunits]
sw	VELLING [sctSWELLING]	
In	case of large swelling reaction at the injection lim	b, please fill in ALSO the large Swelling Reaction form
4.*		[itmSW_YN: SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_MM_D0:
5.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clSYMPCODE]
6.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI] [clsympunits]
PA	IN [sctPAIN]	
7.* •	Occurred?	[itmPA_YN:SOLAE.SYMP_EXP] NO Yes -> [itmSYMP_VAL_INTEN_D0: [itmSYMP_VAL_INTEN_D1: [itmSYMP_VAL_INTEN_D2: [itmSYMP_VAL_INTEN_D3: SOLVAL.SYMP_VAL] Day 0: Day 1: Day 2: Day 3:

		[clintensitysol] [itmPA_ONG: SOLAE.SYMP_ONG] After Day 3: Ongoing? No	[clintensitysol]	[dINTENSITYSOL]	[clintensitysol]
		Yes ->	[itmSYMP_MAX_INTEN: S Maximum intensity: [clintensitySOL_MAX]		
			[itmERDAT: SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Ui	nk	(2013-2018)
		[itmMED_TYPE: SOLAE.MED_TYPE			
		Medically attended visit:Emer	gency Room Hospitalisation Medical P	ersonnel None	
8.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_C	OD]		
1	ey: [✔] = Source verification required ote: Source verification critical settings made in InFor	m will override any settings made in Co	entral Designer.		

DTPA-HBV-IPV-135 (117119): SOLICITED SYMPTOMS (Large swell flg) [frmLARGESWELLING_FLAG] LARGE SWELLING REACTION_FLG [sctLARGSWELLING_FLG] Definition of a Large swelling reaction: - any local swelling with diameter >50 mm - and/or any noticeable diffuse injection site swelling (diameter not measurable) - and/or any noticeable increased circumference of the injected limb 1.* Is a large swelling reaction as defined above present? [Large swelling reaction] Key: [*] = Item is required [✓] = Source verification required Note: Source verification critical settings made in Inform will override any settings made in Central Designer.

DTF	А-Н	BV-IPV-13	5 (1171	19): LA	RGE SV	WELLING R	EACTION	(Large	swelling) - Re _l	pea	ting Forn	1 [frmLARG	ESWELLINGREACTION_CHI	LD]	
# Va	ccine	Date of physical examination	Start date of swelling		Type of swelling	Circumference	Temperature	Redness	Induration	Pruritis	Pain	Functional impairment		Last date when the swelling was still considered to be a large swelling reaction:	Outcome of the large swelling reaction	Is there an alternative explanation for the swelling?
1																
If hos	pitalis	sation is require	ed, please a	ilso compl	ete a Seri	ious Adverse Ev	ent Report.									
VAC	INE [sctVACCINE]														
1.* •	Vaccii [Vacc				ΙŌ	nP_CODE_LSW: S\	_	DDE]								
REPO	RT O	F PHYSICAL E	XAMINATIO	ON [sctPH	YSICALE)	KAMINATION]										
2.*		of physical exa of physical exa			l N [itr Wa	mPHYSDAT: SWEL Req / NReq mPHYEXAM: SWE as the examinat No Yes	/ NReq LRPT.PHYSEX	(2013-20 (AM]		ly persor	nnel	during the la	rge swelling	reaction period?		
3. [*] ✓	to be	when the swel a large swellin t date of swellir	g reaction:	st conside	1.5	m SWFDAT: SWELL Req / NReq		_	18)							
4.* ✔		of swelling: of swelling]				nSWSIZE : SWELL asurement of th		ameter: r	nm _{N10}							
5.		of swelling unit of swelling unit			I Ā	nSWSIZE_UNI_HID		SWFUNIT]							
6.* ✓	Pleas	of swelling: e specify in the of swelling]	case descrip	tion sectic	n I	nSWTYPE: SWELL Local swelling an Diffuse swelling, Swelling, involving	ound injection not involving	n site, no adjacent		djacent j	oint					
7.* •		mference: imference]				mCIRC_SWOLLEN: cumference of s			of maximun	n swelling	g): m	nm _{N10}				
8.		mference swolle Imference swol				mCIRC_SW_UNI_H		ed - for in	ternal use]							
9.	same	mference of the level): [hidden] Imference of th	J · ·	•		nCIRC_OPPOSITE cumference of t			e same leve	l): mm //	10					
10.	[hidde	mference of the en] imference of th				mCIRC_OPP_UNI_ clSYMPUNITS]		tted - for	internal use]							
11.	pleas [hidde [If oc	urring within 24 e specify how I en] curring within 2 e specify how I	long after va 24 hours aft	accination er vaccina	tion,	nSWFHH: SWELLI occurring within	RPT.SWFHH] 24 hours after	r vaccinat	ion, please	specify h	ow l	ong after vac	ccination: 🛭 🏻 🏲	IReq 24-hour clock		
ASSC	CIAT	ED SIGNS [sct	LASSOCIATE	DSIGN_C	HILD]											
		s, Induration, F rge swelling, pl					select the Ye	es/No box	for each sy	mptom o	ccuri	ring during th	ne large swe	elling reaction period. If oth	er symptoms	are associated
12.* •	Please has b report	erature: e record the tem een taken more t the highest va perature]	than once a	,	ure Tei	mTEMP_VAL: SWE mperature (°F) mTEMP_ROUTE: SN ute: Axillary (I	XXX.X VELLRPT.SWT	_SITE]	ctal Tymn	anic						
13 *						mREDNESS: SWEL			ссаттуппр							

•	[Redness]	No [itmDIAMETER_RED: SWELLRPT.SWRED] Yes -> Largest diameter: mm N10
14.*	Induration [Induration]	[itmINDURATION: SWELLRPT.SWIND_YN] No [itmDIAMETER_IND: SWELLRPT.SWIND] Yes -> Largest diameter: mm N10
15. [*] ✓	Pruritis [Pruritis]	[itmPRURITIS: SWELLRPT.SWPRU_YN] No ItmINTENS_PRURI: SWELLRPT.SWPRU] Yes -> Grade 1 (An AE which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.) Grade 2 (An AE which is sufficiently discomforting to interfere with normal everyday activities.) Grade 3 (An AE which prevents normal, everyday activities. In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care center and would cause the parent(s)/LAR(s) to seek medical advice)
16.* ✓	Pain (at administration site): [Pain]	[itmPAIN_CHILD: SWELLRPT.SWPAI_YN] No [itmINSTENS_PAIN: SWELLRPT.SWPAI] Yes -> Intensity Grade 1 (Minor reaction to touch) Grade 2 (Cries / protests on touch) Grade 3 (Cries when limb is moved / spontaneously painful)
17.*	Functional impairment: [Functional impairment]	[itmIMPAIR: SWELLRPT.SWFUN_YN] No [itmINSTENS_IMPAIR: SWELLRPT.SWFUN] Yes -> Grade 1 (An AE which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.) Grade 2 (An AE which is sufficiently discomforting to interfere with normal everyday activities.) Grade 3 (An AE which prevents normal, everyday activities. In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care center and would cause the parent(s)/LAR(s) to seek medical advice)
CLIN	IICAL CASE DESCRIPTION [sctCLINICALCASED	DESCRIPTION]
18.*	Case description [Case description]	[itmCASE_DESC: SWELLRPT.CAS_DESC] Please give a clinical description of the observed swelling reaction, including a description of the joint involved and specific associated symptoms. Please mention also eventual diagnostic(s) procedures and therapeutic interventions. A500
19. ✓	Last date when the swelling was still considered to be a large swelling reaction: [Last date when the swelling was still considered to be a large swelling reaction:]	[itmSWLDAT: SWELLRPT.SWLDAT] NReq / NReq / NReq (2013-2018)
20.*	Outcome of the large swelling reaction: [Outcome of the large swelling reaction]	[itmOUTCOME_SW: SWELLRPT.OUTCOME] Recovered / Resolved Recovering / Resolving Not recovered / Not resolved -> Please provide further follow-up data Recovered / Resolved with sequelae -> Please specify in the case description section
21.*	Is there an alternative explanation for the swelling? (e.g.: allergy, infection, trauma, underlying conditions) [Is there an alternative explanation for the swelling?]	[itmSW_ALT: SWELLRPT.SWALT_YN] No [itmSW_EXPLAIN: SWELLRPT.SWEXPLN] Yes -> Please specify: A500

22.	If lasting for less than 24 hours, please specify duration: [hidden] [If lasting for less than 24 hours, please specify duration]	[itmSWLHH: SWELLRPT.SWLHH] NReq 24-hour clock	
	y: [♥] = Source verification required te: Source verification critical settings made in InForr	n will override any settings made in Central Designer.	

DT	PA-HBV-IPV-135 (117119): SOLIC	CITED ADVERSE EVENTS - G	GENERAL	SIGNS/SYMPTOMS (G	en symp) [frmGENSYMPTOMS	_BST]
Ifan	y of these adverse events meets the definition	of serious, complete a Serious Advers	se Event Repo	ort.		
TEM	PERATURE (°F) [sctTEMPERATURE_SOL]					
Reco	rd temperatures if during the solicited period at	t least one axillary/oral/tympanic/recta	al measure is	above or equal to 100.4 °F		
1.* •	Occurred?	[itmFE_YN: SOLAE.SYMP_EXP] No Not taken Yes -> Day 0:	Da	ay 1:	Day 2:	Day 3:
		[itmFE_VAL_D0: SOLVAL.SYMP_VAL] Not taken [itmFE_NT_D0: SOLVAL.T_ [itmTEMP_ROUTE: SOLAE.SYMP_T_S Route: Axillary (Preferred) Or [itmFE_ONG: SOLAE.SYMP_ONG] After Day 3: Ongoing? No Yes -> [[it SC XX	TEMP: SOLAE.SYMP_MAX	[itmFE_VAL_D2: SOLVAL.SYMP_VAL] XXX.X [itmFE_NT_D2: SOLVAL.T_N_TAK]	[itmFE_VAL_D3: SOLVAL.SYMP_VAL]
			Date of last d [itmCONT_END Continuing at that the AE m	: SOLAE.SYMPCONT] : the end of the study? hay have been caused by the in	Yes	013-2018)
2.	Unit: [hidden] [Unit]	[itmTEMP_UNIT: Not submitted - for intell Fahrenheit	ernal use]			
3.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD [clsympcode]	DD]			
4.	Threshold for fever based on route and unit [hidden]	[itmFEV_VAL_HID: Not submitted - for in	nternal use]			
5.	Unit: [hidden]	[itmSYMP_UNI_HID: SOLAE.SYMP_UNI [clsympunits]	II]			
DRO	WSINESS [sctDROWSINESS]					
6.* •	Occurred?] [Maximum inte [itmERDAT: SO Date of last d [itmCONT_END Continuing at	: SOLAE.SYMPCONT] : the end of the study?	7	[itmSYMP_VAL_INTEN_D3: SOLVAL.SYMP_VAL] Day 3: [clintensitysol]

		[itmMED_TYPE: SOLAE.MED_TYPE] Medically attended visit: Emergency Room Hospitalisation Medical Personnel None
7.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]
IRRI	TABILITY/FUSSINESS [sctIRRITABILITY]	
8.*	Occurred?	[itmIF_VN: SOLAE.SYMP_EXP] No Yes -> [itmSYMP_VAL_INTEN_D0: [itmSYMP_VAL_INTEN_D1: [itmSYMP_VAL_INTEN_D2: SOLVAL.SYMP_VAL] Intensity: SOLVAL.SYMP_VAL] Day 0: Day 1: Day 2: Day 3: [clintensity: Solae.Symp_ONG] After Day 3: Ongoing? No Yes -> [itmSYMP_MAX_INTEN: SOLAE.SYMP_MAX] Maximum intensity: [clintensitySol_max] [itmERDAT: SOLAE.SYMP_LST] Date of last day of sign/symptom: Req/Unk / Req/Unk / Req/Unk (2013-2018) [itmCONT_END: SOLAE.SYMPCONT] Continuing at the end of the study? [itmCAUSAL: SOLAE.CAUSAL] Is there a reasonable possibility that the AE may have been caused by the investigational product? No Yes [itmMED_TYPE: SOLAE.MED_TYPE] Medically attended visit: Emergency Room Hospitalisation Medical Personnel None
9.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clsympcode]
LOS	S OF APPETITE [sctLOSSOFAPPETITE]	
10.*	Occurred?	ItimLO_VN:SOLAE.SYMP_EXP No
11.	SYMP_COD [hidden]	[itmSYMP_COD_HID: SOLAE.SYMP_COD] [clSYMPCODE]
	y: [♥] = Source verification required ce: Source verification critical settings made in InForm	m will override any settings made in Central Designer.

DTPA-HBV-IPV-135 (117119): CHECK FOR STUDY CONTINUATION (Study cont.) [frmSTUDYCONTINUATION] CHECK FOR STUDY CONTINUATION [sctSTUDYCONTINUATION] Did the subject return for this visit? [itmVIS_FLG: VIS_INFO.VIS_FLG] [itmACTRDATE: ACTDATES.ACTRDATE] Yes -> Date of visit: Req / Req / Req (2013-2018) No [itmVIS_REAS: VIS_INFO.V_REAS] -> Please select the major reason: Serious Adverse Event [itmSAE_CASE: VIS_INFO.SAE_CASE] -> Please complete a **SAE** Report and specify SAE Report No. N2 [itmFATAL: VIS_INFO.FATAL] -> Tick box if SAE is fatal: Non-Serious Adverse Event [itmAE_NB: VIS_INFO.AE_NB] -> Please complete Non-Serious Adverse Event section and specify AE No. N2 [itmSYMP_COD: VIS_INFO.SYMP_COD] or Solicited AE code: [cISYMPCODE] [itmPTV_SP: VIS_INFO.REAS_COM] Protocol violation, please specify: A50 Consent Withdrawal not due to an adverse event ->Please specify the reason (only if the Subject's parents / Legally Acceptable Representative has / have spontaneously explained it): [itmCWS_SP: VIS_INFO.REAS_COM] A50 [itmCWS_NA: Not submitted - for internal use] Or tick box if reason not provided Migrated / moved from the study area Lost to follow-up Sponsor study termination [itmV_OTH: VIS_INFO.REAS_COM] Other, please specify A100 [itmDECISION: VIS_INFO.DECISION] -> For serious (except death), non-serious adverse events and Other reasons only: Please select who made the decision: Subject's parents / Legally Acceptable Representatives Key: [*] = Item is required [✓] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.

DT	PA-HBV-IPV-135 (117119): LOG STATUS (Log sta	itus) [frmLOG_STATUS]
COI	NCOMITANT VACCINATION [sctCONC_VACCINATION_FLG]	
	Have any vaccines required to be reported as per protocol other than the study vaccine(s) been administered?	[itmCV_FLAG: CVSHEET.CV_FLAG] Yes -> Please complete the following page No
ME	DICATION [sctMEDICATION_FLG]	
	Have any medications that are required to be reported per protocol been administered?	[itmMD_FLAG: MDSHEET.MD_FLAG] Yes -> Please complete the following page No
NO	N-SERIOUS ADVERSE EVENTS AND INTERCURRENT MEDICAL CON	DITIONS [sctnonserious_aes_flg]
Plea	ase report serious adverse events only in the Serious Adverse Events	Report, not here.
3.* •	Have any non-serious adverse events that are required to be reported per protocol occurred?	[itmAE_FLAG: AESHEET.AE_FLAG] Yes -> Please complete the following page No
	ey: [*] = Item is required [✔] = Source verification required one: Source verification critical settings made in InForm will override any settings.	ings made in Central Designer.

DT	TPA-HBV-IPV-135 (117119): CONC	OMITANT V	ACCINATION (Conc	vacc) - Repeating Form [frmconc_vaccinat	ION]
#	Vaccine name		Route	Date of admir	nistration
1					
со	NCOMITANT VACCINATION [sctCONC_VACCINA	TION_DET]			
	ase record any concomitant vaccination according	to the protocol	reporting requirements. Vac	ccination admistered prior to the first dose of study v	accine are to be recorded in vaccination history
1.*	Vaccine name:	[itmCVACC_TRAD	NAME: VACC_CON.TRADNAME	i)	_
•	(Trade name is preferred) [Vaccine name]	A60			
2.* •	Route: [Route]	[itmCVACC_ROUT	E: VACC_CON.MED_ROUT] CVACC]		
3.* •	Date of administration: [Date of administration]		Req/Unk / Req/Unk (2	2013-2018)	
4.	For GSK - MON: [hidden]	[itmMON_TRANS	: VACC_CON.MD_TRANS]		
	[For GSK - MON]	A60			
5.	For GSK - DM: [hidden]	[itmGSK_MOD_H	TD: VACC_CON.GSK_MOD]		
	[For GSK - DM]	A60			
	rey: [♥] = Source verification required lote: Source verification critical settings made in InFor	m will override ar	ny settings made in Central Des	igner.	

DT	PA-HBV-IPV-135 (11	7119): MEDIC	CATION (Medic) - Repea	ting Form [CONMEDS_CR]			
#	Drug Name	М	edical indication:	Total daily dose	Route	Start date	End date
1							
MED	DICATION [sctCM]						
Plea	se record any concomitant me	edication according	to the protocol reporting requirer	ments.			
1.*	Drug name:		[CMTERM: MEDIC.TRADNAME]				
~	[Drug Name]		A100				
2.	Modified reported term [hidd	den]	[CMMODIFY: MEDIC.GSK_MOD]				
			A100				
3.	GSK Drug synonym [hidden]		[CMDRGSYN: Not submitted - for interest.]	ternal use]			
			A100				
4.	GSK Drug Collection code [h	idden]	[CMDRGCOL: MEDIC.GSK_COD]				
5.	Failed coding [hidden]		[calCM_FAILED: Not submitted - for	internal use]			
			A10				
6.*	Medical indication:		[itmMEDINDIC: MEDIC.MEDINDIC	1			
_			A80				
			[itmPROPH_CK : MEDIC.PROPH_CK	K1			
			In anticipation of study vaccine r				
			[itmCHRON_CK : MEDIC.CHRON_CK	K]			
			Chronic use				
7.*	Total daily dose: [Total daily dose]		[itmMED_DOSE: MEDIC.MED_DOSE Dose: A20	<u>=]</u>			
			[itmMED_UNIT: MEDIC.MED_UNIT				
			Unit: A20	1			
*							
8.* •	Route: [Route]		[itmMED_ROUT: MEDIC.MED_ROUT	1]			
9.* ✓	Start date: [Start date]		[itmSRDAT: MEDIC.MEDSRDAT] Req/Unk / Req/Unk / Req/Unk	eg/Unk (2013-2018)			
	-			(2010 2010)			
10.*	End date: or tick box if continuing at the	ne end of the	[itmERDAT: MEDIC.MEDERDAT] Req/Unk / Req/Unk / Req	eg/Unk (2013-2018)			
	study		[itmCONT_END : MEDIC.CONT_END				
	[End date]		Continuing at the end of the stu				
11.	For GSK - MON: [hidden]		[itmMD_TRANS: MEDIC.MD_TRANS	S]			
	[For GSK - MON]		A60				
12.	Drug name: Generic name is preferred b	ut trade namo io	[CMCOMPARE: Not submitted - for in	nternal use]			
	preferred in case of multi-co		A100				
	[hidden] [Drug name]						
13.			[CMMODCOMPARE: Not submitted - 1	for internal use1			
13.	Generic name is preferred b		A100				
Prop	preferred in case of multi-co erty of GlaxoSmithKline Biolog		Annotated S	Study Book - DTPA-HBV-IPV-135 (117119)		I	94/10

	1:	[hidden] [Drug name]	
--	----	-------------------------	--

Key: [\checkmark] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.

[AE_	CR]				SERIOUS ADVERSE EVENTS AND INTERCURRENT MEDICAL CONDITIONS (Non-Ser AE) - Repeating Form	
# AE	No. Event Site:	Start date: 0	utcome	End date Ma	Maximum intensity Is there a reasonable possibility that the AE may have been caused by the investigational product? Medically attended v	isit
1						
					RENT MEDICAL CONDITIONS [sctAE]	
			s to the p	i	porting requirements.	—
1.	AE No. [read-on	iy]		l r	[itmAE_NO: AE.AE_NB] N3	
2.*	Event:	(:C1) .		l F	[AETERM: AE.AE_DESC]	
~	Diagnosis only sign/symptom [Event]	(IF KNOWN), OT	nerwise		A100	
3.	Modified term			1 =	[AEMODIFY: Not submitted - for internal use]	
	Do not query to for sites. [hidden] [Modified term]		s not dis	played	A100	
4.	MedDRA synon	ym [hidden]		Ī	[AEMEDSYN: Not submitted - for internal use]	
					A100	
5.	MedDRA lower	level term cod	de [hidde	1 In	[AELLTCD: AE.MD_CODE] A10	
6.	Failed coding [/	nidden]		17	[calAE_FAILED: Not submitted - for internal use] A10	
7.	New Onset of Conly) [hidden] [NOCD?]	Chronic Disea	se (NOCI))?(for DM [[itmNOCD : AE.GSK_NOCD] NOCD	
8.* •	Site:				[itmAE_LG: AE.AE_LG] [itmP_CODE: AE.P_CODE] Administration site: [clpRODNAMES] Non-administration site	
9. [*] ✔	Start date:]]	[itmSRDAT: AE.AE_SRDAT] Req/Unk / Req/Unk / Req/Unk (2013-2018) [itmAEPOSTVC: AE.AEPOSTVC] 30 minutes immediate post-vaccination	
10.	For incomplete [For incomplete		nidden]		[itmAE_VACC: AE.AE_VACC] [clafterBefore]	
11.* •	Outcome: [Outcome]				[itmOUTCOME_NSAE: AE.OUTCOME] Recovered/resolved Recovering/resolving Not recovered/not resolved Recovered/resolved with sequelae	
12. ✓	End date: [End date]			[[itmERDAT: AE.AE_ERDAT] Req/Unk	
13. [*] ✓	Maximum inten [Maximum inter				[itmAE_INTEN: AE.AE_INTEN] Mild	
14.* ✔	Is there a reas may have been product?	onable possit caused by th	oility that ne invest	the AE [gational	[itmCAUSAL : AE.CAUSAL] No Yes	

15.* •	Medically attended visit: [Medically attended visit]	[itmMED_TYPE: AE.MED_TYPE] Emergency Room Hospitalisation Medical Personnel None						
16.	For MON: [hidden] [For MON]	[itmAE_TRANS: AE.AE_TRANS] A80						
17.	AE description: Diagnosis only (if known), otherwise sign/symptom [hidden] [AE description]	[AECOMPARE: Not submitted - for internal use] A100						
18.	AE description: Diagnosis only (if known), otherwise sign/symptom [hidden] [AE description]	[AEMODCOMPARE: Not submitted - for internal use] A100						
Key: [✔] = Source verification required Note: Source verification critical settings made in Inform will override any settings made in Central Designer								

D.	ГРА-	HBV-IP\	/-135 (11	7119): SI	ERIO	US ADVERSE	EVENTS (SA	AE) - Repea	ating F	orm [AE_SER_	_CR]				
#	SAE Did SAE occur after SERIOUS Report initiation of study ADVERSE No. medication? EVENT			Seriousness		EVANT NT/TREATMENT /VACCINATION	т	RELEVANT MED CONDITIONS/I FACTORS	RISK	RELEVAN DIAGNOS RESULTS	TIC	Relevant diagnostic results not noted on the left columns	General narrative comments		
1															
If i	/es, re not clin	cord the de ically or ter	tails below us nporally relate	ing the 'Add d, create a	Entry' new SA	button in this for	nically or tempora m. bject by clicking o	•		•		orm.			
SA	E REP	ORT NO. [s	ctSAE_REPOR	RT_NO]											
1. •		E Report No E Report No	. [read-only]			[itmSAE_NB: SAE.SAE_NB] N2									
2.	[hic	lden]	AE (minimum AE (minimum		,		t submitted - for integral (_							
3.	[hid	iden]	AE (maximum SAE (maximum		ctSAE)	[itmSAE_STOP: Not submitted - for internal use] NReq / NReq (2013-2018)									
ΤY	PE OF	REPORT [sctSAE_TOR]												
4.	- 1	ial Report [tial Report]	hidden]			[chkSAE: Not submitted - for internal use] [Initial									
5.		ow-Up Rep llow-Up Rep	ort [hidden] oort]			[chkFU: Not submitted - for internal use] Follow-Up									
R/	NDOM	IIZATION [sctSAE_RAND]		I									
6.*	inve [Did	estigationa	occur after init product(s)? after initiation			[rdcSAERAND: SAE.SAE_RAND] No Yes									
	No. E	vent Star date and time	End date and time		inves	action taken with tigational produ result of the ev	ct(s) withdraw	e subject v from study this event?	event	Is there a reasonable possibility that the event may have been caused by the investigational product(s)?			ne AE caused by activities rela study participation other than investigational product?	Medically attended visit	
7. 🗸															
SE	RIOU	S ADVERSE	EVENT Entry	[sctSAE]											
						. For additional S er ONE event pe		cally or tempora	ally relate	d (e.g., SAEs th	at occur o	during the sa	me ho	spitalization) use the 'Add Entry	' button to
7.	No. [read-only] [No.]					[AESEQ: AE.AESEQ] N5									
7.:	2* Event: Diagnosis only (if known), otherwise sign/symptom [Event]				[AETERM: AE.AE_DESC] A100										
7.3	7.3 Serious? [hidden] [Serious?]					[itmAESER: AE.AE_SER] Serious Non-Serious									
7.4		otential imm idden]	nune mediated	d disease (pl	IMD)?	[itmPIMD : AE.P_IMD] pIMD Non pIMD									
7.	5 M	edDRA sync	nym [hidden]			[AEMEDSYN: Not	submitted - for inte	ernal use]							

l	<u> </u>	
7.6	MedDRA lower level term code [hidden]	[AFLLTCD: AE.MD_CODE] A10
7.7	Failed coding [hidden]	[calAE_FAILED: Not submitted - for internal use] A10
7.8	New Onset of Chronic Disease (NOCD)?(for DM only) [hidden] [NOCD?]	[itmNOCD : AE.GSK_NOCD] NOCD
7.9*	Start date and time Hr:Min (00:00-23:59) [Start date and time]	[AESTDTTM: AE.AE_SRDAT] Req/Unk
7.10*	Outcome / End date and time Hr:Min (00:23-59) [Outcome / End date and time]	[AEOUTCD1: AE.OUTCOME] [AEENDTTM1: AE.AE_ERDAT] Recovered/resolved, provide End date and time Req/Unk / Req/Unk (2013-2018) NReq : NReq 24-hour clock Recovering/resolving Not recovered/not resolved [AEENDTTM2: AE.AE_ERDAT] Recovered/resolved with sequelae, provide End date and time Req/Unk / Req/Unk (2013-2018) NReq : NReq 24-hour clock [AEENDTTM3: AE.AE_ERDAT] Fatal, record Date and time of Death Req/Unk / Req/Unk / Req/Unk (2013-2018) NReq : NReq 24-hour clock [AEENDTTM3: AE.AE_ERDAT] Fatal, record Date and time of Death Req/Unk / Req/Unk (2013-2018) NReq : NReq 24-hour clock
7.11*	Maximum Intensity Record maximum intensity throughout duration of event [Maximum Intensity]	[AESEVCD : AE.AE_INTEN] Mild Moderate Severe Not applicable
7.12	Intensity at onset of event Record intensity at the onset of the event [hidden] [Intensity at onset of event]	[ADSEVCD: Not submitted - for internal use] Mild Moderate Severe Not applicable
7.13	Maximum Grade Record maximum grade throughout duration of event [hidden] [Maximum Grade]	[AFTOXCD: Not submitted - for internal use] Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
7.14	Grade at onset of event Record grade at the onset of the event [hidden] [Grade at onset of event]	[ADTOXCD: Not submitted - for internal use] Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
7.15	Maximum Grade or Intensity Record maximum grade or intensity throughout duration of event [hidden] [Maximum Grade or Intensity]	[AFIXHVCD: Not submitted - for internal use] Mild or Grade 1 Moderate or Grade 2 Severe or Grade 3 Grade 4 Not applicable
7.16	Grade or Intensity at onset of event Record grade or intensity at the onset of the event [hidden] ty of Glave Smith Kline Richards	[ADTXHVCD: Not submitted - for internal use] Mild or Grade 1 Moderate or Grade 2 Appointed Study Rook, DTPA HRV IDV 125 (117110)

	[Grade or Intensity at onset of event]	Severe or Grade 3 Grade 4 Not applicable							
7.17*	Action taken with investigational product(s) as a result of the event: [Action taken with investigational product(s) as a result of the event]	[AEACTRCD: OC_SAE.SAE_ACT] Investigational product(s) withdrawn Dose not changed Dose delayed Not applicable							
7.18	Modified term Do not query this item. it is not displayed for sites. [hidden] [Modified term]	AEMODIFY: AE.MD_MOD] A100							
7.19*	Did the subject withdraw from study due to this event? [Did the subject withdraw from study due to this event?]	[AEWD: OC_SAE.WITHDRAW] Yes No							
7.20*	Is there a reasonable possibility that the event may have been caused by the investigational product(s)? Use best judgment at initial entry. May be am ended when additional information becomes available. [Is there a reasonable possibility that the event may have been caused by the investigational product(s)?]	[AEREL: AE.CAUSAL] No Yes							
7.21	Duration of AE if < 24 hours [hidden] [Duration of AE if < 24 hours]	[AEDURHR: Not submitted - for internal use] [AEDURMIN: Not submitted - for internal use] $ 0 <= N2 <= 23 $ $ Hr(s) Min(s) $							
7.22	Time to Onset Since Last Dose [hidden] [Time to Onset]	[AFONLDSH: Not submitted - for internal use] [AFONLDSM: Not submitted - for internal use] Hr(s) $0 <= N2 <= 23$ $0 <= N2 <= 59$							
7.23*	Was the AE caused by activities related to study participation other than investigational product? [Was the AE caused by activities related to study participation other than investigational product?]	[rdcAESREL: OC_SAE.REL_PART] Yes No							
7.24	Was the event serious? [hidden] [Was the event serious?]	[AESER: Not submitted - for internal use] Yes No							
7.25	Related Investigational Product [hidden] [Related Investigational Product]	[btAERDG: Not submitted - for internal use] A80							
7.26	AE description: Diagnosis only (if known), otherwise sign/symptom [hidden] [AE description]	[AECOMPARE: Not submitted - for internal use] A100							
7.27	AE description: Diagnosis only (if known), otherwise sign/symptom [hidden] [AE description]	[AEMODCOMPARE: Not submitted - for internal use] A100							
7.28	Yes, select appropriate investigational product(s) [hidden] [Investigational product(s)]	[AERDGCD: Not submitted - for internal use] [enter protocol specific IP definition 1] [enter protocol specific IP definition 2] [enter protocol specific IP definition 3]							
7.29	SAEEmailFlag [hidden] [SAEEmailFlag]	[txtSAEEmailFlag: Not submitted - for internal use] A6							

	1		1							
7.30 [*]	Medically attended visit: [Medically attended visit]	[itmMED_TYPE: AE.MED_TYPE] Emergency Room Hospitalisation Medical Personnel None								
7.31	Narrative include clinical [[itmNARRATIVEINCLUDECLINICAL: Not submitted - for internal use] A255								
[sctE	[sctEMERGENT]									
8.	Sequence Number [hidden] [Sequence Number]	1	[AESEQ2 : Not su	bmitted - for interr	nal use]					
9.	AE description: Diagnosis only (if known), sign/symptom [hidden]	otherwise	[AETERM_1: Not A100	submitted - for int	ernal use]					
10.	Start Date and Time of eve Hr:Min (00:00-23:59) [hidd [Start Date of event segme	[ADSTDTTM: Not submitted - for internal use] Req / Req (2013-2018) NReq : NReq 24-hour clock								
11.	Intensity of event segment [Intensity of event segment	[ADSEVCD1: Not submitted - for internal use] Mild Moderate Severe								
12.	Grade of event segment [h. [Grade of event segment]	[ADTOXCD2: Not submitted - for internal use] Grade 1 Grade 2 Grade 3 Grade 4 Grade 5								
13.	Grade or Intensity of even [Grade or Intensity of ever	[ADTXHVCD2: Not submitted - for internal use] Mild or Grade 1 Moderate or Grade 2 Severe or Grade 3 Grade 4 Grade 5								
SERI	OUSNESS [sctSAE_SER]									
14.	Specify the reason for cons as SAE. (Tick all that apply) [Seriousness]	ChKAESER: SAE.SER_CRIT Results in death Is life-threatening (subject was at risk of death at time of event) Requires hospitalisation or prolongation of hospitalisation (Provide admission and discharge date(s) in narrative) Results in disability/incapacity (substantial / permanent) Congenital anomaly/birth defect (in offspring of subject) Other, specify within general narrative comment								
	Drug Name	Total daily	dose	Route	Start Date	End date	Medical	Indication	Drug type	
15. ✔										
RELE	RELEVANT CONCOMITANT/TREATMENT MEDICATIONS/VACCINATIONS Entry [sctSAE_CM]									
	Ise the 'Add Entry' button to enter details of any medication/vaccine that may help to explain the SAE, may have caused the SAE or was used to treat the SAE. Ensure each concomitant vaccination or nedication recorded in this section is also recorded in the corresponding form located in the LOGS section of the eCRF.									
15.1	CM Sequence Number [/ [CM Sequence Number]		[txtSAECMSEQ:	Not submitted - fo	r internal use]					

15.2 [*] ✓	Drug name: [Drug Name]	[CMTERM: OC_CMVAC.TRADNAME] (Trade name is preferred) A100	(Trade name is preferred)						
15.3	Modified reported term [hidden] [Modified reported term]	[bxtCMMODIFY: OC_CMVAC.GSK_MC	ExtCMMODIFY: OC_CMVAC.GSK_MOD] A100						
15.4 ✓	Total daily dose: [Total daily dose]	[btsAECMDOS: SAE.CT_DOSE] Dose: xxxxxxxxxx [pdcCMUNIT: OC_CMMED.MED Unit: [cicMUNITSAE]	Dose: XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX						
15.5	Frequency [hidden] [Frequency]	[pdcSAECMFRQ: Not submitted - for ir	dcSAECMFRQ: Not submitted - for internal use] clSAECMFRQ]						
15.6*	Route [Route]	[pdcCMROUTCD: OC_CMVAC.MED_R	OUT]						
15.7*	Start Date [Start Date]	[dtmSAECMSTD: OC_CMVAC.MEDSRI							
15.8 ✓	End date: or tick box if continuing at the end of the study [End date]	[rdcSAECMONG: SAE.CT_CONT]	NReq/Unk / NReq/Unk / NReq/Unk (2002-2018)						
15.9	Medical indication Enter a medical diagnosis not description [Medical Indication]	[txtCMIND: Not submitted - for interral A50	[txtCMIND: Not submitted - for internal use] A50						
15.10	Modified reported term [hidden] [Modified reported term]	[bxtCMINDMODIFY: Not submitted - fo	[txtCMINDMODIFY: Not submitted - for internal use] A100						
15.11*	Drug type: [Drug type]	[pdcCMDRGTYP: OC_CMVAC.DRUG_ [cldrugtyp]	[pdcCMDRGTYP: OC_CMVAC.DRUG_TYP] [clDRUGTYP]						
15.12	CM COMPARE (Hidden) [hidden] [CM COMPARE (Hidden)]	[bxtCMCOMPARE: Not submitted - for internal use] A100							
15.13	CMIN COMPARE (Hidden) [hidden] [CMIN COMPARE (Hidden)]	[txtCMINCOMPARE: Not submitted - for Al 00	or internal use]						
	Condition	Start date	Continuing at time of	SAE?					
16. ✓									
RELEV	RELEVANT MEDICAL CONDITIONS/RISK FACTORS Entry [sctSAE_MHX]								
Use the 'Add Entry' button to enter each past or current medical disorder, allergy or surgery that may be RELEVANT to the SAE. Enter a diagnosis, not description. Relevant family or social history so be described in the 'General Narrative Comments' at the bottom of this form. Ensure each medical condition/risk factor recorded in this section is also recorded in the General Medical History form located at the beginning of the eCRF.									
16.1	MHx Sequence Number [hidden] [MHx Sequence Number]	[bxtMHXSEQ : Not submitted - for interest A4	nal use]						
16.2*	Condition Enter a medical diagnosis not description. [Condition]	[bdSAEMHTRM: OC_MDCON.CON_DE A100	sc]						

16.3	Modified reported term (Modified reported term		[bxtSAEMHMODIFY: OC_MDCON.MD_MOD] A100					
16.4*	16.4* Start date: [Start date]		[dtmMHSTDTM: OC_MDCON.MCSTR_DT] Req/Unk / Req/Unk (2002-2018)					
16.5* Continuing at time of SAE? [Continuing at time of SAE?]		[rdcMHCONT: OC_MDCON.CONT_SAE] Yes [dtmMHLSTOC: OC_MDCON.MCEND_DT] No, specify end date or date of last occurrence Req/Unk / Req/Unk (2002-2018) Unknown, no information available						
16.6	SAE MHX COmpare (Hidd [SAE MHX COmpare (Hidd		[txtMHXCOMPARE: Not submitted A100	ed - for internal use]				
	Test name	Test date	Test result	Test units	Normal low range	Normal high range		
17.								
RELE	VANT DIAGNOSTIC RES	ULTS Entry (sctSAE L	AB1					
		,,	-	out to diagnose or confirm t	he SAE or rule out other diagnoses			
17.1	Lab Sequence Number [[Lab Sequence Number]		[txtSAELBSEQ : Not submitted A4	- for internal use]				
17.2*	Test name [Test name]		[pdcLBTST: OC_LABRS.LAB_NAME] [clSAELBTST]					
17.3*	Test date [Test date]		[dtmLABDTM: OC_LABRS.LAB_DT] Req/Unk / Req (2002-2018)					
17.4*	Test result [Test result]		[bxtLABRES: OC_LABRS.LAB_RES] A12					
17.5*	Test units [Test units]		[txtLABUNIT: OC_LABRS.LAB_U] A12					
17.6*	Normal low range [Normal low range]		[bxtLABNLR: OC_LABRS.LAB	_L]				
17.7*	Normal high range [Normal high range]		[txtLABNHR: OC_LABRS.LAB	<u>L</u> H]				
[sctS	AE_LABTXT]							
	Enter here only the diagn		[txtLABTEXT: OC_LABRS.LAB_	DET]				
could not be entered in the above grid, including procedure such as ECG, X rays, etc and tests on stool, CSF etc. Also provide dates. [Relevant diagnostic results not noted on the left columns]		A1000						
			[txtLABTEXT1 : OC_LABRS.LAB	TEXT1]				
		A1000						
[sctS	AE_IP]							
19.	If investigational product	(s) were stopped	IrdcSAEIP: Not submitted - for	internal use1				

	temporarily, did the reported event(s) recur after investigational products were restarted? [hidden] [If investigational product(s) were stopped temporarily, did the reported event(s) recur after investigation products were restarted?]	No Yes Unknown at this time Not applicable						
GEN	ERAL NARRATIVE COMMENTS [sctSAE_COM]							
- Ass - Clir - No - Oth - Rel - Pos - Rat	vide a clear (this narrative will be provided to regulatory authorities) and brief chronological description (with dates) of the clinical course of the event including: sociated signs and symptoms inical evolution (hospitalisation, outcome, description of sequelae if any, autopsy results, etc.) on-drug treatment such as surgery their information useful for the medical assessment of the case (e.g. reason for diagnosis if not obvious or if diagnosis changed) elevant additional risk factors including family or social history (negative sentence can also be helpful) assible cause(s) of the event at one of the event at one of the event are including selevant and the event at one of the event at one of the event are including selevant and the event are included and the event are included as a selevant and the event are included as a selevant are inclu							
	plete a new box only when the previous one is fu T							
20.*	General narrative comments	[txtsaecomm: oc_saedt.saecomm1] A1000 [txtsaecomm2: oc_saedt.saecomm1] A1000 [txtsaecomm2: oc_saedt.saecomm2] A1000						

		[txtSAECOMM3: OC_SAEDT.SAECOMM3]	
		A1000	
NON	CLINICAL [sctSAE_NC]		
	Send incomplete SAE data to GSK Safety	[chkSENDI: OC_SAFAD.REQDLOAD]	
21.	[hidden]	Incomplete SAE	
	[Send incomplete SAE data to GSK Safety]		
22.	Receipt by GSK date [hidden]	[dtmSAEDTM: AE.DTMSAEDTM]	
	[Receipt by GSK date]	Req / Req (2013-2018)	
		Req : Req 24-hour clock	
23.	Was the event serious? [hidden]	[AESER: Not submitted - for internal use]	
	[Was the event serious?]	Yes	
		No	
24.	Sequence Number [hidden]	[AESEQ1: Not submitted - for internal use]	
	[Sequence Number]	N5	
25.	Version Number [hidden]	[txtSAEVERSION: Not submitted - for internal use]	
	[Version Number]		
	2 72 71 11 7	L	
26.	Case ID [hidden] [Case ID]	[txtSAFID: OC_SAFAD.OCEAN_ID] A20	
	[6466 12]	[A20	
27.	Randomisation Number [hidden]	[txtSAERNDNO: Not submitted - for internal use]	
	[Randomisation Number]	A255	
28.	OCEANS Code [hidden]	[bxtOCEANSCD : SAE.CASE_ID]	
20.	[OCEANS Code]	A13	
29.	eMail flag [hidden]	[calSAEEmailFlag: Not submitted - for internal use]	
		<u>A6</u>	
30.	Message sender identifier [hidden]	[itmMessagesenderIdentIFIer: Not submitted - for internal use]	
	[mssgsendid]	A128	

31.	Study Type [hidden]	[itmSAESTUDYTPE: Not submitted - for internal use]			
	[Study Type]	A128			
32.	Modification datetime [hidden]	[itmMOD_DATE: SAE_MNGT.MODIFIED_DT]			
32.	Modification datetime [hidden]	NReq / NReq / NReq (2013-2018)			
32.	Modification datetime [hidden]				
Key	:: [✔] = Source verification required	NReq / NReq / NReq (2013-2018)			

DI	TPA-HBV-IPV-135 (117119): STUDY CONCLUSION (Conclusion) [frmstudyconclusion]						
ST	JDY CONCLUSION [sctSTUDYCONCLUSION]						
	Date of subject completion or withdrawal (or date of death if applicable):	[itmLC_RDAT: CONCLUS.LC_RDAT] Req / Req (2013-2018)					
2.	For Data Managers only: Tick or untick this box to require the investigator to re-sign the case book By ticking or unticking this box you are evoking a change to this form back to an unsigned state. This should be done when significant changes (e.g. those that require medical opinion or other significants situation) occur after the original signature. If the box is already ticked upon arrival on this form, unticking and submitting it accomplishes the same task as ticking and submitting it; that is, the signature will be validated in both [hidden]	[INVSIG2: Not submitted - for internal use]					
	ey: [♥] = Source verification required ote: Source verification critical settings made in InForm will override	any settings made in Central Designer.					

#	Text Text Please check GSK Biologica 3A 3B 4		Please check GSK Biologic	als sample storage period specified in the ICF in use at your centre.		h the new ICF version was first signed by a Subject :	
1							
In	additio	n to the	tests	described in the study proto	col, please check what may also be done with the subject samp	les as per the Informed Consent Form	(ICF) in use at your center.
1.		orm ver form ve			[itmUHS_NB_HID: Not submitted - for internal use] N10		
ΤY	PE 3A	TESTS	sctUH	IS_3A]			
2. ²	new to the never	tests lin e diseas r include litary ch	ked to e und tests	mprove tests and develop study vaccine(s)/product(s) er study. These tests will related to genes' eristics.	[itmCONS_YN_3A: UHS.CONS_YN] Yes No		
ΤY	PE 3B	TESTS	sctUH	IS_3B]			
3.	Use on the or the never	s Commi of sample tests lin e diseas r include litary ch	ttee / es to i ked to e und tests	nission of independent Institutional Review Board: mprove tests and develop study vaccine(s)/product(s) er study. These tests will related to genes' eristics.	[itmCONS_YN_3B: UHS.CONS_YN] Yes No		
TY	PE 4 T	ESTS [s	ctUHS	_4]			
4.	parer GSK r samp samp	nts / Leg nay perf les. Any les colle ning app EC.	jally Ad form fu resea cted v	nission of the Subject's cceptable Representatives: uture research on collected arch undertaken with vill be performed after for the research by an	[itmCONS_YN_4: UHS.CONS_YN] Yes No		
SA	AMPLE S	STORAG	E PEF	RIOD [sctUHS_PERIOD]			
5. [°]	centre [Pleas	d specifi e. se check d specifi	ed in t	Siologicals sample storage the ICF in use at your Biologicals sample storage the ICF in use at your	[itmPERIOD: UHS.PERIOD] For a maximum of 20 years [itmPERIODSP: UHS.PERIODSP] Other, please specify: A200		
IF	NEW V	ERSIO	NOFL	JHS FORM [sctUHS_DATE]			
Сс	mplete	and sub	omit a	new Use of Human Samples	by GSK form for each change in the ICF that affects the use of s	samples.	
6. ✓	signe [If ne	d by a S w version	Subjection of U	new ICF version was first t: JHS: Date at which the new st signed by a Subject :]	[itmUHS_DATE: UHS.UHS_DATE] NReq / NReq / NReq (2013-2018)		

gsk GlaxoSmithKline

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Clinical Study Protocol

Sponsor:

GlaxoSmithKline Biologicals

Rue de l'Institut 89 1330 Rixensart, Belgium

Primary Study vaccine and number

GlaxoSmithKline (GSK) Biologicals' Combined Diphtheria-Tetanus-acellular Pertussis (DTaP), Hepatitis B, Poliovirus and *Haemophilus influenzae* type b vaccine (DTPa-HBV-IPV/Hib) (SB217744, *Infanrix hexa*TM).

Other Study vaccines

- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine (*Pediarix*[®], GSK Biologicals)
- Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) (ActHIB[®], Sanofi Pasteur SA)
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) vaccine (Pentacel[®], Sanofi Pasteur SA)
- Hepatitis B Vaccine (Recombinant) (Engerix-B[®], GSK Biologicals)
- Pneumoccocal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) (*Prevnar13*[®], Manufactured by Wyeth Pharmaceuticals Inc. Marketed by Pfizer Inc.)
- Rotavirus Vaccine, Live, Oral (*Rotarix*®, GSK Biologicals)
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (*Infanrix*®, GSK Biologicals)
- Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) (Hiberix[™], GSK Biologicals)

117119 (DTPA-HBV-IPV-135)

eTrack study number and Abbreviated Title Investigational New Drug (IND) number EudraCT number: Date of protocol

BB-IND 006687

2013-004304-19

Final Version 01: 18 October 2013 Amendment 1 Final: 18 September 2014

Amendment 2 Final Version 02: 17 April 2015

Title

Date of protocol

amendment

Immunogenicity and safety study of GSK Biologicals' Infanrix hexaTM at 2, 4 and 6 months of age in healthy infants

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

eTrack study number and Abbreviated Title Investigational New Drug (IND) number EudraCT number: Detailed Title 117119 (DTPA-HBV-IPV-135)

BB-IND 006687

2013-004304-19

A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa[™] vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar[®] and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age.

Co-ordinating author Contributing authors

Prapti Bose, Scientific Writer

- PPD , Clinical Research and Development Lead (CRDL)
- PPD , Senior Director and Head, Portfolio Head CRDL
- PPD , Project Statistician
- PPD , Director, Biostatistics
- PPD , PPD , Study Delivery Manager
- PPD , PPD , Study Delivery Lead
- PPD , GVCL Project Manager
- PPD , Clinical Safety representative
- PPD , Study Data Manager
- PPD , Global Regulatory Lead
- PPD , Global Patents representative
- PPD , Global Regulatory Affairs, GSK Vaccines
- PPD , Director, Clinical Medical Affairs, Pediatric Vaccines, US, GSK Vaccines
- PPD , Director, Clinical Medical Affairs, US, GSK Vaccines
- PPD , Local Delivery Lead
- US Medical Affairs Lead

GSK Biologicals' Protocol DS v 14.0

Copyright 2013-2015 the GlaxoSmithKline group of companies. All rights reserved. Unauthorized copying or use of this information is prohibited.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Protocol Amendment 2 Sponsor Signatory Approval

Abbreviated Title	11/119 (D1PA-HBV-IPV-135)
IND number	BB-IND 006687
EudraCT number:	2013-004304-19
Date of protocol amendment	Amendment 2 Final Version 02: 17 April 2015
Detailed Title	A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa [™] vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, coadministered with Prevnar [®] and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age.
Sponsor signatory	Narcisa Elena Mesaros Project level CRDL, DTP/Polio Vaccines Late Clinical Development, Vaccine Discovery and Development, GlaxoSmithKline Biologicals.
Signature	
Date	

For internal use only

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Protocol Amendment 2 Rationale

Amendment number: Amendment 2

Rationale/background for changes:

The amendment 2 has been implemented to amend the following sections of the protocol:

- The assay for testing antibodies against polyribosyl ribitol phosphate (anti-PRP) has been re-developed but is not yet qualified or validated for testing the one month post dose-3 samples. This has been clarified in the protocol in Table 7 Humoral immunity (antibody determination) and Section 5.7.3 Laboratory assays.
- Investigator sign-off on the patient identification (PIDS) will be done after Visit 4 instead of extended safety follow-up (ESFU). In Table 4 List of study procedures, the bullets pertaining to investigator sign-off and analysis of Epoch 001 has been removed from the ESFU visit and retained at Visit 4 to reflect this change.
- The collection of baseline measurement of limb length has been removed since it will not be used in analysis; only limb circumference will be used in analysis. Accordingly, text related to this has been amended in Table 4 List of study procedures, Sections 5.6.2.11, Baseline measurement of limb circumference after booster vaccination at visit 5 and 5.6.2.13 Recording of AEs, SAEs and NOCDs.
- Errors in the vaccines dictionary of Study Master Repository (SMR) have been rectified for *Infanrix hexa*, *Pediarix* and *Pentacel* vaccines. The corresponding correction has been made in Table 9 Study vaccines.
- The sequence of analysis in Section 10.9.1 Sequence of analyses, has been amended to reflect that there will first be an analysis of immunogencity for anti-PRP and safety for Epoch 001, followed by a final analysis covering both Epochs at the end of the study.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Protocol Amendment 2 Investigator Agreement

I agree:

- To conduct the study in compliance with this protocol, any future protocol amendments or protocol administrative changes, with the terms of the clinical trial agreement and with any other study conduct procedures and/or study conduct documents provided by GlaxoSmithKline (GSK) Biologicals.
- To assume responsibility for the proper conduct of the study at this site.
- That I am aware of, and will comply with, 'Good Clinical Practice' (GCP) and all applicable regulatory requirements.
- To ensure that all persons assisting me with the study are adequately informed about the GSK Biologicals' investigational vaccine and other study-related duties and functions as described in the protocol.
- To acquire the reference ranges for laboratory tests performed locally and, if required by local regulations, obtain the laboratory's current certification or Quality Assurance procedure manual.
- To ensure that no clinical samples (including serum samples) are retained onsite or elsewhere without the approval of GSK Biologicals and the express written informed consent of the subject and/or the subject's legally acceptable representative.
- To perform no other biological assays on the clinical samples except those described in the protocol or its amendment(s).
- To co-operate with a representative of GSK Biologicals in the monitoring process of the study and in resolution of queries about the data.
- That I have been informed that certain regulatory authorities require the sponsor to obtain and supply, as necessary, details about the investigator's ownership interest in the sponsor or the investigational vaccine, and more generally about his/her financial ties with the sponsor. GSK Biologicals will use and disclose the information solely for the purpose of complying with regulatory requirements.

Hence I.

- Agree to supply GSK Biologicals with any necessary information regarding ownership interest and financial ties (including those of my spouse and dependent children).
- Agree to promptly update this information if any relevant changes occur during the course of the study and for one year following completion of the study.
- Agree that GSK Biologicals may disclose any information it has about such ownership interests and financial ties to regulatory authorities.
- Agree to provide GSK Biologicals with an updated Curriculum Vitae and other documents required by regulatory agencies for this study.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

eTrack	study	number	and
Abbrev	iated [Γitle	

117119 (DTPA-HBV-IPV-135)

IND number BB-IND 006687

EudraCT number: 2013-004304-19

Date of protocol amendment Amendment 2 Final Version 02: 17 April 2015

Detailed Title A Phase III, randomized, open-label, controlled,

multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa[™] vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar[®] and Rotarix[™] with a booster dose of GSK Biologicals' Infanrix[®] and Hiberix[™] vaccines at 15-18 months of age.

Investigator name	
Signature	
Date	

a799184c9b15497796cc43497dd0e1b0c61d882 3.0 4/20/2015 3:46:31 PM -	٠

For internal use only

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Sponsor Information

1. Sponsor

GlaxoSmithKline Biologicals, Rue de l'Institut 89, 1330 Rixensart, Belgium.

2. Sponsor Medical Expert for the Study

Refer to the local study contact information document.

3. Sponsor Study Monitor

Refer to the local study contact information document.

4. Sponsor Study Contact for Reporting of a Serious Adverse Event

GSK Biologicals Central Back-up Study Contact for Reporting SAEs: refer to protocol Section 8.4.2.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

SYNOPSIS

Detailed Title

A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexaTM vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar[®] and RotarixTM with a booster dose of GSK Biologicals' Infanrix[®] and HiberixTM vaccines at 15-18 months of age.

Indication

Active immunization against diphtheria, tetanus, pertussis infection caused by all known subtypes of hepatitis B virus, poliomyelitis, and invasive disease caused by *Haemophilus influenzae* type B (Hib) in infants.

Rationale for the study and study design

• Rationale for the study

Infanrix hexa was first licensed in the European Union in 2000. More than 100 million doses have been distributed to date and the benefit/risk profile remains favorable. Licensure of Infanrix hexa combination vaccine in the United States (US) will provide an additional option for vaccination within the routine US pediatric schedule with the fewest number of injections, which would create opportunities to add further injections in case other novel vaccines against important pediatric diseases become available. Furthermore, Infanrix hexa will provide an additional source of DTaP, hepatitis B, poliovirus, and Hib-containing vaccine to the US market, which will help ensure a more stable supply.

The present study 117119 (DTPA-HBV-IPV-135) is intended to generate pivotal immunogenicity data demonstrating non-inferiority of the immune responses against pertussis antigens of *Infanrix hexa* compared to *Pediarix*, which is currently one of the DTaP combination vaccines widely used as a standard of care in the US. Additionally, this study will also provide descriptive data with regard to the immunogenicity of the other vaccine antigens and the safety profile in US subjects. These pivotal immunogenicity non-inferiority data for pertussis and descriptive safety data are intended to support the registration of GSK Biologicals' combined DTPa-HBV-IPV/Hib (*Infanrix hexa*) vaccine in the US. A subsequent Phase III study is planned to provide pivotal data regarding lot-to-lot consistency, safety and the immunogenicity of the other vaccine antigens.

Comparison of immunogenicity data from separate clinical studies for *Infanrix hexa* and *Pentacel*, given on a 2-4-6 month schedule, suggests that the immune response to the Hib

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

component of these vaccines is similar. This study will provide descriptive information regarding the immune response to the Hib components of *Infanrix hexa* and *Pentacel* following a 3 dose primary series, prior to further evaluation in Phase III studies.

• Rationale for the study design

Design of Epoch 001 (primary vaccination):

The study is designed as a randomized, controlled, open-label study with five parallel groups:

- The first three groups (Hexa_1, Hexa_2 and Hexa_3 group) will receive three doses of the *Infanrix hexa* vaccine (either lot A, lot B or lot C, respectively). These three groups will be pooled together for the analyses and the pooled group will be called the Hexa group.
- The Pedia Group (Control 1) will receive three doses of the US-licensed control vaccines, *Pediarix* and *ActHIB*.
- The Penta Group (Control 2) will receive three doses of the US-licensed control vaccines, *Pentacel* (only two doses of *Engerix-B* will be administered if a subject has received a birth dose of hepatitis B vaccine).

Three distinct vaccine lots manufactured according to the same procedures will be used in the Hexa group in order to obtain more representative data for the vaccine.

The study will be open-label due to the differences in the number of injections and the appearance of the vaccines administered.

Vaccines (i.e., *Prevnar13* and *Rotarix*) that are recommended for children in the US during the first year of life will be administered concomitantly with the other study vaccines as part of the study.

Design of Epoch 002 (booster vaccination):

In Epoch 002, the subjects will be assessed for antibody persistence to the vaccine antigens of *Infanrix hexa*. This epoch will also assess the adequacy of priming subjects with *Infanrix hexa* by evaluating the boostability of D, T, Pa and Hib antigens with the US-licensed vaccines. The pooled Hexa Group will receive booster doses of *Infanrix* and *Hiberix* vaccines at 15 through 18 months of age, the subjects in the Penta Group will receive *Pentacel* vaccine as a booster, and

117119 (DTPA-HBV-IPV-135)
Protocol Amendment 2 Final Version 02
the subjects in the Pedia Group will receive a booster dose of *Infanrix* and *ActHIB* vaccines at 15 through 18 months of age.

The study will continue to be open-label in Epoch 002.

Objectives

Primary

Epoch 001 (primary vaccination)

• To demonstrate the non-inferiority of *Infanrix hexa* to *Pediarix* co-administered with *ActHIB*, in terms of antibody geometric mean concentrations (GMCs) for pertussis antigens [pertussis toxoid (PT), filamentous hemagglutinin (FHA) and pertactin (PRN)] one month after the third dose of the primary vaccination.

Criteria for non-inferiority:

Non-inferiority in terms of immune response to pertussis antigens will be demonstrated if, for each of the three antigens, the upper limit of the 95% confidence interval (CI) on the GMC ratio [Pedia divided by Hexa] is ≤ 1.5 .

Secondary

Epoch 001 (Primary vaccination)

- To assess the immune response to *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B*, in terms of seroprotection status, seropositivity status and concentrations or titers of antibodies to D, T, HBs, pertussis, poliovirus types 1, 2 and 3 and PRP antigens, one month after the third dose of the primary vaccination.
- To assess the safety and reactogenicity of a 3-dose primary vaccination course of *Infanrix hexa*, of *Pentacel* co-administered with *Engerix-B*, and that of *Pediarix* co-administered with *ActHIB*, in terms of solicited local symptoms.
- To assess the safety and reactogenicity of all study vaccines in terms of solicited general events, unsolicited adverse events, new-onset chronic diseases (NOCDs) and serious adverse events.

Epoch 002 (Booster vaccination)

• To assess the immunogenicity of *Infanrix hexa, Pentacel, Engerix-B, Pediarix* and *ActHIB*, in terms of persistence of the antibodies to D, T, pertussis, HBs, poliovirus types 1, 2 and 3 and PRP antigens, before the booster dose.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- To assess the immune response to *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*, in terms of seroprotection status, seropositivity status and antibody concentrations or titers for D, T, pertussis and PRP antigens, and in terms of booster response for pertussis antigens following *Infanrix* and *Pentacel*, one month after the booster dose.
- To assess the safety and reactogenicity of booster doses of *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*.

Study design

- Experimental design: Phase III, open-label, randomized, controlled, multi-centric, single-country study with five parallel groups.
- Duration of the study: The intended duration of the study per subject is approximately 14-17 months.
 - Epoch 001: Primary, starting at Visit 1 (Day 0) and ending at safety follow up contact (i.e. six months following the third dose, Month 10),
 - Epoch 002: Booster, starting at Visit 5 (Month 13-16) and ending at Visit 6 (Month 14-17).
- Study groups: The study groups are presented in Synopsis Table 1.

Synopsis Table 1 Study groups and epochs foreseen in the study

Chudu aroung	Number of subjects	Age (Min/Mey) of Vielt 4	Epochs		
Study groups	Number of subjects	Age (Min/Max) at Visit 1	Epoch 001	Epoch 002	
Hexa_1	65	6 WEEK -12weeks	Х	Х	
Hexa_2	65	6 WEEK -12weeks	Х	Х	
Hexa_3	65	6 WEEK -12weeks	Х	Х	
Pedia	195	6 WEEK -12weeks	Х	Х	
Penta	195	6 WEEK -12weeks	Х	Х	

The study groups and treatment foreseen in the study is presented in Synopsis Table 2.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Synopsis Table 2 Study groups and treatment foreseen in the study

Treatment	Vaccine/Product		St	udy Groups		
name	name	Hexa_1	Hexa_2	Hexa_3	Pedia	Penta
		E	Epoch 001			
Infanrix		.,		.,		
hexa	Hib	Х	Х	Х		
Pediarix					Х	
ActHIB	ActHIB					
	NaCl				Х	
Pentacel	DTaP-IPV (Sanofi					
	Pasteur)					Х
	ActHIB					
Engerix-B *	HBV					Х
Prevnar13	Prevenar 13	Х	Х	Х	Х	Х
Rotarix	HRV	v	v	V	v	
	CaCO ₃	Х	X	Х	Х	Х
		E	Epoch 002			
Infanrix	DTPa					
		Х	Х	Х	Х	
Hiberix	Hib	V	V	V		
	NaCl	Х	Х	Х		
ActHIB	ActHIB		_		Х	
	NaCl				X	
Pentacel	DTaP-IPV (Sanofi					
	Pasteur)					Х
	ActHIB					

^{*} Engerix-B should not be given at Month 2 (4 months of age) if a dose of hepatitis B vaccine was given at birth up to 30 days prior to study dose 1 to the subject in the Penta Group.

- Control: active controls.
 - Epoch 001: Pediarix + ActHIB and Pentacel + Engerix-B
 - Epoch 002: *Infanrix* + *ActHIB* and *Pentacel*
- Vaccination schedules:

Epoch 001

- Hexa Group: Subjects in this group will receive three doses of *Infanrix hexa* (lot A, lot B or lot C as per the group allocation) co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
 - Hexa_1 Group: Subjects will receive lot A of Infanrix hexa,
 - Hexa_2 Group: Subjects will receive lot B of Infanrix hexa
 - Hexa_3 Group: Subjects will receive lot C of Infanrix hexa.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- Pedia Group: Subjects in this group will receive three doses of *Pediarix* and *ActHIB* co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
- Penta Group: Subjects in this group will receive three doses of *Pentacel* and *Engerix-B** coadministered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.

*Subjects in the Penta Group who have received a dose of hepatitis B vaccine from birth up to 30 days prior to study vaccination should not receive *Engerix-B* at 4 months of age (Visit 2).

Epoch 002

- Hexa Group: Subjects will receive a booster dose of *Infanrix* and *Hiberix* vaccines at 15-18 months of age.
- Pedia Group: Subjects will receive a booster dose of *Infanrix* and *ActHIB* vaccines at 15-18 months of age.
- Penta Group: Subjects will receive a booster dose of Pentacel vaccine at 15-18 months of age.

The fourth dose of pneumococcal conjugate vaccine is recommended to be administered at approximately 12-15 months of age. Since the booster dose of the candidate vaccine/active controls will be given in this study at 15-18 months of age, the fourth dose of *Prevnar13* will not be administered as part of the study protocol. Subject's parent(s)/Legally Acceptable Representative(s) (LARs) will be reminded at Visit 3 and Visit 4 to consult their primary health care provider regarding the fourth dose of *Prevnar13* at 12-15 months for their child

As the analyses will be performed regardless of the lot of *Infanrix hexa* received, unless otherwise specified, the Hexa_1, Hexa_2 and Hexa_3 groups will be pooled together for the analysis and will be called the Hexa group.

- Treatment allocation: The subjects will be randomized at a [1:1:1]:3:3 ratio to Hexa_1, Hexa_2, Hexa_3, Pedia and Penta groups. This will be done at study entry using GSK Biologicals' central randomization system on internet (SBIR).
- Blinding: The study is open-label for both epochs due to the differences in the number of injections and the appearance of the vaccines administered. However, the

117119 (DTPA-HBV-IPV-135)
Protocol Amendment 2 Final Version 02
laboratory in charge of the serology testing will be
blinded to the treatment, and codes will be used to link
the subject and study (without any link to the treatment
attributed to the subject) to each sample.

The blinding of study epochs is presented in Synopsis Table 3.

Synopsis Table 3 Blinding of study epochs

Study Epochs	Blinding
Epoch 001	open
Epoch 002	open

- Sampling schedule: Blood samples will be drawn from all subjects at the following time points:
 - Post-Pri (Visit 4): One month after the third dose of primary vaccination, a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) will be collected.
 - Pre-Bst (Visit 5): Before the administration of the booster dose, a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) will be collected.
 - Post-Bst (Visit 6): One month after the booster vaccination, a volume of at least 3.5 mL of whole blood (to provide at least 1.2 mL of serum) will be collected.
- Type of study: self-contained.
- Data collection: electronic Case Report Form (eCRF).

Number of subjects

The total number of subjects planned to be enrolled is 585 subjects (65 each in Hexa_1, Hexa_2, Hexa_3 groups and 195 each in Pedia and Penta groups).

Endpoints Primary

Epoch 001 (Primary vaccination)

- Immunogenicity with respect to pertussis components of the study vaccines *Infanrix hexa* and *Pediarix*.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination

Secondary

Epoch 001 (Primary vaccination)

- Immunogenicity (other parameters) with respect to the pertussis component of the study vaccines *Infanrix hexa*, *Pentacel* and *Pediarix*.
 - Anti-PT, anti-FHA, anti-PRN seropositivity status, one month after the third dose of the primary vaccination.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination (for *Pentacel* only).
- Immunogenicity with respect to the other components of the study vaccines *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B*.
 - Anti-D, anti-T, anti-HBs, anti-poliovirus types 1, 2 and 3 and anti-PRP seroprotection status, anti-PRP antibody concentrations ≥1.0 µg/mL and antibody concentrations/titers, one month after the third dose of the primary vaccination.
- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0 − Day 3) after each vaccination (*Infanrix hexa, Pediarix, ActHIB, Pentacel* and *Engerix-B*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0 Day 3) after each vaccination.
- Unsolicited adverse events.
 - Occurrence of unsolicited AEs within 31 days (Day 0 Day 30) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.
- Specific adverse events.
 - Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies) from Day 0 up to six months post primary vaccination.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- Serious adverse events.
 - Occurrence of serious adverse events from Day 0 up to six months post primary vaccination.

Epoch 002 (Booster vaccination)

- Immunogenicity with respect to all study vaccines.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-HBs, anti-PRP and anti-poliovirus 1, 2, 3 seroprotection/ seropositivity status, anti-PRP antibody concentrations ≥1 μg/mL and antibody concentrations/ titers before the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccine *Pentacel*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-PRP seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
 - Anti-PRP antibody concentrations ≥1 µg/mL one month after the booster dose (Dose 4).
 - Anti-D and anti-T antibody concentrations ≥1 IU/mL one month after the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccine *Infanrix*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
 - Anti-D and anti-T antibody concentrations ≥1 IU/mL one month after the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccines *ActHIB* and *Hiberix*.
 - Anti-PRP seroprotection status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PRP antibody concentrations ≥1 µg/mL one month after the booster dose (Dose 4).

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0 – Day 3) after booster vaccination (*Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0 Day 3) after booster vaccination.
- Unsolicited adverse events.
 - Occurrence of unsolicited AEs within 31 days (Day 0 Day 30) after booster vaccination, according to the MedDRA classification.
- Specific adverse events.
 - Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies) from the booster dose up to one month after the booster vaccination.
- Serious adverse events.
 - Occurrence of serious adverse events from the booster dose up to one month after the booster vaccination.

TABLE OF CONTENTS

						PAGE
SPO	OSNC	R INFORM	MATION			7
SYI	NOPSI	S				8
LIS	T OF A	BBREVIA	TIONS			24
GLO	OSSAF	RY OF TEI	RMS			27
IIV						
1.						
	1.1.					
	1.2.				dy design	
		1.2.1. 1.2.2.			y	
		1.2.2.			y design Epoch 001 (primary vaccination):	
					Epoch 001 (primary vaccination): Epoch 002 (booster vaccination):	
2.	OBJE	CTIVES				33
	2.1.					
		2.1.1.			accination)	
	2.2.	Seconda	ary objective	es		33
		2.2.1.	Epoch 00	1 (Primary v	accination)	33
		2.2.2.	Epoch 00	2 (Booster v	accination)	34
3.	STUE	Y DESIGI	N OVERVI	ΞW		35
4.	STUD	У СОНОР	RT			38
	4.1.	Number	of subjects	/centers		38
	4.2.					
	4.3.	Exclusio	n criteria fo	r enrolment		39
5.	CONI					40
	5.1.	_	•		rations, including the informed	
		consent	process			40
	5.2.				mization of treatment	
		5.2.1.				
		5.2.2.			atment	
			5.2.2.1.		ation of supplies	
				5.2.2.1.1.		
			5.2.2.2.	5.2.2.1.2.	1	
			5.2.2.2.	5.2.2.2.1.	allocation to the subject	42
				J.Z.Z.Z. I.	Study group and treatment number allocation	42
				5.2.2.2.2.	Treatment number allocation for	42
				U.L.L.L.L.	subsequent doses	43
	5.3.	Method	of blinding			
	5.4.					

			117119 (DTPA-HBV-IP Protocol Amendment 2 Final Vers	
5.5.	Outline of	of study pro	cedures	44
5.6.	Detailed	description	of study procedures	48
	5.6.1.		es prior to study participation	
		5.6.1.1.	Informed consent	
	5.6.2.	Procedure	es during the study	
		5.6.2.1.	Check inclusion and exclusion criteria	48
		5.6.2.2.	Collect demographic data	
		5.6.2.3.	Medical history	
		5.6.2.4.	Vaccination history	
		5.6.2.5.	History directed physical examination	
		5.6.2.6.	Study group and treatment number allocation	
		5.6.2.7.	Treatment number allocation for subsequent	
		5.0.2.7.	doses	40
		5.6.2.8.	Assess pre-vaccination body temperature	
		5.6.2.9.	Sampling	
		5.0.2.9.	1 0	50
			5.6.2.9.1. Blood sampling for immune	E 0
		F C O 40	response assessments	
		5.6.2.10.	Check contraindications, warnings and precautions to vaccination	
		50044	precautions to vaccination	50
		5.6.2.11.	Baseline measurement of limb circumference	
			after booster vaccination at visit 5	
		5.6.2.12.	J	
			Recording of AEs, SAEs and NOCDs	51
		5.6.2.14.	Check and record concomitant	
			medication/vaccination and intercurrent	
			medical conditions	
		5.6.2.15.	,	
5.7.			andling and analysis	
	5.7.1.	•	ecified study materials	
	5.7.2.	Biological	samples	54
	5.7.3.	Laborator	y assays	54
	5.7.4.	Biological	samples evaluation	56
		5.7.4.1.	Immunological read-outs	56
	5.7.5.	Immunolo	gical correlates of protection	56
STUD			ADMINISTRATION	
6.1.			vaccines	
6.2.	Storage	and handling	ng of study vaccines	59
6.3.	Dosage	and admini	stration of study vaccines	60
6.4.			usable vaccine doses	
6.5.	Contrain	dications to	subsequent vaccination	61
	6.5.1.	Absolute of	contraindications:	61
	6.5.2.	Temporar	y contraindications:	62
6.6.	Warning		autions	
6.7.			ation/product and concomitant vaccination	
	6.7.1.		of concomitant medications/products and	
			ant vaccination	64
	6.7.2.		ant medications/products/vaccines that may lead	
			nination of a subject from ATP analyses	64
6.8.	Intercurr		I conditions that may lead to elimination of a	
			nalyses	65
	•		-	

6.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

7.	HEAL	TH ECON	NOMICS	65
8.	SAFE	TY		65
	8.1.	Safety of	definitions	
		8.1.1.		
		8.1.2.	Definition of a serious adverse event	66
		8.1.3.	Solicited adverse events	
			8.1.3.1. Solicited local (injection-site) adverse events	
			8.1.3.2. Solicited general adverse events	68
		8.1.4.	Clinical laboratory parameters and other abnormal	
			assessments qualifying as adverse events or serious	
			adverse events	
		8.1.5.	Adverse events of specific interest	69
	8.2.		or outcomes not qualifying as adverse events or serious	
	0.0		e events	69
	8.3.		ng and recording adverse events and serious adverse	00
				69
		8.3.1.	Time period for detecting and recording adverse events	00
		0.00	and serious adverse events	69
		8.3.2.	Post-Study adverse events and serious adverse events	
		8.3.3.	Evaluation of adverse events and serious adverse events	/ 2
			8.3.3.1. Active questioning to detect adverse events and serious adverse events	70
			8.3.3.2. Assessment of adverse events	
			8.3.3.2.1. Assessment of intensity	
			8.3.3.2.2. Assessment of causality	
			8.3.3.3. Assessment of outcomes	
			8.3.3.4. Medically attended visits	
	8.4.	Panortir	ng of serious adverse events and other events	
	0.7.	8.4.1.	Prompt reporting of serious adverse events and other	/ /
		0.4.1.	events to GSK Biologicals	77
		8.4.2.	Contact information for reporting serious adverse events	
		0.1.2.	and other events to GSK Biologicals	77
		8.4.3.	Completion and transmission of SAE reports to GSK	
		0. 1.0.	Biologicals	77
			8.4.3.1. Back-up system in case the electronic SAE	
			reporting system does not work	77
		8.4.4.	Updating of SAE information after freezing of the subject's	
		• • • • • • • • • • • • • • • • • • • •	eCRF	78
		8.4.5.	Regulatory reporting requirements for serious adverse	
			events	78
	8.5.	Follow-u	up of adverse events and serious adverse events	
		8.5.1.	Follow-up during the study	
		8.5.2.	Follow-up after the subject is discharged from the study	
	8.6.	Treatme	ent of adverse events	
	8.7.	Subject	card	<mark>79</mark>
		•		
9.	SUBJ		MPLETION AND WITHDRAWAL	
	9.1.		completion	
	9.2.	•	withdrawal	
		9.2.1.	Subject withdrawal from the study	80
		9.2.2.	Subject withdrawal from investigational vaccine	80

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

		r totocoi Amendinent 2 i mai versio	
10.	STATI	STICAL METHODS	81
	10.1.	Primary endpoint	
		10.1.1. Epoch 001 (Primary vaccination)	
	10.2.	Secondary endpoints	81
		10.2.1. Epoch 001 (Primary vaccination)	81
		10.2.2. Epoch 002 (Booster vaccination)	82
	10.3.	Determination of sample size	83
		10.3.1. Control on type I error	84
		10.3.2. References for sample size	84
		10.3.3. Power computation	
	10.4.	Study cohorts/ data sets to be analysed	
		10.4.1. Primary Total vaccinated cohort	
		10.4.2. Primary ATP cohort for analysis of safety	
		10.4.3. Primary ATP cohort for analysis of immunogenicity	
		10.4.4. Booster Total vaccinated cohort	86
		10.4.5. Booster ATP cohort for analysis of safety	
		10.4.6. Booster ATP cohort for analysis of immunogenicity	
	10.5.	Derived and transformed data	
	10.6.	Final analysis of the Epoch 001	
	10.0.	10.6.1. Analysis of demographics	
		10.6.2. Analysis of immunogenicity	
		10.6.2.1. Within group assessment	80
		10.6.2.2. Between group assessment	
		10.6.2.3. Interpretation of analyses	
		10.6.3. Analysis of safety	
	10.7.	Final analysis of the Epoch 002	
	10.7.	10.7.1. Analysis of demographics/baseline characteristics	
		10.7.2. Analysis of immunogenicity	
		10.7.2.1. Within group assessment	
		10.7.2.2. Between group assessment	
		10.7.2.3. Interpretation of analyses	
		10.7.3. Analysis of safety	02
	10.8.	Statistical methods	
	10.8.	Conduct of analyses	
	10.9.		
		10.9.1. Sequence of analyses10.9.2. Statistical considerations for interim analyses	94 0./
		10.9.2. Statistical Considerations for interim analyses	94
11	ΔΡΜΙΝ	NISTRATIVE MATTERS	0/
11.	11.1.	Remote Data Entry instructions	
	11.2.	Study Monitoring by GSK Biologicals	
	11.3.	Record retention	
	11.4.	Quality assurance	
	11. 4 . 11.5.	Posting of information on publicly available clinical trial registers and	90
	11.5.	publication policy	06
	11.6.	Provision of study results to investigators	90 90
	11.0.	r tovision of study results to investigators	90
12	COLIN	TRY SPECIFIC REQUIREMENTS	07
۰۷.	COUN	TITL OF LOTE TO INLIGHTENIUM	31
12	DEEE	DENCES	as

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

LIST OF TABLES

		PAGE
Table 1	Study groups and epochs foreseen in the study	36
Table 2	Study groups and treatment foreseen in the study	36
Table 3	Blinding of study epochs	38
Table 4	List of study procedures	45
Table 5	Intervals between study visits	48
Table 6	Biological samples	54
Table 7	Humoral Immunity (Antibody determination)	55
Table 8	Immunological read-outs	56
Table 9	Study vaccines	58
Table 10	Dosage and administration	61
Table 11	Solicited local adverse events	68
Table 12	Solicited general adverse events	68
Table 13	Reporting periods for adverse events and serious adverse events	71
Table 14	Intensity scales for solicited symptoms in infants/toddlers	73
Table 15	Timeframes for submitting serious adverse event and other events reports to GSK Biologicals	77
Table 16	Standard deviation for log ₁₀ transformed concentration post vaccination	84
Table 17	Power for pertussis NI post-Dose 3	84
Table 18	GSK Biologicals' laboratories	100
Table 19	Outsourced laboratories	100

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

LIST OF APPENDICES

	PAGE
APPENDIX A CLINICAL LABORATORIES	100
APPENDIX B AMENDMENTS AND ADMINISTRATIVE CHANGES TO THE PROTOCOL	101

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

LIST OF ABBREVIATIONS

ACIP: Advisory Committee on Immunization Practices

AE: Adverse Event

ANCOVA: Analysis of Co-variance

ANOVA: Analysis of Variance

ATP: According-To-Protocol

CDC: Centers for Disease Control and Prevention, United States

of America

CI: Confidence Interval

CSR: Clinical Study Report

D: Diphtheria

DTPa-HBV-IPV/Hib: Combined diphtheria-tetanus-acellular pertussis-hepatitis

B-inactivated poliovirus and Haemophilus influenzae

type b vaccine (Infanrix hexa).

eCRF: electronic Case Report Form

EL.U: ELISA unit(s)

ELISA: Enzyme-linked immunosorbent assay

ESFU: Extended safety follow-up

eTDF: electronic Temperature excursion Decision Form

FHA: Filamentous hemagglutinin

GCP: Good Clinical Practice

GMC: Geometric Mean Concentration

GMT: Geometric Mean Titer

GSK: GlaxoSmithKline

HBs: Hepatitis B surface antigen

Hib: *Haemophilus influenzae (H. influenzae)* type b

HRV: Human Rotavirus

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

IB: Investigator Brochure

ICF: Informed Consent Form

ICH: International Conference on Harmonisation

IEC: Independent Ethics Committee

IM: Intramuscular

IMP: Investigational Medicinal Product

IND: Investigational New Drug

IRB: Institutional Review Board

IU: International unit(s)

LAR: Legally Acceptable Representative

Limits of flocculation unit(s)

LSLV: Last Subject Last Visit

MedDRA: Medical Dictionary for Regulatory Activities

NI: Non-inferiority

NOCD: New Onset of Chronic Disease

Pa: Acellular Bordetella pertussis component

PI: Product Information

PRN: Pertactin

PRP: Polyribosyl-Ribitol-Phosphate: polysaccharide

component of the Hib bacterium capsule

PT: Pertussis toxoid: a secreted exotoxin of the *Bordetella*

pertussis bacterium

RCC: Reverse Cumulative Curve

RDE: Remote Data Entry

SAE: Serious Adverse Event

SBIR: Randomization System on Internet

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

SCID: Severe Combined Immunodeficiency Disease

SDV: Source Document Verification

SPC: Summary of Product Characteristics

SPM: Study Procedures Manual

T: Tetanus

TVC: Total Vaccinated cohort

US: United States

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

GLOSSARY OF TERMS

Adverse event:

Any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

An adverse event (AE) can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse.

Blinding:

A procedure in which one or more parties to the trial are kept unaware of the treatment assignment in order to reduce the risk of biased study outcomes. The level of blinding is maintained throughout the conduct of the trial, and only when the data are cleaned to an acceptable level of quality will appropriate personnel be unblinded or when required in case of a serious adverse event. In an open-label study, no blind is used. Both the investigator and the subject know the identity of the treatment assigned.

Child in care:

A child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation. The definition of a child in care can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. The definition of a child in care does not include a child who is adopted or has an appointed legal guardian.

Eligible:

Qualified for enrolment into the study based upon strict adherence to inclusion/exclusion criteria.

Epoch:

An epoch is a self-contained set of consecutive timepoints or a single timepoint from a single protocol. Self-contained means that data collected for all subjects at all timepoints within that epoch allows to draw a complete conclusion to define or precise the targeted label of the product. Typical examples of epochs are primary vaccinations, boosters, yearly immunogenicity follow-ups, and surveillance periods for efficacy or safety.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

eTrack: GSK's tracking tool for clinical trials.

Evaluable: Meeting all eligibility criteria, complying with the

procedures defined in the protocol, and, therefore,

included in the according-to-protocol (ATP) analysis (see

Sections 6.7.2 and 10.4 for details on criteria for

evaluability).

Immunological correlate

of protection:

The defined humoral antibody response above which there is a high likelihood of protection in the absence of any host factors that might increase susceptibility to the

infectious agent.

Intercurrent medical

condition:

A condition that has the capability of altering a subject's

immune response or are confirmed to have an immunodeficiency condition during the study.

Investigational vaccine/product:

A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorization when used in a way different from the approved form, or when

used for an unapproved indication, or when used to gain further information about an approved use.

(Synonym of

Investigational Medicinal

Primary completion

Product)

date:

The date that the final subject was examined or received an intervention for the purpose of final collection of data

for the primary outcome, whether the clinical trial concluded according to the pre-specified protocol or was

terminated.

Randomization: Process of random attribution of treatment to subjects in

order to reduce bias of selection.

Self-contained study: Study with objectives not linked to the data of another

study.

Site Monitor: An individual assigned by the sponsor who is responsible

for assuring proper conduct of clinical studies at one or

more investigational sites.

Solicited adverse event: AEs to be recorded as endpoints in the clinical study. The

presence/occurrence/intensity of these events is actively solicited from the subject or an observer during a

specified post-vaccination follow-up period.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Subject: Term used throughout the protocol to denote an

individual who has been contacted in order to participate or participates in the clinical study, either as a recipient of

the vaccines or as a control.

Subject number: A unique number identifying a subject, assigned to each

subject consenting to participate in the study.

Treatment: Term used throughout the clinical study to denote a set of

investigational product(s) or marketed product(s) or placebo intended to be administered to a subject, identified by a unique number, according to the study

randomization or treatment allocation.

Treatment number: A number identifying a treatment to a subject, according

to the study randomization or treatment allocation.

Unsolicited adverse Any AE reported in addition to those solicited during the

clinical study. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse

event.

event:

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

TRADEMARKS

The following trademarks are used in the present protocol.

In the body of the protocol (including the synopsis), the names of the vaccines will be written without the superscript symbol TM or $\mathbb R$ and in *italics*.

Trademarks of the GlaxoSmithKline group of
companies
Engerix-B [®]
Hiberix™
Infanrix [®]
Infanrix hexa™
Pediarix [®]
Rotarix®

Generic description
Hepatitis B vaccine (recombinant)
Haemophilus b conjugate vaccine (tetanus toxoid conjugate)
Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
Combined Diphtheria-Tetanus-acellular Pertussis (DTaP), Hepatitis B, Poliovirus and <i>Haemophilus influenzae</i> type b vaccine
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine
Rotavirus Vaccine, Live, Oral

Trademarks not owned by the GlaxoSmithKline group of companies	
ActHIB® (Sanofi Pasteur SA)	
Pentacel® (Sanofi Pasteur SA)	
Prevnar® (Wyeth Pharmaceuticals Inc.; Marketed by Pfizer Inc.)	
Prevnar13® (Wyeth Pharmaceuticals Inc.; Marketed by Pfizer Inc.)	

Generic description		
Haamanbilus tuna haaniuseta vassina (tatanus		
Haemophilus type b conjugate vaccine (tetanus toxoid conjugate)		
Diphtheria and tetanus toxoids and acellular		
pertussis adsorbed, inactivated poliovirus and		
Haemophilus b conjugate (tetanus toxoid conjugate)		
Pneumoccocal 7-valent conjugate vaccine		
(diphtheria CRM ₁₉₇ protein)		
Pneumoccocal 13-valent conjugate vaccine		
(diphtheria CRM ₁₉₇ protein)		

1. INTRODUCTION

1.1. Background

Combination vaccines have been developed to provide multiple immunizations in a single injection. They can simplify vaccine administration and have the potential to promote compliance and cost-effectiveness by decreasing the number of injections needed to immunize a child [Zinke, 2010; Kalies, 2006]. Use of combination vaccines can alleviate concerns associated with the number of injections to be given at one time [ACIP, 2011].

GlaxoSmithKline (GSK) Biologicals' *Infanrix hexa* vaccine helps prevent six diseases in a single injection. *Infanrix hexa* is licensed for primary and booster vaccination in more than 98 countries around the globe, including the entire European Union. The vaccine complies with the WHO requirements for manufacture of biological substances for all of its antigenic components. The *Infanrix hexa* vaccine consists of a combination of GSK's *Pediarix* (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined); STN 103907, approved in the United States (US) on December 13, 2002 and a Hib vaccine consisting of purified polyribosyl-ribitol-phosphate (PRP) capsular polysaccharide of *Haemophilus influenzae* type b covalently bound to tetanus toxoid (TT). The conjugated Hib-TT is the same as that used for the formulation of *Hiberix* [*Haemophilus* b Conjugate Vaccine (Tetanus Toxoid Conjugate)] (licensed in the US as a booster dose in August 2009), with the only difference that in *Infanrix hexa*, the Hib-conjugate is adsorbed onto aluminum phosphate.

The *Infanrix hexa* combination vaccine would provide an additional source of DTaP, hepatitis B, poliovirus, and Hib containing vaccines for the US market and would potentially reduce the number of injections required to provide infants with recommended vaccinations.

GSK has an extensive clinical safety database for *Infanrix hexa*. The safety and immunogenicity data of the vaccine have been evaluated in numerous controlled studies [Dhillon, 2010; Zepp, 2009], of which 4 were conducted in the US with approximately 3000 US subjects exposed to a primary vaccination with *Infanrix hexa*.

Please refer to the current Investigator Brochure for information regarding the preclinical and clinical studies and the potential risks and benefits of *Infanrix hexa*.

1.2. Rationale for the study and study design

1.2.1. Rationale for the study

Infanrix hexa was first licensed in the European Union in 2000. More than 100 million doses have been distributed to date and the benefit/risk profile remains favorable. Licensure of Infanrix hexa combination vaccine in the US will provide an additional option for vaccination within the routine US pediatric schedule with the fewest number of injections, which would create opportunities to add further injections in case other novel vaccines against important pediatric diseases become available. Furthermore, Infanrix hexa will provide an additional source of DTaP, hepatitis B, poliovirus, and Hibcontaining vaccine to the US market, which will help ensure a more stable supply.

The present study 117119 (DTPA-HBV-IPV-135) is intended to generate pivotal immunogenicity data demonstrating non-inferiority of the immune responses against pertussis antigens of *Infanrix hexa* compared to *Pediarix*, which is currently one of the DTaP combination vaccines widely used as a standard of care in the US. Additionally, this study will also provide descriptive data with regard to the immunogenicity of the other vaccine antigens and the safety profile in US subjects. These pivotal immunogenicity non-inferiority data for pertussis and descriptive safety data are intended to support the registration of GSK Biologicals' combined DTPa-HBV-IPV/Hib (*Infanrix hexa*) vaccine in the US. A subsequent Phase III study is planned to provide pivotal data regarding lot-to-lot consistency, safety and the immunogenicity of the other vaccine antigens.

Comparison of immunogenicity data from separate clinical studies for *Infanrix hexa* and *Pentacel*, given on a 2-4-6 month schedule, suggests that the immune response to the Hib component of these vaccines is similar. This study will provide descriptive information regarding the immune response to the Hib components of *Infanrix hexa* and *Pentacel* following a 3-dose primary series, prior to further evaluation in Phase III studies.

1.2.2. Rationale for the study design

1.2.2.1. Design of Epoch 001 (primary vaccination):

The study is designed as a randomized, controlled, open-label study with five parallel groups:

- The first three groups (Hexa_1, Hexa_2 and Hexa_3 group) will receive three doses of the *Infanrix hexa* vaccine (either lot A, lot B or lot C, respectively). These three groups will be pooled together for the analyses and the pooled group will be called the Hexa group.
- The Pedia Group (Control 1) will receive three doses of the US-licensed control vaccines, *Pediarix* and *ActHIB*.
- The Penta Group (Control 2) will receive three doses of the US-licensed control vaccines, *Pentacel* (only two doses of *Engerix-B* will be administered if a subject has received a birth dose of hepatitis B vaccine).

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Three distinct vaccine lots manufactured according to the same procedures will be used in the Hexa group in order to obtain more representative data for the vaccine.

The study will be open-label due to the differences in the number of injections and the appearance of the vaccines administered.

Vaccines (i.e., *Prevnar13* and *Rotarix*) that are recommended for children in the US during the first year of life will be administered concomitantly with the other study vaccines as part of the study.

1.2.2.2. Design of Epoch 002 (booster vaccination):

In Epoch 002, the subjects will be assessed for antibody persistence to the vaccine antigens of *Infanrix hexa*. This epoch will also assess the adequacy of priming subjects with *Infanrix hexa* by evaluating the boostability of D, T, Pa and Hib antigens with the US-licensed vaccines. The pooled Hexa Group will receive booster doses of *Infanrix* and *Hiberix* vaccines at 15 through 18 months of age, the subjects in the Penta Group will receive *Pentacel* vaccine as a booster, and the subjects in the Pedia Group will receive a booster dose of *Infanrix* and *ActHIB* vaccines at 15 through 18 months of age.

The study will continue to be open-label in Epoch 002.

2. OBJECTIVES

2.1. Primary objective

2.1.1. Epoch 001 (Primary vaccination)

• To demonstrate the non-inferiority of *Infanrix hexa* to *Pediarix* co-administered with *ActHIB*, in terms of antibody geometric mean concentrations (GMCs) for pertussis antigens [pertussis toxoid (PT), filamentous hemagglutinin (FHA) and pertactin (PRN)] one month after the third dose of the primary vaccination.

Criteria for non-inferiority:

Non-inferiority in terms of immune response to pertussis antigens will be demonstrated if, for each of the three antigens, the upper limit of the 95% confidence interval (CI) on the GMC ratio [Pedia divided by Hexa] is ≤ 1.5 .

Refer to Section 10.1 for the definition of the primary endpoint.

2.2. Secondary objectives

2.2.1. Epoch 001 (Primary vaccination)

• To assess the immune response to *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B*, in terms of seroprotection status, seropositivity status and concentrations or titers of antibodies to D, T, HBs, pertussis, poliovirus types 1, 2 and 3 and PRP antigens, one month after the third dose of the primary vaccination.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02


- To assess the safety and reactogenicity of a 3-dose primary vaccination course of *Infanrix hexa*, of *Pentacel* co-administered with *Engerix-B*, and that of *Pediarix* co-administered with *ActHIB*, in terms of solicited local symptoms.
- To assess the safety and reactogenicity of all study vaccines in terms of solicited general events, unsolicited adverse events, new-onset chronic diseases (NOCDs) and serious adverse events.

2.2.2. Epoch 002 (Booster vaccination)

- To assess the immunogenicity of *Infanrix hexa, Pentacel, Engerix-B, Pediarix* and *ActHIB*, in terms of persistence of the antibodies to D, T, pertussis, HBs, poliovirus types 1, 2 and 3 and PRP antigens, before the booster dose.
- To assess the immune response to *Infanrix, Hiberix, ActHIB* and *Pentacel,* in terms of seroprotection status, seropositivity status and antibody concentrations or titers for D, T, pertussis and PRP antigens, and in terms of booster response for pertussis antigens following *Infanrix and Pentacel*, one month after the booster dose.
- To assess the safety and reactogenicity of booster doses of *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*.

Refer to Section 10.2 for the definition of the secondary endpoints.

3. STUDY DESIGN OVERVIEW



N = number of subjects in the study; n = number of subjects in each group; Mo = months

Visit 3 should be conducted at least 8 weeks after Visit 2, with subjects at least 24 weeks of age, in order to comply with US recommendations on hepatitis B dosing

Post-Pri = blood sample collected from subjects, one month after the administration of the third dose in the Epoch 001 Pre-Bst = blood sample collected from subjects, before the administration of the booster dose in the Epoch 002 Post-Bst = blood sample collected from subjects, one month after the administration of booster dose in the Epoch 002 * Engerix-B should not be given at Month 2 (4 months of age) if a dose of hepatitis B vaccine was given at birth up to 30 days prior to study dose 1 to the subject in the Penta Group ESFU = Extended safety follow-up

Protocol waivers or exemptions are not allowed with the exception of immediate safety concerns. Therefore, adherence to the study design requirements, including those specified in the outline of study procedures (Section 5.5), are essential and required for study conduct.

- Experimental design: Phase III, open-label, randomized, controlled, multi-centric, single-country study with five parallel groups.
- Duration of the study: The intended duration of the study per subject is approximately 14-17 months.
 - Epoch 001: Primary, starting at Visit 1 (Day 0) and ending at safety follow up contact (i.e. six months following the third dose, Month 10),

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- Epoch 002: Booster, starting at Visit 5 (Month 13-16) and ending at Visit 6 (Month 14-17).
- Study groups: The study groups and epochs foreseen in the study are presented in Table 1.

Table 1 Study groups and epochs foreseen in the study

Study groups	Number of aubicate	Age (Min/Mey) of Visit 4	Epochs		
	Number of subjects	Age (Min/Max) at Visit 1	Epoch 001	Epoch 002	
Hexa_1	65	6 WEEK -12weeks	Х	Х	
Hexa_2	65	6 WEEK -12weeks	Х	Х	
Hexa_3	65	6 WEEK -12weeks	Х	Х	
Pedia	195	6 WEEK -12weeks	Х	Х	
Penta	195	6 WEEK -12weeks	Х	Х	

The study groups and treatment foreseen in the study are presented in Table 2.

Table 2 Study groups and treatment foreseen in the study

Treatment	Vaccine/Product	Study Groups					
name	name	Hexa_1	Hexa_2	Hexa_3	Pedia	Penta	
			poch 001				
Infanrix hexa				,			
	Hib	Х	Х	Х			
Pediarix					Х		
ActHIB	ActHIB						
	NaCl				Х		
Pentacel	DTaP-IPV						
	(Sanofi Pasteur)					Х	
	ActHIB						
Engerix-B *	HBV					Х	
Prevnar13	Prevenar 13	Х	Х	Х	Х	Х	
Rotarix	HRV	Х	Х	Х	Х	Х	
	CaCO ₃						
		E	poch 002				
Infanrix	DTPa	Х	Х	Х	Х		
Hiberix	Hib	Х	Х	Х			
	NaCl						
ActHIB	ActHIB				.,		
	NaCl				Х		
Pentacel	DTaP-IPV						
	(Sanofi Pasteur)					Х	
	ActHIB						

^{*} Engerix-B should not be given at Month 2 (4 months of age) if a dose of hepatitis B vaccine was given at birth up to 30 days prior to study dose 1 to the subject in the Penta Group.

- Control: active controls.
 - Epoch 001: Pediarix + ActHIB and Pentacel + Engerix-B
 - Epoch 002: *Infanrix* + *ActHIB* and *Pentacel*.

Vaccination schedules:

Epoch 001

- Hexa Group: Subjects in this group will receive three doses of *Infanrix hexa* (lot A, lot B or lot C as per the group allocation) co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
 - Hexa_1 Group: Subjects will receive lot A of Infanrix hexa,
 - Hexa_2 Group: Subjects will receive lot B of Infanrix hexa
 - Hexa 3 Group: Subjects will receive lot C of *Infanrix hexa*.
- Pedia Group: Subjects in this group will receive three doses of *Pediarix* and *ActHIB* co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
- Penta Group: Subjects in this group will receive three doses of *Pentacel* and *Engerix-B** co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.

Epoch 002

- Hexa Group: Subjects will receive a booster dose of *Infanrix* and *Hiberix* vaccines at 15-18 months of age.
- Pedia Group: Subjects will receive a booster dose of *Infanrix* and *ActHIB* vaccines at 15-18 months of age.
- Penta Group: Subjects will receive a booster dose of *Pentacel* vaccine at 15-18 months of age.

The fourth dose of pneumococcal conjugate vaccine is recommended to be administered at approximately 12-15 months of age. Since the booster dose of the candidate vaccine/active controls will be given in this study at 15-18 months of age, the fourth dose of *Prevnar13* will not be administered as part of the study protocol. Subject's parent(s)/Legally Acceptable Representative(s) (LARs) will be reminded at Visit 3 and Visit 4 to consult their primary health care provider regarding the fourth dose of *Prevnar13* at 12-15 months for their child.

- As the analyses will be performed regardless of the lot of *Infanrix hexa* received, unless otherwise specified, the Hexa_1, Hexa_2 and Hexa_3 groups will be pooled together for the analysis and will be called the Hexa group.
- Treatment allocation: The subjects will be randomized at a [1:1:1]:3:3 ratio to Hexa_1, Hexa_2, Hexa_3, Pedia and Penta groups. This will be done at study entry using GSK Biologicals' central randomization system on internet (SBIR).
- Blinding: The study is open-label for both epochs (Table 3) due to the differences in the number of injections and the appearance of the vaccines administered. However, the laboratory in charge of the serology testing will be blinded to the treatment, and

^{*}Subjects in the Penta Group who have received a dose of hepatitis B vaccine from birth up to 30 days prior to study vaccination should not receive *Engerix-B* at 4 months of age (Visit 2).

117119 (DTPA-HBV-IPV-135)

Protocol Amendment 2 Final Version 02

codes will be used to link the subject and study (without any link to the treatment attributed to the subject) to each sample.

The blinding of study epochs is presented in Table 3.

Table 3 Blinding of study epochs

Study Epochs	Blinding
Epoch 001	open
Epoch 002	open

- Sampling schedule: Blood samples will be drawn from all subjects at the following time points:
 - Post-Pri (Visit 4): One month after the third dose of primary vaccination, a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) will be collected.
 - Pre-Bst (Visit 5): Before the administration of the booster dose, a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) will be collected.
 - Post-Bst (Visit 6): One month after the booster vaccination, a volume of at least
 3.5 mL of whole blood (to provide at least 1.2 mL of serum) will be collected.
- Type of study: self-contained.
- Data collection: electronic Case Report Form (eCRF).

4. STUDY COHORT

4.1. Number of subjects/centers

Target enrolment will be 585 subjects (65 each in Hexa_1, Hexa_2, Hexa_3 groups and 195 each in Pedia and Penta groups). Enrolment will be terminated when the target number of subjects has been enrolled. Refer to Section 10.3 for a detailed description of the criteria used in the estimation of sample size.

This study will be conducted at multiple centers in the US.

Actual numbers of subjects enrolled versus target will be monitored by the site monitor using SBIR.

4.2. Inclusion criteria for enrolment

Deviations from inclusion criteria are not allowed because they can potentially jeopardize the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol is essential.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

All subjects must satisfy ALL the following criteria at study entry:

- Subjects' parent(s)/ LAR(s) who, in the opinion of the investigator, can and will comply, with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
- A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.
- Born full-term (i.e. after a gestation period of 37 weeks to less than 42 completed weeks [259 to 293 days]).
- Written informed consent obtained from parent(s)/LAR(s) of the subject.
- Healthy subjects as established by medical history and clinical examination before entering into the study.
- Infants who have not received a previous dose of hepatitis B vaccine or those who have received only 1 dose of hepatitis B vaccine administered at least 30 days prior to enrolment.

4.3. Exclusion criteria for enrolment

Deviations from exclusion criteria are not allowed because they can potentially jeopardize the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol is essential.

The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:

- Child in care
 - Please refer to the glossary of terms for the definition of child in care.
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccines, or planned use during the study period.
- Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs since birth. For corticosteroids, this will mean prednisone ≥ 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
- Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting from 30 days before the first vaccination until 30 days after Dose 3 (Epoch 001, primary vaccination) and from 30 days before the booster Dose 4 until 30 days after booster Dose 4 (Epoch 002, booster vaccination), i.e. the end of the study:
 - Inactivated influenza and hepatitis A vaccines are allowed throughout the study.
 - Routine administration(s) of vaccines are allowed from 30 days after the last dose of primary vaccination until 30 days before the booster dose and after postbooster blood sampling. Routine administration of measles-mumps-rubella

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

vaccine, varicella, pneumococcal vaccines are allowed from 30 days after last dose of primary vaccine until 30 days before booster dose and from post-booster blood sampling, as well as according to the recommended immunization schedule in US.

- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- History of Hib, diphtheria, tetanus, pertussis, pneumococcal, rotavirus, poliovirus and hepatitis B diseases.
- Previous vaccination against Hib, diphtheria, tetanus, pertussis, pneumococcus, rotavirus and/or poliovirus; more than one previous dose of hepatitis B vaccine.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- Family history of congenital or hereditary immunodeficiency.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines (including yeast).
- Hypersensitivity to latex.
- Major congenital defects or serious chronic illness.
- History of any neurological disorders including seizures.
- Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
- History of intussusception or of any uncorrected congenital malformation of the gastrointestinal tract that would predispose the infant to intussusception.
- History of Severe Combined Immunodeficiency Disease (SCID).
- Acute disease and/or fever at the time of enrolment.
 - Fever is defined as temperature ≥38.0°C /100.4°F by any route. The preferred route for recording temperature in this study will be rectal for Epoch 001 and axillary for Epoch 002.
 - Subjects with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.

5. CONDUCT OF THE STUDY

5.1. Regulatory and ethical considerations, including the informed consent process

The study will be conducted in accordance with all applicable regulatory requirements.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

The study will be conducted in accordance with the ICH Guideline for Good Clinical Practice (GCP), all applicable subject privacy requirements and the guiding principles of the Declaration of Helsinki.

The study has been designed and will be conducted in accordance with the ICH Harmonised Tripartite Guideline for clinical investigation of medicinal products in the paediatric population (ICH E11) and all other applicable ethical guidelines.

GSK will obtain favorable opinion/approval to conduct the study from the appropriate regulatory agency, in accordance with applicable regulatory requirements, prior to a site initiating the study in that country.

Conduct of the study includes, but is not limited to, the following:

- Institutional Review Board (IRB)/Independent Ethics Committee (IEC) review and favorable opinion/approval of study protocol and any subsequent amendments.
- Subject's parent(s)/LAR(s) informed consent.
- Investigator reporting requirements as stated in the protocol.

GSK will provide full details of the above procedures to the investigator, either verbally, in writing, or both.

Freely given and written informed consent must be obtained from each subject's parent(s)/LAR(s) prior to participation in the study.

GSK Biologicals will prepare a model Informed Consent Form (ICF) which will embody the ICH GCP and GSK Biologicals required elements. While it is strongly recommended that this model ICF is to be followed as closely as possible, the informed consent requirements given in this document are not intended to pre-empt any local regulations which require additional information to be disclosed for informed consent to be legally effective. Clinical judgement, local regulations and requirements should guide the final structure and content of the local version of the ICF.

The investigator has the final responsibility for the final presentation of the ICF, respecting the mandatory requirements of local regulations. The ICF generated by the investigator with the assistance of the sponsor's representative must be acceptable to GSK Biologicals and be approved (along with the protocol, and any other necessary documentation) by the IRB/IEC.

5.2. Subject identification and randomization of treatment

5.2.1. Subject identification

After checking the inclusion/exclusion criteria, subject numbers will be assigned sequentially to subjects whose parent(s)/LAR(s) give consent for their child to participate in the study, according to the range of subject numbers allocated to each study center. Subject numbers will also be used to identify blood samples collected during the study.

5.2.2. Randomization of treatment

5.2.2.1. Randomization of supplies

The numbering of supplies will be performed at GSK Biologicals, using MATerial EXcellence (MATEX), a program developed for use in Statistical Analysis System (SAS®) (Cary, NC, USA) by GSK Biologicals.

To allow GSK Biologicals to take advantage of greater rates of recruitment than anticipated at individual centers in this multi-center study and to thus reduce the overall study recruitment period, an over-randomization of supplies will be prepared.

5.2.2.1.1. Epoch 001

A first list based on a randomization blocking scheme using a [1:1:1]:3:3 randomization ratio will be used to number the following vaccines for Doses 1, 2 and 3.

- DTPa-HBV-IPV/Hib lot A
- DTPa-HBV-IPV/Hib lot B
- DTPa-HBV-IPV/Hib lot C
- Pediarix
- Pentacel

The vaccines from this list will be distributed to the study center while respecting the randomization block size.

ActHIB, Engerix-B, Prevnar13 and Rotarix will be numbered independently using a sequential numbering.

5.2.2.1.2. Epoch 002

Four sequential lists (one for *Infanrix*, one for *Hiberix*, one for *ActHIB* and one for *Pentacel*) will be used to number the vaccine doses for the Epoch 002.

The study staff in charge of the vaccine administration will access SBIR, provide the subject identification number and the dose number. The system will provide a new treatment number for all the vaccines to be administered to a subject (*Pentacel*, *Infanrix* + *ActHIB* or *Infanrix* + *Hiberix*). This will be consistent with the allocated study group.

5.2.2.2. Treatment allocation to the subject

The treatment numbers will be allocated by dose.

5.2.2.2.1. Study group and treatment number allocation

The target is to enroll 585 subjects to be randomly assigned to five study groups in a [1:1:1]:3:3 ratio (195 subjects in the pooled lots group).

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Allocation of the subject to a study group at the investigator site will be performed using SBIR. The randomization algorithm will use a minimization procedure accounting for the study as a whole and each of the centers.

After obtaining the signed and dated ICF from the subject's parent(s)/LAR(s) and having checked the eligibility of the subject, the site staff in charge of the vaccine administration will access SBIR. Upon providing the subject identification number, the randomization system will ask whether the subject had a previous hepatitis B vaccination and will use the minimization algorithm to determine the group allocation and the appropriate treatment number for *Pentacel*, *Pediarix* or for *Infanrix hexa* (lot A, lot B or lot C) to be used for the subject.

SBIR will also provide treatment numbers for co-administered vaccines *Engerix B*, *ActHib*, *Prevnar13* vaccine and a *Rotarix* vaccine, each one labelled with a different treatment number. Therefore a subject will have three or four different treatment numbers allocated at dose 1.

The number of each administered treatment must be recorded in the eCRF on the Vaccine Administration screen.

When SBIR is not available, please refer to the SBIR user guide or the Study Procedures Manual (SPM) for specific instructions.

5.2.2.2.2. Treatment number allocation for subsequent doses

For each dose subsequent to the first dose, the study staff in charge of the vaccine administration will access SBIR, provide the subject identification number, the dose number and the system will provide new treatment numbers consistent with the allocated study group.

Each vaccine will be labeled with a different treatment number.

The number of each administered treatment must be recorded in the eCRF on the Vaccine Administration screen.

Note that in the Penta Group, the investigator will be reminded that *Engerix-B* is not allowed at dose 2 for subjects with previous hepatitis B vaccination. So for these subjects, the treatment identified by SBIR for dose 2 should not be used.

5.3. Method of blinding

The study will be open-label for both epochs due to the differences in the number of injections and the appearance of the vaccines administered. However, the laboratory in charge of the serology testing will be blinded to the treatment, and codes will be used to link the subject and study (without any link to the treatment attributed to the subject) to each sample.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

5.4. General study aspects

Supplementary study conduct information not mandated to be present in this protocol is provided in the accompanying SPM. The SPM provides the investigator and the site personnel with administrative and detailed technical information that does not impact the safety of the subjects.

5.5. Outline of study procedures

The outline of study procedures is presented in Table 4.

Table 4 List of study procedures

(Amendment 2: 17 April 2015)

	EPOCH 001 (PRIMARY VACCINATION)					EPOCH 002 (BOOSTER VACCINATION)	
Age	2 Months	4 Months	6 Months	7 Months	12 Months	15-18 Months	
Age Visit	VISIT 1	VISIT 2	VISIT 3†	VISIT 4	ESFU CONTACT (PHONE)	VISIT 5	VISIT 6
Time point	Day 0	Month 2	Month 4	Month 5	Month 10	Month 13 -16	Month 14 - 17
Sampling time point				Post-Pri		Pre-Bst	Post-Bst
Informed consent	•						
Check inclusion/exclusion criteria	•						
Medical history	•						
Collect demography data	•						
Vaccination history including HepB vaccination history	•						
Informed consent for Tdap vaccination history of mother ^α	•						
Last Tdap vaccination history of mother ^β	•						
History directed physical examination including length and weight	•					•	
Study group and treatment number allocation (Randomization)	0						
Treatment number allocation for subsequent doses		0	0			0	
Recording of administered treatment number	•	•	•			•	
Pre-vaccination body temperature	•	•	•			•	
Blood sampling				•		•	•
Check warnings and precautions	0	0	0			0	
Check contraindications to subsequent vaccination		•	•			•	
Pre-vaccination measurement of circumference of limb(s) at site of injection							
by investigator $^{\delta}$						•	
Vaccination	•	• **	•			•	
Distribution of thermometer	0						
Distribution of measuring device	0					0	
Distribution of diary cards	0	0	0			0	

117119 (DTPA-HBV-IPV-135)

Protocol Amendment 2 Final Version 02

					Protocol Al	nenament 2 Fi	nai version uz
		Еросн	001 (PRIMARY	VACCINATION)		EPOC	н 002
						(Booster V	ACCINATION)
Age	2 Months	4 Months	6 Months	7 Months	12 Months	15-18 Months	16-19 Months
Visit	Visit 1	VISIT 2	VISIT 3 †	Visit 4	ESFU	VISIT 5	VISIT 6
					CONTACT		
					(PHONE)		
Time point	Day 0	Month 2	Month 4	Month 5	Month 10	Month 13 -16	Month 14 - 17
Sampling time point				Post-Pri		Pre-Bst	Post-Bst
Daily post-vaccination recording of solicited adverse events during the 4-day							
(Day 0-3) follow-up period, recorded by the subjects' parent(s)/LAR(s) in	•	•	•			•	
diary card							
Recording of non-serious (unsolicited) adverse events during the 31-day							
(Day 0–30) follow-up period, recorded by the subjects' parent(s)/LAR(s) in	•	•	•			•	
diary card							
Recording of any large injection site reactions in the eCRF by the							
investigator*						•	
Return of diary cards and transcription by the investigator		•	•	•			•
Record any concomitant medication and vaccination §	•	•	•	•	•	•	•
Record any intercurrent medical conditions		•	•	•	•	•	•
Recording of serious adverse events including related to study participation	_						
or to a concurrent GSK medication/vaccine	•	•	•	•	•	•	•
Recording of NOCDs‡	•	•	•	•	•	•	•
Investigator sign-off				•			•
Analysis of the Epoch 001 #				0			
Analysis of the Epoch 002 #							0
Study Conclusion							•
•		l			1		1

Note: The double-line border indicates the analyses which will be performed on all data obtained up to that visit or contact.

- is used to indicate a study procedure that requires documentation in the individual eCRF
- o is used to indicate a study procedure that does not require documentation in the individual eCRF

Post-Pri = blood sample collected from subjects, one month after the administration of the third dose in the Epoch 001

Pre-Bst = blood sample collected from subjects, before the administration of the booster dose in the Epoch 002

Post-Bst = blood sample collected from subjects, one month after the administration of booster dose in the Epoch 002

† Visit 3 should be conducted at least 8 weeks after Visit 2 and when the subject is at least 24 weeks of age

^a The child can still continue in the study even if the mother does not wish to provide consent to record her Tdap vaccination history.

^β Only the Tdap vaccination history (during the pregnancy of the enrolled child) from mothers who have given consent to provide this information will be obtained and recorded in the eCRF.

117119 (DTPA-HBV-IPV-135)

Protocol Amendment 2 Final Version 02

§ Refer to Section 6.7 for details

Refer to Section 6.8 for details

‡ New onset of chronic disease (NOCD) includes events such as autoimmune disorders, asthma, type I diabetes and allergies

Refer to Section 10.9.1 for details

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

^δ For the Penta group, which receives only one vaccine at Visit 5, baseline measurement of only the limb receiving the vaccine is required
*** If subject in the Penta Group received a birth dose of Hep B vaccine, no administration of *Engerix-B* is foreseen at Visit 2 (4-months of age)

^{*} Refer to Section 8.1.3.1 and 5.6.2.11 for detailed explanation on the reporting of large injection site reactions

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

It is the investigator's responsibility to ensure that intervals between visits are strictly followed. The intervals between study visits are presented in Table 5.

Table 5 Intervals between study visits

Interval	Optimal length of interval ¹
Birth→Visit 1	6-12 weeks (42-90 days) of age ²
Visit 1 →Visit 2	49-83 days ²
Visit 2 →Visit 3 *	56-90 days²
Visit $3 \rightarrow \text{Visit } 4$	30-48 days ² †
Visit 3 → Phone call (ESFU contact)	180-210 days**
Birth→ Visit 5 [^]	15-18 months of age ²
Visit 5 → Visit 6	30-48 days ² †

¹ Whenever possible the investigator should arrange within this interval:

5.6. Detailed description of study procedures

5.6.1. Procedures prior to study participation

5.6.1.1. Informed consent

The signed informed consent of the subject's parent(s)/LAR(s) must be obtained before study participation.

5.6.2. Procedures during the study

5.6.2.1. Check inclusion and exclusion criteria

Check all inclusion and exclusion criteria as described in Sections 4.2 and 4.3 before enrolment

5.6.2.2. Collect demographic data

Record demographic data such as date of birth, gender, geographic ancestry and ethnicity in the subject's eCRF.

² Subjects may not be eligible for inclusion in one or more cohorts for analysis if they make the study visit outside this interval. For Visit 3-Visit 4 and Visit 5-Visit 6, an interval of 21-48 days will be considered for the According-to-protocol (ATP) cohort of immunogenicity. Refer to Section 10.4 for the definition of the cohorts for analysis;

^{*} Advisory Committee on Immunization Practices (ACIP) recommendation states that minimum age of last Hep B dose is 24 weeks and this last dose should be administered at least 8 weeks after the previous dose. So, Visit 3 should be conducted at least 8 weeks after Visit 2 and when the subject is at least 24 weeks of age

[†] It is preferred that subjects come in for Visit 4 and Visit 6, at least 30 days after Visits 3 and 5, respectively. If subjects return for the visit prior to 30 days, they should take home the diary card and continue to record unsolicited safety information until 30 days post-vaccination and mail/send it upon completion. Investigators will make an attempt to retrieve diary cards from subjects who have not mailed/sent them in.

[^] Visit 5 should occur after the ESFU. ESFU must occur prior to vaccination if Visit 5 coincides with the 6 months post-Visit 3 time-point

^{**} Adherence to the interval pertaining to phone contact is only indicative and will not determine a subject's eligibility for inclusion for ATP analysis. However, the interval should be respected in order to obtain safety information over the complete 6 months extended safety follow up period.

5.6.2.3. Medical history

Obtain the subject's medical history by interview and/or review of the subject's medical records and record any pre-existing conditions or signs and/or symptoms present in a subject prior to the first study vaccination in the eCRF.

5.6.2.4. Vaccination history

Obtain the subject's vaccination history by interview and/or review of the subject's medical records and record any vaccinations given to the subject, including hepatitis B vaccines, prior to the first study vaccination in the eCRF. The Tdap vaccination history of the mother during pregnancy will also be collected and recorded in the eCRF (provided that the mother has consented to provide this information).

Note: Maternal vaccination is requested in order to be able to summarize the responses of the subjects to pertussis antigens according to whether or not the mothers received a pertussis vaccine during their pregnancy. This information will aid in understanding the effect of transplacentally transferred antibodies on the childs' immune response to vaccination.

5.6.2.5. History directed physical examination

Perform a history directed physical examination at Visit 1 (Epoch 001) and Visit 5 (Epoch 002). If the investigator determines that the subject's health on the day of vaccination temporarily precludes vaccination, the visit will be rescheduled. Collected information, including length and weight, needs to be recorded in the eCRF.

Treatment of any abnormality observed during this examination has to be performed according to local medical practice outside this study or by referral to an appropriate health care provider.

5.6.2.6. Study group and treatment number allocation

Study group and treatment number allocation will be performed as described in Section 5.2.2. The number of each administered treatment must be recorded in the eCRF.

5.6.2.7. Treatment number allocation for subsequent doses

The treatment number allocation for subsequent doses will be performed at Visits 2, 3 and 5 as described in Section 5.2.2. The number of each administered treatment must be recorded in the eCRF

5.6.2.8. Assess pre-vaccination body temperature

The axillary, rectal, oral or tympanic body temperature of all subjects needs to be measured prior to the study vaccine administration at Visits 1, 2, 3 and 5. The preferred route for recording temperature in this study will be rectal for Epoch 001 and axillary for Epoch 002. If the subject has fever [fever is defined as temperature ≥38.0°C /100.4°F by any route] on the day of vaccination, the vaccination visit will be rescheduled within the allowed interval for this visit (see Table 5).

5.6.2.9. **Sampling**

Refer to the Module on Biospecimen Management in the SPM for detailed instructions for the collection, handling and processing of the samples.

5.6.2.9.1. Blood sampling for immune response assessments

Blood samples will be taken during certain study visits as specified in Section 5.5 List of Study Procedures.

• A volume of approximately 5.0 mL of whole blood to provide approximately 1.7 mL of serum should be drawn from all subjects for the analysis of humoral immune response at Visits 4 and 5. At least 3.5 mL of whole blood to provide approximately 1.2 mL of serum should be drawn from all subjects for the analysis of humoral immune response at Visit 6. After centrifugation, serum samples should be kept at – 20°C/–4°F or below until shipment. Refer to the SPM for more details on sample storage conditions.

5.6.2.10. Check contraindications, warnings and precautions to vaccination

Contraindications, warnings and precautions to vaccination must be checked at the beginning of each vaccination visit. Refer to Sections 6.5 and 6.6 for more details.

5.6.2.11. Baseline measurement of limb circumference after booster vaccination at visit 5

(Amendment 2: 17 April 2015)

During Epoch 002, baseline measurement of limb circumference (arms or legs according to where the vaccine was administered) at the level of the injection site should be obtained. For the Penta group, baseline measurement is only required for the limb that will be vaccinated. Clothing should be removed so as not to interfere with the measurement of the limb circumference. For measuring upper arm circumference, the measurement will be performed while the arm is held parallel to the trunk and the elbow is flexed in front at 90° (as if the subject is carrying a tray) [Kohl, 2007]. For measuring leg circumference the child should be standing or lying flat, as appropriate, as long as the leg is straight.

5.6.2.12. Study Vaccines administration

- After completing all prerequisite procedures prior to vaccination, one dose of study vaccine/control vaccines will be administered intramuscularly (IM) (refer to Section 6.3 for detailed description of the vaccines administration procedure). If the investigator or delegate determines that the subject's health on the day of administration temporarily precludes vaccine administration, the visit will be rescheduled within the allowed interval for this visit (refer to Table 5).
- The subjects will be observed closely for at least 30 minutes following the administration of the vaccines, with appropriate medical treatment readily available in case of anaphylaxis.

5.6.2.13. Recording of AEs, SAEs and NOCDs

(Amendment 2: 17 April 2015)

 Refer to Section 8.3 for procedures for the investigator to record AEs, SAEs and NOCDs. NOCDs include events such as autoimmune disorders, asthma, type I diabetes and allergies. Refer to Section 8.4 for guidelines on how to submit SAE reports to GSK Biologicals.

The subjects' parent(s)/LAR(s) will be instructed to contact the investigator immediately should the subjects manifest any signs or symptoms they perceive as serious.

- At each vaccination visit, diary cards will be provided to the subject's parent(s)/LAR(s). The subject's parent(s)/LAR(s) will record body (rectal for subjects in Epoch 001 and axillary for subjects in Epoch 002) temperature and any solicited local/general AEs (i.e. on the day of vaccination and during the next 3 days) or any unsolicited AEs (i.e. on the day of vaccination and during the next 30 days occurring after vaccination). The subject's parent(s)/LAR(s) will be instructed to return the completed diary card to the investigator at the next study visit.
- Collect and verify completed diary cards during discussion with the subject's parent(s)/LAR(s) on Visits 2, 3, 4 and 6.
- During Epoch 002, following the fourth dose vaccination, the parents/LAR(s) should be provided with a measurement device for recording circumference of injected limbs (arms or legs according to where vaccine was administered) at the level of the injection site on the day of vaccination and during the next three days on a diary card. The parents/LAR(s) should be instructed on how and where to perform the measurement of the circumference of the vaccinated limb. Daily measurements should be performed in the same manner preferably by the same person and at the same time of day during the 4-day follow-up (Day 0-Day 3) period.
- If the parent(s) /LAR(s) of infants observe any large injection site reaction (defined as swelling with a diameter > 50 mm, noticeable diffuse swelling or noticeable increase of limb circumference) during the 4-day follow-up (Day 0-Day 3) period they are to contact study personnel and to visit the investigator's office for evaluation as soon as possible and to bring the diary card with them.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- In addition to the diameter of the swelling and the circumference of the limb that are reported as solicited symptoms, the parent(s)/LAR(s) will record the following additional symptoms/characteristics that may be associated with large injection site swelling reactions on the diary card:
 - Type of swelling (local swelling only around the injection site, diffuse swelling not involving the elbow or knee joint, swelling involving the elbow or knee joint)
 - Induration at injection site (largest diameter)
 - Pruritis at the injection site (intensity scale provided)
 - Functional impairment (intensity scale and description provided)
- The study personnel's evaluation will be recorded in the medical chart. In case the diary card score is not in line with the medical chart score, the medical chart will indicate what is the most intense score. The largest or most intense score for a given day will be recorded in the eCRF at the level of the solicited symptoms and at the level of the large swelling report form.
- Any unreturned diary cards will be sought from the subject's parent(s)/LAR(s) through telephone call(s) or any other convenient procedure. The investigator will transcribe the collected information into the eCRF in English.

5.6.2.14. Check and record concomitant medication/vaccination and intercurrent medical conditions

Concomitant medication/vaccination must be checked and recorded in the eCRF as described in Section 6.7.

Intercurrent medical conditions must be checked and recorded in the eCRF as described in Section 6.8

5.6.2.15. Study conclusion

The investigator will:

- review data collected to ensure accuracy and completeness at ESFU contact and Visit 6
- complete the Study Conclusion screen in the eCRF.

At study completion, post-trial commercial vaccines will not be provided to the subjects.

5.7. Biological sample handling and analysis

Please refer to the SPM for details on biospecimen management (handling, storage and shipment).

Samples will not be labelled with information that directly identifies the subject but will be coded with the identification number for the subject (subject number).

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Under the following circumstances, additional testing on the samples may be performed by GSK Biologicals outside the scope of this protocol:

- Collected samples may be used in other assays, for test improvement or development
 of analytical methods related to the study vaccines and its constituents or the disease
 under study.
- Collected samples may be used for purposes related to the quality assurance of data generated linked to the study vaccines or the disease under study, such as for maintenance of assays described in this protocol and comparison between analytical methods and/or laboratories.

Information on further investigations and their rationale can be obtained from GSK Biologicals.

Any sample testing will be done in line with the consent of the individual subject's parent(s)/LAR(s).

Refer also to the Investigator Agreement, where it is noted that the investigator cannot perform any other biological assays except those described in the protocol or its amendment(s).

If additional testing is performed, the marker priority ranking given in Section 5.7.4 may be changed.

Collected samples will be stored for a maximum of 20 years (counting from when the last subject performed the last study visit), unless local rules, regulations or guidelines require different timeframes or different procedures, which will then be in line with the subject consent. These extra requirements need to be communicated formally to and discussed and agreed with GSK Biologicals.

5.7.1. Use of specified study materials

When materials are provided by GSK Biologicals, it is MANDATORY that all clinical samples (including serum samples) be collected and stored exclusively using those materials in the appropriate manner. The use of other materials could result in the exclusion of the subject from the ATP analysis (See Section 10.4 for the definition of study cohorts/ data sets to be analysed). The investigator must ensure that his/her personnel and the laboratory(ies) under his/her supervision comply with this requirement. However, when GSK Biologicals does not provide material for collecting and storing clinical samples, appropriate materials from the investigator's site must be used. Refer to the Module on Clinical Trial Supplies in the SPM.

5.7.2. Biological samples

Table 6 Biological samples

Sample type	Quantity*	Unit	Timepoint
Blood	5	mL	Month 5 (Post-Pri)
Blood	5	mL	Month 13-16 (Pre-Bst)
Blood	3.5	mL	Month 14-17 (Post-Bst)

^{*} Approximate quantity

Post-Pri = blood sample collected from subjects, one month after the administration of the third dose in the Epoch 001 Pre-Bst = blood sample collected from subjects, before the administration of the booster dose in the Epoch 002 Post-Bst = blood sample collected from subjects, one month after the administration of booster dose in the Epoch 002

5.7.3. Laboratory assays

(Amendment 2: 17 April 2015)

Please refer to APPENDIX A for the address of the clinical laboratories used for sample analysis.

At Visits 4, 5 and 6, blood will be collected for measurement of immune response. Total blood volume to be taken from each subject over the study period is approximately 13.5 mL (approximately 5.0 mL of whole blood to provide approximately 1.7 mL of serum at Visits 4 and 5 and at least 3.5 mL of whole blood to provide approximately 1.2 mL of serum at Visit 6). All serology will be determined in GSK Biologicals' laboratories, or in a laboratory designated by GSK, using standardized procedures with adequate controls. All serology for primary endpoints will be determined in GSK Biologicals' laboratories, or in a laboratory designated by GSK, using standardized, validated procedures with adequate controls.

117119 (DTPA-HBV-IPV-135)

Protocol Amendment 2 Final Version 02

The laboratory assays for humoral immunity are presented in Table 7.

Table 7 Humoral Immunity (Antibody determination)

(Amendment 2: 17 April 2015)

System	Component	Method	Test kit/ Manufacturer	Unit	Cut-off [†]	Laboratory**
Serum	Bordetella pertussis.Pertussis Toxin Ab.IgG	ELISA	In-house*	EL.U/mL	5	GSK Biologicals§
Serum	Bordetella pertussis.Filamentous Hemaglutinin Ab.lgG	ELISA	In-house*	EL.U/mL	5	GSK Biologicals§
Serum	Bordetella pertussis.Pertactin Ab.IgG	ELISA	In-house*	EL.U/mL	5	GSK Biologicals§
Serum	Corynebacterium diphtheriae.Diphtheria Toxoid Ab.IgG	ELISA	In-house*	IU/mL	0.1	GSK Biologicals§
Serum	Clostridium tetani.Tetanus Toxoid Ab.lgG	ELISA	In-house*	IU/mL	0.1	GSK Biologicals§
Serum	Hepatitis B Virus.Surface Ab	CLIA	Centaur (Siemens Healthcare)	mIU/mL	6.2	GSK Biologicals§
Serum	Poliovirus Sabin Types 1, 2 and 3	NEUTRA	In-house*	ED ₅₀	8	GSK Biologicals§
Serum	Haemophilus influenzae type b.Polyribosyl Ribitol Phosphate Ab ‡	ELISA	In-house*	µg/mL	0.15	GSK Biologicals§

^{*}In-house refers to assays developed internally by GSK which can be performed at GSK Biologicals' laboratories or external laboratory designated by GSK

§GSK Biologicals laboratory refers to the Global Vaccines Clinical Laboratories (GVCL) in Rixensart, Belgium; Wavre, † †Due to ongoing re-validation of all assays, the cut-offs may be subject to change.

‡For anti-PRP post-dose 3, the assay is not yet qualified or validated.

Belgium and Laval, Canada.

ELISA = Enzyme-Linked Immunosorbent Assay

NEUTRA = Neutralization Assay

CLIA = ChemiLuminescence ImmunoAssay

The GSK Biologicals' clinical laboratories have established a Quality System supported by procedures. The activities of GSK Biologicals' clinical laboratories are audited regularly for quality assessment by an internal (sponsor-dependent) but laboratory-independent Quality Department.

^{**}Refer to APPENDIX A for the laboratory addresses.

5.7.4. Biological samples evaluation

5.7.4.1. Immunological read-outs

The immunological read-outs are presented in Table 8.

Table 8 Immunological read-outs

Blood sampling time point		No. of	
Type of contact and time point	Sampling time point	subjects	Components and priority rank
Visit 4 (Month 5)	Post-Pri	585 (All)	PRN, FHA, PT PRP, D, T, HBs, Poliovirus type 1,
			Poliovirus type 2, Poliovirus type 3
Visit 5 (Month 13-16)	Pre-Bst	585 (All)	PRN, FHA, PT PRP, D, T, HBs, Poliovirus type 1,
			Poliovirus type 2, Poliovirus type 3
Visit 6 (Month 14-17)	Post-Bst	585 (All)	PRN, FHA, PT, PRP, D, T

Post-Pri = blood sample collected from subjects, one month after the administration of the third dose in the Epoch 001 Pre-Bst = blood sample collected from subjects, before the administration of the booster dose in the Epoch 002 Post-Bst = blood sample collected from subjects, one month after the administration of booster dose in the Epoch 002

In case of insufficient blood sample volume to perform assays for all antibodies, the samples will be analysed according to priority ranking provided in Table 8.

5.7.5. Immunological correlates of protection

The following cut-offs are accepted as immunological correlates of protection:

- Specific antibodies against diphtheria toxoid (anti-diphtheria) and tetanus toxoid (anti-tetanus) will be measured by enzyme-linked immunosorbent assay (ELISA). The assay cut-off of ELISA is set at 0.1 International Units per ml (IU/ml), which provides a conservative estimate of the percentage of subjects deemed to be protected [Camargo, 1984; Melville-Smith, 1983].
- Antibodies to the hepatitis B surface antigen (anti-HBs) will be measured using CLIA. The cut-off of the test is set at 6.2 mIU/ml. An antibody concentration ≥10 mIU/ml defines seroprotection [CDC, 1991; WHO, 1988].
- Antibodies against poliovirus types 1, 2 and 3 will be determined by a virus micro-neutralization test adapted from the World Health Organization Guidelines for WHO/EPI Collaborative Studies on Poliomyelitis [WHO, 1993]. The lowest dilution at which serum samples will be tested is 1:8, from which a test will be considered positive. Titers will be expressed in terms of the reciprocal of the dilution resulting in 50% inhibition. Antibody titers greater than or equal to this value are considered as protective.
- Data from subjects given unconjugated Hib vaccine suggest that, in the absence of induction of immunological memory, a concentration of 0.15 μg/mL is indicative of short-term protection, with 1 μg/mL considered indicative of long-term protection [Käyhty, 1983; Anderson, 1984].
- No serological correlate of protection against pertussis has been established [Granström, 1987; Karpinsky, 1987]. Antibodies against the pertussis components

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

s PT, FHA and PRN will be measured by ELISA. The seropositivity cut-off for all three pertussis antibodies in ELISA is 5 EL.U/ml. Subjects with antibody concentration below the cut-off will be considered seronegative.

For the purpose of identification of sub-optimal responders and communication to the investigators, anti-HBs and anti-poliovirus types 1, 2 and 3 assessment of the protection level will be done for each subject on samples taken approximately 4 weeks after the 3rd dose of the primary vaccination. For PRP, D and T antigens, the assessment of the protection level will be done for each subject on samples taken approximately 4 weeks after the administration of the booster dose. In addition a listing of subjects who did not seroconvert to anti-PT, anti-FHA and anti-PRN will be provided.

The immunological assay results will be communicated to the investigator within one year following the last subject visit for the relevant time point (Visit 4 for HBV and poliovirus; Visit 6 for PRP, D, T and pertussis antigens).

The investigator is encouraged to share the immunological assay results for non-responders with the study subjects' parent(s)/LAR(s).

For the study subjects identified as non-responders, it remains the responsibility of the study investigator in charge of the subject's clinical management to determine the medical need for re-vaccination and to re-vaccinate the subjects as per local/regional practices.

6. STUDY VACCINES AND ADMINISTRATION

6.1. Description of study vaccines

All candidate vaccines to be used have been developed and manufactured by GSK Biologicals.

The Quality Control Standards and Requirements for each candidate vaccine are described in separate Quality Assurance documents (e.g. release protocols, certificate of analysis) and the required approvals have been obtained.

The vaccines are labeled and packed according to applicable regulatory requirements.

Commercial vaccines are assumed to comply with the specifications given in the manufacturer's Summary of Product Characteristics.

Table 9 Study vaccines

(Amendment 2: 17 April 2015)

Treatment name	Vaccine/ Product name	Formulation	Presentation	Volume	Number of doses
Infanrix	DTPa-HBV- IPV	DT>=30IU; TT>=40IU; PT=25µg; FHA=25µg; PRN=8µg; HBsAg=10µg; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; Aluminium=700µg Al3+	The DTPa-HBV-IPV component is presented as a turbid white suspension in a pre-filled syringe.	full	3
hexa	Hib	PRP=10µG; TT~=25µG Aluminum as salts = 0.12 mg	The lyophilized Hib component is presented as a white pellet in a glass vial; it must be reconstituted before use with the DTPa-HBV-IPV component.	volume^	3
Pediarix	DTPa-HBV- IPV	DT>=30IU; TT>=40IU; PT=25µg; FHA=25µg; PRN=8µg; HBsAg=10µg; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; Aluminium=700µg Al3+	The DTPa-HBV-IPV component is presented as a turbid white suspension in a pre-filled syringe.	0.5 mL	3
ActHIB	ActHIB	Hib=10µg TT, TT=24µg	White lyophilized pellet in a single dose vial, it must be reconstituted before use with sterile 0.4% saline solution	0.5 mL*	4
	NaCl	NaCl=60mM	Sterile 0.4% saline solution		
Pentacel	DTaP-IPV (Sanofi Pasteur)	PT=20μg; FHA=20μg; FIM=5μg; PRN=3μg; DT=15Lf; TT=5Lf; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; PRP=10μg TT,TT=24μg; AIPO ₄ =330μg Al3+	Suspension for injection (0.5-mL dose) supplied as a liquid vaccine component in a single dose vial. The lyophilized Hib component is presented as a white pellet in a separate glass vial. It must be reconstituted with the liquid DTaP-IPV component before use.	0.5 mL*	4
Engerix-B	HBV	HBsAg=10μg; Al(OH) ₃ =250μg Al3+	Suspension pre-filled syringe	0.5 mL	2 or 3**

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Treatment	Vaccine/				Number
name	Product name	Formulation	Presentation	Volume	of doses
Infanrix	DTPa	DT>=30IU; TT>=40IU; PT=25µg; FHA=25µg; PRN=8µg; AIPO ₄ =500µg AI3+	Homogeneous, turbid, white suspension in a pre-filled syringe	0.5 mL	1
Hiberix	Hib	PRP=10μG; TT~=25μG	The lyophilized Hib component is presented as a white pellet in a glass vial; it must be reconstituted before use with sterile 0.9% saline solution.	0.5 mL*	1
	NaCl	NaCI=150mM	Sterile 0.9% saline solution		
Prevnar13	Prevenar 13	PS1=2.2µg CRM197; PS3=2.2µg CRM197; PS4=2.2µg CRM197; PS5=2.2µg CRM197; PS6A=2.2µg CRM197; PS6B=4.4µg CRM197; PS7F=2.2µg CRM197; PS9V=2.2µg CRM197; PS14=2.2µg CRM197; PS18C=2.2µg CRM197; PS19A=2.2µg CRM197; PS19F=2.2µg CRM197; PS23F=2.2µg CRM197; AIPO ₄ =125µg AI3+	Suspension for injection in a pre-filled syringe.	0.5 mL	3
Rotarix	HRV CaCO ₃	HRV RIX4144=10 ⁶ · ⁰ CCID ₅₀ CaCO ₃ =60μg	Lyophilized vaccine in a monodose glass vial to be reconstituted with the calcium carbonate buffer diluent) Diluent (calcium carbonate liquid buffer) supplied separately in prefilled syringe	1.0 mL*	2

CCID₅₀ = median Cell Culture Infective Dose; DMEM = Dulbecco's Modified Eagle Medium

6.2. Storage and handling of study vaccines

The study vaccines must be stored at the respective label storage temperature conditions in a safe and locked place. Access to the storage space should be limited to authorized study personnel. The storage conditions will be assessed during pre-study activities under the responsibility of the sponsor study contact. The storage temperature should be continuously monitored with calibrated (if not validated) temperature monitoring device(s) and recorded. Refer to the Module on Clinical Trial Supplies in the SPM for more details on storage of the study vaccines.

Temperature excursions must be reported in degree Celsius.

Any temperature excursion outside the range of 0.0 to +8.0°C (for +2 to +8°C/+36 to +46°F label storage condition) impacting investigational medicinal products (IMPs) must

^{*} After reconstitution

^{**} Subjects in the Penta Group who receive a birth dose of hepatitis B vaccine should not receive *Engerix-B* at the Month 4 visit (Visit 2)

[^] Full volume after reconstitution (approximately 0.5 mL) to be administered

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

be reported in the appropriate (electronic) temperature excursion decision form ([e]TDF). The impacted IMPs must not be used and must be stored in quarantine at label temperature conditions until usage approval has been obtained from the sponsor.

In case of temperature excursion below +2.0°C down to 0.0°C impacting IMP(s) there is no need to report in (e)TDF, but adequate actions must be taken to restore the +2 to +8°C/+36 to +46°F label storage temperature conditions. The impacted IMP(s) may still be administered, but the site should avoid re-occurrence of such temperature excursion. Refer to the Module on Clinical Trial Supplies in the SPM for more details on actions to take.

Refer to the Module on Clinical Trial Supplies in the SPM for details and instructions on the temperature excursion reporting and usage decision process, packaging and accountability of the study vaccines.

6.3. Dosage and administration of study vaccines

The injectable vaccines must be administered intramuscularly, at a 90-degree angle into the anterolateral side of the thigh [CDC, 2002] on the side stated in Table 10. The buttock should not be used.

In order to ensure proper intramuscular injection of the vaccines, a needle of at least 1 inch (2.54 cm) length, 25 gauge will be used [Diggle, 2006; Zuckerman, 2000].

For reconstitution of *Infanrix hexa* vaccine, an appropriate needle should be attached to the prefilled syringe containing the DTPa-HBV-IPV liquid vaccine and inserted into the vial containing the lyophilized Hib vaccine. The entire contents of the syringe should be transferred to the vial. With needle still inserted, the vial should be vigorously shaken. After reconstitution, the full volume of the vial (approximately 0.5 mL) is then withdrawn using the same syringe. A new needle should then be affixed to the syringe for administration of the vaccine.

NOTE: After reconstitution, *Infanrix hexa* should be injected immediately. However the vaccine may be kept for up to 8 hours at room temperature (21°C).

The vaccinees will be observed closely for at least 30 minutes following the administration of vaccines, with appropriate medical treatment readily available in case of a rare anaphylactic reaction.

Rotarix must be exclusively administered orally. DO NOT INJECT.

Table 10 Dosage and administration

Visit	Study Group	Treatment name	Route ¹	Site ²	Side ³
		Epoch 001			
1, 2, 3	Hexa Group	Infanrix hexa	IM	T	R
		(lot A, lot B or lot C)			
1, 2, 3		Prevnar13	IM	T	LoL
1, 2		Rotarix	0	-	-
1, 2, 3	Pedia Group	Pediarix	IM	T	R
1, 2, 3		ActHIB	IM	T	UpL
1, 2, 3		Prevnar13	IM	T	LoL
1, 2		Rotarix	0	-	-
1, 2, 3	Penta Group	Pentacel	IM	T	R
1, 2, 3		Engerix-B [†]	IM	T	UpL
1, 2, 3		Prevnar13	IM	T	LoL
1, 2		Rotarix	0	-	-
		Epoch 002*			
5	Hexa Group	Infanrix	IM	T	R
	·	Hiberix	IM	T	L
5	Pedia Group	Infanrix	IM	T	R
	•	ActHIB	IM	T	L
5	Penta Group	Pentacel	IM	T	R

¹Oral (O), Intramuscular (IM); ²Thigh (T), ³Left (L), Right (R), Upper Left (UpL), Lower Left (LoL)

6.4. Replacement of unusable vaccine doses

In addition to the vaccine doses provided for the planned number of subjects (including over-randomization when applicable), at least 60% additional vaccine doses will be supplied to replace those that are unusable.

6.5. Contraindications to subsequent vaccination

6.5.1. Absolute contraindications:

The following events constitute absolute contraindications to further administration of the study and co-administration vaccines. If any of these events occur during the study, the subject must not receive additional doses of vaccine but may continue other study procedures at the discretion of the investigator.

- Anaphylaxis following the administration of vaccine(s).
- Other hypersensitivity reaction to any component of the vaccine(s) and any excipients in the formulation, including yeast.
- Hypersensitivity to latex.

Note: Vaccination can be performed in the opposite side in case of medical indication preventing vaccination in the side stated in the table, as judged by the investigator

[†]Subjects in the Penta Group who receive a birth dose of hepatitis B vaccine should not receive *Engerix-B* at the Month 4 visit (Visit 2).

^{*}Toddlers (12 Months through 2 Years): For toddlers, the vastus lateralis muscle in the anterolateral thigh is preferred. The needle should be at least 1-inch long. The deltoid muscle can be used if the muscle mass is adequate.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- Contraindication for pertussis-containing vaccines:
 - Encephalopathy of unknown etiology, defined as an acute, severe central
 nervous system disorder, occurring within 7 days following previous vaccination
 with pertussis-containing vaccine and generally consisting of major alterations
 in consciousness, unresponsiveness, generalised or focal seizures that persist
 more than a few hours, with failure to recover within 24 hours.
 - Individuals with progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy should not receive a pertussis-containing vaccine until a treatment regimen has been established and the condition has stabilized.
- Contraindications to *Rotarix*:
 - Subjects with uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract that would predispose for intussusceptions.
 - History of intussusception or history of SCID.

6.5.2. Temporary contraindications:

The following events constitute contraindications to administration of the study and coadministration vaccines at that point in time; if any of these events occur at the time scheduled for vaccination, the subject may be vaccinated at a later date, within the time window specified in the protocol, or withdrawn at the discretion of the investigator.

- Acute disease and/or fever at the time of vaccination.
 - Fever is defined as temperature ≥ 38.0°C/100.4°F by any route. The preferred route for recording temperature in this study will be rectal for Epoch 001 and axillary for Epoch 002.
 - Subjects with a minor illness (such as mild upper respiratory infection) without fever can be administered all vaccines.
- Acute diarrhea or vomiting is a contra-indication to the administration of *Rotarix* at that point in time.

6.6. Warnings and precautions

The information below presents, in addition to the contraindications in Section 6.5, warnings and precautions to administration of *Infanrix hexa*.

- As with other vaccines, administration of *Infanrix hexa* should be postponed in subjects suffering from acute severe febrile illness. The presence of a minor infection is not a contra-indication.
- Vaccination should be preceded by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable events) and a clinical examination.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- If any of the following events are known to have occurred in temporal relation to receipt of pertussis-containing vaccine, the decision to give further doses of pertussis-containing vaccines should be carefully considered:
 - Temperature of ≥ 40.0 °C within 48 hours, not due to another identifiable cause.
 - Collapse or shock-like state (hypotonic-hyporesponsiveness episode) within 48 hours of vaccination.
 - Persistent, inconsolable crying lasting ≥ 3 hours, occurring within 48 hours of vaccination.
 - Convulsions with or without fever, occurring within 3 days of vaccination.
- As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.
- *Infanrix hexa* should be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects.
- *Infanrix hexa* should under no circumstances be administered intravascularly or intradermally.
- A protective immune response may not be elicited in all vaccinees.
- A history of febrile convulsions, a family history of convulsions or Sudden Infant Death Syndrome (SIDS) do not constitute contraindications for the use of *Infanrix hexa*. Vaccinees with a history of febrile convulsions should be closely followed up as such adverse events may occur within 2 to 3 days post vaccination.
- Since the Hib capsular polysaccharide antigen is excreted in the urine a positive urine test can be observed within 1-2 weeks following vaccination. Other tests should be performed in order to confirm Hib infection during this period.
- Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from faints.

Refer to the approved product label/package insert for warnings and precautions for the use of *Pediarix, ActHIB, Pentacel, Engerix-B, Prevnar13, Rotarix, Hiberix* and *Infanrix* vaccines.

6.7. Concomitant medication/product and concomitant vaccination

At each study visit/contact, the investigator should question the subject's parent(s)/LAR(s) about any medication/product taken and vaccination received by the subject.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

6.7.1. Recording of concomitant medications/products and concomitant vaccination

The following concomitant medications/products/vaccines must be recorded in the eCRF if administered during the indicated recording period:

- All concomitant medications/products, except vitamins and dietary supplements, administered within 30 days following each dose of study vaccine.
- Any concomitant vaccination administered since birth and ending 30 days after the booster dose (Visit 6). Vaccinations listed prior to the first dose of study vaccine are to be recorded as vaccination history. The fourth dose of *Prevnar 13* will be recorded as concomitant vaccination.
- Prophylactic medication (i.e. medication administered in the absence of ANY symptom and in anticipation of a reaction to the vaccination).
 - E.g. an anti-pyretic is considered to be prophylactic when it is given in the absence of fever and any other symptom, to prevent fever from occurring [fever is defined as temperature $\geq 38.0^{\circ}\text{C}/100.4^{\circ}\text{F}$ by any route].
- Any concomitant medications/products/vaccines listed in Section 6.7.2.
- Any concomitant medication/product/vaccine relevant to a SAE* or administered at any time during the study period for the treatment of a SAE*.

6.7.2. Concomitant medications/products/vaccines that may lead to the elimination of a subject from ATP analyses

The use of the following concomitant medications/products/vaccines will not require withdrawal of the subject from the study but may determine a subject's evaluability in the ATP analysis. See Section 10.4 for study cohorts/ data sets to be analysed.

- Any investigational or non-registered product (drug or vaccine) other than the study vaccines used during the study period (starting from Visit 1 and ending at Visit 6).
- Immunosuppressants or other immune-modifying drugs administered chronically (i.e. more than 14 days) during the study period until the final blood sample (Visit 6). For corticosteroids, this will mean prednisone ≥ 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
- A vaccine not foreseen by the study protocol administered during the period starting from 30 days before the first vaccination until Post-Pri blood sampling i.e. approximately 30 days after Dose 3 (Epoch 001) and from 30 days before Pre-Bst until Post-Bst blood sampling i.e. approximately 30 days after Dose 4 (Epoch 002). Thus, routine administration(s) of measles-mumps-rubella, varicella and pneumococcal vaccines are allowed from 30 days after the last dose of primary vaccination (after Post-Pri blood sampling) until 30 days before the booster dose and from 30 days after the booster dose (after Post-Bst blood sampling), as well as according to the recommended immunization schedule in the US.

^{*} Refer to those SAEs that are required to be reported per protocol.

• Exceptions:

 Inactivated influenza vaccine and hepatitis A vaccines are allowed throughout the study.

In case an emergency mass vaccination for an unforeseen public health threat (e.g.: a pandemic) is organized by the public health authorities, outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine provided it is licensed and used according to its SPC or PI and according to the local governmental recommendations and provided a written approval of the Sponsor is obtained.

• Immunoglobulins and/or any blood products administered during the study period until the final blood sample (Visit 6).

6.8. Intercurrent medical conditions that may lead to elimination of a subject from ATP analyses

At each study visit subsequent to the first vaccination visit, it must be verified if the subject has experienced or is experiencing any intercurrent medical condition. If it is the case, the condition(s) must be recorded in the eCRF.

- Subjects may be eliminated from the ATP cohort for immunogenicity if they incur a condition that has the capability of altering their immune response or are confirmed to have an immunodeficiency condition.
- Subjects will be eliminated from the ATP cohort for immunogenicity if they experience intercurrent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and/or Hib prior to the post-dose 3 blood draw and diphtheria, tetanus, pertussis and/or Hib post-dose 4 blood draw.

7. HEALTH ECONOMICS

Not applicable.

8. SAFETY

The investigator or site staff is/are responsible for the detection, documentation and reporting of events meeting the criteria and definition of an adverse event (AE) or serious adverse event (SAE) as provided in this protocol.

Each subject's parent(s)/LAR(s) will be instructed to contact the investigator immediately should the subject manifest any signs or symptoms they perceive as serious.

8.1. Safety definitions

8.1.1. Definition of an adverse event

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse.

Examples of an AE include:

- Significant or unexpected worsening or exacerbation of the condition/indication under study.
- New conditions detected or diagnosed after investigational vaccines administration even though they may have been present prior to the start of the study.
- Signs, symptoms, or the clinical sequelae of a suspected interaction.
- Signs, symptoms, or the clinical sequelae of a suspected overdose of either investigational vaccines or a concurrent medication (overdose per se should not be reported as an AE/SAE).
- Signs, symptoms temporally associated with vaccine administration.
- Significant failure of expected pharmacological or biological action.
- Pre- or post-treatment events that occur as a result of protocol-mandated procedures (i.e. invasive procedures, modification of subject's previous therapeutic regimen).

AEs to be recorded as endpoints (solicited AEs) are described in Section 8.1.3. All other AEs will be recorded as UNSOLICITED AEs.

Examples of an AE DO NOT include:

- Medical or surgical procedures (e.g. endoscopy, appendectomy); the condition that leads to the procedure is an AE/SAE.
- Situations where an untoward medical occurrence did not occur (e.g. social and/or convenience admission to a hospital, admission for routine examination).
- Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen.
- Pre-existing conditions or signs and/or symptoms present in a subject prior to the first study vaccination. These events will be recorded in the medical history section of the eCRF.

8.1.2. Definition of a serious adverse event

A serious adverse event is any untoward medical occurrence that:

- a. Results in death,
- b. Is life-threatening,

Note: The term 'life-threatening' in the definition of 'serious' refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, had it been more severe.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

c. Requires hospitalisation or prolongation of existing hospitalisation,

Note: In general, hospitalisation signifies that the subject has been admitted at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician's office or in an out-patient setting. Complications that occur during hospitalisation are also considered AEs. If a complication prolongs hospitalisation or fulfils any other serious criteria, the event will also be considered serious. When in doubt as to whether 'hospitalisation' occurred or was necessary, the AE should be considered serious.

Hospitalisation for elective treatment of a pre-existing condition (known or diagnosed prior to informed consent signature) that did not worsen from baseline is NOT considered an AE.

d. Results in disability/incapacity,

Note: The term disability means a substantial disruption of a person's ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza like illness, and accidental trauma (e.g. sprained ankle) which may interfere or prevent everyday life functions but do not constitute a substantial disruption.

Medical or scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation.

8.1.3. Solicited adverse events

A 4-day follow-up (Day 0-Day 3) of solicited local (at each injection site) and general AEs will be performed after administration of the vaccine. Data concerning the following AEs will be solicited using diary cards provided by the sponsor.

117119 (DTPA-HBV-IPV-135)

Protocol Amendment 2 Final Version 02

8.1.3.1. Solicited local (injection-site) adverse events

The following local (injection-site) AEs will be solicited (Table 11):

Table 11 Solicited local adverse events

Pain at injection site
Redness at injection site
Swelling at injection site
Post-dose 4 measurements of
circumference of limbs (arm or leg
according to where vaccine was
administered)

N.B. If parent(s) /LAR(s) of infants observe any large injection site reaction (defined as swelling with a diameter > 50 mm, noticeable diffuse swelling or noticeable increase of limb circumference) after the booster dose at Visit 5, they are to contact study personnel and to visit the investigator's office for evaluation as soon as possible and bring the diary card with them. The investigator will record detailed information describing the AE on a specific large injection site reaction form in the eCRF. In addition to the diameter of the swelling and the circumference of the limb that are reported as solicited symptoms the parent(s)/LAR(s) will need to record additional symptoms/characteristics as mentioned in Section 5.6.2.13.

Note: local AEs will not be solicited for co-administered vaccines like *Prevnar 13*.

8.1.3.2. Solicited general adverse events

The following general AEs will be solicited (Table 12):

Table 12 Solicited general adverse events

Drowsiness				
Fever				
Irritability/Fussiness				
Loss of appetite				

Note: Temperature will be recorded in the evening. Should additional temperature measurements be performed at other times of day, the highest temperature will be recorded. Fever is defined as temperature $\geq 38.0^{\circ}\text{C}/100.4^{\circ}\text{F}$ by any route. The preferred route for recording temperature in this study will be rectal for Epoch 001 and axillary for Epoch 002.

8.1.4. Clinical laboratory parameters and other abnormal assessments qualifying as adverse events or serious adverse events

In absence of diagnosis, abnormal laboratory findings (e.g. clinical chemistry, haematology, urinalysis) or other abnormal assessments (e.g. vital signs etc.) that are judged by the investigator to be clinically significant will be recorded as AE or SAE if they meet the definition of an AE or SAE (refer to Sections 8.1.1 and 8.1.2). Clinically significant abnormal laboratory findings or other abnormal assessments that are present at

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

baseline and significantly worsen following the start of the study will also be reported as AEs or SAEs. However, clinically significant abnormal laboratory findings or other abnormal assessments that are associated with the disease being studied, unless judged by the investigator as more severe than expected for the subject's condition, or that are present or detected at the start of the study and do not worsen, will not be reported as AEs or SAEs

The investigator will exercise his or her medical and scientific judgement in deciding whether an abnormal laboratory finding or other abnormal assessment is clinically significant.

8.1.5. Adverse events of specific interest

Adverse events of specific interest (i.e. NOCDs such as autoimmune disorders, asthma, type I diabetes and allergies) will be recorded from Day 0 up to 6 months after the last primary vaccination (Epoch 001) and from booster dose up to one month after booster vaccination (Epoch 002). NOCDs will be reported as either AEs or SAEs, as appropriate in the eCRF.

8.2. Events or outcomes not qualifying as adverse events or serious adverse events

Not applicable.

8.3. Detecting and recording adverse events and serious adverse events

8.3.1. Time period for detecting and recording adverse events and serious adverse events

All AEs starting within 30 days following administration of each dose of study vaccine/comparator must be recorded into the appropriate section of the eCRF, irrespective of intensity or whether or not they are considered vaccination-related.

The time period for collecting and recording SAEs and AEs of specific interest will begin at the first receipt of study vaccine/comparator and will end 180 days following administration of the last dose of study vaccine/comparator of the primary vaccination course for each subject and 30 days following administration of the booster dose. See Section 8.4 for instructions on reporting of SAEs.

All AEs/SAEs leading to withdrawal from the study will be collected and recorded from the time of the first receipt of study vaccine/comparator.

In addition to the above-mentioned reporting requirements and in order to fulfil international reporting obligations, SAEs that are related to study participation (i.e. protocol-mandated procedures, invasive tests, a change from existing therapy) or are related to a concurrent GSK medication/vaccine will be collected and recorded from the time the subject consents to participate in the study until she/he is discharged from the study.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Note: With the exception of AEs/SAEs leading to withdrawal, study participation and concurrent GSK medications or vaccines, there is no reporting of SAEs from the time of the Epoch 1 ESFU phone contact and administration of dose 4 (approximately three months).

An overview of the protocol-required reporting periods for AEs and SAEs is given in Table 13.

Table 13 Reporting periods for adverse events and serious adverse events

Study activity	C.O	V1	4-days post vac	31-days post- vac	V2	4-days post vac	31-days post-vac	V3	4-days post- vac	31-days post-vac	Phone call 6 months post-V3	V5	4-days post- vac	31-days post-vac
Age of subject		2 months			4 months			6 months		7 months	12 months	15-18 months		16-19 months
Solicited local and general AEs														
Large injection site reactions														
Unsolicited AEs														
AEs/SAEs leading to withdrawal from the study														
NOCDs														
SAEs														
SAEs related to study participation or concurrent GSK medication/vaccine														

NOCD: New Onset of Chronic Diseases; C.O: consent obtained; V: Visit; Post-V: Post-Visit; vac: vaccination

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

8.3.2. Post-Study adverse events and serious adverse events

A post-study AE/SAE is defined as any event that occurs outside of the AE/SAE reporting period defined in Table 13. Investigators are not obligated to actively seek AEs or SAEs in former study participants. However, if the investigator learns of any SAE at any time after a subject has been discharged from the study, and he/she considers the event reasonably related to the investigational vaccine/product, the investigator will promptly notify the Study Contact for Reporting SAEs.

8.3.3. Evaluation of adverse events and serious adverse events

8.3.3.1. Active questioning to detect adverse events and serious adverse events

As a consistent method of collecting AEs, the subject's parent(s)/LAR(s) should be asked a non-leading question such as:

'Has your child acted differently or felt different in any way since receiving the vaccine or since the last visit?'

When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (e.g. hospital progress notes, laboratory and diagnostics reports) relative to the event. The investigator will then record all relevant information regarding an AE/SAE in the eCRF. The investigator is not allowed to send photocopies of the subject's medical records to GSK Biologicals instead of appropriately completing the eCRF. However, there may be instances when copies of medical records for certain cases are requested by GSK Biologicals. In this instance, all subject identifiers will be blinded on the copies of the medical records prior to submission to GSK Biologicals.

The investigator will attempt to establish a diagnosis pertaining to the event based on signs, symptoms, and/or other clinical information. In such cases, the diagnosis should be documented as the AE/SAE and not the individual signs/symptoms.

8.3.3.2. Assessment of adverse events

8.3.3.2.1. Assessment of intensity

The intensity of the following solicited AEs will be assessed as described:

Table 14 Intensity scales for solicited symptoms in infants/toddlers

	Infant/Too	ddler (15–24 months)		
Adverse Event	Intensity grade	Parameter		
Pain at injection site	0	None		
	1	Mild: Minor reaction to touch		
	2	Moderate: Cries/protests on touch		
	3	Severe: Cries when limb is moved/spontaneously painful		
Redness at injection	on site	Record greatest surface diameter in mm		
Swelling at injection	on site	Record greatest surface diameter in mm		
Increase in limb circumference		Record the limb circumference at the level of the injection site		
or leg according to where administered				
Fever*	1	Record temperature in °C/°F		
Irritability/Fussiness	0	Behaviour as usual		
,	1	Mild: Crying more than usual/no effect on normal activity		
	2	Moderate: Crying more than usual/interferes with normal activity		
	3	Severe: Crying that cannot be comforted/prevents normal		
		activity		
Drowsiness	0	Behaviour as usual		
	1	Mild: Drowsiness easily tolerated		
	2	Moderate: Drowsiness that interferes with normal activity		
	3	Severe: Drowsiness that prevents normal activity		
Loss of appetite	0	Appetite as usual		
	1	Mild: Eating less than usual/no effect on normal activity		
	2	Moderate: Eating less than usual/interferes with normal activity		
* F	3	Severe: Not eating at all		

^{*} Fever is defined as temperature ≥38.0°C /100.4°F by any route. The preferred route for recording temperature in this study will be rectal for Epoch 001 and axillary for Epoch 002.

The maximum intensity of local injection site redness/swelling/fever will be scored at GSK Biologicals as follows:

0 : Absent 1 : ≤ 5 mm

2 : $> 5 \text{ mm and} \le 20 \text{ mm}$

3 : > 20 mm

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

The maximum intensity of fever will be scored at GSK Biologicals as follows:

0	=	<100.4°F	<38.0°C
1	=	≥ 100.4 °F to ≤ 102.2 °F	≥38.0°C to ≤39.0°C
2	=	>102.2 °F to ≤ 104.0 °F	>39.0°C to ≤40.0°C
3	=	> 104 0°F	> 40 0°C

Following each vaccination (3 doses during the primary vaccination course and one booster dose) during the 4 days after the vaccine dose has been administered (day of vaccination and subsequent 3 days), the child's temperature will be screened each evening, at bedtime, for signs of fever by means of the rectal/axillary thermometer. Children < 15 months will have their temperature taken rectally and children ≥ 15 months will have their temperature taken by the axillary route. Rectal/axillary temperatures will be recorded on the diary card. Temperature measured by any route will be presented in 0.5° C increments starting at 38° C/ 100.4° F.

Prior to analysis, the increase in limb circumference of each limb as compared to the baseline pre-vaccination measurement will be scored for each subject at GSK Biologicals' as follows:

Grade $0 = \text{Increase in limb circumference} \le 5 \text{ mm}$

1 = Increase in limb circumference > 5 mm but ≤ 20 mm

2 = Increase in limb circumference >20 mm but \le 40 mm

3 = Increase in limb circumference >40 mm

The investigator will assess the maximum intensity that occurred over the duration of the event for all unsolicited AEs (including SAEs) recorded during the study. The assessment will be based on the investigator's clinical judgement.

74

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

For unsolicited symptoms and adverse events associated with large injection site reactions (e.g. pruritus, induration and functional impairment, the intensity should be assigned to one of the following categories:

1 (mild)	=	An AE which is easily tolerated by the subject, causing minimal
		discomfort and not interfering with everyday activities.

2 (moderate) = An AE which is sufficiently discomforting to interfere with normal everyday activities.

3 (severe) = An AE which prevents normal, everyday activities. In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care center and would cause the parent(s)/LAR(s) to seek medical advice.

An AE that is assessed as Grade 3 (severe) should not be confused with a SAE. Grade 3 is a category used for rating the intensity of an event; and both AEs and SAEs can be assessed as Grade 3. An event is defined as 'serious' when it meets one of the predefined outcomes as described in Section 8.1.2.

8.3.3.2.2. Assessment of causality

The investigator is obligated to assess the relationship between investigational vaccines and the occurrence of each AE/SAE. The investigator will use clinical judgement to determine the relationship. Alternative plausible causes, such as natural history of the underlying diseases, concomitant therapy, other risk factors, and the temporal relationship of the event to the investigational vaccines will be considered and investigated. The investigator will also consult the IB and/or PI for marketed products to determine his/her assessment. Investigational vaccines include vaccines such as *Infanrix hexa*, *Pediarix*, *Pentacel*, *ActHIB*, *Engerix-B*, *Rotarix*, *Prevnar 13*, *Infanrix* and *Hiberix*.

There may be situations when a SAE has occurred and the investigator has minimal information to include in the initial report to GSK Biologicals. However, it is very important that the investigator always makes an assessment of causality for every event prior to submission of the SAE report to GSK Biologicals. The investigator may change his/her opinion of causality in light of follow-up information and update the SAE information accordingly. The causality assessment is one of the criteria used when determining regulatory reporting requirements.

In case of concomitant administration of multiple vaccines, it may not be possible to determine the causal relationship of general AEs to the individual vaccines administered. The investigator should, therefore, assess whether the AE could be causally related to vaccination rather than to the individual vaccines.

All solicited local (injection site) reactions will be considered causally related to vaccination. Causality of all other AEs should be assessed by the investigator using the following question:

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Is there a reasonable possibility that the AE may have been caused by the investigational vaccines?

YES : There is a reasonable possibility that the vaccines contributed to the

AE.

NO : There is no reasonable possibility that the AE is causally related to

the administration of the study vaccine(s). There are other, more likely causes and administration of the study vaccine(s) is not

suspected to have contributed to the AE.

If an event meets the criteria to be determined as 'serious' (see Section 8.1.2), additional examinations/tests will be performed by the investigator in order to determine ALL possible contributing factors for each SAE.

Possible contributing factors include:

- Medical history.
- Other medication.
- Protocol required procedure.
- Other procedure not required by the protocol.
- Lack of efficacy of the vaccines, if applicable.
- Erroneous administration.
- Other cause (specify).

8.3.3.3. Assessment of outcomes

The investigator will assess the outcome of all unsolicited AEs (including SAEs) recorded during the study as:

- Recovered/resolved.
- Recovering/resolving.
- Not recovered/not resolved.
- Recovered with sequelae/resolved with sequelae.
- Fatal (SAEs only).

8.3.3.4. Medically attended visits

For each solicited and unsolicited symptom the subject experiences, the subject's parent(s)/LAR(s) will be asked if the subject received medical attention defined as hospitalisation, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. This information will be recorded in the eCRF.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

8.4. Reporting of serious adverse events and other events

8.4.1. Prompt reporting of serious adverse events and other events to GSK Biologicals

SAEs that occur in the time period defined in Section 8.3 will be reported promptly to GSK within the timeframes described in Table 15, once the investigator determines that the event meets the protocol definition of a SAE.

Table 15 Timeframes for submitting serious adverse event and other events reports to GSK Biologicals

Type of Event	ı	nitial Reports	Follow-up of Relevant Information on a Previous Report			
	Timeframe	Documents	Timeframe	Documents		
SAEs	24 hours*	electronic SAE report	24 hours*	electronic SAE report		

^{*} Timeframe allowed after receipt or awareness of the information.

8.4.2. Contact information for reporting serious adverse events and other events to GSK Biologicals

Back-up Study Contact for Reporting SAEs						
24/24 hour and 7/7 day availability:						
GSK Biologicals Clinical Safety & Pharmacovigilance Fax: +PPD or +PPD or +PPD						
Please refer to the Study Procedure Manual for the dedicated US Fax Machine number.						

8.4.3. Completion and transmission of SAE reports to GSK Biologicals

Once an investigator becomes aware that a SAE has occurred in a study subject, the investigator (or designate) must complete the information in the electronic SAE report WITHIN 24 HOURS. The SAE report will always be completed as thoroughly as possible with all available details of the event. Even if the investigator does not have all information regarding a SAE, the report should still be completed within 24 hours. Once additional relevant information is received, the report should be updated WITHIN 24 HOURS.

The investigator will always provide an assessment of causality at the time of the initial report.

8.4.3.1. Back-up system in case the electronic SAE reporting system does not work

If the electronic SAE reporting system does not work, the investigator (or designate) must complete, then date and sign a paper SAE report and fax it to the GSK Biologicals Clinical Safety and Pharmacovigilance department within 24 hours. Please refer to the Study Procedure Manual for the dedicated US Fax Machine number.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

This back-up system should only be used if the electronic SAE reporting system is not working and NOT if the system is slow. As soon as the electronic SAE reporting system is working again, the investigator (or designate) must complete the electronic SAE report within 24 hours. The final valid information for regulatory reporting will be the information reported through the electronic SAE reporting system.

8.4.4. Updating of SAE information after freezing of the subject's eCRF

When additional SAE information is received after freezing of the subject's eCRF, new or updated information should be recorded on a paper report, with all changes signed and dated by the investigator. The updated report should be faxed to the GSK Biologicals Clinical Safety and Pharmacovigilance department or to the Study Contact for Reporting SAEs (refer to the Sponsor Information Sheet) within the designated reporting time frames specified in Table 15.

8.4.5. Regulatory reporting requirements for serious adverse events

The investigator will promptly report all SAEs to GSK in accordance with the procedures detailed in Section 8.4.1. GSK Biologicals has a legal responsibility to promptly notify, as appropriate, both the local regulatory authority and other regulatory agencies about the safety of a product under clinical investigation. Prompt notification of SAEs by the investigator to the Study Contact for Reporting SAEs is essential so that legal obligations and ethical responsibilities towards the safety of other subjects are met.

Investigator safety reports are prepared according to the current GSK policy and are forwarded to investigators as necessary. An investigator safety report is prepared for a SAE(s) that is both attributable to the investigational vaccine/product and unexpected. The purpose of the report is to fulfil specific regulatory and GCP requirements, regarding the product under investigation.

8.5. Follow-up of adverse events and serious adverse events

8.5.1. Follow-up during the study

After the initial AE/SAE report, the investigator is required to proactively follow each subject and provide additional relevant information on the subject's condition to GSK Biologicals (within 24 hours for SAEs; refer to Table 15).

All SAEs documented at a previous visit/contact and designated as not recovered/not resolved or recovering/resolving will be reviewed at subsequent visits/contacts until the end of the study.

All AEs documented at a previous visit/contact and designated as not recovered/not resolved or recovering/resolving will be reviewed at subsequent visits/contacts until 30 days after the last vaccination.

New onset of chronic diseases (such as autoimmune disorders, asthma, type I diabetes and allergies) documented at a previous visit/contact and designated as not recovered/not

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

resolved or recovering/resolving will be reviewed at subsequent visits/contacts until end of the study.

8.5.2. Follow-up after the subject is discharged from the study

The investigator will follow subjects:

- with SAEs, or subjects withdrawn from the study as a result of an AE, until the event has resolved, subsided, stabilized, disappeared, or until the event is otherwise explained, or the subject is lost to follow-up.
- with other non-serious AEs of specific interest, i.e. NOCDs, such as autoimmune disorders, asthma, type I diabetes and allergies, until the end of the study period or they are lost to follow-up.

If the investigator receives additional relevant information on a previously reported SAE, he/she will provide this information to GSK Biologicals using a paper SAE form.

GSK Biologicals may request that the investigator performs or arranges the conduct of additional clinical examinations/tests and/or evaluations to elucidate as fully as possible the nature and/or causality of the AE or SAE. The investigator is obliged to assist. If a subject dies during participation in the study or during a recognized follow-up period, GSK Biologicals will be provided with any available post-mortem findings, including histopathology.

8.6. Treatment of adverse events

Treatment of any AE is at the sole discretion of the investigator and according to current good medical practice. Any medication administered for the treatment of an AE should be recorded in the subject's eCRF (refer to Section 6.7).

8.7. Subject card

Study subjects' parent(s)/LAR(s) must be provided with the address and telephone number of the main contact for information about the clinical study.

The investigator (or designate) must therefore provide a "subject card" to each subject's parent(s)/LAR(s). In an emergency situation this card serves to inform the responsible attending physician that the subject is in a clinical study and that relevant information may be obtained by contacting the investigator.

Subjects' parent(s)/LAR(s) must be instructed to keep subject cards in their possession at all times.

9. SUBJECT COMPLETION AND WITHDRAWAL

9.1. Subject completion

A subject who returns for the concluding visit/is available for the concluding contact foreseen in the protocol is considered to have completed the study.

9.2. Subject withdrawal

Withdrawals will not be replaced.

9.2.1. Subject withdrawal from the study

From an analysis perspective, a 'withdrawal' from the study refers to any subject who did not come back for the concluding visit/was not available for the concluding contact foreseen in the protocol.

All data collected until the date of withdrawal/last contact of the subject will be used for the analysis.

A subject is considered a 'withdrawal' from the study when no study procedure has occurred, no follow-up has been performed and no further information has been collected for this subject from the date of withdrawal/last contact.

Investigators will make an attempt to contact those subjects who do not return for scheduled visits or follow-up.

Information relative to the withdrawal will be documented in the eCRF. The investigator will document whether the decision to withdraw a subject from the study was made by the subject's parent(s) or LAR(s), or by the investigator, as well as which of the following possible reasons was responsible for withdrawal:

- Serious adverse event.
- Non-serious adverse event.
- Protocol violation (specify).
- Consent withdrawal, not due to an adverse event*.
- Moved from the study area.
- Lost to follow-up.
- Other (specify).

*In case a subject is withdrawn from the study because the subject's parent(s) has withdrawn consent, the investigator will document the reason for withdrawal of consent, if specified by the subject, in the eCRF.

Subjects who are withdrawn from the study because of SAEs/AEs must be clearly distinguished from subjects who are withdrawn for other reasons. Investigators will follow subjects who are withdrawn from the study as result of a SAE/AE until resolution of the event (see Section 8.5.2).

9.2.2. Subject withdrawal from investigational vaccine

A 'withdrawal' from the investigational vaccine refers to any subject who does not receive the complete treatment, i.e. when no further planned dose is administered from

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

the date of withdrawal. A subject withdrawn from the investigational vaccine may not necessarily be withdrawn from the study as further study procedures or follow-up may be performed (safety or immunogenicity) if planned in the study protocol.

Information relative to premature discontinuation of the investigational vaccine will be documented on the Vaccine Administration screen of the eCRF. The investigator will document whether the decision to discontinue further vaccination/treatment was made by the subject's parent(s) or LAR(s), or by the investigator, as well as which of the following possible reasons was responsible for withdrawal:

- Serious adverse event.
- Non-serious adverse event.
- Other (specify).

10. STATISTICAL METHODS

10.1. Primary endpoint

10.1.1. Epoch 001 (Primary vaccination)

- Immunogenicity with respect to pertussis components of the study vaccines *Infanrix* hexa and *Pediarix*.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination.

10.2. Secondary endpoints

10.2.1. Epoch 001 (Primary vaccination)

- Immunogenicity (other parameters) with respect to the pertussis component of the study vaccines *Infanrix hexa*, *Pentacel* and *Pediarix*.
 - Anti-PT, anti-FHA, anti-PRN seropositivity status, one month after the third dose of the primary vaccination.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination (for *Pentacel* only).
- Immunogenicity with respect to the other components of the study vaccines *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B*.
 - Anti-D, anti-T, anti-HBs, anti-poliovirus types 1, 2 and 3 and anti-PRP seroprotection status, anti-PRP antibody concentrations ≥1.0 μg/mL and antibody concentrations/titers, one month after the third dose of the primary vaccination.

- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0 Day 3) after each vaccination (*Infanrix hexa, Pediarix, ActHIB, Pentacel* and *Engerix-B*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0 Day 3) after each vaccination.
- Unsolicited adverse events.
 - Occurrence of unsolicited AEs within 31 days (Day 0 Day 30) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.
- Specific adverse events.
 - Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies) from Day 0 up to six months post primary vaccination.
- Serious adverse events.
 - Occurrence of serious adverse events from Day 0 up to six months post primary vaccination.

10.2.2. Epoch 002 (Booster vaccination)

- Immunogenicity with respect to all study vaccines.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-HBs, anti-PRP and anti-poliovirus 1, 2, 3 seroprotection/ seropositivity status, anti-PRP antibody concentrations ≥1 µg/mL and antibody concentrations/ titers before the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccine *Pentacel*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-PRP seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
 - Anti-PRP antibody concentrations $\geq 1 \mu g/mL$ one month after the booster dose (Dose 4).
 - Anti-D and anti-T antibody concentrations ≥1 IU/mL one month after the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccine *Infanrix*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
- Anti-D and anti-T antibody concentrations ≥1 IU/mL one month after the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccines *ActHIB* and *Hiberix*.
 - Anti-PRP seroprotection status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PRP antibody concentrations ≥1 µg/mL one month after the booster dose (Dose 4)
- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0 Day 3) after booster vaccination (*Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0 Day 3) after booster vaccination.
- Unsolicited adverse events.
 - Occurrence of unsolicited AEs within 31 days (Day 0 Day 30) after booster vaccination, according to the MedDRA classification.
- Specific adverse events.
 - Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies) from the booster dose up to one month after the booster vaccination.
- Serious adverse events.
 - Occurrence of serious adverse events from the booster dose up to one month after the booster vaccination.

10.3. Determination of sample size

Target enrolment will be 585 subjects. Assuming 65% of the subjects will be evaluable post-dose 3, this will provide approximately 378 subjects (126 subjects in each group) evaluable for immunogenicity in the Epoch 001.

The sample size has been estimated in order to obtain at least 94% power to demonstrate the primary inferential objective (i.e. non-inferiority of the response to the pertussis antigens). The power associated to the target sample size for the conclusion on the inferential primary objective of this study is detailed in the next section.

10.3.1. Control on type I error

A 2.5% nominal type I error will be used for each pertussis non-inferiority (NI) evaluation. Since NI has to be met simultaneously for the 3 pertussis antigens, the global type I error will be below 2.5%.

10.3.2. References for sample size

References were chosen based on observed standard deviations observed in studies Hib-MenCY-TT-005 (101858) and Hib-MenCY-TT-009 (103813) one month post-dose 3 from the subjects that receive *ActHIB* co-administered with *Pediarix* and *Prevnar*, and from study DTPa-HBV-IPV-027 (217744/027) one month post-dose 3 from the DTPa-HBV-IPV/Hib pooled groups. All these studies enrolled subjects in the US.

The standard deviation for log_{10} transformed concentrations post vaccination for pertussis antigens is presented in Table 16.

Table 16 Standard deviation for log₁₀ transformed concentration post vaccination

Study			Ant	tigen		
-		PT	F	HA	P	RN
	N	SD	N	SD	N	SD
Hib-MenCY-TT-005-US	215	0.274	213	0.312	217	0.392
Hib-MenCY-TT-009 - US	100	0.258	97	0.252	101	0.482
cohort						
DTPa-HBV-IPV-027-US	865	0.274	802	0.254	869	0.376
Reference taken		0.274		0.307		0.392

N: Number of subjects; SD: standard deviation

10.3.3. Power computation

Out of the 585 subjects enrolled, 65% (126 in each pooled group) are expected to be evaluable post-Dose 3.

The individual type II error for each pertussis antigen was obtained using PASS 2005, one-sided non-inferiority test for 2 means from normal data with common variance between groups, under the alternative of equal means and alpha=2.5% (Table 17).

To account for the multiplicity of comparisons, the global type II error was conservatively estimated as the sum of individual type II errors, ensuring a global power for the study of 94.02% as presented in Table 17.

Table 17 Power for pertussis NI post-Dose 3

Antigen	Margin	SD on log ₁₀ transformed titer	Type I error	N evaluable per pooled group	Type II error		
PT	1.5	0.274	2.5%	126	0.08%		
FHA	1.5	0.307	2.5%	126	0.48%		
PRN	1.5	0.392	2.5%	126	5.42%		
Global Powe	Global Power = 100-(0.08+0.48+5.42) % = 94.02%						

10.4. Study cohorts/ data sets to be analysed

Six cohorts are defined for the purpose of the analysis:

- Primary Total Vaccinated cohort
- Primary ATP cohort for analysis of safety
- Primary ATP cohort for analysis of immunogenicity
- Booster Total Vaccinated cohort
- Booster ATP cohort for analysis of safety
- Booster ATP cohort for analysis of immunogenicity

10.4.1. Primary Total vaccinated cohort

The Primary Total Vaccinated cohort (TVC) will include all vaccinated subjects for whom data are available.

- A safety analysis based on the Primary TVC will include all subjects with at least one vaccine administration documented.
- An immunogenicity analysis based on the Primary TVC will include all vaccinated subjects for whom data concerning at least one immunogenicity endpoint measure is available.

10.4.2. Primary ATP cohort for analysis of safety

The Primary ATP cohort for safety will consist of all subjects from the Primary TVC who complied with the protocol up to the end of Epoch 001, namely all subjects:

- who meet all inclusion criteria and no exclusion criteria for the study
- who have received all planned study vaccines for each completed vaccination visit in Epoch 001;
- for whom administration site of study vaccines is known and is according to protocol;
- who did not receive a product before the blood sampling at Visit 4 (Month 5) leading to elimination from an ATP analysis as listed in Section 6.7.2.

Note that for the purpose of ATP cohort definition, the Epoch 001 ends at Visit 4.

Adherence to the interval related to ESFU phone contact will not be taken into account for inclusion in ATP cohort for safety.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

10.4.3. Primary ATP cohort for analysis of immunogenicity

The Primary ATP cohort for immunogenicity will consist of all subjects from the Primary ATP cohort for safety who complied with eligibility criteria and study procedures (see Table 5 for the definition of the intervals) up to the post-dose 3 blood sample and had immunogenicity results for the post-dose 3 blood sample. The analysis will be performed per treatment (first dose) actually administered.

More specifically, the analysis post-dose 3 based on the ATP cohort for immunogenicity will include all eligible subjects:

- who receive all the study vaccines up to dose 3 as per the vaccination schedule;
- for whom administration site and route of study vaccines up to dose 3 is as per protocol;
- who did not receive a medication/product before the blood sampling at Visit 4 (Month 5) leading to elimination from an ATP analysis as listed in Section 6.7.2
- who did not present with a medical condition before the blood sampling at Visit 4 (Month 5) leading to elimination from an ATP analysis as listed in Section 6.8.
- who comply with the post-dose 3 blood sample schedule, i.e. 21-48 days post-dose 3.
- who were not administered a vaccine not foreseen by the study protocol before the corresponding post-vaccination blood sample.
- who have immunogenicity results post-dose 3.

10.4.4. Booster Total vaccinated cohort

The Booster TVC will include all subjects from primary TVC that received the booster vaccine dose.

- For the Booster-TVC analysis of safety, this will include all subjects with booster vaccine administration documented.
- For the Booster-TVC analysis of immunogenicity, this will include vaccinated subjects for whom data concerning immunogenicity endpoint measures are available.

10.4.5. Booster ATP cohort for analysis of safety

The Booster ATP cohort for safety will consist of all subjects from the Booster TVC who complied with the protocol up to the end of Epoch 002, namely all subjects:

- who meet all inclusion criteria and no exclusion criteria for the study
- who have received the planned booster dose at 15-18 months of age;
- who received 3 doses in Epoch 001;
- for whom administration site of study vaccines is known and is according to protocol;

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

• who did not receive a product before the blood sampling at Visit 6 (Months 14-17) leading to elimination from an ATP analysis as listed in Section 6.7.2.

10.4.6. Booster ATP cohort for analysis of immunogenicity

The Booster ATP cohort for immunogenicity will consist of all subjects from the Booster ATP cohort for safety who complied with eligibility criteria and study procedures (see Table 5 for the definition of the intervals) up to the post-dose 4 blood sample and had immunogenicity results for the post-dose 4 blood sample.

More specifically, the analysis pre- and post-dose 4 based on the Booster ATP cohort for immunogenicity will include all eligible subjects:

- who receive all the study vaccines up to dose 4 as per the vaccination schedule;
- for whom administration site and route of the study vaccines up to dose 4 is as per protocol;
- who did not receive a medication/product before the blood sampling at Visit 6 (Months 14-17) leading to elimination from an ATP analysis (see Section 6.7.2);
- who did not present with a medical condition before the blood sampling at Visit 6 (Months 14-17) leading to elimination from an ATP analysis (see Section 6.8);
- who comply with the booster vaccination schedule at 15-18 months of age and with the post-dose 4 blood sample schedule i.e. 21-48 days for post-dose 4;
- who have immunogenicity results post-dose 4.

10.5. Derived and transformed data

- A seronegative subject is a subject whose antibody concentration/titer is below the assay cut-off.
- A seropositive subject is a subject whose antibody concentration/titer is greater than or equal to the assay cut-off defined in Table 7.
 - Note: Due to ongoing re-validation of all assays, these cut-offs may be subject to change.
- A seroprotected subject is a subject whose antibody concentration/titer is greater than or equal to the level defining clinical protection. The following seroprotection thresholds are applicable:
 - Anti-diphtheria antibody concentrations ≥ 0.1 IU/mL.
 - Anti-tetanus antibody concentrations ≥ 0.1 IU/mL.
 - Anti-HBs antibody concentrations ≥ 10 mIU/mL.
 - Anti-poliovirus types 1, 2 and 3 antibody titers ≥ 8 .
 - Anti-PRP antibody concentrations $\geq 0.15 \,\mu \text{g/mL}$.
- Other cut-offs to be considered:
 - Anti-PRP antibody concentrations ≥ 1.0 μg/mL.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- Anti-diphtheria and anti-tetanus antibody concentrations $\geq 1.0 \text{ IU/mL}$
- Booster responses for anti-PT, anti-FHA and anti-PRN antibodies are defined as:
 - initially seronegative subjects (pre-booster antibody concentration below cutoff: < 5 ELISA EL.U/mL) with an increase of at least four times the cut-off one
 month after vaccination (post-booster antibody concentration ≥20 EL.U/mL),
 and
 - initially seropositive subjects with pre-booster antibody concentration
 ≥ 5 EL.U./mL and < 20 EL.U/mL with an increase of at least four times the pre-booster antibody concentration one month after vaccination, and,
 - For initially seropositive subjects with pre-booster antibody concentration
 ≥ 20 EL.U/mL with an increase of at least two times the pre-booster antibody concentration, one month after vaccination.

Note: Due to ongoing re-validation of pertussis assays, the definition of booster responses may be subject to change.

• The GMC/GMT calculations will be performed by taking the anti-log of the mean of the log₁₀ titer/ concentration transformations. Antibody titers/concentrations below the cut-off of the assay will be given an arbitrary value of half the cut-off for the purpose of GMC/GMT calculation.

Handling of missing data:

Immunogenicity:

 For a given subject and a given immunogenicity measurement, missing or nonevaluable measurements will not be replaced.

Safety/reactogenicity:

- For a given subject and the analysis of solicited symptom within 4 days post-vaccination, missing or non-evaluable measurements will not be replaced. Therefore the analysis of the solicited symptoms based on the Total Vaccinated cohort will include only vaccinated subjects and doses with documented safety data (i.e. symptom screen completed).
- For analysis of unsolicited adverse events, such as serious adverse events or adverse
 events by primary MedDRA term, and for the analysis of concomitant medications,
 all vaccinated subjects will be considered. Subjects who did not report the event or
 the concomitant medication will be considered as subjects without the event or the
 concomitant medication respectively.
- For summaries reporting both solicited and unsolicited adverse events, all vaccinated subjects will be considered. Subjects for whom the event will not be reported will be considered as subjects without the event.

10.6. Final analysis of the Epoch 001

10.6.1. Analysis of demographics

Demographic characteristics (age [weeks], gender, geographical ancestry, height in length [cm], weight [kg] at first dose, Hep B vaccination history, vaccination history of mother with respect to administration of Tdap vaccine during pregnancy) and withdrawal status will be summarised by group using descriptive statistics:

- Frequency tables will be generated for categorical variables such as center;
- Mean, median and standard error will be provided for continuous data such as age.

The distribution of subjects enrolled among the study sites will be tabulated as a whole and per group.

10.6.2. Analysis of immunogenicity

The primary analysis will be based on the primary ATP cohort for immunogenicity. An analysis on the primary Total Vaccinated cohort will be performed only if, in any vaccine group and at any time point, more than 5% of the vaccinated subjects with immunological data post-dose 3 are excluded from the primary ATP cohort for immunogenicity.

The following section describes the analyses that will be performed.

10.6.2.1. Within group assessment

For each group, one month post-dose 3 and for each assay for which a serological result is available:

- Seropositivity and seroprotection rates with exact 95% CIs will be calculated.
- GMCs/GMTs with 95% CIs will be tabulated.
- For D,T and pertussis antigens, additional summaries will be provided according to the Tdap vaccination history of mother during pregnancy.

For each antigen, antibody concentration or titer distribution one month post-vaccination will be tabulated and displayed using reverse cumulative curves (RCCs).

10.6.2.2. Between group assessment

At one month post-dose 3,

- The asymptotic standardized 95% CI for the group difference in the seropositivity/ seroprotection rates will be computed for each antigen.
- The 95% CI for each group GMC/GMT ratio will be computed using an Analysis of Variance (ANOVA) model on the logarithm-transformed concentrations/titers. The ANOVA model will include the vaccine group as fixed effect and the DTP vaccination of the mother during pregnancy as regressor leading to an Analysis of

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Co-variance (ANCOVA) model. For hepatitis B antigen, the hepatitis b at birth vaccine dose status will also be used as regressor.

10.6.2.3. Interpretation of analyses

Except for analyses addressing criteria specified in the primary objective, comparative analyses will be descriptive/ exploratory with the aim to characterise the difference between groups in immunogenicity. These descriptive/exploratory analyses should not be interpreted for formal conclusions since there is no adjustment for multiplicity of endpoints.

10.6.3. Analysis of safety

The primary analysis will be based on the primary Total Vaccinated cohort. If, in any vaccine group and at any time point of the Epoch 001, the percentage of vaccinated subjects excluded from the primary ATP cohort for safety is more than 5%, a second analysis based on the primary ATP cohort for safety will be performed to complement the primary Total Vaccinated cohort analysis.

- The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) or 31-day (Days 0-30) follow-up period will be tabulated after each vaccine dose and overall (for the Epoch 001) with exact 95% CI.
- The percentage of doses followed by at least one local AE (solicited and unsolicited), by at least one general AE (solicited and unsolicited) and by any AE during the 4-day or 31-day follow-up period will be tabulated over the primary vaccination period, with exact 95% CI.
- The percentage of subjects/doses with local AEs (solicited and unsolicited) will be calculated at each injection site for *Infanrix hexa, Pediarix, ActHIB, Pentacel and Engerix-B* vaccines, as well as overall (all sites considered).
- The percentage of subjects/doses reporting each individual solicited local and general AE during the 4-day follow-up period will be tabulated for each group as follows:
 - Over the primary doses, the percentage of subjects with the symptom and its exact 95% CI.
 - Over the primary doses, the percentage of doses with the symptom and its exact 95% CI.
 - At each study dose, the percentage of subjects with the symptom and its exact 95% CI.

The exact 95% CIs will be calculated assuming independence between doses.

All computations mentioned above will be done for Grade ≥2 (solicited symptoms only) and Grade 3 symptoms, for symptoms considered related to vaccination (general symptoms only), for Grade 3 symptoms considered related to vaccination (general symptoms only) and for symptoms that resulted in a medically-attended visit.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- For fever, analyses will be performed by 0.5°C increments.
- The percentage of subjects/doses with concomitant medication, antipyretic medication and prophylactic antipyretic medication during the 4-day and 31-day follow-up period post-vaccination will be tabulated after each dose and over the Epoch 001.
- The verbatim reports of unsolicited AEs will be reviewed by a clinical development manager and the signs and symptoms will be coded according to MedDRA. Every verbatim term will be matched with the appropriate Preferred Term. The percentage of subjects/doses with unsolicited AEs occurring within 31 days with exact 95% CI will be tabulated by Preferred Term. Similar tabulations will be done for Grade 3 unsolicited AEs, for unsolicited AEs considered related to vaccination and for Grade 3 unsolicited AEs considered related to vaccination.
- Subjects who experienced AEs of specific interest (i.e. new onset of chronic disease such as autoimmune disorders, asthma, type I diabetes and allergies) from Day 0 up to 6 months after the last primary vaccination will be tabulated by Preferred Term.
- Subjects who experienced at least one SAE reported before the database lock for the Epoch 001 analysis with an onset date in the Epoch 001 will be reported and the SAE will be described in detail.

10.7. Final analysis of the Epoch 002

10.7.1. Analysis of demographics/baseline characteristics

Demographic characteristics (age in months at Visit 5) and withdrawal status will be summarized by group using descriptive statistics:

- Frequency tables will be generated for categorical variables such as race/ethnicity;
- Mean, median and standard error will be provided for continuous data such as age.

The distribution of subjects vaccinated at Visit 5 among the study sites will be tabulated as a whole and per group.

For enrolled subjects that do not participate in the Epoch 002, the reason for not participating will be summarized.

10.7.2. Analysis of immunogenicity

The primary analysis will be based on the booster ATP cohort for immunogenicity. An analysis on the booster Total Vaccinated cohort will be performed only if, in any vaccine group and at any time point of the Epoch 002, more than 5% of the vaccinated subjects with immunological data are excluded from the booster ATP cohort for immunogenicity.

The following section describes the analyses that will be performed.

10.7.2.1. Within group assessment

For each group, prior to the booster dose and one month post-booster dose and for each assay for which a serological result is available:

- Seropositivity and seroprotection rates and booster response rates for pertussis with exact 95% CIs will be calculated.
- GMCs/GMTs with 95% CIs will be tabulated.

For D,T and pertussis antigens, additional summaries will be provided according to the Tdap vaccination history of mother during pregnancy.

For each antigen, antibody concentration or titer distribution before and one month Post-booster (when available) will be tabulated and displayed using RCCs.

10.7.2.2. Between group assessment

At pre-booster and at one month post-booster,

- The asymptotic standardized 95% CI for the group difference in the seroprotection/ seropositivity rates will be computed for each antigen.
- The 95% CI for each group GMC/GMT ratio will be computed using an ANOVA model on the logarithm-transformed concentrations/titers. The ANOVA model will include the vaccine group as fixed effect and the DTP vaccination of the mother during pregnancy as regressor leading to an Analysis of Co-variance (ANCOVA) model. For hepatitis B antigen, the hepatitis B at birth vaccine dose status will also be used as regressor.

10.7.2.3. Interpretation of analyses

In Epoch 002, all comparative analyses will be descriptive/ exploratory with the aim to characterise the difference between groups in immunogenicity. These descriptive/exploratory analyses should not be interpreted for formal conclusions since there is no adjustment for multiplicity of endpoints.

10.7.3. Analysis of safety

The primary analysis for the Epoch 002 will be based on the booster Total Vaccinated cohort and will only look at the booster dose. If, in any vaccine group, the percentage of vaccinated subjects excluded from the booster ATP cohort for safety is more than 5%, a second analysis based on the booster ATP cohort for safety will be performed to complement the booster Total Vaccinated cohort analysis.

• The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) and 31-day (Days 0-30) follow-up period after the booster dose, will be tabulated with exact 95% CI for each group.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- The incidence of local AEs (solicited and unsolicited) will be calculated at each injection site as well as overall (all sites considered) for each group.
- The percentage of subjects reporting each individual solicited local and general AE during the 4-day follow-up period will be tabulated with its exact 95% CI for each group.
- All computations mentioned above will be done for Grade ≥2 (solicited symptoms only) and Grade 3 symptoms, for symptoms considered related to vaccination (general symptoms only), for Grade 3 symptoms considered related to vaccination (general symptoms only) and for symptoms that resulted in a medically-attended visit.
- For fever, analyses will be performed by 0.5°C increments.
- The percentage of subjects with concomitant medication, antipyretic medication and prophylactic antipyretic medication during the 4-day and 31-day follow-up period post-vaccination will be tabulated for each group.
- The verbatim reports of unsolicited AEs will be reviewed by a clinical development manager and the signs and symptoms will be coded according to MedDRA. Every verbatim term will be matched with the appropriate Preferred Term. The percentage of subjects with unsolicited AEs occurring within 31 days following the booster dose with its exact 95% CI will be tabulated by Preferred Term. Similar tabulations will be done for Grade 3 unsolicited AEs, for unsolicited AEs considered related to vaccination and for Grade 3 unsolicited AEs considered related to vaccination.

Additionally,

- Any large injection site reaction (defined as a swelling with a diameter > 50 mm, noticeable diffuse swelling or noticeable increase in limb circumference) reported within 4 days (Days 0-3) following the booster dose will be described in detail.
- Subjects who experienced AEs of specific interest (i.e. new onset of chronic disease such as autoimmune disorders, asthma, type I diabetes and allergies) from booster dose up to one month after booster vaccination will be tabulated by Preferred Term.
- Subjects who experienced at least one SAE from the booster dose to study end will be reported and the SAEs will be described in detail.

10.8. Statistical methods

- The exact CIs for a proportion within a group will be calculated from Proc StatXact [Clopper, 1934].
- The standardized asymptotic CI for the group difference in proportion is the method implemented in Proc StatXact 7.0. It corresponds to method 6 in the Newcombe paper [Newcombe, 1998].
- The CI for GMTs/GMCs will be obtained within each group separately. The CI for the mean of log-transformed titer/concentration will be first obtained assuming that log-transformed values were normally distributed with unknown variance. The CI for

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

the GMTs/GMCs will then be obtained by exponential-transformation of the CI for the mean of log-transformed titer/concentration.

• The GMT/GMC group ratio will be obtained using an ANOVA model on the logarithm-transformed concentrations/titers. The ANOVA model will include the vaccine group as fixed effect and the DTP vaccination of the mother during pregnancy as regressor leading to an Analysis of Co-variance (ANCOVA) model. For hepatitis B antigen, the hepatitis B status at birth vaccine dose will also be used as regressor. The GMC/GMT group ratio and its CI will be derived as exponential-transformation of the corresponding group contrast in the model.

10.9. Conduct of analyses

Any deviation(s) or change(s) from the original statistical plan outlined in this protocol will be described and justified in the final study report.

10.9.1. Sequence of analyses

(Amendment 2: 17 April 2015)

The analyses will be performed *stepwise*:

- 1. A partial analysis of Epoch 001 up to one month after the third primary vaccine dose will be conducted. This analysis will include the final analysis of anti-PRP, solicited and unsolicited symptoms on data as clean as possible. This analysis will be displayed on GSK clinical trial registry as soon as possible.
- 2. The final data analysis of the study covering both the epochs will be conducted at the end of the study. All these analyses will be presented in a final clinical study report.

10.9.2. Statistical considerations for interim analyses

All analyses will be conducted on final data and therefore no statistical adjustment for interim analyses is required.

11. ADMINISTRATIVE MATTERS

To comply with ICH GCP administrative obligations relating to data collection, monitoring, archiving data, audits, confidentiality and publications must be fulfilled.

11.1. Remote Data Entry instructions

RDE, a validated computer application, will be used as the method for data collection.

In all cases, subject initials will not be collected nor transmitted to GSK. Subject data necessary for analysis and reporting will be entered/transmitted into a validated database or data system. Clinical data management will be performed in accordance with applicable GSK standards and data cleaning procedures.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

While completed eCRFs are reviewed by a GSK Biologicals' Site Monitor at the study site, omissions or inconsistencies detected by subsequent eCRF review may necessitate clarification or correction of omissions or inconsistencies with documentation and approval by the investigator or appropriately qualified designee. In all cases, the investigator remains accountable for the study data.

The investigator will be provided with a CD-ROM of the final version of the data generated at the investigational site once the database is archived and the study report is complete and approved by all parties.

11.2. Study Monitoring by GSK Biologicals

GSK will monitor the study to verify that, amongst others, the:

- Data are authentic, accurate, and complete.
- Safety and rights of subjects are being protected.
- Study is conducted in accordance with the currently approved protocol, any other study agreements, GCP and all applicable regulatory requirements.

The investigator and the head of the medical institution (where applicable) agrees to allow the monitor direct access to all relevant documents.

The investigator must ensure provision of reasonable time, space and qualified personnel for monitoring visits.

Direct access to all study-site related and source data is mandatory for the purpose of monitoring review. The monitor will perform a RDE review and a Source Document Verification (SDV). By SDV we understand verifying RDE entries by comparing them with the source data that will be made available by the investigator for this purpose.

The Source Documentation Agreement Form describes the source data for the different data in the RDE. This document should be completed and signed by the site monitor and investigator and should be filed in the monitor's and investigator's study file. Any data item for which the RDE will serve as the source must be identified, agreed and documented in the source documentation agreement form.

For RDE, the monitor will mark completed and approved screens at each visit.

Upon completion or premature discontinuation of the study, the monitor will conduct site closure activities with the investigator or site staff, as appropriate, in accordance with applicable regulations, GCP, and GSK procedures.

11.3. Record retention

Following closure of the study, the investigator must maintain all site study records (except for those required by local regulations to be maintained elsewhere) in a safe and secure location. The records must be easily accessible, when needed (e.g. audit or inspection), and must be available for review in conjunction with assessment of the facility, supporting systems, and staff. Where permitted by applicable laws/regulations or

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

institutional policy, some or all of these records can be maintained in a validated format other than hard copy (e.g. microfiche, scanned, electronic); however, caution needs to be exercised before such action is taken. The investigator must ensure that all reproductions are legible and are a true and accurate copy of the original and meet accessibility and retrieval standards, including re-generating a hard copy, if required. Furthermore, the investigator must ensure that an acceptable back-up of the reproductions exists and that there is an acceptable quality control procedure in place for making these reproductions.

GSK will inform the investigator/institution of the time period for retaining these records to comply with all applicable regulatory requirements. However, the investigator/institution should seek the written approval of the sponsor before proceeding with the disposal of these records. The minimum retention time will meet the strictest standard applicable to a particular site, as dictated by ICH GCP, any institutional requirements, applicable laws or regulations, or GSK standards/procedures; otherwise, the minimum retention period will default to 15 years.

The investigator/institution must notify GSK of any changes in the archival arrangements, including, but not limited to archival at an off-site facility, transfer of ownership of the records in the event the investigator leaves the site.

11.4. Quality assurance

To ensure compliance with GCP and all applicable regulatory requirements, GSK may conduct a quality assurance audit. Regulatory agencies may also conduct a regulatory inspection of this study. Such audits/inspections can occur at any time during or after completion of the study. If an audit or inspection occurs, the investigator and institution agree to allow the auditor/inspector direct access to all relevant documents and to allocate his/her time and the time of his/her staff to the auditor/inspector to discuss findings and any relevant issues.

11.5. Posting of information on publicly available clinical trial registers and publication policy

Study information from this protocol will be posted on publicly available clinical trial registers before enrolment of subjects begins.

Summaries of the results of GSK interventional studies (phase I-IV) are posted on publicly available results registers within 12 months of the primary completion date for studies of authorized vaccines and 18 months for studies of non-authorized vaccines.

GSK also aims to publish the results of these studies in the searchable, peer reviewed scientific literature. Manuscripts are submitted for publication within 24 months of the last subject's last visit.

11.6. Provision of study results to investigators

Where required by applicable regulatory requirements, an investigator signatory will be identified for the approval of the study report. The investigator will be provided reasonable access to statistical tables, figures, and relevant reports and will have the

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

opportunity to review the complete study results at a GSK site or other mutually-agreeable location.

GSK Biologicals will also provide the investigator with the full summary of the study results. The investigator is encouraged to share the summary results with the study subjects, as appropriate.

12. COUNTRY SPECIFIC REQUIREMENTS

Not applicable.

13. REFERENCES

Anderson P. The protective levels of serum antibodies to the capsular polysaccharide of *Haemophilus influenzae* type b. *J Infect Dis* 1984;149:1034-1035.

Camargo ME, et al. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. *J Clin Microbiol* 1984;20(4):772-4.

Centers for Disease Control and Prevention (CDC). Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States Through Universal Childhood Vaccination: Recommendations of the Immunisation Practices Advisory Committee (ACIP). *MMWR* 1991; 40(RR-13): 1-19.

Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunisation Practices (ACIP) and the American Academy of Family Physicians (AAFP). *MMWR* 2002, 51(RR02); 1-36.

Clopper C J, Pearson E S. The Use Of Confidence Or Fiducial Limits Illustrated In The Case Of The Binomial. *Biometrika* 1934;26(4):404-13.

Dhillon S. DTPa-HBV-IPV/Hib Vaccine (*Infanrix hexa*[™]): A Review of its Use as Primary and Booster Vaccination. *Drugs* 2010; 70(8): 1021-58

Diggle L, Deeks JJ, Pollard AJ. Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomized controlled trial. *BMJ* 2006;333 (7568):571.

General recommendations on immunization—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Surveill Summ, 60 (2011), pp. 1–64. http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf. Accessed on 26 September 2013.

Granström M, Thoren M, Sato Y et al. Acellular Pertussis Vaccine in Adults: Adverse Reactions and Immune Response. *Eur J Clin Microbiol* 1987;6 (1):18-21.

Kalies H, Grote V, Verstraeten T, et al. The Use of Combination Vaccines Has Improved Timeliness of Vaccination in Children. *Pediatr Infect Dis J* 2006;25(6):507-12.

Karpinsky KF, Hayward S and Tryphonas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). *J Immunol Methods* 1987;103:189-94.

Käyhty H, Peltola H, Karanko V and Makela PH. The protective level of serum antibodies to the capsular polysaccharide of *Haemophilus influenzae* type b. *J Infect Dis* 1983;147:1100.

Kohl KS, Walop W, Gidudu J, et al. Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data. *Vaccine*. 2007; 25(31):5858-74.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralisation test in mice as a method for the estimation of tetanus antitoxin in human sera. *J Biol Stand* 1983;11:137-44.

Newcombe R G. Two-sided confidence intervals for the single proportion: Comparison of seven methods. *Statistics in Medicine* 1998;17(8):857–72.

World Health Organization (WHO). Progress in the control of viral hepatitis: memorandum for a WHO meeting. *Bull WHO* 1988;66:443-45.

World Health Organisation (WHO). Standard Procedure for Determining Immunity to Poliovirus using the Microneutralisation Test (WHO/EPI/GEN 93.9) 1993.

Zepp F, Schmitt HJ, Cleerbout J et al. Review of 8 years of experience with *Infanrix hexa*[™] (DTPa-HBV-IPV/Hib hexavalent vaccine). *Expert Rev Vaccines* 2009;8(6):663-78.

Zinke M, Disselhoff J, Gartner B et al. Immunological persistence in 4–6 and 7–9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib. Human *vaccines* 2010;6(2):1-5.

Zuckerman JN. The importance of injecting vaccines into muscles. BMJ 2000;321:1.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

APPENDIX A CLINICAL LABORATORIES

Table 18 GSK Biologicals' laboratories

Laboratory	Address
GSK Biologicals Global Vaccine	Biospecimen Reception - B7/44
Clinical Laboratory, Rixensart	Rue de l'Institut, 89 - B-1330 Rixensart - Belgium
GSK Biologicals Global Vaccine	Biospecimen Reception - Clinical Serology
Clinical Laboratory, North America-	525 Cartier blvd West - Laval - Quebec - Canada -
Laval	H7V 3S8
GSK Biologicals Global Vaccine	Avenue Fleming, 20 - B-1300 Wavre - Belgium
Clinical Laboratory, Wavre-Nord	_
Noir Epine	

Table 19 Outsourced laboratories

Laboratory	Address
Quest Diagnostics Clinical Trials	27027 Tourney Road, Suite 2E
(US)	Valencia, CA 91355
	USA
Quest Diagnostics Clinical Trials	27027 Tourney Road, Suite 2E
(Biomarkers)	Valencia, CA 91355
	USA
Quest Diagnostics Nichols Institute	33608 Ortega Highway
	San Juan Capistrano,
	CA 92675-2042
	USA
Quest Diagnostics, Inc.	1 Malcolm Way
	Teterboro, NJ 07608
	USA
Quest Diagnostics Nichols Institute	14225 Newbrook Drive
	Chantilly, VA 20153
	USA

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

APPENDIX B AMENDMENTS AND ADMINISTRATIVE CHANGES TO THE PROTOCOL

GlaxoSmithKline Biologicals		
Clinical Research & Development		
Protocol Amendment 1		
eTrack study number	117119 (DTPA-HBV-IPV-135)	
and Abbreviated Title		
IND number	BB-IND 006687	
EudraCT number	2013-004304-19	
A d d b	Amondurout 1	
Amendment number:	Amendment 1	
Amendment date:	Final: 18 September 2014	
Timenament date.		
Co-ordinating author:	, Scientific Writer	

Rationale/background for changes:

- Clarification has been provided that large injection site reactions and measurement of the injected limb should be collected as a solicited symptom. Specific instructions regarding measurement of limb circumference and clinical details of large injection site reactions have been added.
- Additional minor clarifications of study procedures and data analyses have been made throughout the document.
- Instructions regarding interval between preparation and administration of vaccine has been aligned with the stability data described in the current Investigator Brochure.
- Due to ongoing re-validation of serological assays for antibodies to diphtheria and tetanus toxoids, pertussis antigens, poliovirus, hepatitis B surface antigen and polyribosyl ribitol phosphate, the cut-offs for these assays could potentially change and hence a note has been added in the protocol regarding this. The definition of booster response to pertussis antigens could also potentially be revised.
- Sequence of reporting the results has been clarified.
- The contributing authors and sponsor signatory were updated to reflect changes in the study team.

Amended text has been included in *bold italics* and deleted text in strikethrough in the following sections:

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Primary study vaccine and number	GlaxoSmithKline (GSK) Biologicals' Combined Diphtheria-Tetanus-acellular Pertussis (DTaP), Hepatitis B, Poliovirus and <i>Haemophilus influenzae</i> type b vaccine (DTPa-HBV-IPV/Hib) (GSK SB217744, Infanrix hexa [™]).
----------------------------------	---

Section 1.2.1 Rationale for the study

More than 73 100 million doses have been distributed to date and the benefit/risk profile remains favorable.

Section 5.5 Outline of study procedures

Table 4 List of study procedures

		Еросн	EPOCH 002 (BOOSTER VACCINATION)				
Age	2 Months	4 Months	6 Months	7 Months	12 Months	15-18 Months	16-19 Months
Visit	VISIT 1	VISIT 2	VISIT 3†	VISIT 4	ESFU CONTACT (PHONE)	VISIT 5	VISIT 6
Time point	Day 0	Month 2	Month 4	Month 5	Month 10	Month 13 -16	Month 14 - 17
Sampling time point				Post-Pri		Pre-Bst	Post-Bst
Informed consent	•						
Check inclusion/exclusion criteria	•						
Medical history	•						
Collect demography data	•						
Vaccination history including HepB vaccination history	•						
Informed consent for Tdap vaccination history of mother ^a	•						
Last Tdap vaccination history of mother ^β	•						
History directed physical examination including length and weight	•					•	
Study group and treatment number allocation (Randomization)	0						
Treatment number allocation for subsequent doses		0	0			0	
Recording of administered treatment number	•	•	•			•	
Pre-vaccination body temperature	•	•	•			•	
Blood sampling				•		•	•
Check warnings and precautions	0	0	0			0	
Check contraindications to subsequent vaccination		•	•			•	
Pre-vaccination measurement of limb length and circumference of							
$limb(s)$ at site of injection by investigator ^{δ}						•	
Vaccination	•	• **	•			•	
Distribution of thermometer	0						
Distribution of measuring device	0					0	
Distribution of diary cards	0	0	0			0	

117119 (DTPA-HBV-IPV-135)

Protocol Amendment 2 Final Version 02

					PTOLOCOL AL		nai version uz
		Еросн	EPOCH 002				
			(BOOSTER VACCINATION)				
Age	2 Months	4 Months	6 Months	7 Months	12 Months	15-18 Months	16-19 Months
Visit	Visit 1	VISIT 2	VISIT 3 †	Visit 4	ESFU	VISIT 5	VISIT 6
					CONTACT		
					(PHONE)		
Time point	Day 0	Month 2	Month 4	Month 5	Month 10	Month 13 -16	Month 14 - 17
Sampling time point				Post-Pri		Pre-Bst	Post-Bst
Daily post-vaccination recording of solicited adverse events during the 4-							
day (Day 0–3) follow-up period, recorded by the subjects' parent(s)/LAR(s)	•	•	•			•	
in diary card							
Recording of non-serious (unsolicited) adverse events during the 31-day							
(Day 0-30) follow-up period, recorded by the subjects' parent(s)/LAR(s) in	•	•	•			•	
diary card							
Recording of any large injection site reactions in the eCRF by the							
investigator*						•	
Return of diary cards and transcription by the investigator		•	•	•			•
Record any concomitant medication and vaccination §	•	•	•	•	•	•	•
Record any intercurrent medical conditions		•	•	•	•	•	•
Recording of serious adverse events including related to study participation	•	•					
Investigator sign-off					•		0
Analysis of the Epoch 001 #				0	0		
Analysis of the Epoch 002 #							0
Study Conclusion							•

 $[\]alpha$ Child can still continue in the study if the mother does not wish to provide consent to record her Tdap vaccination history.

^β Only the Tdap vaccination history (during the pregnancy of the enrolled child) from mothers who have given consent to provide this information will be obtained and recorded in the eCRF..

⁶ For the Penta group, which receives only one vaccine at Visit 5, baseline measurement of only the limb receiving the vaccine is required * Refer to Section 8.1.3.1 and 5.6.2.9 for detailed explanation on the reporting of large injection site reaction

Section 5.6.2.4 Vaccination history

The Tdap vaccination history of the mother during pregnancy will also be collected and recorded in the eCRF (provided that the mother has consented to provide this information).

Note: Maternal vaccination is requested in order to be able to summarize the responses of the subjects to pertussis antigens according to whether or not the mothers received a pertussis vaccine during their pregnancy. This information will aid in understanding the effect of transplacentally transferred antibodies on the childs' immune response to vaccination.

Section 5.6.2.9.1 Blood sampling for immune response assessments

• A volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) should be drawn from all subjects for the analysis of humoral immune response at Visits 4 and 5. At least 3.5 mL of whole blood (to provide atleast approximately 1.2 mL of serum) should be drawn from all subjects for the analysis of humoral immune response at Visit 6. After centrifugation, serum samples should be kept at -20°C/-4°F or below until shipment. Refer to the SPM for more details on sample storage conditions.

Section 5.6.2.11 Baseline measurement of limb length and circumference after booster vaccination at visit 5

During Epoch 002, baseline measurement of length of limb(s) and circumference (arms or legs according to where the vaccine was administered) at the level of the injection site should be obtained. For the Penta group, baseline measurement is only required for the limb that will be vaccinated. Clothing should be removed so as not to interfere with the measurement of the length of the limb and the circumference. Upper arm length will be determined from the acromion process of the scapula to the tip of the elbow and thigh length will be determined from the midpoint of the abdomen thigh flexure crease and the proximal end of the patella. For measuring upper arm circumference, the measurement will be performed while the arm is held parallel to the trunk and the elbow is flexed in front at 90° (as if the subject is carrying a tray) [Kohl, 2007]. For measuring leg circumference the child should be standing or lying flat, as appropriate, as long as the leg is straight.

Section 5.6.2.13 Recording of AEs, SAEs and NOCDs

- During Epoch 002, following the fourth dose vaccination, the parents/LAR(s) should be provided with a measurement device for recording circumference of injected limbs (arms or legs according to where vaccine was administered) at the level of the injection site on the day of vaccination and during the next three days on a diary card. The parents/LAR(s) should be instructed on how and where to perform the measurement of the circumference of the vaccinated limb. Daily measurements should be performed in the same manner preferably by the same person and at the same time of day during the 4-day follow-up (Day 0-Day3) period.
- During Epoch 002, iIf the parent(s) /LAR(s) of infants observe any large injection site reaction (defined as swelling with a diameter > 50 mm, noticeable diffuse swelling or noticeable increase of arm limb circumference) during the 4-day follow-up (Day 0-Day 3) period, they will be asked are to contact study personnel and to visit the investigator's office for evaluation as soon as possible and to bring the diary card with them. The investigator will record detailed information describing the AE on a specific large injection site reaction in the eCRF.
- In addition to the diameter of the swelling and the circumference of the limb that are reported as solicited symptoms, the parents(s)/LAR(s) will record the following additional symptoms/characteristics that may be associated with large injection site swelling reactions on the diary card:
 - Type of swelling (local swelling only around the injection site, diffuse swelling not involving the elbow or knee joint, swelling involving the elbow or knee joint)
 - Whether or not the diameter of the swelling involves more than 50% of the limb (baseline measurement of the length of the limb taken by study personnel at the vaccination visit will be provided on the diary cards)
 - Induration at injection site (largest diameter)
 - Pruritis at the injection site (intensity scale provided)
 - Functional impairment (intensity scale and description provided)
- The study personnel's evaluation will be recorded in the medical chart. In case the diary card score is not in line with the medical chart score, the medical chart will indicate what is the most intense score. The largest or most intense score for a given day will be recorded in the eCRF at the level of the solicited symptoms and at the level of the large swelling report form.

Section 5.7.3 Laboratory assays

At Visits 4, 5 and 6, blood will be collected for measurement of immune response. Total blood volume to be taken from each subject over the study period is approximately 13.5 mL (approximately 5.0 mL of whole blood *to provide* approximately 1.7 mL of serum at Visits 4 and 5 and at least 3.5 mL of whole blood *to provide approximately 1.2 mL of serum* at Visit 6).

Table 7 Humoral Immunity (Antibody determination)

System	Component	Component Method Test kit/ U		Unit	Cut-off†	Laboratory**
Serum	Bordetella pertussis.Pertussis Toxin Ab.IgG	ELISA	In-house*	EL.U/m L	5	GSK Biologicals§
Serum			In-house*	EL.U/m L	5	GSK Biologicals§
Serum	Bordetella pertussis.Pertactin Ab.IgG	ELISA	In-house*	EL.U/m L	5	GSK Biologicals§
Serum	Corynebacterium diphtheriae.Diphtheria Toxoid Ab.IgG	ELISA	In-house*	IU/mL	0.1	GSK Biologicals§
Serum	Clostridium tetani.Tetanus Toxoid Ab.lgG	ELISA	In-house*	IU/mL	0.1	GSK Biologicals§
Serum	Hepatitis B Virus.Surface Ab	CLIA	Centaur (Siemens Healthcare)	mIU/mL	6.2	GSK Biologicals§
Serum	Poliovirus Sabin Types 1, 2 and 3	NEUTRA	In-house*	ED50	8	GSK Biologicals§
Serum	Haemophilus influenzae type b.Polyribosyl Ribitol Phosphate Ab	ELISA	In-house*	μg/mL	0.15	GSK Biologicals§

^{*}In-house refers to **assays developed internally by GSK which can be performed at** GSK Biologicals' laboratories or **external** laboratory designated by GSK

^{**}Refer to APPENDIX A for the laboratory addresses.

[§]GSK Biologicals laboratory refers to the Global Vaccines Clinical Laboratories (GVCL) in Rixensart, Belgium; Wavre.

[†]Due to ongoing re-validation of all assays, the cut-offs may be subject to change. Belgium and Laval, Canada.

Section 6.1 Description of study vaccines

Table 9 Study vaccines

Treatment name	Vaccine/ Product name	Formulation	Presentation	Volume	Number of doses
Pentacel	DTaP-IPV (Sanofi Pasteur)	PT=20µg; FHA=20µg; FIM=5µg; PRN=3µg; DT=15Lf; TT=5Lf; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; PRP=10µg TT,TT=24µg; AIPO ₄ =330µg AI3+	Suspension for injection (0.5-mL dose) supplied as a liquid vaccine component in a single dose vial	0.5 mL*	4
	ActHIB Hib	Hib=10μg TT, TT=24μg PRP=10μG; TT~=25μG	White lyophilized pellet in a single dose vial, it must be reconstituted before use with the liquid DTaP-IPV component. The lyophilized Hib component is presented as a white pellet in a glass vial; it must be reconstituted with the liquid DTaP-IPV component before use		

Section 6.3 Dosage and administration of study vaccines

NOTE: After reconstitution, Infanrix hexa should be administered promptly or stored refrigerated between 2° and 8° C and administered within 24 hours. If the vaccine is not administered promptly, shake the solution vigorously again before injection injected immediately. However the vaccine may be kept for up to 8 hours at room temperature $(21^{\circ}C)$.

Section 6.7.1 Recording of concomitant medications/products and concomitant vaccination

• Any concomitant vaccination administered *since birth* in the period starting 30 days before the first dose of the study vaccine and ending 30 days after the booster dose (Visit 6). Notes: 1). Vaccinations listed prior to the first dose of study vaccine are to be recorded as vaccination history. 2) The fourth dose of *Prevnar 13* will be recorded as concomitant vaccination.

^{*} *Refer to those* SAEs that are required to be reported per protocol.

Section 8.1.3.1 Solicited local (injection-site) adverse events

Table 11 Solicited local adverse events

Pain at injection site

Redness at injection site

Swelling at injection site

Post-dose 4 measurements of circumference of limbs (arm or leg according to where vaccine was administered)

N.B. If parent(s) /LAR(s) of infants observe any large injection site reaction (defined as swelling with a diameter > 50 mm, noticeable diffuse swelling or noticeable increase of arm limb circumference) after the booster dose at Visit 5, they will be asked are to contact study personnel and to visit the investigator's office for evaluation as soon as possible and bring the diary card with them. The investigator will record detailed information describing the AE on a specific large injection site reaction form in the eCRF. In addition to the diameter of the swelling and the circumference of the limb that are reported as solicited symptoms the parent(s)/LAR(s) will need to record additional symptoms/characteristics as mentioned in Section 5.6.2.13.

Note: local AEs will not be collected solicited for co-administered vaccines like *Prevnar 13* and *Rotarix*.

Section 8.3.1 Time period for detecting and recording adverse events and serious adverse events

Note: With the exception of AEs/SAEs leading to withdrawal, study participation and concurrent GSK medications or vaccines, there is no reporting of SAEs from the time of the Epoch 1 ESFU phone contact and administration of dose 4 (approximately three months).

Section 8.3.3.2.1 Assessment of intensity

Table 14 Intensity scales for solicited symptoms in infants/toddlers

Infant/Toddler (15–24 months)						
Adverse Event	Intensity grade	Parameter				
Pain at injection site 0		None				
	1	Mild: Minor reaction to touch				
	2	Moderate: Cries/protests on touch				
	3	Severe: Cries when limb is moved/spontaneously painful				
Redness at injection	on site	Record greatest surface diameter in mm				
Swelling at injection	on site	Record greatest surface diameter in mm				
Increase in limb circumference post-dose 4 (arm		Record the limb circumference at the level of the injection				
or leg according to where vaccine was administered)		site				

The maximum intensity of fever was will be scored at GSK Biologicals as follows:

0	= <100.4°F	<38.0°C
1	$= \geq 100.4^{\circ}F \text{ to } \leq 102.2^{\circ}F$	≥38.0°C to ≤39.0°C
2	$= >102.2$ °F to ≤ 104.0 °F	>39.0°C to ≤40.0°C
3	= > 104.0°F	> 40.0°C

Prior to analysis, the increase in limb circumference of each limb as compared to the baseline pre-vaccination measurement will be scored for each subject at GSK Biologicals' as follows:

Grade 0 = Increase in limb circumference ≤ 5 mm

- 1 = Increase in limb circumference >5 mm but ≤20 mm
- 2 = Increase in limb circumference >20 mm but ≤40 mm
- 3 = Increase in limb circumference >40 mm

For unsolicited symptoms and adverse events associated with large injection site reactions (e.g. pruritus, induration and functional impairment, t\(\pm \) he intensity should be assigned to one of the following categories:

Section 10.4.2 Primary ATP cohort for analysis of safety

• who have received all *planned* study vaccines as planned for each completed vaccination visit in up to the end of Epoch 001;

Section 10.4.5 Booster ATP cohort for analysis of safety

• who have received the *planned* booster dose at 15-18 months of age;

Section 10.5 Derived and transformed data

- A seropositive subject is a subject whose antibody concentration/titer is greater than or equal to the assay cut-off defined in Table 7.
 - Note: Due to ongoing re-validation of all assays, these cut-offs may be subject to change.
- Booster responses for anti-PT, anti-FHA and anti-PRN antibodies are defined as:
 - For initially seropositive subjects with pre-booster antibody concentration
 ≥ 20 EL.U/mL with an increase of at least two times the pre-booster antibody concentration, one month after vaccination.

Note: Due to ongoing re-validation of pertussis assays, the definition of booster responses may be subject to change.

Section 10.6.2.2 Between group assessment

• The 95% CI for each group GMC/GMT ratio will be computed using an Analysis of Variance (ANOVA) model on the logarithm-transformed concentrations/titers. The ANOVA model will include the vaccine group as fixed effect and the DTP vaccination of the mother during pregnancy as regressor leading to an Analysis of Co-variance (ANCOVA) model.. For hepatitis B antigen, the hepatitis b at birth vaccine dose status will also be used as regressor leading to an Analysis of Co-variance (ANCOVA) model.

Section 10.7.2.2 Between group assessments

• The 95% CI for each group GMC/GMT ratio will be computed using an ANOVA model on the logarithm-transformed concentrations/titers. The ANOVA model will include the vaccine group as fixed effect and the DTP vaccination of the mother during pregnancy as regressor leading to an Analysis of Co-variance (ANCOVA) model. For hepatitis B antigen, the hepatitis B at birth vaccine dose status will also be used as regressor leading to an ANCOVA model.

Section 10.8 Statistical methods

• The GMT/GMC group ratio will be obtained using an ANOVA model on the logarithm-transformed concentrations/titers. The ANOVA model will include the vaccine group as fixed effect and the DTP vaccination of the mother during pregnancy as regressor leading to an Analysis of Co-variance (ANCOVA) model. For hepatitis B antigen, the hepatitis B status at birth vaccine dose will also be used as regressor leading to an Analysis of Co-variance (ANCOVA) model.

Section 10.9.1 Sequence of analyses

- 1. The final data analysis of Epoch 001 including all as clean as possible data, up to one month after the third primary vaccine dose, and some partial data from the ESFU contact will be conducted as soon as possible. This analysis will include the final analysis of immunogenicity and the final analysis of solicited symptoms for the primary vaccination course. All analyses will be presented in Clinical Study Report (CSR). The CSR will be shared with the investigators.
- 2. All these analyses will be presented in an Epoch 002 specific *final* CSR. The final CSR will be shared with the investigators.

Section 13 References

Kohl KS, Walop W, Gidudu J, et al. Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine. 2007; 25(31):5858-74.

Appendix A Clinical laboratories

Table 19 Outsourced laboratories

Laboratory	Address
BARC USA Inc	5, Delaware Drive
	Lake Success
	NY 11042-1114
	USA

GlaxoSmithKline Biologicals								
Cli	Clinical Research & Development							
	Protocol Amendment 2							
eTrack study number	117119 (DTPA-HBV-IPV-135)							
and Abbreviated Title								
IND number	BB-IND 006687							
EudraCT number	2013-004304-19							
	A 1 42							
Amendment number:	Amendment 2							
Amendment date:	Final Version 02: 17 April 2015							
Amenument date.	1 mai v 01510m 02. 17 April 2015							
Co-ordinating author:	, Scientific Writer							

Rationale/background for changes:

The amendment 2 has been implemented to amend the following sections of the protocol:

- The assay for testing antibodies against polyribosyl ribitol phosphate (anti-PRP) has been re-developed but is not yet qualified or validated for testing the one month post dose-3 samples. This has been clarified in the protocol in Table 7 Humoral immunity (antibody determination) and Section 5.7.3 Laboratory assays.
- Investigator sign-off on the patient identification (PIDS) will be done after Visit 4 instead of extended safety follow-up (ESFU). In Table 4 List of study procedures, the bullets pertaining to investigator sign-off and analysis of Epoch 001 has been removed from the ESFU visit and retained at Visit 4 to reflect this change.
- The collection of baseline measurement of limb length has been removed since it will not be used in analysis; only limb circumference will be used in analysis. Accordingly, text related to this has been amended in Table 4 List of study procedures, Sections 5.6.2.11, Baseline measurement of limb circumference after booster vaccination at visit 5 and 5.6.2.13 Recording of AEs, SAEs and NOCDs.
- Errors in the vaccines dictionary of Study Master Repository (SMR) have been rectified for *Infanrix hexa*, *Pediarix* and *Pentacel* vaccines. The corresponding correction has been made in Table 9 Study vaccines.
- The sequence of analysis in Section 10.9.1 Sequence of analyses, has been amended to reflect that there will first be an analysis of immunogencity for anti-PRP and safety for Epoch 001, followed by a final analysis covering both Epochs at the end of the study.

Amended text has been included in *bold italics* and deleted text in strikethrough in the following sections:

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Section 5.5 Outline of study procedures:

Table 4 List of study procedures

	EPOCH 001 (PRIMARY VACCINATION)					Epoch 002	
						(BOOSTER VACCINATION)	
Age	2 Months	4 Months	6 Months	7 Months	12 Months	15-18 Months	16-19 Months
Visit	VISIT 1	VISIT 2	Visit 3 †	Visit 4	ESFU	VISIT 5	VISIT 6
					CONTACT		
					(PHONE)		
Time point	Day 0	Month 2	Month 4	Month 5	Month 10	Month 13 -16	Month 14 - 17
Sampling time point				Post-Pri		Pre-Bst	Post-Bst
Pre-vaccination measurement of limb length and circumference of limb(s) at							
site of injection by investigator $^{\delta}$						•	
Investigator sign-off				•	•		•
Analysis of the Epoch 001 #				0	θ		

In Section 5.6.2.11 Baseline measurement of limb circumference after booster vaccination at visit 5

In Section 5.6.2.11 Baseline measurement of limb length and circumference after booster vaccination at visit 5

During Epoch 002, baseline measurement of length of limb(s) and circumference (arms or legs according to where the vaccine was administered) at the level of the injection site should be obtained. For the Penta group, baseline measurement is only required for the limb that will be vaccinated. Clothing should be removed so as not to interfere with the measurement of the length of the limb and the circumference. Upper arm length will be determined from the acromion process of the scapula to the tip of the elbow and thigh length will be determined from the midpoint of the abdomen thigh flexure crease and the proximal end of the patella.

In Section 5.6.2.13 Recording of AEs, SAEs and NOCDs:

— Whether or not the diameter of the swelling involves more than 50% of the limb (baseline measurement of the length of the limb taken by study personnel at the vaccination visit will be provided on the diary cards).

In Section 5.7.3 Laboratory assays

All serology will be determined in GSK Biologicals' laboratories, or in a laboratory designated by GSK, using standardized validated procedures with adequate controls. All serology for primary endpoints will be determined in GSK Biologicals' laboratories, or in a laboratory designated by GSK, using standardized, validated procedures with adequate controls.

	7 TT 1	• • • • • • • • • • • • • • • • • • • •	/ 4.1 1	1 4 • 4• \
Table	/ Humoral	ımmıınıt	v (antihody	determination)

System	Component	Method	Test kit/ Manufacturer	Unit	Cut-off [†]	Laboratory**
Serum	Haemophilus influenzae type b.Polyribosyl Ribitol Phosphate Ab ‡	ELISA	In-house*	μg/mL	0.15	GSK Biologicals§

‡For anti-PRP post-dose 3, the assay is not yet qualified or validated.

Section 6.1 Description of study vaccines

Table 9 Study vaccines

Treatment name	Vaccine/ Product name	Formulation	Presentation	Volume	Number of doses
Infanrix hexa	DTPa- HBV-IPV	DT>=30IU; TT>=40IU; PT=25µg; FHA=25µg; PRN=8µg; HBsAg=10µg; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; Aluminium=700µg Al3+	The DTPa-HBV-IPV component is presented as a turbid white suspension in a pre-filled syringe.	full volume^	3
Pediarix	DTPa- HBV-IPV	DT>=30IU; TT>=40IU; PT=25µg; FHA=25µg; PRN=8µg; HBsAg=10µg; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; Aluminium=700µg Al3+	The DTPa-HBV-IPV component is presented as a turbid white suspension in a pre-filled syringe.	0.5 mL	3
Pentacel	DTaP-IPV (Sanofi Pasteur)	PT=20µg; FHA=20µg; FIM=5µg; PRN=3µg; DT=15Lf; TT=5Lf; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; PRP=10µg TT,TT=24µg; AIPO ₄ =330µg AI3+ PRP=10µG; TT~=25µG	Suspension for injection (0.5-mL dose) supplied as a liquid vaccine component in a single dose vial. The lyophilized Hib component is presented as a white pellet in a separate glass vial. It must be reconstituted with the liquid DTaP-IPV component before use.	0.5 mL*	4

Section 10.9.1 Sequence of analyses

The analyses will be performed *stepwise* in 2 steps:

- 1. The final data analysis of Epoch 001 including all as clean as possible data, up to one month after the third primary vaccine dose, and some partial data from the ESFU contact will be conducted as soon as possible. This analysis will include the final analysis of immunogenicity and the final analysis of solicited symptoms for the primary vaccination course. A partial analysis of Epoch 001 up to one month after the third primary vaccine dose will be conducted. This analysis will include the final analysis of anti-PRP, solicited and unsolicited symptoms on data as clean as possible. This analysis will be displayed on GSK clinical trial registry as soon as possible.
- 2. The final data analysis of Epoch 002 will be conducted subsequently. This analysis will include final analysis of the ESFU from Epoch 001 and the final analysis of immunogenicity and safety from Epoch 002. All these analyses will be presented in a final CSR. The final data analysis of the study covering both the epochs will be conducted at the end of the study. All these analyses will be presented in a final clinical study report.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Protocol Amendment 2 Sponsor Signatory Approval

eTrack study number and

117119 (DTPA-HBV-IPV-135)

Abbreviated Title

IND number

BB-IND 006687

EudraCT number:

2013-004304-19

Date of protocol amendment

Amendment 2 Final Version 02: 17 April 2015

Detailed Title

A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa[™] vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar[®] and Rotarix[™] with a booster dose of GSK Biologicals' Infanrix[®] and Hiberix[™] vaccines at 15-18 months of age.

Sponsor signatory

Narcisa Elena Mesaros

Project level CRDL, DTP/Polio Vaccines

Late Clinical Development, Vaccine Discovery and

icals.

Signature

Date

D. 04. 2015

For internal use only

- ------Checksum-----!Ver.!Created On - - 6a799184c9b15497796cc43497dd0e1b0c61d882 3.0 4/20/2015 3:46:31 PM - -

GlaxoSmithKline Biologicals, SA

Study detailed title

A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' *Infanrix hexa* vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with *Prevnar* and *Rotarix* with a booster dose of GSK Biologicals' *Infanrix* and *Hiberix* vaccines at 15-18 months of age.

Clinical Study Report for Study 117119 (DTPA-HBV-IPV-135)

Development Phase III

IND Number: BB-IND 006687

EUDRACT Number: 2013-004304-19

Name of Investigational Product: GlaxoSmithKline (GSK) Biologicals' Combined Diphtheria-Tetanus-acellular Pertussis (DTaP), Hepatitis B, Poliovirus and *Haemophilus influenzae* type b vaccine (DTPa-HBV-IPV/Hib) (SB217744, *Infanrix hexa*).

Indication Studied: Active immunization against diphtheria, tetanus, pertussis infection caused by all known subtypes, of hepatitis B virus, poliomyelitis, and invasive disease caused by *Haemophilus influenzae* type B (Hib) in infants.

Study initiation date: 16-April-2014

Study completion date: 13-November-2015

Data lock point (Date of

database freeze):

15-March-2018

Date of report: Final: 06-July-2018

Earlier Study Reports

Abridged Interim Report

19-October-2015

Sponsor Signatory: Narcisa Mesaros, MD,

Clinical and Epidemiology R&D Project Leader,

DTP, Polio and Hib containing vaccines -

R&D Centre Belgium, GlaxoSmithKline Biologicals.

This study was performed according to the principles of GCP including the archiving of essential documents.

Based on GSK Biologicals' Study Report INS-BIO-CLIN-1010 v05

©2015-2018 GSK group of companies or its licensor.

SYNOPSIS

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and <i>Haemophilus</i>
	Infanrix hexa vaccine	influenzae type b vaccine
	· ·	

Study No.: 117119 (DTPA-HBV-IPV-135)

Title of the study:

A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' *Infanrix hexa* vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co administered with *Prevnar* and *Rotarix* with a booster dose of GSK Biologicals' *Infanrix* and *Hiberix* vaccines at 15-18 months of age.

Investigator(s) and study centre(s):

Multicenter study conducted in 43 centers in the United States of America (USA).

Principal investigator: Dr Nicola Klein, M.D. at the Kaiser Permanente Oakland, One Kaiser Plaza, Oakland, CA, USA.

Publication (reference): None at the time of this report		
Study period:	Phase:	
Study initiation date: 16-April-2014		
Study completion date: 13-November-2015	Phase III	
Data lock point (Date of database freeze): 15-March-2018		

Indication: Active immunization against diphtheria, tetanus, pertussis infection caused by all known subtypes, of hepatitis B virus, poliomyelitis, and invasive disease caused by *Haemophilus influenzae* type B (Hib) in infants.

Objectives:

Primary: Epoch 001 (Primary vaccination):

• To demonstrate the non-inferiority of *Infanrix hexa* to *Pediarix* co-administered with *ActHIB*, in terms of antibody geometric mean concentrations (GMCs) for pertussis antigens [pertussis toxoid (PT), filamentous haemagglutinin (FHA) and pertactin (PRN)] one month after the third dose of the primary vaccination.

Criteria for non-inferiority:

Non-inferiority in terms of immune response to pertussis antigens was to be demonstrated if, for each of the three antigens, the upper limit (UL) of the 95% confidence interval (CI) on the GMC ratio [Pedia divided by Hexa] was < 1.5.

Secondary: Epoch 001 (Primary vaccination)

- To assess the immune response to *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B*, in terms of seroprotection status, seropositivity status and concentrations or titers of antibodies to D (Diphtheria), T (Tetanus), HBs (Hepatitis B surface antigen), pertussis, poliovirus types 1, 2 and 3 and PRP (Polyribosyl-Ribitol-Phosphate) antigens, one month after the third dose of the primary vaccination.
- To assess the safety and reactogenicity of a 3-dose primary vaccination course of *Infanrix hexa*, of *Pentacel* coadministered with *Engerix-B*, and that of *Pediarix* co-administered with *ActHIB*, in terms of solicited local symptoms.
- To assess the safety and reactogenicity of all study vaccines in terms of solicited general events, unsolicited
 adverse events, new-onset chronic illnesses (NOCIs; referred to as new-onset chronic diseases (NOCDs) in the
 protocol) and serious adverse events.

117119 (DTPA-HBV-IPV-135) Report Final

N	lame of company:	Name of finished	Name of active substance:
G	SlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
((GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and <i>Haemophilus</i>
,		Infanrix hexa vaccine	influenzae type b vaccine

Secondary: Epoch 002 (Booster vaccination)

- To assess the immunogenicity of *Infanrix hexa*, *Pentacel*, *Engerix-B*, *Pediarix* and *ActHIB*, in terms of persistence of the antibodies to D, T, pertussis, HBs, poliovirus types 1, 2 and 3 and PRP antigens, before the booster dose.
- To assess the immune response to *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*, in terms of seroprotection status, seropositivity status and antibody concentrations or titers for D, T, pertussis and PRP antigens, and in terms of booster response for pertussis antigens following *Infanrix* and *Pentacel*, one month after the booster dose.
- To assess the safety and reactogenicity of booster doses of *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*.

Methodology:

- Experimental design: Phase III, open-label, randomized, controlled, multi-centric, single-country study with five parallel groups.
 - Epoch 001: Primary, starting at Visit 1 (Day 0) and ending at safety follow up contact (i.e. six months following the third dose, Month 10);
 - **Epoch 002**: Booster, starting at Visit 5 (Month 13-16) and ending at Visit 6 (Month 14-17).
- Control: active controls.
 - Epoch 001: *Pediarix* + *ActHIB* and *Pentacel* + *Engerix-B*;
 - Epoch 002: *Infanrix* + *ActHIB* and *Pentacel*.

Vaccination schedules:

Epoch 001

- **Hexa Group**: Subjects in this group were to receive three doses of *Infanrix hexa* (lot A, lot B or lot C as per the group allocation) co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age
 - Hexa 1 Group: Subjects were to receive lot A of *Infanrix hexa*;
 - Hexa 2 Group: Subjects were to receive lot B of *Infanrix hexa*;
 - Hexa 3 Group: Subjects were to receive lot C of *Infanrix hexa*.
- **Pedia Group:** Subjects in this group were to receive three doses of *Pediarix* and *ActHIB* co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
- **Penta Group:** Subjects in this group were to receive three doses of *Pentacel* and *Engerix-B** co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
- *Subjects in the Penta Group who received a dose of hepatitis B vaccine from birth up to 30 days prior to study vaccination were not to receive *Engerix-B* at 4 months of age (Visit 2).

Epoch 002

- **Hexa Group:** Subjects were to receive a booster dose of *Infanrix* and *Hiberix* vaccines at 15-18 months of age.
- Pedia Group: Subjects were to receive a booster dose of *Infanrix* and *ActHIB* vaccines at 15-18 months of age.
- **Penta Group:** Subjects were to receive a booster dose of *Pentacel* vaccine at 15-18 months of age.
 - The fourth dose of pneumococcal conjugate vaccine is recommended to be administered at approximately 12-15 months of age. Since the booster dose of the candidate vaccine/active controls were given in this study at 15-18 months of age, the fourth dose of *Prevnar13* was not to be administered as part of the study protocol. Subject's parent(s)/Legally Acceptable Representative(s) (LARs) were to be reminded at Visit 3 and Visit 4 to consult their primary health care provider regarding the fourth dose of *Prevnar13* at 12-15 months for their child.

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and Haemophilus
	Infanrix hexa vaccine	influenzae type b vaccine

- As the analyses were to be performed regardless of the lot of *Infanrix hexa* received, unless otherwise specified, the Hexa 1, Hexa 2 and Hexa 3 groups were pooled together for the analysis and were called the Hexa group.
- Treatment allocation: The subjects were randomized at a [1:1:1]:3:3 ratio to Hexa_1, Hexa_2, Hexa_3, Pedia and Penta groups. This was done at study entry using GSK Biologicals' central randomization system on internet (SBIR).
- Blinding: The study was open-label for both epochs due to the differences in the number of injections and the appearance of the vaccines administered. However, the laboratory in charge of the serology testing was blinded to the treatment, and codes were used to link the subject and study (without any link to the treatment attributed to the subject) to each sample.
- Sampling schedule: Blood samples were drawn from all subjects at the following time points:
 - Post-Pri (Visit 4): One month after the third dose of primary vaccination, a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) was collected.
 - Pre-Bst (Visit 5): Before the administration of the booster dose, a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) was collected.
 - Post-Bst (Visit 6): One month after the booster vaccination, a volume of at least 3.5 mL of whole blood (to provide at least 1.2 mL of serum) was collected.
- Type of study: self-contained.
- Data collection: electronic Case Report Form (eCRF).

Study vaccine, dose, mode of administration, lot no.:

Vaccination schedule /site: See Vaccination schedules for the Hexa group in Epoch 001 and Epoch 002 in Methodology section above. Injections of *Infanrix hexa, Infanrix, Hiberix* and *Prevnar13* were via intramuscular injection in the thigh, with *Rotarix* given orally.

Vaccine composition /dose /lot number: AC21VB448C and AHIBC950C (Infanrix hexa Lot A);

AC21B514A and AHIBC907D (Infanrix hexa Lot B);

AC21B510B and AHIBC954A (Infanrix hexa Lot C); AC14B195A (Infanrix);

AHIBC875A and DEXTA517AZ (*Hiberix*); AROTVA291D and AD05VA833A (*Rotarix*); DLOCA107A (Alternative Lot no. H39264; *Prevnar13*).

Reference vaccine /Comparator, dose and mode of administration, lot no.:

Vaccination schedule /site: See Vaccination schedules for the Pedia and Penta groups in Epoch 001 and Epoch 002 in Methodology section above. Injections of *Pediarix, ActHIB, Pentacel, Engerix-B* and *Prevnar13* were via intramuscular injection in the thigh, with *Rotarix* given orally.

Vaccine composition /dose /lot number: AC21VB448C (*Pediarix*); AHBVC253A (*Engerix-B*); AROTVA291D and AD05VA833A (*Rotarix*);

First Pentacel Lot: Lot no. DLOCA102AY (Alternative Lot no. C4507AA), Lot no. DLOCA102AZ (Alternative Lot no. C4557AA); Second Pentacel Lot: Lot no. DLOCA108AY (Alternative Lot no. C4517BA), Lot no. DLOCA108AZ (Alternative Lot no. C4574AA);

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and Haemophilus
	Infanrix hexa vaccine	influenzae type b vaccine

Third Pentacel Lot: Lot no. DLOCA144AY (Alternative Lot no. C4724AA), Lot no. DLOCA144AZ (Alternative Lot no. C4642AA);

Lot no.: DLOCA106AZ (Alternative Lot no. UH971AA), DLOCA150AZ (Alternative Lot no. UI117AA; only for Epoch 2; *ActHIB*); Lot no.: DLOCA106AY (Alternative Lot no. UH954AB), DLOCA150AY (Alternative Lot no. UI128AA; only for Epoch 2; *ActHIB*);

DLOCA107A (Alternative Lot no. H39264; Prevnar13)

Study Population: Healthy male and female infants, between and including, 6 and 12 weeks of age at the time of the first dose who were free of obvious health problems, born full-term after a gestation period of 37 weeks to less than 42 completed weeks and who had not received vaccination against diphtheria, tetanus, pertussis, *Haemophilus influenzae* type b, rotavirus, pneumococcus, and/or poliovirus; or more than one previous dose of hepatitis B vaccine administered at least 30 days prior to enrolment. Written informed consent was obtained from the parent/guardian of the subject prior to any study-related activity.

Duration of treatment: The intended duration of the study per subject is approximately 14-17 months.

Criteria for evaluations:

Primary endpoint: Epoch 001 (Primary vaccination)

- Immunogenicity with respect to pertussis components of the study vaccines *Infanrix hexa* and *Pediarix*.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination.

Secondary endpoints: Epoch 001 (Primary vaccination)

- Immunogenicity (other parameters) with respect to the pertussis component of the study vaccines *Infanrix hexa*, *Pentacel* and *Pediarix*.
 - Anti-PT, anti-FHA, anti-PRN seropositivity status, one month after the third dose of the primary vaccination.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination (for *Pentacel* only).
- Immunogenicity with respect to the other components of the study vaccines *Infanrix hexa, Pediarix, ActHIB, Pentacel* and *Engerix-B*.
 - Anti-D, anti-T, anti-HBs, anti-poliovirus types 1, 2 and 3 and anti-PRP seroprotection status, anti-PRP antibody concentrations ≥1.0 μg/mL and antibody concentrations/titers, one month after the third dose of the primary vaccination.
- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0 Day 3) after each vaccination (*Infanrix hexa, Pediarix, ActHIB, Pentacel* and *Engerix-B*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0 Day 3) after each vaccination.
- Unsolicited adverse events.
 - Occurrence of unsolicited adverse events (AEs) within 31 days (Day 0 Day 30) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and <i>Haemophilus</i>
	Infanrix hexa vaccine	influenzae type b vaccine

- Specific adverse events.
 - Occurrence of specific adverse events, i.e., new onset chronic illnesses (NOCI; e.g. autoimmune disorders, asthma, type I diabetes and allergies) from Day 0 up to six months post primary vaccination.
- Serious adverse events (SAEs).
 - Occurrence of serious adverse events from Day 0 up to six months post primary vaccination.

Secondary endpoints: Epoch 002 (Booster vaccination)

- Immunogenicity with respect to all study vaccines.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-HBs, anti-PRP and anti-poliovirus 1, 2, 3 seroprotection/ seropositivity status, anti-PRP antibody concentrations ≥1.0 µg/mL and antibody concentrations/ titers before the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccine *Pentacel*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-PRP seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
 - Anti-PRP antibody concentrations ≥1.0 µg/mL one month after the booster dose (Dose 4).
 - Anti-D and anti-T antibody concentrations ≥1.0 IU/mL one month after the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccine *Infanrix*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
 - Anti-D and anti-T antibody concentrations ≥1.0 IU/mL one month after the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccines ActHIB and Hiberix.
 - Anti-PRP seroprotection status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PRP antibody concentrations ≥1.0 µg/mL one month after the booster dose (Dose 4)
- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0 Day 3) after booster vaccination (*Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0 Day 3) after booster vaccination.
- Unsolicited adverse events.
 - Occurrence of unsolicited AEs within 31 days (Day 0 Day 30) after booster vaccination, according to the MedDRA classification.
- Serious adverse events (SAEs).
 - Occurrence of serious adverse events from the booster dose up to one month after the booster vaccination.

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and Haemophilus
	Infanrix hexa vaccine	influenzae type b vaccine

Statistical methods: Final analysis of the Epoch 001

Analysis of demographics

Demographic characteristics (age [weeks], gender, geographical ancestry, height in length [cm], weight [kg] at first dose, Hep B vaccination history, vaccination history of mother with respect to administration of Tdap vaccine during pregnancy) and withdrawal status were summarised by group using descriptive statistics:

- Frequency tables were generated for categorical variables such as center;
- Mean, median and standard error were provided for continuous data such as age.

The distribution of subjects enrolled among the study sites was tabulated as a whole and per group.

Analysis of immunogenicity

The primary analysis was based on the Primary according-to-protocol (ATP) cohort for immunogenicity. An analysis on the Primary Total Vaccinated cohort (TVC) was performed only if, in any vaccine group and at any time point, more than 5% of the vaccinated subjects with immunological data post-dose 3 were excluded from the Primary ATP cohort for immunogenicity.

The following sections describe the analyses that were performed.

Within group assessment

For each group, one month post-dose 3 and for each assay for which a serological result was available:

- Seropositivity and seroprotection rates with exact 95% CIs were calculated.
- GMCs/geometric mean titers (GMTs) with 95% CIs were tabulated.
- For each antigen, antibody concentration or titer distribution one month post-vaccination was tabulated and displayed using reverse cumulative curves (RCCs).
- For anti-PRP post primary vaccinate at Visit 4, seropositivity and seroprotection rates and GMCs were calculated per *Infanrix hexa* lot.

All the above within group analysis for Epoch 001, except the reverse cumulative curves (RCCs) and the presentation per *Infanrix hexa* lot, were also to be performed by gender, by geographical ancestry (the most frequent geographical ancestry versus all other geographical ancestries, namely White Caucasian versus any other geographical ancestry), by Tdap vaccination history of mothers during pregnancy and by Hepatitis B vaccination of the subjects at birth (for anti-HBs antigen).

Between group assessment

At one month post-dose 3,

• The asymptotic standardized 95% CI for the group difference (Pedia group minus Hexa group and Penta group minus Hexa group) in the seroprotection rates was computed for each antigen.

8 17 1	
Antigen	Threshold considered for protection
Anti-D	• 0.1 IU/mL (short term protection)
	• 1.0 IU/mL (long term protection)
Anti-T	• 0.1 IU/mL (short term protection)
	• 1.0 IU/mL (long term protection)
Anti-polio	8 dilution
Anti-PRP	 0.15 μg/mL (short term protection) 1.0 μg/mL (long term protection)
Anti-HBs	• 10 mIU/mL

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and <i>Haemophilus</i>
	Infanrix hexa vaccine	influenzae type b vaccine
	v	·

• The 95% CI for each group GMC/GMT ratio (Pedia group divided by Hexa group and Penta group divided by Hexa group) was computed using an Analysis of Variance (ANOVA) model on the logarithm-transformed concentrations/titers. The ANOVA model was to include the vaccine group as fixed effect and the Tdap vaccination of the mother during pregnancy as continuous regressor leading to an Analysis of Co-variance (ANCOVA) model. For hepatitis B antigen, the hepatitis B vaccine birth dose status was also to be used as regressor leading to an ANCOVA model. The model was to include the data from the 3 groups compared. For analysis purpose, DTP vaccination of the mother during pregnancy and Hepatitis B vaccination at birth were considered as continuous variables. More specifically 2 continuous indicator variables were to be used for Tdap vaccination of mother during pregnancy (an indicator for no Tdap vaccination at birth and an indicator for unknown vaccination at birth) while one indicator of hepatitis B vaccination at birth was used.

Interpretation of analyses

Except for analyses addressing criteria specified in the primary objective, comparative analyses were descriptive/exploratory with the aim to characterise the difference between groups in immunogenicity. These descriptive/exploratory analyses were not to be interpreted for formal conclusions since there was no adjustment for multiplicity of endpoints.

Analysis of safety

The primary analysis was based on the primary Total Vaccinated cohort. If, in any vaccine group and at any time point of the Epoch 001, the percentage of vaccinated subjects excluded from the primary ATP cohort for safety was more than 5%, a second analysis based on the primary ATP cohort for safety was to be performed to complement the primary Total Vaccinated cohort analysis.

- The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) or 31-day (Days 0-30) follow-up period was tabulated after each vaccine dose and overall (for the Epoch 001) with exact 95% CI.
- The percentage of doses followed by at least one local AE (solicited and unsolicited), by at least one general AE (solicited and unsolicited) and by any AE during the 4-day or 31-day follow-up period was tabulated over the primary vaccination period, with exact 95% CI.
- The percentage of subjects/doses with local AEs (solicited and unsolicited) were calculated at each injection site for *Infanrix hexa, Pediarix, ActHIB, Pentacel and Engerix-B* vaccines, as well as overall (all sites considered) during the 4-day follow-up period was tabulated over the primary vaccination period, with exact 95% CI.
- The percentage of subjects/doses reporting each individual solicited local and general AE during the 4-day follow-up period were tabulated for each group as follows:
 - Over the primary doses, the percentage of subjects with the symptom and its exact 95% CI.
 - Over the primary doses, the percentage of doses with the symptom and its exact 95% CI.
 - At each study dose, the percentage of subjects with the symptom and its exact 95% CI.

The exact 95% CIs were calculated assuming independence between doses.

• All computations mentioned above were done for Grade ≥2 (solicited symptoms only) and Grade 3 symptoms, for symptoms considered related to vaccination (general symptoms only), for Grade 3 symptoms considered related to vaccination (general symptoms only) and for symptoms that resulted in a medically-attended visit. The percentage of subjects/doses reporting each individual solicited local symptom (any grade, grade 2, grade 3, medical advice) during the 4-day follow-up period were also to be tabulated at each injection site for *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel and Engerix-B* vaccines with exact 95% CI after each vaccine dose and overall where the same row on the table was used for all vaccines given at the same site across the three study groups (e.g. *Infanrix hexa*, *Pentacel* and *Pediarix* together were in one row and *ActHIB* and *Engerix-B* together were in one row). The percentage of subjects/doses reporting each individual general solicited symptom (any grade, Grade ≥2, Grade 3,

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and <i>Haemophilus</i>
	Infanrix hexa vaccine	influenzae type b vaccine

causally related, Grade 3 causally related, medical advice) during the 4-day follow-up period were also to be tabulated with exact 95% CI. For fever, the analyses were also to be performed by 0.5°C increments.

- The percentage of subjects/doses with concomitant medication, antipyretic medication and prophylactic antipyretic medication during the 4-day and 31-day follow-up period post-vaccination was tabulated after each dose and over the Epoch 001.
- The verbatim reports of unsolicited AEs were reviewed by a Clinical Research and Development Lead (CRDL) and the signs and symptoms were coded according to MedDRA. Every verbatim term was matched with the appropriate Preferred Term. The percentage of subjects/doses with unsolicited AEs occurring within 31 days with exact 95% CI was tabulated by Preferred Term. Similar tabulations were done for Grade 3 unsolicited AEs, for unsolicited AEs considered related to vaccination and for Grade 3 unsolicited AEs considered related to vaccination.
- Subjects who experienced AEs of specific interest (i.e. convulsions, Hypotonic Hyporesponsive Episode) during 31 days with exact 95% CI were tabulated by Preferred Term. Similar tabulations were done for AEs considered related to vaccination. Subjects who experienced AEs of specific interest were also to be described in detail.
- Subjects who experienced AEs of specific interest (i.e. new onset of chronic disease such as autoimmune disorders, asthma, type I diabetes and allergies) from Day 0 up to 6 months after the last primary vaccination were tabulated by Preferred Term.
- Subjects who experienced at least one SAE with onset from Dose 1 up to six months post primary vaccination were tabulated with MedDRA primary preferred term.
 - All analyses of reactogenicity and for unsolicited symptoms were also to be performed by gender and geographical ancestry (the most frequent geographical ancestry versus all other geographical ancestries, namely White Caucasian versus any other geographical ancestry).

Statistical methods: Final analysis of the Epoch 002

Analysis of demographics/baseline characteristics

Demographic characteristics (age [months] at Visit 5, gender, geographical ancestry, Hep B vaccination history, vaccination history of mother with respect to administration of Tdap vaccine during pregnancy) and withdrawal status were summarized by group using descriptive statistics:

- Frequency tables were generated for categorical variables such as race/ethnicity;
- Mean, median and standard error were provided for continuous data such as age.

Analysis of immunogenicity

The primary analysis was based on the booster ATP cohort for immunogenicity. An analysis on the booster Total Vaccinated cohort was to be performed only if, in any vaccine group and at any time point of the Epoch 002, more than 5% of the vaccinated subjects with immunological data were excluded from the booster ATP cohort for immunogenicity.

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and <i>Haemophilus</i>
	Infanrix hexa vaccine	influenzae type b vaccine

The following section describes the analyses that were performed.

Within group assessment

For each group, prior to the booster dose and one month post-booster dose and for each assay, for which a serological result was available:

- Seropositivity and seroprotection rates and, for pertussis, booster response rates were calculated with exact 95% CIs
- GMCs/GMTs with 95% CIs were tabulated.
- For each antigen, antibody concentration or titer distribution before and one month Post-booster (when available) were tabulated and displayed using RCCs.

All the above within group analysis for Epoch 002 except the reverse cumulative curves were also to be performed by gender, by geographical ancestry (the most frequent geographical ancestry versus all other geographical ancestries, namely White Caucasian versus any other geographical ancestry), by Tdap vaccination history of mothers during pregnancy and Hepatitis B vaccination of the subjects at birth (for anti-HBs antigen).

Between group assessment

At pre-booster and at one month post-booster,

• The asymptotic standardized 95% CI for the group difference (Pedia group minus Hexa group and Penta group minus Hexa group) in the seroprotection rates were computed for each antigen.

Antigen	Threshold considered for protection
Anti-D	 0.1 IU/mL (short term protection) 1.0 IU/mL (long term protection)
Anti-T	 0.1 IU/mL (short term protection) 1.0 IU/mL (long term protection)
Anti-polio (Pre-Booster)	8 dilution
Anti-PRP	 0.15 μg/mL (short term protection) 1.0 μg/mL (long term protection)
Anti-HBs (Pre-Booster)	• 10 mIU/mL

• The 95% CI for each group GMC/GMT ratio (Pedia group divided by Hexa group and Penta group divided by Hexa group) were computed using an ANOVA model on the logarithm-transformed concentrations/titers. The ANOVA model was to include the vaccine group as fixed effect and the Tdap vaccination of the mother during pregnancy as regressor leading to an ANCOVA. For hepatitis B antigen, the hepatitis B vaccine birth dose status was also to be used as regressor leading to an ANCOVA model. The model was also to include the data from the 3 groups compared. For analysis purpose, DTP vaccination of the mother during pregnancy and Hepatitis B vaccination at birth were considered as continuous variables. More specifically 2 continuous indicator variables were used for Tdap vaccination of mother during pregnancy (an indicator for no Tdap vaccination at birth and an indicator for unknown vaccination at birth) while one indicator of hepatitis B vaccination at birth was used.

Interpretation of analyses

In Epoch 002, all comparative analyses were descriptive/ exploratory with the aim to characterise the difference between groups in immunogenicity. These descriptive/exploratory analyses were not to be interpreted for formal conclusions since there was no adjustment for multiplicity of endpoints.

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and <i>Haemophilus</i>
	Infanrix hexa vaccine	influenzae type b vaccine

Analysis of safety

The primary analysis for the Epoch 002 was based on the booster Total Vaccinated cohort and was only to look at the booster dose. If, in any vaccine group, the percentage of vaccinated subjects excluded from the booster ATP cohort for safety was more than 5%, a second analysis based on the booster ATP cohort for safety was to be performed to complement the booster Total Vaccinated cohort analysis.

- The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) and 31-day (Days 0-30) follow-up period after the booster dose, were tabulated with exact 95% CI for each group.
- The incidence of local AEs (solicited and unsolicited) was calculated at each injection site as well as overall (all sites considered) for each group during the 4-day (Days 0-3) follow-up period after the booster dose.
- The percentage of subjects reporting each individual solicited local and general AE during the 4-day follow-up period was tabulated with its exact 95% CI for each group.
- All computations mentioned above were to be done for Grade ≥2 (solicited symptoms only) and Grade 3 symptoms, for symptoms considered related to vaccination (general symptoms only), for Grade 3 symptoms considered related to vaccination (general symptoms only) and for symptoms that resulted in a medically-attended visit. The percentage of subjects reporting each individual solicited local symptoms (any grade, Grade ≥2, Grade 3, medical advice) during the 4-day follow-up period were also to be tabulated at each injection site for *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel* vaccines with exact 95% CI after each vaccine dose and overall where vaccination with same vaccine site was considered together (e.g. *Infanrix* and *Pentacel* together were on one row and *ActHIB* and *Hiberix* together were on one row). The percentage of subjects reporting each individual general solicited symptom (any grade, Grade ≥2, Grade 3, causally related, Grade 3 causally related, medical advice) during the 4-day follow-up period was also to be tabulated with exact 95% CI. For fever, analyses were also to be performed by 0.5°C increments.
- The percentage of subjects with concomitant medication, antipyretic medication and prophylactic antipyretic medication during the 4-day and 31-day follow-up period post-vaccination were tabulated for each group.
- The verbatim reports of unsolicited AEs were reviewed by a Clinical Research and Development Lead and the signs and symptoms were coded according to MedDRA. Every verbatim term was matched with the appropriate Preferred Term. The percentage of subjects with unsolicited AEs occurring within 31 days following the booster dose with its exact 95% CI was tabulated by Preferred Term. Similar tabulations were done for Grade 3 unsolicited AEs, for unsolicited AEs considered related to vaccination and for Grade 3 unsolicited AEs considered related to vaccination.

Additionally,

- Any large injection site reaction (defined as a swelling with a diameter > 50 mm, noticeable diffuse swelling or increase in limb circumference of greater than 50 mm) reported within 4 days (Days 0-3) following the booster dose was to be tabulated.
- Subjects who experienced AEs of specific interest (i.e. new onset of chronic disease such as autoimmune disorders, asthma, type I diabetes and allergies) from booster dose up to one month after booster vaccination were tabulated by Preferred Term.

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and <i>Haemophilus</i>
	Infanrix hexa vaccine	influenzae type b vaccine
	•	-

• Subjects who experienced at least one SAE from the booster dose up to one month after were tabulated with MedDRA primary preferred term. The same summary was provided for all SAEs reported after dose 1 up to study end.

All analyses of reactogenicity and for unsolicited symptoms were also to be performed by gender and geographical ancestry (the most frequent geographical ancestry versus all other geographical ancestry, namely White Caucasian versus any other geographical ancestry).

Synopsis Table 1 - Study population (Primary Total vaccinated cohort)

Number of subjects	Hexa group	Pedia group	Penta group
Planned, N	195	195	195
Randomised, N (Total Vaccinated Cohort)	195	194	196
Completed to visit 6 M 14-17, n (%)	161 (82.6)	158 (81.4)	157 (80.1)
Demographics	Hexa group	Pedia group	Penta group
N (Total Vaccinated Cohort)	195	194	196
Females:Males	101:94	80:114	95:101
Mean Age, weeks (SD)	8.5 (1.0)	8.6 (1.1)	8.6 (1.1)
Median Age, weeks (minimum, maximum)	8 (6, 12)	9 (6, 12)	8 (6, 12)
White - Caucasian / European Heritage, n (%)	118 (60.5)	128 (66.0)	115 (58.7)

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine N = total number of subjects

n/% = number/percentage of subjects

SD = standard deviation

Synopsis Table 2 - Ratio of GMCs for anti-PT, anti-FHA and ant-PRN between groups (Pedia group divided by Hexa group), one month post primary vaccination (Primary ATP cohort for immunogenicity)

					(P	Adjusted GMC ratio (Pedia group / Hexa group)				
	Pe	dia group		Hexa group		95% CI				
Antibody	N	Adjusted	N	N Adjusted		LL	UL			
-		GMC		GMC						
anti-PT antibody (IU/mL)	149	47.9	146	43.6	1.10	0.92	1.31			
anti-FHA antibody (IU/mL)	149	122.6	146	107.3	1.14	0.97	1.35			
anti-PRN antibody (IU/mL)	149	46.1	146	58.2	0.79	0.63	0.99			

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Adjusted GMC = geometric mean antibody concentration adjusted for Tdap vaccination of the mother

N = Number of subjects with both pre- and post-primary vaccination results available

95% CI = 95% confidence interval for the adjusted GMC ratio (ANCOVA model: adjustment for Tdap vaccination of mother - pooled variance); LL = lower limit, UL = upper limit

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and <i>Haemophilus</i>
	Infanrix hexa vaccine	influenzae type b vaccine
	v	

Synopsis Table 3 - Number and percentage of subjects with anti-PT, anti-FHA and anti-PRN antibody concentration equal to or above the assay cut-off and geometric mean concentration (GMC), one month post primary vaccination (Primary ATP cohort for immunogenicity)

					≥ ass	ay cut-d	off		GMC			
						95	% CI			95% CI		
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL		
anti-PT antibody	Hexa group	PIII(M5)	146	146	100	97.5	100	43.2	38.1	48.9		
	Pedia group	PIII(M5)	149	148	99.3	96.3	100	48.3	42.7	54.5		
	Penta group	PIII(M5)	149	148	99.3	96.3	100	24.2	21.1	27.7		
anti-FHA antibody	Hexa group	PIII(M5)	146	146	100	97.5	100	106.3	95.0	119.0		
	Pedia group	PIII(M5)	149	149	100	97.6	100	122.7	109.9	137.0		
	Penta group	PIII(M5)	149	149	100	97.6	100	59.9	51.7	69.3		
anti-PRN antibody	Hexa group	PIII(M5)	146	146	100	97.5	100	57.4	49.5	66.6		
	Pedia group	PIII(M5)	149	148	99.3	96.3	100	46.9	39.9	55.3		
	Penta group	PIII(M5)	149	148	99.3	96.3	100	33.0	27.8	39.1		

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Note: The assay cut off is 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

Synopsis Table 4 - Number and percentage of subjects with anti-D and anti-T antibody concentration equal to or above the assay cut-off, 0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC), one month post primary vaccination (Primary ATP cohort for immunogenicity)

				≥a	≥ assay cut-off		1	≥ 0.1 IU/mL			≥ 1.0 IU/mL				GMC			
						95%	6 CI			95%	% CI			95%	6 CI		9	95% CI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-D antibody	Hexa group	PIII(M5)	142	142	100	97.4	100	142	100	97.4	100	112	78.9	71.2	85.3	1.777	1.551	2.036
	Pedia group	PIII(M5)	144	144	100	97.5	100	144	100	97.5	100	105	72.9	64.9	80.0	1.648	1.440	1.886
	Penta	PIII(M5)	149	149	100	97.6	100	149	100	97.6	100	88	59.1	50.7	67.0	1.249	1.095	1.425
	group																	
anti-T antibody	Hexa group	PIII(M5)	146	146	100	97.5	100	146	100	97.5	100	130	89.0	82.8	93.6	2.458	2.195	2.753
	Pedia group	PIII(M5)	149	149	100	97.6	100	149	100	97.6	100	134	89.9	83.9	94.3	2.633	2.338	2.966
	Penta	PIII(M5)	149	149	100	97.6	100	148	99.3	96.3	100	119	79.9	72.5	86.0	2.012	1.768	2.290
	group																	

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Note: The assay cut off is 0.057 IU/mL for anti-D, 0.043 IU/mL for anti-T.

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and Haemophilus
	Infanrix hexa vaccine	influenzae type b vaccine

Synopsis Table 5 - Number and percentage of subjects with anti-Polio 1, 2, and 3 antibody titer equal to or above 8 and geometric mean titer (GMT), one month post primary vaccination (Primary ATP cohort for immunogenicity)

					≥ 8	8 ED50			GMT			
						959	% CI			95% CI		
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL		
anti-Polio 1 antibody	Hexa group	PIII(M5)	137	137	100	97.3	100	546.9	447.7	668.0		
•	Pedia group	PIII(M5)	134	134	100	97.3	100	604.1	495.9	736.0		
	Penta group	PIII(M5)	136	135	99.3	96.0	100	319.5	256.8	397.5		
anti-Polio 2 antibody	Hexa group	PIII(M5)	133	133	100	97.3	100	483.5	394.2	593.0		
	Pedia group	PIII(M5)	131	131	100	97.2	100	567.7	448.8	718.1		
	Penta group	PIII(M5)	134	134	100	97.3	100	283.0	229.4	349.2		
anti-Polio 3 antibody	Hexa group	PIII(M5)	129	129	100	97.2	100	722.2	577.4	903.4		
	Pedia group	PIII(M5)	132	132	100	97.2	100	927.0	740.7	1160.3		
	Penta group	PIII(M5)	126	124	98.4	94.4	99.8	294.6	221.6	391.7		

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium	-	hepatitis B, inactivated polio vaccine and <i>Haemophilus</i>
	Infanrix hexa vaccine	influenzae type b vaccine
	V	· · · · · · · · · · · · · · · · · · ·

Synopsis Table 6 - Number and percentage of subjects with anti-PRP antibody concentration equal to or above the assay cut-off, 0.15 µg/mL and 1.0 µg/mL and geometric mean concentration (GMC), one month post primary vaccination (Primary ATP cohort for immunogenicity)

7111 001101			,	>	≥ assay cut-off				≥ 0.15 µg/mL				> 1 0	≥ 1.0 µg/mL				GMC		
				_	uoou		95% CI				95% CI				95% CI		95% CI			
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL		
anti-PRP – qualified assay	Hexa group	PIII(M5)	149	140	94.0	88.8	97.2	140	94.0	88.8	97.2	83	55.7	47.3	63.8	1.373	1.083	1.740		
accay	Pedia group	PIII(M5)	153	151	98.7	95.4	99.8	151	98.7	95.4	99.8	144	94.1	89.1	97.3	10.327	8.127	13.122		
	Penta group	PIII(M5)	153	151	98.7	95.4	99.8	151	98.7	95.4	99.8	126	82.4	75.4	88.0	6.485	4.922	8.544		
anti-PRP – fully validated assay	Hexa group	PIII(M5)	154		98.7		99.8			90.0		85		47.0	63.2	1.348		1.688		
	Pedia group	PIII(M5)	154	153	99.4	96.4	100	151	98.1	94.4	99.6	145	94.2	89.2	97.3	9.258	7.362	11.642		
	Penta group	PIII(M5)	156	154	98.7	95.4	99.8	154	98.7	95.4	99.8	130	83.3	76.5	88.8	5.717	4.363	7.492		

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Note: Two assays were used for anti-PRP, for the fully validated assay, the assay cut off is 0.066 µg/mL while 0.15 µg/mL was used for the gualified assay.

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and <i>Haemophilus</i>
	Infanrix hexa vaccine	influenzae type b vaccine

Synopsis Table 7 - Number and percentage of subjects with anti-HBs antibody concentration equal to or above 6.2 mlU/mL and 10.0 mlU/mL and geometric mean concentration (GMC), one month post primary vaccination (Primary ATP cohort for immunogenicity)

					≥ 6.2	mIU/mL			≥ 10 n	nIU/mL			GMC			
						959	% CI			959	% CI		95%	% CI		
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL		
anti-HBs	Hexa	PIII(M5)	134	134	100	97.3	100	134	100	97.3	100	2258.8	1910.7	2670.4		
antibody	group															
	Pedia	PIII(M5)	138	138	100	97.4	100	138	100	97.4	100	1886.0	1565.6	2271.9		
	group															
	Penta	PIII(M5)	136	134	98.5	94.8	99.8	133	97.8	93.7	99.5	1053.4	780.2	1422.4		
	group															

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and <i>Haemophilus</i>
	Infanrix hexa vaccine	influenzae type b vaccine
		·

Synopsis Table 8 - Number and percentage of subjects with anti-PT, anti-FHA and anti-PRN antibody concentration equal to or above the assay cut-off and geometric mean concentration (GMC), before and one month post booster vaccination (Booster ATP cohort for immunogenicity)

					≥ assa	y cut-	off	GMC			
						95	% CI			95% CI	
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL	
anti-PT antibody	Hexa	PRE-BST	131	107	81.7	74.0	87.9	5.3	4.6	6.2	
	group										
		POST-BST	138	138	100	97.4	100	71.4	62.6	81.5	
	Pedia group	PRE-BST	132	114	86.4	79.3	91.7	6.5	5.6	7.7	
		POST-BST	136	136	100	97.3	100	87.6	76.6	100.2	
	Penta group	PRE-BST	121	63	52.1	42.8	61.2	3.1	2.6	3.7	
		POST-BST	126	126	100	97.1	100	55.5	47.4	65.1	
anti-FHA antibody	Hexa group	PRE-BST	131	130	99.2	95.8	100	17.1	14.7	19.9	
		POST-BST	138	138	100	97.4	100	186.9	165.1	211.5	
	Pedia group	PRE-BST	132	130	98.5	94.6	99.8	21.8	18.3	26.1	
		POST-BST	136	136	100	97.3	100	250.4	220.4	284.6	
	Penta group	PRE-BST	121	113	93.4	87.4	97.1	8.1	6.6	9.9	
		POST-BST	126	126	100	97.1	100	101.0	86.2	118.3	
anti-PRN antibody	Hexa group	PRE-BST	131	110	84.0	76.5	89.8	6.8	5.5	8.3	
		POST-BST	137	136	99.3	96.0	100	208.0	172.3	251.1	
	Pedia group	PRE-BST	132	104	78.8	70.8	85.4	5.5	4.5	6.6	
		POST-BST	136	136	100	97.3	100	215.6	176.1	263.8	
	Penta group	PRE-BST	120	91	75.8	67.2	83.2	6.0	4.8	7.5	
		POST-BST	125	124	99.2	95.6	100	130.5	105.9	160.9	

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Note: The assay cut off is 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and <i>Haemophilus</i>
	Infanrix hexa vaccine	influenzae type b vaccine

Synopsis Table 9 - Booster response for anti-PT, anti-FHA and anti-PRN antibodies, one month post booster vaccination (Booster ATP cohort for immunogenicity)

					Boos	ter re	sponse
							95% CI
Antibody	Group	Pre-vaccination status	N	n	%	LL	UL
anti-PT antibody (IU/mL)	Hexa group	S-	24	22	91.7	73.0	99.0
,		S+ (<4*cut_off IU/mL)	78	75	96.2	89.2	99.2
		S+ (≥4*cut_off IU/mL)	29	29	100	88.1	100
		Total	131	126	96.2	91.3	
	Pedia group	S-	18	18	100	81.5	100
		S+ (<4*cut_off IU/mL)	86	81		87.0	
		S+ (≥4*cut_off IU/mL)	26	22	84.6	65.1	95.6
		Total	130	121	93.1	87.3	96.8
	Penta group	S-	56	52	92.9	82.7	98.0
		S+ (<4*cut_off IU/mL)	46	45	97.8	88.5	99.9
		S+ (≥4*cut_off IU/mL)	14	14	100	76.8	100
		Total	116	111	95.7	90.2	98.6
anti-FHA antibody (IU/mL)	Hexa group	S-	1	1	100	2.5	100
• , ,		S+ (<4*cut_off IU/mL)	27	27	100	87.2	100
		S+ (≥4*cut_off IU/mL)	1 1 100 27 27 100 103 102 99.0 131 130 99.2 2 2 100 17 17 100	94.7	100		
		Total	131	130	99.2	95.8	100 100
	Pedia group	S-	2	2	100	15.8	100
		S+ (<4*cut_off IU/mL)	17	17	100	80.5	100
		S+ (≥4*cut_off IU/mL)	111	108	97.3	92.3	99.4
		Total	130	127	97.7	93.4	99.5
	Penta group	S-	8	8	100	63.1	
		S+ (<4*cut_off IU/mL)	57	56	98.2	90.6	100
		S+ (≥4*cut_off IU/mL)	51	50	98.0	89.6	100
		Total	116	114	98.3	93.9	99.8
anti-PRN antibody (IU/mL)	Hexa group	S-	21	20	95.2	76.2	99.9
,		S+ (<4*cut_off IU/mL)	54	54	100	93.4	100
		S+ (≥4*cut_off IU/mL)	55	54	98.2	90.3	100
		Total	130	128	98.5	94.6	99.8
	Pedia group	S-	28	27	96.4	81.7	99.9
		S+ (<4*cut_off IU/mL)	55	54	98.2	90.3	
		S+ (≥4*cut_off IU/mL)	47	47	100	92.5	100
		Total	130	128		94.6	
	Penta group	S-	28	26	92.9	76.5	99.1
		S+ (<4*cut_off IU/mL)	40	39	97.5	86.8	99.9
		S+ (≥4*cut_off IU/mL)	47	47		92.5	
		Total	115	112	97.4	92.6	99.5

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

bjects: For subjects with pre-vaccination antibody concentration below the assay cut off, post-vaccination antibody concentration ≥ 4 times the assay cut-off

<4*cut_off IU/mL) subjects: For subjects with pre-vaccination antibody concentration between the assay cut off and below 4 times the assay cut-off, post-vaccination antibody concentration equal or above 4 times the pre-vaccination antibody concentration</p>

S+ (≥4*cut_off IU/mL) subjects: For subjects with pre-vaccination antibody concentration equal or above 4 times the assay cut off,

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine Booster response to PT, FHA and PRN antigens is defined as:

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline Biologicals	product:	Combined diphtheria-tetanus-acellular pertussis,
(GSK), SA, Rixensart, Belgium		hepatitis B, inactivated polio vaccine and <i>Haemophilus</i>
	Infanrix hexa vaccine	influenzae type b vaccine

post-vaccination antibody concentration equal or above 2 times the pre-vaccination antibody concentration

N = number of subjects with pre- and post-vaccination results available

n/% = number/percentage of subjects with booster response

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Note: The assay cut off is 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

Synopsis Table 10 - Number and percentage of subjects with anti-D and anti-T antibody concentration equal to or above the assay cut-off, 0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC), before and one month post booster

vaccination (Booster ATP cohort for immunogenicity)

				≥	assay	cut-	off		≥ 0.1	IU/ml	_		≥ 1.0	IU/m	L		1	
						959	% CI			95%	6 CI			959	% CI		95	% CI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-D antibody	Hexa group	PRE-BST	131	131	100	97.2	100	128	97.7	93.5	99.5	43	32.8	24.9	41.6	0.701	0.597	0.825
	Ŭ .	POST-BST	138	138	100	97.4	100	138	100	97.4	100	138	100	97.4	100	8.334	7.479	9.286
	Pedia group	PRE-BST	132	129	97.7	93.5	99.5	123	93.2	87.5	96.8	48	36.4	28.2	45.2	0.622	0.514	0.753
		POST-BST	136	136	100	97.3	100	136	100	97.3	100	136	100	97.3	100	7.886	6.972	8.920
	Penta group	PRE-BST	121	118	97.5	92.9	99.5	115	95.0	89.5	98.2	51	42.1	33.2	51.5	0.764	0.629	0.928
	Ŭ .	POST-BST	126	126	100	97.1	100	126	100	97.1	100	126	100	97.1	100	8.537	7.524	9.687
anti-T antibody	Hexa group	PRE-BST	131	130	99.2	95.8	100	118	90.1	83.6	94.6	16	12.2	7.1	19.1	0.327	0.281	0.380
		POST-BST	138	138	100	97.4	100	138	100	97.4	100	138	100	97.4	100	9.212	7.863	10.793
	Pedia group	PRE-BST	132	129	97.7	93.5	99.5	123	93.2	87.5	96.8	17	12.9	7.7	19.8	0.402	0.340	0.474
		POST-BST	136	136	100	97.3	100	136	100	97.3	100	133	97.8	93.7	99.5	8.870	7.668	10.261
	Penta group	PRE-BST	121	119	98.3	94.2	99.8	107	88.4	81.3	93.5	19	15.7	9.7	23.4	0.340	0.281	0.410
		POST-BST	126	126	100	97.1	100	125	99.2	95.7	100	125	99.2	95.7	100	6.880	5.905	8.015

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Note: The assay cut off is 0.057 IU/mL for anti-D, 0.043 IU/mL for anti-T.

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline	product:	Combined diphtheria-tetanus-acellular pertussis,
Biologicals (GSK), SA,		hepatitis B, inactivated polio vaccine and
Rixensart, Belgium	Infanrix hexa vaccine	Haemophilus influenzae type b vaccine

Synopsis Table 11 - Number and percentage of subjects with anti-PRP antibody concentration equal to or above 0.066 μg/mL, 0.15 μg/mL and 1.0 μg/mL and geometric mean concentration (GMC), before and one month post booster vaccination (Booster ATP cohort for immunogenicity)

				≥(0.06	6 µg/	mL	≥	≥ 0.15 µg/mL ≥ 1.0 µg/mL			L	GMC					
						95%	6 CI			95%	6 CI			959	% CI		95%	6 CI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-PRP –	Hexa group	PRE-BST	131	118	90.1	83.6	94.6	91	69.5	60.8	77.2	23	17.6	11.5	25.2	0.301	0.242	0.373
fully validated		POST-BST	138	138	100	97.4	100	138	100	97.4	100	136	98.6	94.9	99.8	39.365	31.520	49.164
assay	Pedia group	PRE-BST	132	129	97.7	93.5	99.5	122	92.4	86.5	96.3	71	53.8	44.9	62.5	0.987	0.775	1.256
		POST-BST	139	139	100	97.4	100	139	100	97.4	100	138	99.3	96.1	100	51.140	41.954	62.339
	Penta group	PRE-BST	121	111	91.7	85.3	96.0	94	77.7	69.2	84.8	47	38.8	30.1	48.1	0.614	0.458	0.822
		POST-BST	131	130	99.2	95.8	100	129	98.5	94.6	99.8	128	97.7	93.5	99.5	27.318	21.140	35.302

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Synopsis Table 12 - Number and percentage of subjects with anti-Polio 1, 2 and 3 antibody titers equal to or above 8 and geometric mean titers (GMT), before the booster vaccination (Booster ATP cohort for immunogenicity)

					≥ 8	ED50			GMT	GMT			
						95	% CI		95	5% CI			
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL			
anti-Polio 1 antibody	Hexa group	PRE-BST	128	124	96.9	92.2	99.1	99.5	79.4	124.8			
	Pedia group	PRE-BST	128	121	94.5	89.1	97.8	107.4	83.7	137.9			
	Penta group	PRE-BST	116	100	86.2	78.6	91.9	42.2	32.6	54.6			
anti-Polio 2 antibody	Hexa group	PRE-BST	128	119	93.0	87.1	96.7	94.9	73.2	123.1			
	Pedia group	PRE-BST	128	122	95.3	90.1	98.3	111.9	88.0	142.4			
	Penta group	PRE-BST	117	109	93.2	87.0	97.0	51.2	40.8	64.3			
anti-Polio 3 antibody	Hexa group	PRE-BST	127	123	96.9	92.1	99.1	122.1	95.1	156.9			
	Pedia group	PRE-BST	129	126	97.7	93.4	99.5	160.4	125.8	204.6			
	Penta group	PRE-BST	117	80	68.4	59.1	76.7	28.4	20.6	39.1			

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline	product:	Combined diphtheria-tetanus-acellular pertussis,
Biologicals (GSK), SA,		hepatitis B, inactivated polio vaccine and
Rixensart, Belgium	Infanrix hexa vaccine	Haemophilus influenzae type b vaccine
-		

Synopsis Table 13 - Number and percentage of subjects with anti-HBs antibody concentration equal to or above 6.2 mIU/mL and 10 mIU/mL and geometric mean concentration (GMC), before the booster vaccination (Booster ATP cohort for immunogenicity)

			≥	6.2 m	IU/mL		≥ 10 mIU/mL					GMC			
						95%	CI			95% (CI		95	95% CI	
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL	
anti-HBs antibody	Hexa group	PRE- BST	133	132	99.2	95.9	100	131	98.5	94.7	99.8	328.7	261.5	413.2	
	Pedia group	PRE- BST	131	130	99.2	95.8	100	128	97.7	93.5	99.5	235.8	188.2	295.5	
	Penta group	PRE- BST	121	110	90.9	84.3	95.4	105	86.8	79.4	92.2	149.4	100.5	222.3	

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

Summary:

Immunogenicity results: Primary Vaccination Epoch

- The primary objective to demonstrate the non-inferiority of *Infanrix hexa* to *Pediarix* co-administered with *ActHIB*, in terms of antibody GMCs for pertussis antigens (PT, FHA and PRN) one month after the third dose of the primary vaccination was reached:
 - For PT, FHA and PRN, the upper limit of the 95% CI for the GMC ratio [Pedia group divided by Hexa group] was ≤ 1.5 : For anti-PT antibody -1.31; for anti-FHA antibody -1.35; for anti-PRN antibody -0.99 (Synopsis Table 2).
- Anti-Diphtheria and anti-Tetanus antibody responses: All subjects had anti-D antibody concentrations ≥ 0.1 IU/mL and at least 99.3% of subjects had anti-T antibody concentrations ≥ 0.1 IU/mL, indicating seroprotection against these diseases (Synopsis Table 4).
- Anti-Polio 1, 2, and 3 antibody responses: At least 99.3% of subjects had anti-Polio 1 antibody titer ≥ 8 , all subjects had anti-Polio 2 antibody titer ≥ 8 and at least 98.4% of subjects had anti-Polio 3 antibody titer ≥ 8 (Synopsis Table 5).
- Anti-PRP antibody responses: Short-term seroprotection against Haemophilus influenzae type b disease (anti-PRP antibody concentrations $\geq 0.15~\mu g/mL$) was met by at least 94.8% across groups using the fully validated assay (Synopsis Table 6).
- Anti-HBs antibody responses: Seroprotection against Hepatitis B virus (HBV) disease (anti-HBs ≥ 10 mIU/mL) was reached by at least 97.8% of subjects across the groups (Synopsis Table 7).

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline	product:	Combined diphtheria-tetanus-acellular pertussis,
Biologicals (GSK), SA,		hepatitis B, inactivated polio vaccine and
Rixensart, Belgium	Infanrix hexa vaccine	Haemophilus influenzae type b vaccine
· -		

Immunogenicity results: Booster Vaccination Epoch

- The proportion of subjects with an anti-Pertussis antibody booster response was: For anti-PT antibody: ≥93.1% across groups; for anti-FHA antibody: ≥97.7% across groups; for anti-PRN antibody: ≥97.4% across groups.
- Anti-D and Anti-T immune response: Seroprotection (≥ 0.1 IU/mL) was reached for at least 99.2% of subjects across groups and long-term seroprotection (antibody concentrations ≥1.0 IU/mL) was reached by all subjects for anti-D and for anti-T antibody by between 97.8-100% of subjects (Synopsis Table 10).
- Anti-PRP immune response: Short-term seroprotection (≥ 0.15 μg/mL): Between 98.5-100% of subjects across groups and long-term seroprotection (≥ 1.0 μg/mL) for between 97.7-99.3% of subjects across groups.

Safety results:

Primary Total vaccinated cohort - Safety summary

- Any Symptom: In all three groups (Hexa, Pedia and Penta) over the primary doses, symptoms (solicited and/or unsolicited, local and/or general) were reported for 93.4-96.4% of subjects.
- Solicited local symptoms: Pain was the most frequently reported solicited local symptom reported in 67.9% of subjects in the Hexa group, in 82.0% of subjects in the Pedia group and in 79.8% of subjects in the Penta group.
- Pain was also the most frequently reported Grade 3 solicited local symptom reported in 4.3% of subjects in the Hexa group, 18.0% of subjects in the Pedia group and 11.7% of subjects in the Penta group.
- Solicited *general symptoms:* Irritability / Fussiness was the most frequently reported solicited general symptom in all groups, reported in 87.7% of subjects in the Hexa group, in 96.3% of subjects in the Pedia group and in 94.1% of subjects in the Penta group overall.
 - Irritability was also the most commonly reported grade 3 solicited general symptom, reported for 9.6% of subjects in the Hexa group, 18.5% of subjects in the Pedia group and 16.0% of subjects in the Penta group overall.
- Unsolicited adverse events: At least one unsolicited symptom within the 31-day post-vaccination period after each vaccination was reported for 57.9%, 55.7% and 49.0% of subjects in the Hexa, Pedia and Penta groups, respectively.
 - The most commonly reported unsolicited symptom in the three groups was Upper Respiratory Tract Infection (URTI): Hexa group: 15.4%; Pedia group: 11.9%; Penta group: 13.3%.
 - Grade 3 unsolicited symptoms were reported for 6.7%, 6.2% and 3.6% of subjects in Hexa, Pedia and Penta groups, respectively. The most commonly reported grade 3 unsolicited symptoms were: Hexa group: URTI and Otitis media (1.5%);
 - Pedia group: URTI, Conjunctivitis and Irritability (1.0%); Penta group: URTI (1.0%).
- Adverse events of interest: New Onset of Chronic Illness (NOCI) symptoms were reported for 7 subjects (3.6%) in the Hexa group, 11 subjects (5.7%) in the Pedia group and 10 subjects (5.1%) in the Penta group. The two reported symptoms in the Hexa group were Dermatitis atopic (2.6%) followed by Bronchial hyperreactivity (1.0%). In the Pedia group, the symptom reported by more than one subject was Dermatitis atopic (3.6%). In the Penta group, the symptoms reported by more than one subject were Dermatitis atopic (3.6%) and Asthma (1.0%).

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline	product:	Combined diphtheria-tetanus-acellular pertussis,
Biologicals (GSK), SA,		hepatitis B, inactivated polio vaccine and
Rixensart, Belgium	Infanrix hexa vaccine	Haemophilus influenzae type b vaccine
· -		

• Serious adverse events: Non-fatal SAEs from Dose 1 up to 6 months following priming doses were reported for 7 (3.6%) subjects in the Hexa group and Penta group, and 1 (0.5%) subject in the Pedia group. All SAE were considered recovered/resolved without sequelae at the end of the study except one non-causally related event of Choking in a 47-week-old female in the Hexa group which was considered recovered/resolved with sequelae.

Three SAEs occurring in two subjects were considered causally related to primary vaccination by the investigator: An SAE of Lethargy in an 8-week-old female subject in the Hexa group which recovered/resolved after one day without sequelae; 2 SAEs in the same subject: one "Apparent life-threatening event" and one event of Leukocytosis were observed in a 10-week-old female subject in the Hexa group which recovered/resolved over 1-2 days without sequelae.

- No fatal SAEs were reported during the primary vaccination Epoch of the study.
- Withdrawals due to AEs /SAEs: Two subjects had adverse events leading to premature discontinuation during the primary vaccination period: one Hexa group subject with an SAE of Lethargy reported after the first vaccination; one Penta group subject with a Non-Serious Adverse Event of Seizure reported after the Month 2 dose.

Booster Total vaccinated cohort - Safety summary

- Any Symptom: At least one solicited or unsolicited symptom was reported during the Booster phase for 77.2% of Hexa group subjects, 81.6% of Pedia group subjects and 70.2% of Penta group subjects.
- Solicited local symptoms: Pain was the most frequently reported solicited local symptom reported in 46.8% of subjects in the Hexa group, 51.0% of Pedia group subjects and 39.3% of Penta group subjects.
 - Redness was the most frequently reported Grade 3 solicited local symptom reported in 1.3-5.2% of subjects in the three groups.
- Solicited general symptoms: Irritability / Fussiness was the most frequently reported solicited general symptom in all the groups, reported in 56.2% of Hexa group subjects, in 62.7% of Pedia group subjects and in 50.3% of Penta group subjects.
 - Irritability / Fussiness was also the most commonly reported grade 3 solicited general symptom reported for between 2.0 and 2.7% of subjects across groups.
- Unsolicited adverse events: At least one unsolicited symptom within the 31-day post-vaccination period after the booster vaccination was recorded for 22.2%, 22.2% and 25.5% of subjects in the Hexa, Pedia and Penta groups, respectively.

The most commonly reported unsolicited symptoms were:

Hexa group: Pyrexia (3.0%); Pedia group: Pyrexia, Otitis media and URTI (3.2%); Penta group: URTI (5.0%).

A grade 3 unsolicited symptom was reported for 3.0%, 1.9% and 1.9% of subjects in Hexa, Pedia and Penta groups, respectively. No grade 3 unsolicited symptom was reported by more than one subject in any group.

• Adverse events of interest: NOCI were reported for 4 subjects (2.4%) in the Hexa group, 1 subject (0.6%) in the Pedia group and 1 subject (0.6%) in the Penta group. Only Seasonal allergy symptoms were reported by more than one subject in any group: 3 (1.8%) subjects.

117119 (DTPA-HBV-IPV-135) Report Final

Name of company:	Name of finished	Name of active substance:
GlaxoSmithKline	product:	Combined diphtheria-tetanus-acellular pertussis,
Biologicals (GSK), SA,		hepatitis B, inactivated polio vaccine and
Rixensart, Belgium	Infanrix hexa vaccine	Haemophilus influenzae type b vaccine

- Large injection site reactions up to 4 days (D0-D3) after vaccination: Two subjects (1.3%) in the Hexa group and one subject (0.7%) in the Pedia group had Local Swelling, and Diffuse Swelling was recorded in one subject (0.6%) in the Hexa group.
- Serious adverse events within 31 days post booster: Non-fatal SAEs within 31 days post-booster dose were reported for one (0.6%) subject in the Hexa group (Petechiae), for one (0.6%) subject in the Penta group (Seizure like phenomena), and no subject in the Pedia group. None of the two non-fatal SAEs were considered to be causally-related to vaccination and both were recorded to have an outcome of "recovered/resolved".
- Withdrawals due to AEs /SAEs: No subject was withdrawn due to an AE or SAE during the booster Epoch.
- **SAEs for the full study**: There were no fatal SAEs throughout the study. SAEs were reported for 8 subjects in *the* Hexa group and Penta group, and for one subject in the Pedia group throughout the study.

Conclusion:

- The primary objective of the study was met: One month post-primary vaccination, *Infanrix hexa* was demonstrated to be non-inferior to *Pediarix+ACTHib* in terms of antibody GMCs for the three pertussis antigens (PT, FHA, and PRN).
- One month after the primary vaccination: The immune responses to Infanrix hexa, Pediarix+ACTHib and Pentacel/Engerix-B were similar between the different groups, in terms of seroprotection/seropositivity rates and GMCs.
 - The lowest anti-PRP GMCs were observed after *Infanrix hexa* vaccination as compared to *Pediarix+ACTHib* and *Pentacel+Engerix-B*.
- One month after the booster vaccination: The immune responses to Infanrix+Hiberix (booster vaccines used after Infanrix hexa priming), Infanrix+ActHIB (booster vaccines used after Pediarix+ActHIB priming) and Pentacel were similar between the different groups, in terms of seroprotection/seropositivity rates and GMCs.
 - Similar Anti-PRP long-term protection antibody levels were observed ($\geq 1.0 \,\mu g/mL$) between *Infanrix+Hiberix*, *Infanrix+ActHIB* and *Pentacel* after booster vaccination.
- Safety, reactogenicity: Clinically acceptable safety and reactogenicity profile in the different vaccination groups, aligned with the very well-known profiles of the study vaccines.

References: None.

Date of report: Final: 06-July-2018

TABLE OF CONTENTS

	PAG
SYNOPSIS	
LIST OF ABBREVIATIONS	5
GLOSSARY OF TERMS	5
TRADEMARKS	5
1. ETHICS	6
1.1. Institutional Review Board (IRB)	6
1.2. Ethical conduct of the study	6
1.3. Subject information and consent	6
2. INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE	6
3. INTRODUCTION	6
3.1. Rationale for the study	6
4. STUDY OBJECTIVES	6
4.1. Primary objective	6
4.1.1. Epoch 001 (Primary vaccination)	6
4.2. Secondary objectives	(
4.2.1. Epoch 001 (Primary vaccination)	(
4.2.2. Epoch 002 (Booster vaccination)	(
5. INVESTIGATIONAL PLAN	(
5.1. Study design	(
5.1.1. Overview	(
5.1.2. Overall study design – Description	(
5.1.3. Discussion of study design	(
5.1.3.1. Design of Epoch 001 (primary vaccination):	(
5.1.3.2. Design of Epoch 002 (booster vaccination):	(
5.2. Study procedures	
5.3. Selection of study population	
5.3.1. Number of subjects/centers	•
5.3.2. Inclusion criteria for enrolment	•
5.3.3. Exclusion criteria	
5.3.4. Withdrawal criteria	•
5.3.4.1. Subject completion	
5.3.4.2. Subject withdrawal	
5.4. Composition and administration of vaccine(s)	
5.4.1. Description of vaccines	
5.4.2. Dosage and administration of study vaccines	8
5.4.3. Treatment allocation and randomisation	8
5.4.3.1. Subject identification	
5.4.3.2. Randomization of treatment	
5.5. Blinding	
5.6. Prior and concomitant medication /vaccinations	
5.6.1. Recording of concomitant medications/products and	
concomitant vaccination	

5.6.2. Concomitant medications/products/vaccines that may lead to	701111110
the elimination of a subject from ATP analyses	85
5.7. Intercurrent medical conditions that may lead to elimination of a	86
subject from ATP analyses	86
5.8. Assessment of immunogenicity variables	86
5.8.1. Biological samples	
5.8.2. Laboratory assays	86
5.8.3. Biological samples evaluation	88
5.8.3.1. Immunological read-outs	88
5.8.4. Immunological correlates of protection	88
5.9. Assessment of safety variables	89
5.9.1. Safety definitions	89
5.9.1.1. Definition of an adverse event	89
5.9.1.2. Definition of a serious adverse event	90
5.9.2. Solicited adverse events	91
5.9.2.1. Solicited local (injection-site) adverse events	91
5.9.2.2. Solicited general adverse events	92
5.9.3. Clinical laboratory parameters and other abnormal	
assessments qualifying as adverse events or serious adverse events	92
5.9.4. Adverse events of specific interest	93
5.9.5. Detecting and recording adverse events and serious	
adverse events	93
5.9.5.1. Time period for detecting and recording adverse	
events and serious adverse events	93
5.9.6. Post-Study adverse events and serious adverse events	95
5.9.7. Evaluation of adverse events and serious adverse events	95
5.9.7.1. Active questioning to detect adverse events and	
serious adverse events	95
5.9.7.2. Assessment of adverse events	96
5.9.7.3. Assessment of outcomes	99
5.9.7.4. Medically attended visits	99
5.9.8. Follow-up of adverse events and serious adverse events	99
5.9.8.1. Follow-up during the study	99
5.9.8.2. Follow-up after the subject was discharged from the	
study	100
5.10. Statistical methods	100
5.10.1. Primary endpoint	100
5.10.1.1. Epoch 001 (Primary vaccination)	100
5.10.2. Secondary endpoints	101
5.10.2.1. Epoch 001 (Primary vaccination)	101
5.10.2.2. Epoch 002 (Booster vaccination)	101
5.10.3. Determination of sample size	103
5.10.3.1. Control on type I error	103
5.10.3.2. References for sample size	103
5.10.3.3. Power computation	103
5.10.4. Study cohorts /data sets analyzed	104
5.10.4.1. Primary Total vaccinated cohort	104

	447440 (DTDA LID) (ID) (405)
	117119 (DTPA-HBV-IPV-135) Report Final
5.10.4.2. Primary ATP cohort for analysis of sa	•
5.10.4.3. Primary ATP cohort for analysis of im	J
5.10.4.4. Booster Total vaccinated cohort	
5.10.4.5. Booster ATP cohort for analysis of sa	
5.10.4.6. Booster ATP cohort for analysis of im	······································
5.10.5. Derived and transformed data	
5.10.5.1. Demography	
5.10.5.2. Immunogenicity	
5.10.5.3. Safety/reactogenicity:	
5.10.6. Final analysis of the Epoch 001	
5.10.6.1. Analysis of demographics	
5.10.6.2. Analysis of immunogenicity	
5.10.6.3. Analysis of safety	
5.10.7. Final analysis of the Epoch 002	
5.10.7.1. Analysis of demographics/baseline c	
5.10.7.2. Analysis of immunogenicity	
5.10.7.3. Analysis of safety	
5.10.8. Sequence of analyses	
5.10.9. Interim analysis	
5.11. Data quality assurance at study level	
5.12. Changes in the conduct of the study or planned	
5.12.1. Protocol amendments	
5.12.1.1. Protocol Amendment 1	116
5.12.1.2. Protocol Amendment 2	117
5.12.2. Other changes	
5.12.2.1. Changes in the Statistical Analysis P	lan (SAP) from
the protocol	118
6. STUDY POPULATION RESULTS	119
6.1. Study dates	
6.2. Subject disposition	
6.3. Important Protocol deviations at subject level	
6.3.1. Protocol Deviations leading to elimination from	
analyses	
6.3.2. Protocol Deviations not leading to elimination	
analyses	
6.4. Demographic characteristics and other baseline c	
7. IMMUNOGENICITY RESULTS	
7.1. Primary Vaccination Epoch	
7.1.1. Non-inferiority of Infanrix hexa to Pediarix co	
with ActHIB - Immunogenicity of study vac	
antigens (PT, FHA and PRN)	
7.1.2. Immune response to the Primary vaccination	
7.1.2.1. Anti-Pertussis (PT, FHA, PRN) antibod	•
7.1.2.2. Anti-Diphtheria (D) and anti-Tetanus (A	·
responses	
7.1.2.3. Anti-Polio 1, 2, and 3 antibody respons	
7.1.2.4. Anti-PRP antibody responses	
7.1.2.5. Anti-HBs antibody responses	133

117119 (DTPA-HBV	
	eport Final
7.1.3. Primary Total Vaccinated cohort analysis	
7.2. Booster Vaccination Epoch	135
7.2.1. Immune response to the Booster vaccinations	135
7.2.1.1. Anti-Pertussis (PT, FHA, PRN) antibody persistence	
and booster response	135
7.2.1.2. Booster responses for anti-PT, anti-FHA, and anti-	
PRN antibodies	136
7.2.1.3. Anti-D and anti-T antibody persistence and booster	
response	138
7.2.1.4. Anti-PRP antibody persistence and booster response	
7.2.1.5. Anti-Polio antibody persistence	
7.2.1.6. Anti-HBs antibody persistence	142
7.2.2. Booster Total Vaccinated cohort analysis	
7.3. Immunogenicity summary	
7.3.1. Primary Vaccination Epoch	
7.3.2. Booster Vaccination Epoch	
8. SAFETY RESULTS	145
8.1. Primary Total vaccinated cohort analysis	
8.1.1. Primary vaccination doses received	145
8.1.2. Symptom eCRF screen compliance	
8.1.3. Overall incidence of adverse events	
8.1.4. Solicited local adverse events	
8.1.5. Solicited general adverse events	160
8.1.6. Unsolicited adverse events	
8.1.7. According-to-protocol cohort analysis	
8.1.8. Serious adverse events	
8.1.8.1. Fatal events	
8.1.8.2. Non-fatal events	175
8.1.9. Adverse events leading to premature discontinuation of	
study vaccine and/or study	
8.1.10. Other significant adverse events	177
8.1.10.1. New Onset of Chronic Illness (NOCI)	177
8.1.10.2. Hypotonic-Hyporesponsive Episode (HHE) and	
Convulsion	177
8.1.11. Concomitant medications /vaccinations	
8.1.12. Clinical laboratory evaluations	
8.1.13. Pregnancy	180
8.1.14. Important safety information received after the data lock	
point (database freeze date)	180
8.1.15. Primary Total vaccinated cohort - Safety summary	180
8.2. Booster Total vaccinated cohort analysis	181
8.2.1. Booster vaccination doses received	
8.2.2. Symptom eCRF screen compliance	182
8.2.3. Overall incidence of adverse events	
8.2.4. Solicited local adverse events	
8.2.5. Solicited general adverse events	
8.2.6. Unsolicited adverse events	
8.2.7. According-to-protocol cohort analysis	195

117119 (DTPA-HB)	/-IPV-135,
R	eport Fina
8.2.8. Serious adverse events	195
8.2.8.1. Fatal events	195
8.2.8.2. Non-fatal events	195
8.2.8.3. SAEs for the full study	195
8.2.9. Adverse events leading to premature discontinuation of	
study vaccine and/or study	
8.2.10. Other significant adverse events	
8.2.10.1. New Onset of Chronic Illness (NOCI)	196
8.2.10.2. Hypotonic-Hyporesponsive Episode and Convulsion	
8.2.11. Concomitant medications /vaccinations	
8.2.12. Clinical laboratory evaluations	
8.2.13. Pregnancy	198
8.2.14. Important safety information received after the data lock	
point (database freeze date)	
8.2.15. Booster Total vaccinated cohort - Safety summary	
9. OVERALL CONCLUSIONS	199
10. REFERENCES	200
11. STUDY REPORT AUTHORS /CONTRIBUTING AUTHORS	202
12. SERIOUS ADVERSE EVENTS / OTHER SIGNIFICANT ADVERSE	
EVENTS / PREGNANCY	203
12.1. SAE Listing(s)	203
12.2. Clinical narratives for SAEs	
13. POST-TEXT TABLES AND FIGURES	228
MODULAR APPENDICES	

LIST OF TABLES

	PAGE
Table 1 Study groups and epochs foreseen in the study	66
Table 2 Study groups and treatment foreseen in the study	66
Table 3 Blinding of study epochs	68
Table 4 List of study procedures	70
Table 5 Intervals between study visits	73
Table 6 Study vaccines	78
Table 7 Dosage and administration	81
Table 8 Biological samples	86
Table 9 Humoral Immunity (Antibody determination)	87
Table 10 Immunological read-outs	88
Table 11 Solicited local adverse events	91
Table 12 Solicited general adverse events	92
Table 13 Reporting periods for adverse events and serious	
adverse events	94
Table 14 Intensity scales for solicited symptoms in	
infants/toddlers	96
Table 15 Standard deviation for log10 transformed concentration	
post vaccination	103
Table 16 Power for pertussis NI post-Dose 3	104
Table 17 Number of subjects vaccinated, completed and	
withdrawn at visit 6 (Month 14-17) with reason for withdrawal	
(Primary Total vaccinated cohort)	120
Table 18 Number of subjects enrolled into the study as well as	
number excluded from Primary ATP analyses with reasons for	
exclusion	122
Table 19 Number of subjects who received a booster dose as well	
as number excluded from Booster ATP analyses with reasons for	
exclusion	123
Table 20 Summary of demographic characteristics (Primary ATP	
cohort for immunogenicity)	125
Table 21 Summary of demographic characteristics (Booster ATP	
cohort for immunogenicity)	126
Table 22 Ratio of GMCs for anti-PT, anti-FHA and anti-PRN	
between groups (Pedia group divided by Hexa group), one month	
post primary vaccination (Primary ATP cohort for immunogenicity)	128
Table 23 Number and percentage of subjects with anti-PT, anti-	
FHA and anti PRN antibody concentration equal to or above the	
assay cut-off and geometric mean concentration (GMC), one	
month post primary vaccination (Primary ATP cohort for	
immunogenicity)	129

Table 24 Number and percentage of subjects with anti-D and anti-T antibody concentration equal to or above the assay cut-off, 0.1	
IU/mL and 1.0 IU/mL and geometric mean concentration (GMC), one month post primary vaccination (Primary ATP cohort for	
immunogenicity)	130
Table 25 Number and percentage of subjects with anti-Polio 1, 2,	130
and 3 antibody titer equal to or above 8 and geometric mean titer	
(GMT), one month post primary vaccination (Primary ATP cohort	131
for immunogenicity)	131
Table 26 Number and percentage of subjects with anti-PRP	
antibody concentration equal to or above the assay cut-off, 0.15	
μg/mL and 1.0 μg/mL and geometric mean concentration (GMC),	
one month post primary vaccination (Primary ATP cohort for	400
immunogenicity)	132
Table 27 Number and percentage of subjects with anti-HBs	
antibody concentration equal to or above 6.2 mlU/mL and 10.0	
mIU/mL and geometric mean concentration (GMC), one month	400
post primary vaccination (Primary ATP cohort for immunogenicity)	133
Table 28 Number and percentage of subjects with anti-HBs	
antibody concentration equal to or above 6.2 mlU/mL and 10.0	
mIU/mL and geometric mean concentration (GMC), one month	
post primary vaccination – by Hepatitis B vaccination at birth	
(Primary ATP cohort for immunogenicity)	134
Table 29 Number and percentage of subjects with anti-PT, anti-	
FHA and anti PRN antibody concentration equal to or above the	
assay cut-off and geometric mean concentration (GMC), before	
and one month post booster vaccination (Booster ATP cohort for	
immunogenicity)	136
Table 30 Booster response for anti-PT, anti-FHA and anti-PRN	
antibodies, one month post booster vaccination (Booster ATP	
cohort for immunogenicity)	137
Table 31 Number and percentage of subjects with anti-D and anti-T	
antibody concentration equal to or above the assay cut-off, 0.1	
IU/mL and 1.0 IU/mL and geometric mean concentration (GMC),	
before and one month post booster vaccination (Booster ATP	
cohort for immunogenicity)	139
Table 32 Number and percentage of subjects with anti-PRP	
antibody concentration equal to or above 0.066 μg/mL, 0.15 μg/mL	
and 1.0 µg/mL and geometric mean concentration (GMC), before	
and one month post booster vaccination (Booster ATP cohort for	
immunogenicity)	141
Table 33 Number and percentage of subjects with anti-Polio 1, 2	
and 3 antibody titers equal to or above 8 and geometric mean	
titers (GMT), before the booster vaccination (Booster ATP cohort	
for immunogenicity)	142

Table 34 Number and percentage of subjects with anti-HBs	toport i ilia
antibody concentration equal to or above 6.2 mlU/mL and 10	
mIU/mL and geometric mean concentration (GMC), before the	
	143
booster vaccination (Booster ATP cohort for immunogenicity)	143
Table 35 Number and percentage of subjects who received	4.40
priming doses by vaccine (Primary Total vaccinated cohort)	146
Table 36 Compliance in returning symptom sheets for priming	4.47
doses (Primary Total vaccinated cohort)	147
Table 37 Incidence and nature of symptoms (solicited and	
unsolicited) reported during the 4-day (Days 0-3) post-vaccination	
period following each priming dose and overall (Primary Total	4.40
vaccinated cohort)	149
Table 38 Incidence and nature of grade 3 symptoms (solicited and	
unsolicited) reported during the 4-day (Days 0-3) post-vaccination	
period following each priming dose and overall (Primary Total	4=0
vaccinated cohort)	150
Table 39 Incidence of local symptoms (solicited and unsolicited)	
reported for Infanrix hexa, Pediarix, ActHIB, Pentacel and Engerix-	
B vaccines during the 4-day (Days 0-3) post-vaccination period	
following each priming dose and overall (Primary Total vaccinated	
cohort)	151
Table 40 Incidence of grade 3 local symptoms (solicited and	
unsolicited) reported for Infanrix hexa, Pediarix, ActHIB, Pentacel	
and Engerix-B vaccines during the 4-day (Days 0-3) post-	
vaccination period following each priming dose and overall	
(Primary Total vaccinated cohort)	152
Table 41 Incidence of solicited local symptoms reported during	
the 4-day (Days 0-3) post-vaccination period following each	
priming dose and overall (Primary Total vaccinated cohort)	154
Table 42 Incidence of solicited general symptoms reported during	
the 4-day (Days 0-3) post-vaccination period following each	
priming dose and overall (Primary Total vaccinated cohort)	161
Table 43 Percentage of subjects reporting the occurrence of	
unsolicited symptoms classified by MedDRA Primary System	
Organ Class and Preferred Term within the 31-day (Days 0-30)	
post-vaccination period following priming doses (Primary Total	
vaccinated cohort)	168
Table 44 Percentage of subjects reporting the occurrence of grade	
3 unsolicited symptoms classified by MedDRA Primary System	
Organ Class and Preferred Term within the 31-day (Days 0-30)	
post-vaccination period following priming doses (Primary Total	
vaccinated cohort)	173
Table 45 Number (%) of subjects with serious adverse events	
(SAE) from Dose 1 up to 6 months following priming doses	
(Primary Total vaccinated cohort)	176
Table 46 Number % of subjects with adverse events of New Onset	
of Chronic Illness (NOCI) from Dose 1 up to 6 months following	
priming doses (Primary Total vaccinated cohort)	178

	toport i ilia
Table 47 Number and percentage of subjects with concomitant	
medication during the 4-day (Days 0-3) post-vaccination period	
following each priming dose and overall (Primary Total vaccinated	
cohort)	. 179
Table 48 Number and percentage of subjects who received the	
study vaccine dose by vaccine (Booster Total vaccinated cohort)	. 182
Table 49 Compliance in returning symptom sheets for the booster	
dose (Booster Total vaccinated cohort)	. 182
Table 50 Incidence and nature of symptoms (solicited and	
unsolicited) reported during the 4-day (Days 0-3) post-vaccination	
period following the booster dose (Booster Total vaccinated	
cohort)	. 184
Table 51 Incidence of local symptoms (solicited and unsolicited)	
reported for Infanrix, Hiberix, ActHIB and Pentacel vaccines during	
the 4-day (Days 0-3) post-vaccination period following the booster	
dose (Booster Total vaccinated cohort)	. 184
Table 52 Incidence and nature of grade 3 symptoms (solicited and	
unsolicited) reported during the 4-day (Days 0-3) post-vaccination	
period following the booster dose (Booster Total vaccinated	
cohort)	. 185
Table 53 Incidence of grade 3 local symptoms (solicited and	
unsolicited) reported for Infanrix, Hiberix, ActHIB and Pentacel	
vaccines during the 4-day (Days 0-3) post-vaccination period	
following the booster dose (Booster Total vaccinated cohort)	185
Table 54 Incidence of solicited local symptoms reported during	
the 4-day (Days 0-3) post-vaccination period following the booster	
dose (Booster Total vaccinated cohort)	187
Table 55 Incidence of solicited general symptoms reported during	
the 4-day (Days 0-3) post-vaccination period following the booster	
dose (Booster Total vaccinated cohort)	189
Table 56 Percentage of subjects reporting the occurrence of	
unsolicited symptoms classified by MedDRA Primary System	
Organ Class and Preferred Term within the 31-day (Days 0-30)	
post-vaccination period following the booster dose (Booster Total	
vaccinated cohort)	191
Table 57 Percentage of subjects reporting the occurrence of grade	
3 unsolicited symptoms classified by MedDRA Primary System	
Organ Class and Preferred Term within the 31-day (Days 0-30)	
post-vaccination period following the booster dose (Booster Total	
vaccinated cohort)	194
Table 58 Number (%) of subjects reporting the occurrence of	104
serious adverse event (SAE) within the 31-day (Days 0-30) post-	
vaccination period following the booster dose (Booster Total	
vaccinated cohort)	196
Table 59 Number and percentage of subjects starting a	100
concomitant medication during the 4-day (Days 0-3) post-	
vaccination period (Booster Total vaccinated cohort)	. 197
vaccination delica iduatel i dial vaccillatea collotti	. 101

LIST OF POST-TEXT TABLES DEMOGRAPHY

	PAGE
Table 6.1 Number of subjects by center (Primary Total vaccinated	
cohort)	229
Table 6.2 Number of subjects at each visit and list of withdrawn	
subjects (Primary Total vaccinated cohort)	230
Table 6.3 Summary of demographic characteristics (Primary Total	
vaccinated cohort)	233
Table 6.4 Summary of demographic characteristics (Booster Total	
vaccinated cohort)	234
Table 6.5 Deviations from specifications for age and intervals	
between study visits (Primary Total vaccinated cohort)	235
Table 6.6 Deviations from specifications for age and intervals	
between study visits (Booster Total vaccinated cohort)	236
Table 6.7 Summary of demographic characteristics (Primary ATP	
cohort for safety)	237
Table 6.8 Summary of demographic characteristics (Booster ATP	
cohort for safety)	238

LIST OF POST-TEXT TABLES IMMUNOGENICITY

	PAGE
Table 7.1 Number and percentage of subjects with anti-PT, anti-FHA and anti-PRN antibody concentration equal to or above the assay cut-off and geometric mean concentration (GMC), one	
month post primary vaccination - by gender (Primary ATP cohort	
for immunogenicity)	240
Table 7.2 Number and percentage of subjects with anti-PT, anti-	
FHA and anti-PRN antibody concentration equal to or above the	
assay cut-off and geometric mean concentration (GMC), one month post primary vaccination – by geographical ancestry	
(Primary ATP cohort for immunogenicity)	241
Table 7.3 Number and percentage of subjects with anti-PT, anti-	241
FHA and anti-PRN antibody concentration equal to or above the	
assay cut-off and geometric mean concentration (GMC), one	
month post primary vaccination – by Tdap vaccination of mother	
(Primary ATP cohort for immunogenicity)	242
Table 7.4 Number and percentage of subjects with anti-D and anti-	
T antibody concentration equal to or above the assay cut-off, 0.1	
IU/mL and 1.0 IU/mL and geometric mean concentration (GMC),	
one month post primary vaccination - by gender (Primary ATP	
cohort for immunogenicity)	243
Table 7.5 Number and percentage of subjects with anti-D and anti-	
T antibody concentration equal to or above the assay cut-off, 0.1	
IU/mL and 1.0 IU/mL and geometric mean concentration (GMC),	
one month post primary vaccination – by geographical ancestry	
(Primary ATP cohort for immunogenicity)	244
Table 7.6 Number and percentage of subjects with anti-D and anti-	
T antibody concentration equal to or above the assay cut-off, 0.1	
IU/mL and 1.0 IU/mL and geometric mean concentration (GMC),	
one month post primary vaccination – by Tdap vaccination of	
mother (Primary ATP cohort for immunogenicity)	245
Table 7.7 Number and percentage of subjects with anti-Polio 1, 2,	
and 3 antibody titer equal to or above 8 and geometric mean titer	
(GMT), one month post primary vaccination - by gender (Primary	0.40
ATP cohort for immunogenicity)	246
Table 7.8 Number and percentage of subjects with anti-Polio 1, 2,	
and 3 antibody titer equal to or above 8 and geometric mean titer	
(GMT), one month post primary vaccination – by geographical	247
ancestry (Primary ATP cohort for immunogenicity)	241
Table 7.9 Number and percentage of subjects with anti-Polio 1, 2, and 3 antibody titer equal to or above 8 and geometric mean titer	
(GMT), one month post primary vaccination – by Tdap vaccination	
of mother (Primary ATP cohort for immunogenicity)	248
or motion (it initially Art. Conton for initiallogenicity)	270

Table 7.10 Number and percentage of subjects with anti-PRP	
antibody concentration equal to or above the assay cut-off, 0.15	
μg/mL and 1.0 μg/mL and geometric mean concentration (GMC),	
one month post primary vaccination – by study lot (Primary ATP	
cohort for immunogenicity)	249
Table 7.11 Number and percentage of subjects with anti-PRP	
antibody concentration equal to or above the assay cut-off, 0.15	
μg/mL and 1.0 μg/mL and geometric mean concentration (GMC),	
one month post primary vaccination – by gender (Primary ATP	
cohort for immunogenicity)	250
Table 7.12 Number and percentage of subjects with anti-PRP	200
antibody concentration equal to or above the assay cut-off, 0.15	
μg/mL and 1.0 μg/mL and geometric mean concentration (GMC),	
one month post primary vaccination – by geographical ancestry	
(Primary ATP cohort for immunogenicity)	251
Table 7.13 Number and percentage of subjects with anti-PRP	201
antibody concentration equal to or above the assay cut-off, 0.15	
μg/mL and 1.0 μg/mL and geometric mean concentration (GMC),	
one month post primary vaccination – by Tdap vaccination of	
mother (Primary ATP cohort for immunogenicity)	252
Table 7.14 Number and percentage of subjects with anti-HBs	232
antibody concentration equal to or above 6.2 mlU/mL and 10.0	
mIU/mL and geometric mean concentration (GMC), one month	
post primary vaccination - by gender (Primary ATP cohort for	
immunogenicity)	253
Table 7.15 Number and percentage of subjects with anti-HBs	200
antibody concentration equal to or above 6.2 mlU/mL and 10.0	
mIU/mL and geometric mean concentration (GMC), one month	
post primary vaccination – by geographical ancestry (Primary ATP	
cohort for immunogenicity)	253
Table 7.16 Number and percentage of subjects with anti-HBs	200
antibody concentration equal to or above 6.2 mlU/mL and 10.0	
mIU/mL and geometric mean concentration (GMC), one month	
post primary vaccination – by Tdap vaccination of mother	
(Primary ATP cohort for immunogenicity)	254
Table 7.17 Number and percentage of subjects with anti-HBs	207
antibody concentration equal to or above 6.2 mlU/mL and 10.0	
mIU/mL and geometric mean concentration (GMC), one month	
post primary vaccination – by Hepatitis B vaccination of subject	
(Primary ATP cohort for immunogenicity)	255
Table 7.18 Ratio of GMCs/GMTs for antibody concentrations/titers	200
between groups (Pedia group divided by Hexa group), one month post primary vaccination (Primary ATP cohort for immunogenicity)	267
Table 7.19 Ratio of GMCs/GMTs for antibody concentrations/titers	201
between groups (Penta group divided by Hexa group), one month	267
post primary vaccination (Primary ATP cohort for immunogenicity)	201

·	toport i ilia
Table 7.20 Ratio of GMC for anti-HBs antibody concentrations	
between groups (Pedia group divided by Hexa group), one month	
post primary vaccination (Primary ATP cohort for immunogenicity)	268
Table 7.21 Ratio of GMC for anti-HBs antibody concentrations	
between groups (Penta group divided by Hexa group), one month	
post primary vaccination (Primary ATP cohort for immunogenicity)	268
Table 7.22 Difference between groups (Pedia group minus Hexa	
group) in percentage of subjects with antibody concentration/titer	
equal to or above the proposed cut-off, one month post primary	
vaccination (Primary ATP cohort for immunogenicity)	269
Table 7.23 Difference between groups (Penta group minus Hexa	
group) in percentage of subjects with antibody concentration/titer	
equal to or above the proposed cut-off, one month post primary	070
vaccination (Primary ATP cohort for immunogenicity)	270
Table 7.24 Number and percentage of subjects with anti-PT, anti-	
FHA and anti-PRN antibody concentration equal to or above the	
assay cut-off and geometric mean concentration (GMC), before	
and one month post booster vaccination - by gender (Booster ATP	074
cohort for immunogenicity)	271
Table 7.25 Number and percentage of subjects with anti-PT, anti-	
FHA and anti-PRN antibody concentration equal to or above the	
assay cut-off and geometric mean concentration (GMC), before	
and one month post booster vaccination – by geographical	272
ancestry (Booster ATP cohort for immunogenicity)	212
Table 7.26 Number and percentage of subjects with anti-PT, anti-FHA and anti-PRN antibody concentration equal to or above the	
assay cut-off and geometric mean concentration (GMC), before	
and one month post booster vaccination – by Tdap vaccination of	
mother (Booster ATP cohort for immunogenicity)	273
Table 7.27 Booster response for anti-PT, anti-FHA and anti-PRN	210
antibodies, one month post booster vaccination - by gender	
(Booster ATP cohort for immunogenicity)	275
Table 7.28 Booster response for anti-PT, anti-FHA and anti-PRN	2.0
antibodies, one month post booster vaccination – by geographical	
ancestry (Booster ATP cohort for immunogenicity)	277
Table 7.29 Booster response for anti-PT, anti-FHA and anti-PRN	
antibodies, one month post booster vaccination – by Tdap	
vaccination of mother (Booster ATP cohort for immunogenicity)	279
Table 7.30 Number and percentage of subjects with anti-D and	
anti-T antibody concentration equal to or above the assay cut-off,	
0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC),	
before and one month post booster vaccination - by gender	
(Booster ATP cohort for immunogenicity)	282
Table 7.31 Number and percentage of subjects with anti-D and	
anti-T antibody concentration equal to or above the assay cut-off,	
0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC),	
before and one month post booster vaccination – by geographical	
anc (Booster ATP cohort for immunogenicity)	283

Table 7.32 Number and percentage of subjects with anti-D and	
anti-T antibody concentration equal to or above the assay cut-off,	
0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC),	
before and one month post booster vaccination – by Tdap	
vaccination (Booster ATP cohort for immunogenicity)	285
Table 7.33 Number and percentage of subjects with anti-PRP	
antibody concentration equal to or above 0.066 µg/mL and 0.15	
μg/mL and 1.0 μg/mL and geometric mean concentration (GMC),	
before and one month post booster vaccination – by gender	
(Booster ATP cohort for immunogenicity)	287
Table 7.34 Number and percentage of subjects with anti-PRP	201
antibody concentration equal to or above 0.066 µg/mL and 0.15	
μg/mL and 1.0 μg/mL and geometric mean concentration (GMC),	
before and one month post booster vaccination – by geographical	
	288
ancestry (Booster ATP cohort for immunogenicity)	200
Table 7.35 Number and percentage of subjects with anti-PRP	
antibody concentration equal to or above 0.066 µg/mL and 0.15	
μg/mL and 1.0 μg/mL and geometric mean concentration (GMC),	
before and one month post booster vaccination – by Tdap	200
vaccination of the (Booster ATP cohort for immunogenicity)	289
Table 7.36 Number and percentage of subjects with anti-Polio 1, 2,	
and 3 antibody titer equal to or above 8 and geometric mean titer	
(GMT), before booster vaccination - by gender (Booster ATP	000
cohort for immunogenicity)	290
Table 7.37 Number and percentage of subjects with anti-Polio 1, 2,	
and 3 antibody titer equal to or above 8 and geometric mean titer	
(GMT), before booster vaccination – by geographical ancestry	004
(Booster ATP cohort for immunogenicity)	291
Table 7.38 Number and percentage of subjects with anti-Polio 1, 2,	
and 3 antibody titer equal to or above 8 and geometric mean titer	
(GMT), before booster vaccination – by Tdap vaccination of	
mother (Booster ATP cohort for immunogenicity)	292
Table 7.39 Number and percentage of subjects with anti-HBs	
antibody concentration equal to or above 6.2 mlU/mL and 10.0	
mIU/mL and geometric mean concentration (GMC), before booster	
vaccination - by gender (Booster ATP cohort for immunogenicity)	293
Table 7.40 Number and percentage of subjects with anti-HBs	
antibody concentration equal to or above 6.2 mlU/mL and 10.0	
mIU/mL and geometric mean concentration (GMC), before booster	
vaccination – by geographical ancestry (Booster ATP cohort for	
immunogenicity)	293
Table 7.41 Number and percentage of subjects with anti-HBs	
antibody concentration equal to or above 6.2 mlU/mL and 10.0	
mIU/mL and geometric mean concentration (GMC), before booster	
vaccination – by Tdap vaccination of mother (Booster ATP cohort	
for immunogenicity)	294

Table 7.42 Number and percentage of subjects with anti-HBs	
antibody concentration equal to or above 6.2 mlU/mL and 10.0	
mlU/mL and geometric mean concentration (GMC), before booster	
vaccination – by Hepatitis B vaccination of subject (Booster ATP	
cohort for immunogenicity)	295
Table 7.43 Ratio of GMCs/GMTs for antibody concentrations/titers	
between groups (Pedia group divided by Hexa group), before	
booster vaccination (Booster ATP cohort for immunogenicity)	306
Table 7.44 Ratio of GMCs/GMTs for antibody concentrations/titers	
between groups (Penta group divided by Hexa group), before	
booster vaccination (Booster ATP cohort for immunogenicity)	307
Table 7.45 Ratio of GMC for anti-HBs antibody concentrations	
between groups (Pedia group divided by Hexa group), before	
booster vaccination (Booster ATP cohort for immunogenicity)	307
Table 7.46 Ratio of GMC for anti-HBs antibody concentrations	
between groups (Penta group divided by Hexa group), before	
booster vaccination (Booster ATP cohort for immunogenicity)	308
Table 7.47 Difference between groups (Pedia group minus Hexa	
group) in percentage of subjects with antibody concentration/titer	
equal to or above the proposed cut-off, before booster vaccination	
(Booster ATP cohort for immunogenicity)	308
Table 7.48 Difference between groups (Penta group minus Hexa	
group) in percentage of subjects with antibody concentration/titer	
equal to or above the proposed cut-off, before booster vaccination	
(Booster ATP cohort for immunogenicity)	309
Table 7.49 Ratio of GMCs/GMTs for antibody concentrations/titers	
between groups (Pedia group divided by Hexa group), one month	
post booster vaccination (Booster ATP cohort for	
immunogenicity)	309
Table 7.50 Ratio of GMCs/GMTs for antibody concentrations/titers	
between groups (Penta group divided by Hexa group), one month	
post booster vaccination (Booster ATP cohort for	
immunogenicity)	310
Table 7.51 Difference between groups (Pedia group minus Hexa	
group) in percentage of subjects with antibody concentration/titer	
equal to or above the proposed cut-off, one month post booster	
vaccination (Booster ATP cohort for immunogenicity)	310
Table 7.52 Difference between groups (Penta group minus Hexa	
group) in percentage of subjects with antibody concentration/titer	
equal to or above the proposed cut-off, one month post booster	
vaccination (Booster ATP cohort for immunogenicity)	311
Table 7.53 Number and percentage of subjects with anti-PT, anti-	
FHA and anti-PRN antibody concentration equal to or above the	
assay cut-off and geometric mean concentration (GMC), one	
month post primary vaccination (Primary Total vaccinated cohort).	311

Table 7.54 Number and percentage of subjects with anti-D and anti-T antibody concentration equal to or above the assay cut-off, 0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC), one month post primary vaccination (Primary Total vaccinated	
cohort)	312
vaccinated cohort)	313
cohort)	314 314
post primary vaccination – by Hepatitis B vaccination at birth (Primary Total vaccinated cohort)	315 316
Table 7.60 Booster response for anti-PT, anti-FHA and anti-PRN antibodies, one month post booster vaccination (Booster Total vaccinated cohort)	317
anti-T antibody concentration equal to or above the assay cut-off, 0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC), before and one month post booster vaccination (Booster Total vaccinated cohort)	318
Table 7.62 Number and percentage of subjects with anti-PRP antibody concentration equal to or above 0.066 μg/mL,0.15 μg/mL and 1.0 μg/mL and geometric mean concentration (GMC), before and one month post booster vaccination (Booster Total	240
vaccinated cohort)	319 320

Table 7.64 Number and percentage of subjects with anti-HBs	
antibody concentration equal to or above 6.2 mIU/mL and 10	
mIU/mL and geometric mean concentration (GMC), before the	
booster vaccination (Booster Total vaccinated cohort)	320

LIST OF POST-TEXT FIGURES IMMUNOGENICITY

	PAGE
Figure 7.1 Reverse cumulative distribution curves for anti-PT	
concentrations one month post primary vaccination (Primary ATP	
cohort for immunogenicity)	256
Figure 7.2 Reverse cumulative distribution curves for anti-FHA	
concentrations one month post primary vaccination (Primary ATP	
cohort for immunogenicity)	257
Figure 7.3 Reverse cumulative distribution curves for anti-PRN	
concentrations one month post primary vaccination (Primary ATP	
cohort for immunogenicity)	258
Figure 7.4 Reverse cumulative distribution curves for anti-D	
concentrations one month post primary vaccination (Primary ATP	
cohort for immunogenicity)	259
Figure 7.5 Reverse cumulative distribution curves for anti-T	
concentrations one month post primary vaccination (Primary ATP	
cohort for immunogenicity)	260
Figure 7.6 Reverse cumulative distribution curves for anti-Polio 1	
titers one month post primary vaccination (Primary ATP cohort for	
immunogenicity)	26 ⁻
Figure 7.7 Reverse cumulative distribution curves for anti-Polio 2	
titers one month post primary vaccination (Primary ATP cohort for	
immunogenicity)	262
Figure 7.8 Reverse cumulative distribution curves for anti-Polio 3	
titers one month post primary vaccination (Primary ATP cohort for	
immunogenicity)	263
Figure 7.9 Reverse cumulative distribution curves for anti-PRP	
(fully validated assay) concentrations one month post primary	
vaccination (Primary ATP cohort for immunogenicity)	264
Figure 7.10 Reverse cumulative distribution curves for anti-PRP	
(qualified assay) concentrations one month post primary	
vaccination (Primary ATP cohort for immunogenicity)	26
Figure 7.11 Reverse cumulative distribution curves for anti-HBs	
concentrations one month post primary vaccination (Primary ATP	
cohort for immunogenicity)	26
Figure 7.12 Reverse cumulative distribution curves for anti-PT	
concentration, before and one month post booster vaccination	
(Booster ATP cohort for immunogenicity)	29
Figure 7.13 Reverse cumulative distribution curves for anti-FHA	_5
concentration, before and one month post booster vaccination	
(Booster ATP cohort for immunogenicity)	29
Figure 7.14 Reverse cumulative distribution curves for anti-PRN	
concentration, before and one month post booster vaccination	
(Booster ATP cohort for immunogenicity)	298
(Dooster Arr conference initiallogement)	200

	report i ilia
Figure 7.15 Reverse cumulative distribution curves for anti-D	•
concentration, before and one month post booster vaccination	
(Booster ATP cohort for immunogenicity)	. 299
Figure 7.16 Reverse cumulative distribution curves for anti-T	
concentration, before and one month post booster vaccination	
(Booster ATP cohort for immunogenicity)	. 300
Figure 7.17 Reverse cumulative distribution curves for anti-Polio 1	
antibody titer before booster vaccination (Booster ATP cohort for	
immunogenicity)	. 301
Figure 7.18 Reverse cumulative distribution curves for anti-Polio 2	
antibody titer before booster vaccination (Booster ATP cohort for	
immunogenicity)	. 302
Figure 7.19 Reverse cumulative distribution curves for anti-Polio 3	
antibody titer before booster vaccination (Booster ATP cohort for	
immunogenicity)	. 303
Figure 7.20 Reverse cumulative distribution curves for anti-PRP	
concentration, before and one month post booster vaccination	
(Booster ATP cohort for immunogenicity)	. 304
Figure 7.21 Reverse cumulative distribution curve for anti-HBs	
antibody concentration, before booster vaccination (Booster ATP	
cohort for immunogenicity)	. 305

LIST OF POST-TEXT TABLES REACTOGENICITY

	PAGE
Table 8.1 Incidence and nature of symptoms (solicited and unsolicited) that are causally related to vaccination reported during the 4-day (Days 0-3) post-vaccination period following each	
priming dose and overall (Primary Total vaccinated cohort)	321
during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)	322
(Primary Total vaccinated cohort)	323
(Primary Total vaccinated cohort)	324
each priming dose and overall (Primary Total vaccinated cohort) Table 8.6 Incidence and nature of grade 3 symptoms (solicited and unsolicited) that are causally related to vaccination reported during the 31-day (Days 0-30) post-vaccination period following	325
each priming dose and overall (Primary Total vaccinated cohort) Table 8.7 Incidence of local symptoms (solicited and unsolicited) that are causally related to vaccination reported for Infanrix hexa, Pediarix, ActHIB, Pentacel and Engerix-B vaccines during the 4- day (Days 0-3) post-vaccination period following each priming	326
dose and overall (Primary Total vaccinated cohort)	327
priming dose and overall (Primary Total vaccinated cohort)	328
cohort) Table 8.10 Incidence of solicited local symptoms reported during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall – by geographical ancestry (Primary	329
Total vaccinated cohort)	338

Table 8.11 Incidence of solicited general symptoms reported	
during the 4-day (Days 0-3) post-vaccination period following each	
priming dose and overall- by gender (Primary Total vaccinated	
cohort)	347
Table 8.12 Incidence of solicited general symptoms reported	
during the 4-day (Days 0-3) post-vaccination period following each	
priming dose and overall- by geographical ancestry (Primary Total	
vaccinated cohort)	354
Table 8.13 Percentage of doses with unsolicited symptoms	004
classified by MedDRA Primary System Organ Class and Preferred	
Term within the 31-day (Days 0-30) post-vaccination period	
following priming doses (Primary Total vaccinated cohort)	361
Table 8.14 Percentage of doses with grade 3 unsolicited	301
symptoms classified by MedDRA Primary System Organ Class	
and Preferred Term within the 31-day (Days 0-30) post-vaccination	207
period following priming doses (Primary Total vaccinated cohort)	367
Table 8.15 Percentage of subjects reporting the occurrence of	
unsolicited symptoms classified by MedDRA Primary System	
Organ Class and Preferred Term with causal relationship to	
vaccination, within the 31-day (Days 0-30) post-vaccination period	
following priming doses (Primary Total vaccinated cohort)	368
Table 8.16 Percentage of doses with unsolicited symptoms	
classified by MedDRA Primary System Organ Class and Preferred	
Term with causal relationship to vaccination, within the 31-day	
(Days 0-30) post-vaccination period following priming doses	
(Primary Total vaccinated cohort)	370
Table 8.17 Percentage of subjects reporting the occurrence of	
grade 3 unsolicited symptoms classified by MedDRA Primary	
System Organ Class and Preferred Term with causal relationship	
to vaccination, within the 31-day (Days 0-30) post-vaccination	
period following priming doses (Primary Total vaccinated cohort)	372
Table 8.18 Percentage of doses with grade 3 unsolicited	
symptoms classified by MedDRA Primary System Organ Class	
and Preferred Term with causal relationship to vaccination, within	
the 31-day (Days 0-30) post-vaccination period following priming	
doses (Primary Total vaccinated cohort)	373
Table 8.19 Percentage of subjects reporting the occurrence of	
unsolicited symptoms classified by MedDRA Primary System	
Organ Class and Preferred Term, within the 31-day (Days 0-30)	
post-vaccination period following priming doses – by gender	
(Primary Total vaccinated cohort)	374
Table 8.20 Percentage of subjects reporting the occurrence of	
unsolicited symptoms classified by MedDRA Primary System	
Organ Class and Preferred Term within the 31-day (Days 0-30)	
post-vaccination period following priming doses-by geographical	
ancestry (Primary Total vaccinated cohort)	381

Table 8.21 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following priming doses- by gender	
(Primary Total vaccinated cohort)	389
geographical ancestry (Primary Total vaccinated cohort)	391 393
Table 8.24 Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship with vaccination, within the 31-day (Days 0-30) post-vaccination period following priming doses-by geographical ancestry (Primary Total vaccinated cohort)	395
Table 8.25 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship with vaccination, within the 31-day (Days 0-30) post-vaccination period following priming doses- by gender (Primary Total vaccinated cohort)	398
Table 8.26 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship with vaccination, within the 31-day (Days 0-30) post-vaccination period following priming doses- by geographical ancestry (Primary Total vaccinated cohort)	399
Table 8.27 Percentage of doses with unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term, within the 31-day (Days 0-30) post-vaccination period following priming doses – by gender (Primary Total vaccinated cohort)	400
Table 8.28 Percentage of doses with unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following priming doses-by geographical ancestry (Primary Total vaccinated cohort)	407

Table 8.29 Percentage of doses with grade 3 unsolicited	
symptoms classified by MedDRA Primary System Organ Class	
and Preferred Term within the 31-day (Days 0-30) post-vaccination	
period following priming doses- by gender (Primary Total	
vaccinated cohort)	415
Table 8.30 Percentage of doses with grade 3 unsolicited	
symptoms classified by MedDRA Primary System Organ Class	
and Preferred Term within the 31-day (Days 0-30) post-vaccination	
period following priming doses- by geographical ancestry	
(Primary Total vaccinated cohort)	417
Table 8.31 Percentage of doses with unsolicited symptoms	417
<u> </u>	
classified by MedDRA Primary System Organ Class and Preferred	
Term with causal relationship with vaccination, within the 31-day	
(Days 0-30) post-vaccination period following priming doses – by	440
gender (Primary Total vaccinated cohort)	419
Table 8.32 Percentage of doses with unsolicited symptoms	
classified by MedDRA Primary System Organ Class and Preferred	
Term with causal relationship with vaccination, within the 31-day	
(Days 0-30) post-vaccination period following priming doses-by	
geographical ancestry (Primary Total vaccinated cohort)	421
Table 8.33 Percentage of doses with grade 3 unsolicited	
symptoms classified by MedDRA Primary System Organ Class	
and Preferred Term with causal relationship with vaccination,	
within the 31-day (Days 0-30) post-vaccination period following	
priming doses- by gender (Primary Total vaccinated cohort)	423
Table 8.34 Percentage of doses with grade 3 unsolicited	
symptoms classified by MedDRA Primary System Organ Class	
and Preferred Term with causal relationship with vaccination,	
within the 31-day (Days 0-30) post-vaccination period following	
priming doses- by geographical ancestry (Primary Total	
vaccinated cohort)	424
Table 8.35 Percentage of subjects reporting at least one preferred	
term from broad MedDRA SMQ 'Hypotonic-Hyporesponsive	
Episode (HHE)', within the 31-day (Days 0-30) post-vaccination	
period following priming doses (Primary Total vaccinated cohort)	425
Table 8.36 Percentage of subjects reporting at least one preferred	
term from narrow MedDRA SMQ 'convulsion' within the 31-day	
(Days 0-30) post-vaccination period following priming doses	
(Primary Total vaccinated cohort)	425
Table 8.37 Percentage of subjects reporting at least one preferred	
term from broad MedDRA SMQ 'Hypotonic-Hyporesponsive	
Episode (HHE)', within the 31-day (Days 0-30) post-vaccination	
period following priming doses- by gender (Primary Total	
vaccinated cohort)	425

Table 8.38 Percentage of subjects reporting at least one preferred	
term from broad MedDRA SMQ 'Hypotonic-Hyporesponsive	
Episode (HHE)', within the 31-day (Days 0-30) post-vaccination	
period following priming doses- by geographical ancestry	
(Primary Total vaccinated cohort)	426
Table 8.39 Percentage of subjects reporting at least one preferred	
term from narrow MedDRA SMQ 'convulsion' within the 31-day	
(Days 0-30) post-vaccination period following priming doses-by	
gender (Primary Total vaccinated cohort)	426
Table 8.40 Percentage of subjects reporting at least one preferred	
term from narrow MedDRA SMQ 'convulsion' within the 31-day	
(Days 0-30) post-vaccination period following priming doses-by	
geographical ancestry (Primary Total vaccinated cohort)	426
Table 8.41 Percentage of subjects reporting the occurrence of New	
Onset of Chronic Illness (NOCI) from Dose 1 up to 6 months	
following priming doses- by gender (Primary Total vaccinated	
cohort)	427
Table 8.42 Percentage of subjects reporting the occurrence of New	721
Onset of Chronic Illness (NOCI) from Dose 1 up to 6 months	
following priming doses-by geographical ancestry (Primary Total	
vaccinated cohort)	428
Table 8.43 Number and percentage of subjects with concomitant	420
medication during the 31-day (Days 0-30) post-vaccination period	
following each priming dose and overall (Primary Total vaccinated cohort)	429
Table 8.44 Percentage of subjects reporting the occurrence of	429
serious adverse event (SAE) from Dose 1 up to 6 months following	
•	430
priming doses-by gender (Primary Total vaccinated cohort)	430
Table 8.45 Percentage of subjects reporting the occurrence of	
serious adverse event (SAE) from Dose 1 up to 6 months following	
priming doses-by geographical ancestry (Primary Total vaccinated	424
Cohort)	431
Table 8.46 Listing of SAE from dose 1 up to study end (Primary	433
Total vaccinated cohort)	433
Table 8.47 Compliance in returning symptom sheets for the	407
booster dose (Booster Total vaccinated cohort)	437
Table 8.48 Incidence of grade 3 local symptoms (solicited and	
unsolicited) reported for Infanrix, Hiberix, ActHIB and Pentacel	
vaccines during the 4-day (Days 0-3) post-vaccination period	407
following the booster dose (Booster Total vaccinated cohort)	437
Table 8.49 Incidence and nature of grade 3 symptoms (solicited	
and unsolicited)that are causally related to vaccination reported	
during the 4-day (Days 0-3) post-vaccination period following the	
booster dose (Booster Total vaccinated cohort)	438
Table 8.50 Incidence and nature of symptoms (solicited and	
unsolicited) reported during the 31-day (Days 0-30) post-	
vaccination period following the booster dose (Booster Total	
vaccinated cohort)	438

Table 8.51 Incidence and nature of grade 3 symptoms (solicited and unsolicited) reported during the 31-day (Days 0-30) post-vaccination period following the booster dose (Booster Total	400
vaccinated cohort) Table 8.52 Incidence and nature of symptoms (solicited and	439
unsolicited) that are causally related to vaccination reported	
during the 31-day (Days 0-30) post-vaccination period following	
the booster dose (Booster Total vaccinated cohort)	439
Table 8.53 Incidence and nature of grade 3 symptoms (solicited	400
and unsolicited)that are causally related to vaccination reported	
during the 31-day (Days 0-30) post-vaccination period following	
the booster dose (Booster Total vaccinated cohort)	440
Table 8.54 Incidence of local symptoms (solicited and unsolicited)	
that are causally related to vaccination reported for Infanrix,	
Hiberix, ActHIB and Pentacel vaccines during the 4-day (Days 0-3)	
post-vaccination period following the booster dose (Booster Total	
vaccinated cohort)	440
Table 8.55 Incidence of grade 3 local symptoms (solicited and	
unsolicited) that are causally related to vaccination reported for	
Infanrix, Hiberix, ActHIB and Pentacel vaccines during the 4-day	
(Days 0-3) post-vaccination period following the booster dose	
(Booster Total vaccinated cohort)	441
Table 8.56 Incidence of solicited local symptoms reported during	
the 4-day (Days 0-3) post-vaccination period following the booster	
dose -by gender (Booster Total vaccinated cohort)	442
Table 8.57 Incidence of solicited local symptoms reported during	
the 4-day (Days 0-3) post-vaccination period following the booster	444
dose-by geographical ancestry (Booster Total vaccinated cohort)	444
Table 8.58 Incidence of large injection site reaction reported	
during the 4-day (Days 0-3) post-vaccination period following the	446
booster dose (Booster Total vaccinated cohort) Table 8.59 Incidence of solicited general symptoms reported	440
during the 4-day (Days 0-3) post-vaccination period following the	
booster dose-by gender (Booster Total vaccinated cohort)	447
Table 8.60 Incidence of solicited general symptoms reported	771
during the 4-day (Days 0-3) post-vaccination period following the	
booster dose-by geographical ancestry (Booster Total vaccinated	
cohort)	448
Table 8.61 Percentage of subjects reporting the occurrence of	
unsolicited symptoms classified by MedDRA Primary System	
Organ Class and Preferred Term with causal relationship to	
vaccination, within the 31-day (Days 0-30) post-vaccination period	
following the booster dose (Booster Total vaccinated cohort)	450

Table 8.62 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship to vaccination, within the 31-day (Days 0-30) post-vaccination period following the booster dose (Booster Total vaccinated	450
cohort) Table 8.63 Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System	450
Organ Class and Preferred Term within the 31-day (Days 0-30)	
post-vaccination period following the booster dose-by gender	
(Booster Total vaccinated cohort)	451
Table 8.64 Percentage of subjects reporting the occurrence of	
unsolicited symptoms classified by MedDRA Primary System	
Organ Class and Preferred Term within the 31-day (Days 0-30)	
post-vaccination period following the booster dose-by	
geographical ancestry (Booster Total vaccinated cohort)	455
Table 8.65 Percentage of subjects reporting the occurrence of	
grade 3 unsolicited symptoms classified by MedDRA Primary	
System Organ Class and Preferred Term within the 31-day (Days	
0-30) post-vaccination period following the booster dose-by	
gender (Booster Total vaccinated cohort)	459
Table 8.66 Percentage of subjects reporting the occurrence of	
grade 3 unsolicited symptoms classified by MedDRA Primary	
System Organ Class and Preferred Term within the 31-day (Days	
0-30) post-vaccination period following the booster dose-by	
geographical ancestry (Booster Total vaccinated cohort)	460
Table 8.67 Percentage of subjects reporting the occurrence of	
unsolicited symptoms classified by MedDRA Primary System	
Organ Class and Preferred Term with causal relationship to	
vaccination within the 31-day (Days 0-30) post-vaccination period	
following the booster dose -by gender (Booster Total vaccinated	404
cohort)	461
Table 8.68 Percentage of subjects reporting the occurrence of	
unsolicited symptoms classified by MedDRA Primary System	
Organ Class and Preferred Term with causal relationship to vaccination within the 31-day (Days 0-30) post-vaccination period	
following the booster dose -by geographical ancestry (Booster	
Total vaccinated cohort)	462
Table 8.69 Percentage of subjects reporting the occurrence of	702
grade 3 unsolicited symptoms classified by MedDRA Primary	
System Organ Class and Preferred Term with causal relationship	
to vaccination within the 31-day (Days 0-30) post-vaccination	
period following the booster dose -by gender (Booster Total	
vaccinated cohort)	463

Table 8.70 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship to vaccination within the 31-day (Days 0-30) post-vaccination period following the booster dose -by geographical ancestry (Booster Total vaccinated cohort)	463
Table 8.71 Percentage of subjects reporting at least one preferred term from broad MedDRA SMQ 'Hypotonic-Hyporesponsive Episode (HHE)', within the 31-day (Days 0-30) post-vaccination	400
period following the booster dose (Booster Total vaccinated cohort)	463
Table 8.72 Percentage of subjects reporting at least one preferred term from narrow MedDRA SMQ 'convulsion' within the 31-day (Days 0-30) post-vaccination period following the booster dose	
(Booster Total vaccinated cohort)Table 8.73 Percentage of subjects reporting at least one preferred	463
term from broad MedDRA SMQ 'Hypotonic-Hyporesponsive Episode (HHE)', within the 31-day (Days 0-30) post-vaccination period following the booster dose–by gender (Booster Total	
vaccinated cohort)	464
by gender (Booster Total vaccinated cohort)	464
Episode (HHE)', within the 31-day (Days 0-30) post-vaccination period following the booster dose– by geographical ancestry (Booster Total vaccinated cohort)	464
Table 8.76 Percentage of subjects reporting at least one preferred term from narrow MedDRA SMQ 'convulsion' within the 31-day (Days 0-30) post-vaccination period following the booster dose–	101
by geographical ancestry (Booster Total vaccinated cohort)	465
vaccinated cohort)	466
Total vaccinated cohort)	467
ancestry (Booster Total vaccinated cohort)	468

Table 8.80 Number (%) of subjects reporting the occurrence of	
serious adverse event (SAE) within the 31-day (Days 0-30) post-	
vaccination period following the booster dose-by gender (Booster	
Total vaccinated cohort)	469

LIST OF ABBREVIATIONS

ACIP Advisory Committee on Immunization Practices

AE Adverse Event

ANCOVA Analysis of Co-variance

ANOVA Analysis of Variance

ATP According-To-Protocol

CBER Center for Biologics Evaluation and Research

CCID₅₀ median Cell Culture Infective Dose

CDC Centers for Disease Control and Prevention (United

States of America)

CEPL Clinical and Epidemiology R&D Project Leader

CRDL Clinical Research and Development Lead

CI Confidence Interval

CLIA ChemiLuminescence ImmunoAssay

CRO Contract Reseach Organisation

CTSU Clinical Trial Supply Unit

D Diphtheria

DMEM Dulbecco's Modified Eagle Medium

DTPa or DTaP Combined diphtheria-tetanus-acellular pertussis vaccine

DTPa-HBV-IPV/Hib Combined diphtheria-tetanus-acellular pertussis-hepatitis

B-inactivated poliovirus and Haemophilus influenzae type

b vaccine (*Infanrix hexa*).

eCRF electronic Case Report Form

EL.U ELISA unit(s)

ELISA Enzyme-linked immunosorbent assay

117119 (DTPA-HBV-IPV-135) Report Final

ESFU Extended safety follow-up

eTDF electronic Temperature excursion Decision Form

FHA Filamentous haemagglutinin

GCP Good Clinical Practice

GMC Geometric Mean Concentration

GMT Geometric Mean Titer

GSK GlaxoSmithKline

HBs Hepatitis B surface antigen

HHE Hypotonic Hyporesponsive Episode

Hib Haemophilus influenzae (H. influenzae) type b

HRV Human Rotavirus

IB Investigators Brochure

ICF Informed Consent Form

IM Intramuscular

IND Investigational New Drug

IRB Institutional Review Board

IU International unit(s)

LAR Legally Acceptable Representative

MedDRA Medical Dictionary for Regulatory Activities

NI Non-inferiority

NOCI New Onset of Chronic Illness; referred to as new-onset

chronic diseases (NOCDs) in the protocol

Pa Acellular Bordetella pertussis component

PI Principal Investigator

Post-Bst Post Booster

Post-Pri Post Primary vaccination

117119 (DTPA-HBV-IPV-135) Report Final

Pre-Bst Pre Booster

PRN Pertactin

PRP Polyribosyl-Ribitol-Phosphate: polysaccharide

component of the Hib bacterium capsule

PT Pertussis toxoid: a secreted exotoxin of the *Bordetella*

pertussis bacterium

RCC Reverse Cumulative Curve

pIMD Potential Immune-Mediated Disease

SAE Serious Adverse Event

SAS Statistical Analysis Software

SBIR Randomization System on Internet

SCID Severe Combined Immunodeficiency Disease

SD Standard Deviation

SDL Study Delivery Lead

SM Study Management

SMQ Standardised MedDRA Queries

SOP Standard Operating Procedures

SPC Summary of Product Characteristics

T Tetanus

TMF Trial Master File (TMF)

TT Tetanus Toxoid

TVC Total Vaccinated cohort

US (USA) United States (United States of America)

URTI Upper Respiratory Tract Infection

WHO World Health Organization

GLOSSARY OF TERMS

Adverse event:

Any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

An adverse event (AE) can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse.

Blinding:

A procedure in which one or more parties to the trial are kept unaware of the treatment assignment in order to reduce the risk of biased study outcomes. The level of blinding is maintained throughout the conduct of the trial, and only when the data are cleaned to an acceptable level of quality will appropriate personnel be unblinded or when required in case of a serious adverse event. In an open-label study, no blind is used. Both the investigator and the subject know the identity of the treatment assigned.

Child in care:

A child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation. The definition of a child in care can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. The definition of a child in care does not include a child who is adopted or has an appointed legal guardian.

Eligible:

Qualified for enrolment into the study based upon strict adherence to inclusion/exclusion criteria.

Epoch:

An epoch is a self-contained set of consecutive timepoints or a single timepoint from a single protocol. Self-contained means that data collected for all subjects at all timepoints within that epoch allows to draw a complete conclusion to define or precise the targeted label of the product. Typical examples of epochs are primary vaccinations, boosters, yearly immunogenicity follow-ups, and surveillance periods for efficacy or safety.

for efficacy of surery

eTrack:

GSK's tracking tool for clinical trials.

117119 (DTPA-HBV-IPV-135) Report Final

Evaluable: Meeting all eligibility criteria, complying with the

procedures defined in the protocol, and, therefore, included in the according-to-protocol (ATP) analysis (see Sections 5.6.2 and 5.10.4 for details on criteria for evaluability).

Immunological correlate of protection:

The defined humoral antibody response above which there is a high likelihood of protection in the absence of any host factors that might increase susceptibility to the infectious agent.

Intercurrent medical condition:

A condition that has the capability of altering a subject's immune response or are confirmed to have an immunodeficiency condition during the study.

Investigational vaccine/product:

A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorization when used in a way different from the approved form, or when used for an unapproved indication, or when used to gain further information about an approved use.

(Synonym of Investigational Medicinal Product)

Primary completion date:

The date that the final subject was examined or received an intervention for the purpose of final collection of data for the primary outcome, whether the clinical trial concluded according to the pre-specified protocol or was terminated.

Randomization:

Process of random attribution of treatment to subjects in order to reduce bias of selection.

Self-contained study:

Study with objectives not linked to the data of another study.

Site Monitor:

An individual assigned by the sponsor who is responsible for assuring proper conduct of clinical studies at one or more investigational sites.

Solicited adverse event:

AEs to be recorded as endpoints in the clinical study. The presence/occurrence/intensity of these events is actively solicited from the subject or an observer during a specified post-vaccination follow-up period.

Subject:

Term used throughout the protocol to denote an individual who has been contacted in order to participate or participates in the clinical study, either as a recipient of the vaccines or as a control.

Subject number:

A unique number identifying a subject, assigned to each subject consenting to participate in the study.

117119 (DTPA-HBV-IPV-135) Report Final

Treatment: Term used throughout the clinical study to denote a set of

investigational product(s) or marketed product(s) or placebo intended to be administered to a subject, identified by a unique number, according to the study randomization or

treatment allocation.

Treatment number: A number identifying a treatment to a subject, according to

the study randomization or treatment allocation.

Unsolicited adverse

event:

Any AE reported in addition to those solicited during the clinical study. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.

TRADEMARKS

The following trademarks are used in the present report.

Note: In the body of the Study Report, the names of the vaccines/products and/or medications will be written without the superscript symbol TM or ® and in *italics*.

Trademarks of the GlaxoSmithKline group of companies	Generic description
Engerix-B	Hepatitis B vaccine (recombinant)
Hiberix	Haemophilus influenzae type b conjugate vaccine (tetanus toxoid conjugate)
Infanrix	Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
Infanrix hexa	Combined diphtheria-tetanus-acellular pertussis, hepatitis B, inactivated polio vaccine and <i>Haemophilus influenzae</i> type b vaccine
Pediarix	Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine
Rotarix	Rotavirus Vaccine, Live, Oral

Trademarks not owned by the GlaxoSmithKline group of companies	Generic description
ActHIB (Sanofi Pasteur SA)	Haemophilus influenzae type b conjugate vaccine (tetanus toxoid conjugate)
Pentacel (Sanofi Pasteur SA)	Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and <i>Haemophilus influenzae</i> type b conjugate (tetanus toxoid conjugate)
Prevnar (Wyeth Pharmaceuticals Inc.; Marketed by Pfizer Inc.)	Pneumococcal 7-valent conjugate vaccine (diphtheria CRM ₁₉₇ protein)
Prevnar13 (Wyeth Pharmaceuticals Inc.; Marketed by Pfizer Inc.)	Pneumococcal 13-valent conjugate vaccine (diphtheria CRM ₁₉₇ protein)

1. ETHICS

1.1. Institutional Review Board (IRB)

The study protocol, two protocol amendments, the informed consent, and other information that required pre-approval were reviewed and approved by a national, regional, or investigational centre IRB.

1.2. Ethical conduct of the study

This study was conducted in accordance with ethical principles that have their origins in the Declaration of Helsinki, the principles of "good clinical practice" (GCP) and all applicable regulatory requirements.

1.3. Subject information and consent

Written informed consent was obtained from each subject's parent(s) / legally acceptable representative (LAR) prior to the performance of any study-specific procedures.

2. INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE

This study was conducted by multiple investigators across 43 centers in the United States (US). GSK Biologicals, King of Prussia, PA, US was responsible for administration of the study including clinical trial supply management and laboratory facilities.

Dr. Nicola Klein at the Kaiser Permanente Oakland, One Kaiser Plaza, Oakland, CA, USA was the principal investigator.

The following contract research organisations (CROs) were involved in this study:

Name of vendor	Address	Role
Q ² Solutions	Global Headquarters	Sample management and
	5827 South Miami Blvd	Logistics
	Morrisville, NC 27560, USA	
InVentiv Clinical	Corporate Headquarters	Clinical Trial
Solutions	3201 Beechleaf Court	Administration, Study
	Suite 600	Management (SM),
	Raleigh, NC 27604-1547, USA	Contract support
Randstad North America	Randstad USA Corporate Office,	Clinical Trial Supply Unit
	3625 Cumberland Blvd, Atlanta,	(CTSU), and
	Georgia 30339, USA	Cold Chain support
Bartech Group Inc	Corporate Headquarters	Clinical Trial Supply Unit
_	The Bartech Group	(CTSU), and
	27777 Franklin Road,	Cold Chain support
	Suite 600, Southfield, Michigan, USA	
	48034	

117119 (DTPA-HBV-IPV-135) Report Final

Name of war 1	Adduses	Report Final
Name of vendor	Address	Role
Novella Clinical	USA Headquarters	Monitoring support
Resourcing	1700 Perimeter Park Drive	
	Morrisville, NC 27560, USA	
Quorum Review Inc	1501 Fourth Avenue	Central Institutional
	Suite 800	Review Board (IRB)
	Seattle, WA 98101, USA	
Fisher Scientific	Headquarters	Non-vaccine supplies
	Thermo Fisher Scientific	
	168 Third Avenue	
	Waltham, MA, USA 02451	
Creative Edge	Email address:	Non-vaccine supplies
Promotions	PPD	
McVeigh Associates	275 Dixon Ave	Investigator Meeting
8	Amityville, NY 11701, USA	Planners
United Parcel Service	UPS World Headquarters	Courier
	55 Glenlake Parkway NE	
	Atlanta, GA 30328, USA	
Federal Express	FedEx, 7900 Legacy Drive	Courier
r	Plano, TX 75024, USA	
Henry Schein, Inc	Corporate Headquarters	Vaccines purchased
, , , , , , , , , , , , , , , , , , ,	135 Duryea Road	locally (Pentacel, ActHib)
	Melville, NY 11747, USA	
Sanofi Pasteur Inc	U.S. Headquarters	Vaccine purchased
	Discovery Drive	locally (Pentacel)
	Swiftwater, PA 18370, USA	
Pfizer Inc	235 East 42nd Street NY, NY 10017,	Vaccines purchased
	USA	locally (ActHib, Prevnar
		13)
Tata Consultancy	Gopalan Global Axis Campus,	Data Management
Services	Gopalan Enterprises, 152,	
	EPIP Industrial Area,	
	White Field, K R Puram Hobli,	
	Bangalore, 560066, India	
Synteract, Inc.	Global Headquarters:	Study Delivery
j	5909 Sea Otter Place	Management (Study
	Suite 100	Delivery Lead (SDL))
	Carlsbad, CA 92010, USA	Trial Master File (TMF)
	Curiscua, Cri y 2010, OSI 1	Management
		(TMF Specialist)
Syneos Health TM	Corporate Headquarters	Study Delivery
Syncos Health Tivi	3201 Beechleaf Court	Management (Study
	Suite 600	Delivery Associate)
	Raleigh, NC 27604-1547, USA	Delivery 11350clate)
	Naicigii, INC 2/004-134/, USA	

3. INTRODUCTION

Combination vaccines have been developed to provide multiple immunizations in a single injection. They can simplify vaccine administration and have the potential to promote compliance and cost-effectiveness by decreasing the number of injections needed to immunize a child [Zinke, 2010; Kalies, 2006]. Use of combination vaccines can alleviate concerns associated with the number of injections to be given at one time [ACIP, 2011].

GlaxoSmithKline (GSK) Biologicals' *Infanrix hexa* vaccine helps prevent six diseases in a single injection. *Infanrix hexa* is licensed for primary and booster vaccination in more than 98 countries around the globe, including the entire European Union. The vaccine complies with the World Health Organization (WHO) requirements for manufacture of biological substances for all of its antigenic components. The *Infanrix hexa* vaccine consists of a combination of GSK's *Pediarix* (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined); STN 103907, approved in the US on December 13, 2002 and a *Haemophilus influenzae* (*H. influenzae*) type B (Hib) vaccine consisting of purified polyribosyl-ribitol-phosphate (PRP) capsular polysaccharide of *Haemophilus influenzae* type b covalently bound to tetanus toxoid (TT). The conjugated Hib-TT is the same as that used for the formulation of *Hiberix* [*Haemophilus* b Conjugate Vaccine (Tetanus Toxoid Conjugate)] (licensed in the US as a booster dose in August 2009, and as a primary dose in January 2016), with the only difference that in *Infanrix hexa*, the Hibconjugate is adsorbed onto aluminium phosphate.

The *Infanrix hexa* combination vaccine would provide an additional source of DTaP (combined diphtheria-tetanus-acellular pertussis vaccine), hepatitis B, poliovirus, and Hib containing vaccines for the US market and would potentially reduce the number of injections required to provide infants with recommended vaccinations.

GSK has an extensive clinical safety database for *Infanrix hexa*. The safety and immunogenicity data of the vaccine have been evaluated in numerous controlled studies [Dhillon, 2010; Zepp, 2009], of which 4 were conducted in the US with approximately 3000 US subjects exposed to a primary vaccination with *Infanrix hexa*.

3.1. Rationale for the study

Infanrix hexa was licensed in the European Union in 2000. More than 150 million doses have been distributed to date and the benefit/risk profile remains favorable. Licensure of Infanrix hexa combination vaccine in the US was to provide an additional option for vaccination within the routine US pediatric schedule with the fewest number of injections, which would create opportunities to add further injections in case other novel vaccines against important pediatric diseases become available. Furthermore, Infanrix hexa was to provide an additional source of DTaP, hepatitis B, poliovirus, and Hib-containing vaccine to the US market, which would help ensure a more stable supply.

The present study 117119 (DTPA-HBV-IPV-135) was intended to generate pivotal immunogenicity data demonstrating non-inferiority of the immune responses against pertussis antigens of *Infanrix hexa* compared to *Pediarix*, which is currently one of the DTaP combination vaccines widely used as a standard of care in the US. Additionally, this study was to also provide descriptive data with regard to the immunogenicity of the other vaccine antigens and the safety profile in US subjects. These pivotal immunogenicity non-inferiority data for pertussis and descriptive safety data were intended to support the registration of GSK Biologicals' combined DTPa-HBV-IPV/Hib (*Infanrix hexa*) vaccine in the US. A subsequent Phase III study was planned to provide pivotal data regarding lot-to-lot consistency, safety and the immunogenicity of the other vaccine antigens.

Comparison of immunogenicity data from separate clinical studies for *Infanrix hexa* and *Pentacel*, given on a 2-4-6 month schedule, suggests that the immune response to the Hib component of these vaccines is similar. This study was to provide descriptive information regarding the immune response to the Hib components of *Infanrix hexa* and *Pentacel* following a 3-dose primary series, prior to further evaluation in Phase III studies.

4. STUDY OBJECTIVES

4.1. Primary objective

4.1.1. Epoch 001 (Primary vaccination)

• To demonstrate the non-inferiority of *Infanrix hexa* to *Pediarix* co-administered with *ActHIB*, in terms of antibody geometric mean concentrations (GMCs) for pertussis antigens [pertussis toxoid (PT), filamentous haemagglutinin (FHA) and pertactin (PRN)] one month after the third dose of the primary vaccination.

Criteria for non-inferiority:

Non-inferiority in terms of immune response to pertussis antigens was to be demonstrated if, for each of the three antigens, the upper limit of the 95% confidence interval (CI) on the GMC ratio [Pedia divided by Hexa] was ≤ 1.5 .

Refer to Section 5.10.1 for the definition of the primary endpoint.

4.2. Secondary objectives

4.2.1. Epoch 001 (Primary vaccination)

- To assess the immune response to *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B*, in terms of seroprotection status, seropositivity status and concentrations or titers of antibodies to D (Diphtheria), T (Tetanus), HBs (Hepatitis B surface antigen), pertussis, poliovirus types 1, 2 and 3 and PRP (Polyribosyl-Ribitol-Phosphate) antigens, one month after the third dose of the primary vaccination.
- To assess the safety and reactogenicity of a 3-dose primary vaccination course of *Infanrix hexa*, of *Pentacel* co-administered with *Engerix-B*, and that of *Pediarix* co-administered with *ActHIB*, in terms of solicited local symptoms.
- To assess the safety and reactogenicity of all study vaccines in terms of solicited general events, unsolicited adverse events, new-onset chronic illnesses (NOCIs; referred to as new-onset chronic diseases (NOCDs) in the protocol) and serious adverse events (SAEs).

4.2.2. Epoch 002 (Booster vaccination)


- To assess the immunogenicity of *Infanrix hexa*, *Pentacel*, *Engerix-B*, *Pediarix* and *ActHIB*, in terms of persistence of the antibodies to D, T, pertussis, HBs, poliovirus types 1, 2 and 3 and PRP antigens, before the booster dose.
- To assess the immune response to *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*, in terms of seroprotection status, seropositivity status and antibody concentrations or titers for D, T, pertussis and PRP antigens, and in terms of booster response for pertussis antigens following *Infanrix* and *Pentacel*, one month after the booster dose.
- To assess the safety and reactogenicity of booster doses of *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*.

Refer to Section 5.10.2 for the definition of the secondary endpoints.

5. INVESTIGATIONAL PLAN

5.1. Study design

5.1.1. Overview



N = number of subjects in the study; n = number of subjects in each group; Mo = months

Visit 3 should be conducted at least 8 weeks after Visit 2, with subjects at least 24 weeks of age, in order to comply with US recommendations on hepatitis B dosing

Post-Pri = blood sample collected from subjects, one month after the administration of the third dose in the Epoch 001 Pre-Bst = blood sample collected from subjects, before the administration of the booster dose in the Epoch 002 Post-Bst = blood sample collected from subjects, one month after the administration of booster dose in the Epoch 002 * Engerix-B should not be given at Month 2 (4 months of age) if a dose of hepatitis B vaccine was given at birth up to 30 days prior to study dose 1 to the subject in the Penta Group ESFU = Extended safety follow-up

5.1.2. Overall study design – Description

- Experimental design: Phase III, open-label, randomized, controlled, multi-centric, single-country study with five parallel groups.
- Duration of the study: The intended duration of the study per subject was approximately 14-17 months.
 - Epoch 001: Primary, starting at Visit 1 (Day 0) and ending at safety follow up contact (i.e. six months following the third dose, Month 10);
 - Epoch 002: Booster, starting at Visit 5 (Month 13-16) and ending at Visit 6 (Month 14-17).
- Study groups: The study groups and epochs foreseen in the study are presented in Table 1.

Table 1 Study groups and epochs foreseen in the study

Study groups	Number of publicate	Age (Min/Mex) et Vieit 1	Epochs		
Study groups	Number of subjects	Age (Min/Max) at Visit 1	Epoch 001	Epoch 002	
Hexa_1	65	6 weeks -12 weeks	Х	Х	
Hexa_2	65	6 weeks -12 weeks	Х	Х	
Hexa_3	65	6 weeks -12 weeks	Х	Х	
Pedia	195	6 weeks -12 weeks	Х	Х	
Penta	195	6 weeks -12 weeks	Х	Х	

The study groups and treatment foreseen in the study are presented in Table 2.

Table 2 Study groups and treatment foreseen in the study

Treatment	Vaccine/Product name		Stud	y Groups		
name		Hexa_1	Hexa_2	Hexa_3	Pedia	Penta
	E	poch 001	•			
Infanrix hexa						
-	Hib	X	Х	Х		
Pediarix					Х	
ActHIB	ActHIB					
-	NaCl				Х	
Pentacel	DTaP-IPV (Sanofi Pasteur)					
-	ActHIB					Х
Engerix-B *	HBV					Х
Prevnar13	Prevenar 13	Х	Х	Х	Х	Х
Rotarix	HRV	Х	Х	Х	Х	Х
	CaCO ₃					
	E	poch 002	•	•		
Infanrix	DTPa	Х	Х	Х	Х	
Hiberix	Hib	Х	Х	Х		
<u> </u>	NaCl					
ActHIB	ActHIB				V	
	NaCl				Х	
Pentacel	DTaP-IPV (Sanofi Pasteur)					х
	ActHIB					٨

^{*} Engerix-B should not be given at Month 2 (4 months of age) if a dose of hepatitis B vaccine was given at birth up to 30 days prior to study dose 1 to the subject in the Penta Group.

- Control: active controls.
 - Epoch 001: *Pediarix* + *ActHIB* and *Pentacel* + *Engerix-B*;
 - Epoch 002: *Infanrix* + *ActHIB* and *Pentacel*.

Vaccination schedules:

Epoch 001

- Hexa Group: Subjects in this group were to receive three doses of *Infanrix hexa* (lot A, lot B or lot C as per the group allocation) co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
 - Hexa_1 Group: Subjects were to receive lot A of *Infanrix hexa*;
 - Hexa_2 Group: Subjects were to receive lot B of *Infanrix hexa;*
 - Hexa_3 Group: Subjects were to receive lot C of *Infanrix hexa*.
- Pedia Group: Subjects in this group were to receive three doses of *Pediarix* and *ActHIB* co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
- Penta Group: Subjects in this group were to receive three doses of *Pentacel* and *Engerix-B** co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
- *Subjects in the Penta Group who received a dose of hepatitis B vaccine from birth up to 30 days prior to study vaccination were not to receive *Engerix-B* at 4 months of age (Visit 2).

Epoch 002

- Hexa Group: Subjects were to receive a booster dose of *Infanrix* and *Hiberix* vaccines at 15-18 months of age.
- Pedia Group: Subjects were to receive a booster dose of *Infanrix* and *ActHIB* vaccines at 15-18 months of age.
- Penta Group: Subjects were to receive a booster dose of *Pentacel* vaccine at 15-18 months of age.

The fourth dose of pneumococcal conjugate vaccine is recommended to be administered at approximately 12-15 months of age. Since the booster dose of the candidate vaccine/active controls were given in this study at 15-18 months of age, the fourth dose of *Prevnar13* was not to be administered as part of the study protocol. Subject's parent(s)/LARs were to be reminded at Visit 3 and Visit 4 to consult their primary health care provider regarding the fourth dose of *Prevnar13* at 12-15 months for their child.

- As the analyses were to be performed regardless of the lot of *Infanrix hexa* received, unless otherwise specified, the Hexa_1, Hexa_2 and Hexa_3 groups were pooled together for the analysis and were called the Hexa group.
- Treatment allocation: The subjects were randomized at a [1:1:1]:3:3 ratio to Hexa_1, Hexa_2, Hexa_3, Pedia and Penta groups. This was done at study entry using GSK Biologicals' central randomization system on internet (SBIR).

• Blinding: The study was open-label for both epochs (Table 3) due to the differences in the number of injections and the appearance of the vaccines administered. However, the laboratory in charge of the serology testing was blinded to the treatment, and codes were used to link the subject and study (without any link to the treatment attributed to the subject) to each sample.

The blinding of study epochs is presented in Table 3.

Table 3 Blinding of study epochs

Study Epochs	Blinding
Epoch 001	open
Epoch 002	open

- Sampling schedule: Blood samples were drawn from all subjects at the following time points:
 - Post-Pri (Visit 4): One month after the third dose of primary vaccination,
 a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) was collected.
 - Pre-Bst (Visit 5): Before the administration of the booster dose, a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) was collected.
 - Post-Bst (Visit 6): One month after the booster vaccination, a volume of at least
 3.5 mL of whole blood (to provide at least 1.2 mL of serum) was collected.
- Type of study: self-contained.
- Data collection: electronic Case Report Form (eCRF).

5.1.3. Discussion of study design

5.1.3.1. Design of Epoch 001 (primary vaccination):

The study was designed as a randomized, controlled, open-label study with five parallel groups:

- The first three groups (Hexa_1, Hexa_2 and Hexa_3 group) were to receive three doses of the *Infanrix hexa* vaccine (either lot A, lot B or lot C, respectively). These three groups were pooled together for the analyses and the pooled group was called the Hexa group.
- The Pedia Group (Control 1) was to receive three doses of the US-licensed control vaccines, *Pediarix* and *ActHIB*.
- The Penta Group (Control 2) was to receive three doses of the US-licensed control vaccines, *Pentacel* and *Engerix-B* (only two doses of *Engerix-B* were to be administered if a subject had received a birth dose of hepatitis B vaccine).

Three distinct vaccine lots manufactured according to the same procedures were used in the Hexa group in order to obtain more representative data for the vaccine.

The study was open-label due to the differences in the number of injections and the appearance of the vaccines administered.

Vaccines (i.e., *Prevnar13* and *Rotarix*) that were recommended for children in the US during the first year of life were administered concomitantly with the other study vaccines as part of the study.

5.1.3.2. Design of Epoch 002 (booster vaccination):

In Epoch 002, the subjects were assessed for antibody persistence to the vaccine antigens of *Infanrix hexa*. This epoch was also to assess the adequacy of priming subjects with *Infanrix hexa* by evaluating the boostability of D, T, Pa (Acellular *Bordetella pertussis* component) and Hib antigens with the US-licensed vaccines. The pooled Hexa Group was to receive booster doses of *Infanrix* and *Hiberix* vaccines at 15 through 18 months of age, the subjects in the Penta Group were to receive *Pentacel* vaccine as a booster, and the subjects in the Pedia Group were to receive a booster dose of *Infanrix* and *ActHIB* vaccines at 15 through 18 months of age.

The study was to continue to be open-label in Epoch 002.

5.2. Study procedures

Table 4 List of study procedures

	EPOCH 001 (PRIMARY VACCINATION)					EPOCH 002 (BOOSTER VACCINATION)	
Age	2 Months	4 Months	6 Months	7 Months	12 Months	15-18 Months	
Visit	Visit 1	VISIT 2	VISIT 3 †	VISIT 4	ESFU CONTACT (PHONE)	VISIT 5	VISIT 6
Time point	Day 0	Month 2	Month 4	Month 5	Month 10	Month 13 -16	Month 14 - 17
Sampling time point				Post-Pri		Pre-Bst	Post-Bst
Informed consent	•						
Check inclusion/exclusion criteria	•						
Medical history	•						
Collect demography data	•						
Vaccination history including HepB vaccination history	•						
Informed consent for Tdap vaccination history of mother $^{\alpha}$	•						
Last Tdap vaccination history of mother ^β	•						
History directed physical examination including length and weight	•					•	
Study group and treatment number allocation (Randomization)	0						
Treatment number allocation for subsequent doses		0	0			0	
Recording of administered treatment number	•	•	•			•	
Pre-vaccination body temperature	•	•	•			•	
Blood sampling				•		•	•
Check warnings and precautions	0	0	0			0	
Check contraindications to subsequent vaccination		•	•			•	
Pre-vaccination measurement of circumference of limb(s) at site of injection						•	
by investigator $^{\delta}$						•	
Vaccination	•	• **	•			•	
Distribution of thermometer	0						
Distribution of measuring device	0					0	
Distribution of diary cards	0	0	0			0	

117119 (DTPA-HBV-IPV-135)

Report Final

	EPOCH 001 (PRIMARY VACCINATION)				Еросн 002		
			-			(Booster V	ACCINATION)
Age	2 Months	4 Months	6 Months	7 Months	12 Months	15-18 Months	16-19 Months
Visit	VISIT 1	VISIT 2	VISIT 3 †	Visit 4	ESFU	VISIT 5	VISIT 6
					CONTACT (PHONE)		
Time point	Day 0	Month 2	Month 4	Month 5	Month 10	Month 13 -16	Month 14 - 17
Sampling time point	•			Post-Pri		Pre-Bst	Post-Bst
Daily post-vaccination recording of solicited adverse events during the 4-day (Day 0–3) follow-up period, recorded by the subjects' parent(s)/LAR(s) in diary card	•	•	•			•	
Recording of non-serious (unsolicited) adverse events during the 31-day (Day 0–30) follow-up period, recorded by the subjects' parent(s)/LAR(s) in diary card	•	•	•			•	
Recording of any large injection site reactions in the eCRF by the investigator*						•	
Return of diary cards and transcription by the investigator		•	•	•			•
Record any concomitant medication and vaccination §	•	•	•	•	•	•	•
Record any intercurrent medical conditions		•	•	•	•	•	•
Recording of serious adverse events including related to study participation or to a concurrent GSK medication/vaccine	•	•	•	•	•	•	•
Recording of NOCIs‡	•	•	•	•	•	•	•
Investigator sign-off				•			•
Analysis of the Epoch 001 #				0			
Analysis of the Epoch 002 #							0
Study Conclusion							•

Note: The double-line border indicated the analyses which were performed on all data obtained up to that visit or contact.

- was used to indicate a study procedure that required documentation in the individual eCRF
- o was used to indicate a study procedure that did not require documentation in the individual eCRF

Post-Pri = blood sample collected from subjects, one month after the administration of the third dose in the Epoch 001

Pre-Bst = blood sample collected from subjects, before the administration of the booster dose in the Epoch 002

Post-Bst = blood sample collected from subjects, one month after the administration of booster dose in the Epoch 002

- † Visit 3 was to be conducted at least 8 weeks after Visit 2 and when the subject was at least 24 weeks of age
- ^a The child could still continue in the study even if the mother did not wish to provide consent to record her Tdap vaccination history.

^β Only the Tdap vaccination history (during the pregnancy of the enrolled child) from mothers who had given consent to provide this information, was obtained and recorded in the eCRF.

117119 (DTPA-HBV-IPV-135)

Report Final

§ Refer to Section 5.6 for details

Refer to Section 5.7 for details

‡ New onset of chronic illness (NOCI) included events such as autoimmune disorders, asthma, type I diabetes and allergies

Refer to Section 5.10.8 for details

^δ For the Penta group, which received only one vaccine at Visit 5, baseline measurement of only the limb receiving the vaccine was required *** If subject in the Penta Group received a birth dose of Hep B vaccine, no administration of *Engerix-B* was foreseen at Visit 2 (4-months of age)

^{*} Refer to Section 5.9.2.1 and the study protocol (Section on Baseline measurement of limb circumference after booster vaccination at Visit 5) for detailed explanation on the reporting of large injection site reactions

It was the investigator's responsibility to ensure that intervals between visits were strictly followed. The intervals between study visits are presented in Table 5.

Table 5 Intervals between study visits

Interval	Optimal length of interval ¹
Birth→Visit 1	6-12 weeks (42-90 days) of age ²
Visit 1 →Visit 2	49-83 days ²
Visit 2 →Visit 3 *	56-90 days²
Visit 3 → Visit 4	30-48 days ² †
Visit 3 → Phone call (ESFU contact)	180-210 days**
Birth→ Visit 5 [^]	15-18 months of age ²
Visit 5 → Visit 6	30-48 days ² †

¹ Whenever possible the investigator was to arrange within this interval:

5.3. Selection of study population

5.3.1. Number of subjects/centers

Target enrolment was 585 subjects (65 each in Hexa_1, Hexa_2, Hexa_3 groups and 195 each in Pedia and Penta groups). Enrolment was to be terminated when the target number of subjects had been enrolled. Refer to Section 5.10.3 for a detailed description of the criteria used in the estimation of sample size.

This study was conducted at multiple centers (43 centers) in the US.

Actual numbers of subjects enrolled versus target was monitored by the site monitor using SBIR.

² Subjects were not to be eligible for inclusion in one or more cohorts for analysis if they made the study visit outside this interval. For Visit 3-Visit 4 and Visit 5-Visit 6, an interval of 21-48 days was considered for the According-to-protocol (ATP) cohort of immunogenicity. Refer to Section 5.10.4 for the definition of the cohorts for analysis;

^{*} Advisory Committee on Immunization Practices (ACIP) recommendation stated that minimum age of last Hep B dose was 24 weeks and this last dose was to be administered at least 8 weeks after the previous dose. So, Visit 3 was to be conducted at least 8 weeks after Visit 2 and when the subject was at least 24 weeks of age

[†] It was preferred that subjects came in for Visit 4 and Visit 6, at least 30 days after Visits 3 and 5, respectively. If subjects returned for the visit prior to 30 days, they were to take home the diary card and continue to record unsolicited safety information until 30 days post-vaccination and mail/send it upon completion. Investigators were to make an attempt to retrieve diary cards from subjects who had not mailed/sent them in.

[^] Visit 5 was to occur after the ESFU. ESFU was to occur prior to vaccination if Visit 5 coincided with the 6 months post-Visit 3 time-point.

^{**} Adherence to the interval pertaining to phone contact was only indicative and was not to determine a subject's eligibility for inclusion for ATP analysis. However, the interval was to be respected in order to obtain safety information over the complete 6 months extended safety follow up period.

5.3.2. Inclusion criteria for enrolment

Deviations from inclusion criteria were not allowed because they could potentially jeopardize the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol was essential.

All subjects were to satisfy ALL the following criteria at study entry:

- Subjects' parent(s)/ LAR(s) who, in the opinion of the investigator, could and would comply, with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
- A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.
- Born full-term (i.e. after a gestation period of 37 weeks to less than 42 completed weeks [259 to 293 days]).
- Written informed consent obtained from parent(s)/LAR(s) of the subject.
- Healthy subjects as established by medical history and clinical examination before entering into the study.
- Infants who had not received a previous dose of hepatitis B vaccine or those who had received only 1 dose of hepatitis B vaccine administered at least 30 days prior to enrolment.

5.3.3. Exclusion criteria

Deviations from exclusion criteria were not allowed because they could potentially jeopardize the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol was essential.

The following criteria were to be checked at the time of study entry. If ANY exclusion criterion applied, the subject must not be included in the study:

- Child in care
 - Please refer to the GLOSSARY OF TERMS for the definition of child in care.
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccines, or planned use during the study period.
- Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs since birth. For corticosteroids, this meant prednisone ≥ 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids were allowed.

- Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting from 30 days before the first vaccination until 30 days after Dose 3 (Epoch 001, primary vaccination) and from 30 days before the booster Dose 4 until 30 days after booster Dose 4 (Epoch 002, booster vaccination), i.e. the end of the study:
 - Inactivated influenza and hepatitis A vaccines were allowed throughout the study.
 - Routine administration(s) of vaccines were allowed from 30 days after the last dose of primary vaccination until 30 days before the booster dose and after post-booster blood sampling. Routine administration of measles-mumps-rubella vaccine, varicella, pneumococcal vaccines were allowed from 30 days after last dose of primary vaccine until 30 days before booster dose and from post-booster blood sampling, as well as according to the recommended immunization schedule in US.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject had been or was to be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- History of Hib, diphtheria, tetanus, pertussis, pneumococcal, rotavirus, poliovirus and hepatitis B diseases.
- Previous vaccination against Hib, diphtheria, tetanus, pertussis, pneumococcus, rotavirus and/or poliovirus; more than one previous dose of hepatitis B vaccine.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- Family history of congenital or hereditary immunodeficiency.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines (including yeast).
- Hypersensitivity to latex.
- Major congenital defects or serious chronic illness.
- History of any neurological disorders including seizures.
- Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
- History of intussusception or of any uncorrected congenital malformation of the gastrointestinal tract that would predispose the infant to intussusception.
- History of Severe Combined Immunodeficiency Disease (SCID).
- Acute disease and/or fever at the time of enrolment.
 - Fever was defined as temperature ≥38.0°C /100.4°F by any route. The preferred route for recording temperature in this study was rectal for Epoch 001 and axillary for Epoch 002.
 - Subjects with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever could be enrolled at the discretion of the investigator.

5.3.4. Withdrawal criteria

5.3.4.1. Subject completion

Any subject who returned for the concluding visit / was available for the concluding contact foreseen in the protocol, was considered to have completed the study.

5.3.4.2. Subject withdrawal

Withdrawals were not to be replaced.

5.3.4.2.1. Subject withdrawal from the study

From an analysis perspective, a 'withdrawal' from the study referred to any subject who did not come back for the concluding visit/was not available for the concluding contact foreseen in the protocol.

All data collected until the date of withdrawal/last contact of the subject was used for the analysis.

A subject was considered a 'withdrawal' from the study when no study procedure had occurred, no follow-up had been performed and no further information had been collected for this subject from the date of withdrawal/last contact.

Investigators were to make an attempt to contact those subjects who did not return for scheduled visits or follow-up.

Information relative to the withdrawal was documented in the eCRF. The investigator was to document whether the decision to withdraw a subject from the study was made by the subject's parent(s) or LAR(s), or by the investigator, as well as which of the following possible reasons was responsible for withdrawal:

- Serious adverse event
- Non-serious adverse event
- Protocol violation (specify)
- Consent withdrawal, not due to an adverse event*
- Moved from the study area
- Lost to follow-up
- Other (specify)

^{*}In case a subject was withdrawn from the study because the subject's parent(s) had withdrawn consent, the investigator was to document the reason for withdrawal of consent, if specified by the parents/ LARs, in the eCRF.

117119 (DTPA-HBV-IPV-135) Report Final

Subjects who were withdrawn from the study because of SAEs/AEs were to be clearly distinguished from subjects who were withdrawn for other reasons. Investigators were to follow subjects who were withdrawn from the study as result of a SAE/AE until resolution of the event (see Section 5.9.8.2).

5.3.4.2.2. Subject withdrawal from investigational vaccine

A 'withdrawal' from the investigational vaccine referred to any subject who did not receive the complete treatment, i.e. when no further planned dose was administered from the date of withdrawal. A subject withdrawn from the investigational vaccine could not necessarily be withdrawn from the study as further study procedures or follow-up could be performed (safety or immunogenicity) if planned in the study protocol.

Information relative to premature discontinuation of the investigational vaccine was to be documented on the Vaccine Administration screen of the eCRF. The investigator was to document whether the decision to discontinue further vaccination/treatment was made by the subject's parent(s) or LAR(s), or by the investigator, as well as which of the following possible reasons was responsible for withdrawal:

- Serious adverse event.
- Non-serious adverse event.
- Other (specify).

5.4. Composition and administration of vaccine(s)

5.4.1. Description of vaccines

All candidate vaccines that were used were developed and manufactured by GSK Biologicals, except for the following four marketed vaccines with name of manufacturer provided in brackets: *ActHIB* (Sanofi Pasteur SA), *Pentacel* (Sanofi Pasteur SA), *Prevnar* (Wyeth Pharmaceuticals Inc.; Marketed by Pfizer Inc.), and *Prevnar13* (Wyeth Pharmaceuticals Inc.; Marketed by Pfizer Inc.).

The Quality Control Standards and Requirements for each candidate vaccine were described in separate Quality Assurance documents (e.g. release protocols, certificate of analysis) and the required approvals were obtained.

The vaccines were labelled and packed according to applicable regulatory requirements.

Commercial vaccines were assumed to comply with the specifications given in the manufacturer's Summary of Product Characteristics (SPC).

Table 6 Study vaccines

Treatment name	Vaccine/ Product name	Formulation	Presentation	Volume	Number of doses		
Infanrix hexa Lot A: AC21VB448C and AHIBC950C; Lot B:	DTPa-HBV-IPV	DT>=30IU; TT>=40IU; PT=25µg; FHA=25µg; PRN=8µg; HBsAg=10µg; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; Aluminium=700µg Al3+	The DTPa-HBV-IPV component was presented as a turbid white suspension in a pre-filled syringe.	full volume^		full values A	3
AC21B514A and AHIBC907D; Lot C: AC21B510B and AHIBC954A.	Hib	PRP=10µg; TT~=25µg Aluminum as salts = 0.12 mg The lyophilized Hib component was presented as a white pellet in a glass vial; it was reconstituted before use with the DTPa-HBV- IPV component.					
Pediarix Lot no.: AC21VB448C	DTPa-HBV-IPV	DT>=30IU; TT>=40IU; PT=25µg; FHA=25µg; PRN=8µg; HBsAg=10µg; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; Aluminium=700µg Al3+	The DTPa-HBV-IPV component was presented as a turbid white suspension in a pre-filled syringe.	0.5 mL	3		
ActHIB Lot no.: DLOCA106AZ (Alternative Lot no. UH971AA), DLOCA150AZ	ActHIB	Hib=10μg TT, TT=24μg	White lyophilized pellet in a single dose vial, it was reconstituted before use with sterile 0.4% saline solution				
(Alternative Lot no. UI117AA; only for Epoch 2). Lot no.: DLOCA106AY (Alternative Lot no. UH954AB), DLOCA150AY (Alternative Lot no. UI128AA; only for Epoch 2).	NaCl	NaCl=60mM	Sterile 0.4% saline solution	0.5 mL*	4		

117119 (DTPA-HBV-IPV-135) Report Final

		T	T	1 (0)	ort Final
Treatment name	Vaccine/ Product name	Formulation	Presentation	Volume	Number of doses
Pentacel First Lot: Lot no. DLOCA102AY (Alternative Lot no. C4507AA) Lot no.: DLOCA102AZ	DTaP-IPV (Sanofi Pasteur)	PT=20µg; FHA=20µg; FIM=5µg; PRN=3µg; DT=15Lf; TT=5Lf; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU	Suspension for injection (0.5-mL dose) supplied		
(Alternative Lot no. C4557AA) Second Lot: Lot no. DLOCA108AY (Alternative Lot no. C4517BA) Lot no.: DLOCA108AZ (Alternative Lot no. C4574AA) Third Lot Lot no. DLOCA144AY (Alternative Lot. No. C4724AA) DLOCA144AZ (Alternative Lot. No. C4724AA) DLOCA144AZ (Alternative Lot. No. C4642AA)	Hib	PRP=10µg TT,TT=24µg; AIPO₄=330µg Al3+	as a liquid vaccine component in a single dose vial. The lyophilized Hib component was presented as a white pellet in a separate glass vial. It was reconstituted with the liquid DTaP-IPV component before use.	0.5 mL*	4
Engerix-B Lot no.: AHBVC253A	HBV	HBsAg=10μg; Al(OH) ₃ =250μg Al3+	Suspension pre- filled syringe	0.5 mL	2 or 3**
Infanrix Lot no.: AC14B195A	DTPa	DT>=30IU; TT>=40IU; PT=25µg; FHA=25µg; PRN=8µg; AIPO₄=500µg AI3+	Homogeneous, turbid, white suspension in a pre-filled syringe	0.5 mL	1
Hiberix Lot no.: AHIBC875A Lot no.: DEXTA517AZ	Hib	PRP=10μg; TT~=25μg	The lyophilized Hib component was presented as a white pellet in a glass vial; it was reconstituted before use with sterile 0.9% saline solution.	0.5 mL*	1
	NaCl	NaCl=150mM	Sterile 0.9% saline solution		

117119 (DTPA-HBV-IPV-135) Report Final

Treatment name	Vaccine/ Product name	Formulation	Presentation	Volume	Number of doses
Prevnar13 Lot no.: DLOCA107A (Alternative Lot no. H39264)	Prevenar 13	PS1=2.2µg CRM197; PS3=2.2µg CRM197; PS4=2.2µg CRM197; PS5=2.2µg CRM197; PS6A=2.2µg CRM197; PS6B=4.4µg CRM197; PS7F=2.2µg CRM197; PS9V=2.2µg CRM197; PS14=2.2µg CRM197; PS18C=2.2µg CRM197; PS19A=2.2µg CRM197; PS19F=2.2µg CRM197; PS23F=2.2µg CRM197; AIPO ₄ =125µg AI3+	Suspension for injection in a pre-filled syringe.	0.5 mL	3
Rotarix Lot no.: AROTVA291D Lot no. AD05VA833A	HRV CaCO ₃	HRV RIX4414=10 ⁶ · ⁰ CCID ₅₀ CaCO ₃ =60μg	Lyophilized vaccine in a monodose glass vial was reconstituted with the calcium carbonate buffer diluent Diluent (calcium carbonate liquid	1.0 mL*	2
			buffer) supplied separately in prefilled syringe		

CCID₅₀ = median Cell Culture Infective Dose; DMEM = Dulbecco's Modified Eagle Medium

5.4.2. Dosage and administration of study vaccines

The injectable vaccines must be administered intramuscularly, at a 90-degree angle into the anterolateral side of the thigh [Centers for Disease Control and Prevention (CDC), 2002] on the side stated in Table 7. The buttock was not to be used.

In order to ensure proper intramuscular injection of the vaccines, a needle of at least 1 inch (2.54 cm) length, 25 gauge was used [Diggle, 2006; Zuckerman, 2000].

For reconstitution of *Infanrix hexa* vaccine, an appropriate needle was attached to the prefilled syringe containing the DTPa-HBV-IPV liquid vaccine and inserted into the vial containing the lyophilized Hib vaccine. The entire contents of the syringe were to be transferred to the vial. With needle still inserted, the vial was to be vigorously shaken. After reconstitution, the full volume of the vial (0.5 mL) was then withdrawn using the same syringe. A new needle was then to be affixed to the syringe for administration of the vaccine.

^{*} After reconstitution

^{**} Subjects in the Penta Group who received a birth dose of hepatitis B vaccine were not to receive *Engerix-B* at the Month 4 visit (Visit 2)

[^] Full volume after reconstitution (0.5 mL) to be administered

NOTE: After reconstitution, *Infanrix hexa* was to be injected immediately. However the vaccine might have been kept for up to 8 hours at room temperature (21°C).

The vaccinees were observed closely for at least 30 minutes following the administration of vaccines, with appropriate medical treatment readily available in case of a rare anaphylactic reaction.

Rotarix must be exclusively administered orally. DO NOT INJECT.

The contraindications and warnings/precautions to vaccination were specified in the protocol (see protocol for details).

Table 7 Dosage and administration

Visit	Study Group	Treatment name Route 1 Site				
		Epoch 001	•			
1, 2, 3	Hexa Group	Infanrix hexa	IM	T	R	
		(lot A, lot B or lot C)				
1, 2, 3		Prevnar13	IM	T	LoL	
1, 2		Rotarix	0	-	-	
1, 2, 3	Pedia Group	Pediarix	IM	T	R	
1, 2, 3		ActHIB	IM	T	UpL	
1, 2, 3		Prevnar13	IM	T	LoL	
1, 2		Rotarix	0	-	-	
1, 2, 3	Penta Group	Pentacel	IM	T	R	
1, 2, 3		Engerix-B [†]	IM	T	UpL	
1, 2, 3		Prevnar13	IM	T	LoL	
1, 2		Rotarix	0	-	-	
		Epoch 002*				
5	Hexa Group	Infanrix	IM	T	R	
		Hiberix	IM	T	L	
5	Pedia Group	Infanrix IM T		R		
		ActHIB	IM	T	L	
5	Penta Group	Pentacel IM T R				

¹Oral (O), Intramuscular (IM); ²Thigh (T), ³Left (L), Right (R), Upper Left (UpL), Lower Left (LoL)

5.4.3. Treatment allocation and randomisation

5.4.3.1. Subject identification

After checking the inclusion/exclusion criteria, subject numbers were assigned sequentially to subjects whose parent(s)/LAR(s) gave consent for their child to participate in the study, according to the range of subject numbers allocated to each study center. Subject numbers were also to be used to identify blood samples collected during the study.

Note: Vaccination could be performed in the opposite side in case of medical indication preventing vaccination in the side stated in the table, as judged by the investigator

[†]Subjects in the Penta Group who received a birth dose of hepatitis B vaccine were not to receive *Engerix-B* at the Month 4 visit (Visit 2).

^{*} Toddlers (12 Months through 2 Years): For toddlers, the vastus lateralis muscle in the anterolateral thigh was preferred. The needle was at least 1-inch long. The deltoid muscle could be used if the muscle mass was adequate.

5.4.3.2. Randomization of treatment

5.4.3.2.1. Randomization of supplies

The numbering of supplies was performed at GSK Biologicals, using MATerial EXcellence (MATEX), a program developed for use in Statistical Analysis System (SAS®) (Cary, NC, USA) by GSK Biologicals.

To allow GSK Biologicals to take advantage of greater rates of recruitment than anticipated at individual centers in this multi-center study and to thus reduce the overall study recruitment period, an over-randomization of supplies was prepared.

Epoch 001

A first list based on a randomization blocking scheme using a [1:1:1]:3:3 randomization ratio was used to number the following vaccines for Doses 1, 2 and 3.

- DTPa-HBV-IPV/Hib lot A
- DTPa-HBV-IPV/Hib lot B
- DTPa-HBV-IPV/Hib lot C
- Pediarix
- Pentacel

The vaccines from this list were distributed to the study center while respecting the randomization block size

ActHIB, Engerix-B, Prevnar13 and Rotarix were numbered independently using a sequential numbering.

Epoch 002

Four sequential lists (one for *Infanrix*, one for *Hiberix*, one for *ActHIB* and one for *Pentacel*) were used to number the vaccine doses for the Epoch 002.

The study staff members in charge of the vaccine administration were to access SBIR, provide the subject identification number and the dose number. The system was to provide a new treatment number for all the vaccines to be administered to a subject (*Pentacel*, *Infanrix* + *ActHIB* or *Infanrix* + *Hiberix*). This was consistent with the allocated study group.

5.4.3.2.2. Treatment allocation to the subject

The treatment numbers were allocated by dose.

Study group and treatment number allocation

The target was to enroll 585 subjects to be randomly assigned to five study groups in a [1:1:1]:3:3 ratio (195 subjects in the pooled lots group).

Allocation of each subject to a study group at the investigator site was performed using SBIR. The randomization algorithm was to use a minimization procedure accounting for the study as a whole and for each of the centers with equal weight.

After obtaining the signed and dated Informed Consent Form (ICF) from the subject's parent(s)/LAR(s) and having checked the eligibility of the subject, the site staff member in charge of the vaccine administration was to access SBIR. Upon providing the subject identification number, the randomization system was to ask whether the subject had a previous hepatitis B vaccination and was to use the minimization algorithm to determine the group allocation and the appropriate treatment number for *Pentacel*, *Pediarix* or for *Infanrix hexa* (lot A, lot B or lot C) to be used for the subject.

SBIR was to also provide treatment numbers for co-administered vaccines *Engerix B*, *ActHib*, *Prevnar13* vaccine and a *Rotarix* vaccine, each one labelled with a different treatment number. Therefore a subject was to have three or four different treatment numbers allocated at dose 1.

The number of each administered treatment had to be recorded in the eCRF on the Vaccine Administration screen.

When SBIR was not available, study staff members were referred to the SBIR user guide or the SPM for specific instructions.

Treatment number allocation for subsequent doses

For each dose subsequent to the first dose, the study staff member in charge of the vaccine administration was to access SBIR, provide the subject identification number, the dose number and the system was to provide new treatment numbers consistent with the allocated study group.

Each vaccine was to be labelled with a different treatment number.

The number of each administered treatment must be recorded in the eCRF on the Vaccine Administration screen.

Note that in the Penta Group, the investigator was to be reminded that *Engerix-B* was not allowed at dose 2, for subjects with previous hepatitis B vaccination. So for these subjects, the treatment identified by SBIR for dose 2 was not to be used.

5.5. Blinding

The study was open-label for both epochs due to the differences in the number of injections and the appearance of the vaccines administered. However, the laboratory in charge of the serology testing was to be blinded to the treatment, and codes were used to link the subject and study (without any link to the treatment attributed to the subject) to each sample.

5.6. Prior and concomitant medication /vaccinations

At each study visit/contact, the investigator was to question the subject's parent(s)/LAR(s) about any medication/product taken and vaccination received by the subject.

5.6.1. Recording of concomitant medications/products and concomitant vaccination

The following concomitant medications/products/vaccines must be recorded in the eCRF if administered during the indicated recording period:

- All concomitant medications/products, except vitamins and dietary supplements, administered within 30 days following each dose of study vaccine.
- Any concomitant vaccination administered since birth and ending 30 days after the booster dose (Visit 6). Vaccinations listed prior to the first dose of study vaccine were to be recorded as vaccination history. The fourth dose of *Prevnar13* was to be recorded as concomitant vaccination.
- Prophylactic medication (i.e. medication administered in the absence of ANY symptom and in anticipation of a reaction to the vaccination).
 - E.g. an anti-pyretic was considered to be prophylactic when it was given in the absence of fever and any other symptom, to prevent fever from occurring [fever was defined as temperature $\geq 38.0^{\circ}\text{C}/100.4^{\circ}\text{F}$ by any route].
- Any concomitant medications/products/vaccines listed in Section 5.6.2.
- Any concomitant medication/product/vaccine relevant to a SAE* or administered at any time during the study period for the treatment of a SAE*.
 - * Refer to those SAEs that are required to be reported per protocol.

5.6.2. Concomitant medications/products/vaccines that may lead to the elimination of a subject from ATP analyses

The use of the following concomitant medications/products/vaccines was not to require withdrawal of the subject from the study but may determine a subject's evaluability in the ATP analysis. See Section 5.10.4 for study cohorts/ data sets to be analysed.

- Any investigational or non-registered product (drug or vaccine) other than the study vaccines used during the study period (starting from Visit 1 and ending at Visit 6).
- Immunosuppressants or other immune-modifying drugs administered chronically (i.e. more than 14 days) during the study period until the final blood sample (Visit 6). For corticosteroids, this meant prednisone ≥ 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids were allowed.
- A vaccine not foreseen by the study protocol administered during the period starting from 30 days before the first vaccination until Post-Pri blood sampling i.e. approximately 30 days after Dose 3 (Epoch 001) and from 30 days before Pre-Bst until Post-Bst blood sampling i.e. approximately 30 days after Dose 4 (Epoch 002). Thus, routine administration(s) of measles-mumps-rubella, varicella and pneumococcal vaccines were allowed from 30 days after the last dose of primary vaccination (after Post-Pri blood sampling) until 30 days before the booster dose and from 30 days after the booster dose (after Post-Bst blood sampling), as well as according to the recommended immunization schedule in the US.

• Exceptions:

- Inactivated influenza vaccine and hepatitis A vaccines were allowed throughout the study.
 - In case an emergency mass vaccination for an unforeseen public health threat (e.g.: a pandemic) was organized by the public health authorities, outside the routine immunization program, the time period described above could be reduced if necessary for that vaccine provided it is licensed and used according to its SPC or Product Information and according to the local governmental recommendations and provided a written approval of the Sponsor was obtained.
- Immunoglobulins and/or any blood products administered during the study period until the final blood sample (Visit 6).

5.7. Intercurrent medical conditions that may lead to elimination of a subject from ATP analyses

At each study visit subsequent to the first vaccination visit, it had to be verified if the subject had experienced or was experiencing any intercurrent medical condition. If it was the case, the condition(s) had to be recorded in the eCRF.

- Subjects could be eliminated from the ATP cohort for immunogenicity if they incurred a condition that had the capability of altering their immune response or were confirmed to have an immunodeficiency condition.
- Subjects were to be eliminated from the ATP cohort for immunogenicity if they experienced intercurrent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and/or Hib prior to the post-dose 3 blood draw and diphtheria, tetanus, pertussis and/or Hib post-dose 4 blood draw.

5.8. Assessment of immunogenicity variables

5.8.1. Biological samples

Table 8 Biological samples

Sample type	Quantity*	Unit	Timepoint
Blood	5	mL	Month 5 (Post-Pri)
Blood	5	mL	Month 13-16 (Pre-Bst)
Blood	3.5	mL	Month 14-17 (Post-Bst)

^{*} Approximate quantity

Post-Pri = blood sample collected from subjects, one month after the administration of the third dose in the Epoch 001 Pre-Bst = blood sample collected from subjects, before the administration of the booster dose in the Epoch 002 Post-Bst = blood sample collected from subjects, one month after the administration of booster dose in the Epoch 002

5.8.2. Laboratory assays

At Visits 4, 5 and 6, blood was to be collected for measurement of immune response. Total blood volume to be taken from each subject over the study period was approximately 13.5 mL (approximately 5.0 mL of whole blood to provide approximately 1.7 mL of serum at Visits 4 and 5 and at least 3.5 mL of whole blood to provide approximately 1.2 mL of serum at Visit 6). All serology was to be determined in GSK Biologicals' laboratories, or in a laboratory designated by GSK, using standardized procedures with adequate controls. All serology for primary endpoints were to be determined in GSK Biologicals' laboratories, or in a laboratory designated by GSK, using standardized, validated procedures with adequate controls.

The laboratory assays for humoral immunity are presented in Table 9.

Table 9 Humoral Immunity (Antibody determination)

System	Component	Method	Test kit/	Unit	Cut-off	Laboratory
			Manufacturer			
Serum	Bordetella pertussis.	ELISA	In-house*	IU/mL	2.693	GSK Biologicals§
	Pertussis Toxin Ab.lgG					
Serum	Bordetella pertussis.	ELISA	In-house*	IU/mL	2.046	GSK Biologicals§
	Filamentous Hemaglutinin					
	Ab.lgG					
Serum	Bordetella pertussis.	ELISA	In-house*	IU/mL	2.187	GSK Biologicals§
Ì	Pertactin Ab.lgG					
Serum	Corynebacterium diphtheriae.	ELISA	In-house*	IU/mL	0.057	GSK Biologicals§
	Diphtheria Toxoid Ab.lgG					
Serum	Clostridium tetani.	ELISA	In-house*	IU/mL	0.043	GSK Biologicals§
	Tetanus Toxoid Ab.lgG					
Serum	Hepatitis B Virus.Surface Ab	CLIA	Centaur	mIU/mL	6.2	GSK Biologicals§
			(Siemens			
			Healthcare)			
Serum	Poliovirus Sabin	NEUTRA	In-house*	ED ₅₀	8	GSK Biologicals§
	Types 1, 2 and 3					
Serum	Haemophilus influenzae type	ELISA	In-house*	μg/mL	0.15	GSK Biologicals§
	b.				(qualified	
	Polyribosyl Ribitol Phosphate				assay)	
	Ab ‡				•,	
	•				0.066	
					(fully	
					vaÌidated	
					assay)	

^{*}In-house refers to assays developed internally by GSK which could be performed at GSK Biologicals' laboratories or external laboratory designated by GSK.

ELISA = Enzyme-Linked Immunosorbent Assay

NEUTRA = Neutralization Assay

CLIA = ChemiLuminescence ImmunoAssay

The GSK Biologicals' clinical laboratories have established a Quality System supported by procedures. The activities of GSK Biologicals' clinical laboratories are audited regularly for quality assessment by an internal (sponsor-dependent) but laboratory-independent Quality Department.

[§]GSK Biologicals laboratory referred to the Global Vaccines Clinical Laboratories (GVCL) (current name: Clinical Laboratory Sciences) in Rixensart and Wavre, Belgium.

[‡]For anti-PRP post-dose 3, the primary vaccination results were presented using the qualified assay and the fully validated assay. The booster vaccination results were presented only using the fully validated assay.

5.8.3. Biological samples evaluation

5.8.3.1. Immunological read-outs

The immunological read-outs are presented in Table 10.

Table 10 Immunological read-outs

Blood sampling time point		No. of		
Type of contact and time point	Sampling time point	subjects	Components and priority rank	
Visit 4 (Month 5)	Post-Pri	585 (All)	PRN, FHA, PT, PRP, D, T, HBs, Poliovirus type 1,	
			Poliovirus type 2, Poliovirus type 3	
Visit 5 (Month 13-16)	Pre-Bst	585 (All)	PRN, FHA, PT, PRP, D, T, HBs, Poliovirus type 1,	
·			Poliovirus type 2, Poliovirus type 3	
Visit 6 (Month 14-17)	Post-Bst	585 (All)	PRN, FHA, PT, PRP, D, T	

Post-Pri = blood sample collected from subjects, one month after the administration of the third dose in the Epoch 001 Pre-Bst = blood sample collected from subjects, before the administration of the booster dose in the Epoch 002 Post-Bst = blood sample collected from subjects, one month after the administration of booster dose in the Epoch 002

In case of insufficient blood sample volume to perform assays for all antibodies, the samples were analysed according to priority ranking provided in Table 10.

5.8.4. Immunological correlates of protection

The following cut-offs were accepted as immunological correlates of protection:

- Specific antibodies against diphtheria toxoid (anti-diphtheria) and tetanus toxoid (anti-tetanus) were to be measured by enzyme-linked immunosorbent assay (ELISA). An antibody concentration ≥0.1 International Units per ml (IU/ml) was considered a conservative estimate of the percentage of subjects deemed to be protected [Camargo, 1984; Melville-Smith, 1983].
- Antibodies to the hepatitis B surface antigen (anti-HBs) were measured using ChemiLuminescence ImmunoAssay (CLIA). An antibody concentration ≥10 mIU/ml defined seroprotection [Centers for Disease Control and Prevention (CDC), 1991; WHO, 1988].
- Antibodies against poliovirus types 1, 2 and 3 were determined by a virus micro-neutralization test adapted from the WHO Guidelines for WHO/EPI Collaborative Studies on Poliomyelitis [WHO, 1993]. The lowest dilution at which serum samples were tested was 1:8, from which a test was considered positive. Titers were expressed in terms of the reciprocal of the dilution resulting in 50% inhibition. Antibody titers greater than or equal to this value were considered as protective.
- Data from subjects given unconjugated Hib vaccine suggested that, in the absence of induction of immunological memory, a concentration of 0.15 μg/mL was indicative of short-term protection, with 1 μg/mL considered indicative of long-term protection [Käyhty, 1983; Anderson, 1984].

• No serological correlate of protection against pertussis has been established [Granström, 1987; Karpinsky, 1987]. Antibodies against the pertussis components PT, FHA and PRN were measured by ELISA. The assay cut-off values were: 2.693 IU/mL for anti-PT (pertussis toxoid), 2.046 IU/mL for anti-FHA (filamentous haemagglutinin), and 2.187 IU/mL for anti-PRN (pertactin). Subjects with antibody concentration below the cut-off were considered seronegative.

For the purpose of identification of sub-optimal responders and communication to the investigators, anti-HBs and anti-poliovirus types 1, 2 and 3 assessment of the protection level were done for each subject on samples taken approximately 4 weeks after the 3rd dose of the primary vaccination. For PRP, D and T antigens, the assessment of the protection level was done for each subject on samples taken approximately 4 weeks after the administration of the booster dose. In addition a listing of subjects who did not seroconvert to anti-PT, anti-FHA and anti-PRN was provided.

The immunological assay results were communicated to the investigator (Visit 4 for HBV and poliovirus; Visit 6 for PRP, D, T and pertussis antigens).

The investigator was encouraged to share the immunological assay results for non-responders with the study subjects' parent(s)/LAR(s).

For the study subjects identified as non-responders, it remained the responsibility of the study investigator in charge of the subject's clinical management to determine the medical need for re-vaccination and to re-vaccinate the subjects as per local/regional practices.

5.9. Assessment of safety variables

The investigator or site staff was/were responsible for the detection, documentation and reporting of events meeting the criteria and definition of an adverse event (AE) or serious adverse event (SAE) as provided in the protocol.

Each subject's parent(s)/LAR(s) were instructed to contact the investigator immediately should the subject manifest any signs or symptoms they perceived as serious.

5.9.1. Safety definitions

5.9.1.1. Definition of an adverse event

An AE was any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

An AE could therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also included failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse.

Examples of an AE included:

- Significant or unexpected worsening or exacerbation of the condition/indication under study.
- New conditions detected or diagnosed after investigational vaccines administration even though they may have been present prior to the start of the study.
- Signs, symptoms, or the clinical sequelae of a suspected interaction.
- Signs, symptoms, or the clinical sequelae of a suspected overdose of either investigational vaccines or a concurrent medication (overdose per se was not to be reported as an AE/SAE).
- Signs, symptoms temporally associated with vaccine administration.
- Significant failure of expected pharmacological or biological action.
- Pre- or post-treatment events that occurred as a result of protocol-mandated procedures (i.e. invasive procedures, modification of subject's previous therapeutic regimen).

AEs to be recorded as endpoints (solicited AEs) are described in Section 5.9.2. All other AEs were recorded as UNSOLICITED AEs.

Examples of an AE DO NOT include:

- Medical or surgical procedures (e.g. endoscopy, appendectomy); the condition that led to the procedure was an AE/SAE.
- Situations where an untoward medical occurrence did not occur (e.g. social and/or convenience admission to a hospital, admission for routine examination).
- Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that did not worsen.
- Pre-existing conditions or signs and/or symptoms present in a subject prior to the first study vaccination. These events were recorded in the medical history section of the eCRF.

5.9.1.2. Definition of a serious adverse event

A serious adverse event was any untoward medical occurrence that:

- a. Resulted in death,
- b. Was life-threatening,
 - Note: The term 'life-threatening' in the definition of 'serious' refers to an event in which the subject was at risk of death at the time of the event. It did not refer to an event, which hypothetically might have caused death, had it been more severe.
- c. Required hospitalisation or prolongation of existing hospitalisation,
 - Note: In general, hospitalisation signified that the subject had been admitted at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician's office or in an out-patient setting. Complications

117119 (DTPA-HBV-IPV-135) Report Final

that occurred during hospitalisation were also considered AEs. If a complication prolonged hospitalisation or fulfilled any other serious criteria, the event was also to be considered serious. When in doubt as to whether 'hospitalisation' occurred or was necessary, the AE was to be considered serious.

Hospitalisation for elective treatment of a pre-existing condition (known or diagnosed prior to informed consent signature) that did not worsen from baseline was NOT considered an AE.

d. Resulted in disability/incapacity,

Note: The term disability meant a substantial disruption of a person's ability to conduct normal life functions. This definition was not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza like illness, and accidental trauma (e.g. sprained ankle) which could interfere or prevent everyday life functions but did not constitute a substantial disruption.

Medical or scientific judgement was to be exercised in deciding whether reporting was appropriate in other situations, such as important medical events that were not immediately life-threatening or resulted in death or hospitalisation but could jeopardise the subject or could require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These were also to be considered serious. Examples of such events were invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that did not result in hospitalisation.

5.9.2. Solicited adverse events

A 4-day follow-up (Day 0-Day 3) of solicited local (at each injection site) and general AEs was performed after administration of the vaccine. Data concerning the following AEs were solicited using diary cards provided by the sponsor.

5.9.2.1. Solicited local (injection-site) adverse events

The following local (injection-site) AEs were solicited (Table 11):

Table 11 Solicited local adverse events

Pain at injection site
Redness at injection site
Swelling at injection site
Post-dose 4 measurements of
circumference of limbs (arm or leg
according to where vaccine was
administered)

N.B. If parent(s) /LAR(s) of infants observed any large injection site reaction (defined as swelling with a diameter > 50 mm, noticeable diffuse swelling or noticeable increase of limb circumference) after the booster dose at Visit 5, they were to contact study personnel and to visit the investigator's office for evaluation as soon as possible and bring

the diary card with them. The investigator was to record detailed information describing the AE on a specific large injection site reaction form in the eCRF. In addition to the diameter of the swelling and the circumference of the limb that were reported as solicited symptoms the parent(s)/LAR(s) were to record additional symptoms/characteristics as mentioned in the protocol (Section on Recording of AEs, SAEs and NOCIs).

Note: local AEs were not solicited for co-administered vaccines like *Prevnar 13*.

5.9.2.2. Solicited general adverse events

The following general AEs were solicited (Table 12):

Table 12 Solicited general adverse events

Drowsiness
Fever
Irritability/Fussiness
Loss of appetite

Note: Temperature was recorded in the evening. Should additional temperature measurements be performed at other times of day, the highest temperature was recorded. Fever was defined as temperature ≥38.0°C /100.4°F by any route. The preferred route for recording temperature in this study was rectal for Epoch 001 and axillary for Epoch 002.

5.9.3. Clinical laboratory parameters and other abnormal assessments qualifying as adverse events or serious adverse events

In absence of diagnosis, abnormal laboratory findings (e.g. clinical chemistry, haematology, urinalysis) or other abnormal assessments (e.g. vital signs etc.) that were judged by the investigator to be clinically significant were recorded as AE or SAE if they met the definition of an AE or SAE (refer to Sections 5.9.1.1 and 5.9.1.2). Clinically significant abnormal laboratory findings or other abnormal assessments that were present at baseline and significantly worsened following the start of the study were also reported as AEs or SAEs. However, clinically significant abnormal laboratory findings or other abnormal assessments that were associated with the disease being studied, unless judged by the investigator as more severe than expected for the subject's condition, or that were present or detected at the start of the study and did not worsen, were not reported as AEs or SAEs.

The investigator was to exercise his or her medical and scientific judgement in deciding whether an abnormal laboratory finding or other abnormal assessment was clinically significant.

5.9.4. Adverse events of specific interest

Adverse events of specific interest (i.e. NOCIs such as autoimmune disorders, asthma, type I diabetes and allergies) were recorded from Day 0 up to 6 months after the last primary vaccination (Epoch 001) and from booster dose up to one month after booster vaccination (Epoch 002). NOCIs were reported as either AEs or SAEs, as appropriate in the eCRF.

5.9.5. Detecting and recording adverse events and serious adverse events

5.9.5.1. Time period for detecting and recording adverse events and serious adverse events

All AEs starting within 30 days following administration of each dose of study vaccine/comparator were recorded into the appropriate section of the eCRF, irrespective of intensity or whether or not they were considered vaccination-related.

The time period for collecting and recording SAEs and AEs of specific interest was to begin at the first receipt of study vaccine/comparator and to end 180 days following administration of the last dose of study vaccine/comparator of the primary vaccination course for each subject and 30 days following administration of the booster dose. Instructions on reporting of SAEs were specified in the protocol (see protocol for details).

All AEs/SAEs leading to withdrawal from the study were collected and recorded from the time of the first receipt of study vaccine/comparator.

In addition to the above-mentioned reporting requirements and in order to fulfil international reporting obligations, SAEs that were related to study participation (i.e. protocol-mandated procedures, invasive tests, a change from existing therapy) or were related to a concurrent GSK medication/vaccine were collected and recorded from the time the subject consented to participate in the study until she/he was discharged from the study.

Note: With the exception of AEs/SAEs leading to withdrawal, study participation and concurrent GSK medications or vaccines, there was no reporting of SAEs from the time of the Epoch 1 extended safety follow-up (ESFU) phone contact and administration of dose 4 (approximately three months).

An overview of the protocol-required reporting periods for AEs and SAEs is given in Table 13.

Table 13 Reporting periods for adverse events and serious adverse events

Study activity	C.O	V1	4-days post vac	31-days post- vac	V2	4-days post vac	31-days post-vac	V3	4-days post- vac	31-days post-vac	Phone call 6 months post-V3	V5	4-days post- vac	31-days post-vac
Age of subject		2 months			4 months			6 months		7 months	12 months	15-18 months		16-19 months
Solicited local and general AEs														
Large injection site reactions														
Unsolicited AEs														
AEs/SAEs leading to withdrawal from the study														
NOCIs														
SAEs														
SAEs related to study participation or concurrent GSK medication/vaccine								-						

NOCI: New Onset of Chronic Illnesses; C.O: consent obtained; V: Visit; Post-V: Post-Visit; vac: vaccination

5.9.6. Post-Study adverse events and serious adverse events

A post-study AE/SAE was defined as any event that occurred outside of the AE/SAE reporting period defined in Table 13. Investigators were not obligated to actively seek AEs or SAEs in former study participants. However, if the investigator learned of any SAE at any time after a subject had been discharged from the study, and he/she considered the event reasonably related to the investigational vaccine/product, the investigator was to promptly notify the Study Contact for Reporting SAEs.

5.9.7. Evaluation of adverse events and serious adverse events

5.9.7.1. Active questioning to detect adverse events and serious adverse events

As a consistent method of collecting AEs, the subject's parent(s)/LAR(s) were to be asked a non-leading question such as:

'Has your child acted differently or felt different in any way since receiving the vaccine or since the last visit?'

When an AE/SAE occurred, it was the responsibility of the investigator to review all documentation (e.g. hospital progress notes, laboratory and diagnostics reports) relative to the event. The investigator would then record all relevant information regarding an AE/SAE in the eCRF. The investigator was not allowed to send photocopies of the subject's medical records to GSK Biologicals instead of appropriately completing the eCRF. However, there could be instances when copies of medical records for certain cases were requested by GSK Biologicals. In this instance, all subject identifiers were blinded on the copies of the medical records prior to submission to GSK Biologicals.

The investigator was to attempt to establish a diagnosis pertaining to the event based on signs, symptoms, and/or other clinical information. In such cases, the diagnosis was to be documented as the AE/SAE and not the individual signs/symptoms.

5.9.7.2. Assessment of adverse events

5.9.7.2.1. Assessment of intensity

The intensity of the following solicited AEs were assessed as described:

Table 14 Intensity scales for solicited symptoms in infants/toddlers

	Infant/Too	ddler (15–24 months)					
Adverse Event	Intensity grade	Parameter					
Pain at injection site	0	None					
	1	Mild: Minor reaction to touch					
	2	Moderate: Cries/protests on touch					
	3	Severe: Cries when limb is moved/spontaneously painful					
Redness at injection		Record greatest surface diameter in mm					
Swelling at injection		Record greatest surface diameter in mm					
Increase in limb circumference		Record the limb circumference at the level of the injection site					
or leg according to where							
administered)						
Fever*		Record temperature in °C/°F					
Irritability/Fussiness	0	Behaviour as usual					
	1	Mild: Crying more than usual/no effect on normal activity					
	2	Moderate: Crying more than usual/interferes with normal activity					
	3	Severe: Crying that cannot be comforted/prevents normal					
		activity					
Drowsiness	0	Behaviour as usual					
	1	Mild: Drowsiness easily tolerated					
	2	Moderate: Drowsiness that interferes with normal activity					
	3	Severe: Drowsiness that prevents normal activity					
Loss of appetite	0	Appetite as usual					
	1	Mild: Eating less than usual/no effect on normal activity					
	2	Moderate: Eating less than usual/interferes with normal activity					
* F	3	Severe: Not eating at all					

^{*} Fever was defined as temperature ≥38.0°C /100.4°F by any route. The preferred route for recording temperature in this study was rectal for Epoch 001 and axillary for Epoch 002.

The maximum intensity of local injection site redness/swelling/fever was scored at GSK Biologicals as follows:

0 : Absent 1 : ≤ 5 mm

2 : > 5 mm and ≤ 20 mm

3 : > 20 mm

The maximum intensity of fever was scored at GSK Biologicals as follows:

0	=	<100.4°F	<38.0°C
1	=	≥100.4°F to ≤102.2°F	≥38.0°C to ≤39.0°C
2	=	>102.2°F to ≤104.0°F	>39.0°C to ≤40.0°C
3	=	> 104.0°F	>40.0°C

Following each vaccination (3 doses during the primary vaccination course and one booster dose) during the 4 days after the vaccine dose had been administered (day of vaccination and subsequent 3 days), the child's temperature was screened each evening, at bedtime, for signs of fever by means of the rectal/axillary thermometer. Children < 15 months were to have their temperature taken rectally and children ≥ 15 months were to have their temperature taken by the axillary route. Rectal/axillary temperatures were recorded on the diary card. Temperatures measured by any route were presented in 0.5° C increments starting at 38° C/ 100.4° F.

Prior to analysis, the increase in limb circumference of each limb as compared to the baseline pre-vaccination measurement was scored at GSK Biologicals for each subject with large injection site reaction as follows:

Grade $0 = \text{Increase in limb circumference } \le 5 \text{ mm}$

- 1 = Increase in limb circumference >5 mm but ≤20 mm
- 2 = Increase in limb circumference >20 mm but \le 40 mm
- 3 = Increase in limb circumference >40 mm

The investigator was to assess the maximum intensity that occurred over the duration of the event for all unsolicited AEs (including SAEs) recorded during the study. The assessment was based on the investigator's clinical judgement.

For unsolicited symptoms and adverse events associated with large injection site reactions (e.g. pruritus, induration and functional impairment), the intensity was to be assigned to one of the following categories:

- 1 (mild) = An AE which was easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.
- 2 (moderate) = An AE which was sufficiently discomforting to interfere with normal everyday activities.
- 3 (severe) = An AE which prevented normal, everyday activities. In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care center and would cause the parent(s)/LAR(s) to seek medical advice.

An AE that was assessed as Grade 3 (severe) was not to be confused with a SAE. Grade 3 was a category used for rating the intensity of an event; and both AEs and SAEs could be assessed as Grade 3. An event was defined as 'serious' when it met one of the pre-defined outcomes as described in Section 5.9.1.2.

5.9.7.2.2. Assessment of causality

The investigator was obligated to assess the relationship between investigational vaccines and the occurrence of each AE/SAE. The investigator used clinical judgement to determine the relationship. Alternative plausible causes, such as natural history of the underlying diseases, concomitant therapy, other risk factors, and the temporal relationship of the event to the investigational vaccines were considered and investigated. The investigator was also to consult the IB (Investigators Brochure) and/or Product Information for marketed products to determine his/her assessment. Investigational vaccines included vaccines such as *Infanrix hexa*, *Pediarix*, *Pentacel*, *ActHIB*, *Engerix-B*, *Rotarix*, *Prevnar 13*, *Infanrix* and *Hiberix*.

There could be situations when a SAE had occurred and the investigator had minimal information to include in the initial report to GSK Biologicals. However, it was very important that the investigator always made an assessment of causality for every event prior to submission of the SAE report to GSK Biologicals. The investigator could change his/her opinion of causality in light of follow-up information and update the SAE information accordingly. The causality assessment was one of the criteria used when determining regulatory reporting requirements.

Due to concomitant administration of multiple vaccines, it might not be possible to determine the causal relationship of general AEs to the individual vaccines administered. The investigator was to, therefore, assess whether the AE could be causally related to vaccination rather than to the individual vaccines.

All solicited local (injection site) reactions were considered causally related to vaccination. As the individual vaccines were administered to separate sites, the investigator was to make an assessment of local reactogenicity at the vaccine level e.g. *Infanrix* or *Hiberix*. Causality of all other AEs were assessed by the investigator using the following question:

Is there a reasonable possibility that the AE could have been caused by the investigational vaccines?

YES : There was a reasonable possibility that the vaccines contributed to

the AE.

NO : There was no reasonable possibility that the AE was causally

related to the administration of the study vaccine(s). There were other, more likely causes and administration of the study vaccine(s)

was not suspected to have contributed to the AE.

If an event met the criteria to be determined as 'serious' (see Section 5.9.1.2), additional examinations/tests were performed by the investigator in order to determine ALL possible contributing factors for each SAE.

Possible contributing factors included:

- Medical history
- Other medication
- Protocol required procedure
- Other procedure not required by the protocol
- Lack of efficacy of the vaccines, if applicable
- Erroneous administration
- Other cause (specify)

5.9.7.3. Assessment of outcomes

The investigator was to assess the outcome of all unsolicited AEs (including SAEs) recorded during the study as:

- Recovered/resolved
- Recovering/resolving
- Not recovered/not resolved
- Recovered with sequelae/resolved with sequelae
- Fatal (SAEs only)

5.9.7.4. Medically attended visits

For each solicited and unsolicited symptom the subject experienced, the subject's parent(s)/LAR(s) were asked if the subject received medical attention defined as hospitalisation, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. This information was recorded in the eCRF.

5.9.8. Follow-up of adverse events and serious adverse events

5.9.8.1. Follow-up during the study

After the initial AE/SAE report, the investigator was required to proactively follow each subject and provide additional relevant information on the subject's condition to GSK Biologicals (within 24 hours for SAEs; refer to the protocol for further details).

All SAEs documented at a previous visit/contact and designated as not recovered/not resolved or recovering/resolving were reviewed at subsequent visits/contacts until the end of the study.

All AEs documented at a previous visit/contact and designated as not recovered/not resolved or recovering/resolving were reviewed at subsequent visits/contacts until 30 days after the last vaccination.

New onset of chronic diseases (such as autoimmune disorders, asthma, type I diabetes and allergies) documented at a previous visit/contact and designated as not recovered/not resolved or recovering/resolving were reviewed at subsequent visits/contacts until end of the study.

5.9.8.2. Follow-up after the subject was discharged from the study

The investigator was to follow subjects:

- with SAEs, or subjects withdrawn from the study as a result of an AE, until the event had resolved, subsided, stabilized, disappeared, or until the event was otherwise explained, or the subject was lost to follow-up.
- with other non-serious AEs of specific interest, i.e. NOCIs, such as autoimmune disorders, asthma, type I diabetes and allergies, until the end of the study period or they were lost to follow-up.

If the investigator received additional relevant information on a previously reported SAE, he/she was to provide this information to GSK Biologicals using a paper SAE form.

GSK Biologicals could request that the investigator perform or arrange the conduct of additional clinical examinations/tests and/or evaluations to elucidate as fully as possible the nature and/or causality of the AE or SAE. The investigator was obliged to assist. If a subject died during participation in the study or during a recognized follow-up period, GSK Biologicals would provide any available post-mortem findings, including histopathology.

5.10. Statistical methods

The statistical analyses were performed using the SAS version 9. Refer to Section 5.12.2 for a description of differences with planned statistical methods.

5.10.1. Primary endpoint

5.10.1.1. Epoch 001 (Primary vaccination)

- Immunogenicity with respect to pertussis components of the study vaccines *Infanrix hexa* and *Pediarix*.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination.

5.10.2. Secondary endpoints

5.10.2.1. Epoch 001 (Primary vaccination)

- Immunogenicity (other parameters) with respect to the pertussis component of the study vaccines *Infanrix hexa*, *Pentacel* and *Pediarix*.
 - Anti-PT, anti-FHA, anti-PRN seropositivity status, one month after the third dose of the primary vaccination.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination (for *Pentacel* only).
- Immunogenicity with respect to the other components of the study vaccines *Infanrix hexa, Pediarix, ActHIB, Pentacel* and *Engerix-B*.
 - Anti-D, anti-T, anti-HBs, anti-poliovirus types 1, 2 and 3 and anti-PRP seroprotection status, anti-PRP antibody concentrations ≥1.0 µg/mL and antibody concentrations/titers, one month after the third dose of the primary vaccination.
- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0 Day 3) after each vaccination (*Infanrix hexa, Pediarix, ActHIB, Pentacel* and *Engerix-B*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0 Day 3) after each vaccination.
- Unsolicited adverse events.
 - Occurrence of unsolicited AEs within 31 days (Day 0 Day 30) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.
- Specific adverse events.
 - Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies) from Day 0 up to six months post primary vaccination.
- Serious adverse events.
 - Occurrence of serious adverse events from Day 0 up to six months post primary vaccination.

5.10.2.2. Epoch 002 (Booster vaccination)

- Immunogenicity with respect to all study vaccines.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-HBs, anti-PRP and anti-poliovirus 1, 2, 3 seroprotection/ seropositivity status, anti-PRP antibody concentrations ≥1.0 µg/mL and antibody concentrations/ titers before the booster dose (Dose 4).

- Immunogenicity with respect to the study vaccine *Pentacel*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-PRP seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
 - Anti-PRP antibody concentrations ≥1.0 µg/mL one month after the booster dose (Dose 4).
 - Anti-D and anti-T antibody concentrations ≥1.0 IU/mL one month after the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccine *Infanrix*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
 - Anti-D and anti-T antibody concentrations ≥1.0 IU/mL one month after the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccines *ActHIB* and *Hiberix*.
 - Anti-PRP seroprotection status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PRP antibody concentrations ≥1.0 µg/mL one month after the booster dose (Dose 4)
- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0 Day 3) after booster vaccination (*Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0 Day 3) after booster vaccination.
- Unsolicited adverse events.
 - Occurrence of unsolicited AEs within 31 days (Day 0 Day 30) after booster vaccination, according to the MedDRA classification.
- Specific adverse events.
 - Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies) from the booster dose up to one month after the booster vaccination.
- Serious adverse events.
 - Occurrence of serious adverse events from the booster dose up to one month after the booster vaccination.

5.10.3. Determination of sample size

Target enrolment was 585 subjects. Assuming 65% of the subjects were evaluable post-dose 3, this would provide approximately 378 subjects (126 subjects in each group) evaluable for immunogenicity in the Epoch 001.

The sample size was estimated in order to obtain at least 94% power to demonstrate the primary inferential objective (i.e. non-inferiority of the response to the pertussis antigens). The power associated to the target sample size for the conclusion on the inferential primary objective of this study is detailed in the next section.

5.10.3.1. Control on type I error

A 2.5% nominal type I error was used for each pertussis non-inferiority (NI) evaluation. Since NI was to be met simultaneously for the 3 pertussis antigens, the global type I error would be below 2.5%.

5.10.3.2. References for sample size

References were chosen based on observed standard deviations (SDs) observed in studies Hib-MenCY-TT-005 (101858) and Hib-MenCY-TT-009 (103813) one month post-dose 3 from the subjects that received *ActHIB* co-administered with *Pediarix* and *Prevnar*, and from study DTPa-HBV-IPV-027 (217744/027) one month post-dose 3 from the DTPa-HBV-IPV/Hib pooled groups. All these studies enrolled subjects in the US.

The standard deviation for log_{10} transformed concentrations post vaccination for pertussis antigens is presented in Table 15.

Table 15 Standard deviation for log₁₀ transformed concentration post vaccination

Study	Antigen									
-	I	PT	F	HA	PRN					
	N	SD	N	SD	N	SD				
Hib-MenCY-TT-005-US	215	0.274	213	0.312	217	0.392				
Hib-MenCY-TT-009 - US	100	0.258	97	0.252	101	0.482				
cohort										
DTPa-HBV-IPV-027-US	865	0.274	802	0.254	869	0.376				
Reference taken		0.274		0.307		0.392				

N: Number of subjects; SD: standard deviation

5.10.3.3. Power computation

Out of the 585 subjects enrolled, 65% (126 in each pooled group) were expected to be evaluable post-Dose 3.

The individual type II error for each pertussis antigen was obtained using PASS 2005, one-sided non-inferiority test for 2 means from normal data with common variance between groups, under the alternative of equal means and alpha=2.5% (Table 16).

To account for the multiplicity of comparisons, the global type II error was conservatively estimated as the sum of individual type II errors, ensuring a global power for the study of 94.02% as presented in Table 16.

Table 16 Power for pertussis NI post-Dose 3

Antigen	Margin	SD on log ₁₀ transformed titer	Type I error	N evaluable per pooled group	Type II error
PT	1.5	0.274	2.5%	126	0.08%
FHA	1.5	0.307	2.5%	126	0.48%
PRN	1.5	0.392	2.5%	126	5.42%
Global Powe	er = 100-(0.0	08+0.48+5.42) % = 94.02%			

5.10.4. Study cohorts /data sets analyzed

Six cohorts were defined for the purpose of the analysis:

- Primary Total Vaccinated cohort (TVC)
- Primary ATP cohort for analysis of safety
- Primary ATP cohort for analysis of immunogenicity
- Booster Total Vaccinated cohort
- Booster ATP cohort for analysis of safety
- Booster ATP cohort for analysis of immunogenicity

5.10.4.1. Primary Total vaccinated cohort

The Primary Total Vaccinated cohort (TVC) included all vaccinated subjects for whom data were available.

- A safety analysis based on the Primary TVC included all subjects with at least one vaccine administration documented.
- An immunogenicity analysis based on the Primary TVC included all vaccinated subjects for whom data concerning at least one immunogenicity endpoint measure was available.

5.10.4.2. Primary ATP cohort for analysis of safety

The Primary ATP cohort for safety consisted of all subjects from the Primary TVC who complied with the protocol up to the end of Epoch 001, namely all subjects:

- who met all inclusion criteria and no exclusion criteria for the study;
- who had received all planned study vaccines for each completed vaccination visit in Epoch 001;
- for whom administration site of study vaccines was known and was according to protocol;
- who did not receive a product before the blood sampling at Visit 4 (Month 5) leading to elimination from an ATP analysis as listed in the study protocol.

Note that for the purpose of ATP cohort definition, the Epoch 001 ended at Visit 4.

Adherence to the interval related to ESFU phone contact was not to be taken into account for inclusion in the ATP cohort for safety.

5.10.4.3. Primary ATP cohort for analysis of immunogenicity

The Primary ATP cohort for immunogenicity consisted of all subjects from the Primary ATP cohort for safety who complied with eligibility criteria and study procedures (see the protocol for the definition of the intervals) up to the post-dose 3 blood sample and had immunogenicity results for the post-dose 3 blood sample. The analysis was performed per treatment (first dose) actually administered.

More specifically, the analysis post-dose 3 based on the ATP cohort for immunogenicity included all eligible subjects:

- who received all the study vaccines up to dose 3 as per the vaccination schedule;
- for whom administration site and route of study vaccines up to dose 3 was as per protocol;
- who did not receive a medication/product before the blood sampling at Visit 4 (Month 5) which led to elimination from an ATP analysis as listed in the protocol;
- who did not present with a medical condition before the blood sampling at Visit 4 (Month 5) which led to elimination from an ATP analysis as listed in the protocol.
- who complied with the post-dose 3 blood sample schedule, i.e. 21-48 days post-dose 3.
- who were not administered a vaccine not foreseen by the study protocol before the corresponding post-vaccination blood sample.
- who had immunogenicity results post-dose 3.

In addition for Hep-B analysis, hemolysed samples were excluded from the Primary ATP cohort for immunogenicity.

5.10.4.4. Booster Total vaccinated cohort

The Booster TVC included all subjects from the primary TVC that received the booster vaccine dose

- For the Booster-TVC analysis of safety, this included all subjects with booster vaccine administration documented.
- For the Booster-TVC analysis of immunogenicity, this included vaccinated subjects for whom data concerning immunogenicity endpoint measures were available.

5.10.4.5. Booster ATP cohort for analysis of safety

The Booster ATP cohort for safety consisted of all subjects from the Booster TVC who complied with the protocol up to the end of Epoch 002, namely all subjects:

- who met all inclusion criteria and no exclusion criteria for the study;
- who had received the planned booster dose at 15-18 months of age;
- who received 3 doses in Epoch 001;
- for whom administration site of study vaccines was known and was according to protocol;
- who did not receive a product before the blood sampling at Visit 6 (Months 14-17) which led to elimination from an ATP analysis as listed in the protocol.

5.10.4.6. Booster ATP cohort for analysis of immunogenicity

The Booster ATP cohort for immunogenicity consisted of all subjects from the Booster ATP cohort for safety who complied with eligibility criteria and study procedures (see the protocol for the definition of the intervals) up to the post-dose 4 blood sample and had immunogenicity results for the post-dose 4 blood sample.

More specifically, the analysis pre- and post-dose 4 based on the Booster ATP cohort for immunogenicity included all eligible subjects:

- who received all the study vaccines up to dose 4 as per the vaccination schedule;
- for whom administration site and route of the study vaccines up to dose 4 was as per protocol;
- who did not receive a medication/product before the blood sampling at Visit 6 (Months 14-17) which led to elimination from an ATP analysis (see the protocol);
- who did not present with a medical condition before the blood sampling at Visit 6 (Months 14-17) which led to elimination from an ATP analysis (see the protocol);
- who complied with the booster vaccination schedule at 15-18 months of age and with the post-dose 4 blood sample schedule i.e. 21-48 days for post-dose 4;
- who had immunogenicity results post-dose 4.

5.10.5. Derived and transformed data

5.10.5.1. Demography

For a given subject and a given demographic variable, missing measurements were not to be replaced except for age.

Age was to be calculated as the number of years between the date of birth and the date of vaccination.

5.10.5.2. Immunogenicity

- A seronegative subject was a subject whose antibody concentration/titer was below the assay cut-off (see Section 5.8.2 for cut-off details).
- A seropositive subject was a subject whose antibody concentration/titer was greater than or equal to the assay cut-off.
- A seroprotected subject was a subject whose antibody concentration/titer was greater than or equal to the level defining clinical protection. The following seroprotection thresholds were applicable:
 - Anti-diphtheria antibody concentrations ≥ 0.1 IU/mL.
 - Anti-tetanus antibody concentrations $\geq 0.1 \text{ IU/mL}$.
 - Anti-HBs antibody concentrations ≥ 10 mIU/mL.
 - Anti-poliovirus types 1, 2 and 3 antibody titers ≥ 8 .
 - Anti-PRP antibody concentrations $\geq 0.15 \,\mu \text{g/mL}$.
- Other cut-offs were to be considered:
 - Anti-PRP antibody concentrations $\geq 1.0 \,\mu g/mL$.
 - Anti-diphtheria and anti-tetanus antibody concentrations ≥ 1.0 IU/mL
- Booster responses for anti-PT, anti-FHA and anti-PRN antibodies were defined as:
 - initially seronegative subjects (pre-booster antibody concentration below the assay cut-off) presenting an increase of at least four times the assay cut-off one month after vaccination;
 - initially seropositive subjects with antibody concentration < four times the assay cut-off presenting an increase of at least four times the pre-booster antibody concentration one month after vaccination;
 - initially seropositive subjects with anti-body concentration ≥ four times the assay cut-off presenting an increase of at least two times the pre-booster antibody concentration one month after vaccination

- The GMC/geometric mean titer (GMT) calculations were performed by taking the anti-log of the mean of the log₁₀ titer/ concentration transformations. Antibody titers/concentrations below the cut-off of the assay were given an arbitrary value of half the cut-off for the purpose of GMC/GMT calculation.
- Handling of missing data For a given subject and a given immunogenicity measurement, missing or non-evaluable measurements were not to be replaced.

5.10.5.3. Safety/reactogenicity:

- For a given subject and the analysis of solicited symptom within 4 days post-vaccination, missing or non-evaluable measurements were not to be replaced. Therefore the analysis of the solicited symptoms based on the Total Vaccinated cohort was to include only vaccinated subjects and doses with documented safety data (i.e. symptom screen completed).
- For analysis of unsolicited adverse events, such as serious adverse events or adverse events by primary MedDRA term, and for the analysis of concomitant medications, all vaccinated subjects were considered. Subjects who did not report the event or the concomitant medication were considered as subjects without the event or the concomitant medication, respectively.
- For analysis of convulsion, the adverse event was to be identified by using narrow standard MedDRA query.
- For analysis of Hypotonic Hyporesponsive Episode (HHE), the adverse event was identified by using broad standard MedDRA query.
- For analysis of NOCI, the adverse event was identified by using narrow standard MedDRA query.
- For summaries reporting both solicited and unsolicited adverse events, all vaccinated subjects were considered. Subjects for whom the event was not reported were considered as subjects without the event.
- Large injection site reactions were defined as either swelling with a diameter of >50 mm or a >50 mm increase in the circumference of any limb when compared to the baseline (pre-vaccination) measurement, or any diffuse swelling that interferred with or prevented everyday activities (for example, active playing, eating, sleeping).

5.10.6. Final analysis of the Epoch 001

5.10.6.1. Analysis of demographics

Demographic characteristics (age [weeks], gender, geographical ancestry, height in length [cm], weight [kg] at first dose, Hep B vaccination history, vaccination history of mother with respect to administration of Tdap vaccine during pregnancy) and withdrawal status were summarised by group using descriptive statistics:

- Frequency tables were generated for categorical variables such as center;
- Mean, median and standard error were provided for continuous data such as age.

The distribution of subjects enrolled among the study sites was tabulated as a whole and per group.

5.10.6.2. Analysis of immunogenicity

The primary analysis was based on the Primary ATP cohort for immunogenicity. An analysis on the Primary Total Vaccinated cohort was performed only if, in any vaccine group and at any time point, more than 5% of the vaccinated subjects with immunological data post-dose 3 were excluded from the Primary ATP cohort for immunogenicity.

The following sections describe the analyses that were performed.

5.10.6.2.1. Within group assessment

For each group, one month post-dose 3 and for each assay for which a serological result was available:

- Seropositivity and seroprotection rates with exact 95% CIs were calculated.
- GMCs/GMTs with 95% CIs were tabulated.
- For each antigen, antibody concentration or titer distribution one month post-vaccination was tabulated and displayed using reverse cumulative curves (RCCs).
- For anti-PRP post primary vaccination at Visit 4 using the qualified assay and the fully validated assay, seropositivity and seroprotection rates and GMCs were calculated per *Infanrix hexa* lot.

All the above within group analysis for Epoch 001, except the reverse cumulative curves and the presentation per *Infanrix hexa* lot, were also to be performed by gender, by geographical ancestry (the most frequent geographical ancestry versus all other geographical ancestries, namely White Caucasian versus any other geographical ancestry), by Tdap vaccination history of mothers during pregnancy and by Hepatitis B vaccination of the subjects at birth (for anti-HBs antigen).

5.10.6.2.2. Between group assessment

At one month post-dose 3,

• The asymptotic standardized 95% CI for the group difference (Pedia group minus Hexa group and Penta group minus Hexa group) in the seroprotection rates was computed for each antigen.

Antigen	Threshold considered for protection
• Anti-D	• 0.1 IU/mL (short term protection)
	• 1.0 IU/mL (long term protection)
• Anti-T	• 0.1 IU/mL (short term protection)
	• 1.0 IU/mL (long term protection)
Anti-polio	8 dilution
Anti-PRP	• 0.15 μg/mL (short term protection)
	• 1.0 μg/mL (long term protection)
Anti-HBs	• 10 mIU/mL

The 95% CI for each group GMC/GMT ratio (Pedia group divided by Hexa group and Penta group divided by Hexa group) was computed using an Analysis of Variance (ANOVA) model on the logarithm-transformed concentrations/titers. The ANOVA model was to include the vaccine group as fixed effect and the Tdap vaccination of the mother during pregnancy as continuous regressor leading to an Analysis of Co-variance (ANCOVA) model. For hepatitis B antigen, the hepatitis B vaccine birth dose status was also to be used as regressor leading to an ANCOVA model. The model was to include the data from the 3 groups compared. For analysis purpose, DTP vaccination of the mother during pregnancy and Hepatitis B vaccination at birth were considered as continuous variables. More specifically 2 continuous indicator variables were to be used for Tdap vaccination of mother during pregnancy (an indicator for no Tdap vaccination at birth and an indicator for unknown vaccination at birth) while one indicator of hepatitis B vaccination at birth was used.

5.10.6.2.3. Interpretation of analyses

Except for analyses addressing criteria specified in the primary objective, comparative analyses were descriptive/ exploratory with the aim to characterise the difference between groups in immunogenicity. These descriptive/exploratory analyses were not to be interpreted for formal conclusions since there was no adjustment for multiplicity of endpoints.

5.10.6.3. Analysis of safety

The primary analysis was based on the primary Total Vaccinated cohort. If, in any vaccine group and at any time point of the Epoch 001, the percentage of vaccinated subjects excluded from the primary ATP cohort for safety was more than 5%, a second

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Report Final

analysis based on the primary ATP cohort for safety was to be performed to complement the primary Total Vaccinated cohort analysis.

- The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) or 31-day (Days 0-30) follow-up period was tabulated after each vaccine dose and overall (for the Epoch 001) with exact 95% CI.
- The percentage of doses followed by at least one local AE (solicited and unsolicited), by at least one general AE (solicited and unsolicited) and by any AE during the 4-day or 31-day follow-up period was tabulated over the primary vaccination period, with exact 95% CI.
- The percentage of subjects/doses with local AEs (solicited and unsolicited) were calculated at each injection site for *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel and Engerix-B* vaccines, as well as overall (all sites considered) during the 4-day follow-up period was tabulated over the primary vaccination period, with exact 95% CI.
- The percentage of subjects/doses reporting each individual solicited local and general AE during the 4-day follow-up period were tabulated for each group as follows:
 - Over the primary doses, the percentage of subjects with the symptom and its exact 95% CI.
 - Over the primary doses, the percentage of doses with the symptom and its exact 95% CI.
 - At each study dose, the percentage of subjects with the symptom and its exact 95% CI.

The exact 95% CIs were calculated assuming independence between doses.

• All computations mentioned above were done for Grade ≥2 (solicited symptoms only) and Grade 3 symptoms, for symptoms considered related to vaccination (general symptoms only), for Grade 3 symptoms considered related to vaccination (general symptoms only) and for symptoms that resulted in a medically-attended visit. The percentage of subjects/doses reporting each individual solicited local symptom (any grade, grade 2, grade 3, medical advice) during the 4-day follow-up period were also to be tabulated at each injection site for *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel and Engerix-B* vaccines with exact 95% CI after each vaccine dose and overall where the same row on the table was used for all vaccines given at the same site across the three study groups (e.g. *Infanrix hexa*, *Pentacel* and *Pediarix* together were in one row and *ActHIB* and *Engerix-B* together were in one row). The percentage of subjects/doses reporting each individual general solicited symptom (any grade, Grade ≥2, Grade 3, causally related, Grade 3 causally related, medical advice) during the 4-day follow-up period were also to be tabulated with exact 95% CI. For fever, the analyses were also to be performed by 0.5°C increments.

- The percentage of subjects/doses with concomitant medication, antipyretic medication and prophylactic antipyretic medication during the 4-day and 31-day follow-up period post-vaccination was tabulated after each dose and over the Epoch 001.
- The verbatim reports of unsolicited AEs were reviewed by a Clinical Research and Development Lead and the signs and symptoms were coded according to MedDRA. Every verbatim term was matched with the appropriate Preferred Term. The percentage of subjects/doses with unsolicited AEs occurring within 31 days with exact 95% CI was tabulated by Preferred Term. Similar tabulations were done for Grade 3 unsolicited AEs, for unsolicited AEs considered related to vaccination and for Grade 3 unsolicited AEs considered related to vaccination.
- Subjects who experienced AEs of specific interest (i.e. convulsions, Hypotonic Hyporesponsive Episode) during 31 days with exact 95% CI were tabulated by Preferred Term. Similar tabulations were done for AEs considered related to vaccination. Subjects who experienced AEs of specific interest were also to be described in detail.
- Subjects who experienced AEs of specific interest (i.e. new onset of chronic disease such as autoimmune disorders, asthma, type I diabetes and allergies) from Day 0 up to 6 months after the last primary vaccination were tabulated by Preferred Term.
- Subjects who experienced at least one SAE with onset from Dose 1 up to six months post primary vaccination were tabulated with MedDRA primary preferred term.
- All reactogenicity analyses and analyses for unsolicited symptoms were also to be performed by gender and geographical ancestry (the most frequent geographical ancestry versus all other geographical ancestries, namely White Caucasian versus any other geographical ancestry).

5.10.7. Final analysis of the Epoch 002

5.10.7.1. Analysis of demographics/baseline characteristics

Demographic characteristics (age [months] at Visit 5, gender, geographical ancestry, Hep B vaccination history, vaccination history of mother with respect to administration of Tdap vaccine during pregnancy) and withdrawal status were summarized by group using descriptive statistics:

- Frequency tables were generated for categorical variables such as race/ethnicity;
- Mean, median and standard error were provided for continuous data such as age.

The distribution of subjects vaccinated at Visit 5 among the study sites was tabulated as a whole and per group.

For enrolled subjects that did not participate in the Epoch 002, the reason for not participating was summarized.

5.10.7.2. Analysis of immunogenicity

The primary analysis was based on the booster ATP cohort for immunogenicity. An analysis on the booster Total Vaccinated cohort was to be performed only if, in any vaccine group and at any time point of the Epoch 002, more than 5% of the vaccinated subjects with immunological data were excluded from the booster ATP cohort for immunogenicity.

The following section describes the analyses that were performed.

5.10.7.2.1. Within group assessment

For each group, prior to the booster dose and one month post-booster dose and for each assay, for which a serological result was available:

- Seropositivity and seroprotection rates and booster response rates for pertussis with exact 95% CIs were calculated.
- GMCs/GMTs with 95% CIs were tabulated.
- For each antigen, antibody concentration or titer distribution before and one month Post-booster (when available) were tabulated and displayed using RCCs.

All the above within group analysis for Epoch 002 except the reverse cumulative curves were also to be performed by gender, by geographical ancestry (the most frequent geographical ancestry versus all other geographical ancestries, namely White Caucasian versus any other geographical ancestry), by Tdap vaccination history of mothers during pregnancy and Hepatitis B vaccination of the subjects at birth (for anti-HBs antigen).

5.10.7.2.2. Between group assessment

At pre-booster and at one month post-booster,

• The asymptotic standardized 95% CI for the group difference (Pedia group minus Hexa group and Penta group minus Hexa group) in the seroprotection rates was computed for each antigen except for group difference (Penta group minus Hexa group).

Antigen	Threshold considered for protection
Anti-D	• 0.1 IU/mL (short term protection)
	• 1.0 IU/mL (long term protection)
• Anti-T	• 0.1 IU/mL (short term protection)
	• 1.0 IU/mL (long term protection)
Anti-polio (Pre-Booster)	8 dilution
Anti-PRP	• 0.15 μg/mL (short term protection)
	• 1.0 μg/mL (long term protection)
Anti-HBs (Pre-Booster)	• 10 mIU/mL

• The 95% CI for each group GMC/GMT ratio (Pedia group divided by Hexa group and Penta group divided by Hexa group) were computed using an ANOVA model on the logarithm-transformed concentrations/titers. The ANOVA model was to include the vaccine group as fixed effect and the Tdap vaccination of the mother during pregnancy as regressor leading to an ANCOVA. For hepatitis B antigen, the hepatitis B vaccine birth dose status was also to be used as regressor leading to an ANCOVA model. The model was also to include the data from the 3 groups compared. For analysis purpose, DTP vaccination of the mother during pregnancy and Hepatitis B vaccination at birth were considered as continuous variables. More specifically 2 continuous indicator variables were used for Tdap vaccination of mother during pregnancy (an indicator for no Tdap vaccination at birth and an indicator for unknown vaccination at birth) while one indicator of hepatitis B vaccination at birth was used.

5.10.7.2.3. Interpretation of analyses

In Epoch 002, all comparative analyses were descriptive/exploratory with the aim to characterise the difference between groups in immunogenicity. These descriptive/exploratory analyses were not to be interpreted for formal conclusions since there was no adjustment for multiplicity of endpoints.

5.10.7.3. Analysis of safety

The primary analysis for the Epoch 002 was based on the booster Total Vaccinated cohort and was only to look at the booster dose. If, in any vaccine group, the percentage of vaccinated subjects excluded from the booster ATP cohort for safety was more than 5%, a second analysis based on the booster ATP cohort for safety was to be performed to complement the booster Total Vaccinated cohort analysis.

- The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) and 31-day (Days 0-30) follow-up period after the booster dose, were tabulated with exact 95% CI for each group.
- The incidence of local AEs (solicited and unsolicited) was calculated at each injection site as well as overall (all sites considered) for each group during the 4-day (Days 0-3) follow-up period after the booster dose.
- The percentage of subjects reporting each individual solicited local and general AE during the 4-day follow-up period was tabulated with its exact 95% CI for each group.
- All computations mentioned above were to be done for Grade ≥2 (solicited symptoms only) and Grade 3 symptoms, for symptoms considered related to vaccination (general symptoms only), for Grade 3 symptoms considered related to vaccination (general symptoms only) and for symptoms that resulted in a medically-attended visit. The percentage of subjects reporting each individual solicited local symptoms (any grade, Grade ≥2, Grade 3, medical advice) during the 4-day follow-up period were also to be tabulated at each injection site for *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*

vaccines with exact 95% CI after each vaccine dose and overall where vaccination with same vaccine site was considered together (e.g. *Infanrix* and *Pentacel* together were on one row and *ActHIB* and *Hiberix* together were on one row). The percentage of subjects reporting each individual general solicited symptom (any grade, Grade ≥2, Grade 3, causally related, Grade 3 causally related, medical advice) during the 4-day follow-up period was also to be tabulated with exact 95% CI. For fever, analyses were also to be performed by 0.5°C increments.

- The percentage of subjects with concomitant medication, antipyretic medication and prophylactic antipyretic medication during the 4-day and 31-day follow-up period post-vaccination were tabulated for each group.
- The verbatim reports of unsolicited AEs were reviewed by a Clinical Research and Development Lead and the signs and symptoms were coded according to MedDRA. Every verbatim term was matched with the appropriate Preferred Term. The percentage of subjects with unsolicited AEs occurring within 31 days following the booster dose with its exact 95% CI was tabulated by Preferred Term. Similar tabulations were done for Grade 3 unsolicited AEs, for unsolicited AEs considered related to vaccination and for Grade 3 unsolicited AEs considered related to vaccination.

Additionally,

- Any large injection site reaction (defined as a swelling with a diameter > 50 mm, noticeable diffuse swelling or increase in limb circumference of greater than 50 mm) reported within 4 days (Days 0-3) following the booster dose was to be tabulated.
- Subjects who experienced AEs of specific interest (i.e. new onset of chronic disease such as autoimmune disorders, asthma, type I diabetes and allergies) from booster dose up to one month after booster vaccination were tabulated by Preferred Term.
- Subjects who experienced at least one SAE from the booster dose up to one month after were tabulated with MedDRA primary preferred term. The same summary was provided for all SAEs reported from dose 1 up to study end.

All reactogenicity analyses and analyses for unsolicited symptoms were also to be performed by gender and geographical ancestry (the most frequent geographical ancestry versus all other geographical ancestry, namely White Caucasian versus any other geographical ancestry).

5.10.8. Sequence of analyses

The analyses were performed stepwise:

- 1. A partial analysis of Epoch 001 up to one month after the third primary vaccine dose was conducted. This analysis included the final analysis of anti-PRP, solicited and unsolicited symptoms on data as clean as possible. This analysis was displayed on the GSK clinical trial registry.
- 2. The final data analysis of the study covering both the epochs was conducted at the end of the study. All these analyses are presented in an integrated final clinical study report.

5.10.9. Interim analysis

All analyses were conducted on final data and therefore no statistical adjustment for interim analyses was required – see Section 5.10.8 and first bullet point for details of the interim analysis.

5.11. Data quality assurance at study level

To ensure that the study procedures conformed across all investigator sites, the protocol, eCRF and safety reporting were reviewed with the investigator(s) and his/her/their personnel responsible for the conduct of the study by the Company representative(s) prior to study start. A multi-investigator meeting was held on 05-06 March 2014 Face to Face in Dallas, Texas, USA, prior to the study start.

Adherence to the protocol requirements and verification of data generation accuracy were achieved through monitoring visits to each investigator site. Computer checks and blinded review of subject tabulations were performed to ensure consistency of eCRF completion. All procedures were performed according to methodologies detailed in GSK Biologicals Standard Operating Procedures (SOPs).

All protocol deviations collected during the study were reviewed by the GSK study team in order to identify important protocol deviations. Consistent with International Conference on Harmonisation E3 guidance, important deviations are defined as deviations that were likely to affect the interpretation of the results and/or led to exclusion of any subject data from an analysis. Important deviations include, but are not limited to, those related to study inclusion or exclusion criteria, adherence to the protocol, conduct of the study, subject management or subject assessment.

The Table in Section 2 summarises the roles of the different CROs that were employed in this study. The CRO responsibilities were conducted according to SOPs agreed between GSK and the CRO

Independent Audit statement:

• This study was subject to audit by GlaxoSmithKline's R&D Global Quality Compliance (GQC) - Clinical Development Quality Assurance. (CDQA) department.

5.12. Changes in the conduct of the study or planned analyses

5.12.1. Protocol amendments

5.12.1.1. Protocol Amendment 1

Protocol Amendment 1 was implemented at all study sites from the date of approval on 18-September-2014 onwards.

Rationale/background for changes:

- Clarification was provided that large injection site reactions and measurement of the injected limb was to be collected as a solicited symptom. Specific instructions regarding measurement of limb circumference and clinical details of large injection site reactions were added.
- Additional minor clarifications of study procedures and data analyses were made throughout the document.
- Instructions regarding interval between preparation and administration of vaccine was aligned with the stability data described in the current Investigator Brochure.
- Due to ongoing re-validation of serological assays for antibodies to diphtheria and tetanus toxoids, pertussis antigens, poliovirus, hepatitis B surface antigen and polyribosyl ribitol phosphate, the cut-offs for these assays could potentially change and hence a note was added in the protocol regarding this. The definition of booster response to pertussis antigens could also potentially have been revised.
- Sequence of reporting the results was clarified.
- The contributing authors and sponsor signatory were updated to reflect changes in the study team.

5.12.1.2. Protocol Amendment 2

Protocol Amendment 2 was implemented at all study sites from the date of approval on 17-April-2015 onwards.

Rationale/background for changes:

- The assay for testing antibodies against polyribosyl ribitol phosphate (anti-PRP) was re-developed but was not yet qualified or validated for testing the one month post dose-3 samples. This was clarified in the protocol in Table 7 Humoral immunity (antibody determination) and Section 5.7.3 Laboratory assays.
- Investigator sign-off on the patient identification (PIDS) was done after Visit 4 instead of ESFU. In Table 4 List of study procedures, the bullets pertaining to investigator sign-off and analysis of Epoch 001 were removed from the ESFU visit and retained at Visit 4 to reflect this change.
- The collection of baseline measurement of limb length was removed since it was not to be used in analysis; only limb circumference was used in the analysis. Accordingly, text related to this was amended in Table 4 List of study procedures, Sections 5.6.2.11, Baseline measurement of limb circumference after booster vaccination at Visit 5 and 5.6.2.13 Recording of AEs, SAEs and NOCIs.
- Errors in the vaccines dictionary of Study Master Repository were rectified for *Infanrix hexa*, *Pediarix* and *Pentacel* vaccines. The corresponding correction was made in Table 9 Study vaccines.
- The sequence of analysis in Section 10.9.1 Sequence of analyses, was amended to reflect that there would first be an analysis of immunogenicity for anti-PRP and safety for Epoch 001, followed by a final analysis covering both Epochs at the end of the study.

5.12.2. Other changes

5.12.2.1. Changes in the Statistical Analysis Plan (SAP) from the protocol

- During the course of the study, the assays used to measure the anti-D, -T, -PRP, -PT, -FHA and -PRN IgG concentrations were re-developed and re-validated and both assay units and assay cut-offs were adapted. The new ELISAs for PT, FHA and PRN were calibrated against the WHO International Standard (NIBSC 06/140). This allowed the expression of concentrations measured with the new ELISAs in International Units per milliliter (IU/mL) instead of the formerly used ELISA units per milliliter (EL.U/mL). The newly validated DTPa ELISA's had a lower assay cut-offs as compared to the ones described in the protocol. The current assay cut-off was 0.057 IU/mL for anti-D, 0.043 IU/mL for anti-T, 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, 2.187 IU/mL for anti-PRN and 0.066 μg/mL for the fully validated anti-PRP assay.
- Since for anti-D and anti-T, a threshold of 0.1 IU/mL provided a conservative estimate of the percentage of subjects deemed to be protected, the anti-D, anti-T seropositivity endpoints initially defined by the previous assay cut-off of 0.1 IU/mL were replaced by seroprotection rate endpoints defined as the percentage of subjects with concentration above 0.1 IU/mL.
- In the absence of a correlate of protection for the *B. pertussis* antigens, the pertussis vaccine response endpoints were redefined based on the assay cut-off (see Section 5.10.1 and 5.10.2 for the definition of the endpoints).
- Subgroup analyses by gender and geographical ancestry was added for summaries of solicited symptoms and for summaries of unsolicited symptoms.
- During the review of protocol deviations, hemolysed samples were identified among blood samples obtained one month post dose 3. Not knowing the impact on the anti-HBs assay the samples were conservatively excluded from the Primary ATP cohort for immunogenicity analyses of anti-HBs. This concerned 36 subjects (14 in the Penta group and 11 in each of Pedia and Hexa groups).
- A descriptive summary per lot was added for anti-PRP post priming.
- The ANCOVA model was revised to include the 3 study groups rather than the 2 groups compared. This allowed identical adjusted GMC estimates regardless of the groups involved in the comparison.
- The DTPA-HBV-IPV-135 (117119) Abridged Interim Report Main (19-Oct-2015) included immunogenicity data against PRP antigen at Visit 4 using an assay which was not fully validated. For the final analysis, the Visit 4 samples were retested together with the samples pre- and post-booster using a newly validated assay. In the final analysis, the results of both assays are descriptively presented at Visit 4.
- Analyses of HHE within the 31-day (Days 0-30) post-vaccination period and of convulsion within 31-day (Days 0-30) post vaccination were added following a request from CBER [GlaxoSmithKline Vaccines, 2014].
- The distribution of vaccinated subjects by center and the summary of reason for withdrawal were performed for the full study rather than by Epoch.

6. STUDY POPULATION RESULTS

6.1. Study dates

Primary vaccination epoch

The first subject was enrolled in the primary vaccination study on 16-April-2014 and the last visit for the primary epoch took place on 31-March-2015. The last contact (ESFU) of the primary vaccination epoch was made on 12-August-2015.

Booster vaccination epoch

The first subject first visit for the Booster vaccination epoch was on 14-May-2015 and the last contact (ESFU) of the booster vaccination epoch was made on 13-November-2015.

6.2. Subject disposition

The number of subjects enrolled in the study at each centre is presented in Table 6.1. The deviations from specifications for age and intervals between study visits is presented in Table 6.5 (Primary Total vaccinated cohort) and Table 6.6 (Booster Total vaccinated cohort).

Table 17 represents the number of subjects who were vaccinated, completed and withdrawn at visit 6 (Month 14-17) with reason for withdrawal from the study.

A total of 585 subjects were vaccinated and 476 subjects completed the study. The most frequent reasons for withdrawal were: migrated/moved from the study area (21 subjects) and consent withdrawal (not due to an AE; 20 subjects).

Report Final

Table 17 Number of subjects vaccinated, completed and withdrawn at visit 6 (Month 14-17) with reason for withdrawal (Primary Total vaccinated cohort)

	Hexa group	Pedia group	Penta group	Total
Number of subjects vaccinated	195	194	196	585
Number of subjects completed	161	158	157	476
Number of subjects withdrawn	34	36	39	109
Reasons for withdrawal:				
Subject died	0	0	0	0
Serious Adverse Event	1	0	0	1
Non-Serious Adverse Event	0	0	1	1
Eligibility criteria not fulfilled (inclusion and exclusion criteria)	0	0	0	0
Protocol violation	7	2	8	17
Consent withdrawal (not due to an adverse event)	5	7	8	20
Migrated/moved from study area	6	10	5	21
Lost to follow-up (subjects with incomplete vaccination course)	5	8	6	19
Lost to follow-up (subjects with complete vaccination course)	3	0	4	7
Sponsor study termination	0	0	1	1
Other - change their doctor	1	0	0	1
Other - loss of kaiser coverage	3	8	2	13
Other - medical history updated information	0	1	0	1
Other - received vaccines in injection clinic	0	0	1	1
Other - refuses blood draws	0	0	1	1
Other - subject got a new doctor	1	0	0	1
Other - subject unable to complete visit 5 during the gsk shortened window for visit 5	0	0	1	1
Other - subject was discontiued due to non-compliance	0	0	1	1
Other - terminated by pi due to non-compliance with appointment schedules	1	0	0	1
Other - unknown	1	0	0	1

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Vaccinated = number of subjects who were vaccinated in the study

Completed = number of subjects who completed last study visit

Withdrawn = number of subjects who did not come back for the last visit

pi = Principal Investigator

6.3. Important Protocol deviations at subject level

6.3.1. Protocol Deviations leading to elimination from ATP analyses

The details on number of subjects excluded from Primary ATP analysis with reasons for exclusion are presented in Table 18.

For Hepatitis B / anti-HBs analysis, hemolysed samples were excluded from the Primary ATP cohort for immunogenicity – see Section 5.12.2.1 for further details of which subjects were excluded.

The details on number of subjects excluded from Booster ATP analysis with reasons for exclusion are presented in Table 19.

117119 (DTPA-HBV-IPV-135)

Report Final

Table 18 Number of subjects enrolled into the study as well as number excluded from Primary ATP analyses with reasons for exclusion

	•	Tot	al	Неха с	group	Pedia g	group	Penta (group
Title	n	s	%	n	S	n	S	n	S
Primary Total vaccinated cohort	585		100	195		194		196	
Administration of vaccine(s) forbidden in the protocol (code 1040)	7	7		1	1	1	1	5	5
Study vaccine dose not administered according to protocol (code 1070)	0	2		0	0	0	0	0	2
ATP cohort for safety	578		98.8	194		193		191	
Underlying medical condition forbidden by the protocol (code 2050)	2	2		0	0	0	0	2	2
Concomitant infection related to the vaccine which may influence immune response (code 2060)	0	2		0	0	0	0	0	2
Non compliance with vaccination schedule (including wrong and unknown dates) (code 2080)	19	20		5	5	8	8	6	7
Non compliance with blood sampling schedule (including wrong and unknown dates (code 2090)	6	9		4	6	2	3	0	0
Essential serological data missing (code 2100)	85	93		31	34	27	27	27	32
ATP cohort for immunogenicity *	466		79.7	154		156		156	

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

Note: Subjects may have more than one elimination code assigned

n = number of subjects with the elimination code assigned excluding subjects who have been assigned a lower elimination code number

s = number of subjects with the elimination code assigned

^{% =} percentage of subjects in the considered ATP cohort relative to the Primary Total vaccinated cohort

^{*} Subjects with hemolysed samples were excluded from the Primary ATP cohort for immunogenicity – see Section 5.12.2.1 for further details of which subjects were excluded.

117119 (DTPA-HBV-IPV-135)

Report Final

Table 19 Number of subjects who received a booster dose as well as number excluded from Booster ATP analyses with reasons for exclusion

		Tota	al	Hexa g	roup	Pedia g	group	Penta (group
Title	n	S	%	n	s	n	S	n	S
Booster Total vaccinated cohort	486		100	167		158		161	
Administration of vaccine(s) forbidden in the protocol (code 1040)	1	1		0	0	0	0	1	1
ATP cohort for safety	485		99.8	167		158		160	
Administration of any medication forbidden by the protocol (code 2040)	2	2		0	0	0	0	2	2
Non compliance with vaccination schedule (including wrong and unknown dates) (code 2080)	6	6		4	4	0	0	2	2
Non compliance with blood sampling schedule (including wrong and unknown dates (code 2090)	17	17		8	8	2	2	7	7
Essential serological data missing (code 2100)	52	57		17	20	17	17	18	20
ATP cohort for immunogenicity	408		84.0	138		139		131	

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Note: Subjects may have more than one elimination code assigned

n = number of subjects with the elimination code assigned excluding subjects who have been assigned a lower elimination code number

s = number of subjects with the elimination code assigned

% = percentage of subjects in the considered ATP cohort relative to the Booster Total vaccinated cohort

6.3.2. Protocol Deviations not leading to elimination from ATP analyses

None

6.4. Demographic characteristics and other baseline characteristics

The demographic characteristics are summarised for the Primary ATP cohort for immunogenicity in Table 20 and for the Booster ATP cohort for immunogenicity in Table 21.

In the Primary ATP cohort for immunogenicity, the mean age of the subjects was 8.6 weeks at the time of first vaccination (SD = 1.0; Table 20). There were more males (52.8%) compared to females (47.2%). The majority of the subjects were of White - Caucasian / European Heritage (62.9%), with African Heritage / African American (8.2%) and American Indian or Alaskan Native (7.7%) racial categories being the next two most frequent categories.

In the Booster ATP cohort for immunogenicity, the mean age of the subjects was 15.3 months at the time of vaccination (SD = 0.7; Table 21). There were more males (56.6%) compared to females (43.4%). The distribution of Booster phase subjects in the racial categories remained similar to the corresponding Primary cohort.

Table 20 Summary of demographic characteristics (Primary ATP cohort for immunogenicity)

		Hexa group N = 154		Pedia group N = 156		Penta group N = 156		Total N = 466	
	Parameters or	Value	%	Value	%	Value	%	Value	%
Characteristics	Categories	or n		or n		or n		or n	
Age [Weeks] at first primary dose		8.6	-	8.6	-	8.6	-	8.6	-
	SD	0.9	-	1.1	-	1.0	-	1.0	-
	Median	8.0	-	9.0	-	9.0	-	9.0	-
	Minimum	6.0	-	6.0	-	6.0	-	6.0	-
	Maximum	12.0	-	12.0	-	11.0	-	12.0	-
Gender	Female	85	55.2	61	39.1	74	47.4	220	47.2
	Male	69	44.8	95	60.9	82	52.6	246	52.8
Race	African Heritage / African American	13	8.4	8	5.1	17	10.9	38	8.2
	American Indian or Alaskan Native	12	7.8	8	5.1	16	10.3	36	7.7
	Asian - Central/South Asian Heritage	1	0.6	1	0.6	0	0.0	2	0.4
	Asian - East Asian Heritage	1	0.6	2	1.3	0	0.0	3	0.6
	Asian - Japanese Heritage	1	0.6	0	0.0	1	0.6	2	0.4
	Asian - South East Asian Heritage	5	3.2	8	5.1	5	3.2	18	3.9
	Native Hawaiian or Other Pacific Islande	r 1	0.6	0	0.0	2	1.3	3	0.6
	White - Arabic / North African Heritage	0	0.0	1	0.6	0	0.0	1	0.2
	White - Caucasian / European Heritage	98	63.6	106	67.9	89	57.1	293	62.9
	Other	22	14.3	22	14.1	26	16.7	70	15.0
Height	Mean	58.0	-	58.2	-	59.0	-	58.4	-
-	SD	3.5	-	3.8	-	3.1	-	3.5	-
	Median	58.0	-	58.0	-	58.0	-	58.0	-
	Minimum	38.0	-	37.0	-	51.0	-	37.0	-
	Maximum	65.0	-	69.0	-	66.0	-	69.0	-
Weight	Mean	5.3	-	5.4	-	5.4	-	5.4	-
	SD	0.7	-	0.7	-	0.7	-	0.7	-
	Median	5.2	-	5.4	-	5.5	-	5.4	-
	Minimum	3.4	-	3.6	-	3.7	-	3.4	-
	Maximum	7.9	-	7.1	-	7.4	-	7.9	-
Hepatitis B vaccination at birth	Yes	143	92.9	136	87.2	144	92.3	423	90.8
	No	11	7.1	20	12.8	12	7.7	43	9.2

117119 (DTPA-HBV-IPV-135)

Report Final

		Hexa group N = 154			Pedia group N = 156		ta group I = 156	Total N = 466	
	Parameters or	Value	%	Value	%	Value	%	Value	%
Characteristics	Categories	or n		or n		or n		or n	
Tdap vaccination of mother	Yes	83	66.4	79	64.8	81	61.4	243	64.1
	No	42	33.6	43	35.2	51	38.6	136	35.9
	Missing	29	-	34	-	24	-	87	-

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

N = number of subjects

n = number of subjects in a given category

Value = value of the considered parameter

% = n / Number of subjects with available results x 100

SD = Standard deviation

Table 21 Summary of demographic characteristics (Booster ATP cohort for immunogenicity)

		Hexa group N = 138		Pedia group N = 139		Penta group N = 131		Total N = 408	
	Parameters or	Value	%	Value	%	Value	%	Value	%
Characteristics	Categories	or n		or n		or n		or n	
Age [months] at booster dose	Mean	15.3	-	15.3	-	15.3	-	15.3	-
	SD	0.6	-	0.6	-	0.7	-	0.7	-
	Median	15.0	-	15.0	-	15.0	-	15.0	-
	Minimum	15.0	-	15.0	-	15.0	-	15.0	-
	Maximum	18.0	-	18.0	-	18.0	-	18.0	-
Gender	Female	72	52.2	47	33.8	58	44.3	177	43.4
	Male	66	47.8	92	66.2	73	55.7	231	56.6
Race	African Heritage / African American	12	8.7	8	5.8	12	9.2	32	7.8
	American Indian or Alaskan Native	11	8.0	10	7.2	14	10.7	35	8.6
	Asian - Central/South Asian Heritage	1	0.7	2	1.4	0	0.0	3	0.7
	Asian - East Asian Heritage	3	2.2	2	1.4	0	0.0	5	1.2
	Asian - Japanese Heritage	0	0.0	0	0.0	1	0.8	1	0.2
	Asian - South East Asian Heritage	5	3.6	8	5.8	5	3.8	18	4.4
	Native Hawaiian or Other Pacific Islander	1	0.7	0	0.0	2	1.5	3	0.7

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135)

Report Final

		Hexa group N = 138		Pedia group N = 139		Penta group N = 131		Total N = 408		
	Parameters or	Value	%	Value	%	Value	%	Value	%	
Characteristics	Categories	or n		or n		or n		or n		
	White - Arabic / North African Heritage	0	0.0	1	0.7	0	0.0	1	0.2	
	White - Caucasian / European Heritage	84	60.9	90	64.7	72	55.0	246	60.3	
	Other	21	15.2	18	12.9	25	19.1	64	15.7	
Height	Mean	58.0	-	58.5	-	59.0	-	58.5	-	
	SD	3.6	-	4.6	-	3.2	-	3.9	-	
	Median	58.0	-	58.0	-	58.0	-	58.0	-	
	Minimum	38.0	-	37.0	-	48.0	-	37.0	-	
	Maximum	64.0	-	86.0	-	66.0	-	86.0	-	
Weight	Mean	5.3	-	5.4	-	5.4	-	5.4	-	
_	SD	0.7	-	0.7	-	0.7	-	0.7	-	
	Median	5.3	-	5.4	-	5.5	-	5.4	-	
	Minimum	4.0	-	4.0	-	3.7	-	3.7	-	
	Maximum	7.9	-	7.1	-	7.4	-	7.9	-	
Hepatitis B vaccination at birth	Yes	129	93.5	122	87.8	120	91.6	371	90.9	
•	No	9	6.5	17	12.2	11	8.4	37	9.1	
Tdap vaccination of mother	Yes	79	69.9	75	68.2	73	62.9	227	67.0	
•	No	34	30.1	35	31.8	43	37.1	112	33.0	
	Missing	25	-	29	-	15	-	69	-	

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

N = number of subjects

n = number of subjects in a given category

Value = value of the considered parameter

% = n / Number of subjects with available results x 100

SD = Standard deviation

7. IMMUNOGENICITY RESULTS

The primary analysis of immunogenicity was performed on the Primary ATP cohort for analysis of immunogenicity and the Booster ATP cohort for analysis of immunogenicity. Refer to Section 5.10.4 for the definition of the cohorts identified for analyses.

7.1. Primary Vaccination Epoch

7.1.1. Non-inferiority of *Infanrix hexa* to *Pediarix* co-administered with *ActHIB* - Immunogenicity of study vaccine pertussis antigens (PT, FHA and PRN)

The primary objective to demonstrate the non-inferiority of *Infanrix hexa* to *Pediarix* co-administered with *ActHIB*, in terms of antibody geometric mean concentrations (GMCs) for pertussis antigens (PT, FHA and PRN) one month after the third dose of the primary vaccination was reached (Table 22) – see Section 4.1.1 for the definition of the primary objective.

For each of the three pertussis antigens, the upper limit of the 95% confidence interval (CI) for the GMC ratio [Pedia group divided by Hexa group] was \leq 1.5 (Table 22):

- For anti-PT antibody 1.31;
- For anti-FHA antibody 1.35;
- For anti-PRN antibody 0.99.

Table 22 Ratio of GMCs for anti-PT, anti-FHA and anti-PRN between groups (Pedia group divided by Hexa group), one month post primary vaccination (Primary ATP cohort for immunogenicity)

					Adjusted GMC ratio (Pedia group / Hexa group)				
	F	Pedia group	Н	exa group		95% CI			
Antibody	N	Adjusted GMC	N	Adjusted GMC	Value	LL	UL		
anti-PT antibody (IU/mL)	149	47.9	146	43.6	1.10	0.92	1.31		
anti-FHA antibody (IU/mL)	149	122.6	146	107.3	1.14	0.97	1.35		
anti-PRN antibody (IU/mL)	149	46.1	146	58.2	0.79	0.63	0.99		

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

Adjusted GMC = geometric mean antibody concentration adjusted for Tdap vaccination of the mother N = Number of subjects with both pre- and post-primary vaccination results available

95% CI = 95% confidence interval for the adjusted GMC ratio (ANCOVA model: adjustment for Tdap vaccination of mother - pooled variance); LL = lower limit, UL = upper limit

7.1.2. Immune response to the Primary vaccinations

7.1.2.1. Anti-Pertussis (PT, FHA, PRN) antibody responses

The percentage of subjects with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ the assay cut-off and GMC are presented in Table 23.

One month after primary vaccination for subjects in the Hexa, Pedia and Penta groups:

- At least 99.3% of subjects had anti-PT antibody concentrations ≥2.693 IU/mL (assay cut-off) and also anti-PRN antibody concentrations ≥2.187 IU/mL (assay cut-off).
- All subjects had an anti-FHA antibody concentrations ≥2.046 IU/mL (assay cut-off).
- GMC values across the three groups ranged for anti-PT antibody from 24.2-48.3, for anti-FHA antibody from 59.9-122.7, and for anti-PRN antibody from 33.0-57.4.

Table 23 Number and percentage of subjects with anti-PT, anti-FHA and anti-PRN antibody concentration equal to or above the assay cut-off and geometric mean concentration (GMC), one month post primary vaccination (Primary ATP cohort for immunogenicity)

					≥ assay cut-off				GMC		
						9:	95% CI		95% CI		
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL	
-	Hexa group	PIII(M5)	146	146	100	97.5	100	43.2	38.1	48.9	
	Pedia group	PIII(M5)	149	148	99.3	96.3	100	48.3	42.7	54.5	
	Penta group	PIII(M5)	149	148	99.3	96.3	100	24.2	21.1	27.7	
-	Hexa group	PIII(M5)	146	146	100	97.5	100	106.3	95.0	119.0	
	Pedia group	PIII(M5)	149	149	100	97.6	100	122.7	109.9	137.0	
	Penta group	PIII(M5)	149	149	100	97.6	100	59.9	51.7	69.3	
	Hexa group	PIII(M5)	146	146	100	97.5	100	57.4	49.5	66.6	
	Pedia group	PIII(M5)	149	148	99.3	96.3	100	46.9	39.9	55.3	
	Penta group	PIII(M5)	149	148	99.3	96.3	100	33.0	27.8	39.1	

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Note: The assay cut off is 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

The corresponding data is also presented by gender (Table 7.1), geographical ancestry (Table 7.2) and Tdap vaccination of mother (Table 7.3).

Reverse cumulative distribution curves for anti-PT concentrations one month post primary vaccination is provided in Figure 7.1, with corresponding curves for anti-FHA concentrations in Figure 7.2, and anti-PRN concentrations in Figure 7.3.

7.1.2.2. Anti-Diphtheria (D) and anti-Tetanus (Anti-T) antibody responses

The percentage of subjects with anti-D and anti-T antibody concentrations \geq the assay cut-off, \geq 0.1 IU/mL, \geq 1.0 IU/mL and GMC are presented in Table 24.

One month after primary vaccination for subjects in the Hexa, Pedia and Penta groups:

• All subjects had anti-D antibody concentrations ≥ 0.1 IU/mL and at least 99.3% of subjects had anti-T antibody concentrations ≥ 0.1 IU/mL, which were the protocoldefined levels of seroprotection against these diseases (see Section 5.8.4 and 5.10.5.2).

The corresponding data is also presented by gender (Table 7.4), geographical ancestry (Table 7.5) and Tdap vaccination of mother (Table 7.6).

Reverse cumulative distribution curves for anti-D concentrations one month post primary vaccination is provided in Figure 7.4, with a corresponding curve for anti-T concentrations in Figure 7.5.

Table 24 Number and percentage of subjects with anti-D and anti-T antibody concentration equal to or above the assay cut-off, 0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC), one month post primary vaccination (Primary ATP cohort for immunogenicity)

					≥ cı	ıt-off		2	≥ 0.1	IU/ml	L	2	≥ 1.0	IU/m	L		GMC	
						95%	G CI			95%	6 CI			95%	6 CI		95%	δCI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-D antibody																		
	Pedia group	PIII(M5)	144	144	100	97.5	100	144	100	97.5	100	105	72.9	64.9	80.0	1.648	1.440	1.886
	Penta group	PIII(M5)	149	149	100	97.6	100	149	100	97.6	100	88	59.1	50.7	67.0	1.249	1.095	1.425
anti-T antibody	Hexa group	PIII(M5)	146	146	100	97.5	100	146	100	97.5	100	130	89.0	82.8	93.6	2.458	2.195	2.753
	Pedia group	PIII(M5)	149	149	100	97.6	100	149	100	97.6	100	134	89.9	83.9	94.3	2.633	2.338	2.966
	Penta group	PIII(M5)	149	149	100	97.6	100	148	99.3	96.3	100	119	79.9	72.5	86.0	2.012	1.768	2.290

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Note: The assay cut off is 0.057 IU/mL for anti-D, 0.043 IU/mL for anti-T.

7.1.2.3. Anti-Polio 1, 2, and 3 antibody responses

The percentage of subjects with anti-Polio 1, 2, and 3 antibody titer ≥ 8 - the protocol-defined seroprotection level (see Section 5.8.4 and 5.10.5.2) and GMT are e presented in Table 25.

One month after primary vaccination for subjects in the Hexa, Pedia and Penta groups:

• At least 99.3% of subjects had anti-Polio 1 antibody titer ≥ 8 , all subjects had anti-Polio 2 antibody titer ≥ 8 and at least 98.4% of subjects had anti-Polio 3 antibody titer ≥ 8 .

The corresponding data is also presented by gender (Table 7.7), geographical ancestry (Table 7.8) and Tdap vaccination of mother (Table 7.9).

Reverse cumulative distribution curves for anti-Polio 1 titres one month post primary vaccination is provided in Figure 7.6, with corresponding curves for anti-Polio 2 titres in Figure 7.7 and anti-Polio 3 titres in Figure 7.8.

Table 25 Number and percentage of subjects with anti-Polio 1, 2, and 3 antibody titer equal to or above 8 and geometric mean titer (GMT), one month post primary vaccination (Primary ATP cohort for immunogenicity)

					≥	8 ED50			GMT	
						95	% CI		95	% CI
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL
anti-Polio 1 antibody	Hexa group	PIII(M5)	137	137	100	97.3	100	546.9	447.7	668.0
	Pedia group	PIII(M5)	134	134	100	97.3	100	604.1	495.9	736.0
	Penta group	PIII(M5)	136	135	99.3	96.0	100	319.5	256.8	397.5
anti-Polio 2 antibody	Hexa group	PIII(M5)	133	133	100	97.3	100	483.5	394.2	593.0
	Pedia group	PIII(M5)	131	131	100	97.2	100	567.7	448.8	718.1
	Penta group	PIII(M5)	134	134	100	97.3	100	283.0	229.4	349.2
anti-Polio 3 antibody	Hexa group	PIII(M5)	129	129	100	97.2	100	722.2	577.4	903.4
	Pedia group	PIII(M5)	132	132	100	97.2	100	927.0	740.7	1160.3
	Penta group	PIII(M5)	126	124	98.4	94.4	99.8	294.6	221.6	391.7

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

7.1.2.4. Anti-PRP antibody responses

The percentage of subjects with anti-PRP antibody concentrations \geq the assay cut-off, $\geq 0.1 \ \mu g/mL$, $\geq 1.0 \ \mu g/mL$ and GMC are presented in Table 26.

One month after primary vaccination for subjects in the Hexa, Pedia and Penta groups:

• Short-term seroprotection against *Haemophilus influenzae* type b disease is defined as an anti-PRP antibody concentrations ≥ 0.15 μg/mL (see Section 5.8.4 and 5.10.5.2). This level of seroprotection was reached by at least 94.0% of subjects across the groups using the qualified assay and at least 94.8% across groups using the fully validated assay.

Table 26 Number and percentage of subjects with anti-PRP antibody concentration equal to or above the assay cut-off, 0.15 μg/mL and 1.0 μg/mL and geometric mean concentration (GMC), one month post primary vaccination (Primary ATP cohort for immunogenicity)

				≥ :	assay	y cut-	-off	≥	0.15	μg/n	nL	2	≥ 1.0	μg/m	ıL		GMC	
						95%	6 CI			95%	6 CI			95%	6 CI		959	% CI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-PRP -	Hexa	PIII(M5)	149	140	94.0	88.8	97.2	140	94.0	88.8	97.2	83	55.7	47.3	63.8	1.373	1.083	1.740
qualified	group																	
assay																		
	Pedia	PIII(M5)	153	151	98.7	95.4	99.8	151	98.7	95.4	99.8	144	94.1	89.1	97.3	10.327	8.127	13.122
	group																	
	Penta	PIII(M5)	153	151	98.7	95.4	99.8	151	98.7	95.4	99.8	126	82.4	75.4	88.0	6.485	4.922	8.544
	group																	
anti-PRP -	Hexa	PIII(M5)	154	152	98.7	95.4	99.8	146	94.8	90.0	97.7	85	55.2	47.0	63.2	1.348	1.076	1.688
fully validated	group																	
assay																		
	Pedia	PIII(M5)	154	153	99.4	96.4	100	151	98.1	94.4	99.6	145	94.2	89.2	97.3	9.258	7.362	11.642
	group																	
	Penta	PIII(M5)	156	154	98.7	95.4	99.8	154	98.7	95.4	99.8	130	83.3	76.5	88.8	5.717	4.363	7.492
	group																	

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval: LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Note: Two assays were used for anti-PRP, for the fully validated assay, the assay cut off is 0.066 μ g/mL while 0.15 μ g/mL was used for the qualified assay.

The corresponding data is also presented by study lot (Table 7.10), by gender (Table 7.11), geographical ancestry (Table 7.12) and Tdap vaccination of mother (Table 7.13).

Reverse cumulative distribution curves for anti-PRP (fully validated assay) concentrations one month post primary vaccination is provided in Figure 7.9, with a corresponding curve for anti-PRP (qualified assay) concentrations in Figure 7.10.

7.1.2.5. Anti-HBs antibody responses

The percentage of subjects with anti-HBs antibody concentrations \geq assay cut-off of 6.2 mIU/mL or seroprotection threshold of \geq 10.0 mIU/mL and GMC are presented in Table 27.

One month after primary vaccination for subjects in the Hexa, Pedia and Penta groups:

Seroprotection against Hepatitis B virus (HBV) disease is defined as anti-HBs antibody concentrations greater than or equal to 10 mIU/mL (see Section 5.8.4 and 5.10.5.2). This level of seroprotection was met by at least 97.8% of subjects across the groups.

The results were re-presented this time by either receiving a HepB vaccination at birth or not (Table 28).

Table 27 Number and percentage of subjects with anti-HBs antibody concentration equal to or above 6.2 mlU/mL and 10.0 mlU/mL and geometric mean concentration (GMC), one month post primary vaccination (Primary ATP cohort for immunogenicity)

				≥	6.2 n	nIU/m	L	2	≥ 10 m	ılU/m	L		GMC	
						95%	6 CI			95%	6 CI		95%	CI
Antibody	Group	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL	
anti-HBs antibody	Hexa group	134	134	100	97.3	100	134	100	97.3	100	2258.8	1910.7	2670.4	
	Pedia group	PIII(M5)	138	100	97.4	100	138	100	97.4	100	1886.0	1565.6	2271.9	
	Penta group	PIII(M5)	136	134	98.5	94.8	99.8	133	97.8	93.7	99.5	1053.4	780.2	1422.4

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

117119 (DTPA-HBV-IPV-135) Report Final

The corresponding data is also presented by gender (Table 7.14), geographical ancestry (Table 7.15) and Tdap vaccination of mother (Table 7.16).

Reverse cumulative distribution curves for anti-HBs concentrations one month post primary vaccination is provided in Figure 7.11.

Table 28 Number and percentage of subjects with anti-HBs antibody concentration equal to or above 6.2 mlU/mL and 10.0 mlU/mL and geometric mean concentration (GMC), one month post primary vaccination – by Hepatitis B vaccination at birth (Primary ATP cohort for immunogenicity)

					≥	6.2 ו	nIU/n	nL	≥	: 10 n	nIU/n	ıL		GMC	
							95%	6 CI			95%	6 CI		95%	6 CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-HBs antibody	Hexa group	HepB at birth Yes	PIII(M5)	124	124	100	97.1	100	124	100	97.1	100	2322.2	1951.3	2763.6
		HepB at birth No	PIII(M5)	10	10	100	69.2	100	10	100	69.2	100	1602.9	799.9	3212.1
	Pedia group	HepB at birth Yes	PIII(M5)	122	122	100	97.0	100	122	100	97.0	100	2026.9	1681.8	2442.9
		HepB at birth No	PIII(M5)	16	16	100	79.4	100	16	100	79.4	100	1088.7	506.6	2339.6
	Penta group	HepB at birth Yes	PIII(M5)	126	124	98.4	94.4	99.8	123	97.6	93.2	99.5	1043.4	755.4	1441.2
		HepB at birth No	PIII(M5)		10	100	69.2	100	10	100		100		755.3	1869.1

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

7.1.3. Primary Total Vaccinated cohort analysis

A total of 119 (20.3%) subjects, out of 585 vaccinated subjects were eliminated from the Primary ATP cohort for immunogenicity (466 subjects; Table 18). As more than 5% of the vaccinated subjects with immunological data post-dose 3 were excluded from the Primary ATP cohort for immunogenicity, a complementary analysis was carried out on the Primary Total Vaccinated cohort (see Section 5.10.6.2).

No apparent or clinically meaningful differences were observed between the immunogenicity results for the Primary Total Vaccinated cohort and the Primary ATP cohort for immunogenicity.

The results of the Primary Total Vaccinated cohort analyses are presented in Table 7.53 to Table 7.58.

7.2. Booster Vaccination Epoch

7.2.1. Immune response to the Booster vaccinations

7.2.1.1. Anti-Pertussis (PT, FHA, PRN) antibody persistence and booster response

The percentage of subjects with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ the assay cut-off and GMC are presented in Table 29.

Before the Booster vaccination for subjects in the Hexa, Pedia and Penta groups:

- Between 52.1-86.4% of subjects had anti-PT antibody concentrations ≥2.693 IU/mL, between 93.4-99.2% of subjects had anti-FHA antibody concentrations ≥2.046 IU/mL, and between 75.8-84.0% of subjects had anti-PRN antibody concentrations ≥2.187 IU/mL.
- The most pronounced anti-pertussis antibody levels decay (especially PT and FHA) between the primary and booster vaccinations is observed after *Pentacel+Engerix-B* vaccination.

One month after Booster vaccination for subjects in the Hexa, Pedia and Penta groups:

 All subjects had anti-PT antibody concentrations ≥2.693 IU/mL, all subjects had anti-FHA antibody concentrations ≥2.046 IU/mL, and all Pedia group subjects had anti-PRN antibody concentrations ≥2.187 IU/mL. The other anti-PRN antibody concentrations results were both above 99%.

The corresponding data is also presented by gender (Table 7.24), geographical ancestry (Table 7.25) and Tdap vaccination of mother (Table 7.26).

Reverse cumulative distribution curves for anti-PT concentrations, before and one month post booster vaccination is provided in Figure 7.12, with corresponding curves for anti-FHA concentrations in Figure 7.13, and anti-PRN concentrations in Figure 7.14.

117119 (DTPA-HBV-IPV-135) Report Final

Table 29 Number and percentage of subjects with anti-PT, anti-FHA and anti-PRN antibody concentration equal to or above the assay cut-off and geometric mean concentration (GMC), before and one month post booster vaccination (Booster ATP cohort for immunogenicity)

					≥ ass	ay cut-	off		GMC	
						9	5% CI		959	% CI
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL
anti-PT antibody	Hexa group	PRE-BST	131	107	81.7	74.0	87.9	5.3	4.6	6.2
		POST-BST	138	138	100	97.4	100	71.4	62.6	81.5
	Pedia group	PRE-BST	132	114	86.4	79.3	91.7	6.5	5.6	7.7
		POST-BST	136	136	100	97.3	100	87.6	76.6	100.2
	Penta group	PRE-BST	121	63	52.1	42.8	61.2	3.1	2.6	3.7
		POST-BST	126	126	100	97.1	100	55.5	47.4	65.1
anti-FHA antibody	Hexa group	PRE-BST	131	130	99.2	95.8	100	17.1	14.7	19.9
		POST-BST	138	138	100	97.4	100	186.9	165.1	211.5
	Pedia group	PRE-BST	132	130	98.5	94.6	99.8	21.8	18.3	26.1
		POST-BST	136	136	100	97.3	100	250.4	220.4	284.6
	Penta group	PRE-BST	121	113	93.4	87.4	97.1	8.1	6.6	9.9
		POST-BST	126	126	100	97.1	100	101.0	86.2	118.3
anti-PRN antibody	Hexa group	PRE-BST	131	110	84.0	76.5	89.8	6.8	5.5	8.3
		POST-BST	137	136	99.3	96.0	100	208.0	172.3	251.1
	Pedia group	PRE-BST	132	104	78.8	70.8	85.4	5.5	4.5	6.6
		POST-BST	136	136	100	97.3	100	215.6	176.1	263.8
	Hexa group Pedia group Penta group Hexa group Pedia group Penta group Hexa group Hexa group	PRE-BST	120	91	75.8	67.2	83.2	6.0	4.8	7.5
		POST-BST	125	124	99.2	95.6	100	130.5	105.9	160.9

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Note: The assay cut off is 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

7.2.1.2. Booster responses for anti-PT, anti-FHA, and anti-PRN antibodies

The proportion of subjects with an anti-Pertussis antibody booster response was:

- For anti-PT antibody: ≥93.1% across groups;
- For anti-FHA antibody: ≥97.7% across groups;
- For anti-PRN antibody: ≥97.4% across groups (Table 30).

Table 30 Booster response for anti-PT, anti-FHA and anti-PRN antibodies, one month post booster vaccination (Booster ATP cohort for immunogenicity)

					Booste		
						95	% CI
Antibody	Group	Pre-vaccination status	N	n	%	LL	UL
anti-PT antibody (IU/mL)	Hexa group	S-	24	22	91.7	73.0	99.0
, , , , , , , , , , , , , , , , , , , ,	3 3 3 4	S+ (<4*cut_off IU/mL)	78	75	96.2	89.2	99.2
		S+ (≥4*cut_off IU/mL)	29	29	100	88.1	100
		Total	131	126	96.2	91.3	98.7
	Pedia group	S-	18	18	100	81.5	100
		S+ (<4*cut_off IU/mL)	86	81	94.2	87.0	98.1
		S+ (≥4*cut_off IU/mL)	26	22	84.6	65.1	95.6
		Total	130	121	93.1	87.3	96.8
	Penta group	S-	56	52	92.9	82.7	98.0
		S+ (<4*cut_off IU/mL)	46	45	97.8	88.5	99.9
		S+ (≥4*cut_off IU/mL)	14	14	100	76.8	100
		Total	116	111	95.7	90.2	98.6
anti-FHA antibody (IU/mL)	Hexa group	S-	1	1	100	2.5	100
, ,		S+ (<4*cut_off IU/mL)	27	27	100	87.2	100
		S+ (≥4*cut_off IU/mL)	103	102	99.0	94.7	100
		Total	131	130	99.2	95.8	100
	Pedia group	S-	2	2	100	15.8	100
		S+ (<4*cut_off IU/mL)	17	17	100	80.5	100
		S+ (≥4*cut_off IU/mL)	111	108	97.3	92.3	99.4
		Total	130	127	97.7	93.4	99.5
	Penta group	S-	8	8	100	63.1	100
		S+ (<4*cut_off IU/mL)	57	56	98.2	90.6	100
		S+ (≥4*cut_off IU/mL)	51	50	98.0	89.6	100
		Total	116	114	98.3	93.9	99.8
nti-PRN antibody (IU/mL)	Hexa group	S-	21	20	95.2	76.2	99.9
		S+ (<4*cut_off IU/mL)	54	54	100	93.4	100
		S+ (≥4*cut_off IU/mL)	55	54	98.2	90.3	100
		Total	130	128	98.5	94.6	99.8
	Pedia group	S-	28	27	96.4	81.7	99.9
		S+ (<4*cut_off IU/mL)	55	54	98.2	90.3	100
		S+ (≥4*cut_off IU/mL)	47	47	100	92.5	100
		Total	130	128	98.5	94.6	99.8
	Penta group	S-	28	26	92.9	76.5	99.1
		S+ (<4*cut_off IU/mL)	40	39	97.5	86.8	99.9
		S+ (≥4*cut_off IU/mL)	47	47	100	92.5	100
		Total	115	112	97.4	92.6	99.5

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

Booster response to PT, FHA and PRN antigens is defined as:

S- subjects: For subjects with pre-vaccination antibody concentration below the assay cut off, post-vaccination antibody concentration ≥ 4 times the assay cut-off

S+ (<4*cut_off IU/mL) subjects: For subjects with pre-vaccination antibody concentration between the assay cut off and below 4 times the assay cut-off, post-vaccination antibody concentration equal or above 4 times the pre-vaccination antibody concentration

117119 (DTPA-HBV-IPV-135) Report Final

S+ (≥4*cut_off IU/mL) subjects: For subjects with pre-vaccination antibody concentration equal or above 4 times the assay cut off, post-vaccination antibody concentration equal or above 2 times the pre-vaccination antibody concentration

N = number of subjects with pre- and post-vaccination results available n/% = number/percentage of subjects with booster response 95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit Note: The assay cut off is 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

The corresponding data is also presented by gender (Table 7.27), geographical ancestry (Table 7.28) and Tdap vaccination of mother (Table 7.29).

7.2.1.3. Anti-D and anti-T antibody persistence and booster response

The percentage of subjects with anti-D and anti-T antibody concentrations \geq the assay cut-off, $\geq 0.1 \text{ IU/mL}$, $\geq 1.0 \text{ IU/mL}$ and GMC are presented in Table 31.

Antibody persistence data before the Booster vaccination for subjects in the Hexa, Pedia and Penta groups:

• Between 93.2-97.7% of subjects had anti-D antibody concentrations ≥ 0.1 IU/mL and between 88.4-93.2% of subjects had anti-T antibody concentrations ≥ 0.1 IU/mL, which were the protocol-defined levels of seroprotection against these diseases.

One month after Booster vaccination for subjects in the Hexa, Pedia and Penta groups:

- All subjects had anti-D antibody concentrations and anti-T antibody concentrations ≥ 0.1 IU/mL, except for the Penta group for which anti-T antibody concentration was ≥ 0.1 IU/mL for 99.2% of subjects.
- The conservative level of ≥ 1.0 IU/mL seroprotection was exhibited for anti-D antibody by all subjects and for anti-T antibody by between 97.8-100% of subjects.

The corresponding data is also presented by gender (Table 7.30), geographical ancestry (Table 7.31) and Tdap vaccination of mother (Table 7.32).

Reverse cumulative distribution curves for anti-D concentrations, before and one month post booster vaccination is provided in Figure 7.15, with a corresponding curve for anti-T concentrations in Figure 7.16.

117119 (DTPA-HBV-IPV-135) Report Final

Table 31 Number and percentage of subjects with anti-D and anti-T antibody concentration equal to or above the assay cut-off, 0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC), before and one month post booster vaccination (Booster ATP cohort for immunogenicity)

				≥ :	assa	y cut	-off	2	≥ 0.1	IU/m	L	2	≥ 1.0	IU/m	L		GMC	
						95%	6 CI			95%	6 CI			95%	6 CI		959	% CI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-D	Hexa	PRE-	131	131	100	97.2	100	128	97.7	93.5	99.5	43	32.8	24.9	41.6	0.701	0.597	0.825
antibody	group	BST																
		POST-	138	138	100	97.4	100	138	100	97.4	100	138	100	97.4	100	8.334	7.479	9.286
		BST																
	Pedia	PRE-	132	129	97.7	93.5	99.5	123	93.2	87.5	96.8	48	36.4	28.2	45.2	0.622	0.514	0.753
	group	BST																
		POST-	136	136	100	97.3	100	136	100	97.3	100	136	100	97.3	100	7.886	6.972	8.920
		BST																
	Penta	PRE-	121	118	97.5	92.9	99.5	115	95.0	89.5	98.2	51	42.1	33.2	51.5	0.764	0.629	0.928
	group	BST																
		POST-	126	126	100	97.1	100	126	100	97.1	100	126	100	97.1	100	8.537	7.524	9.687
		BST																
anti-T	Hexa	PRE-	131	130	99.2	95.8	100	118	90.1	83.6	94.6	16	12.2	7.1	19.1	0.327	0.281	0.380
antibody	group	BST																
		POST-	138	138	100	97.4	100	138	100	97.4	100	138	100	97.4	100	9.212	7.863	10.793
		BST																
	Pedia	PRE-	132	129	97.7	93.5	99.5	123	93.2	87.5	96.8	17	12.9	7.7	19.8	0.402	0.340	0.474
	group	BST																
		POST-	136	136	100	97.3	100	136	100	97.3	100	133	97.8	93.7	99.5	8.870	7.668	10.261
		BST																
	Penta	PRE-	121	119	98.3	94.2	99.8	107	88.4	81.3	93.5	19	15.7	9.7	23.4	0.340	0.281	0.410
	group	BST																
		POST-	126	126	100	97.1	100	125	99.2	95.7	100	125	99.2	95.7	100	6.880	5.905	8.015
		BST																

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Note: The assay cut off is 0.057 IU/mL for anti-D, 0.043 IU/mL for anti-T.

7.2.1.4. Anti-PRP antibody persistence and booster response

The percentage of subjects with anti-PRP antibody concentration $\geq 0.066 \,\mu\text{g/mL}$, $\geq 0.15 \,\mu\text{g/mL}$ and $\geq 1.0 \,\mu\text{g/mL}$ and GMC are presented in Table 32.

Antibody persistence data before the Booster vaccination for subjects in the Hexa, Pedia and Penta groups:

- Between 69.5-92.4% of subjects had anti-PRP antibody concentrations $\geq 0.15 \, \mu g/mL$, which indicated short-term seroprotection.
- Between 17.6-53.8% of subjects had anti-PRP antibody concentrations $\geq 1.0 \,\mu\text{g/mL}$, which indicated long-term seroprotection.
- The most pronounced Anti-PRP antibody levels decay between the primary and booster vaccinations is observed after *Infanrix hexa* vaccination.

One month after Booster vaccination for subjects in the Hexa, Pedia and Penta groups:

- Between 98.5-100% of subjects had anti-PRP antibody concentrations $\geq 0.15 \ \mu g/mL$.
- Between 97.7-99.3% of subjects had anti-PRP antibody concentrations $\geq 1.0 \,\mu\text{g/mL}$.

The corresponding data is also presented by gender (Table 7.33), geographical ancestry (Table 7.34) and Tdap vaccination of mother (Table 7.35).

Reverse cumulative distribution curves for anti-PRP (fully validated assay) concentrations, before and one month post booster vaccination is provided in Figure 7.20.

Table 32 Number and percentage of subjects with anti-PRP antibody concentration equal to or above 0.066 μg/mL, 0.15 μg/mL and 1.0 μg/mL and geometric mean concentration (GMC), before and one month post booster vaccination (Booster ATP cohort for immunogenicity)

				≥	0.066	β μg/ı	mL	≥	0.15	μg/n	nL	2	≥ 1.0	μg/m	ıL		GMC	
						95%	6 CI			95%	6 CI			95%	6 CI		95%	6 CI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-PRP – fully validated assay	Hexa group	PRE- BST	131	118	90.1	83.6	94.6	91	69.5	60.8	77.2	23	17.6	11.5	25.2	0.301	0.242	0.373
doody		POST- BST	138	138	100	97.4	100	138	100	97.4	100	136	98.6	94.9	99.8	39.365	31.520	49.164
	Pedia group	PRE- BST	132	129	97.7	93.5	99.5	122	92.4	86.5	96.3	71	53.8	44.9	62.5	0.987	0.775	1.256
		POST- BST	139	139	100	97.4	100	139	100	97.4	100	138	99.3	96.1	100	51.140	41.954	62.339
	Penta group	PRE- BST	121	111	91.7	85.3	96.0	94	77.7	69.2	84.8	47	38.8	30.1	48.1	0.614	0.458	0.822
		POST- BST	131	130	99.2	95.8	100	129	98.5	94.6	99.8	128	97.7	93.5	99.5	27.318	21.140	35.302

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

7.2.1.5. Anti-Polio antibody persistence

The percentage of subjects with anti-Polio 1, 2, and 3 antibody titers ≥ 8 – the protocol-defined seroprotection level (see Section 5.8.4 and 5.10.5.2) and GMT are e presented in Table 33.

Antibody persistence data at the Month 13-16 or Pre-Bst timepoint (Visit 5; Section 5.1.1) for the Hexa, Pedia and Penta groups:

- Between 86.2-96.9% of subjects had anti-Polio 1 antibody titer ≥8, between 93.0-95.3% of subjects had anti-Polio 2 antibody titer ≥8, and between 68.4-97.7% of subjects had anti-Polio 3 antibody titer ≥8.
- The most pronounced anti-polio antibody levels decay (especially polio 1 and polio 3) between the primary and booster vaccinations is observed after *Pentacel+Engerix-B* vaccination.

The corresponding data is also presented by gender (Table 7.36), geographical ancestry (Table 7.37) and Tdap vaccination of mother (Table 7.38).

Reverse cumulative distribution curves for anti-Polio 1 antibody titres before booster vaccination is provided in Figure 7.17, with corresponding curves for anti-Polio 2 titres in Figure 7.18 and anti-Polio 3 titres in Figure 7.19.

Table 33 Number and percentage of subjects with anti-Polio 1, 2 and 3 antibody titers equal to or above 8 and geometric mean titers (GMT), before the booster vaccination (Booster ATP cohort for immunogenicity)

					≥81	ED50			GMT	
						95%	6 CI		95%	δCI
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL
anti-Polio 1 antibody	Hexa group	PRE-BST	128	124	96.9	92.2	99.1	99.5	79.4	124.8
	Pedia group									137.9
	Penta group	PRE-BST	116	100	86.2	78.6	91.9	42.2	32.6	54.6
anti-Polio 2 antibody	Hexa group	PRE-BST	128	119	93.0	87.1	96.7	94.9	73.2	123.1
	Pedia group	PRE-BST	128	122	95.3	90.1	98.3	111.9	88.0	142.4
	Penta group	PRE-BST	117	109	93.2	87.0	97.0	51.2	40.8	64.3
anti-Polio 3 antibody	Hexa group	PRE-BST	127	123	96.9	92.1	99.1	122.1	95.1	156.9
	Pedia group	PRE-BST	129	126	97.7	93.4	99.5	160.4	125.8	204.6
	Penta group	PRE-BST	117	80	68.4	59.1	76.7	28.4	20.6	39.1

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

7.2.1.6. Anti-HBs antibody persistence

The percentage of subjects with anti-HBs antibody concentration \geq the assay cut-off of 6.2 mIU/mL or \geq 10.0 mIU/mL which was the protocol-defined seroprotection level (see Section 5.8.4 and 5.10.5.2), and GMC are presented in Table 34.

Antibody persistence data at the Month 13-16 or Pre-Bst timepoint (Visit 5; Section 5.1.1) for the Hexa, Pedia and Penta groups:

- Between 86.8-98.5% of subjects had anti-HBs antibody concentrations ≥ 10.0 mIU/mL.
- The most pronounced anti-HBs antibody levels decay between the primary and booster vaccinations is observed after *Pentacel+Engerix-B* vaccination.

117119 (DTPA-HBV-IPV-135) Report Final

The corresponding data is also presented by gender (Table 7.39), geographical ancestry (Table 7.40), Tdap vaccination of mother (Table 7.41) and by Hepatitis B vaccination of subject (Table 7.42).

Reverse cumulative distribution curves for anti-HBs antibody concentrations before booster vaccination is provided in Figure 7.21.

Table 34 Number and percentage of subjects with anti-HBs antibody concentration equal to or above 6.2 mlU/mL and 10 mlU/mL and geometric mean concentration (GMC), before the booster vaccination (Booster ATP cohort for immunogenicity)

				2	≥ 6.2	mIU/n	nL		≥ 10	mIU/m	L		GMC	
						95%	6 CI			95%	6 CI		95%	% CI
,	Group							n	%	LL	UL	value	LL	UL
anti-HBs antibody	Hexa group	PRE-BST	133	132	99.2	95.9	100	131	98.5	94.7	99.8	328.7	261.5	413.2
	Pedia group	PRE-BST	131	130	99.2	95.8	100	128	97.7	93.5	99.5	235.8	188.2	295.5
	Penta group	PRE-BST	121	110	90.9	84.3	95.4	105	86.8	79.4	92.2	149.4	100.5	222.3

Hexa group = Subjects who received primary doses of *Infanrix* hexa and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

7.2.2. Booster Total Vaccinated cohort analysis

A total of 78 (16.1%) subjects, out of 486 booster vaccinated subjects were eliminated from the Booster ATP cohort for immunogenicity (408 subjects; Table 19). As more than 5% of the booster vaccinated subjects with immunological data post-booster were excluded from the Booster ATP cohort for immunogenicity, a complementary analysis was carried out on the Booster Total Vaccinated cohort (see Section 5.10.7.2).

No apparent or clinically meaningful differences were observed between the immunogenicity results for the Booster Total Vaccinated cohort and the Booster ATP cohort for immunogenicity.

The results of the Booster Total Vaccinated cohort analyses are presented in Table 7.59 to Table 7.64.

7.3. Immunogenicity summary

7.3.1. Primary Vaccination Epoch

The primary objective to demonstrate the non-inferiority of *Infanrix hexa* to *Pediarix* co-administered with *ActHIB*, in terms of antibody GMCs for pertussis antigens (PT, FHA and PRN) one month after the third dose of the primary vaccination was reached:

- For PT, FHA and PRN, the upper limit of the 95% CI for the GMC ratio [Pedia group divided by Hexa group] was ≤ 1.5 : For anti-PT antibody 1.31; for anti-FHA antibody 1.35; for anti-PRN antibody 0.99.
- Anti-Diphtheria and anti-Tetanus antibody responses: All subjects had anti-D antibody concentrations ≥ 0.1 IU/mL and at least 99.3% of subjects had anti-T antibody concentrations ≥ 0.1 IU/mL, indicating seroprotection against these diseases.
- Anti-Polio 1, 2, and 3 antibody responses: At least 99.3% of subjects had anti-Polio 1 antibody titer ≥8, all subjects had anti-Polio 2 antibody titer ≥8 and at least 98.4% of subjects had anti-Polio 3 antibody titer ≥8.
- Anti-PRP antibody responses: Short-term seroprotection against Haemophilus influenzae type b disease (anti-PRP antibody concentrations ≥ 0.15 μg/mL) was met by at least 94.8% across groups using the fully validated assay.
- Anti-HBs antibody responses: Seroprotection against Hepatitis B virus (HBV) disease (anti-HBs ≥ 10 mIU/mL) was reached by at least 97.8% of subjects across the groups.

7.3.2. Booster Vaccination Epoch

- The proportion of subjects with an anti-Pertussis antibody booster response was: For anti-PT antibody: ≥93.1% across groups; for anti-FHA antibody: ≥97.7% across groups; for anti-PRN antibody: ≥97.4% across groups.
- Anti-D and Anti-T immune response: Seroprotection (≥ 0.1 IU/mL) was reached for at least 99.2% of subjects across groups and long-term seroprotection (antibody concentrations ≥1.0 IU/mL) was reached by all subjects for anti-D and for anti-T antibody by between 97.8-100% of subjects.
- Anti-PRP immune response: Short-term seroprotection (≥ 0.15 μg/mL): Between 98.5-100% of subjects across groups and long-term seroprotection (≥ 1.0 μg/mL) for between 97.7-99.3% of subjects across groups.

8. SAFETY RESULTS

8.1. Primary Total vaccinated cohort analysis

8.1.1. Primary vaccination doses received

All enrolled subjects received at least one dose of study vaccine (Table 35):

- For the Hexa group, the correct number of doses of *Infanrix hexa*, *Prevnar13* and *Rotarix* were received by 93.8%, 93.8% and 95.4%, respectively.
- For the Pedia group, the correct number of doses of *ActHIB*, *Pediarix*, *Prevnar13* and *Rotarix* were received by 95.4%, 95.4%, 95.4% and 96.9%, respectively.
- For the Penta group, the correct number of doses of *Engerix-B, Pentacel, Prevnar13* and *Rotarix* were received by 91.8%, 91.8%, 91.8%, and 96.4%, respectively.

117119 (DTPA-HBV-IPV-135)

Report Final

Table 35 Number and percentage of subjects who received priming doses by vaccine (Primary Total vaccinated cohort)

	INFANE	group RIX HEXA = 195	PRE\	a group /NAR 13 = 195	RO1	group ARIX = 195	AC	group THIB : 194	PED		PREV	a group NAR 13 = 194	RO		ENGE		PENT		PREV	group NAR 13 = 196	RO1	
Total number of	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
doses received	9	4.6	9	4.6	9	4.6	6	3.1	6	3.1	6	3.1	6	3.1	16	8.2	9	4.6	7	3.6	7	3.6
2	3	1.5	3	1.5	186	95.4	3	1.5	3	1.5	3	1.5	188	96.9	167	85.2	7	3.6	9		189	96.4
3	183	93.8	183	93.8	0	0.0	185	95.4	185	95.4	185	95.4	0	0.0	13	6.6	180	91.8	180	91.8	0	0.0
Any	195	100	195	100	195	100	194	100	194	100	194	100	194	100	196	100	196	100	196	100	196	100

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

N = number of subjects in each group included in the considered cohort

n/% = number/percentage of subjects receiving the specified total number of doses

Any = number and percentage of subjects receiving at least one dose

8.1.2. Symptom eCRF screen compliance

Compliance in recording general symptom eCRF screens or local symptom eCRF screens was typically very high across groups for each of the three scheduled doses i.e. total results per group were at least 95% and results per treatment group across doses were at least 94% (Table 36).

Table 36 Compliance in returning symptom sheets for priming doses (Primary Total vaccinated cohort)

Dose	Group	Number of doses	Doses NOT according to protocol	Number of general SS	Compliance % general SS	Number of local SS	Compliance % local SS
1	Hexa group	195	1	185	94.9	185	94.9
	Pedia group	194	0	189	97.4	189	97.4
	Penta group	196	1	188	95.9	188	95.9
2	Hexa group	186	0	182	97.8	182	97.8
	Pedia group	188	0	184	97.9	184	97.9
	Penta group	189	0	179	94.7	180	95.2
3	Hexa group	183	2	172	94.0	172	94.0
	Pedia group	185	0	175	94.6	175	94.6
	Penta group	180	0	170	94.4	171	95.0
Total	Hexa group	564	3	539	95.6	539	95.6
	Pedia group	567	0	548	96.6	548	96.6
	Penta group	565	1	537	95.0	539	95.4

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

SS = Symptom screens/sheets used for the collection of local and general solicited AEs

Compliance % = (number of doses with symptom screen/sheet return / number of administered doses) X 100

8.1.3. Overall incidence of adverse events

Please refer to the following Tables:

- 1. Incidence and nature of symptoms (solicited and unsolicited): Table 37;
 - In all three groups (Hexa, Pedia and Penta) over the primary doses, symptoms (solicited and/or unsolicited, local and/or general) were reported for 93.4-96.4% of subjects.
- 2. Incidence and nature of grade 3 symptoms (solicited and unsolicited): Table 38;
 - In all three groups (Hexa, Pedia and Penta) over the primary doses, grade 3 symptoms (solicited and/or unsolicited, local and/or general) were reported for 17.4-37.1% of subjects.
- 3. Incidence of local symptoms (solicited and unsolicited) reported for *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B* vaccines: Table 39;
 - Overall local symptoms (solicited and unsolicited) over the primary doses, were recorded for subjects receiving: Infanrix hexa (76.4%); Pediarix (82.0%), ActHIB (84.5%), Pentacel (79.6%), and *Engerix-B* (74.0%).
- 4. Incidence of grade 3 local symptoms (solicited and unsolicited) reported for *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B* vaccines: Table 40;
 - Overall grade 3 local symptoms (solicited and unsolicited) over the primary doses, were recorded for subjects receiving: Infanrix hexa (8.2%);
 Pediarix (18.6%), ActHIB (19.6%), Pentacel (17.3%), and Engerix-B (9.7%).

Please also refer to the following Tables:

- 1. Incidence and nature of symptoms (solicited and unsolicited) that were causally related to vaccination reported during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall: Table 8.1.
- 2. Incidence and nature of grade 3 symptoms (solicited and unsolicited) that were causally related to vaccination reported during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall: Table 8.2.
- 3. Incidence and nature of symptoms (solicited and unsolicited) reported during the 31-day (Days 0-30) post-vaccination period following each priming dose and overall: Table 8.3.
- 4. Incidence and nature of grade 3 symptoms (solicited and unsolicited) reported during the 31-day (Days 0-30) post-vaccination period following each priming dose and overall: Table 8.4.
- 5. Incidence and nature of symptoms (solicited and unsolicited) that were causally related to vaccination reported during the 31-day (Days 0-30) post-vaccination period following each priming dose and overall: Table 8.5.
- 6. Incidence and nature of grade 3 symptoms (solicited and unsolicited) that were causally related to vaccination reported during the 31-day (Days 0-30) post-vaccination period following each priming dose and overall: Table 8.6.

Table 37 Incidence and nature of symptoms (solicited and unsolicited) reported during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)

			Any	sym	pton	1	Ge	ener	al sy	mpto	ms	L	.ocal	sym	pton	18
					95%	6 CI				95%	6 CI					6 CI
	Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Hexa group	195	165	84.6	78.8	89.4	195	153	78.5	72.0	84.0	195	111	56.9	49.7	64.0
	Pedia group	194	182	93.8	89.4	96.8	194	179	92.3	87.6	95.6	194	144	74.2	67.5	80.2
	Penta group	196	178	90.8	85.9	94.5	196	173	88.3	82.9	92.4	196	128	65.3	58.2	71.9
Dose 2	Hexa group	186	161	86.6	80.8	91.1	186	151	81.2	74.8	86.5	186	105	56.5	49.0	63.7
	Pedia group	188	167	88.8	83.4	93.0	188	160	85.1	79.2	89.9	188	135	71.8	64.8	78.1
	Penta group	189	162	85.7	79.9	90.4	189	156	82.5	76.4	87.7	189	117	61.9	54.6	68.9
Dose 3	Hexa group	183	152	83.1	76.8	88.2	183	142	77.6	70.9	83.4	183	103	56.3	48.8	63.6
	Pedia group	185	161	87.0	81.3	91.5	185	155	83.8	77.7	88.8	185	118	63.8	56.4	70.7
	Penta group	180	146	81.1	74.6	86.5	180	138	76.7	69.8	82.6	180	107	59.4	51.9	66.7
Overall/dose	Hexa group	564	478	84.8	81.5	87.6	564	446	79.1	75.5	82.4	564	319	56.6	52.4	60.7
	Pedia group	567	510	89.9	87.2	92.3	567	494	87.1	84.1	89.8	567	397	70.0	66.1	73.8
	Penta group	565	486	86.0	82.9	88.8	565	467	82.7	79.3	85.7	565	352	62.3	58.2	66.3
Overall/subject	Hexa group	195	185	94.9	90.8	97.5	195	182	93.3	88.9	96.4	195	151	77.4	70.9	83.1
	Pedia group	194	187	96.4	92.7	98.5	194	186	95.9	92.0	98.2	194	168	86.6	81.0	91.1
	Penta group	196	183	93.4	88.9	96.4	196	182	92.9	88.3	96.0	196	162	82.7	76.6	87.7

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

For each dose and overall/subject:

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects presenting at least one type of symptom whatever the study vaccine administered

For overall/dose:

N = number of administered doses

n/% = number/percentage of doses followed by at least one type of symptom whatever the study vaccine administered 95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Table 38 Incidence and nature of grade 3 symptoms (solicited and unsolicited) reported during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)

			Any	symp	otom		(Sener	al syn	nptom	ıs		Loca	al sym	ptom	S
			•	_	95%	6 CI			-	95%	6 CI			-	95	% CI
	Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Hexa group	195	17	8.7	5.2	13.6	195	10	5.1	2.5	9.2	195	12	6.2	3.2	10.5
	Pedia group	194	41	21.1	15.6	27.6	194	22	11.3	7.2	16.7	194	32	16.5	11.6	22.5
	Penta group	196	35	17.9	12.8	23.9	196	24	12.2	8.0	17.7	196	22	11.2	7.2	16.5
Dose 2	Hexa group	186	17	9.1	5.4	14.2	186	13	7.0	3.8	11.7	186	5	2.7	0.9	6.2
	Pedia group	188	26	13.8	9.2	19.6	188	19	10.1	6.2	15.3	188	13	6.9	3.7	11.5
	Penta group	189	16	8.5	4.9	13.4	189	12	6.3	3.3	10.8	189	10	5.3	2.6	9.5
Dose 3	Hexa group	183	9	4.9	2.3	9.1	183	8	4.4	1.9	8.4	183	1	0.5	0.0	3.0
	Pedia group	185	27	14.6	9.8	20.5	185	20	10.8	6.7	16.2	185	13	7.0	3.8	11.7
	Penta group	180	20	11.1	6.9	16.6	180	15	8.3	4.7	13.4	180	8	4.4	1.9	8.6
Overall/dose	Hexa group	564	43	7.6	5.6	10.1	564	31	5.5	3.8	7.7	564	18	3.2	1.9	5.0
	Pedia group	567	94	16.6	13.6	19.9	567	61	10.8	8.3	13.6	567	58	10.2	7.9	13.0
	Penta group	565	71	12.6	9.9	15.6	565	51	9.0	6.8	11.7	565	40	7.1	5.1	9.5
Overall/subject	Hexa group	195	34	17.4	12.4	23.5	195	24	12.3	8.0	17.8	195	16	8.2	4.8	13.0
-	Pedia group	194	72	37.1	30.3	44.3	194	45	23.2	17.5	29.8	194	46	23.7	17.9	30.3
	Penta group	196	54	27.6	21.4	34.4	196	39	19.9	14.5	26.2	196	35	17.9	12.8	23.9

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

For each dose and overall/subject:

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects presenting at least one type of symptom whatever the study vaccine administered

For overall/dose:

N = number of administered doses

n/% = number/percentage of doses followed by at least one type of symptom whatever the study vaccine administered 95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Report Final

Table 39 Incidence of local symptoms (solicited and unsolicited) reported for *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B* vaccines during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)

		I	NFA	NRIX	HEX	Ά		Pl	EDIA	RIX			F	ACTH	IB			PE	NTA	CEL			EN	IGER	IX-B	
					95%	6 CI				95	% CI															
	Group	Ν	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Hexa group	195	111	56.9	49.7	64.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	194	131	67.5	60.4	74.1	194	139	71.6	64.8	77.9	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	196	123	62.8	55.6	69.5	196	118	60.2	53.0	67.1
Dose 2	Hexa group	186	104	55.9	48.5	63.2	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	188	127	67.6	60.4	74.2	188	122	64.9	57.6	71.7	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	187	116	62.0	54.7	69.0	13	7	53.8	25.1	8.08
Dose 3	Hexa group	183	101	55.2	47.7	62.5	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	185	108	58.4	50.9	65.6	185	113	61.1	53.7	68.1	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	180	98	54.4	46.9	61.9	180	95	52.8	45.2	2 60.2
Overall/dose	Hexa group	564	316	56.0	51.8	60.2	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	567	366	64.6	60.5	68.5	567	374	66.0	61.9	69.9	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	563	337	59.9	55.7	63.9	389	220	56.6	51.5	61.5
Overall/subject	Hexa group	195	149	76.4	69.8	82.2	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	194	159	82.0	75.8	87.1	194	164	84.5	78.7	89.3	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	196	156	79.6	73.3	85.0	196	145	74.0	67.2	80.0

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine For each dose and overall/subject:

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects presenting at least one type of symptom at the study vaccine site For overall/dose:

N = number of administered doses

n/% = number/percentage of doses followed by at least one type of symptom at the study vaccine site

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Report Final

Table 40 Incidence of grade 3 local symptoms (solicited and unsolicited) reported for *Infanrix hexa*, *Pediarix*, *ActHİB*, *Pentacel* and *Engerix-B* vaccines during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)

		INI	FAN	(IRI	HE	XA		P	EDIA	RIX				ACTH	ΗB			PI	ENTA	CEL			EN	GEF	RIX-	В
					95	% CI				95%	6 CI				95%	6 CI				95%	6 CI				95	% CI
	Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Hexa group	195	12	6.2	3.2	10.5	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	194	21	10.8	6.8	16.1	194	28	14.4	9.8	20.2	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	196	22	11.2	7.2	16.5	196	13	6.6	3.6	11.1
Dose 2	Hexa group	186	5	2.7	0.9	6.2	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	188	11	5.9	3.0	10.2	188	10	5.3	2.6	9.6	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	187	10	5.3	2.6	9.6	13	0	0.0	0.0	24.7
Dose 3	Hexa group	183	1	0.5	0.0	3.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	185	11	5.9	3.0	10.4	185	9	4.9	2.2	9.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	180	7	3.9	1.6	7.8	180	7	3.9	1.6	7.8
Overall/dose	Hexa group	564	18	3.2	1.9	5.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	567	43	7.6	5.5	10.1	567	47	8.3	6.2	10.9	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	563	39	6.9	5.0	9.3	389	20	5.1	3.2	7.8
Overall/subject	Hexa group	195	16	8.2	4.8	13.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	194	36	18.6	13.3	24.8	194	38	19.6	14.2	25.9	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	196	34	17.3	12.3	23.4	196	19	9.7	5.9	14.7

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine For each dose and overall/subject:

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects presenting at least one type of symptom at the study vaccine site For overall/dose:

N = number of administered doses

n/% = number/percentage of doses followed by at least one type of symptom at the study vaccine site

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

8.1.4. Solicited local adverse events

Incidence of solicited local symptoms is summarized in Table 41.

Pain was the most frequently reported solicited local symptom reported in 67.9% of subjects in the Hexa group, in 82.0% of subjects in the Pedia group and in 79.8% of subjects in the Penta group.

Pain was also the most frequently reported Grade 3 solicited local symptom reported in 4.3% of subjects in the Hexa group, 18.0% of subjects in the Pedia group and 11.7% of subjects in the Penta group.

Medical advice was sought for not more than 1.1% of subjects following any one local symptom.

Please also refer to the following Tables:

- 1. Incidence of local symptoms (solicited and unsolicited) that were causally related to vaccination reported for *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B* vaccines during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall: Table 8.7.
- 2. Incidence of grade 3 local symptoms (solicited and unsolicited) that were causally related to vaccination reported for *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B* vaccines during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall: Table 8.8.

The incidence of solicited local symptoms reported during the 4-day (Days 0-3) post-vaccination period for the Primary Total Vaccinated Cohort by gender and by geographical ancestry is presented in Table 8.9 and Table 8.10, respectively.

Report Final

Table 41 Incidence of solicited local symptoms reported during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)

				He	xa gr	oup			Ped	dia gi	roup			Per	nta g	roup	
						95	% CI					% CI				95 °	% CI
Symptom	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
_				Dos	se 1			•									
Pain	Total	All	185	94													70.2
		Grade 2 or 3	185				28.3					47.0					36.9
		Grade 3	185		4.3	1.9	8.3	189			8.3	18.3			6.4	3.3	10.9
		Medical advice	185	1	0.5	0.0	3.0	189			0.0	2.9	188		0.0	0.0	1.9
	ActHIB/Engerix B	All							123			71.9					60.5
		Grade 2 or 3							66	34.9	28.1	42.2			23.9		30.7
		Grade 3						189	22	11.6		17.1			5.3	2.6	9.6
		Medical advice						189	1		0.0	2.9	188		0.0	0.0	1.9
	Hexa/Pediarix/Pentacel		185	94			58.2			59.8						53.8	68.2
		Grade 2 or 3	185	40			28.3					41.6			27.1	20.9	
		Grade 3	185		4.3	1.9	8.3	189			5.3	14.0			6.4	3.3	10.9
		Medical advice	185	1		0.0	3.0	189			0.0	1.9	188		0.0	0.0	1.9
Redness (mm)	Total	All	185			19.3						46.0			35.6		
		>5	185			4.6	13.0			14.3		20.1			14.4		20.2
		>20	185			0.3	4.7	189			2.6	9.5	188		2.1	0.6	5.4
		Medical advice	185	0	0.0	0.0	2.0	189			0.0	2.9	188		0.0	0.0	1.9
	ActHIB/Engerix B	All						189		33.3					29.3		36.3
		>5						189			6.2	15.3			6.4	3.3	10.9
		>20						189		4.2	1.8	8.2	188		0.5	0.0	2.9
		Medical advice						189			0.0	2.9	188		0.0	0.0	1.9
	Hexa/Pediarix/Pentacel	All	185				32.3				23.2					23.8	
		>5	185		8.1	4.6	13.0			7.9	4.5	12.8			10.6		16.0
		>20	185			0.3	4.7	189			0.6	5.3	188		1.6	0.3	4.6
		Medical advice				0.0	2.0	189			0.0	1.9	188		0.0	0.0	1.9
Swelling (mm)	Total	All	185		16.8		22.9	189		24.3	18.4		188		28.2	21.9	
		>5	185			2.6	9.7	189			5.7	14.6			12.8		18.4
		>20	185			0.1	3.9	189		3.7	1.5	7.5	188		5.9	3.0	10.2
		Medical advice	185	0	0.0	0.0	2.0	189			0.0	2.9	188		0.0	0.0	1.9
	ActHIB/Engerix B	All						189	41	21.7	16.0	28.3	188	39	20.7	15.2	27.2

				He	xa gr	oup			Pe	dia g	roup			Pe	nta g	roup	
						95 9	% CI				95	% CI					% CI
Symptom	Product	Туре	N	n	%	LL	UL		n	%	LL	UL	N	n	%	LL	UL
		>5						189		7.4	4.1	12.1			7.4	4.1	12.2
		>20						189		3.2	1.2	6.8	188		1.6	0.3	4.6
		Medical advice						189			0.0	2.9	188		0.0	0.0	1.9
	Hexa/Pediarix/Pentacel		185				22.9					24.8			23.9		30.7
		>5	185				9.7	189		7.4	4.1	12.1			12.8		18.4
		>20	185			0.1	3.9	189			0.3	4.6	188		5.9	3.0	10.2
		Medical advice	185			0.0	2.0	189	0	0.0	0.0	1.9	188	0	0.0	0.0	1.9
	1	T	,		se 2			,	,		,		,	,			
Pain	Total	All	182				53.7					68.0			51.7		59.2
		Grade 2 or 3	182			9.1	19.6					36.5			17.8		24.2
		Grade 3	182			0.0	3.0	184			2.6	9.8	180		3.3	1.2	7.1
		Medical advice	182	0	0.0	0.0	2.0	184			0.0	2.0	180		0.0	0.0	2.0
	ActHIB/Engerix B	All										63.8		6	46.2		
		Grade 2 or 3						184				32.5		2	15.4		45.4
		Grade 3						184			2.3	9.1	13	0	0.0	0.0	24.7
		Medical advice						184			0.0	2.0	13	0	0.0	0.0	24.7
	Hexa/Pediarix/Pentacel		182			38.8						65.9			51.7	44.1	59.2
		Grade 2 or 3	182		13.7		19.6					30.7			17.2		23.5
		Grade 3	182			0.0	3.0	184		3.8	1.5	7.7	180		3.3	1.2	7.1
		Medical advice					2.0	184			0.0	2.0	180		0.0	0.0	2.0
Redness (mm)	Total	All	182		32.4		39.7	184				49.3			35.6		43.0
		>5	182			4.7	13.2	184		12.0		17.5			8.9	5.2	14.0
		>20	182			0.3	4.7	184			0.3	4.7	180		1.1	0.1	4.0
		Medical advice	182	0	0.0	0.0	2.0	184			0.0	2.0	180		0.0	0.0	2.0
	ActHIB/Engerix B	All						184				43.3		5	38.5		68.4
		>5						184			5.5	14.4		1	7.7	0.2	36.0
		>20						184			0.0	3.0	13	0	0.0	0.0	24.7
		Medical advice						184			0.0	2.0	13	0	0.0	0.0	24.7
	Hexa/Pediarix/Pentacel		182				39.7	184				40.5					43.0
		>5	182			4.7	13.2			6.5	3.4	11.1			8.3	4.7	13.4
		>20	182			0.3	4.7	184			0.3	4.7	180		1.1	0.1	4.0
		Medical advice	182	0			2.0	184	-		0.0	2.0	180		0.0	0.0	2.0
Swelling (mm)	Total	All	182	41	22.5	16.7	29.3	184	51	27.7	21.4	34.8	180	44	24.4	18.4	31.4

				He	xa gı	oup			Pe	dia g	roup			Pei	nta g	roup)
						95 9	6 CI				95 9	% CI					% CI
Symptom	Product	Туре	N	n	%	LL			n	%	LL			n	%	LL	UL
		>5	182			2.7	9.9	184			5.1		180		3.9	1.6	7.8
		>20	182			0.1	3.9	184			0.1	3.9	180		1.7	0.3	4.8
		Medical advice	182	0	0.0	0.0	2.0	184				2.0	180		0.0	0.0	2.0
	ActHIB/Engerix B	All						184		21.7		28.4		3	23.1	5.0	53.8
		>5						184	11	6.0	3.0	10.4	13	0	0.0	0.0	24.7
		>20						184			0.0	3.0		0	0.0	0.0	24.7
		Medical advice						184			0.0	2.0		0	0.0	0.0	24.7
	Hexa/Pediarix/Pentacel	All	182	41			29.3			21.7	16.0	28.4	180	42	23.3		30.2
		>5	182		5.5	2.7	9.9	184	12	6.5	3.4	11.1	180	7	3.9	1.6	7.8
		>20	182			0.1	3.9	184			0.1	3.9	180		1.7	0.3	4.8
		Medical advice	182			0.0	2.0	184	0	0.0	0.0	2.0	180	0	0.0	0.0	2.0
					se 3												
Pain	Total	All	172				46.7						171				56.3
		Grade 2 or 3	172		10.5		16.0						171				22.8
		Grade 3	172				2.1	175					171		4.1	1.7	8.3
		Medical advice	172	0	0.0	0.0	2.1	175				3.1	171		0.0	0.0	2.1
	ActHIB/Engerix B	All						175					169		44.4		52.2
		Grade 2 or 3						175					169		14.8		21.1
		Grade 3						175		4.0		8.1	169		3.0	1.0	6.8
		Medical advice						175				3.1	169		0.0	0.0	2.2
	Hexa/Pediarix/Pentacel		172				46.7						170		44.7	37.1	52.5
		Grade 2 or 3	172		10.5		16.0						170		11.8		17.6
		Grade 3	172			0.0	2.1	175		4.0		8.1	170		4.1	1.7	8.3
		Medical advice				0.0	2.1	175				3.1	170		0.0	0.0	2.1
Redness (mm)	Total	All	172				44.3						171		38.0	30.7	
		>5	172		4.1		8.2	175			4.4		171		9.4	5.4	14.7
		>20	172			0.0	3.2	175				5.7	171		1.2	0.1	4.2
		Medical advice	172	0	0.0	0.0	2.1	175				3.1	171		0.0	0.0	2.1
	ActHIB/Engerix B	All						175					169				37.7
		>5						175				8.1	169			2.5	9.9
		>20						175				3.1	169		1.2	0.1	4.2
		Medical advice						175	0			2.1	169		0.0	0.0	2.2
	Hexa/Pediarix/Pentacel	All	172	63	36.6	29.4	44.3	175	66	37.7	30.5	45.3	170	56	32.9	25.9	40.6

				He	xa gı	oup			Pe	dia g	roup			Pe	nta g	roup	
						95	% CI				95	% CI					% CI
Symptom	Product	Туре	N	n	%	LL	UL		n	%	LL	UL	N	n	%	LL	UL
		>5	172		4.1	1.7	8.2	175			3.6	11.7			6.5	3.3	11.3
		>20	172			0.0	3.2	175			0.4	4.9	170		0.0	0.0	2.1
		Medical advice				0.0	2.1	175			0.0	3.1	170		0.0	0.0	2.1
Swelling (mm)	Total	All	172		25.0	18.7	32.2	175				37.7			25.7		33.0
		>5	172		4.1	1.7	8.2	175	12	6.9	3.6	11.7	171	8	4.7	2.0	9.0
		>20	172			0.0	3.2	175		1.7	0.4	4.9	171	0	0.0	0.0	2.1
		Medical advice	172	0	0.0	0.0	2.1	175		0.6	0.0	3.1		0	0.0	0.0	2.1
	ActHIB/Engerix B	All						175	42	24.0	17.9	31.0			21.9	15.9	28.9
		>5						175	7	4.0	1.6	8.1	169		4.1	1.7	8.3
		>20						175	1	0.6	0.0	3.1	169		0.0	0.0	2.2
		Medical advice						175	0		0.0	2.1	169		0.0	0.0	2.2
	Hexa/Pediarix/Pentacel	All	172	43	25.0	18.7	32.2	175	44	25.1		32.2		35	20.6		27.5
		>5	172		4.1	1.7	8.2	175		5.7	2.8	10.3			2.4	0.6	5.9
		>20	172			0.0	3.2	175		1.7	0.4	4.9	170		0.0	0.0	2.1
		Medical advice				0.0	2.1	175	1	0.6	0.0	3.1	170	0	0.0	0.0	2.1
					II/dos												
Pain	Total	All										65.8					59.0
			539									35.8					25.2
		Grade 3	539			8.0	3.1	548			5.6	10.2			4.6	3.0	6.8
		Medical advice	539	1	0.2	0.0	1.0	548			0.0		539		0.0	0.0	0.7
	ActHIB/Engerix B	All										62.6					
		Grade 2 or 3										32.1			19.5		
		Grade 3						548			5.0	9.4	370		4.1	2.3	6.6
		Medical advice						548			0.0	1.3	370		0.0	0.0	1.0
	Hexa/Pediarix/Pentacel											60.9					
		Grade 2 or 3	539									30.9					
		Grade 3	539			8.0	3.1	548			3.9		538		4.6	3.0	6.8
		Medical advice				0.0	1.0	548			0.0	1.0	538		0.0	0.0	0.7
Redness (mm)	Total	All															40.6
		>5	539			4.9	9.3	548		11.5		14.5			10.9		13.9
		>20	539			0.5	2.7	548		3.1	1.8		539		1.5	0.6	2.9
		Medical advice	539	0	0.0	0.0	0.7	548			0.0		539		0.0	0.0	0.7
	ActHIB/Engerix B	All						548	198	36.1	32.1	40.3	370	111	30.0	25.4	35.0

				He	xa gr	oup			Ped	dia gi	roup			Pei	nta g	roup	
							% CI			Ī		% CI			Ĭ		% CI
Symptom	Product	Туре	N	n	%	LL	UL	N	n	%			N	n	%	LL	UL
		>5						548			5.7	10.4			5.9	3.8	8.9
		>20						548				3.3	370		8.0	0.2	2.4
		Medical advice						548				1.0	370		0.0	0.0	1.0
	Hexa/Pediarix/Pentacel				31.4					33.4						28.9	
		>5	539	37		4.9	9.3	548	39			9.6	538		8.6	6.3	11.2
		>20	539			0.5	2.7	548				3.3	538		0.9	0.3	2.2
		Medical advice	539				0.7	548			0.0	1.0	538		0.0	0.0	0.7
Swelling (mm)	Total	All	539	115	21.3	17.9	25.0	548	150	27.4	23.7	31.3	539	141	26.2	22.5	30.1
		>5	539	27		3.3	7.2	548	46	8.4	6.2	11.0	539	39	7.2	5.2	9.8
		>20	539	5	0.9	0.3	2.2	548	12	2.2	1.1	3.8	539	14	2.6	1.4	4.3
		Medical advice	539	0	0.0	0.0	0.7	548	2	0.4	0.0	1.3	539	0	0.0	0.0	0.7
	ActHIB/Engerix B	All						548	123	22.4	19.0	26.2	370	79	21.4	17.3	25.9
		>5						548	32	5.8	4.0	8.1	370	21	5.7	3.5	8.5
		>20						548	8	1.5	0.6	2.9	370	3	8.0	0.2	2.4
		Medical advice						548	1	0.2	0.0	1.0	370	0	0.0	0.0	1.0
	Hexa/Pediarix/Pentacel	All	539	115	21.3	17.9	25.0	548	119	21.7	18.3	25.4	538	122	22.7	19.2	26.5
		>5	539	27	5.0	3.3	7.2	548	36	6.6	4.6	9.0	538	35	6.5	4.6	8.9
		>20	539	5	0.9	0.3	2.2	548	8	1.5	0.6	2.9	538	14	2.6	1.4	4.3
		Medical advice	539	0	0.0	0.0	0.7	548	1	0.2	0.0	1.0	538	0	0.0	0.0	0.7
	·				subj		•										•
Pain	Total	All	187	127	67.9	60.7	74.5	189	155	82.0	75.8	87.2	188	150	79.8	73.3	85.3
		Grade 2 or 3	187	58	31.0	24.5	38.2	189	104	55.0	47.6	62.3	188	88	46.8	39.5	54.2
		Grade 3	187	8	4.3	1.9	8.3	189	34	18.0	12.8	24.2	188	22	11.7	7.5	17.2
		Medical advice	187	1	0.5	0.0	2.9	189				3.8	188		0.0	0.0	1.9
	ActHIB/Engerix B	All						189	148	78.3	71.7	84.0			67.6	60.4	74.2
		Grade 2 or 3						189	96	50.8	43.4	58.1	188	62	33.0	26.3	40.2
		Grade 3						189	30	15.9	11.0	21.9	188	14	7.4	4.1	12.2
		Medical advice						189	2			3.8	188		0.0	0.0	1.9
	Hexa/Pediarix/Pentacel	All	187	127	67.9	60.7	74.5	189	151	79.9	73.5	85.4	188	147	78.2	71.6	83.9
		Grade 2 or 3	187		31.0				93	49.2	41.9	56.6	188	80	42.6	35.4	50.0
		Grade 3	187	8		1.9	8.3	189		14.3	9.6	20.1	188		11.7		17.2
		Medical advice	187	1	0.5	0.0	2.9	189		0.5	0.0	2.9	188	0	0.0	0.0	1.9
Redness (mm)	Total	All	187	94	50.3	42.9	57.6	189	120	63.5	56.2	70.4	188	106	56.4	49.0	63.6

117119 (DTPA-HBV-IPV-135) Report Final

				He	xa gr	oup			Ped	dia gi	roup			Pe	nta g	roup	
					_	95 %	6 CI					% CI			_		% CI
Symptom	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
		>5	187	27	14.4	9.7	20.3	189	49	25.9	19.8	32.8	188	45	23.9	18.0	30.7
		>20	187	7	3.7	1.5	7.6	189	15	7.9	4.5	12.8	188	8	4.3	1.9	8.2
		Medical advice	187	0	0.0	0.0	2.0	189	2	1.1	0.1	3.8	188	0	0.0	0.0	1.9
	ActHIB/Engerix B	All						189	108	57.1		64.3		77	41.0	33.9	48.3
		>5						189	38	20.1	14.6	26.5	188	20	10.6	6.6	16.0
		>20						189				9.5	188	3	1.6	0.3	4.6
		Medical advice						189				2.9	188		0.0	0.0	1.9
	Hexa/Pediarix/Pentacel	All	187	94	50.3	42.9	57.6	189	98	51.9	44.5	59.2	188	97	51.6	44.2	58.9
		>5	187	27	14.4		20.3	189	32			23.1	188	37			26.1
		>20	187	7	3.7	1.5	7.6	189		4.8		8.8	188	5	2.7	0.9	6.1
		Medical advice	187	0	0.0	0.0	2.0	189	1	0.5	0.0	2.9	188	0	0.0	0.0	1.9
Swelling (mm)	Total	All	187	73			46.4	189	88	46.6	39.3	53.9	188	81	43.1	35.9	50.5
		>5	187	20	10.7	6.7	16.0	189	34	18.0	12.8	24.2	188	29	15.4		21.4
		>20	187			0.6	5.4	189			2.9	10.2	188		6.4	3.3	10.9
		Medical advice	187	0	0.0	0.0	2.0	189	2		0.1	3.8	188		0.0	0.0	1.9
	ActHIB/Engerix B	All						189				48.6			34.0		41.3
		>5						189	25	13.2	8.7	18.9	188	18	9.6	5.8	14.7
		>20						189		3.7	1.5	7.5	188		1.6	0.3	4.6
		Medical advice						189			0.0	2.9	188		0.0	0.0	1.9
	Hexa/Pediarix/Pentacel	All	187				46.4					44.3	188		38.3	31.3	45.7
		>5	187	20	10.7	6.7	16.0			13.8	9.2	19.5			13.8		19.6
		>20	187	4			5.4	189		3.7	1.5	7.5	188		6.4	3.3	10.9
		Medical advice	187	0	0.0	0.0	2.0	189	1	0.5	0.0	2.9	188	0	0.0	0.0	1.9

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines
Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines
Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine
For each dose and overall/subject:

N = number of subjects with at least one documented dose n/% = number/percentage of subjects reporting the symptom at least once For Overall/dose:

N = number of documented doses n/% = number/percentage of doses followed by at least one type of symptom 95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

8.1.5. Solicited general adverse events

Incidence of solicited general symptoms are summarised in Table 42.

- Irritability / Fussiness was the most frequently reported solicited general symptom in all the groups, reported in 87.7% of subjects in the Hexa group, in 96.3% of subjects in the Pedia group and in 94.1% of subjects in the Penta group overall.
- Irritability was also the most commonly reported solicited general symptom graded 3 in intensity; reported for 9.6% of subjects in the Hexa group, 18.5% of subjects in the Pedia group and 16.0% of subjects in the Penta group overall.
- Grade 3 fever (>40.0°C rectal temperature) was reported for 0.0% of subjects in the Hexa and Penta groups, and 1.1% of subjects (2 subjects) in the Pedia group.
- Medical advice was sought in ≤ 1.6% of subjects following any one general symptom.
- The majority of solicited general symptoms following vaccination were considered by the investigator to be causally related to vaccination in the three groups.

The incidence of solicited general symptoms reported during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall for the Primary Total vaccinated cohort according to gender and geographical ancestry is presented in Table 8.11 and Table 8.12, respectively.

Report Final

Table 42 Incidence of solicited general symptoms reported during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)

			He	xa gr	oup			Ped	dia g	roup			Pei	nta g	roup	
					95 °	% CI				95 %	6 CI				95 9	% CI
Symptom	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
				Dos	e 1											
Drowsiness	All	185	114	61.6	54.2	68.7	189	143	75.7	68.9	81.6	188	149	79.3	72.8	84.8
	Grade 2 or 3	185		19.5	14.0	25.9	189			23.2	36.7	188	53	28.2	21.9	35.2
	Grade 3	185				4.7	189		4.2		8.2	188		6.4	3.3	10.9
	Related			60.5	53.1	67.6	189	136	72.0	65.0	78.2	188	141		68.2	81.0
	Grade 3 Related			1.6	0.3	4.7	189		3.7	1.5	7.5	188		6.4	3.3	10.9
	Medical advice	185				3.0	189			0.0	1.9	188		0.0	0.0	1.9
Irritability / Fussiness	All	185		62.2	54.8	69.2	189				91.7		153	81.4	75.1	86.7
	Grade 2 or 3	185				29.4					49.2					43.5
	Grade 3	185	9	4.9	2.2	9.0	189	17	9.0	5.3	14.0	188	15	8.0	4.5	12.8
	Related	185		61.1	53.7	68.1	189	163	86.2	80.5	90.8	188			71.6	83.9
	Grade 3 Related	185	9	4.9	2.2	9.0	189	17	9.0	5.3	14.0	188	15	8.0	4.5	12.8
	Medical advice	185	1			3.0	189			0.0	1.9	188	0	0.0	0.0	1.9
Loss Of Appetite	All	185			22.3		189				47.6					50.0
	Grade 2 or 3	185			1.9	8.3	189			3.7	11.5	188	26	13.8	9.2	19.6
	Grade 3	185				2.0	189			0.0	2.9	188		2.1	0.6	5.4
	Related	185		25.9	19.8	32.9			38.6	31.6	46.0	188	77		33.9	48.3
	Grade 3 Related	185				2.0	189			0.0	2.9	188		2.1	0.6	5.4
	Medical advice	185	0			2.0	189			0.0	1.9	188		0.0	0.0	1.9
Temperature/(Rectally) (°C)	All	185		11.9		17.4	189		18.0		24.2			15.4		21.4
	>38.5	185		1.1	0.1	3.9	189			0.6	5.3	188		2.7	0.9	6.1
	>39.0	185		0.0	0.0	2.0	189			0.0	1.9	188	2	1.1	0.1	3.8
	>39.5	185	0	0.0		2.0	189	0	0.0	0.0	1.9	188	0	0.0	0.0	1.9
	>40.0	185	0		0.0	2.0	189			0.0	1.9	188		0.0	0.0	1.9
	Related	185		8.1	4.6	13.0	189				22.5			14.4	9.7	20.2
	>40.0 Related	185				2.0	189			0.0	1.9	188		0.0	0.0	1.9
	Medical advice	185	0	0.0	0.0	2.0	189	0	0.0	0.0	1.9	188	0	0.0	0.0	1.9

117119 (DTPA-HBV-IPV-135) Report Final

		Hexa group						Ped	dia g	roup		Penta group					
				95 % CI					95 %	% CI				95	% CI		
Symptom	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	
				Dos													
Drowsiness	All	182														68.1	
	Grade 2 or 3	182		17.0		23.3				17.5				21.8		28.6	
	Grade 3	182		4.4		8.5	184		3.8	1.5	7.7	179		2.2	0.6	5.6	
	Related	182			44.1	59.1	184			61.2	75.1	179	108	60.3	52.8	67.6	
	Grade 3 Related	182		3.8	1.6	7.8	184			1.5	7.7	179		1.7	0.3	4.8	
	Medical advice	182		0.0	0.0	2.0	184				2.0	179		0.0	0.0	2.0	
Irritability / Fussiness	All	182	_			76.9				73.4						82.0	
	Grade 2 or 3	182		29.1	22.6	36.3	184	70		31.0	45.5	179	61			41.5	
	Grade 3	182		3.3	1.2	7.0	184			4.2	12.4			6.1	3.1	10.7	
	Related			68.7	61.4	75.3	184	143	77.7	71.0			133		67.2	80.5	
	Grade 3 Related	182	6	3.3	1.2	7.0	184	13	7.1	3.8	11.8	179	11	6.1	3.1	10.7	
	Medical advice	182		0.0	0.0	2.0	184				2.0	179	2	1.1	0.1	4.0	
Loss Of Appetite	All	182				38.0	184			23.4			56		24.6	38.6	
	Grade 2 or 3	182		9.3	5.5	14.5				4.6	13.1			8.4	4.8	13.4	
	Grade 3	182	1	0.5	0.0	3.0	184		0.5		3.0	179	2	1.1	0.1	4.0	
	Related	182		28.6		35.7	184		27.7	21.4	34.8	179	55	30.7	24.1	38.0	
	Grade 3 Related	182	1	0.5	0.0	3.0	184	1	0.5	0.0	3.0	179	2	1.1	0.1	4.0	
	Medical advice	182	0	0.0	0.0	2.0	184	0	0.0	0.0	2.0	179	1	0.6	0.0	3.1	
Temperature/(Rectally)) (°C)	All	182		25.8	19.6	32.8	184	36	19.6	14.1	26.0	179	35	19.6	14.0	26.1	
	>38.5	182	15	8.2	4.7	13.2	184	13	7.1	3.8	11.8	179	9	5.0	2.3	9.3	
	>39.0	182	2	1.1	0.1	3.9	184	3	1.6	0.3	4.7	179	2	1.1	0.1	4.0	
	>39.5	182	0	0.0	0.0	2.0	184	0	0.0	0.0	2.0	179	1	0.6	0.0	3.1	
	>40.0	182	-	0.0	0.0	2.0	184				2.0	179		0.0	0.0	2.0	
	Related	182	37	20.3	14.7	26.9	184	32	17.4	12.2	23.7	179	33	18.4	13.0	24.9	
	>40.0 Related	182	0	0.0	0.0	2.0	184		0.0	0.0	2.0	179	0	0.0	0.0	2.0	
	Medical advice	182	0	0.0	0.0	2.0	184	0	0.0	0.0	2.0	179	0	0.0	0.0	2.0	

117119 (DTPA-HBV-IPV-135) Report Final

		Hexa group						Ped	dia g	roup			Pe	roup		
				95 % CI					95 %	6 CI				95	% CI	
Symptom	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
				Dos												
Drowsiness	All	172			41.7			108			68.9					59.5
	Grade 2 or 3	172		13.4		19.4	175		21.1		27.9			14.7		20.9
	Grade 3	172				5.0	175				6.5	170		5.3	2.4	9.8
	Related	172									67.3					58.3
	Grade 3 Related					5.0	175				6.5	170	9	5.3	2.4	9.8
	Medical advice	172			0.0	2.1	175		1.1	0.1	4.1	170		0.6	0.0	3.2
Irritability / Fussiness	All	172			66.0				77.1		83.1		122	71.8		78.4
	Grade 2 or 3	172		26.7	20.3	34.0	175			26.2	40.6				27.0	41.8
	Grade 3	172	-			7.4	175			4.9	13.7			6.5	3.3	11.3
	Related	172			62.9	77.1	175		73.7	66.5	80.1		120		63.1	77.3
	Grade 3 Related			3.5	1.3	7.4	175			4.0	12.4	170	11	6.5	3.3	11.3
	Medical advice	172	0			2.1	175	3			4.9	170	1	0.6	0.0	3.2
Loss Of Appetite	All	172			19.8					26.2	40.6					38.7
	Grade 2 or 3	172			3.2	11.2				4.0	12.4			8.8	5.0	14.1
	Grade 3	172				3.2	175			0.1	4.1	170	2	1.2	0.1	4.2
	Related	172									39.5				23.8	38.1
	Grade 3 Related	172	1			3.2	175				4.1	170		1.2	0.1	4.2
	Medical advice	172		0.0		2.1	175			0.0	3.1	170		0.0	0.0	2.1
Temperature/(Rectally)) (°C)	All	172	40	23.3	17.2				25.7		32.9	170	37	21.8	15.8	28.7
	>38.5	172		7.0	3.7	11.9			12.0		17.8			8.8	5.0	14.1
	>39.0	172			0.6	5.8	175	11		3.2	11.0	170	7	4.1	1.7	8.3
	>39.5	172	1		0.0	3.2	175	3		0.4	4.9	170		0.6	0.0	3.2
	>40.0	172		0.0		2.1	175			0.1	4.1	170		0.0	0.0	2.1
	Related	172		20.3	14.6		175		22.3		29.2	170	35	20.6	14.8	27.5
	>40.0 Related	172				2.1	175			0.1	4.1	170	0	0.0	0.0	2.1
	Medical advice	172	1	0.6	0.0	3.2	175	2	1.1	0.1	4.1	170	1	0.6	0.0	3.2

		Hexa group						Pe	dia g	roup		Penta group					
					95 % CI				95 % CI						% CI		
Symptom	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	
				erall/													
Drowsiness	All															68.5	
	Grade 2 or 3	539				20.1										25.5	
	Grade 3	539		2.6			548			2.2	5.6	537		4.7	3.0	6.8	
	Related			53.2													
	Grade 3 Related			2.4	1.3	4.1	548		3.5	2.1	5.4	537		4.5	2.9	6.6	
	Medical advice	539		0.2	0.0	1.0	548		0.4	0.0	1.3	537		0.2	0.0	1.0	
Irritability / Fussiness	All			68.5							84.7		411		72.7		
	Grade 2 or 3	539		26.2	22.5	30.1	548	207	37.8		42.0				30.8	39.0	
	Grade 3	539		3.9	2.4	5.9	548	46	8.4	6.2	11.0	537	37	6.9	4.9	9.4	
	Related	539	359	66.6			548	435	79.4	75.7	82.7	537	400	74.5	70.6	78.1	
	Grade 3 Related	539	21	3.9	2.4	5.9	548		7.8	5.7	10.4	537	37	6.9	4.9	9.4	
	Medical advice	539		0.2	0.0	1.0	548		0.5	0.1	1.6	537		0.6	0.1	1.6	
Loss Of Appetite	All	539	154	28.6	24.8	32.6	548	189	34.5	30.5	38.6	537	189	35.2	31.2	39.4	
	Grade 2 or 3	539		6.7	4.7	9.1	548		7.5	5.4	10.0	537	56	10.4	8.0	13.3	
	Grade 3	539		0.4	0.0	1.3	548		0.7	0.2	1.9	537		1.5	0.6	2.9	
	Related			26.7	23.0	30.7	548	180	32.8	28.9	37.0	537	184	34.3	30.3	38.4	
	Grade 3 Related			0.4	0.0	1.3	548		0.7	0.2	1.9	537		1.5	0.6	2.9	
	Medical advice	539				0.7	548		0.2	0.0	1.0	537		0.2	0.0	1.0	
Temperature/(Rectally)) (°C)	All			20.2	16.9	23.9			21.0	17.6	24.6	537	101	18.8	15.6	22.4	
	>38.5	539	29	5.4	3.6	7.6	548	38	6.9	5.0	9.4	537		5.4	3.6	7.7	
	>39.0	539		1.1	0.4	2.4	548		2.6	1.4	4.2	537	11	2.0	1.0	3.6	
	>39.5	539		0.2	0.0	1.0	548		0.5	0.1	1.6	537	2	0.4	0.0	1.3	
	>40.0	539				0.7	548		0.4	0.0	1.3	537		0.0	0.0	0.7	
	Related	539		16.1	13.1	19.5			18.6	15.4	22.1	537	95	17.7	14.6	21.2	
	>40.0 Related	539	0	0.0	0.0	0.7	548	2	0.4	0.0	1.3	537	0	0.0	0.0	0.7	
	Medical advice	539					548	2	0.4	0.0	1.3	537	1	0.2	0.0	1.0	
Overall/subject																	
Drowsiness	All	187	147					172	91.0	86.0	94.7	188	168	89.4	84.0	93.4	
	Grade 2 or 3	187				42.6			46.6	39.3	53.9	188	81			50.5	
	Grade 3	187				10.3			10.1		15.3			11.7		17.2	
	Related	187	144			82.8	189	169	89.4		93.4	188	166	88.3	82.8	92.5	
	Grade 3 Related	187	11	5.9	3.0	10.3	189	18	9.5	5.7	14.6	188	21	11.2	7.0	16.6	

117119 (DTPA-HBV-IPV-135) Report Final

		Hexa group						Pe	dia g	oup		Penta group						
		95 % CI					95 %	6 CI				95 % CI						
Symptom	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL		
	Medical advice	187	1	0.5	0.0	2.9	189	2	1.1	0.1	3.8	188	1	0.5	0.0	2.9		
Irritability / Fussiness	All	187	164	87.7	82.1	92.0	189	182	96.3	92.5	98.5	188	177	94.1	89.8	97.0		
	Grade 2 or 3	187	96	51.3	43.9	58.7	189	128	67.7	60.6	74.3	188	120	63.8	56.5	70.7		
	Grade 3	187	18	9.6	5.8	14.8	189	35	18.5	13.3	24.8	188	30	16.0	11.0	22.0		
	Related	187	161	86.1	80.3	90.7	189	180	95.2	91.2	97.8	188	175	93.1	88.5	96.3		
	Grade 3 Related	187	18	9.6	5.8	14.8	189	34	18.0	12.8	24.2			16.0	11.0	22.0		
	Medical advice	187	1	0.5	0.0	2.9	189			0.3	4.6	188			0.3	4.6		
Loss Of Appetite	All	187	95	50.8	43.4	58.2	189	111	58.7	51.4	65.8	188	117	62.2	54.9	69.2		
	Grade 2 or 3	187	28	15.0	10.2	20.9	189	32	16.9	11.9	23.1	188	39	20.7	15.2	27.2		
	Grade 3	187	2	1.1	0.1	3.8	189	3	1.6	0.3	4.6	188	6	3.2	1.2	6.8		
	Related	187	91	48.7	41.3	56.1	189	108	57.1	49.8	64.3	188	116	61.7	54.3	68.7		
	Grade 3 Related	187	2	1.1	0.1	3.8	189	3	1.6	0.3	4.6	188	6	3.2	1.2	6.8		
	Medical advice	187	0	0.0	0.0	2.0	189	1	0.5	0.0	2.9	188	1	0.5	0.0	2.9		
Temperature/(Rectally)) (°C)	All	187	72	38.5	31.5	45.9	189	78	41.3					38.3	31.3	45.7		
	>38.5	187	24	12.8	8.4	18.5	189	34	18.0	12.8	24.2			13.8	9.2	19.6		
	>39.0	187	6	3.2	1.2	6.9	189		7.4	4.1	12.1			5.3	2.6	9.6		
	>39.5	187	1	0.5	0.0	2.9	189	3	1.6	0.3	4.6	188		1.1	0.1	3.8		
	>40.0	187	0	0.0	0.0	2.0	189	2	1.1	0.1	3.8	188	0	0.0	0.0	1.9		
	Related	187	61	32.6	26.0	39.8	189	74	39.2	32.2	46.5			36.7	29.8	44.0		
	>40.0 Related	187	0	0.0	0.0	2.0	189	2		0.1	3.8	188		0.0	0.0	1.9		
	Medical advice	187		0.5	0.0	2.9	189	2	1.1	0.1	3.8	188		0.5	0.0	2.9		

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

For each dose and overall/subject:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the symptom at least once

For Overall/dose:

N = number of documented doses

n/% = number/percentage of doses followed by at least one type of symptom

95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

8.1.6. Unsolicited adverse events

The percentage of subjects who recorded the occurrence of unsolicited symptoms and grade 3 unsolicited symptoms within the 31-day (Days 0-30) post-vaccination period for the Primary Total vaccinated cohort is presented in Table 43 and Table 44, respectively.

- At least one unsolicited symptom within the 31-day post-vaccination period after each vaccination, classified by MedDRA Primary System Organ Class and Preferred Term was reported for 57.9%, 55.7% and 49.0% of subjects in the Hexa, Pedia and Penta groups, respectively (Table 43). The corresponding unsolicited symptoms within the 31-day (Days 0-30) post vaccination period following priming doses is provided in Table 8.13.
- The most commonly reported unsolicited symptoms in the Hexa group was Upper Respiratory Tract Infection (URTI) (15.4%) followed by Cough (7.7%) and Pyrexia (6.2%). In the Pedia group, the most commonly reported symptom was URTI (11.9%) followed by Conjunctivitis, Gastrooesophageal reflux disease, Teething, and Vomiting (4.1%). The most commonly reported symptoms in the Penta group were URTI (13.3%) followed by Pyrexia (7.7%), Diarrhoea (5.1%) and Vomiting (5.1%).
- A grade 3 unsolicited symptom was reported for 6.7%, 6.2% and 3.6% of subjects in Hexa, Pedia and Penta groups, respectively (Table 44). The most commonly reported grade 3 unsolicited symptom in the Hexa group were URTI and Otitis media (1.5%) followed by Pyrexia and Vomiting (1.0%). In the Pedia group, grade 3 unsolicited symptoms reported in more than one subject were URTI, Conjunctivitis and Irritability (1.0%). In the Penta group, grade 3 unsolicited symptoms reported in more than one subject were URTI (1.0%). The corresponding grade 3 unsolicited symptoms within the 31-day (Days 0-30) post vaccination period following priming doses is provided in Table 8.14.
- The investigator assessed a causal relationship between at least one unsolicited symptom and primary vaccination for 12.3%, 14.4% and 17.3% of subjects in the Hexa, Pedia and Penta groups, respectively Table 8.15.

The percentage of doses followed by an unsolicited symptom with causal relationship to vaccination, grade 3 unsolicited symptom with causal relationship to primary vaccination, and doses followed by a grade 3 unsolicited symptom with causal relationship to primary vaccination, within the 31-day (Days 0-30) post-vaccination period for the Primary Total vaccinated cohort are presented in Table 8.16, Table 8.17 and Table 8.18.

The following data are summarised in the following tables:

- The percentage of subjects who reported the occurrence of unsolicited symptoms by gender (Table 8.19), and of unsolicited symptoms by geographical ancestry (Table 8.20).
- The percentage of subjects who reported the occurrence of grade 3 unsolicited symptoms by gender (Table 8.21), and of grade 3 unsolicited symptoms by geographical ancestry (Table 8.22).
- The percentage of subjects who reported the occurrence of unsolicited symptoms with causal relationship to primary vaccination by gender (Table 8.23), and of unsolicited symptoms with causal relationship to primary vaccination by geographical ancestry (Table 8.24).
- The percentage of subjects who reported the occurrence of grade 3 unsolicited symptoms with causal relationship to primary vaccination by gender (Table 8.25), and of grade 3 unsolicited symptoms with causal relationship to primary vaccination by geographical ancestry (Table 8.26).
- The percentage of subjects who reported the occurrence of unsolicited symptoms following priming doses by gender (Table 8.27), and of unsolicited symptoms following priming doses by geographical ancestry (Table 8.28).
- The percentage of subjects who reported the occurrence of grade 3 unsolicited symptoms following priming doses by gender (Table 8.29), and of grade 3 unsolicited symptoms following priming doses by geographical ancestry (Table 8.30).
- The percentage of subjects who reported the occurrence of unsolicited symptoms with causal relationship to vaccination following priming doses by gender (Table 8.31), and of unsolicited symptoms with causal relationship to vaccination following priming doses by geographical ancestry (Table 8.32).
- The percentage of subjects who reported the occurrence of grade 3 unsolicited symptoms with causal relationship to vaccination following priming doses by gender (Table 8.33), and of grade 3 unsolicited symptoms with causal relationship to vaccination following priming doses by geographical ancestry (Table 8.34).

Table 43 Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following priming doses (Primary Total vaccinated cohort)

		Hexa g N = 1				ı		grou = 194			ta gro	
				_	6 CI				% CI			% CI
Primary System Organ Class (CODE)	n	%	LL	UL	n	%	LL	UL	n %		UL	
At least one symptom		113	57.9	50.7	65.0	0 108	55.7	48.4	62.8	96 49.	0 41.8	56.2
Blood and lymphatic system disorders (10005329)	Anaemia (10002034)	1	0.5		2.8			0.0	1.9	0.0	0.0	1.9
	Leukocytosis (10024378)	1	0.5		2.8			0.0	1.9	0.0	0.0	1.9
	Lymphadenopathy (10025197)	2	1.0	0.1	3.7	1	0.5	0.0	2.8	0.0	0.0	1.9
Cardiac disorders (10007541)	Cyanosis (10011703)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	2 1.0	0.1	3.6
Congenital, familial and genetic disorders (10010331)	Congenital skin dimples (10072978)	0	0.0	0.0	1.9	3	1.5	0.3	4.5	1 0.5	0.0	2.8
	Dermoid cyst (10012522)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0.0	0.0	1.9
	Hydrocele (10020488)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0.0	0.0	1.9
	Hypospadias (10021093)	0	0.0	0.0	1.9	2	1.0	0.1	3.7	0.0	0.0	1.9
	Macrocephaly (10050183)	2	1.0	0.1	3.7	1			2.8	0.0	0.0	1.9
	Plagiocephaly (10048586)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0.0	0.0	1.9
Ear and labyrinth disorders (10013993)	Cerumen impaction (10050337)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	2 1.0	0.1	3.6
	Ear disorder (10014004)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1 0.5	0.0	2.8
	Ear pain (10014020)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1 0.5	0.0	2.8
Eye disorders (10015919)	Dacryostenosis acquired (10053990)	2	1.0	0.1	3.7	1	0.5	0.0	2.8	0.0	0.0	1.9
Gastrointestinal disorders (10017947)	Abdominal pain upper (10000087)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0.0	0.0	1.9
	Anal fistula (10002156)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0.0	0.0	1.9
	Constipation (10010774)	1	0.5		2.8	2	1.0	0.1	3.7	5 2.6		5.9
	Diarrhoea (10012735)	6	3.1		6.6				5.9	10 5.1	2.5	9.2
	Flatulence (10016766)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	1 0.5	0.0	2.8
	Frequent bowel movements (10017367)	0	0.0	0.0	1.9		0.5	0.0	2.8	0.0	0.0	1.9
	Gastrooesophageal reflux disease (10017885)	0	0.0	0.0	1.9	8	4.1	1.8	8.0	1 0.5	0.0	2.8
	Inguinal hernia (10022016)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0.0		1.9
	Teething (10043183)	6	3.1		6.6		4.1	1.8	8.0	9 4.6		8.5
	Vomiting (10047700)	9	4.6	2.1	8.6	8	4.1	1.8	8.0	10 5.1	2.5	9.2
	Vomiting projectile (10047708)	1	0.5	0.0	2.8		0.0	0.0	1.9	0.0	0.0	1.9
General disorders and administration site conditions (10018065)	Adverse drug reaction (10061623)	0	0.0	0.0			0.0	0.0	1.9	1 0.5	0.0	2.8
	Crying (10011469)	1	0.5	0.0	2.8	1	0.5	0.0	2.8	0.0	0.0	1.9

117119 (DTPA-HBV-IPV-135)

			Report Final
		Hexa group Pedia group	Penta group
		N = 195 N = 194	N = 196
	<u> </u>	95% CI 95% C	
Primary System Organ Class (CODE)	Preferred Term (CODE)	n % LL UL n % LL UL	
	III-defined disorder (10061520)	0 0.0 0.0 1.9 1 0.5 0.0 2.8	
	Injection site bruising (10022052)		5 2.6 0.8 5.9
	Injection site erythema (10022061)	4 2.1 0.6 5.2 2 1.0 0.1 3.7	
	Injection site induration (10022075)		0 0.0 0.0 1.9
	Injection site mass (10022081)	0 0.0 0.0 1.9 2 1.0 0.1 3.7	
	Injection site pain (10022086)	4 2.1 0.6 5.2 6 3.1 1.1 6.6	
	Injection site pruritus (10022093)		0 0.0 0.0 1.9
	Injection site rash (10022094)	1 0.5 0.0 2.8 0 0.0 0.0 1.9	
	Injection site swelling (10053425)		4 2.0 0.6 5.1
	Injection site warmth (10022112)	0 0.0 0.0 1.9 2 1.0 0.1 3.7	
	Oedema peripheral (10030124)		0 0.0 0.0 1.9
	Peripheral swelling (10048959)		0 0.0 0.0 1.9
	Pyrexia (10037660)		15 7.7 4.3 12.3
	Swelling (10042674)	0 0.0 0.0 1.9 1 0.5 0.0 2.8	0 0.0 0.0 1.9
	Vaccination site bruising (10069484)	0 0.0 0.0 1.9 2 1.0 0.1 3.7	1 0.5 0.0 2.8
	Vaccination site erythema (10059079)	2 1.0 0.1 3.7 4 2.1 0.6 5.2	
	Vaccination site induration (10065117)	0 0.0 0.0 1.9 1 0.5 0.0 2.8	0 0.0 0.0 1.9
	Vaccination site pain (10068879)	2 1.0 0.1 3.7 1 0.5 0.0 2.8	3 1.5 0.3 4.4
	Vaccination site swelling (10069620)	3 1.5 0.3 4.4 1 0.5 0.0 2.8	2 1.0 0.1 3.6
Immune system disorders (10021428)	Food allergy (10016946)	0 0.0 0.0 1.9 1 0.5 0.0 2.8	0 0.0 0.0 1.9
, , ,	Milk allergy (10027633)	0 0.0 0.0 1.9 0 0.0 0.0 1.9	1 0.5 0.0 2.8
Infections and infestations (10021881)	Acute sinusitis (10001076)	0 0.0 0.0 1.9 1 0.5 0.0 2.8	0 0.0 0.0 1.9
, , ,	Anal abscess (10048946)	1 0.5 0.0 2.8 0 0.0 0.0 1.9	0 0.0 0.0 1.9
	Bronchiolitis (10006448)	3 1.5 0.3 4.4 0 0.0 0.0 1.9	1 0.5 0.0 2.8
	Bronchitis (10006451)	1 0.5 0.0 2.8 0 0.0 0.0 1.9	0 0.0 0.0 1.9
	Candida infection (10074170)	2 1.0 0.1 3.7 2 1.0 0.1 3.7	
	Candida nappy rash (10007135)	0 0.0 0.0 1.9 1 0.5 0.0 2.8	0 0.0 0.0 1.9
	Cellulitis (10007882)	1 0.5 0.0 2.8 0 0.0 0.0 1.9	1 0.5 0.0 2.8
	Conjunctivitis (10010741)	10 5.1 2.5 9.2 8 4.1 1.8 8.0	1 0.5 0.0 2.8
	Conjunctivitis bacterial (10061784)	0 0.0 0.0 1.9 1 0.5 0.0 2.8	
	Conjunctivitis viral (10010755)	0 0.0 0.0 1.9 0 0.0 0.0 1.9	
	Croup infectious (10011416)	2 1.0 0.1 3.7 2 1.0 0.1 3.7	

117119 (DTPA-HBV-IPV-135)

		1										t Fina
				grou			Pedia	_	-			roup
			N	= 195			N =	194			N = 1	
					% CI			_	% CI	ı		95% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL		n	%	LL		n %		
	Ear infection (10014011)	0	0.0	0.0		0		0.0	_	1 0.		
	Eczema herpeticum (10014197)	0	0.0	0.0	1.9			0.0	1.9	1 0.		
	Exanthema subitum (10015586)	0	0.0		1.9					0 0.	0.0	
	Fungal infection (10017533)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1 0.	5 0.0	0 2.8
	Fungal skin infection (10017543)	1	0.5	0.0	2.8	1	0.5	0.0	2.8	0 0.	0.0	0 1.9
	Gastric infection (10056663)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0 0.	0.0	0 1.9
	Gastroenteritis (10017888)	1	0.5	0.0	2.8	2	1.0	0.1	3.7	1 0.	5 0.0	0 2.8
	Hand-foot-and-mouth disease (10019113)	1	0.5	0.0	2.8	1	0.5	0.0	2.8	1 0.	5 0.0	0 2.8
	Herpangina (10019936)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0 0.	0 0.	0 1.9
	Impetigo (10021531)	1		0.0			0.0	0.0	1.9	2 1.	0 0.	1 3.6
	Influenza (10022000)	0		0.0	1.9				2.8		0 0.	0 1.9
	Nasopharyngitis (10028810)	2	1.0		3.7				2.8			
	Oral candidiasis (10030963)	0							2.8		5 0.0	
	Otitis externa (10033072)	0		0.0	1.9				2.8			
	Otitis media (10033078)	9	4.6		8.6				7.3			
	Otitis media acute (10033079)	1			2.8					0 0.		
	Otitis media chronic (10033081)	0		0.0	1.9				1.9			
	Parainfluenzae virus infection (10061907)	0		0.0	1.9				1.9			
	Pertussis (10034738)	0	0.0		1.9				1.9	1 0.		
	Pharyngitis (10034835)	1			2.8					0 0.		
	Pneumonia (10035664)	1			2.8					0 0.		
	Respiratory syncytial virus bronchiolitis	1		0.0				0.0			0 0.0	
	(10038718)	'	0.0	0.0			0.0	0.0		J .	0.1	
	Respiratory syncytial virus infection (10061603)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0 0.	0 0.0	0 1.9
	Respiratory tract infection (10062352)	1		0.0						0 0.		
	Rhinitis (10039083)	0		0.0					1.9			
	Roseola (10039222)	0	0.0		1.9		0.5		2.8			
	Sinusitis (10040753)	0 0.0 0.0 1.9							1 0.			
	Skin candida (10054152)	1 0.5 0.0 2.8				0.0	0.0		1 0.	5 0.0		
	Upper respiratory tract infection (10046306)	30 15.4 10.6 21.2										
	Urinary tract infection (10046571)	0		0.0							5 0.0	
		0							1.9	1 U.	5 0.0	
	Viraemia (10058874)	U	0.0	0.0	1.9	U	U.U	U.U	1.9	ı U.	J U.	U 2.8

117119 (DTPA-HBV-IPV-135)

												rt Fina
			Hexa				Pedia	•	•	Pe		group
			N	= 19			N =	194			N =	
			1	_	% CI		1	_	% CI	1		95% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL		%	LL		n %		
	Viral infection (10047461)	2	1.0							3 1		.3 4.4
	Viral rash (10047476)	3	1.5					0.0	1.9			
	Viral upper respiratory tract infection (10047482)	0	0.0					0.0	1.9			
Injury, poisoning and procedural complications (10022117)	Arthropod bite (10003399)	2	1.0		3.7				2.8			
	Arthropod sting (10003402)	1	0.5		2.8				1.9			
	Clavicle fracture (10009245)	0	0.0						2.8			
	Concussion (10010254)	0		0.0					2.8			
	Corneal abrasion (10010984)	1	0.5		2.8				1.9			
	Craniocerebral injury (10070976)	0		0.0					2.8			
	Fall (10016173)	0	0.0						_	1 0		
	Foreign body (10070245)	0		0.0						1 0		
	Head injury (10019196)	0		0.0					1.9			.1 3.6
	Nasal injury (10078651)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1 0	.5 0	.0 2.8
	Thermal burn (10053615)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0 0	.0 0	.0 1.9
Investigations (10022891)	Body temperature increased (10005911)	1	0.5	0.0				0.0	1.9	1 0	.5 0	.0 2.8
	Cardiac murmur (10007586)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1 0	.5 0	.0 2.8
	Weight decreased (10047895)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	1 0	.5 0	.0 2.8
Musculoskeletal and connective tissue disorders (10028395)	Asymmetric gluteal fold (10072189)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0 0	.0 0	.0 1.9
, ,	Pain in extremity (10033425)	2	1.0	0.1	3.7	0	0.0	0.0	1.9	1 0	.5 0	.0 2.8
	Positional plagiocephaly (10068711)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0 0	.0 0	.0 1.9
Neoplasms benign, malignant and unspecified (incl cysts and polyps) (10029104)	Haemangioma (10018814)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0 0	.0 0	.0 1.9
Nervous system disorders (10029205)	Hyperreflexia (10020745)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0 0	.0 0	.0 1.9
	Lethargy (10024264)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0 0	.0 0	.0 1.9
	Poor quality sleep (10062519)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0 0	.0 0	.0 1.9
	Tremor (10044565)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0 0	.0 0	.0 1.9
Psychiatric disorders (10037175)	Irritability (10022998)	4							4.5	1 0		
	Screaming (10039740)	0	0.0						2.8		.0 0	.0 1.9
Renal and urinary disorders (10038359)	Urethral meatus stenosis (10058463)	0	0.0							0 0		
Reproductive system and breast disorders (10038604)	Balanoposthitis (10004078)	2	1.0		3.7					0 0		
,	Genital labial adhesions (10064162)	0	0.0							0 0		
	Penile adhesion (10059636)	3			4.4				4.5		0 0	

117119 (DTPA-HBV-IPV-135)

		Uava mma								Report Fi		
				gro			Pedia				nta gr	
			N	= 195			N:	= 194			N = 19	
					% CI				% CI			5% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL		%	LL		n %		UL
	Penile erythema (10070655)	0	0.0	0.0	1.9	0	0.0	0.0	1.9		5 0.0	
Respiratory, thoracic and mediastinal disorders (10038738)	Apparent life threatening event (10065044)	1	0.5	0.0	2.8		0.0	0.0			0.0	
	Bronchial hyperreactivity (10066091)	2	1.0	0.1	3.7	0	0.0	0.0		0 0.	0.0	1.9
	Cough (10011224)	15	7.7	4.4	12.4	4 7	3.6	1.5	7.3	7 3.	6 1.4	7.2
	Dysphonia (10013952)	1	0.5	0.0	2.8		0.5	0.0	2.8	0 0.		
	Epistaxis (10015090)	0	0.0	0.0	1.9		0.0	0.0	1.9		5 0.0	
	Nasal congestion (10028735)	2	1.0	0.1	3.7		3.1	1.1	6.6	2 1.		
	Respiratory arrest (10038669)	0	0.0	0.0	1.9			0.0		0 0.		1.9
	Respiratory disorder (10038683)	1	0.5	0.0	2.8		1.0	0.1	3.7		5 0.0	
	Rhinitis allergic (10039085)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0 0.	0.0	1.9
	Rhinorrhoea (10039101)	3	1.5	0.3	4.4		1.0	0.1			0.6	
	Sinus congestion (10040742)	1	0.5	0.0	2.8		0.0	0.0			0.0	
	Sneezing (10041232)	1	0.5	0.0	2.8		0.0	0.0	1.9	0 0.	0.0	1.9
	Upper respiratory tract congestion (10052252)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	1 0.	5 0.0	2.8
	Wheezing (10047924)	2	1.0	0.1	3.7	0	0.0	0.0	1.9	2 1.	0.1	
Skin and subcutaneous tissue disorders (10040785)	Dermatitis (10012431)	3	1.5	0.3	4.4	1	0.5	0.0		0 0.		1.9
	Dermatitis atopic (10012438)	2	1.0	0.1	3.7	3	1.5	0.3	4.5	5 2.	6 0.8	5.9
	Dermatitis contact (10012442)	1	0.5	0.0	2.8		1.0	0.1	3.7	0 0.		
	Dermatitis diaper (10012444)	2	1.0	0.1	3.7		1.5	0.3			6 2.1	8.5
	Dry skin (10013786)	1	0.5	0.0	2.8	1	0.5	0.0		0 0.		1.9
	Eczema (10014184)	4	2.1	0.6	5.2	5	2.6	8.0		4 2.	0.6	5.1
	Erythema (10015150)	0	0.0	0.0	1.9		1.5	0.3			0.0	
	Hair growth abnormal (10019044)	1	0.5	0.0	2.8	0	0.0	0.0			0.0	
	Hypertrichosis (10020864)	0	0.0	0.0	1.9	1	0.5	0.0			0.0	
	Intertrigo (10022622)	0	0.0	0.0	1.9		0.0	0.0	1.9	1 0.	5 0.0	2.8
	Post inflammatory pigmentation change	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0 0.	0.0	1.9
	(10036229)											
	Rash (10037844)	4	2.1	0.6	5.2	4	2.1	0.6	5.2	6 3.	1 1.1	6.5
	Rash macular (10037867)	0	0.0	0.0	1.9	0	0.0	0.0	1.9		5 0.0	
	Seborrhoea (10039792)	1	0.5	0.0	2.8	1	0.5	0.0	2.8	1 0.	5 0.0	2.8
	Seborrhoeic dermatitis (10039793)	3	1.5	0.3	4.4		0.5	0.0	2.8		0.0	
	Urticaria (10046735)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0 0.	0.0	1.9

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 44 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following priming doses (Primary Total vaccinated cohort)

		Hexa grou N = 195 95%			= 195			ia gro = 19			a group = 196
									% CI		95% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)										LL UL
At least one symptom		13	6.7	3.6	3 11.	1 1:	2 6.2	2 3.2	10.6	7 3.6	1.4 7.2
Gastrointestinal disorders (10017947)	Abdominal pain upper (10000087)	0	0.0	0.0	1.9	1	0.	5 0.0	2.8	0.0	0.0 1.9
	Diarrhoea (10012735)	1			2.8						0.0 1.9
	Teething (10043183)	1			2.8						0.0 2.8
	Vomiting (10047700)	2			3.7						0.0 1.9
General disorders and administration site conditions (10018065)		1			2.8						0.0 1.9
	III-defined disorder (10061520)	0			1.9						0.0 1.9
	Injection site erythema (10022061)	0			1.9						0.0 1.9
	Injection site pain (10022086)	0	0.0	0.0	1.9	1					0.0 2.8
	Injection site swelling (10053425)	0			1.9						0.0 1.9
	Injection site warmth (10022112)	0			1.9						0.0 1.9
	Pyrexia (10037660)	2			3.7			0.0	1.9	1 0.5	0.0 2.8
Infections and infestations (10021881)	Bronchiolitis (10006448)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0.0	0.0 1.9
	Conjunctivitis (10010741)	0	0.0	0.0	1.9	2	1.0	0.1	3.7	0.0	0.0 1.9
	Croup infectious (10011416)	0	0.0	0.0	1.9	1	0.	5 0.0	2.8	0.0	0.0 1.9
	Gastroenteritis (10017888)	1			2.8			0.0			0.0 1.9
	Hand-foot-and-mouth disease (10019113)	1	0.5	0.0	2.8	1	0.	5 0.0	2.8	0.0	0.0 1.9
	Nasopharyngitis (10028810)	0			1.9						0.0 2.8
	Otitis media (10033078)	3	1.5	0.3	4.4	1	0.	5 0.0	2.8	1 0.5	0.0 2.8
	Pharyngitis (10034835)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0.0	0.0 1.9

117119 (DTPA-HBV-IPV-135)

Report Final

		ŀ		gro = 19	oup	F	Pedia group N = 194				nta gr N = 19	
					% CI		- ' '		, CI	_		% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n %	LL	UL
	Respiratory syncytial virus bronchiolitis (10038718)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0 0	0.0	1.9
	Respiratory syncytial virus infection (10061603)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0 0	0.0	1.9
	Rhinitis (10039083)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1 0	5 0.0	2.8
	Sinusitis (10040753)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1 0	.5 0.0	2.8
	Upper respiratory tract infection (10046306)	3	1.5	0.3	4.4	2	1.0	0.1	3.7	2 1	.0 0.1	3.6
Psychiatric disorders (10037175)	Irritability (10022998)	0	0.0	0.0	1.9	2	1.0	0.1	3.7	0 0	0.0	1.9
Respiratory, thoracic and mediastinal disorders (10038738)	Bronchial hyperreactivity (10066091)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0 0	0.0	1.9
	Cough (10011224)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1 0	.5 0.0	2.8
	Respiratory arrest (10038669)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0 0	0.0	1.9
	Upper respiratory tract congestion (10052252)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1 0	.5 0.0	2.8
	Wheezing (10047924)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0 0	0.0	1.9

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines
Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once 95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

8.1.7. According-to-protocol cohort analysis

In the Hexa, Pedia and Penta groups less than 5% of subjects who received a vaccine dose were excluded from the Primary ATP cohort for safety: 0.5%, 0.5% and 2.6%, respectively (Table 18). Thus a complementary analysis was not carried out on the Primary ATP cohort for safety.

8.1.8. Serious adverse events

The SAE Summary Table(s) are in Section 12.1 (Table 8.46) and the SAE Clinical Narratives reports are in Section 12.2.

8.1.8.1. Fatal events

No fatal SAEs were reported during the course of the study.

8.1.8.2. Non-fatal events

Non-fatal SAEs from Dose 1 up to 6 months following priming doses were reported for 7 (3.6%) subjects in the Hexa group and Penta group, and 1 (0.5%) subject in the Pedia group (Table 45). Only two SAEs were reported by more than one subject in any group: 2 subjects (1.0%) with Respiratory distress in the Hexa group and 2 subjects with Parainfluenzae virus infection in the Penta group.

All subjects who experienced an SAE were considered recovered/ resolved at the end of the study except one non-causally related event of Choking in a 47-week-old female in the Hexa group which was considered recovered/ resolved with sequelae (Table 8.46).

Three SAEs occurring in two subjects were considered causally related to primary vaccination by the investigator:

- An SAE of Lethargy in an 8-week-old female subject in the Hexa group which recovered/resolved after one day.
- Two SAEs in the same subject: one "Apparent life-threatening event" and one event of Leukocytosis were observed in a 10-week-old female subject in the Hexa group which recovered/resolved over 1-2 days.

The percentage of subjects for whom the occurrence of SAEs was reported following priming doses by gender and geographical ancestry are presented in Table 8.44 and Table 8.45.

117119 (DTPA-HBV-IPV-135)

Report Final

Table 45 Number (%) of subjects with serious adverse events (SAE) from Dose 1 up to 6 months following priming doses (Primary Total vaccinated cohort)

			Hexa N =	grou 195		Pedia group N = 194					Penta N =	-	
				95	% CI			95	% CI			95	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
At least one symptom		7	3.6	1.5	7.3	1	0.5	0.0	2.8	7	3.6	1.4	7.2
Blood and lymphatic system disorders (10005329)	Leukocytosis (10024378)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0	0.0	0.0	1.9
Gastrointestinal disorders (10017947)	Gastrooesophageal reflux disease (10017885)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0	0.0	0.0	1.9
Infections and infestations (10021881)	Gastroenteritis viral (10017918)	1	0.5	0.0	2.8	1	0.5	0.0	2.8	0	0.0	0.0	1.9
` '	Meningitis viral (10027260)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0	0.0	0.0	1.9
	Parainfluenzae virus infection (10061907)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	2	1.0	0.1	3.6
	Pneumonia (10035664)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1	0.5	0.0	2.8
	Respiratory syncytial virus bronchiolitis (10038718)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	1	0.5	0.0	2.8
	Respiratory syncytial virus infection (10061603)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1	0.5	0.0	2.8
Injury, poisoning and procedural complications (10022117)	Road traffic accident (10039203)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1	0.5	0.0	2.8
Metabolism and nutrition disorders (10027433)	Dehydration (10012174)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1	0.5	0.0	2.8
Nervous system disorders (10029205)	Febrile convulsion (10016284)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1	0.5	0.0	2.8
	Lethargy (10024264)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0	0.0	0.0	1.9
	Seizure (10039906)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0	0.0	0.0	1.9
Psychiatric disorders (10037175)	Mental status changes (10048294)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1	0.5	0.0	2.8
Respiratory, thoracic and mediastinal disorders (10038738)	Apparent life threatening event (10065044)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0	0.0	0.0	1.9
· · · · · · · · · · · · · · · · · · ·	Choking (10008589)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0	0.0	0.0	1.9
	Hypoxia (10021143)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0	0.0	0.0	1.9
	Respiratory distress (10038687)	2	1.0	0.1	3.7	0	0.0	0.0	1.9	0	0.0	0.0	1.9

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

8.1.9. Adverse events leading to premature discontinuation of study vaccine and/or study

Two subjects had adverse events leading to premature discontinuation of the study (Table 6.2):

- One Hexa group subject with an SAE of Lethargy reported after the first vaccination;
- One Penta group subject with a Non-Serious Adverse Event of Seizure reported after the Month 2 dose.

8.1.10. Other significant adverse events

8.1.10.1. New Onset of Chronic Illness (NOCI)

NOCI symptoms were reported for 7 subjects (3.6%) in the Hexa group, 11 subjects (5.7%) in the Pedia group and 10 subjects (5.1%) in the Penta group (Table 46).

• The two reported symptoms in the Hexa group were Dermatitis atopic (2.6%) followed by Bronchial hyperreactivity (1.0%). In the Pedia group, the symptom reported by more than one subject was Dermatitis atopic (3.6%). In the Penta group, the symptoms reported by more than one subject were Dermatitis atopic (3.6%) and Asthma (1.0%).

The percentage of subjects for whom the occurrence of NOCI classified by MedDRA Primary System Organ Class and Preferred Term was reported following priming doses by gender and geographical ancestry are presented in Table 8.41 and Table 8.42.

8.1.10.2. Hypotonic-Hyporesponsive Episode (HHE) and Convulsion

A search of the study data for symptoms which could be related to HHE within 31 days post-vaccination was conducted (broad MedDRA SMQ (Standardised MedDRA Queries) hypotonic-hyporesponsive episode) and 2 subjects with Cyanosis in the Penta group were identified (Table 8.35), who were both female (Table 8.37) and of the White Caucasian geographical ancestry (Table 8.38). After medical review of the cases, both of them were assessed as not meeting criteria for HHE.

A similar search this time for the narrow MedDRA SMQ "convulsion" with 31 days post-vaccination did not identify any subjects (Table 8.36, Table 8.39, Table 8.40).

117119 (DTPA-HBV-IPV-135)

Report Final

Table 46 Number % of subjects with adverse events of New Onset of Chronic Illness (NOCI) from Dose 1 up to 6 months following priming doses (Primary Total vaccinated cohort)

		Hexa group N = 195						group = 194)	Penta grou N = 196			р
				95	% CI			959	% CI			95	5% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
At least one symptom		7	3.6	1.5	7.3	11	5.7	2.9	9.9	10	5.1	2.5	9.2
Immune system disorders (10021428)	Drug hypersensitivity (10013700)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0	0.0	0.0	1.9
	Food allergy (10016946)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	1	0.5	0.0	2.8
Respiratory, thoracic and mediastinal disorders (10038738)	Asthma (10003553)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	2	1.0	0.1	3.6
	Bronchial hyperreactivity (10066091)	2	1.0	0.1	3.7	1	0.5	0.0	2.8	0	0.0	0.0	1.9
	Rhinitis allergic (10039085)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1	0.5	0.0	2.8
Skin and subcutaneous tissue disorders (10040785)	Dermatitis atopic (10012438)	5	2.6	8.0	5.9	7	3.6	1.5	7.3	7	3.6	1.4	7.2
,	Urticaria (10046735)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0	0.0	0.0	1.9

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

8.1.11. Concomitant medications /vaccinations

The intake of any concomitant medication was reported for between 60.0-75.8% of subjects in all three groups (Hexa, Pedia and Penta) during the 4-day (Day 0-3) post-vaccination period (Table 47).

• Between 54.9-69.1% of subjects across groups received any antipyretic and between 12.8-13.9% of subjects across groups received a prophylactic antipyretic concomitant medication.

The corresponding concomitant medication results during the 31-day (Days 0-30) post-vaccination period following each priming dose and overall are provided in Table 8.43.

Table 47 Number and percentage of subjects with concomitant medication during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)

	Hexa group							Ped	dia g	roup			Pei	nta g	roup	
				95	% CI					95%	6 CI				95%	6 CI
	N	n	%	LL	UL	١	_	n	%	LL	UL	N	n	%	LL	UL
					D	ose	e 1									
Any	195	69	35.4	28.7	42.	5 1	194	107	55.2	47.9	62.3	196	83	42.3	35.3	49.6
Any antipyretic	195	63	32.3	25.8	39.	4 1	194	99	51.0	43.8	58.3	196	79	40.3	33.4	47.5
Prophylactic antipyretic	195	17	8.7	5.2	13.	6 1	194	16	8.2	4.8	13.0	196	12	6.1	3.2	10.5
					D	ose	e 2									
Any	186	78	41.9	34.8	49.	4 1	88	87	46.3	39.0	53.7	189	70	37.0	30.1	44.3
Any antipyretic	186	75	40.3	33.2	47.	7 1	88	86	45.7	38.5	53.2	189	64	33.9	27.2	41.1
Prophylactic antipyretic	186	12	6.5	3.4	11.	0 1	88	9	4.8	2.2	8.9	189	10	5.3	2.6	9.5
	•	•		•	D	ose	e 3					•				
Any	183	65	35.5	28.6	42.	9 1	185	91	49.2	41.8	56.6	180	67	37.2	30.1	44.7
Any antipyretic	183	60	32.8	26.0	40.	1 1	185	82	44.3	37.0	51.8	180	63	35.0	28.1	42.4
Prophylactic antipyretic	183	13	7.1	3.8	11.	8 1	85	9	4.9	2.2	9.0	180	10	5.6	2.7	10.0
	•	•		(Over	all	/do	se				•				
Any	564	212	37.6	33.6	41.	7 5	67	285	50.3	46.1	54.5	565	220	38.9	34.9	43.1
Any antipyretic	564	198	35.1	31.2	39.	2 5	67	267	47.1	42.9	51.3	565	206	36.5	32.5	40.6
Prophylactic antipyretic	564	42	7.4	5.4	9.9	5	67	34	6.0	4.2	8.3	565	32	5.7	3.9	7.9
				0	vera	II/s	sub	ject								
Any	195	117	60.0	52.8	66.						81.6					
Any antipyretic	195	107	54.9	47.6	62.	0 1	194	134	69.1	62.1	75.5	196	114	58.2	50.9	65.2
Prophylactic antipyretic			13.3		18.		194		13.9		19.6			12.8		18.3

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

For each dose and overall/subject:

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects who started to take the specified concomitant medication at least once during the mentioned period

For overall/dose:

N = number of administered doses

117119 (DTPA-HBV-IPV-135) Report Final

n/% = number/percentage of doses after which the specified concomitant medication was started at least once during the mentioned period

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

8.1.12. Clinical laboratory evaluations

Not applicable

8.1.13. Pregnancy

Not applicable

8.1.14. Important safety information received after the data lock point (database freeze date)

None

8.1.15. Primary Total vaccinated cohort - Safety summary

- Any Symptom: In all three groups (Hexa, Pedia and Penta) over the primary doses, symptoms (solicited and/or unsolicited, local and/or general) were reported for 93.4-96.4% of subjects.
- Solicited local symptoms: Pain was the most frequently reported solicited local symptom reported in 67.9% of subjects in the Hexa group, in 82.0% of subjects in the Pedia group and in 79.8% of subjects in the Penta group.
 - Pain was also the most frequently reported Grade 3 solicited local symptom reported in 4.3% of subjects in the Hexa group, 18.0% of subjects in the Pedia group and 11.7% of subjects in the Penta group.
- Solicited general symptoms: Irritability / Fussiness was the most frequently reported solicited general symptom in all groups, reported in 87.7% of subjects in the Hexa group, in 96.3% of subjects in the Pedia group and in 94.1% of subjects in the Penta group overall.
 - Irritability was also the most commonly reported grade 3 solicited general symptom, reported for 9.6% of subjects in the Hexa group, 18.5% of subjects in the Pedia group and 16.0% of subjects in the Penta group overall.
- *Unsolicited adverse events:* At least one unsolicited symptom within the 31-day post-vaccination period after each vaccination was reported for 57.9%, 55.7% and 49.0% of subjects in the Hexa, Pedia and Penta groups, respectively.
 - The most commonly reported unsolicited symptom in the three groups was URTI: Hexa group: 15.4%; Pedia group: 11.9%; Penta group: 13.3%.

117119 (DTPA-HBV-IPV-135) Report Final

Grade 3 unsolicited symptoms were reported for 6.7%, 6.2% and 3.6% of subjects in Hexa, Pedia and Penta groups, respectively. The most commonly reported grade 3 unsolicited symptoms were:

Hexa group: URTI and Otitis media (1.5%);

Pedia group: URTI, Conjunctivitis and Irritability (1.0%);

Penta group: URTI (1.0%).

- Adverse events of interest: NOCI symptoms were reported for 7 subjects (3.6%) in the Hexa group, 11 subjects (5.7%) in the Pedia group and 10 subjects (5.1%) in the Penta group. The two reported symptoms in the Hexa group were Dermatitis atopic (2.6%) followed by Bronchial hyperreactivity (1.0%). In the Pedia group, the symptom reported by more than one subject was Dermatitis atopic (3.6%). In the Penta group, the symptoms reported by more than one subject were Dermatitis atopic (3.6%) and Asthma (1.0%).
- Serious adverse events: Non-fatal SAEs from Dose 1 up to 6 months following priming doses were reported for 7 (3.6%) subjects in the Hexa group and Penta group, and 1 (0.5%) subject in the Pedia group. All SAE were considered recovered/resolved without sequelae at the end of the study except one non-causally related event of Choking in a 47-week-old female in the Hexa group which was considered recovered/resolved with sequelae.

Three SAEs occurring in two subjects were considered causally related to primary vaccination by the investigator: An SAE of Lethargy in an 8-week-old female subject in the Hexa group which recovered/resolved after one day without sequelae; 2 SAEs in the same subject: one "Apparent life-threatening event" and one event of Leukocytosis were observed in a 10-week-old female subject in the Hexa group which recovered/resolved over 1-2 days without sequelae.

- No fatal SAEs were reported during the primary vaccination Epoch of the study.
- Withdrawals due to AEs /SAEs: Two subjects had adverse events leading to
 premature discontinuation during the primary vaccination period: one Hexa group
 subject with an SAE of Lethargy reported after the first vaccination; one Penta group
 subject with a Non-Serious Adverse Event of Seizure reported after the Month 2
 dose.

8.2. Booster Total vaccinated cohort analysis

8.2.1. Booster vaccination doses received

All subjects in the Booster Total vaccinated cohort received the planned booster vaccine doses as shown in Table 48.

Table 48 Number and percentage of subjects who received the study vaccine dose by vaccine (Booster Total vaccinated cohort)

HIB	group SERIX = 167	INFA	group NRIX 167	ACT	group THIB 158	INFA	group NRIX 158	PEN	group FACEL = 161
n	%	n	%	n	%	n	%	n	%
167	100	167	100	158	100	158	100	161	100

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

N = number of subjects in each group included in the considered cohort

n/% = number/percentage of subjects receiving the dose

8.2.2. Symptom eCRF screen compliance

Compliance in recording general symptom eCRF screens or local symptom eCRF screens was typically very high across groups: at least 91.6% and at least 92.2%, respectively (Table 49).

Table 49 Compliance in returning symptom sheets for the booster dose (Booster Total vaccinated cohort)

•	Number of doses	NOT according to	of	%	of	Compliance % local SS
		protocol				
Hexa group	167	0	153	91.6	154	92.2
Pedia group	158	0	150	94.9	151	95.6
Penta group	161	0	151	93.8	150	93.2

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

SS = Symptom screens/sheets used for the collection of local and general solicited AEs

Compliance % = (number of doses with symptom screen/sheet return / number of administered doses) X 100

8.2.3. Overall incidence of adverse events

At least one solicited or unsolicited symptom was reported during the Booster phase for 77.2% of Hexa group subjects, 81.6% of Pedia group subjects and 70.2% of Penta group subjects (Table 50). General symptoms were reported by between 62.7-69.6% of subjects across groups and local symptoms were reported by between 47.2-63.3% of subjects across groups.

117119 (DTPA-HBV-IPV-135) Report Final

- 1. Incidence of local symptoms (solicited and unsolicited) reported for *Infanrix*, *Hiberix*, *ActHIB*, and *Pentacel* vaccines: Table 51;
 - Overall local symptoms (solicited and unsolicited) were recorded for subjects receiving: *Infanrix* (52.7% for Hexa group and 60.1% for Pedia group);
 Hiberix (47.9% for Hexa group), *ActHIB* (52.5% for Pedia group) and *Pentacel* (47.2% for Penta group).
- 2. Incidence and nature of grade 3 symptoms (solicited and unsolicited): Table 52;
 - In all three groups (Hexa, Pedia and Penta) grade 3 symptoms (solicited and/or unsolicited, local and/or general) were reported for 6.2-10.8% of subjects.
- 3. Incidence of grade 3 local symptoms (solicited and unsolicited) reported for *Infanrix*, *Hiberix*, *ActHIB*, and *Pentacel* vaccines: Table 53;
 - Overall local symptoms (solicited and unsolicited) were recorded for subjects receiving: *Infanrix* (6.0% for Hexa group and 7.0% for Pedia group); *Hiberix* (0.6% for Hexa group), *ActHIB* (3.2% for Pedia group) and *Pentacel* (3.7% for Penta group).

Please also refer to the following Tables:

- 1. Incidence and nature of grade 3 symptoms (solicited and unsolicited) that were causally related to Booster vaccination: Table 8.49.
- 2. Incidence and nature of symptoms (solicited and unsolicited) reported during the 31-day (Days 0-30) post-vaccination period following the booster dose: Table 8.50.
- 3. Incidence and nature of grade 3 symptoms (solicited and unsolicited) reported during the 31-day (Days 0-30) post-vaccination period following the booster dose:

 Table 8 51
- 4. Incidence and nature of symptoms (solicited and unsolicited) that were causally related to vaccination reported during the 31-day (Days 0-30) post-vaccination period following the booster dose: Table 8.52.
- 5. Incidence and nature of grade 3 symptoms (solicited and unsolicited) that were causally related to vaccination reported during the 31-day (Days 0-30) post-vaccination period following the booster dose: Table 8.53.
- 6. Incidence of local symptoms (solicited and unsolicited) that were causally related to vaccination reported for *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel* vaccines during the 4-day (Days 0-3) post-vaccination period following the booster dose: Table 8.54.
- 7. Incidence of grade 3 local symptoms (solicited and unsolicited) that were causally related to vaccination reported for *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel* vaccines during the 4-day (Days 0-3) post-vaccination period following the booster dose: Table 8.55.

Table 50 Incidence and nature of symptoms (solicited and unsolicited) reported during the 4-day (Days 0-3) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

		Any	sym	ptom)	Ge	ener	al syr	mpto	ms	L	oca	l sym	pton	าร
				95%	6 CI				95%	6 CI				95%	6 CI
Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Hexa group	167	129	77.2	70.1	83.4	167	105	62.9	55.1	70.2	167	95	56.9	49.0	64.5
Pedia group	158	129	81.6	74.7	87.3	158	110	69.6	61.8	76.7	158	100	63.3	55.3	70.8
Penta group	161	113	70.2	62.5	77.1	161	101	62.7	54.8	70.2	161	76	47.2	39.3	55.2

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

N = number of subjects with the administered dose

n/% = number/percentage of subjects presenting at least one type of symptom whatever the study vaccine administered

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Table 51 Incidence of local symptoms (solicited and unsolicited) reported for Infanrix, Hiberix, ActHIB and Pentacel vaccines during the 4-day (Days 0-3) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

			ACTH	IIB			PI	ENTA	CEL			II	NFAN	RIX			I	HIBE	RIX	
				95%	6 CI															
Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Hexa group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	167	88	52.7	44.8	60.5	167	80	47.9	40.1	55.8
Pedia group	158	83	52.5	44.4	60.5	0	0	0.0	0.0	0.0	158	95	60.1	52.0	67.8	0	0	0.0	0.0	0.0
Penta group	0	0	0.0	0.0	0.0	161	76	47.2	39.3	55.2	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

N = number of subjects with the administered dose

n/% = number/percentage of subjects presenting at least one type of symptom at the study vaccine site 95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Table 52 Incidence and nature of grade 3 symptoms (solicited and unsolicited) reported during the 4-day (Days 0-3) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

	F	۱ny	sym	pto	m	Gen	era	al sy	mpt	oms	Lo	cal	syn	npto	ms
				959	% CI				95%	6 CI				95	S %
Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Hexa group															
Pedia group	158	17	10.8	6.4	16.7	158	6	3.8	1.4	8.1	158	12	7.6	4.0	12.9
Penta group	161	10	6.2	3.0	11.1	161	5	3.1	1.0	7.1	161	6	3.7	1.4	7.9

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

N = number of subjects with the administered dose

n/% = number/percentage of subjects presenting at least one type of symptom whatever the study vaccine administered

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Table 53 Incidence of grade 3 local symptoms (solicited and unsolicited) reported for *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel* vaccines during the 4-day (Days 0-3) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

		Α	CTI	ΗВ		P	E	NTA	CEI			INI	FAN	IRIX			Н	IBE	RIX	
				95%	6 CI				95%	6 CI				95	% CI				95%	6 CI
Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Hexa group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	167	10	6.0	2.9	10.7	167	1	0.6	0.0	3.3
Pedia group	158	5	3.2	1.0	7.2	0	0	0.0	0.0	0.0	158	11	7.0	3.5	12.1	0	0	0.0	0.0	0.0
Penta group	0	0	0.0	0.0	0.0	161	6	3.7	1.4	7.9	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

N = number of subjects with the administered dose

n/% = number/percentage of subjects presenting at least one type of symptom at the study vaccine site 95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

8.2.4. Solicited local adverse events

Incidence of solicited local symptoms are summarized in Table 54.

Pain was the most frequently reported solicited local symptom reported in 46.8% of subjects in the Hexa group, in 51.0% of subjects in the Pedia group and in 39.3% of subjects in the Penta group.

Redness was the most frequently reported Grade 3 (>20; Section 5.9.2.1) solicited local symptom reported in 5.2% of subjects in the Hexa group, 4.0% of subjects in the Pedia group and 1.3% of subjects in the Penta group.

117119 (DTPA-HBV-IPV-135) Report Final

Medical advice was sought for not more than 1.3% of subjects following any one symptom.

Please also refer to the following Tables:

- 1. Incidence of local symptoms (solicited and unsolicited) that were causally related to vaccination reported for *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel* vaccines during the 4-day (Days 0-3) post-vaccination period following the booster dose: Table 8.54.
- 2. Incidence of grade 3 local symptoms (solicited and unsolicited) that were causally related to vaccination reported for *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel* vaccines during the 4-day (Days 0-3) post-vaccination period following the booster dose: Table 8.55.

The incidence of solicited local symptoms reported during the 4-day (Days 0-3) post-vaccination period following the booster dose by gender and by geographical ancestry are presented in Table 8.56 and Table 8.57, respectively.

The incidence of large injection site reaction reported during the 4-day (Days 0-3) post-vaccination period following the booster dose is presented in Table 8.58. A total of two subjects (1.3%) in the Hexa group and one subject (0.7%) in the Pedia group had Local Swelling, and Diffuse Swelling was recorded in one subject (0.6%) in the Hexa group. See Section 5.9.2.1 and Section 5.10.5.3 for the definition of large injection site reactions defined as swelling with a diameter > 50 mm, noticeable diffuse swelling or noticeable increase of limb circumference, with details of how these events were recorded.

Table 54 Incidence of solicited local symptoms reported during the 4-day (Days 0-3) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

				Н	exa g	roup			Pe	dia g				Pe	nta g	group)
						95	% CI				95 °	% CI				95	% CI
Symptom	Product	Туре	N	n	%	LL	UL	N					N	n	%	LL	UL
Pain	Total	All	154	72	46.8	38.7	55.0	151	77	51.0	42.7	59.2	150	59	39.3	31.5	47.6
		Grade 2 or 3	154	13	8.4	4.6	14.0	151	22	14.6	9.4	21.2	150	16	10.7	6.2	16.7
		Grade 3	154	2	1.3	0.2	4.6	151	3	2.0	0.4	5.7	150	2	1.3	0.2	4.7
		Medical advice	154	1	0.6	0.0	3.6	151	0	0.0	0.0	2.4	150	0	0.0	0.0	2.4
	ActHIB/Hiberix	All	153	61	39.9	32.1	48.1	151	64	42.4	34.4	50.7					
		Grade 2 or 3	153	11	7.2	3.6	12.5	151	15	9.9	5.7	15.9					
		Grade 3	153	1	0.7	0.0	3.6	151	2	1.3	0.2	4.7					
		Medical advice	153	0	0.0	0.0	2.4	151	0	0.0	0.0	2.4					
	Infanrix/Pentacel	All	154	62	40.3	32.4	48.5	151	74	49.0	40.8	57.3	150	59	39.3	31.5	47.6
		Grade 2 or 3	154	12	7.8	4.1	13.2	151	19	12.6	7.7	19.0	150	16	10.7	6.2	16.7
		Grade 3	154	2	1.3	0.2	4.6	151	3	2.0	0.4	5.7	150	2	1.3	0.2	4.7
		Medical advice	154	1	0.6	0.0	3.6	151	0	0.0	0.0	2.4	150	0	0.0	0.0	2.4
Redness (mm)	Total	All	154	55	35.7	28.2	43.8	151	66	43.7	35.7	52.0	150	47	31.3	24.0	39.4
,		>5	154	19	12.3	7.6	18.6	151	16	10.6	6.2	16.6	150	13	8.7	4.7	14.4
		>20	154	8	5.2	2.3	10.0	151	6	4.0	1.5	8.4	150	2	1.3	0.2	4.7
		Medical advice	154	2	1.3	0.2	4.6	151	0	0.0	0.0	2.4	150	0	0.0	0.0	2.4
	ActHIB/Hiberix	All	153	42	27.5	20.6	35.2	151	49	32.5	25.1	40.5					
		>5	153	7	4.6	1.9	9.2	151	4	2.6	0.7	6.6					
		>20	153	0	0.0	0.0	2.4	151	2	1.3	0.2	4.7					
		Medical advice	153	0	0.0	0.0	2.4	151	0	0.0	0.0	2.4					
	Infanrix/Pentacel	All	154	49	31.8	24.6	39.8	151	60	39.7	31.9	48.0	150	47	31.3	24.0	39.4
		>5	154	17	11.0	6.6	17.1	151	14	9.3	5.2	15.1	150	13	8.7	4.7	14.4
		>20	154	8	5.2	2.3	10.0	151	4	2.6	0.7	6.6	150	2	1.3	0.2	4.7
		Medical advice	154	2	1.3	0.2	4.6	151	0	0.0	0.0	2.4	150	0	0.0	0.0	2.4
Swelling (mm)	Total	All	154	47	30.5	23.4	38.4	151	50	33.1	25.7	41.2	150	35	23.3	16.8	30.9
,		>5	154	17	11.0	6.6	17.1	151	18	11.9	7.2	18.2	150	14	9.3	5.2	15.2
		>20	154	5	3.2	1.1	7.4	151	7	4.6	1.9	9.3	150	4	2.7	0.7	6.7
		Medical advice	154	2	1.3	0.2	4.6	151	0	0.0	0.0	2.4	150	0	0.0	0.0	2.4
	ActHIB/Hiberix	All	153	29	19.0	13.1	26.1	151	29	19.2	13.3	26.4					
		>5	153	7	4.6	1.9	9.2	151	6	4.0	1.5	8.4					
		>20	153	0	0.0	0.0	2.4	151	2	1.3	0.2	4.7					
		Medical advice	153	0	0.0	0.0	2.4	151	0	0.0	0.0	2.4					
	Infanrix/Pentacel				27.3	20.4	35.0			29.1	22.0	37.1	150	35	23.3	16.8	30.9
		>5	154			4.6	14.0			11.3		17.4				5.2	15.2
		>20	154		3.2	1.1	7.4	151			1.9	9.3	150		2.7	0.7	6.7
		Medical advice					4.6	151		0.0			150		0.0	0.0	2.4
	Cubicata wha was																

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

N = number of subjects with the documented dose

n/% = number/percentage of subjects reporting the symptom at least once

95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

8.2.5. Solicited general adverse events

Incidence of solicited general symptoms are summarised in Table 55.

- Irritability / Fussiness was the most frequently reported solicited general symptom in all the groups, reported in 56.2% of subjects in the Hexa group, in 62.7% of subjects in the Pedia group and in 50.3% of subjects in the Penta group.
- Irritability / Fussiness was also the most commonly reported solicited general symptom graded 3 in intensity; reported for 2.0% of subjects in the Hexa group, 2.7% of subjects in the Pedia group and 2.6% of subjects in the Penta group.
- Grade 3 fever (>40.0°C rectal temperature) was reported for none of the subjects in any group.
- Medical advice was sought by only 2 subjects in the Pedia group and 2 subjects in the Penta group.
- The majority of solicited general symptoms following vaccination were considered by the investigator to be causally related to vaccination in the three groups.

The incidence of solicited general symptoms reported during the 4-day (Days 0-3) post-vaccination period following the booster dose by gender and geographical ancestry are presented in Table 8.59 and Table 8.60, respectively.

Table 55 Incidence of solicited general symptoms reported during the 4-day (Days 0-3) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

			Не	exa g	roup			Pe	dia g	roup			Pe	nta g	jroup)
					95 9	% CI				95 %					95 9	% CI
Symptom	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Drowsiness	All	153	59	38.6	30.8	46.8	150	67	44.7	36.6	53.0	151	65	43.0	35.0	51.3
	Grade 2 or 3	153	18	11.8	7.1	18.0			13.3		19.8	151	17	11.3		17.4
	Grade 3	153	1	0.7	0.0	3.6	150				5.7	151	2	1.3	0.2	4.7
	Related	153	55	35.9	28.4	44.1	150	65	43.3	35.3	51.7	151	61			48.7
	Grade 3 Related	153	1	0.7	0.0	3.6	150	3	2.0	0.4	5.7	151	2	1.3	0.2	4.7
	Medical advice	153			0.0	2.4	150		0.0	0.0	2.4	. • .		0.0	0.0	2.4
Irritability / Fussiness	All	153	86	56.2	48.0	64.2	150	94	62.7	54.4	70.4			50.3	42.1	58.6
	Grade 2 or 3	153			11.4		150	35	23.3			151			9.9	22.0
	Grade 3	153			0.4	5.6	150		2.7		6.7	151		-	0.7	6.6
	Related			55.6	47.3	63.6			61.3	53.0	69.2	151	68		36.9	53.3
	Grade 3 Related	153	3	2.0	0.4	5.6	150	4	2.7	0.7	6.7	151	4	2.6	0.7	6.6
	Medical advice	153	0		0.0	2.4	150		0.0	0.0	2.4	151		0.7	0.0	3.6
Loss Of Appetite	All	153	47	30.7	23.5	38.7	150	47	31.3	24.0	39.4	151	46	30.5		38.5
	Grade 2 or 3	153	8	5.2	2.3	10.0	150	9	6.0	2.8	11.1	151	11	7.3	3.7	12.7
	Grade 3	153	1	0.7	0.0	3.6	150	2	1.3	0.2	4.7	151	2	1.3	0.2	4.7
	Related	153	44	28.8	21.7	36.6	150	44	29.3	22.2	37.3	151		27.2	20.2	35.0
	Grade 3 Related	153	1	0.7	0.0	3.6	150	2	1.3	0.2	4.7	151	2	1.3	0.2	4.7
	Medical advice	153	0	0.0		2.4	150	0	0.0		2.4	151	0	0.0	0.0	2.4
Temperature/(Axillary) (°C)		153				6.6	150			3.2	11.9	151		7.3	3.7	12.7
	>38.5	153			0.2	4.6	150		3.3	1.1	7.6	151		2.6	0.7	6.6
	>39.0	153		0.7	0.0	3.6	150		0.7	0.0	3.7	151		0.7	0.0	3.6
	>39.5	153		0.0	0.0	2.4	150		0.0	0.0	2.4	151		0.0	0.0	2.4
	>40.0	153			0.0	2.4	150		0.0	0.0	2.4	151		0.0	0.0	2.4
	Related	153	2	1.3	0.2	4.6	150	10	6.7	3.2	11.9	151	9	6.0	2.8	11.0
	>40.0 Related	153	0	0.0	0.0	2.4	150	0	0.0	0.0	2.4	151	0	0.0	0.0	2.4
	Medical advice	153	0	0.0	0.0	2.4	150	2	1.3	0.2	4.7	151	1	0.7	0.0	3.6

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

N = number of subjects with the documented dose

n/% = number/percentage of subjects reporting the symptom at least once

95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

8.2.6. Unsolicited adverse events

The percentage of subjects for whom the occurrence of unsolicited symptoms and grade 3 unsolicited symptoms within the 31-day (Days 0-30) post-vaccination period for the Primary Total vaccinated cohort is presented in Table 56 and Table 57, respectively.

- At least one unsolicited symptom within the 31-day post-vaccination period after the booster vaccination, classified by MedDRA Primary System Organ Class and Preferred Term was reported for 22.2%, 22.2% and 25.5% of subjects in the Hexa, Pedia and Penta groups, respectively (Table 56).
- The most commonly reported unsolicited symptoms in the Hexa group was Pyrexia (3.0%) followed by Teething (2.4%) and Vomiting (2.4%). In the Pedia group, the most commonly reported symptoms were Pyrexia (3.2%), Otitis Media (3.2%) and URTI (3.2%). The most commonly reported symptoms in the Penta group were URTI (5.0%) followed by Viral Infection (3.1%), Otitis Media (1.9%), Diarrhoea (1.9%) and Teething (1.9%).
- A grade 3 unsolicited symptom was reported for 3.0%, 1.9% and 1.9% of subjects in Hexa, Pedia and Penta groups, respectively (Table 57). No grade 3 unsolicited symptom was reported by more than one subject in any group.
- The investigator assessed a causal relationship between at least one unsolicited symptom and booster vaccination for 1.8%, 1.9% and 1.9% of subjects in the Hexa, Pedia and Penta groups, respectively Table 8.61. None of these unsolicited symptoms were reported by more than one subject in any group.

No subject reported a grade 3 unsolicited symptom with causal relationship to booster vaccination (Table 8.62).

The following data are summarised in the following tables:

- The percentage of subjects who reported the occurrence of unsolicited symptoms by gender (Table 8.63), and of unsolicited symptoms by geographical ancestry (Table 8.64).
- The percentage of subjects who reported the occurrence of grade 3 unsolicited symptoms by gender (Table 8.65), and of grade 3 unsolicited symptoms by geographical ancestry (Table 8.66).
- The percentage of subjects who reported the occurrence of unsolicited symptoms with causal relationship to booster vaccination by gender (Table 8.67), and of unsolicited symptoms with causal relationship to booster vaccination by geographical ancestry (Table 8.68).
- No subjects reported the occurrence of grade 3 unsolicited symptoms with causal relationship to booster vaccination by gender (Table 8.69), or of grade 3 unsolicited symptoms with causal relationship to primary vaccination by geographical ancestry (Table 8.70).

Table 56 Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

		Hexa gr N = 10			a group = 158		Penta N	a gro = 161	
		9:	5% CI		95% C	I		95%	6 CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n % LL		n %	LL UL		%		UL
At least one symptom		37 22.2 16		35 22.2	2 15.9 29		25.5	18.9	32.9
Blood and lymphatic system disorders (10005329)	Iron deficiency anaemia (10022972)	0.0 0.0		0.0	0.0 2.3		0.6	0.0	3.4
Congenital, familial and genetic disorders (10010331)	Dacryostenosis congenital (10011850)	1 0.6 0.0		0.0					2.3
	Phimosis (10034878)	0.0 0.0		1 0.6			0.0		2.3
Ear and labyrinth disorders (10013993)	Ear pain (10014020)	0.0 0.0		0.0	0.0 2.3		0.6		3.4
	Tympanic membrane perforation (10045210)	1 0.6 0.0		0.0	0.0 2.3		0.0		2.3
Eye disorders (10015919)	Chalazion (10008388)	0.0 0.0		1 0.6		0	0.0		2.3
Gastrointestinal disorders (10017947)	Diarrhoea (10012735)	0.0 0.0		2 1.3			1.9		5.3
	Nausea (10028813)	0.0 0.0		1 0.6	0.0 3.5		0.0		2.3
	Stomatitis (10042128)	1 0.6 0.0		0.0	0.0 2.3		0.0		2.3
	Teething (10043183)	4 2.4 0.7		2 1.3		3	1.9		5.3
	Vomiting (10047700)	4 2.4 0.7		3 1.9	0.4 5.4		1.2		4.4
General disorders and administration site conditions (10018065)	Injection site induration (10022075)	0.0 0.0		1 0.6	0.0 3.5		0.0		2.3
	Injection site nodule (10057880)	1 0.6 0.0		0.0					2.3
	Injection site scab (10066210)	0.0 0.0		0.0	0.0 2.3		0.6		3.4
	Pyrexia (10037660)	5 3.0 1.0		5 3.2	1.0 7.2		1.2		4.4
	Vaccination site erythema (10059079)	0.0 0.0		1 0.6	0.0 3.5		0.0		2.3
Immune system disorders (10021428)		3 1.8 0.4		0.0	0.0 2.3		0.0		2.3
Infections and infestations (10021881)	Bronchitis (10006451)	0.0 0.0		1 0.6	0.0 3.5		0.0		2.3
	Cellulitis (10007882)	0.0 0.0		1 0.6	0.0 3.5		0.0		2.3
	Conjunctivitis (10010741)	0.0 0.0		2 1.3			0.0		2.3
	Conjunctivitis bacterial (10061784)	0.0 0.0		0.0	0.0 2.3		0.6		3.4
	Croup infectious (10011416)	0.0 0.0		0.0	0.0 2.3		1.2		4.4
	Eye infection (10015929)	1 0.6 0.0		0.0	0.0 2.3				3.4
	Folliculitis (10016936)	1 0.6 0.0		0.0	0.0 2.3		0.0		2.3
	Gastroenteritis (10017888)	1 0.6 0.0		0.0	0.0 2.3		0.0		2.3
		0.0 0.0		1 0.6			0.6		3.4
	Herpangina (10019936)	0.0 0.0	2.2	0.0	0.0 2.3	3 1	0.6	0.0	3.4

117119 (DTPA-HBV-IPV-135)

				a gr = 10	67		Pedi N	= 15	8		Pent N	= 161	
				_	5% CI				% CI				% CI
Primary System Organ Class (CODE)	, ,		%	LL		n		LL	UL				UL
	,			0.1				0.0					3.4
	1 7 0 \			0.1		0	0.0	0.0			0.6		3.4
	Otitis media (10033078)	1	0.6			5	3.2	1.0	7.2		1.9		5.3
	Otitis media acute (10033079)		0.6	0.0		1	0.6	0.0	3.5		0.0		2.3
	<i>,</i>		0.0	0.0		0	0.0	0.0	2.3		0.6		3.4
	/		0.0	0.0		0	0.0	0.0	2.3		1.2		4.4
	Sinusitis (10040753)		0.6	0.0		0	0.0	0.0	2.3		0.0		2.3
	Staphylococcal infection (10058080)	1	0.6	0.0		0	0.0	0.0	2.3		0.0		2.3
		3	1.8	0.4		5	3.2	1.0			5.0		9.6
	Viral infection (10047461)	2	1.2	0.1		2		0.2			3.1		7.1
			0.0	0.0		0	0.0	0.0	2.3		0.6		3.4
	Viral upper respiratory tract infection (10047482)		0.0	0.0		0	0.0	0.0	2.3		0.6		3.4
Injury, poisoning and procedural complications (10022117)			0.0	0.0			0.0	0.0	2.3		0.6		3.4
	Contusion (10050584)		0.6	0.0		0	0.0	0.0	2.3		0.0		2.3
	Corneal abrasion (10010984)		0.0	0.0		1	0.6	0.0			0.0		2.3
	· • · • · • · • · • · • · · · · · · · ·		0.0	0.0		1	0.6	0.0			0.0		2.3
	Foreign body in gastrointestinal tract (10079846)		0.0				1.3	0.2			0.6		3.4
	Head injury (10019196)		0.6	0.0				0.0			0.6		3.4
	J. J ()		0.0					0.0			0.6		3.4
	Skin abrasion (10064990)		0.6					0.0			0.0		2.3
Nervous system disorders (10029205)			0.0					0.0			0.6		3.4
	Speech disorder developmental (10041467)		0.6		3.3	0	0.0				0.6		3.4
Reproductive system and breast disorders (10038604)	\ /		0.0			1	0.6	0.0	3.5		0.0		2.3
Respiratory, thoracic and mediastinal disorders (10038738)	1		0.0					0.0			0.6		3.4
			1.2	0.1		1	0.6	0.0	3.5		0.0		2.3
	Nasal congestion (10028735)		0.6	0.0			0.0	0.0	2.3		0.0		2.3
	Rhinitis allergic (10039085)		0.6	0.0		0		0.0	2.3				2.3
				0.1		2		0.2			0.6	0.0	3.4
				0.0		0	0.0	0.0			0.6		3.4
Skin and subcutaneous tissue disorders (10040785)	Dermatitis (10012431)			0.0		0	0.0	0.0	2.3		0.0		2.3
				0.0		1	0.6	0.0	3.5				2.3
	Dermatitis contact (10012442)	1	0.6	0.0	3.3	0	0.0	0.0	2.3	0	0.0	0.0	2.3

117119 (DTPA-HBV-IPV-135)

Report Final

				a gro	-		Pedia N	a gro = 158				a gro = 161	
					% CI				% CI		•		% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
	Dermatitis diaper (10012444)	2	1.2	0.1	4.3	1	0.6	0.0	3.5	1	0.6	0.0	3.4
	Eczema (10014184)	1	0.6	0.0	3.3	0	0.0	0.0	2.3	0	0.0	0.0	2.3
	Ingrowing nail (10022013)	1	0.6	0.0	3.3	0	0.0	0.0	2.3	0	0.0	0.0	2.3
	Petechiae (10034754)	1	0.6	0.0	3.3	0	0.0	0.0	2.3	0	0.0	0.0	2.3
	Pruritus (10037087)	1	0.6	0.0	3.3	0	0.0	0.0	2.3	0	0.0	0.0	2.3
	Rash (10037844)	2	1.2	0.1	4.3	4	2.5	0.7	6.4	0	0.0	0.0	2.3
	Rash erythematous (10037855)	0	0.0	0.0	2.2	0	0.0	0.0	2.3	1	0.6	0.0	3.4
	Rash generalised (10037858)	0	0.0	0.0	2.2	1	0.6	0.0	3.5	0	0.0	0.0	2.3
	Urticaria (10046735)	0	0.0	0.0	2.2	1	0.6	0.0	3.5	0	0.0	0.0	2.3

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n/% = number/percentage of subjects reporting the symptom at least once

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

117119 (DTPA-HBV-IPV-135)

Report Final

Table 57 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

		ŀ	lexa	gr	oup) l	Pedi	a gi	rou	o P	enta	gro	oup
			N	= 10	67		N	= 1	58		N:	= 16	1
				95	% C	:1		95	% C	1		95%	CI
Primary System Organ Class (CODE)												LL	
At least one symptom												0.4	
Gastrointestinal disorders (10017947)	Diarrhoea (10012735)											0.0	
	Vomiting (10047700)											0.0	
General disorders and administration site conditions (10018065)												0.0	
Infections and infestations (10021881)												0.0	
												0.0	
	Upper respiratory tract infection (10046306)	0	0.0	0.0	2.2	2 (0.0	0.0	2.3	3 1	0.6	0.0	3.4
	Viral infection (10047461)											0.0	
Injury, poisoning and procedural complications (10022117)	Corneal abrasion (10010984)											0.0	
	Head injury (10019196)	1	0.6	0.0	3.3	3 (0.0	0.0	2.	3 0	0.0	0.0	2.3
Skin and subcutaneous tissue disorders (10040785)	Rash (10037844)	0	0.0	0.0	2.2	2 ′	0.6	0.0	3.	5 0	0.0	0.0	2.3

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n/% = number/percentage of subjects reporting the symptom at least once

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

8.2.7. According-to-protocol cohort analysis

In the Hexa, Pedia and Penta groups less than 5% of subjects who received a vaccine dose were excluded from the Primary ATP cohort for safety: 0.0%, 0.0% and 0.6%, respectively (Table 19). Thus a complementary analysis was not carried out on the Booster ATP cohort for safety.

8.2.8. Serious adverse events

The SAE Summary Table(s) are in Section 12.1 (Table 8.80) and the SAE Clinical Narratives reports are in Section 12.2.

8.2.8.1. Fatal events

No fatal SAEs were reported during the course of the study.

8.2.8.2. Non-fatal events

Non-fatal SAEs within 31 days post-booster were recorded for one (0.6%) subject in the Hexa group (Petechiae), for one (0.6%) subject in the Penta group (Seizure like phenomena), and no subject in the Pedia group during the booster vaccination epoch of the study (Table 58 and Table 8.46). None of the two non-fatal SAEs were considered to be causally-related to vaccination and both were recorded to have an outcome of "recovered/resolved" (Table 8.46).

The percentage of subjects for whom the occurrence of SAEs was reported following the booster dose by gender is presented in Table 8.80.

8.2.8.3. SAEs for the full study

There were no fatal SAEs throughout the study. Non-fatal SAEs were reported for 8 subjects in the Hexa group and Penta group, and one subject in the Pedia group throughout the study (Table 45 and Table 58). Only two SAEs were reported by more than one subject in a group during the primary epoch: 2 subjects (1.0%) with Respiratory distress in the Hexa group and 2 subjects with Parainfluenzae virus infection in the Penta group (Table 45). See Section 8.1.8.2 for details of non-fatal SAEs which were not considered fully recovered/resolved and were causally-related to primary vaccination in the primary Epoch.

117119 (DTPA-HBV-IPV-135) Report Final

Table 58 Number (%) of subjects reporting the occurrence of serious adverse event (SAE) within the 31-day (Days 0-30) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

		F		gro = 16	-	P		a gro = 15	-	P		a gr	oup 31
					5% Cl				5% Cl				5% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)								UL				
At least one symptom		1	0.6	0.0	3.3	0	0.0	0.0	2.3	1	0.6	0.0	3.4
Nervous system disorders (10029205)	Seizure like phenomena (10071048)	0	0.0	0.0	2.2	0	0.0	0.0	2.3	1	0.6	0.0	3.4
Skin and subcutaneous tissue disorders (10040785)	Petechiae (10034754)	1	0.6	0.0	3.3	0	0.0	0.0	2.3	0	0.0	0.0	2.3

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n/% = number/percentage of subjects reporting the symptom at least once

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

8.2.9. Adverse events leading to premature discontinuation of study vaccine and/or study

None

8.2.10. Other significant adverse events

8.2.10.1. New Onset of Chronic Illness (NOCI)

NOCI symptoms were reported for 4 subjects (2.4%) in the Hexa group, 1 subject (0.6%) in the Pedia group and 1 subject (0.6%) in the Penta group (Table 8.77). Only Seasonal allergy symptoms were reported by more than one subject in any group: 3 (1.8%) subjects.

The percentage of subjects for whom the occurrence of NOCI classified by MedDRA Primary System Organ Class and Preferred Term was reported following booster dose by gender and geographical ancestry are presented in Table 8.78 and Table 8.79.

8.2.10.2. Hypotonic-Hyporesponsive Episode and Convulsion

A search of the study data for symptoms reported within 31 days post-vaccination which could be related to HHE was conducted (broad MedDRA SMQ hypotonic-hyporesponsive episode) and no subjects were identified (Table 8.71, Table 8.73, Table 8.75).

A search of the study data for symptoms reported within 31 days post-vaccination which could be related to "convulsion" was conducted (narrow MedDRA SMQ 'convulsion') and 1 subject that developed seizure like phenomena in the Penta group was identified (Table 8.72), who was female (Table 8.74) and of the "Other" geographical ancestry (Table 8.76). The case narrative suggested that the subject was suspected of having frontal lobe epilepsy and up to the end of follow-up was undergoing treatment with Levetiracetam.

8.2.11. Concomitant medications /vaccinations

The intake of any concomitant medication was reported for between 23.4-28.5% of subjects in all three groups (Hexa, Pedia and Penta) during the 4-day (Day 0-3) post-booster vaccination period (Table 59).

Between 21.1-27.2% of subjects across groups received any antipyretic and between 3.8-7.2% of subjects across groups received a prophylactic antipyretic concomitant medication.

Table 59 Number and percentage of subjects starting a concomitant medication during the 4-day (Days 0-3) post-vaccination period (Booster Total vaccinated cohort)

		Не	exa g	roup			Pe	dia g	roup	1		Pe	nta g	roup	1
				95%	6 CI				95%	6 CI				95%	O %
	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Any	167	39	23.4	17.2	30.5	158	45	28.5	21.6	36.2	161	38	23.6	17.3	30.9
Any antipyretic	167	36	21.6	15.6	28.6	158	43	27.2	20.4	34.9	161	34	21.1	15.1	28.2
Prophylactic antipyretic	167	12	7.2	3.8	12.2	158	6	3.8	1.4	8.1	161	7	4.3	1.8	8.8

Hexa group = Subjects who received primary doses of *Infanrix hexa* and a booster dose of *Infanrix* and *Hiberix* vaccines

Pedia group = Subjects who received primary doses of *Pediarix* and *ActHIB* and a booster dose of *Infanrix* and *ActHIB* vaccines

Penta group = Subjects who received primary doses of *Pentacel* and *Engerix-B* and a booster dose of *Pentacel* vaccine

N = number of subjects with the administered dose

n/% = number/percentage of subjects who started to take the specified concomitant medication at least once during the mentioned period

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

8.2.12. Clinical laboratory evaluations

Not applicable

8.2.13. Pregnancy

Not applicable

8.2.14. Important safety information received after the data lock point (database freeze date)

None

8.2.15. Booster Total vaccinated cohort - Safety summary

- Any Symptom: At least one solicited or unsolicited symptom was reported during the Booster phase for 77.2% of Hexa group subjects, 81.6% of Pedia group subjects and 70.2% of Penta group subjects.
- Solicited local symptoms: Pain was the most frequently reported solicited local symptom reported in 46.8% of subjects in the Hexa group, 51.0% of Pedia group subjects and 39.3% of Penta group subjects.
 - Redness was the most frequently reported Grade 3 solicited local symptom reported in 1.3-5.2% of subjects in the three groups.
- Solicited general symptoms: Irritability / Fussiness was the most frequently reported solicited general symptom in all the groups, reported in 56.2% of Hexa group subjects, in 62.7% of Pedia group subjects and in 50.3% of Penta group subjects.
 - Irritability / Fussiness was also the most commonly reported grade 3 solicited general symptom, reported for between 2.0 and 2.7% of subjects across groups.
- Unsolicited adverse events: At least one unsolicited symptom within the 31-day post-vaccination period after the booster vaccination was recorded for 22.2%, 22.2% and 25.5% of subjects in the Hexa, Pedia and Penta groups, respectively.
 - The most commonly reported unsolicited symptoms were: Hexa group: Pyrexia (3.0%); Pedia group: Pyrexia, Otitis media and URTI (3.2%); Penta group: URTI (5.0%).
 - A grade 3 unsolicited symptom was reported for 3.0%, 1.9% and 1.9% of subjects in Hexa, Pedia and Penta groups, respectively. No grade 3 unsolicited symptom was reported by more than one subject in any group.
- Adverse events of interest: NOCI were reported for 4 subjects (2.4%) in the Hexa group, 1 subject (0.6%) in the Pedia group and 1 subject (0.6%) in the Penta group. Only Seasonal allergy symptoms were reported by more than one subject in any group: 3 (1.8%) subjects.
- Large injection site reactions up to 4 days (D0-D3) after vaccination: Two subjects (1.3%) in the Hexa group and one subject (0.7%) in the Pedia group had Local Swelling, and Diffuse Swelling was recorded in one subject (0.6%) in the Hexa group.

- Serious adverse events within 31 days post booster: Non-fatal SAEs within 31 days post-booster dose were reported for one (0.6%) subject in the Hexa group (Petechiae), for one (0.6%) subject in the Penta group (Seizure like phenomena), and no subject in the Pedia group. None of the two non-fatal SAEs were considered to be causally-related to vaccination and both were recorded to have an outcome of "recovered/resolved".
- Withdrawals due to AEs /SAEs: No subject was withdrawn due to an AE or SAE during the booster Epoch.
- **SAEs for the full study:** There were no fatal SAEs throughout the study. SAEs were reported for 8 subjects in the Hexa group and Penta group, and for one subject in the Pedia group throughout the study

9. OVERALL CONCLUSIONS

- The primary objective of the study was met: One month post-primary vaccination, *Infanrix hexa* was demonstrated to be non-inferior to *Pediarix+ACTHib* in terms of antibody GMCs for the three pertussis antigens (PT, FHA, and PRN).
- One month after the primary vaccination: The immune responses to Infanrix hexa, Pediarix+ACTHib and Pentacel/Engerix-B were similar between the different groups, in terms of seroprotection/seropositivity rates and GMCs.
 - The lowest anti-PRP GMCs were observed after *Infanrix hexa* vaccination as compared to *Pediarix+ACTHib* and *Pentacel+Engerix-B*.
- One month after the booster vaccination: The immune responses to Infanrix+Hiberix (booster vaccines used after Infanrix hexa priming), Infanrix+ActHIB (booster vaccines used after Pediarix+ActHIB priming) and Pentacel were similar between the different groups, in terms of seroprotection/seropositivity rates and GMCs.
 - Similar Anti-PRP long-term protection antibody levels were observed (≥1.0 µg/mL) between *Infanrix+Hiberix*, *Infanrix+ActHIB* and *Pentacel* after booster vaccination.
- Safety, reactogenicity: Clinically acceptable safety and reactogenicity profile in the different vaccination groups, aligned with the very well-known profiles of the study vaccines.

10. REFERENCES

Anderson P. The protective levels of serum antibodies to the capsular polysaccharide of *Haemophilus influenzae* type b. *J Infect Dis* 1984;149:1034-1035.

Camargo ME, et al. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. *J Clin Microbiol* 1984;20(4):772-4.

Centers for Disease Control and Prevention (CDC). Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States Through Universal Childhood Vaccination: Recommendations of the Immunisation Practices Advisory Committee (ACIP). *MMWR* 1991; 40(RR-13): 1-19.

Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunisation Practices (ACIP) and the American Academy of Family Physicians (AAFP). *MMWR* 2002, 51(RR02); 1-36.

Dhillon S. DTPa-HBV-IPV/Hib Vaccine (*Infanrix hexa*): A Review of its Use as Primary and Booster Vaccination. *Drugs* 2010; 70(8): 1021-58.

Diggle L, Deeks JJ, Pollard AJ. Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomized controlled trial. *BMJ* 2006;333(7568):571.

General recommendations on immunization—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Surveill Summ, 60 (2011), pp. 1–64. http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf. Accessed on 26 September 2013.

Granström M, Thoren M, Sato Y et al. Acellular Pertussis Vaccine in Adults: Adverse Reactions and Immune Response. *Eur J Clin Microbiol* 1987;6 (1):18-21.

GlaxoSmithKline Vaccines. m1.11.3 Efficacy information amendment – Responses to CBER comments on Infanrix study 135 model ICF update. 2014 – Page 9.

Kalies H, Grote V, Verstraeten T, et al. The Use of Combination Vaccines Has Improved Timeliness of Vaccination in Children. *Pediatr Infect Dis J* 2006;25(6):507-12.

Karpinsky KF, Hayward S and Tryphonas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). *J Immunol Methods* 1987;103:189-94.

Käyhty H, Peltola H, Karanko V and Makela PH. The protective level of serum antibodies to the capsular polysaccharide of *Haemophilus influenzae* type b. *J Infect Dis* 1983;147:1100.

Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralisation test in mice as a method for the estimation of tetanus antitoxin in human sera. *J Biol Stand* 1983;11:137-44.

117119 (DTPA-HBV-IPV-135) Report Final

World Health Organization (WHO). Progress in the control of viral hepatitis: memorandum for a WHO meeting. *Bull WHO* 1988;66:443-45.

World Health Organisation (WHO). Standard Procedure for Determining Immunity to Poliovirus using the Microneutralisation Test (*WHO*/EPI/GEN 93.9) 1993.

Zepp F, Schmitt HJ, Cleerbout J et al. Review of 8 years of experience with *Infanrix hexa* (DTPa-HBV-IPV/Hib hexavalent vaccine). *Expert Rev Vaccines* 2009;8(6):663-78.

Zinke M, Disselhoff J, Gartner B et al. Immunological persistence in 4–6 and 7–9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib. *Human vaccines* 2010;6(2):1-5.

Zuckerman JN. The importance of injecting vaccines into muscles. BMJ 2000;321:1.

11. STUDY REPORT AUTHORS /CONTRIBUTING AUTHORS

Scientific Writer: PPD

Statistician: PPD

Study Delivery Lead/Study Delivery Manager: PPD

Central Safety Contact: PPD

Clinical Read-Out Team Leader: PPD

Clinical Trial Supply Management Team: PPD

Clinical Research and Development Lead (CRDL): PPD

Regulatory Affairs representative: PPD

Clinical and Epidemiology R&D Project Leader (CEPL): PPD

12. SERIOUS ADVERSE EVENTS / OTHER SIGNIFICANT ADVERSE EVENTS / PREGNANCY

12.1. SAE Listing(s)

Table 8.46 and Table 8.80

12.2. Clinical narratives for SAEs

Confidential Clinical Narrative report with Both Serious & Non-Serious Events

Study Number: 117119
Study Center ID: PPD
Subject ID: PPD
Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: PPD Respiratory distress, Hyponatraemia

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [DTPa-HBV-IPV+Hib vaccine]:[Solution for injection] <Blank> <Blank>;[Prevnar 13]:[Solution for injection] <Blank> <B

Narrative: This 15-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 3rd dose of Infanrix hexa (intramuscular) on 15th October 2014, for prophylaxis. The subject received the 3rd dose of Prevnar 13 (intramuscular) on 15th October 2014, for prophylaxis. The subject received the 2nd dose of Rotavirus vaccine lyophilized formulation (oral) on 15th August 2014, for prophylaxis.

On PPD 277 days after receiving Infanrix hexa and Prevnar 13 and 338 days after receiving Rotavirus vaccine lyophilized formulation, the subject developed moderate - grade 2 respiratory distress. Serious criteria included hospitalization, GSK medically significant and life threatening. Additional event(s) included moderate - grade 2 hyponatremia on 19th July 2015 with serious criteria of hospitalization and life threatening and moderate - grade 2 PPD on 19th July 2015 19:30 with serious criteria of hospitalization, GSK medically significant and life threatening. The subject was treated with oxygen. The outcome of respiratory distress was recovered/resolved on 20th July 2015. The outcome(s) of the additional event(s) included hyponatremia (recovered/resolved on 20th July 2015) and PPD (recovered/resolved on 20th July 2015 14:30).

The investigator considered that there was no reasonable possibility that the respiratory distress, hyponatremia and PPD may have been caused by Infanrix hexa, Prevnar 13 and Rotavirus vaccine lyophilized formulation.

Relevant Tests: Chest X-Ray 07/19/2015: "CXR looks pretty clear but does have mild metabolic acidosis...."

Diagnostic results (unless otherwise stated, normal values were not provided): On 19th July 2015, Alanine aminotransferase result was 36 IU/L (normal low: 10, normal high: 35), Base excess result was -7 mmol/L (normal low: -2.5, normal high: 2.5), Blood bicarbonate result was 19 mmol/L (normal low: 22, normal high: 28), Blood creatine result was 0.25 mg/dL (normal low: 0.4, normal high: 0.7), Blood creatine result was less than 0.2 mg/dL (normal low: 0.4, normal high: 0.7), Blood glucose result was 112 mg/dL (normal low: 65, normal high: 99), Blood glucose result was 104 mg/dL (normal low: 65, normal high: 99),

Clinical Narrative report with Both Serious & Non-Serious Events

Blood sodium result was 133 mmol/L (normal low: 135, normal high: 145), Blood sodium result was 134 mmol/L (normal low: 135, normal high: 145), Mean platelet volume result was 8.2 fL (normal low: 9, normal high: 12), Oxygen saturation result was 93 % (normal low: 60, normal high: 80), PCO2 result was 34 mmHg (normal low: 41, normal high: 51), PO2 result was 68 mmHg (normal low: 30, normal high: 45) and Red cell distribution width result was 34.3 fL (normal low: 38, normal high: 49). On 20th July 2015, Blood creatine result was 0.23 mg/dL (normal low: 0.4, normal high: 0.7), Blood glucose result was 80 mg/dL (normal low: 65, normal high: 99) and Blood sodium result was 140 mmol/L (normal low: 135, normal high: 145).

Investigator's text:

20JUL2015 subject's mother contacted the office. Mother stated that the subject suffered a PPD episode on 19JUL2015. The subject was PPD Subject was taken to the hospital. Subject was just discharged.

21JUL2015 Study Coordinator contacted parent for more information. Parent states that the episode took place 19JUL2015 at approximately 19:30. Subject was PPD was unconscious and required CPR. Subject was given oxygen and taken by helicopter to the hospital. At the hospital, mother states that subject had an initial blood test and a second blood test prior to discharge. Subject also had a chest X-ray and parent was told by the doctor and a nurse that there was a small amount of water in the lung/s. No medications were given, per mother. Subject was hospitalized for observation and discharged the next day on 20JUL2015. At the time of this conversation, mother states that subject is doing well. She will be seen in clinic on Friday 24JUL2015.

28JUL2015-Additional information: When subject suffered the PPD episode and arrived at the hospital, mild respiratory distress was present. Oxygen was already being administered. Hospital blood lab test indicated mild hyponatremia, which resolved by the next day13AUG2015 Update: Blood laboratory results on the initial arrival to hospital on 19JUL2015 also showed the following; high levels of BUN/Creatinine Ratio, ALT, PO2 VBG, O2 Sat VBG. Low levels of RDW-SD, MPV, Creatinine, PCO2 VBG, HCO3 (Bicarb) VBG, Base Excess VBG. Per hospital report, chemistry was considered normal limits except for the expected low TCO2 due to acidosis and the hyperglycemia which was a stress reaction. The glucose and sodium levels returned to normal limits by the following day of 20JUL201519AUG2015-Information from paper SAE report: Discharge notification states: "PPD No apparent Neuro deficits. Initial mild respiratory distress resolved quickly."

31.07.2015: No reasonable possibility of a causal association with Rotarix, 338 days after vaccination. No reasonable possibility to be related to Infanrix Hexa vaccination

Study Number: 117119

Study Center ID: PPD

Subject ID: PPD

Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: Parainfluenzae virus infection

Non Serious Events:

Clinical Narrative report with Both Serious & Non-Serious Events

Suspect Product Name With Formulation, Dose, Units and Frequency: [Pentacel]:[Solution for injection] <Blank> <Blank> <Blank> ;[Hepatitis B vaccine]:[Solution for injection] <Blank> <Blank> <Blank> ;[Prevnar 13]:[Solution for injection] <Blank> <

Narrative: This 5-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 2nd dose of Pentacel (intramuscular) on 3rd September 2014, for prophylaxis. The subject received the 1st dose of Hepatitis B vaccine (intramuscular) 10 µg on 30th June 2014, for prophylaxis. The subject received the 2nd dose of Rotavirus vaccine lyophilized formulation (oral) on 3rd September 2014, for prophylaxis. The subject received the 2nd dose of Prevnar 13 (intramuscular) on 3rd September 2014, for prophylaxis.

On PPD 14:55, 5 days after receiving Pentacel, Rotavirus vaccine lyophilized formulation and Prevnar 13 and 70 days after receiving Hepatitis B vaccine, the subject developed moderate - grade 2 parainfluenzae virus infection. Serious criteria included hospitalization and GSK medically significant. The subject was treated with azithromycin. The outcome of parainfluenzae virus infection was recovered/resolved on 10th October 2014.

The investigator considered that there was no reasonable possibility that the parainfluenzae virus infection may have been caused by Pentacel, Hepatitis B vaccine, Rotavirus vaccine lyophilized formulation and Prevnar 13.

Relevant Tests: Respiratory Panel PCR positive for Parainfluenza. Rotavirus and bordetella pertussis testing negative. Workup in the ED include stool culture, urine culture, CBC and blood culture. CBC was reassuring, UA was normal, and cultures all returned negative Diagnostic results (unless otherwise stated, normal values were not provided): On 3rd October 2014, Blood calcium result was 10.6 mg/dL (normal low: 8.6, normal high: 10.5) and Blood urea result was 2 mg/dL (normal low: 5, normal high: 20).

Investigator comments:

Subject is a 5 month old female brought in to the ED today due to chronic diarrhea and dehydration. Per review of EMR, when baby was 4 month of age (Sep 3rd), child presented to our clinic for well child care. Mother reported concern of decreased po intake (breastfeeding per notes), thus mother started supplementing with formula. At that visit subject was immunized (including rotavirus) and was diagnosed with nasal congestion, but otherwise normal well child exam. One week later (Sep 10) she presented to primary care provider with complaint of vomiting and diarrhea x 2 days (onset sep 8), with report of 12 loose stools w/o blood in a 24 hr period and 6 episodes of non bloody emesis and temp to 103. Of note there are ill contacts with grandmother and sibling having cough and runny nose. Child appeared well and playful on physical exam was sent home with diagnosis of acute gastroenteritis with reassurance and instructions to come back if fever persisted or if there were signs of dehydration

with reassurance and instructions to come back if fever persisted or if there were signs of dehydration. Subject remained ill, mother called PCC Sep 12 due to persistent symptoms, they direct them to the ED. In the ED parents report vomiting has resolved, but diarrhea persists consisting of 2 stools per hr, stools are mucosy and runny, and some upper respiratory symptoms including sneezing and mild cough. Her sibling also has URI. Workup in the ED include stool culture, urine culture, CBC and blood culture. CBC was reassuring, UA was normal, and cultures all returned negative, she was sent home with diagnosis of viral illness.

Clinical Narrative report with Both Serious & Non-Serious Events

On sep 23 she returns to primary care provider with what is reported in EMR as new onset cough, rhinorrhea and fever x 3 days (however mother has reported to us in phone calls diarrhea and fever have persisted since onset September 8th). Today subject presents again to ED due to vomiting and diarrhea again, and admitted due to chronic diarrhea, concerns for pertussis and dehydration. More extensive testing is ordered today, O and P, rotavirus, viral culture, BMP and pertussis PCR and cultures. Child is being admitted on 10/3/14, was started on azythromycin and admitted for further observation. Subject tested negative for bordetella pertussis and also rotavirus. Subject tested positive for parainfluenza. During hospitalization patient was stable on room air with stable vital signs. Patient did continue to have loose stool while in hospital but prior to discharge seemed to be decreasing in frequency/amount. At time of discharge on 10/5/2014 patient appeared well hydrated, stable vitals, on room air with improved feeding. Subject was instructed to continue Azithromycin course for 2 more days following discharge and follow up with PCP. Originally it was determined that the SAE was possibly related to the Investigational Product. Now that more tests have been run, a diagnosis of parainfluenza was made and more data gathered it has been decided by the PI that this SAE is not related the IP.

Study Number: 117119

Study Center ID: PPD

Subject ID: PPD

Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: Respiratory syncytial virus bronchiolitis

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [Hepatitis B vaccine]:[Solution for injection] <Blank> <Blan

Narrative: This 11-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 2nd dose of Hepatitis B vaccine (intramuscular) 10 µg on 26th September 2014, for prophylaxis. The subject received the 2nd dose of Pentacel (intramuscular) on 26th September 2014, for prophylaxis. The subject received the 2nd dose of Rotavirus vaccine lyophilized formulation (oral) on 8th July 2014, for prophylaxis. The subject received the 3rd dose of Prevnar 13 (intramuscular) on 26th September 2014, for prophylaxis.

On PPD 140 days after receiving Hepatitis B vaccine, Pentacel and Prevnar 13 and 220 days after receiving Rofavirus vaccine lyophilized formulation, the subject developed mild - grade 1 respiratory syncytial virus bronchiolitis. Serious criteria included hospitalization and GSK medically significant. The subject was treated with prednisolone, salbutamol sulfate (Albuterol Sulfate), oxygen, amoxicillin and salbutamol (Albuterol). Pentacel was continued with no change. Prevnar 13 was continued with no change. The outcome of respiratory syncytial virus bronchiolitis was recovered/resolved on 23rd

Clinical Narrative report with Both Serious & Non-Serious Events

February 2015.

The investigator considered that there was no reasonable possibility that the respiratory syncytial virus bronchiolitis may have been caused by Hepatitis B vaccine, Pentacel, Rotavirus vaccine lyophilized formulation and Prevnar 13.

Relevant Tests: WBC - 2/14/15 - 13.0 T/MM3; Influenza A and B Swab - 2/14/15 - Negative; Respiratory Virus Antigen Screen - 2/14/15 - Positive; CXR - 2/14/15 - No Focal Pneumonia

INVESTIGATOR TEXT

Pt presented to hospital with fever, cough and respiratory distress. Pt found to be RSV positive and hypoxic. Subject was admitted to hospital on 2/14/15. She was started on O2, breathing treatments, steroids and IV fluids. Subject improved overnight and was discharged from hospital on 2/15/15. Upon discharge subject continued nebulizer treatments and steroids. RSV resolved 2/23/15.

PP 04.02.2016: TTO 220 days makes causal relationship between Rotarix and LRTI unlikely.

Study Number: 117119

Study Center ID: PPD

Subject ID: PPD

Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: Febrile convulsion

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [Pentacel]:[Solution for injection] <Blank> <Blank> ;[Hepatitis B vaccine]:[Solution for injection] 10 mcg <Blank>;[Prevnar 13]:[Solution for injection] <Blank> <Blank> <Blank> ;[Rotavirus vaccine lyophilized formulation]:[Oral drops] <Blank> <Blank> <Blank>

Narrative: This 29-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 2nd dose of Pentacel (intramuscular) on 15th August 2014, for prophylaxis. The subject received the 1st dose of Hepatitis B vaccine (intramuscular) 10 mcg on 30th May 2014, for prophylaxis. The subject received the 2nd dose of Prevnar 13 (intramuscular) on 15th August 2014, for prophylaxis. The subject received the 2nd dose of Rotavirus vaccine lyophilized formulation (oral) on 15th August 2014, for prophylaxis.

Concurrent medical conditions included fever and urinary tract infection.

On PPD 33 days after receiving Pentacel, Prevnar 13 and Rotavirus vaccine lyophilized formulation, 110 after the 1st dose of Hepatitis B vaccine, the subject developed severe - grade 3 febrile seizure. Serious criteria included hospitalization and GSK medically significant. The subject was treated

Clinical Narrative report with Both Serious & Non-Serious Events

with ceftriaxone (Rocephin), paracetamol (Tylenol) and cefdinir (Omnicef). The outcome of febrile seizure was recovered/resolved on 18th September 2014.

The investigator considered that there was no reasonable possibility that the febrile seizure may have been caused by Pentacel, Hepatitis B vaccine, Prevnar 13 and Rotavirus vaccine lyophilized formulation.

Relevant Tests: Urine Culture 18SEP2014 positive for greater than 100,000 colonies of E.Coli Renal Sonogram 19SEP2014 Trace perihepatic fluid found and minimal debris found within the bladder. Diagnostic results (unless otherwise stated, normal values were not provided): On 18th September 2014, White blood cell count result was 31.3 k/mcl (normal low: 4.8, normal high: 10.8).

INVESTIGATOR TEXT

Subject had fever starting 9/17/14. Febrile seizure on the morning of 9/18/14 and was admitted to the hospital for futher workup. Fever started 09/17/2014-went to ER was diagnosed with viral infection. Baby had a Febrile Seizure 09/18/2014-mom called PPD and went back to ER. Blood work(CBC) showed high WBC. Urinalysis was abnormal. Baby was admitted to the hospital 09/18/2014. Started IV fluids and Rocephin IV. Tylenol po for fever. Renal sonogram performed-debris found with in bladder and trace perihepatic fluid found-seen with UTI. Baby was discharged on 09/19/2014 with fever resolved. Sent home on Omnicef for UTI. Rechecked in clinic after finishing abx-UTI resolved 29SEP2014 after finishing Omnicef.

Likely causation intercurrent febrile medical condition_UTI

Study Number: 117119

Study Center ID: PPD

Subject ID: PPD

Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: Gastroenteritis viral

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [DTPa-HBV-IPV+Hib vaccine]:[Solution for injection] <Blank> <Blank> ;[Prevnar 13]:[Solution for injection] <Blank> <Blank> ;[Rotavirus vaccine lyophilized formulation]:[Oral drops] <Blank> <Blank> <Blank>

Narrative: This 8-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 3rd dose of Infanrix hexa (intramuscular) on 4th November 2014, for prophylaxis. The subject received the 2rd dose of Rotavirus vaccine lyophilized formulation (oral) on 2rd September 2014, for prophylaxis.

On PPD 64 days after receiving Infanrix hexa and Prevnar 13 and 127 days after receiving

Clinical Narrative report with Both Serious & Non-Serious Events

Rotavirus vaccine lyophilized formulation, the subject developed severe - grade 3 viral gastroenteritis. Serious criteria included hospitalization. The subject was treated with paracetamol (Tylenol), ondansetron (Zofran), sodium chloride and glucose, potassium nos, sodium chloride (Dextrose + Sodium + Potassium). The outcome of viral gastroenteritis was recovered/resolved on 12th January 2015.

The investigator considered that there was no reasonable possibility that the viral gastroenteritis may have been caused by Infanrix hexa, Prevnar 13 and Rotavirus vaccine lyophilized formulation. Diagnostic results (unless otherwise stated, normal values were not provided): On 8th January 2015, Blood calcium result was 9.6 mg/dL (normal low: 9, normal high: 11), Blood chloride result was 105.00 mmol/L (normal low: 96, normal high: 105), Blood creatine result was 0.3 mg/dL (normal low: 0.4, normal high: 1.1), Blood glucose result was 73 mg/dL (normal low: 60, normal high: 100), Blood potassium result was 5.1 mmol/L (normal low: 3.7, normal high: 5.6), Blood sodium result was 138 mmol/L (normal low: 132, normal high: 140), Blood urea result was 14 mg/dL (normal low: 10, normal high: 18) and Carbon dioxide result was 21.0 mmol/L (normal low: 20, normal high: 28).

Investigator Comments:

Patient presented to the ER on 1/8/2015 with a 1 day history of decreased po intake, decreased urine output, 2 episodes of emesis and about 6 loose stools in 24 hours. Based on the history and physical exam, the ER physician diagnosed the patient with viral gastroenteritis and admitted her for IV fluids. In the ER, they gave her a normal saline bolus and then started her on maintenance IV fluids. They also gave her Zofran as needed for nausea/vomiting and Tylenol as needed for fever. The patient was discharged on 1/9/2015

No data on laboratory testing.

Study Number: 117119

Study Center ID: PPD

Subject ID: PPD

Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: Seizure, Gastrooesophageal reflux disease, Choking

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [DTPa-HBV-IPV+Hib vaccine]:[Solution for injection] <Blank> <Blank> ;[Prevnar 13]:[Solution for injection] <Blank> <Blank> ;[Rotavirus vaccine lyophilized formulation]:[Oral drops] <Blank> <Blank> <Blank> |

Narrative: This 10-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 3rd dose of Infanrix hexa on 25th September 2014, for prophylaxis. The subject received the 3rd dose of Prevnar 13 on 25th September 2014, for prophylaxis. The subject received the 2nd dose of Rotavirus vaccine lyophilized formulation on 30th July 2014, for prophylaxis.

Clinical Narrative report with Both Serious & Non-Serious Events

On PPD 23:00, 140 days after receiving Infanrix hexa and Prevnar 13 and 197 days after receiving Rotavirus vaccine lyophilized formulation, the subject developed moderate - grade 2 seizure. Serious criteria included hospitalization and GSK medically significant. Additional event(s) included moderate - grade 2 gastroesophageal reflux on 19th February 2015 23:00 with serious criteria of hospitalization and moderate - grade 2 choking on 19th February 2015 23:00 with serious criteria of hospitalization and GSK medically significant. The outcome of seizure was recovered/resolved on 13th February 2015 16:23. The outcome(s) of the additional event(s) included gastroesophageal reflux (recovered/resolved on 21st February 2015 14:30).

The investigator considered that there was no reasonable possibility that the seizure, gastroesophageal reflux and choking may have been caused by Infanrix hexa, Prevnar 13 and Rotavirus vaccine lyophilized formulation.

Relevant Tests: CXR normal, Abdominal x-ray normal. EKG normal. Head CT normal. All completed on 2/13/15 GI series without KUB: Gastroesophageal reflux intermittent to the midesophagus (2/21/15). EEG normal (2/21/15)

Study Number: 117119

Study Center ID: PPD

Subject ID: PPD

Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: Petechiae

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [DTPa vaccine]:[Solution for injection] <Blank> <Blank> <Blank> ;[Haemophilus influenzae type b vaccine]:[Solution for injection] <Blank> <B

Narrative: This 16-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 1st dose of DTPa vaccine (intramuscular) on 13th July 2015, for prophylaxis. The subject received the 1st dose of Haemophilus influenzae type b vaccine (intramuscular) on 13th July 2015, for prophylaxis. The subject received the 3rd dose of Infanrix hexa (intramuscular) on 25th September 2014, for prophylaxis. The subject received the 2nd dose of Rotavirus vaccine lyophilized formulation (oral) on 30th July 2014, for prophylaxis. The subject received the 3rd dose of Prevnar 13 (intramuscular) on 25th September 2014, for prophylaxis.

Clinical Narrative report with Both Serious & Non-Serious Events

The subject's past medical history included seizures, gastroesophageal reflux, alte and choking.

On PPD 12:40, 19 days after receiving DTPa vaccine and Haemophilus influenzae type b vaccine, 310 days after receiving Infanrix hexa and Prevnar 13 and 1 year and 2 days after receiving Rotavirus vaccine lyophilized formulation, the subject developed moderate - grade 2 petechial rash. Serious criteria included hospitalization. The outcome of petechial rash was recovered/resolved on 13th October 2015 10:15.

The investigator considered that there was no reasonable possibility that the petechial rash may have been caused by DTPa vaccine, Haemophilus influenzae type b vaccine, Infanrix hexa, Rotavirus vaccine lyophilized formulation and Prevnar 13.

Diagnostic results (unless otherwise stated, normal values were not provided): On 1st August 2015, Full blood count result was normal, Metabolic function test result was normal, Platelet count result was normal and Prothrombin time ratio result was normal.

Investigator Text:

Subject seen in our office on 8/1/15 for petechial rash. Sent to ER for work up and further evaluation and admission. All labs WNL. Discharged 8/3/15. Subject was seen in our office on 10/13/15 for a routine scheduled exam. Petechial rash was resolved, healthy exam noted. Subjects admission date was on 01Aug2015, discharge date of 03Aug15. Reported SAE of possible seizure on 2/12/15 is possibly related to ALTE on same date. All diagnostic testing were within normal limits

There is no description on the location of the petechial rash, nevertheless, laboratory results do not indicate a low platelet count nor other abnormal values PT/PTT, blood count, or alteration in other biochemichal parameters, these results argue against an immune mediated thrombocytopenia PP 17.01.2016: unlikely causal relationship with Rotarix over a year after vaccination

Study Number: 117119

Study Center ID: PPD

Subject ID: PPD

Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: Respiratory syncytial virus infection, Parainfluenzae virus infection, Pneumonia

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [Hepatitis B vaccine]:[Solution for injection] <Blank> <Blank> <Blank>;[Rotavirus vaccine lyophilized formulation]:[Oral drops] <Blank> <Blank> <Blank>;[Pentacel]:[Solution for injection] <Blank>
Narrative: This 11-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 2nd dose of Hepatitis B

Clinical Narrative report with Both Serious & Non-Serious Events

vaccine (intramuscular) 10 µg on 29th September 2014, for prophylaxis. The subject received the 2nd dose of Rotavirus vaccine lyophilized formulation (oral) on 29th July 2014, for prophylaxis. The subject received the 3rd dose of Prevnar 13. (intramuscular) on 29th September 2014, for prophylaxis. The subject received the 3rd dose of Pentacel (intramuscular) on 29th September 2014, for prophylaxis.

On PPD 152 days after receiving Hepatitis B vaccine, Prevnar 13. and Pentacel and 214 days after receiving Rotavirus vaccine lyophilized formulation, the subject developed severe - grade 3 respiratory syncytial virus infection. Serious criteria included hospitalization. Additional event(s) included moderate - grade 2 parainfluenzae virus infection on 28th February 2015 with serious criteria of hospitalization and GSK medically significant and moderate - grade 2 community acquired pneumonia on 6th March 2015 with serious criteria of hospitalization and GSK medically significant. The subject was treated with glucose + potassium chloride + sodium chloride (5% Dextrose 1/2 Normal Saline With 20 Meq Of Kcl), amoxicillin, ampicillin, oxygen, ibuprofen (Children'S Motrin), ketorolac trometamol (Toradol), salbutamol (Albuterol) and paracetamol (Tylenol Childrens). The outcome of respiratory syncytial virus infection was recovered/resolved on 13th March 2015. The outcome(s) of the additional event(s) included parainfluenzae virus infection (recovered/resolved on 11th March 2015).

The investigator considered that there was no reasonable possibility that the respiratory syncytial virus infection, parainfluenzae virus infection and community acquired pneumonia may have been caused by Hepatitis B vaccine, Rotavirus vaccine lyophilized formulation, Prevnar 13. and Pentacel.

Relevant Tests: chest x-ray results suggested a possible right sided perihelia pneumonia. Blood Culture was done with no growth in nine hours. This was done on 3/6/2015 Diagnostic results (unless otherwise stated, normal values were not provided): On 7th March 2015, Band neutrophil count result was 18 %, C-reactive protein result was 7.6 % (normal low: 1, normal high: 3), Haematocrit result was 32.3 % (normal low: 33, normal high: 39), Haemoglobin result was 10.6 g (normal low: 10.5, normal high: 13.5), Neutrophil count result was 37 % (normal low: 1.5, normal high: 5), Platelet count result was 396 cells/mm3 (normal low: 300, normal high: 750) and White blood cell count result was 13.5 cells/mm3 (normal low: 6, normal high: 17).

INVESTIGATOR COMMENTS

Per mom symptoms started on 28FEB2015 and became sever enough that they took subject to the hospital on 06MAR2015 where subject was treated and diagnosed with Respiratory Syncytial Virus, Para Influenza, Pneumonia. Subject was released on 11MAR2015 from the hospital. Per mom subject is feeling much better and symptoms are resolved today on 13MAR2015. Symptoms on admit were Respiratory distress, hypoxia, bronchiolitis. Was placed on oxygen via nasal- cannula. Patient was placed on a Biphasic Intermittent Positive Airway Pressure and nasal gastric tube. Then was placed on continuous positive airway pressure and then went to high flow nasal cannula for 3 days. Then improved and was returned to regular nasal cannula. patient was discharged to home on room air and oral antibiotics. The time to onset is not consistent with a vaccine-related effect.

Study Number: 117119

Study Center ID: PPD

Subject ID: PPD

Randomization Number: UNKNOWN

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Report Final

Confidential

Clinical Narrative report with Both Serious & Non-Serious Events

Case ID: PPD

Serious Events: Gastroenteritis viral

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [DTPa-HBV-IPV vaccine]:[Solution for injection] <Blank> <Blank> <Blank>;[ActHIB]:[Solution for injection] <Blank> <Blank> <Blank> <Blank> ;[Rotavirus vaccine lyophilized formulation]:[Oral drops] <Blank> <Blank> <Blank> <Blank>

Narrative: This 8-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 3rd dose of DTPa-HBV-IPV vaccine (intramuscular) on 5th November 2014, for prophylaxis. The subject received the 3rd dose of Prevnar 13 (intramuscular) on 5th November 2014, for prophylaxis. The subject received the 2nd dose of Rotavirus vaccine lyophilized formulation (oral) on 29th August 2014, for prophylaxis.

On PPD 63 days after receiving DTPa-HBV-IPV vaccine, ActHIB and Prevnar 13 and 131 days after receiving Rotavirus vaccine lyophilized formulation, the subject developed severe - grade 3 viral gastroenteritis. Serious criteria included hospitalization. The subject was treated with paracetamol (Acetaminophen), ondansetron (Zofran) and d5 1/2 normal saline + potassium chloride. The outcome of viral gastroenteritis was recovered/resolved on 12th January 2015.

The investigator considered that there was no reasonable possibility that the viral gastroenteritis may have been caused by DTPa-HBV-IPV vaccine, ActHIB, Prevnar 13 and Rotavirus vaccine lyophilized formulation.

Relevant Tests: BUN/CREATININE RATIO on10JAN2015 was 48.00 (Normal 7.00-25.00) Diagnostic results (unless otherwise stated, normal values were not provided): On 10th January 2015, Blood chloride result was 123 mmol/L (normal low: 97, normal high: 109), Blood creatine result was 0.50 mg/dL (normal low: 0.7, normal high: 1.2), Blood glucose result was 44 mg/dL (normal low: 65, normal high: 125), Blood sodium result was 144 mmol/L (normal low: 135, normal high: 145) and Blood urea result was 24 mg/dL (normal low: 4, normal high: 15).

Investigator comments:

Subject started having Vomiting, diaarhea and dehydration on January 7, 2015. Subject admitted to ER on January 10, 2015 with a diagnosis of Viiral Gastroenteritis and Dehydration. Subject discharged from hospital on January 12, 2015. -

Report of dehydration from acute gastroenteritis 4.4 months after 2nd dose Rotarix vaccination. Recovery under a week with medical intervention. Viral cause diagnosed. No stool test confirmation.

Study Number: 117119

Study Center ID: PPD

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Report Final

Confidential

Clinical Narrative report with Both Serious & Non-Serious Events

Subject ID: PPD

Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: Dehydration

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [Pentacel]:[Solution for injection] <Blank> <Blank> <Blank>;[Prevnar 13]:[Solution for injection] <Blank> <Blank> <Blank> ;[Hepatitis B vaccine]:[Solution for injection] <Blank> <Blank> <Blank> ;[Rotavirus vaccine lyophilized formulation]:[Oral drops] <Blank> <Blank> <Blank> <Blank>

Narrative: This 6-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 2nd dose of Pentacel (intramuscular) on 4th August 2014, for prophylaxis. The subject received the 1st dose of Hepatitis B vaccine (intramuscular) 10 on 2nd June 2014, for prophylaxis. The subject received the 2nd dose of Rotavirus vaccine lyophilized formulation (intramuscular) on 4th August 2014, for prophylaxis.

Concurrent medical conditions included gastroenteritis.

On PPD 68 days after receiving Pentacel, Prevnar 13 and Rotavirus vaccine lyophilized formulation and 131 days after receiving Hepatitis B vaccine, the subject developed moderate - grade 2 dehydration. Serious criteria included hospitalization. The subject was treated with Iv Fluids-Sodium Chloride. The outcome of dehydration was recovered/resolved on 14th October 2014.

The investigator considered that there was no reasonable possibility that the dehydration may have been caused by Pentacel, Prevnar 13, Hepatitis B vaccine and Rotavirus vaccine lyophilized formulation.

Relevant Tests: Viral panel positive for pertussis, adenovirus, rhinovirus. the date for this was 10/13/14.

Investigator Comment:

Per mom child has been vomiting quite a bit lately (11 Oct 2014). Child was taken to the ER last night (12 Oct 2014). They ran some tests there. (We are awaiting the results of these tests at this time). Per mother Diaper has been dry for the last 5 hours or so. Per mother child is listless and lethargic. Therefore Dr. felt it was in the best interest of the child to admit to the hospital for IV therapy for dehydration. will report other information as we receive it.

Study Number: 117119

Study Center ID: PPD

Subject ID: PPD

Clinical Narrative report with Both Serious & Non-Serious Events

Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: Lethargy

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [DTPa-HBV-IPV+Hib vaccine]:[Solution for injection] <Blank> <Blank> ;[Prevnar 13]:[Solution for injection] <Blank> <Blank> ;[Rotavirus vaccine lyophilized formulation]:[Oral drops] <Blank> <Blank> <Blank> |

Narrative: This female subject was enrolled in the prophylactic open study 117119 (DTPA-HBV-IPV-135). On 01 July 2014, she received a 1st dose of combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio, Haemophilus influenzae type b vaccine (Infanrix hexa), Pfizer's 13 valent pneumococcal vaccine (Prevenar 13) and rotavirus vaccine (Rotarix lyophilized formulation).

On PPD approximately 6 hours after the 1st dose of Infanrix hexa, approximately 6 hours after the 1st dose of Prevnar 13, and approximately 6 hours after the 1st dose of Rotarix lyophilized formulation, this two-month-old subject developed lethargy event. The subject was hospitalised. The event resolved on 01 July 2014. The investigator considered that there was a reasonable possibility that the lethargy event may have been caused by Infanrix hexa, Prevnar 13 and Rotarix lyophilized formulation. The subject was withdrawn from the study due to this event.

Investigator text:

Baby was given vaccines at 10:20 this morning. At approximately 16:00. Baby was noted by mother to be blue around the lips baby was aroused, and then had 2 more times that this happened and at that time mother noted baby appeared to have some floppiness. Mother also noted some short breathing patterns and it appeared that the baby was having a hard time expelling air. Brought into the Clinic to be examined by the MD. Per exam, it was normal at that time. Baby was admitted to the hospital for observation at this time. No treatment or labs completed. It was observation only. Per the Principal Investigator this SAE is possibly related as there is noted to be a possibility of an lethargic event after episodes that can be traumatic to infants under 3 months of age. It was not a cyanosis, the baby was somewhat hyporesponsive and there was some hypotonia. There is no seizure disorder noted or a family history of seizure disorder.

Study Number: 117119

Study Center ID: PPD

Subject ID: PPD

Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: Dehydration

Non Serious Events:

Clinical Narrative report with Both Serious & Non-Serious Events

Suspect Product Name With Formulation, Dose, Units and Frequency: [DTPa-HBV-IPV+Hib vaccine]:[Solution for injection] <Blank> <Blank> <Blank>;[Haemophilus influenzae type b vaccine]:[Solution for injection] <Blank> <Blank> <Blank> ;[Rotavirus vaccine lyophilized formulation]:[Oral drops] <Blank> <Blan

Narrative: This 16-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 3rd dose of Infanrix hexa (intramuscular) on 10th November 2014, for prophylaxis. The subject received the 1st dose of Haemophilus influenzae type b vaccine (intramuscular) on 30th July 2015, for prophylaxis. The subject received the 2nd dose of Rotavirus vaccine lyophilized formulation (oral) on 15th September 2014, for prophylaxis. The subject received the 1st dose of DTPa vaccine (intramuscular) on 30th July 2015, for prophylaxis. The subject received the 3rd dose of Prevnar 13. (intramuscular) on 10th November 2014, for prophylaxis.

Concomitant products included paracetamol (Tylenol).

On PPD 303 days after receiving Infanrix hexa and Prevnar 13., 41 days after receiving Haemophilus influenzae type b vaccine and DTPa vaccine and 359 days after receiving Rotavirus vaccine lyophilized formulation, the subject developed severe - grade 3 dehydration. Serious criteria included hospitalization. The subject was treated with glucose + potassium chloride + sodium chloride (5% Dextrose + 0.9% Sodium Chloride + 20 Meq Potassium Chloride), sodium chloride (Normal Saline Bolus) and ondansetron (Zofran). The outcome of dehydration was recovered/resolved on 11th September 2015.

The investigator considered that there was no reasonable possibility that the dehydration may have been caused by Infanrix hexa, Haemophilus influenzae type b vaccine, Rotavirus vaccine lyophilized formulation, DTPa vaccine and Prevnar 13..

Relevant Tests: CBC was with in normal limits.

Investigator comments:

Patient fell and hit head on the evening of 9/8/2015. Was acting fine that night . on the morning of 9/9/2015 patient started vomiting. Seen in clinic about noon and physician told mother to call with concerns if not improved later in the evening. Mother call into the clinic and talked to MD. and patient was admitted to the hospital for dehydration. Patient was started on IV therapy. Per physician he feels the dehydration is a stomach virus as there are other family members that are starting to exhibit the same symptoms today (9/10/2015). The head injury and vomiting will be listed as A/E. Patient was discharged from the hospital 9/11/2015.

15.09.2015: Onset about a year after Rotarix makes causal relationship unlikely. The report suggests a gastroenteritis due to an infectious agent may be responsible for the child's symptoms.

Study Number: 117119

Study Center ID: PPD

Subject ID: PPD

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Report Final

Confidential Clinical Narrative report with Both Serious & Non-Serious Events

Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: Apparent life threatening event, Leukocytosis

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [DTPa-HBV-IPV+Hib vaccine]:[Solution for injection] <Blank> <Blank> ;[Prevnar 13]:[Solution for injection] <Blank> <Blank> ;[Rotavirus vaccine lyophilized formulation]:[Oral drops] <Blank> <Blank> <Blank>

Narrative: This 2-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 1st dose of DTPa-HBV-IPV+Hib vaccine (intramuscular) on 9th July 2014, for prophylaxis. The subject received the 1st dose of Prevnar 13 (intramuscular) on 9th July 2014, for prophylaxis. The subject received the 1st dose of Rotavirus vaccine lyophilized formulation (oral) on 9th July 2014, for prophylaxis.

On PPD less than a day after receiving DTPa-HBV-IPV+Hib vaccine, Prevnar 13 and Rotavirus vaccine lyophilized formulation, the subject developed moderate - grade 2 apparent life threatening event. Serious criteria included hospitalization, GSK medically significant and life threatening. Additional event(s) included mild - grade 1 leukocytosis on 9th July 2014 with serious criteria of hospitalization and life threatening. DTPa-HBV-IPV+Hib vaccine was continued with no change. Prevnar 13 was continued with no change. The action taken with Rotavirus vaccine lyophilized formulation was unknown. The outcome of apparent life threatening event was recovered/resolved on 9th July 2014. The outcome(s) of the additional event(s) included leukocytosis (recovered/resolved on 10th July 2014).

The investigator considered that there was a reasonable possibility that the apparent life threatening event and leukocytosis may have been caused by DTPa-HBV-IPV+Hib vaccine, Prevnar 13 and Rotavirus vaccine lyophilized formulation.

Relevant Tests: CBC with manual Difficile which showed white blood count that was slightly elevated at 20,000 and a little mildly elevated lactic acid. and urine culture and blood culture was negative so far. CRP was 20 but on the normal level would be 2. Diagnostic results (unless otherwise stated, normal values were not provided): On an unknown date, Blood culture result was negative unknown. On an unknown date, C-reactive protein result was 20 unknown. On an unknown date, Culture urine result was negative unknown. On an unknown date, White blood cell count result was 20000 unknown.

Investigator comments: On the evening of the 09 July 2014 baby was very irritable then finally went to sleep. Mom went to check on the baby and the skin was pale and the lips were pale, breathing was noted to be very shallow and baby tried to go back to sleep. Lips were not blue at all. Mom states that the baby acts like she is trying to let out a big cry and can't quite get it out. Was instructed by the afterhours nurse on call to take baby to the ER to be evaluated. Baby was taken in and from there admitted to the hospital. Baby did well with some mild fussiness and decreased stooling. Was discharged from the hospital on 10 July 2014. Baby is to return to the clinic for a check up on 11 July 2014. Mom also reported limp floppy extremities. This didn't occur after breast feeding or immediately after. No relevant medical history. No history of seizure disorder in family. No x-rays taken. Due to the time frame of onset and the test results it

Clinical Narrative report with Both Serious & Non-Serious Events

is determined by the PI to be related.

Report of life-threathening event occuring in 2 month old within 24 hours of Rotavirus vaccination. Co-administered vaccines DTPa-HBV-IPV+Hib and Prevenar. Clinical picture vague, but included limp floppy extremities, irritability and leucocytosis of 20,000 (unit of measure unknown). Hospitalised and discharged the next day with review to follow at subsequent outpatient visit. No information about intervention measures or treatment. Insufficient information for case definition/causality assessment

Study Number: 117119

Study Center ID: PPD

Subject ID: PPD

Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: Respiratory distress, Hypoxia

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [DTPa-HBV-IPV+Hib vaccine]:[Solution for injection] <Blank> <Blank> ;[Prevnar 13]:[Solution for injection] <Blank> <Blank> ;[Rotavirus vaccine lyophilized formulation]:[Oral drops] <Blank> <Blank> <Blank> |

Narrative: This 11-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 3rd dose of Infanrix hexa (intramuscular) on 11th November 2014, for prophylaxis. The subject received the 2rd dose of Rotavirus vaccine lyophilized formulation (oral) on 11th September 2014, for prophylaxis.

Concurrent medical conditions included bronchiolitis.

On PPD 163 days after receiving Infanrix hexa and Prevnar 13 and 224 days after receiving Rotavirus vaccine lyophilized formulation, the subject developed severe - grade 3 respiratory distress. Serious criteria included hospitalization and GSK medically significant. Additional event(s) included severe - grade 3 hypoxia on 24th April 2015 with serious criteria of hospitalization and GSK medically significant. The subject was treated with salbutamol (Albuterol), prednisolone sodium phosphate (Orapred), oxygen, glucose, potassium nos, sodium chloride (Dextrose + Saline + Potassium), methylprednisolone sodium succinate (Solumedrol) and paracetamol (Tylenol). The outcome of respiratory distress was recovered/resolved on 30th April 2015. The outcome(s) of the additional event(s) included hypoxia (recovered/resolved on 25th April 2015).

The investigator considered that there was no reasonable possibility that the respiratory distress and hypoxia may have been caused by Infanrix hexa, Prevnar 13 and Rotavirus vaccine lyophilized formulation.

Clinical Narrative report with Both Serious & Non-Serious Events

Relevant Tests: Chest x-ray on 04/24/2015: Defined opacity in right lower lung concerning for pneumonia. Respiratory Film Array PCR: Rhinovirus is detected.

INVESTIGATOR TEXT

Subject was admitted to hospital on 04/24/2015 after he was treated in the emergency room on 04/24/2015. Medical history: 1-2 days prior had history of congestion, cough and started wheezing. Parent brought subject into the clinic and subject has low oxygen saturations of 70 to 80. Nurse practioner sent subject to the emergency room after giving a albuterol nebulizer treatment. At the emergency room subject was stabilized with continuous albuterol treatments and admitted to the hospital for continued care. Once admitted, albuterol treatments and oxygen were continuous for approximately 12 hours then subject was weaned down to albuterol treatments every 2 hours and oxygen was rapidly weaned to room air. At discharge, parent was to continue albuterol treatments every 4 hours as needed. No oxygen for home. Subject discharged to home on 04/25/2015.

The time to onset from vaccination of 163 days is not consistent with a vaccine-related effect.

Study Number: 117119

Study Center ID: PPD

Subject ID: PPD

Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: Seizure like phenomena

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [Hepatitis B vaccine]:[Solution for injection] <Blank> <Blank> <Blank>;[Rotavirus vaccine lyophilized formulation]:[Oral drops] <Blank> <Blank> <Blank>;[Pentacel]:[Solution for injection] <Blank>
Narrative: This 15-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 4th dose of Pentacel (intramuscular) on 30th July 2015, for prophylaxis. The subject received the 2nd dose of Hepatitis B vaccine (intramuscular) 10 ug on 30th October 2014, for prophylaxis. The subject received the 2nd dose of Prevnar 13 (intramuscular) on 30th October 2014, for prophylaxis. The subject received the 2nd dose of Rotavirus vaccine lyophilized formulation (intramuscular) on 19th August 2014, for prophylaxis.

On PPD 25 days after receiving Pentacel, 298 days after receiving Hepatitis B vaccine and Prevnar 13 and 1 year and 5 days after receiving Rotavirus vaccine lyophilized formulation, the subject developed moderate - grade 2 seizure like phenomena. Serious criteria included hospitalization and GSK medically significant. The subject was treated with lidocaine, levetiracetam (Keppra (Levetiracetam)), Keppra, glucose, sodium chloride (5% Dextrose + Sodium Chloride Solution), ketamine and dexmedetomidine hydrochloride (Precedex). The outcome of seizure like phenomena was

Clinical Narrative report with Both Serious & Non-Serious Events

recovered/resolved on 1st September 2015.

The investigator considered that there was no reasonable possibility that the seizure like phenomena may have been caused by Pentacel, Hepatitis B vaccine, Prevnar 13 and Rotavirus vaccine lyophilized formulation.

Relevant Tests: Renal Function Panel Results: Abnormal, Albumin 5.0 (H), range (3.0- 4.8 g/dL) test date: 08/27/2015 unremarkable. EKG and ECHO returned unremarkable test, EKG showed sinus rhythm, no deltas appreciated date: 08/28/2015. EEG on 08/27/15 interpretation: this video EEG tracing in the awake, drowsey and asleep state is normal. There were no electroclinical seizures. No evidence of any epileptiform or focal abnormalities. EEG on 08/28/15 Interepretation: This EEG tracing in the awake, drowsey and asleep state with photic stimulation is normal. Clinical correlation is recommended. MRI Head without contrast on 08/28/2015: Impression: Unremarkable MRI of the brain.

Investigator Text:

The subject is a 15 month old born by induced vaginal delivery at 37 weeks due to intrauterine growth restriction with a history of neonatal hyperbilirubinemia treated with phototherapy and seasonal allergies formerly trated with claritin who presents to the emergency room with 4 episodes of seizure-like activity. During these episodes, she tenses up, makes choking noises, and her eyes deviate upwards. After these episodes on the first two nights and again this morning(08/27/15), she cried, appeared temporarily disoriented, and then acted fussy for a few minutes. During the episode last night (08/26/15) she did not seem to be post-ictal. Nursing reports that the subject had an observed 1-minute period of tachycardia to 240 bpm accompanied by inactivity but no obvious change in mental status. She was breathing during this episode. Her immunizations are up to date. She has been out of daycare since 07/28/2015 and no known sick contacts or recent travel. There is no family history of

arrhythmia or epilepsy. She eats table food and drinks milk, juice, and water. She has been making 5-7 wet and 2-3 dirty diapers a day. Child remains in the hospital at the initial SAE report on 08/28/2015. Study staff spoke with parent today to inquire about the start date, parent reported via telephone started having first episode on Monday evening at home on 08/24/2015. Child admitted to the hospital on the afternoon of 08/27/2015.

Follow up report as of 09/01/15: Hospital course: Upon admission child remained stable without any seizure like activity observed. She continued on KEPPRA 15mg/kg twice a day. Neurological evaluation with EEG and MRI returned unremarkable. Cardiology consultation was placed given tachycardia in ED, concerning fr underlying arrhytmia. Cardiac evaluation with EKG and ECHO returned unremarkable. Decision was made to discharge child as she remained clinically stable without any noted seizure like activity and adequate appetite and oral intake. The child has undergone EEG which was normal. At this point and time impression was that this child is likely having frontal lobe seizures resulting in these events. These episodes are not related to reflux, choking, or obstructive sleep apnea. KEPPRA was started. Family educated about seizures. Suggested primary care MD to make referral to pediatric sleep medicine to evaluate snoring. Child was discharged home with seizure like activity nocturnal partial seizures, and placed on KEPPRA. Discharged from hospital on 08/29/2015. Parent took the child back to the ED on 08/31/15. Mom stated she noticed an episode of twitching of her right arm andone leg in her sleep lasting 20 seconds and self resolving. The child's eyes were closed. Neuro was consulted in the ED who deferred change in medication at this visit. Parent was instructed to follow up with primary MD. Child was discharged from the ED on 08/31/15. Chil went to primary MD office for ER follow up on 09/01/15. Plan from the follow up visit: child referred to sleep medicine on 08/31/15 for snoring, continue KEPPRA as prescribed. Mom was requested by primary MD to call neurology to schedule an appointment as soon as possible. There is no more information available. Update on 09/25/2015, spoke with parent today she reports the child has not experienced any new seizure like episodes since the follow up visit on

Urine

Confidential

Clinical Narrative report with Both Serious & Non-Serious Events

09/01/2015, initial hospitalized event has resolved per parent report. TTO implausible for causality due to Hepatitis B or Rotavirus vaccine

Study Number: 117119

Study Center ID: PPD

Subject ID: PPD

Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: Respiratory distress, Respiratory syncytial virus bronchiolitis

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [DTPa-HBV-IPV+Hib vaccine]:[Solution for injection] <Blank> <Blank> ;[Prevnar 13]:[Solution for injection] <Blank> <Blank> ;[Rotavirus vaccine lyophilized formulation]:[Oral drops] <Blank> <Blank> <Blank> |

Narrative: This 6-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 3rd dose of Infanrix hexa (intramuscular) on 3rd November 2014, for prophylaxis. The subject received the 3rd dose of Prevnar 13 (intramuscular) on 3rd November 2014, for prophylaxis. The subject received the 2nd dose of Rotavirus vaccine lyophilized formulation (oral) on 8th September 2014, for prophylaxis.

On PPD 28 days after receiving Infanrix hexa, 28 days after receiving Prevnar 13 and 84 days after receiving Rotavirus vaccine lyophilized formulation, the subject developed severe - grade 3 respiratory syncytial virus bronchiolitis. Serious criteria included hospitalization and GSK medically significant. Additional event(s) included severe - grade 3 respiratory distress on 7th December 2014 with serious criteria of hospitalization and GSK medically significant. The subject was treated with furosemide (Lasix), paracetamol (Tylenol), salbutamol (Albuterol), 5% dextrose + normal saline solution, ibuprofen and sucrose (Sucrose Oral Solution). The outcome of respiratory syncytial virus bronchiolitis was recovered/resolved on 12th December 2014. The outcome(s) of the additional event(s) included respiratory distress (recovered/resolved on 12th December 2014).

The investigator considered that there was no reasonable possibility that the respiratory syncytial virus bronchiolitis and respiratory distress may have been caused by Infanrix hexa, Prevnar 13 and Rotavirus vaccine lyophilized formulation.

Relevant Tests: Respiratory Panel: 07Dec2014, RSV positive, Flu negative.

Chest X-ray: 07Dec2014, showed viral illness Blood culture: 07Dec2014, no growth

culture: 07Dec2014: no growth

Investigator Comment:

On 07 Dec 2014, subject's mother brought her to the ER with a 1-week history of cough, congestion, and

Clinical Narrative report with Both Serious & Non-Serious Events

rhinorrhea. Approximately 3 days prior, fever, worsening cough, decreased intake and decreased urine output as well as loose stools and increased sleepiness and increased work of breathing was noted by the mother. Mother brought the subject to the ER in the early morning hours of 07Dec2014 due to those worsening symptoms. In the ER, subject presented with grunting, lethargy, oxygen saturation of 84%, and was treated with suctioning, oxygen by mask. Work of breathing was still increased and subject's temperature was 105F. Subject was then admitted to the hospital service for 23-hour observation. No familial risk factors were noted. Care included nasal suctioning, breathing treatments and supportive care. In the morning of 08Dec2014, increased work of breathing and tachypnea was noted, and subject was transferred to the Pediatric Intensive Care Unit for increased care and management.Respiratory panel returned with positive for Repiratory Syncitial Virus. While in the Pediatric Intensive Care Unit, subject required up to 15 liters of 100% Oxygen via Vapotherm, and was weaned down to 5L of 28%. Subject was transferred to the general care floor on 10Dec2014 and was weaned to room air on the evening of 11Dec2014. She continued to require suctioning until 24 hours prior to discharge. Subject was discharged on 12Dec2014. Subject was well at discharge.

RSV bronchiolitis 28 days after multiple vaccines. RSV bronchiolitis is a risk for infants of this age, regardless of the vaccination administered. In this case, due to co-administration of several vaccines, an individual assessment of causality cannot be made.

Study Number: 117119

Study Center ID: PPD

Subject ID: PPD

Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: Mental status changes

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [Pentacel]:[Solution for injection] <Blank> <Blank> ;[Hepatitis B vaccine]:[Solution for injection] <Blank> <Blank> ;[Prevnar 13]:[Solution for injection] <Blank> <Blank> <Blank> ;[Rotavirus vaccine lyophilized formulation]:[Oral drops] <Blank> <Blank> <Blank> <Blank>

Narrative: This 9-month-old male subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 3rd dose of Pentacel (intramuscular) on 11th November 2014, for prophylaxis. The subject received the 2nd dose of Prevnar 13 (intramuscular) on 11th November 2014, for prophylaxis. The subject received the 2nd dose of Rotavirus vaccine lyophilized formulation (oral) on 15th September 2014, for prophylaxis.

On PPD 108 days after receiving Pentacel, Hepatitis B vaccine and Prevnar 13 and 165 days after receiving Rotavirus vaccine lyophilized formulation, the subject developed severe - grade 3 mental status changes. Serious criteria included hospitalization. The subject was treated with sodium

Clinical Narrative report with Both Serious & Non-Serious Events

chloride (Sodium Chloride Infusion), lidocaine (Lidocain) and naloxone hydrochloride (Narcan (Naloxone)). The outcome of mental status changes was recovered/resolved on 28th February 2015.

The investigator considered that there was no reasonable possibility that the mental status changes may have been caused by Pentacel, Hepatitis B vaccine, Prevnar 13 and Rotavirus vaccine lyophilized formulation.

Relevant Tests: The following blood tests were also conducted: Ethanol: Negative. Salicylate: less tha 1.0 mg/dl (range 2-20). Valproic Acid: less tha 10.0 ug/mL (range 50-150). Diff-Cells Counted: 114. Atypical lymph%: 11 10*3/ul (range 0-8). Atypical lymph#: 1.3, (range 0-1.4). Poikilocytes: 1+(A). Ovalocytes: 1+(A). Platelet Estimate: Adequate. Urine Culture: Rpt. Acetaminophen: less tha 10.0 ug/ml (range 10-30). Amphetamine - Urine screen: Negative. Barbiturate - Urine Screen: Negative. Benzodiazepine Screen - Urine: Negative. Cocaine/Metab-Urine Screen: Negative.Opiates - Urine: Negative. Cannabinoids - Urine Screen: Negative. Tricyclics - Urine Screen: Negative. Diagnostic results (unless otherwise stated, normal values were not provided): On 27th February 2015, Alanine aminotransferase result was 40 u/L (normal low: 13, normal high: 69), Amylase result was 130 u/L (normal low: 30, normal high: 110), Aspartate aminotransferase result was 48 u/L (normal low: 15, normal high: 46), Basophil count result was 1 % (normal low: 0.00, normal high: 2), Basophil count result was 0.12 unknown (normal low: 0.00, normal high: 0.4), Blood albumin result was 4.3 g/dL (normal low: 3, normal high: 4.8), Blood alkaline phosphatase result was 252 u/L (normal low: 80, normal high: 270). Blood bilirubin result was 0.3 mg/dL (normal low: 0.00, normal high: 0.9), Blood calcium result was 10.0 mg/dL (normal low: 8.6, normal high: 11.2), Blood chloride result was 103 NA (normal low: 98, normal high: 107), Blood creatinine result was 0.3 mg/dL (normal low: 0.3, normal high: 0.5), Blood glucose result was 99 mg/dL (normal low: 60, normal high: 100), Blood potassium result was 4.4 NA (normal low: 3.5, normal high: 5.1), Blood sodium result was 138 NA (normal low: 132, normal high: 142), Blood urea result was 8 mg/dL (normal low: 4, normal high: 15), Carbon dioxide result was 20 NA (normal low: 18, normal high: 27), Eosinophil count result was 1 % (normal low: 0.00, normal high: 7), Eosinophil count result was 0.12 unknown (normal low: 0.00, normal high: 1.2), Haematocrit result was 38.2 % (normal low: 30, normal high: 42), Haemoglobin result was 12.8 g/dL (normal low: 10.5, normal high: 13.5), Lymphocyte count result was 62 % (normal low: 35, normal high: 74), Lymphocyte count result was 7.17 unknown (normal low: 2.1, normal high: 13), Mean cell haemoglobin result was 25.0 pg (normal low: 25, normal high: 31), Mean cell haemoglobin concentration result was 33.5 g/dL (normal low: 29, normal high: 37), Mean cell volume result was 74.6 fL (normal low: 70, normal high: 86), Mean platelet volume result was 9.5 fL (normal low: 6.7, normal high: 10.8), Monocyte count result was 14 % (normal low: 0.00, normal high: 15), Monocyte count result was 1.62 unknown (normal low: 0.00, normal high: 2.6), Neutrophil count result was 11 % (normal low: 16, normal high: 48), Neutrophil count result was 1.27 unknown (normal low: 1, normal high: 8.4), Platelet count result was 292 unknown (normal low: 140, normal high: 440), Protein total result was 6.8 g/dL (normal low: 5, normal high: 7.5), Red blood cell count result was 5.12 unknown (normal low: 3.7, normal high: 5.3), Red cell distribution width result was 13.3 % (normal low: 14.1, normal high: 21.6) and White blood cell count result was 11.57 unknown (normal low: 6, normal high: 17.5).

Investigator text:

On 27Feb2015, subject was in the care of grandparents for the day. When the subject's mother arrived to pick him up, around 0810 PM, he was drowsy and not acting like himself. Grandparents reported that the subject had slept 6-7 hours straight that afternoon. No known injury or ingestion was reported by the grandparents. Subject was taken to an Immediate Care Center and was minimally responsive there, so subject was transported via ambulance to the local children's hospital Emergency Department. There, he was minimally responsive to sternal rubs and had fixed pupils. Vital signs were stable. He did not respond when the IV was placed. After receipt of 1 gm of Narcan, he immediately began to respond, and within 15

Clinical Narrative report with Both Serious & Non-Serious Events

minutes was back to normal behavior. Urine and serum toxicity screenings were negative, and EKG shows sinus arrhythmia. Subject was sent to the floor for observation and the remainder of the hospitalization was unremarkable. He was discharged on 28 February 2015 after the shorthospital stay. Final discharge diagnosis was Altered Mental State. Per mother's report today (02Mar2015) subject is doing fine. She reported that they feel that the subject must have ingested one of the many pills that the grandparents have in their home. The start date 27 FEB 2015= date of first signs and symptoms.

Study Number: 117119
Study Center ID: PPD
Subject ID: PPD
Randomization Number: UNKNOWN
Case ID: PPD
Serious Events: PPD

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [Pentacel]:[Solution for injection] <Blank> <Blank> ;[Hepatitis B vaccine]:[Solution for injection] 10 mcg <Blank>;[Prevnar 13]:[Solution for injection] <Blank> <Blank> <Blank> ;[Rotavirus vaccine lyophilized formulation]:[Oral drops] <Blank> <Blank> <Blank>

Narrative: This 5-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. The subject received the 2nd dose of Pentacel (intramuscular) on 13th August 2014, for prophylaxis. The subject received the 1st dose of Hepatitis B vaccine (intramuscular) 10 mcg on 18th June 2014, for prophylaxis. The subject received the 2nd dose of Prevnar 13 (intramuscular) on 13th August 2014, for prophylaxis. The subject received the 2nd dose of Rotavirus vaccine lyophilized formulation (oral) on 13th August 2014, for prophylaxis.

On PPD 32 days after receiving Pentacel, Prevnar 13 and Rotavirus vaccine lyophilized formulation and 88 days after receiving Hepatitis B vaccine, the subject developed moderate - grade 2 PPD Serious criteria included hospitalization. The outcome of PPD was recovered/resolved on 15th September 2014.

The investigator considered that there was no reasonable possibility that the PPD may have been caused by Pentacel, Hepatitis B vaccine, Prevnar 13 and Rotavirus vaccine lyophilized formulation.

Relevant Tests: chest xray Negative

INVESTIGATOR TEXT

Subject involved in PPD on 14Sep2014. Admitted to ICU for observation on 14Sep2014. Subject released in good condition on 15Sep2014. Multiple trauma ruled out.

Clinical Narrative report with Both Serious & Non-Serious Events

Subject involved in PPD on 14Sep2014. Admitted to ICU for observation on 14Sep2014. Subject released in good condition on 15Sep2014 -

Study Number: 117119

Study Center ID: PPD

Subject ID: PPD

Randomization Number: UNKNOWN

Case ID: PPD

Serious Events: Meningitis viral

Non Serious Events:

Suspect Product Name With Formulation, Dose, Units and Frequency: [DTPa-HBV-IPV+Hib vaccine]:[Solution for injection] <Blank> <Blank> ;[Prevnar 13]:[Solution for injection] <Blank> <Blank> ;[Rotavirus vaccine lyophilized formulation]:[Oral drops] <Blank> <Blank> <Blank> |

Narrative: This 7-month-old female subject was enrolled in an open label study titled A phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa' vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age. On 21st August 2014, the subject received the 3rd dose of Infanrix hexa (intramuscular) for prophylaxis and the 3rd dose of Prevnar 13 (intramuscular) for prophylaxis. On 26th June 2014, the subject received the 2nd dose of Rotavirus vaccine lyophilized formulation (oral) for prophylaxis.

The subject's past medical history included allergic reaction to antibiotics.

On PPD 31 days after receiving Infanrix hexa and Prevnar 13 and 87 days after receiving Rotavirus vaccine lyophilized formulation the subject developed moderate - grade 2 viral meningitis. Serious criteria included hospitalization and GSK medically significant. The subject was treated with PARACETAMOL (ACETAMINOPHEN), LIDOCAINE, vancomycin, ceftriaxone, (Naci 0.9% (Sodium Chloride)), ibuprofen and D5w 0.45% Sodium Choride + 20 Meq Potassium Chloride. The outcome of viral meningitis was recovered/resolved on 25th September 2014.

The investigator considered that there was no reasonable possibility that the viral meningitis may have been caused by Infanrix hexa, Prevnar 13 and Rotavirus vaccine lyophilized formulation.

Relevant Tests: cerebrospinal fluid culture negative. Urine culture negative. Erythrocyte sedimentation rate 25 mm/hr (high) Normal range = 0-20 mm/hr. C-reactive protein 8.8 mg/L (high) Normal range = 0.0-8.0 mg/L

INVESTIGATOR TEXT

Patient developed fever and rash on 21Sep2014. Patient seen in emergency department on 21Sep2014 (two times) and admitted to outside medical facility on 21Sep2014 to be treated for viral meningitis. During

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Report Final

Confidential

Clinical Narrative report with Both Serious & Non-Serious Events

the course of hospitalization, patient had a post-vancomycin infusion allergic reaction. Patient was discharged on 24Sep2014 in good condition. Patient seen for follow-up in clinic on 25Sep2014, patient afebrile and clinically stable.

Patient develop 31 days postvacciantion with Infanrix hexa viral meningitis. There is no causal relationship to relate this event with vaccination.

Overall Case Count: 19

13. POST-TEXT TABLES AND FIGURES

 Table 6.1
 Number of subjects by center (Primary Total vaccinated cohort)

	Hexa group	Pedia group	Penta group	Total			
Center	n	n	n	n	%		
PPD	4	3	4	11	1.9		
	4	3	3	10	1.7		
	4	5	5	14	2.4		
	2	2	1	5	0.9		
	4	5	3	12	2.1		
	1	2	3	6	1.0		
	2	4	4	10	1.7		
	3	3	1	7	1.2		
	1	0	1	2	0.3		
	1	1	1	3	0.5		
	7	6	6	19	3.2		
	4	2	3	9	1.5		
	0	1	2	3	0.5		
	1	1	1	3	0.5		
	2	2	2	6	1.0		
	4	3	3	10	1.7		
	4	3	4	11	1.9		
	0	1	1	2	0.3		
	1	1	0	2	0.3		
		2	2	7	0.3		
	2	5	6	14	2.4		
	<u>3</u>	3	3	9	1.5		
	3 3 3 5	2	3		1.7		
	4			10	1.7		
		4	3	11	1.9		
	7	7	7	21	3.6		
	5	3	3	11	1.9		
	0	2	0	2	0.3		
	8 3 3	6	6	20	3.4		
	3	3	5	11	1.9		
	3	2	2	7	1.2		
	5	5	5	15	2.6		
	5 2 14	5	4	11	1.9		
	14	15	16	45	7.7		
	10	11	12	33	5.6		
	15	13	14	42	7.2		
	5	8	6	19	3.2		
	11	9	7	27	4.6		
	4	2	2	8	1.4		
	16	16	17	49	8.4		
	6	7	6	19	3.2		
	8	7	8	23	3.9		
	8 3 3	5	5	13	2.2		
		4	6	13	2.2		
All	195	194	196	585	100		

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel

n = number of subjects included in each group or in total for a given center or for all centers

All = sum of all subjects in each group or in total (sum of all groups) $\% = n/All \times 100$

Center = GSK Biologicals assigned center number

Table 6.2 Number of subjects at each visit and list of withdrawn subjects (Primary Total vaccinated cohort)

Group	VISIT	N	Withdrawn Subject numbers	Reason for withdrawal
Hexa	VISIT 1 D0 DOSE	195		
group			no.PPD	Lost to follow-up
			no.	Migrated / moved from the study area
			no.	Terminated by PI due to non-compliance with appointment
			110.	schedules
			no.	loss of kaiser coverage
			no.	loss of kaiser coverage
			no.	Consent withdrawal
			no.	Consent withdrawal
			no.	Serious Adverse Event
			no.	Consent withdrawal
	VISIT 2 M2 DOSE	186		
			no.PPD	Migrated / moved from the study area
			no.	Lost to follow-up
	VISIT 3 M4 DOSE	184		·
			no.PPD	Lost to follow-up
	VISIT 4 M5 POST ESFU CONTACT	183		
			no.PPD	Protocol violation*Lost to follow-up
		182		
			no.PPD	loss of kaiser coverage
			no.	Lost to follow-up
			no.	Protocol violation
			no.	Protocol violation
			no.	Protocol violation
			no.	Protocol violation
			no.	unknown
			no.	subject got a new doctor
			no.	Migrated / moved from the study area
			no.	Protocol violation
			no.	Migrated / moved from the study area
			no.	Protocol violation
			no.	Migrated / moved from the study area
			no.	Lost to follow-up
			no.	Consent withdrawal / not willing to participate, not due to a (S)AE
	VISIT 5 M 13-16	167		
			noPPD	Consent withdrawal
			no	Lost to follow-up
			no	Migrated / moved from the study area
			no	change their doctor
			no	Lost to follow-up
	\(\(\text{\tinit}\\ \text{\ti}}\\ \text{\text{\text{\text{\text{\text{\text{\text{\text{\text{\tex{\tex	10:	no	Lost to follow-up
	VISIT 6 M 14-17	161		

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Report Final

_	I				Report Final				
Group	VISIT	N	Withdrav	vn	Reason for withdrawal				
			Subject						
		4.5	numbers	3					
Pedia	VISIT 1 D0 DOSE	194	-						
group		-	no.PPD		less of ligitary sources				
					loss of kaiser coverage				
			no.		loss of kaiser coverage				
			no.		loss of kaiser coverage				
			no.		Consent withdrawal				
			no.		Consent withdrawal				
			no.		Migrated / moved from the study area				
	VISIT 2 M2 DOSE	188							
			no.PPD		Migrated / moved from the study area				
			no.		Migrated / moved from the study area				
			no.		Consent withdrawal				
	VISIT 3 M4 DOSE	185							
			noPPD		Consent withdrawal				
			no		Consent withdrawal				
	VISIT 4 M5 POST	183	3						
			no.PPD		Lost to follow-up				
	ESFU CONTACT	182			•				
			noPPD		medical history updated information				
			no		Migrated / moved from the study area				
			no		Protocol violation				
			no		Lost to follow-up				
			no		Lost to follow-up				
			no		loss of kaiser coverage				
				_	Migrated / moved from the study area				
			no						
			no	_	Migrated / moved from the study area				
			no	_	Lost to follow-up				
			no		loss of kaiser coverage				
			no	_	loss of kaiser coverage				
			no		loss of kaiser coverage				
			no		loss of kaiser coverage				
			no		Consent withdrawal / not willing to participate, not due to a (S)AE				
			no		Migrated / moved from the study area				
			no		Lost to follow-up				
			no		Lost to follow-up				
			no		Migrated / moved from the study area				
			no		Lost to follow-up				
			no		Migrated / moved from the study area				
			no		Lost to follow-up				
			no		Protocol violation				
			no		Consent withdrawal / not willing to participate, not due to a (S)AE				
			no		Migrated / moved from the study area				
	VISIT 5 M 13-16	158			inigrated i mered nem the etady area				
	VISIT 6 M 14-17	158							
Penta	VISIT 1 D0 DOSE	196							
	VIOLI I DO DOSE	130	<u>'</u>						
group			noPPD		Consent withdrawal				
			no		Consent withdrawal				
			no		Consent withdrawal				
			no		Consent withdrawal				
	V/OIT 0 1:0 = 0 0	1.0	no		loss of kaiser coverage				
	VISIT 2 M2 DOSE	191		-					
			noPPD		Lost to follow-up				

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Report Final

Group	VISIT	N Withdra Subject numbe	t rs	Reason for withdrawal
		no.PPD		loss of kaiser coverage
		no.		subject was discontiued due to non-compliance
		no.		Consent withdrawal
		no.		Protocol violation
		no.		Non-Serious Adverse Event
		no.		Protocol violation
		no.		Lost to follow-up
		no.		Protocol violation
	VISIT 3 M4 DOSE	182		
	VISIT 4 M5 POST	182		
		noPPD		Migrated / moved from the study area
	ESFU CONTACT	181		,
		no.PPD		Migrated / moved from the study area
		no.		Protocol violation
		no.		Lost to follow-up
		no.		received vaccines in injection clinic
		no.		refuses blood draws
		no.		Lost to follow-up
		no.		Protocol violation
		no.		Protocol violation
		no.		Consent withdrawal / not willing to participate, not due to a (S)AE
		no.		Lost to follow-up
		no.		Consent withdrawal / not willing to participate, not due to a (S)AE
		no.		Migrated / moved from the study area
		no.		subject unable to complete visit 5 during the GSK shortened window for visit 5
		no.		Migrated / moved from the study area
		no.		Lost to follow-up
		no.		Sponsor study termination
		no.		Protocol violation
		no.		Migrated / moved from the study area
	VISIT 5 M 13-16 16			wingrated / moved from the study area
	VIOTI O IVI TO TO	no PPD		Lost to follow-up
		no		Lost to follow-up
		no		Lost to follow-up
		no		Consent withdrawal
		no		Lost to follow-up
		no		Protocol violation
	VISIT 6 M 14-17			TOTOGOT FIGURIOTI
	VISIT 6 M 14-17	157		

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = Number of subjects who are still in the study up to the visit

Withdrawn = Subject who did not return after the visit

Table 6.3 Summary of demographic characteristics (Primary Total vaccinated cohort)

			Hexa group N = 195		Pedia group N = 194		Penta group N = 196		585
Characteristics	Parameters or	Value	%	Value	%		%		%
	Categories	or n		or n		or n		or n	
Age [Weeks] at first primary dose	Mean	8.5	-	8.6	-	8.6	-	8.6	-
	SD	1.0	-	1.1	-	1.1	-	1.1	-
	Median	8.0	-	9.0	-	8.0	-	8.0	-
	Minimum	6.0	-	6.0	-	6.0	-		-
	Maximum	12.0	-	12.0	-	12.0	-	12.0	-
Gender	Female	101	51.8	80	41.2	95	48.5	276	47.2
	Male	94	48.2	114	58.8	101	51.5	309	52.8
Race	African Heritage / African American	16	8.2	9	4.6	20	10.2	45	7.7
	American Indian or Alaskan Native	15	7.7	15	7.7	17	8.7	47	8.0
	Asian - Central/South Asian Heritage	2	1.0	2	1.0	1	0.5	5	0.9
	Asian - East Asian Heritage	3	1.5	2	1.0	0	0.0	5	0.9
	Asian - Japanese Heritage	1	0.5	0	0.0	1	0.5		0.3
	Asian - South East Asian Heritage	9	4.6	9	4.6	8	4.1	26	4.4
	Native Hawaiian or Other Pacific Islander	2	1.0	1	0.5	2	1.0	5 5 2 26 5 1 7 361 3 88 58.5	0.9
	White - Arabic / North African Heritage	0	0.0	1	0.5	0	0.0	1	0.2
	White - Caucasian / European Heritage	118	60.5	128	66.0	115	58.7	361	61.7
	Other	29	14.9	27	13.9	32	16.3	Value or n 8.6 1.1 8.0 6.0 12.0 276 309 45 47 5 2 26 5 1 361 88 58.5 4.0 58.0 32.0 86.0 5.4 0.7 5.3 3.4 7.9 533	15.0
Height	Mean	58.0	-	58.6	-	58.8	-	58.5	-
	SD	4.1	-	4.7	-	3.1	-	4.0	-
	Median	58.0	-	58.0	-	58.0	-	58.0	-
	Minimum	32.0	-	37.0	-	48.0	-	32.0	-
	Maximum	74.0	-	86.0	-	69.0	-	86.0	-
Weight	Mean	5.3	-	5.4	-	5.4	-	5.4	-
-	SD	0.7	-	0.7	-	0.7	-	0.7	-
	Median	5.2	-	5.4	-	5.4	-	8.6 1.1 8.0 6.0 12.0 276 309 45 47 5 2 26 5 1 361 88 58.5 4.0 58.0 32.0 86.0 5.4 0.7 5.3 3.4 7.9 533 52 294 170	-
	Minimum	3.4	-	3.6	-	3.7	-	3.4	-
	Maximum	7.9	-	7.1	-	7.5	-	7.9	-
Hepatitis B vaccination at birth	Yes	181	92.8	172	88.7	180	91.8	533	91.1
	No	14	7.2	22	11.3	16	8.2	52	8.9
Tdap vaccination of mother	Yes	102		94		98	60.9	N = Value or n 8.6 1.1 8.0 6.0 12.0 276 309 45 47 5 2 26 5 1 361 88 58.5 4.0 58.0 32.0 86.0 5.4 0.7 5.3 3.4 7.9 533 52 294 170	63.4
	No	51	33.3		37.3		39.1		36.6
	Missing	42	-	44	-	35	-		-

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects

n = number of subjects in a given category

Value = value of the considered parameter

% = n / Number of subjects with available results x 100

SD = Standard deviation

Table 6.4 Summary of demographic characteristics (Booster Total vaccinated cohort)

		Hexa		Ped	lia	Per	nta	Total	
		gro	up	gro	up	gro	up	N =	486
		N =		N =					
Characteristics	Parameters or		%	Value	%			Value	%
	Categories	or n		or n		or n		or n	
Age [months] at booster dose	Mean	15.3	-	15.3	-	15.3	-	15.3	-
	SD	0.7	-	0.6	-	0.7	-	0.7	-
	Median	15.0	-	15.0	-	15.0	-	15.0	-
	Minimum	14.0	-	15.0	-	14.0	-	14.0	-
	Maximum	18.0	-	18.0	-	18.0	-	14.0 18.0 3 218 7 268 39 42 4 5 2 22 4 1	-
Gender	Female	87	52.1	58	36.7	73	45.3	218	44.9
	Male	80	47.9	100	63.3	88	54.7	268	55.1
Race	African Heritage / African American	14	8.4	9	5.7	16	9.9	39	8.0
	American Indian or Alaskan Native	12	7.2	14	8.9	16	9.9		8.6
	Asian - Central/South Asian Heritage	2	1.2	2	1.3	0	0.0	4	8.0
	Asian - East Asian Heritage	3	1.8	2	1.3	group N = 4 N = 161 Value or n 15.3 - 15.3 - 15.3 - 15.0 - 15.0 - 15.0 - 15.0 - 16.0 - 18.	1.0		
	Asian - Japanese Heritage	1	0.6	0	0.0	1	0.6	2	0.4
	Asian - South East Asian Heritage	8	4.8	9	5.7	5	3.1	or n 15.3 0.7 15.0 14.0 18.0 218 268 39 42 4 5 2 22 4 1 296 71 58.5 3.9 58.0 37.0 86.0 5.4 0.7 5.4 3.4 7.9 441	4.5
	Native Hawaiian or Other Pacific Islander	2	1.2	0	0.0	2	1.2 4	8.0	
	White - Arabic / North African Heritage	0	0.0	1	0.6	0	0.0	1	0.2
	White - Caucasian / European Heritage	101	60.5	101	63.9	94	58.4	296	60.9
	Other	24	14 4	20	12 7	27	16.8	N = N = N = N = N = N = N = N = N = N =	14.6
Height	Mean	58.0	-		-		-		-
rioignt	SD	3.7	_		_		_		_
	Median	58.0	_		_		_		_
	Minimum	38.0	-		_		_		_
	Maximum	74.0	_		_		_		_
Weight	Mean	5.3	_		_		_		_
	SD	0.7	-		_		_		-
	Median	5.3	_		_		_		_
	Minimum	3.4	_		_		_		_
	Maximum	7.9	_		_		_	15.3 0.7 15.0 14.0 18.0 218 268 39 42 4 5 2 22 4 1 296 71 58.5 3.9 58.0 37.0 86.0 5.4 0.7 5.4 3.4 7.9 441 45 257	_
Hepatitis B vaccination at birth	Yes	153	91.6		88.0		92.5		90.7
	No	14	8.4	19	12.0	12	7.5	45	9.3
Tdap vaccination of mother	Yes	90							65.1
p	No	43		0.6 - 0.7 - 0.7 15.0 - 15.0 - 15.0 15.0 - 14.0 - 14.0 18.0 - 18.0 - 18.0 18.0 - 18.0 - 18.0 18.0 - 18.0 - 18.0 18.0 - 18.0 - 18.0 20.1 18.0 - 18.0 - 18.0 34.3 9 10.0 63.3 88 54.7 268 34.4 9 5.7 16 9.9 39 37.2 14 8.9 16 9.9 42 1.2 2 1.3 0 0.0 4 1.8 2 1.3 0 0.0 5 1.8 9 5.7 5 3.1 22 1.2 0 0.0 1 0.6 2 1.2 0 0.0 1 0.0 1 30.5 10.1 63.9		34.9			
	Missing	34	-				1		_

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects

n = number of subjects in a given category

Value = value of the considered parameter

% = n / Number of subjects with available results x 100

SD = Standard deviation

117119 (DTPA-HBV-IPV-135) Report Final

Table 6.5 Deviations from specifications for age and intervals between study visits (Primary Total vaccinated cohort)

		Age	Dose:1-Dose:2	Dose:2-Dose:3	Dose:3-PIII(M5)			
Group		Protocol	Protocol	Protocol	Protocol	Adapted		
_		from 42 to 90 days	from 49 to 83 days	from 56 to 90 days	from 30 to 48 days	from 21 to 48 days		
Hexa group	N	195	186	183	161	161		
	n	0	1	4	7	6		
	%	0.0	0.5	2.2	4.3	3.7		
	range	44 to 85	49 to 98	56 to 119	29 to 88	29 to 88		
Pedia group	N	194	188	185	167	167		
	n	0	5	3	5	3		
	%	0.0	2.7	1.6	3.0	1.8		
	range	42 to 89	49 to 95	56 to 113	28 to 69	28 to 69		
Penta group	N	196	189	180	164	164		
	n	0	2	5	1	0		
	%	0.0	1.1	2.8	0.6	0.0		
	range	42 to 87	49 to 96	56 to 98	28 to 48	28 to 48		

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Adapted = interval used for defining the ATP cohorts for immunogenicity

N = total number of subjects with available results

n/% = number / percentage of subjects with results outside of the interval

range = minimum-maximum for age and intervals

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Table 6.6 Deviations from specifications for age and intervals between study visits (Booster Total vaccinated cohort)

		age	Dose:4-POST-BST					
Group		Protocol	Protocol	Adapted				
		from 15 to 18 months	from 30 to 48 days	from 21 to 48 days				
Hexa group	N	167	150	150				
	n	4	10	8				
	%	2.4	6.7	5.3				
	range	14 to 18	28 to 78	28 to 78				
Pedia group	N	158	146	146				
	n	0	2	2				
	%	0.0	1.4	1.4				
	range	15 to 18	30 to 60	30 to 60				
Penta group	N	161	146	146				
	n	2	8	8				
	%	1.2	5.5	5.5				
	range	14 to 18	30 to 103	30 to 103				

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Adapted = interval used for defining the ATP cohorts for immunogenicity

N = total number of subjects with available results

n/% = number / percentage of subjects with results outside of the interval

range = minimum-maximum for age and intervals

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Table 6.7 Summary of demographic characteristics (Primary ATP cohort for safety)

	g		Hexa group N = 194		Pedia group N = 193		Penta group N = 191		
Characteristics	Parameters or	Value	%	Value	%	Value	%	Value	%
	Categories	or n		or n		or n		or n	
Age [Weeks] at first primary dose	Mean	8.5	-	8.6	-	8.6	-	8.6	-
	SD	1.0	-	1.1	-	1.1	-	1.0	-
	Median	8.0	-	9.0	-	8.0	-	8.0	-
	Minimum	6.0	-	6.0	-	6.0	-	6.0	-
	Maximum	12.0	-	12.0	-	12.0	-	12.0	-
Gender	Female	101	52.1	80	41.5	90	47.1	271	46.9
	Male	93	47.9	113	58.5	101	52.9	307	53.1
Race	African Heritage / African American	16	8.2	9	4.7	19	9.9	44	7.6
	American Indian or Alaskan Native	15	7.7	15	7.8	17	8.9	47	8.1
Race	Asian - Central/South Asian Heritage	2	1.0	1	0.5	1	0.5	4	0.7
	Asian - East Asian Heritage	3	1.5	2	1.0	0	0.0	5	0.9
	Asian - Japanese Heritage	1	0.5	0	0.0	1	0.5		0.3
	Asian - South East Asian Heritage	9	4.6	9	4.7	8	4.2	26	4.5
	Native Hawaiian or Other Pacific Islander	2	1.0	1	0.5	2	1.0	5	0.9
	White - Arabic / North African Heritage	0	0.0	1	0.5	0	0.0	1	0.2
	White - Caucasian / European Heritage	117	60.3	128	66.3	112	58.6	357	61.8
	Other	29	14.9	27	14.0	31	16.2	87	15.1
Height	Mean	58.0	-	58.6	-	58.8	-	58.5	-
_	SD	4.1	-	4.7	-	3.1	-	4.0	-
	Median	58.0	-	58.0	-	58.0	-	58.0	-
	Minimum	32.0	-	37.0	-	48.0	-	32.0	-
	Maximum	74.0	-	86.0	-	69.0	-	86.0	-
Weight	Mean	5.3	-	5.4	-	5.4	-	5.4	-
	SD	0.7	-	0.7	-	0.7	-	0.7	-
	Median	5.2	-	5.4	-	5.4	-	8.6 1.0 8.0 6.0 12.0 1 271 9 307 44 47 4 5 2 26 5 1 6 357 2 87 58.5 4.0 58.0 32.0 86.0 5.4 0.7 5.3 3.4 7.9 7 528 50 1 290 9 168 120	-
	Minimum	3.4	-	3.6	-	3.7	-		-
	Maximum	7.9	-	7.1	-	7.5	-		-
Hepatitis B vaccination at birth	Yes	180	92.8	171	88.6	177	92.7	528	91.3
	No	14	7.2	22	11.4	14	7.3	Value or n 8.6 1.0 8.0 6.0 12.0 271 307 44 47 4 5 2 26 5 1 1 357 58.5 4.0 58.0 32.0 86.0 5.4 0.7 5.3 3.4 7.9 528 50 290 168 120	8.7
Tdap vaccination of mother	Yes	101	66.4					N = 5 Value or n 8.6 1.0 8.0 6.0 12.0 271 307 44 47 4 5 2 26 5 1 357 87 58.5 4.0 58.0 32.0 86.0 5.4 0.7 5.3 3.4 7.9 528 50 290 168	63.3
	No	51	33.6			N = 191 Value or n 8.6 - 8.6 1.1 - 1.0 8.0 - 8.0 6.0 - 6.0 12.0 - 12.0 1.5 90 47.1 271 8.5 101 52.9 307 7 19 9.9 44 8 17 8.9 47 5 1 0.5 4 0 0 0.0 5 0 1 0.5 2 7 8 4.2 26 5 2 1.0 5 1.0 10 10 10 10 10 10 10 10 10 10 10 10 10		36.7	
	Missing	42	-	44	-		-		-

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects

n = number of subjects in a given category

Value = value of the considered parameter

% = n / Number of subjects with available results x 100

SD = Standard deviation

Table 6.8 Summary of demographic characteristics (Booster ATP cohort for safety)

		Hexa group N = 16	7	Pedia group N = 15	i8	Penta group N = 16	0	Total N = 4	
Characteristics	Parameters or	Value	%	Value	%	Value	%	Value	%
	Categories	or n		or n		or n		or n	
Age [months] at booster dose	Mean	15.3	-	15.3	-	15.3	-	15.3	-
	SD	0.7	-	0.6	-	0.7	-	0.7	-
	Median	15.0	-	15.0	-	15.0	-	15.0	-
	Minimum	14.0	-	15.0	-	14.0	-	14.0	-
	Maximum	18.0	-	18.0	-	18.0	-	18.0	-
Gender	Female	87	52.1	58	36.7	72	45.0	217	44.7
	Male	80	47.9	100	63.3	88	55.0	268	55.3
Race	African Heritage / African American	14	8.4	9	5.7	16	10.0		8.0
	American Indian or Alaskan Native	12	7.2	14	8.9	16	10.0	42	8.7
	Asian - Central/South Asian Heritage	2	1.2	2		0	0.0	4	8.0
	Asian - East Asian Heritage	3	1.8	2	1.3	0	0.0	5	1.0
	Asian - Japanese Heritage	1	0.6	0	0.0	1		2	0.4
	Asian - South East Asian Heritage	8	4.8	9	5.7	5	3.1	22	4.5
	Native Hawaiian or Other Pacific Islander	2	1.2	0	0.0	2	1.3	4	8.0
	White - Arabic / North African Heritage	0	0.0	1		0	0.0	1	0.2
	White - Caucasian / European Heritage	101	60.5	101	63.9	93	58.1	295	60.8
	Other	24	14.4	20	12.7	27	16.9	71	14.6
Height	Mean	58.0	-	58.6	-	58.9	-	58.5	-
·	SD	3.7	-	4.6	-	3.2	-	3.9	-
	Median	58.0	-	58.0	-	58.0	-	58.0	-
	Minimum	38.0	-	37.0	-	48.0	-	37.0	-
	Maximum	74.0	-	86.0	-	69.0	-	86.0	-
Weight	Mean	5.3	-	5.4	-	5.4	-	5.4	-
•	SD	0.7	-	0.7	-	0.7	-	0.7	-
	Median	5.3	-	5.4	-	5.5	-	5.4	-
	Minimum	3.4	-	4.0	-	3.7	-	3.4	-
	Maximum	7.9	-	7.1	-	7.5	-	7.9	-
Hepatitis B vaccination at birth	Yes	153	91.6	139	88.0	148	92.5	440	90.7
	No	14		19	12.0	12	7.5	45	9.3
Tdap vaccination of mother	Yes	90	67.7	85	68.0	82	59.9	257	65.1
•	No	43	32.3	40	32.0	55	40.1		34.9
	Missing	34	-	33	-	23	-	90	-

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects

n = number of subjects in a given category

Value = value of the considered parameter

% = n / Number of subjects with available results x 100

SD = Standard deviation

7. IMMUNOGENICITY

117119 (DTPA-HBV-IPV-135) Report Final

Number and percentage of subjects with anti-PT, anti-FHA and anti-PRN antibody concentration equal to or above the assay cut-off and

geometric mean concentration (GMC), one month post primary vaccination - by gender (Primary ATP cohort for immunogenicity)

						≥ cı	ut_of	·		GMC	
							95%	CI		95%	6 CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	value	LL	UL
anti-PT antibody	Hexa group	Female	PIII(M5)	81	81	100	95.5	100	41.1	34.9	48.5
		Male	PIII(M5)	65	65	100	94.5	100	45.8	37.7	55.8
	Pedia group	Female	PIII(M5)	56	56	100	93.6	100	43.0	35.2	52.6
		Male	PIII(M5)	93	92	98.9	94.2	100	51.8	44.4	60.4
	Penta group	Female	PIII(M5)	71	71	100	94.9	100	23.1	19.3	27.6
		Male	PIII(M5)	78	77	98.7	93.1	100	25.3	20.6	31.1
anti-FHA antibody	Hexa group	Female	PIII(M5)	81	81	100	95.5	100	98.9	85.1	114.9
-		Male	PIII(M5)	65	65	100	94.5	100	116.4	98.0	138.3
	Pedia group	Female	PIII(M5)	56	56	100	93.6	100	114.7	95.0	138.4
		Male	PIII(M5)	93	93	100	96.1	100	127.9	111.5	146.7
	Penta group	Female	PIII(M5)	71	71	100	94.9	100	54.0	43.6	66.9
		Male	PIII(M5)	78	78	100	95.4	100	65.8	53.8	80.5
anti-PRN antibody	Hexa group	Female	PIII(M5)	81	81	100	95.5	100	56.6	46.9	68.3
		Male	PIII(M5)	65	65	100	94.5	100	58.5	45.9	74.5
	Pedia group	Female	PIII(M5)	56	55	98.2	90.4	100	52.9	39.9	70.3
		Male	PIII(M5)	93	93	100	96.1	100	43.7	35.7	53.4
	Penta group	Female	PIII(M5)	71	71	100	94.9	100	34.9	28.3	43.2
		Male	PIII(M5)	78	77	98.7	93.1	100	31.3	24.0	40.8

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

Table 7.1

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Table 7.2 Number and percentage of subjects with anti-PT, anti-FHA and anti-PRN antibody concentration equal to or above the assay cut-off and geometric mean concentration (GMC), one month post primary vaccination – by geographical ancestry (Primary ATP cohort for immunogenicity)

							≥ cu	t_off			GMC	
								95%	CI		95%	6 CI
Antibody	Group	Sub-group	Timin	g	N	n	%	LL	UL	value	LL	UL
anti-PT antibody	Hexa group	White Caucasian	PIII(M	15)	93	93	100	96.1	100	38.1	32.5	44.6
		other	PIII(M	15)	53	53	100	93.3	100	53.7	44.0	65.6
	Pedia group	White Caucasian	PIII(M	15)	101	100	99.0	94.6	100	43.8	37.5	51.2
		other	PIII(M	15)	48	48	100	92.6	100	59.1	49.2	71.1
	Penta group	White Caucasian	PIII(M	15)	84	83	98.8	93.5	100	21.6	17.8	26.2
		other	PIII(M	15)	65	65	100	94.5	100	28.1	23.3	33.8
anti-FHA antibody	Hexa group	White Caucasian	PIII(M	15)	93	93	100	96.1	100	95.8	83.2	110.5
		other	PIII(M	15)	53	53	100	93.3	100	127.6	106.5	152.8
	Pedia group	White Caucasian	PIII(M	15)	101	101	100	96.4	100	114.2	99.9	130.6
		other	PIII(M	15)	48	48	100	92.6	100	142.8	117.6	173.4
	Penta group	White Caucasian	PIII(M	15)	84	84	100	95.7	100	51.7	42.5	62.8
		other	PIII(M	15)	65	65	100	94.5	100	72.4	58.2	90.1
anti-PRN antibody	Hexa group	White Caucasian	PIII(M	15)	93	93	100	96.1	100	53.0	43.9	64.0
		other	PIII(M	15)	53	53	100	93.3	100	66.1	51.9	84.2
	Pedia group	White Caucasian	PIII(M	15)	101	100	99.0	94.6	100	44.0	35.7	54.3
		other	PIII(M	,		48	100	92.6	100	53.7	41.6	69.2
	Penta group	White Caucasian	PIII(M	15)	84	83	98.8	93.5	100	29.5	23.4	37.2
		other	PIII(M	15)	65	65	100	94.5	100	38.2	29.7	49.1

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Table 7.3 Number and percentage of subjects with anti-PT, anti-FHA and anti-PRN antibody concentration equal to or above the assay cut-off and geometric mean concentration (GMC), one month post primary vaccination - by Tdap vaccination of mother (Primary ATP cohort for immunogenicity)

						≥ c	ut_of	f		GMC	
							95%	6 CI		95%	6 CI
Antibody	Group	Sub-group	Timing	N	n	%		UL	value	LL	UL
anti-PT antibody	Hexa group	Tdap Vaccination Yes	PIII(M5)	81	81	100	95.5	100	37.7	31.5	45.1
		Tdap Vaccination No	PIII(M5)				91.2		51.2	41.9	62.5
		Tdap Vaccination Missing							51.2	37.5	69.9
	Pedia group	Tdap Vaccination Yes	PIII(M5)	74	74	100	95.1	100	41.2	35.6	47.6
		Tdap Vaccination No	PIII(M5)	42	41	97.6	87.4	99.9	59.8	45.6	78.5
		Tdap Vaccination Missing								39.8	69.4
	Penta group	Tdap Vaccination Yes	PIII(M5)	79	78	98.7	93.1	100	19.0	16.1	22.4
		Tdap Vaccination No	PIII(M5)				92.3	100	34.9	26.8	45.4
		Tdap Vaccination Missing					85.8		26.6	19.0	37.4
anti-FHA antibody	Hexa group	Tdap Vaccination Yes	PIII(M5)	81	81	100	95.5	100	94.3	80.4	110.6
		Tdap Vaccination No	PIII(M5)						136.0		165.8
		Tdap Vaccination Missing	PIII(M5)	25	25	100	86.3	100	105.9	82.5	135.9
	Pedia group	Tdap Vaccination Yes	PIII(M5)	74	74		95.1		108.6		125.4
		Tdap Vaccination No	PIII(M5)	42	42	100	91.6	100	166.3	133.6	207.0
		Tdap Vaccination Missing	PIII(M5)	33	33	100	89.4	100	109.6	86.0	139.6
	Penta group	Tdap Vaccination Yes	PIII(M5)				95.4		45.7	38.0	55.0
		Tdap Vaccination No	PIII(M5)	46	46	100	92.3	100	95.9	78.0	118.0
		Tdap Vaccination Missing					85.8		58.9	36.4	95.1
anti-PRN antibody	Hexa group	Tdap Vaccination Yes	PIII(M5)	81	81	100	95.5	100	48.8	40.1	59.3
		Tdap Vaccination No	PIII(M5)				91.2		71.2	55.2	92.0
		Tdap Vaccination Missing	PIII(M5)	25	25	100	86.3	100	68.9	44.6	106.4
	Pedia group	Tdap Vaccination Yes	PIII(M5)	74	74	100	95.1	100	34.4	28.0	42.3
		Tdap Vaccination No	PIII(M5)							38.0	80.1
		Tdap Vaccination Missing	PIII(M5)	33	33	100	89.4	100	76.4	58.3	100.1
	Penta group	Tdap Vaccination Yes	PIII(M5)	79	78	98.7	93.1	100	27.7	22.2	34.5
		Tdap Vaccination No	PIII(M5)						36.8	26.7	50.9
		Tdap Vaccination Missing	PIII(M5)	24	24	100	85.8	100	47.6	30.0	75.7

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

117119 (DTPA-HBV-IPV-135) Report Final

Table 7.4 Number and percentage of subjects with anti-D and anti-T antibody concentration equal to or above the assay cut-off, 0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC), one month post primary vaccination - by gender (Primary ATP cohort for immunogenicity)

						≥ cı	ut_of	f		≥ 0.1	IU/m	L		≥1	IU/ml	L		GMC	
							95%	CI			95%	6 CI			95%	6 CI		95%	6 CI
Antibody	Group	Sub-	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
		group																	
anti-D antibody	Hexa group	Female	PIII(M5)																
		Male	PIII(M5)	63	63	100	94.3	100	63	100	94.3	100	52	82.5	70.9	90.9	1.893	1.567	2.288
	Pedia group	Female	PIII(M5)	55	55	100	93.5	100	55	100	93.5	100	40	72.7	59.0	83.9	1.866	1.492	2.333
		Male	PIII(M5)	89	89	100	95.9	100	89	100	95.9	100	65	73.0	62.6	81.9	1.526	1.287	1.810
	Penta group	Female	PIII(M5)	71	71	100	94.9	100	71	100	94.9	100	44	62.0	49.7	73.2	1.335	1.114	1.599
		Male	PIII(M5)	78	78	100	95.4	100	78	100	95.4	100	44	56.4	44.7	67.6	1.176	0.970	1.427
anti-T antibody	Hexa group	Female	PIII(M5)	81	81	100	95.5	100	81	100	95.5	100	74	91.4	83.0	96.5	2.342	2.041	2.688
•		Male	PIII(M5)	65	65	100	94.5	100	65	100	94.5	100	56	86.2	75.3	93.5	2.610	2.157	3.159
	Pedia group	Female	PIII(M5)																
		Male	PIII(M5)	93	93	100	96.1	100	93	100	96.1	100	84	90.3	82.4	95.5	2.796	2.414	3.238
	Penta group	Female	PIII(M5)																
		Male	PIII(M5)	78	78	100	95.4	100	77	98.7	93.1	100	61	78.2	67.4	86.8	2.082	1.701	2.550

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Note: The assay cut off is 0.057 IU/mL for anti-D, 0.043 IU/mL for anti-T.

117119 (DTPA-HBV-IPV-135)

Report Final

Table 7.5 Number and percentage of subjects with anti-D and anti-T antibody concentration equal to or above the assay cut-off, 0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC), one month post primary vaccination – by geographical ancestry (Primary ATP cohort for immunogenicity)

							≥ cu	ıt_off	:	2	≥ 0.1	IU/m	L		≥1	IU/m	L		GMC	
								95%	CI			95%	G CI			95%	6 CI		95%	6 CI
Antibody	Group	Sub-group	Tim	ing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-D antibody	Hexa group	White Caucasian	PIII(M5)	91	91	100	96.0	100	91	100	96.0	100	69	75.8	65.7	84.2	1.633	1.377	1.937
		other	PIII(M5)	51	51	100	93.0	100	51	100	93.0	100	43	84.3	71.4	93.0	2.065	1.645	2.593
	Pedia group	White Caucasian	PIII(M5)	99	99	100	96.3	100	99	100	96.3	100	67	67.7	57.5	76.7	1.408	1.205	1.644
		other	PIII(M5)	45	45	100	92.1	100	45	100	92.1	100	38	84.4	70.5	93.5	2.330	1.828	2.971
	Penta group	White Caucasian	PIII(M5)	84	84	100	95.7	100	84	100	95.7	100	44	52.4	41.2	63.4	1.085	0.927	1.271
		other	PIII(M5)	65	65	100	94.5	100	65	100	94.5	100	44	67.7	54.9	78.8	1.499	1.203	1.866
anti-T antibody	Hexa group	White Caucasian	PIII(M5)	93	93	100	96.1	100	93	100	96.1	100	79	84.9	76.0	91.5	2.009	1.759	2.295
		other	PIII(M5)	53	53	100	93.3	100	53	100	93.3	100	51	96.2	87.0	99.5	3.502	2.946	4.163
	Pedia group	White Caucasian	PIII(M5)	101	101	100	96.4	100	101	100	96.4	100	89	88.1	80.2	93.7	2.383	2.058	2.761
		other	PIII(M5)	48	48	100	92.6	100	48	100	92.6	100	45	93.8	82.8	98.7	3.247	2.668	3.952
	Penta group	White Caucasian	PIII(M5)	84	84	100	95.7	100	83	98.8	93.5	100	67	79.8	69.6	87.7	1.813	1.521	2.162
		other	PIII(M5)	65	65	100	94.5	100	65	100	94.5	100	52	80.0	68.2	88.9	2.301	1.901	2.785

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Note: The assay cut off is 0.057 IU/mL for anti-D, 0.043 IU/mL for anti-T.

Table 7.6 Number and percentage of subjects with anti-D and anti-T antibody concentration equal to or above the assay cut-off, 0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC), one month post primary vaccination – by Tdap vaccination of mother (Primary ATP cohort for immunogenicity)

						≥ c	ut_of	f		≥ 0.1	IU/m	L		≥1	IU/m	L		GMC	
							95%	CI			95%	CI			95%	% CI		959	% CI
Antibody	Group	Sub-group	Timing					_		%				%	LL	_	value		UL
anti-D antibody	Hexa group	Tdap Vaccination Yes	PIII(M5)	78	78	100	95.4	100	78	100	95.4	100	55	70.5	59.1	80.3	1.440	1.194	1.737
		Tdap Vaccination No	PIII(M5)	40	40	100	91.2	100	40	100	91.2	100	39	97.5	86.8	99.9	2.432	2.027	2.918
		Tdap Vaccination Missing	PIII(M5)	24	24	100	85.8	100	24	100	85.8	100	18	75.0	53.3	90.2	2.083	1.390	3.121
	Pedia group		PIII(M5)																
			PIII(M5)																
		Tdap Vaccination Missing																	
	Penta group	Tdap Vaccination Yes	PIII(M5)	79	79	100	95.4	100	79	100	95.4	100	37	46.8	35.5	58.4	1.005	0.837	1.208
			PIII(M5)																
		Tdap Vaccination Missing	PIII(M5)	24	24	100	85.8	100	24	100	85.8	100	16	66.7	44.7	84.4	1.449	1.061	1.978
anti-T antibody	Hexa group	Tdap Vaccination Yes	PIII(M5)	81	81	100	95.5	100	81	100	95.5	100	71	87.7	78.5	93.9	2.405	2.065	2.801
-		Tdap Vaccination No	PIII(M5)	40	40	100	91.2	100	40	100	91.2	100	38	95.0	83.1	99.4	2.569	2.053	3.215
		Tdap Vaccination Missing	PIII(M5)	25	25	100	86.3	100	25	100	86.3	100	21	84.0	63.9	95.5	2.460	1.836	3.295
	Pedia group	Tdap Vaccination Yes	PIII(M5)	74	74	100	95.1	100	74	100	95.1	100	68	91.9	83.2	97.0	2.739	2.299	3.263
		Tdap Vaccination No	PIII(M5)	42	42	100	91.6	100	42	100	91.6	100	35	83.3	68.6	93.0	2.344	1.844	2.978
		Tdap Vaccination Missing	PIII(M5)	33	33	100	89.4	100	33	100	89.4	100	31	93.9	79.8	99.3	2.795	2.225	3.513
	Penta group	Tdap Vaccination Yes	PIII(M5)	79	79	100	95.4	100	78	98.7	93.1	100	66	83.5	73.5	90.9	2.180	1.804	2.633
		Tdap Vaccination No	PIII(M5)	46	46	100	92.3	100	46	100	92.3	100	33	71.7	56.5	84.0	1.850	1.456	2.351
		Tdap Vaccination Missing	PIII(M5)	24	24	100	85.8	100	24	100	85.8	100	20	83.3	62.6	95.3	1.815	1.405	2.345

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Note: The assay cut off is 0.057 IU/mL for anti-D, 0.043 IU/mL for anti-T

Table 7.7 Number and percentage of subjects with anti-Polio 1, 2, and 3 antibody titer equal to or above 8 and geometric mean titer (GMT), one month post primary vaccination - by gender (Primary ATP cohort for immunogenicity)

						≥ 8	ED50)		GMT	
							95%	6 CI		959	% CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	value	LL	UL
anti-Polio 1 antibody	Hexa group	Female	PIII(M5)	76	76	100	95.3	100	730.9	564.8	945.8
		Male	PIII(M5)	61	61	100	94.1	100	381.0	283.0	513.1
	Pedia group	Female	PIII(M5)	51	51	100	93.0	100	846.6	631.0	1135.8
		Male	PIII(M5)	83	83	100	95.7	100	491.0	379.8	634.8
	Penta group	Female	PIII(M5)	66	66	100	94.6	100	461.0	342.5	620.3
		Male	PIII(M5)	70	69	98.6	92.3	100	226.1	166.9	306.4
anti-Polio 2 antibody	Hexa group	Female	PIII(M5)	74	74	100	95.1	100	551.7	409.8	742.8
		Male	PIII(M5)	59	59	100	93.9	100	409.7	311.7	538.5
	Pedia group	Female	PIII(M5)	49	49	100	92.7	100	660.6	443.6	984.0
		Male	PIII(M5)	82	82	100	95.6	100	518.5	386.0	696.6
	Penta group	Female	PIII(M5)	65	65	100	94.5	100	356.1	260.9	486.1
		Male	PIII(M5)	69	69	100	94.8	100	228.0	172.0	302.2
anti-Polio 3 antibody	Hexa group	Female	PIII(M5)	74	74	100	95.1	100	889.7	658.1	1202.9
		Male	PIII(M5)	55	55	100	93.5	100	545.5	392.6	757.9
	Pedia group	Female	PIII(M5)	52	52	100	93.2	100	1154.6	808.5	1648.8
		Male	PIII(M5)	80	80	100	95.5	100	803.8	601.0	1075.0
	Penta group	Female	PIII(M5)	63	63	100	94.3	100	458.7	322.4	652.6
		Male	PIII(M5)	63	61	96.8	89.0	99.6	189.2	123.2	290.7

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 7.8 Number and percentage of subjects with anti-Polio 1, 2, and 3 antibody titer equal to or above 8 and geometric mean titer (GMT), one month post primary vaccination – by geographical ancestry (Primary ATP cohort for immunogenicity)

						≥ 8	ED50)		GMT	
							95%	6 CI		95%	6 CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	value	LL	UL
anti-Polio 1 antibody	Hexa group	White Caucasian	PIII(M5)	87	87	100	95.8	100	465.4	359.0	603.4
		other	PIII(M5)	50	50	100	92.9	100	724.1	533.1	983.6
	Pedia group	White Caucasian	PIII(M5)	91	91	100	96.0	100	506.2	393.1	651.7
		other	PIII(M5)	43	43	100	91.8	100	878.6	660.5	1168.7
	Penta group	White Caucasian	PIII(M5)	75	74	98.7	92.8	100	305.1	220.2	422.7
		other	PIII(M5)	61	61	100	94.1	100	338.2	254.0	450.2
anti-Polio 2 antibody	Hexa group	White Caucasian	PIII(M5)	84	84	100	95.7	100	396.4	303.7	517.4
		other	PIII(M5)	49	49	100	92.7	100	679.5	502.5	918.9
	Pedia group	White Caucasian	PIII(M5)	88	88	100	95.9	100	494.3	367.1	665.5
		other	PIII(M5)	43	43	100	91.8	100	753.7	515.9	1101.2
	Penta group	White Caucasian	PIII(M5)	76	76	100	95.3	100	265.3	199.8	352.2
		other	PIII(M5)	58	58	100	93.8	100	308.2	223.5	424.9
anti-Polio 3 antibody	Hexa group	White Caucasian	PIII(M5)	83	83	100	95.7	100	566.1	424.8	754.3
		other	PIII(M5)	46	46	100	92.3	100	1121.0	805.9	1559.2
	Pedia group	White Caucasian	PIII(M5)	91	91	100	96.0	100	721.6	543.8	957.6
		other	PIII(M5)	41	41	100	91.4	100	1616.3	1188.0	2199.1
	Penta group	White Caucasian	PIII(M5)	67	65	97.0	89.6	99.6	244.3	160.9	371.1
		other	PIII(M5)	59	59	100	93.9	100	364.4	247.6	536.2

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 7.9 Number and percentage of subjects with anti-Polio 1, 2, and 3 antibody titer equal to or above 8 and geometric mean titer (GMT), one month post primary vaccination – by Tdap vaccination of mother (Primary ATP cohort for immunogenicity)

						≥8	ED50)		GMT	
							95%	6 CI		959	% CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL			UL
anti-Polio 1 antibody	Hexa group	Tdap Vaccination Yes	PIII(M5)	76	76	100	95.3	100	526.1	396.3	698.5
		Tdap Vaccination No	PIII(M5)							373.0	
		Tdap Vaccination Missing	PIII(M5)						645.5		1078.0
	Pedia group	Tdap Vaccination Yes	PIII(M5)				94.9	100	619.4	491.4	780.7
		Tdap Vaccination No	PIII(M5)						640.9		1035.6
		Tdap Vaccination Missing								321.3	
	Penta group	Tdap Vaccination Yes	PIII(M5)	70	69	98.6	92.3	100	307.3	221.1	427.2
		Tdap Vaccination No	PIII(M5)							207.4	
		Tdap Vaccination Missing								239.2	
anti-Polio 2 antibody	Hexa group	Tdap Vaccination Yes	PIII(M5)						421.7	318.4	
		Tdap Vaccination No	PIII(M5)	37	37	100	90.5	100	531.5	378.3	
		Tdap Vaccination Missing	PIII(M5)						666.7		1220.5
	Pedia group	Tdap Vaccination Yes	PIII(M5)							379.3	
		Tdap Vaccination No	PIII(M5)								1283.4
		Tdap Vaccination Missing								220.1	
	Penta group	Tdap Vaccination Yes	PIII(M5)	69	69	100	94.8	100	278.8	210.0	370.1
		Tdap Vaccination No	PIII(M5)						247.1	165.5	
		Tdap Vaccination Missing								214.4	
anti-Polio 3 antibody	Hexa group	Tdap Vaccination Yes	PIII(M5)							542.9	
		Tdap Vaccination No	PIII(M5)								1036.6
		Tdap Vaccination Missing	PIII(M5)	24	24				767.4		1431.1
	Pedia group	Tdap Vaccination Yes	PIII(M5)						1029.3		
		Tdap Vaccination No	PIII(M5)						1004.9		
		Tdap Vaccination Missing									1160.7
	Penta group	Tdap Vaccination Yes	PIII(M5)								374.9
		Tdap Vaccination No	PIII(M5)							187.6	
		Tdap Vaccination Missing								253.6	

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 7.10 Number and percentage of subjects with anti-PRP antibody concentration equal to or above the assay cut-off, 0.15 μg/mL and 1.0 μg/mL and geometric mean concentration (GMC), one month post primary vaccination – by study lot (Primary ATP cohort for immunogenicity)

					≥cu	t_of		≥	0.15	μg/n	ηL		≥1µ	ıg/ml	_		GMC	
						95%	6 CI			95%	6 CI			95%	6 CI		959	% CI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-PRP – qualified assay	Hexa_1 group	PIII(M5)	53	50	94.3	84.3	98.8	50	94.3	84.3	98.8	34	64.2	49.8	76.9	1.461	1.002	2.132
	Hexa_2 group	PIII(M5)	48	45	93.8	82.8	98.7	45	93.8	82.8	98.7	24	50.0	35.2	64.8	1.204	0.778	1.865
	Hexa_3 group	PIII(M5)	48	45	93.8	82.8	98.7	45	93.8	82.8	98.7	25	52.1	37.2	66.7	1.461	0.934	2.285
	Pedia group	PIII(M5)	153	151	98.7	95.4	99.8	151	98.7	95.4	99.8	144	94.1	89.1	97.3	10.327	8.127	13.122
	Penta group	PIII(M5)	153	151	98.7	95.4	99.8	151	98.7	95.4	99.8	126	82.4	75.4	88.0	6.485	4.922	8.544
anti-PRP - fully validated assay	Hexa_1 group	PIII(M5)	54	54	100	93.4	100	53	98.1	90.1	100	34	63.0	48.7	75.7	1.546	1.084	2.204
	Hexa_2 group																0.754	1.720
	Hexa_3 group	PIII(M5)	49	48	98.0	89.1	99.9	47	95.9	86.0	99.5	24	49.0	34.4	63.7	1.381	0.901	2.115
	Pedia group	PIII(M5)	154	153	99.4	96.4	100	151	98.1	94.4	99.6	145	94.2	89.2	97.3	9.258	7.362	11.642
	Penta group	PIII(M5)	156	154	98.7	95.4	99.8	154	98.7	95.4	99.8	130	83.3	76.5	88.8	5.717	4.363	7.492

Hexa_1 group = Subjects who received primary doses of Infanrix hexa from lot A and a booster dose of Infanrix and Hiberix vaccines

Hexa_2 group = Subjects who received primary doses of Infanrix hexa from lot B and a booster dose of Infanrix and Hiberix vaccines

Hexa 3 group = Subjects who received primary doses of Infanrix hexa from lot C and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Note: Two assays were used for anti-PRP, for the fully validated assay, the assay cut off is $0.066 \,\mu\text{g/mL}$ while $0.15 \,\mu\text{g/mL}$ was used for the qualified assay.

Table 7.11 Number and percentage of subjects with anti-PRP antibody concentration equal to or above the assay cut-off, 0.15 μg/mL and 1.0 μg/mL and geometric mean concentration (GMC), one month post primary vaccination – by gender (Primary ATP cohort for immunogenicity)

						≥c	ut_of	ff	≥	≥ 0.15	μg/i	mL		≥1	μg/m	L		GMC	
							959	% CI			95%	6 CI			95%	6 CI		95	% CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-PRP – qualified assay	Hexa group	Female	PIII(M5	83 (78	94.0	86.5	98.0	78	94.0	86.5	98.0	46	55.4	44.1	66.3	1.365	0.985	1.892
		Male	PIII(M5	66 (62	93.9	85.2	98.3	62	93.9	85.2	98.3	37	56.1	43.3	68.3	1.383	0.972	1.967
	Pedia group	Female	PIII(M5	60	59	98.3	91.1	100	59	98.3	91.1	100	57	95.0	86.1	99.0	10.639	7.271	15.568
		Male	PIII(M5	93	92	98.9	94.2	100	92	98.9	94.2	100	87	93.5	86.5	97.6	10.130	7.401	13.866
	Penta group	Female	PIII(M5	74	73	98.6	92.7	100	73	98.6	92.7	100	63	85.1	75.0	92.3	7.881	5.403	11.496
		Male	PIII(M5	79	78	98.7	93.1	100	78	98.7	93.1	100	63	79.7	69.2	88.0	5.402	3.606	8.091
anti-PRP - fully validated assay	Hexa group	Female	PIII(M5	85	84	98.8	93.6	100	80	94.1	86.8	98.1	46	54.1	43.0	65.0	1.328	0.972	1.813
		Male	PIII(M5	69	68	98.6	92.2	100	66	95.7	87.8	99.1	39	56.5	44.0	68.4	1.373	0.985	1.914
	Pedia group	Female	PIII(M5	61	60	98.4	91.2	100	60	98.4	91.2	100	58	95.1	86.3	99.0	9.251	6.348	13.482
		Male	PIII(M5	93	93	100	96.1	100	91	97.8	92.4	99.7	87	93.5	86.5	97.6	9.262	6.904	12.426
	Penta group	Female	PIII(M5	74	74	100	95.1	100	74	100	95.1	100	64	86.5	76.5	93.3	6.995	4.903	9.980
		Male	PIII(M5	82	80	97.6	91.5	99.7	80	97.6	91.5	99.7	66	80.5	70.3	88.4	4.766	3.179	7.146

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Note: Two assays were used for anti-PRP, for the fully validated assay, the assay cut off is 0.066 µg/mL while 0.15 µg/mL was used for the qualified assay.

Table 7.12 Number and percentage of subjects with anti-PRP antibody concentration equal to or above the assay cut-off, 0.15 μg/mL and 1.0 μg/mL and geometric mean concentration (GMC), one month post primary vaccination – by geographical ancestry (Primary ATP cohort for immunogenicity)

						≥cı	t_off		≥	0.15	μg/n	nL		≥1	μg/m	L		GMC	
							95%	6 CI			95%	6 CI			95%	6 CI		95%	6 CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-PRP – qualified assay	Hexa group	White Caucasian	PIII(M5)	95	87	91.6	84.1	96.3	87	91.6	84.1	96.3	49	51.6	41.1	62.0	1.090	0.818	1.453
		other	PIII(M5)	54	53	98.1	90.1	100	53	98.1	90.1	100	34	63.0	48.7	75.7	2.061	1.377	3.085
	Pedia group	White Caucasian	PIII(M5)	103	101	98.1	93.2	99.8	101	98.1	93.2	99.8	95	92.2	85.3	96.6	7.778	5.747	10.529
		other	PIII(M5)	50	50	100	92.9	100	50	100	92.9	100	49	98.0	89.4	99.9	18.514	13.122	26.122
	Penta group	White Caucasian	PIII(M5)	88	88	100	95.9	100	88	100	95.9	100	72	81.8	72.2	89.2	6.058	4.218	8.699
		other	PIII(M5)	65	63	96.9	89.3	99.6	63	96.9	89.3	99.6	54	83.1	71.7	91.2	7.111	4.598	10.999
anti-PRP - fully validated assay	Hexa group	White Caucasian	PIII(M5)	98	97	99.0	94.4	100	92	93.9	87.1	97.7	50	51.0	40.7	61.3	1.151	0.880	1.507
		other	PIII(M5)	56	55	98.2	90.4	100	54	96.4	87.7	99.6	35	62.5	48.5	75.1	1.775	1.187	2.654
	Pedia group	White Caucasian	PIII(M5)	104	103	99.0	94.8	100	101	97.1	91.8	99.4	97	93.3	86.6	97.3	7.173	5.368	9.585
		other	PIII(M5)	50	50	100	92.9	100	50	100	92.9	100	48	96.0	86.3	99.5	15.739	11.279	21.963
	Penta group	White Caucasian	PIII(M5)	89	88	98.9	93.9	100	88	98.9	93.9	100	74	83.1	73.7	90.2	5.592	3.896	8.027
		other	PIII(M5)	67	66	98.5	92.0	100	66	98.5	92.0	100	56	83.6	72.5	91.5	5.887	3.876	8.942

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Note: Two assays were used for anti-PRP, for the fully validated assay, the assay cut off is 0.066 µg/mL while 0.15 µg/mL was used for the qualified assay.

Table 7.13 Number and percentage of subjects with anti-PRP antibody concentration equal to or above the assay cut-off, 0.15 μg/mL and 1.0 μg/mL and geometric mean concentration (GMC), one month post primary vaccination – by Tdap vaccination of mother (Primary ATP cohort for immunogenicity)

							≥ cu	t_off	L	2	: 0.1	i μg/	mL		≥1	μg/n	ıL		GMC	
								95%	6 CI			959	% CI				% CI		95%	% CI
Antibody	Group	Sub-group	Timi					LL					UL		%	LL	UL	value	LL	UL
anti-PRP – qualified assay	Hexa group	Tdap Vaccination Yes	PIII(I	M5)	81	73	90.1	81.5	95.6	73	90.1	81.5	95.6	47	58.0	46.5	68.9	1.223	0.881	1.698
		Tdap Vaccination No	PIII(I	M5)	41	41	100	91.4	100	41	100	91.4	100	23	56.1	39.7	71.5	1.866	1.210	2.879
		Tdap Vaccination Missing	PIII(I	M5)	27	26	96.3	81.0	99.9	26	96.3	81.0	99.9	13	48.1	28.7	68.1	1.219	0.670	2.219
	Pedia group	Tdap Vaccination Yes	PIII(I	M5)	77	77	100	95.3	100	77	100	95.3	100	75	97.4	90.9	99.7	14.977	11.254	19.932
		Tdap Vaccination No	PIII(I	M5)	43	41	95.3	84.2	99.4	41	95.3	84.2	99.4	38	88.4	74.9	96.1	6.289	3.652	10.828
		Tdap Vaccination Missing	PIII(I	M5)	33	33	100	89.4	100	33	100	89.4	100	31	93.9	79.8	99.3	8.277	4.942	13.863
	Penta group	Tdap Vaccination Yes	PIII(I	M5)	80	80	100	95.5	100	80	100	95.5	100	70	87.5	78.2	93.8	9.628	6.653	13.934
		Tdap Vaccination No	PIII(I	M5)	49	47	95.9	86.0	99.5	47	95.9	86.0	99.5	37	75.5	61.1	86.7	3.469	2.134	5.637
		Tdap Vaccination Missing																	3.045	12.748
anti-PRP – fully validated assay	Hexa group	Tdap Vaccination Yes	PIII(I	M5)	83	81	97.6	91.6	99.7	78	94.0	86.5	98.0	47	56.6	45.3	67.5	1.182	0.872	1.601
		Tdap Vaccination No																1.776	1.145	2.756
		Tdap Vaccination Missing	PIII(I	M5)	29	29	100	88.1	100	28	96.6	82.2	99.9	14	48.3	29.4	67.5	1.316	0.751	2.305
	Pedia group	Tdap Vaccination Yes	PIII(I	M5)	79	79	100	95.4	100	79	100	95.4	100	76	96.2	89.3	99.2	12.839	9.743	16.918
		Tdap Vaccination No	PIII(I	M5)	42	41	97.6	87.4	99.9	39	92.9	80.5	98.5	38	90.5	77.4	97.3	5.844	3.440	9.926
		Tdap Vaccination Missing	PIII(I	M5)	33	33	100	89.4	100	33	100	89.4	100	31	93.9	79.8	99.3	7.600	4.649	12.427
	Penta group	Tdap Vaccination Yes																8.584	5.963	12.358
		Tdap Vaccination No	PIII(I	M5)	51	50	98.0	89.6	100	50	98.0	89.6	100	37	72.5	58.3	84.1	3.003	1.882	4.791
		Tdap Vaccination Missing	PIII(I	M5)	24	24	100	85.8	100	24	100	85.8	100	21	87.5	67.6	97.3	5.699	2.833	11.463

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Note: Two assays were used for anti-PRP, for the fully validated assay, the assay cut off is 0.066 µg/mL while 0.15 µg/mL was used for the qualified assay.

Table 7.14 Number and percentage of subjects with anti-HBs antibody concentration equal to or above 6.2 mlU/mL and 10.0 mlU/mL and geometric mean concentration (GMC), one month post primary vaccination - by gender (Primary ATP cohort for immunogenicity)

					2	≥ 6.2	mIU/r	nL	2	≥ 10	mIU/r	nL		GMC	
							95%	CI			95%	6 CI		95%	6 CI
Antibody	Group	Sub-group	Timin	ng N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-HBs antibody	Hexa group	Female	PIII(N	15) 7	3 73	100	95.1	100	73	100	95.1	100	2283.9	1870.9	2788.1
		Male	PIII(N	15) 6	1 61	100	94.1	100	61	100	94.1	100	2229.2	1674.2	2968.2
	Pedia group	Female	PIII(N	15) 5	2 52	100	93.2	100	52	100	93.2	100	2266.7	1763.9	2912.8
		Male	PIII(N	15) 8	6 86	100	95.8	100	86	100	95.8	100	1687.6	1303.4	2185.0
	Penta group	Female	PIII(N	15) 6	8 67	98.5	92.1	100	67	98.5	92.1	100	1493.6	1014.0	2200.0
		Male	PIII(N	15) 6	8 67	98.5	92.1	100	66	97.1	89.8	99.6	743.0	472.1	1169.3

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Table 7.15 Number and percentage of subjects with anti-HBs antibody concentration equal to or above 6.2 mlU/mL and 10.0 mlU/mL and geometric mean concentration (GMC), one month post primary vaccination – by geographical ancestry (Primary ATP cohort for immunogenicity)

					2	6.2	mIU/r	nL	3	≥ 10 :	mIU/r	nL		GMC	
							95%	6 CI			95%	6 CI		95%	6 CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-HBs	Hexa	White	PIII(M5)	84	84	100	95.7	100	84	100	95.7	100	2277.1	1822.9	2844.5
antibody	group	Caucasian													
		other	PIII(M5)	50	50	100	92.9	100	50	100	92.9	100	2228.5	1721.7	2884.5
	Pedia	White	PIII(M5)	91	91	100	96.0	100	91	100	96.0	100	1734.9	1351.0	2227.9
	group	Caucasian	, ,												
		other	PIII(M5)	47	47	100	92.5	100	47	100	92.5	100	2216.9	1710.4	2873.6
	Penta	White	PIII(M5)	78	77	98.7	93.1	100	76	97.4	91.0	99.7	889.0	587.5	1345.2
	group	Caucasian	, ,												
		other	PIII(M5)	58	57	98.3	90.8	100	57	98.3	90.8	100	1323.5	854.2	2050.7

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 7.16 Number and percentage of subjects with anti-HBs antibody concentration equal to or above 6.2 mlU/mL and 10.0 mlU/mL and geometric mean concentration (GMC), one month post primary vaccination – by Tdap vaccination of mother (Primary ATP cohort for immunogenicity)

		·			2	≥ 6.2	mlŪ/	mĹ	2	≥ 10	mIU/r	nL		GMC	
							95%	% CI			95%	6 CI		95%	6 CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-HBs antibody	Hexa group	Tdap Vaccination Yes	PIII(M5)	74	74	100	95.1	100	74	100	95.1	100	2014.5	1571.2	2582.8
,		Tdap Vaccination No	PIII(M5)	38	38	100	90.7	100	38	100	90.7	100	2652.1	2030.0	3464.8
		Tdap Vaccination Missing	PIII(M5)	22	22	100	84.6	100	22	100	84.6	100	2516.2	1689.4	3747.8
	Pedia group	Tdap Vaccination Yes	PIII(M5)	71	71	100	94.9	100	71	100	94.9	100	2001.3	1536.4	2606.9
		Tdap Vaccination No	PIII(M5)	37	37	100	90.5	100	37	100	90.5	100	1651.9	1125.6	2424.3
		Tdap Vaccination Missing	PIII(M5)	30	30	100	88.4	100	30	100	88.4	100	1930.0	1306.3	2851.5
	Penta group	Tdap Vaccination Yes	PIII(M5)	71	70	98.6	92.4	100	69	97.2	90.2	99.7	1160.4	763.4	1763.8
		Tdap Vaccination No	PIII(M5)	41	40	97.6	87.1	99.9	40	97.6	87.1	99.9	893.7	488.4	1635.3
		Tdap Vaccination Missing	PIII(M5)	24	24	100	85.8	100	24	100	85.8	100	1048.1	542.9	2023.5

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 7.17 Number and percentage of subjects with anti-HBs antibody concentration equal to or above 6.2 mlU/mL and 10.0 mlU/mL and geometric mean concentration (GMC), one month post primary vaccination – by Hepatitis B vaccination of subject (Primary ATP cohort for immunogenicity)

					≥	6.2 ו	nIU/r	nL	≥	: 10 n	nIU/n	ıL		GMC	
							95%	6 CI			95%	6 CI		95%	6 CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-HBs	Hexa	HepB at birth	PIII(M5)	124	124	100	97.1	100	124	100	97.1	100	2322.2	1951.3	2763.6
antibody	group	Yes													
		HepB at birth	PIII(M5)	10	10	100	69.2	100	10	100	69.2	100	1602.9	799.9	3212.1
		No													
	Pedia	HepB at birth	PIII(M5)	122	122	100	97.0	100	122	100	97.0	100	2026.9	1681.8	2442.9
	group	Yes													
		HepB at birth	PIII(M5)	16	16	100	79.4	100	16	100	79.4	100	1088.7	506.6	2339.6
		No													
	Penta	HepB at birth	PIII(M5)	126	124	98.4	94.4	99.8	123	97.6	93.2	99.5	1043.4	755.4	1441.2
	group	Yes													
		HepB at birth	PIII(M5)	10	10	100	69.2	100	10	100	69.2	100	1188.2	755.3	1869.1
		No													

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Figure 7.1 Reverse cumulative distribution curves for anti-PT concentrations one month post primary vaccination (Primary ATP cohort for immunogenicity)




Figure 7.2 Reverse cumulative distribution curves for anti-FHA concentrations one month post primary vaccination (Primary ATP cohort for immunogenicity)




Figure 7.3 Reverse cumulative distribution curves for anti-PRN concentrations one month post primary vaccination (Primary ATP cohort for immunogenicity)




Figure 7.4 Reverse cumulative distribution curves for anti-D concentrations one month post primary vaccination (Primary ATP cohort for immunogenicity)




Figure 7.5 Reverse cumulative distribution curves for anti-T concentrations one month post primary vaccination (Primary ATP cohort for immunogenicity)




Figure 7.6 Reverse cumulative distribution curves for anti-Polio 1 titers one month post primary vaccination (Primary ATP cohort for immunogenicity)




Figure 7.7 Reverse cumulative distribution curves for anti-Polio 2 titers one month post primary vaccination (Primary ATP cohort for immunogenicity)




Figure 7.8 Reverse cumulative distribution curves for anti-Polio 3 titers one month post primary vaccination (Primary ATP cohort for immunogenicity)




Figure 7.9 Reverse cumulative distribution curves for anti-PRP (fully validated assay) concentrations one month post primary vaccination (Primary ATP cohort for immunogenicity)




Figure 7.10 Reverse cumulative distribution curves for anti-PRP (qualified assay) concentrations one month post primary vaccination (Primary ATP cohort for immunogenicity)




Figure 7.11 Reverse cumulative distribution curves for anti-HBs concentrations one month post primary vaccination (Primary ATP cohort for immunogenicity)




Table 7.18 Ratio of GMCs/GMTs for antibody concentrations/titers between groups (Pedia group divided by Hexa group), one month post primary vaccination (Primary ATP cohort for immunogenicity)

							io ka group)
Antibody	Ped N	dia group Adjusted		xa group Adjusted	Value		% CI UL
Antibody	IN	GMC/T	IN	GMC/T	value	LL	UL
anti-D antibody (IU/mL)	144	1.629	142	1.795	0.91	0.75	1.09
anti-T antibody (IU/mL)	149	2.635	146	2.454	1.07	0.91	1.27
anti-Polio 1 antibody (ED50)	134	603.4	137	547.2	1.10	0.83	1.47
anti-Polio 2 antibody (ED50)	131	567.0	133	485.8	1.17	0.86	1.58
anti-Polio 3 antibody (ED50)	132	926.5	129	722.8	1.28	0.91	1.81
anti-PRP – qualified assay (µg/mL)	153	10.380	149	1.359	7.64	5.37	10.86
anti-PRP - fully validated assay (µg/mL)	154	9.249	154	1.337	6.92	4.93	9.71

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Adjusted GMC/T = geometric mean antibody concentration/titer adjusted for Tdap vaccination of the mother N = Number of subjects with both pre- and post-primary vaccination results available

95% CI = 95% confidence interval for the adjusted GMC ratio (ANCOVA model: adjustment for Tdap vaccination of mother - pooled variance); LL = lower limit, UL = upper limit

Table 7.19 Ratio of GMCs/GMTs for antibody concentrations/titers between groups (Penta group divided by Hexa group), one month post primary vaccination (Primary ATP cohort for immunogenicity)

						djusted MC/T ratio up / Hexa	
	Per	nta group		xa group		95%	6 CI
Antibody	N	Adjusted	N	Adjusted	Value	LL	UL
		GMC/T		GMC/T			
anti-PT antibody (IU/mL)	149	24.2	146	43.6	0.55	0.47	0.66
anti-FHA antibody (IU/mL)	149	59.4	146	107.3	0.55	0.47	0.65
anti-PRN antibody (IU/mL)	149	33.2	146	58.2	0.57	0.46	0.71
anti-D antibody (IU/mL)	149	1.251	142	1.795	0.70	0.58	0.84
anti-T antibody (IU/mL)	149	2.014	146	2.454	0.82	0.69	0.97
anti-Polio 1 antibody (ED50)	136	319.6	137	547.2	0.58	0.44	0.78
anti-Polio 2 antibody (ED50)	134	282.1	133	485.8	0.58	0.43	0.79
anti-Polio 3 antibody (ED50)	126	294.5	129	722.8	0.41	0.29	0.58
anti-PRP – qualified assay (µg/mL)	153	6.514	149	1.359	4.79	3.37	6.81
anti-PRP – fully validated assay (µg/mL)	156	5.769	154	1.337	4.32	3.08	6.06

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Adjusted GMC/T = geometric mean antibody concentration/titer adjusted for Tdap vaccination of the mother N = Number of subjects with both pre- and post-primary vaccination results available

95% CI = 95% confidence interval for the adjusted GMC ratio (ANCOVA model: adjustment for Tdap vaccination of mother - pooled variance); LL = lower limit, UL = upper limit

117119 (DTPA-HBV-IPV-135) Report Final

Table 7.20 Ratio of GMC for anti-HBs antibody concentrations between groups (Pedia group divided by Hexa group), one month post primary vaccination (Primary ATP cohort for immunogenicity)

				(Pedia ç	Adjusted GMC rati group / He	
Ped	dia group	He	xa group		9	5% CI
N	Adjusted GMC	N	Adjusted GMC	Value	LL	UL
138	1899.9	134	2250.0	0.84	0.61	1.16

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Adjusted GMC/T = geometric mean antibody concentration/titer adjusted for Tdap vaccination of the mother and Hepatitis B vaccination of the subject

N = Number of subjects with both pre- and post-primary vaccination results available

95% CI = 95% confidence interval for the adjusted GMC ratio (ANCOVA model: adjustment for Tdap vaccination of mother and Hepatitis B vaccination history of the subject - pooled variance); LL = lower limit, UL = upper limit

Table 7.21 Ratio of GMC for anti-HBs antibody concentrations between groups (Penta group divided by Hexa group), one month post primary vaccination (Primary ATP cohort for immunogenicity)

					djusted MC ratio up / Hexa	a group)
Penta group Hexa group					95%	6 CI
N	Adjusted GMC	N	Adjusted GMC	Value	LL	UL
136	1049.7	134	2250.0	0.47	0.34	0.64

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Adjusted GMC/T = geometric mean antibody concentration/titer adjusted for Tdap vaccination of the mother and Hepatitis B vaccination of the subject

N = Number of subjects with both pre- and post-primary vaccination results available

95% CI = 95% confidence interval for the adjusted GMC ratio (ANCOVA model: adjustment for Tdap vaccination of mother and Hepatitis B vaccination history of the subject - pooled variance); LL = lower limit, UL = upper limit

117119 (DTPA-HBV-IPV-135) Report Final

Table 7.22 Difference between groups (Pedia group minus Hexa group) in percentage of subjects with antibody concentration/titer equal to or above the proposed cut-off, one month post primary vaccination (Primary ATP cohort for immunogenicity)

		Hex	ca gr	oup	Ped	lia gi	roup	in ¡ (Pedia He	ifference percental group exa grou 95%	age minus ıp)
Antibody	Type	N	n	%	N	n	%	%	LL	UL
anti-D antibody	0.1 IU/mL	142	142	100	144	144	100	0.00	-2.61	2.64
	1 IU/mL	142	112	78.9	144	105	72.9	-5.96	-15.85	4.01
anti-T antibody	0.1 IU/mL	146	146	100	149	149	100	0.00	-2.52	2.57
-	1 IU/mL	146	130	89.0	149	134	89.9	0.89	-6.32	8.18
anti-Polio 1 antibody	8 ED50	137	137	100	134	134	100	0.00	-2.80	2.74
anti-Polio 2 antibody	8 ED50	133	133	100	131	131	100	0.00	-2.86	2.82
anti-Polio 3 antibody	8 ED50	129	129	100	132	132	100	0.00	-2.84	2.90
anti-PRP – qualified assay	0.15 µg/mL	149	140	94.0	153	151	98.7	4.73	0.59	9.95
	1 µg/mL	149	83	55.7	153	144	94.1	38.41	29.52	47.11
anti-PRP - fully validated assay	0.15 µg/mL	154	146	94.8	154	151	98.1	3.25	-1.06	8.23
-	1 µg/mL	154	85	55.2	154	145	94.2	38.96	30.17	47.53
anti-HBs antibody	10 mIU/mL	141	141	100	147	147	100	0.00	-2.56	2.66

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

N = number of subjects with available results

n/% = number/percentage of subjects with titer and concentration within the specified range

95% CI = Standardized asymptotic 95% confidence interval; LL = lower limit, UL = upper limit

Table 7.23 Difference between groups (Penta group minus Hexa group) in percentage of subjects with antibody concentration/titer equal to or above the proposed cut-off, one month post primary vaccination (Primary ATP cohort for immunogenicity)

		Hex	ca qı	oup	Pen	ta q	roup	in p (Penta He:	fference ercenta group xa grou 95%	age minus ıp)
Antibody	Туре	N	n	%	N	n		%	LL	UL
anti-D antibody	0.1 IU/mL	142	142	100	149	149	100	0.00	-2.52	2.64
,	1 IU/mL	142	112	78.9	149	88	59.1	-19.81	-29.98	-9.26
anti-T antibody	0.1 IU/mL	146	146	100	149	148	99.3	-0.67	-3.71	1.91
	1 IU/mL	146	130	89.0	149	119	79.9	-9.18	-17.57	-0.91
anti-Polio 1 antibody	8 ED50	137	137	100	136	135	99.3	-0.74	-4.06	2.01
anti-Polio 2 antibody	8 ED50	133	133	100	134	134	100	0.00	-2.80	2.82
anti-Polio 3 antibody	8 ED50	129	129	100	126	124	98.4	-1.59	-5.61	1.34
anti-PRP – qualified assay	0.15 µg/mL	149	140	94.0	153	151	98.7	4.73	0.59	9.95
	1 µg/mL	149	83	55.7	153	126	82.4	26.65	16.44	36.44
anti-PRP - fully validated assay	0.15 µg/mL	154	146	94.8	156	154	98.7	3.91	-0.03	8.80
	1 µg/mL	154	85	55.2	156	130	83.3	28.14	18.14	37.71
anti-HBs antibody	10 mIU/mL	141	141	100	146	143	97.9	-2.05	-5.88	0.63

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects with available results

n/% = number/percentage of subjects with titer and concentration within the specified range

95% CI = Standardized asymptotic 95% confidence interval; LL = lower limit, UL = upper limit

Table 7.24 Number and percentage of subjects with anti-PT, anti-FHA and anti-PRN antibody concentration equal to or above the assay cut-off and geometric mean concentration (GMC), before and one month post booster vaccination - by gender (Booster ATP cohort for immunogenicity)

						≥ c	ut_of		GMC		
							959	95% CI		95% CI	
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	value	LL	UL
anti-PT antibody	Hexa group	Female	PRE-BST	70	55	78.6	67.1	87.5	4.9	4.0	6.1
			POST-BST	72	72	100	95.0	100	73.7	62.4	87.0
		Male	PRE-BST	61	52	85.2	73.8	93.0	5.9	4.7	7.3
			POST-BST	66	66	100	94.6	100	69.0	55.7	85.4
	Pedia group	Female	PRE-BST	45	40	88.9	75.9	96.3	6.8	5.1	9.0
			POST-BST	47	47	100	92.5	100	86.5	66.6	112.5
		Male	PRE-BST	87	74	85.1	75.8	91.8	6.4	5.3	7.8
			POST-BST	89	89	100	95.9	100	88.2	75.4	103.1
	Penta group	Female	PRE-BST	53	29	54.7	40.4	68.4	3.0	2.4	3.8
			POST-BST	57	57	100	93.7	100	50.6	40.4	63.3
		Male	PRE-BST	68	34	50.0	37.6	62.4	3.1	2.4	4.0
			POST-BST	69	69	100	94.8	100	59.9	47.8	75.2
anti-FHA antibody	Hexa group	Female	PRE-BST	70	69	98.6	92.3	100	16.3	13.2	20.2
			POST-BST	72	72	100	95.0	100	190.3	162.4	222.9
		Male	PRE-BST	61	61	100	94.1	100	18.0	14.5	22.5
			POST-BST	66	66	100	94.6	100	183.2	150.3	223.3
	Pedia group	Female	PRE-BST	45	45	100	92.1	100	20.8	15.7	27.6
			POST-BST	47	47	100	92.5	100	255.0	200.3	324.6
		Male	PRE-BST	87	85	97.7	91.9	99.7	22.4	17.8	28.2
			POST-BST	89	89	100	95.9	100	248.0	213.1	288.7
	Penta group	Female	PRE-BST	53	50	94.3	84.3	98.8	8.0	6.1	10.6
			POST-BST	57	57	100	93.7	100	87.3	69.5	109.6
		Male	PRE-BST	68	63	92.6	83.7	97.6	8.1	6.0	10.9
			POST-BST	69	69	100	94.8	100	113.9	91.4	141.9
anti-PRN antibody	Hexa group	Female	PRE-BST	70	59	84.3	73.6	91.9	6.9	5.2	9.2
			POST-BST	71	71	100	94.9	100	221.0	171.5	285.0
		Male	PRE-BST	61	51	83.6	71.9	91.8	6.6	4.8	9.1
			POST-BST	66	65	98.5	91.8	100	194.9	146.4	259.4
	Pedia group	Female	PRE-BST	45	35	77.8	62.9	88.88	5.9	4.0	8.6
			POST-BST	47	47	100	92.5	100	203.6	144.0	287.9
		Male	PRE-BST	87	69	79.3	69.3	87.3	5.2	4.2	6.6
			POST-BST	89	89	100	95.9	100	222.1	172.4	286.3
	Penta group	Female	PRE-BST	53	42	79.2	65.9	89.2	6.2	4.4	8.6
			POST-BST	57	57	100	93.7	100	127.1	96.2	167.8
		Male	PRE-BST	67	49	73.1	60.9	83.2	5.9	4.3	8.0
			POST-BST	68			92.1	100	133.5	97.6	182.4

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Note: The assay cut off is 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

Table 7.25 Number and percentage of subjects with anti-PT, anti-FHA and anti-PRN antibody concentration equal to or above the assay cut-off and geometric mean concentration (GMC), before and one month post booster vaccination – by geographical ancestry (Booster ATP cohort for immunogenicity)

						≥ cut_off			GMC			
						95% CI				95%	6 CI	
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	value	LL	UL	
anti-PT antibody	Hexa group	White Caucasian	PRE-BST	80	67	83.8	73.8	91.1	5.3	4.4	6.4	
			POST-BST	84	84	100	95.7	100	61.3	52.1	72.2	
		other	PRE-BST	51	40	78.4	64.7	88.7	5.4	4.1	7.0	
			POST-BST	54	54	100	93.4	100	90.5	73.1	112.0	
	Pedia group	White Caucasian					79.7			5.3	7.6	
			POST-BST	88	88	100	95.9	100	74.4	62.6	88.5	
		other	PRE-BST	46	38	82.6	68.6	92.2	6.9	5.1	9.5	
			POST-BST							97.8	142.7	
	Penta group	White Caucasian	PRE-BST	67	33	49.3	36.8	61.8	3.0	2.3	3.8	
			POST-BST	70	70	100	94.9	100	47.2	37.8	58.9	
		other	PRE-BST	54	30	55.6	41.4	69.1	3.2	2.5	4.1	
			POST-BST	56	56	100	93.6	100	68.0	54.5	84.8	
anti-FHA antibody	Hexa group	White Caucasian	PRE-BST	80	80	100	95.5	100	16.9	14.0	20.2	
			POST-BST	84	84	100	95.7	100	163.1	140.6	189.2	
		other	PRE-BST	51	50	98.0	89.6	100	17.5	13.4	22.9	
			POST-BST	54	54	100	93.4	100	230.8	187.0	285.0	
	Pedia group	White Caucasian	PRE-BST	86	84	97.7	91.9	99.7	20.7	16.5	25.9	
			POST-BST	88	88	100	95.9	100	213.1	179.9	252.4	
		other	PRE-BST	46	46	100	92.3	100	24.3	18.1	32.4	
			POST-BST	48	48	100	92.6	100	336.7	286.0	396.4	
	Penta group	White Caucasian	PRE-BST	67	63	94.0	85.4	98.3	7.0	5.5	9.1	
			POST-BST	70	70	100	94.9	100	72.9	60.0	88.5	
		other	PRE-BST	54	50	92.6	82.1	97.9	9.5	6.8	13.3	
			POST-BST	56	56	100	93.6	100	151.8	121.6	189.6	
anti-PRN antibody	Hexa group	White Caucasian					72.4			4.7	7.9	
			POST-BST	84	83	98.8	93.5	100	191.2	149.2	245.0	
		other	PRE-BST	51	44	86.3	73.7	94.3	8.0	5.6	11.2	
			POST-BST	53	53	100	93.3	100	237.7	177.1	319.1	
	Pedia group	White Caucasian	PRE-BST	86	67	77.9	67.7	86.1	5.0	4.0	6.3	
			POST-BST	88	88	100	95.9	100	183.6	142.4	236.8	
		other	PRE-BST	46	37	80.4	66.1	90.6	6.4	4.5	9.2	
			POST-BST	48	48	100	92.6	100	289.2	208.2	401.6	
	Penta group	White Caucasian	PRE-BST	66	44	66.7	54.0	77.8	4.7	3.5	6.3	
			POST-BST								175.5	
		other					75.1			5.9	11.3	
			POST-BST							1	176.8	

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Table 7.26 Number and percentage of subjects with anti-PT, anti-FHA and anti-PRN antibody concentration equal to or above the assay cut-off and geometric mean concentration (GMC), before and one month post booster vaccination – by Tdap vaccination of mother (Booster ATP cohort for immunogenicity)

				≥ 0		ut_of	f	GMC				
							95%	95% CI		95%	5% CI	
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	value	LL	UL	
anti-PT antibody	Hexa group	Tdap Vaccination Yes	PRE-BST		58	75.3	64.2			3.7	5.5	
		•	POST-BST							51.2	72.9	
		Tdap Vaccination No	PRE-BST			93.5				5.4	9.5	
			POST-BST							71.7	126.3	
		Tdap Vaccination Missing				87.0				4.2	9.1	
			POST-BST							61.0	102.4	
	Pedia group		PRE-BST			83.6				4.8	7.4	
	3		POST-BST							63.8	91.9	
		Tdap Vaccination No	PRE-BST			94.1				5.8	9.9	
			POST-BST									
		Tdap Vaccination Missing				84.0				4.4	10.7	
		3	POST-BST							56.8	111.5	
	Penta group	Tdap Vaccination Yes	PRE-BST			49.3				2.2	3.4	
	. onta group	raap vaccination rec	POST-BST							38.9	59.0	
		Tdap Vaccination No	PRE-BST			64.1				2.9	6.0	
		raap vacomation no	POST-BST							50.4	93.4	
		Tdap Vaccination Missing		13		30.8		61.4		1.3	4.0	
		raap vaconiation miconing	POST-BST							43.6	97.5	
anti-FHA antibody	Hexa group	Tdap Vaccination Yes	PRE-BST	77		100			14.9	12.4	17.9	
			POST-BST				95.4		172.7		205.0	
		Tdap Vaccination No	PRE-BST						23.8		31.1	
			POST-BST									
		Tdap Vaccination Missing							17.3		28.1	
			POST-BST									
	Pedia group	Tdap Vaccination Yes	PRE-BST						18.3		23.4	
			POST-BST									
		Tdap Vaccination No	PRE-BST							25.4	43.5	
			POST-BST									
		Tdap Vaccination Missing				100			20.8	13.3	32.5	
		ruap vaccination iviissing	POST-BST									
	Denta group	Tdap Vaccination Yes	PRE-BST			91.3				5.4	9.5	
	r enta group	ruap vaccination res	POST-BST							67.2	101.8	
		Tdap Vaccination No	PRE-BST	30	30	100	01.0	100		7.8	14.6	
		ruap vaccination No	POST-BST									
		Tdap Vaccination Missing	DDE DOT	12	11	84.6	51.0	00 1	6.5	3.3	13.1	
		ruap vaccination iviissing	POST-BST							5.5 60.4	163.6	
	Hove group	Tdan Vaccination Vac								4.3		
anti-PRN antibody	i iexa group	Tdap Vaccination Yes	PRE-BST POST-BST			80.5					7.3	
		· ·	PRE-BST						11.7	7.6	17.8	
		Tdon \/accinction Mic-i	POST-BST									
		Tdap Vaccination Missing	LKE-R91	23	ΙQ	78.3	ათ.პ	92.5	0.2	3.7	10.4	

117119 (DTPA-HBV-IPV-135) Report Final

						≥ c	ut_of	f		GMC	·
							95%	6 CI		95%	6 CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	value	LL	UL
			POST-BST	25	25	100	86.3	100	183.3	107.8	311.9
	Pedia group	Tdap Vaccination Yes	PRE-BST	73	50	68.5	56.6	78.9	4.1	3.2	5.4
			POST-BST	73	73	100	95.1	100	192.4	142.5	259.6
		Tdap Vaccination No	PRE-BST	34	31	91.2	76.3	98.1	8.3	5.7	12.2
			POST-BST	34	34	100	89.7	100	258.4	184.0	362.9
		Tdap Vaccination Missing	PRE-BST	25	23	92.0	74.0	99.0	6.9	4.6	10.4
			POST-BST	29	29	100	88.1	100	232.1	147.8	364.5
	Penta group	Tdap Vaccination Yes	PRE-BST	69	49	71.0	58.8	81.3	5.3	3.9	7.2
			POST-BST	72	71	98.6	92.5	100	146.4	111.0	193.1
		Tdap Vaccination No	PRE-BST	38	31	81.6	65.7	92.3	6.0	4.1	8.9
			POST-BST	38	38	100	90.7	100	109.9	74.4	162.5
		Tdap Vaccination Missing	PRE-BST	13	11	84.6	54.6	98.1	11.0	5.3	22.8
			POST-BST	15	15	100	78.2	100	116.0	59.9	224.8

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Table 7.27 Booster response for anti-PT, anti-FHA and anti-PRN antibodies, one month post booster vaccination - by gender (Booster ATP cohort for immunogenicity)

					Во	oster	resp	onse
								6 CI
Antibody	Group	Sub-group	Pre-vaccination status	N	n	%	LL	UL
anti-PT antibody (IU/mL)	Hexa group	Female	S-	15	15	100	78.2	100
• • •			S+ (<4*cut_off IU/mL)	41	40	97.6	87.1	99.9
			S+ (≥4*cut_off IU/mL)	14	14	100	76.8	100
			Total	70	69	98.6	92.3	100
		Male	S-	9	7	77.8	40.0	97.2
			S+ (<4*cut_off IU/mL)	37	35	94.6	81.8	99.3
			S+ (≥4*cut_off IU/mL)	15	15	100	78.2	
			Total					98.2
	Pedia group	Female	S-	5	5	100	47.8	100
			S+ (<4*cut_off IU/mL)			93.1	77.2	
			S+ (≥4*cut_off IU/mL)				58.7	
			Total			93.3		98.6
		Male	S-	13		100	75.3	
			S+ (<4*cut_off IU/mL)			94.7	85.4	
			S+ (≥4*cut_off IU/mL)					
			Total				85.3	
	Penta group	Female	S-				78.9	
			S+ (<4*cut_off IU/mL)			100		100
			S+ (≥4*cut_off IU/mL)	6	6	100	54.1	100
			Total			98.1	89.7	100
		Male	S-			90.6		98.0
			S+ (<4*cut_off IU/mL)				78.9	
			- 1 1	8	8	100		100
anti FIIA antibado (III/m)	Have meun	Famala	Total				84.8	
anti-FHA antibody (IU/mL)	nexa group	Female	S- (<4*out off 1/m)	1	1	100	2.5	100
			S+ (<4*cut_off IU/mL) S+ (≥4*cut_off IU/mL)			100	78.2 93.4	
			, – ,			100	94.9	100
		Male	Total S-	0	70	100	94.9	100
		iviale	S+ (<4*cut_off IU/mL)	-	12	100	73.5	100
			S+ (≥4*cut_off IU/mL)					
			Total			98.4		100
	Pedia group	Female	S-	0	-	-	-	-
	i cala group	Tomaic	S+ (<4*cut_off IU/mL)		5	100	47 8	100
			S+ (≥4*cut_off IU/mL)					
			Total				88.2	
		Male	S-				15.8	
			S+ (<4*cut_off IU/mL)			100	73.5	
			S+ (≥4*cut_off IU/mL)				90.2	
			Total				91.8	
	Penta group	Female	S-	3	3	100		100
	3 - 4					100	85.2	
			S+ (≥4*cut_off IU/mL)					
			Total				89.7	
		Male	S-				47.8	
			S+ (<4*cut_off IU/mL)					
			S+ (≥4*cut_off IU/mL)					
			Total				91.6	

117119 (DTPA-HBV-IPV-135) Report Final

					Во	oster	resp	onse
								6 CI
Antibody	Group	Sub-group	Pre-vaccination	N	n	%	LL	UL
			status					
anti-PRN antibody (IU/mL)	Hexa group	Female	S-		11		71.5	100
			S+ (<4*cut_off IU/mL)	29	29	100	88.1	100
			S+ (≥4*cut_off IU/mL)				82.2	
			Total	69	68	98.6	92.2	100
		Male	S-	10	-		55.5	
			S+ (<4*cut_off IU/mL)		25			
			S+ (≥4*cut_off IU/mL)				86.8	
			Total			98.4		
	Pedia group	Female	S-	10			69.2	
			S+ (<4*cut_off IU/mL)	16			79.4	
			S+ (≥4*cut_off IU/mL)	19				
			Total		45		92.1	100
		Male	S-	18		94.4	72.7	99.9
			S+ (<4*cut_off IU/mL)				86.5	
			S+ (≥4*cut_off IU/mL)		28		87.7	100
			Total			97.6	91.8	
	Penta group	Female	S-		11		71.5	
			S+ (<4*cut_off IU/mL)	21	21	100	83.9	100
			S+ (≥4*cut_off IU/mL)	20		100	83.2	
			Total		52		93.2	
		Male	S-	17			63.6	
			S+ (<4*cut_off IU/mL)	19		94.7		
			S+ (≥4*cut_off IU/mL)		27	100	87.2	100
			Total	63	60	95.2	86.7	99.0

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Booster response to PT, FHA and PRN antigens is defined as:

For subjects with pre-vaccination antibody concentration below the assay cut off, post-vaccination antibody concentration = 4 times the assay cut-off,

For subjects with pre-vaccination antibody concentration between the assay cut off and below 4 times the assay cutoff, post-vaccination antibody concentration equal or above 4 times the pre-vaccination antibody concentration, For subjects with pre-vaccination antibody concentration equal or above 4 times the assay cut off, post-vaccination antibody concentration equal or above 2 times the pre-vaccination antibody concentration

N = number of subjects with pre- and post-vaccination results available

n/% = number/percentage of subjects with booster response

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 7.28 Booster response for anti-PT, anti-FHA and anti-PRN antibodies, one month post booster vaccination – by geographical ancestry (Booster ATP cohort for immunogenicity)

					Во	oster		
								6 CI
Antibody	Group	Sub-group	Pre-vaccination status	N	n	%		UL
anti-PT antibody (IU/mL)	Hexa group	White Caucasian		13	12	92.3	64.0	99.8
, ,						94.1		
			S+ (≥4*cut_off IU/mL)	16	16	100	79.4	100
			Total			95.0		
		other	S-			90.9		
			S+ (<4*cut_off IU/mL)		27	100		
			S+ (≥4*cut_off IU/mL)		13	100	75.3	
			Total	51		98.0		
	Pedia group	White Caucasian	S-				69.2	
			S+ (<4*cut_off IU/mL)					
				12			42.8	
			Total	84	76	90.5	82.1	95.8
		other	S-	8	8	100	63.1	100
			S+ (<4*cut_off IU/mL)	24	24	100	85.8	100
			S+ (≥4*cut_off IU/mL)					
			Total	46	45	97.8	88.5	99.9
	Penta group	White Caucasian	S-	33	29	87.9	71.8	96.6
			S+ (<4*cut_off IU/mL)	24	23	95.8	78.9	99.9
			S+ (≥4*cut_off IU/mL)	8	8	100	63.1	100
			Total	65	60	92.3	83.0	97.5
		other	S-	23	23	100	85.2	100
			S+ (<4*cut_off IU/mL)	22	22	100	84.6	100
			S+ (≥4*cut_off IU/mL)	6	6		54.1	
			Total	51	51	100	93.0	100
anti-FHA antibody (IU/mL)	Hexa group	White Caucasian	S-	0	-	-	-	-
• • • •			S+ (<4*cut_off IU/mL)	16	16	100	79.4	100
			S+ (≥4*cut_off IU/mL)	64	63	98.4	91.6	100
			Total	80	79	98.8	93.2	100
		other	S-	1	1	100	2.5	100
			S+ (<4*cut_off IU/mL)	11	11	100	71.5	100
			S+ (≥4*cut_off IU/mL)	39	39	100	91.0	100
			Total	51	51	100	93.0	100
	Pedia group	White Caucasian	S-	2	2	100	15.8	
			S+ (<4*cut_off IU/mL)	12	12	100	73.5	100
			S+ (≥4*cut_off IU/mL)	70	68	97.1	90.1	99.7
			Total	84	82	97.6	91.7	99.7
		other	S-	0	-	-	-	-
			S+ (<4*cut_off IU/mL)	5	5	100	47.8	100
			S+ (≥4*cut_off IU/mL)					
			Total	46	45	97.8	88.5	99.9
	Penta group	White Caucasian		4	4	100	39.8	100
			S+ (<4*cut_off IU/mL)			97.0		
				28	27	96.4	81.7	99.9
			Total	65	63	96.9	89.3	99.6
		other	S-		4		39.8	
			S+ (<4*cut_off IU/mL)	24	24			
			S+ (≥4*cut_off IU/mL)					
			Total			100		

117119 (DTPA-HBV-IPV-135) Report Final

					Во	oster	resp	onse
								6 CI
Antibody	Group	Sub-group	Pre-vaccination	N	n	%	LL	UL
-			status					
anti-PRN antibody (IU/mL)	Hexa group	White Caucasian	S-	14	13	92.9	66.1	99.8
			S+ (<4*cut_off IU/mL)	33	33	100	89.4	100
			S+ (≥4*cut_off IU/mL)	33	33	100	89.4	100
			Total	80	79	98.8	93.2	100
		other	S-	7	7	100	59.0	100
			S+ (<4*cut_off IU/mL)				83.9	100
			S+ (≥4*cut_off IU/mL)			95.5		
			Total			98.0		
	Pedia group	White Caucasian				94.7		
			S+ (<4*cut_off IU/mL)			97.4		
			S+ (≥4*cut_off IU/mL)				87.2	
			Total			97.6		
		other	S-	9	9		66.4	
			S+ (<4*cut_off IU/mL)		17		80.5	
			S+ (≥4*cut_off IU/mL)				83.2	
			Total				92.3	_
	Penta group	White Caucasian		21		90.5		
						95.0		
			S+ (≥4*cut_off IU/mL)				85.2	
			Total	_	_	95.3		
		other	S-	7	7		59.0	
			S+ (<4*cut_off IU/mL)		20		83.2	
					24		85.8	
			Total	51	51	100	93.0	100

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Booster response to PT, FHA and PRN antigens is defined as:

For subjects with pre-vaccination antibody concentration below the assay cut off, post-vaccination antibody concentration = 4 times the assay cut-off,

For subjects with pre-vaccination antibody concentration between the assay cut off and below 4 times the assay cutoff, post-vaccination antibody concentration equal or above 4 times the pre-vaccination antibody concentration, For subjects with pre-vaccination antibody concentration equal or above 4 times the assay cut off, post-vaccination antibody concentration equal or above 2 times the pre-vaccination antibody concentration

N = number of subjects with pre- and post-vaccination results available

n/% = number/percentage of subjects with booster response

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 7.29 Booster response for anti-PT, anti-FHA and anti-PRN antibodies, one month post booster vaccination – by Tdap vaccination of mother (Booster ATP cohort for immunogenicity)

					RO	oster		onse
							95%	% CI
Antibody	Group	Sub-group	Pre-vaccination status	N	n	%	LL	UL
anti-PT antibody (IU/mL)	Hexa group	Tdap Vaccination Yes	S-	19	17	89.5	66.9	98.7
, ,	3 11		S+ (<4*cut_off IU/mL)			97.7		
			S+ (≥4*cut_off IU/mL)			100		
			Total			96.1		
		Tdap Vaccination No	S-	2	2	100	15.8	
		'	S+ (<4*cut_off IU/mL)	20	19	95.0		
			S+ (≥4*cut_off IU/mL)	9	9	100	66.4	100
			Total	31	30	96.8	83.3	99.9
		Tdap Vaccination Missing	S-	3	3	100	29.2	100
			S+ (<4*cut_off IU/mL)	14	13	92.9	66.1	99.8
			S+ (≥4*cut_off IU/mL)	6	6	100	54.1	100
			Total			95.7	78.1	99.9
	Pedia group	Tdap Vaccination Yes	S-			100	73.5	
			S+ (<4*cut_off IU/mL)			88.9		
			S+ (≥4*cut_off IU/mL)			86.7		
			Total		65	90.3		
		Tdap Vaccination No	S-	2	2	100	15.8	
				26			86.8	
			S+ (≥4*cut_off IU/mL)	5	5	100	47.8	
			Total	33	33		89.4	
		Tdap Vaccination Missing		4	4	100	39.8	
			S+ (<4*cut_off IU/mL)		15		78.2	
			S+ (≥4*cut_off IU/mL)	6	4		22.3	
			Total			92.0		
	Penta group	Tdap Vaccination Yes	S-			91.2		
			S+ (<4*cut_off IU/mL)		26	96.3		
			S+ (≥4*cut_off IU/mL)	7	7		59.0	
			Total			94.1		
		Tdap Vaccination No	S-	13		92.3		
			S+ (<4*cut_off IU/mL)			100	79.4	
			S+ (≥4*cut_off IU/mL)		6		54.1	
		T	Total				85.1	
		Tdap Vaccination Missing	S-		9		66.4	
					3		29.2	
			S+ (≥4*cut_off IU/mL)		1		2.5	100
		T-l Viti V	Total	-	13	100	75.3	100
anti-FHA antibody (IU/mL)	nexa group	Tdap Vaccination Yes	S-	0	-	100	- 02.2	100
							83.2	
			S+ (≥4*cut_off IU/mL)				93.7	
		Tdon Vaccination No.	Total S-		11	100	95.3	100
		Tdap Vaccination No		0 3	-	100	20.2	100
			S+ (<4*cut_off IU/mL)		3	100	29.2	
			S+ (≥4*cut_off IU/mL)			100	87.7	
		Tdon Vaccination Mississ	Total				88.8	
		Tdap Vaccination Missing		1	1		2.5	100
			S+ (<4*cut_off IU/mL) S+ (≥4*cut_off IU/mL)	4	4	100 94.4	39.8	
	1	Ĺ	1.5+ 1/4 CH OTHU/MI	ווא	1/	94 4	11/1	144

117119 (DTPA-HBV-IPV-135) Report Final

							R	eport
					Во	oster		onse 6 Cl
Antibody	Group	Sub-group	Pre-vaccination status	N	n	%	LL	UL
	Pedia group	Tdap Vaccination Yes	S-	2	2	100	15.8	100
	i oala gioap	raap vacomation roo				100	71.5	
			, – ,				88.3	
			Total				90.3	
		Tdap Vaccination No	S-	0	-	-	-	-
		raap vacomation no		0	_	_	_	_
			S+ (≥4*cut_off IU/mL)		33	100	89 4	100
			Total				89.4	
		Tdap Vaccination Missing	S-	0	-	-	-	-
		Tudp vaconiation miconing		6	6	100	54.1	100
			S+ (≥4*cut_off IU/mL)					99.9
			Total				79.6	
	Penta group	Tdap Vaccination Yes	S-	6	6		54.1	
	i cina group	raap vaccination res					85.5	
			S+ (≥4*cut_off IU/mL)					
			Total				89.8	
		Tdap Vaccination No	S-	0	00	31.1	03.0	33.0
		Tuap vaccination No	S+ (<4*cut_off IU/mL)		15	100	78.2	100
			S+ (≥4*cut_off IU/mL)				83.2	
			Total				90.0	
		Tdon Vassination Missina		2	2		15.8	
		Tdap Vaccination Missing						
			S+ (<4*cut_off IU/mL)		6	100	54.1 47.8	
			S+ (≥4*cut_off IU/mL) Total	ວ 13	5	100	75.3	
anti DDN antihady /ILI/ml \	Hoyo group	Tdon Vassination Vas	S-	15			68.1	
anti-PRN antibody (IU/mL)	nexa group	ruap vaccination res						
							89.4	
			S+ (≥4*cut_off IU/mL)				88.1	
		Tdon Vassination No.	Total S-	77 1	70 1		93.0	
		Tdap Vaccination No		1	•		2.5	100
						100	71.5	
			S+ (≥4*cut_off IU/mL)					
		Telem Messinstian Missins	Total				82.8	
		Tdap Vaccination Missing	S- (*aut off </td <td>5</td> <td>5</td> <td></td> <td>47.8</td> <td></td>	5	5		47.8	
			S+ (<4*cut_off IU/mL) S+ (≥4*cut_off IU/mL)				69.2	
					8		63.1 85.2	
	Dodio group	Tdap Vaccination Yes						
	redia group	Tuap vaccination res	S+ (<4*cut_off IU/mL)	20	21	95.7	78.1	00.0
			S+ (≥4*cut_off IU/mL)				90.3	
		Tdon Vassination No.	Total S-		3		29.2	
		Tdap Vaccination No	S+ (<4*cut_off IU/mL)	3				
			S+ (≥4*cut_off IU/mL)					
							81.5	
		Tdon Vassination Missina	Total			100	89.4	
		Tdap Vaccination Missing		2	2	100	15.8	
							71.5	
						100	73.5	
	Dants - :	Talam Vanadinadia VVV	Total				86.3	
	renta group	Tdap Vaccination Yes					75.1	
			S+ (<4*cut_off IU/mL)					
			S+ (≥4*cut_off IU/mL)					
			Total	Öδ	0/	98.5	92.1	IUU

117119 (DTPA-HBV-IPV-135) Report Final

					Во	oster	resp	onse
							95%	6 CI
Antibody	Group	Sub-group	Pre-vaccination status	N	n	%	LL	UL
		Tdap Vaccination No	S-	6	5	83.3	35.9	99.6
		·	S+ (<4*cut_off IU/mL)	13	12	92.3	64.0	99.8
			S+ (≥4*cut_off IU/mL)	15	15	100	78.2	100
			Total	34	32	94.1	80.3	99.3
		Tdap Vaccination Missing	S-	2	2	100	15.8	100
			S+ (<4*cut_off IU/mL)	1	1	100	2.5	100
			S+ (≥4*cut_off IU/mL)	10	10	100	69.2	100
			Total	13	13	100	75.3	100

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Booster response to PT, FHA and PRN antigens is defined as:

For subjects with pre-vaccination antibody concentration below the assay cut off, post-vaccination antibody concentration = 4 times the assay cut-off,

For subjects with pre-vaccination antibody concentration between the assay cut off and below 4 times the assay cutoff, post-vaccination antibody concentration equal or above 4 times the pre-vaccination antibody concentration, For subjects with pre-vaccination antibody concentration equal or above 4 times the assay cut off, post-vaccination antibody concentration equal or above 2 times the pre-vaccination antibody concentration

N = number of subjects with pre- and post-vaccination results available

n/% = number/percentage of subjects with booster response

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 7.30 Number and percentage of subjects with anti-D and anti-T antibody concentration equal to or above the assay cut-off, 0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC), before and one month post booster vaccination - by gender (Booster ATP cohort for immunogenicity)

						≥ c	ut_of	f		<u>≥</u> 0.1	IU/m	ı <u>L</u>		≥ 1	IU/m	<u>L</u>		GMC	
							95%					6 CI				6 CI		95	% CI
Antibody	Group	Sub- group	Timing	N	n	%			n	%		UL	n	%			value	LL	UL
anti-D antibody	Hexa group	Female	PRE- BST	70	70	100	94.9	100	68	97.1	90.1	99.7	22	31.4	20.9	43.6	0.716	0.577	0.887
·			POST- BST	72	72	100	95.0	100	72	100	95.0	100	72	100	95.0	100	8.447	7.344	9.715
		Male	PRE- BST	61	61	100	94.1	100	60	98.4	91.2	100	21	34.4	22.7	47.7	0.685	0.533	0.882
			POST- BST														8.212		
	Pedia group	Female	PRE- BST														0.716		
			BST														8.905		
		Male	PRE- BST														0.578		
			POST- BST														7.395		
	Penta group	Female	PRE- BST														0.939		
			POST- BST														9.335		
		Male	PRE- BST														0.650		
			POST- BST														7.930		
anti-T antibody	Hexa group	Female	PRE- BST POST-									96.8 100			3.2 95.0		0.313 9.240		
		Male	BST PRE-	61	60	98.4	91.2	100	54	88.5	77.8	95.3	10	16.4	8.2	28.1	0.344	0.268	0.442
			BST POST- BST	66	66	100	94.6	100	66	100	94.6	100	66	100	94.6	100	9.182	7.177	11.74
	Pedia group	Female	PRE- BST	45	44	97.8	88.2	99.9	42	93.3	81.7	98.6	6	13.3	5.1	26.8	0.366	0.278	0.484
	9.000			47	47	100	92.5	100	47	100	92.5	100	45	95.7	85.5	99.5	8.289	6.318	10.87
		Male	PRE- BST														0.421		
			POST- BST														9.193		
	Penta group	Female	PRE- BST														0.348		
			POST- BST	57	57	100	93.7	100	57	100	93.7	100	57	100	93.7	100	6.754	5.545	8.22

117119 (DTPA-HBV-IPV-135) Report Final

						≥ c	ut_of	f		≥ 0.1	IU/m	ıL		≥1	IU/m	L		GMC	
						95% CI				95%	6 CI			95%	6 CI		95	% CI	
Antibody	Group	Sub-	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
		group																	
		Male	PRE- BST	68	67	98.5	92.1	100	59	86.8	76.4	93.8	11	16.2	8.4	27.1	0.333	0.256	0.433
			POST- BST	69	69	100	94.8	100	68	98.6	92.2	100	68	98.6	92.2	100	6.986	5.546	8.800

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Note: The assay cut off is 0.057 IU/mL for anti-D, 0.043 IU/mL for anti-T.

Table 7.31 Number and percentage of subjects with anti-D and anti-T antibody concentration equal to or above the assay cut-off, 0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC), before and one month post booster vaccination – by geographical anc (Booster ATP cohort for immunogenicity)

						≥ c	ut_of	f		≥ 0.1	IU/m	۱L		≥1	IU/m	L		GMC	
								6 CI				6 CI			95%	6 CI			% CI
Antibody	Group	Sub-	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
		group																	
anti-D	Hexa	White		80	80	100	95.5	100	77	96.3	89.4	99.2	21	26.3	17.0	37.3	0.589	0.472	0.735
antibody	group	Caucasian	POST- BST															6.838	9.087
		other	PRE- BST	51	51	100	93.0	100	51	100	93.0	100	22	43.1	29.3	57.8	0.922	0.742	1.145
			BST														9.087		
	Pedia group	White Caucasian		86	83	96.5	90.1	99.3	79	91.9	83.9	96.7	27	31.4	21.8	42.3	0.517	0.406	0.660
	9.000	o a a ca	POST- BST	88	88	100	95.9	100	88	100	95.9	100	88	100	95.9	100	6.736	5.785	7.845
		other	PRE- BST	46	46	100	92.3	100	44	95.7	85.2	99.5	21	45.7	30.9	61.0	0.876	0.655	1.172
			BST														10.526	8.705	12.728
	Penta group	White Caucasian		67	65	97.0	89.6	99.6	62	92.5	83.4	97.5	25	37.3	25.8	50.0	0.660	0.494	0.884
			POST- BST	70	70	100	94.9	100	70	100	94.9	100	70	100	94.9	100	7.672	6.432	9.151
		other	PRE- BST	54	53	98.1	90.1	100	53	98.1	90.1	100	26	48.1	34.3	62.2	0.915	0.715	1.171
				56	56	100	93.6	100	56	100	93.6	100	56	100	93.6	100	9.757	8.155	11.675

117119 (DTPA-HBV-IPV-135) Report Final

_								_				_							l Fillal
						≥ cı	ut_of	f		≥ 0.1	IU/n	ıL		≥1	IU/ml	L		GMC	
							95%	6 CI			95%	6 CI			95%	6 CI		959	% CI
Antibody	Group	Sub-	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
		group																	
anti-T	Hexa	White	PRE-	80	79	98.8	93.2	100	70	87.5	78.2	93.8	7	8.8	3.6	17.2	0.279	0.230	0.340
antibody	group	Caucasian																	
			BST													100	7.591	6.233	9.244
		other	PRE- BST	51	51	100	93.0	100	48	94.1	83.8	98.8	9	17.6	8.4	30.9	0.418	0.333	0.524
			POST- BST	54	54	100	93.4	100	54	100	93.4	100	54	100	93.4	100	12.449	9.687	16.000
	Pedia group	White Caucasian		86	83	96.5	90.1	99.3	78	90.7	82.5	95.9	8	9.3	4.1	17.5	0.366	0.294	0.454
				88	88	100	95.9	100	88	100	95.9	100	85	96.6	90.4	99.3	7.723	6.389	9.337
		other	PRE- BST	46	46	100	92.3	100	45	97.8	88.5	99.9	9	19.6	9.4	33.9	0.478	0.372	0.614
			POST- BST	48	48	100	92.6	100	48	100	92.6	100	48	100	92.6	100	11.433	9.249	14.133
	Penta group	White Caucasian		67	66	98.5	92.0	100	59	88.1	77.8	94.7	8	11.9	5.3	22.2	0.315	0.244	0.407
			POST- BST	70	70	100	94.9	100	69	98.6	92.3	100	69	98.6	92.3	100	6.226	4.961	7.813
		other	PRE- BST	54	53	98.1	90.1	100	48	88.9	77.4	95.8	11	20.4	10.6	33.5	0.372	0.279	0.496
				56	56	100	93.6	100	56	100	93.6	100	56	100	93.6	100	7.795	6.405	9.487

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Note: The assay cut off is 0.057 IU/mL for anti-D, 0.043 IU/mL for anti-T.

Table 7.32 Number and percentage of subjects with anti-D and anti-T antibody concentration equal to or above the assay cut-off, 0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC), before and one month post booster vaccination – by Tdap vaccination (Booster ATP cohort for immunogenicity)

						≥c	ut_of	f		≥ 0.1	IU/m	ıL		≥1	IU/m	L		GMC	
							95%	6 CI			95%	6 CI			95%	% CI		95	% CI
Antibody	Group	Sub-group	Timing	N		%				%		UL		%	LL	UL	value		UL
anti-D antibody	Hexa group	Tdap Vaccination Yes	PRE-BST															0.508	
			POST-BST														7.308	6.319	8.453
		Tdap Vaccination No															1.066	0.792	
			POST-BST																12.932
		Tdap Vaccination Missing					85.2										0.592	0.373	
			POST-BST														8.915		11.764
	Pedia group	Tdap Vaccination Yes															0.654	0.508	
			POST-BST															6.234	
		Tdap Vaccination No															0.609	0.423	
			POST-BST																10.356
		Tdap Vaccination Missing					79.6										0.551	0.325	
			POST-BST														8.863	6.854	11.461
	Penta group	Tdap Vaccination Yes	PRE-BST	69	67	97.1	89.9	99.6	65	94.2	85.8	98.4	29	42.0	30.2	54.5	0.747	0.576	0.969
			POST-BST														9.004		10.662
		Tdap Vaccination No																0.567	1.136
			POST-BST																11.255
		Tdap Vaccination Missing															0.741	0.360	
			POST-BST																8.512
anti-T antibody	Hexa group	Tdap Vaccination Yes	PRE-BST				93.0							10.4			0.326	0.269	
			POST-BST														10.346		
		Tdap Vaccination No					88.8											0.226	
			POST-BST																12.362
		Tdap Vaccination Missing					85.2							13.0			0.337	0.233	0.487
			POST-BST														6.554		10.705
	Pedia group	Tdap Vaccination Yes					92.6										0.435	0.348	
			POST-BST														9.896		11.760
		Tdap Vaccination No					80.3							8.8	1.9		0.346	0.242	
			POST-BST																10.718
		Tdap Vaccination Missing	PRE-BST	25	25	100	86.3	100	23	92.0	74.0	99.0	2	8.0	1.0	26.0	0.391	0.269	0.566

117119 (DTPA-HBV-IPV-135)

Report Final

						≥ c	ut_of	f		≥ 0.1	IU/m	ıL		≥1	IU/m	L		GMC	
							95%	6 CI			95%	6 CI			95%	6 CI		959	% CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
			POST-BST	29	29	100	88.1	100	29	100	88.1	100	29	100	88.1	100	8.203	5.788	11.627
	Penta group	Tdap Vaccination Yes	PRE-BST	69	68	98.6	92.2	100	63	91.3	82.0	96.7	15	21.7	12.7	33.3	0.398	0.311	0.511
			POST-BST																
		Tdap Vaccination No	PRE-BST	39	38	97.4	86.5	99.9	32	82.1	66.5	92.5	3	7.7	1.6	20.9	0.278	0.196	0.395
			POST-BST	39	39	100	91.0	100	39	100	91.0	100	39	100	91.0	100	5.878	4.576	7.550
		Tdap Vaccination Missing																	
			POST-BST	15	15	100	78.2	100	15	100	78.2	100	15	100	78.2	100	4.541	3.402	6.062

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Note: The assay cut off is 0.057 IU/mL for anti-D, 0.043 IU/mL for anti-T.

Table 7.33 Number and percentage of subjects with anti-PRP antibody concentration equal to or above 0.066 μg/mL and 0.15 μg/mL and 1.0 μg/mL and geometric mean concentration (GMC), before and one month post booster vaccination – by gender (Booster ATP cohort for immunogenicity)

					≥	0.06	6 µg/	mL	2	≥ 0.15	μg/i	mL		≥1	ug/m	L		GMC	
							95%	6 CI			95%	6 CI			959	% CI		95%	% CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-PRP - fully validated assay	Hexa group	Female	PRE-BST	70	66	94.3	86.0	98.4	48	68.6	56.4	79.1	14	20.0	11.4	31.3	0.319	0.238	0.428
			POST-BST	72	72	100	95.0	100	72	100	95.0	100	72	100	95.0	100	43.889	33.093	58.207
		Male	PRE-BST	61	52	85.2	73.8	93.0	43	70.5	57.4	81.5	9	14.8	7.0	26.2	0.280	0.203	0.388
			POST-BST	66	66	100	94.6	100	66	100	94.6	100	64	97.0	89.5	99.6	34.961	24.545	49.797
	Pedia group	Female	PRE-BST	45	43	95.6	84.9	99.5	40	88.9	75.9	96.3	26	57.8	42.2	72.3	0.994	0.640	1.546
			POST-BST	47	47	100	92.5	100	47	100	92.5	100	47	100	92.5	100	53.188	39.017	72.506
		Male	PRE-BST	87	86	98.9	93.8	100	82	94.3	87.1	98.1	45	51.7	40.8	62.6	0.983	0.734	1.316
			POST-BST	92	92	100	96.1	100	92	100	96.1	100	91	98.9	94.1	100	50.125	38.734	64.866
	Penta group	Female	PRE-BST	53	50	94.3	84.3	98.8	42	79.2	65.9	89.2	20	37.7	24.8	52.1	0.628	0.401	0.984
			POST-BST	58	58	100	93.8	100	58	100	93.8	100	57	98.3	90.8	100	29.112	20.128	42.106
		Male	PRE-BST	68	61	89.7	79.9	95.8	52	76.5	64.6	85.9	27	39.7	28.0	52.3	0.602	0.406	0.894
			POST-BST	73	72	98.6	92.6	100	71	97.3	90.5	99.7	71	97.3	90.5	99.7	25.971	18.083	37.301

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

117119 (DTPA-HBV-IPV-135)

Report Final

Table 7.34 Number and percentage of subjects with anti-PRP antibody concentration equal to or above 0.066 μg/mL and 0.15 μg/mL and 1.0 μg/mL and geometric mean concentration (GMC), before and one month post booster vaccination – by geographical ancestry (Booster ATP cohort for immunogenicity)

					≥	0.06	δ μg	/mL	2	≥ 0.15	μg/ı	mL		≥1	μg/m	L		GMC	
							95%	6 CI			95%	6 CI			95%	6 CI		95%	% CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-PRP - fully validated assay	Hexa group	White Caucasian	PRE-BST	80	71	88.8	79.7	94.7	52	65.0	53.5	75.3	11	13.8	7.1	23.3	0.267	0.204	0.351
			POST-BST	84	84	100	95.7	100	84	100	95.7	100	82	97.6	91.7	99.7	35.337	26.365	47.362
		other	PRE-BST	51	47	92.2	81.1	97.8	39	76.5	62.5	87.2	12	23.5	12.8	37.5	0.361	0.252	0.516
			POST-BST	54	54	100	93.4	100	54	100	93.4	100	54	100	93.4	100	46.564	32.943	65.815
	Pedia group	White Caucasian	PRE-BST	86	83	96.5	90.1	99.3	76	88.4	79.7	94.3	38	44.2	33.5	55.3	0.702	0.528	0.934
			POST-BST	90	90	100	96.0	100	90	100	96.0	100	90	100	96.0	100	42.570	33.277	54.458
		other	PRE-BST	46	46	100	92.3	100	46	100	92.3	100	33	71.7	56.5	84.0	1.864	1.262	2.754
			POST-BST	49	49	100	92.7	100	49	100	92.7	100	48	98.0	89.1	99.9	71.627	51.854	98.940
	Penta group	White Caucasian	PRE-BST	67	61	91.0	81.5	96.6	51	76.1	64.1	85.7	25	37.3	25.8	50.0	0.581	0.383	0.881
			POST-BST	72	71	98.6	92.5	100	71	98.6	92.5	100	71	98.6	92.5	100	27.853	19.598	39.584
		other	PRE-BST	54	50	92.6	82.1	97.9	43	79.6	66.5	89.4	22	40.7	27.6	55.0	0.657	0.433	0.995
			POST-BST	59	59	100	93.9	100	58	98.3	90.9	100	57	96.6	88.3	99.6	26.679	18.140	39.239

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Table 7.35 Number and percentage of subjects with anti-PRP antibody concentration equal to or above 0.066 μg/mL and 0.15 μg/mL and 1.0 μg/mL and geometric mean concentration (GMC), before and one month post booster vaccination – by Tdap vaccination of the (Booster ATP cohort for immunogenicity)

					≥	0.06	6 µg	/mL	2	≥ 0.15	ī μg/	mL		≥1	μg/m	ıL		GMC	
							95	% CI			95%	6 CI			95%	% CI		959	% CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-PRP - fully validated assay	Hexa group	Tdap Vaccination Yes	PRE-BST	77	67	87.0	77.4	93.6	51	66.2	54.6	76.6	12	15.6	8.3	25.6	0.265	0.199	0.352
			POST-BST	79	79	100	95.4	100	79	100	95.4	100	78	98.7	93.1	100	42.173	31.237	56.936
		Tdap Vaccination No	PRE-BST	31	31	100	88.88	100	24	77.4	58.9	90.4	9	29.0	14.2	48.0	0.425	0.287	0.629
			POST-BST	34	34	100	89.7	100	34	100	89.7	100	34	100	89.7	100	42.094	27.788	63.766
		Tdap Vaccination Missing	PRE-BST	23	20	87.0	66.4	97.2	16	69.6	47.1	86.8	2	8.7	1.1	28.0	0.289	0.159	0.524
			POST-BST	25	25	100	86.3	100	25	100	86.3	100	24	96.0	79.6	99.9	28.907	16.015	52.177
	Pedia group	Tdap Vaccination Yes	PRE-BST	73	72	98.6	92.6	100	70	95.9	88.5	99.1	46	63.0	50.9	74.0	1.286	0.922	1.794
			POST-BST	75	75	100	95.2	100	75	100	95.2	100	74	98.7	92.8	100	59.334	45.893	76.712
		Tdap Vaccination No	PRE-BST	34	33	97.1	84.7	99.9	31	91.2	76.3	98.1	13	38.2	22.2	56.4	0.727	0.474	1.115
			POST-BST	35	35	100	90.0	100	35	100	90.0	100	35	100	90.0	100	44.301	30.348	64.669
		Tdap Vaccination Missing	PRE-BST	25	24	96.0	79.6	99.9	21	84.0	63.9	95.5	12	48.0	27.8	68.7	0.690	0.383	1.244
			POST-BST	29	29	100	88.1	100	29	100	88.1	100	29	100	88.1	100	41.409	24.272	70.646
	Penta group	Tdap Vaccination Yes	PRE-BST	69	64	92.8	83.9	97.6	57	82.6	71.6	90.7	33	47.8	35.6	60.2	0.892	0.595	1.339
			POST-BST	73	72	98.6	92.6	100	72	98.6	92.6	100	71	97.3	90.5	99.7	34.428	24.144	49.093
		Tdap Vaccination No	PRE-BST	39	36	92.3	79.1	98.4	28	71.8	55.1	85.0	9	23.1	11.1	39.3	0.360	0.241	0.539
		,	POST-BST	43	43	100	91.8	100	42	97.7	87.7	99.9	42	97.7	87.7	99.9	17.724	11.258	27.902
		Tdap Vaccination Missing																	
			POST-BST																

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Table 7.36 Number and percentage of subjects with anti-Polio 1, 2, and 3 antibody titer equal to or above 8 and geometric mean titer (GMT), before booster vaccination - by gender (Booster ATP cohort for immunogenicity)

						≥ 8	ED50)		GMT	
							95%	6 CI		95%	6 CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	value	LL	UL
anti-Polio 1 antibody	Hexa group	Female	PRE-BST	68	68	100	94.7	100	130.0	98.8	171.2
		Male	PRE-BST	60	56	93.3	83.8	98.2	73.5	51.2	105.5
	Pedia group	Female	PRE-BST	45	45	100	92.1	100	149.4	101.1	220.9
		Male	PRE-BST	83	76	91.6	83.4	96.5	89.9	65.3	123.7
	Penta group	Female	PRE-BST	50	45	90.0	78.2	96.7	59.3	40.3	87.1
		Male	PRE-BST	66	55	83.3	72.1	91.4	32.7	23.2	46.0
anti-Polio 2 antibody	Hexa group	Female	PRE-BST	67	63	94.0	85.4	98.3	133.3	93.3	190.5
		Male	PRE-BST	61	56	91.8	81.9	97.3	65.3	45.2	94.4
	Pedia group	Female	PRE-BST	45	43	95.6	84.9	99.5	133.1	86.4	205.2
		Male	PRE-BST	83	79	95.2	88.1	98.7	101.9	76.1	136.5
	Penta group	Female	PRE-BST	51	47	92.2	81.1	97.8	66.5	45.5	97.4
		Male	PRE-BST	66	62	93.9	85.2	98.3	41.8	31.8	55.1
anti-Polio 3 antibody	Hexa group	Female	PRE-BST	66	65	98.5	91.8	100	162.0	117.4	223.6
		Male	PRE-BST	61	58	95.1	86.3	99.0	89.9	61.3	131.9
	Pedia group	Female	PRE-BST	45	44	97.8	88.2	99.9	198.6	133.6	295.3
		Male	PRE-BST	84	82	97.6	91.7	99.7	143.1	104.9	195.2
	Penta group	Female	PRE-BST	51	37	72.5	58.3	84.1	39.5	23.5	66.5
		Male	PRE-BST	66	43	65.2	52.4	76.5	22.0	14.7	32.9

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 7.37 Number and percentage of subjects with anti-Polio 1, 2, and 3 antibody titer equal to or above 8 and geometric mean titer (GMT), before booster vaccination – by geographical ancestry (Booster ATP cohort for immunogenicity)

						≥ 8	ED50)		GMT	
							95%	6 CI		95%	6 CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	value	LL	UL
anti-Polio 1 antibody	Hexa group	White Caucasian	PRE-BST	78	74	94.9	87.4	98.6	86.6	63.9	117.4
		other	PRE-BST	50	50	100	92.9	100	123.7	88.5	172.9
	Pedia group	White Caucasian	PRE-BST	82	76	92.7	84.8	97.3	99.9	72.2	138.1
		other	PRE-BST	46	45	97.8	88.5	99.9	122.4	82.3	182.0
	Penta group	White Caucasian	PRE-BST	63	50	79.4	67.3	88.5	34.8	24.3	49.8
		other	PRE-BST	53	50	94.3	84.3	98.8	53.2	36.7	77.2
anti-Polio 2 antibody	Hexa group	White Caucasian	PRE-BST	77	68	88.3	79.0	94.5	68.3	48.1	97.2
		other	PRE-BST	51	51	100	93.0	100	155.8	109.8	221.1
	Pedia group	White Caucasian	PRE-BST	82	76	92.7	84.8	97.3	96.2	69.8	132.4
		other	PRE-BST	46	46	100	92.3	100	146.8	103.3	208.6
	Penta group	White Caucasian	PRE-BST	64	57	89.1	78.8	95.5	44.2	31.3	62.5
		other	PRE-BST	53	52	98.1	89.9	100	61.1	46.0	81.3
anti-Polio 3 antibody	Hexa group	White Caucasian	PRE-BST	76	72	94.7	87.1	98.5	92.1	66.5	127.5
		other	PRE-BST	51	51	100	93.0	100	186.0	127.6	271.0
	Pedia group	White Caucasian	PRE-BST	83	80	96.4	89.8	99.2	142.7	103.5	196.8
		other	PRE-BST	46	46	100	92.3	100	198.1	137.2	286.1
	Penta group	White Caucasian	PRE-BST	64	42	65.6	52.7	77.1	24.3	15.9	37.0
		other	PRE-BST	53	38	71.7	57.7	83.2	34.3	20.8	56.7

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 7.38 Number and percentage of subjects with anti-Polio 1, 2, and 3 antibody titer equal to or above 8 and geometric mean titer (GMT), before booster vaccination – by Tdap vaccination of mother (Booster ATP cohort for immunogenicity)

						≥ 8	ED50)		GMT	
							95%	6 CI		95%	δCI
Antibody	Group	Sub-group		N		%	LL	UL	value	LL	UL
anti-Polio 1 antibody	Hexa group	Tdap Vaccination Yes	PRE-BST							69.0	124.3
		Tdap Vaccination No	PRE-BST								173.0
		Tdap Vaccination Missing									210.6
	Pedia group	Tdap Vaccination Yes	PRE-BST	72	70	97.2	90.3	99.7	113.0	82.2	155.4
		Tdap Vaccination No	PRE-BST							69.9	212.0
		Tdap Vaccination Missing								40.5	138.9
	Penta group	Tdap Vaccination Yes	PRE-BST	68	58	85.3	74.6	92.7	41.0	29.0	58.1
		Tdap Vaccination No	PRE-BST	36	31	86.1	70.5	95.3	43.5	27.3	69.2
		Tdap Vaccination Missing	PRE-BST	12	11	91.7	61.5	99.8	45.4	18.6	111.1
anti-Polio 2 antibody	Hexa group	Tdap Vaccination Yes	PRE-BST	76	70	92.1	83.6	97.0	75.6	54.1	105.7
		Tdap Vaccination No	PRE-BST	30	29	96.7	82.8	99.9	120.9	75.7	193.1
		Tdap Vaccination Missing	PRE-BST	22	20	90.9	70.8	98.9	149.8	69.2	324.6
	Pedia group	Tdap Vaccination Yes	PRE-BST	72	70	97.2	90.3	99.7	110.4	81.9	148.7
		Tdap Vaccination No	PRE-BST	34	33	97.1	84.7	99.9	175.8	107.7	286.9
		Tdap Vaccination Missing	PRE-BST	22	19	86.4	65.1	97.1	58.4	30.6	111.3
	Penta group	Tdap Vaccination Yes	PRE-BST	68	62	91.2	81.8	96.7	47.1	34.6	64.1
		Tdap Vaccination No	PRE-BST	37	36	97.3	85.8	99.9	58.2	39.2	86.4
		Tdap Vaccination Missing	PRE-BST	12	11	91.7	61.5	99.8	55.3	23.9	127.9
anti-Polio 3 antibody	Hexa group	Tdap Vaccination Yes	PRE-BST	75	73	97.3	90.7	99.7	120.4	88.3	164.2
		Tdap Vaccination No	PRE-BST	30	29	96.7	82.8	99.9	126.7	73.2	219.4
		Tdap Vaccination Missing									256.9
	Pedia group	Tdap Vaccination Yes	PRE-BST	73	72	98.6	92.6	100	162.4	118.3	222.9
		Tdap Vaccination No	PRE-BST	34	34	100	89.7	100	275.0	181.8	415.9
		Tdap Vaccination Missing	PRE-BST	22	20	90.9	70.8	98.9	67.0	35.3	127.2
	Penta group	Tdap Vaccination Yes	PRE-BST	68	45	66.2	53.7	77.2	25.9	16.8	40.0
		Tdap Vaccination No	PRE-BST	37	27	73.0	55.9	86.2	37.2	20.9	66.1
		Tdap Vaccination Missing	PRE-BST	12	8	66.7	34.9	90.1	20.7	7.3	58.7

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 7.39 Number and percentage of subjects with anti-HBs antibody concentration equal to or above 6.2 mlU/mL and 10.0 mlU/mL and geometric mean concentration (GMC), before booster vaccination - by gender (Booster ATP cohort for immunogenicity)

					2	6.2	mIU/ı	mL	2	≥ 10 ı	mIU/r	nL		GMC	
							95%	6 CI			95%	6 CI		95%	δCI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-HBs antibody	Hexa group	Female	PRE-BST	70	70	100	94.9	100	69	98.6	92.3	100	354.2	266.9	470.1
		Male	PRE-BST	63	62	98.4	91.5	100	62	98.4	91.5	100	302.5	208.1	439.7
	Pedia group	Female	PRE-BST	45	45	100	92.1	100	45	100	92.1	100	276.7	188.3	406.8
		Male	PRE-BST	86	85	98.8	93.7	100	83	96.5	90.1	99.3	216.9	163.6	287.5
	Penta group	Female	PRE-BST	53	50	94.3	84.3	98.8	48	90.6	79.3	96.9	173.5	102.4	294.2
		Male	PRE-BST	68	60	88.2	78.1	94.8	57	83.8	72.9	91.6	133.0	74.1	238.6

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

Table 7.40 Number and percentage of subjects with anti-HBs antibody concentration equal to or above 6.2 mlU/mL and 10.0 mlU/mL and geometric mean concentration (GMC), before booster vaccination – by geographical ancestry (Booster ATP cohort for immunogenicity)

					2	≥ 6.2	mIU/	mL	:	≥ 10 :	mIU/r	nL		GMC	
							95%	6 CI			95%	6 CI		95%	6 CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-HBs	Hexa group	White	PRE-	81	81	100	95.5	100	81	100	95.5	100	363.7	277.1	477.5
antibody		Caucasian	BST												
,		other	PRE-	52	51	98.1	89.7	100	50	96.2	86.8	99.5	280.8	186.0	423.8
			BST												
	Pedia	White	PRE-	84	83	98.8	93.5	100	81	96.4	89.9	99.3	188.6	141.8	250.9
	group	Caucasian	BST												
		other	PRE-	47	47	100	92.5	100	47	100	92.5	100	351.6	247.4	499.6
			BST												
	Penta	White	PRE-	66	59	89.4	79.4	95.6	56	84.8	73.9	92.5	115.6	68.4	195.2
	group	Caucasian	BST												
		other	PRE-	55	51	92.7	82.4	98.0	49	89.1	77.8	95.9	203.4	110.1	375.9
			BST												

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 7.41 Number and percentage of subjects with anti-HBs antibody concentration equal to or above 6.2 mlU/mL and 10.0 mlU/mL and geometric mean concentration (GMC), before booster vaccination – by Tdap vaccination of mother (Booster ATP cohort for immunogenicity)

					2	≥ 6.2	mIU/	mL	2	≥ 10 ı	mIU/r	nL		GMC	
							95%	6 CI			95%	6 CI		95%	6 CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-HBs	Hexa	Tdap Vaccination	PRE-	78	77	98.7	93.1	100	76	97.4	91.0	99.7	290.9	209.4	404.0
antibody	group	Yes	BST												
		Tdap Vaccination No	PRE-	32	32	100	89.1	100	32	100	89.1	100	384.1	247.5	595.9
			BST												
		Tdap Vaccination	PRE-	23	23	100	85.2	100	23	100	85.2	100	400.8	259.0	620.2
		Missing	BST												
	Pedia	Tdap Vaccination	PRE-	74	74	100	95.1	100	72	97.3	90.6	99.7	259.2	191.6	350.7
	group	Yes	BST												
		Tdap Vaccination No	PRE-	34	33	97.1	84.7	99.9	33	97.1	84.7	99.9	156.2	96.4	252.9
		'	BST												
		Tdap Vaccination	PRE-	23	23	100	85.2	100	23	100	85.2	100	319.9	201.3	508.6
		Missing	BST												
	Penta	Tdap Vaccination	PRE-	69	63	91.3	82.0	96.7	59	85.5	75.0	92.8	158.6	94.7	265.5
	group	Yes	BST												
		Tdap Vaccination No	PRE-	40	36	90.0	76.3	97.2	35	87.5	73.2	95.8	149.5	67.4	331.6
			BST												
		Tdap Vaccination	PRE-	12	11	91.7	61.5	99.8	11	91.7	61.5	99.8	106.0	39.0	288.5
		Missing	BST												

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

117119 (DTPA-HBV-IPV-135) Report Final

Table 7.42 Number and percentage of subjects with anti-HBs antibody concentration equal to or above 6.2 mlU/mL and 10.0 mlU/mL and geometric mean concentration (GMC), before booster vaccination – by Hepatitis B vaccination of subject (Booster ATP cohort for immunogenicity)

					≥	6.2 ו	mIU/n	nL	2	: 10 n	nIU/n	٦L		GMC	
							95%	6 CI			95%	6 CI		95%	6 CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-HBs	Hexa	HepB at birth	PRE-	124	123	99.2	95.6	100	122	98.4	94.3	99.8	358.4	283.6	452.9
antibody	group	Yes	BST												
•		HepB at birth	PRE-	9	9	100	66.4	100	9	100	66.4	100	99.8	46.4	214.9
		No	BST												
	Pedia	HepB at birth	PRE-	115	114	99.1	95.3	100	113	98.3	93.9	99.8	251.1	197.7	318.9
	group	Yes	BST												
		HepB at birth	PRE-	16	16	100	79.4	100	15	93.8	69.8	99.8	150.0	73.8	305.0
		No.	BST												
	Penta	HepB at birth	PRE-	111	100	90.1	83.0	94.9	95	85.6	77.6	91.5	152.4	99.6	233.1
	group	Yes	BST												
		HepB at birth	PRE-	10	10	100	69.2	100	10	100	69.2	100	119.9	39.1	367.3
		No.	BST												

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Figure 7.12 Reverse cumulative distribution curves for anti-PT concentration, before and one month post booster vaccination (Booster ATP cohort for immunogenicity)




Figure 7.13 Reverse cumulative distribution curves for anti-FHA concentration, before and one month post booster vaccination (Booster ATP cohort for immunogenicity)




Figure 7.14 Reverse cumulative distribution curves for anti-PRN concentration, before and one month post booster vaccination (Booster ATP cohort for immunogenicity)




Figure 7.15 Reverse cumulative distribution curves for anti-D concentration, before and one month post booster vaccination (Booster ATP cohort for immunogenicity)




Figure 7.16 Reverse cumulative distribution curves for anti-T concentration, before and one month post booster vaccination (Booster ATP cohort for immunogenicity)




Figure 7.17 Reverse cumulative distribution curves for anti-Polio 1 antibody titer before booster vaccination (Booster ATP cohort for immunogenicity)




Figure 7.18 Reverse cumulative distribution curves for anti-Polio 2 antibody titer before booster vaccination (Booster ATP cohort for immunogenicity)




Figure 7.19 Reverse cumulative distribution curves for anti-Polio 3 antibody titer before booster vaccination (Booster ATP cohort for immunogenicity)




Figure 7.20 Reverse cumulative distribution curves for anti-PRP concentration, before and one month post booster vaccination (Booster ATP cohort for immunogenicity)




Figure 7.21 Reverse cumulative distribution curve for anti-HBs antibody concentration, before booster vaccination (Booster ATP cohort for immunogenicity)




Table 7.43 Ratio of GMCs/GMTs for antibody concentrations/titers between groups (Pedia group divided by Hexa group), before booster vaccination (Booster ATP cohort for immunogenicity)

					Adjusted GMC/T ratio (Pedia group / Hexa group				
Antibody	Pec N	lia group Adjusted GMC/T		xa group Adjusted GMC/T	Value	95% CI LL UL			
anti-PT antibody (IU/mL)	132		131	5.4	1.21	0.97	1.51		
anti-FHA antibody (IU/mL)	132	21.9	131	17.4	1.26	0.99	1.61		
anti-PRN antibody (IU/mL)	132	5.4	131	6.8	0.79	0.60	1.06		
anti-D antibody (IU/mL)	132	0.625	131	0.707	0.88	0.69	1.14		
anti-T antibody (IU/mL)	132	0.402	131	0.325	1.24	0.98	1.56		
anti-Polio 1 antibody (ED50)	128	107.7	128	100.0	1.08	0.77	1.51		
anti-Polio 2 antibody (ED50)	128	112.0	128	96.1	1.17	0.83	1.63		
anti-Polio 3 antibody (ED50)	129	162.1	127	124.6	1.30	0.90	1.89		
anti-PRP - fully validated assay (µg/mL)	132	0.994	131	0.299	3.33	2.36	4.69		

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Adjusted GMC/T = geometric mean antibody concentration/titer adjusted for Tdap vaccination of the mother N = Number of subjects with both pre- and post-primary vaccination results available

95% CI = 95% confidence interval for the adjusted GMC ratio (ANCOVA model: adjustment for Tdap vaccination of mother - pooled variance); LL = lower limit, UL = upper limit

Table 7.44 Ratio of GMCs/GMTs for antibody concentrations/titers between groups (Penta group divided by Hexa group), before booster vaccination (Booster ATP cohort for immunogenicity)

					Adjusted GMC/T ratio (Penta group / Hexa group			
	Per	nta group	He	xa group		95%	% CI	
Antibody	N	Adjusted GMC/T	N	Adjusted GMC/T	Value	LL	UL	
anti-PT antibody (IU/mL)	121	3.0	131	5.4	0.56	0.45	0.71	
anti-FHA antibody (IU/mL)	121	7.9	131	17.4	0.45	0.35	0.58	
anti-PRN antibody (IU/mL)	120	6.0	131	6.8	0.87	0.65	1.17	
anti-D antibody (IU/mL)	121	0.754	131	0.707	1.07	0.82	1.38	
anti-T antibody (IU/mL)	121	0.341	131	0.325	1.05	0.83	1.33	
anti-Polio 1 antibody (ED50)	116	41.9	128	100.0	0.42	0.30	0.59	
anti-Polio 2 antibody (ED50)	117	50.4	128	96.1	0.52	0.37	0.74	
anti-Polio 3 antibody (ED50)	117	27.5	127	124.6	0.22	0.15	0.32	
anti-PRP - fully validated assay (µg/mL)	121	0.612	131	0.299	2.05	1.44	2.91	

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Adjusted GMC/T = geometric mean antibody concentration/titer adjusted for Tdap vaccination of the mother N = Number of subjects with both pre- and post-primary vaccination results available

95% CI = 95% confidence interval for the adjusted GMC ratio (ANCOVA model: adjustment for Tdap vaccination of mother - pooled variance); LL = lower limit, UL = upper limit

Table 7.45 Ratio of GMC for anti-HBs antibody concentrations between groups (Pedia group divided by Hexa group), before booster vaccination (Booster ATP cohort for immunogenicity)

				Adjusted GMC ratio (Pedia group / Hexa group)					
Pedia group Hexa group		95% CI							
N	Adjusted GMC	N	Adjusted GMC	Value	LL	UL			
131	239.4	133	321.9	0.74	0.50	1.11			

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Adjusted GMC/T = geometric mean antibody concentration/titer adjusted for Tdap vaccination of the mother and Hepatitis B vaccination of the subject

N = Number of subjects with both pre- and post-primary vaccination results available

95% CI = 95% confidence interval for the adjusted GMC ratio (ANCOVA model: adjustment for Tdap vaccination of mother and Hepatitis B vaccination history of the subject - pooled variance); LL = lower limit, UL = upper limit

Table 7.46 Ratio of GMC for anti-HBs antibody concentrations between groups (Penta group divided by Hexa group), before booster vaccination (Booster ATP cohort for immunogenicity)

				Adjusted GMC ratio (Penta group / Hexa group)					
Penta group Hexa group			95% CI						
N	Adjusted	N	Adjusted	Value	LL	UL			
	GMC		GMC						
121	150.4	133	321.9	0.47	0.31	0.70			

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Adjusted GMC/T = geometric mean antibody concentration/titer adjusted for Tdap vaccination of the mother and Hepatitis B vaccination of the subject

N = Number of subjects with both pre- and post-primary vaccination results available

95% CI = 95% confidence interval for the adjusted GMC ratio (ANCOVA model: adjustment for Tdap vaccination of mother and Hepatitis B vaccination history of the subject - pooled variance); LL = lower limit, UL = upper limit

Table 7.47 Difference between groups (Pedia group minus Hexa group) in percentage of subjects with antibody concentration/titer equal to or above the proposed cut-off, before booster vaccination (Booster ATP cohort for immunogenicity)

								in p (Pedia	Difference in percentage (Pedia group minus Hexa group)			
	I –			group Pedia group			•	95%				
Antibody	Type	N	n	%	N	n	%	%	LL	UL		
anti-D antibody	0.1 IU/mL	131	128	97.7	132	123	93.2	-4.53	-10.47	0.61		
	1 IU/mL	131	43	32.8	132	48	36.4	3.54	-7.97	14.96		
anti-T antibody	0.1 IU/mL	131	118	90.1	132	123	93.2	3.11	-3.81	10.29		
	1 IU/mL	131	16	12.2	132	17	12.9	0.67	-7.58	8.91		
anti-Polio 1 antibody	8 ED50	128	124	96.9	128	121	94.5	-2.34	-8.16	3.02		
anti-Polio 2 antibody	8 ED50	128	119	93.0	128	122	95.3	2.34	-3.76	8.76		
anti-Polio 3 antibody	8 ED50	127	123	96.9	129	126	97.7	0.82	-3.88	5.80		
anti-PRP - fully validated assay	0.15 µg/mL	131	91	69.5	132	122	92.4	22.96	13.89	32.20		
	1 µg/mL	131	23	17.6	132	71	53.8	36.23	25.12	46.50		
anti-HBs antibody	10 mIU/mL	133	131	98.5	131	128	97.7	-0.79	-5.20	3.30		

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

N = number of subjects with available results

n/% = number/percentage of subjects with titer and concentration within the specified range 95% CI = Standardized asymptotic 95% confidence interval; LL = lower limit, UL = upper limit

Table 7.48 Difference between groups (Penta group minus Hexa group) in percentage of subjects with antibody concentration/titer equal to or above the proposed cut-off, before booster vaccination (Booster ATP cohort for immunogenicity)

					Difference in percentage (Penta group minus Hexa group)					age minus
		Hex	(a gr	oup	Pen	ta g	roup		95% CI	
Antibody	Type	N	n	%	N	n	%	%	LL	UL
anti-D antibody	0.1 IU/mL	131	128	97.7	121	115	95.0	-2.67	-8.41	2.25
-	1 IU/mL	131	43	32.8	121	51	42.1	9.32	-2.64	21.10
anti-T antibody	0.1 IU/mL	131	118	90.1	121	107	88.4	-1.65	-9.74	6.19
-	1 IU/mL	131	16	12.2	121	19	15.7	3.49	-5.16	12.40
anti-Polio 1 antibody	8 ED50	128	124	96.9	116	100	86.2	-10.67	-18.51	-4.02
anti-Polio 2 antibody	8 ED50	128	119	93.0	117	109	93.2	0.19	-6.77	6.95
anti-Polio 3 antibody	8 ED50	127	123	96.9	117	80	68.4	-28.47	-37.76	-19.83
anti-PRP - fully validated assay	0.15 µg/mL	131	91	69.5	121	94	77.7	8.22	-2.75	18.97
	1 µg/mL	131	23	17.6	121	47	38.8	21.29	10.30	32.02
anti-HBs antibody	10 mIU/mL	133	131	98.5	121	105	86.8	-11.72	-19.10	-5.90

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects with available results

n/% = number/percentage of subjects with titer and concentration within the specified range 95% CI = Standardized asymptotic 95% confidence interval; LL = lower limit, UL = upper limit

Table 7.49 Ratio of GMCs/GMTs for antibody concentrations/titers between groups (Pedia group divided by Hexa group), one month post booster vaccination (Booster ATP cohort for immunogenicity)

					G	Adjusted GMC ratio (Pedia group / Hexa group)				
	Ped	dia group	He	xa group	95% CI					
Antibody	N			Adjusted	Value	LL	UL			
		GMC		GMC						
anti-PT antibody (IU/mL)	136	87.6	138	72.0	1.22	1.01	1.48			
anti-FHA antibody (IU/mL)	136	251.0	138	188.5	1.33	1.11	1.60			
anti-PRN antibody (IU/mL)	136	216.0	137	208.4	1.04	0.79	1.37			
anti-D antibody (IU/mL)	136	7.897	138	8.359	0.94	0.80	1.11			
anti-T antibody (IU/mL)	136	8.970	138	9.194	0.98	0.79	1.20			
anti-PRP - fully validated assay (µg/mL)	139	51.402	138	39.145	1.31	0.96	1.80			

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Adjusted GMC/T = geometric mean antibody concentration/titer adjusted for Tdap vaccination of the mother N = Number of subjects with both pre- and post-primary vaccination results available

95% CI = 95% confidence interval for the adjusted GMC ratio (ANCOVA model: adjustment for Tdap vaccination of mother - pooled variance); LL = lower limit, UL = upper limit

Table 7.50 Ratio of GMCs/GMTs for antibody concentrations/titers between groups (Penta group divided by Hexa group), one month post booster vaccination (Booster ATP cohort for immunogenicity)

						Adjusted SMC ratio Sup / Hexa	
	Per	nta group	He	xa group		95%	6 CI
Antibody	N	Adjusted		Adjusted	Value	LL	UL
-		GMC		GMC			
anti-PT antibody (IU/mL)	126	55.0	138	72.0	0.76	0.63	0.93
anti-FHA antibody (IU/mL)	126	99.8	138	188.5	0.53	0.44	0.64
anti-PRN antibody (IU/mL)	125	129.9	137	208.4	0.62	0.47	0.83
anti-D antibody (IU/mL)	126	8.495	138	8.359	1.02	0.86	1.20
anti-T antibody (IU/mL)	126	6.812	138	9.194	0.74	0.60	0.92
anti-PRP - fully validated assay (µg/mL)	131	27.332	138	39.145	0.70	0.51	0.96

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Adjusted GMC/T = geometric mean antibody concentration/titer adjusted for Tdap vaccination of the mother N = Number of subjects with both pre- and post-primary vaccination results available

95% CI = 95% confidence interval for the adjusted GMC ratio (ANCOVA model: adjustment for Tdap vaccination of mother - pooled variance); LL = lower limit, UL = upper limit

Table 7.51 Difference between groups (Pedia group minus Hexa group) in percentage of subjects with antibody concentration/titer equal to or above the proposed cut-off, one month post booster vaccination (Booster ATP cohort for immunogenicity)

								in p (Pedia	fference ercenta group xa grou	age minus
							95%	CI		
Antibody	Туре	N	n	%	N	n	%	%	LL	UL
anti-D antibody	0.1 IU/mL	138	138	100	136	136	100	0.00	-2.76	2.72
-	1 IU/mL	138	138	100	136	136	100	0.00	-2.76	2.72
anti-T antibody	0.1 IU/mL	138	138	100	136	136	100	0.00	-2.76	2.72
•	1 IU/mL	138	138	100	136	133	97.8	-2.21	-6.30	0.54
anti-PRP - fully validated assay	0.15 µg/mL	138	138	100	139	139	100	0.00	-2.70	2.72
	1 µg/mL	138	136	98.6	139	138	99.3	0.73	-2.65	4.50

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

N = number of subjects with available results

n/% = number/percentage of subjects with titer and concentration within the specified range 95% CI = Standardized asymptotic 95% confidence interval; LL = lower limit, UL = upper limit

Table 7.52 Difference between groups (Penta group minus Hexa group) in percentage of subjects with antibody concentration/titer equal to or above the proposed cut-off, one month post booster vaccination (Booster ATP cohort for immunogenicity)

								in p (Penta	ifference ercenta group xa grou	age minus
		Hex	ca gr	oup	Pen	ta g	roup		95%	6 CI
Antibody	Туре	N	n	%	N	n	%	%	LL	UL
anti-D antibody	0.1 IU/mL	138	138	100	126	126	100	0.00	-2.97	2.72
•	1 IU/mL	138	138	100	126	126	100	0.00	-2.97	2.72
anti-T antibody	0.1 IU/mL	138	138	100	126	125	99.2	-0.79	-4.37	1.94
•	1 IU/mL	138	138	100	126	125	99.2	-0.79	-4.37	1.94
anti-PRP - fully validated assay	0.15 µg/mL	138	138	100	131	129	98.5	-1.53	-5.41	1.21
-	1 µg/mL	138	136	98.6	131	128	97.7	-0.84	-5.25	3.12

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects with available results

n/% = number/percentage of subjects with titer and concentration within the specified range

95% CI = Standardized asymptotic 95% confidence interval; LL = lower limit, UL = upper limit

Table 7.53 Number and percentage of subjects with anti-PT, anti-FHA and anti-PRN antibody concentration equal to or above the assay cut-off and geometric mean concentration (GMC), one month post primary vaccination (Primary Total vaccinated cohort)

					≥ cu	t_off			GMC	
						95%	CI		95%	6 CI
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL
anti-PT antibody	Hexa group	PIII(M5)	152	152	100	97.6	100	42.8	37.8	48.5
	Pedia group								43.2	54.7
	Penta group								21.6	28.1
anti-FHA antibody										119.0
	Pedia group	PIII(M5)	158	158	100	97.7	100	126.3	113.3	140.7
	Penta group	PIII(M5)	156	156	100	97.7	100	60.6	52.4	70.2
anti-PRN antibody	Hexa group	PIII(M5)	152	152	100	97.6	100	54.7	47.0	63.5
	Pedia group								41.1	56.5
	Penta group	PIII(M5)	156	155	99.4	96.5	100	32.2	27.3	38.0

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Note: The assay cut off is 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

117119 (DTPA-HBV-IPV-135) Report Final

Table 7.54 Number and percentage of subjects with anti-D and anti-T antibody concentration equal to or above the assay cut-off, 0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC), one month post primary vaccination (Primary Total vaccinated cohort)

					≥ cu	ıt_off	:	2	≥ 0.1	IU/ml	L		≥11	U/mL			GMC	
						95%	6 CI			95%	CI			95%	6 CI		95%	δCI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-D antibody	Hexa group	PIII(M5)	148	148	100	97.5	100	148	100	97.5	100	116	78.4	70.9	84.7	1.733	1.511	1.987
	Pedia group	PIII(M5)	152	152	100	97.6	100	152	100	97.6	100	112	73.7	65.9	80.5	1.695	1.484	1.937
	Penta group																	
anti-T antibody	Hexa group	PIII(M5)	152	152	100	97.6	100	152	100	97.6	100	136	89.5	83.5	93.9	2.457	2.204	2.740
	Pedia group	PIII(M5)	158	158	100	97.7	100	158	100	97.7	100	143	90.5	84.8	94.6	2.667	2.378	2.990
	Penta group	PIII(M5)	156	156	100	97.7	100	155	99.4	96.5	100	126	80.8	73.7	86.6	2.026	1.788	2.295

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Note: The assay cut off is 0.057 IU/mL for anti-D, 0.043 IU/mL for anti-T.

Table 7.55 Number and percentage of subjects with anti-Polio 1, 2, and 3 antibody titer equal to or above 8 and geometric mean titer (GMT), one month post primary vaccination (Primary Total vaccinated cohort)

					≥81	ED50			GMT	
						95%	6 CI		959	% CI
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL
anti-Polio 1 antibody	Hexa group	PIII(M5)	143	143	100	97.5	100	534.9	439.7	650.7
	Pedia group	PIII(M5)	143	143	100	97.5	100	626.0	517.1	757.9
	Penta group	PIII(M5)	142	141	99.3	96.1	100	311.9	251.4	387.0
anti-Polio 2 antibody										
	Pedia group									
	Penta group	PIII(M5)	141	141	100	97.4	100	287.3	234.3	352.2
anti-Polio 3 antibody	Hexa group	PIII(M5)	135	135	100	97.3	100	707.6	566.0	884.7
	Pedia group	PIII(M5)	141	141	100	97.4	100	958.5	773.0	1188.5
	Penta group	PIII(M5)	133	131	98.5	94.7	99.8	297.0	225.7	390.9

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Table 7.56 Number and percentage of subjects with anti-PRP antibody concentration equal to or above the assay cut-off, 0.15 µg/mL and 1.0 µg/mL and geometric mean concentration (GMC), one month post primary vaccination (Primary Total vaccinated cohort)

					≥cu	ıt_off		≥	0.15	μg/n	nL		≥1 բ	ıg/ml	_		GMC	
						95%	6 CI			95%	6 CI			95%	6 CI		959	% CI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	υL
anti-PRP -	Hexa	PIII(M5)	155	146	94.2	89.3	97.3	146	94.2	89.3	97.3	87	56.1	47.9	64.1	1.372	1.091	1.727
qualified assay	group																	
	Pedia	PIII(M5)	162	160	98.8	95.6	99.9	160	98.8	95.6	99.9	153	94.4	89.7	97.4	10.512	8.363	13.213
	group																	
	Penta	PIII(M5)	161	159	98.8	95.6	99.8	159	98.8	95.6	99.8	134	83.2	76.5	88.6	6.608	5.071	8.609
	group																	
anti-PRP -	Hexa	PIII(M5)	161	159	98.8	95.6	99.8	153	95.0	90.4	97.8	89	55.3	47.3	63.1	1.348	1.084	1.676
fully validated	group																	
assay																		
	Pedia	PIII(M5)	165	164	99.4	96.7	100	162	98.2	94.8	99.6	156	94.5	89.9	97.5	9.518	7.664	11.822
	group																	
	Penta	PIII(M5)	164	162	98.8	95.7	99.9	162	98.8	95.7	99.9	138	84.1	77.6	89.4	5.803	4.478	7.521
	group																	

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Note:Two assays were used for anti-PRP, for the fully validated assay, the assay cut off is 0.066 µg/mL while 0.15 µg/mL was used for the gualified assay.

Table 7.57 Number and percentage of subjects with anti-HBs antibody concentration equal to or above 6.2 mlU/mL and 10.0 mlU/mL and geometric mean concentration (GMC), one month post primary vaccination (Primary Total vaccinated cohort)

				≥	6.2 r	nIU/r	nL	≥	: 10 n	nIU/m	ıL		GMC	
						95%	6 CI			95%	6 CI		95%	6 CI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-HBs antibody	Hexa group	PIII(M5)	146	146	100	97.5	100	146	100	97.5	100	2218.2	1888.7	2605.1
	Pedia group	PIII(M5)	156	156	100	97.7	100	156	100	97.7	100	1803.8	1511.3	2152.8
	Penta group	PIII(M5)	154	152	98.7	95.4	99.8	151	98.1	94.4	99.6	1058.1	805.6	1389.6

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

Table 7.58 Number and percentage of subjects with anti-HBs antibody concentration equal to or above 6.2 mlU/mL and 10.0 mlU/mL and geometric mean concentration (GMC), one month post primary vaccination – by Hepatitis B vaccination at birth (Primary Total vaccinated cohort)

					≥	6.2 ı	nIU/n	nL	≥	10 n	nIU/n	٦L		GMC	
							95%	6 CI			95%	6 CI		95%	6 CI
Antibody	Group	Sub-group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-HBs	Hexa	HepB at birth	PIII(M5)	135	135	100	97.3	100	135	100	97.3	100	2318.7	1970.0	2729.1
antibody	group	Yes													
		HepB at birth	PIII(M5)	11	11	100	71.5	100	11	100	71.5	100	1287.8	585.5	2832.6
		No													
	Pedia	HepB at birth	PIII(M5)	137	137	100	97.3	100	137	100	97.3	100	1922.2	1602.3	2306.0
	group	Yes													
		HepB at birth	PIII(M5)	19	19	100	82.4	100	19	100	82.4	100	1140.4	603.1	2156.3
		No													
	Penta	HepB at birth	PIII(M5)	143	141	98.6	95.0	99.8	140	97.9	94.0	99.6	1041.7	777.7	1395.1
	group	Yes													
		HepB at birth	PIII(M5)	11	11	100	71.5	100	11	100	71.5	100	1296.5	828.3	2029.2
		No	, ,												

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PIII(M5) = Post primary vaccine dose 3 at month 5 (Visit 4)

117119 (DTPA-HBV-IPV-135) Report Final

Table 7.59 Number and percentage of subjects with anti-PT, anti-FHA and anti-PRN antibody concentration equal to or above the assay cut-off and geometric mean concentration (GMC), before and one month post booster vaccination (Booster Total vaccinated cohort)

					≥cu	ıt_off	1		GMC	
						95%	6 CI		95%	6 CI
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL
anti-PT antibody	Hexa group	PRE-BST	153	124	81.0	73.9	86.9	5.3	4.6	6.1
-		POST-BST	147	147	100	97.5	100	74.2	65.1	84.5
	Pedia group	PRE-BST	147	123	83.7	76.7	89.3	6.2	5.3	7.2
		POST-BST	138	138	100	97.4	100	87.1	76.2	99.5
	Penta group	PRE-BST	144	79	54.9	46.4	63.2	3.2	2.7	3.7
		POST-BST	136	136	100	97.3	100	56.3	48.5	65.4
anti-FHA antibody	Hexa group	PRE-BST	153	151	98.7	95.4	99.8	16.8	14.5	19.3
		POST-BST	147	147	100	97.5	100	187.2	166.1	211.0
	Pedia group	PRE-BST	147	145	98.6	95.2	99.8	21.2	18.0	24.9
		POST-BST	138	138	100	97.4	100	247.7	218.1	281.2
	Penta group	PRE-BST	144	136	94.4	89.3	97.6	8.6	7.2	10.3
		POST-BST	136	136	100	97.3	100	102.6	88.5	119.0
anti-PRN antibody	Hexa group	PRE-BST	153	129	84.3	77.6	89.7	7.1	5.8	8.6
		POST-BST	146	145	99.3	96.2	100	202.0	167.7	243.2
	Pedia group	PRE-BST	147	116	78.9	71.4	85.2	5.5	4.6	6.7
		POST-BST	138	138	100	97.4	100	217.6	178.2	265.7
	Penta group	PRE-BST	143	112	78.3	70.7	84.8	6.3	5.1	7.7
		POST-BST	135	134	99.3	95.9	100	127.5	104.8	155.2

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Note: The assay cut off is 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

Table 7.60 Booster response for anti-PT, anti-FHA and anti-PRN antibodies, one month post booster vaccination (Booster Total vaccinated cohort)

				Boo	ster	respo	onse
							6 CI
Antibody	Group	Pre-vaccination status	N	n	%	LL	UL
anti-PT antibody (IU/mL)	Hexa group	S-	26	24	92.3	74.9	99.1
		S+ (<4*cut_off IU/mL)	83	80	96.4	89.8	99.2
		S+ (≥4*cut_off IU/mL)	29	29	100	88.1	100
		Total	138	133	96.4	91.7	98.8
	Pedia group	S-	19	19	100	82.4	100
		S+ (<4*cut_off IU/mL)	87	82	94.3	87.1	98.1
		S+ (≥4*cut_off IU/mL)	26	22	84.6	65.1	95.6
		Total	132	123	93.2	87.5	96.8
	Penta group	S-	57	53	93.0	83.0	98.1
		S+ (<4*cut_off IU/mL)	53	52	98.1	89.9	100
		S+ (≥4*cut_off IU/mL)	15	14	93.3	68.1	99.8
		Total	125	119	95.2	89.8	98.2
anti-FHA antibody (IU/mL)	Hexa group	S-	1	1		2.5	100
		S+ (<4*cut_off IU/mL)	30	30	100	88.4	100
		S+ (≥4*cut_off IU/mL)	107			94.9	
		Total		137	99.3	96.0	100
	Pedia group	S-	2	2		15.8	
		S+ (<4*cut_off IU/mL)	18	18		81.5	
		S+ (≥4*cut_off IU/mL)				92.4	
		Total				93.5	
	Penta group		8	8		63.1	
		S+ (<4*cut_off IU/mL)	59	58	98.3	90.9	100
		S+ (≥4*cut_off IU/mL)	58	57		90.8	
		Total				94.3	
anti-PRN antibody (IU/mL)	Hexa group	S-	22	21		77.2	
		S+ (<4*cut_off IU/mL)	57	57		93.7	
		S+ (≥4*cut_off IU/mL)	58	57		90.8	
		Total	137			94.8	
	Pedia group	S-	28	27		81.7	
		S+ (<4*cut_off IU/mL)	56	55	98.2	90.4	100
		S+ (≥4*cut_off IU/mL)	48	48		92.6	
		Total				94.6	
	Penta group		29	27		77.2	_
		S+ (<4*cut_off IU/mL)	44	43		88.0	
		S+ (≥4*cut_off IU/mL)	51	51		93.0	
		Total	124	121	97.6	93.1	99.5

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

Booster response to PT, FHA and PRN antigens is defined as:

For subjects with pre-vaccination antibody concentration below the assay cut off, post-vaccination antibody concentration = 4 times the assay cut-off,

For subjects with pre-vaccination antibody concentration between the assay cut off, post-vaccination antibody concentration equal or above 4 times the pre-vaccination antibody concentration, For subjects with pre-vaccination antibody concentration equal or above 4 times the assay cut off, post-vaccination antibody concentration equal or above 2 times the pre-vaccination antibody concentration

N = number of subjects with pre- and post-vaccination results available

n/% = number/percentage of subjects with booster response

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Note: The assay cut off is 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA, and 2.187 IU/mL for anti-PRN.

Table 7.61 Number and percentage of subjects with anti-D and anti-T antibody concentration equal to or above the assay cut-off, 0.1 IU/mL and 1.0 IU/mL and geometric mean concentration (GMC), before and one month post booster vaccination (Booster Total vaccinated cohort)

					≥ cu	t_off		2	≥ 0.1	IU/m	L		≥1I	U/mL	•		GMC	
						95%	6 CI			95%	6 CI			95%	6 CI		95	% CI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-D antibody	Hexa group	PRE- BST	152	150	98.7	95.3	99.8	146	96.1	91.6	98.5	51	33.6	26.1	41.7	0.686	0.584	0.807
		POST- BST	147	147	100	97.5	100	147	100	97.5	100	146	99.3	96.3	100	8.136	7.282	9.090
	Pedia group	PRE- BST	147	144	98.0	94.2	99.6	137	93.2	87.8	96.7	53	36.1	28.3	44.4	0.629	0.527	0.752
		POST- BST	138	138	100	97.4	100	138	100	97.4	100	138	100	97.4	100	7.806	6.908	8.821
	Penta group	PRE- BST				92.1	98.9	136	94.4	89.3	97.6	64	44.4	36.2	52.9	0.789	0.650	0.959
		POST- BST	136	136	100	97.3	100	136	100	97.3	100	136	100	97.3	100	8.370	7.403	9.464
anti-T antibody	Hexa group	PRE- BST	153	151	98.7	95.4	99.8	135	88.2	82.0	92.9	16	10.5	6.1	16.4	0.312	0.271	0.360
		POST- BST	147	147	100	97.5	100	147	100	97.5	100	147	100	97.5	100	9.041	7.738	10.563
	Pedia group	PRE- BST	147	144	98.0	94.2	99.6	138	93.9	88.7	97.2	20	13.6	8.5	20.2	0.402	0.344	0.469
		POST- BST	138	138	100	97.4	100	138	100	97.4	100	135	97.8	93.8	99.5	8.787	7.607	10.150
	Penta group	PRE- BST	144	142	98.6	95.1	99.8	128	88.9	82.6	93.5	23	16.0	10.4	23.0	0.340	0.287	0.404
	,	POST- BST	136	136	100	97.3	100	135	99.3	96.0	100	135	99.3	96.0	100	6.835	5.898	7.921

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Note: The assay cut off is 0.057 IU/mL for anti-D, 0.043 IU/mL for anti-T.

117119 (DTPA-HBV-IPV-135) Report Final

Table 7.62 Number and percentage of subjects with anti-PRP antibody concentration equal to or above 0.066 μg/mL,0.15 μg/mL and 1.0 μg/mL and geometric mean concentration (GMC), before and one month post booster vaccination (Booster Total vaccinated cohort)

				≥	0.066	μg/i	mL	≥	0.15	μg/n	nL		≥1 µ	ıg/ml	L		GMC	
						95%	6 CI			95%	6 CI			95%	6 CI		95%	6 CI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-PRP -	Hexa	PRE-	153	137	89.5	83.6	93.9	104	68.0	60.0	75.3	29	19.0	13.1	26.1	0.309	0.250	0.383
fully validated	group	BST																
assay																		
		POST-	147	147	100	97.5	100	147	100	97.5	100	145	98.6	95.2	99.8	38.049	30.626	47.270
		BST																
	Pedia	PRE-	147	142	96.6	92.2	98.9	135	91.8	86.2	95.7	80	54.4	46.0	62.6	0.989	0.783	1.250
	group	BST																
		POST-	141	141	100	97.4	100	141	100	97.4	100	140	99.3	96.1	100	49.429	40.409	60.463
		BST																
	Penta	PRE-	144	134	93.1	87.6	96.6	117	81.3	73.9	87.3	53	36.8	28.9	45.2	0.607	0.472	0.781
	group	BST																
		POST-	141	140	99.3	96.1	100	139	98.6	95.0	99.8	138	97.9	93.9	99.6	26.875	21.099	34.231
		BST																

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

POST-BST = Post booster vaccination at Month 14-17 (Visit 6)

Table 7.63 Number and percentage of subjects with anti-Polio 1, 2 and 3 antibody titers equal to or above 8 and geometric mean titers (GMT), before the booster vaccination (Booster Total vaccinated cohort)

					≥81	ED50			GMT	
						95%	6 CI		95%	6 CI
Antibody	Group	Timing	N	n	%	LL	UL	value	LL	UL
anti-Polio 1 antibody	Hexa group	PRE-BST	149	145	97.3	93.3	99.3	99.1	81.1	121.2
	Pedia group	PRE-BST	142	135	95.1	90.1	98.0	110.1	86.8	139.5
	Penta group	PRE-BST	137	119	86.9	0.08	92.0	45.5	36.0	57.4
anti-Polio 2 antibody	Hexa group	PRE-BST	149	139	93.3	0.88	96.7	90.8	71.8	114.9
	Pedia group	PRE-BST	141	134	95.0	90.0	98.0	113.9	90.3	143.5
	Penta group	PRE-BST	137	128	93.4	87.9	97.0	55.4	44.8	68.5
anti-Polio 3 antibody	Hexa group	PRE-BST	148	143	96.6	92.3	98.9	116.7	92.7	147.0
	Pedia group	PRE-BST	143	138	96.5	92.0	98.9	155.1	122.3	196.6
	Penta group	PRE-BST	136	97	71.3	62.9	78.7	32.1	23.8	43.4

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMT = geometric mean antibody titer calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titer equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

Table 7.64 Number and percentage of subjects with anti-HBs antibody concentration equal to or above 6.2 mlU/mL and 10 mlU/mL and geometric mean concentration (GMC), before the booster vaccination (Booster Total vaccinated cohort)

				≥	6.2 r	nIU/n	nL	≥	: 10 n	nIU/m	ıL		GMC	
						95%	6 CI			95%	6 CI		95%	6 CI
Antibody	Group	Timing	N	n	%	LL	UL	n	%	LL	UL	value	LL	UL
anti-HBs antibody	Hexa group	PRE-BST	156	154	98.7	95.4	99.8	153	98.1	94.5	99.6	304.9	244.1	380.9
	Pedia group	PRE-BST	145	144	99.3	96.2	100	142	97.9	94.1	99.6	230.8	186.1	286.3
	Penta group	PRE-BST	143	131	91.6	85.8	95.6	126	88.1	81.6	92.9	150.5	105.8	214.1

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

GMC = geometric mean antibody concentration calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with concentration equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

PRE-BST = Pre booster vaccination at Month 13-16 (Visit 5)

Table 8.1 Incidence and nature of symptoms (solicited and unsolicited) that are causally related to vaccination reported during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)

			Any	sym	pton	1	Ge	ener	al syı	mpto	ms	L	.oca	l sym	pton	ns
			Ī		95%	6 CI				95%	6 CI				95%	6 CI
	Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Hexa group	195	159	81.5	75.4	86.7	195	144	73.8	67.1	79.9	195	111	56.9	49.7	64.0
	Pedia group	194	180	92.8	88.2	96.0	194	175	90.2	85.1	94.0	194	144	74.2	67.5	80.2
	Penta group	196	177	90.3	85.3	94.1	196	169	86.2	80.6	90.7	196	128	65.3	58.2	71.9
	Hexa group															
	Pedia group	188	165	87.8	82.2	92.1	188	155	82.4	76.2	87.6	188	135	71.8	64.8	78.1
	Penta group	189	161	85.2	79.3	89.9	189	154	81.5	75.2	86.7	189	117	61.9	54.6	68.9
Dose 3	Hexa group	183	150	82.0	75.6	87.2	183	134	73.2	66.2	79.5	183	103	56.3	48.8	63.6
	Pedia group	185	156	84.3	78.3	89.2	185	147	79.5	72.9	85.0	185	118	63.8	56.4	70.7
	Penta group	180	146	81.1	74.6	86.5	180	135	75.0	68.0	81.1	180	107	59.4	51.9	66.7
Overall/dose	Hexa group	564	465	82.4	79.1	85.5	564	421	74.6	70.8	78.2	564	319	56.6	52.4	60.7
	Pedia group	567	501	88.4	85.4	90.9	567	477	84.1	80.9	87.0	567	397	70.0	66.1	73.8
	Penta group	565	484	85.7	82.5	88.4	565	458	81.1	77.6	84.2	565	352	62.3	58.2	66.3
Overall/subject	Hexa group	195	181	92.8	88.2	96.0	195	173	88.7	83.4	92.8	195	151	77.4	70.9	83.1
	Pedia group															
	Penta group	196	182	92.9	88.3	96.0	196	180	91.8	87.1	95.3	196	162	82.7	76.6	87.7

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

For each dose and overall/subject:

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects presenting at least one type of symptom whatever the study vaccine administered

For overall/dose:

N = number of administered doses

Table 8.2 Incidence and nature of grade 3 symptoms (solicited and unsolicited) that are causally related to vaccination reported during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)

			Any	/ syn	pton	n	Ge	ner	al sy	mpto	ms	L	oca	l syn	nptor	ns
					95%	6 CI				95%	6 CI				95%	6 CI
	Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Hexa group	195	17	8.7	5.2	13.6	195	10	5.1	2.5	9.2	195	12	6.2	3.2	10.5
	Pedia group	194	40	20.6	15.2	27.0	194	21	10.8	6.8	16.1	194	32	16.5	11.6	22.5
	Penta group	196	35	17.9	12.8	23.9	196	24	12.2	8.0	17.7	196	22	11.2	7.2	16.5
Dose 2	Hexa group	186	17	9.1	5.4	14.2	186	13	7.0	3.8	11.7	186	5	2.7	0.9	6.2
	Pedia group	188	26	13.8	9.2	19.6	188	18	9.6	5.8	14.7	188	13	6.9	3.7	11.5
	Penta group	189	16	8.5	4.9	13.4	189	12	6.3	3.3	10.8	189	10	5.3	2.6	9.5
Dose 3	Hexa group	183	9	4.9	2.3	9.1	183	8	4.4	1.9	8.4	183	1	0.5	0.0	3.0
	Pedia group	185	27	14.6	9.8	20.5	185	18	9.7	5.9	14.9	185	13	7.0	3.8	11.7
	Penta group	180	20	11.1	6.9	16.6	180	15	8.3	4.7	13.4	180	8	4.4	1.9	8.8
Overall/dose	Hexa group	564	43	7.6	5.6	10.1	564	31	5.5	3.8	7.7	564	18	3.2	1.9	5.0
	Pedia group	567	93	16.4	13.4	19.7	567	57	10.1	7.7	12.8	567	58	10.2	7.9	13.0
	Penta group	565	71	12.6	9.9	15.6	565	51	9.0	6.8	11.7	565	40	7.1	5.1	9.5
Overall/subject	Hexa group	195	34	17.4	12.4	23.5	195	24	12.3	8.0	17.8	195	16	8.2	4.8	13.0
	Pedia group	194	71	36.6	29.8	43.8	194	43	22.2	16.5	28.7	194	46	23.7	17.9	30.3
	Penta group	196	54	27.6	21.4	34.4	196	39	19.9	14.5	26.2	196	35	17.9	12.8	23.9

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

For each dose and overall/subject:

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects presenting at least one type of symptom whatever the study vaccine administered

For overall/dose:

N = number of administered doses

Table 8.3 Incidence and nature of symptoms (solicited and unsolicited) reported during the 31-day (Days 0-30) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)

			Any	sym	ptom	1	Ge	ener	al sy	mpto	ms	L	.oca	sym	pton	าร
					95%	6 CI				95%	6 CI				95%	6 CI
	Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Hexa group	195	169	86.7	81.1	91.1	195	158	81.0	74.8	86.3	195	111	56.9	49.7	64.0
	Pedia group	194	185	95.4	91.4	97.9	194	182	93.8	89.4	96.8	194	144	74.2	67.5	80.2
	Penta group	196	180	91.8	87.1	95.3	196	176	89.8	84.7	93.7	196	128	65.3	58.2	71.9
Dose 2	Hexa group	186	164	88.2	82.6	92.4	186	155	83.3	77.2	88.4	186	105	56.5	49.0	63.7
	Pedia group	188	173	92.0	87.2	95.5	188	166	88.3	82.8	92.5	188	135	71.8	64.8	78.1
	Penta group															
Dose 3	Hexa group	183	160	87.4	81.7	91.9	183	153	83.6	77.4	88.7	183	104	56.8	49.3	64.1
	Pedia group	185	163	88.1	82.6	92.4	185	159	85.9	80.1	90.6	185	118	63.8	56.4	70.7
	Penta group	180	153	85.0	78.9	89.9	180	148	82.2	75.8	87.5	180	107	59.4	51.9	66.7
Overall/dose	Hexa group	564	493	87.4	84.4	90.0	564	466	82.6	79.2	85.7	564	320	56.7	52.5	60.9
	Pedia group	567	521	91.9	89.3	94.0	567	507	89.4	86.6	91.8	567	397	70.0	66.1	73.8
	Penta group	565	498	88.1	85.2	90.7	565	485	85.8	82.7	88.6	565	352	62.3	58.2	66.3
Overall/subject	Hexa group	195	186	95.4	91.4	97.9	195	185	94.9	90.8	97.5	195	152	77.9	71.5	83.6
	Pedia group	194	189	97.4	94.1	99.2	194	188	96.9	93.4	98.9	194	168	86.6	81.0	91.1
	Penta group	196	186	94.9	90.8	97.5	196	186	94.9	90.8	97.5	196	162	82.7	76.6	87.7

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

For each dose and overall/subject:

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects presenting at least one type of symptom whatever the study vaccine administered

For overall/dose:

N = number of administered doses

Table 8.4 Incidence and nature of grade 3 symptoms (solicited and unsolicited) reported during the 31-day (Days 0-30) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)

			Any	/ syn	npton	n	Ge	nei	al sy	mpto	oms	L	oca	l syn	nptor	ns
					95%	6 CI				95%	6 CI				95%	6 CI
	Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Hexa group	195	17	8.7	5.2	13.6	195	10	5.1	2.5	9.2	195	12	6.2	3.2	10.5
	Pedia group	194	41	21.1	15.6	27.6	194	22	11.3	7.2	16.7	194	32	16.5	11.6	22.5
	Penta group	196	35	17.9	12.8	23.9	196	24	12.2	8.0	17.7	196	22	11.2	7.2	16.5
Dose 2	Hexa group	186	17	9.1	5.4	14.2	186	13	7.0	3.8	11.7	186	5	2.7	0.9	6.2
	Pedia group	188	26	13.8	9.2	19.6	188	19	10.1	6.2	15.3	188	13	6.9	3.7	11.5
	Penta group	189	16	8.5	4.9	13.4	189	12	6.3	3.3	10.8	189	10	5.3	2.6	9.5
Dose 3	Hexa group	183	9	4.9	2.3	9.1	183	8	4.4	1.9	8.4	183	1	0.5	0.0	3.0
	Pedia group	185	27	14.6	9.8	20.5	185	20	10.8	6.7	16.2	185	13	7.0	3.8	11.7
	Penta group	180	20	11.1	6.9	16.6	180	15	8.3	4.7	13.4	180	8	4.4	1.9	8.6
Overall/dose	Hexa group	564	43	7.6	5.6	10.1	564	31	5.5	3.8	7.7	564	18	3.2	1.9	5.0
	Pedia group	567	94	16.6	13.6	19.9	567	61	10.8	8.3	13.6	567	58	10.2	7.9	13.0
	Penta group	565	71	12.6	9.9	15.6	565	51	9.0	6.8	11.7	565	40	7.1	5.1	9.5
Overall/subject	Hexa group	195	34	17.4	12.4	23.5	195	24	12.3	8.0	17.8	195	16	8.2	4.8	13.0
	Pedia group	194	72	37.1	30.3	44.3	194	45	23.2	17.5	29.8	194	46	23.7	17.9	30.3
	Penta group	196	54	27.6	21.4	34.4	196	39	19.9	14.5	26.2	196	35	17.9	12.8	23.9

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

For each dose and overall/subject:

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects presenting at least one type of symptom whatever the study vaccine administered

For overall/dose:

N = number of administered doses

Table 8.5 Incidence and nature of symptoms (solicited and unsolicited) that are causally related to vaccination reported during the 31-day (Days 0-30) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)

			Any	sym	ptom	1	Ge	ener	al syı	mpto	ms	L	.oca	sym	pton	าร
					95%	6 CI				95%	6 CI			-	95%	6 CI
	Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Hexa group															64.0
	Pedia group	194	180	92.8	88.2	96.0	194	175	90.2	85.1	94.0	194	144	74.2	67.5	80.2
	Penta group	196	177	90.3	85.3	94.1	196	169	86.2	80.6	90.7	196	128	65.3	58.2	71.9
Dose 2	Hexa group															
	Pedia group	188	165	87.8	82.2	92.1	188	155	82.4	76.2	87.6	188	135	71.8	64.8	78.1
	Penta group	189	162	85.7	79.9	90.4	189	155	82.0	75.8	87.2	189	117	61.9	54.6	68.9
Dose 3	Hexa group	183	150	82.0	75.6	87.2	183	135	73.8	66.8	80.0	183	104	56.8	49.3	64.1
	Pedia group	185	156	84.3	78.3	89.2	185	147	79.5	72.9	85.0	185	118	63.8	56.4	70.7
	Penta group	180	146	81.1	74.6	86.5	180	135	75.0	68.0	81.1	180	107	59.4	51.9	66.7
Overall/dose	Hexa group	564	465	82.4	79.1	85.5	564	422	74.8	71.0	78.4	564	320	56.7	52.5	60.9
	Pedia group	567	501	88.4	85.4	90.9	567	477	84.1	80.9	87.0	567	397	70.0	66.1	73.8
	Penta group	565	485	85.8	82.7	88.6	565	459	81.2	77.8	84.4	565	352	62.3	58.2	66.3
Overall/subject	Hexa group	195	181	92.8	88.2	96.0	195	173	88.7	83.4	92.8	195	152	77.9	71.5	83.6
	Pedia group	194	186	95.9	92.0	98.2	194	183	94.3	90.1	97.1	194	168	86.6	81.0	91.1
	Penta group	196	182	92.9	88.3	96.0	196	180	91.8	87.1	95.3	196	162	82.7	76.6	87.7

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

For each dose and overall/subject:

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects presenting at least one type of symptom whatever the study vaccine administered

For overall/dose:

N = number of administered doses

Table 8.6 Incidence and nature of grade 3 symptoms (solicited and unsolicited) that are causally related to vaccination reported during the 31-day (Days 0-30) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)

			Any	/ syn	npton	n	Ge	nei	al sy	mpto	ms	L	oca	l syn	nptor	ns
					95%	6 CI				95%	6 CI				95%	6 CI
	Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Hexa group	195	17	8.7	5.2	13.6	195	10	5.1	2.5	9.2	195	12	6.2	3.2	10.5
	Pedia group	194	40	20.6	15.2	27.0	194	21	10.8	6.8	16.1	194	32	16.5	11.6	22.5
	Penta group	196	35	17.9	12.8	23.9	196	24	12.2	8.0	17.7	196	22	11.2	7.2	16.5
Dose 2	Hexa group	186	17	9.1	5.4	14.2	186	13	7.0	3.8	11.7	186	5	2.7	0.9	6.2
	Pedia group	188	26	13.8	9.2	19.6	188	18	9.6	5.8	14.7	188	13	6.9	3.7	11.5
	Penta group	189	16	8.5	4.9	13.4	189	12	6.3	3.3	10.8	189	10	5.3	2.6	9.5
Dose 3	Hexa group	183	9	4.9	2.3	9.1	183	8	4.4	1.9	8.4	183	1	0.5	0.0	3.0
	Pedia group	185	27	14.6	9.8	20.5	185	18	9.7	5.9	14.9	185	13	7.0	3.8	11.7
	Penta group	180	20	11.1	6.9	16.6	180	15	8.3	4.7	13.4	180	8	4.4	1.9	8.6
Overall/dose	Hexa group	564	43	7.6	5.6	10.1	564	31	5.5	3.8	7.7	564	18	3.2	1.9	5.0
	Pedia group	567	93	16.4	13.4	19.7	567	57	10.1	7.7	12.8	567	58	10.2	7.9	13.0
	Penta group	565	71	12.6	9.9	15.6	565	51	9.0	6.8	11.7	565	40	7.1	5.1	9.5
Overall/subject	Hexa group	195	34	17.4	12.4	23.5	195	24	12.3	8.0	17.8	195	16	8.2	4.8	13.0
	Pedia group	194	71	36.6	29.8	43.8	194	43	22.2	16.5	28.7	194	46	23.7	17.9	30.3
	Penta group	196	54	27.6	21.4	34.4	196	39	19.9	14.5	26.2	196	35	17.9	12.8	23.9

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

For each dose and overall/subject:

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects presenting at least one type of symptom whatever the study vaccine administered

For overall/dose:

N = number of administered doses

Report Final

Table 8.7 Incidence of local symptoms (solicited and unsolicited) that are causally related to vaccination reported for Infanrix hexa, Pediarix, ActHIB, Pentacel and Engerix-B vaccines during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)

		I	NFA	NRIX	HEX	Α		Pl	EDIA	RIX			A	ACTH	IIB			PE	NTA	CEL			ΕN	IGER	IX-B	
					95%	6 CI				95	% CI															
	Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Hexa group	195	111	56.9	49.7	64.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	194	131	67.5	60.4	74.1	194	139	71.6	64.8	77.9	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	196	123	62.8	55.6	69.5	196	118	60.2	53.0	67.1
Dose 2	Hexa group	186	104	55.9	48.5	63.2	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	188	127	67.6	60.4	74.2	188	122	64.9	57.6	71.7	0	0	0.0	0.0	0.0	0			0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	187	116	62.0	54.7	69.0	13	7	53.8	25.1	80.8
Dose 3	Hexa group	183	101	55.2	47.7	62.5	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	185	108	58.4	50.9	65.6	185	113	61.1	53.7	68.1	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group					0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	180	98	54.4	46.9	61.9	180	95	52.8	45.2	2 60.2
Overall/dose	Hexa group	564	316	56.0	51.8	60.2					0.0	0	0			•.•	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	567	366	64.6	60.5	68.5	567	374	66.0	61.9	69.9	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	563	337	59.9	55.7	63.9	389	220	56.6	51.5	61.5
Overall/subject	Hexa group	195	149	76.4	69.8	82.2	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	194	159	82.0	75.8	87.1	194	164	84.5	78.7	89.3	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	196	156	79.6	73.3	85.0	196	145	74.0	67.2	80.0

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

For each dose and overall/subject:

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects presenting at least one type of symptom at the study vaccine site For overall/dose:

N = number of administered doses

n/% = number/percentage of doses followed by at least one type of symptom at the study vaccine site

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Report Final

Table 8.8 Incidence of grade 3 local symptoms (solicited and unsolicited) that are causally related to vaccination reported for Infanrix hexa, Pediarix, ActHIB, Pentacel and Engerix-B vaccines during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)

		IN	FAI	NRI)	(HE	XA		P	EDIA	RIX				ACTI	ΗВ			Pl	ENTA	CEL			EN	GEF	RIX-I	3
					95	% CI				95%	% CI				959	% CI				959	% CI				95	% CI
	Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Dose 1	Hexa group	195	12	6.2	3.2	10.5	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	194	21	10.8	6.8	16.1	194	28	14.4	9.8	20.2	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	196	22	11.2	7.2	16.5	196	13	6.6	3.6	11.1
Dose 2	Hexa group	186	5	2.7	0.9	6.2	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	188	11	5.9	3.0	10.2	188	10	5.3	2.6	9.6	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	187	10	5.3	2.6	9.6	13	0	0.0	0.0	24.7
Dose 3	Hexa group	183	1	0.5	0.0	3.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	185	11	5.9	3.0	10.4	185	9	4.9	2.2	9.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group						0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	180	7	3.9	1.6	7.8	180	7	3.9	1.6	7.8
Overall/dose	Hexa group	564	18	3.2	1.9	5.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	567	43	7.6	5.5	10.1	567	47	8.3	6.2	10.9	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	563	39	6.9	5.0	9.3	389	20	5.1	3.2	7.8
Overall/subject	Hexa group	195	16	8.2	4.8	13.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Pedia group	0	0	0.0	0.0	0.0	194	36	18.6	13.3	24.8	194	38	19.6	14.2	25.9	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0
	Penta group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	196	34	17.3	12.3	23.4	196	19	9.7	5.9	14.7

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine For each dose and overall/subject:

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects presenting at least one type of symptom at the study vaccine site For overall/dose:

N = number of administered doses

117119 (DTPA-HBV-IPV-135)

Table 8.9 Incidence of solicited local symptoms reported during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall – by gender (Primary Total vaccinated cohort)

						ŀ	lexa	gro	up							F	Pedia	gro	up							P	enta	gro	oup	-	
					Fema	le				Mal	-				Fem	ale				Mal	-				Fem	ale				Male	_
						95	% CI				95	% CI					% CI				95	% CI				95	% CI				95 % CI
Symptom	Product	Type	N	n	%	LL	UL	N	n	%	LL			n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL UL
												Dos																			
Pain	Total	All							49	55.1	44.1	65.6	76	51	67.	1 55.4	177.5	113	77	68.1	58.7	76.6	90	51	56.7	7 45.8	67.1	98	68	69.4	59.3 78.3
		Grade 2 3	or 96	22	22.9	15.0	32.6	89	18	20.2	12.4	30.1	76	33	43.4	4 32.1	1 55.3	3 113	42	37.2	28.3	46.8	90	28	31.	1 21.8	41.7	98	28	28.6	19.9 38.6
		Grade 3	96		4.2	1.1	10.3	89	4	4.5	1.2	11.1	76	11	14.	57.5	24.4	1113	13	11.5	6.3	18.9	90	5	5.6	1.8	12.5	98	7	7.1	2.9 14.2
		Medical	96	1	1.0	0.0	5.7	89	0	0.0	0.0	4.1	76	0	0.0	0.0	4.7	113	1	0.9	0.0	4.8	90	0	0.0	0.0	4.0	98	0	0.0	0.0 3.7
		advice																													
	ActHIB/Engerix B	All											76	49	64.	5 52.7	75.1	113	74	65.5	56.0	74.2	90	44	48.9	38.2	59.7	98	56	57.1	46.7 67.1
		Grade 2 3	or										76	30	39.	5 28.4	151.4	1113	36	31.9	23.4	41.3	90	23	25.6	6 16.9	35.8	398	22	22.4	14.6 32.0
		Grade 3											76	10	13.2	26.5	22.9	113	12	10.6	5.6	17.8	90	3	3.3	0.7	9.4	98	7	7.1	2.9 14.2
		Medical											76	0	0.0	0.0	4.7	113	1	0.9	0.0	4.8	90	0	0.0	0.0	4.0	98	0	0.0	0.0 3.7
		advice																													
	Hexa/Pediarix/Pentacel	All	96	45	46.9	36.6	57.3	89	49	55.1	44.1	65.6	76	47	61.8	8 50.0	72.8	113	66	58.4	48.8	67.6	90	49	54.4	43.6	65.0	98	66	67.3	57.1 76.5
		Grade 2 3	or 96	22	22.9	15.0	32.6	89	18	20.2	12.4	30.1	76	31	40.8	8 29.6	52.7	113	34	30.1	21.8	39.4	90	26	28.9	19.8	39.4	198	25	25.5	17.2 35.3
		Grade 3	96	4	4.2	1.1	10.3	89	4	4.5	1.2	11.1	76	8	10.	54.7	19.7	113	9	8.0	3.7	14.6	90	5	5.6	1.8	12.5	98	7	7.1	2.9 14.2
		Medical advice	96	1			5.7				0.0		76	0	0.0	0.0	4.7	113			0.0				0.0		4.0				0.0 3.7
Redness (mm)	Total	All	96	25	26.0	17.6	36.0	89	22	24.7	16.2	35.0	76	29	38.2	2 27.2	50.0	113	44	38.9	29.9	48.6	90	31	34.4	1 24.7	45.2	98	36	36.7	27.2 47.1
, ,		>5	96	8	8.3	3.7	15.8	89	7	7.9	3.2	15.5	76	9	11.8	85.6	21.3	113	18	15.9	9.7	24.0	90	14	15.6	8.8	24.7	98	13	13.3	7.3 21.6
		>20	96		2.1	0.3	7.3	89	1	1.1	0.0	6.1	76	1	1.3	0.0	7.1	113	9	8.0	3.7	14.6	90	1	1.1	0.0	6.0	98	3	3.1	0.6 8.7
		Medical advice	96	0	0.0	0.0	3.8	89	0	0.0	0.0	4.1	76	0	0.0	0.0	4.7	113	3 1	0.9	0.0	4.8	90	0	0.0	0.0	4.0	98	0	0.0	0.0 3.7
	ActHIB/Engerix B	All											76	24	31.0	6 21.4	143.3	113	39	34.5	25.8	44.0	90	28	31.1	1 21.8	41.7	798	27	27.6	19.0 37.5
		>5											76	6	7.9	3.0	16.4	113	13	11.5	6.3	18.9	90	9	10.0	4.7	18.1	98	3	3.1	0.6 8.7
		>20											76	1	1.3	0.0	7.1	113	7	6.2	2.5	12.3	90	1	1.1	0.0	6.0	98	0	0.0	0.0 3.7

117119 (DTPA-HBV-IPV-135)

						F	lexa	gro	un							P	edia	group							P	enta	gro		Rep	OIL I	IIIai
					Fema		IOAG	9.0	чР	Mal	e				Fem		ouiu	group	Ma	le				Fem		Onto	9.0	чр	Mal	e	
							% CI				-	% CI			• • • • • • • • • • • • • • • • • • • •		% CI			-	% CI			• • • • • • • • • • • • • • • • • • • •		% CI					% CI
Symptom	Product	Туре	N	n	%				n	%	LL		N	n	%		UL		%	LL			n	%				n	%		UL
- , ,		Medical											76							0.0	4.8				0.0		98		0.0		
		advice																													
	Hexa/Pediarix/Pentacel	All	96	25	26.0	17.6	36.0	89	22	24.7	16.2	35.0	76	22	28.9	19.1	40.5	113 34	30.	1 21.8	39.4	190	25	27.8	3 18.9	38.2	98	32	32.7	23.5	42.9
		>5	96	8	8.3	3.7	15.8	89	7	7.9	3.2	15.5	76	6	7.9	3.0	16.4	1139	8.0	3.7	14.6	90	9	10.0	34.7	18.1	1 98	11	11.2	5.7	19.2
		>20		2	2.1	0.3	7.3	89	1	1.1	0.0	6.1	76	1	1.3	0.0	7.1	1133	2.7	0.6	7.6	90	0	0.0	0.0	4.0	98	3	3.1	0.6	8.7
		Medical	96	0	0.0	0.0	3.8	89	0	0.0	0.0	4.1	76	0	0.0			1130	0.0	0.0				0.0	0.0	4.0	98	0	0.0	0.0	3.7
		advice																													
Swelling (mm)	Total	All	96	14	14.6	8.2	23.3	89	17	19.1	11.5	28.8	76	23	30.3	20.2	41.9	113 23	20.	4 13.4	129.0	90	20	22.2	2 14.1	32.2	98	33	33.7	24.4	43.9
,		>5	96	4	4.2	1.1	10.3	89			2.5		76	8	10.5	4.7	19.7	113 10						11.1	1 5.5	19.5	98	14	14.3	8.0	22.8
		>20	96	1		0.0		89			0.0		76					1135	4.4	1.5	10.0	90	3	3.3	0.7	9.4	98	8	8.2	3.6	15.5
		Medical	96	0	0.0	0.0	3.8	89	0	0.0	0.0	4.1	76	0	0.0	0.0	4.7	113 1	0.9	0.0	4.8	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
		advice																													
	ActHIB/Engerix B	All											76					113 22													
		>5											76					113 10							2.5						15.5
		>20											76	2						1.0					0.0				2.0		
		Medical											76	0	0.0	0.0	4.7	113 1	0.9	0.0	4.8	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
		advice																													
	Hexa/Pediarix/Pentacel		96	14		8.2					11.5			17						99.7									27.6		
		>5	96	4					6		2.5	14.1		7						2.5					1 5.5				14.3		
		>20	96	1		0.0		89	1		0.0		76	1				1132		0.2							98				15.5
		Medical	96	0	0.0	0.0	3.8	89	0	0.0	0.0	4.1	76	0	0.0	0.0	4.7	1130	0.0	0.0	3.2	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
		advice										<u></u>																			
	-		0.4	40	14	0 = 4		200	4.4	40.0		Dose		14-	00 -	J-0 -		140000		0 40 6		200	0.7	1444	alaa -				I	14-0	
Pain	Total	All	-	43		35.4					35.9							109 65													
		Grade 2 or	94	12	12.8	6.8	21.2	288	13	14.8	8.1	23.9	75	20	26.7	17.1	38.1	109 34	31.	2 22.7	40.8	383	11	13.3	36.8	22.5	97	21	21.6	13.9	31.2
		3	0.4	_	0.0	0.0	0 0	00		4.4	0.0	0.0	7-		- 0	4.5	40.4	1000		0.0	444	200	_	0.4	0.0	0.4	~-		4.4	4.4	40.0
			-	0		0.0		88			0.0									2.0					0.3						10.2
		Medical	94	0	0.0	0.0	3.8	88	U	0.0	0.0	4.1	15	U	0.0	0.0	4.8	1090	0.0	0.0	3.3	83	U	0.0	0.0	4.3	97	U	0.0	0.0	3.7
	A att IID/Earnain D	advice						-					75	4.4	T 4 -	7 40 3		100 00	F 7	0 40 6	07.	2 -	4	00.4	200.4	00.7	- 0	0	05.0	2.0	CF 4
	ActHIB/Engerix B	All									1							109 63					4		28.4			2	25.0		
		Grade 2 or 3											75	18	24.(14.9	35.3	109 29	26.	6 18.6	35.	95	1	20.0	0.5	71.6	οδ	1	12.5	0.3	52.7

117119 (DTPA-HBV-IPV-135)

						H	lexa	gro	up							Р	edia	group							P	enta	gro	up	•		
				F	Fema			Ĭ	•	Mal	е				ema			ľ	Ma	le				Fem			Ĭ	•	Male	е	
						95 9	% CI				95	% CI				95	% CI			95	% CI				95	% CI				95 °	% CI
Symptom	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N				UL		%		UL		n	%		UL		n	%	LL	UL
•		Grade 3											75	3	4.0	8.0	11.2			2.0	11.6	5 5	0	0.0	0.0	52.2	8	0	0.0	0.0	36.9
		Medical											75	0	0.0	0.0	4.8	1090	0.0	0.0	3.3	5	0	0.0	0.0	52.2	8	0	0.0	0.0	36.9
		advice																													
	Hexa/Pediarix/Pentacel																	109 63													
		Grade 2 or 3	94	12	12.8	86.8	21.2	288	13	14.8	8.1	23.9	75	16	21.3	12.7	32.3	109 28	25.	7 17.8	34.9	83	10	12.0	5.9	21.0	97	21	21.6	13.9	31.2
			94			0.0			1	1.1	0.0	6.2	75							1.0					0.3				4.1	1.1	10.2
		Medical advice	94	0	0.0	0.0	3.8	88	0	0.0	0.0	4.1	75	0	0.0	0.0	4.8	1090	0.0	0.0	3.3	83	0	0.0	0.0	4.3	97	0	0.0	0.0	3.7
Redness (mm)	Total	All	94	26	27.7	18.9	37.8	88	33	37.5	27.4	48.5	75	33	44.0	32.5	55.9	109 44	40.4	431.1	50.2	283	32	38.6	328.1	49.9	97	32	33.0	23.8	43.3
, ,		>5	94			4.5			6	6.8	2.5	14.3	75	11	14.7	7.6	24.7			15.1				9.6	4.3	18.1	97	8	8.2	3.6	15.6
		>20	94	2	2.1	0.3	7.5	88	1	1.1	0.0	6.2	75	1	1.3	0.0	7.2	1092	1.8	0.2	6.5	83	1	1.2	0.0	6.5	97	1	1.0	0.0	5.6
		Medical	94	0	0.0	0.0	3.8	88	0	0.0	0.0	4.1	75	0	0.0	0.0	4.8	1090	0.0	0.0	3.3	83	0	0.0	0.0	4.3	97	0	0.0	0.0	3.7
		advice																													
	ActHIB/Engerix B	All																109 38					3		14.7						65.1
		>5											75	10						2.6			1		0.5						36.9
		>20											75	1				1090		0.0			0		0.0						36.9
		Medical advice											75	0	0.0	0.0	4.8	1090	0.0	0.0	3.3	5	0	0.0	0.0	52.2	8	0	0.0	0.0	36.9
	Hexa/Pediarix/Pentacel	All	94	26	27.7	18.9	37.8	88	33	37.5	27.4	48.5	75	27	36.0	25.2	47.9	109 34	31.	222.7	40.8	83	32	38.6	28.1	49.9	97	32	33.0	23.8	43.3
		>5	94	9	9.6	4.5	17.4	4 88	6	6.8	2.5	14.3	75	5	6.7	2.2	14.9	1097	6.4	2.6	12.8	83	7	8.4	3.5	16.6	97	8	8.2	3.6	15.6
		>20		2	2.1	0.3	7.5	88	1	1.1	0.0	6.2	75	1	1.3	0.0	7.2	1092	1.8	0.2	6.5	83	1	1.2	0.0	6.5	97	1	1.0	0.0	5.6
		Medical advice	94	0	0.0	0.0	3.8	88	0	0.0	0.0	4.1	75	0	0.0	0.0	4.8	1090	0.0	0.0	3.3	83	0	0.0	0.0	4.3	97	0	0.0	0.0	3.7
Swelling (mm)	Total	All	94	21	22.3	14.4	32.′	1 88	20	22.7	14.5	32.9	75	21	28.0	18.2	39.6	109 30	27.	5 19.4	36.9	83	24	28.9	19.5	39.9	97	20	20.6	13.1	30.0
			94		5.3	1.7	12.0	88			1.9									3.8					2.0				2.1		
						0.3				0.0			75							0.0					0.3		97		1.0		
		Medical advice	94	0	0.0	0.0	3.8	88	0	0.0	0.0	4.1	75							0.0					0.0			0	0.0		
· ·	ActHIB/Engerix B	All											75					109 25							5.3			1			52.7
		>5											75	6	8.0	3.0	16.6	1095	4.6	1.5	10.4	15	0	0.0	0.0	52.2	8	0	0.0	0.0	36.9

117119 (DTPA-HBV-IPV-135)

						ŀ	lexa	gro	un							F	edia	group							P	enta	aro		rch	OI L I	Final
					Fema		ICAU	9.0	чр	Mal	e				Fema		Cuit	group	Ma	le				Fem		Ciita	gio	чр	Mal	e	
					<u> </u>		% CI				-	% CI					% CI			-	% CI			• • • • • • • • • • • • • • • • • • • •		% CI				-	% CI
Symptom	Product	Туре	N	n	%	LL			n	%	LL		N	n	%	LL	UL	N n	%	LL		N	n	%	LL	UL		n	%		UL
		>20											75	1	1.3	0.0	7.2	1090	0.0	0.0	3.3	5	0	0.0	0.0	52.2	28	0	0.0	0.0	36.9
		Medical											75	0	0.0	0.0	4.8	1090	0.0	0.0	3.3	5	0	0.0	0.0	52.2	28	0	0.0	0.0	36.9
		advice																													
	Hexa/Pediarix/Pentacel	All		21	22.3	14.4	32.1	1 88	20	22.7	14.5	32.9	75	17	22.7	13.8	33.8	3 109 23	21.	1 13.9	30.0	83	22	26.5	5 17.4	37.3	97	20	20.6	13.1	30.0
		>5		5				88			1.9			5				1097		2.6					2.0				2.1		
		>20				0.3		88		0.0	0.0			2	2.7			1090		0.0	3.3				0.3		97			0.0	
		Medical	94	0	0.0	0.0	3.8	88	0	0.0	0.0	4.1	75	0	0.0	0.0	4.8	1090	0.0	0.0	3.3	83	0	0.0	0.0	4.3	97	0	0.0	0.0	3.7
		advice																													
												Dos																			
Pain	Total	All	88			26.4				41.7								3 107 56							33.6						62.1
		Grade 2 or 3	88	6	6.8	2.5	14.3	84	12	14.3	7.6	23.6	68	16	23.5	14.1	35.4	107 29	27.	1 19.0	36.6	78	14	17.9	10.2	28.3	393	14	15.1	8.5	24.0
		Grade 3	88	0	0.0	0.0	4.1	84		0.0					4.4	0.9	12.4	1 107 5	4.7	1.5	10.6	78	4	5.1	1.4	12.6	93	3	3.2	0.7	9.1
		Medical	88	0	0.0	0.0	4.1	84	0	0.0	0.0	4.3	68	0	0.0	0.0	5.3	107 1	0.9	0.0	5.1	78	0	0.0	0.0	4.6	93	0	0.0	0.0	3.9
		advice																													
	ActHIB/Engerix B	All											68					3 107 54													
		Grade 2 or 3	-										68	13	19.1	10.6	30.	5 107 28	26.	2 18.1	35.6	78	13	16.7	79.2	26.8	391	12	13.2	7.0	21.9
		Grade 3											68	2	2.9	0.4	10.2	2 107 5	4.7	1.5	10.6	78	3	3.8	8.0	10.8	91	2	2.2	0.3	7.7
		Medical											68	0	0.0	0.0	5.3	107 1	0.9	0.0	5.1	78	0	0.0	0.0	4.6	91	0	0.0	0.0	4.0
		advice																													
	Hexa/Pediarix/Pentacel					26.4				41.7										6 38.8											256.4
		Grade 2 or 3		6	6.8	2.5	14.3			14.3								3 107 24							18.2						16.4
		Grade 3	88			0.0		84		0.0				3				1 107 4		1.0					1.4				3.3		
		Medical	88	0	0.0	0.0	4.1	84	0	0.0	0.0	4.3	68	0	0.0	0.0	5.3	107 1	0.9	0.0	5.1	78	0	0.0	0.0	4.6	92	0	0.0	0.0	3.9
		advice																													
Redness (mm)	Total	All	88	35		329.5														8 36.1											350.5
		>5	88	7		3.3				0.0								3 107 9		3.9											12.1
		>20	88	1		0.0				0.0								2 107 2		0.2					0.3				0.0		
		Medical advice	88	0	0.0	0.0	4.1	84	0	0.0	0.0	4.3	68	0	0.0	0.0	5.3	107 1	0.9	0.0	5.1	78	0	0.0	0.0	4.6	93	0	0.0	0.0	3.9

117119 (DTPA-HBV-IPV-135)

						ŀ	lexa	arc	au							F	edia	a gro	auc							F	enta g	iroun		,O1 L 1	-ınaı
					Fem			9. 4	- up	Mal	e				Fema		04.0	- g. c	~ P	Mal	e				Fem		Jintu	,. 	Ma	le	
							% CI				-	% CI					% CI	I				% CI					% CI			-	% CI
Symptom	Product	Туре	N	n	%			N	n	%	LL		N	n	%	LL	UL	N	n	%	LL		N	n	%	LL	UL N	l n	%	LL	
	ActHIB/Engerix B	All											68	29	42.6	30.7	55.2	2 107	40	37.4	28.2	47.3	78	23	29.5	19.7	40.9	1 28	30.8	3 21.5	41.3
		>5											68	3	4.4												17.6			0.3	
		>20											68	1		0.0		107				3.4				0.3				0.0	
		Medical											68	0	0.0	0.0	5.3	107	70	0.0	0.0	3.4	78	0	0.0	0.0	4.6	0 10	0.0	0.0	4.0
		advice																													
	Hexa/Pediarix/Pentace		88	35		3 29.5						4 44.5			35.3							49.2					40.9				46.5
		>5	88	7	8.0	3.3								3	4.4			4 107								2.9				1.8	
		>20	88	1	1.1		6.2							1		0.0		107								0.0			0.0		
		Medical	88	0	0.0	0.0	4.1	84	0	0.0	0.0	4.3	68	0	0.0	0.0	5.3	107	1	0.9	0.0	5.1	78	0	0.0	0.0	4.6	0	0.0	0.0	3.9
- III	<u> </u>	advice		0-	00	1400			40	0.4.4	140	004-		00	00.4	40.6		- 40-		00.0	20.6	10.5		4.0	00		20406			10	1000
Swelling (mm)	Total	All	88	25	28.4	19.3	39.0)84	18	21.4	13.	2 31.7	68	20	29.4	19.0)41.	7 107	/33	30.8	22.3	340.5	78	18	23.1	14.3	34.09	3 26	28.0) 19.1	38.2
		>5	88	6	6.8					1.2						0.9		4 107			3.9					2.1	14.3			0.7	
		>20	88	1	1.1		6.2				0.0			2		0.4		2 107			0.0		78			0.0	4.6			0.0	
		Medical	88	0	0.0	0.0	4.1	84	0	0.0	0.0	4.3	68	0	0.0	0.0	5.3	107	1	0.9	0.0	5.1	78	0	0.0	0.0	4.6	3 0	0.0	0.0	3.9
		advice																													
	ActHIB/Engerix B	All											68	16	23.5							33.5					28.3				35.5
		>5											68	2	2.9					4.7		10.6					12.6			0.7	
		>20											68	1		0.0		107				3.4				0.0				0.0	
		Medical											68	0	0.0	0.0	5.3	107	70	0.0	0.0	3.4	78	0	0.0	0.0	4.6	0 10	0.0	0.0	4.0
		advice																													
	Hexa/Pediarix/Pentace		88	25		19.3				_		231.7			23.5							35.6					26.8				33.9
		>5	88	6	6.8							6.5	68	3	4.4			4 107				13.0				0.0				0.7	
		>20	88	1	1.1						0.0			2	2.9							5.1				0.0				0.0	
		Medical advice	88	0	0.0	0.0	4.1	84	U	0.0	0.0	4.3	68	0	0.0	0.0	5.3	107	1	0.9	0.0	5.1	/8	U	0.0	0.0	4.6	12 0	0.0	0.0	3.9

117119 (DTPA-HBV-IPV-135)

						-	lava	gro	ıın								Padis	group				1			P	enta	arr		кер	ort F	inal
					ema		ICAA	gio	up	Mal					Fem		Cuic	group	Ma	ale				Fem		GIILL	gic	Jup	Mal	_	
				•	CITIC		% CI			IVIUI	-	% CI					% CI	1	1410	-	% CI		'	Cili		% CI	l		iviai	-	% CI
Symptom	Product	Туре	N	n	%	LL			n	%	LL			n	%	LL			%	LL			n	%	LL			n	%	LL	
												erall				•			•	•					•		,	•		•	•
Pain	Total																	3 329 19													
		Grade 2 or 3																													
			278			0.4												7 329 24												2.7	
			278	1	0.4	0.0	2.0	261	0	0.0	0.0	1.4	219	0	0.0	0.0	1.7	329 2	0.6	0.1	2.2	251	0	0.0	0.0	1.5	288	30	0.0	0.0	1.3
		advice																													
	ActHIB/Engerix B	All																5 329 19													
		Grade 2 or 3																3 329 93													
		Grade 3																329 23							1.3					2.1	
		Medical											219	0	0.0	0.0	1.7	329 2	0.6	0.1	2.2	173	30	0.0	0.0	2.1	197	70	0.0	0.0	1.9
		advice																													
	Hexa/Pediarix/Pentacel																	9 329 18													
		Grade 2 or 3																													
			278			0.4												5 329 17											_		
			278	1	0.4	0.0	2.0	261	0	0.0	0.0	1.4	219	0	0.0	0.0	1.7	329 1	0.3	0.0	1.7	251	0	0.0	0.0	1.5	287	70	0.0	0.0	1.3
		advice																													
Redness (mm)	Total																	8 329 13													
																		4 329 38											_		
			278			0.6		261			0.1					0.5		329 13				251			0.4				_	0.4	
		Medical advice	278	0	0.0	0.0	1.3	261	0	0.0	0.0	1.4	219	0	0.0	0.0	1.7	329 2	0.6	0.1	2.2	251	0	0.0	0.0	1.5	288	30	0.0	0.0	1.3
	ActHIB/Engerix B	All																329 11											28.9	22.7	35.8
		>5											219	19				2 329 24												8.0	
		>20											219					329 7			4.3		3		0.4					0.0	
		Medical											219	0	0.0	0.0	1.7	329 1	0.3	0.0	1.7	173	0	0.0	0.0	2.1	197	70	0.0	0.0	1.9
		advice																													
	Hexa/Pediarix/Pentacel																	329 11													
																		5 329 25											_	_	
		>20	278	5	1.8	0.6	4.1	261	2	8.0	0.1	2.7	219	3	1.4	0.3	4.0	329 7	2.1	0.9	4.3	251	1	0.4	0.0	2.2	287	74	1.4	0.4	3.5

117119 (DTPA-HBV-IPV-135)

						ŀ	lexa	gro	up								Pedi	a group							Р	enta	gro		Rep		
					Fema			٠.٠	p*	Mal	е				Fem			. 5	Ma	ale				Fem			J. U		Mal	е	
							% CI	ı			-	% CI					% C	I		_	% C	I				% CI					% CI
Symptom	Product	Туре	N	n	%	LL	UL		n	%	LL		N	n	%	LL	UL		%	LL	UL		n	%				n	%		UL
			278	30	0.0	0.0	1.3	261	0	0.0	0.0	1.4	219	90	0.0	0.0	1.7	329 1	0.3	0.0	1.7	25	10	0.0	0.0	1.5	287	70	0.0	0.0	1.3
		advice																													
Swelling (mm)	Total	All	278	60	21.6	16.9	26.9	9 261	55	21.1	16.3	326.5	219	964	29.	2 23.	335.	7 329 86	26.	121.	531.	2 25	162	24.	7 19.5	30.	5 288	379	27.4	22.4	33.0
, ,					5.4	3.1	8.7	261	12	4.6	2.4	7.9	219	9 18	8.2	4.9	12.	7 329 28						8.0	4.9	12.0	288	3 19	6.6	4.0	10.1
		>20	278	34	1.4	0.4	3.6	261	1	0.4	0.0	2.1	219	96	2.7	1.0	5.9	3296	1.8	0.7	3.9	25	15	2.0	0.6	4.6	288	39	3.1	1.4	5.8
		Medical	278	30	0.0	0.0	1.3	261	0	0.0	0.0	1.4	219	90	0.0	0.0	1.7	329 2	0.6	0.1	2.2	25	10	0.0	0.0	1.5	288	30	0.0	0.0	1.3
		advice																													
		All																0 329 73													
		>5											219	9 12	5.5	2.9	9.4	329 20	6.1	3.8	9.2	173	3 10	5.8	2.8	10.4	4 197	711	5.6	2.8	9.8
		>20											219	94	1.8	0.5	4.6	3294	1.2	0.3	3.1	173	3 1	0.6	0.0	3.2	197	72	1.0	0.1	3.6
		Medical											219	90	0.0	0.0	1.7	329 1	0.3	0.0	1.7	173	30	0.0	0.0	2.1	197	70	0.0	0.0	1.9
		advice																													
	Hexa/Pediarix/Pentacel	All	278	60	21.6	16.9	26.9	9 261	55	21.1	16.3	26.5	219	9 50	22.	8 17.	4 29.	0 329 69	21.	0 16.	7 25.	8 25	153	21.	1 16.2	26.	7 287	769	24.0	19.2	29.4
		>5	278	15	5.4	3.1	8.7	261	12	4.6	2.4	7.9	219	9 15	6.8	3.9	11.	0 329 21	6.4	4.0	9.6	25	1 16	6.4	3.7	10.	1 287	719	6.6	4.0	10.1
		>20	278	34	1.4	0.4	3.6	261	1	0.4	0.0	2.1	219	95	2.3	0.7	5.2	3293	0.9	0.2	2.6	25	15	2.0	0.6	4.6	287	79	3.1	1.4	5.9
		Medical	278	30	0.0	0.0	1.3	261	0	0.0	0.0	1.4	219					329 1	0.3	0.0	1.7	25	10	0.0	0.0	1.5	287	70	0.0	0.0	1.3
		advice																													
											Ove	rall/s	subj	ject						,	1				,						
Pain	Total	All	97	64	66.0	55.7	75.3	3 90	63	70.0	59.4	179.2	76	64	84.	274.	091.	6 113 91	80.	5 72.	387.	4 90	68	75.0	65.4	84.0	98	82	83.7	74.8	90.4
		Grade 2 or 3	97	29	29.9	21.0	40.0	90	29	32.2	22.8	342.9	76	43	56.	644.	767.	911361	54.	0 44.4	463.	4 90	41	45.0	35.0	56.4	4 98	47	48.0	37.8	58.3
			٠.	4	4.1	1.1	10.2	2 90	4	4.4	1.2	11.0	76	15	19.	7 11.	5 30.	5 113 19	16.	8 10.4	4 25.	0 90	11	12.	26.3	20.8	8 98	11	11.2	5.7	19.2
			97	1	1.0	0.0	5.6	90	0	0.0	0.0	4.0	76	0	0.0	0.0	4.7	1132	1.8	0.2	6.2	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
		advice																													
	ActHIB/Engerix B	All											76	61	80.	3 69.	588.	5 113 87	77.	0 68.	184.	4 90	58	64.4	4 53.7	74.3	3 98	69	70.4	60.3	79.2
		Grade 2 or	•										76	38	50.	0 38.	361.	7 113 58	51.	3 41.	760.	8 90	32	35.0	3 25.7	46.3	3 98	30	30.6	21.7	40.7
		3																													
		Grade 3											76	12	15.	88.4	26.	0 113 18	15.	99.7	24.	0 90	6	6.7	2.5	13.9	98	8	8.2	3.6	15.5
		Medical											76	0	0.0	0.0	4.7	1132	1.8	0.2	6.2	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
		advice																													
	Hexa/Pediarix/Pentacel	All	97															6 113 88													
		Grade 2 or	97	29	29.9	21.0	40.0	0 90	29	32.2	22.8	42.9	76	38	50.	0 38.	361.	7 113 55	48.	7 39.	2 58.	3 90	38	42.	2 31.9	53.	198	42	42.9	32.9	53.3

117119 (DTPA-HBV-IPV-135)

						H	lexa	gro	up							Р	edia	group							Р	enta	gro		кер		
					Fema				•	Mal	е				Fema				Ma	le				Fem			Ī	•	Male	е	
						95	% CI				95	% CI				95 9	% CI			95	% CI				95	% CI				95	% CI
Symptom	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
•		3																													
		Grade 3	97	4	4.1	1.1	10.2	90	4	4.4	1.2	11.0	76	12	15.8	8.4	26.0	113 15	13.3	3 7.6	20.9	90	11	12.2	6.3	20.8	98	11	11.2	5.7	19.2
		Medical	97	1	1.0	0.0	5.6	90	0	0.0	0.0	4.0	76	0	0.0	0.0	4.7	113 1	0.9	0.0	4.8	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
		advice																													
Redness (mm)	Total	All	97	48	49.5	39.2	59.8	3 90	46	51.1	40.3	61.8	76	51	67.1	55.4	77.5	113 69	61.	151.4	70.1	90	48	53.3	342.5	63.9	98	58	59.2	48.8	69.0
,		>5	97	17	17.5	10.6	26.6	90	10	11.1	5.5	19.5	76	20	26.3	16.9	37.7	113 29	25.	7 17.9	34.7	90	26	28.9	19.8	39.4	98	19	19.4	12.1	28.6
		>20			5.2	1.7	11.6	90	2	2.2	0.3	7.8	76	4	5.3	1.5	12.9	113 11	9.7	5.0	16.8	90	4	4.4	1.2	11.0	98	4	4.1	1.1	10.1
		Medical	97	0	0.0	0.0	3.7	90	0	0.0	0.0	4.0	76	0	0.0	0.0	4.7	113 2	1.8	0.2	6.2	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
		advice																													
	ActHIB/Engerix B	All											76					113 62	54.9	9 45.2	64.2	90							41.8		
		>5											76	17	22.4	13.6	33.4	113 21	18.	6 11.9	27.0	90	16	17.8	10.5	27.3	98	4	4.1	1.1	10.1
		>20											76	3	3.9	8.0	11.1	113 7	6.2	2.5	12.3	90	3	3.3	0.7	9.4	98	0	0.0	0.0	3.7
		Medical											76	0	0.0	0.0	4.7	113 1	0.9	0.0	4.8	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
		advice																													
	Hexa/Pediarix/Pentace	All	-	48		39.2						61.8						113 62											56.1		
		>5	97	17		10.6						19.5						113 21		6 11.9									18.4		
		>20				1.7						7.8								2.0					0.0				4.1		
		Medical	97	0	0.0	0.0	3.7	90	0	0.0	0.0	4.0	76	0	0.0	0.0	4.7	113 1	0.9	0.0	4.8	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
		advice																													
Swelling (mm)	Total	All	97	38	39.2	29.4	49.6	90	35	38.9	28.8	49.7	76	40	52.6	40.8	64.2	113 48	42.	5 33.2	252.1	90	33	36.7	26.8	47.5	98	48	49.0	38.7	59.3
		>5		10	10.3	35.1	18.1	1 90			5.5				18.4	10.5	29.0	113 20	17.	7 11.2	26.0	90	15	16.7	9.6	26.0	98	14	14.3	8.0	22.8
		>20		3	3.1	0.6	8.8	90	1	1.1	0.0	6.0	76	5	6.6	2.2	14.7	1136	5.3	2.0	11.2	90	4	4.4	1.2	11.0	98	8	8.2	3.6	15.5
		Medical advice	97	0	0.0	0.0	3.7	90	0	0.0	0.0	4.0	76	0	0.0	0.0	4.7	1132	1.8	0.2	6.2	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
	ActHIB/Engerix B	All											76	33	43.4	32.1	55.3	113 45	39.	8 30.7	49.5	90	27	30.0	20.8	40.6	98	37	37.8	28.2	48.1
		>5																113 15							4.7				9.2		
		>20										1	_							1.0					0.0				2.0		

117119 (DTPA-HBV-IPV-135)

Report Final

						Н	lexa	gro	up							Р	edia	grou	лb							P	enta	gro	up	-		
					Fema	le				Mal	е				ema	le				Male	е			F	Fema	le				Male	9	
						95 9	6 CI				95 9	% CI				95	% CI				95 9	% CI				95	% CI				95	% CI
Symptom	Product	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
		Medical											76	0	0.0	0.0	4.7	113	1	0.9	0.0	4.8	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
		advice																														
	Hexa/Pediarix/Pentacel	All	97	38	39.2	29.4	49.6	90	35	38.9	28.8	49.7	76	30	39.5	28.4	51.4	1113	40	35.4	26.6	45.0	90	29	32.2	22.8	42.9	98	43	43.9	33.9	54.3
		>5	97	10	10.3	5.1	18.1	90	10	11.1	5.5	19.5	76	11	14.5	7.5	24.4	1113	15	13.3	7.6	20.9	90	12	13.3	7.1	22.1	98	14	14.3	8.0	22.8
		>20	97	3	3.1	0.6	8.8	90	1	1.1	0.0	6.0	76	4	5.3	1.5	12.9	113	3	2.7	0.6	7.6	90	4	4.4	1.2	11.0	98	8	8.2	3.6	15.5
		Medical	97	0	0.0	0.0	3.7	90	0	0.0	0.0	4.0	76	0	0.0	0.0	4.7	113	1	0.9	0.0	4.8	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
		advice																														

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

For each dose and overall/subject:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the symptom at least once

For Overall/dose:

N = number of documented doses

n/% = number/percentage of doses followed by at least one type of symptom

95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

117119 (DTPA-HBV-IPV-135)

Table 8.10 Incidence of solicited local symptoms reported during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall – by geographical ancestry (Primary Total vaccinated cohort)

						Н	lexa	grou	ір						F	edia	gro	up							P	enta	gro	up			
			W	hite	Cau	ıcas	ian			othe	er		White	e Ca	ucas	ian			othe				/hite	e Ca	ucas	ian			othe		
						95	% CI				95 %	% CI			95	% CI				95	% CI				95	% CI				95 %	o CI
Symptom	Product	Туре	N	n	%	LL	UL	N	n ^c	%	LL	UL	N n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL (JL
												Dose																			
Pain	Total	All	112	60	53.6	43.9	63.0	73	34	46.6	34.8	58.6	123 85	69.	1 60.1	77.1	66	43	65.2	52.4	76.5	112	74	66.1	56.5	74.7	76	45			
		Grade 2 or 3	112	25	22.3	15.0	31.2	73	152	20.5	12.0	31.6	123 46	37.	4 28.8	46.6	66	29	43.9	31.7	56.7	112	41	36.6	327.7	46.2	76	15	19.7	11.5	30.5
		Grade 3	112	6	5.4	2.0	11.3	73	2 2	2.7	0.3	9.5	123 14	11.4	46.4	18.4	66	10	15.2	7.5	26.1	1112	10	8.9	4.4	15.8	76	2	2.6	0.3	9.2
		Medical advice	112	1	0.9	0.0	4.9	73	0 (0.0	0.0	4.9	1231	8.0	0.0	4.4	66	0	0.0	0.0	5.4	112	0	0.0	0.0	3.2	76	0	0.0	0.0	1.7
	ActHIB/Engerix B	All											123 82	66.	7 57.6	74.9	66	41	62.1	49.3	73.8	112	61	54.5	44.8	63.9	76	39	51.3	39.6	63.0
		Grade 2 or 3											123 39	31.	7 23.6	40.7	66	27	40.9	29.0	53.7	112	32	28.6	20.4	37.9	76	13	17.1	9.4	27.5
		Grade 3											123 13	10.	65.7	17.4	66	9	13.6	6.4	24.3	112	9	8.0	3.7	14.7	76	1	1.3	0.0	7.1
		Medical advice											1231	8.0	0.0	4.4	66	0	0.0	0.0	5.4	112	0	0.0	0.0	3.2	76	0	0.0	0.0	1.7
	Hexa/Pediarix/Pentacel	All	112	60	53.6	43.9	63.0	73	34	46.6	34.8	58.6	123 77	62.	653.4	71.2	66	36	54.5	41.8	66.9	112	71	63.4	153.8	72.3	76	44	57.9	46.06	39.1
		Grade 2 or 3	112	25	22.3	15.0	31.2	73	152	20.5	12.0	31.6	123 42	34.	1 25.8	343.2	66	23	34.8	23.5	47.6	112	36	32.1	1 23.6	41.6	76	15	19.7	11.5	30.5
		Grade 3	112	6	5.4	2.0	11.3	73	2 2	2.7	0.3	9.5	123 11	8.9	4.5	15.4	66	6	9.1	3.4	18.7	112	10	8.9	4.4	15.8	76	2	2.6	0.3	9.2
		Medical advice	112	1	0.9	0.0	4.9	73	0 (0.0	0.0	4.9	123 0	0.0	0.0	3.0	66	0	0.0	0.0	5.4	112	0	0.0	0.0	3.2	76	0	0.0	0.0	1.7
Redness (mm)	Total	All	112	35	31.3	22.8	340.7	73	12	16.4	8.8	27.0	123 56	45.	5 36.5	54.8	66	17	25.8	15.8	38.0	112	44		30.2				30.3	20.2	11.9
		>5	112	13	11.6	6.3	19.0	73	2 2	2.7	0.3	9.5	123 20	16.	3 10.2	24.0	66	7	10.6	4.4	20.6	112	20	17.9	11.3	26.2	76	7	9.2	3.8	18.1
		>20	112			0.6							1237		2.3							112			0.2			2		0.3	
		Medical advice	112	0	0.0	0.0	3.2	73	0 (0.0	0.0	4.9	1231	8.0	0.0	4.4	66	0	0.0	0.0	5.4	112	0	0.0	0.0	3.2	76	0	0.0	0.0	1.7
	ActHIB/Engerix B	All											123 48																	16.93	
		>5											123 13									112			3.1					1.5	
		>20											1235	4.1	1.3	9.2	66	3	4.5	0.9	12.7	112	1	0.9	0.0	4.9	76	0	0.0	0.0	4.7

117119 (DTPA-HBV-IPV-135)

					Н	exa gro	up							P	edia	gro	oup							F	enta	qro		rveh	OI L I	-ınaı
			Whit	e Caı					her		١	White	e Ca	ucasi				oth	er		٧	Vhite	e Ca	ucas			- -	othe	er	
						% CI			95	% CI				95	% CI				95	% CI					% C				95 9	% CI
Symptom	Product	Туре	N n	%	LL	UL N	n	%		UL		n	%		UL		n	%		UL		n	%		UL		n	%	LL	UL
		Medical									12	3 1	8.0	0.0	4.4	66	0	0.0	0.0	5.4	112	20	0.0	0.0	3.2	76	0	0.0	0.0	4.7
		advice																												
	Hexa/Pediarix/Pentacel					40.7 73													6.4									23.7		
		>5				19.0 73													0.9											14.7
		>20	1123			7.6 73						33		0.5					0.0					0.0				2.6		
		Medical	1120	0.0	0.0	3.2 73	0	0.0	0.0	4.9	12	30	0.0	0.0	3.0	66	0	0.0	0.0	5.4	112	20	0.0	0.0	3.2	76	0	0.0	0.0	4.7
		advice																												
Swelling (mm)	Total	All	112 20	17.9	11.3	26.273	11	1 15.	17.8	25.4	112	3 32	26.0	18.5	34.7	766	14	21.	2 12.1	33.0	112	234	30.4	4 22.0	39.8	3 76	19	25.0	15.8	36.3
		>5	1128	7.1	3.1	13.673	2	2.7	0.3	9.5	12	3 14	11.4	16.4	18.4	166	4	6.1	1.7	14.8	3 112	2 16	14.3	38.4	22.	2 76	8	10.5	4.7	19.7
		>20	1122	1.8	0.2	6.3 73	0	0.0	0.0	4.9	12	36	4.9	1.8	10.3	366	1	1.5	0.0	8.2	112	28	7.1	3.1	13.0	376	3	3.9	8.0	11.1
		Medical	1120	0.0	0.0	3.2 73	0	0.0	0.0	4.9	12	31	8.0	0.0	4.4	66	0	0.0	0.0	5.4	112	20	0.0	0.0	3.2	76	0	0.0	0.0	4.7
		advice																												
		All									12	3 29	23.6	16.4	32.1	1 66	12	18.	2 9.8	29.6	3 112	224	21.4	1 14.2	2 30.2	2 76	15	19.7	11.5	30.5
		>5												5.7					0.0					3.1				7.9	3.0	16.4
		>20									12	35	4.1	1.3	9.2	66	1	1.5	0.0	8.2	112	23	2.7	0.6	7.6	76	0	0.0	0.0	4.7
		Medical									12	31	8.0	0.0	4.4	66	0	0.0	0.0	5.4	112	20	0.0	0.0	3.2	76	0	0.0	0.0	4.7
		advice																												
	Hexa/Pediarix/Pentacel	All	112 20	17.9		26.273												13.	6.4					17.3	34.	1 76	17	22.4	13.6	33.4
		>5	1128			13.6 73								4.0					1.7					38.4				10.5	4.7	19.7
		>20	1122			6.3 73								0.2					0.0				7.1	3.1	13.0	6 76	3	3.9	8.0	11.1
		Medical	1120	0.0	0.0	3.2 73	0	0.0	0.0	4.9	12	30	0.0	0.0	3.0	66	0	0.0	0.0	5.4	112	20	0.0	0.0	3.2	76	0	0.0	0.0	4.7
		advice																												
										Dos									_											
Pain	Total	All	110 54																											
		Grade 2 or 3	110 15	13.6	7.8	21.572	10	13.	96.9	24.1	111	9 28	23.5	16.2	32.2	265	26	40.	28.0	52.9	107	7 20	18.7	7 11.8	3 27.4	473	12	16.4	8.8	27.0
		Grade 3	1101			5.0 72							3.4	0.9	8.4	65	6	9.2	3.5	19.0	107	73	2.8	0.6	8.0	73	3	4.1	0.9	11.5
		Medical advice	1100	0.0	0.0	3.3 72	0	0.0	0.0	5.0	11	90	0.0	0.0	3.1	65	0	0.0	0.0	5.5	107	70	0.0	0.0	3.4	73	0	0.0	0.0	4.9
	ActHIB/Engerix B	All									11	967	56.3	46.9	65.4	465	37	56.	9 44.0	69.2	29	5	55.6	3 21.2	286.	3 4	1	25.0	0.6	80.6
		Grade 2 or 3									119	9 24	20.2	13.4	28.5	65	23	35.	4 23.9	48.2	29	1	11.	10.3	48.2	24	1	25.0	0.6	80.6

117119 (DTPA-HBV-IPV-135)

					Н	exa g	rou	р								edia	gro	oup								enta	gro	up			
			White	e Ca					othe	er		٧	/hite	Cau	ıcasi		Ĭ		oth	er		٧	Vhite	e Ca	ucas			•	othe	er	
					95	% CI				95 9	% CI				95	% CI				95	% CI				95	% CI				95 9	% CI
Symptom	Product	Туре	N n	%	LL	UL I	N ı	n ⁹	%	LL	UL	N				UL			%		UL		n	%	LL	UL		n	%	LL	UL
		Grade 3										119	3	2.5	0.5	7.2			9.2	3.5	19.0	9	0	0.0	0.0	33.6	4	0	0.0	0.0	60.2
		Medical										119	0	0.0	0.0	3.1	65	0	0.0	0.0	5.5	9	0	0.0	0.0	33.6	4	0	0.0	0.0	60.2
		advice																													
	Hexa/Pediarix/Pentacel		110 54																												
		Grade 2 or 3	110 15											20.2	13.4	28.5	65	20	30.8	3 19.9	43.4	107	720			327.4			15.1	7.8	25.4
		Grade 3	1101	0.9	0.0	5.0	72 (0 (0.0	0.0	5.0	119	2	1.7	0.2	5.9	65	5	7.7	2.5	17.0	107	73	2.8	0.6	8.0	73	3	4.1	0.9	11.5
		Medical advice	1100	0.0	0.0	3.3	72 (0 (0.0	0.0	5.0	119	0	0.0	0.0	3.1	65	0	0.0	0.0	5.5	107	70	0.0	0.0	3.4	73	0	0.0	0.0	4.9
Redness (mm)		All	11040																												
		>5	1109			15.0														1.7				8.4	3.9	15.4	73	7	9.6	3.9	18.8
		>20	1101													4.6				0.4						5.1			1.4		
		Medical advice	1100	0.0	0.0	3.3	72 (0 (0.0	0.0	5.0	119	0	0.0	0.0	3.1	65	0	0.0	0.0	5.5	107	70	0.0	0.0	3.4	73	0	0.0	0.0	4.9
		All										119	49	41.2	32.2	50.6	65	17	26.2	16.0	38.5	9	3	33.3	37.5	70.1	4	2	50.0	6.8	93.2
		>5										119	14	11.8	6.6	19.0	65	3	4.6	1.0	12.9	9	0	0.0	0.0	33.6	4	1	25.0	0.6	80.6
		>20										119	0	0.0	0.0	3.1	65	1	1.5	0.0	8.3	9	0	0.0	0.0	33.6	4	0	0.0	0.0	60.2
		Medical										119	0	0.0	0.0	3.1	65	0	0.0	0.0	5.5	9	0	0.0	0.0	33.6	4	0	0.0	0.0	60.2
		advice																													
	Hexa/Pediarix/Pentacel	All	110 40			46.1										48.0				13.5						1 48.2					43.4
		>5	1109			15.0										14.9				0.4	10.7					15.4			8.2		17.0
		>20	1101			5.0						119		8.0		4.6				0.4						5.1				0.0	
		Medical advice	1100	0.0	0.0	3.3	72 (0 0	0.0	0.0	5.0	119	0	0.0	0.0	3.1	65	0	0.0	0.0	5.5	107	70	0.0	0.0	3.4	73	0	0.0	0.0	4.9
Swelling (mm)	Total	All	110 21	19.	1 12.2	27.7	72	20 2	27.8	17.9	39.6	119	36	30.3	22.2	39.3	365	15	23.	1 13.5	35.2	107	729	27.	1 19.0	36.6	73	15	20.5	12.0	31.6
		>5	1104			9.0														1.0						10.6			2.7		
		>20	1100			3.3										3.1				0.4						8.0			0.0		
		Medical advice	1100	0.0	0.0	3.3	72 (0 0	0.0	0.0	5.0					3.1				0.0			70			3.4		0	0.0		
		All																11					2			60.0		1	25.0	0.6	80.6
		>5										119	8	6.7	2.9	12.8	65	3	4.6	1.0	12.9	9	0	0.0	0.0	33.6	4	0	0.0	0.0	60.2

117119 (DTPA-HBV-IPV-135)

					Н	exa gro	au							P	edia	arc	quo							F	Penta	a gro		, top	JI L I	-inal
			White	e Ca				oth	er		٧	Vhite	e Cai			J. \		oth	er		٧	Vhite	e Ca	ucas		J. U		othe	er	
						% CI			-	% CI					% CI	1			-	% CI					% CI					% CI
Symptom	Product	Туре	N n	%	LL	UL N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
-		>20									119	90	0.0	0.0	3.1	65	1	1.5	0.0	8.3	9	0	0.0	0.0	33.6	64	0	0.0	0.0	60.2
		Medical									119	90	0.0	0.0	3.1	65	0	0.0	0.0	5.5	9	0	0.0	0.0	33.6	64	0	0.0	0.0	60.2
		advice																												
	Hexa/Pediarix/Pentacel					27.7 72																								
		>5	1104			9.0 72				17.3				3.5					1.0						10.6			2.7		
		>20	1100		0.0					9.7			0.0						0.4						8.0			0.0		
		Medical	1100	0.0	0.0	3.3 72	0	0.0	0.0	5.0	119	90	0.0	0.0	3.1	65	0	0.0	0.0	5.5	107	70	0.0	0.0	3.4	73	0	0.0	0.0	4.9
		advice																												
				,						Dos					,	,		,		,			,				,			,
Pain	Total	All	106 43																											61.9
		Grade 2 or 3	106 10	9.4	4.6	16.7 66	8	12.	15.4	22.5	116	31	26.7	18.9	35.7	7 59	14	23.	7 13.6	36.6	106	6 16	15.	18.9	23.4	465	12	18.5	9.9	30.0
		Grade 3	1060	0.0	0.0	3.4 66	0	0.0	0.0	5.4	116	6	5.2	1.9	10.9	9 59	2	3.4	0.4	11.7	106	6	5.7	2.1	11.9	965	1	1.5	0.0	8.3
		Medical advice	106 0	0.0	0.0	3.4 66	0	0.0	0.0	5.4	116	60	0.0	0.0	3.1	59	1	1.7	0.0	9.1	106	60	0.0	0.0	3.4	65	0	0.0	0.0	5.5
		All									116	559	50.9	41.4	160.3	3 59	34	57.0	344.1	70.4	1104	145	43.3	333.6	353.	365	30	46.2	33.7	759.0
		Grade 2 or											24.1						12.3											28.3
		Grade 3									116	3.5	4.3	1 4	9.8	59	2	3 4	0.4	11 7	7 104	14	3.8	1 1	9.6	65	1	1.5	0.0	8.3
		Medical									116			0.0					0.0						3.5				0.0	
		advice											0.0				-			• • •	. •									0.0
	Hexa/Pediarix/Pentacel		106 43	40.6	31.1	50.5 66	24	136.4	124.9	49.1	116	559	50.9	41.4	160.3	3 59	31	52.	39.1	65.7	106	346	43.4	133.8	3 53.4	464	30	46.9	34.3	359.8
		Grade 2 or 3				16.766													311.0											25.0
		Grade 3	1060	0.0	0.0	3.4 66	0	0.0	0.0	5.4	116	35	4.3	1.4	9.8	59	2	3.4	0.4	11.7	106	6	5.7	2.1	11.9	964	1	1.6	0.0	8.4
		Medical	1060		0.0					5.4			0.0						0.0						3.4			0.0		
		advice																												
Redness (mm)	Total	All	106 47	44.3	34.7	54.3 66	16	24.2	2 14.5	36.4	116	60	51.7	42.3	861.	1 59	21	35.6	23.6	49.1	106	343	40.6	31.	1 50.	565	22	33.8	22.6	46.6
,		>5	1066			11.966				8.2									1.1									9.2	3.5	19.0
		>20	1060			3.4 66				8.2			2.6						0.0		106				6.6			0.0		
		Medical advice	106 0	0.0	0.0	3.4 66	0	0.0	0.0	5.4	116	60	0.0					1.7	0.0	9.1	106	0	0.0	0.0	3.4	65	0	0.0	0.0	5.5

117119 (DTPA-HBV-IPV-135)

					Ш	0.00	aro	ın							П)odio	ara	NIID.							-	Penta	ara		кер	ort F	-ına
			White	۰ ۲۰			grou	ψ	oth	or		۱۸	/hit-	. Ca:	r ucas	edia	gro		oth	or		1.	Nhi+	e Ca	up	othe					
			VVIIIU	- Ud		ıan % CI			Ull	•	% CI		riilt	- Udl		ıan % CI	1		Ull	-	% CI		VIII(- Ud		% CI	ı		ouil		% CI
Symptom	Product	Туре	N n	%	LL	UL		n	%	LL		N	n	%	11	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%		UL
o y pto	ActHIB/Engerix B	All		70		-	-	•	70		-				35.6					3 17.8								1		16.0	
	, toti iib, Erigorix B	>5										116					59			0.4					2.7		465			0.4	
		>20										116			0.0		59					104				6.8				0.0	
		Medical										116			0.0					0.0						3.5				0.0	
		advice																													
	Hexa/Pediarix/Pentacel	All		44.3	3 34.7	54.3	366	16	24.2	14.5	36.4	116	49	42.2	33.1	51.8	359	17	28.8	3 17.8	42.	1 106	35	33.0	24.	242.8	8 64	21	32.8	321.6	45.7
		>5	1066	5.7		11.9					8.2				3.6		259			1.1		1 106		4.7	1.5	10.7	764	6		3.5	
		>20	1060	0.0			66				8.2				0.2		59			0.0		106								0.0	
		Medical	1060	0.0	0.0	3.4	66	0	0.0	0.0	5.4	116	0	0.0	0.0	3.1	59	1	1.7	0.0	9.1	100	60	0.0	0.0	3.4	64	0	0.0	0.0	5.6
		advice																								1				1	
Swelling (mm)	Total	All	106 26	24.	5 16.7	33.8	366	17	25.8	15.8	38.0	116	37	31.9	23.6	341.2	2 59	16	27.	1 16.4	40.3	3 106	6 24						30.8	3 19.9	43.4
(111111)		>5	1064	3.8			66				12.7				3.6					1.1						11.9				0.4	
		>20	1060	0.0							8.2				0.0		59			0.4										0.0	
		Medical advice	1060	0.0	0.0	3.4	66	0	0.0	0.0	5.4	116	0	0.0	0.0	3.1	59	1	1.7	0.0	9.1	106	60	0.0	0.0	3.4	65	0	0.0	0.0	5.5
	ActHIB/Engerix B	All										116	29	25.0	17.4	33.9	59	13	22.0	12.3	34.7	7 104	119	18.3	3 11.4	427.	165	18	27.7	717.3	40.2
	3	>5										116			0.9				5.1			1 104		4.8							
		>20										116			0.0		59			0.0						3.5				0.0	
		Medical										116			0.0		59			0.0			40			3.5				0.0	
		advice																													
	Hexa/Pediarix/Pentacel	All	106 26	24.	5 16.7	33.8		17	25.8	15.8	38.0	116	30	25.9	18.2	34.8	359	14	23.7	7 13.6	36.6	3 106	320	18.9	9 11.9	9 27.6	664	15	23.4	13.8	35.7
		>5	1064	3.8		9.4			4.5		12.7				2.5				5.1	1.1	14.	1 106	3			8.0		1	1.6	0.0	8.4
		>20	1060	0.0	0.0									0.9	0.0	4.7	59	2	3.4	0.4	11.7	7 106	6 0	0.0	0.0	3.4	64	0	0.0	0.0	5.6
		Medical	1060	0.0	0.0	3.4	66	0	0.0	0.0	5.4	116	0	0.0	0.0	3.1	59	1	1.7	0.0	9.1	106	60	0.0	0.0	3.4	64	0	0.0	0.0	5.6
		advice																													
		1			1	1					erall				T	1	_											_	1	1	
Pain	Total	All	328 157																												
		Grade 2 or 3	328 50																										18.2	13.3	24.1
		Grade 3	3287	2.1	0.9	4.3	211	2	0.9	0.1	3.4	358	24	6.7	4.3	9.8	190	18	9.5	5.7	14.6	32	5 19	5.8	3.6	9.0	214	16	2.8	1.0	6.0

117119 (DTPA-HBV-IPV-135)

						Н	exa	grou	ıp						F	Pedia	gro	up							Р	enta	group	- -	ort Final
			W	hite	Cau					oth	er		Whit	e Ca	ucas	ian	9.4		othe	er		W	hite	Cau	ıcas	ian	3	othe	er
							% CI				95	% CI				% CI				95	% CI					% CI			95 % CI
Symptom	Product	Туре	N	n	%	LL	UL	N	n ^c	%	LL	UL	N n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N n	%	LL UL
, ,		Medical	328	1	0.3	0.0	1.7	211	0 (0.0			358 1	0.3	0.0	1.5	190	1	0.5	0.0	2.9	325	0	0.0	0.0	1.1	2140	0.0	0.0 1.7
		advice																											
	ActHIB/Engerix B	All																											39.9 56.7
		Grade 2 or 3											358 91	25.	4 21.0	30.3	190	63	33.2	26.5	40.3	225	47	20.9	15.8	26.8	145 25	17.2	11.5 24.4
		Grade 3											358 21	5.9	3.7	8.8	190	17	8.9	5.3	13.9	225	13	5.8	3.1	9.7	1452	1.4	0.2 4.9
		Medical											358 1			1.5			0.5							1.6			0.0 2.5
		advice																											
	Hexa/Pediarix/Pentace	IAII	328	157	47.9	42.3	53.4	211	884	41.7	35.0	48.7	358 202	2 56.	451.	161.6	190	109	57.4	50.0	64.5	325	177	54.5	48.9	60.0	213 10°	7 50.2	43.3 57.1
		Grade 2 or 3	328	50	15.2	11.5	19.6	211	33 ′	15.6	11.0	21.3	358 93	26.	0 21.	5 30.8	190	55	28.9	22.6	36.0	325	67	20.6	16.3	25.4	213 35	16.4	11.7 22.1
		Grade 3	328	7	2.1	0.9	4.3	211	2 (0.9	0.1	3.4	358 18	5.0	3.0	7.8	190	13	6.8	3.7	11.4	325	19	5.8	3.6	9.0	2136	2.8	1.0 6.0
		Medical advice	328	1	0.3	0.0	1.7	211	0 (0.0	0.0	1.7	358 0	0.0	0.0	1.0	190	1	0.5	0.0	2.9	325	0	0.0	0.0	1.1	213 0	0.0	0.0 1.7
Redness (mm)	Total	All	328	122	37.2	31.9	42.7	211	472	22.3	16.8	28.5	358 172	248.	0 42.8	3 53.4	190	59	31.1	24.6	38.2	325	128	39.4	34.0	44.9	214 68	31.8	25.6 38.5
,		>5	328	28	8.5	5.7	12.1	211	9 4	4.3	2.0	7.9	358 49	13.	7 10.3	3 17.7	190	14	7.4	4.1	12.1	325	39	12.0	8.7	16.0	214 20	9.3	5.8 14.1
		>20	328					211			0.3		358 11						3.2			325		1.5	0.5	3.6	2143	1.4	0.3 4.0
		Medical advice	328	0	0.0	0.0	1.1	211	0 (0.0	0.0	1.7	358 1	0.3	0.0	1.5	190	1	0.5	0.0	2.9	325	0	0.0	0.0	1.1	214 0	0.0	0.0 1.7
	ActHIB/Engerix B	All											358 149	941.	6 36.	546.9	190	49	25.8	19.7	32.6	225	72	32.0	26.0	38.5	145 39	26.9	19.9 34.9
		>5											358 32	8.9	6.2	12.4	190	11	5.8	2.9	10.1	225	15	6.7	3.8	10.8	1457	4.8	2.0 9.7
		>20											3586	1.7	0.6	3.6	190	4	2.1	0.6	5.3	225					1450	0.0	0.0 2.5
		Medical advice											358 1	0.3	0.0	1.5	190	0	0.0	0.0	1.9	225	0	0.0	0.0	1.6	145 0	0.0	0.0 2.5
	Hexa/Pediarix/Pentace	IAII	328	122	37.2	31.9	42.7	211	47 2	22.3	16.8	28.5	358 142	2 39.	7 34.0	344.9	190	41	21.6	16.0	28.1	325	115	35.4	30.2	40.9	213 62	29.1	23.1 35.7
		>5	328				12.1						358 31						4.2								213 17	8.0	4.7 12.5
		>20	328				3.1						3586			3.6			2.1								2133		0.3 4.1
		Medical advice	328	0	0.0	0.0	1.1	211	0 (0.0	0.0	1.7	3580	0.0	0.0	1.0	190	1	0.5	0.0	2.9	325	0	0.0	0.0	1.1	213 0	0.0	0.0 1.7
Swelling (mm)	Total	All	328	67	20.4	16.2	25.2	211	482	22.7	17.3	29.0	358 10	5 29.	3 24.	7 34.3	190	45	23.7	17.8	30.4	325	87	26.8	22.0	31.9	214 54	25.2	19.6 31.6
,		>5	328	16	4.9	2.8	7.8	211	115	5.2	2.6	9.1	358 36	10.	17.1	13.6	190	10	5.3	2.6	9.5	325	27	8.3	5.5	11.9	214 12	5.6	2.9 9.6

117119 (DTPA-HBV-IPV-135)

					Н	exa	grou	р							P	edia	grou	ıp							F	enta	gro		op	ort F	
			Whit	e Ca					oth	er		٧	Vhite	Ca	ucas				othe	er		٧	Vhite	e Ca	ucas			ı	othe	er	
					95	% CI				95 °	% CI				95	% CI				95 9	% CI					% CI				95	% CI
Symptom	Product	Туре	N n	%	LL	UL		n '		LL		N		%			N			LL				%			N		%	LL	UL
-		>20	328 2	0.6	0.1	2.2	211	3	1.4	0.3	4.1	358	37	2.0	8.0	4.0	190	5 2	2.6	0.9	6.0	325	511	3.4	1.7	6.0	214	.3	1.4	0.3	4.0
		Medical advice	328 0	0.0	0.0	1.1	211	0 (0.0	0.0	1.7	358	31	0.3	0.0	1.5	190	1 (0.5	0.0	2.9	325	50	0.0	0.0	1.1	214	0	0.0	0.0	1.7
	ActHIB/Engerix B	All										358	87	24.3	19.9	29.1	190	36	18.9	13.6	25.3	3225	545	20.0	15.0	25.8	3 145	34	23.4	16.8	31.2
		>5										358	325	7.0	4.6	10.1	190	7 3	3.7	1.5	7.4	225	5 13	5.8	3.1	9.7	145	8	5.5	2.4	10.6
		>20										358					190			0.3					0.3					0.0	
		Medical										358					190			0.0					0.0					0.0	
		advice																													
	Hexa/Pediarix/Pentacel	All	328 67	20.4	16.2	25.2	211	48	22.7	17.3																					
		>5	328 16	4.9	2.8	7.8	211	11	5.2	2.6	9.1	358	326	7.3	4.8	10.5	190	10 5	5.3	2.6	9.5	325	524	7.4	4.8	10.8	3 213	11	5.2	2.6	9.1
		>20	328 2	0.6	0.1	2.2	211	3	1.4	0.3	4.1	358	3	8.0	0.2	2.4	190	5 2	2.6	0.9	6.0	325	511	3.4	1.7	6.0	213	3	1.4	0.3	4.1
		Medical	3280	0.0	0.0	1.1	211	0	0.0	0.0	1.7	358	30	0.0	0.0	1.0	190	1 (0.5	0.0	2.9	325	50	0.0	0.0	1.1	213	0	0.0	0.0	1.7
		advice																													
						•				Ove				•		•		•			•	•						•			
Pain	Total	All	113 80																						73.8					65.2	
		Grade 2 or 3	113 38	33.6	25.0	43.1	74	20	27.0	17.4	38.6	123	364	52.0	42.8	61.1	166	40 6	60.6	47.8	72.4	1112	2 57	50.9	941.3	360.	76	31	40.8	29.6	52.7
		Grade 3	1136	5.3	2.0	11.2	74	2	2.7	0.3	9.4	123	320	16.3	10.2	24.0	66	14 2	21.2	12.1	33.0	112	2 16	14.3	38.4	22.2	276	6	7.9	3.0	16.4
		Medical advice	1131	0.9	0.0	4.8	74	0 (0.0	0.0	4.9	123	31	8.0	0.0	4.4	66	1 ′	1.5	0.0	8.2	112	20	0.0	0.0	3.2	76	0	0.0	0.0	4.7
	ActHIB/Engerix B	All										123	97	78.9	70.6	85.7	66	51	77.3	65.3	86.7	112	277	68.8	3 59.3	377.2	276	50	65.8	54.0	76.3
		Grade 2 or 3										123	358	47.2	38.1	56.4	166	38 5	57.6	44.8	69.7	112	240	35.7	7 26.9	45.3	3 76	22	28.9	19.1	40.5
		Grade 3										123	3 17	13.8	8.3	21.2	266	13	19.7	10.9	31.3	3 112	2 12	10.7	75.7	18.0	76	2	2.6	0.3	9.2
		Medical										123	3 1	8.0	0.0	4.4	66	1 ′	1.5	0.0	8.2	112	20	0.0	0.0	3.2	76	0	0.0	0.0	4.7
		advice																													
	Hexa/Pediarix/Pentacel	All	113 80	70.8	61.5	79.0	74	47	63.5	51.5	74.4	123	98	79.7	71.5	86.4	166	53 8	30.3	68.7	89.1	112	90	80.4	471.8	87.3	376	57	75.0	63.7	84.2
		Grade 2 or 3	113 38	33.6	25.0	43.1	74	20	27.0	17.4	38.6	123	358	47.2	38.1	56.4	166	35 5	53.0	40.3	65.4	1112	251	45.	5 36.	1 55.2	276	29	38.2	27.2	50.0
		Grade 3	1136		2.0																				38.4				7.9	3.0	16.4
		Medical advice	1131		0.0												66		1.5	0.0	8.2	112	20	0.0	0.0	3.2	76	0	0.0	0.0	4.7

117119 (DTPA-HBV-IPV-135)

					Н	exa g	roup)						F	Pedia	gro	up							P	enta	gro	up			
			White	e Cau	ucasi	ian		0	ther			White	e Ca	ucas	ian			oth	er		١	White	e Ca	ucas	ian			othe	er	
					95 9	% CI			95	% C	I			95	% CI				95	% CI				95	% CI				95 9	% CI
Symptom	Product	Туре	N n	%	LL	UL	N r	۱ %	LL	UL	N	l n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Redness	Total	All	113 65	57.5	47.9	66.8	74 2	29 39	.2 28	0 51.	2 1	23 86	69.9	61.0	77.9	966	34	51.5	38.9	64.0	11:	265	58.0	48.3	67.3	376	41	53.9	42.1	65.5
(mm)																														
		>5	113 19																									21.1	12.5	31.9
		>20	1134									23 10							2.5				4.5	1.5	10.1	176	3	3.9	8.0	11.1
		Medical	1130	0.0	0.0	3.2	74 (0.0	0.0	4.9	1:	23 1	8.0	0.0	4.4	66	1	1.5	0.0	8.2	11:	20	0.0	0.0	3.2	76	0	0.0	0.0	4.7
		advice																												
		All									1:	23 78	63.4	154.3	71.9	966	30	45.5	5 33.1	58.2	2 11:	2 50	44.6	35.2	54.3	76	27	35.5	24.9	47.3
		>5									1:	23 28	22.8	15.7	31.2	266			27.5				12.5	7.0	20.1	76	6	7.9	3.0	16.4
		>20									1:	236	4.9	1.8	10.3	366	4	6.1	1.7	14.8	3 11:	23	2.7	0.6	7.6	76	0	0.0	0.0	4.7
		Medical									1:	23 1	8.0	0.0	4.4	66	0	0.0	0.0	5.4	11:	20	0.0	0.0	3.2	76	0	0.0	0.0	4.7
		advice																												
	Hexa/Pediarix/Pentacel	All	113 65														28											47.4	35.8	59.2
		>5	113 19	16.8	10.4	25.0	74 8	3 10	.84.8	20.	2 1:	23 25	20.3	3 13.6	28.5	66	7	10.6	34.4	20.6	311	2 23	20.5	13.5	29.2	2 76	14	18.4	10.5	29.0
		>20	1134	3.5	1.0	8.8	74 3	3 4.	1 0.8	11.	4 1:	235	4.1	1.3	9.2	66	4	6.1	1.7	14.8	3 11:	22	1.8	0.2	6.3	76	3	3.9	8.0	11.1
		Medical	1130	0.0	0.0	3.2	74 (0.0	0.0	4.9	1:	230	0.0	0.0	3.0	66	1	1.5	0.0	8.2	11:	20	0.0	0.0	3.2	76	0	0.0	0.0	4.7
		advice																												
Swelling (mm)	Total	All	113 43	38.1	29.1	47.7	74 3	30 40).5 29.	3 52.	6 1:	23 62	50.4	141.2	259.5	566	26	39.4	127.6	52.2	211:	249	43.8	34.4	153.4	176	32	42.1	30.9	54.0
, ,		>5	113 12	10.6	5.6	17.8	74 8	3 10	0.84.8	20.	2 1	23 27	22.0	15.0	30.3	366	7	10.6	34.4	20.6	311	2 20	17.9	11.3	26.2	276	9	11.8	5.6	21.3
		>20	1132	1.8	0.2	6.2	74 2	2.	7 0.3	9.4	1:	237	5.7	2.3	11.4	166	4	6.1	1.7	14.8	3 11:	29	8.0	3.7	14.7	776	3	3.9	8.0	11.1
		Medical	1130	0.0	0.0	3.2	74 (0.0	0.0	4.9	1:	23 1	8.0	0.0	4.4	66	1	1.5	0.0	8.2	11:	20	0.0	0.0	3.2	76	0	0.0	0.0	4.7
		advice																												
	ActHIB/Engerix B	All									1:	23 55	44.7	35.7	753.9	966	23	34.8	3 23.5	47.6	11:	2 37	33.0	24.4	42.6	676	27	35.5	24.9	47.3
		>5									1:	23 19	15.4	19.6	23.1	166	6	9.1	3.4	18.7	711:	2 11	9.8	5.0	16.9	76	7	9.2	3.8	18.1
		>20									1:	235	4.1	1.3	9.2	66	2	3.0	0.4	10.5	11:	23	2.7	0.6	7.6	76	0	0.0	0.0	4.7
		Medical									1:	231			4.4			0.0	0.0	5.4	11:	20	0.0	0.0	3.2	76	0	0.0	0.0	4.7
	Hexa/Pediarix/Pentacel	advice																												
		All	113 43	38.1	29.1	47.7	74 3	30 40	.5 29.	3 52.	6 1	23 49	39.8	31.1	1 49.1	166	21	31.8	3 20.9	44.4	111	244	39.3	30.2	49.0	76	28	36.8	26.1	48.7
		>5	113 12	10.6	5.6	17.8	74 8	3 10	.84.8	20.	2 1:	23 19	15.4	19.6	23.1	166	7	10.6	34.4	20.6	311	2 18	16.1	9.8	24.2	276	8	10.5	4.7	19.7
		>20	1132	1.8	0.2	6.2	74 2	2.	7 0.3	9.4	1:	233	2.4	0.5	7.0	66	4	6.1	1.7	14.8	3 11:	29	8.0	3.7	14.7	776	3	3.9	8.0	11.1
		Medical advice	1130			3.2									3.0				0.0					0.0				0.0		

117119 (DTPA-HBV-IPV-135) Report Final

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines
Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines
Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine
For each dose and overall/subject:

N = number of subjects with at least one documented dose n/% = number/percentage of subjects reporting the symptom at least once For Overall/dose:

N = number of documented doses n/% = number/percentage of doses followed by at least one type of symptom 95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

117119 (DTPA-HBV-IPV-135)

Table 8.11 Incidence of solicited general symptoms reported during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall- by gender (Primary Total vaccinated cohort)

					ŀ	Hexa	gro	ир							F	Pedia	gro	up								Pent	a gro	up		-	
				Fema	ile				Male	е				Fema	le				Mal	е				Fem	ale				Mal	е	
					95	% CI				95 9	% CI				95	% CI				95	% CI				95	% C	I			95 °	% CI
Symptom	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
•		•	•	•				•	•			D	ose	1		•		,	•	•	•	'	•			•			•		•
Drowsiness	All	96	58	60.4	49.9	70.3	89	56	62.9	52.0	72.9	76	57	75.0	63.7	84.2	113	86	76.1	67.2	83.6	90	74	82.2	72.	7 89.	5 98	75	76.5	66.9	84.5
	Grade 2 or 3	96	19	19.8	12.4	29.2	89	17	19.1	11.5	28.8	76	26	34.2	23.7	46.0	113	30	26.5	18.7	35.7	90	29		22.8			24	24.5	16.4	34.2
	Grade 3	96	2	2.1	0.3	7.3	89	1	1.1	0.0	6.1	76	5	6.6	2.2	14.7	113	3	2.7	0.6	7.6	90	6	6.7	2.5	13.	9 98	6	6.1	2.3	12.9
	Related	96	58	60.4	49.9	70.3	89	54	60.7	49.7	70.9	76	53	69.7	58.1	79.8	113	83	73.5	64.3	81.3	90	70				9 98		72.4	62.5	81.0
	Grade 3 Related	96	2	2.1	0.3	7.3	89	1	1.1	0.0	6.1	76	4	5.3	1.5	12.9	113	3	2.7	0.6	7.6	90	6	6.7	2.5	13.	9 98	6	6.1	2.3	12.9
	Medical advice	96	1	1.0	0.0	5.7	89	0	0.0	0.0	4.1	76	0	0.0	0.0	4.7	113	0	0.0	0.0	3.2	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
Irritability / Fussiness	All	96	63	65.6	55.2	75.0	89	52	58.4	47.5	68.8	76	64	84.2	74.0	91.6	113	3 10°	1 89.4	82.2	94.4	90	73	81.1	71.	5 88.	6 98		81.6	72.5	88.7
	Grade 2 or 3	96	25	26.0	17.6			17	19.1	11.5	28.8	76	34	44.7	33.3	56.6	113	45	39.8	30.7	49.5	90	32	35.6	25.7	7 46.	3 98	36		27.2	47.1
	Grade 3	96	4	4.2		10.3			5.6	1.8				9.2													9 98				16.7
	Related	96	62	64.6	54.2			51	57.3	46.4	67.7	76	64	84.2		91.6	113	99			93.1	90	70				9 98	77		69.1	86.2
	Grade 3 Related	96	4	4.2	1.1	10.3	89	5	5.6	1.8	12.6	76	7	9.2	3.8	18.1	113	10	8.8	4.3	15.7	90	6	6.7	2.5	13.	9 98	9	9.2	4.3	16.7
	Medical advice	96	1	1.0	0.0	5.7	89	0	0.0	0.0	4.1	76	0	0.0	0.0	4.7	113	0	0.0	0.0	3.2	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
Loss Of Appetite	All	96	27	28.1	19.4	38.2	89	26	29.2	20.1	39.8	76	30	39.5	28.4	51.4	113	46	40.7	31.6	50.4	90	38	42.2	31.9	9 53.	1 98	42	42.9	32.9	53.3
	Grade 2 or 3	96	4	4.2	1.1	10.3	89	4	4.5	1.2	11.1	76	5	6.6	2.2	14.7	113	8	7.1	3.1	13.5	90	13	14.4	7.9	23.	4 98	13	13.3	7.3	21.6
	Grade 3	96	0	0.0	0.0	3.8	89	0		0.0		76	0		0.0		113			0.0	4.8	90	1	1.1	0.0	6.0	98	3	3.1	0.6	8.7
	Related	96	25	26.0	17.6			23	25.8	17.1			29	38.2	27.2	50.0	113	3 44	38.9	29.9	48.6	90	36				9 98	41		31.9	52.2
	Grade 3 Related	96			0.0		89	0	0.0	0.0	4.1	76	0	0.0	0.0	4.7	113	3 1	0.9	0.0	4.8	90	1	1.1	0.0	6.0	98	3	3.1	0.6	8.7
	Medical advice	96	0	0.0	0.0	3.8	89	0	0.0	0.0	4.1	76	0	0.0	0.0	4.7	113	0	0.0	0.0	3.2	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7

117119 (DTPA-HBV-IPV-135)

						Hexa	gro	up							F	Pedia	gro	up								Penta	gro	up	1 (0)	,0111	-ınaı
				Fema			Ĭ	•	Mal	е				Fema			Ĭ	•	Ма	le				Fem				•	Mal	е	
					95	% CI				95 9	% CI				95	% CI				95	% C	I			95	% CI				95	% CI
Symptom	Туре	N	n	%	LL	UL		n	%	LL	UL	N	n			UL		n	%	LL			n	%	LL	UL	N	n	%	LL	UL
Temperature/(Rectally) (°C)	All	96	14	14.6	8.2	23.3	89	8	9.0	4.0	16.9	76	14	18.4	10.5	29.0	113	3 20	17.	7 11.	2 26.	0 90	15	16.7	9.6	26.0	98	14	14.3	8.0	22.8
	>38.5	96	2		0.3		89				4.1	76			0.3		113					90			0.0						11.5
	>39.0		0		0.0			0			4.1	76	0	0.0	0.0	4.7	113		0.0			90		0.0	0.0	4.0	98	2			7.2
	>39.5		0	0.0	0.0	3.8	89	0		0.0	4.1	76	0	0.0	0.0	4.7	113	3 0	0.0	0.0		90		0.0	0.0	4.0		0	0.0	0.0	3.7
	>40.0	96	0	0.0	0.0	3.8	89	0	0.0	0.0	4.1	76	0	0.0	0.0	4.7	113	3 0	0.0	0.0	3.2	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
	Related	96	11	11.5	5.9	19.6	89	4	4.5	1.2	11.1	76	12	15.8	8.4	26.0	113	3 19	16.8	8 10.	4 25.	0 90	14	15.6	8.8	24.	7 98	13	13.3	7.3	21.6
	>40.0 Related	96	0	0.0	0.0	3.8	89	0	0.0	0.0	4.1	76	0	0.0	0.0	4.7	113	3 0	0.0	0.0	3.2	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
	Medical advice	96	0	0.0	0.0	3.8	89	0	0.0	0.0	4.1	76	0	0.0	0.0	4.7	113	3 0	0.0	0.0	3.2	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
		1			ļ		I		ļ		1	D	ose	2	ļ.		1		- !	ļ	- 1	- 1	1			ļ	-1		ļ	1	
Drowsiness	All	94	45	47.9	37.5	58.4	- 88	52	59.1	48.1	69.5			69.3	57.6	79.5	109	9 80	73.4	4 64.	1 81.	4 82	52	63.4	52.0	73.8	3 97	57	58.8	48.3	68.7
	Grade 2 or 3	94	15	16.0	9.2	25.0	88	16		10.8									22.0										20.6	13.1	30.0
	Grade 3	94	5	5.3	1.7	12.0	88	3	3.4	0.7	9.6	75	3	4.0	0.8	11.2	109	9 4	3.7	1.0	9.1	82	1	1.2	0.0	6.6	97	3	3.1	0.6	8.8
	Related					56.3				47.0				64.0								8 82			52.0						67.7
	Grade 3 Related	94				12.0				0.3				4.0								82			0.0				2.1		
	Medical advice	94	0	0.0	0.0	3.8	88	0	0.0	0.0	4.1	75	0	0.0	0.0	4.8	109	9 0	0.0	0.0	3.3	82	0	0.0	0.0	4.4	97	0	0.0	0.0	3.7
Irritability / Fussiness	All	94	61	64.9	54 4	74.5	88	67	76 1	65.9	84 6	75	57	76.0	64 7	85 1	109	90	82 (6 74	1 89	2 82	57	69.5	58.4	1 79 2	97	79	81 4	72 3	88.6
	Grade 2 or 3					37.8				21.3				37.3								3 82			21.9			35			46.5
	Grade 3	94	3	3.2	0.7	9.0	88	3	3.4	0.7	9.6	75	4	5.3	1.5	13.1	109	9 10	9.2	4.5	16.	2 82	2	2.4	0.3	8.5	97	9	9.3	4.3	16.9
	Related					73.5				63.4			54	72.0								4 82			55.8			78			87.8
	Grade 3	94									9.6			4.0		11.2				4.5		2 82		2.4	0.3			9			16.9
	Related Medical	94					88										109		0.0												
	advice									0.0					0.0						3.3				0.3					0.0	
Loss Of Appetite	All	94				37.8				24.3									31.												41.1
	Grade 2 or 3	94	8	8.5	3.7	16.1	88	9	10.2	4.8	18.5	75	7	9.3	3.8	18.3	109	8 6	7.3	3.2	14.	0 82	6	7.3	2.7	15.2	2 97	9	9.3	4.3	16.9

117119 (DTPA-HBV-IPV-135)

						Hexa	gro	up							F	Pedia	gro	up								Penta	a gro	up			Fina
				Fema			Ĭ		Male	е				Fema				- 1	Mal	е				Fema					Mal	е	
					95	% CI				95	% CI				95	% CI				95	% CI					% CI				95	% CI
Symptom	Type	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
	Grade 3	94	1	1.1	0.0	5.8	88	0	0.0	0.0	4.1	75	0	0.0	0.0	4.8	109	1	0.9	0.0	5.0	82	0	0.0	0.0	4.4	97	2	2.1	0.3	7.3
	Related	94	24	25.5	17.1	35.6	88	28	31.8	22.3	42.6	75	19	25.3	16.0	36.7	109	32	29.4	21.0	38.8	82	25	30.5	20.8	41.6	97	30	30.9	21.9	41.1
	Grade 3 Related	94	1				88					75	0			4.8	109								0.0			2		0.3	
	Medical advice	94	0	0.0	0.0	3.8	88	0	0.0	0.0	4.1	75	0	0.0	0.0	4.8	109	0	0.0	0.0	3.3	82	1	1.2	0.0	6.6	97	0	0.0	0.0	3.7
Temperature/(Rectally) (°C)	All	94	26	27.7	18.9	37.8	88	21	23.9	15.4	34.1	75	15	20.0	11.6	30.8	109	21	19.3	12.3	3 27.9	82	15	18.3	10.6	28.4	4 97	20	20.6	13.1	30.0
· /	>38.5	94	9	9.6	4.5	17.4	88	6	6.8	2.5	14.3	75	6	8.0	3.0	16.6	109	7	6.4	2.6	12.8	82	2	2.4	0.3	8.5	97	7	7.2	3.0	14.3
	>39.0	94	2	2.1	0.3	7.5	88	0	0.0	0.0	4.1	75	2	2.7	0.3	9.3	109	1	0.9	0.0	5.0	82	0	0.0	0.0	4.4	97	2	2.1	0.3	7.3
	>39.5	94	0	0.0	0.0	3.8	88	0	0.0	0.0	4.1	75	0	0.0	0.0	4.8	109	0	0.0	0.0	3.3	82	0	0.0	0.0	4.4	97	1	1.0	0.0	5.6
	>40.0	94	0	0.0	0.0	3.8	88	0	0.0	0.0	4.1	75	0	0.0	0.0	4.8	109	0	0.0	0.0	3.3	82	0	0.0	0.0	4.4	97	0	0.0	0.0	3.7
	Related	94	19	20.2	12.6	29.8	88	18	20.5	12.6	30.4	75	14	18.7	10.6	29.3	109	18	16.5	10.1	24.8	82	14	17.1	9.7	27.0	97	19	19.6	12.2	28.9
	>40.0	94	0	0.0	0.0	3.8	88	0	0.0	0.0	4.1	75	0	0.0	0.0	4.8	109	9 0	0.0	0.0	3.3	82	0	0.0	0.0	4.4	97	0	0.0	0.0	3.7
	Related																														
	Medical	94	0	0.0	0.0	3.8	88	0	0.0	0.0	4.1	75	0	0.0	0.0	4.8	109	0	0.0	0.0	3.3	82	0	0.0	0.0	4.4	97	0	0.0	0.0	3.7
	advice											_		2																	
Decusiones	AII	00	11	46.6	25.0	E7 E	0.4	11	EO 4	44.0	60.4		ose		E0 7	74.6	10-	7 00	60.7	E0 (70.0	170	40	E2 0	10.0	O GE	202	10	E0.0	20.4	I 60 6
Drowsiness	All	88 88	41			57.5			52.4					63.2																	60.6
	Grade 2 or 3		9		4.8	18.5		14	16.7					23.5							3 28.4				11.2						19.1
	Grade 3	88	1			6.2	84	2				68				12.4					6.6				3.7					0.3	
	Related	88	39			55.3		42	50.0					61.8							68.3										60.6
	Grade 3 Related	88	1	1.1	0.0	6.2	84	2	2.4	0.3	8.3	68	3	4.4	0.9	12.4	107	7 2	1.9	0.2	6.6	78	7	9.0	3.7	17.6	92	2	2.2	0.3	7.6
	Medical advice	88	0	0.0	0.0	4.1	84	0	0.0	0.0	4.3	68	0	0.0	0.0	5.3	107	7 2	1.9	0.2	6.6	78	0	0.0	0.0	4.6	92	1	1.1	0.0	5.9
Irritability / Fussiness	All	88	59	67.0	56.2	76.7	84	67	79.8	69.6	87.7	68	52	76.5	64.6	85.9	107	83	77.6	68.5	85.	78	55	70.5	59.1	80.3	3 92	67	72.8	62.6	81.6
•	Grade 2 or 3	88	18	20.5	12.6	30.4	84	28	33.3	23.4	44.5	68	23	33.8	22.8	46.3	107	35	32.7	24.0	42.5	78	34	43.6	32.4	1 55.3	3 92	24	26.1	17.5	36.3
	Grade 3	88	3	3.4	0.7	9.6	84	3	3.6	0.7	10.1	68	5	7.4	2.4	16.3	107	7 10	9.3	4.6	16.5	78	7	9.0	3.7	17.6	92	4	4.3	1.2	10.8
	Related					73.6			77.4				48	70.6					75.7						57.8						80.6
	Grade 3	88			0.7			3			10.1					14.4			8.4		15.4		_		3.7		6 92				10.8

117119 (DTPA-HBV-IPV-135)

					I	Hexa	aroı	an							F	Pedia	aro	au								Penta	aro	au	тср	OILI	-inal
				Fema			J	- P	Mal	e				Fema			3		Mal	е				Fema			J		Male	•	
						% CI				95 9	% CI				95	% CI				95	% CI					% CI					% CI
Symptom	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
•	Related																														
	Medical advice	88	0	0.0	0.0	4.1	84	0	0.0	0.0	4.3	68	1	1.5	0.0	7.9	107	2	1.9	0.2	6.6	78	0	0.0	0.0	4.6	92	1	1.1	0.0	5.9
Loss Of Appetite	All	88	19	21.6	13.5	31.6	84	26	31.0	21.3	42.0	68	27	39.7	28.0	52.3	107	31	29.0	20.6	38.5	78	22	28.2	18.6	39.5	92	31	33.7	24.2	44.3
''	Grade 2 or 3	88	5	5.7	1.9	12.8	84				14.9				1.6	14.4				3.9		78		7.7			92				17.8
	Grade 3	88	0	0.0	0.0	4.1	84	1	1.2	0.0	6.5	68	1	1.5	0.0	7.9	107	1	0.9	0.0	5.1	78	1	1.3	0.0	6.9	92	1	1.1	0.0	5.9
	Related	88	18	20.5	12.6	30.4	84	26	31.0	21.3	42.0	68	25	36.8	25.4	49.3	107	31	29.0	20.6	38.5	78	21	26.9	17.5	38.2	92	31	33.7	24.2	44.3
	Grade 3 Related	88	0	0.0	0.0	4.1	84	1	1.2	0.0	6.5	68	1	1.5	0.0	7.9	107	1	0.9	0.0	5.1	78	1	1.3	0.0	6.9	92	1	1.1	0.0	5.9
	Medical advice	88	0	0.0	0.0	4.1	84	0	0.0	0.0	4.3	68	0	0.0	0.0	5.3	107	1	0.9	0.0	5.1	78	0	0.0	0.0	4.6	92	0	0.0	0.0	3.9
Temperature/(Rectally) (°C)	All	88	24	27.3	18.3	37.8	84	16	19.0	11.3	29.1	68	21	30.9	20.2	43.3	107	24	22.4	14.9	31.5	78	20	25.6	16.4	36.8	92	17	18.5	11.1	27.9
. ,	>38.5		5			12.8	84	7		3.4	16.4	68	7	10.3	4.2	20.1	107	14	13.1	7.3	21.0	78	8	10.3	4.5	19.2	92	7	7.6	3.1	15.1
	>39.0	88	1	1.1	0.0	6.2	84	3	3.6	0.7	10.1	68	4	5.9	1.6	14.4	107	7	6.5	2.7	13.0	78	2	2.6	0.3	9.0	92	5	5.4	1.8	12.2
	>39.5	88	0	0.0	0.0	4.1	84	1	1.2	0.0	6.5	68	0			5.3	107	3	2.8	0.6	8.0	78	0	0.0	0.0	4.6	92		1.1	0.0	5.9
	>40.0		0				84					68				5.3	107		1.9			78			0.0		92			0.0	
	Related			23.9					16.7		26.4		18	26.5							28.4					35.4			17.4		26.7
	>40.0 Related	88	0	0.0	0.0	4.1	84	0	0.0	0.0	4.3	68	0	0.0	0.0	5.3	107	2	1.9	0.2	6.6	78	0	0.0	0.0	4.6	92	0	0.0	0.0	3.9
	Medical advice	88	0	0.0	0.0	4.1	84	1	1.2	0.0	6.5	68	0	0.0	0.0	5.3	107	2	1.9	0.2	6.6	78	0	0.0	0.0	4.6	92	1	1.1	0.0	5.9
			•					•					rall/d					•	•		•		•					•			
Drowsiness	All	278	144	51.8	45.8	57.8	261	152	58.2	52.0	64.3	219	152	69.4	62.8	75.4	329	23	1 70.2	65.0	75.1	250	168	67.2	61.0	73.0	287	178	62.0	56.1	67.7
	Grade 2 or 3			15.5															22.8												23.8
	Grade 3	278		2.9			261							5.0					2.7					5.6					3.8		
	Related																		4 68.1												66.0
	Grade 3 Related	278			1.3		261							4.6							5.1								3.5		6.3
	Medical advice	278	1	0.4	0.0	2.0	261	0	0.0	0.0	1.4	219	0	0.0	0.0	1.7	329	2	0.6	0.1	2.2	250	0	0.0	0.0	1.5	287	1	0.3	0.0	1.9

117119 (DTPA-HBV-IPV-135)

						Hexa	aro	au							F	Pedia	aro	up								Penta	aro	up	1 (0)		Fina
				Fema			3		Mal	е			I	Fema				-	Mal	е				Fema			J .		Mal	е	
					95	% CI				95	% CI				95	% CI				95	% CI					% CI				95	% CI
Symptom	Type	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Irritability / Fussiness	All	278	183	65.8	59.9	71.4	261	186	71.3	65.4	76.7	219	173	79.0	73.0	84.2	329	274	83.3	78.8	87.2	250	185	74.0	68.1	79.3	287	226	78.7	73.6	83.3
·	Grade 2 or 3	278	69	24.8	19.9	30.3	261	72	27.6	22.3	33.4	219	85	38.8	32.3	45.6	329	122	37.1	31.8	42.6	250	92	36.8	30.8	43.1	287	95	33.1	27.7	38.9
	Grade 3	278	10	3.6	1.7	6.5	261	11	4.2	2.1	7.4	219	16	7.3	4.2	11.6	329	30	9.1	6.2	12.8	250	15	6.0	3.4	9.7	287	22	7.7	4.9	11.4
	Related	278	178	64.0	58.1	69.7	261	181	69.3	63.4	74.9	219	166	75.8	69.6	81.3	329	269	81.8	77.2	85.8	250	179	71.6	65.6	77.1	287	221	77.0	71.7	81.7
	Grade 3 Related	278	10	3.6	1.7	6.5	261	11	4.2	2.1	7.4	219	14	6.4	3.5	10.5	329	29	8.8	6.0	12.4	250	15	6.0	3.4	9.7	287	22	7.7	4.9	11.4
	Medical advice	278	1	0.4	0.0	2.0	261	0	0.0	0.0	1.4	219	1	0.5	0.0	2.5	329	2	0.6	0.1	2.2	250	2	8.0	0.1	2.9	287	1	0.3	0.0	1.9
Loss Of Appetite	All	278	72	25.9	20.9	31.5	261	82	31.4	25.8	37.4	219	78	35.6	29.3	42.3	329	111	33.7	28.6	39.1	250	86	34.4	28.5	40.6	287	103	35.9	30.3	3 41.7
	Grade 2 or 3	278	17	6.1	3.6	9.6	261	19	7.3	4.4	11.1	219	16	7.3	4.2	11.6	329	25	7.6	5.0	11.0	250	25	10.0	6.6	14.4	287	31	10.8	7.5	15.0
	Grade 3	278	1	0.4	0.0	2.0	261	1		0.0		219				2.5	329			0.2		250		8.0			287			8.0	
	Related	278	67	24.1	19.2	29.6	261	77	29.5	24.0	35.4	219	73	33.3	27.1	40.0	329	107	32.5	27.5	37.9	250	82	32.8	27.0	39.0	287	102	35.5	30.0	41.4
	Grade 3 Related	278	1	0.4	0.0	2.0	261	1	0.4	0.0	2.1	219	1	0.5	0.0	2.5	329	3	0.9	0.2	2.6	250	2	8.0	0.1	2.9	287	6	2.1	8.0	4.5
	Medical advice	278	0	0.0	0.0	1.3	261	0	0.0	0.0	1.4	219	0	0.0	0.0	1.7	329	1	0.3	0.0	1.7	250	1	0.4	0.0	2.2	287	0	0.0	0.0	1.3
Temperature/(Rectally) (°C)	All	278	64	23.0	18.2	28.4	261	45	17.2	12.9	22.4	219	50	22.8	17.4	29.0	329	65	19.8	15.6	24.5	250	50	20.0	15.2	25.5	287	51	17.8	13.5	22.7
(- /	>38.5	278	16	5.8	3.3	9.2	261	13	5.0	2.7	8.4	219	15	6.8	3.9	11.0	329	23	7.0	4.5	10.3	250	10	4.0	1.9	7.2	287	19	6.6	4.0	10.1
	>39.0	278	3	1.1	0.2	3.1	261	3	1.1	0.2	3.3	219			1.0	5.9	329		2.4	1.1	4.7	250	2	8.0	0.1	2.9	287	9	3.1	1.4	5.9
	>39.5	278	0	0.0	0.0	1.3	261	1	0.4	0.0	2.1	219	0	0.0	0.0	1.7	329	3	0.9	0.2	2.6	250	0	0.0	0.0	1.5	287	2	0.7	0.1	2.5
	>40.0	278	0	0.0	0.0	1.3	261	0	0.0	0.0	1.4	219	0	0.0	0.0	1.7	329	2	0.6	0.1	2.2	250	0	0.0	0.0	1.5	287	0	0.0	0.0	1.3
	Related	278	51	18.3	14.0	23.4	261	36	13.8	9.9	18.6	219	44	20.1	15.0	26.0	329	58	17.6	13.7	22.2	250	47	18.8	14.2	24.2	287	48	16.7	12.6	21.6
	>40.0 Related	278	0	0.0	0.0	1.3	261	0	0.0	0.0	1.4	219	0	0.0	0.0	1.7	329	2	0.6	0.1	2.2	250	0	0.0	0.0	1.5	287	0	0.0	0.0	1.3
	Medical advice	278	0	0.0	0.0	1.3	261	1	0.4	0.0	2.1	219	0	0.0	0.0	1.7	329	2	0.6	0.1	2.2	250	0	0.0	0.0	1.5	287	1	0.3	0.0	1.9
	auvice		1	1	1	1	1	1	1	1		vera	ll/eu	bject				1	1	1											
Drowsiness	All	97	74	76.3	66.6	84.3	90	73	81.1	71.5						97.8	113	101	89.4	82.2	94.4	90	80	88.9	80.5	94.5	98	88	89.8	82.0	95.0
	Grade 2 or 3									24.7																					50.2

117119 (DTPA-HBV-IPV-135)

						Hexa	gro	up							F	Pedia	gro	up								Penta	gro	up		, , , , ,	-ınaı
				Fema				•	Male	•				Fema				•	Ma	le				Fem				•	Mal	е	
					95	% CI				95 9	% CI				95	% CI				95	% CI				95	% CI				95	% CI
Symptom	Туре	N	n	%	LL	UL		n			UL		n		LL			n	%	LL	UL		n	%	LL	UL		n	%		UL
	Grade 3	97	7	7.2	3.0	14.3	90	4	4.4	1.2	11.0	76	11	14.5	7.5	24.4	113	8	7.1	3.1	13.5	90	13	14.4	7.9	23.4	1 98	9	9.2	4.3	16.7
	Related	97	72			82.6			80.0				69	90.8									79		79.2				88.8	80.8	94.3
	Grade 3 Related	97	7	7.2	3.0	14.3	90	4	4.4	1.2	11.0	76	10	13.2	6.5	22.9	113	8	7.1	3.1	13.5	90	13	14.4	7.9	23.4	1 98	8	8.2	3.6	15.5
	Medical	97	1	1.0	0.0	5.6	90	0	0.0	0.0	4.0	76	0	0.0	0.0	4.7	113	2	1.8	0.2	6.2	90	0	0.0	0.0	4.0	98	1	1.0	0.0	5.6
Imitability / Funciones	advice	97	02	OF C	77.0	04.0	00	0.4	00.0	04.0	OE 3	76	70	04.7	07.4	00.5	112	111	07	2 02	4 00 4	1 00	00	04.4	1 02 (06.	1 00	O.F.	00.0	04.2	00.4
Irritability / Fussiness	All			85.6					90.0					94.7																	99.4
	Grade 2 or 3	97				59.8			53.3					65.8											1 53.7						
	Grade 3	97				15.6			11.1				12	15.8										14.4	7.9	23.4	1 98	17	17.3		
	Related	97		83.5	74.6				88.9					93.4											81.9				95.9	89.9	98.9
	Grade 3 Related	97	8	8.2	3.6	15.6	90	10	11.1	5.5	19.5	76	11	14.5	7.5	24.4	113	23	20.	4 13.4	4 29.0	90	13	14.4	7.9	23.4	1 98	17	17.3	10.4	26.3
	Medical	97	1	1 0	0.0	5.6	an	Λ	0.0	0.0	<i>1</i> ∩	76	1	1.3	n n	7 1	113	2	1 2	0.2	6.2	an	2	22	0.3	7.8	98	1	1 0	0.0	5.6
	advice																														
Loss Of Appetite	All	97				58.8			53.3				46	60.5							9 66.8								65.3	55.0	74.6
	Grade 2 or 3	97	13	13.4	7.3	21.8	90	15	16.7	9.6	26.0	76	15	19.7	11.5	30.5	113	17	15.	9.0	23.0	90	18	20.0	12.3	3 29.8	98	21	21.4	13.8	30.9
	Grade 3	97	1	1.0	0.0	5.6	90	1	1.1	0.0	6.0	76	1	1.3	0.0	7.1	113	2	1.8	0.2	6.2	90	2	2.2	0.3	7.8	98	4	4.1	1.1	10.1
	Related	97	45			56.8		46	51.1				44	57.9							0 65.9				3 46.9						74.6
	Grade 3	97						1				76	1			7.1	113		1.8		6.2				0.3			4	_		10.1
	Related Medical	97	0	0.0	0.0	2.7	90	0	0.0	0.0	4.0	70	0	0.0	0.0	17	113	1	0.9	0.0	4.8	90	4	1 1	0.0	6.0	98	٥	0.0	0.0	2.7
	advice														0.0																
Temperature/(Rectally) (°C)	All	97	42	43.3	33.3	53.7	90	30	33.3	23.7	44.1	76	33	43.4	32.1	55.3	113	45	39.	8 30.	7 49.5	5 90	34	37.8	3 27.8	48.6	98	38	38.8	29.1	49.2
	>38.5	97	15			24.2			10.0	4.7	18.1	76	13	17.1	9.4	27.5	113	21	18.	6 11.	9 27.0	90	10					16	16.3	9.6	25.2
	>39.0	97	3	3.1	0.6	8.8	90	3	3.3	0.7	9.4	76	6	7.9	3.0	16.4	113	8	7.1	3.1	13.5	90	2	2.2	0.3	7.8	98	8	8.2	3.6	15.5
	>39.5	97	0	0.0	0.0	3.7	90	1	1.1	0.0	6.0	76	0	0.0	0.0	4.7	113	3	2.7	0.6	7.6	90	0	0.0	0.0	4.0	98	2	2.0	0.2	7.2
	>40.0	97		0.0	0.0	3.7	90	0	0.0	0.0	4.0	76	0	0.0	0.0	4.7	113	2	1.8	0.2	6.2	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7
	Related	97	34	35.1	25.6	45.4	90	27	30.0	20.8	40.6	76	31	40.8	29.6	52.7	113	43	38.	1 29.	1 47.7	7 90	33	36.7	7 26.8	3 47.	98	36	36.7	27.2	47.1
	>40.0 Related	97	0	0.0	0.0	3.7	90	0	0.0	0.0	4.0	76	0	0.0	0.0	4.7	113	2	1.8	0.2	6.2	90	0	0.0	0.0	4.0	98	0	0.0	0.0	3.7

117119 (DTPA-HBV-IPV-135)

Report Final

						Hexa	grou	ıp							F	Pedia	grou	р							F	enta	gro	up	-		
				Fema	ale				Mal	е				Fema	le				Male	9				Fema	ale				Mal	е	
					95	% CI				95 (% CI				95	% CI				95	% CI				95	% CI				95	% CI
Symptom	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
	Medical	97	0	0.0	0.0	3.7	90	1	1.1	0.0	6.0	76	0	0.0	0.0	4.7	113	2	1.8	0.2	6.2	90	0	0.0	0.0	4.0	98	1	1.0	0.0	5.6
	advice																														

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

For each dose and overall/subject:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the symptom at least once

For Overall/dose:

N = number of documented doses

n/% = number/percentage of doses followed by at least one type of symptom

117119 (DTPA-HBV-IPV-135)

Table 8.12 Incidence of solicited general symptoms reported during the 4-day (Days 0-3) post-vaccination period following each priming dose and overall- by geographical ancestry (Primary Total vaccinated cohort)

						Hexa	grou	ιр							F	Pedia	gro	up							F	Penta	gro	up			
		٧	Vhite	e Cai	ucasi	an			othe	er		W	/hite	Cau	casi	an			othe	r		V	/hite	e Cau	ıcasi	an			othe	r	
					95	% CI				95 %	6 CI				95	% CI				95 9	% CI				95	% CI				95	% CI
Symptom	Type	N	n	%	LL	UL	N	n	%	LL	UL	N I	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
													se '																		
Drowsiness	All	112			60.2			36		37.4																88.7			75.0		
	Grade 2 or 3	112	26	23.2	15.8	32.1	73	10	13.7	6.8	23.8	123	39	31.7	23.6	40.7	66	17	25.8	15.8	38.0	112	36	32.1	23.6	41.6	76	17	22.4	13.6	33.4
	Grade 3	112	3	2.7	0.6	7.6	73	0	0.0	0.0	4.9	123	7	5.7	2.3	11.4	66	1	1.5	0.0	8.2	112	9	8.0	3.7	14.7	76	3	3.9	0.8	11.1
	Related	112			58.4			36		37.4				72.4				47	71.2							84.2					82.0
	Grade 3 Related	112		2.7	0.6	7.6		0	0.0		4.9	123				10.3			1.5			112		8.0	3.7	14.7					11.1
	Medical advice	112	1	0.9	0.0	4.9	73	0	0.0	0.0	4.9	123 (0	0.0	0.0	3.0	66	0	0.0			112			0.0	3.2	76	0	0.0	0.0	4.7
Irritability / Fussiness	All	112	73	65.2	55.6	73.9	73	42	57.5	45.4	69.0	123	108	87.8	80.7	93.0	66	57			93.6					90.2					86.4
	Grade 2 or 3	112	28	25.0	17.3	34.1	73	14	19.2	10.9	30.1	123	55	44.7	35.7	53.9	66	24	36.4	24.9	49.1	112	43	38.4	29.4	48.1	76	25	32.9	22.5	44.6
	Grade 3	112	6	5.4	2.0	11.3	73	3	4.1	0.9	11.5	123	14	11.4	6.4	18.4	66	3	4.5	0.9	12.7	112	13	11.6	6.3	19.0	76	2	2.6	0.3	9.2
	Related	112	71	63.4	53.8	72.3	73	42	57.5	45.4	69.0	123	108	87.8	80.7	93.0	66	55	83.3	72.1	91.4	112	89	79.5	70.8	86.5	76	58	76.3	65.2	85.3
	Grade 3 Related	112	6	5.4	2.0	11.3	73	3	4.1	0.9	11.5	123	14	11.4	6.4	18.4	66	3	4.5	0.9	12.7	112	13	11.6	6.3	19.0	76	2	2.6	0.3	9.2
	Medical advice	112	1	0.9	0.0	4.9	73	0	0.0	0.0	4.9	123 (0	0.0	0.0	3.0	66	0	0.0	0.0	5.4	112	0	0.0	0.0	3.2	76	0	0.0	0.0	4.7
Loss Of Appetite	All	112	38	33.9	25.3	43.5	73	15	20.5	12.0	31.6	123	51	41.5	32.7	50.7	66	25	37.9	26.2	50.7	112	55	49.1	39.5	58.7	76	25	32.9	22.5	44.6
	Grade 2 or 3	112	7	6.3	2.5	12.5	73	1	1.4	0.0	7.4	123	9	7.3	3.4	13.4	66	4	6.1	1.7	14.8	112	14	12.5	7.0	20.1	76	12	15.8	8.4	26.0
	Grade 3	112	0	0.0	0.0	3.2	73	0	0.0	0.0	4.9	123	1	8.0	0.0	4.4	66	0	0.0	0.0	5.4	112	3	2.7	0.6	7.6	76	1	1.3	0.0	7.1
	Related	112	35	31.3	22.8	40.7	73	13	17.8	9.8	28.5	123	49	39.8	31.1	49.1	66	24	36.4	24.9	49.1	112	52	46.4	37.0	56.1	76	25	32.9	22.5	44.6
	Grade 3 Related	112	0	0.0	0.0	3.2	73	0	0.0	0.0	4.9	123	1	8.0	0.0	4.4	66	0	0.0	0.0	5.4	112			0.6	7.6	76	1		0.0	
	Medical advice	112	0	0.0	0.0	3.2	73	0	0.0	0.0	4.9	123 (0	0.0	0.0	3.0	66	0	0.0	0.0	5.4	112	0	0.0	0.0	3.2	76	0	0.0	0.0	4.7

117119 (DTPA-HBV-IPV-135)

						Hexa	gro	up						F	Pedia	gro	up								Penta	gro	up	1 (0)	,0111	Finai
		٧	Vhite	e Cau					othe	r		Whit	e Cau					oth	er		٧	Vhite	e Cau					othe		
					95	% CI				95 9	% CI			95	% CI				95	% CI				95	% CI				95	% CI
Symptom	Type			%	LL	UL		n	%			N n	%	LL	UL		n	%		UL		n	%	LL	UL		n			UL
Temperature/(Rectally) (°C)	All	112	9	8.0	3.7	14.7	73	13	17.8	9.8	28.5	123 17	13.8	8.3	21.2	66	17	25.8	15.8	38.0	112	15	13.4	7.7	21.1	76	14	18.4	10.5	29.0
,	>38.5	112	1	0.9	0.0	4.9	73	1	1.4	0.0	7.4	123 2	1.6	0.2	5.8	66	2	3.0	0.4	10.5	112	3	2.7	0.6	7.6	76	2	2.6	0.3	9.2
	>39.0	112			0.0	3.2	73	0		0.0	4.9	123 0	0.0	0.0	3.0	66	0	0.0	0.0	5.4	112	1		0.0		76	1		0.0	7.1
	>39.5	112	0	0.0	0.0	3.2	73	0		0.0	4.9	123 0	0.0	0.0	3.0	66	0	0.0	0.0	5.4	112	0			3.2	76	0	0.0	0.0	4.7
	>40.0	112							0.0	0.0	4.9	123 0	0.0	0.0	3.0	66	0	0.0	0.0	5.4	112	0	0.0	0.0	3.2	76	0	0.0	0.0	4.7
	Related	112				12.5			11.0		20.5	123 15			19.3		16	24.2	14.5	36.4	112	15			21.1	76	12	15.8		26.0
	>40.0 Related	112	0	0.0	0.0	3.2	73	0	0.0	0.0	4.9	123 0	0.0	0.0	3.0	66	0	0.0	0.0	5.4	112	0	0.0	0.0	3.2	76	0	0.0	0.0	4.7
	Medical advice	112	0	0.0	0.0	3.2	73	0	0.0	0.0	4.9	123 0	0.0	0.0	3.0	66	0	0.0	0.0	5.4	112	0	0.0	0.0	3.2	76	0	0.0	0.0	4.7
							1	l		1		Dose	2				1		-	-1		l					1			
Drowsiness	All	110	60	54.5	44.8	64.1	72	37	51.4	39.3	63.3	119 88		65.1	81.6	65	44	67.7	54.9	78.8	107	73	68.2	58.5	76.9	72	36	50.0	38.0	62.0
	Grade 2 or 3	110				26.7						119 32								28.3								_		32.0
	Grade 3	110	5	4.5	1.5	10.3	72	3	4 2	0.9	11 7	119 5	4 2	1 4	9.5	65	2	3 1	0.4	10.7	107	2	1.9	0.2	6.6	72	2	28	0.3	9 7
	Related	110				62.3						119 84			78.6					3 76.1					76.0			1		62.0
	Grade 3 Related	110				9.0						119 5	4.2						0.4		107				5.1			2.8		
	Medical advice	110	0	0.0	0.0	3.3	72	0	0.0	0.0	5.0	119 0	0.0	0.0	3.1	65	0	0.0	0.0	5.5	107	0	0.0	0.0	3.4	72	0	0.0	0.0	5.0
Irritability / Fussiness	All	110	86	78.2	69.3	85.5	72	42	58.3	46.1	69.8	119 96	80.7	72.4	87.3	65	51	78.5	66.5	87.7	107	82	76.6	67.5	84.3	72	54	75.0	63.4	84.5
,	Grade 2 or 3	110				43.3						119 45								51.4					48.2					39.6
	Grade 3	110	4	3.6	1.0	9.0	72	2	2.8	0.3	9.7	119 11	9.2	4.7	15.9	65	3	4.6	1.0	12.9	107	6	5.6	2.1	11.8	72	5	6.9	2.3	15.5
	Related					83.2						119 93								86.5										83.3
	Grade 3 Related	110										119 10			14.9			4.6			107				11.8					15.5
	Medical advice	110	0	0.0	0.0	3.3	72	0	0.0	0.0	5.0	119 0	0.0	0.0	3.1	65	0	0.0	0.0	5.5	107	1	0.9	0.0	5.1	72	1	1.4	0.0	7.5
Loss Of Appetite	All	110	37	33.6	24.9	43.3	72	19	26.4	16.7	38.1	119 37	31.1	22.9	40.2	2 65	18	27.7	17.3	3 40.2	107	37	34.6	25.6	44.4	72	19	26.4	16.7	38.1
PP	Grade 2 or 3					17.2						119 10													15.4					17.3

117119 (DTPA-HBV-IPV-135)

		White Caucasian 95 %					gro	ир								edia	gro	up								Penta	gro	up	•		
		٧	Vhite	e Cau	ıcasi	an			othe			W	nite	Cau	casia	an			othe			٧	Vhit	e Cau	ıcasi	an		•	othe		
					95	% CI				95 (% CI				95	% CI				95	% CI				95	% CI				95	% CI
Symptom	Туре	1		%	LL	UL		n	%	LL		N n			LL	UL	N	n	%	LL	UL		n	%	LL	UL	1	n	%	LL	UL
•	Grade 3	White Caucasi 95			3.3	72	1			7.5	119 1			0.0	4.6	65	0	0.0	0.0		107			0.0	5.1	72	1			7.5	
	Related				18	25.0	15.5	36.6	119 3			20.7	37.6		17	26.2		38.5			33.6	24.8	43.4	1 72	19	26.4	16.7	38.1			
	Grade 3 Related						72				7.5	119 1				4.6		0	0.0		5.5	107			0.0						7.5
	Medical advice	110	0	0.0	0.0	3.3	72	0	0.0	0.0	5.0	119 0	(0.0	0.0	3.1	65	0			5.5	107			0.0		72		0.0	0.0	5.0
Temperature/(Rectally) (°C)	All	110	26	23.6	16.1	32.7	72	21	29.2	19.0	41.1	119 2	3 1	19.3	12.7	27.6	65	13	20.0	11.	1 31.8	107	24	22.4	14.9	31.5	72	11	15.3	7.9	25.7
. ,	>38.5	110	7		2.6	12.7	72	8	11.1			119 7	. [5.9	2.4	11.7	65	6	9.2		19.0	107	6		2.1					0.9	11.7
	>39.0	110	2	1.8	0.2	6.4	72	0	0.0	0.0	5.0	119 1	(3.8	0.0	4.6	65	2	3.1	0.4	10.7	107	1	0.9	0.0	5.1	72	1	1.4	0.0	7.5
	>39.5	110	0	0.0	0.0	3.3	72	0		0.0	5.0	119 0) (0.0	0.0	3.1	65	0	0.0	0.0	5.5	107	1	0.9	0.0	5.1	72	0	0.0	0.0	5.0
	>40.0	110		0.0			72				5.0	119 0		0.0	0.0	3.1	65	0	0.0	0.0		107			0.0				0.0	0.0	5.0
	Related	110	21	19.1	12.2	27.7	72	16	22.2	13.3	33.6	119 2	0 1	16.8	10.6	24.8	65	12	18.5	9.9	30.0	107	23	21.5	14.1	30.5	72	10	13.9	6.9	24.1
	>40.0	110	0	0.0	0.0	3.3	72	0	0.0	0.0	5.0	119 0) (0.0	0.0	3.1	65	0	0.0	0.0	5.5	107	0	0.0	0.0	3.4	72	0	0.0	0.0	5.0
	Related																														
	Medical advice	110	0	0.0	0.0	3.3	72	0	0.0	0.0	5.0	119 0) (0.0	0.0	3.1	65	0	0.0	0.0	5.5	107	0	0.0	0.0	3.4	72	0	0.0	0.0	5.0
				1	1	1			-	1		Dos	se 3						-						-	-			-1	1	-
Drowsiness	All	106	55	51.9	42.0	61.7	66	30	45.5	33.1	58.2	116 7			51.7	70.1	59	37	62.7	49.	1 75.0	105	58	55.2	45.2	65.0	65	30	46.2	33.7	59.0
	Grade 2 or 3					20.1			15.2			116 2									27.0				8.2						26.5
	Grade 3	106	2	1.9	0.2	6.6	66	1	1.5	0.0	8.2	116 3	1 2	2.6	0.5	7.4	59	2	3.4	0.4	11.7	105	5	4.8	1.6	10.8	65	4	6.2	1.7	15.0
	Related	106	51	48.1	38.3	58.0	66	30				116 7				70.1		34			1 70.4				43.3						59.0
	Grade 3 Related	106	2	1.9	0.2	6.6	66	1	1.5	0.0	8.2	116 3	3	2.6	0.5	7.4	59	2	3.4	0.4		105			1.6	10.8	65	4	6.2	1.7	15.0
	Medical advice	106	0	0.0	0.0	3.4	66	0	0.0	0.0	5.4	116 0	(0.0	0.0	3.1	59	2	3.4	0.4	11.7	105	0	0.0	0.0	3.5	65	1	1.5	0.0	8.3
Irritability / Fussiness	All	106	78	73.6	64.1	81.7	66	48	72.7	60.4	83.0	116 9	3 8	30.2	71.7	87.0	59	42	71.2					75.2	65.9	83.1	1 65	43	66.2	53.4	77.4
•	Grade 2 or 3	106	28	26.4	18.3	35.9	66	18	27.3	17.0	39.6	116 3	8 3	32.8	24.3	42.1	59	20	33.9	22.1	1 47.4	105	38	36.2	27.0	46.1	1 65	20	30.8	19.9	43.4
	Grade 3	106	4	3.8	1.0	9.4	66	2	3.0	0.4	10.5	116 1	1 9	9.5	4.8	16.3	59	4	6.8	1.9	16.5	105	7	6.7	2.7	13.3	65	4	6.2	1.7	15.0
	Related	106				77.5						116 8				84.1					1 79.4				63.8				66.2	53.4	77.4
	Grade 3	106		3.8				2				116 9		7.8		14.2				1.9					2.7	13.3		4	6.2		15.0

117119 (DTPA-HBV-IPV-135)

					ŀ	lexa	grou	ıp						F	Pedia	gro	up							F	Penta	gro	ир			Final
		٧	Vhite	e Cau	casi	an			othe	r		Whit	e Cau	casi	an			othe	er		٧	Vhite	e Caı	ıcasi	an			othe	r	
					95	% CI				95 %	% CI			95	% CI				95	% CI				95	% CI				95 (% CI
Symptom	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
	Related																													
	Medical advice	106	0	0.0	0.0	3.4	66	0	0.0	0.0	5.4	116 1	0.9	0.0	4.7	59	2	3.4	0.4	11.7	105	0	0.0	0.0	3.5	65	1	1.5	0.0	8.3
Loss Of Appetite	All	106	30	30.2	21.7	30.0	66	12	10.7	10 0	21.2	116 40	21 5	25.0	13.0	50	10	30.5	10.2	13.0	105	35	33 3	24.4	13.3	65	1Ω	27.7	17 2	40.2
LUSS Of Appellie	Grade 2	106					-	7	10.6			116 10			15.3				1.1		105			3.3						20.9
	or 3	100	4					ľ				110 10														00	1			
	Grade 3	106		0.9				0		0.0		116 2			6.1			0.0			105					65	1		0.0	
	Related	106		29.2				13	19.7	10.9	31.3	116 39			43.0			28.8	17.8	42.1	105	34			42.2		18	27.7	17.3	40.2
	Grade 3	106	1	0.9	0.0	5.1	66	0	0.0	0.0	5.4	116 2	1.7	0.2	6.1	59	0	0.0	0.0	6.1	105	1	1.0	0.0	5.2	65	1	1.5	0.0	8.3
	Related																													
	Medical advice	106	0	0.0	0.0	3.4	66	0	0.0	0.0	5.4	116 0	0.0	0.0	3.1	59	1	1.7	0.0	9.1	105	0	0.0	0.0	3.5	65	0	0.0	0.0	5.5
Temperature/(Rectally) (°C)	All	106	21	19.8	12.7	28.7	66	19	28.8	18.3	41.3	116 25	21.6	14.5	30.1	59	20	33.9	22.1	47.4	105	20	19.0	12.0	27.9	65	17	26.2	16.0	38.5
. ,	>38.5	106	7	6.6	2.7	13.1	66	5	7.6	2.5	16.8	116 12	10.3	5.5	17.4	59	9	15.3	7.2	27.0	105	8	7.6	3.3	14.5	65	7	10.8	4.4	20.9
	>39.0	106	0	0.0	0.0	3.4	66	4	6.1	1.7	14.8	116 5	4.3	1.4	9.8	59	6	10.2	3.8	20.8	105	3	2.9	0.6	8.1	65	4	6.2	1.7	15.0
	>39.5	106	0	0.0	0.0	3.4	66	1	1.5	0.0	8.2	116 1	0.9	0.0	4.7	59		3.4	0.4	11.7	105	0	0.0	0.0	3.5	65	1	1.5	0.0	8.3
	>40.0	106	0	0.0	0.0	3.4	66	0	0.0	0.0	5.4	116 0	0.0	0.0	3.1	59	2	3.4	0.4	11.7	105	0	0.0	0.0	3.5	65	0	0.0	0.0	5.5
	Related	106	18	17.0	10.4	25.5	66	17	25.8	15.8	38.0	116 22	19.0	12.3	27.3	59	17	28.8	17.8	42.1	105	20	19.0	12.0	27.9	65	15	23.1	13.5	35.2
	>40.0	106	0	0.0	0.0	3.4	66	0	0.0	0.0	5.4	116 0	0.0	0.0	3.1	59	2	3.4	0.4	11.7	105	0	0.0	0.0	3.5	65	0	0.0	0.0	5.5
	Related																													
	Medical	106	0	0.0	0.0	3.4	66	1	1.5	0.0	8.2	116 0	0.0	0.0	3.1	59	2	3.4	0.4	11.7	105	0	0.0	0.0	3.5	65	1	1.5	0.0	8.3
	advice																													
												Overall/																		
Drowsiness	All											358 252																		
	Grade 2 or 3	328	59	18.0	14.0	22.6	211	31	14.7	10.2	20.2	358 99	27.7	23.1	32.6	190	37	19.5	14.1	25.8	324	75	23.1	18.7	28.1	213	42	19.7	14.6	25.7
	Grade 3	328	10	3.0	1.5	5.5	211	4	1.9	0.5	4.8	358 15	4.2	2.4	6.8	190	5	2.6	0.9	6.0	324	16	4.9	2.8	7.9	213	9	4.2	2.0	7.9
	Related	328	185	56.4	50.8	61.8	211	102	48.3	41.4	55.3	358 244	4 68.2	63.1	73.0	190	123	64.7	57.5	71.5	324	214	66.0	60.6	71.2	213	121	56.8	49.9	63.6
	Grade 3 Related	328	9	2.7	1.3	5.1	211	4	1.9	0.5	4.8	358 14	3.9	2.2	6.5	190	5	2.6	0.9	6.0	324	15	4.6	2.6	7.5	213	9	4.2	2.0	7.9
	Medical	328	1	0.3	0.0	1.7	211	0	0.0	0.0	1.7	358 0	0.0	0.0	1.0	190	2	1.1	0.1	3.8	324	0	0.0	0.0	1.1	213	1	0.5	0.0	2.6
	advice																													

117119 (DTPA-HBV-IPV-135)

						Hexa	gro	up							F	Pedia	gro	up								Penta	gro	ир	•		
		٧	Vhite	e Cau	ucasi	an		-	othe	er		١	Vhite	Cau	casi	an			oth	er		٧	Vhite	Cau	ıcasi			-	othe	r	
					95	% CI				95	% CI				95	% CI				95	% CI				95	% CI				95	% CI
Symptom	Туре		n	%		UL		n	%			N			LL	UL		n	%	LL	UL			%	LL	UL		n	%		UL
Irritability / Fussiness	All	328	237	72.3	67.1	77.0	211			55.7																			73.2	66.8	79.1
	Grade 2	328	93	28.4	23.5	33.6	211	48	22.7	17.3	29.0	358	138	38.5	33.5	43.8	190	69	36.3	3 29.5	43.6	324	122	37.7	32.4	43.2	213	65	30.5	24.4	37.2
	or 3																														
	Grade 3				2.4		211		3.3		6.7			10.1							9.5								5.2		
	Related									55.7																					
	Grade 3	328	14	4.3	2.4	7.1	211	7	3.3	1.3	6.7	358	33	9.2	6.4	12.7	190	10	5.3	2.6	9.5	324	26	8.0	5.3	11.5	213	11	5.2	2.6	9.1
	Related																														
	Medical	328	1	0.3	0.0	1.7	211	0	0.0	0.0	1.7	358	1	0.3	0.0	1.5	190	2	1.1	0.1	3.8	324	1	0.3	0.0	1.7	213	2	0.9	0.1	3.4
	advice																														
Loss Of Appetite	All									16.8											39.2								29.1		
	Grade 2	328	22	6.7	4.3	10.0	211	14	6.6	3.7	10.9	358	29	8.1	5.5	11.4	190	12	6.3	3.3	10.8	324	31	9.6	6.6	13.3	213	25	11.7	7.7	16.8
	or 3																														
	Grade 3	328			0.0		211			0.0					0.3		190				1.9					3.6				0.3	
	Related				25.5					15.6											1 37.6								29.1		
	Grade 3	328	1	0.3	0.0	1.7	211	1	0.5	0.0	2.6	358	4	1.1	0.3	2.8	190	0	0.0	0.0	1.9	324	5	1.5	0.5	3.6	213	3	1.4	0.3	4.1
	Related Medical	200	^	0.0	0.0	4.4	044	^	0.0	0.0	4 7	250	^	0.0	0.0	4.0	400		0.5	0.0	0.0	204	4	0.0	0.0	4 7	040	^	0.0	0.0	4 7
	advice	328	U	0.0	0.0	1.1	211	U	0.0	0.0	1.7	358	U	0.0	0.0	1.0	190	1	0.5	0.0	2.9	324	1	0.3	0.0	1.7	213	U	0.0	0.0	1.7
To you a rate wa //Da atally /		328	EC	17 1	13.2	24.6	044	E 2	OF 4	19.4	24.5	250	C.E.	10.0	112	22.5	100	ΕO	200.0	200	2 33.2	224	EΟ	40.0	111	2 22.9	042	40	10.7	116	05.7
Temperature/(Rectally) (°C)	All	320	90	17.1	13.2	21.0	211	53	25.1	19.4	31.5	330	00	18.2	14.3	22.0	190	50	20.3	20.4	2 33.2	324	59	10.2	14.2	2 22.5	1213	42	19.7	14.0	25.7
(0)	>38.5	328	15	4.6	2.6	7.4	211	14	6.6	3.7	10.9	358	21	5.9	3.7	8.8	190	17	8.9	5.3	13 0	324	17	5.2	3.1	8.3	213	12	5.6	2.9	9.6
	>39.0	328			0.1		211					358				3.6	190		4.2			324				3.6	213				6.0
	>39.5	328			0.0		211					358			0.0	1.5	190		1.1	0.1	3.8	324				1.7	213				2.6
	>40.0	328			0.0		211				1.7	358				1.0	190					324			0.0		213				1.7
	Related				10.5					14.3				15.9							30.4					22.5					23.1
	>40.0	328			0.0							358		0.0			190									1.1				0.0	
	Related												-																		
	Medical	328	0	0.0	0.0	1.1	211	1	0.5	0.0	2.6	358	0	0.0	0.0	1.0	190	2	1.1	0.1	3.8	324	0	0.0	0.0	1.1	213	1	0.5	0.0	2.6
	advice																														
	•				*	•	•	•	•	•				bject					•		•	•	•			•			*	•	
Drowsiness	All				75.0					59.9																			84.2	74.0	91.6
	Grade 2	113	43	38.1	29.1	47.7	74	23	31.1	20.8	42.9	123	60	48.8	39.7	58.0	66	28	42.4	30.3	3 55.2	112	54	48.2	38.7	57.9	76	27	35.5	24.9	47.3
	or 3																														

117119 (DTPA-HBV-IPV-135)

						lexa	gro	up							F	edia	gro	up							ı	Penta	gro	up			-ınaı
		٧	Vhite	e Cau	ıcasi	an			othe	r		٧	Vhite	Cau	casi	an			oth	er		٧	Vhite	e Ca	ucasi				othe		
					95	% CI				95	% CI				95	% CI				95	% CI				95	% CI				95	% CI
Symptom	Type	1	n	%	LL	UL		n				1			LL			n	%	LL	UL		n	%	LL	UL		n			UL
	Grade 3	113		7.1	3.1	13.5	74	3			11.4			11.4			66			2.5					7.0				10.5	4.7	19.7
	Related	113				87.4								88.6							96.6										91.6
	Grade 3 Related	113				13.5								10.6		17.4				2.5					6.3			8			19.7
	Medical advice	113		0.9			74			0.0		123		0.0			66			0.4		112			0.0					0.0	
Irritability / Fussiness	All	113	102	90.3	83.2	95.0	74							97.6					93.9	85.2	98.3	112	107	95.5	89.9	98.5	76	70	92.1	83.6	97.0
	Grade 2 or 3	113	64	56.6	47.0	65.9	74	32	43.2	31.8	55.3	123	85	69.1	60.1	77.1	66	43	65.2	52.4	76.5	112	72	64.3	3 54.7	73.1	76	48	63.2	51.3	73.9
	Grade 3	113	11	9.7	5.0	16.8	74	7	9.5	3.9	18.5	123	28	22.8	15.7	31.2	66	7	10.6	4.4	20.6	112	20	17.9	11.3	26.2	76	10	13.2	6.5	22.9
	Related	113	99	87.6	80.1	93.1	74	62	83.8	73.4	91.3	123	119	96.7	91.9	99.1	66	61	92.4	83.2	97.5	112	105	93.8	87.5	97.5	76	70	92.1	83.6	97.0
	Grade 3	113	11	9.7	5.0	16.8	74							22.0					10.6	4.4	20.6	112	20	17.9	11.3	26.2	76	10	13.2	6.5	22.9
	Related																														
	Medical advice	113	1	0.9	0.0	4.8	74	0	0.0	0.0	4.9	123	1	8.0	0.0	4.4	66	2	3.0	0.4	10.5	112	1	0.9	0.0	4.9	76	2	2.6	0.3	9.2
Loss Of Appetite	All	113	65	57.5	47.9	66.8	74	30	40.5	29.3	52.6	123	77	62.6	53.4	71.2	66	34	51.5	38.9	64.0	112	76	67.9	58.4	76.4	76	41	53.9	42.1	65.5
	Grade 2 or 3					22.0			16.2					18.7				9			24.3				5 13.5				21.1		
	Grade 3	113	1	0.9	0.0	4 8	74	1	1.4	0.0	7.3	123	3	2.4	0.5	7.0	66	0	0.0	0.0	5.4	112	3	27	0.6	76	76	3	3.9	8.0	11.1
	Related	113				64.2					51.2			61.0							1 62.6				57.4						65.5
	Grade 3 Related	113		0.9			74			0.0		123		2.4			66			0.0		112			0.6		76				11.1
	Medical advice	113	0	0.0	0.0	3.2	74	0	0.0	0.0	4.9	123	0	0.0	0.0	3.0	66	1	1.5	0.0	8.2	112	1	0.9	0.0	4.9	76	0	0.0	0.0	4.7
Temperature/(Rectally) (°C)	All	113	38	33.6	25.0	43.1	74	34	45.9	34.3	57.9	123	47	38.2	29.6	47.4	66	31	47.0	34.6	59.7	112	44	39.3	30.2	49.0	76	28	36.8	26.1	48.7
	>38.5	113	12			17.8			16.2		26.6			15.4	9.6	23.1	66	15	22.7	13.3	34.7	112	16	14.3	8.4	22.2	76	10			22.9
	>39.0	113	2	1.8	0.2	6.2	74	4	5.4	1.5	13.3	123	6	4.9	1.8	10.3	66	8	12.1	5.4	22.5	112	5	4.5	1.5	10.1	76	5	6.6	2.2	14.7
	>39.5	113				3.2		1			7.3	123					66			0.4		112		0.9	0.0	4.9	76	1			7.1
	>40.0	113	0	0.0	0.0	3.2	74		0.0	0.0	4.9	123	0	0.0	0.0	3.0	66	2	3.0	0.4		112		0.0	0.0	3.2	76	0	0.0	0.0	4.7
	Related	113	33	29.2	21.0	38.5	74	28	37.8	26.8	49.9	123	44	35.8	27.3	44.9	66	30	45.5	33.1	58.2	112	43	38.4	1 29.4	48.1	76	26	34.2	23.7	46.0
	>40.0 Related	113	0	0.0	0.0	3.2	74	0	0.0	0.0	4.9	123	0	0.0	0.0	3.0	66	2	3.0	0.4	10.5	112	0	0.0	0.0	3.2	76	0		0.0	

117119 (DTPA-HBV-IPV-135)

Report Final

						Hexa	grou	ıp							F	Pedia	gro	oup							F	Penta	gro	up			
		٧	Vhit	e Cau	ıcasi	an			othe	er			White	e Caı	ıcasi	an			othe	er		1	Nhit	e Caı	ucasi	an			oth	er	
					95	% CI				95 9	% CI				95	% CI				95	% CI				95	% CI				95	% CI
Symptom	Туре	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
	Medical	113	0	0.0	0.0	3.2	74	1	1.4	0.0	7.3	12	3 0	0.0	0.0	3.0	66	2	3.0	0.4	10.5	112	0	0.0	0.0	3.2	76	1	1.3	0.0	7.1
	advice																														

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

For each dose and overall/subject:

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the symptom at least once

For Overall/dose:

N = number of documented doses

n/% = number/percentage of doses followed by at least one type of symptom

Table 8.13 Percentage of doses with unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following priming doses (Primary Total vaccinated cohort)

			Hexa	grou	ıp		Pedia	grou	р	Per	ta gro	up
			N =	564			N =	567		1	l = 56	
					% CI				6 CI			% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)		%				%		UL		LL	UL
At least one symptom										143 25		
Blood and lymphatic system disorders (10005329)	Anaemia (10002034)		0.2		1.0		0.0		0.6			0.7
	Leukocytosis (10024378)		0.2				0.0		0.6			0.7
	Lymphadenopathy (10025197)		0.4				0.2		1.0			0.7
Cardiac disorders (10007541)	Cyanosis (10011703)		0.0		0.7		0.0		0.6			1.3
Congenital, familial and genetic disorders (10010331)	Congenital skin dimples (10072978)			0.0	0.7				1.5		0.0	
	Dermoid cyst (10012522)		0.0				0.2		1.0			0.7
	Hydrocele (10020488)	0	0.0	0.0	0.7	1	0.2	0.0	1.0		0.0	
	Hypospadias (10021093)	0	0.0	0.0	0.7	2	0.4	0.0	1.3	0.0	0.0	0.7
	Macrocephaly (10050183)		0.4		1.3	1	0.2		1.0		0.0	
	Plagiocephaly (10048586)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0.0	0.0	0.7
Ear and labyrinth disorders (10013993)	Cerumen impaction (10050337)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	2 0.4	0.0	1.3
	Ear disorder (10014004)	0	0.0	0.0	0.7	0	0.0	0.0	0.6	1 0.2	0.0	1.0
	Ear pain (10014020)		0.0	0.0	0.7	0	0.0	0.0	0.6	1 0.2	0.0	1.0
Eye disorders (10015919)	Dacryostenosis acquired (10053990)	2	0.4	0.0	1.3	1	0.2	0.0	1.0	0.0	0.0	0.7
Gastrointestinal disorders (10017947)	Abdominal pain upper (10000087)	0	0.0	0.0	0.7	1	0.2		1.0	0.0	0.0	0.7
	Anal fistula (10002156)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	0.0	0.0	0.7
	Constipation (10010774)	1	0.2	0.0	1.0	3	0.5	0.1	1.5	5 0.9	0.3	2.1
	Diarrhoea (10012735)	7	1.2	0.5	2.5	5		0.3				
	Flatulence (10016766)	1	0.2	0.0	1.0	0	0.0		0.6		0.0	
	Frequent bowel movements (10017367)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0.0	0.0	0.7
	Gastrooesophageal reflux disease (10017885)	0	0.0	0.0	0.7	8	1.4	0.6	2.8	1 0.2	0.0	1.0
	Inguinal hernia (10022016)	0	0.0	0.0	0.7	1	0.2		1.0		0.0	0.7
	Teething (10043183)	6	1.1	0.4	2.3	8	1.4	0.6	2.8	9 1.0	0.7	3.0
	Vomiting (10047700)	9	1.6	0.7				0.6			0.9	
	Vomiting projectile (10047708)	1	0.2		1.0		0.0		0.6			0.7
General disorders and administration site conditions (10018065)	Adverse drug reaction (10061623)		0.0		0.7		0.0		0.6			1.0
,	Crying (10011469)	1	0.2	0.0	1.0	1	0.2	0.0	1.0	0.0	0.0	0.7

117119 (DTPA-HBV-IPV-135)

			Hexa	grou = 564		ı	Pedia N =	grou = 567		Pen	ta gro	up
			14		, % CI		14 -		% CI	<u> </u>		% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%		UL		%		UL	n %		UL
	III-defined disorder (10061520)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0.0	0.0	0.7
	Injection site bruising (10022052)	2	0.4	0.0	1.3	2	0.4	0.0	1.3	5 0.9	0.3	2.1
	Injection site erythema (10022061)	4	0.7	0.2	1.8	2		0.0	1.3	5 0.9		
	Injection site induration (10022075)	3	0.5	0.1	1.5	0			0.6			0.7
	Injection site mass (10022081)	0		0.0	0.7	2	0.4	0.0	1.3	0.0	0.0	0.7
	Injection site pain (10022086)	5			2.1		1.4	0.6	2.8	7 1.2	0.5	2.5
	Injection site pruritus (10022093)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0.0	0.0	0.7
	Injection site rash (10022094)	1			1.0		0.0		0.6			1.3
	Injection site swelling (10053425)	4	0.7	0.2	1.8	1	0.2	0.0	1.0	4 0.7	7 0.2	1.8
	Injection site warmth (10022112)	0		0.0	0.7	2	0.4	0.0	1.3	0.0	0.0	0.7
	Oedema peripheral (10030124)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0.0	0.0	0.7
	Peripheral swelling (10048959)	0	0.0	0.0	0.7		0.5	0.1	1.5	0.0	0.0	0.7
	Pyrexia (10037660)	13	2.3	1.2	3.9	6	1.1	0.4	2.3	16 2.8	3 1.6	4.6
	Swelling (10042674)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0.0	0.0	0.7
	Vaccination site bruising (10069484)	0	0.0	0.0	0.7	3	0.5	0.1	1.5	1 0.2	0.0	1.0
	Vaccination site erythema (10059079)	2	0.4	0.0	1.3	4	0.7	0.2	1.8	3 0.5	5 0.1	1.5
	Vaccination site induration (10065117)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0.0	0.0	0.7
	Vaccination site pain (10068879)	2	0.4	0.0	1.3	1	0.2	0.0	1.0	3 0.5	0.1	1.5
	Vaccination site swelling (10069620)	3	0.5	0.1	1.5	1		0.0	1.0	2 0.4	1 0.0	1.3
Immune system disorders (10021428)	Food allergy (10016946)	0	0.0	0.0	0.7	1	0.2	0.0	1.0			0.7
· · · · · · · · · · · · · · · · · · ·	Milk allergy (10027633)	0	0.0	0.0	0.7	0	0.0	0.0	0.6	1 0.2	0.0	1.0
Infections and infestations (10021881)	Acute sinusitis (10001076)	0			0.7	1	0.2	0.0	1.0	0.0	0.0	0.7
. ,	Anal abscess (10048946)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	0.0	0.0	0.7
	Bronchiolitis (10006448)	3	0.5	0.1	1.5	0	0.0		0.6		0.0	1.0
	Bronchitis (10006451)	1	0.2						0.6	0.0	0.0	0.7
	Candida infection (10074170)	2	0.4	0.0	1.3			0.0	1.3			0.7
	Candida nappy rash (10007135)	0	0.0	0.0	0.7	1	0.2		1.0	0.0	0.0	0.7
	Cellulitis (10007882)	1	0.2	0.0	1.0				0.6		0.0	1.0
	Conjunctivitis (10010741)	10				8	1.4		2.8	1 0.2		1.0
	Conjunctivitis bacterial (10061784)	0	0.0			1	0.2		1.0			
	Conjunctivitis viral (10010755)	0			0.7				0.6			
	Croup infectious (10011416)	2			1.3			0.0	1.3			

117119 (DTPA-HBV-IPV-135)

		1										ort F	
			Hexa				Pedia				Penta		
			N:	564			N =	= 567			N =	565	
					% CI		1		% CI				% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%		UL		%		UL				UL
	Ear infection (10014011)	0			0.7				0.6				1.0
	Eczema herpeticum (10014197)	0			0.7				0.6				1.0
	Exanthema subitum (10015586)	0			0.7				1.0			0.0	
	Fungal infection (10017533)	0			0.7				0.6				1.0
	Fungal skin infection (10017543)	1			1.0			0.0	1.0				0.7
	Gastric infection (10056663)	0	0.0					0.0	1.0				0.7
	Gastroenteritis (10017888)	1			1.0				1.3				1.0
	Hand-foot-and-mouth disease (10019113)	1			1.0				1.0				1.0
	Herpangina (10019936)	2			1.3				0.6				0.7
	Impetigo (10021531)	1			1.0				0.6			0.1	1.5
	Influenza (10022000)	0			0.7			0.0	1.0			0.0	0.7
	Nasopharyngitis (10028810)	3			1.5			0.0	1.0				1.5
	Oral candidiasis (10030963)	0			0.7			0.0	1.0	1			1.0
	Otitis externa (10033072)	0			0.7		0.2	0.0	1.0				0.7
	Otitis media (10033078)	9			3.0				2.5			0.7	3.0
	Otitis media acute (10033079)	1	0.2	0.0	1.0	2	0.4	0.0	1.3	0		0.0	0.7
	Otitis media chronic (10033081)	0	0.0	0.0	0.7	0	0.0	0.0	0.6	1	0.2		1.0
	Parainfluenzae virus infection (10061907)	0	0.0	0.0	0.7	0	0.0		0.6	1	0.2	0.0	1.0
	Pertussis (10034738)	0	0.0	0.0	0.7	0			0.6	1	0.2	0.0	1.0
	Pharyngitis (10034835)	2	0.4	0.0	1.3	0	0.0	0.0	0.6	0	0.0	0.0	0.7
	Pneumonia (10035664)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	0	0.0	0.0	0.7
	Respiratory syncytial virus bronchiolitis (10038718)	1	0.2		1.0		0.0	0.0	0.6	0	0.0	0.0	0.7
	Respiratory syncytial virus infection (10061603)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	0	0.0	0.0	0.7
	Respiratory tract infection (10062352)	1			1.0				0.6		0.0	0.0	0.7
	Rhinitis (10039083)	0			0.7		0.0		0.6		0.2	0.0	
	Roseola (10039222)	0			0.7				1.0				0.7
	Sinusitis (10040753)	0			0.7				0.6				1.0
	Skin candida (10054152)	1			1.0				0.6				1.0
	Upper respiratory tract infection (10046306)				7.9				6.6		4.8		
	Urinary tract infection (10046571)	0			0.7			0.0	1.3				1.0
	Viraemia (10058874)	0			0.7					1			1.0

117119 (DTPA-HBV-IPV-135)

			Hexa	grou = 564			Pedia	a gro			Penta		
			14		% CI		11		% CI		14		, % CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%		UL		%	LL	UL		%		UL
· · · · · · · · · · · · · · · · · · ·		2	0.4	0.0	1.3	1	0.2	0.0	1.0	3	0.5	0.1	1.5
	Viral rash (10047476)	3	0.5	0.1	1.5	0	0.0	0.0	0.6	3	0.5	0.1	1.5
	Viral upper respiratory tract infection (10047482)	0	0.0	0.0	0.7	0	0.0	0.0	0.6	2	0.4	0.0	1.3
Injury, poisoning and procedural complications (10022117)	Arthropod bite (10003399)	2	0.4	0.0	1.3	1	0.2	0.0	1.0	0	0.0	0.0	0.7
	Arthropod sting (10003402)	1	0.2	0.0	1.0	0		0.0	0.6	0	0.0	0.0	0.7
	Clavicle fracture (10009245)	0		0.0			0.2	0.0	1.0	0		0.0	0.7
	Concussion (10010254)	0	0.0					0.0	1.0		0.0	0.0	0.7
	Corneal abrasion (10010984)	1		0.0					0.6			0.0	0.7
	Craniocerebral injury (10070976)	0		0.0	0.7	1		0.0	1.0			0.0	0.7
	Fall (10016173)	0	0.0	0.0	0.7	0			0.6			0.0	1.0
	Foreign body (10070245)	0	0.0	0.0	0.7	0	0.0	0.0	0.6	1	0.2	0.0	1.0
	Head injury (10019196)	0	0.0	0.0	0.7	0	0.0	0.0	0.6	2	0.4	0.0	1.3
	Nasal injury (10078651)	0	0.0	0.0	0.7	0	0.0	0.0	0.6	1	0.2	0.0	1.0
	Thermal burn (10053615)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0	0.0	0.0	0.7
Investigations (10022891)		1	0.2	0.0	1.0	0			0.6				1.0
	Cardiac murmur (10007586)	0	0.0	0.0	0.7	0	0.0	0.0	0.6	1	0.2	0.0	1.0
	Weight decreased (10047895)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	1	0.2	0.0	1.0
Musculoskeletal and connective tissue disorders (10028395)	Asymmetric gluteal fold (10072189)	1	0.2	0.0	1.0	0		0.0	0.6	0		0.0	0.7
	Pain in extremity (10033425)	2		0.0				0.0	0.6				1.0
	Positional plagiocephaly (10068711)	0	0.0	0.0	0.7	1		0.0	1.0	0	0.0	0.0	0.7
Neoplasms benign, malignant and unspecified (incl cysts and polyps) (10029104)	Haemangioma (10018814)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	0	0.0	0.0	0.7
Nervous system disorders (10029205)	Hyperreflexia (10020745)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0	0.0	0.0	0.7
		1	0.2	0.0	1.0	0	0.0	0.0	0.6	0	0.0	0.0	0.7
		1	0.2	0.0	1.0	0			0.6	0	0.0	0.0	0.7
		0	0.0						1.0				0.7
Psychiatric disorders (10037175)	Irritability (10022998)	5		0.3				0.1	1.5		0.2	0.0	1.0
		0	0.0	0.0	0.7	1	0.2	0.0	1.0	0	0.0	0.0	0.7
Renal and urinary disorders (10038359)	Urethral meatus stenosis (10058463)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0	0.0		0.7
Reproductive system and breast disorders (10038604)		2	0.4						0.6		0.0		0.7
		0	0.0	0.0	0.7	1	0.2		1.0	0	0.0	0.0	0.7
		3	0.5		1.5		0.5		1.5		0.0		

117119 (DTPA-HBV-IPV-135)

		1								1			Fina
			Hexa				Pedia	•	•		Penta		
			N =	= 564			N:	= 567			N =	565	
	T				% CI	_			% CI				% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL		%	LL	UL				UL
	Penile erythema (10070655)	0		0.0				0.0	0.6				1.0
Respiratory, thoracic and mediastinal disorders (10038738)	Apparent life threatening event (10065044)	1		0.0			0.0	0.0	0.6	0			0.7
	Bronchial hyperreactivity (10066091)	2		0.0				0.0	0.6				0.7
	Cough (10011224)	16	2.8		4.6								2.5
	Dysphonia (10013952)	1		0.0				0.0	1.0				0.7
	Epistaxis (10015090)	0		0.0					0.6			0.0	1.0
	Nasal congestion (10028735)	2		0.0			1.1		2.3				1.3
	Respiratory arrest (10038669)	0		0.0					1.0				0.7
	Respiratory disorder (10038683)	1		0.0				0.0	1.3				1.0
	Rhinitis allergic (10039085)	0		0.0				0.0	1.0			0.0	0.7
	Rhinorrhoea (10039101)	3	0.5	0.1	1.5	2		0.0	1.3	4	0.7	0.2	1.8
	Sinus congestion (10040742)	1		0.0			0.0	0.0	0.6			0.0	0.7
	Sneezing (10041232)	1	0.2	0.0	1.0	0		0.0	0.6	0		0.0	0.7
	Upper respiratory tract congestion (10052252)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	1	0.2	0.0	1.0
	Wheezing (10047924)	3	0.5		1.5		0.0	0.0	0.6	2	0.4	0.0	1.3
Skin and subcutaneous tissue disorders (10040785)	Dermatitis (10012431)	3	0.5	0.1	1.5	1	0.2	0.0	1.0	0	0.0	0.0	0.7
	Dermatitis atopic (10012438)	2	0.4	0.0	1.3	3	0.5	0.1	1.5	5	0.9	0.3	2.1
	Dermatitis contact (10012442)	1	0.2	0.0	1.0	2		0.0	1.3	0	0.0	0.0	0.7
	Dermatitis diaper (10012444)	2	0.4	0.0	1.3	3	0.5		1.5	10	1.8	0.9	3.2
	Dry skin (10013786)	1	0.2	0.0	1.0	1	0.2	0.0	1.0	0	0.0	0.0	0.7
	Eczema (10014184)	4	0.7	0.2	1.8	5	0.9	0.3	2.0	4	0.7	0.2	1.8
	Erythema (10015150)	0	0.0	0.0	0.7	3	0.5	0.1	1.5	0		0.0	0.7
	Hair growth abnormal (10019044)	1		0.0				0.0	0.6	0	0.0	0.0	0.7
	Hypertrichosis (10020864)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0		0.0	0.7
	Intertrigo (10022622)	0	0.0	0.0	0.7	0	0.0	0.0	0.6	1	0.2	0.0	1.0
	Post inflammatory pigmentation change	1		0.0			0.0	0.0	0.6	0	0.0	0.0	0.7
	(10036229)												
	Rash (10037844)	4	0.7	0.2	1.8	4	0.7	0.2	1.8	6	1.1	0.4	2.3
	Rash macular (10037867)	0		0.0				0.0	0.6				1.0
	Seborrhoea (10039792)	1		0.0				0.0	1.0				1.0
	Seborrhoeic dermatitis (10039793)	3			1.5			0.0	1.0				0.7
	Urticaria (10046735)	0			0.7		0.2		1.0				0.7

117119 (DTPA-HBV-IPV-135) Report Final

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines
Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines
Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine
At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)
N = number of administered doses
n/% = number/percentage of doses with the symptom
95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 8.14 Percentage of doses with grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following priming doses (Primary Total vaccinated cohort)

		Н	exa N =	gro 56	•	P	edia N =	gro = 56	•	P		gre = 56	
					5% Cl				5% Cl				5% Cl
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%		UL	n	%	LL		n	%		UL
At least one symptom	,						2.1					0.6	2.8
Gastrointestinal disorders (10017947)	Abdominal pain upper (10000087)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0	0.0	0.0	0.7
	Diarrhoea (10012735)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	0	0.0	0.0	0.7
	Teething (10043183)	1	0.2	0.0	1.0								1.0
	Vomiting (10047700)	2	0.4	0.0	1.3	0	0.0						
General disorders and administration site conditions (10018065)	Crying (10011469)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	0	0.0	0.0	0.7
·	Ill-defined disorder (10061520)	0					0.2	0.0	1.0	0	0.0	0.0	0.7
	Injection site erythema (10022061)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0	0.0	0.0	0.7
	Injection site pain (10022086)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	1	0.2	0.0	1.0
	, , , ,	0	0.0										0.7
	Injection site warmth (10022112)	0			0.7								0.7
	Pyrexia (10037660)	2			1.3		0.0	0.0	0.6	1	0.2	0.0	1.0
Infections and infestations (10021881)	Bronchiolitis (10006448)	1			1.0		0.0						
,	Conjunctivitis (10010741)	0	0.0										0.7
	Croup infectious (10011416)	0	0.0										0.7
	Gastroenteritis (10017888)	1					0.0						
	Hand-foot-and-mouth disease (10019113)	1	0.2	0.0	1.0	1	0.2	0.0	1.0	0	0.0	0.0	0.7
	Nasopharyngitis (10028810)	0	0.0	0.0	0.7	0	0.0	0.0	0.6	1	0.2	0.0	1.0
	Otitis media (10033078)	3	0.5	0.1	1.5	1							1.0
	Pharyngitis (10034835)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	0	0.0	0.0	0.7
	Respiratory syncytial virus bronchiolitis (10038718)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	0	0.0	0.0	0.7
	Respiratory syncytial virus infection (10061603)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	0	0.0	0.0	0.7
	Rhinitis (10039083)	0	0.0	0.0	0.7	0	0.0	0.0	0.6	1	0.2	0.0	1.0
		0					0.0						
	Upper respiratory tract infection (10046306)	3					0.4						
Psychiatric disorders (10037175)	Irritability (10022998)	0	0.0	0.0	0.7	2	0.4	0.0	1.3	0	0.0	0.0	0.7
Respiratory, thoracic and mediastinal disorders (10038738)	Bronchial hyperreactivity (10066091)	1					0.0						
, ,	Cough (10011224)	0	0.0	0.0	0.7	0	0.0	0.0	0.6	1	0.2	0.0	1.0
	Respiratory arrest (10038669)	0	0.0				0.2	0.0	1.0	0	0.0	0.0	0.7
	Upper respiratory tract congestion (10052252)		0.0										1.0
	Wheezing (10047924)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	0	0.0	0.0	0.7

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term) N = number of administered doses

n/% = number/percentage of doses with the symptom

Table 8.15 Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship to vaccination, within the 31-day (Days 0-30) post-vaccination period following priming doses (Primary Total vaccinated cohort)

		I	Hexa N =	gro = 19		F	Pedia N =	gro = 194	•		Pent	a gro = 196	
			- 14		% CI		- 14		% CI		- 14		, % CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%		UL		%			n	%	LL	UL
At least one symptom		24	12.3	8.0	17.8	28	14.4	9.8	20.2	34	17.3	12.3	23.4
Blood and lymphatic system disorders (10005329)	Leukocytosis (10024378)	1	0.5					0.0			0.0	0.0	1.9
Gastrointestinal disorders (10017947)	Constipation (10010774)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1	0.5	0.0	2.8
	Diarrhoea (10012735)	1	0.5	0.0	2.8	2	1.0	0.1	3.7	3	1.5	0.3	4.4
	Flatulence (10016766)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	1	0.5	0.0	2.8
	Vomiting (10047700)	3	1.5	0.3	4.4	3				3	1.5	0.3	4.4
General disorders and administration site conditions (10018065)	III-defined disorder (10061520)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0	0.0	0.0	1.9
,	Injection site bruising (10022052)	2	1.0			2		0.1		4	2.0	0.6	5.1
	Injection site erythema (10022061)	4	2.1	0.6	5.2	2	1.0	0.1	3.7	5	2.6	8.0	5.9
	Injection site induration (10022075)	3	1.5		4.4			0.0			0.0	0.0	1.9
	Injection site mass (10022081)	0	0.0			2		0.1			0.0	0.0	1.9
	Injection site pain (10022086)	4	2.1		5.2	6	3.1				3.6	1.4	7.2
	Injection site pruritus (10022093)	0	0.0		1.9	1		0.0			0.0	0.0	1.9
	Injection site rash (10022094)	1	0.5		2.8			0.0		2	1.0	0.1	3.6
	Injection site swelling (10053425)	4	2.1		5.2	1		0.0			2.0	0.6	5.1
	Injection site warmth (10022112)	0	0.0	0.0	1.9	2	1.0	0.1	3.7	0	0.0	0.0	1.9
	Oedema peripheral (10030124)	0	0.0	0.0	1.9			0.0			0.0	0.0	1.9
	Peripheral swelling (10048959)	0	0.0		1.9	1	0.5	0.0	2.8	0	0.0	0.0	1.9
	Pyrexia (10037660)	1						0.0		3	1.5	0.3	4.4
	Swelling (10042674)					1					0.0	0.0	1.9
	Vaccination site bruising (10069484)		0.0			2		0.1			0.5	0.0	2.8
	Vaccination site erythema (10059079)		0.5								1.5	0.3	4.4
	Vaccination site induration (10065117)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0	0.0	0.0	1.9

117119 (DTPA-HBV-IPV-135) Report Final

			Llova	ara	n		Jod:-						rilla
			Hexa	gro = 19:	•	'	Pedia N :	i gro = 19	•			a gro = 19	•
			14 .		յ % CI		14 -		+ % CI		14		о % СІ
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%		UL	n	%		UL	n	%	LL	UL
	Vaccination site pain (10068879)	2	1.0	0.1	3.7	1	0.5	0.0	2.8	3	1.5	0.3	4.4
	Vaccination site swelling (10069620)	3	1.5		4.4	1	0.5	0.0	2.8	2	1.0	0.1	3.6
Infections and infestations (10021881)	Nasopharyngitis (10028810)	1	0.5		2.8	0	0.0		1.9	0	0.0	0.0	1.9
	Upper respiratory tract infection (10046306)	0	0.0		1.9	0	0.0		1.9	1	0.5	0.0	2.8
	Viral rash (10047476)	0	0.0		1.9	0	0.0		1.9	1	0.5	0.0	2.8
Musculoskeletal and connective tissue disorders (10028395)	Pain in extremity (10033425)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0	0.0	0.0	1.9
Nervous system disorders (10029205)	Hyperreflexia (10020745)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0	0.0	0.0	1.9
	Lethargy (10024264)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0	0.0	0.0	1.9
	Poor quality sleep (10062519)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0	0.0	0.0	1.9
Psychiatric disorders (10037175)	Irritability (10022998)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0	0.0	0.0	1.9
Respiratory, thoracic and mediastinal disorders (10038738)	Apparent life threatening event (10065044)	1	0.5		2.8	0	0.0		1.9	0	0.0	0.0	1.9
	Cough (10011224)	1	0.5		2.8	1	0.5		2.8	1	0.5	0.0	2.8
	Nasal congestion (10028735)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	1	0.5	0.0	2.8
	Respiratory arrest (10038669)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0	0.0	0.0	1.9
	Rhinorrhoea (10039101)	0	0.0	0.0	1.9	1	0.5		2.8	1	0.5	0.0	2.8
Skin and subcutaneous tissue disorders (10040785)	Erythema (10015150)	0	0.0		1.9	1	0.5		2.8	0	0.0	0.0	1.9
	Rash (10037844)	0	0.0	0.0	1.9	2	1.0	0.1	3.7	2	1.0	0.1	3.6

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Table 8.16 Percentage of doses with unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship to vaccination, within the 31-day (Days 0-30) post-vaccination period following priming doses (Primary Total vaccinated cohort)

Primary System Organ Class (CODE)			Н	exa N =	gro 56		P		gro = 56	oup	Pe	enta N =		oup 5
Primary System Organ Class (CODE)								-				-		5%
At least one symptom Leukocytosis (10024378) 1					_									CI
Blood and lymphatic system disorders (10005329) Leukocytosis (10024378) 1	(CODE)	Preferred Term (CODE)												UL
Gastrointestinal disorders (10017947) Diarrhoea (10012735) Constipation (10010774) Color Constipation (10010774) Color Constipation (10010774) Constipation (100107774) Constitation (1001077774) Constitation (10010777774) Constitation (10010777774) Constitation (1001077774) Constitation (1001077774) Constitation (1001077774) Constitation (1001077774) Constitation (10010777774) Constitation (1001077774) Constitation (1001077774) Constita														
Diarrhoea (10012735)	disorders (10005329)													
Flatulence (10016766)		,												
Vomiting (10047700) 3 0.5 0.1 1.5 3 0.5 0.1 1.5 3 0.5 0.1 0.0														
Ceneral disorders and administration site conditions (10018065) Injection site bruising (10022052) 2														
administration site conditions (10018065) Injection site bruising (10022052) 2														
Injection site erythema (10022061)	administration site conditions	III-defined disorder (10061520)										0.0	0.0	0.7
Injection site induration (10022075) 3 0.5 0.1 1.5 0 0.0														
Injection site mass (10022081)								0.4	0.0	1.3	5			
Injection site pain (10022086) 5 0.9 0.3 2.1 8 1.4 0.6 2.8 7 1.2 0.5 0.5 0								0.0	0.0	0.6	0	0.0	0.0	0.7
Injection site pruritus (10022093)														
Injection site rash (10022094)														
Injection site swelling (10053425)														
Injection site warmth (10022112)														
Oedema peripheral (10030124) 0 0.0 0.0 0.7 1 0.2 0.0 1.0 0 0.0 0.0 0.7 1 0.2 0.0 1.0 0 0.0														
Peripheral swelling (10048959)														
Pyrexia (10037660)														
Swelling (10042674)														
Vaccination site bruising (10069484) 0 0.0 0.0 0.7 3 0.5 0.1 1.5 1 0.2 0.0 Vaccination site erythema (10059079) 1 0.2 0.0 1.0 4 0.7 0.2 1.8 3 0.5 0.7 Vaccination site induration (10065117) 0.0 0.0 0.0 0.7 1 0.2 0.0 1.0 0 0.0 0.0 0.7 1 0.2 0.0 1.0 0 0.0 0.0 0.7 1 0.2 0.0 1.0 0 0.0 0.0 0.0 0.7 1 0.2 0.0 1.0 0 0.0 0														
Vaccination site erythema (10059079) 1 0.2 0.0 1.0 4 0.7 0.2 1.8 3 0.5 0.7 Vaccination site induration (10065117) 0 0.0 0.0 0.0 0.7 1 0.2 0.0 1.0 0 0.0 0.0 0.7 1 0.2 0.0 1.0 0 0.0 <td></td>														
(10059079) Vaccination site induration (10065117) Vaccination site pain (10068879) Vaccination site pain (10069620) Vaccination site swelling (10069620) Vaccinations Vaccination site swelling (10069620) Vaccination site swelling (10028810) Vaccinations								0.5	0.1	1.5	1			
(10065117)		(10059079)												
Vaccination site swelling (10069620) 3 0.5 0.1 1.5 1 0.2 0.0 1.0 2 0.4 0.0 Infections and infestations Nasopharyngitis (10028810) 1 0.2 0.0 1.0 0 0.0 0.0 0.6 0 0.0 0.0		(10065117)												
Infections and infestations Nasopharyngitis (10028810) 1 0.2 0.0 1.0 0 0.0 0.0 0.6 0 0.0 0.0			2	0.4	0.0	1.3	1	0.2	0.0	1.0	3			
	Infections and infestations (10021881)													
Upper respiratory tract infection 0 0.0 0.0 0.7 0 0.0 0.0 0.6 1 0.2 0.0 (10046306)		(10046306)												
Viral rash (10047476) 0 0.0 0.0 0.7 0 0.0 0.0 0.6 1 0.2 0.0		Viral rash (10047476)	0	0.0	0.0	0.7	0	0.0	0.0	0.6	1	0.2	0.0	1.0

117119 (DTPA-HBV-IPV-135)

Report Final

										170	-po		IIIai
		Н	exa N =	gro 56	-	P	edia N =	gro = 56	•	P	enta N =	gro 56	•
					5%				5%			9	5%
Primary System Organ Class	Preferred Term (CODE)	n	%		UL UL	n	%	LL	UL UL	n	%		UL
(CODE) Musculoskeletal and connective tissue disorders (10028395)	Pain in extremity (10033425)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	0	0.0	0.0	0.7
Nervous system disorders (10029205)	Hyperreflexia (10020745)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0	0.0	0.0	0.7
	Lethargy (10024264)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	0	0.0	0.0	0.7
	Poor quality sleep (10062519)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	0	0.0	0.0	0.7
Psychiatric disorders (10037175)	Irritability (10022998)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0	0.0	0.0	0.7
Respiratory, thoracic and mediastinal disorders (10038738)	Apparent life threatening event (10065044)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	0	0.0	0.0	0.7
,	Cough (10011224)	1	0.2	0.0	1.0	1	0.2	0.0	1.0	1	0.2	0.0	1.0
	Nasal congestion (10028735)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	1	0.2	0.0	1.0
	Respiratory arrest (10038669)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0	0.0	0.0	0.7
	Rhinorrhoea (10039101)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	1	0.2	0.0	1.0
Skin and subcutaneous tissue disorders (10040785)	Erythema (10015150)	0	0.0				0.2	0.0	1.0	0			0.7
	Rash (10037844)	0	0.0	0.0	0.7	2	0.4	0.0	1.3	2	0.4	0.0	1.3

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of administered doses

n/% = number/percentage of doses with the symptom

117119 (DTPA-HBV-IPV-135) Report Final

Table 8.17 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship to vaccination, within the 31-day (Days 0-30) post-vaccination period following priming doses (Primary Total vaccinated cohort)

		Н		gro = 19	•	P		a gro = 19	•	P		a gro	oup 6
					5%				· %				5%
				,				C				,	Cl
Primary System Organ Class (CODE)	Preferred Term (CODE)							LL					
At least one symptom		1	0.5	0.0	2.8	4	2.1	0.6	5.2	1	0.5	0.0	2.8
Gastrointestinal disorders (10017947)	Vomiting (10047700)	1	0.5	0.0	2.8	0	0.0	0.0	1.9	0	0.0	0.0	1.9
General disorders and administration site	III-defined disorder	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0	0.0	0.0	1.9
conditions (10018065)	(10061520)												
	Injection site erythema	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0	0.0	0.0	1.9
	(10022061)												
	Injection site pain	0	0.0	0.0	1.9	1	0.5	0.0	2.8	1	0.5	0.0	2.8
	(10022086)												
	Injection site swelling	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0	0.0	0.0	1.9
	(10053425)												
	Injection site warmth	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0	0.0	0.0	1.9
	(10022112)												
Psychiatric disorders (10037175)	Irritability (10022998)	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0	0.0	0.0	1.9
Respiratory, thoracic and mediastinal disorders	Respiratory arrest	0	0.0	0.0	1.9	1	0.5	0.0	2.8	0	0.0	0.0	1.9
(10038738)	(10038669)												

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Table 8.18 Percentage of doses with grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship to vaccination, within the 31-day (Days 0-30) post-vaccination period following priming doses (Primary Total vaccinated cohort)

		Н		gro = 56	•	P		a gro = 56	•	P		a gr = 56	oup 55
					5%				%				5%
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	,	UL UL	n	%		UL.	n	%	,	UL UL
At least one symptom	(0022)												1.0
Gastrointestinal disorders (10017947)	Vomiting (10047700)	1	0.2	0.0	1.0	0	0.0	0.0	0.6	0	0.0	0.0	0.7
General disorders and administration site conditions (10018065)	III-defined disorder (10061520)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0	0.0	0.0	0.7
, ,	Injection site erythema (10022061)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0	0.0	0.0	0.7
	Injection site pain (10022086)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	1	0.2	0.0	1.0
	Injection site swelling (10053425)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0	0.0	0.0	0.7
	Injection site warmth (10022112)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0	0.0	0.0	0.7
Psychiatric disorders (10037175)	Irritability (10022998)	0	0.0	0.0	0.7	1	0.2	0.0	1.0	0	0.0	0.0	0.7
Respiratory, thoracic and mediastinal disorders (10038738)	Respiratory arrest (10038669)	0	0.0	0.0			0.2		1.0			0.0	0.7

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of administered doses

n/% = number/percentage of doses with the symptom

Table 8.19 Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term, within the 31-day (Days 0-30) post-vaccination period following priming doses – by gender (Primary Total vaccinated cohort)

					Hexa	gro	up					F	Pedia	gro	oup					F	Penta	gr	oup		
				male			N	lale			Fe	male			N	lale				male				/lale	
			N	= 10			N	= 94			N	= 80			N	= 114			N	= 95			N	= 101	
					% CI			_	6 CI			_	% CI				% CI				% CI				% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)		%	LL	UL	n		LL			%			n			UL		%	LL	UL				UL
At least one symptom		57																	46.3	36.0	56.8	52	51.5	41.3	61.6
Blood and lymphatic system disorders (10005329)	Anaemia (10002034)	1									0.0								0.0	0.0	3.8				3.6
	Leukocytosis (10024378)	1		0.0	5.4				3.8			0.0				0.0			0.0	0.0	3.8				3.6
	Lymphadenopathy (10025197)			0.2	7.0			0.0				0.0	4.5						0.0	0.0	3.8				3.6
Cardiac disorders (10007541)			0.0	0.0	3.6							0.0	4.5						2.1	0.3		0			3.6
Congenital, familial and genetic disorders (10010331)	(10072978)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	3	2.6	0.5	7.5	1	1.1	0.0	5.7	0	0.0	0.0	3.6
			0.0	0.0	3.6				3.8	0	0.0	0.0	4.5	1		0.0	4.8	0	0.0	0.0	3.8		0.0	0.0	3.6
			0.0	0.0	3.6							0.0	4.5				4.8		0.0	0.0	3.8	0			3.6
	Hypospadias (10021093)		0.0	0.0	3.6					0		0.0	4.5						0.0	0.0	3.8	0			3.6
	Macrocephaly (10050183)	1	1.0	0.0	5.4		1.1		5.8	1		0.0	6.8		0.0		3.2		0.0	0.0	3.8	0	0.0	0.0	3.6
	Plagiocephaly (10048586)		0.0	0.0	3.6				3.8			0.0	4.5			0.0			0.0	0.0	3.8				3.6
Ear and labyrinth disorders (10013993)	Cerumen impaction (10050337)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	1	1.3	0.0	6.8	0	0.0	0.0	3.2	1	1.1	0.0	5.7	1	1.0	0.0	5.4
	Ear disorder (10014004)		0.0	0.0	3.6	0				0		0.0	4.5	0		0.0		0	0.0	0.0	3.8	1	1.0	0.0	5.4
			0.0	0.0	3.6							0.0	4.5	0			3.2		1.1	0.0	5.7				3.6
Eye disorders (10015919)	Dacryostenosis acquired (10053990)	0	0.0	0.0	3.6	2	2.1	0.3	7.5	0	0.0	0.0	4.5	1	0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
Gastrointestinal disorders (10017947)	Abdominal pain upper (10000087)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	1	1.3	0.0	6.8	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
			0.0	0.0	3.6	1	1.1		5.8			0.0	4.5	0	0.0		3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Constipation (10010774)		0.0	0.0	3.6	1	1.1			2		0.3	8.7				3.2	1	1.1	0.0		4	4.0	1.1	9.8
	Diarrhoea (10012735)	3		0.6	8.4				9.0	1	1.3	0.0	6.8	4	3.5	1.0	8.7	6	6.3	2.4	13.2	2 4	4.0	1.1	9.8
	Flatulence (10016766)	1	1.0	0.0	5.4	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	1	1.1	0.0	5.7	0	0.0	0.0	3.6

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	oun					F	Pedia g	roun						Penta	ar		JUIL	Final
				male = 10)	gic	· N	/lale = 94				male = 80)		Male	1			male = 95)	gi	٠ ١	Male = 10 ⁻	1
			IN		ı % CI		IN	-	% CI		IN		% CI	<u> </u>		4 % CI		- 1		% CI		IN		<u>'</u> % CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%				%			%	LL	UL		%	LL	UL		%		UL
,	Frequent bowel movements (10017367)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	1	1.3	0.0	6.8 0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	disease (10017885)												10.6 5									1.0		
	<u> </u>			0.0									4.5 1		0.0					3.8				3.6
					8.4								8.7 6		2.0				1.2					11.2
	, , , , , , , , , , , , , , , , , , ,		4.0		9.8								12.3 4						1.2					12.5
	Vomiting projectile (10047708)		0.0		3.6			0.0	5.8	0	0.0	0.0	4.5 0	0.0	0.0				0.0	3.8				3.6
General disorders and administration site conditions (10018065)	Adverse drug reaction (10061623)	0	0.0	0.0	3.6								4.5 0					0.0	0.0	3.8		1.0	0.0	5.4
	Crying (10011469)			0.0				0.0					6.8 0					0.0	0.0					3.6
	III-defined disorder (10061520)	0	0.0		3.6								4.5 1											
	(10022052)			0.2									4.5 2		0.2	6.2	0	0.0	0.0	3.8	5	5.0	1.6	11.2
	Injection site erythema (10022061)	2	2.0	0.2	7.0	2	2.1	0.3	7.5	1	1.3	0.0	6.8 1	0.9	0.0	4.8	4	4.2	1.2	10.4	1	1.0	0.0	5.4
	Injection site induration (10022075)	2	2.0	0.2	7.0	1	1.1	0.0	5.8	0	0.0	0.0	4.5 0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Injection site mass (10022081)												6.8 1		0.0								0.0	3.6
	Injection site pain (10022086)	3		0.6				0.0					12.3 2						0.3	7.4	5	5.0	1.6	11.2
	Injection site pruritus (10022093)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	1	1.3	0.0	6.8 0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Injection site rash (10022094)	0	0.0	0.0	3.6								4.5 0		0.0	3.2	1	1.1	0.0	5.7	1	1.0	0.0	5.4
	Injection site swelling (10053425)	3	3.0	0.6	8.4	1	1.1	0.0	5.8	0	0.0	0.0	4.5 1	0.9	0.0	4.8	3	3.2	0.7	9.0	1	1.0	0.0	5.4
	(10022112)												4.5 2							3.8		0.0		
	(10030124)			0.0									6.8 0					0.0	0.0			0.0		
	Peripheral swelling (10048959)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	3	3.8	8.0	10.6 0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	าเมา						Pedia	a ara	วเมต					F	Penta	ar		JOIL	Finai
			Fe	male		9.4		/lale			Fe	male		, g. \		/lale			Fe	male		9.		/lale	
				= 10				= 94				= 80				= 114	4			= 95				= 10°	1
				959	% CI			95	% CI			959	% CI			95	% CI			959	% CI			959	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%				%	LL	UL	n		LL	UL			LL	UL			LL	UL
	Pyrexia (10037660)						9.6					0.0	6.8	4	3.5		8.7		7.4	3.0			7.9	3.5	15.0
	Swelling (10042674)	0	0.0		3.6				3.8			0.0					3.2		0.0	0.0	3.8				3.6
	Vaccination site bruising (10069484)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	2	1.8	0.2	6.2	1	1.1	0.0	5.7	0	0.0	0.0	3.6
	Vaccination site erythema (10059079)	0	0.0	0.0	3.6	2	2.1	0.3	7.5	2	2.5	0.3	8.7	2	1.8	0.2	6.2	3	3.2	0.7	9.0	0	0.0	0.0	3.6
	Vaccination site induration (10065117)										0.0				0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Vaccination site pain (10068879)	2	2.0	0.2	7.0	0	0.0	0.0	3.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	2	2.1	0.3	7.4	1	1.0	0.0	5.4
	Vaccination site swelling (10069620)	1	1.0	0.0	5.4	2	2.1	0.3	7.5	0	0.0	0.0	4.5	1	0.9	0.0	4.8	1	1.1	0.0	5.7	1	1.0	0.0	5.4
Immune system disorders (10021428)	Food allergy (10016946)				3.6						0.0						4.8							0.0	3.6
	Milk allergy (10027633)				3.6						0.0						3.2			0.0	5.7			0.0	3.6
Infections and infestations (10021881)	Acute sinusitis (10001076)				3.6		0.0					0.0					3.2			0.0	3.8		0.0	0.0	3.6
	Anal abscess (10048946)				3.6						0.0						3.2			0.0	3.8	0			3.6
	Bronchiolitis (10006448)			0.2	7.0				5.8		0.0		4.5				3.2		0.0	0.0	3.8	1			5.4
	Bronchitis (10006451)	1	1.0		5.4	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0			3.2			0.0	3.8				3.6
	Candida infection (10074170)			0.2	7.0		0.0					0.0					4.8		0.0	0.0	3.8				3.6
	Candida nappy rash (10007135)	0			3.6	0					0.0						4.8		0.0	0.0	3.8	0	0.0	0.0	3.6
	Cellulitis (10007882)				3.6		1.1	0.0	5.8	0	0.0	0.0	4.5	0			3.2				3.8		1.0	0.0	5.4
	Conjunctivitis (10010741)	1			5.4						2.5						11.1				5.7		0.0	0.0	3.6
	Conjunctivitis bacterial (10061784)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Conjunctivitis viral (10010755)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	1	1.1	0.0	5.7	0	0.0	0.0	3.6
	Croup infectious (10011416)	1	1.0	0.0	5.4		1.1	0.0	5.8	0	0.0	0.0	4.5	2	1.8	0.2	6.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Ear infection (10014011)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	1	1.0	0.0	5.4
	Eczema herpeticum (10014197)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	1	1.1	0.0	5.7	0	0.0	0.0	3.6

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	าเมา					-	Pedia	a ar	ดเมต						Penta	ar		ort I	IIIIa
			Fe	male		9.0		Male			Fe	male		, g. \		Vlale			Fe	emale		9.		/lale	
				= 10				= 94	ļ			= 80				= 114	4			l = 95				= 101	1
					% CI				% CI				% CI				% CI				% CI				% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)		%	LL	UL	n		LL	UL	n		LL	UL	n		LL	UL	n		LL	UL	n	%	LL	UL
	Exanthema subitum (10015586)											0.0				0.0								0.0	
	Fungal infection (10017533)		0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	1		0.0	
	Fungal skin infection (10017543)											0.0				0.0				0.0	3.8		0.0	0.0	3.6
	Gastric infection (10056663)								3.8	1	1.3	0.0	6.8	0	0.0	0.0	3.2	0	0.0					0.0	
	Gastroenteritis (10017888)		0.0		3.6				5.8			0.0				0.0				0.0	5.7			0.0	
	Hand-foot-and-mouth disease (10019113)	0	0.0	0.0	3.6							0.0				0.0				0.0	5.7	0	0.0	0.0	3.6
	Herpangina (10019936)			0.0												0.0							0.0	0.0	3.6
	Impetigo (10021531)			0.0											0.0	0.0	3.2	1	1.1	0.0	5.7	1	1.0	0.0	5.4
	Influenza (10022000)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Nasopharyngitis (10028810)	1	1.0	0.0	5.4	1	1.1	0.0	5.8	1	1.3	0.0	6.8	0	0.0	0.0	3.2	3	3.2	0.7	9.0	0	0.0	0.0	3.6
	Oral candidiasis (10030963)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	1	1.3	0.0	6.8	0	0.0	0.0	3.2	0	0.0	0.0	3.8	1	1.0	0.0	5.4
	Otitis externa (10033072)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	1	1.3	0.0	6.8	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Otitis media (10033078)	4	4.0	1.1	9.8	5	5.3	1.7	12.0	2	2.5	0.3	8.7	5	4.4	1.4	9.9	2	2.1	0.3	7.4	7	6.9	2.8	13.
	Otitis media acute (10033079)	1	1.0	0.0	5.4				3.8			0.0				0.0				0.0	3.8	0	0.0	0.0	3.6
	Otitis media chronic (10033081)		0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	1	1.0	0.0	5.4
	Parainfluenzae virus infection (10061907)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	1	1.1	0.0	5.7	0	0.0	0.0	3.6
	Pertussis (10034738)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	1	1.0	0.0	5.4
	Pharyngitis (10034835)	0	0.0	0.0	3.6		1.1	0.0	5.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0			0.0	0.0	3.6
	Pneumonia (10035664)	1	1.0		5.4		0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8				3.6
	Respiratory syncytial virus	1	1.0	0.0	5.4	0	0.0	0.0	3.8	0	0.0	0.0	4.5			0.0			0.0	0.0			0.0	0.0	3.6
	bronchiolitis (10038718)																								
	Respiratory syncytial virus infection (10061603)	0	0.0	0.0	3.6	1	1.1	0.0	5.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Respiratory tract infection (10062352)	1	1.0	0.0	5.4	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Rhinitis (10039083)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	1	1.1	0.0	5.7	0	0.0	0.0	3.6

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	auc					F	Pedia	arc	auc						Penta	ar	_	,ort i	Finai
			Fe	male		9. 0		/lale			Fe	male		J. 3. \		/lale			Fe	male		J.		/lale	
				= 10				= 94				= 80				= 114	4			= 95				= 101	ı
				959	% CI			959	% CI			959	% CI			959	% CI			95	% CI			95°	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
	Roseola (10039222)		0.0	0.0	3.6			0.0				0.0					4.8			0.0	3.8			0.0	3.6
	Sinusitis (10040753)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0			4.5				3.2		1.1	0.0	5.7		0.0	0.0	3.6
	Skin candida (10054152)	1				0	0.0	0.0	3.8	0			4.5	0	0.0	0.0	3.2	0		0.0	3.8	1	1.0	0.0	5.4
	Upper respiratory tract infection (10046306)	12	11.9	6.3	19.8	18	19.1	11.8	28.6	7	8.8	3.6	17.2	16	14.0	8.2	21.8	3 11	11.6	5.9	19.8	15	14.9	8.6	23.3
	Urinary tract infection (10046571)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	2	1.8	0.2	6.2	1	1.1	0.0	5.7	0	0.0	0.0	3.6
	Viraemia (10058874)	0	0.0	0.0	3.6												3.2		1.1	0.0	5.7			0.0	3.6
	Viral infection (10047461)	1	1.0	0.0	5.4	1	1.1	0.0	5.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	1	1.1	0.0	5.7	2	2.0	0.2	7.0
	Viral rash (10047476)	1	1.0	0.0	5.4	2	2.1	0.3	7.5	0	0.0	0.0	4.5	0	0.0	0.0	3.2	2	2.1	0.3	7.4	1	1.0	0.0	5.4
	Viral upper respiratory tract infection (10047482)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	2	2.0	0.2	7.0
Injury, poisoning and procedural complications (10022117)	Arthropod bite (10003399)	1	1.0	0.0	5.4	1	1.1	0.0	5.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Arthropod sting (10003402)	0	0.0	0.0	3.6	1						0.0	4.5	0			3.2		0.0	0.0	3.8		0.0	0.0	3.6
	Clavicle fracture (10009245)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Concussion (10010254)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Corneal abrasion (10010984)	1	1.0	0.0	5.4	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Craniocerebral injury (10070976)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	1	1.3	0.0	6.8	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Fall (10016173)	0	0.0	0.0	3.6	0	0.0	0.0			0.0	0.0	4.5	0	0.0	0.0	3.2	1	1.1	0.0	5.7	0	0.0	0.0	3.6
	Foreign body (10070245)	0	0.0	0.0	3.6			0.0	3.8	0		0.0	4.5	0			3.2		1.1	0.0		0	0.0	0.0	3.6
	Head injury (10019196)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	2	2.0	0.2	7.0
	Nasal injury (10078651)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	1	1.0	0.0	5.4
	Thermal burn (10053615)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
Investigations (10022891)	Body temperature increased (10005911)	0	0.0	0.0	3.6	1	1.1	0.0	5.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	1	1.0	0.0	5.4
	Cardiac murmur (10007586)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	1	1.1	0.0	5.7	0	0.0	0.0	3.6
	Weight decreased (10047895)		0.0	0.0	3.6	1	1.1	0.0	5.8				4.5		0.0	0.0	3.2	1	1.1	0.0	5.7	0	0.0	0.0	3.6
Musculoskeletal and connective tissue disorders (10028395)	Asymmetric gluteal fold (10072189)	1	1.0	0.0	5.4	0	0.0	0.0				0.0					3.2		0.0	0.0	3.8	0	0.0	0.0	3.6

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	un						Pedia	ara	nun						Penta	ar	_	JOIL	Final
			Fe	male		gic		/lale			Fe	male		git		/lale			Fe	male		y.		/lale	
				= 10°				i = 94				= 80				= 114	1			= 95				= 10 ⁴	1
					% CI				% CI				% CI				% CI				% CI				% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%		UL	n	%			n	%		UL	n	%	LL	UL	n	%		UL
	Pain in extremity (10033425)	2			7.0			0.0					4.5			0.0				0.0	3.8			0.0	5.4
	Positional plagiocephaly (10068711)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
Neoplasms benign, malignant and unspecified (incl cysts and polyps) (10029104)	Haemangioma (10018814)				3.6								4.5							0.0	3.8			0.0	3.6
Nervous system disorders (10029205)	Hyperreflexia (10020745)		0.0		3.6			0.0			0.0					0.0			0.0	0.0	3.8				3.6
	Lethargy (10024264)	1	1.0	0.0	5.4	0	0.0	0.0				0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Poor quality sleep (10062519)		0.0	0.0	3.6						0.0					0.0			0.0	0.0	3.8			0.0	3.6
	Tremor (10044565)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
Psychiatric disorders (10037175)	Irritability (10022998)	0	0.0	0.0	3.6	4	4.3	1.2	10.5	2	2.5	0.3	8.7	1	0.9	0.0	4.8	1	1.1	0.0	5.7	0	0.0	0.0	3.6
	Screaming (10039740)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	1	1.3	0.0	6.8	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
Renal and urinary disorders (10038359)	Urethral meatus stenosis (10058463)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
Reproductive system and breast disorders (10038604)	Balanoposthitis (10004078)	0	0.0	0.0	3.6	2	2.1	0.3	7.5	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
,	Genital labial adhesions (10064162)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	1	1.3	0.0	6.8	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Penile adhesion (10059636)	0	0.0	0.0	3.6	3	3.2	0.7	9.0	0	0.0	0.0	4.5	3	2.6	0.5	7.5	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Penile erythema (10070655)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	1	1.0	0.0	5.4
Respiratory, thoracic and mediastinal disorders (10038738)	Apparent life threatening event (10065044)	1	1.0	0.0	5.4	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
,	Bronchial hyperreactivity (10066091)	0	0.0	0.0	3.6	2	2.1	0.3	7.5	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Cough (10011224)	6	5.9	2.2	12.5	5 9	9.6	4.5	17.4	10	0.0	0.0	4.5	7	6.1	2.5	12.2	2	2.1	0.3	7.4	5	5.0	1.6	11.2
	Dysphonia (10013952)	0	0.0	0.0	3.6						0.0			1		0.0					3.8		0.0	0.0	3.6
	Epistaxis (10015090)	0	0.0	0.0	3.6	0	0.0				0.0					0.0	3.2	0	0.0	0.0	3.8	1	1.0	0.0	5.4
	Nasal congestion (10028735)	0	0.0	0.0	3.6	2	2.1	0.3	7.5	3	3.8	8.0	10.6	3	2.6	0.5	7.5	0	0.0	0.0	3.8			0.2	7.0
	Respiratory arrest (10038669)	0	0.0	0.0	3.6						0.0	0.0	4.5			0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Respiratory disorder (10038683)	1	1.0	0.0	5.4			0.0	3.8	1	1.3	0.0	6.8	1	0.9	0.0	4.8	0	0.0	0.0	3.8	1	1.0	0.0	5.4

117119 (DTPA-HBV-IPV-135)

Report Final

					Hexa	aro	guo					F	Pedia	arc	auc						Penta	ar	_	7011	rilla
			Fe	male		J .		/lale			Fe	male		J		/lale			Fe	emale				Male	
				= 10				= 94				= 80				= 114	4			1 = 95				= 10	1
				95	% CI			95	% CI			959	% CI			959	% CI			95	% CI			95	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
,	Rhinitis allergic (10039085)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Rhinorrhoea (10039101)		2.0	0.2	7.0			0.0		1		0.0	6.8			0.0			2.1	0.3	7.4	2	2.0	0.2	7.0
	Sinus congestion (10040742)	0	0.0	0.0	3.6	1	1.1	0.0	5.8	0	0.0	0.0		0			3.2		0.0	0.0	3.8				3.6
	Sneezing (10041232)	0	0.0	0.0	3.6	1					0.0		4.5	0		0.0			0.0	0.0	3.8	0	0.0	0.0	3.6
	Upper respiratory tract congestion (10052252)	1	1.0	0.0	5.4	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	1	1.0	0.0	5.4
	Wheezing (10047924)	0											4.5	0	0.0	0.0	3.2	1	1.1	0.0	5.7	1	1.0	0.0	5.4
Skin and subcutaneous tissue disorders (10040785)	Dermatitis (10012431)	0	0.0	0.0	3.6			0.7				0.0				0.0			0.0	0.0	3.8	0	0.0	0.0	3.6
	Dermatitis atopic (10012438)	0	0.0		3.6			0.3					6.8						1.1	0.0					9.8
	Dermatitis contact (10012442)	1	1.0	0.0	5.4			0.0					4.5			0.2					3.8				
	Dermatitis diaper (10012444)	1	1.0	0.0	5.4		1.1	0.0	5.8	2	2.5	0.3	8.7	1	0.9	0.0	4.8	6	6.3	2.4	13.2				8.4
	Dry skin (10013786)	1	1.0	0.0	5.4						0.0					0.0			0.0		3.8				
	Eczema (10014184)	3	3.0	0.6	8.4								8.7			0.5				0.3	7.4				
	Erythema (10015150)	0	0.0	0.0	3.6								10.6			0.0			0.0	0.0	3.8				3.6
	Hair growth abnormal (10019044)	1	1.0	0.0	5.4	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Hypertrichosis (10020864)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	1	1.3	0.0	6.8		0.0	0.0	3.2	0	0.0	0.0	3.8				
	Intertrigo (10022622)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5			0.0					3.8		1.0	0.0	5.4
	Post inflammatory pigmentation change (10036229)	1	1.0	0.0	5.4	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Rash (10037844)	1	1.0	0.0	5.4								8.7												11.2
	Rash macular (10037867)	0	0.0	0.0	3.6								4.5			0.0					3.8				5.4
	Seborrhoea (10039792)	1	1.0										4.5			0.0									5.4
	Seborrhoeic dermatitis (10039793)	0	0.0					0.7					6.8			0.0			0.0						
	Urticaria (10046735)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines
Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines
Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term) N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Table 8.20 Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following priming doses—by geographical ancestry (Primary Total vaccinated cohort)

					Hexa	gro	up					F	Pedia	gro	oup					F	Penta	a gr	oup		
				/hite			-	ther			W	/hite			ot	her			W	/hite				ther	
				casia			N	= 77				casia			N	= 66				casia			N	= 81	
			N	= 118							N	= 128							N	= 11:					
			1		% CI		1		% CI		1		% CI		1		% CI	_	1		% CI		1	_	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)		%	LL	UL	n			UL	n	%			n			UL	n	%	LL	UL		%		UL
At least one symptom		71	60.2	50.7	69.1	42	54.5	42.8	65.9	71	55.5	46.4	64.3	37	56.1	43.3	68.3	61	53.0	43.5	62.4	4 35	43.2	32.2	2 54.7
Blood and lymphatic system disorders (10005329)	Anaemia (10002034)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Leukocytosis (10024378)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Lymphadenopathy (10025197)	1	8.0	0.0	4.6	1	1.3	0.0	7.0	0	0.0	0.0	2.8	1	1.5	0.0	8.2	0	0.0	0.0	3.2	0	0.0	0.0	4.5
Cardiac disorders (10007541)	Cyanosis (10011703)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	2	1.7	0.2	6.1	0	0.0	0.0	4.5
Congenital, familial and genetic disorders (10010331)	Congenital skin dimples (10072978)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	2	1.6	0.2	5.5	1	1.5	0.0	8.2	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	Dermoid cyst (10012522)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Hydrocele (10020488)	0	0.0	0.0	3.1		0.0		4.7	1	8.0	0.0	4.3			0.0	5.4		0.0	0.0	3.2	0	0.0	0.0	4.5
	Hypospadias (10021093)	0	0.0	0.0	3.1				4.7	2	1.6	0.2	5.5			0.0	5.4		0.0	0.0	3.2	0	0.0	0.0	4.5
	Macrocephaly (10050183)	2	1.7	0.2	6.0		0.0	0.0	4.7	1	8.0	0.0	4.3				5.4		0.0	0.0	3.2	0	0.0	0.0	4.5
	Plagiocephaly (10048586)	0	0.0	0.0	3.1				4.7	1	8.0	0.0	4.3				5.4		0.0	0.0	3.2	0	0.0		4.5
Ear and labyrinth disorders (10013993)	Cerumen impaction (10050337)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	1	1.5	0.0	8.2	1	0.9	0.0	4.7	1	1.2	0.0	6.7
	Ear disorder (10014004)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	1	0.9	0.0	4.7	0	0.0	0.0	4.5
	Ear pain (10014020)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	1	0.9	0.0	4.7	0	0.0	0.0	4.5
Eye disorders (10015919)	Dacryostenosis acquired (10053990)	1	8.0	0.0	4.6	1			7.0			0.0					5.4		0.0	0.0	3.2				
Gastrointestinal disorders (10017947)	Abdominal pain upper (10000087)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	auc					F	Pedia	ara	auc						Penta	ar		וווטונו	Final
			V	/hite		. 9		ther			V	/hite		9. \		ther			V	Vhite		9.		ther	
				casia				= 77				casia	an			= 66				ıcasia				= 81	
				= 118								= 128			-					= 11					
				95	% CI			95	% CI			959	% CI			959	% CI			95	% CI			95	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL		%		UL	n	%	LL			%		UL		%		UL	n	%	LL	
,	Anal fistula (10002156)	0	0.0	0.0	3.1	1	1.3	0.0	7.0	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Constipation (10010774)			0.0	4.6	0	0.0	0.0	4.7	2	1.6	0.2	5.5	0		0.0				0.2			3.7	8.0	10.4
		4	3.4	0.9	8.5			0.3				0.0					14.8		4.3	1.4	9.9	5	6.2	2.0	13.8
	Flatulence (10016766)	1			4.6			0.0		0		0.0					5.4		0.9		4.7		0.0	0.0	4.5
	Frequent bowel movements (10017367)	0	0.0	0.0	3.1	0	0.0	0.0			8.0	0.0	4.3		0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Gastrooesophageal reflux disease (10017885)	0	0.0	0.0	3.1							1.3			4.5	0.9	12.7	1	0.9	0.0	4.7	0	0.0	0.0	4.5
	Inguinal hernia (10022016)		0.0	0.0	3.1			0.0				0.0				0.0			0.0	0.0	3.2			0.0	4.5
	Teething (10043183)		4.2	1.4	9.6							1.3				0.9					9.9		4.9	1.4	12.2
	Vomiting (10047700)	3	2.5	0.5	7.3							1.3			4.5	0.9	12.7	' 3	2.6	0.5	7.4	7	8.6	3.5	17.0
	Vomiting projectile (10047708)	1	8.0	0.0	4.6							0.0				0.0			0.0	0.0	3.2	0	0.0	0.0	4.5
General disorders and administration site conditions (10018065)	Adverse drug reaction (10061623)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	Crying (10011469)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	1		0.0			0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	III-defined disorder (10061520)	0	0.0	0.0	3.1					1		0.0				0.0			0.0	0.0	3.2	0	0.0	0.0	4.5
	Injection site bruising (10022052)	2	1.7	0.2	6.0	0	0.0	0.0	4.7	2	1.6	0.2	5.5	0	0.0	0.0	5.4	3	2.6	0.5	7.4	2	2.5	0.3	8.6
	Injection site erythema (10022061)	2	1.7	0.2	6.0	2	2.6	0.3	9.1	2	1.6	0.2	5.5	0	0.0	0.0	5.4	3	2.6	0.5	7.4	2	2.5	0.3	8.6
	Injection site induration (10022075)	1	8.0	0.0	4.6	2	2.6	0.3	9.1	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Injection site mass (10022081)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	2	1.6	0.2	5.5	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Injection site pain (10022086)	2	1.7	0.2	6.0	2	2.6	0.3	9.1	5	3.9	1.3	8.9	1	1.5	0.0	8.2	6	5.2	1.9	11.0		1.2	0.0	6.7
	Injection site pruritus (10022093)		0.0	0.0	3.1							0.0				0.0			0.0	0.0	3.2	0	0.0	0.0	4.5
	Injection site rash (10022094)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	1	0.9	0.0	4.7	1	1.2	0.0	6.7
	Injection site swelling (10053425)	2	1.7	0.2	6.0	2	2.6	0.3	9.1	1	8.0	0.0	4.3	0	0.0	0.0	5.4	1	0.9	0.0	4.7	3	3.7	8.0	10.4
	Injection site warmth	0	0.0	0.0	3.1	0	0.0	0.0	4.7	2	1.6	0.2	5.5	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5

117119 (DTPA-HBV-IPV-135)

					Hex	a gro	auc					F	Pedia	arc	auc					-	Penta	ar	_	JOIL	Fina
			٧	/hite		- g. ·		ther			V	/hite		. g		ther			٧	/hite		9.		ther	
				casi			N	l = 77	,			casia			N	= 66				casi			N	I = 81	
			N	= 118				0.5			N	= 128				0.50	·		N	= 11					0/ 01
D:	D (17 (00DE)		0/		% C		0/		% CI		0/		% CI		0/		% CI		0/		% CI		0/		% CI
Primary System Organ Class (CODE)	, ,	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
	(10022112)																								
	Oedema peripheral (10030124)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Peripheral swelling (10048959)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	2	1.6	0.2				0.0	8.2	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Pyrexia (10037660)	11	9.3	4.7	16.	11	1.3	0.0	7.0	4	3.1		7.8	1	1.5	0.0			7.0	3.1			8.6	3.5	17.0
	Swelling (10042674)		0.0	0.0	3.1							0.0		1		0.0			0.0	0.0	3.2		0.0	0.0	4.5
	Vaccination site bruising (10069484)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	2	1.6	0.2	5.5	0	0.0	0.0	5.4	1	0.9	0.0	4.7	0	0.0	0.0	4.5
	Vaccination site erythema (10059079)	2	1.7	0.2	6.0	0	0.0	0.0	4.7	4	3.1	0.9	7.8	0	0.0	0.0	5.4	2	1.7	0.2	6.1	1	1.2	0.0	6.7
	Vaccination site induration (10065117)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Vaccination site pain (10068879)	2	1.7	0.2	6.0	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	2	1.7	0.2	6.1	1	1.2	0.0	6.7
	Vaccination site swelling (10069620)	3	2.5	0.5	7.3	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	1	0.9	0.0	4.7	1	1.2	0.0	6.7
Immune system disorders (10021428)	Food allergy (10016946)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Milk allergy (10027633)	0	0.0		3.1			0.0		0		0.0				0.0			0.9	0.0	4.7		0.0	0.0	
Infections and infestations (10021881)	Acute sinusitis (10001076)	0	0.0	0.0	3.1					1		0.0	4.3				5.4		0.0	0.0	3.2		0.0	0.0	4.5
	Anal abscess (10048946)	1	8.0	0.0	4.6			0.0				0.0	2.8				5.4		0.0	0.0	3.2		0.0	0.0	4.5
	Bronchiolitis (10006448)		8.0	0.0	4.6			0.3		0		0.0	2.8				5.4		0.0	0.0	3.2			0.0	6.7
	Bronchitis (10006451)		8.0	0.0	4.6			0.0				0.0		0		0.0			0.0	0.0	3.2				
	Candida infection (10074170)	1	8.0	0.0	4.6			0.0	7.0	2		0.2				0.0			0.0	0.0	3.2		0.0	0.0	4.5
	Candida nappy rash (10007135)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Cellulitis (10007882)			0.0							0.0													0.0	6.7
	Conjunctivitis (10010741)	5	4.2		9.6						3.9					0.9			0.9	0.0					4.5
	Conjunctivitis bacterial (10061784)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5

117119 (DTPA-HBV-IPV-135)

					Hexa	a arc	guo					F	Pedia	ara	auc						Penta	ar		JUILI	Final
			V	/hite		- g. \		ther			V	/hite		J		ther			٧	Vhite		9.		ther	
				casi				= 77	,			casia	an			= 66				ıcasi				= 81	
				= 11								= 128								= 11:					
				95	% CI			95	% CI			959	% CI			95	% CI			95	% CI			95	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
,	Conjunctivitis viral (10010755)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	1	0.9	0.0	4.7	0	0.0	0.0	4.5
	Croup infectious (10011416)	2		0.2					4.7			0.2					5.4			0.0		0	0.0	0.0	4.5
	Ear infection (10014011)		0.0	0.0	3.1						0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	Eczema herpeticum (10014197)								4.7								5.4		0.0	0.0	3.2	1	1.2	0.0	6.7
	Exanthema subitum (10015586)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Fungal infection (10017533)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	1	0.9	0.0	4.7	0	0.0	0.0	4.5
	Fungal skin infection (10017543)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Gastric infection (10056663)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	1	1.5	0.0	8.2	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Gastroenteritis (10017888)	1	8.0	0.0	4.6												10.5						1.2	0.0	6.7
	Hand-foot-and-mouth disease (10019113)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0				0.0	8.2	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	Herpangina (10019936)	1	8.0	0.0	4.6				4.7		0.0				0.0		5.4		0.0	0.0			0.0	0.0	4.5
	Impetigo (10021531)	1	8.0	0.0	4.6				4.7	0	0.0						5.4		0.9	0.0	4.7		1.2	0.0	6.7
	Influenza (10022000)	0	0.0	0.0	3.1		0.0			1		0.0		0			5.4	0	0.0					0.0	4.5
	Nasopharyngitis (10028810)	0	0.0	0.0	3.1		2.6			1							5.4		1.7		6.1				6.7
	Oral candidiasis (10030963)	0	0.0	0.0	3.1				4.7			0.0					5.4		0.0	0.0	3.2				6.7
	Otitis externa (10033072)		0.0						4.7		8.0		4.3				5.4		0.0	0.0	3.2				4.5
	Otitis media (10033078)		5.1	1.9			3.9				5.5						5.4		5.2						10.4
	Otitis media acute (10033079)		0.0	0.0	3.1				7.0								10.5		0.0	0.0	3.2				4.5
	Otitis media chronic (10033081)		0.0						4.7		0.0						5.4		0.9	0.0	4.7	0	0.0	0.0	4.5
	Parainfluenzae virus infection (10061907)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	Pertussis (10034738)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	1	0.9	0.0	4.7	0	0.0	0.0	4.5
	Pharyngitis (10034835)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0		0.0	4.5
	Pneumonia (10035664)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Respiratory syncytial virus	0	0.0	0.0	3.1	1	1.3	0.0	7.0	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	าเมา					F	Pedia	ara	าเมต						Penta	ar		ווטכ	Fina
			V	/hite		9.0		ther			W	/hite	ouiu	9. (ther			٧	Vhite		. <u>.</u>		ther	
				casi				= 77				casia	an			= 66				ıcasia				I = 81	
				= 11								= 128							N	= 115	5				
				95	% CI			95	% CI			959	% CI			95	% CI			95	% CI			959	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
	bronchiolitis (10038718)																								
	Respiratory syncytial virus infection (10061603)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Respiratory tract infection (10062352)	1	8.0	0.0							0.0			0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Rhinitis (10039083)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	Roseola (10039222)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Sinusitis (10040753)	0	0.0	0.0							0.0									0.0	3.2	1	1.2	0.0	6.7
	Skin candida (10054152)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	Upper respiratory tract infection (10046306)	16	13.6	8.0	21.	1 14	18.2	10.3	28.6	15	11.7	6.7	18.6	8	12.1	5.4	22.5	20	17.4	11.0	25.6	6	7.4	2.8	15.4
	Urinary tract infection (10046571)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	1	8.0	0.0	4.3	1	1.5	0.0	8.2	1	0.9	0.0	4.7	0	0.0	0.0	4.5
	Viraemia (10058874)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	1	0.9	0.0	4.7	0	0.0	0.0	4.5
	Viral infection (10047461)	2	1.7	0.2	6.0	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	3	2.6	0.5	7.4	0	0.0	0.0	4.5
	Viral rash (10047476)	1	8.0	0.0	4.6	2	2.6	0.3	9.1	0	0.0	0.0	2.8		0.0	0.0	5.4	0	0.0	0.0	3.2	3	3.7	8.0	10.4
	Viral upper respiratory tract infection (10047482)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0					5.4		0.0	0.0	3.2	2	2.5	0.3	8.6
Injury, poisoning and procedural complications (10022117)	Arthropod bite (10003399)	2	1.7	0.2	6.0	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
. ,	Arthropod sting (10003402)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Clavicle fracture (10009245)	0	0.0	0.0	3.1		0.0			1	0.8	0.0	4.3		0.0	0.0	5.4	0	0.0	0.0			0.0	0.0	4.5
	Concussion (10010254)		0.0	0.0	3.1		0.0										8.2		0.0	0.0			0.0	0.0	4.5
	Corneal abrasion (10010984)		8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8				5.4		0.0				0.0	0.0	4.5
	Craniocerebral injury (10070976)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	1	1.5	0.0	8.2	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Fall (10016173)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	1	0.9		4.7		0.0	0.0	4.5
	Foreign body (10070245)				3.1		0.0				0.0								0.0	0.0					6.7
	Head injury (10019196)				3.1			0.0						0			5.4				4.7				6.7
	Nasal injury (10078651)										0.0						5.4				4.7			0.0	

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	าเมต					F	Pedia	ara	าเมา			1		-	Penta	ar		ו אוטנ	Final
			V	/hite	IIOAC	, g. c		ther			V	/hite	Cuit	9.0		ther			٧	/hite	Ciito	9.	_	ther	
			Cau	casia = 11				= 77			Cau	casia = 128				= 66	i		Cau	casia = 11				= 81	
				95	% CI			95	% CI			95%	% CI			959	% CI			95	% CI			95°	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
,	Thermal burn (10053615)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
Investigations (10022891)	Body temperature increased (10005911)	0	0.0	0.0	3.1	1	1.3	0.0	7.0	0	0.0	0.0	2.8	0	0.0	0.0	5.4	1	0.9	0.0	4.7	0	0.0	0.0	4.5
	Cardiac murmur (10007586)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0				0.0	0.0	5.4	1	0.9	0.0	4.7	0	0.0	0.0	4.5
I	Weight decreased (10047895)	1	8.0	0.0	4.6		0.0					0.0			0.0	0.0	5.4	1	0.9	0.0	4.7		0.0	0.0	4.5
Musculoskeletal and connective tissue disorders (10028395)	Asymmetric gluteal fold (10072189)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
,	Pain in extremity (10033425)	0	0.0	0.0	3.1			0.3	9.1	0	0.0	0.0	2.8	0	0.0	0.0	5.4	1	0.9	0.0	4.7	0	0.0	0.0	4.5
	Positional plagiocephaly (10068711)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
Neoplasms benign, malignant and unspecified (incl cysts and polyps) (10029104)	Haemangioma (10018814)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
Nervous system disorders (10029205)	Hyperreflexia (10020745)	0	0.0	0.0	3.1	0		0.0	4.7	0	0.0		2.8	1	1.5	0.0	8.2	0	0.0	0.0	3.2		0.0	0.0	4.5
	Lethargy (10024264)	1	8.0	0.0	4.6			0.0		0			2.8						0.0	0.0	3.2		0.0	0.0	4.5
	Poor quality sleep (10062519)	1	8.0	0.0	4.6			0.0		0		0.0	2.8				5.4	0	0.0	0.0	3.2		0.0	0.0	4.5
	Tremor (10044565)	0	0.0	0.0	3.1		0.0	0.0	4.7	1		0.0	4.3				5.4		0.0	0.0	3.2			0.0	4.5
Psychiatric disorders (10037175)	Irritability (10022998)		2.5	0.5	7.3			0.0	7.0	3		0.5	6.7				5.4		0.9	0.0					4.5
	Screaming (10039740)		0.0	0.0	3.1			0.0	4.7	1		0.0	4.3						0.0	0.0	3.2				4.5
Renal and urinary disorders (10038359)	Urethral meatus stenosis (10058463)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
Reproductive system and breast disorders (10038604)	Balanoposthitis (10004078)	2	1.7	0.2	6.0	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4		0.0	0.0	3.2	0	0.0	0.0	4.5
	Genital labial adhesions (10064162)						0.0		4.7			0.0		0			5.4		0.0	0.0	3.2				4.5
	Penile adhesion (10059636)				7.3		0.0		4.7			0.2					8.2		0.0	0.0	3.2	0			4.5
	Penile erythema (10070655)		0.0	0.0	3.1			0.0		0			2.8						0.0	0.0	3.2	1		0.0	6.7
Respiratory, thoracic and mediastinal disorders (10038738)	Apparent life threatening event (10065044)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5

117119 (DTPA-HBV-IPV-135)

		I			Hexa	arr	nun					-	Pedia	ar	nun			Τ			Penta	a ar		ווטנ	Final
			v	/hite		gic		ther			v	/hite	Guia	giv		ther			V	Vhite	Ciito	ı gı		ther	
				casi				l = 77	,			casia	n			l = 66				ıcasia	an			= 81	
				= 11			•	• • •				= 128								= 11				٠.	
					% CI			95	% CI				% CI			95	% CI				% CI			95'	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL		%		UL		%	LL			%		UL	n	%		UL		%	LL	
	Bronchial hyperreactivity (10066091)	0	0.0	0.0	3.1	2	2.6	0.3	9.1	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Cough (10011224)	10	8.5	4.1	15.0	0 5	6.5	2.1	14.5	5 4	3.1	0.9	7.8	3	4.5	0.9	12.7	5	4.3	1.4	9.9		2.5	0.3	8.6
	Dysphonia (10013952)		8.0	0.0	4.6				4.7			0.0					8.2		0.0	0.0	3.2			0.0	4.5
	Epistaxis (10015090)	0	0.0	0.0				0.0				0.0					5.4			0.0	4.7				4.5
	Nasal congestion (10028735)	1	8.0	0.0	4.6						2.3						12.7		0.9	0.0	4.7		1.2	0.0	6.7
	Respiratory arrest (10038669)	0	0.0	0.0	3.1			0.0			0.8						5.4		0.0	0.0	3.2		0.0	0.0	4.5
	Respiratory disorder (10038683)	0	0.0	0.0	3.1	1	1.3	0.0	7.0	2	1.6	0.2	5.5	0	0.0	0.0	5.4	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	Rhinitis allergic (10039085)		0.0	0.0	3.1			0.0				0.0				0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Rhinorrhoea (10039101)	2	1.7	0.2	6.0	1	1.3	0.0	7.0	2	1.6	0.2	5.5	0	0.0	0.0	5.4	3	2.6	0.5	7.4	1	1.2	0.0	6.7
	Sinus congestion (10040742)	0	0.0	0.0	3.1	1	1.3	0.0	7.0		0.0			0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Sneezing (10041232)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Upper respiratory tract congestion (10052252)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	Wheezing (10047924)	1	8.0	0.0	4.6						0.0						5.4		1.7	0.2	6.1	0	0.0	0.0	4.5
Skin and subcutaneous tissue disorders (10040785)	Dermatitis (10012431)	2	1.7	0.2	6.0	1	1.3	0.0	7.0	0	0.0	0.0	2.8	1	1.5	0.0	8.2	0	0.0	0.0	3.2	0	0.0	0.0	4.5
, ,	Dermatitis atopic (10012438)	1	8.0	0.0	4.6	1	1.3	0.0	7.0	1	8.0	0.0	4.3	2	3.0	0.4	10.5	0	0.0	0.0	3.2	5	6.2	2.0	13.8
	Dermatitis contact (10012442)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	2	1.6	0.2	5.5	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Dermatitis diaper (10012444)	1	8.0	0.0	4.6	1	1.3	0.0	7.0	2	1.6	0.2	5.5	1	1.5	0.0	8.2	3	2.6	0.5	7.4	6	7.4	2.8	15.4
	Dry skin (10013786)	0	0.0	0.0	3.1			0.0				0.0				0.0	8.2	0	0.0	0.0	3.2		0.0	0.0	4.5
	Eczema (10014184)		2.5	0.5	7.3							0.2		3	4.5		12.7		1.7	0.2	6.1		2.5	0.3	8.6
	Erythema (10015150)	0	0.0	0.0	3.1						0.8	0.0		2			10.5		0.0	0.0	3.2				4.5
	Hair growth abnormal (10019044)	0	0.0	0.0	3.1	1	1.3	0.0	7.0	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Hypertrichosis (10020864)			0.0				0.0												0.0				0.0	
	Intertrigo (10022622)	0	0.0	0.0	3.1	0		0.0									5.4			0.0	4.7			0.0	
	Post inflammatory pigmentation change	0	0.0	0.0	3.1	1	1.3	0.0	7.0	0	0.0	0.0	2.8	0	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5

117119 (DTPA-HBV-IPV-135)

Report Final

					Hex	a gr	oup					F	Pedia	grou	ıp					F	enta	gr	oup		
			٧	Vhite			0	ther			V	Vhite			of	ther			W	/hite			0	ther	
				ıcasi 11 =			N	= 77				ıcasia = 128			N	= 66				casia = 115			N	= 81	
				95	% C			95	% CI			959	% CI			959	% CI			959	% CI			95%	6 CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n 9	6	LL	UL	n	%	LL	UL	n	%	LL	UL
	(10036229)																								
	Rash (10037844)	2	1.7	0.2	6.0	2	2.6	0.3	9.1	4	3.1	0.9	7.8	0 (0.0	0.0	5.4	2	1.7	0.2	6.1	4	4.9	1.4	12.2
	Rash macular (10037867)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0 (0.0	0.0	5.4	1	0.9	0.0	4.7	0	0.0	0.0	4.5
	Seborrhoea (10039792)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	1 1	.5	0.0	8.2	1	0.9	0.0	4.7	0	0.0	0.0	4.5
	Seborrhoeic dermatitis (10039793)	2	1.7	0.2	6.0	1	1.3	0.0	7.0	1	8.0	0.0	4.3	0 (0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Urticaria (10046735)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	1	0.8	0.0	4.3	0 (0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Table 8.21 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following priming doses- by gender (Primary Total vaccinated cohort)

				Hexa	grou	ıр			Ped	lia gro	up			Penta	gro	up	
		F	em	ale	Ĭ	Ma	le	F	emale		Mal	е	Fe	male		Male	
		N	1 =	101		N =	94		N = 80		N = 1	14	N	= 95		N = 10	1
			Ĝ	5% C	I	9	5% CI		95%	CI	95	5% CI		95% C	I	95	%
																C	;l
Primary System Organ Class (CODE)	Preferred Term (CODE)	n %	L	L UL	n %	LI	_ UL	n %	LL U	L n %	LL	. UL	n %	LL UL	n	% LL	UL
At least one symptom		5 5.0	0 1	.6 11.2	2 8 8.	.5 3.	7 16.1	3 3.8	0.8 10).6 9 7	.9 3.7	7 14.5	4 4.2	1.2 10.	4 3 3	3.0 0.6	8.4
Gastrointestinal disorders (10017947)	Abdominal pain upper (10000087)	0.0	0 0	.0 3.6					3 0.0 6.					0.0 3.8		0.0	3.6
	Diarrhoea (10012735)	1 1.0	0 0	.0 5.4	0 0.	.0 0.	0 3.8	0.0	0.0 4.	5 0 0	0.0			0.0 3.8		0.0	3.6
	Teething (10043183)	1 1.0	0 0	.0 5.4	0 0.	.0 0.	0 3.8	0.0	0.0 4.	5 0 0	0.0	3.2	1 1.1	0.0 5.7	0 (0.0	3.6
	Vomiting (10047700)	1 1.0	0 0	.0 5.4	1 1.	.1 0.	0 5.8	0.0	0.0 4.	5 0 0	0.0	3.2	0.0	0.0 3.8	0 (0.0	3.6
General disorders and administration site conditions (10018065)	Crying (10011469)	0 0.0	0 0	.0 3.6	1 1.	.1 0.	0 5.8	0.0	0.0 4.	5 0 0	0.0	3.2	0.0	0.0 3.8	0 (0.0	3.6
,	III-defined disorder (10061520)	0.0	0 0	.0 3.6	0 0.	.0 0.	0 3.8	0.0	0.0 4.	5 1 0	.9 0.0	4.8	0.0	0.0 3.8	0 (0.0	3.6
	Injection site erythema (10022061)			.0 3.6					0.0 4.		.9 0.0	4.8	0.0	0.0 3.8	0 (0.0	3.6
	Injection site pain (10022086)	0.0	0 0	.0 3.6									0.0	0.0 3.8	1 1	0.0	5.4
	Injection site swelling (10053425)								0.0 4.					0.0 3.8		0.0	
	Injection site warmth (10022112)			.0 3.6					0.04.					0.0 3.8		0.0	3.6
	Pyrexia (10037660)			.0 5.4					0.04.					0.0 3.8		0.0	5.4
Infections and infestations (10021881)	Bronchiolitis (10006448)	0.0	0 0	.0 3.6									0.0	0.0 3.8		0.0	
,	Conjunctivitis (10010741)	0.0	0 0	.0 3.6	0 0.	.0 0.	0 3.8	0.0	0.0 4.	5 2 1	.8 0.2	2 6.2	0.0	0.0 3.8	0 (0.0	3.6
	Croup infectious (10011416)	0.0	0 0	.0 3.6	0 0.	.0 0.			0.04.					0.0 3.8		0.0	
	Gastroenteritis (10017888)	0.0	0 0	.0 3.6	1 1.	.1 0.	0 5.8	0.0	0.0 4.	5 0 0	0.0	3.2	0.0	0.0 3.8	0 (0.0	3.6
	Hand-foot-and-mouth disease (10019113)	0 0.0	0 0	.0 3.6	1 1.	.1 0.	0 5.8	0.0	0.0 4.	5 1 0	.9 0.0	4.8	0.0	0.0 3.8	0 (0.0	3.6
	Nasopharyngitis (10028810)	0.0	0 0	.0 3.6	0 0.	.0 0.	0 3.8	0.0	0.0 4.	5 0 0	0.0	3.2	1 1.1	0.0 5.7	0 (0.0	3.6
	Otitis media (10033078)	1 1.0	0 0	.0 5.4	2 2.	.1 0.	3 7.5	0.0	0.0 4.	5 1 0	.9 0.0	4.8	1 1.1	0.0 5.7	0 (0.0	3.6
	Pharyngitis (10034835)	0.0	0 0	.0 3.6	1 1.	.1 0.	0 5.8	0.0	0.0 4.	5 0 0	0.0	3.2	0.0	0.0 3.8	0 (0.0	3.6
	Respiratory syncytial virus bronchiolitis (10038718)								0.0 4.					0.0 3.8		0.0	
	Respiratory syncytial virus infection (10061603)	0 0.0	0 0	.0 3.6	1 1.	.1 0.	0 5.8	0.0	0.0 4.	5 0 0	0.0	3.2	0.0	0.0 3.8	0 (0.0	3.6

117119 (DTPA-HBV-IPV-135)

Report Final

			He	exa (grou	р			Pedia	grou	ıp		Penta)
		Fe	male	!		Male)	Fe	emale		Male	F	emale		Male
		N	= 101			N = 9	4	N	l = 80	N	N = 114	1	l = 95	N	= 101
			95%	CI		95	% CI		95% CI		95% CI		95% CI		95%
															CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n %									LL UL		LL UL		
	Rhinitis (10039083)	0.0	0.0 3	3.6	0.0	0.0	3.8	0.0	0.0 4.5	0.0	0.0 3.2	1 1.1	0.0 5.7	0.0	0.0 3.6
	Sinusitis (10040753)	0.0	0.03	3.6	0.0	0.0	3.8	0.0	0.0 4.5	0.0	0.0 3.2	1 1.1	0.0 5.7	0.0	0.0 3.6
	Upper respiratory tract infection	0.0	0.03	3.6	3 3.2	2 0.7	9.0	0.0	0.0 4.5	2 1.8	8 0.2 6.2	2 2.1	0.3 7.4	0.0	0.0 3.6
	(10046306)														
Psychiatric disorders (10037175)	Irritability (10022998)	0.0	0.0 3	3.6	0.0	0.0	3.8	1 1.3	0.0 6.8	1 0.9	9 0.0 4.8	0.0	0.0 3.8	0.0	0.0 3.6
Respiratory, thoracic and mediastinal disorders	Bronchial hyperreactivity (10066091)	0.0	0.0 3	3.6	1 1.	1 0.0	5.8	0.0	0.0 4.5	0.0	0.0 3.2	0.0	0.0 3.8	0.0	0.0 3.6
(10038738)															
	Cough (10011224)	0.0	0.0 3	3.6	0.0	0.0	3.8	0.0	0.0 4.5	0.0	0.0 3.2	0.0	0.0 3.8	1 1.0	0.0 5.4
	Respiratory arrest (10038669)	0.0	0.0 3	3.6	0.0	0.0	3.8	0.0	0.0 4.5	1 0.9	9 0.0 4.8	0.0	0.0 3.8	0.0	0.0 3.6
	Upper respiratory tract congestion	0.0	0.0 3	3.6	0.0	0.0	3.8	0.0	0.0 4.5	0.0	0.0 3.2	0.0	0.0 3.8	1 1.0	0.0 5.4
	(10052252)														
	Wheezing (10047924)	0.0	0.0 3	3.6	1 1.	1 0.0	5.8	0.0	0.0 4.5	0.0	0.0 3.2	0.0	0.0 3.8	0.0	0.0 3.6

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Table 8.22 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following priming doses- by geographical ancestry (Primary Total vaccinated cohort)

					Hexa	gro	oup						Pedia	gro	up					Per	nta g	group	ρ	
			1	Whit	е		(oth	er			Whi	te		0	ther			Wh	ite			othe	r
			Ca	ucas	sian		ı	V =	77		Ca	uca	sian		N	= 66	3	C	auca	asia	n	I	N = 8	31
			N	l = 1	18						1	\ = 1	28						N =	115		l		
					5% C				5% C				5% CI				6 CI			95%		L		% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)		%		UL				L UL				UL			LL				L I	UL	n %	LL	UL
At least one symptom					12.9																			10.4
Gastrointestinal disorders (10017947)	Abdominal pain upper (10000087)				3.1				0 4.7				4.3			0.0							0.0	
	Diarrhoea (10012735)				4.6				0 4.7				2.8										0.0	
	Teething (10043183)	1	8.0	0.0	4.6								2.8			0.0							0.0	
	Vomiting (10047700)	0	0.0	0.0	3.1	2	2.6	0.	3 9.1	1 (0.0	0.0	2.8	0	0.0	0.0	5.4	0 0	.0 0	.0	3.2	0 0.	0.0	4.5
General disorders and administration site conditions (10018065)	Crying (10011469)	1	0.8	0.0	4.6	0	0.0	0.	0 4.7	7 (0.0	0.0	2.8	0	0.0	0.0	5.4	0 0	.0 0	.0 :	3.2	0 0.0	0.0	4.5
, ,	III-defined disorder (10061520)	0	0.0	0.0	3.1	0	0.0	0.	0 4.7	7 1	0.8	0.0	4.3	0	0.0	0.0	5.4	0 0	.0 0	.0 ;	3.2	0 0.	0.0	4.5
	Injection site erythema (10022061)	0	0.0	0.0	3.1	0	0.0	0.	0 4.7	7 1	0.8	0.0	4.3	0	0.0	0.0	5.4	0 0	.0 0	.0 3	3.2	0 0.	0.0	4.5
	Injection site pain (10022086)	0	0.0	0.0	3.1	0	0.0	0.	0 4.7	7 1	0.8	0.0	4.3	0	0.0	0.0	5.4	1 0	.9 0	.0	4.7	0 0.	0.0	4.5
	Injection site swelling (10053425)	0	0.0	0.0	3.1	0	0.0	0.	0 4.7	7 1	0.8	0.0	4.3	0	0.0	0.0	5.4	0 0	.0 0	.0	3.2	0 0.	0.0	4.5
	Injection site warmth (10022112)	0	0.0	0.0	3.1	0	0.0	0.	0 4.7	7 1	0.8	0.0	4.3	0	0.0	0.0	5.4	0 0	.0 0	.0 3	3.2	0 0.	0.0	4.5
	Pyrexia (10037660)	1	8.0	0.0	4.6	1	1.3	3 0.	0 7.0) (0.0	0.0	2.8	0	0.0	0.0	5.4	1 0	.9 0	.0	4.7	0 0.	0.0	4.5
Infections and infestations (10021881)	Bronchiolitis (10006448)	1	8.0	0.0	4.6	0	0.0	0.	0 4.7	7 (0.0	0.0	2.8	0	0.0	0.0	5.4	0 0	.0 0	.0	3.2	0 0.	0.0	4.5
	Conjunctivitis (10010741)	0	0.0	0.0	3.1	0	0.0	0.	0 4.7	7 (0.0	0.0	2.8	2	3.0	0.4	10.5	0 0	.0 0	.0 ;	3.2	0 0.	0.0	4.5
	Croup infectious (10011416)	0	0.0	0.0	3.1	0	0.0	0.	0 4.7	7 1	0.8	0.0	4.3	0	0.0	0.0	5.4	0 0	.0 0	.0 3	3.2	0 0.	0.0	4.5
	Gastroenteritis (10017888)	1	8.0	0.0	4.6	0	0.0	0.	0 4.7	7 (0.0	0.0	2.8	0	0.0	0.0	5.4	0 0	.0 0	.0 ;	3.2	0 0.	0.0	4.5
	Hand-foot-and-mouth disease (10019113)	1	0.8	0.0	4.6	0	0.0	0.	0 4.7	7 (0.0	0.0	2.8	1	1.5	0.0	8.2	0 0	.0 0	.0 :	3.2	0 0.0	0.0	4.5
	Nasopharyngitis (10028810)	0	0.0	0.0	3.1	0	0.0	0.	0 4.7	7 (0.0	0.0	2.8	0	0.0	0.0	5.4	1 0	.9 0	.0	4.7	0 0.	0.0	4.5
	Otitis media (10033078)	3	2.5	0.5	7.3	0	0.0	0.	0 4.7	7 1	0.8	0.0	4.3	0	0.0	0.0	5.4	1 0	.9 0	.0	4.7	0 0.	0.0	4.5
	Pharyngitis (10034835)	1	8.0	0.0	4.6	0	0.0	0.	0 4.7	7 (0.0	0.0	2.8	0	0.0	0.0	5.4	0 0	.0 0	.0	3.2	0 0.	0.0	4.5
	Respiratory syncytial virus bronchiolitis (10038718)				3.1								2.8										0.0	
	Respiratory syncytial virus infection (10061603)	1	8.0	0.0	4.6	0	0.0	0.	0 4.7	7 (0.0	0.0	2.8	0	0.0	0.0	5.4	0 0	.0 0	.0 :	3.2	0 0.	0.0	4.5

117119 (DTPA-HBV-IPV-135)

Report Final

					Hexa	gr	oup						Р	edia (gro	лр					Pe	nta		-		mai
			1	W hi	te		(oth	er			W	hite)		of	her			W	hite			0	ther	
					sian		١	1 =	77		(casi			N	= 6	6		Cau				N	= 8	1
			N		118				-0/	<u> </u>		N:	= 12				0.50	, <u>a</u>		N	= 11			1	0.50	, <u>aı</u>
	- (200F)		٥,	_	5% C				5% (% CI	ļ.,			6 CI		•		6 CI	ļ ,			6 CI
Primary System Organ Class (CODE)	Preferred Term (CODE)		%		. UL		า %				1 %		LL		n '		LL		n		LL		n '		LL	
	Rhinitis (10039083)	0	0.0	0.0	0 3.1	(0.0	0.0	0 4.	7 (0 0	.0	0.0	2.8	0 (0.0	0.0	5.4	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	Sinusitis (10040753)	0	0.0	0.0	0 3.1	(0.0	0.0	0 4.	7 (0 0	.0	0.0	2.8	0 (0.0	0.0	5.4	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	Upper respiratory tract infection	3	2.5	0.	5 7.3	(0.0	0.0	0 4.	7 (0 0	.0	0.0	2.8	2 3	3.0	0.4	10.5	5 1	0.9	0.0	4.7	1	1.2	0.0	6.7
	(10046306)																									
Psychiatric disorders (10037175)	Irritability (10022998)	0	0.0	0.0	0 3.1	(0.0	0.	0 4.	7 2	2 1	.6	0.2	5.5	0 (0.0	0.0	5.4	0	0.0	0.0	3.2	0 (0.0	0.0	4.5
Respiratory, thoracic and mediastinal	Bronchial hyperreactivity (10066091)	0	0.0	0.0	0 3.1	1	1 1.3	0.	0 7.	0 (0 (.0	0.0	2.8	0 (0.0	0.0	5.4	0	0.0	0.0	3.2	0 (0.0	0.0	4.5
disorders (10038738)																										
	Cough (10011224)	0	0.0	0.0	0 3.1	(0.0	0.0	0 4.	7 (0 (.0	0.0	2.8	0 (0.0	0.0	5.4	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	Respiratory arrest (10038669)	0	0.0	0.0	0 3.1	(0.0	0.0	0 4.	7	1 0	.8	0.0	4.3	0 (0.0	0.0	5.4	0	0.0	0.0	3.2	0 (0.0	0.0	4.5
	Upper respiratory tract congestion	0	0.0	0.0	0 3.1	(0.0	0.	0 4.	7 (0 (.0	0.0	2.8	0 (0.0	0.0	5.4	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	(10052252)																									
	Wheezing (10047924)	1	8.0	0.0	0 4.6	(0.0	0.0	0 4.	7 (0 (.0	0.0	2.8	0 (0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Table 8.23 Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship with vaccination, within the 31-day (Days 0-30) post-vaccination period following priming doses – by gender (Primary Total vaccinated cohort)

					Hexa	gro	oup					Р	edia	gro	oup					F	Penta	a gr	oup		
			Fe	mal	е		N	lale			Fei	male)		M	ale			Fe	male	,		N	/lale	
			N	= 10			N	= 94			N	= 80			N =	= 11 ₄			N	= 95			N	= 101	
					% CI				% CI				% CI				% CI				% CI				% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)		%		UL				UL	n				n				n			UL				UL
At least one symptom																								10.9	26.7
Blood and lymphatic system disorders (10005329)	Leukocytosis (10024378)	1	1.0	0.0	5.4	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
Gastrointestinal disorders (10017947)	Constipation (10010774)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0			3.2		0.0	0.0	3.8	1	1.0	0.0	5.4
·	Diarrhoea (10012735)	1	1.0	0.0	5.4	0	0.0	0.0	3.8	0	0.0	0.0	4.5	2	1.8	0.2	6.2		2.1	0.3	7.4	1	1.0	0.0	5.4
	Flatulence (10016766)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	1	1.1	0.0	5.7	0	0.0	0.0	3.6
	Vomiting (10047700)	1	1.0	0.0	5.4	2	2.1	0.3	7.5	2	2.5	0.3	8.7	1	0.9	0.0	4.8	0	0.0		3.8		3.0	0.6	8.4
General disorders and administration site conditions (10018065)	III-defined disorder (10061520)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Injection site bruising (10022052)	2	2.0	0.2	7.0	0	0.0	0.0	3.8	0	0.0	0.0	4.5	2	1.8	0.2	6.2	0	0.0	0.0	3.8	4	4.0	1.1	9.8
	Injection site erythema (10022061)	2	2.0	0.2	7.0	2	2.1	0.3	7.5	1	1.3	0.0	6.8	1	0.9	0.0	4.8	4	4.2	1.2	10.4	1	1.0	0.0	5.4
	Injection site induration (10022075)	2	2.0	0.2	7.0	1	1.1	0.0	5.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Injection site mass (10022081)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	1	1.3	0.0	6.8	1	0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Injection site pain (10022086)				8.4	1	1.1		5.8		5.0	1.4	12.3	2	1.8	0.2	6.2	2	2.1	0.3	7.4	5	5.0	1.6	11.2
	Injection site pruritus (10022093)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	1	1.3	0.0	6.8	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Injection site rash (10022094)	0	0.0	0.0	3.6	1	1.1	0.0	5.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2		1.1		5.7		1.0	0.0	5.4
	Injection site swelling (10053425)	3	3.0	0.6	8.4	1	1.1	0.0	5.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	3	3.2	0.7	9.0	1	1.0	0.0	5.4
	Injection site warmth (10022112)				3.6					0	0.0										3.8			0.0	3.6
	Oedema peripheral (10030124)				3.6					1							3.2		0.0		3.8				3.6
		0			3.6					1			6.8		0.0						3.8			_	3.6
	Pyrexia (10037660)	1	1.0	0.0	5.4	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	1	1.1	0.0	5.7	2	2.0	0.2	7.0

117119 (DTPA-HBV-IPV-135)

				-	Hexa	ar	NIIN.			1			Pedia	arr	nun.					-	Dant	2 (1)	roup	JUIT I	Final
			F۵	mal		gre		lale			Fai	mal		git		lale			Fο	male		a yı		Male	
				= 10				= 94				= 80				= 11	4			= 95				= 101	1
					% CI				% CI				% CI				% C	ı			, % CI				% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
	Swelling (10042674)						0.0			1			6.8				3.2		0.0		3.8			0.0	3.6
	Vaccination site bruising (10069484)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	2	1.8	0.2	6.2	1	1.1	0.0	5.7	0	0.0	0.0	3.6
	Vaccination site erythema (10059079)	0	0.0	0.0	3.6	1	1.1	0.0	5.8	2	2.5	0.3	8.7	2	1.8	0.2	6.2	3	3.2	0.7	9.0	0	0.0	0.0	3.6
	Vaccination site induration (10065117)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5				4.8		0.0		3.8		0.0	0.0	3.6
	Vaccination site pain (10068879)	2	2.0	0.2	7.0	0	0.0	0.0	3.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	2	2.1	0.3	7.4	1	1.0	0.0	5.4
	Vaccination site swelling (10069620)	1	1.0	0.0	5.4	2	2.1	0.3	7.5	0	0.0	0.0	4.5	1	0.9	0.0	4.8	1	1.1	0.0	5.7	1	1.0	0.0	5.4
Infections and infestations (10021881)	Nasopharyngitis (10028810)				3.6	1	1.1						4.5		0.0						3.8				3.6
	Upper respiratory tract infection (10046306)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	1	1.1		5.7		0.0	0.0	3.6
	Viral rash (10047476)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0			4.5		0.0				0.0	0.0	3.8	1	1.0	0.0	5.4
Musculoskeletal and connective tissue disorders (10028395)	Pain in extremity (10033425)	1	1.0	0.0	5.4	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
Nervous system disorders (10029205)	Hyperreflexia (10020745)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0			4.5				4.8		0.0		3.8	0	0.0	0.0	3.6
	Lethargy (10024264)	1	1.0		5.4	0	0.0			0							3.2		0.0		3.8		0.0	0.0	3.6
	Poor quality sleep (10062519)	0	0.0	0.0	3.6	1	1.1	0.0	5.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2		0.0		3.8		0.0	0.0	3.6
Psychiatric disorders (10037175)	Irritability (10022998)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
Respiratory, thoracic and mediastinal disorders (10038738)	Apparent life threatening event (10065044)	1	1.0	0.0	5.4	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
,	Cough (10011224)	0	0.0	0.0	3.6	1	1.1	0.0	5.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	0	0.0	0.0	3.8	1	1.0	0.0	5.4
	Nasal congestion (10028735)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	1	1.3	0.0	6.8	0	0.0	0.0	3.2	0	0.0	0.0	3.8	1	1.0	0.0	5.4
	Respiratory arrest (10038669)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	1	0.9	0.0	4.8	0	0.0	0.0	3.8	0	0.0	0.0	3.6
	Rhinorrhoea (10039101)		0.0				0.0			1			6.8				3.2		0.0		3.8	1	1.0	0.0	5.4
Skin and subcutaneous tissue disorders (10040785)	Erythema (10015150)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	1	1.3	0.0	6.8	0	0.0	0.0	3.2	0	0.0	0.0	3.8	0	0.0	0.0	3.6
·	Rash (10037844)	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	2	1.8	0.2	6.2	1	1.1	0.0	5.7	1	1.0	0.0	5.4

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Table 8.24 Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship with vaccination, within the 31-day (Days 0-30) post-vaccination period following priming doses—by geographical ancestry (Primary Total vaccinated cohort)

				Н	еха (group					Pedia	gro	ир					Р	enta	gro	up		
			W Cau	hite			ther = 7			_	hite asian			ther = 66			WI Cauc	nite Pasia	n			ther = 81	
				= 118			_ '	•			: 128			- 00		`		: 115				- 01	
				95	% CI		95	% CI			95% C	I		95%	CI			95%	6 CI			95%	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)		%	LL		n %			n		LL UL			LL (LL		n '			UL
At least one symptom		15									9.8 23.												
Blood and lymphatic system disorders (10005329)	Leukocytosis (10024378)	1	8.0	0.0	4.6	0.0	0.0	4.7	0	0.0	0.0 2.8	0 0	0.0	0.0 5	5.4	0	0.0	0.0	3.2	0 (0.0	0.0	4.5
Gastrointestinal disorders (10017947)	Constipation (10010774)	0	0.0	0.0	3.1	0.0	0.0	4.7	0	0.0	0.0 2.8	0 0	0.0	0.0 5	5.4	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	Diarrhoea (10012735)	1	8.0	0.0	4.6	0.0	0.0	4.7	0	0.0	0.0 2.8	2 3	3.0	0.4	10.5	1	0.9	0.0	4.7	2 :	2.5	0.3	8.6
	Flatulence (10016766)	0	0.0	0.0	3.1	0.0	0.0	4.7	0	0.0	0.0 2.8	0 0	0.0	0.0 5	5.4	1	0.9	0.0	4.7	0	0.0	0.0	4.5
	Vomiting (10047700)	1	8.0	0.0	4.6	2 2.6	0.3	9.1	1	8.0	0.0 4.3			0.4	10.5	1	0.9	0.0	4.7	2	2.5	0.3	8.6
General disorders and administration site conditions (10018065)	III-defined disorder (10061520)	0	0.0	0.0	3.1	0.0	0.0	4.7	1	8.0	0.0 4.3	0 0	0.0	0.0 5	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Injection site bruising (10022052)	2	1.7	0.2	6.0	0.0	0.0	4.7	2	1.6	0.2 5.5	0 0	0.0	0.0	5.4	2	1.7	0.2	6.1	2	2.5	0.3	8.6
	Injection site erythema (10022061)	2	1.7	0.2	6.0	2 2.6	0.3	9.1	2	1.6	0.2 5.5	0 0	0.0	0.0 5	5.4	3	2.6	0.5	7.4	2	2.5	0.3	8.6
	Injection site induration (10022075)	1	8.0	0.0	4.6	2 2.6	0.3	9.1	0	0.0	0.0 2.8	0 0	0.0	0.0 5	5.4	0	0.0	0.0	3.2	0 (0.0	0.0	4.5
	Injection site mass (10022081)	0	0.0	0.0	3.1	0.0	0.0	4.7			0.2 5.5	0 0	0.0	0.0 5	5.4			0.0	3.2	0	0.0	0.0	4.5
	Injection site pain (10022086)	2	1.7	0.2	6.0	2 2.6	0.3	9.1	5	3.9	1.3 8.9	1 1	1.5	0.0	3.2	6	5.2	1.9	11.0	1	1.2	0.0	6.7
	Injection site pruritus (10022093)	0	0.0	0.0	3.1	0.0	0.0	4.7	0	0.0	0.0 2.8	1 1	1.5	0.0	3.2	0	0.0	0.0	3.2	0	0.0	0.0	4.5

117119 (DTPA-HBV-IPV-135)

				F	lexa (group					Р	edia	group					ı	Penta	a ar		<i>7</i> 0111	Finai
			V	/hite			othe	r		W	hite			othe	r		W	hite	• • • • • • • • • • • • • • • • • • • •	. 9.		ther	
				casi			1 = 7			Cauc		an		V = 6			Cau		an			= 81	
				= 11							= 128							= 11					
				95	% CI		95	5% CI			95	% CI		95	% C	I		95	% CI			95°	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n %	LL	UL	n	%	LL	UL	n %	LL	UL	n	%	LL	UL	n	%	LL	UL
	Injection site rash (10022094)	1	8.0	0.0	4.6	0.0	0.0	4.7	0	0.0	0.0	2.8	0.0	0.0	5.4	1	0.9	0.0	4.7	1	1.2	0.0	6.7
	Injection site swelling (10053425)	2	1.7	0.2	6.0	2 2.6	0.3	9.1	1	8.0	0.0	4.3	0.0	0.0	5.4	1	0.9	0.0	4.7	3	3.7	8.0	10.4
	Injection site warmth (10022112)		0.0	0.0	3.1	0 0.0							0.0					0.0	3.2	0	0.0	0.0	4.5
			0.0	0.0		0.0							0.0						3.2			0.0	
	Peripheral swelling (10048959)	0	0.0	0.0		0.0		4.7				2.8	1 1.5		8.2				3.2				4.5
	Pyrexia (10037660)	1				0.0							0.0						3.2				10.4
	Swelling (10042674)	0	0.0	0.0		0.0		4.7				2.8	1 1.5		8.2			0.0	3.2	0	0.0	0.0	4.5
	Vaccination site bruising (10069484)	0	0.0	0.0	3.1	0.0	0.0	4.7	2	1.6	0.2	5.5	0.0	0.0	5.4	1	0.9	0.0	4.7	0	0.0	0.0	4.5
	Vaccination site erythema (10059079)	1	8.0	0.0	4.6	0.0	0.0	4.7	4	3.1	0.9	7.8	0.0	0.0	5.4	2	1.7	0.2	6.1	1	1.2	0.0	6.7
	Vaccination site induration (10065117)	0	0.0	0.0	3.1	0.0	0.0	4.7	1	8.0	0.0	4.3	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Vaccination site pain (10068879)	2	1.7	0.2	6.0	0.0	0.0	4.7	1	8.0	0.0	4.3	0.0	0.0	5.4	2	1.7	0.2	6.1	1	1.2	0.0	6.7
	Vaccination site swelling (10069620)	3	2.5	0.5	7.3	0.0	0.0	4.7	1	8.0	0.0	4.3	0.0	0.0	5.4	1	0.9	0.0	4.7	1	1.2	0.0	6.7
Infections and infestations (10021881)	Nasopharyngitis (10028810)		0.0	0.0	3.1	1 1.3	0.0	7.0	0				0.0					0.0	3.2	0	0.0	0.0	4.5
	Upper respiratory tract infection (10046306)	0	0.0	0.0	3.1	0.0	0.0	4.7	0	0.0	0.0	2.8	0.0	0.0	5.4	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	Viral rash (10047476)	0	0.0	0.0	3.1	0.0	0.0	4.7	0	0.0	0.0	2.8	0.0	0.0	5.4	0	0.0	0.0	3.2	1	1.2	0.0	6.7
Musculoskeletal and connective tissue disorders (10028395)	Pain in extremity (10033425)	0	0.0	0.0		1 1.3		7.0					0.0						3.2			0.0	
Nervous system disorders (10029205)	Hyperreflexia (10020745)	0	0.0	0.0		0.0							1 1.5						3.2			0.0	
	Lethargy (10024264)	1	8.0			0.0		4.7					0.0						3.2			0.0	
	Poor quality sleep (10062519)	1	8.0			0.0		4.7				2.8	0.0	0.0	5.4	0	0.0		3.2			0.0	
Psychiatric disorders (10037175)	Irritability (10022998)	0	0.0			0.0		4.7					0.0						3.2			0.0	
Respiratory, thoracic and mediastinal disorders (10038738)	Apparent life threatening event (10065044)	1	8.0	0.0	4.6	0.0	0.0	4.7	0	0.0	0.0	2.8	0.0	0.0	5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5

117119 (DTPA-HBV-IPV-135)

Report Final

				H	lexa ç	group					Pedia	group					F	Penta	gr	oup		
			W	/hite		0	ther			W	hite		othe	r		W	hite			0	ther	
			Cau	casi	an	N	= 7	7		Cauc	casian	I	V = 6	66		Cau	casia	an		N	= 81	
			N	= 11	8					N =	128					N :	= 11:	5				
				95	% CI		95	% CI			95% CI		95	5% CI			95	% CI			959	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL			LL	UL	n	%	LL UL	n %	LL	. UL	n	%	LL	UL	n	%	LL	
	Cough (10011224)	0	0.0	0.0	3.1	1 1.3	0.0	7.0	0	0.0	0.0 2.8	1 1.5	0.0	8.2	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	Nasal congestion (10028735)	0	0.0	0.0	3.1	0.0	0.0	4.7	0	0.0	0.0 2.8	1 1.5	0.0	8.2	0	0.0	0.0	3.2	1	1.2	0.0	6.7
	Respiratory arrest (10038669)	0	0.0	0.0	3.1	0.0	0.0	4.7	1	8.0	0.0 4.3	0.0	0.0	5.4	0	0.0	0.0	3.2	0		0.0	
	Rhinorrhoea (10039101)	0	0.0	0.0			0.0	4.7	1	8.0	0.0 4.3	0.0		5.4			0.0	3.2	1	1.2	0.0	6.7
Skin and subcutaneous tissue disorders	Erythema (10015150)	0	0.0	0.0	3.1	0.0	0.0	4.7	0	0.0	0.0 2.8	1 1.5	0.0	8.2	0	0.0	0.0	3.2	0	0.0	0.0	4.5
(10040785)																						
	Rash (10037844)	0	0.0	0.0	3.1	0.0	0.0	4.7	2	1.6	0.2 5.5	0.0	0.0	5.4	0	0.0	0.0	3.2	2	2.5	0.3	8.6

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

117119 (DTPA-HBV-IPV-135)

Report Final

Table 8.25 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship with vaccination, within the 31-day (Days 0-30) post-vaccination period following priming doses- by gender (Primary Total vaccinated cohort)

			Не	exa ç	group)			Pe	dia g	grou	р			Pen	ta g	roup	
		Fe	male)	Ň	/lale		Fe	male	9	ı	Male		Fe	male		M	ale
		N:	= 101	1	N	= 94	1	N	= 80)	N	= 11	4	N	= 95		N =	= 101
			95	%		95%	6 CI		95%	6 CI		95%	S S		95%	CI		95% CI
			С	-														
Primary System Organ Class (CODE)	Preferred Term (CODE)																	LL UL
At least one symptom		0.0	0.0	3.6	1 1.1	0.0	5.8	1 1.3	0.0	6.8	3 2.6	0.5	7.5	0.0	0.0	.8 1	1.0	0.0 5.4
Gastrointestinal disorders (10017947)	Vomiting (10047700)	0.0	0.0	3.6	1 1.1	0.0	5.8	0.0	0.0	4.5	0.0	0.0	3.2	0.0	0.0 3	.8 0	0.0	0.0 3.6
General disorders and administration site conditions	Ill-defined disorder (10061520)	0.0	0.0	3.6	0.0	0.0	3.8	0.0	0.0	4.5	1 0.9	0.0	4.8	0.0	0.0 3	.8 0	0.0	0.0 3.6
(10018065)																		
	Injection site erythema	0.0	0.0	3.6	0.0	0.0	3.8	0.0	0.0	4.5	1 0.9	0.0	4.8	0.0	0.0 3	.8 0	0.0	0.0 3.6
	(10022061)																	
	Injection site pain (10022086)																	0.0 5.4
	Injection site swelling (10053425)	0.0	0.0	3.6	0.0	0.0	3.8	0.0	0.0	4.5	1 0.9	0.0	4.8	0.0	0.0 3	.8 0	0.0	0.0 3.6
	Injection site warmth (10022112)	0.0	0.0	3.6	0.0	0.0	3.8	0.0	0.0	4.5	1 0.9	0.0	4.8	0.0	0.0 3	.8 0	0.0	0.0 3.6
Psychiatric disorders (10037175)	Irritability (10022998)																	0.0 3.6
Respiratory, thoracic and mediastinal disorders (10038738)	Respiratory arrest (10038669)	0.0	0.0	3.6	0.0	0.0	3.8	0.0	0.0	4.5	1 0.9	0.0	4.8	0.0	0.0 3	.8 0	0.0	0.0 3.6

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Report Final

Table 8.26 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship with vaccination, within the 31-day (Days 0-30) post-vaccination period following priming doses- by geographical ancestry (Primary Total vaccinated cohort)

			Не	exa g	rou	ıp				Pe	dia g	rou	0				Pe	nta g	roup		
		Cau	Vhite Icasi = 11	an			ther = 77		Cau	Vhite ucasia = 12	an		oth N =	-		Cau	Vhite Icasi = 11	an		other	
			95	% CI			95			959	% CI			95%)		959	% CI			5%
				1			С				1			CI		1		1	1		CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n %			-		-	UL r		_		n %					LL		n %		
At least one symptom		0.0						7.0 4			7.8						0.0	4.7	0.0	0.0	4.5
Gastrointestinal disorders (10017947)	Vomiting (10047700)	0.0	0.0	3.1	1	1.3	0.0	7.0 0	0.0	0.0	2.8	0 0	.0 0	.0 5	.4 0	0.0	0.0	3.2	0.0	0.0	4.5
General disorders and administration site conditions (10018065)	III-defined disorder (10061520)	0.0	0.0	3.1	0	0.0	0.0	4.7 1	8.0	0.0	4.3	0 0	.0 0	.0 5	.4 0	0.0	0.0	3.2	0.0	0.0	4.5
	Injection site erythema (10022061)	0.0	0.0	3.1	0	0.0	0.0	4.7 1	8.0	0.0	4.3	0 0	.0 0	.0 5	.4 0	0.0	0.0	3.2	0.0	0.0	4.5
	Injection site pain (10022086)	0.0	0.0	3.1	0	0.0	0.0	4.7 1	0.8	0.0	4.3	0 0	.0 0	.0 5	.4 1	0.9	0.0	4.7	0.0	0.0	4.5
	Injection site swelling (10053425)	0.0	0.0	3.1	0	0.0	0.0	4.7 1	8.0	0.0	4.3	0 0	.0 0	.0 5	.4 0	0.0	0.0	3.2	0.0	0.0	4.5
	Injection site warmth (10022112)	0.0	0.0	3.1	0	0.0	0.0	4.7 1	8.0	0.0	4.3	0 0	.0 0	.0 5	.4 0	0.0	0.0	3.2	0.0	0.0	4.5
Psychiatric disorders (10037175)	Irritability (10022998)	0.0	0.0	3.1	0	0.0	0.0	4.7 1	0.8	0.0	4.3	0 0	.0 0	.0 5	.4 0	0.0	0.0	3.2	0.0	0.0	4.5
Respiratory, thoracic and mediastinal disorders (10038738)	Respiratory arrest (10038669)	0.0	0.0	3.1	0	0.0	0.0	4.7 1	8.0	0.0	4.3	0 0	.0 0	.0 5	.4 0	0.0	0.0	3.2	0.0	0.0	4.5

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Table 8.27 Percentage of doses with unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term, within the 31-day (Days 0-30) post-vaccination period following priming doses – by gender (Primary Total vaccinated cohort)

				I	lexa	gro	oup					P	edia	gro	up					F	enta	gre	oup	-	
				male = 292			· N	lale = 272				male = 230			· N	lale = 337	7			male = 268	ļ		· N	/lale = 297	7
				959	6 CI			95%	6 CI			95%	6 CI			959	% CI			959	% CI			95%	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)		%	LL	UL	n			UL		%				%	LL	UL	n	%	LL		n			UL
At least one symptom		72	24.7	19.8	30.0	87	32.0	26.5	37.9	56	24.3	18.9	30.4	93	27.6	22.9	32.	7 66	24.6	19.6	30.2	77	25.9	21.0	31.3
Blood and lymphatic system disorders (10005329)	Anaemia (10002034)	1	0.3		1.9	0	0.0	0.0				0.0	1.6				1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Leukocytosis (10024378)	1		0.0				0.0									1.1	0	0.0	0.0		0	0.0	0.0	1.2
	Lymphadenopathy (10025197)	2		0.1				0.0			0.0		1.6		0.3	0.0	1.6		0.0	0.0	1.4			0.0	1.2
Cardiac disorders (10007541)	Cyanosis (10011703)	0		0.0				0.0								0.0			0.7		2.7			0.0	1.2
Congenital, familial and genetic disorders (10010331)	Congenital skin dimples (10072978)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	3	0.9	0.2	2.6	1	0.4	0.0	2.1	0	0.0	0.0	1.2
	Dermoid cyst (10012522)	0		0.0				0.0					1.6	1	0.3	0.0	1.6		0.0	0.0	1.4	0	0.0	0.0	1.2
	Hydrocele (10020488)	0	0.0	0.0	1.3			0.0	1.3	0	0.0		1.6		0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Hypospadias (10021093)	0	0.0	0.0		0		0.0			0.0		1.6		0.6	0.1	2.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	, , , , , , , , , , , , , , , , , , , ,	1		0.0	1.9				2.0		0.4					0.0	1.1	0	0.0	0.0	1.4			0.0	1.2
	Plagiocephaly (10048586)	0		0.0				0.0			0.0		1.6		0.3	0.0	1.6		0.0	0.0	1.4		0.0	0.0	1.2
Ear and labyrinth disorders (10013993)	Cerumen impaction (10050337)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	1	0.4	0.0	2.4	0	0.0	0.0	1.1	1	0.4	0.0	2.1	1	0.3	0.0	1.9
	Ear disorder (10014004)	0		0.0		0		0.0		0	0.0	0.0	1.6		0.0	0.0	1.1	0	0.0	0.0	1.4	1	0.3	0.0	1.9
	Ear pain (10014020)	0		0.0				0.0								0.0	1.1		0.4	0.0	2.1			0.0	1.2
Eye disorders (10015919)	Dacryostenosis acquired (10053990)	0	0.0	0.0	1.3	2	0.7	0.1	2.6	0	0.0	0.0	1.6	1	0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
Gastrointestinal disorders (10017947)	Abdominal pain upper (10000087)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	1	0.4	0.0	2.4	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Anal fistula (10002156)	0		0.0	1.3								1.6			0.0	1.1	0	0.0	0.0			0.0		1.2
	Constipation (10010774)	0	0.0	0.0	1.3		0.4			3	1.3			0	0.0	0.0	1.1	1	0.4	0.0	2.1	4	1.3	0.4	
	Diarrhoea (10012735)	4		0.4		3	1.1		3.2	1	0.4			4	1.2	0.3	3.0	6	2.2		4.8	5	1.7	0.5	3.9
	Flatulence (10016766)	1	0.3	0.0	1.9	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	1	0.4	0.0	2.1	0	0.0	0.0	1.2

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	auc					F	Pedia	arc	auc						Penta	a ar		JOIL	Finai
			Fe	male		J		Male			Fe	male		. g		Viale			Fe	emal		. g.		Male	
			N	= 292	2		N	= 27	2		N	= 230)		N	= 337	7		N	= 26	8		N	= 29	7
				959	% CI				% CI				% CI			959	% CI			95	% CI			95	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
	Frequent bowel movements (10017367)							0.0								0.0			0.0			0	0.0	0.0	1.2
	disease (10017885)															0.5								0.0	
	Inguinal hernia (10022016)		0.0		1.3			0.0			0.0					0.0			0.0		1.4				1.2
	Teething (10043183)	3	1.0	0.2							0.9						3.8								3.9
	Vomiting (10047700)		1.4								1.7					0.3									4.3
	Vomiting projectile (10047708)		0.0		1.3						0.0					0.0			0.0		1.4				1.2
General disorders and administration site conditions (10018065)	Adverse drug reaction (10061623)	0	0.0	0.0	1.3			0.0			0.0					0.0			0.0		1.4	1	0.3	0.0	1.9
			0.0		1.3	1	0.4	0.0	2.0	1	0.4	0.0	2.4	0		0.0			0.0		1.4		0.0	0.0	1.2
	III-defined disorder (10061520)	0	0.0	0.0	1.3						0.0					0.0			0.0	0.0	1.4	0	0.0	0.0	1.2
	Injection site bruising (10022052)	2	0.7	0.1	2.5	0	0.0	0.0	1.3	0	0.0	0.0	1.6	2	0.6	0.1	2.1	0	0.0	0.0	1.4	5	1.7	0.5	3.9
	Injection site erythema (10022061)	2	0.7	0.1	2.5	2	0.7	0.1	2.6	1	0.4	0.0	2.4	1	0.3	0.0	1.6	4	1.5	0.4	3.8	1	0.3	0.0	1.9
	Injection site induration (10022075)	2	0.7	0.1	2.5	1	0.4	0.0	2.0	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Injection site mass (10022081)	0	0.0					0.0				0.0				0.0							0.0	0.0	1.2
	Injection site pain (10022086)	4			3.5			0.0				0.5				0.3			0.7	0.1		5		0.5	3.9
	Injection site pruritus (10022093)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	1	0.4	0.0	2.4	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Injection site rash (10022094)	0	0.0	0.0	1.3	1	0.4	0.0	2.0	0	0.0	0.0	1.6	0	0.0	0.0	1.1	1	0.4		2.1	1	0.3	0.0	1.9
	Injection site swelling (10053425)	3	1.0	0.2	3.0	1	0.4	0.0	2.0	0	0.0	0.0	1.6	1	0.3	0.0	1.6	3	1.1	0.2	3.2	1	0.3	0.0	1.9
	Injection site warmth (10022112)	0		0.0				0.0				0.0				0.1			0.0			0		0.0	
	Oedema peripheral (10030124)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	1						0.0						0	0.0	0.0	1.2
	Peripheral swelling (10048959)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	3	1.3	0.3	3.8	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2

117119 (DTPA-HBV-IPV-135)

					Hexa	aro	un					F	Pedia	arc	าเมา					-	enta	ar		וווטכ	Final
			Fe	male		9.0		lale			Fe	male		. 9. \		/lale			Fe	male		9.		Male	
				= 292				= 272	2			= 230				= 337	7			= 26				= 297	7
					% CI				% CI				% CI				% CI				% CI				% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
	Pyrexia (10037660)	3	1.0		3.0			1.8		1		0.0				0.5			2.6	1.1	5.3	9	3.0	1.4	5.7
	Swelling (10042674)	0	0.0	0.0	1.3		0.0		1.3	1		0.0				0.0			0.0	0.0	1.4			0.0	1.2
	Vaccination site bruising (10069484)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	3	0.9	0.2	2.6	1	0.4	0.0	2.1	0	0.0	0.0	1.2
	Vaccination site erythema (10059079)	0	0.0	0.0	1.3	2	0.7	0.1	2.6	2	0.9	0.1	3.1	2	0.6	0.1	2.1	3	1.1	0.2	3.2	0	0.0	0.0	1.2
	Vaccination site induration (10065117)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	1	0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Vaccination site pain (10068879)	2	0.7	0.1	2.5	0	0.0	0.0	1.3	0	0.0	0.0	1.6	1	0.3	0.0	1.6	2	0.7	0.1	2.7	1	0.3	0.0	1.9
	Vaccination site swelling (10069620)	1	0.3	0.0	1.9	2	0.7	0.1	2.6	0	0.0	0.0	1.6	1	0.3	0.0	1.6	1	0.4	0.0	2.1	1	0.3	0.0	1.9
Immune system disorders (10021428)	Food allergy (10016946)			0.0	1.3		0.0				0.0					0.0				0.0	1.4			0.0	1.2
	Milk allergy (10027633)			0.0	1.3		0.0				0.0		1.6			0.0			0.4	0.0	2.1	0	0.0	0.0	1.2
Infections and infestations (10021881)	Acute sinusitis (10001076)			0.0	1.3			0.0			0.4					0.0			0.0	0.0	1.4			0.0	1.2
	Anal abscess (10048946)			0.0	1.3						0.0		1.6			0.0			0.0	0.0	1.4			0.0	1.2
	Bronchiolitis (10006448)		0.7	0.1	2.5						0.0		1.6			0.0			0.0	0.0	1.4			0.0	1.9
	Bronchitis (10006451)		0.3	0.0	1.9		0.0				0.0		1.6						0.0	0.0	1.4			0.0	1.2
	Candida infection (10074170)	2	0.7	0.1	2.5		0.0		1.3			0.0	2.4				1.6		0.0	0.0	1.4			0.0	1.2
	Candida nappy rash (10007135)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	1	0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Cellulitis (10007882)	0	0.0	0.0	1.3			0.0								0.0	1.1	0	0.0	0.0	1.4	1	0.3	0.0	1.9
	Conjunctivitis (10010741)	1	0.3	0.0	1.9					2	0.9	0.1	3.1	6	1.8	0.7	3.8	1	0.4	0.0	2.1	0	0.0	0.0	1.2
	Conjunctivitis bacterial (10061784)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	1	0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Conjunctivitis viral (10010755)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	1	0.4	0.0	2.1	0	0.0	0.0	1.2
	Croup infectious (10011416)	1		0.0	1.9			0.0	2.0	0		0.0	1.6						0.0	0.0	1.4	0		0.0	1.2
	Ear infection (10014011)	0		0.0	1.3	0	0.0	0.0	1.3	0	0.0		1.6						0.0	0.0	1.4	1		0.0	1.9
	Eczema herpeticum (10014197)			0.0			0.0				0.0					0.0	1.1			0.0	2.1	0	0.0	0.0	1.2

117119 (DTPA-HBV-IPV-135)

		Τ			Hexa	arc	าเมา					F	Pedia	ara	าเมต						Penta	ar		ort I	1110
			Fe	male		. 9		Male			Fe	male		9.,		Male			Fe	male		. g.		/lale	
				= 29				= 27	2			= 230				= 337	7			= 26				= 297	7
					% CI				% CI				% CI				% CI				% CI				% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)		%	LL	UL	n		LL	UL	n		LL				LL	UL	n			UL	n	%	LL	UL
	Exanthema subitum (10015586)											0.0				0.0					1.4			0.0	
	Fungal infection (10017533)					0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0		1.4			0.0	
	Fungal skin infection (10017543)			0.0	1.3							0.0				0.0			0.0	0.0	1.4	0		0.0	
	Gastric infection (10056663)							0.0								0.0				0.0	1.4			0.0	
	Gastroenteritis (10017888)	0	0.0	0.0	1.3			0.0				0.0				0.0				0.0	2.1			0.0	
	Hand-foot-and-mouth disease (10019113)											0.0				0.0				0.0	2.1	0		0.0	
	Herpangina (10019936)		0.0	0.0							0.0					0.0			0.0	0.0	1.4			0.0	1.2
	Impetigo (10021531)			0.0	1.3							0.0			0.0	0.0	1.1	1	0.4	0.0	2.1	2	0.7	0.1	2.4
	Influenza (10022000)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	1	0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Nasopharyngitis (10028810)		0.7	0.1	2.5	1	0.4	0.0	2.0	1	0.4	0.0	2.4	0	0.0	0.0	1.1	3	1.1	0.2	3.2	0	0.0	0.0	1.2
	Oral candidiasis (10030963)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	1	0.4	0.0	2.4	0	0.0	0.0	1.1	0	0.0	0.0	1.4	1	0.3	0.0	1.9
	Otitis externa (10033072)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	1	0.4	0.0	2.4	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Otitis media (10033078)	4	1.4	0.4	3.5	5	1.8	0.6	4.2	2	0.9	0.1	3.1	5	1.5	0.5	3.4	2	0.7	0.1	2.7	7	2.4	1.0	4.8
	Otitis media acute (10033079)	1	0.3	0.0	1.9	0	0.0	0.0	1.3	1	0.4	0.0	2.4	1	0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Otitis media chronic (10033081)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	1	0.3	0.0	1.9
	Parainfluenzae virus infection (10061907)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	1	0.4	0.0	2.1	0	0.0	0.0	1.2
	Pertussis (10034738)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	1	0.3	0.0	1.9
	Pharyngitis (10034835)	0	0.0	0.0	1.3			0.1								0.0			0.0	0.0	1.4	0	0.0	0.0	1.2
	Pneumonia (10035664)	1	0.3	0.0	1.9			0.0			0.0		1.6			0.0			0.0	0.0	1.4				1.2
	Respiratory syncytial virus	1	0.3	0.0	1.9						0.0					0.0			0.0	0.0	1.4			0.0	
	bronchiolitis (10038718)																								
	Respiratory syncytial virus infection (10061603)	0	0.0	0.0	1.3	1	0.4	0.0	2.0	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Respiratory tract infection (10062352)	1	0.3	0.0	1.9	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Rhinitis (10039083)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	1	0.4	0.0	2.1	0	0.0	0.0	1.2

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	auc					F	Pedia	arc	auc					-	Penta	ar	_	<i>,</i> 011 1	-ınaı
			Fe	male		9.0		/lale			Fe	male]		/lale			Fe	male		J.		/lale	
				= 292				= 272	2			= 230				= 337	7			= 26				= 297	1
				95	% CI			959	% CI			959	% CI			959	% CI			95	% CI			95%	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
	Roseola (10039222)	0	0.0	0.0	1.3	0	0.0		1.3		0.0	0.0	1.6	1	0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Sinusitis (10040753)	0	0.0	0.0	1.3			0.0	1.3		0.0	0.0	1.6	0	0.0	0.0	1.1	1	0.4	0.0	2.1	0	0.0	0.0	1.2
	Skin candida (10054152)	1	0.3	0.0	1.9	0	0.0	0.0	1.3			0.0	1.6	0					0.0	0.0	1.4	1	0.3	0.0	1.9
	Upper respiratory tract infection (10046306)	13	4.5	2.4	7.5	19	7.0	4.3	10.7	9	3.9	1.8	7.3	17	5.0	3.0	8.0	11	4.1	2.1	7.2	16	5.4	3.1	8.6
	Urinary tract infection (10046571)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	2	0.6	0.1	2.1	1	0.4	0.0	2.1	0	0.0	0.0	1.2
	Viraemia (10058874)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	1	0.4	0.0	2.1	0	0.0	0.0	1.2
	Viral infection (10047461)	1	0.3	0.0	1.9			0.0					1.6	1	0.3	0.0	1.6	1	0.4	0.0	2.1	2	0.7	0.1	2.4
	Viral rash (10047476)	1	0.3	0.0	1.9			0.1					1.6			0.0	1.1	2	0.7	0.1	2.7	1	0.3	0.0	1.9
	Viral upper respiratory tract infection (10047482)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0		0	0.0	0.0	1.1	0	0.0	0.0	1.4	2	0.7	0.1	2.4
Injury, poisoning and procedural complications (10022117)	Arthropod bite (10003399)	1	0.3	0.0	1.9	1	0.4	0.0	2.0	0	0.0	0.0	1.6	1	0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Arthropod sting (10003402)	0	0.0	0.0	1.3	1	0.4	0.0	2.0	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Clavicle fracture (10009245)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	1	0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Concussion (10010254)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	1	0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Corneal abrasion (10010984)	1	0.3	0.0	1.9	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Craniocerebral injury (10070976)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	1	0.4	0.0	2.4	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Fall (10016173)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	1	0.4	0.0	2.1	0	0.0	0.0	1.2
	Foreign body (10070245)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	1	0.4	0.0	2.1	0	0.0	0.0	1.2
	Head injury (10019196)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	2	0.7	0.1	2.4
	Nasal injury (10078651)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	1	0.3	0.0	1.9
	Thermal burn (10053615)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	1	0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
Investigations (10022891)	Body temperature increased (10005911)	0	0.0	0.0	1.3	1	0.4	0.0	2.0	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	1	0.3	0.0	1.9
	Cardiac murmur (10007586)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	1	0.4	0.0	2.1	0	0.0	0.0	1.2
	Weight decreased (10047895)		0.0	0.0	1.3	1	0.4	0.0	2.0			0.0	1.6			0.0	1.1		0.4	0.0		0	0.0	0.0	1.2
Musculoskeletal and connective tissue disorders (10028395)	Asymmetric gluteal fold (10072189)		0.3	0.0	1.9			0.0	1.3		0.0		1.6			0.0			0.0	0.0	1.4	0		0.0	1.2

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	auc					F	Pedia	ara	auc					F	Penta	ar	_	JUILI	Finai
			Fe	male		9		Male			Fe	male		9.1		/lale			Fe	male		9.		/lale	
				= 292				= 27	2			= 230				= 337	7			= 268				= 297	7
				95	% CI			95	% CI			959	% CI			959	% CI			959	% CI			959	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
	Pain in extremity (10033425)	2	0.7	0.1	2.5			0.0	1.3			0.0				0.0	1.1		0.0	0.0	1.4	1		0.0	1.9
	Positional plagiocephaly (10068711)	0	0.0	0.0	1.3		0.0	0.0	1.3			0.0	1.6			0.0	1.6		0.0	0.0		0		0.0	1.2
Neoplasms benign, malignant and unspecified (incl cysts and polyps) (10029104)	Haemangioma (10018814)															0.0				0.0	1.4			0.0	
Nervous system disorders (10029205)	Hyperreflexia (10020745)		0.0	0.0	1.3				1.3		0.0		1.6			0.0			0.0	0.0	1.4				1.2
	Lethargy (10024264)	1	0.3	0.0	1.9		0.0	0.0		0		0.0	1.6			0.0	1.1	0	0.0	0.0	1.4	0		0.0	1.2
	Poor quality sleep (10062519)		0.0	0.0	1.3			0.0				0.0	1.6			0.0	1.1		0.0	0.0	1.4	0		0.0	1.2
	Tremor (10044565)		0.0	0.0	1.3				1.3			0.0	1.6				1.6		0.0	0.0		0		0.0	1.2
Psychiatric disorders (10037175)	Irritability (10022998)		0.0	0.0	1.3				4.2			0.1	3.1			0.0			0.4	0.0	2.1			0.0	1.2
	Screaming (10039740)	0	0.0	0.0	1.3			0.0	1.3				2.4			0.0	1.1		0.0	0.0	1.4			0.0	1.2
Renal and urinary disorders (10038359)	Urethral meatus stenosis (10058463)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	1	0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
Reproductive system and breast disorders (10038604)	Balanoposthitis (10004078)	0	0.0	0.0	1.3	2	0.7	0.1	2.6	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
, ,	Genital labial adhesions (10064162)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	1	0.4	0.0	2.4	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Penile adhesion (10059636)	0	0.0	0.0	1.3	3	1.1	0.2	3.2	0	0.0	0.0	1.6	3	0.9	0.2	2.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Penile erythema (10070655)	0	0.0	0.0	1.3		0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	1	0.3	0.0	1.9
Respiratory, thoracic and mediastinal disorders (10038738)	Apparent life threatening event (10065044)	1	0.3	0.0	1.9	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
. ,	Bronchial hyperreactivity (10066091)	0	0.0	0.0	1.3	2	0.7	0.1	2.6	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Cough (10011224)	7	2.4	1.0	4.9	9	3.3	1.5	6.2	0	0.0	0.0	1.6	7	2.1	8.0	4.2	2	0.7	0.1	2.7	5	1.7	0.5	3.9
	Dysphonia (10013952)	0	0.0	0.0	1.3	1	0.4	0.0	2.0	0	0.0	0.0	1.6	1	0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Epistaxis (10015090)	0	0.0	0.0	1.3				1.3		0.0		1.6			0.0			0.0	0.0	1.4	1		0.0	1.9
	Nasal congestion (10028735)	0	0.0	0.0	1.3			0.1				0.3	3.8			0.2			0.0	0.0	1.4	2		0.1	2.4
	Respiratory arrest (10038669)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	1	0.3	0.0	1.6	0	0.0	0.0	1.4	0		0.0	1.2
	Respiratory disorder (10038683)	1	0.3	0.0	1.9	0	0.0	0.0	1.3	1	0.4	0.0	2.4	1	0.3	0.0	1.6	0	0.0	0.0	1.4	1	0.3	0.0	1.9

117119 (DTPA-HBV-IPV-135)

					Hexa	aro	าเท					ŗ	Pedia	ara	าแท						Penta	ar		וווטכ	Finai
			Fe	male		gic		/lale			Fe	male		giv		/lale			Fe	male		ı gı		Male	
				= 292				= 272	2			= 23(= 337	7			= 26				= 297	7
					% CI				- % CI				% CI				% CI				% CI				% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL		n	%			n	%			n	%	LL	UL		%	_	UL
	Rhinitis allergic (10039085)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	1	0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Rhinorrhoea (10039101)		0.7	0.1	2.5			0.0		1	0.4	0.0	2.4	1		0.0	1.6	2	0.7	0.1	2.7	2	0.7	0.1	2.4
	Sinus congestion (10040742)	0	0.0	0.0	1.3	1	0.4	0.0	2.0	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Sneezing (10041232)	0	0.0	0.0	1.3	1	0.4	0.0	2.0	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Upper respiratory tract congestion (10052252)	1	0.3	0.0	1.9	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	1	0.3	0.0	1.9
	Wheezing (10047924)	0	0.0	0.0	1.3	3	1.1	0.2	3.2	0	0.0	0.0	1.6	0	0.0	0.0	1.1	1	0.4	0.0	2.1	1	0.3	0.0	1.9
Skin and subcutaneous tissue disorders (10040785)	Dermatitis (10012431)	0	0.0	0.0	1.3				3.2	1	0.4					0.0			0.0	0.0	1.4			0.0	1.2
	Dermatitis atopic (10012438)	0	0.0	0.0	1.3			0.1		1	0.4					0.1			0.4	0.0		4			3.4
	Dermatitis contact (10012442)	1	0.3	0.0	1.9			0.0	1.3		0.0						2.1		0.0	0.0		0		0.0	1.2
	Dermatitis diaper (10012444)	1	0.3	0.0	1.9				2.0	2	0.9		3.1						2.2	8.0	4.8	4		0.4	3.4
	Dry skin (10013786)	1	0.3	0.0	1.9			0.0	1.3			0.0	1.6			0.0			0.0	0.0	1.4	0		0.0	1.2
	Eczema (10014184)	3	1.0	0.2	3.0				2.0		0.9		3.1			0.2	2.6	2	0.7	0.1	2.7	2	0.7	0.1	2.4
	Erythema (10015150)	0	0.0	0.0	1.3			0.0	1.3		1.3	0.3	3.8			0.0	1.1	0	0.0	0.0	1.4	0		0.0	1.2
	Hair growth abnormal (10019044)	1	0.3	0.0	1.9	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Hypertrichosis (10020864)	0	0.0	0.0	1.3		0.0		1.3		0.4					0.0			0.0	0.0	1.4	0		0.0	1.2
	Intertrigo (10022622)	0	0.0	0.0	1.3		0.0		1.3		0.0						1.1		0.0	0.0	1.4	1		0.0	1.9
	Post inflammatory pigmentation change (10036229)	1	0.3	0.0	1.9	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0	0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Rash (10037844)	1	0.3	0.0	1.9				3.2		0.9						2.1		0.4	0.0	2.1	5		0.5	3.9
	Rash macular (10037867)		0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0		0.0				0.0	1.4				1.9
	Seborrhoea (10039792)	1	0.3	0.0	1.9			0.0	1.3	0	0.0		1.6			0.0			0.0	0.0	1.4				1.9
	Seborrhoeic dermatitis (10039793)	0		0.0					3.2		0.4								0.0	0.0	1.4	0			1.2
	Urticaria (10046735)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	1	0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of administered doses

n/% = number/percentage of doses with the symptom

Table 8.28 Percentage of doses with unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following priming doses- by geographical ancestry (Primary Total vaccinated cohort)

				ŀ	Hexa	gro	oup					Р	edia	gro	up					F	enta	gr	oup		
			W	hite			C	ther		Wł	nite C	auca	sian		0	ther			٧	/hite			0	ther	
				casia			N	= 225	5		N =	= 370			N	= 197	7			casia			N	= 230	J
			N	= 339				1				T				1			N	= 335				1	
				-	% CI		T		% CI		T		% CI		I		% CI		1		% CI		T	_	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)		%	LL	UL		%	LL	UL	n	%	LL	UL		%	LL	UL		%	LL	UL		%	LL	UL
At least one symptom		99	29.2	24.4	34.	4 60	26.7	21.0	33.0	103	27.8	23.3	32.7	46	23.4	17.6	29.9	9 86	25.7	21.1	30.7	57	24.8	19.3	30.9
Blood and lymphatic system disorders (10005329)	Anaemia (10002034)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Leukocytosis (10024378)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Lymphadenopathy (10025197)	1	0.3	0.0	1.6	1	0.4	0.0	2.5	0	0.0	0.0	1.0	1	0.5	0.0	2.8	0	0.0	0.0	1.1	0	0.0	0.0	1.6
Cardiac disorders (10007541)	Cyanosis (10011703)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	2	0.6	0.1	2.1	0	0.0	0.0	1.6
Congenital, familial and genetic disorders (10010331)	Congenital skin dimples (10072978)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	2	0.5	0.1	1.9	1	0.5	0.0	2.8	0	0.0	0.0	1.1	1	0.4	0.0	2.4
, ,	Dermoid cyst (10012522)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Hydrocele (10020488)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Hypospadias (10021093)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	2	0.5	0.1	1.9	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Macrocephaly (10050183)	2	0.6	0.1	2.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Plagiocephaly (10048586)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
Ear and labyrinth disorders	Cerumen impaction	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	1	0.5	0.0	2.8	1	0.3	0.0	1.7	1	0.4	0.0	2.4
(10013993)	(10050337)																								
	Ear disorder (10014004)			0.0	1.1		0.0	0.0		0	0.0	0.0				0.0	1.9	1	0.3	0.0			0.0	0.0	1.6
	Ear pain (10014020)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	auc					Р	edia	aro	up						Penta	ar		JOILI	Finai
			W	/hite		9. 3		ther		W	hite C					ther			٧	Vhite	0	· 9·		ther	
			Cau		an			= 22	5			= 370				= 197	7		Cau	casi: = 33				= 230	
				95	% CI			95	% CI			959	% CI			959	% CI			95	% CI			959	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
Eye disorders (10015919)	Dacryostenosis acquired (10053990)	1	0.3	0.0	1.6	1	0.4	0.0	2.5	1		0.0							0.0	0.0	1.1	0	0.0	0.0	1.6
Gastrointestinal disorders (10017947)	Abdominal pain upper (10000087)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Anal fistula (10002156)	0	0.0	0.0	1.1	1	0.4	0.0	2.5	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Constipation (10010774)	1	0.3					0.0	1.6	3	8.0	0.2	2.4	0	0.0	0.0	1.9	2	0.6	0.1	2.1	3	1.3	0.3	3.8
	Diarrhoea (10012735)	5	1.5	0.5	3.4	2	0.9	0.1	3.2	1	0.3	0.0	1.5	4	2.0	0.6	5.1	5	1.5	0.5	3.4	6	2.6	1.0	5.6
	Flatulence (10016766)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Frequent bowel movements (10017367)		0.0						1.6	1		0.0	1.5	0		0.0			0.0	0.0	1.1	0	0.0	0.0	1.6
	Gastrooesophageal reflux disease (10017885)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	5	1.4	0.4	3.1	3	1.5	0.3	4.4	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Inguinal hernia (10022016)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Teething (10043183)	5	1.5	0.5	3.4	1	0.4	0.0	2.5	5	1.4	0.4	3.1	3	1.5	0.3	4.4	5	1.5	0.5	3.4	4	1.7	0.5	4.4
	Vomiting (10047700)	3	0.9	0.2	2.6	6	2.7	1.0	5.7	5	1.4	0.4	3.1	3	1.5	0.3	4.4	3	0.9	0.2	2.6	7	3.0	1.2	6.2
	Vomiting projectile (10047708)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
General disorders and administration site conditions (10018065)	Adverse drug reaction (10061623)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	1	0.4	0.0	2.4
,	Crying (10011469)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	III-defined disorder (10061520)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Injection site bruising (10022052)	2	0.6	0.1	2.1	0	0.0	0.0	1.6	2	0.5	0.1	1.9	0	0.0	0.0	1.9	3	0.9	0.2	2.6	2	0.9	0.1	3.1
	Injection site erythema (10022061)	2	0.6	0.1	2.1	2	0.9	0.1	3.2	2	0.5	0.1	1.9	0	0.0	0.0	1.9	3	0.9	0.2	2.6	2	0.9	0.1	3.1
	Injection site induration (10022075)	1	0.3	0.0	1.6	2	0.9	0.1				0.0								0.0	1.1			0.0	
	Injection site mass (10022081)		0.0									0.1			0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Injection site pain (10022086)	2	0.6	0.1	2.1	3	1.3	0.3	3.8	7	1.9	8.0	3.9	1	0.5	0.0	2.8	6	1.8	0.7	3.9	1	0.4	0.0	2.4

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	un					P	edia	aro	un						Penta	aar		JOIL	Final
			Cau	/hite casi = 33	an	9.0	0	ther = 22	5	W	hite C N =			9.0	01	ther = 197	7		Cau	White ucasi = 33	an	. 9.	· o	ther = 230)
			11		₃ % CI			959	% CI			959	6 CI			959	% CI		IN		у % СІ			959	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%			n	%			n	%	LL			%	LL	UL		%		UL
\(\frac{1}{2}\)	Injection site pruritus (10022093)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	1	0.5	0.0	2.8	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Injection site rash (10022094)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	1	0.4	0.0	2.4
	Injection site swelling (10053425)		0.6	0.1	2.1	2	0.9	0.1	3.2	1	0.3		1.5	0	0.0	0.0	1.9	1	0.3	0.0	1.7	3		0.3	
	Injection site warmth (10022112)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	2	0.5	0.1	1.9	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Oedema peripheral (10030124)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Peripheral swelling (10048959)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	2	0.5	0.1	1.9	1	0.5	0.0	2.8	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Pyrexia (10037660)	12	3.5	1.8	6.1	1	0.4	0.0	2.5	5	1.4	0.4	3.1	1	0.5	0.0	2.8	9	2.7	1.2	5.0	7	3.0	1.2	6.2
	Swelling (10042674)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	1	0.5	0.0	2.8	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Vaccination site bruising (10069484)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	3	0.8	0.2	2.4	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Vaccination site erythema (10059079)	2	0.6	0.1	2.1	0	0.0	0.0	1.6	4	1.1	0.3	2.7	0	0.0	0.0	1.9	2	0.6	0.1	2.1	1	0.4	0.0	2.4
	Vaccination site induration (10065117)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Vaccination site pain (10068879)	2	0.6	0.1	2.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	2	0.6	0.1	2.1	1	0.4	0.0	2.4
	Vaccination site swelling (10069620)	3	0.9	0.2	2.6	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	1	0.3	0.0	1.7	1	0.4	0.0	2.4
Immune system disorders (10021428)	Food allergy (10016946)	0	0.0	0.0	1.1	0	0.0	0.0		1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Milk allergy (10027633)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
Infections and infestations (10021881)	Acute sinusitis (10001076)		0.0		1.1				1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Anal abscess (10048946)								1.6		0.0				0.0					0.0		0	0.0		
	Bronchiolitis (10006448)				1.6		0.9			0	0.0				0.0					0.0	1.1	1			2.4
	Bronchitis (10006451)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	un					P	edia	aro	un			I			Penta	anr		ort	Final
			W	/hite	IIGAC	gic		ther		W	Vhite C					ther			v	Vhite		y y i		ther	
			Cau	casi:				= 22	5			= 370				= 197	7		Cau	casia = 33	an			= 23(
				95	% CI			95	% CI			959	% CI			959	% CI			95	% CI			959	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
,	Candida infection (10074170)	1	0.3	0.0	1.6	1	0.4	0.0	2.5	2	0.5	0.1	1.9	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Candida nappy rash (10007135)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Cellulitis (10007882)	0	0.0	0.0	1.1	1	0.4	0.0	2.5	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	1	0.4	0.0	2.4
	Conjunctivitis (10010741)	5	1.5	0.5	3.4	5	2.2	0.7	5.1	5	1.4	0.4	3.1	3	1.5	0.3	4.4	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Conjunctivitis bacterial (10061784)		0.0						1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Conjunctivitis viral (10010755)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
			0.6		2.1		0.0	0.0		2	0.5	0.1	1.9	0		0.0			0.0	0.0	1.1	0	0.0	0.0	1.6
	Ear infection (10014011)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	1	0.4	0.0	2.4
	Eczema herpeticum (10014197)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	1	0.4	0.0	2.4
	Exanthema subitum (10015586)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Fungal infection (10017533)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Fungal skin infection (10017543)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Gastric infection (10056663)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	1	0.5	0.0	2.8	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Gastroenteritis (10017888)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0			0.1	3.6	0	0.0	0.0	1.1	1	0.4	0.0	2.4
	Hand-foot-and-mouth disease (10019113)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0	1	0.5	0.0	2.8	0	0.0	0.0	1.1	1	0.4	0.0	2.4
	Herpangina (10019936)	2	0.6	0.1	2.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Impetigo (10021531)		0.3					0.0		0	0.0		1.0			0.0				0.1		1			2.4
	Influenza (10022000)		0.0					0.0	1.6	1		0.0	1.5			0.0				0.0		0			1.6
				0.0				0.3	3.8	1		0.0	1.5			0.0				0.1	2.1	1			2.4
			0.0				0.0	0.0	1.6	1		0.0	1.5			0.0				0.0	1.1	1			2.4
	Otitis externa (10033072)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1		0.0	1.5			0.0			0.0	0.0	1.1	_			1.6
	\ /			0.7				0.3	3.8	7		8.0	3.9			0.0			1.8	0.7		3		0.3	3.8
	Otitis media acute (10033079)	0	0.0	0.0	1.1	1	0.4	0.0	2.5	0	0.0	0.0	1.0	2	1.0	0.1	3.6	0	0.0	0.0	1.1	0	0.0	0.0	1.6

117119 (DTPA-HBV-IPV-135)

					Hex	a gro	auc					Р	edia	aro	au					-	Penta	aar		ort I	IIIa
			V	/hite		- g. v		ther		W	hite C					ther			٧	Vhite	0	. <u>g</u> .		ther	-
			Cau	casi	an			= 22	5			= 370				= 197	7		Cau	ıcasi				= 230	
			N	= 33		ı		050	/ CI			0.50	/ CI			0.50)/ CI		N	= 33				OE	0/ CI
Drimany System Organ Class	Dreferred Term (CODE)	_	%		% CI		%		% CI	_	%		% CI		0/	LL	% CI		0/		% CI UL		0/	LL	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)				UL				UL			LL													
	Otitis media chronic (10033081)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Parainfluenzae virus infection (10061907)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	1	0.4	0.0	2.4
	Pertussis (10034738)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Pharyngitis (10034835)	2	0.6	0.1	2.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Pneumonia (10035664)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Respiratory syncytial virus bronchiolitis (10038718)	0	0.0	0.0	1.1	1	0.4	0.0	2.5	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Respiratory syncytial virus infection (10061603)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Respiratory tract infection (10062352)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Rhinitis (10039083)	0	0.0	0.0	1.1	0	0.0	0.0		0	0.0	0.0	1.0	0		0.0			0.0	0.0	1.1	1	0.4	0.0	2.4
	Roseola (10039222)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Sinusitis (10040753)		0.0				0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	1	0.4	0.0	2.4
	Skin candida (10054152)		0.3				0.0	0.0	_	0	0.0	0.0	1.0			0.0			0.0	0.0	1.1	1			2.4
	Upper respiratory tract infection (10046306)	17	5.0	2.9	7.9	15	6.7	3.8	10.8	18	4.9	2.9	7.6	8	4.1	1.8	7.8	21	6.3	3.9	9.4	6	2.6	1.0	5.6
	Urinary tract infection (10046571)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	1	0.5	0.0	2.8	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Viraemia (10058874)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Viral infection (10047461)		0.6	0.1	2.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0		0.0			0.9	0.2	2.6	0	0.0	0.0	1.6
	Viral rash (10047476)		0.3				0.9	0.1	3.2				1.0			0.0			0.0		1.1		1.3	0.3	3.8
	Viral upper respiratory tract infection (10047482)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	2	0.9	0.1	3.1
Injury, poisoning and procedural complications (10022117)	Arthropod bite (10003399)	2	0.6	0.1	2.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
. , ,	Arthropod sting (10003402)		0.3						1.6	0		0.0							0.0	0.0	1.1	0	0.0	0.0	1.6
	Clavicle fracture (10009245)		0.0						1.6	1		0.0				0.0			0.0	0.0	1.1	0	0.0	0.0	1.6

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	un					Р	edia	aro	un					F	Penta	ar		JOIL I	-ınaı
			W	/hite		9. 4		ther		w	hite C					ther			٧	Vhite	01110	· 9·		ther	
			Cau		an			= 22	5			= 370			_	= 197				ıcasia	n			= 230)
				= 33								-								= 33					
		95% CI 95% CI n % LL UL n %									959	% CI			959	% CI			959	% CI			95%	% CI	
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
	Concussion (10010254)			0.0	1.1		0.0	0.0	1.6	0		0.0	1.0				2.8		0.0			0			1.6
	Corneal abrasion (10010984)	1	0.3		1.6		0.0	0.0	1.6	0	0.0	0.0	1.0				1.9		0.0	0.0	1.1		0.0	0.0	1.6
	Craniocerebral injury (10070976)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	1	0.5	0.0	2.8	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Fall (10016173)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Foreign body (10070245)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9		0.0	0.0	1.1	1	0.4	0.0	2.4
	Head injury (10019196)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	1	0.4	0.0	2.4
	Nasal injury (10078651)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Thermal burn (10053615)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
Investigations (10022891)	Body temperature increased (10005911)	0	0.0	0.0	1.1	1	0.4	0.0	2.5	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Cardiac murmur (10007586)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Weight decreased (10047895)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
Musculoskeletal and connective tissue disorders (10028395)	Asymmetric gluteal fold (10072189)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0				0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
·	Pain in extremity (10033425)	0	0.0	0.0	1.1	2	0.9	0.1	3.2	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Positional plagiocephaly (10068711)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
Neoplasms benign, malignant and unspecified (incl cysts and polyps) (10029104)	Haemangioma (10018814)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
Nervous system disorders (10029205)	Hyperreflexia (10020745)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	1	0.5	0.0	2.8	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Lethargy (10024264)	1	0.3		1.6	0	0.0	0.0	1.6	0		0.0	1.0	0	0.0	0.0		0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Poor quality sleep (10062519)	1			1.6		0.0	0.0	1.6	0	0.0	0.0	1.0			0.0	1.9	0	0.0	0.0	1.1	0		0.0	1.6
	Tremor (10044565)	0			1.1		0.0	0.0	1.6	1	0.3	0.0	1.5			0.0			0.0	0.0		0		0.0	1.6
Psychiatric disorders (10037175)	Irritability (10022998)				3.0		0.4	0.0	2.5	3	8.0	0.2	2.4				1.9			0.0	1.7	0		0.0	1.6
	Screaming (10039740)				1.1		0.0	0.0	1.6	1		0.0	1.5				1.9		0.0	0.0		0		0.0	1.6
Renal and urinary disorders (10038359)	Urethral meatus stenosis (10058463)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	un					P	edia	aro	un			I			Penta	ar		וווטכ	Final
			W	hite	ICAC	gic		ther		w	hite C					ther			v	Vhite	Ciita	ı gı		ther	
			Cau		an			= 22	5	"		= 370				= 197	7			ıcasia	an			= 23(n
				= 339				LL	•			310	'			131				= 33			.,	200	,
					% CI			95	% CI			959	% CI			959	% CI				% CI			959	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%		UL		%		UL		%				%		UL	n	%		UL		%		UL
Reproductive system and breast disorders (10038604)	,		0.6						1.6			0.0								0.0	1.1	0		0.0	1.6
	(10064162)		0.0						1.6			0.0									1.1			0.0	
			0.9						1.6			0.1	1.9			0.0			0.0		1.1				1.6
	Penile erythema (10070655)		0.0					0.0	1.6			0.0	1.0			0.0			0.0	0.0	1.1				2.4
Respiratory, thoracic and mediastinal disorders (10038738)	Apparent life threatening event (10065044)		0.3						1.6			0.0				0.0			0.0	0.0	1.1				1.6
	Bronchial hyperreactivity (10066091)	0	0.0	0.0	1.1	2	0.9	0.1	3.2	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Cough (10011224)	11	3.2	1.6	5.7	5	2.2	0.7	5.1	4	1.1	0.3	2.7	3	1.5	0.3	4.4	5	1.5	0.5	3.4	2	0.9	0.1	3.1
	Dysphonia (10013952)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0	1	0.5	0.0	2.8	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Epistaxis (10015090)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Nasal congestion (10028735)	1	0.3	0.0	1.6	1	0.4	0.0	2.5	3	0.8	0.2	2.4	3	1.5	0.3	4.4	1	0.3	0.0	1.7	1	0.4	0.0	2.4
		0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Respiratory disorder (10038683)	0	0.0	0.0	1.1	1	0.4	0.0	2.5	2	0.5	0.1	1.9	0	0.0	0.0	1.9	0	0.0	0.0	1.1	1	0.4	0.0	2.4
	Rhinitis allergic (10039085)	0	0.0	0.0	1.1	0	0.0		1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Rhinorrhoea (10039101)	2	0.6	0.1	2.1	1	0.4	0.0	2.5	2	0.5	0.1	1.9	0	0.0	0.0	1.9	3	0.9	0.2	2.6	1	0.4	0.0	2.4
	Sinus congestion (10040742)	0	0.0	0.0	1.1	1	0.4	0.0	2.5	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Sneezing (10041232)	1	0.3	0.0	1.6		0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Upper respiratory tract congestion (10052252)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	1	0.4	0.0	2.4
	Wheezing (10047924)	1	0.3	0.0	16	2	0.9	0.1	3.2	0	0.0	0.0	1.0	0	0.0	0.0	19	2	0.6	0.1	2.1	0	0.0	0.0	1.6
Skin and subcutaneous tissue disorders (10040785)	Dermatitis (10012431)		0.6					0.0				0.0	1.0			0.0			0.0		1.1		0.0		1.6
,	Dermatitis atopic (10012438)	1	0.3	0.0	1.6	1	0.4	0.0	2.5	1	0.3	0.0	1.5	2	1.0	0.1	3.6	0	0.0	0.0	1.1	5	2.2	0.7	5.0
	Dermatitis contact (10012442)		0.3		1.6		0.0		1.6			0.1				0.0			0.0		1.1		0.0	0.0	1.6
	Dermatitis diaper (10012444)		0.3		1.6		0.4		2.5		0.5		1.9				2.8		0.9				3.0	1.2	6.2
			0.0		1.1							0.0				0.0					1.1				1.6

117119 (DTPA-HBV-IPV-135)

Report Final

					Hexa	gro	up					Р	edia	grou	ıp					F	Penta	gr			rillai
			Cau	Vhite casi = 33			_	ther = 22	5	W	hite C N =	auca = 370			_	ther = 197	,		Cau	/hite casia = 335			_	ther = 23(
				95	% CI			959	% CI			95%	6 CI			959	% CI			959	% CI			959	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
	Eczema (10014184)	3	0.9	0.2		1	0.4	0.0	2.5	2	0.5	0.1	1.9	3	1.5				0.6	0.1	2.1	2	0.9	0.1	3.1
	Erythema (10015150)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	2	1.0	0.1	3.6	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Hair growth abnormal (10019044)	0	0.0	0.0	1.1	1	0.4	0.0	2.5	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Hypertrichosis (10020864)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Intertrigo (10022622)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Post inflammatory pigmentation change (10036229)	0	0.0	0.0	1.1	1	0.4		2.5	0	0.0	0.0	1.0	0	0.0	0.0	1.9		0.0	0.0	1.1	0	0.0	0.0	1.6
	Rash (10037844)	2	0.6	0.1	2.1	2	0.9	0.1	3.2	4	1.1	0.3	2.7	0	0.0	0.0	1.9	2	0.6	0.1	2.1	4	1.7	0.5	4.4
	Rash macular (10037867)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9		0.3	0.0	1.7	0	0.0	0.0	1.6
	Seborrhoea (10039792)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0	1	0.5		2.8		0.3	0.0	1.7	0	0.0	0.0	1.6
	Seborrhoeic dermatitis (10039793)	2	0.6	0.1	2.1	1	0.4	0.0	2.5	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Urticaria (10046735)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of administered doses

n/% = number/percentage of doses with the symptom

Table 8.29 Percentage of doses with grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following priming doses- by gender (Primary Total vaccinated cohort)

		Н	exa ç	group			Pedia g	group			Penta	group	
		Femal	e	Male	!	Fer	nale		ale	Fem		Ma	ile
		N = 29	2	N = 27	72	N=	= 230	N =	337	N =	268	N =	297
		95	5%	9	5%		95%		95%		95%		95%
			CI		CI		CI		CI		CI		CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n % LL	UL	n % LL	UL n	%	LL UL i	n %	LL UL	n % L	L UL	n % L	L UL
At least one symptom		5 1.7 0.6											
Gastrointestinal disorders (10017947)	Abdominal pain upper (10000087)	0.0 0.0											
	Diarrhoea (10012735)	1 0.3 0.0											
	Teething (10043183)	1 0.3 0.0											
	Vomiting (10047700)	1 0.3 0.0											
General disorders and administration site conditions (10018065)	Crying (10011469)	0.0 0.0											
	III-defined disorder (10061520)	0.0 0.0	1.3	0.0 0.0	1.3 0	0.0	0.0 1.6	1 0.3	0.0 1.6	0.0 0	1.4	0.00	1.0
	Injection site erythema (10022061)	0.0 0.0											
	Injection site pain (10022086)	0.0 0.0											
	Injection site swelling (10053425)	0.0 0.0	1.3	0.0 0.0	1.3 0	0.0	0.0 1.6	1 0.3	0.0 1.6	0.0 0	1.4	0.00	1.0
	Injection site warmth (10022112)	0.0 0.0											
	Pyrexia (10037660)	1 0.3 0.0											
Infections and infestations (10021881)	Bronchiolitis (10006448)	0.0 0.0											
	Conjunctivitis (10010741)	0.0 0.0	1.3	0.0 0.0	1.3 0	0.0	0.0 1.6 2	2 0.6	0.1 2.1	0.0 0	0.0 1.4	0.0 0	1.0
	Croup infectious (10011416)	0.0 0.0											
	Gastroenteritis (10017888)	0.0 0.0											
	Hand-foot-and-mouth disease (10019113)	0.0 0.0	1.3	1 0.4 0.0	2.0 0	0.0	0.0 1.6	1 0.3	0.0 1.6	0.0 0	1.4	0.00	1.0
	Nasopharyngitis (10028810)	0.0 0.0	1.3	0.0 0.0	1.3 0	0.0	0.0 1.6	0.0	0.0 1.1	1 0.4 0	0.0 2.1	0.00	1.0
	Otitis media (10033078)	1 0.3 0.0											
	Pharyngitis (10034835)	0.0 0.0	1.3	1 0.4 0.0	2.0 0	0.0	0.0 1.6 (0.0	0.0 1.1	0.0 0	1.4	0.00	1.0
	Respiratory syncytial virus bronchiolitis (10038718)	1 0.3 0.0	1.9	0.0 0.0	1.3 0	0.0	0.0 1.6	0.0	0.0 1.1	0.0	1.4	0.0	0.0 1.2
	Respiratory syncytial virus infection (10061603)	0.0 0.0	1.3	1 0.4 0.0	2.0 0	0.0	0.0 1.6	0.0	0.0 1.1	0.0	0.0 1.4	0.0	1.2
	Rhinitis (10039083)	0.0 0.0	1.3	0.0 0.0	1.3 0	0.0	0.0 1.6 (0.0	0.0 1.1	1 0.4 0	0.0 2.1	0.00	1.0

117119 (DTPA-HBV-IPV-135)

Report Final

		Н	exa	gro	up			Ped	dia g	roup)			Penta		p
		Fema	le		Male		Fe	male		N	lale		Fer	nale		Male
		N = 29	92		N = 27	2	N	= 230)	N	= 337	7	N =	268	N	= 297
		9	5%		95	5%		959	%		95	%		95%		95%
			CI					C			С	•		CI		CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n % LL														
	Sinusitis (10040753)	0.0 0.0	1.3	0 0	0.0	1.3 (0.0	0.0	1.6 0	0.0	0.0	1.1	1 0.4	0.0 2.1	0.0	0.0 1.2
	Upper respiratory tract infection (10046306)	0.0 0.0	1.3	3 1	.1 0.2	3.2	0.0	0.0	1.6 2	0.6	0.1	2.1 2	2 0.7	0.1 2.7	0.0	0.0 1.2
Psychiatric disorders (10037175)		0.0 0.0														
Respiratory, thoracic and mediastinal disorders	Bronchial hyperreactivity (10066091)	0.0 0.0	1.3	1 0	0.0	2.0	0.0	0.0	1.6 0	0.0	0.0	1.1 (0.0	0.0 1.4	0.0	0.0 1.2
(10038738)	0 1 (40044004)	0 0 0 0	1 4 0			4.0		0.0	4 0 0	0.0	0.0	4 4 6		0044	4 0 (20040
		0.0 0.0														
		0.0 0.0														
	Upper respiratory tract congestion	0.0 0.0	1.3	0 0	0.0	1.3 (0.0	0.0	1.6 0	0.0	0.0	1.1	0.0	0.0 1.4	1 0.3	3 0.0 1.9
	(10052252)															
	Wheezing (10047924)	0.0 0.0	1.3	1 0	0.0	2.0	0.0	0.0	1.6 0	0.0	0.0	1.1 (0.0	0.0 1.4	0.0	0.0 1.2

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of administered doses

n/% = number/percentage of doses with the symptom

Table 8.30 Percentage of doses with grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following priming doses- by geographical ancestry (Primary Total vaccinated cohort)

				He	xa g	roup					Ped	dia g	rou	р				Pe	nta g	roup)	
			W	/hite		(the	r		W	/hite			oth	er		٧	Vhite		(other	
			Cau	casia	an	N	= 22	25		Cau	casia	an	ı	V =	197		Cau	ıcasia	an	N	I = 23	30
			N	= 339)					N	= 370)					N	= 33	5			
				95%	6 CI		9:	5%			95%	6 CI			95%	0		95%	6 CI		95	5%
								CI							CI							CI
Primary System Organ Class (CODE)	Preferred Term (CODE)				UL	n %	LL	UL	n	%	LL	UL	n %	6 L	L U	JL r	າ %			n %		
At least one symptom																	1.5					
Gastrointestinal disorders (10017947)	Abdominal pain upper (10000087)																0.0				0.0	
	Diarrhoea (10012735)			0.0		0.0											0.0				0.0	
	Teething (10043183)	1	0.3	0.0	1.6	0.0	0.0	1.6	0	0.0	0.0	1.0	0 0	.0 0	.0 1	.9 1	0.3	0.0	1.7	0 0.	0.0	1.6
	Vomiting (10047700)	0	0.0	0.0	1.1	2 0.9	9 0.1	3.2	0	0.0	0.0	1.0	0 0	.0 0	.0 1	.9 (0.0	0.0	1.1	0 0.	0.0	1.6
General disorders and administration site conditions (10018065)	Crying (10011469)	1	0.3	0.0	1.6	0.0	0.0	1.6	0	0.0	0.0	1.0	0 0	.0 0	.0 1	.9 (0.0	0.0	1.1	0 0.	0.0	1.6
	III-defined disorder (10061520)		0.0		1.1	0.0	0.0	1.6	1	0.3	0.0	1.5	0 0	.0 0	.0 1	.9 (0.0	0.0	1.1	0 0.	0.0	1.6
	Injection site erythema (10022061)		0.0										0 0	.0 0	.0 1	.9 0	0.0	0.0			0.0	
	Injection site pain (10022086)	0	0.0	0.0	1.1	0.0	0.0	1.6	1	0.3	0.0	1.5	0 0	.0 0	.0 1	.9 1	0.3	0.0	1.7	0 0.	0.0	1.6
	Injection site swelling (10053425)		0.0		1.1	0.0	0.0	1.6	1	0.3	0.0	1.5	0 0	.0 0	.0 1	.9 (0.0	0.0	1.1	0 0.	0.0	1.6
	Injection site warmth (10022112)		0.0		1.1	0.0	0.0	1.6	1	0.3	0.0	1.5	0 0	.0 0	.0 1	.9 0	0.0	0.0	1.1	0 0.	0.0	1.6
	Pyrexia (10037660)	1	0.3	0.0	1.6	1 0.4	1 0.0	2.5	0	0.0	0.0	1.0	0 0	.0 0	.0 1	.9 1	0.3	0.0	1.7	0 0.	0.0	1.6
Infections and infestations (10021881)	Bronchiolitis (10006448)	1	0.3	0.0	1.6	0.0	0.0	1.6	0	0.0	0.0	1.0	0 0	.0 0	.0 1	.9 (0.0	0.0	1.1	0 0.	0.0	1.6
	Conjunctivitis (10010741)	0	0.0	0.0	1.1	0.0	0.0	1.6	0	0.0	0.0	1.0	2 1	.0 0	1.1 3	.6 0	0.0	0.0	1.1	0 0.	0.0	1.6
	Croup infectious (10011416)	0	0.0	0.0	1.1	0.0	0.0	1.6	1	0.3	0.0	1.5	0 0	.0 0	.0 1	.9 (0.0	0.0	1.1	0 0.	0.0	1.6
I	Gastroenteritis (10017888)	1	0.3	0.0	1.6	0.0	0.0	1.6	0	0.0	0.0	1.0	0 0	.0 0	.0 1	.9 (0.0	0.0	1.1	0 0.	0.0	1.6
	Hand-foot-and-mouth disease	1	0.3	0.0	1.6	0.0	0.0	1.6	0	0.0	0.0	1.0	10	.5 0	.0 2	.8	0.0	0.0	1.1	0 0.	0.0	1.6
	(10019113)																					
	Nasopharyngitis (10028810)		0.0														0.3		1.7	0 0.	0.0	1.6
	Otitis media (10033078)				2.6	0.0	0.0	1.6	1	0.3	0.0	1.5	0 0	.0 0	.0 1	.9 1	0.3	0.0	1.7	0 0.	0.0	1.6
	Pharyngitis (10034835)	1	0.3	0.0	1.6	0.0	0.0	1.6	0	0.0	0.0	1.0	0 0	.0 0	.0 1	.9 (0.0	0.0	1.1	0 0.	0.0	1.6
	Respiratory syncytial virus bronchiolitis (10038718)	0	0.0	0.0	1.1	1 0.4	1 0.0	2.5	0	0.0	0.0	1.0	0 0	.0 0	.0 1	.9 (0.0	0.0	1.1	0 0.	0.0	1.6

117119 (DTPA-HBV-IPV-135)

Report Final

																					_		l HII	ıaı
				He	xa g	roı	ıр				Pe	dia g	roı	up					Per	nta g	rou	р		
			V	/hite			of	ther		٧	Vhite			ot	her			W	hite			ot	her	
			Cau	casia	an		N:	= 22	5	Cau	ıcasi	an		N=	= 19	7	(Cauc	casia	ın		N =	230	,
			N	= 339	9					N	= 37	0						N=	= 335	5				
				95%	6 CI			95	5%		959	% CI			95	%			95%	6 CI			95%	%
								C							C								CI	
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n 9	6	LL (JL
	Respiratory syncytial virus infection (10061603)	1	0.3	0.0	1.6	0	0.0	0.0	1.6 0	0.0	0.0	1.0	0	0.0	0.0	1.9	0 (0.0	0.0	1.1	0 0	0.0	0.0 1	1.6
	Rhinitis (10039083)	0	0.0	0.0	1.1	0	0.0	0.0	1.6 0	0.0	0.0	1.0	0	0.0	0.0	1.9	0 (0.0	0.0	1.1	1 ().4	0.0 2	2.4
	Sinusitis (10040753)			0.0					1.6 0															
	Upper respiratory tract infection (10046306)	3	0.9	0.2	2.6	0	0.0	0.0	1.6 0	0.0	0.0	1.0	2	1.0	0.1	3.6	1 ().3	0.0	1.7	1 ().4	0.0 2	2.4
Psychiatric disorders (10037175)	Irritability (10022998)	0	0.0	0.0	1.1	0	0.0	0.0	1.6 2	0.5	0.1	1.9	0	0.0	0.0	1.9	0 (0.0	0.0	1.1	0 0	0.0	0.0 1	1.6
Respiratory, thoracic and mediastinal disorders (10038738)	Bronchial hyperreactivity (10066091)	0	0.0	0.0	1.1	1	0.4	0.0	2.5 0	0.0	0.0	1.0	0	0.0	0.0	1.9	0 (0.0	0.0	1.1	0 0	0.0	0.0 1	1.6
, ,	Cough (10011224)	0	0.0	0.0	1.1	0	0.0	0.0	1.6 0	0.0	0.0	1.0	0	0.0	0.0	1.9	0 (0.0	0.0	1.1	1 ().4	0.0 2	2.4
	Respiratory arrest (10038669)	0	0.0	0.0	1.1	0	0.0	0.0	1.6 1	0.3	0.0	1.5	0	0.0	0.0	1.9	0 (0.0	0.0	1.1	0 0	0.0	0.0 1	1.6
	Upper respiratory tract congestion (10052252)			0.0					1.6 0															
	Wheezing (10047924)	1	0.3	0.0	1.6	0	0.0	0.0	1.6 0	0.0	0.0	1.0	0	0.0	0.0	1.9	0 (0.0	0.0	1.1	0 0	0.0	0.0 1	1.6

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of administered doses

n/% = number/percentage of doses with the symptom 95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 8.31 Percentage of doses with unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship with vaccination, within the 31-day (Days 0-30) post-vaccination period following priming doses – by gender (Primary Total vaccinated cohort)

				Н	exa	gro	up					Pe	dia gr	oup					Pen	ta gr	oup	,	
			Fe	male	е		Ma	ale			Fem	ale		M	ale			Fem	ale		1	Vlale	
			N=	= 29	2		N =	272	2		N =	230	1	N=	= 337	7		N =	268		N	= 29	7
				9	5%			95	5%			95	%		95	%		,	95% (),		95%	% CI
					CI							С				:							
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	% I	LL	UL n	%	LL	UL	n ^c	% L	L UI	. n		LL	
At least one symptom		15	5.1	2.9	8.3	13	4.8	2.6	8.0	13	5.7	3.0	9.5 22	2 6.5	4.1	9.7	17 (3.3	.7 10	.0 20) 6.7	4.2	10.2
Blood and lymphatic system disorders (10005329)	Leukocytosis (10024378)																		.0 1.4			0.0	
Gastrointestinal disorders (10017947)	Constipation (10010774)												1.6 0									0.0	
	Diarrhoea (10012735)												1.6 2								0.3	0.0	1.9
	Flatulence (10016766)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6 0	0.0	0.0	1.1	1 (0.4	.0 2.	1 0	0.0	0.0	1.2
	Vomiting (10047700)	1	0.3	0.0	1.9	2	0.7	0.1	2.6	2	0.9 (0.1	3.1 1	0.3	0.0	1.6	0 (0.0	.0 1.4	1 3	1.0	0.2	2.9
General disorders and administration site conditions (10018065)	,												1.6 1									0.0	
	Injection site bruising (10022052)	2	0.7	0.1	2.5	0	0.0	0.0	1.3	0	0.0	0.0	1.6 2	0.6	0.1	2.1	0 (0.0	.0 1.4	4	1.3	0.4	3.4
	Injection site erythema (10022061)				2.5								2.4 1									0.0	
	Injection site induration (10022075)	2	0.7	0.1	2.5	1	0.4	0.0	2.0	0	0.0	0.0	1.6 0	0.0	0.0	1.1	0 (0.0	.0 1.4	1 0	0.0	0.0	1.2
	Injection site mass (10022081)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	1	0.4	0.0	2.4 1	0.3	0.0	1.6	0 (0.0	.0 1.4	1 0	0.0	0.0	1.2
	Injection site pain (10022086)	4	1.4	0.4	3.5	1	0.4	0.0	2.0	4	1.7 (0.5	4.4 4	1.2	0.3	3.0	2 (0.7	.1 2.	7 5	1.7	7 0.5	3.9
	Injection site pruritus (10022093)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	1	0.4	0.0	2.4 0	0.0	0.0	1.1	0 (0.0	.0 1.4	1 0	0.0	0.0	1.2
	Injection site rash (10022094)	0	0.0	0.0	1.3	1	0.4	0.0	2.0	0	0.0	0.0	1.6 0	0.0	0.0	1.1	1 (0.4	.0 2.	1	0.3	0.0	1.9
	Injection site swelling (10053425)	3	1.0	0.2	3.0	1	0.4	0.0	2.0	0	0.0	0.0	1.6 1	0.3	0.0	1.6	3 ′	1.1 0	.2 3.2	2 1	0.3	0.0	1.9
	Injection site warmth (10022112)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6 2	0.6	0.1	2.1	0 (0.0	.0 1.4	1 0	0.0	0.0	1.2
	Oedema peripheral (10030124)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	1	0.4	0.0	2.4 0	0.0	0.0	1.1	0 (0.0	.0 1.4	1 0	0.0	0.0	1.2
	Peripheral swelling (10048959)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	1	0.4	0.0	2.4 0	0.0	0.0	1.1	0 (0.0	.0 1.4	1 0	0.0	0.0	1.2
	Pyrexia (10037660)	1	0.3	0.0	1.9	0	0.0	0.0	1.3				1.6 0		0.0	1.1	1 (0.4	.0 2.	1 2		7 0.1	
	Swelling (10042674)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	1	0.4	0.0	2.4 0	0.0	0.0	1.1	0 (0.0	.0 1.4	1 0	0.0	0.0	1.2
	Vaccination site bruising (10069484)				1.3								1.6 3						.0 2.		0.0	0.0	1.2
	Vaccination site erythema (10059079)		0.0	0.0	1.3	1	0.4	0.0	2.0				3.1 2					1.1 0	.2 3.2	2 0	0.0	0.0	1.2
	Vaccination site induration (10065117)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6 1	0.3	0.0	1.6	0 (0.0	.0 1.4	0	0.0	0.0	1.2

117119 (DTPA-HBV-IPV-135)

Report Final

																									Finai
				Н	exa	gro	•						dia (gro							enta	gro	up		
			Fe	male	е		Ma	ale			Fen	nale			Ma	ale			Fen	nale			M	lale)
			N =	= 29	2		N =	272	2		N =	230)		N =	337	'		N =	268	3		N =	= 29	97
				95	5%			95	%			95	%			95	%			95%	6 CI			95	% CI
					Cl			C				C	- 1			C	-								
Primary System Organ Class (CODE)	Preferred Term (CODE)															LL									UL
	Vaccination site pain (10068879)	2	0.7	0.1	2.5	0	0.0	0.0	1.3	0	0.0	0.0	1.6	1 (0.3	0.0	1.6	2	0.7	0.1 2	2.7	1	0.3	0.0	1.9
	Vaccination site swelling (10069620)	1	0.3	0.0	1.9	2	0.7	0.1	2.6	0	0.0	0.0	1.6	1 (0.3	0.0	1.6	1	0.4	0.0	2.1	1	0.3	0.0	1.9
Infections and infestations (10021881)	Nasopharyngitis (10028810)	0	0.0	0.0	1.3	1	0.4	0.0	2.0	0	0.0	0.0	1.6	0 (0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Upper respiratory tract infection (10046306)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0 (0.0	0.0	1.1	1	0.4	0.0	2.1	0	0.0	0.0	1.2
	Viral rash (10047476)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0 (0.0	0.0	1.1	0	0.0	0.0	1.4	1	0.3	0.0	1.9
Musculoskeletal and connective tissue disorders (10028395)	Pain in extremity (10033425)															0.0					1.4				1.2
Nervous system disorders (10029205)	Hyperreflexia (10020745)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	1 (0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
• , ,	Lethargy (10024264)	1	0.3	0.0	1.9	0	0.0	0.0	1.3	0	0.0	0.0	1.6	0 (0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Poor quality sleep (10062519)	0	0.0	0.0	1.3	1	0.4	0.0	2.0	0	0.0	0.0	1.6	0 (0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
Psychiatric disorders (10037175)	Irritability (10022998)																		0.0	0.0	1.4	0	0.0	0.0	1.2
Respiratory, thoracic and mediastinal disorders (10038738)	Apparent life threatening event (10065044)															0.0					1.4		0.0	0.0	1.2
	Cough (10011224)	0	0.0	0.0	1.3	1	0.4	0.0	2.0	0	0.0	0.0	1.6	1 (0.3	0.0	1.6	0	0.0	0.0	1.4	1	0.3	0.0	1.9
	Nasal congestion (10028735)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	1	0.4	0.0	2.4	0 (0.0	0.0	1.1	0	0.0	0.0	1.4	1	0.3	0.0	1.9
	Respiratory arrest (10038669)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	0	0.0	0.0	1.6	1 (0.3	0.0	1.6	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Rhinorrhoea (10039101)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	1	0.4	0.0	2.4	0 (0.0	0.0	1.1	0	0.0	0.0	1.4	1	0.3	0.0	1.9
Skin and subcutaneous tissue disorders (10040785)	Erythema (10015150)	0	0.0	0.0	1.3	0	0.0	0.0	1.3	1	0.4	0.0	2.4	0 (0.0	0.0	1.1	0	0.0	0.0	1.4	0	0.0	0.0	1.2
	Rash (10037844)			0.0															0.4	۱ n ۲	2 1				1.9

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of administered doses

n/% = number/percentage of doses with the symptom

Table 8.32 Percentage of doses with unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship with vaccination, within the 31-day (Days 0-30) post-vaccination period following priming doses—by geographical ancestry (Primary Total vaccinated cohort)

				Не	exa ç	gro	up					Pe	dia g	grou	ıp					Pe	nta	gro	up		
			W Cau	hite casia	an			ther = 22			W Cau	hite casi				her = 19			W Cau	hite asia	n			her = 23	
			N=	= 339	9						N =	= 37	0						N=	335					
				95	% CI				5% CI			95	% CI			-	5% CI			95%	6 CI			95%	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
At least one symptom	, , ,	17	5.0	2.9	7.9	11	1 4.9	2.5	8.6	27	7.3	4.9	10.4	8	4.1	1.8	7.8	18	5.4	3.2	8.4	19	8.3	5.0	12.6
Blood and lymphatic system disorders (10005329)	Leukocytosis (10024378)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
Gastrointestinal disorders (10017947)	Constipation (10010774)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	1	0.4	0.0	2.4
, , ,	Diarrhoea (10012735)	2	0.6	0.1	2.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	2	1.0	0.1	3.6	1	0.3	0.0	1.7	2	0.9	0.1	3.1
	Flatulence (10016766)	0			1.1						0.0	0.0	1.0	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6
	Vomiting (10047700)	1	0.3	0.0	1.6	2	0.9	0.1	3.2	1	0.3	0.0					3.6		0.3	0.0	1.7	2	0.9	0.1	3.1
General disorders and administration site conditions (10018065)	III-defined disorder (10061520)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	1	0.3	0.0					1.9		0.0	0.0	1.1	0	0.0	0.0	1.6
	Injection site bruising (10022052)	2	0.6	0.1	2.1	0	0.0	0.0	1.6	2	0.5	0.1	1.9	0	0.0	0.0	1.9	2	0.6	0.1	2.1	2	0.9	0.1	3.1
	Injection site erythema (10022061)	2	0.6	0.1	2.1	2	0.9	0.1	3.2	2	0.5	0.1	1.9	0	0.0	0.0	1.9	3	0.9	0.2	2.6	2	0.9	0.1	3.1
	Injection site induration (10022075)	1	0.3	0.0	1.6	2	0.9	0.1	3.2	0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Injection site mass (10022081)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	2	0.5	0.1	1.9	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Injection site pain (10022086)	2	0.6	0.1	2.1	3	1.3	3 0.3	3.8	7	1.9	8.0	3.9	1	0.5	0.0	2.8	6	1.8	0.7	3.9	1	0.4	0.0	2.4
	Injection site pruritus (10022093)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0	1	0.5	0.0	2.8	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Injection site rash (10022094)	1	0.3	0.0	1.6	0	0.0	0.0	1.6	0	0.0	0.0					1.9		0.3	0.0	1.7	1	0.4	0.0	2.4
	Injection site swelling (10053425)	2	0.6	0.1	2.1	2	0.9	0.1	3.2		0.3			0	0.0	0.0	1.9	1	0.3		1.7	-		0.3	
	Injection site warmth (10022112)	0			1.1						0.5						1.9			0.0	1.1		0.0		
	Oedema peripheral (10030124)	0			1.1						0.3						1.9		0.0		1.1		0.0		
	Peripheral swelling (10048959)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	0	0.0	0.0	1.0				2.8			0.0			0.0		
	Pyrexia (10037660)	1			1.6						0.0						1.9			0.0				0.3	
	Swelling (10042674)	0			1.1						0.0						2.8		0.0				0.0		
	Vaccination site bruising (10069484)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	3	8.0	0.2	2.4	0	0.0	0.0	1.9	1	0.3	0.0	1.7	0	0.0	0.0	1.6

117119 (DTPA-HBV-IPV-135)

Report Final

				Ų,	exa	aro.	un					D.	edia g	aro	un					Da	nta			111	ınaı
			14/	hite		JIO	•	thei			v	Vhite		gro	_	ther	,		۱۸/۱	nite	ınıa (gro		her	
			Cau	casia = 339	an 9		_	= 22	25		Cau	ıcas = 37	ian 70		-	= 19	7	(Cauc	asia 335	,			= 230	
				95	% CI				5% CI			95	5% CI				5% CI			95%	6 CI			95%	6 CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	. UI	_ n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
	Vaccination site erythema (10059079)				1.6								2.7				1.9		0.6						
	Vaccination site induration (10065117)				1.1								1.5				1.9		0.0						
	Vaccination site pain (10068879)	2	0.6	0.1	2.1	0	0.0	0.0	1.0	3 1				0	0.0	0.0	1.9	2	0.6	0.1	2.1	1	0.4	0.0	2.4
	Vaccination site swelling (10069620)	3	0.9	0.2	2.6	0	0.0	0.0	1.0	3 1	0.3	0.0	1.5	0	0.0	0.0	1.9	1	0.3	0.0	1.7	1	0.4	0.0	2.4
Infections and infestations (10021881)	Nasopharyngitis (10028810)	0	0.0	0.0	1.1	1	0.4	0.0	2.5	5 0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
,	Upper respiratory tract infection (10046306)				1.1								1.0				1.9		0.0				0.4	0.0	2.4
	Viral rash (10047476)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	3 0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	1	0.4	0.0	2.4
Musculoskeletal and connective tissue disorders (10028395)	Pain in extremity (10033425)	0	0.0	0.0	1.1	1	0.4	0.0	2.	5 0	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
Nervous system disorders (10029205)	Hyperreflexia (10020745)	0	0.0	0.0	1.1	0	0.0	0.0	1.6	3 0	0.0	0.0	1.0	1	0.5	0.0	2.8	0	0.0	0.0	1.1	0	0.0	0.0	1.6
	Lethargy (10024264)	1			1.6								1.0				1.9		0.0				0.0	0.0	1.6
	Poor quality sleep (10062519)	1	0.3	0.0	1.6	0	0.0	0.0	1.0	0 6	0.0	0.0	1.0	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0	0.0	0.0	1.6
Psychiatric disorders (10037175)	Irritability (10022998)	0			1.1								1.5	0	0.0	0.0	1.9		0.0					0.0	
Respiratory, thoracic and mediastinal disorders (10038738)	Apparent life threatening event (10065044)	1			1.6								1.0				1.9		0.0						
	Cough (10011224)			0.0			0.4						1.0				2.8		0.0					0.0	
	Nasal congestion (10028735)			0.0			0.0						1.0				2.8		0.0				-	0.0	
	Respiratory arrest (10038669)	_			1.1								1.5				1.9		0.0					0.0	
	Rhinorrhoea (10039101)	0			1.1								1.5				1.9		0.0					0.0	
Skin and subcutaneous tissue disorders (10040785)	Erythema (10015150)				1.1								1.0				2.8		0.0						
	Rash (10037844)	0	0.0	0.0	1.1	0	0.0	0.0) 1.6	3 2	0.5	0.1	1.9	0	0.0	0.0	1.9	0	0.0	0.0	1.1	2	0.9	0.1	3.1

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

Report Final

N = number of administered doses n/% = number/percentage of doses with the symptom 95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 8.33 Percentage of doses with grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship with vaccination, within the 31-day (Days 0-30) post-vaccination period following priming doses- by gender (Primary Total vaccinated cohort)

				Hex	a gr	oup)			P	edia	gro	up				Pen	ta g	roup		
			Fema	ale		N	lale		Fe	emal	le		Ma	le		Fer	nale		N	ale	
			N = 2	92		N:	= 272	2	N	= 23	30		N =	337	'	N =	268		N:	297	
			9	95%			95%	CI		959	% CI		9	5%	CI		95%	CI		95% (CI
				CI																	
Primary System Organ Class (CODE)	Preferred Term (CODE)		% LI																		
At least one symptom		0	0.0 0.	0 1.	3 1	0.4	0.0	2.0	1 0.4	0.0	2.4	3 0	0.9	.2 2	2.6 0	0.0	0.0 1	.4 1	0.3	0.0 1.	.9
Gastrointestinal disorders (10017947)	Vomiting (10047700)	0	0.0 0.	0 1.	3 1	0.4	0.0	2.0	0.0	0.0	1.6	0 0	0.0	.0 1	1.1 0	0.0	0.0 1	.4 0	0.0	0.0 1.	.2
General disorders and administration site conditions (10018065)	III-defined disorder (10061520)	0	0.0 0.	0 1.	3 0	0.0	0.0	1.3	0.0	0.0	1.6	1 0	0.3	.0 1	1.6 0	0.0	0.0 1	.4 0	0.0	0.0 1.	.2
	Injection site erythema (10022061)	0	0.0 0.	0 1.	3 0	0.0	0.0	1.3	0.0	0.0	1.6	1 0	0.3	.0 1	1.6 0	0.0	0.0 1	.4 0	0.0	0.0 1.	.2
	Injection site pain (10022086)	0	0.0 0.	0 1.	3 0	0.0	0.0	1.3	1 0.4	0.0	2.4	0 0	0.0	.0 1	1.1 0	0.0	0.0 1	.4 1	0.3	0.0 1.	.9
	Injection site swelling (10053425)	0	0.0 0.	0 1.	3 0	0.0	0.0	1.3	0.0	0.0	1.6	1 0	0.3	.0 1	1.6 0	0.0	0.0 1	.4 0	0.0	0.0 1.	.2
	Injection site warmth (10022112)	0	0.0 0.	0 1.	3 0	0.0	0.0	1.3	0.0	0.0	1.6	1 0	0.3	.0 1	1.6 0	0.0	0.0 1	.4 0	0.0	0.0 1.	.2
Psychiatric disorders (10037175)	Irritability (10022998)	0	0.0 0.	0 1.	3 0	0.0	0.0	1.3	0.0	0.0	1.6	1 0	0.3	.0 1	1.6 0	0.0	0.0 1	.4 0	0.0	0.0 1.	.2
Respiratory, thoracic and mediastinal disorders (10038738)	Respiratory arrest (10038669)	0	0.0 0.	0 1.	3 0	0.0	0.0	1.3	0.0	0.0	1.6	1 0	0.3	.0 1	1.6 0	0.0	0.0 1	.4 0	0.0	0.0 1.	.2

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of administered doses

n/% = number/percentage of doses with the symptom

117119 (DTPA-HBV-IPV-135)

Report Final

Table 8.34 Percentage of doses with grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship with vaccination, within the 31-day (Days 0-30) post-vaccination period following priming doses- by geographical ancestry (Primary Total vaccinated cohort)

				Не	xa ç	gro	up				Pe	edia g	rou	ір					Pe	nta g	roup)	
			Cau	Vhite ucasia = 339	an		othe N = 2			Cai	White ucasi I = 37	ian			her = 19			Cau	hite casia = 33				ner 230
				959	% CI		6	95%	0		95	% CI			_	%			95%	6 CI			95%
Drimon, Sustan Orman Class (CODE)	Duefermed Terms (CODE)		0/			_	0/ 1.1	CI	II	0/		111	1	0/	<u> </u>	•		0/			0/		CI
Primary System Organ Class (CODE)	Preferred Term (CODE)		%	LL	UL		% LI				LL	UL 2.7				UL 10						_	LL UL
At least one symptom	(40047700)		0.0	0.0	1.1		0.4 0.			_									0.0			_	0.0 1.6
Gastrointestinal disorders (10017947)	Vomiting (10047700)	_		0.0	1.1		0.4 0.			_									0.0			_	0.0 1.6
General disorders and administration site conditions (10018065)	III-defined disorder (10061520)	0	0.0	0.0	1.1	0	0.0 0.	0 1	.6 1	0.3	0.0	1.5	0 (0.0	0.0	1.9	0	0.0	0.0	1.1	0 0	.0 0	0.0 1.6
	Injection site erythema (10022061)	0	0.0				0.0 0.	0 1	.6 1	0.3	0.0	1.5	0 (0.0	0.0	1.9	0	0.0	0.0	1.1	0 0	.0 0	0.0 1.6
	Injection site pain (10022086)	0	0.0	0.0	1.1	0	0.0 0.	0 1	.6 1	0.3	0.0	1.5	0 (0.0	0.0	1.9	1	0.3	0.0	1.7	0 0	.0 (0.0 1.6
	Injection site swelling (10053425)	0	0.0				0.0 0.	0 1	.6 1	0.3	0.0	1.5	0 (0.0	0.0	1.9	0	0.0	0.0	1.1	0 0	.0 0	0.0 1.6
	Injection site warmth (10022112)	0	0.0	0.0	1.1	0	0.0 0.	0 1	.6 1	0.3	0.0	1.5	0 (0.0	0.0	1.9	0	0.0	0.0	1.1	0 0	.0 0	0.0 1.6
Psychiatric disorders (10037175)	Irritability (10022998)	0	0.0	0.0	1.1	0	0.0 0.	0 1	.6 1	0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0 0	.0 0	0.0 1.6
Respiratory, thoracic and mediastinal disorders (10038738)	Respiratory arrest (10038669)						0.0 0.			0.3	0.0	1.5	0	0.0	0.0	1.9	0	0.0	0.0	1.1	0 0	.0 0	0.0 1.6

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of administered doses

n/% = number/percentage of doses with the symptom

117119 (DTPA-HBV-IPV-135) Report Final

Table 8.35 Percentage of subjects reporting at least one preferred term from broad MedDRA SMQ 'Hypotonic-Hyporesponsive Episode (HHE)', within the 31-day (Days 0-30) post-vaccination period following priming doses (Primary Total vaccinated cohort)

		ŀ		gro = 19	•	P		a gro = 19	•	P		a gro = 19	oup 6
				95%	6 CI			95%	6 CI			95%	6 CI
Primary System Organ Class (CODE)	Preferred Term (CODE) n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
At least one symptom		0	0.0	0.0	1.9	0	0.0	0.0	1.9	2	1.0	0.1	3.6
Cardiac disorders (10007541)	Cyanosis (10011703)	0	0.0	0.0	1.9	0	0.0	0.0	1.9	2	1.0	0.1	3.6

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 8.36 Percentage of subjects reporting at least one preferred term from narrow MedDRA SMQ 'convulsion' within the 31-day (Days 0-30) post-vaccination period following priming doses (Primary Total vaccinated cohort)

No records exist in this table

Table 8.37 Percentage of subjects reporting at least one preferred term from broad MedDRA SMQ 'Hypotonic-Hyporesponsive Episode (HHE)', within the 31-day (Days 0-30) post-vaccination period following priming doses—by gender (Primary Total vaccinated cohort)

				Н	exa	gr	oup)				Pe	dia	gı	roup)				Pe	nta	gı	roup)	
				mal	-			lale			_	mal				lale				mal				lale	
			N:	= 10			N	= 94	-		N	= 80			N:	= 11			N	= 9			N:	= 10	
				95	5%			95	%			95	5%			95	5%			95	5%			95	5%
				(C	:1			(((C)
Primary System	Preferred	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
Organ Class	Term (CODE)																								
(CODE)																									
At least one		0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	2	2.1	0.3	7.4	0	0.0	0.0	3.6
symptom																									
Cardiac disorders	Cyanosis	0	0.0	0.0	3.6	0	0.0	0.0	3.8	0	0.0	0.0	4.5	0	0.0	0.0	3.2	2	2.1	0.3	7.4	0	0.0	0.0	3.6
(10007541)	(10011703)																								

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Table 8.38 Percentage of subjects reporting at least one preferred term from broad MedDRA SMQ 'Hypotonic-Hyporesponsive Episode (HHE)', within the 31-day (Days 0-30) post-vaccination period following priming doses— by geographical ancestry (Primary Total vaccinated cohort)

				Не	exa (gro	oup					Pe	dia	gr	oup)				Pe	nta	gr	oup)	
			Cau	hite casi = 11	an			ther = 7			Cau	/hite casi = 12	an			ther = 60		_	Cau	/hite casi = 11	an		_	ther = 8	
				95%	% CI				5% CI			959	% CI				5% Cl			95%	% CI				5% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)		%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
At least one symptom																									4.5
Cardiac disorders (10007541)	Cyanosis (10011703)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0	0.0	0.0	5.4	2	1.7	0.2	6.1	0	0.0	0.0	4.5

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 8.39 Percentage of subjects reporting at least one preferred term from narrow MedDRA SMQ 'convulsion' within the 31-day (Days 0-30) post-vaccination period following priming doses— by gender (Primary Total vaccinated cohort)

No records exist in this table

Table 8.40 Percentage of subjects reporting at least one preferred term from narrow MedDRA SMQ 'convulsion' within the 31-day (Days 0-30) post-vaccination period following priming doses— by geographical ancestry (Primary Total vaccinated cohort)

No records exist in this table

117119 (DTPA-HBV-IPV-135)

Report Final

Table 8.41 Percentage of subjects reporting the occurrence of New Onset of Chronic Illness (NOCI) from Dose 1 up to 6 months following priming doses- by gender (Primary Total vaccinated cohort)

		Hexa	group	Pedia	group	Penta	group
		Female N = 101	Male N = 94	Female N = 80	Male N = 114	Female N = 95	Male N = 101
		95% CI	95% CI	95% CI	95% CI	95% CI	95% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n % LL UL	n % LL UL	n % LL UL	n % LL UL	n % LL UL	n % LL UL
At least one symptom		0 0.0 0.0 3.6	7 7.4 3.0 14.7	1 1.3 0.0 6.8	10 8.8 4.3 15.5	5 5.3 1.7 11.9	5 5.0 1.6 11.2
Immune system disorders (10021428)	Drug hypersensitivity (10013700)	0 0.0 0.0 3.6	0 0.0 0.0 3.8	0 0.0 0.0 4.5	1 0.9 0.0 4.8	0 0.0 0.0 3.8	0 0.0 0.0 3.6
	Food allergy (10016946)	0 0.0 0.0 3.6	0 0.0 0.0 3.8	0 0.0 0.0 4.5	1 0.9 0.0 4.8	1 1.1 0.0 5.7	0 0.0 0.0 3.6
Respiratory, thoracic and mediastinal disorders (10038738)	Asthma (10003553)	0 0.0 0.0 3.6	0 0.0 0.0 3.8	0 0.0 0.0 4.5	0 0.0 0.0 3.2	1 1.1 0.0 5.7	1 1.0 0.0 5.4
	Bronchial hyperreactivity (10066091)	0 0.0 0.0 3.6	2 2.1 0.3 7.5	0 0.0 0.0 4.5	1 0.9 0.0 4.8	0 0.0 0.0 3.8	0 0.0 0.0 3.6
	Rhinitis allergic (10039085)	0 0.0 0.0 3.6	0 0.0 0.0 3.8	0 0.0 0.0 4.5	0 0.0 0.0 3.2	1 1.1 0.0 5.7	0 0.0 0.0 3.6
Skin and subcutaneous tissue disorders (10040785)	Dermatitis atopic (10012438)	0 0.0 0.0 3.6	5 5.3 1.7 12.0	1 1.3 0.0 6.8	6 5.3 2.0 11.1	3 3.2 0.7 9.0	4 4.0 1.1 9.8
,	Urticaria (10046735)	0 0.0 0.0 3.6	0 0.0 0.0 3.8	0 0.0 0.0 4.5	1 0.9 0.0 4.8	0 0.0 0.0 3.8	0 0.0 0.0 3.6

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

117119 (DTPA-HBV-IPV-135)

Report Final

Table 8.42 Percentage of subjects reporting the occurrence of New Onset of Chronic Illness (NOCI) from Dose 1 up to 6 months following priming doses- by geographical ancestry (Primary Total vaccinated cohort)

				Н	exa ç	jro	up					Pe	dia ç	grou)				P	enta (gro	up		
			Cau	/hite casi = 11	an		-	the = 7			Cau	/hite casia = 128	an		oth N =			Cai	White ucasi = 11	an		_	ther = 8	
				95	% CI			95	% CI			95%	6 CI		9	5% C	1		95	% CI			959	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n %	LL	_ UL	n	%	LL	UL	n	%	LL	UL
At least one symptom		1	8.0	0.0	4.6	6	7.8	2.9	16.2	5	3.9	1.3	8.9	6 9.	1 3.	4 18.	7 4	3.5	1.0	8.7	6	7.4	2.8	15.4
Immune system disorders (10021428)	Drug hypersensitivity (10013700)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	1	8.0	0.0	4.3	0 0.	0 0.	0 5.4	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Food allergy (10016946)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	1	0.8	0.0	4.3	0 0.	0 0.	0 5.4	0	0.0	0.0	3.2	1	1.2	0.0	6.7
Respiratory, thoracic and mediastinal disorders (10038738)	Asthma (10003553)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0 0.	0 0.	0 5.4	1	0.9	0.0	4.7	1	1.2	0.0	6.7
	Bronchial hyperreactivity (10066091)	0	0.0	0.0	3.1	2	2.6	0.3	9.1	0	0.0	0.0	2.8	1 1.	5 0.	0 8.2	0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Rhinitis allergic (10039085)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0 0.	0 0.	0 5.4	1	0.9	0.0	4.7	0	0.0	0.0	4.5
Skin and subcutaneous tissue disorders (10040785)	Dermatitis atopic (10012438)	1	8.0	0.0	4.6	4	5.2	1.4	12.8	3	2.3	0.5	6.7	4 6.	1 1.	7 14.	8 2	1.7	0.2	6.1	5	6.2	2.0	13.8
	Urticaria (10046735)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	1 1.	5 0.	0 8.2	0	0.0	0.0	3.2	0	0.0	0.0	4.5

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Table 8.43 Number and percentage of subjects with concomitant medication during the 31-day (Days 0-30) post-vaccination period following each priming dose and overall (Primary Total vaccinated cohort)

		He	xa gr	oup			Ped	dia g	roup			Per	nta g	roup	
				95%	6 CI				95%	6 CI				95%	6 CI
	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
					Do	se 1									
Any	195	81	41.5	34.5	48.8	194	114	58.8	51.5	65.8	196	90	45.9	38.8	53.2
Any antipyretic	195	66	33.8	27.2	41.0	194	100	51.5	44.3	58.8	196	80	40.8	33.9	48.0
Prophylactic antipyretic	195	17	8.7	5.2	13.6	194	16	8.2	4.8	13.0	196	12	6.1	3.2	10.5
						se 2									
Any	186	88	47.3	40.0	54.7	188	99	52.7	45.3	60.0	189	81	42.9	35.7	50.2
Any antipyretic	186	79	42.5	35.3	49.9	188	91	48.4	41.1	55.8	189	68	36.0	29.1	43.3
Prophylactic antipyretic	186	12	6.5	3.4	11.0	188	9	4.8	2.2	8.9	189	10	5.3	2.6	9.5
					Do	se 3									
Any			46.4	39.1	54.0				49.3				46.7		54.2
Any antipyretic	183	72	39.3		46.8	185	88	47.6	40.2	55.0	180	73		33.3	48.1
Prophylactic antipyretic	183	13	7.1	3.8	11.8	185	9	4.9	2.2	9.0	180	10	5.6	2.7	10.0
					vera										
Any															49.3
Any antipyretic			38.5			567	279	49.2	45.0	53.4			39.1	35.1	43.3
Prophylactic antipyretic	564	42	7.4	5.4	9.9	567		6.0	4.2	8.3	565	32	5.7	3.9	7.9
					verall										
Any	195	140	71.8	64.9	78.0			79.4	73.0	84.8	196	136	69.4	62.4	75.8
Any antipyretic	195	120	61.5						-	77.4	196		61.7	54.5	68.6
Prophylactic antipyretic	195	26	13.3	8.9	18.9	194	27	13.9	9.4	19.6	196	25	12.8	8.4	18.3

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

For each dose and overall/subject:

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects who started to take the specified concomitant medication at least once during the mentioned period

For overall/dose:

N = number of administered doses

n/% = number/percentage of doses after which the specified concomitant medication was started at least once during the mentioned period

Report Final

Table 8.44 Percentage of subjects reporting the occurrence of serious adverse event (SAE) from Dose 1 up to 6 months following priming doses-by gender (Primary Total vaccinated cohort)

			Hexa	grou	р	F	edia g	roup)		Pe	nta	group	
		Fe	male	ĺ	Male	Fema	le	M	lale	F	emale	,	Ma	ale
		N:	= 292	N	= 272	N = 2	30	N =	= 337	N	I = 26	8	N =	297
			95%		95%	9	5%		95%		95	%		95%
			CI		CI		CI		CI		С	-		CI
Primary System Organ Class (CODE)	Preferred Term (CODE)				LL UL									
At least one symptom					0.0 1.3									
Blood and lymphatic system disorders (10005329)	Leukocytosis (10024378)				0.0 1.3									
Gastrointestinal disorders (10017947)	Gastrooesophageal reflux disease	1 0.3	0.0 1.9	0.0	0.0 1.3	0.0 0.0	0 1.6	0.0	0.0 1.1	1 0 0.	0.0	1.4	0.0	ე.0 1.2
	(10017885)													
Infections and infestations (10021881)	Gastroenteritis viral (10017918)				0.0 1.3									
	Meningitis viral (10027260)	1 0.3	0.0 1.9	0.0	0.0 1.3	0.0 0.	0 1.6	0.0	0.0 1.1	1 0 0.	0.0	1.4	0.0	0.0 1.2
	Parainfluenzae virus infection (10061907)	0.0	0.0 1.3	0.0	0.0 1.3	0.0 0.	0 1.6	0.0	0.0 1.1	1 2 0.	7 0.1	2.7	0.0	0.0 1.2
	Pneumonia (10035664)	0.0	0.0 1.3	0.0	0.0 1.3	0.0 0.	0 1.6	0.0	0.0 1.1	1 1 0.	4 0.0	2.1	0.0	0.0 1.2
	Respiratory syncytial virus bronchiolitis (10038718)	1 0.3	0.0 1.9	0.0	0.0 1.3	0.0 0.	0 1.6 0	0.0	0.0 1.	1 1 0.	4 0.0	2.1	0.0).0 1.2
	Respiratory syncytial virus infection (10061603)	0.0	0.0 1.3	0.0	0.0 1.3	0.0 0.	0 1.6 0	0.0	0.0 1.	1 1 0.	4 0.0	2.1	0.0).0 1.2
Injury, poisoning and procedural complications (10022117)	Road traffic accident (10039203)	0.0	0.0 1.3	0.0	0.0 1.3	0.0 0.	0 1.6 0	0.0	0.0 1.	1 1 0.	4 0.0	2.1	0.0).0 1.2
Metabolism and nutrition disorders (10027433)	Dehydration (10012174)	0.0	0.0 1.3	0.0	0.0 1.3	0 0.0 0.	1.6 0	0.0	0.0 1.1	1 1 0.	4 0.0	2.1	0.0	0.0 1.2
Nervous system disorders (10029205)	Febrile convulsion (10016284)	0.0	0.0 1.3	0.0	0.0 1.3	0 0.0 0.	1.6 0	0.0	0.0 1.1	1 1 0.	4 0.0	2.1	0.0	0.0 1.2
, , ,	Lethargy (10024264)	1 0.3	0.0 1.9	0.0	0.0 1.3	0 0.0 0.	1.6 0	0.0	0.0 1.1	1 0 0.	0.0	1.4	0.0	0.0 1.2
	Seizure (10039906)	1 0.3	0.0 1.9	0.0	0.0 1.3	0 0.0 0.	1.6 0	0.0	0.0 1.1	1 0 0.	0.0	1.4	0.0	0.0 1.2
Psychiatric disorders (10037175)	Mental status changes (10048294)	0.0	0.0 1.3	0.0	0.0 1.3	0 0.0 0.	1.6 0	0.0	0.0 1.1	1 0 0.	0.0	1.4	1 0.3	0.0 1.9
Respiratory, thoracic and mediastinal disorders (10038738)	Apparent life threatening event (10065044)				0.0 1.3									
	Choking (10008589)				0.0 1.3									
	Hypoxia (10021143)				0.0 1.3									
	Respiratory distress (10038687)	2 0.7	0.1 2.5	0.0	0.0 1.3	0.00.	0 1.6	0.0	0.0 1.1	1 0 0.	0.0	1.4	0.0	0.0 1.2

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of administered doses

n/% = number/percentage of doses with the symptom

Table 8.45 Percentage of subjects reporting the occurrence of serious adverse event (SAE) from Dose 1 up to 6 months following priming doses-by geographical ancestry (Primary Total vaccinated cohort)

				Н	exa ç	jro	up					Pe	dia g	jrou	р				P	enta	gro	oup		
			V	/hite)		0	ther			W	hite			oth	er		1	Vhite				the	
				ıcasi			N	= 7	7		Cau				N =	66			ıcasi			N	= 8	1
			N	= 11							N:	= 128						N	= 11					
				95	% CI				5%			95%	6 CI		!	95%			95	% CI			95	% CI
	I		1		1								1			CI				1				
Primary System Organ Class (CODE)	Preferred Term (CODE)		%		UL														LL					
At least one symptom																								12.2
Blood and lymphatic system disorders (10005329)	Leukocytosis (10024378)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0 0	.0 0.	.0 5	5.4 0	0.0	0.0	3.2	0	0.0	0.0	4.5
Gastrointestinal disorders (10017947)	Gastrooesophageal reflux disease (10017885)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0 0	.0 0.	0 5	5.4 0	0.0	0.0	3.2	0	0.0	0.0	4.5
Infections and infestations (10021881)	Gastroenteritis viral (10017918)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	1 1	.5 0.	0.8	.2 0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Meningitis viral (10027260)	0	0.0	0.0	3.1	1	1.3	0.0	7.0	0	0.0	0.0	2.8	0 0	.0 0.	0 5	.4 0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Parainfluenzae virus infection (10061907)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0 0	.0 0.	0 5	5.4 1	0.9	0.0	4.7	1	1.2	0.0	6.7
	Pneumonia (10035664)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0 0	.0 0.	0 5	.4 1	0.9	0.0	4.7	0	0.0	0.0	4.5
	Respiratory syncytial virus bronchiolitis (10038718)	0	0.0	0.0	3.1	1	1.3	0.0	7.0	0	0.0	0.0	2.8	0 0	.0 0.	0 5	5.4 1	0.9	0.0	4.7	0	0.0	0.0	4.5
	Respiratory syncytial virus infection (10061603)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0 0	.0 0.	0 5	5.4 1	0.9	0.0	4.7	0	0.0	0.0	4.5
Injury, poisoning and procedural complications (10022117)	Road traffic accident (10039203)				3.1																			
Metabolism and nutrition disorders (10027433)	Dehydration (10012174)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0 0	.0 0.	0 5	5.4 0	0.0	0.0	3.2	1	1.2	0.0	6.7
Nervous system disorders (10029205)	Febrile convulsion (10016284)				3.1																			
,	Lethargy (10024264)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0 0	.0 0.	0 5	.4 0	0.0	0.0	3.2	0	0.0	0.0	4.5
	Seizure (10039906)	1	8.0	0.0	4.6	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0 0	.0 0.	0 5	.4 0	0.0	0.0	3.2	0	0.0	0.0	4.5
Psychiatric disorders (10037175)	Mental status changes (10048294)	0	0.0	0.0	3.1	0	0.0	0.0	4.7	0	0.0	0.0	2.8	0 0	.0 0.	0 5	.4 0	0.0	0.0	3.2	1	1.2	0.0	6.7

117119 (DTPA-HBV-IPV-135)

Report Final

				Не	xa g	rou	р			Ρ	edia (grou	р				Pe	nta ç	jrou)	
		(Cau	hite casi = 11	an			her = 77	Ca	White ucas = 12	ian		othe N = 6		C	auc	nite asia 115			oth N =	
				959	% CI			95% CI		95	% CI		9	5% CI			95%	CI		9	5% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n 9	%	LL	UL	n º	%	LL UL	n %	LL	UL	n %	6 LL		n %	6 I	LL	UL	n %	L	L UL
Respiratory, thoracic and mediastinal disorders (10038738)	Apparent life threatening event (10065044)	1 (8.0	0.0	4.6	0 0	0.0	0.0 4.7	0.0	0.0	2.8	0 0	0.0	5.4	0 0	.0 (0.0	3.2	0 0.	0.	0 4.5
, ,	Choking (10008589)	1 (0.8	0.0	4.6	0 0	0.0	0.0 4.7	0.0	0.0	2.8	0 0	.0 0.0	5.4	0 0	.0	0.0	3.2	0 0.	0.	0 4.5
	Hypoxia (10021143)							0.0 4.7													
	Respiratory distress (10038687)	1 (0.8	0.0	4.6	1 1	1.3	0.0 7.0	0.0	0.0	2.8	0 0	0.0	5.4	0 0	.0 (0.0	3.2	0 0.	0.	0 4.5

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with at least one administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Table 8.46 Listing of SAE from dose 1 up to study end (Primary Total vaccinated cohort)

	Sub. No.	Sex	Country	Race	Age at onset (Week)	Verbatim	Preferred term	Primary System Organ Class	MED type	Dose	Day of onset		Intensity	Causality	Outcome
Hexa group	PPD	F	United States	White - Caucasian / European Heritage	65	Hyponatremia	Hyponatraemia	Metabolism and nutrition disorders	НО	3	277	2	2	N	Recovered/resolved
				Tromago	65	PPD	PPD	Injury, poisoning and procedural complications	НО	3	277	2	2	N	Recovered/resolved
						Respiratory distress	Respiratory distress	Respiratory, thoracic and mediastinal disorders	НО	3	277	2	2	N	Recovered/resolved
	-	F	United States	Asian - East Asian Heritage	31	Viral meningitis	Meningitis viral	Infections and infestations	НО	3	31	5	2	N	Recovered/resolved
	-	F	United States	African Heritage / African American	28	Repiratory syncitial virus bronchiolitis	Respiratory syncytial virus bronchiolitis	Infections and infestations	НО	3	28	12	3	N	Recovered/resolved
						Respiratory distress	Respiratory distress	Respiratory, thoracic and mediastinal disorders	НО	3	34	6	3	N	Recovered/resolved
	-	F	United States	White - Caucasian / European Heritage	8	Lethargy event	Lethargy	Nervous system disorders	НО	1	0	1	1	Υ	Recovered/resolved
		F	United States	White - Caucasian / European Heritage	10	Apparent life- threatening event.	Apparent life threatening event	Respiratory, thoracic and mediastinal disorders	НО	1	0	1	2	Υ	Recovered/resolved

117119 (DTPA-HBV-IPV-135)

Sub. No.	Sex	Country	Race	Age at onset (Week)	Verbatim	Preferred term	Primary System Organ Class	MED type	Dose	Day of onset		Intensity	Causality	Outcome
PPD				10	Elevated leukocytosis	Leukocytosis	Blood and lymphatic system disorders	НО	1	0	2	1	Υ	Recovered/resolved
				71	Dehydration	Dehydration	Metabolism and nutrition disorders	НО	4	41	3	3	N	Recovered/resolved
	F	United States	White - Caucasian / European Heritage	51	Нурохіа	Hypoxia	Respiratory, thoracic and mediastinal disorders	НО	3	164	2	3	N	Recovered/resolved
				51	Rspiratory distress	Respiratory distress	Respiratory, thoracic and mediastinal disorders	НО	3	163	8	3	N	Recovered/resolved
	F	United States	White - Caucasian / European Heritage	35	Viral gastroenteritis	Gastroenteritis viral	Infections and infestations	НО	3	64	6	3	N	Recovered/resolved
	F	United States	White - Caucasian / European Heritage	46	Possible seizure	Seizure	Nervous system disorders	НО	3	140	2	2	N	Recovered/resolved
			, and the second	47	choking episode	Choking	Respiratory, thoracic and mediastinal disorders	НО	3	147	3	2	N	Recovered/resolved with sequelae
				47	Gastroesophageal reflux	Gastrooesophageal reflux disease	Gastrointestinal disorders	НО	3	147	3	2	N	Recovered/resolved
				71	Petechial rash	Petechiae	Skin and subcutaneous tissue disorders	НО	4	19	74	2	N	Recovered/resolved

117119 (DTPA-HBV-IPV-135)

Group	Sub. No.	Sex	Country	Race	Age at onset (Week)	Verbatim	Preferred term	Primary System Organ Class	MED type		Day of onse		Intensity	Causality	Outcome
Pedia group	PPD	F	United States	African Heritage / African American	36	viral gastroenteritis	Gastroenteritis viral	Infections and infestations	НО	3	63	6	3	N	Recovered/resolved
Penta group	-	F	United States	African Heritage / African American	19	Parainfluenza	Parainfluenzae virus infection	Infections and infestations	НО	2	5	33	2	N	Recovered/resolved
	-	F	United States	White - Caucasian / European Heritage	50	Respiratory syncytial virus bronchialitis	Respiratory syncytial virus bronchiolitis	Infections and infestations	НО	3	140	11	1	N	Recovered/resolved
	-	F	United States	White - Caucasian / European Heritage	25	Febrile seizure	Febrile convulsion	Nervous system disorders	НО	2	33	2	3	N	Recovered/resolved
	-	F	United States	African Heritage / African American	68	observed seizure- like activity	Seizure like phenomena	Nervous system disorders	НО	4	25	9	2	N	Recovered/resolved
		M	United States	African Heritage / African American	41	Altered mental status	Mental status changes	Psychiatric disorders	НО	3	108	2	3	N	Recovered/resolved
		F	United States	Other	27	Dehydration	Dehydration	Metabolism and nutrition disorders	НО	2	68	4	2	N	Recovered/resolved
		F	United States	African Heritage / African American	_ '	PPD PPD	PPD	Injury, poisoning and procedural complications	НО	2	32	2	2	N	Recovered/resolved

117119 (DTPA-HBV-IPV-135)

Report Final

Group	Sub.	Sex	Country	Race	Age at	Verbatim	Preferred term	Primary System	MED	Dose	Day	Duratio	on Intensity	Causality	Outcome
	No.				onset (Week)			Organ Class	type		of				
											onset				
	PPD	т		White - Caucasian / European Heritage	49	Para influenza	Parainfluenzae virus infection	Infections and infestations	НО	3	152	12	2	N	Recovered/resolved
				ŭ			Respiratory syncytial virus infection	Infections and infestations	НО	3	152	14	3	N	Recovered/resolved
						Community acquired pneumoina	Pneumonia	Infections and infestations	НО	3	158	6	2	N	Recovered/resolved

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines
Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines
Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine
Med type = Type of medical advice; HO= Hospitalisation, ER = Emergemcy room

117119 (DTPA-HBV-IPV-135) Report Final

Table 8.47 Compliance in returning symptom sheets for the booster dose (Booster Total vaccinated cohort)

	Number of doses	Doses NOT according to protocol	of	%	of	Compliance % local SS
Hexa group	167	0	153	91.6	154	92.2
Pedia group	158	0	150	94.9	151	95.6
Penta group	161	0	151	93.8	150	93.2

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

SS = Symptom screens/sheets used for the collection of local and general solicited AEs

Compliance % = (number of doses with symptom screen/sheet return / number of administered doses) X 100

Table 8.48 Incidence of grade 3 local symptoms (solicited and unsolicited) reported for Infanrix, Hiberix, ActHIB and Pentacel vaccines during the 4-day (Days 0-3) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

			ACTH	ΙΙΒ			PE	ENTA	CEL			II	NFAN	RIX			ı	HIBE	RIX	
				95%	6 CI															
Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Hexa group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	167	88	52.7	44.8	60.5	167	80	47.9	40.1	55.8
Pedia group	158	83	52.5	44.4	60.5	0	0	0.0	0.0	0.0	158	95	60.1	52.0	67.8	0	0	0.0	0.0	0.0
Penta group	0	0	0.0	0.0	0.0	161	76	47.2	39.3	55.2	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects with the administered dose

n% = number/percentage of subjects presenting at least one type of symptom at the study vaccine site

Table 8.49 Incidence and nature of grade 3 symptoms (solicited and unsolicited)that are causally related to vaccination reported during the 4-day (Days 0-3) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

	F	۱ny	sym	pto	m	Gen	era	al sy	mpt	oms	Lo	cal	syn	npto	ms
				959	% CI				95%	6 CI				959	S %
Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Hexa group	167	13	7.8	4.2	12.9	167	3	1.8	0.4	5.2	167	10	6.0	2.9	10.7
Pedia group	158	17	10.8	6.4	16.7	158	6	3.8	1.4	8.1	158	12	7.6	4.0	12.9
Penta group	161	10	6.2	3.0	11.1	161	5	3.1	1.0	7.1	161	6	3.7	1.4	7.9

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects with the administered dose

n/% = number/percentage of subjects presenting at least one type of symptom whatever the study vaccine administered

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Table 8.50 Incidence and nature of symptoms (solicited and unsolicited) reported during the 31-day (Days 0-30) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

		Any	sym	ptom)	Ge	ener	al syr	mpto	ms	L	oca	sym	pton	าร
				95%	6 CI				95%	6 CI				95%	6 CI
Group		n				N									UL
Hexa group	167	136	81.4	74.7	87.0	167	115	68.9	61.2	75.8	167	95	56.9	49.0	64.5
Pedia group	158	135	85.4	79.0	90.5	158	117	74.1	66.5	80.7	158	101	63.9	55.9	71.4
Penta group	161	123	76.4	69.1	82.7	161	114	70.8	63.1	77.7	161	76	47.2	39.3	55.2

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects with the administered dose

n/% = number/percentage of subjects presenting at least one type of symptom whatever the study vaccine administered

Table 8.51 Incidence and nature of grade 3 symptoms (solicited and unsolicited) reported during the 31-day (Days 0-30) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

	A	۱ny	sym	pto	m	Gen	era	al sy	mpt	oms	Lo	cal	syn	npto	ms
				959	% CI				95%	6 CI				95	% CI
Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Hexa group	167	13	7.8	4.2	12.9	167	3	1.8	0.4	5.2	167	10	6.0	2.9	10.7
Pedia group	158	17	10.8	6.4	16.7	158	6	3.8	1.4	8.1	158	12	7.6	4.0	12.9
Penta group	161	10	6.2	3.0	11.1	161	5	3.1	1.0	7.1	161	6	3.7	1.4	7.9

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects with the administered dose

n/% = number/percentage of subjects presenting at least one type of symptom whatever the study vaccine administered

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Table 8.52 Incidence and nature of symptoms (solicited and unsolicited) that are causally related to vaccination reported during the 31-day (Days 0-30) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

		Any	sym	ptom)	Ge	ener	al syı	mpto	ms	L	oca	sym	pton	าร
				95%	6 CI				95%	6 CI				95%	6 CI
Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Hexa group															
Pedia group	158	128	81.0	74.0	86.8	158	107	67.7	59.8	74.9	158	101	63.9	55.9	71.4
Penta group	161	109	67.7	59.9	74.8	161	89	55.3	47.3	63.1	161	76	47.2	39.3	55.2

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects with the administered dose

n/% = number/percentage of subjects presenting at least one type of symptom whatever the study vaccine administered

Table 8.53 Incidence and nature of grade 3 symptoms (solicited and unsolicited)that are causally related to vaccination reported during the 31-day (Days 0-30) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

	Any	sy	mpto	m		Gen	era	al sy	mpto	oms	Loc	al s	ym	ptor	ns
				95%	6 CI				95%	CI				95%	6 CI
Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Hexa group	167	13	7.8	4.2	12.9	167	3	1.8	0.4	5.2	167	10	6.0	2.9	10.7
Pedia group															
Penta group	161	10	6.2	3.0	11.1	161	5	3.1	1.0	7.1	161	6	3.7	1.4	7.9

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects with the administered dose

n/% = number/percentage of subjects presenting at least one type of symptom whatever the study vaccine administered

95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

Table 8.54 Incidence of local symptoms (solicited and unsolicited) that are causally related to vaccination reported for Infanrix, Hiberix, ActHIB and Pentacel vaccines during the 4-day (Days 0-3) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

		-	ACTH	ΙΙΒ			PI	ENTA	CEL			IN	NFAN	RIX			H	HIBE	RIX	
				95%	O %				95%	6 CI				95%	6 CI				95%	6 CI
Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Hexa group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	167	88	52.7	44.8	60.5	167	80	47.9	40.1	55.8
Pedia group	158	83	52.5	44.4	60.5	0	0	0.0	0.0	0.0	158	95	60.1	52.0	67.8	0	0	0.0	0.0	0.0
Penta group	0	0	0.0	0.0	0.0	161	76	47.2	39.3	55.2	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects with the administered dose

n/% = number/percentage of subjects presenting at least one type of symptom at the study vaccine site 95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

117119 (DTPA-HBV-IPV-135) Report Final

Table 8.55 Incidence of grade 3 local symptoms (solicited and unsolicited) that are causally related to vaccination reported for Infanrix, Hiberix, ActHIB and Pentacel vaccines during the 4-day (Days 0-3) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

		Α	CTH	ΗВ		P	Έ	NTA	CEI	_		INI	FAN	IRIX			Н	IBE	RIX	
				95%	6 CI				95%	6 CI				95	% CI				95%	6 CI
Group	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL
Hexa group	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0	167	10	6.0	2.9	10.7	167	1	0.6	0.0	3.3
Pedia group	158	5	3.2	1.0	7.2	0	0	0.0	0.0	0.0	158	11	7.0	3.5	12.1	0	0	0.0	0.0	0.0
Penta group	0	0	0.0	0.0	0.0	161	6	3.7	1.4	7.9	0	0	0.0	0.0	0.0	0	0	0.0	0.0	0.0

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects with the administered dose

n/% = number/percentage of subjects presenting at least one type of symptom at the study vaccine site 95% CI = exact 95% confidence interval, LL = Lower Limit, UL = Upper Limit

117119 (DTPA-HBV-IPV-135)

Table 8.56 Incidence of solicited local symptoms reported during the 4-day (Days 0-3) post-vaccination period following the booster dose -by gender (Booster Total vaccinated cohort)

						Hexa	gro									Pedia	gro	up							Pent	a gr	oup			
				Fem					Male					Fem					Ma				Fe	male				Ma		
					95	% CI				5 %					95	% CI				95	% CI			95	% C	_			95 %	
Symptom	Product	Туре	N n		LL			n %						%	LL	UL		n 9		LL	UL	N n		LL	UL			%		UL
Pain	Total	All	79 36		34.3	57.2																						40.5	29.9	51.7
		Grade 2 or 3	79 4	5.1	1.4	12.5			2.0 5.		21.6				5.4	24.9						66 8				5 84				17.9
		Grade 3	79 1	1.3	0.0	6.9	75					54			0.0		97		2.1	0.3	7.3	66 0			5.4					8.3
		Medical advice		1.3		6.9	75					54			0.0		97			0.0	3.7	66 0	0.0	0.0	5.4	84	10	0.0	0.0	4.3
		All	78 31	39.7	28.8	51.5	75	30 40	0.0 28	3.9 5	52.0	54	23	42.6	29.2	2 56.8	97	41 4	2.3	32.3	52.7									
		Grade 2 or 3	78 3	3.8	8.0	10.8	75	8 10	0.7 4.	7 1	19.9	54	4	7.4	2.1	17.9			1.3	5.8	19.4									
		Grade 3	78 1	1.3	0.0	6.9	75					54			0.0		97			0.3	7.3									
		Medical advice	78 0	0.0		4.6	75					54			0.0	_	97				3.7									
	Infanrix/Pentacel		79 29		26.1	48.3			1.0 32	2.5 5	55.9	54				62.2													29.9	51.7
		Grade 2 or 3	-	5.1	1.4	12.5	75	8 10).7 4.		19.9	54	7	13.0		24.9				6.6		66 8		1 5.4	22.					17.9
		Grade 3	79 1	1.3	0.0	6.9	75					54	1		0.0	9.9	97			0.3	7.3	66 0			5.4					8.3
		Medical advice		1.3	0.0	6.9	75								0.0		97			0.0	3.7	66 0			5.4					4.3
Redness (mm)		All				41.8	75	31 41	1.3 30							58.6								8 23.						
		>5		8.9	3.6	17.4		12 16			26.3				1.2							66 7		6 4.4	20.					14.9
		>20		2.5	0.3	8.8	75				16.6				0.0		97			2.3		66 0			5.4					8.3
		Medical advice		2.5		8.8	75					54			0.0	6.6	97			0.0	3.7	66 0	0.0	0.0	5.4	84	10	0.0	0.0	4.3
		All	78 19		15.3	35.4														22.9	42.2									
		>5		5.1	1.4	12.6					11.2				0.0		97		1.1	1.1	10.2									
		>20	78 0	0.0	0.0	4.6	75					54			0.0	6.6	97			0.3	7.3									
		Medical advice		0.0		4.6	75	-				54			0.0		97			0.0	3.7									
	Infanrix/Pentacel		79 22		18.3																									
		>5		6.3	2.1			12 16			26.3				1.2	15.4				5.8		66 7		6 4.4		6 84				14.9
		>20		2.5		8.8	75				16.6				0.0		97		l.1	1.1		66 0			5.4					8.3
		Medical advice		2.5		8.8	75					54			0.0		97			0.0	3.7	66 0			5.4					4.3
Swelling (mm)		All	79 20	25.3																										
		>5	79 9	11.4	_	20.5).7 4.		19.9				4.2					6.6	20.6			6 4.4		6 84				16.4
		>20		3.8	8.0	10.7						54			0.5				5.2	1.7		66 0			5.4			4.8		11.7
		Medical advice	79 2	2.5	0.3	8.8	75	0 0.	0 0.	0 4	1.8	54	0	0.0	0.0	6.6	97	0 (0.0	0.0	3.7	66 0	0.0	0.0	5.4	84	10	0.0	0.0	4.3

117119 (DTPA-HBV-IPV-135)

Report Final

					I	Hexa	gro	up							F	Pedia	gro	up							F	Penta	gro	up		-	
				Fen	nale			ı	Vlale					Fem	ale				Ma	ıle				Fem	ale				Ма	le	
					95	% CI			9	5 %	CI				95 °	% CI				95	% CI				95	% CI				95 %	6 CI
Symptom	Product	Туре	N n	%	LL	UL	N	n %	LL	_ (JL	N r	ı (%	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N	n '	%	LL	UL
	ActHIB/Hiberix	All	78 14	17.9	10.2	28.3	75	15 20).0 11	1.6 3	8.08	54 1	0	18.5	9.3	31.4	97	19	19.6	12.2	28.9										
		>5	78 5	6.4	2.1	14.3	75	2 2.	7 0.	3 9	9.3	54 3	3 5	5.6	1.2	15.4	97	3	3.1	0.6	8.8										
		>20	78 0	0.0	0.0	4.6	75	0 0.	0 0.	0 4	8.4	54 0) (0.0	0.0	6.6	97	2	2.1	0.3	7.3										
		Medical advice	78 0	0.0	0.0	4.6	75	0 0.	0 0.	0 4	8.4	54 0) (0.0	0.0	6.6	97	0	0.0	0.0	3.7										
	Infanrix/Pentacel	All	79 18	22.8	14.1	33.6	75	24 32	2.0 21	1.7 4	3.8	54 2	20 3	37.0	24.3	51.3	97	24	24.7	16.5	34.5	66	17	25.8	15.8	38.0	84	18	21.4	13.2	31.7
		>5	79 6	7.6	2.8	15.8	75	7 9.	3 3.	8 1	8.3	54 5	5 9	9.3	3.1	20.3	97	12	12.4	6.6	20.6	66	7	10.6	4.4	20.6	84	7	8.3	3.4	16.4
		>20	79 3	3.8	0.8	10.7	75	2 2.	7 0.	3 9	9.3	54 2	2 (3.7	0.5	12.7	97	5	5.2	1.7	11.6	66	0	0.0	0.0	5.4	84	4	4.8	1.3	11.7
		Medical advice	79 2	2.5	0.3	8.8	75	0 0.	0 0.	0 4	1.8	54 C) (0.0	0.0	6.6	97	0	0.0	0.0	3.7	66	0	0.0	0.0	5.4	84	0 (0.0	0.0	4.3

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects with the documented dose

n/% = number/percentage of subjects reporting the symptom at least once 95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

117119 (DTPA-HBV-IPV-135)

Table 8.57 Incidence of solicited local symptoms reported during the 4-day (Days 0-3) post-vaccination period following the booster dose-by geographical ancestry (Booster Total vaccinated cohort)

					ŀ	Hexa	group)						Ρ	edia ç	group)					F	enta	grou)		
			Whi	ite Ca	ucas	ian		otl	ner		V	Vhite	e Cau	ucasi	an		otl	ner		Whi	te Ca	ucas	ian		oth	-	
					95 °	% CI				% CI				95 9	% CI				% CI			95	% CI				% CI
Symptom	Product	Туре			LL			%	LL	UL	N			LL			%	LL		N n		LL			%		UL
Pain	Total																			88 40							
			94 9		4.5	17.4		6.7	1.8	16.2					23.5			5.7		88 11	12.5		21.3			2.7	17.8
			94 2				60 0	0.0	0.0	6.0	100			0.2		51 1	2.0		10.4		1.1	0.0		62 1			8.7
		Medical advice					60 0	0.0		6.0	100					51 0		0.0			0.0	0.0	4.1	62 0	0.0	0.0	5.8
	ActHIB/Hiberix		94 38			51.0			26.5	52.6							2 43.1										
			94 8		3.7		59 3	5.1	1.1	14.1			10.0		17.6			3.3	21.4								
			94 1				59 0	0.0		6.1	100			0.2		51 0		0.0	7.0								
		Medical advice					59 0	0.0		6.1	100					51 0		0.0	7.0								
	Infanrix/Pentacel																			88 40						19.6	43.7
					3.7		60 4	6.7	1.8	16.2					21.2			4.4		88 11				62 5			17.8
		Grade 3	94 2				60 0	0.0		6.0	100					51 1			10.4		1.1	0.0		62 1	1.6		8.7
			94 1				60 0	0.0	0.0	6.0	100			0.0		51 0		0.0			0.0	0.0		62 0			5.8
Redness (mm)																				88 36					17.7		29.5
			94 15			25.0		6.7		16.2					21.2			1.2		88 10				62 3	4.8	1.0	13.5
			94 7		3.0	14.7		1.7		8.9	100				11.3		2.0	0.0	10.4		1.1	0.0		62 1			8.7
			94 2		0.3	_	60 0	0.0		6.0	100			0.0		51 0	0.0	0.0			0.0	0.0	4.1	62 0	0.0	0.0	5.8
			94 25						17.8																		
			94 4			10.5		5.1	1.1	14.1						51 1	2.0	0.0	10.4								
			94 0		0.0		59 0	0.0		6.1	100	1	1.0			51 1	2.0	0.0	10.4								
		Medical advice	94 0				59 0	0.0		6.1	100					51 0	0.0	0.0	7.0								
	Infanrix/Pentacel																			88 36							29.5
			94 14			23.7		5.0	1.0	13.9	100			5.6	18.8			1.2		88 10	11.4			62 3	4.8		13.5
			94 7		3.0	14.7		1.7		8.9	100		4.0	1.1		51 0	0.0	0.0		88 1	1.1	0.0	-	62 1	1.6		8.7
			94 2		0.3		60 0	0.0		6.0	100			0.0		51 0		0.0			0.0	0.0		62 0			5.8
Swelling (mm)				34.0	24.6				14.7											88 25							27.7
			94 14	14.9		23.7		5.0	1.0	13.9			11.0	5.6	18.8			5.7		88 9	10.2	4.8		62 5		2.7	17.8
			94 4		1.2	10.5	60 1	1.7	0.0	8.9	100	4	4.0	1.1	9.9	51 3	5.9	1.2	16.2	88 3	3.4	0.7	9.6	62 1	1.6	0.0	8.7
		Medical advice	94 2	2.1	0.3	7.5	60 0	0.0	0.0	6.0	100	0	0.0	0.0	3.6	51 0	0.0	0.0	7.0	88 0	0.0	0.0	4.1	62 0	0.0	0.0	5.8

117119 (DTPA-HBV-IPV-135)

Report Final

						Hexa	gro	up							Р	edia	gro	up							Penta	a gro	oup	-	
			Wh	ite Ca	ucas	ian			othe	r		٧	Vhit	e Ca	ucas	ian			otl	her		Wh	ite C	auca	sian		ot	her	
					95	% CI				95 %	6 CI				95	% CI				95	% CI			95	% CI			95	% CI
Symptom	Product	Туре	N n	%	LL	UL	N	n %	% L	LL	UL	N	n	%	LL	UL	N	n	%	LL	UL	N n	%	LL	UL	N	n %	LL	UL
	ActHIB/Hiberix	All	94 18	19.1	11.8	28.6	59	11 1	18.6	9.7	30.9	100	19	19.0	11.8	28.1	1 51	10	19.6	9.8	33.1								
		>5	94 6	6.4	2.4	13.4	59	1 1	1.7 (0.0	9.1	100	2	2.0	0.2	7.0	51	4	7.8	2.2	18.9								
		>20	94 0	0.0	0.0	3.8	59	0 0	0.0	0.0	6.1	100	0	0.0	0.0	3.6	51	2	3.9	0.5	13.5								
		Medical advice	94 0	0.0	0.0	3.8	59	0 0	0.0	0.0	6.1	100	0	0.0	0.0	3.6	51	0	0.0	0.0	7.0								
	Infanrix/Pentacel	All	94 29	30.9	21.7	41.2	60	13 2	21.7 1	12.1	34.2	100	25	25.0	16.9	34.7	7 51	19	37.3	3 24.1	51.9	88 2	28.	4 19.	3 39.0	0 62	10 16.	1 8.0	27.7
		>5	94 11	11.7	6.0	20.0	60	2 3	3.3).4	11.5	100	10	10.0	4.9	17.6	51	7	13.7	5.7	26.3	88 9	10.	2 4.8	18.	5 62	5 8.1	2.7	17.8
		>20	94 4	4.3	1.2	10.5	60	1 1	1.7	0.0	8.9	100	4	4.0	1.1	9.9	51	3	5.9	1.2	16.2	88 3	3.4	0.7	9.6	62	1 1.6	0.0	8.7
		Medical advice	94 2	2.1	0.3	7.5	60	0 0	0.0	0.0	6.0	100	0	0.0	0.0	3.6	51	0				88 0	0.0	0.0	4.1	62		0.0	5.8

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects with the documented dose

n/% = number/percentage of subjects reporting the symptom at least once 95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

117119 (DTPA-HBV-IPV-135) Report Final

Table 8.58 Incidence of large injection site reaction reported during the 4-day (Days 0-3) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

	I	Hexa N =	grou 154	р	Р	edia N =	grou 151	p	Р		grou 150	ıp
			95%	6 CI			95%	CI			95%	o CI
Type of swelling	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
Local swelling	2	1.3	0.2	4.6	1	0.7	0.0	3.6	0	0.0	0.0	2.4
Diffuse swelling	1	0.6	0.0	3.6	0		0.0	2.4	0			2.4
No swelling	151	98.1	94.4	99.6	150	99.3	96.4	100	150	100	97.6	100

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects with at least one documented dose

n/% = number/percentage of subjects reporting the symptom at least once

95% CI= exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Large injection site reaction - swelling with a diameter > 50 mm, noticeable diffuse swelling or increase in limb circumference of greater than 50 mm

117119 (DTPA-HBV-IPV-135)

Report Final

Table 8.59 Incidence of solicited general symptoms reported during the 4-day (Days 0-3) post-vaccination period following the booster dose-by gender (Booster Total vaccinated cohort)

					I	Hexa	gro	up								Pedia	a gr	oup								Penta	gro	up		
				Fem	nale				Ma	ale				Fen	nale				Ма	le				Fen	nale			N	/lale	
					95 9	% CI				95	% CI				95	% CI					% CI				95	% CI			95	% CI
Symptom		N		%	LL				%	LL	UL	N			LL	UL		n		LL				%	LL	UL	N		LL	UL
		78		34.6	24.2					31.3				42.6															.9 32.1	
	Grade 2 or 3	78		11.5	5.4	20.8		9		5.6	21.6		_	11.1		22.6			14.6		23.3			9.0	3.4			11 13	.1 6.7	22.2
	Grade 3	78		0.0	0.0	4.6	75	1	1.3	0.0	7.2			3.7	0.5		7 96		1.0	0.0		67		1.5	0.0	8.0	84	1 1.2		6.5
	Related	78	25	32.1	21.9	43.6	75	30	40.0	28.9	52.0	54	22	40.7	27.6	55.0	0 96	43	44.8	34.6	55.3	67	28	41.8	29.8	54.5	84	33 39	.3 28.8	3 50.5
	Grade 3 Related	78	0	0.0	0.0	4.6	75	1	1.3	0.0	7.2	54	2	3.7	0.5	12.	7 96	1	1.0	0.0	5.7	67	1	1.5	0.0	8.0	84	1 1.2	0.0	6.5
	Medical advice	78		0.0		4.6	75		0.0	0.0	4.8	54		0.0	0.0	6.6			0.0	0.0		67		0.0	0.0	5.4	84			4.3
,	All	78	45	57.7																									.8 37.7	60.0
	Grade 2 or 3	78	15	19.2	11.2	29.7	75	11	14.7	7.6	24.7	54	13	24.1	13.5	37.6	6 96	22	22.9	15.0	32.6	67	8	11.9	5.3	22.2	84	15 17	.9 10.4	4 27.7
	Grade 3	78	1	1.3	0.0	6.9	75	2	2.7	0.3	9.3	54	3	5.6	1.2	15.4	4 96	1	1.0	0.0	5.7	67	1	1.5	0.0	8.0	84	3 3.6	0.7	10.1
	Related	78	44	56.4	44.7	67.6	75	41	54.7	42.7	66.2	54	33	61.1	46.9	74.	1 96	59	61.5	51.0	71.2	67	31	46.3	34.0	58.9	84	37 44	.0 33.2	2 55.3
	Grade 3 Related	78	1	1.3	0.0	6.9	75	2	2.7	0.3	9.3	54	3	5.6	1.2	15.4	4 96	1	1.0	0.0	5.7	67	1	1.5	0.0	8.0	84	3 3.6	0.7	10.1
	Medical advice	78	0	0.0	0.0	4.6	75	0	0.0	0.0	4.8	54	0	0.0	0.0	6.6	96	0	0.0	0.0	3.8	67	0	0.0	0.0	5.4	84	1 1.2	0.0	6.5
	All			33.3	23.1	44.9	75	21	28.0	18.2					12.0				36.5	26.9	46.9	67			18.0	40.7	84	27 32	.1 22.4	43.2
	Grade 2 or 3	78		7.7	2.9	16.0	75	2	2.7	0.3	9.3			3.7	0.5	12.	7 96		7.3	3.0	14.4	67	6	9.0	3.4	18.5	84	5 6.0	2.0	13.3
	Grade 3	78		0.0	0.0	4.6	75		1.3	0.0	7.2	54		1.9	0.0	9.9			1.0	0.0		67		1.5	0.0	8.0	84			6.5
	Related	78	24	30.8	20.8	42.2	75	20	26.7	17.1	38.1	54	12	22.2	12.0	35.6	6 96	32	33.3	24.0	43.7	67	16	23.9	14.3	35.9	84	25 29	.8 20.3	3 40.7
	Grade 3 Related	78	0	0.0	0.0	4.6	75	1	1.3	0.0	7.2	54		1.9	0.0	9.9	96		1.0	0.0		67		1.5	0.0	8.0	84	1 1.2	0.0	6.5
	Medical advice	78		0.0	0.0	4.6	75		0.0	0.0	4.8			0.0	0.0	6.6			0.0	0.0		67		0.0	0.0	5.4	84			4.3
Temperature/(Axillary) (°C)	All	78	1	1.3	0.0	6.9	75		4.0	8.0	11.2			3.7	0.5	12.			8.3	3.7	15.8			6.0	1.7	14.6	84			16.4
	>38.5	78	0	0.0	0.0	4.6	75	2	2.7	0.3	9.3	54	1	1.9	0.0	9.9			4.2	1.1	10.3	67	2	3.0	0.4	10.4	84	2 2.4	1 0.3	8.3
	>39.0	78		0.0		4.6	75		1.3	0.0	7.2	54		1.9	0.0	9.9				0.0		67		1.5	0.0	8.0	84		0.0	4.3
	>39.5	78		0.0		4.6	75		0.0	0.0	4.8	54		0.0	0.0	6.6			0.0	0.0		67		0.0	0.0	5.4	84			4.3
	>40.0	78		0.0	0.0	4.6	75		0.0	0.0	4.8	54		0.0	0.0	6.6			0.0	0.0		67		0.0	0.0	5.4	84			4.3
	Related	78		0.0	0.0	4.6	75		2.7	0.3	9.3	54		3.7	0.5	12.			8.3	3.7	15.8			4.5	0.9		84	ô 7.	2.7	14.9
	>40.0 Related	78	0	0.0	0.0	4.6	75	0	0.0	0.0	4.8	54		0.0	0.0	6.6	96	0	0.0	0.0	3.8	67	0	0.0	0.0	5.4	84	0.0	0.0	4.3
	Medical advice	78	0	0.0	0.0	4.6	75	0	0.0	0.0	4.8	54	1	1.9	0.0	9.9	96	1	1.0	0.0	5.7	67	0	0.0	0.0	5.4	84	1 1.2	0.0	6.5

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects with the documented dose n/% = number/percentage of subjects reporting the symptom at least once 95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

Table 8.60 Incidence of solicited general symptoms reported during the 4-day (Days 0-3) post-vaccination period following the booster dose-by geographical ancestry (Booster Total vaccinated cohort)

					H	lexa	group)						Р	edia (group)						F	enta	gro	up		
		V	/hi	te Ca	ucas	ian		oth	er		W	/hite	Ca ı	ıcas	ian		oth	er		W	Vhit	e Ca	ucas	ian			other	
					95 %	6 CI			95	% CI				95	% CI			95	% CI				95	% CI			9	5 % CI
Symptom	Туре	N	n	%	LL	UL	N n	%	LL	UL			%	LL	UL	N n	%	LL	UL			%	LL	UL			6 LL	UL
Drowsiness	All	94	38	40.4	30.4	51.0	59 21	35.6	23.6	49.1	100	45	45.0	35.0	55.3	50 22	2 44.0	30.0	58.7	7 90	38	42.2	31.9	53.1	61	27 4	4.3 31	.5 57.6
	Grade 2 or 3	94	11	11.7	6.0	20.0	59 7	11.9	4.9	22.9	100	12	12.0	6.4	20.0	50 8	16.0	7.2	29.1	1 90	9	10.0	4.7	18.1	61	8 1	3.1 5.8	3 24.2
	Grade 3	94	1	1.1	0.0	5.8	59 0	0.0	0.0	6.1	100	1	1.0	0.0	5.4	50 2	4.0	0.5	13.7	7 90	1	1.1	0.0	6.0	61	1 1	.6 0.0	8.8
	Related	94	35	37.2	27.5	47.8	59 20	33.9	22.1	47.4	100	44	44.0	34.1	54.3	50 2	1 42.0	28.2	56.8	3 90	34	37.8	27.8	48.6	61	27 4	4.3 31	.5 57.6
	Grade 3 Related	94	1	1.1	0.0	5.8	59 0	0.0	0.0	6.1	100	1	1.0	0.0	5.4	50 2	4.0	0.5	13.7	7 90	1	1.1	0.0	6.0	61	1 1	.6 0.0	8.8
	Medical advice	94	0	0.0	0.0	3.8	59 0	0.0	0.0	6.1	100	0	0.0	0.0	3.6	50 0	0.0	0.0	7.1	90	0	0.0	0.0	4.0	61	0 (0.0	5.9
Irritability / Fussiness	All	94	57	60.6	50.0	70.6	59 29	49.2	35.9	62.5	100	60	60.0	49.7	69.7	50 34	1 68.0	53.3	80.5	90	50	55.6	44.7	66.0	61	26 4	2.6 30	.0 55.9
	Grade 2 or 3	94	19	20.2	12.6	29.8	59 7	11.9	4.9	22.9	100	23	23.0	15.2	32.5	50 12	24.0	13.1	38.2	90	16	17.8	10.5	27.3	61	7 1	1.5 4.	22.2
	Grade 3	94	2	2.1	0.3	7.5	59 1	1.7	0.0	9.1	100	3	3.0	0.6	8.5	50 1	2.0	0.1	10.6	90	2	2.2	0.3	7.8	61	2 3	3.3 0.4	11.3
	Related	94	56	59.6	49.0	69.6	59 29	49.2	35.9	62.5	100	60	60.0	49.7	69.7	50 32	64.0	49.2	77.	1 90	43	47.8	37.1	58.6	61	25 4	1.0 28	.6 54.3
	Grade 3 Related	94	2	2.1	0.3	7.5	59 1	1.7	0.0	9.1	100	3	3.0	0.6	8.5	50 1	2.0	0.1	10.6	90	2	2.2	0.3	7.8	61	2 3	3.3 0.4	11.3
	Medical advice	94	0	0.0	0.0	3.8	59 0	0.0	0.0	6.1	100	0	0.0	0.0	3.6	50 0	0.0	0.0	7.1	90	1	1.1	0.0	6.0	61	0 (0.0	5.9
Loss Of Appetite	All	94	33	35.1	25.5	45.6	59 14	23.7	13.6	36.6	100	31	31.0	22.1	41.0	50 16	32.0	19.5	46.7	7 90	29	32.2	22.8	42.9	61	17 2	27.9 17	.1 40.8
	Grade 2 or 3	94	3	3.2	0.7	9.0	59 5	8.5	2.8	18.7	100	5	5.0	1.6	11.3	50 4	8.0	2.2	19.2	90	5	5.6	1.8	12.5	61	6).8 3.	20.2
	Grade 3	94	1	1.1	0.0	5.8	59 0	0.0	0.0	6.1	100	0	0.0	0.0	3.6	50 2	4.0	0.5	13.7	7 90	1	1.1	0.0	6.0	61	1 1	.6 0.0	8.8
	Related	94	30	31.9	22.7	42.3	59 14	23.7	13.6	36.6	100	29	29.0	20.4	1 38.9	50 15	30.0	17.9	44.6	90	24	26.7	17.9	37.0	61	17 2	27.9 17	.1 40.8
	Grade 3 Related	94	1	1.1	0.0	5.8	59 0	0.0	0.0	6.1	100	0	0.0	0.0	3.6	50 2	4.0	0.5	13.7	7 90	1	1.1	0.0	6.0	61	1 1	.6 0.0	8.8
	Medical advice	94	0	0.0	0.0	3.8	59 0	0.0	0.0	6.1	100	0	0.0	0.0	3.6	50 0	0.0	0.0	7.1	90	0	0.0	0.0	4.0	61	0 0	0.0	5.9

117119 (DTPA-HBV-IPV-135)

Report Final

											,														_ 1 (C)	JUILI	
					H	lexa	group)					P	edia	group		Penta group										
		W	/hit	te Ca	ucas	ian		other				White Caucasian					er		Wh	ite Ca	aucas	sian		ot	her		
			95 % CI					95 % C					95	95 % CI			95	% CI			95	% CI			95 (% CI	
Symptom	Туре	N	n	%	LL	UL	N n	%	LL	UL	N n	%	LL	UL	N n	%	LL	UL	N n	%	LL	UL	N n	%	LL	UL	
Temperature/(Axillary) (°C)	All	94	2	2.1	0.3	7.5	59 2	3.4	0.4	11.7	100 5	5.0	1.6	11.3	50 5	10.0	3.3	21.8	90 4	4.4	1.2	11.0	61 7	11.	5 4.7	22.2	
	>38.5	94	2	2.1	0.3	7.5	59 0	0.0	0.0	6.1	100 2	2.0	0.2	7.0	50 3	6.0	1.3	16.5	90 1	1.1	0.0	6.0	61 3	4.9	1.0	13.7	
	>39.0	94	1	1.1	0.0	5.8	59 0	0.0	0.0	6.1	100 0	0.0	0.0	3.6	50 1	2.0	0.1	10.6	90 0	0.0	0.0	4.0	61 1	1.6	0.0	8.8	
	>39.5	94	0	0.0	0.0	3.8	59 0	0.0	0.0	6.1	100 0	0.0	0.0	3.6	50 0	0.0	0.0	7.1	90 0	0.0	0.0	4.0	61 0	0.0	0.0	5.9	
	>40.0	94	0	0.0	0.0	3.8	59 0	0.0	0.0	6.1	100 0	0.0	0.0	3.6	50 0	0.0	0.0	7.1	90 0	0.0	0.0	4.0	61 0	0.0	0.0	5.9	
	Related	94	1	1.1	0.0	5.8	59 1	1.7	0.0	9.1	100 5	5.0	1.6	11.3	50 5	10.0	3.3	21.8	90 3	3.3	0.7	9.4	61 6	9.8	3.7	20.2	
	>40.0 Related	94	0	0.0	0.0	3.8	59 0	0.0	0.0	6.1	100 0	0.0	0.0	3.6	50 0	0.0	0.0	7.1	90 0	0.0	0.0	4.0	61 0	0.0	0.0	5.9	
	Medical advice	94	0	0.0	0.0	3.8	59 0	0.0	0.0	6.1	100 0	0.0	0.0	3.6	50 2	4.0	0.5	13.7	90 1	1.1	0.0	6.0	61 0	0.0	0.0	5.9	

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

N = number of subjects with the documented dose

n/% = number/percentage of subjects reporting the symptom at least once 95%CI = Exact 95% confidence interval; LL = lower limit, UL = upper limit

117119 (DTPA-HBV-IPV-135) Report Final

Table 8.61 Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship to vaccination, within the 31-day (Days 0-30) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

		Н		gro = 16		P		a gro = 15		P		a group = 161	
				95	5%			95	5%			95	5%
				CI					CI				
Primary System Organ Class (CODE)	Preferred Term (CODE)				UL								
At least one symptom		3	1.8	0.4	5.2	3	1.9	0.4	5.4	3	1.9	0.4	5.3
Gastrointestinal disorders (10017947)	Diarrhoea (10012735)	0	0.0	0.0	2.2	1	0.6	0.0	3.5	0	0.0	0.0	2.3
,	Teething (10043183)	1	0.6	0.0	3.3	0	0.0	0.0	2.3	1	0.6	0.0	3.4
	Vomiting (10047700)	1	0.6	0.0	3.3	1	0.6	0.0	3.5	1	0.6	0.0	3.4
General disorders and administration site conditions (10018065)	Injection site nodule (10057880)	1	0.6	0.0	3.3	0	0.0	0.0	2.3	0	0.0	0.0	2.3
,	Vaccination site erythema (10059079)	0	0.0	0.0	2.2	1	0.6	0.0	3.5	0	0.0	0.0	2.3
Skin and subcutaneous tissue disorders (10040785)	Rash (10037844)	0	0.0	0.0	2.2	1	0.6	0.0	3.5	0	0.0	0.0	2.3
	Rash erythematous (10037855)	0	0.0	0.0	2.2	0	0.0	0.0	2.3	1	0.6	0.0	3.4

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n/% = number/percentage of subjects reporting the symptom at least once

95% CI = exact 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Table 8.62 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship to vaccination, within the 31-day (Days 0-30) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

No records exist in this table

Table 8.63 Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following the booster dose-by gender (Booster Total vaccinated cohort)

		Hexa group										F	edia	gro	oup				F	Penta	a gr	group				
			Fe	male)		· N	lale				male			· N	lale			Fe	male				Male		
			N	= 87			N	= 80			N	= 58			N:	= 10			N	= 73			N	I = 88		
					% CI				⁶ CI				6 CI				% CI				% CI				% CI	
Primary System Organ Class (CODE)	Preferred Term (CODE)		%	LL	UL	n		LL			%			n			UL	n	%	LL	UL		%		UL	
At least one symptom		19	21.8	13.7	32.0	18	22.5	13.9	33.2	13	3 22.4	12.5	35.3	22	22.0	14.3	31.4	1 20	27.4	17.6	39.	1 2	23.9	15.4	34.1	
Blood and lymphatic system disorders (10005329)	(10022972)				4.2						0.0								0.0					0.0		
Congenital, familial and genetic disorders (10010331)	Dacryostenosis congenital (10011850)	0		0.0	4.2						0.0								0.0					0.0		
	Phimosis (10034878)	0	0.0	0.0	4.2				4.5				6.2		1.0				0.0	0.0	4.9			0.0		
Ear and labyrinth disorders (10013993)	Ear pain (10014020)	0	0.0	0.0	4.2	0	0.0	0.0	4.5				6.2						0.0	0.0	4.9	1	1.1	0.0	6.2	
	Tympanic membrane perforation (10045210)	1	1.1	0.0	6.2	0	0.0	0.0	4.5	0	0.0	0.0	6.2	0	0.0	0.0	3.6	0	0.0	0.0	4.9	0	0.0	0.0	4.1	
Eye disorders (10015919)	Chalazion (10008388)	0	0.0	0.0	4.2	0	0.0	0.0	4.5	0	0.0	0.0	6.2	1	1.0	0.0	5.4	0	0.0	0.0	4.9	0	0.0	0.0	4.1	
Gastrointestinal disorders (10017947)	Diarrhoea (10012735)	0	0.0	0.0	4.2	0				0	0.0	0.0	6.2	2	2.0	0.2	7.0	3	4.1	0.9	11.5	5 0	0.0	0.0	4.1	
	Nausea (10028813)	0	0.0	0.0	4.2	0	0.0	0.0	4.5	1	1.7	0.0	9.2	0	0.0	0.0	3.6	0	0.0	0.0	4.9	0	0.0	0.0	4.1	
	Stomatitis (10042128)	0	0.0	0.0	4.2			0.0	6.8	0	0.0			0	0.0	0.0	3.6	0	0.0	0.0	4.9	0	0.0	0.0	4.1	
	Teething (10043183)	1	1.1	0.0	6.2				10.6	1	1.7	0.0	9.2			0.0	5.4	2	2.7	0.3	9.5	1	1.1		6.2	
	Vomiting (10047700)	1	1.1	0.0	6.2						3.4		11.9					1	1.4	0.0	7.4		1.1	0.0	6.2	
General disorders and administration site conditions (10018065)	Injection site induration (10022075)	0	0.0	0.0	4.2				4.5				9.2						0.0	0.0	4.9			0.0		
	Injection site nodule (10057880)	0			4.2				6.8										0.0			0		0.0		
	Injection site scab (10066210)	0	0.0	0.0	4.2				4.5										0.0	0.0	4.9	1	1.1	0.0	6.2	
	Pyrexia (10037660)	3	3.4	0.7	9.7							0.4	11.9						2.7	0.3	9.5				4.1	
	Vaccination site erythema (10059079)	0	0.0		4.2			0.0					6.2		1.0				0.0	0.0	4.9				4.1	
Immune system disorders (10021428)		1		0.0	6.2				8.7						0.0				0.0					0.0	4.1	
Infections and infestations (10021881)	Bronchitis (10006451)	0	0.0	0.0	4.2	0	0.0	0.0	4.5	0	0.0	0.0	6.2	1	1.0	0.0	5.4	0	0.0	0.0	4.9	0	0.0	0.0	4.1	

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	auc			Pedia group									ı	Penta	ar	group				
			Fe	male		. g		Male			Fe	male		. g		/lale			Fe	male		<u> </u>		Vlale		
				= 87				= 80)			= 58				= 100)			= 73				I = 88	}	
					% CI				% CI				% CI				% CI				% CI				% CI	
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL			%		UL	n		LL	UL			LL	UL		%	LL	UL		%		UL	
	Cellulitis (10007882)	0	0.0	0.0	4.2	0	0.0	0.0	4.5	0	0.0			1	1.0	0.0	5.4	0	0.0	0.0	4.9		0.0	0.0	4.1	
	Conjunctivitis (10010741)	0	0.0	0.0	4.2	0	0.0	0.0	4.5	0	0.0	0.0	6.2	2	2.0	0.2	7.0	0	0.0	0.0	4.9	0	0.0	0.0	4.1	
	Conjunctivitis bacterial (10061784)	0	0.0	0.0	4.2	0	0.0	0.0	4.5	0	0.0	0.0	6.2	0	0.0	0.0	3.6	1	1.4	0.0	7.4	0	0.0	0.0	4.1	
	Croup infectious (10011416)	0	0.0	0.0	4.2	0	0.0	0.0	4.5	0	0.0	0.0	6.2	0	0.0	0.0	3.6	1	1.4	0.0	7.4	1	1.1	0.0	6.2	
		0	0.0	0.0	4.2				6.8	0	0.0	0.0	6.2	0	0.0	0.0	3.6		0.0	0.0	4.9	1	1.1	0.0	6.2	
	Folliculitis (10016936)	0	0.0	0.0	4.2	1	1.3	0.0	6.8	0	0.0					0.0			0.0	0.0	4.9	0	0.0	0.0	4.1	
	Gastroenteritis (10017888)	0	0.0	0.0	4.2	1	1.3	0.0	6.8	0	0.0	0.0	6.2	0	0.0	0.0	3.6	0	0.0	0.0	4.9	0	0.0	0.0	4.1	
	Hand-foot-and-mouth disease (10019113)	0	0.0	0.0	4.2	0	0.0	0.0	4.5	0	0.0	0.0	6.2	1	1.0	0.0	5.4	1	1.4	0.0	7.4	0	0.0	0.0	4.1	
	Herpangina (10019936)	0	0.0	0.0	4.2	0	0.0	0.0	4.5	0	0.0	0.0	6.2	0	0.0	0.0	3.6	0	0.0	0.0	4.9	1	1.1	0.0	6.2	
	Hordeolum (10020377)	2	2.3	0.3	8.1	0	0.0	0.0	4.5	0	0.0	0.0	6.2	1	1.0	0.0	5.4	0	0.0	0.0	4.9	1	1.1	0.0	6.2	
	Nasopharyngitis (10028810)	1	1.1	0.0	6.2	1	1.3	0.0	6.8	0	0.0	0.0	6.2	0	0.0	0.0	3.6	1	1.4	0.0	7.4	0	0.0	0.0	4.1	
	Otitis media (10033078)	1	1.1	0.0	6.2				4.5			0.0			4.0	1.1	9.9	0		0.0	4.9	3	3.4	0.7	9.6	
	Otitis media acute (10033079)	0	0.0	0.0	4.2						0.0					0.0				0.0	4.9	0	0.0	0.0	4.1	
			0.0	0.0	4.2	0	0.0	0.0	4.5	0	0.0	0.0	6.2	0	0.0	0.0	3.6	1	1.4	0.0	7.4	0	0.0	0.0	4.1	
	Rhinitis (10039083)	0	0.0	0.0	4.2	0	0.0	0.0	4.5	0	0.0	0.0	6.2	0	0.0	0.0	3.6	2	2.7	0.3	9.5	0	0.0	0.0	4.1	
	Sinusitis (10040753)	0	0.0	0.0	4.2	1	1.3	0.0	6.8	0	0.0	0.0	6.2	0	0.0	0.0	3.6	0	0.0	0.0	4.9	0	0.0	0.0	4.1	
	Staphylococcal infection (10058080)	0	0.0	0.0	4.2	1	1.3	0.0	6.8	0	0.0	0.0	6.2	0	0.0	0.0	3.6	0	0.0	0.0	4.9	0	0.0	0.0	4.1	
	Upper respiratory tract infection (10046306)	2	2.3	0.3	8.1	1	1.3	0.0	6.8	1	1.7	0.0	9.2	4	4.0	1.1	9.9	5	6.8	2.3	15.3	3	3.4	0.7	9.6	
	Viral infection (10047461)	1	1.1	0.0	6.2	1	1.3	0.0	6.8	2	3.4	0.4	11.9	9 0	0.0	0.0	3.6	2	2.7	0.3	9.5	3	3.4	0.7	9.6	
	Viral rash (10047476)	0	0.0	0.0	4.2	0	0.0	0.0	4.5	0	0.0	0.0	6.2	0	0.0	0.0	3.6	1	1.4	0.0	7.4	0	0.0	0.0	4.1	
	Viral upper respiratory tract infection (10047482)	0	0.0	0.0	4.2						0.0				0.0	0.0	3.6	0	0.0	0.0	4.9	1	1.1	0.0	6.2	
Injury, poisoning and procedural complications (10022117)	Arthropod bite (10003399)	0	0.0	0.0	4.2				4.5											0.0	7.4	0	0.0	0.0	4.1	
•			0.0	0.0							0.0								0.0	0.0			0.0	0.0	4.1	
	Corneal abrasion (10010984)	0	0.0	0.0	4.2				4.5		1.7									0.0	4.9	0	0.0	0.0	4.1	

117119 (DTPA-HBV-IPV-135)

					Hexa	arc	un						Pedia	ar	nun			Penta g					Report Fina			
			Fe	emale		9.0		/lale			Fe	male		9.		lale			Fe	male		9.		/lale		
				l = 87				= 80				= 58				= 10(0			= 73				= 88	3	
					% CI				% CI				% CI				% CI				% CI				% CI	
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n		LL	UL		%	LL	UL	n			UL		%	LL	UL	n	%		UL	
			0.0	0 .0	4.2	0	0.0	0.0	4.5	0	0.0	0.0	6.2	1	1.0	0.0	5.4	0	0.0			0			4.1	
	Foreign body in gastrointestinal tract (10079846)	0	0.0	0.0	4.2	0	0.0	0.0	4.5	1	1.7	0.0	9.2	1	1.0	0.0	5.4	0	0.0	0.0	4.9	1	1.1	0.0	6.2	
	Head injury (10019196)	1	1.1	0.0	6.2	0	0.0	0.0	4.5	0	0.0	0.0	6.2	0	0.0	0.0	3.6	1	1.4	0.0	7.4	0	0.0	0.0	4.1	
	Mouth injury (10049294)	0	0.0	0.0	4.2															0.0	4.9	1	1.1	0.0	6.2	
	Skin abrasion (10064990)	0	0.0	0.0	4.2		1.3		6.8			0.0	6.2	0	0.0	0.0	3.6	0		0.0	4.9				4.1	
Nervous system disorders (10029205)	(10071048)	0	0.0												0.0			1	1.4	0.0			0.0			
	Speech disorder developmental (10041467)	1	1.1												0.0					0.0					6.2	
Reproductive system and breast disorders (10038604)	(10064162)		0.0						4.5						0.0								0.0			
Respiratory, thoracic and mediastinal disorders (10038738)	Asthma (10003553)	0	0.0	0.0	4.2										0.0				0.0	0.0				0.0	6.2	
	Cough (10011224)	1	1.1		6.2				6.8						0.0				0.0							
	Nasal congestion (10028735)	1	1.1	0.0	6.2			0.0		0	0.0	0.0	6.2		0.0				0.0	0.0	4.9		0.0			
	Rhinitis allergic (10039085)	1	1.1	0.0					4.5	_		0.0			0.0				0.0	0.0	4.9	0			4.1	
	Rhinorrhoea (10039101)	1	1.1	0.0	6.2		1.3			1	1.7	0.0	9.2				5.4	0	0.0		4.9	1			6.2	
	Wheezing (10047924)	0	0.0	0.0	4.2				4.5		0.0	0.0					3.6	1	1.4	0.0	7.4	0				
Skin and subcutaneous tissue disorders (10040785)	Dermatitis (10012431)	0	0.0	0.0	4.2				6.8						0.0				0.0	0.0		0	0.0			
		0	0.0	0.0	4.2				4.5						0.0				0.0					0.0		
		0	0.0	0.0	4.2				6.8	_	0.0	0.0			0.0				0.0	0.0	4.9	0			4.1	
		2	2.3	0.3	8.1		0.0			1	1.7	0.0			0.0				0.0	0.0	4.9	1			6.2	
		0	0.0	0.0	4.2				6.8		0.0	0.0			0.0				0.0	0.0	4.9	0		0.0		
	Ingrowing nail (10022013)	0	0.0	0.0	4.2				6.8			0.0			0.0						4.9				4.1	
	Petechiae (10034754)	1	1.1	0.0	6.2				4.5			0.0			0.0				0.0	0.0	4.9	_			4.1	
	Pruritus (10037087)	1	1.1	0.0	6.2						0.0				0.0				0.0		4.9				4.1	
	Rash (10037844)	1	1.1	0.0	6.2		1.3			1	1.7				3.0			0	0.0	0.0	4.9				4.1	
	Rash erythematous (10037855)	0	0.0	0.0	4.2	0	0.0	0.0	4.5	0	0.0	0.0	6.2	0	0.0	0.0	3.6	1	1.4	0.0	7.4	0	0.0	0.0	4.1	

117119 (DTPA-HBV-IPV-135)

Report Final

					Hexa	gro	oup					F	Pedia	gro	oup					F	enta	gr	oup		
			Fe	emal	е		N	/lale			Fe	male)		N	lale			Fe	male			ı	Vlale	
			N	N = 87 95% CI			N	= 80			N	= 58			N:	= 100)		N	= 73			N	I = 88	į
				95	% CI			959	6 CI			959	% CI			959	% CI			95%	% CI			959	% CI
Primary System Organ Class	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
(CODE)																									
	Rash generalised (10037858)	0	0.0	0.0	4.2	0	0.0	0.0	4.5	1	1.7	0.0	9.2	0	0.0	0.0	3.6	0	0.0	0.0	4.9	0	0.0	0.0	4.1
	Urticaria (10046735)	0	0.0	0.0	4.2	0	0.0	0.0	4.5	1	1.7	0.0	9.2	0	0.0	0.0	3.6	0	0.0	0.0	4.9	0	0.0	0.0	4.1

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Report Final

Table 8.64 Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following the booster dose-by geographical ancestry (Booster Total vaccinated cohort)

					Hexa	a gro	oup					Р	edia	gro	up					F	Penta	gr	oup		
			W	/hite			0	ther			W	/hite			ot	her			W	/hite				ther	
			Cau	casia	an		N	= 66			Cau	casia	ın		N	= 57	,		Cau	casia	an		N	= 67	
			N	= 10 ⁻	1						N	= 101							N	= 94					
					% CI				% CI				6 CI				% CI				% CI				% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL			LL		n				n					%	LL		n		LL	
At least one symptom		24	23.8	15.9	33.																	18	26.9	16.8	39.1
Blood and lymphatic system disorders (10005329)	Iron deficiency anaemia (10022972)	0	0.0	0.0							0.0								0.0	0.0	3.8	1	1.5	0.0	8.0
Congenital, familial and genetic disorders (10010331)	Dacryostenosis congenital (10011850)	1	1.0	0.0	5.4	0	0.0	0.0	5.4	0	0.0			0	0.0	0.0	6.3	0	0.0	0.0	3.8	0	0.0	0.0	5.4
		0	0.0		3.6						0.0		3.6	1	1.8				0.0					0.0	
Ear and labyrinth disorders (10013993)	Ear pain (10014020)	0	0.0	0.0	3.6	0	0.0	0.0	5.4	0									1.1	0.0	5.8	0	0.0	0.0	5.4
	Tympanic membrane perforation (10045210)	0	0.0	0.0	3.6				8.2					0	0.0	0.0	6.3	0	0.0	0.0	3.8	0	0.0	0.0	5.4
Eye disorders (10015919)	Chalazion (10008388)	0	0.0	0.0	3.6	0			5.4				3.6	1	1.8				0.0	0.0	3.8	0	0.0	0.0	5.4
Gastrointestinal disorders (10017947)	Diarrhoea (10012735)	0	0.0	0.0	3.6		0.0		5.4			0.2	7.0	0	0.0	0.0	6.3	2	2.1	0.3	7.5	1	1.5	0.0	8.0
	Nausea (10028813)	0	0.0	0.0	3.6				5.4				3.6				9.4		0.0	0.0	3.8	0	0.0	0.0	5.4
	Stomatitis (10042128)	1	1.0	0.0	5.4	0			5.4					0	0.0	0.0	6.3	0	0.0	0.0	3.8	0	0.0	0.0	5.4
	Teething (10043183)	4	4.0	1.1	9.8						2.0	0.2	7.0				6.3		2.1	0.3	7.5	1			8.0
	Vomiting (10047700)	4	4.0	1.1	9.8	0	0.0	0.0	5.4	0	0.0	0.0	3.6	3	5.3	1.1	14.6	3 1	1.1	0.0	5.8	1		0.0	8.0
General disorders and administration site conditions (10018065)	Injection site induration (10022075)	0	0.0		3.6				5.4										0.0	0.0			0.0	0.0	5.4
	Injection site nodule (10057880)	1	1.0	0.0	5.4				5.4			0.0	3.6	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0	0.0	0.0	5.4
	Injection site scab (10066210)	0	0.0	0.0	3.6				5.4						0.0		6.3		1.1	0.0	5.8	0		0.0	
	Pyrexia (10037660)		3.0	0.6	8.4										3.5				1.1	0.0	5.8	1			8.0
	Vaccination site erythema (10059079)		0.0	0.0	3.6				5.4						0.0				0.0	0.0			0.0		
Immune system disorders (10021428)	Seasonal allergy (10048908)	3	3.0	0.6	8.4	0	0.0	0.0	5.4	0	0.0	0.0	3.6	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0	0.0	0.0	5.4

117119 (DTPA-HBV-IPV-135)

Report Final

					Hexa	gro	oup					F	Pedia	gro	oup						Penta	gr			Fina
			V	/hite				ther			V	/hite				ther			٧	Vhite		Ĭ		ther	-
			Cau	casi	an		N	= 66	i		Cau	casia	an		N	= 57	,		Cau	ıcasia	an			= 67	
			N	= 10	1						N	= 101	1						N	I = 94					
				95	% CI			95	% CI			95%	% CI			959	% CI			959	% CI			95	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL				UL	n							UL				UL			LL	
Infections and infestations (10021881)	Bronchitis (10006451)		0.0		3.6			0.0		1		0.0					6.3				3.8			0.0	
	Cellulitis (10007882)		0.0	0.0	3.6			0.0		1		0.0					6.3			0.0	3.8			0.0	5.4
	Conjunctivitis (10010741)	0	0.0	0.0	3.6				5.4			0.0					12.1		0.0	0.0	3.8		0.0	0.0	5.4
	Conjunctivitis bacterial (10061784)	0	0.0	0.0	3.6	0	0.0	0.0	5.4	0	0.0	0.0	3.6	0	0.0	0.0	6.3	1	1.1	0.0	5.8	0	0.0	0.0	5.4
	Croup infectious (10011416)		0.0	0.0	3.6				5.4			0.0					6.3			0.3	7.5		0.0	0.0	5.4
	Eye infection (10015929)	1	1.0									0.0			0.0	0.0	6.3	1	1.1	0.0	5.8	0	0.0	0.0	5.4
	Folliculitis (10016936)	1	1.0	0.0	5.4							0.0					6.3		0.0	0.0	3.8		0.0	0.0	5.4
	Gastroenteritis (10017888)	1	1.0		5.4							0.0					6.3		0.0	0.0	3.8	0	0.0	0.0	5.4
	Hand-foot-and-mouth disease (10019113)	0	0.0	0.0	3.6	0	0.0	0.0	5.4	1	1.0	0.0	5.4	0	0.0	0.0	6.3	1	1.1	0.0	5.8	0	0.0	0.0	5.4
	Herpangina (10019936)		0.0	0.0	3.6							0.0					6.3		0.0	0.0	3.8		1.5	0.0	8.0
	Hordeolum (10020377)	0	0.0	0.0	3.6							0.0			1.8	0.0	9.4	0	0.0	0.0	3.8	1	1.5	0.0	8.0
	Nasopharyngitis (10028810)	1	1.0	0.0	5.4						0.0	0.0	3.6				6.3		0.0	0.0	3.8			0.0	8.0
	Otitis media (10033078)	1	1.0	0.0	5.4	0	0.0		5.4		4.0	1.1		1	1.8	0.0	9.4	1	1.1	0.0	5.8	2	3.0	0.4	10.4
	Otitis media acute (10033079)		0.0	0.0	3.6				8.2			0.0					6.3		0.0	0.0	3.8			0.0	5.4
	Pharyngitis (10034835)	0	0.0	0.0	3.6		0.0		5.4			0.0	3.6	0	0.0				1.1	0.0	5.8		0.0	0.0	5.4
	Rhinitis (10039083)		0.0	0.0	3.6		0.0		5.4			0.0					6.3		1.1	0.0	5.8				8.0
	Sinusitis (10040753)	1	1.0	0.0	5.4			0.0				0.0					6.3		0.0	0.0	3.8				5.4
	Staphylococcal infection (10058080)	1	1.0	0.0	5.4	0	0.0	0.0	5.4			0.0			0.0	0.0	6.3	0	0.0	0.0	3.8	0	0.0	0.0	5.4
	Upper respiratory tract infection (10046306)	0	0.0	0.0	3.6	3	4.5	0.9	12.7	4	4.0	1.1	9.8	1	1.8	0.0	9.4	5	5.3	1.7	12.0	3	4.5	0.9	12.
	Viral infection (10047461)					0	0.0	0.0	5.4	0	0.0	0.0	3.6	2			12.1				9.0				10.4
	Viral rash (10047476)		0.0	0.0	3.6	0	0.0	0.0	5.4	0	0.0	0.0	3.6	0			6.3		1.1		5.8				5.4
	Viral upper respiratory tract infection (10047482)	0	0.0	0.0	3.6	0	0.0	0.0	5.4	0	0.0	0.0	3.6	0	0.0	0.0	6.3	0	0.0	0.0	3.8	1	1.5	0.0	8.0
Injury, poisoning and procedural complications (10022117)	Arthropod bite (10003399)	0															6.3				5.8			0.0	5.4
	Contusion (10050584)	1	1.0	0.0	5.4	0	0.0	0.0	5.4	0	0.0	0.0	3.6	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0	0.0	0.0	5.4

117119 (DTPA-HBV-IPV-135)

Report Final

					Lav.	arr	nun.						Pedia	arr	aun			1			Donto	ar)OIT I	Final
			١٨	/hite	Hexa	a yrc		ther			١٨	 /hite	tulč	gre		ther			1/	Thite	Penta	ı yr		ther	
				casi				= 66	:			casia	n			= 57	,			ıcasia				= 67	,
				= 10°			IN	- 00	'			= 101			IN	- 31				l = 94			IN	- 01	
					% CI			959	% CI		- ''		, % CI			959	% CI			-	% CI			950	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL		%		_	n	%		UL	n	%		UL	n	%		UL	n	%		UL
,	Corneal abrasion (10010984)	0	0.0	0.0	3.6	0	0.0	0.0	5.4	1	1.0	0.0	5.4	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0	0.0	0.0	5.4
			0.0	0.0	3.6				5.4	0		0.0					9.4		0.0	0.0	3.8	0	0.0	0.0	5.4
	Foreign body in gastrointestinal tract (10079846)	0	0.0	0.0	3.6				5.4			0.0					9.4		0.0	0.0	3.8	1	1.5	0.0	8.0
	Head injury (10019196)	0	0.0	0.0	3.6	1	1.5	0.0	8.2	0	0.0	0.0	3.6	0	0.0	0.0	6.3	0	0.0	0.0	3.8	1	1.5	0.0	8.0
	Mouth injury (10049294)	0	0.0	0.0	3.6	0	0.0	0.0	5.4	0	0.0	0.0	3.6	0	0.0	0.0	6.3	1	1.1	0.0	5.8	0	0.0	0.0	5.4
	Skin abrasion (10064990)	0	0.0	0.0	3.6	1	1.5	0.0	8.2	0	0.0	0.0	3.6	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0	0.0	0.0	5.4
Nervous system disorders (10029205)	Seizure like phenomena (10071048)	0	0.0	0.0	3.6	0	0.0	0.0	5.4	0	0.0	0.0	3.6	0	0.0	0.0	6.3	0	0.0	0.0	3.8	1	1.5	0.0	8.0
	Speech disorder developmental (10041467)	1	1.0	0.0	5.4	0	0.0	0.0	5.4	0	0.0	0.0	3.6	0	0.0	0.0	6.3	1	1.1	0.0	5.8	0	0.0	0.0	5.4
Reproductive system and breast disorders (10038604)	Genital labial adhesions (10064162)	0	0.0	0.0	3.6	0	0.0	0.0	5.4	1	1.0	0.0	5.4	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0	0.0	0.0	5.4
Respiratory, thoracic and mediastinal disorders (10038738)	Asthma (10003553)	0	0.0	0.0	3.6	0	0.0	0.0	5.4	0	0.0	0.0	3.6	0	0.0	0.0	6.3	1	1.1	0.0	5.8	0	0.0	0.0	5.4
	Cough (10011224)		2.0		7.0					0		0.0					9.4		0.0		3.8				5.4
	Nasal congestion (10028735)	1	1.0	0.0	5.4					0			3.6				6.3		0.0	0.0	3.8			0.0	5.4
	Rhinitis allergic (10039085)	1	1.0	0.0	5.4					0			3.6						0.0	0.0	3.8		0.0	0.0	5.4
			2.0	0.2	7.0			0.0		1		0.0	5.4				9.4		1.1	0.0	5.8	0			5.4
	Wheezing (10047924)		0.0	0.0	3.6					0		0.0	3.6		0.0				0.0	0.0	3.8	1		0.0	8.0
Skin and subcutaneous tissue disorders (10040785)	Dermatitis (10012431)	0	0.0	0.0	3.6	1	1.5	0.0	8.2	0	0.0	0.0	3.6	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0	0.0	0.0	5.4
					3.6				5.4		1.0	0.0	5.4			0.0	6.3	0	0.0		3.8				5.4
			0.0	0.0	3.6				8.2			0.0					6.3		0.0		3.8				5.4
			2.0	0.2	7.0				5.4			0.0					6.3		0.0		3.8				8.0
	Eczema (10014184)	1	1.0	0.0	5.4				5.4		0.0								0.0		3.8				5.4
	Ingrowing nail (10022013)			0.0	3.6				8.2			0.0							0.0		3.8				5.4
	Petechiae (10034754)	1		0.0	5.4				5.4			0.0							0.0		3.8				5.4
	1			0.0	3.6				8.2			0.0					6.3		0.0		3.8			_	5.4
	Rash (10037844)	1	1.0	0.0	5.4	1	1.5	0.0	8.2	4	4.0	1.1	9.8	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0	0.0	0.0	5.4

117119 (DTPA-HBV-IPV-135)

Report Final

			V	/hite	Hexa	gro		ther			W	F /hite	Pedia	gro	•	her			W	F /hite	enta	gr	•	ther	
			Cau	casi	an		_	= 66			Cau	casia = 101				= 57			Cau	casia = 94			_	= 67	
				N = 101 95% CI LL UL n %				959	% CI			95%	% CI			959	% CI			959	6 CI			959	% CI
Primary System Organ Class	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
(CODE)																									
	Rash erythematous (10037855)	0	0.0	0.0	3.6	0	0.0	0.0	5.4	0	0.0	0.0	3.6	0	0.0	0.0	6.3	0	0.0	0.0	3.8	1	1.5	0.0	8.0
	Rash generalised (10037858)	0	0.0	0.0	3.6	0	0.0	0.0	5.4	1	1.0	0.0	5.4	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0	0.0	0.0	5.4
	Urticaria (10046735)	0	0.0	0.0	3.6	0	0.0	0.0	5.4	1	1.0	0.0	5.4	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0	0.0	0.0	5.4

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Report Final

Table 8.65 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following the booster dose-by gender (Booster Total vaccinated cohort)

		Hexa g	roup	Pedia	group	Penta	group
		Female	Male	Female	Female	Female	Male
		N = 87	N = 80	N = 58	N = 100	N = 73	N = 88
		95%	95% CI	95% CI	95%	95% CI	95%
		CI			CI		CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n % LL UL n					
At least one symptom		1 1.1 0.0 6.2 4	5.0 1.4 12.3	2 3.4 0.4 11.9	1 1.0 0.0 5.4	3 4.1 0.9 11.5	0 0.0 0.0 4.1
Gastrointestinal disorders (10017947)	Diarrhoea (10012735)	0 0.0 0.0 4.2 0	0.0 0.0 4.5	0 0.0 0.0 6.2	0 0.0 0.0 3.6	1 1.4 0.0 7.4	0 0.0 0.0 4.1
·	Vomiting (10047700)	0 0.0 0.0 4.2 1	1.3 0.0 6.8	0 0.0 0.0 6.2	0 0.0 0.0 3.6	0 0.0 0.0 4.9	0 0.0 0.0 4.1
General disorders and administration site conditions (10018065)	Pyrexia (10037660)	0 0.0 0.0 4.2 1	1.3 0.0 6.8	0 0.0 0.0 6.2	0 0.0 0.0 3.6	0 0.0 0.0 4.9	0 0.0 0.0 4.1
Infections and infestations (10021881)	Croup infectious (10011416)	0 0.0 0.0 4.2 0	0.0 0.0 4.5	0 0.0 0.0 6.2	0 0.0 0.0 3.6	1 1.4 0.0 7.4	0 0.0 0.0 4.1
	Sinusitis (10040753)	0 0.0 0.0 4.2 1	1.3 0.0 6.8	0 0.0 0.0 6.2	0 0.0 0.0 3.6	0 0.0 0.0 4.9	0 0.0 0.0 4.1
	Upper respiratory tract infection (10046306)	0 0.0 0.0 4.2 0	0.0 0.0 4.5	0 0.0 0.0 6.2	0 0.0 0.0 3.6	1 1.4 0.0 7.4	0 0.0 0.0 4.1
	Viral infection (10047461)	0 0.0 0.0 4.2 1	1.3 0.0 6.8	1 1.7 0.0 9.2	0 0.0 0.0 3.6	0 0.0 0.0 4.9	0 0.0 0.0 4.1
Injury, poisoning and procedural complications (10022117)	Corneal abrasion (10010984)	0 0.0 0.0 4.2 0					
	Head injury (10019196)	1 1.1 0.0 6.2 0	0.0 0.0 4.5	0 0.0 0.0 6.2	0 0.0 0.0 3.6	0 0.0 0.0 4.9	0 0.0 0.0 4.1
Skin and subcutaneous tissue disorders (10040785)	Rash (10037844)	0 0.0 0.0 4.2 0	0.0 0.0 4.5	0 0.0 0.0 6.2	1 1.0 0.0 5.4	0 0.0 0.0 4.9	0 0.0 0.0 4.1

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Report Final

Table 8.66 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term within the 31-day (Days 0-30) post-vaccination period following the booster dose-by geographical ancestry (Booster Total vaccinated cohort)

		4 rhoea (10012735) 0 niting (10047700) 1 exia (10037660) 1 up infectious (10011416) 0 usitis (10040753) 1 er respiratory tract infection 0 146306)					ıp				Р	edia g	grou	ıp					Pe	nta g	roup)	
			W	/hite			0	ther			White	•		ot	her			W	hite			oth	er
			Cau	casi	an		N	= 6	6	Ca	ucas	ian		N	= 57	7		Cau	casia	an		N =	67
			N	= 10	1					1	l = 10)1						N	= 94				
				95	% CI			95	%		95	% CI			95	%			95%	6 CI			95%
								()						(ì							CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL						n %	LL					UL							L UL
At least one symptom		4 4.0					1.5	0.0	8.2	2 2.0	0.2	7.0	1	1.8	0.0	9.4	ვ	3.2	0.7	9.0	0 0.	0 0	.0 5.4
Gastrointestinal disorders (10017947)	Diarrhoea (10012735)	4 4.0 noea (10012735) 0 0.0				0	0.0	0.0	5.4	0.0	0.0	3.6	0	0.0	0.0	6.3	1	1.1	0.0	5.8	0 0.	0 0	.0 5.4
	Vomiting (10047700)	1	1.0	0.0	5.4	0	0.0	0.0	5.4	0.0	0.0	3.6	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0 0.	0 0	.0 5.4
General disorders and administration site conditions	Pyrexia (10037660)	1	1.0	0.0	5.4	0	0.0	0.0	5.4	0.0	0.0	3.6	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0 0.	0 0	.0 5.4
(10018065)																							
Infections and infestations (10021881)	Croup infectious (10011416)																						.0 5.4
	Sinusitis (10040753)																						.0 5.4
	Upper respiratory tract infection	0	0.0	0.0	3.6	0	0.0	0.0	5.4	0.0	0.0	3.6	0	0.0	0.0	6.3	1	1.1	0.0	5.8	0 0.	0 0	.0 5.4
	(10046306)																						
	Viral infection (10047461)	1																					.0 5.4
Injury, poisoning and procedural complications (10022117)	Corneal abrasion (10010984)	0	0.0	0.0	3.6	0	0.0	0.0	5.4	1 1.0	0.0	5.4	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0 0.	0 0	.0 5.4
	Head injury (10019196)	0	0.0	0.0	3.6	1	1.5	0.0	8.2	0.0	0.0	3.6	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0 0.	0 0	.0 5.4
Skin and subcutaneous tissue disorders (10040785)	Rash (10037844)									1 1.0	0.0	5.4	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0 0.	0 0	.0 5.4

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

 $\ensuremath{\text{n}}\xspace\ensuremath{\text{\%}}\xspace = \ensuremath{\text{number/percentage}}\xspace$ of subjects reporting the symptom at least once

Report Final

Table 8.67 Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship to vaccination within the 31-day (Days 0-30) post-vaccination period following the booster dose -by gender (Booster Total vaccinated cohort)

				Hexa	a gi	roup)				Ped	dia ç	grou	р			Р	enta	gro	up	
		F	em	ale		N	/lale)		Fem	ale			Mal	е		ema	le		Male	
			N =	87		N	= 8	0		N =	58		N	= 1	00		N = 7	73		N = 8	8
				95%			95	% CI			959	%		,	95%		9	5%		9	5%
				CI							CI				CI			CI			CI
Primary System Organ Class (CODE)	Preferred Term (CODE)																			LL	
At least one symptom		0 0.	0 0	0 4.2	2 3	3.8	8.0	10.6	1 1	.7 0	0.0	9.2	2 2.0	0.2	2 7.0) 2 2	.7 0.3	9.5	1 1.	1 0.0	6.2
Gastrointestinal disorders (10017947)	Diarrhoea (10012735)	0 0.	0 0	0 4.2	2 0	0.0	0.0	4.5	0 0	0.0	0.0	3.2	1 1.0	0.0	0 5.4	4 0 0	0.0	4.9	0 0.	0.0	4.1
	Teething (10043183)																			1 0.0	
	Vomiting (10047700)																			0.0	
General disorders and administration site conditions (10018065)	Injection site nodule (10057880)																			0.0	
	Vaccination site erythema (10059079)																			0.0	
Skin and subcutaneous tissue disorders (10040785)	Rash (10037844)	0 0.	0 0	0 4.2	2 0	0.0	0.0	4.5	0 0	0.0	0.0	3.2	1 1.0	0.0	0 5.4	4 0 0	.0 0.0	4.9	0 0.	0.0	4.1
, ,	Rash erythematous (10037855)																			0.0	

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Report Final

Table 8.68 Percentage of subjects reporting the occurrence of unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship to vaccination within the 31-day (Days 0-30) post-vaccination period following the booster dose -by geographical ancestry (Booster Total vaccinated cohort)

				He	xa g	roup					Ped	ia gı	oup				Pe	nta g	rou	р	
			W	/hite		(othe	r		Wh	ite		(othe	r	V	/hite			otl	her
			Cau	casia	an	N	1 = 6	6	C	Cauc	asia	n	1	1 = 5	7	Cau	casia	an		N =	= 67
			N	= 101						N =	101					N	= 94				
				95%	6 CI		9	5%			95%	CI		9	5%		959	6 CI		9	95% CI
								CI							CI						
Primary System Organ Class (CODE)			%			n %									UL n						L UL
At least one symptom																					0.4 10.4
Gastrointestinal disorders (10017947)	Diarrhoea (10012735)	0	0.0	0.0	3.6	0.0	0.0	5.4	1 1	.0	0.0	5.4	0.0	0.0	6.3 0	0.0	0.0	3.8	0 0.	0 0	1.0 5.4
	Teething (10043183)	1	1.0	0.0	5.4	0.0	0.0	5.4	0 0	0.0	0.0	3.6	0.0	0.0	6.3 1	1.1	0.0	5.8	0 0.	0 0	0.0 5.4
	Vomiting (10047700)																				0.8 0.0
General disorders and administration site conditions	Injection site nodule (10057880)	1	1.0	0.0	5.4	0.0	0.0	5.4	0 0	0.0	0.0	3.6	0 0.	0.0	6.3 0	0.0	0.0	3.8	0 0.	0 0	0.0 5.4
(10018065)																					
	Vaccination site erythema	0	0.0	0.0	3.6	0.0	0.0	5.4	1 1	.0 0	0.0	5.4	0 0.	0.0	6.3 0	0.0	0.0	3.8	0 0.	0 0	1.0 5.4
	(10059079)																				
Skin and subcutaneous tissue disorders (10040785)	Rash (10037844)	0	0.0	0.0	3.6	0.0	0.0	5.4	1 1	.0 0	0.0	5.4	0.0	0.0	6.3 0	0.0	0.0	3.8	0 0.	0 0	1.0 5.4
	Rash erythematous (10037855)	pea (10012735) 0 0.0 ng (10043183) 1 1.0 ng (10047700) 1 1.0 on site nodule (10057880) 1 1.0 ation site erythema 0 0.0 1079) 0 0.0				0.0	0.0	5.4	0 0	0.0	0.0	3.6	0.0	0.0	6.3 0	0.0	0.0	3.8	1 1.	.5 0	0.8 0.0

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n/% = number/percentage of subjects reporting the symptom at least once

117119 (DTPA-HBV-IPV-135) Report Final

Table 8.69 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship to vaccination within the 31-day (Days 0-30) post-vaccination period following the booster dose -by gender (Booster Total vaccinated cohort)

No records exist in this table

Table 8.70 Percentage of subjects reporting the occurrence of grade 3 unsolicited symptoms classified by MedDRA Primary System Organ Class and Preferred Term with causal relationship to vaccination within the 31-day (Days 0-30) post-vaccination period following the booster dose -by geographical ancestry (Booster Total vaccinated cohort)

No records exist in this table

Table 8.71 Percentage of subjects reporting at least one preferred term from broad MedDRA SMQ 'Hypotonic-Hyporesponsive Episode (HHE)', within the 31-day (Days 0-30) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

No records exist in this table

Table 8.72 Percentage of subjects reporting at least one preferred term from narrow MedDRA SMQ 'convulsion' within the 31-day (Days 0-30) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

		ŀ		gro = 16	-	P		a gro = 15	-	P		a gro = 16	oup 1
				95%	% CI			95%	6 CI			95%	6 CI
Primary System Organ Class (CODE)	Preferred Term (CODE)			UL									
At least one symptom		0	0.0	0.0	2.2	0	0.0	0.0	2.3	1	0.6	0.0	3.4
Nervous system disorders (10029205)	Seizure like phenomena (10071048)	0	0.0	0.0	2.2	0	0.0	0.0	2.3	1	0.6	0.0	3.4

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Table 8.73 Percentage of subjects reporting at least one preferred term from broad MedDRA SMQ 'Hypotonic-Hyporesponsive Episode (HHE)', within the 31-day (Days 0-30) post-vaccination period following the booster dose– by gender (Booster Total vaccinated cohort)

No records exist in this table

Table 8.74 Percentage of subjects reporting at least one preferred term from narrow MedDRA SMQ 'convulsion' within the 31-day (Days 0-30) post-vaccination period following the booster dose– by gender (Booster Total vaccinated cohort)

				Н	exa	gr	oup)				Pe	dia	gı	roup)				Pe	nta	gı	roup)	
				mal = 8	-			lale = 80			-	mal = 58	-			lale = 10				mal = 7				lale = 8	
					5% Cl			95	% :I				5% Cl			95 C	5% 31				5% Cl				5% Cl
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
At least one symptom		0	0.0	0.0	4.2	0	0.0	0.0	4.5	0	0.0	0.0	6.2	0	0.0	0.0	3.6	1	1.4	0.0	7.4	0	0.0	0.0	4.1
Nervous system disorders (10029205)	Seizure like phenomena (10071048)	0	0.0	0.0	4.2	0	0.0	0.0	4.5	0	0.0	0.0	6.2	0	0.0	0.0	3.6	1	1.4	0.0	7.4	0	0.0	0.0	4.1

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n/% = number/percentage of subjects reporting the symptom at least once

95% CI = exact 95% confidence interval: LL = Lower Limit. UL = Upper Limit

Table 8.75 Percentage of subjects reporting at least one preferred term from broad MedDRA SMQ 'Hypotonic-Hyporesponsive Episode (HHE)', within the 31-day (Days 0-30) post-vaccination period following the booster dose– by geographical ancestry (Booster Total vaccinated cohort)

No records exist in this table

Report Final

Table 8.76 Percentage of subjects reporting at least one preferred term from narrow MedDRA SMQ 'convulsion' within the 31-day (Days 0-30) post-vaccination period following the booster dose– by geographical ancestry (Booster Total vaccinated cohort)

				He	xa gr	oup				Pe	dia gr	oup					Pe	nta g	roup		
		W	hite (Cauca	sian		othe	r	White (Cauc	asian		oth	er	W	/hite	Cauc	asian	C	ther	•
			N	= 101			N = 6	66	N	= 10 ⁻	1		N =	57		N	l = 94		N	I = 6	7
				95%	6 CI		95	% CI		95	% CI		9	5% (CI		95	% CI		959	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n %	LL	UL	n %	LL	UL	n %	L	LU	Ln	%	LL	UL	n %	LL	UL
At least one symptom		0	0.0	0.0	3.6	0 0.	0.0	5.4	0.0	0.0	3.6	0 0.	0.0	0 6.	3 0	0.0	0.0	3.8	1 1.5	0.0	8.0
Nervous system disorders (10029205)	Seizure like phenomena (1007	71048) 0	0.0	0.0	3.6	0 0.	0.0	5.4	0.0	0.0	3.6	0 0.	0.	0 6.	3 0	0.0	0.0	3.8	1 1.5	0.0	8.0

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n/% = number/percentage of subjects reporting the symptom at least once

117119 (DTPA-HBV-IPV-135) Report Final

Table 8.77 Percentage of subjects reporting the occurrence of New Onset of Chronic Illness (NOCI) within the 31-day (Days 0-30) post-vaccination period following the booster dose (Booster Total vaccinated cohort)

		Н	exa (_	•	P		a gro = 15	oup 8	P		a gro = 16	•
					5% CI				5% Cl			95 C	5% Cl
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL	UL	n	%	LL	UL	n	%	LL	UL
At least one symptom		4	2.4	0.7	6.0	1	0.6	0.0	3.5	1	0.6	0.0	3.4
Immune system disorders (10021428)	Seasonal allergy (10048908)	3	1.8	0.4	5.2	0	0.0	0.0	2.3	0	0.0	0.0	2.3
Respiratory, thoracic and mediastinal disorders (10038738)	Asthma (10003553)	0	0.0	0.0	2.2	0	0.0	0.0	2.3	1	0.6	0.0	3.4
,	Rhinitis allergic (10039085)	1	0.6	0.0	3.3	0	0.0	0.0	2.3	0	0.0	0.0	2.3
Skin and subcutaneous tissue disorders (10040785)	Dermatitis atopic (10012438)	0	0.0	0.0	2.2	1	0.6	0.0	3.5	0	0.0	0.0	2.3

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Report Final

Table 8.78 Percentage of subjects reporting the occurrence of New Onset of Chronic Illness (NOCI) within the 31-day (Days 0-30) post-vaccination period following the booster dose- by gender (Booster Total vaccinated cohort)

				Н	exa	grou	р			Pe	dia	grou	р			Pe	nta (grou	р	
			Fe	mal	е		Ма	le	Fe	male	,	I	Nale		Fe	male	;		Male	
			N	= 8	7		N =	80	N	= 58	}	N	= 10	0	N	= 73	}	N	1 = 8	8
				959	% CI		9	5% CI		95%	CI		95%	6 CI		95%	CI		95°	% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)							L UL												
At least one symptom								.3 8.7												
Immune system disorders (10021428)	Seasonal allergy (1004890																			
Respiratory, thoracic and mediastinal disorders (10038738)								.0 4.5												
	Rhinitis allergic (10039085)																			
Skin and subcutaneous tissue disorders (10040785)	Dermatitis atopic (1001243	8) 0	0.0	0.0	4.2	0 0.	0 0	.0 4.5	1 1.7	0.0	9.2	0.0	0.0	3.6	0.0	0.0	4.9	0.0	0.0	4.1

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Report Final

Table 8.79 Percentage of subjects reporting the occurrence of New Onset of Chronic Illness (NOCI) within the 31-day (Days 0-30) post-vaccination period following the booster dose- by geographical ancestry (Booster Total vaccinated cohort)

				Не	exa gi	roup				Ped	dia g	rou	р					Pe	nta g	roup		
			Cau	/hite casia = 10°		other N = 60			Cau	Vhite ucasia = 101			_	ther = 5			Cau	hite casia = 94			ther = 67	
				959	% CI	95	5%			95%	6 CI			95	5%			95%	% CI		95	5%
			,		,									,							_	
Primary System Organ Class (CODE)	Preferred Term (CODE)	n	%	LL		n % LL		_	%	LL	UL				UL		%	LL		n %		
At least one symptom		4	4.0	1.1	9.8	0.0 0.0	5.4	1	1.0	0.0	5.4				6.3			0.0	5.8	0.0	0.0	5.4
Immune system disorders (10021428)	Seasonal allergy (10048908)	3	3.0	0.6	8.4	0.0 0.0	5.4	0	0.0	0.0	3.6	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0.0	0.0	5.4
Respiratory, thoracic and mediastinal disorders (10038738)	Asthma (10003553)	0	0.0	0.0	3.6	0.0 0.0	5.4	0	0.0	0.0	3.6	0	0.0	0.0	6.3	1	1.1	0.0	5.8	0.0	0.0	5.4
	Rhinitis allergic (10039085)	1	1.0	0.0	5.4	0.0 0.0	5.4	0	0.0	0.0	3.6	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0.0	0.0	5.4
Skin and subcutaneous tissue disorders (10040785)	Dermatitis atopic (10012438)	0	0.0	0.0	3.6	0.0 0.0	5.4	1	1.0	0.0	5.4	0	0.0	0.0	6.3	0	0.0	0.0	3.8	0.0	0.0	5.4

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n/% = number/percentage of subjects reporting the symptom at least once

Report Final

Table 8.80 Number (%) of subjects reporting the occurrence of serious adverse event (SAE) within the 31-day (Days 0-30) post-vaccination period following the booster dose-by gender (Booster Total vaccinated cohort)

				He	xa g	rou)			Ped	dia	grou	р			Pe	nta	grou	р	
			-	nale = 87			/lale = 80)	_	male = 58			/lale = 10			male = 73	-		Male I = 8	
				95%	CI		95%			95%				% CI		95%				% CI
Primary System Organ Class (CODE)	Preferred Term (CODE)	n %	% I	LL (JL r	۱ %	LL	UL	n %	LL (UL	n %	LL	UL	n %	LL	UL	n %	LL	UL
At least one symptom		1 1	1.1 (0.0	3.2 (0.0	0.0	4.5	0.0	0.0	6.2	0.0	0.0	3.6	1 1.4	0.0	7.4	0.0	0.0	4.1
Nervous system disorders (10029205)	Seizure like phenomena (10071048	3) 0 0	0.0	0.0	1.2 (0.0	0.0	4.5	0.0	0.0	6.2	0.0	0.0	3.6	1 1.4	0.0	7.4	0.0	0.0	4.1
Skin and subcutaneous tissue disorders (10040785)	Petechiae (10034754)	1 1	1.1 (0.0	6.2	0.0	0.0	4.5	0.0	0.0	6.2	0.0	0.0	3.6	0.0	0.0	4.9	0.0	0.0	4.1

Hexa group = Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines

Pedia group = Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines

Penta group = Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine

At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term)

N = number of subjects with the administered dose

n/% = number/percentage of subjects reporting the symptom at least once

MODULAR APPENDICES

List of modular appendices available for the study report and ICH-specific appendices - Study Information equivalent numbering

Modular appendices	ICH numbering
Protocol and protocol amendments.	16.1.1
Sample Case Report form (unique pages only).	16.1.2
List of IECs or IRBs & List of Investigators and other important participants in the study	16.1.3 & 16.1.4
Representative written information for patient and sample consent forms.	16.1.3
Investigator CVs or equivalent summaries of training and experience relevant to the performance of the clinical study	16.1.4
Signatures of principal or coordinating investigator(s) or sponsor's responsible medical officer, depending on the regulatory authority's requirement	16.1.5
Listings of patients receiving test drug(s) /investigational product(s) from specific batches, where more than one batch was used	16.1.6
Randomization list (patient identification and treatment assigned).	16.1.7
Audit certificates	16.1.8
Documentation of statistical methods	16.1.9
Documentation of inter-laboratory standardization methods and quality assurance procedures	16.1.10
Publications based on the study.	16.1.11
Important publications referenced in the report	16.1.12
Individual listings	16.2
Case report forms (CRFs /eCRFs) CRFs /eCRFs for deaths, other SAEs and withdrawals due to adverse events	16.3 16.3.1
Study Administrative Table	-

Protocol and Protocol Amendments

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Clinical Study Protocol

Sponsor:

GlaxoSmithKline Biologicals

Rue de l'Institut 89 1330 Rixensart, Belgium

Primary Study vaccine and number

GlaxoSmithKline

GlaxoSmithKline (GSK) Biologicals' Combined Diphtheria-Tetanus-acellular Pertussis (DTaP), Hepatitis B, Poliovirus and *Haemophilus influenzae* type b vaccine (DTPa-HBV-IPV/Hib) (SB217744, Infanrix hexa $^{\text{\tiny TM}}$).

Other Study vaccines

- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine (*Pediarix*®, GSK Biologicals)
- Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) (ActHIB®, Sanofi Pasteur SA)
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) vaccine (*Pentacel*[®], Sanofi Pasteur
- Hepatitis B Vaccine (Recombinant) (*Engerix-B*[®], GSK Biologicals)
- Pneumoccocal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) (*Prevnar13*®, Manufactured by Wyeth Pharmaceuticals Inc. Marketed by Pfizer Inc.)
- Rotavirus Vaccine, Live, Oral (Rotarix[®], GSK Biologicals)
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (*Infanrix*®, GSK Biologicals)
- Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) (*Hiberix*[™], GSK Biologicals)

117119 (DTPA-HBV-IPV-135)

eTrack study number and **Abbreviated Title**

Investigational New Drug

(IND) number

EudraCT number:

Date of protocol Date of protocol

amendment

Title

BB-IND 006687

2013-004304-19

Final Version 01: 18 October 2013 Amendment 1 Final: 18 September 2014

Amendment 2 Final Version 02: 17 April 2015

Immunogenicity and safety study of GSK Biologicals'

Infanrix hexaTM at 2, 4 and 6 months of age in healthy

infants.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135)

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

eTrack study number and

Abbreviated Title

Investigational New Drug

(IND) number

EudraCT number:
Detailed Title

BB-IND 006687

2013-004304-19

A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa[™] vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar® and Rotarix with a booster dose of GSK Biologicals' Infanrix® and Hiberix vaccines at 15-18 months of age.

Prapti Bose, Scientific Writer

Co-ordinating author Contributing authors

- PPD Clinical Research and Development Lead (CRDL)
- PPD Senior Director and Head,
 Portfolio Head CRDL
- PPD Project Statistician
- Director, Biostatistics
- PPD Study Delivery Manager
- PPD Study
 Delivery Lead
- PPD GVCL Project Manager
 PPD Clinical Safety

representative

- PPD Study Data Manager
- Global Regulatory Lead
- Global Patents representative
- Global Regulatory Affairs, GSK
 Vaccines
- PPD Director, Clinical Medical Affairs, Pediatric Vaccines, US, GSK Vaccines
- PPD Director, Clinical Medical Affairs, US, GSK Vaccines
- PPD Local Delivery Lead
- PPD US Medical Affairs Lead

GSK Biologicals' Protocol DS v 14.0

Copyright 2013-2015 the GlaxoSmithKline group of companies. All rights reserved. Unauthorized copying or use of this information is prohibited.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Protocol Amendment 2 Sponsor Signatory Approval

eTrack study number and Abbreviated Title	117119 (DTPA-HBV-IPV-135)
IND number	BB-IND 006687
EudraCT number:	2013-004304-19
Date of protocol amendment	Amendment 2 Final Version 02: 17 April 2015
Detailed Title	A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa [™] vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, coadministered with Prevnar [®] and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age.
Sponsor signatory	Narcisa Elena Mesaros Project level CRDL, DTP/Polio Vaccines Late Clinical Development, Vaccine Discovery and Development, GlaxoSmithKline Biologicals.
Signature	
Date	
For internal use only	
!Ver.!Crea 6a799184c9b15497796cc43497dd0e1b0c61d882	3.0 4/20/2015 3:46:31 PM

06-JUL-2018 b746277d27dc86537be04d8768738edd61b7ab2b

6a799184c9b15497796cc43497dd0e1b0c61d882

17-APR-2015

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Protocol Amendment 2 Rationale

Amendment number: Amendment 2

Rationale/background for changes:

The amendment 2 has been implemented to amend the following sections of the protocol:

- The assay for testing antibodies against polyribosyl ribitol phosphate (anti-PRP) has been re-developed but is not yet qualified or validated for testing the one month post dose-3 samples. This has been clarified in the protocol in Table 7 Humoral immunity (antibody determination) and Section 5.7.3 Laboratory assays.
- Investigator sign-off on the patient identification (PIDS) will be done after Visit 4 instead of extended safety follow-up (ESFU). In Table 4 List of study procedures, the bullets pertaining to investigator sign-off and analysis of Epoch 001 has been removed from the ESFU visit and retained at Visit 4 to reflect this change.
- The collection of baseline measurement of limb length has been removed since it will not be used in analysis; only limb circumference will be used in analysis. Accordingly, text related to this has been amended in Table 4 List of study procedures, Sections 5.6.2.11, Baseline measurement of limb circumference after booster vaccination at visit 5 and 5.6.2.13 Recording of AEs, SAEs and NOCDs.
- Errors in the vaccines dictionary of Study Master Repository (SMR) have been rectified for *Infanrix hexa*, *Pediarix* and *Pentacel* vaccines. The corresponding correction has been made in Table 9 Study vaccines.
- The sequence of analysis in Section 10.9.1 Sequence of analyses, has been amended to reflect that there will first be an analysis of immunogencity for anti-PRP and safety for Epoch 001, followed by a final analysis covering both Epochs at the end of the study.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Protocol Amendment 2 Investigator Agreement

I agree:

- To conduct the study in compliance with this protocol, any future protocol amendments or protocol administrative changes, with the terms of the clinical trial agreement and with any other study conduct procedures and/or study conduct documents provided by GlaxoSmithKline (GSK) Biologicals.
- To assume responsibility for the proper conduct of the study at this site.
- That I am aware of, and will comply with, 'Good Clinical Practice' (GCP) and all applicable regulatory requirements.
- To ensure that all persons assisting me with the study are adequately informed about the GSK Biologicals' investigational vaccine and other study-related duties and functions as described in the protocol.
- To acquire the reference ranges for laboratory tests performed locally and, if required by local regulations, obtain the laboratory's current certification or Quality Assurance procedure manual.
- To ensure that no clinical samples (including serum samples) are retained onsite or elsewhere without the approval of GSK Biologicals and the express written informed consent of the subject and/or the subject's legally acceptable representative.
- To perform no other biological assays on the clinical samples except those described in the protocol or its amendment(s).
- To co-operate with a representative of GSK Biologicals in the monitoring process of the study and in resolution of queries about the data.
- That I have been informed that certain regulatory authorities require the sponsor to obtain and supply, as necessary, details about the investigator's ownership interest in the sponsor or the investigational vaccine, and more generally about his/her financial ties with the sponsor. GSK Biologicals will use and disclose the information solely for the purpose of complying with regulatory requirements.

Hence I:

- Agree to supply GSK Biologicals with any necessary information regarding ownership interest and financial ties (including those of my spouse and dependent children).
- Agree to promptly update this information if any relevant changes occur during the course of the study and for one year following completion of the study.
- Agree that GSK Biologicals may disclose any information it has about such ownership interests and financial ties to regulatory authorities.
- Agree to provide GSK Biologicals with an updated Curriculum Vitae and other documents required by regulatory agencies for this study.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAI	

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

 $eTrack\ study\ number\ and$

Abbreviated Title

117119 (DTPA-HBV-IPV-135)

IND number BB-IND 006687

EudraCT number: 2013-004304-19

Date of protocol amendment Amendment 2 Final Version 02: 17 April 2015

Detailed Title A Phase III, randomized, open-label, controlled,

multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa[™] vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, coadministered with Prevnar[®] and Rotarix [™] with a booster dose of GSK Biologicals' Infanrix[®] and Hiberix [™] vaccines at 15-18 months of age.

Investigator name	
Signature	
Date	

6a799184c9b15497796cc43497dd0e1b0c61d882 3.0 4/20/2015 3:46:31 PM

17-APR-2015 6 6a799184c9b15497796cc43497dd0e1b0c61d882

For internal use only

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Sponsor Information

1. Sponsor

GlaxoSmithKline Biologicals, Rue de l'Institut 89, 1330 Rixensart, Belgium.

2. Sponsor Medical Expert for the Study

Refer to the local study contact information document.

3. Sponsor Study Monitor

Refer to the local study contact information document.

4. Sponsor Study Contact for Reporting of a Serious Adverse Event

GSK Biologicals Central Back-up Study Contact for Reporting SAEs: refer to protocol Section 8.4.2.

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

SYNOPSIS

Detailed Title

A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa [™] vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar[®] and Rotarix [™] with a booster dose of GSK Biologicals' Infanrix and Hiberix [™] vaccines at 15-18 months of age.

Indication

Active immunization against diphtheria, tetanus, pertussis infection caused by all known subtypes of hepatitis B virus, poliomyelitis, and invasive disease caused by *Haemophilus influenzae* type B (Hib) in infants.

Rationale for the study and study design

• Rationale for the study

Infanrix hexa was first licensed in the European Union in 2000. More than 100 million doses have been distributed to date and the benefit/risk profile remains favorable. Licensure of Infanrix hexa combination vaccine in the United States (US) will provide an additional option for vaccination within the routine US pediatric schedule with the fewest number of injections, which would create opportunities to add further injections in case other novel vaccines against important pediatric diseases become available. Furthermore, Infanrix hexa will provide an additional source of DTaP, hepatitis B, poliovirus, and Hib-containing vaccine to the US market, which will help ensure a more stable supply.

The present study 117119 (DTPA-HBV-IPV-135) is intended to generate pivotal immunogenicity data demonstrating non-inferiority of the immune responses against pertussis antigens of *Infanrix hexa* compared to *Pediarix*, which is currently one of the DTaP combination vaccines widely used as a standard of care in the US. Additionally, this study will also provide descriptive data with regard to the immunogenicity of the other vaccine antigens and the safety profile in US subjects. These pivotal immunogenicity non-inferiority data for pertussis and descriptive safety data are intended to support the registration of GSK Biologicals' combined DTPa-HBV-IPV/Hib (*Infanrix hexa*) vaccine in the US. A subsequent Phase III study is planned to provide pivotal data regarding lot-to-lot consistency, safety and the immunogenicity of the other vaccine antigens.

Comparison of immunogenicity data from separate clinical studies for *Infanrix hexa* and *Pentacel*, given on a 2-4-6 month schedule, suggests that the immune response to the Hib

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

component of these vaccines is similar. This study will provide descriptive information regarding the immune response to the Hib components of *Infanrix hexa* and *Pentacel* following a 3 dose primary series, prior to further evaluation in Phase III studies.

• Rationale for the study design

Design of Epoch 001 (primary vaccination):

The study is designed as a randomized, controlled, open-label study with five parallel groups:

- The first three groups (Hexa_1, Hexa_2 and Hexa_3 group) will receive three doses of the *Infanrix hexa* vaccine (either lot A, lot B or lot C, respectively). These three groups will be pooled together for the analyses and the pooled group will be called the Hexa group.
- The Pedia Group (Control 1) will receive three doses of the US-licensed control vaccines, *Pediarix* and *ActHIB*.
- The Penta Group (Control 2) will receive three doses of the US-licensed control vaccines, *Pentacel* (only two doses of *Engerix-B* will be administered if a subject has received a birth dose of hepatitis B vaccine).

Three distinct vaccine lots manufactured according to the same procedures will be used in the Hexa group in order to obtain more representative data for the vaccine.

The study will be open-label due to the differences in the number of injections and the appearance of the vaccines administered.

Vaccines (i.e., *Prevnar13* and *Rotarix*) that are recommended for children in the US during the first year of life will be administered concomitantly with the other study vaccines as part of the study.

Design of Epoch 002 (booster vaccination):

In Epoch 002, the subjects will be assessed for antibody persistence to the vaccine antigens of *Infanrix hexa*. This epoch will also assess the adequacy of priming subjects with *Infanrix hexa* by evaluating the boostability of D, T, Pa and Hib antigens with the US-licensed vaccines. The pooled Hexa Group will receive booster doses of *Infanrix* and *Hiberix* vaccines at 15 through 18 months of age, the subjects in the Penta Group will receive *Pentacel* vaccine as a booster, and

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

the subjects in the Pedia Group will receive a booster dose of *Infanrix* and *ActHIB* vaccines at 15 through 18 months of age.

The study will continue to be open-label in Epoch 002.

Objectives Primary

Epoch 001 (primary vaccination)

• To demonstrate the non-inferiority of *Infanrix hexa* to *Pediarix* co-administered with *ActHIB*, in terms of antibody geometric mean concentrations (GMCs) for pertussis antigens [pertussis toxoid (PT), filamentous hemagglutinin (FHA) and pertactin (PRN)] one month after the third dose of the primary vaccination.

Criteria for non-inferiority:

Non-inferiority in terms of immune response to pertussis antigens will be demonstrated if, for each of the three antigens, the upper limit of the 95% confidence interval (CI) on the GMC ratio [Pedia divided by Hexa] is ≤ 1.5 .

Secondary

Epoch 001 (Primary vaccination)

- To assess the immune response to *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B*, in terms of seroprotection status, seropositivity status and concentrations or titers of antibodies to D, T, HBs, pertussis, poliovirus types 1, 2 and 3 and PRP antigens, one month after the third dose of the primary vaccination.
- To assess the safety and reactogenicity of a 3-dose primary vaccination course of *Infanrix hexa*, of *Pentacel* co-administered with *Engerix-B*, and that of *Pediarix* coadministered with *ActHIB*, in terms of solicited local symptoms.
- To assess the safety and reactogenicity of all study vaccines in terms of solicited general events, unsolicited adverse events, new-onset chronic diseases (NOCDs) and serious adverse events.

Epoch 002 (Booster vaccination)

• To assess the immunogenicity of *Infanrix hexa, Pentacel, Engerix-B, Pediarix* and *ActHIB*, in terms of persistence of the antibodies to D, T, pertussis, HBs, poliovirus types 1, 2 and 3 and PRP antigens, before the booster dose.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- To assess the immune response to *Infanrix*, *Hiberix*, ActHIB and Pentacel, in terms of seroprotection status, seropositivity status and antibody concentrations or titers for D, T, pertussis and PRP antigens, and in terms of booster response for pertussis antigens following *Infanrix* and Pentacel, one month after the booster dose.
- To assess the safety and reactogenicity of booster doses of Infanrix, Hiberix, ActHIB and Pentacel.

Study design

- Experimental design: Phase III, open-label, randomized, controlled, multi-centric, single-country study with five parallel groups.
- Duration of the study: The intended duration of the study per subject is approximately 14-17 months.
 - **Epoch 001**: Primary, starting at Visit 1 (Day 0) and ending at safety follow up contact (i.e. six months following the third dose, Month 10),
 - Epoch 002: Booster, starting at Visit 5 (Month 13-16) and ending at Visit 6 (Month 14-17).
- Study groups: The study groups are presented in Synopsis Table 1.

Synopsis Table 1 Study groups and epochs foreseen in the study

Ctudy around	Number of aubicote	Ago (Min/Mov) at Visit 1	Epo	chs
Study groups	Number of subjects	Age (Min/Max) at Visit 1	Epoch 001	Epoch 002
Hexa_1	65	6 WEEK -12weeks	Х	Х
Hexa_2	65	6 WEEK -12weeks	Х	Х
Hexa_3	65	6 WEEK -12weeks	Х	Х
Pedia	195	6 WEEK -12weeks	Х	Х
Penta	195	6 WEEK -12weeks	Х	Х

The study groups and treatment foreseen in the study is presented in Synopsis Table 2.

11

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Synopsis Table 2 Study groups and treatment foreseen in the study

Treatment	Vaccine/Product		Stı	udy Groups		
name	name	Hexa_1	Hexa_2	Hexa_3	Pedia	Penta
		E	poch 001			
Infanrix		v				
hexa	Hib	Х	Х	Х		
Pediarix					Х	
ActHIB	ActHIB					
	NaCl				Х	
Pentacel	DTaP-IPV (Sanofi					
	Pasteur)					Х
	ActHIB					
Engerix-B *	HBV					Х
Prevnar13	Prevenar 13	Х	Х	Х	Х	Х
Rotarix	HRV		v	v		· ·
	CaCO ₃	Х	Х	Х	X	Х
		E	poch 002			
Infanrix	DTPa	Х	х	х	х	
IIIi	LEF					
Hiberix	Hib	х	Х	X		
A . (111D	NaCl					
ActHIB	ActHIB				х	
	NaCl					
Pentacel	DTaP-IPV (Sanofi					
	Pasteur)					Х
÷=	ActHIB					

^{*} Engerix-B should not be given at Month 2 (4 months of age) if a dose of hepatitis B vaccine was given at birth up to 30 days prior to study dose 1 to the subject in the Penta Group.

- Control: active controls.
 - Epoch 001: Pediarix + ActHIB and Pentacel + Engerix-B
 - Epoch 002: *Infanrix* + *ActHIB* and *Pentacel*
- Vaccination schedules:

Epoch 001

- Hexa Group: Subjects in this group will receive three doses of *Infanrix hexa* (lot A, lot B or lot C as per the group allocation) co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
 - Hexa_1 Group: Subjects will receive lot A of Infanrix hexa,
 - Hexa_2 Group: Subjects will receive lot B of Infanrix hexa
 - Hexa_3 Group: Subjects will receive lot C of Infanrix hexa.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- Pedia Group: Subjects in this group will receive three doses of *Pediarix* and *ActHIB* co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
- Penta Group: Subjects in this group will receive three doses of *Pentacel* and *Engerix-B** coadministered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.

Epoch 002

- Hexa Group: Subjects will receive a booster dose of *Infanrix* and *Hiberix* vaccines at 15-18 months of age.
- Pedia Group: Subjects will receive a booster dose of *Infanrix* and *ActHIB* vaccines at 15-18 months of age.
- Penta Group: Subjects will receive a booster dose of Pentacel vaccine at 15-18 months of age.

The fourth dose of pneumococcal conjugate vaccine is recommended to be administered at approximately 12-15 months of age. Since the booster dose of the candidate vaccine/active controls will be given in this study at 15-18 months of age, the fourth dose of *Prevnar13* will not be administered as part of the study protocol. Subject's parent(s)/Legally Acceptable Representative(s) (LARs) will be reminded at Visit 3 and Visit 4 to consult their primary health care provider regarding the fourth dose of *Prevnar13* at 12-15 months for their child.

As the analyses will be performed regardless of the lot of *Infanrix hexa* received, unless otherwise specified, the Hexa_1, Hexa_2 and Hexa_3 groups will be pooled together for the analysis and will be called the Hexa group.

- Treatment allocation: The subjects will be randomized at a [1:1:1]:3:3 ratio to Hexa_1, Hexa_2, Hexa_3, Pedia and Penta groups. This will be done at study entry using GSK Biologicals' central randomization system on internet (SBIR).
- Blinding: The study is open-label for both epochs due to the differences in the number of injections and the appearance of the vaccines administered. However, the

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

^{*}Subjects in the Penta Group who have received a dose of hepatitis B vaccine from birth up to 30 days prior to study vaccination should not receive *Engerix-B* at 4 months of age (Visit 2).

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

laboratory in charge of the serology testing will be blinded to the treatment, and codes will be used to link the subject and study (without any link to the treatment attributed to the subject) to each sample.

The blinding of study epochs is presented in Synopsis Table 3.

Synopsis Table 3 Blinding of study epochs

Study Epochs	Blinding
Epoch 001	open
Epoch 002	open

- Sampling schedule: Blood samples will be drawn from all subjects at the following time points:
 - Post-Pri (Visit 4): One month after the third dose of primary vaccination, a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) will be collected.
 - Pre-Bst (Visit 5): Before the administration of the booster dose, a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) will be collected.
 - Post-Bst (Visit 6): One month after the booster vaccination, a volume of at least 3.5 mL of whole blood (to provide at least 1.2 mL of serum) will be collected.
- Type of study: self-contained.
- Data collection: electronic Case Report Form (eCRF).

Number of subjects

The total number of subjects planned to be enrolled is 585 subjects (65 each in Hexa_1, Hexa_2, Hexa_3 groups and 195 each in Pedia and Penta groups).

Endpoints Primary

Epoch 001 (Primary vaccination)

- Immunogenicity with respect to pertussis components of the study vaccines *Infanrix hexa* and *Pediarix*.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Secondary

Epoch 001 (Primary vaccination)

- Immunogenicity (other parameters) with respect to the pertussis component of the study vaccines *Infanrix hexa*, *Pentacel* and *Pediarix*.
 - Anti-PT, anti-FHA, anti-PRN seropositivity status, one month after the third dose of the primary vaccination.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination (for *Pentacel* only).
- Immunogenicity with respect to the other components of the study vaccines *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B*.
 - Anti-D, anti-T, anti-HBs, anti-poliovirus types 1, 2 and 3 and anti-PRP seroprotection status, anti-PRP antibody concentrations ≥1.0 µg/mL and antibody concentrations/titers, one month after the third dose of the primary vaccination.
- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0 – Day 3) after each vaccination (*Infanrix hexa, Pediarix, ActHIB, Pentacel* and *Engerix-B*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0 − Day 3) after each vaccination.
- Unsolicited adverse events.
 - Occurrence of unsolicited AEs within 31 days (Day 0 Day 30) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.
- Specific adverse events.
 - Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies) from Day 0 up to six months post primary vaccination.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- Serious adverse events.
 - Occurrence of serious adverse events from Day 0 up to six months post primary vaccination.

Epoch 002 (Booster vaccination)

- Immunogenicity with respect to all study vaccines.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-HBs, anti-PRP and anti-poliovirus 1, 2, 3 seroprotection/ seropositivity status, anti-PRP antibody concentrations ≥1 μg/mL and antibody concentrations/ titers before the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccine *Pentacel*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-PRP seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
 - Anti-PRP antibody concentrations ≥1 µg/mL one month after the booster dose (Dose 4).
 - Anti-D and anti-T antibody concentrations ≥1 IU/mL one month after the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccine *Infanrix*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
 - Anti-D and anti-T antibody concentrations ≥1 IU/mL one month after the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccines *ActHIB* and *Hiberix*.
 - Anti-PRP seroprotection status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PRP antibody concentrations ≥1 μg/mL one month after the booster dose (Dose 4).

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0 – Day 3) after booster vaccination (*Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0 − Day 3) after booster vaccination.
- Unsolicited adverse events.
 - Occurrence of unsolicited AEs within 31 days (Day 0
 Day 30) after booster vaccination, according to the MedDRA classification.
- Specific adverse events.
 - Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies) from the booster dose up to one month after the booster vaccination.
- Serious adverse events.
 - Occurrence of serious adverse events from the booster dose up to one month after the booster vaccination.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

TABLE OF CONTENTS

					PAGE
SP	ONSOF	RINFORMATION	N		7
SYI	NOPSI	3			8
LIS	T OF A	BBREVIATIONS	S		24
GL	OSSAF	Y OF TERMS			27
I FX/	ADEIVIA	IRNS			30
1.	INTRO				
	1.1.	Background			31
	1.2.			y design	
				'	
				design	
		1.2.2		poch 001 (primary vaccination):	
		1.2.2.	.2. Design of E	poch 002 (booster vaccination):	33
2.	OBJECTIVES				
	2.1.				
				accination)	
	2.2.	Secondary obje	ectives		33
				accination)	
		2.2.2. Epoc	h 002 (Booster va	accination)	34
3.	STUD	STUDY DESIGN OVERVIEW			
4.	STUDY COHORT				20
	4.1. Number of subjects/centers				
	4.3. Exclusion criteria for enrolment				
5.	CONDUCT OF THE STUDY				40
	5.1. Regulatory and ethical considerations, including the informed				40
	- 0	consent process			40
	5.2.		Subject identification		
				tment	
		5.2.2		tion of supplies	
				Epoch 001	
		E 2 2	5.2.2.1.2.	Epoch 002	
		5.2.2		allocation to the subject	42
			5.2.2.2.1.	Study group and treatment	40
			E 2 2 2 2	number allocation Treatment number allocation for	42
			5.2.2.2.2.		40
	5.3.	Mothod of bline	lina	subsequent doses	
	5.3. Method of blinding				
				44	

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

			Protocol Amendment 2 Final Version	1 00) n 02
5.5.	Outline	of study prov	cedures	
5.6.			of study procedures	
5.0.	5.6.1.		s prior to study participation	
	3.0.1.	5.6.1.1.	Informed consent	
	5.6.2.		s during the study	
	5.0.2.		Check inclusion and exclusion criteria	
		5.6.2.1.		
		5.6.2.2.	Collect demographic data	
		5.6.2.3.	Medical history	
		5.6.2.4.	Vaccination history	
		5.6.2.5.	History directed physical examination	
		5.6.2.6.	Study group and treatment number allocation	.49
		5.6.2.7.	Treatment number allocation for subsequent	
			doses	
		5.6.2.8.	Assess pre-vaccination body temperature	
		5.6.2.9.	Sampling	. 50
			5.6.2.9.1. Blood sampling for immune	
			response assessments	. 50
		5.6.2.10.	Check contraindications, warnings and	
			precautions to vaccination	. 50
		5.6.2.11.	Baseline measurement of limb circumference	
			after booster vaccination at visit 5	.50
		5.6.2.12.	Study Vaccines administration	.50
		5.6.2.13.	Recording of AEs, SAEs and NOCDs	.51
		5.6.2.14.	Check and record concomitant	
			medication/vaccination and intercurrent	
			medical conditions	.52
		5.6.2.15.	Study conclusion	.52
5.7.	Biologica	al sample ha	andling and analysis	.52
	5.7.1.		ecified study materials	
	5.7.2.		samples	
	5.7.3.		/ assays	
	5.7.4.		samples evaluation	
		5.7.4.1.	Immunological read-outs	
	5.7.5.	Immunolog	gical correlates of protection	
			,	
STUD	Y VACCIN	NES AND A	DMINISTRATION	.57
6.1.	Descripti	on of study	vaccines	.57
6.2.			g of study vaccines	
6.3.	Dosage a	and adminis	stration of study vaccines	.60
6.4.	Replacer	ment of unu	sable vaccine doses	.61
6.5.	Contrain	dications to	subsequent vaccination	.61
	6.5.1.		contraindications:	
	6.5.2.		/ contraindications:	
6.6.			utions	
6.7.			ation/product and concomitant vaccination	
	6.7.1.		of concomitant medications/products and	-
	J		nt vaccination	.64
	6.7.2.		ant medications/products/vaccines that may lead	٠.
	J - .		ination of a subject from ATP analyses	64
6.8.	Intercurre		conditions that may lead to elimination of a	. • •
J.J.			nalyses	.65
	200011	ui	·-··, · · · · · · · · · · · · · ·	

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

6.

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

_		FU 5001	117119 (DTPA-HBV-IF Protocol Amendment 2 Final Ver	rsion 02
7.	HEAL	IH ECON	NOMICS	65
8.				
	8.1.		lefinitions	
		8.1.1.		
		8.1.2.		
		8.1.3.	Solicited adverse events	
			8.1.3.1. Solicited local (injection-site) adverse events	
			8.1.3.2. Solicited general adverse events	68
		8.1.4.	Clinical laboratory parameters and other abnormal	
			assessments qualifying as adverse events or serious	
		0.4 =	adverse events	
	0.0	8.1.5.	Adverse events of specific interest	69
	8.2.		or outcomes not qualifying as adverse events or serious	00
	0.0		events	69
	8.3.	Detectin	g and recording adverse events and serious adverse	00
		events 8.3.1.	Time period for detecting and recording adverse events	69
		0.3.1.	Time period for detecting and recording adverse events and serious adverse events	60
		8.3.2.	Post-Study adverse events and serious adverse events	
		8.3.3.	Evaluation of adverse events and serious adverse events	
		0.3.3.	8.3.3.1. Active questioning to detect adverse events	12
			and serious adverse events	72
			8.3.3.2. Assessment of adverse events	
			8.3.3.2.1. Assessment of intensity	
			8.3.3.2.2. Assessment of causality	
			8.3.3.3. Assessment of outcomes	
			8.3.3.4. Medically attended visits	
	8.4.	Reportin	ng of serious adverse events and other events	
	• • • • • • • • • • • • • • • • • • • •	8.4.1.	Prompt reporting of serious adverse events and other	
		•	events to GSK Biologicals	77
		8.4.2.	Contact information for reporting serious adverse events	
			and other events to GSK Biologicals	77
		8.4.3.	Completion and transmission of SAE reports to GSK	
			Biologicals	77
			8.4.3.1. Back-up system in case the electronic SAE	
			reporting system does not work	77
		8.4.4.	Updating of SAE information after freezing of the subject's eCRF	
		8.4.5.	Regulatory reporting requirements for serious adverse events	78
	8.5.	Follow-u	up of adverse events and serious adverse events	78
		8.5.1.	Follow-up during the study	78
		8.5.2.	Follow-up after the subject is discharged from the study	79
	8.6.	Treatme	ent of adverse events	79
	8.7.	Subject	card	79
		-		
9.			MPLETION AND WITHDRAWAL	
	9.1.		completion	
	9.2.	•	withdrawal	
		9.2.1.	Subject withdrawal from the study	80
		9.2.2.	Subject withdrawal from investigational vaccine	80

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

		117119 (DTPA-HBV-IPV- Protocol Amendment 2 Final Versic	135) on 02
10.	STATI	STICAL METHODS	
	10.1.	Primary endpoint	
		10.1.1. Epoch 001 (Primary vaccination)	
	10.2.	Secondary endpoints	
		10.2.1. Epoch 001 (Primary vaccination)	81
		10.2.2. Epoch 002 (Booster vaccination)	
	10.3.	Determination of sample size	
		10.3.1. Control on type I error	84
		10.3.2. References for sample size	
		10.3.3. Power computation	
	10.4.	Study cohorts/ data sets to be analysed	
		10.4.1. Primary Total vaccinated cohort	
		10.4.2. Primary ATP cohort for analysis of safety	85
		10.4.3. Primary ATP cohort for analysis of immunogenicity	86
		10.4.4. Booster Total vaccinated cohort	
		10.4.5. Booster ATP cohort for analysis of safety	
	40 =	10.4.6. Booster ATP cohort for analysis of immunogenicity	
	10.5.	Derived and transformed data	
	10.6.	Final analysis of the Epoch 001	
		10.6.1. Analysis of demographics	
		10.6.2. Analysis of immunogenicity	
		10.6.2.1. Within group assessment	
		10.6.2.2. Between group assessment	
		10.6.3. Analysis of safety	
	10.7.	Final analysis of the Epoch 002	
	10.7.	10.7.1. Analysis of demographics/baseline characteristics	
		10.7.2. Analysis of immunogenicity	
		10.7.2.1. Within group assessment	
		10.7.2.2. Between group assessment	
		10.7.2.3. Interpretation of analyses	
		10.7.3. Analysis of safety	
	10.8.	Statistical methods	
	10.9.	Conduct of analyses	
		10.9.1. Sequence of analyses	
		10.9.2. Statistical considerations for interim analyses	94
		·	
11.	ADMIN	IISTRATIVE MATTERS	
	11.1.		
	11.2.	Study Monitoring by GSK Biologicals	
	11.3.	Record retention	
	11.4.	Quality assurance	96
	11.5.	Posting of information on publicly available clinical trial registers and	
	44.5	publication policy	
	11.6.	Provision of study results to investigators	96
10	COLIN	TDV CDECIFIC DECLUDEMENTS	07
12.	COUN	TRY SPECIFIC REQUIREMENTS	9/
12	DEEE	DENCES	00

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

LIST OF TABLES

		PAGE
Table 1	Study groups and epochs foreseen in the study	36
Table 2	Study groups and treatment foreseen in the study	36
Table 3	Blinding of study epochs	38
Table 4	List of study procedures	45
Table 5	Intervals between study visits	48
Table 6	Biological samples	54
Table 7	Humoral Immunity (Antibody determination)	55
Table 8	Immunological read-outs	<u>5</u> 6
Table 9	Study vaccines	58
Table 10	Dosage and administration	61
Table 11	Solicited local adverse events	68
Table 12	Solicited general adverse events	68
Table 13	Reporting periods for adverse events and serious adverse events	71
Table 14	Intensity scales for solicited symptoms in infants/toddlers	73
Table 15	Timeframes for submitting serious adverse event and other events reports to GSK Biologicals	77
Table 16	Standard deviation for log ₁₀ transformed concentration post vaccination	84
Table 17	Power for pertussis NI post-Dose 3	84
Table 18	GSK Biologicals' laboratories	100
Table 19	Outsourced laboratories	100

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

LIST OF APPENDICES

	PAGE
APPENDIX A CLINICAL LABORATORIES	100
APPENDIX B AMENDMENTS AND ADMINISTRATIVE CHANGES TO THE PROTOCOL	101

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

LIST OF ABBREVIATIONS

ACIP: **Advisory Committee on Immunization Practices**

AE: Adverse Event

ANCOVA: Analysis of Co-variance

ANOVA: Analysis of Variance

ATP: According-To-Protocol

CDC: Centers for Disease Control and Prevention, United States

of America

CI: Confidence Interval

CSR: Clinical Study Report

D: Diphtheria

DTPa-HBV-IPV/Hib: Combined diphtheria-tetanus-acellular pertussis-hepatitis

B-inactivated poliovirus and Haemophilus influenzae

type b vaccine (*Infanrix hexa*).

eCRF: electronic Case Report Form

EL.U: ELISA unit(s)

ELISA: Enzyme-linked immunosorbent assay

ESFU: Extended safety follow-up

eTDF: electronic Temperature excursion Decision Form

FHA: Filamentous hemagglutinin

Good Clinical Practice GCP:

Geometric Mean Concentration **GMC**:

Geometric Mean Titer **GMT**:

GSK: GlaxoSmithKline

HBs: Hepatitis B surface antigen

Hib: *Haemophilus influenzae* (*H. influenzae*) type b

HRV: **Human Rotavirus**

17-APR-2015

6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

IB: Investigator Brochure

ICF: Informed Consent Form

ICH: International Conference on Harmonisation

IEC: Independent Ethics Committee

IM: Intramuscular

IMP: Investigational Medicinal Product

IND: Investigational New Drug

IRB: Institutional Review Board

IU: International unit(s)

LAR: Legally Acceptable Representative

Lf: Limits of flocculation unit(s)

LSLV: Last Subject Last Visit

MedDRA: Medical Dictionary for Regulatory Activities

NI: Non-inferiority

NOCD: New Onset of Chronic Disease

Pa: Acellular Bordetella pertussis component

PI: Product Information

PRN: Pertactin

PRP: Polyribosyl-Ribitol-Phosphate: polysaccharide

component of the Hib bacterium capsule

PT: Pertussis toxoid: a secreted exotoxin of the *Bordetella*

pertussis bacterium

RCC: Reverse Cumulative Curve

RDE: Remote Data Entry

SAE: Serious Adverse Event

SBIR: Randomization System on Internet

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

SCID: Severe Combined Immunodeficiency Disease

SDV: Source Document Verification

SPC: Summary of Product Characteristics

SPM: Study Procedures Manual

T: Tetanus

TVC: Total Vaccinated cohort

US: United States

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

GLOSSARY OF TERMS

Adverse event:

Any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

An adverse event (AE) can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse.

Blinding:

A procedure in which one or more parties to the trial are kept unaware of the treatment assignment in order to reduce the risk of biased study outcomes. The level of blinding is maintained throughout the conduct of the trial, and only when the data are cleaned to an acceptable level of quality will appropriate personnel be unblinded or when required in case of a serious adverse event. In an open-label study, no blind is used. Both the investigator and the subject know the identity of the treatment assigned.

Child in care:

A child who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation. The definition of a child in care can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. The definition of a child in care does not include a child who is adopted or has an appointed legal guardian.

Eligible: Qualified for enrolment into the study based upon strict adherence to inclusion/exclusion criteria.

Epoch: An epoch is a self-contained set of consecutive

timepoints or a single timepoint from a single protocol. Self-contained means that data collected for all subjects at all timepoints within that epoch allows to draw a complete conclusion to define or precise the targeted label of the product. Typical examples of epochs are primary vaccinations, boosters, yearly immunogenicity follow-ups, and surveillance periods for efficacy or

safety.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

eTrack: GSK's tracking tool for clinical trials.

Evaluable: Meeting all eligibility criteria, complying with the

procedures defined in the protocol, and, therefore, included in the according-to-protocol (ATP) analysis (see

Sections 6.7.2 and 10.4 for details on criteria for

evaluability).

Immunological correlate

of protection:

The defined humoral antibody response above which there is a high likelihood of protection in the absence of any host factors that might increase susceptibility to the

infectious agent.

Intercurrent medical

condition:

A condition that has the capability of altering a subject's

immune response or are confirmed to have an immunodeficiency condition during the study.

Investigational vaccine/product:

(Synonym of

A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial. including a product with a marketing authorization when used in a way different from the approved form, or when used for an unapproved indication, or when used to gain

further information about an approved use.

Investigational Medicinal Product)

Primary completion date:

The date that the final subject was examined or received an intervention for the purpose of final collection of data for the primary outcome, whether the clinical trial concluded according to the pre-specified protocol or was

terminated.

Process of random attribution of treatment to subjects in **Randomization:**

order to reduce bias of selection.

Study with objectives not linked to the data of another **Self-contained study:**

study.

Site Monitor: An individual assigned by the sponsor who is responsible

for assuring proper conduct of clinical studies at one or

more investigational sites.

Solicited adverse event: AEs to be recorded as endpoints in the clinical study. The

> presence/occurrence/intensity of these events is actively solicited from the subject or an observer during a specified post-vaccination follow-up period.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Subject: Term used throughout the protocol to denote an

individual who has been contacted in order to participate or participates in the clinical study, either as a recipient of

the vaccines or as a control.

Subject number: A unique number identifying a subject, assigned to each

subject consenting to participate in the study.

Treatment: Term used throughout the clinical study to denote a set of

investigational product(s) or marketed product(s) or placebo intended to be administered to a subject, identified by a unique number, according to the study

randomization or treatment allocation.

Treatment number: A number identifying a treatment to a subject, according

to the study randomization or treatment allocation.

Unsolicited adverseAny AE reported in addition to those solicited during the event:
clinical study. Also any 'solicited' symptom with onset

clinical study. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse

event.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

TRADEMARKS

The following trademarks are used in the present protocol.

In the body of the protocol (including the synopsis), the names of the vaccines will be written without the superscript symbol TM or $^{\mathbb{R}}$ and in *italics*.

Trademarks of the GlaxoSmithKline group of companies
Engerix-B [®]
Hiberix™
Infanrix [®]
Infanrix hexa™
Pediarix [®]
Rotarix®

Generic description
Hepatitis B vaccine (recombinant)
Haemophilus b conjugate vaccine (tetanus toxoid conjugate)
Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed
Combined Diphtheria-Tetanus-acellular Pertussis (DTaP), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine
Rotavirus Vaccine, Live, Oral

Trademarks not owned by the GlaxoSmithKline group of companies		
ActHIB® (Sanofi Pasteur SA)		
Pentacel® (Sanofi Pasteur SA)		
Prevnar® (Wyeth Pharmaceuticals Inc.; Marketed by Pfizer Inc.)		
Prevnar13® (Wyeth Pharmaceuticals Inc.; Marketed by Pfizer Inc.)		

Generic description
Haemophilus type b conjugate vaccine (tetanus toxoid conjugate)
Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and Haemophilus b conjugate (tetanus toxoid conjugate)
Pneumoccocal 7-valent conjugate vaccine (diphtheria CRM ₁₉₇ protein)
Pneumoccocal 13-valent conjugate vaccine (diphtheria CRM ₁₉₇ protein)

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

1. INTRODUCTION

1.1. Background

Combination vaccines have been developed to provide multiple immunizations in a single injection. They can simplify vaccine administration and have the potential to promote compliance and cost-effectiveness by decreasing the number of injections needed to immunize a child [Zinke, 2010; Kalies, 2006]. Use of combination vaccines can alleviate concerns associated with the number of injections to be given at one time [ACIP, 2011].

GlaxoSmithKline (GSK) Biologicals' *Infanrix hexa* vaccine helps prevent six diseases in a single injection. *Infanrix hexa* is licensed for primary and booster vaccination in more than 98 countries around the globe, including the entire European Union. The vaccine complies with the WHO requirements for manufacture of biological substances for all of its antigenic components. The *Infanrix hexa* vaccine consists of a combination of GSK's *Pediarix* (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined); STN 103907, approved in the United States (US) on December 13, 2002 and a Hib vaccine consisting of purified polyribosyl-ribitol-phosphate (PRP) capsular polysaccharide of *Haemophilus influenzae* type b covalently bound to tetanus toxoid (TT). The conjugated Hib-TT is the same as that used for the formulation of *Hiberix* [*Haemophilus* b Conjugate Vaccine (Tetanus Toxoid Conjugate)] (licensed in the US as a booster dose in August 2009), with the only difference that in *Infanrix hexa*, the Hib-conjugate is adsorbed onto aluminum phosphate.

The *Infanrix hexa* combination vaccine would provide an additional source of DTaP, hepatitis B, poliovirus, and Hib containing vaccines for the US market and would potentially reduce the number of injections required to provide infants with recommended vaccinations.

GSK has an extensive clinical safety database for *Infanrix hexa*. The safety and immunogenicity data of the vaccine have been evaluated in numerous controlled studies [Dhillon, 2010; Zepp, 2009], of which 4 were conducted in the US with approximately 3000 US subjects exposed to a primary vaccination with *Infanrix hexa*.

Please refer to the current Investigator Brochure for information regarding the preclinical and clinical studies and the potential risks and benefits of *Infanrix hexa*.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

1.2. Rationale for the study and study design

1.2.1. Rationale for the study

Infanrix hexa was first licensed in the European Union in 2000. More than 100 million doses have been distributed to date and the benefit/risk profile remains favorable. Licensure of Infanrix hexa combination vaccine in the US will provide an additional option for vaccination within the routine US pediatric schedule with the fewest number of injections, which would create opportunities to add further injections in case other novel vaccines against important pediatric diseases become available. Furthermore, Infanrix hexa will provide an additional source of DTaP, hepatitis B, poliovirus, and Hibcontaining vaccine to the US market, which will help ensure a more stable supply.

The present study 117119 (DTPA-HBV-IPV-135) is intended to generate pivotal immunogenicity data demonstrating non-inferiority of the immune responses against pertussis antigens of *Infanrix hexa* compared to *Pediarix*, which is currently one of the DTaP combination vaccines widely used as a standard of care in the US. Additionally, this study will also provide descriptive data with regard to the immunogenicity of the other vaccine antigens and the safety profile in US subjects. These pivotal immunogenicity non-inferiority data for pertussis and descriptive safety data are intended to support the registration of GSK Biologicals' combined DTPa-HBV-IPV/Hib (*Infanrix hexa*) vaccine in the US. A subsequent Phase III study is planned to provide pivotal data regarding lot-to-lot consistency, safety and the immunogenicity of the other vaccine antigens.

Comparison of immunogenicity data from separate clinical studies for *Infanrix hexa* and *Pentacel*, given on a 2-4-6 month schedule, suggests that the immune response to the Hib component of these vaccines is similar. This study will provide descriptive information regarding the immune response to the Hib components of *Infanrix hexa* and *Pentacel* following a 3-dose primary series, prior to further evaluation in Phase III studies.

1.2.2. Rationale for the study design

1.2.2.1. Design of Epoch 001 (primary vaccination):

The study is designed as a randomized, controlled, open-label study with five parallel groups:

- The first three groups (Hexa_1, Hexa_2 and Hexa_3 group) will receive three doses of the *Infanrix hexa* vaccine (either lot A, lot B or lot C, respectively). These three groups will be pooled together for the analyses and the pooled group will be called the Hexa group.
- The Pedia Group (Control 1) will receive three doses of the US-licensed control vaccines, *Pediarix* and *ActHIB*.
- The Penta Group (Control 2) will receive three doses of the US-licensed control vaccines, *Pentacel* (only two doses of *Engerix-B* will be administered if a subject has received a birth dose of hepatitis B vaccine).

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Three distinct vaccine lots manufactured according to the same procedures will be used in the Hexa group in order to obtain more representative data for the vaccine.

The study will be open-label due to the differences in the number of injections and the appearance of the vaccines administered.

Vaccines (i.e., *Prevnar13* and *Rotarix*) that are recommended for children in the US during the first year of life will be administered concomitantly with the other study vaccines as part of the study.

1.2.2.2. Design of Epoch 002 (booster vaccination):

In Epoch 002, the subjects will be assessed for antibody persistence to the vaccine antigens of *Infanrix hexa*. This epoch will also assess the adequacy of priming subjects with *Infanrix hexa* by evaluating the boostability of D, T, Pa and Hib antigens with the US-licensed vaccines. The pooled Hexa Group will receive booster doses of *Infanrix* and *Hiberix* vaccines at 15 through 18 months of age, the subjects in the Penta Group will receive *Pentacel* vaccine as a booster, and the subjects in the Pedia Group will receive a booster dose of *Infanrix* and *ActHIB* vaccines at 15 through 18 months of age.

The study will continue to be open-label in Epoch 002.

2. OBJECTIVES

2.1. Primary objective

2.1.1. Epoch 001 (Primary vaccination)

• To demonstrate the non-inferiority of *Infanrix hexa* to *Pediarix* co-administered with *ActHIB*, in terms of antibody geometric mean concentrations (GMCs) for pertussis antigens [pertussis toxoid (PT), filamentous hemagglutinin (FHA) and pertactin (PRN)] one month after the third dose of the primary vaccination.

Criteria for non-inferiority:

Non-inferiority in terms of immune response to pertussis antigens will be demonstrated if, for each of the three antigens, the upper limit of the 95% confidence interval (CI) on the GMC ratio [Pedia divided by Hexa] is ≤ 1.5 .

Refer to Section 10.1 for the definition of the primary endpoint.

2.2. Secondary objectives

2.2.1. Epoch 001 (Primary vaccination)

• To assess the immune response to *Infanrix hexa, Pediarix, ActHIB, Pentacel* and *Engerix-B*, in terms of seroprotection status, seropositivity status and concentrations or titers of antibodies to D, T, HBs, pertussis, poliovirus types 1, 2 and 3 and PRP antigens, one month after the third dose of the primary vaccination.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- To assess the safety and reactogenicity of a 3-dose primary vaccination course of *Infanrix hexa*, of *Pentacel* co-administered with *Engerix-B*, and that of *Pediarix* co-administered with *ActHIB*, in terms of solicited local symptoms.
- To assess the safety and reactogenicity of all study vaccines in terms of solicited general events, unsolicited adverse events, new-onset chronic diseases (NOCDs) and serious adverse events.


2.2.2. Epoch 002 (Booster vaccination)

- To assess the immunogenicity of *Infanrix hexa*, *Pentacel*, *Engerix-B*, *Pediarix* and *ActHIB*, in terms of persistence of the antibodies to D, T, pertussis, HBs, poliovirus types 1, 2 and 3 and PRP antigens, before the booster dose.
- To assess the immune response to *Infanrix, Hiberix, ActHIB* and *Pentacel*, in terms of seroprotection status, seropositivity status and antibody concentrations or titers for D, T, pertussis and PRP antigens, and in terms of booster response for pertussis antigens following *Infanrix and Pentacel*, one month after the booster dose.
- To assess the safety and reactogenicity of booster doses of *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*.

Refer to Section 10.2 for the definition of the secondary endpoints.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

3. STUDY DESIGN OVERVIEW



N = number of subjects in the study; n = number of subjects in each group; Mo = months Visit 3 should be conducted at least 8 weeks after Visit 2, with subjects at least 24 weeks of age, in order to comply with US recommendations on hepatitis B dosing

Post-Pri = blood sample collected from subjects, one month after the administration of the third dose in the Epoch 001 Pre-Bst = blood sample collected from subjects, before the administration of the booster dose in the Epoch 002 Post-Bst = blood sample collected from subjects, one month after the administration of booster dose in the Epoch 002 * Engerix-B should not be given at Month 2 (4 months of age) if a dose of hepatitis B vaccine was given at birth up to 30 days prior to study dose 1 to the subject in the Penta Group ESFU = Extended safety follow-up

Protocol waivers or exemptions are not allowed with the exception of immediate safety concerns. Therefore, adherence to the study design requirements, including those specified in the outline of study procedures (Section 5.5), are essential and required for study conduct.

- Experimental design: Phase III, open-label, randomized, controlled, multi-centric, single-country study with five parallel groups.
- Duration of the study: The intended duration of the study per subject is approximately 14-17 months.
 - Epoch 001: Primary, starting at Visit 1 (Day 0) and ending at safety follow up contact (i.e. six months following the third dose, Month 10),

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- **Epoch 002:** Booster, starting at Visit 5 (Month 13-16) and ending at Visit 6 (Month 14-17).
- Study groups: The study groups and epochs foreseen in the study are presented in Table 1.

Table 1 Study groups and epochs foreseen in the study

Ctudy around	Number of aubicate	Age (Min/Max) at Visit 1	Epochs	
Study groups	Number of subjects	Age (Min/Max) at Visit 1	Epoch 001	Epoch 002
Hexa_1	65	6 WEEK -12weeks	Х	Х
Hexa_2	65	6 WEEK -12weeks	Х	Х
Hexa_3	65	6 WEEK -12weeks	Х	Х
Pedia	195	6 WEEK -12weeks	Х	Х
Penta	195	6 WEEK -12weeks	Х	Х

The study groups and treatment foreseen in the study are presented in Table 2.

Table 2 Study groups and treatment foreseen in the study

Treatment	Vaccine/Product		Stı	udy Groups		
name	name	Hexa_1	Hexa_2	Hexa_3	Pedia	Penta
		E	Epoch 001			
Infanrix hexa		,	v			
	Hib	Х	Х	Х		
Pediarix					Х	
ActHIB	ActHIB				.,	
	NaCl				Х	
Pentacel	DTaP-IPV					
	(Sanofi Pasteur)					х
	ActHIB					
Engerix-B *	HBV					Х
Prevnar13	Prevenar 13	Х	Х	Х	Х	Х
Rotarix	HRV	Х	Χ	Х	х	Х
	CaCO ₃					
		E	poch 002			
Infanrix	DTPa	Χ	Х	Х	Х	
Hiberix	Hib	Х	Х	Х		
	NaCl					
ActHIB	ActHIB				х	
	NaCl				Å	
Pentacel	DTaP-IPV					
	(Sanofi Pasteur)					Х
	ActHIB					

^{*} Engerix-B should not be given at Month 2 (4 months of age) if a dose of hepatitis B vaccine was given at birth up to 30 days prior to study dose 1 to the subject in the Penta Group.

- Control: active controls.
 - Epoch 001: *Pediarix* + *ActHIB* and *Pentacel* + *Engerix-B*
 - Epoch 002: *Infanrix* + *ActHIB* and *Pentacel*.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Vaccination schedules:

Epoch 001

- Hexa Group: Subjects in this group will receive three doses of *Infanrix hexa* (lot A, lot B or lot C as per the group allocation) co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
 - Hexa 1 Group: Subjects will receive lot A of *Infanrix hexa*,
 - Hexa 2 Group: Subjects will receive lot B of *Infanrix hexa*
 - Hexa 3 Group: Subjects will receive lot C of Infanrix hexa.
- Pedia Group: Subjects in this group will receive three doses of *Pediarix* and *ActHIB* co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
- Penta Group: Subjects in this group will receive three doses of *Pentacel* and *Engerix-B** co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.

*Subjects in the Penta Group who have received a dose of hepatitis B vaccine from birth up to 30 days prior to study vaccination should not receive *Engerix-B* at 4 months of age (Visit 2).

Epoch 002

- Hexa Group: Subjects will receive a booster dose of *Infanrix* and *Hiberix* vaccines at 15-18 months of age.
- Pedia Group: Subjects will receive a booster dose of *Infanrix* and *ActHIB* vaccines at 15-18 months of age.
- Penta Group: Subjects will receive a booster dose of *Pentacel* vaccine at 15-18 months of age.

The fourth dose of pneumococcal conjugate vaccine is recommended to be administered at approximately 12-15 months of age. Since the booster dose of the candidate vaccine/active controls will be given in this study at 15-18 months of age, the fourth dose of *Prevnar13* will not be administered as part of the study protocol. Subject's parent(s)/Legally Acceptable Representative(s) (LARs) will be reminded at Visit 3 and Visit 4 to consult their primary health care provider regarding the fourth dose of *Prevnar13* at 12-15 months for their child.

- As the analyses will be performed regardless of the lot of *Infanrix hexa* received, unless otherwise specified, the Hexa_1, Hexa_2 and Hexa_3 groups will be pooled together for the analysis and will be called the Hexa group.
- Treatment allocation: The subjects will be randomized at a [1:1:1]:3:3 ratio to Hexa_1, Hexa_2, Hexa_3, Pedia and Penta groups. This will be done at study entry using GSK Biologicals' central randomization system on internet (SBIR).
- Blinding: The study is open-label for both epochs (Table 3) due to the differences in the number of injections and the appearance of the vaccines administered. However, the laboratory in charge of the serology testing will be blinded to the treatment, and

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

codes will be used to link the subject and study (without any link to the treatment attributed to the subject) to each sample.

The blinding of study epochs is presented in Table 3.

Table 3 Blinding of study epochs

Study Epochs	Blinding
Epoch 001	open
Epoch 002	open

- Sampling schedule: Blood samples will be drawn from all subjects at the following time points:
 - Post-Pri (Visit 4): One month after the third dose of primary vaccination, a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) will be collected.
 - Pre-Bst (Visit 5): Before the administration of the booster dose, a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) will be collected.
 - Post-Bst (Visit 6): One month after the booster vaccination, a volume of at least
 3.5 mL of whole blood (to provide at least 1.2 mL of serum) will be collected.
- Type of study: self-contained.
- Data collection: electronic Case Report Form (eCRF).

4. STUDY COHORT

4.1. Number of subjects/centers

Target enrolment will be 585 subjects (65 each in Hexa_1, Hexa_2, Hexa_3 groups and 195 each in Pedia and Penta groups). Enrolment will be terminated when the target number of subjects has been enrolled. Refer to Section 10.3 for a detailed description of the criteria used in the estimation of sample size.

This study will be conducted at multiple centers in the US.

Actual numbers of subjects enrolled versus target will be monitored by the site monitor using SBIR.

4.2. Inclusion criteria for enrolment

Deviations from inclusion criteria are not allowed because they can potentially jeopardize the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol is essential.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

All subjects must satisfy ALL the following criteria at study entry:

- Subjects' parent(s)/ LAR(s) who, in the opinion of the investigator, can and will comply, with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
- A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.
- Born full-term (i.e. after a gestation period of 37 weeks to less than 42 completed weeks [259 to 293 days]).
- Written informed consent obtained from parent(s)/LAR(s) of the subject.
- Healthy subjects as established by medical history and clinical examination before entering into the study.
- Infants who have not received a previous dose of hepatitis B vaccine or those who have received only 1 dose of hepatitis B vaccine administered at least 30 days prior to enrolment.

4.3. Exclusion criteria for enrolment

Deviations from exclusion criteria are not allowed because they can potentially jeopardize the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol is essential.

The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:

- Child in care
 - Please refer to the glossary of terms for the definition of child in care.
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccines, or planned use during the study period.
- Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs since birth. For corticosteroids, this will mean prednisone ≥ 0.5 mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
- Planned administration/administration of a vaccine not foreseen by the study
 protocol within the period starting from 30 days before the first vaccination until 30
 days after Dose 3 (Epoch 001, primary vaccination) and from 30 days before the
 booster Dose 4 until 30 days after booster Dose 4 (Epoch 002, booster vaccination),
 i.e. the end of the study:
 - Inactivated influenza and hepatitis A vaccines are allowed throughout the study.
 - Routine administration(s) of vaccines are allowed from 30 days after the last dose of primary vaccination until 30 days before the booster dose and after postbooster blood sampling. Routine administration of measles-mumps-rubella

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

vaccine, varicella, pneumococcal vaccines are allowed from 30 days after last dose of primary vaccine until 30 days before booster dose and from post-booster blood sampling, as well as according to the recommended immunization schedule in US.

- Concurrently participating in another clinical study, at any time during the study
 period, in which the subject has been or will be exposed to an investigational or a
 non-investigational product (pharmaceutical product or device).
- History of Hib, diphtheria, tetanus, pertussis, pneumococcal, rotavirus, poliovirus and hepatitis B diseases.
- Previous vaccination against Hib, diphtheria, tetanus, pertussis, pneumococcus, rotavirus and/or poliovirus; more than one previous dose of hepatitis B vaccine.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- Family history of congenital or hereditary immunodeficiency.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines (including yeast).
- Hypersensitivity to latex.
- Major congenital defects or serious chronic illness.
- History of any neurological disorders including seizures.
- Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
- History of intussusception or of any uncorrected congenital malformation of the gastrointestinal tract that would predispose the infant to intussusception.
- History of Severe Combined Immunodeficiency Disease (SCID).
- Acute disease and/or fever at the time of enrolment.
 - Fever is defined as temperature ≥38.0°C /100.4°F by any route. The preferred route for recording temperature in this study will be rectal for Epoch 001 and axillary for Epoch 002.
 - Subjects with a minor illness (such as mild diarrhea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.

5. CONDUCT OF THE STUDY

5.1. Regulatory and ethical considerations, including the informed consent process

The study will be conducted in accordance with all applicable regulatory requirements.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

The study will be conducted in accordance with the ICH Guideline for Good Clinical Practice (GCP), all applicable subject privacy requirements and the guiding principles of the Declaration of Helsinki.

The study has been designed and will be conducted in accordance with the ICH Harmonised Tripartite Guideline for clinical investigation of medicinal products in the paediatric population (ICH E11) and all other applicable ethical guidelines.

GSK will obtain favorable opinion/approval to conduct the study from the appropriate regulatory agency, in accordance with applicable regulatory requirements, prior to a site initiating the study in that country.

Conduct of the study includes, but is not limited to, the following:

- Institutional Review Board (IRB)/Independent Ethics Committee (IEC) review and favorable opinion/approval of study protocol and any subsequent amendments.
- Subject's parent(s)/LAR(s) informed consent.
- Investigator reporting requirements as stated in the protocol.

GSK will provide full details of the above procedures to the investigator, either verbally, in writing, or both.

Freely given and written informed consent must be obtained from each subject's parent(s)/LAR(s) prior to participation in the study.

GSK Biologicals will prepare a model Informed Consent Form (ICF) which will embody the ICH GCP and GSK Biologicals required elements. While it is strongly recommended that this model ICF is to be followed as closely as possible, the informed consent requirements given in this document are not intended to pre-empt any local regulations which require additional information to be disclosed for informed consent to be legally effective. Clinical judgement, local regulations and requirements should guide the final structure and content of the local version of the ICF.

The investigator has the final responsibility for the final presentation of the ICF, respecting the mandatory requirements of local regulations. The ICF generated by the investigator with the assistance of the sponsor's representative must be acceptable to GSK Biologicals and be approved (along with the protocol, and any other necessary documentation) by the IRB/IEC.

5.2. Subject identification and randomization of treatment

5.2.1. Subject identification

After checking the inclusion/exclusion criteria, subject numbers will be assigned sequentially to subjects whose parent(s)/LAR(s) give consent for their child to participate in the study, according to the range of subject numbers allocated to each study center. Subject numbers will also be used to identify blood samples collected during the study.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

5.2.2. Randomization of treatment

5.2.2.1. Randomization of supplies

The numbering of supplies will be performed at GSK Biologicals, using MATerial EXcellence (MATEX), a program developed for use in Statistical Analysis System (SAS®) (Cary, NC, USA) by GSK Biologicals.

To allow GSK Biologicals to take advantage of greater rates of recruitment than anticipated at individual centers in this multi-center study and to thus reduce the overall study recruitment period, an over-randomization of supplies will be prepared.

5.2.2.1.1. Epoch 001

A first list based on a randomization blocking scheme using a [1:1:1]:3:3 randomization ratio will be used to number the following vaccines for Doses 1, 2 and 3.

- DTPa-HBV-IPV/Hib lot A
- DTPa-HBV-IPV/Hib lot B
- DTPa-HBV-IPV/Hib lot C
- Pediarix
- Pentacel

The vaccines from this list will be distributed to the study center while respecting the randomization block size.

ActHIB, Engerix-B, Prevnar13 and Rotarix will be numbered independently using a sequential numbering.

5.2.2.1.2. Epoch 002

Four sequential lists (one for *Infanrix*, one for *Hiberix*, one for *ActHIB* and one for *Pentacel*) will be used to number the vaccine doses for the Epoch 002.

The study staff in charge of the vaccine administration will access SBIR, provide the subject identification number and the dose number. The system will provide a new treatment number for all the vaccines to be administered to a subject (*Pentacel, Infanrix + ActHIB* or *Infanrix + Hiberix*). This will be consistent with the allocated study group.

5.2.2.2. Treatment allocation to the subject

The treatment numbers will be allocated by dose.

5.2.2.2.1. Study group and treatment number allocation

The target is to enroll 585 subjects to be randomly assigned to five study groups in a [1:1:1]:3:3 ratio (195 subjects in the pooled lots group).

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Allocation of the subject to a study group at the investigator site will be performed using SBIR. The randomization algorithm will use a minimization procedure accounting for the study as a whole and each of the centers.

After obtaining the signed and dated ICF from the subject's parent(s)/LAR(s) and having checked the eligibility of the subject, the site staff in charge of the vaccine administration will access SBIR. Upon providing the subject identification number, the randomization system will ask whether the subject had a previous hepatitis B vaccination and will use the minimization algorithm to determine the group allocation and the appropriate treatment number for *Pentacel*, *Pediarix* or for *Infanrix hexa* (lot A, lot B or lot C) to be used for the subject.

SBIR will also provide treatment numbers for co-administered vaccines *Engerix B*, *ActHib*, *Prevnar13* vaccine and a *Rotarix* vaccine, each one labelled with a different treatment number. Therefore a subject will have three or four different treatment numbers allocated at dose 1.

The number of each administered treatment must be recorded in the eCRF on the Vaccine Administration screen.

When SBIR is not available, please refer to the SBIR user guide or the Study Procedures Manual (SPM) for specific instructions.

5.2.2.2.2. Treatment number allocation for subsequent doses

For each dose subsequent to the first dose, the study staff in charge of the vaccine administration will access SBIR, provide the subject identification number, the dose number and the system will provide new treatment numbers consistent with the allocated study group.

Each vaccine will be labeled with a different treatment number.

The number of each administered treatment must be recorded in the eCRF on the Vaccine Administration screen.

Note that in the Penta Group, the investigator will be reminded that *Engerix-B* is not allowed at dose 2 for subjects with previous hepatitis B vaccination. So for these subjects, the treatment identified by SBIR for dose 2 should not be used.

5.3. Method of blinding

The study will be open-label for both epochs due to the differences in the number of injections and the appearance of the vaccines administered. However, the laboratory in charge of the serology testing will be blinded to the treatment, and codes will be used to link the subject and study (without any link to the treatment attributed to the subject) to each sample.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

5.4. General study aspects

Supplementary study conduct information not mandated to be present in this protocol is provided in the accompanying SPM. The SPM provides the investigator and the site personnel with administrative and detailed technical information that does not impact the safety of the subjects.

5.5. Outline of study procedures

The outline of study procedures is presented in Table 4.

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Table 4 List of study procedures

(Amendment 2: 17 April 2015)

	EPOCH 001 (PRIMARY VACCINATION)					EPOCH 002 (BOOSTER VACCINATION)	
Age	2 Months	4 Months	6 Months	7 Months	12 Months	15-18 Months	16-19 Months
Visit	Visit 1	VISIT 2	VISIT 3†	VISIT 4	ESFU CONTACT (PHONE)	VISIT 5	VISIT 6
Time point	Day 0	Month 2	Month 4	Month 5	Month 10	Month 13 -16	Month 14 - 17
Sampling time point				Post-Pri		Pre-Bst	Post-Bst
Informed consent	•						
Check inclusion/exclusion criteria	•						
Medical history	•						
Collect demography data	•						
Vaccination history including HepB vaccination history	•						
Informed consent for Tdap vaccination history of mother ^α	•						
Last Tdap vaccination history of mother ^β	•						
History directed physical examination including length and weight	•					•	
Study group and treatment number allocation (Randomization)	0						
Treatment number allocation for subsequent doses		0	0			0	
Recording of administered treatment number	•	•	•			•	
Pre-vaccination body temperature	•	•	•			•	
Blood sampling				•		•	•
Check warnings and precautions	0	0	0			0	
Check contraindications to subsequent vaccination		•	•			•	
Pre-vaccination measurement of circumference of limb(s) at site of injection						_	
by investigator $^{\delta}$						•	
Vaccination	•	• **	•			•	
Distribution of thermometer	0						
Distribution of measuring device	0					0	
Distribution of diary cards	0	0	0			0	

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135)

					Protocol Ar	mendment 2 Fi	nal Version 02
	EPOCH 001 (PRIMARY VACCINATION)			Еросн 002			
						(BOOSTER V	ACCINATION)
Age	2 Months	4 Months	6 Months	7 Months	12 Months	15-18 Months	16-19 Months
Visit	VISIT 1	VISIT 2	VISIT 3 †	VISIT 4	ESFU	VISIT 5	VISIT 6
					CONTACT		1
					(PHONE)		
Time point	Day 0	Month 2	Month 4	Month 5	Month 10	Month 13 -16	Month 14 - 17
Sampling time point				Post-Pri		Pre-Bst	Post-Bst
Daily post-vaccination recording of solicited adverse events during the 4-day							Į į
(Day 0–3) follow-up period, recorded by the subjects' parent(s)/LAR(s) in	•	•	•			•	1
diary card							
Recording of non-serious (unsolicited) adverse events during the 31-day							1
(Day 0–30) follow-up period, recorded by the subjects' parent(s)/LAR(s) in	•	•	•			•	1
diary card							
Recording of any large injection site reactions in the eCRF by the							1
investigator*							
Return of diary cards and transcription by the investigator		•	•	•			•
Record any concomitant medication and vaccination §	•	•	•	•	•	•	•
Record any intercurrent medical conditions		•	•	•	•	•	•
Recording of serious adverse events including related to study participation		_					
or to a concurrent GSK medication/vaccine	•	•	•	•	•	•	•
Recording of NOCDs‡	•	•	•	•	•	•	•
Investigator sign-off				•			•
Analysis of the Epoch 001 #				0			į.
Analysis of the Epoch 002 #							0
Study Conclusion							•

Note: The double-line border indicates the analyses which will be performed on all data obtained up to that visit or contact.

- is used to indicate a study procedure that requires documentation in the individual eCRF
- \circ is used to indicate a study procedure that does not require documentation in the individual eCRF

Post-Pri = blood sample collected from subjects, one month after the administration of the third dose in the Epoch 001

Pre-Bst = blood sample collected from subjects, before the administration of the booster dose in the Epoch 002

Post-Bst = blood sample collected from subjects, one month after the administration of booster dose in the Epoch 002

† Visit 3 should be conducted at least 8 weeks after Visit 2 and when the subject is at least 24 weeks of age

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

^a The child can still continue in the study even if the mother does not wish to provide consent to record her Tdap vaccination history.

^β Only the Tdap vaccination history (during the pregnancy of the enrolled child) from mothers who have given consent to provide this information will be obtained and recorded in the eCRF.

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135)

Protocol Amendment 2 Final Version 02

- ⁸ For the Penta group, which receives only one vaccine at Visit 5, baseline measurement of only the limb receiving the vaccine is required ** If subject in the Penta Group received a birth dose of Hep B vaccine, no administration of *Engerix-B* is foreseen at Visit 2 (4-months of age) * Refer to Section 8.1.3.1 and 5.6.2.11 for detailed explanation on the reporting of large injection site reactions
- § Refer to Section 6.7 for details
- Refer to Section 6.8 for details
- ‡ New onset of chronic disease (NOCD) includes events such as autoimmune disorders, asthma, type I diabetes and allergies
- # Refer to Section 10.9.1 for details

6a799184c9b15497796cc43497dd0e1b0c61d882

518

06-JUL-2018

17-APR-2015

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

It is the investigator's responsibility to ensure that intervals between visits are strictly followed. The intervals between study visits are presented in Table 5.

Table 5 Intervals between study visits

Interval	Optimal length of interval ¹			
Birth→Visit 1	6-12 weeks (42-90 days) of age ²			
Visit 1 →Visit 2	49-83 days ²			
Visit 2 →Visit 3 *	56-90 days ²			
Visit 3 → Visit 4	30-48 days ² †			
Visit 3 → Phone call (ESFU contact)	180-210 days**			
Birth→ Visit 5 [^]	15-18 months of age ²			
Visit 5 → Visit 6	30-48 days ² †			

Whenever possible the investigator should arrange within this interval;

5.6. Detailed description of study procedures

5.6.1. Procedures prior to study participation

5.6.1.1. Informed consent

The signed informed consent of the subject's parent(s)/LAR(s) must be obtained before study participation.

5.6.2. Procedures during the study

5.6.2.1. Check inclusion and exclusion criteria

Check all inclusion and exclusion criteria as described in Sections 4.2 and 4.3 before enrolment.

5.6.2.2. Collect demographic data

Record demographic data such as date of birth, gender, geographic ancestry and ethnicity in the subject's eCRF.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

² Subjects may not be eligible for inclusion in one or more cohorts for analysis if they make the study visit outside this interval. For Visit 3-Visit 4 and Visit 5-Visit 6, an interval of 21-48 days will be considered for the According-to-protocol (ATP) cohort of immunogenicity. Refer to Section 10.4 for the definition of the cohorts for analysis;

^{*} Advisory Committee on Immunization Practices (ACIP) recommendation states that minimum age of last Hep B dose is 24 weeks and this last dose should be administered at least 8 weeks after the previous dose. So, Visit 3 should be conducted at least 8 weeks after Visit 2 and when the subject is at least 24 weeks of age

[†] It is preferred that subjects come in for Visit 4 and Visit 6, at least 30 days after Visits 3 and 5, respectively. If subjects return for the visit prior to 30 days, they should take home the diary card and continue to record unsolicited safety information until 30 days post-vaccination and mail/send it upon completion. Investigators will make an attempt to retrieve diary cards from subjects who have not mailed/sent them in.

[^] Visit 5 should occur after the ESFU. ESFU must occur prior to vaccination if Visit 5 coincides with the 6 months post-Visit 3 time-point

^{**} Adherence to the interval pertaining to phone contact is only indicative and will not determine a subject's eligibility for inclusion for ATP analysis. However, the interval should be respected in order to obtain safety information over the complete 6 months extended safety follow up period.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

5.6.2.3. Medical history

Obtain the subject's medical history by interview and/or review of the subject's medical records and record any pre-existing conditions or signs and/or symptoms present in a subject prior to the first study vaccination in the eCRF.

5.6.2.4. Vaccination history

Obtain the subject's vaccination history by interview and/or review of the subject's medical records and record any vaccinations given to the subject, including hepatitis B vaccines, prior to the first study vaccination in the eCRF. The Tdap vaccination history of the mother during pregnancy will also be collected and recorded in the eCRF (provided that the mother has consented to provide this information).

Note: Maternal vaccination is requested in order to be able to summarize the responses of the subjects to pertussis antigens according to whether or not the mothers received a pertussis vaccine during their pregnancy. This information will aid in understanding the effect of transplacentally transferred antibodies on the childs' immune response to vaccination.

5.6.2.5. History directed physical examination

Perform a history directed physical examination at Visit 1 (Epoch 001) and Visit 5 (Epoch 002). If the investigator determines that the subject's health on the day of vaccination temporarily precludes vaccination, the visit will be rescheduled. Collected information, including length and weight, needs to be recorded in the eCRF.

Treatment of any abnormality observed during this examination has to be performed according to local medical practice outside this study or by referral to an appropriate health care provider.

5.6.2.6. Study group and treatment number allocation

Study group and treatment number allocation will be performed as described in Section 5.2.2. The number of each administered treatment must be recorded in the eCRF.

5.6.2.7. Treatment number allocation for subsequent doses

The treatment number allocation for subsequent doses will be performed at Visits 2, 3 and 5 as described in Section 5.2.2. The number of each administered treatment must be recorded in the eCRF.

5.6.2.8. Assess pre-vaccination body temperature

The axillary, rectal, oral or tympanic body temperature of all subjects needs to be measured prior to the study vaccine administration at Visits 1, 2, 3 and 5. The preferred route for recording temperature in this study will be rectal for Epoch 001 and axillary for Epoch 002. If the subject has fever [fever is defined as temperature \geq 38.0°C /100.4°F by any route] on the day of vaccination, the vaccination visit will be rescheduled within the allowed interval for this visit (see Table 5).

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

5.6.2.9. Sampling

Refer to the Module on Biospecimen Management in the SPM for detailed instructions for the collection, handling and processing of the samples.

5.6.2.9.1. Blood sampling for immune response assessments

Blood samples will be taken during certain study visits as specified in Section 5.5 List of Study Procedures.

• A volume of approximately 5.0 mL of whole blood to provide approximately 1.7 mL of serum should be drawn from all subjects for the analysis of humoral immune response at Visits 4 and 5. At least 3.5 mL of whole blood to provide approximately 1.2 mL of serum should be drawn from all subjects for the analysis of humoral immune response at Visit 6. After centrifugation, serum samples should be kept at – 20°C/-4°F or below until shipment. Refer to the SPM for more details on sample storage conditions.

5.6.2.10. Check contraindications, warnings and precautions to vaccination

Contraindications, warnings and precautions to vaccination must be checked at the beginning of each vaccination visit. Refer to Sections 6.5 and 6.6 for more details.

5.6.2.11. Baseline measurement of limb circumference after booster vaccination at visit 5

(Amendment 2: 17 April 2015)

During Epoch 002, baseline measurement of limb circumference (arms or legs according to where the vaccine was administered) at the level of the injection site should be obtained. For the Penta group, baseline measurement is only required for the limb that will be vaccinated. Clothing should be removed so as not to interfere with the measurement of the limb circumference. For measuring upper arm circumference, the measurement will be performed while the arm is held parallel to the trunk and the elbow is flexed in front at 90° (as if the subject is carrying a tray) [Kohl, 2007]. For measuring leg circumference the child should be standing or lying flat, as appropriate, as long as the leg is straight.

5.6.2.12. Study Vaccines administration

- After completing all prerequisite procedures prior to vaccination, one dose of study vaccine/control vaccines will be administered intramuscularly (IM) (refer to Section 6.3 for detailed description of the vaccines administration procedure). If the investigator or delegate determines that the subject's health on the day of administration temporarily precludes vaccine administration, the visit will be rescheduled within the allowed interval for this visit (refer to Table 5).
- The subjects will be observed closely for at least 30 minutes following the administration of the vaccines, with appropriate medical treatment readily available in case of anaphylaxis.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

5.6.2.13. Recording of AEs, SAEs and NOCDs

(Amendment 2: 17 April 2015)

 Refer to Section 8.3 for procedures for the investigator to record AEs, SAEs and NOCDs. NOCDs include events such as autoimmune disorders, asthma, type I diabetes and allergies. Refer to Section 8.4 for guidelines on how to submit SAE reports to GSK Biologicals.

The subjects' parent(s)/LAR(s) will be instructed to contact the investigator immediately should the subjects manifest any signs or symptoms they perceive as serious.

- At each vaccination visit, diary cards will be provided to the subject's parent(s)/LAR(s). The subject's parent(s)/LAR(s) will record body (rectal for subjects in Epoch 001 and axillary for subjects in Epoch 002) temperature and any solicited local/general AEs (i.e. on the day of vaccination and during the next 3 days) or any unsolicited AEs (i.e. on the day of vaccination and during the next 30 days occurring after vaccination). The subject's parent(s)/LAR(s) will be instructed to return the completed diary card to the investigator at the next study visit.
- Collect and verify completed diary cards during discussion with the subject's parent(s)/LAR(s) on Visits 2, 3, 4 and 6.
- During Epoch 002, following the fourth dose vaccination, the parents/LAR(s) should be provided with a measurement device for recording circumference of injected limbs (arms or legs according to where vaccine was administered) at the level of the injection site on the day of vaccination and during the next three days on a diary card. The parents/LAR(s) should be instructed on how and where to perform the measurement of the circumference of the vaccinated limb. Daily measurements should be performed in the same manner preferably by the same person and at the same time of day during the 4-day follow-up (Day 0-Day 3) period.
- If the parent(s) /LAR(s) of infants observe any large injection site reaction (defined as swelling with a diameter > 50 mm, noticeable diffuse swelling or noticeable increase of limb circumference) during the 4-day follow-up (Day 0-Day 3) period they are to contact study personnel and to visit the investigator's office for evaluation as soon as possible and to bring the diary card with them.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- In addition to the diameter of the swelling and the circumference of the limb that are reported as solicited symptoms, the parent(s)/LAR(s) will record the following additional symptoms/characteristics that may be associated with large injection site swelling reactions on the diary card:
 - Type of swelling (local swelling only around the injection site, diffuse swelling not involving the elbow or knee joint, swelling involving the elbow or knee joint)
 - Induration at injection site (largest diameter)
 - Pruritis at the injection site (intensity scale provided)
 - Functional impairment (intensity scale and description provided)
- The study personnel's evaluation will be recorded in the medical chart. In case the diary card score is not in line with the medical chart score, the medical chart will indicate what is the most intense score. The largest or most intense score for a given day will be recorded in the eCRF at the level of the solicited symptoms and at the level of the large swelling report form.
- Any unreturned diary cards will be sought from the subject's parent(s)/LAR(s) through telephone call(s) or any other convenient procedure. The investigator will transcribe the collected information into the eCRF in English.

5.6.2.14. Check and record concomitant medication/vaccination and intercurrent medical conditions

Concomitant medication/vaccination must be checked and recorded in the eCRF as described in Section 6.7.

Intercurrent medical conditions must be checked and recorded in the eCRF as described in Section 6.8.

5.6.2.15. Study conclusion

The investigator will:

- review data collected to ensure accuracy and completeness at ESFU contact and Visit 6
- complete the Study Conclusion screen in the eCRF.

At study completion, post-trial commercial vaccines will not be provided to the subjects.

5.7. Biological sample handling and analysis

Please refer to the SPM for details on biospecimen management (handling, storage and shipment).

Samples will not be labelled with information that directly identifies the subject but will be coded with the identification number for the subject (subject number).

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Under the following circumstances, additional testing on the samples may be performed by GSK Biologicals outside the scope of this protocol:

- Collected samples may be used in other assays, for test improvement or development
 of analytical methods related to the study vaccines and its constituents or the disease
 under study.
- Collected samples may be used for purposes related to the quality assurance of data generated linked to the study vaccines or the disease under study, such as for maintenance of assays described in this protocol and comparison between analytical methods and/or laboratories.

Information on further investigations and their rationale can be obtained from GSK Biologicals.

Any sample testing will be done in line with the consent of the individual subject's parent(s)/LAR(s).

Refer also to the Investigator Agreement, where it is noted that the investigator cannot perform any other biological assays except those described in the protocol or its amendment(s).

If additional testing is performed, the marker priority ranking given in Section 5.7.4 may be changed.

Collected samples will be stored for a maximum of 20 years (counting from when the last subject performed the last study visit), unless local rules, regulations or guidelines require different timeframes or different procedures, which will then be in line with the subject consent. These extra requirements need to be communicated formally to and discussed and agreed with GSK Biologicals.

5.7.1. Use of specified study materials

When materials are provided by GSK Biologicals, it is MANDATORY that all clinical samples (including serum samples) be collected and stored exclusively using those materials in the appropriate manner. The use of other materials could result in the exclusion of the subject from the ATP analysis (See Section 10.4 for the definition of study cohorts/ data sets to be analysed). The investigator must ensure that his/her personnel and the laboratory(ies) under his/her supervision comply with this requirement. However, when GSK Biologicals does not provide material for collecting and storing clinical samples, appropriate materials from the investigator's site must be used. Refer to the Module on Clinical Trial Supplies in the SPM.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

5.7.2. Biological samples

Table 6 Biological samples

Sample type	Quantity*	Unit	Timepoint
Blood	5	mL	Month 5 (Post-Pri)
Blood	5	mL	Month 13-16 (Pre-Bst)
Blood	3.5	mL	Month 14-17 (Post-Bst)

^{*} Approximate quantity

Post-Pri = blood sample collected from subjects, one month after the administration of the third dose in the Epoch 001 Pre-Bst = blood sample collected from subjects, before the administration of the booster dose in the Epoch 002 Post-Bst = blood sample collected from subjects, one month after the administration of booster dose in the Epoch 002

5.7.3. Laboratory assays

(Amendment 2: 17 April 2015)

Please refer to APPENDIX A for the address of the clinical laboratories used for sample analysis.

At Visits 4, 5 and 6, blood will be collected for measurement of immune response. Total blood volume to be taken from each subject over the study period is approximately 13.5 mL (approximately 5.0 mL of whole blood to provide approximately 1.7 mL of serum at Visits 4 and 5 and at least 3.5 mL of whole blood to provide approximately 1.2 mL of serum at Visit 6). All serology will be determined in GSK Biologicals' laboratories, or in a laboratory designated by GSK, using standardized procedures with adequate controls. All serology for primary endpoints will be determined in GSK Biologicals' laboratories, or in a laboratory designated by GSK, using standardized, validated procedures with adequate controls.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

The laboratory assays for humoral immunity are presented in Table 7.

Table 7 Humoral Immunity (Antibody determination)

(Amendment 2: 17 April 2015)

System	Component	Method	Test kit/ Manufacturer	Unit	Cut-off [†]	Laboratory**
Serum	Bordetella pertussis.Pertussis Toxin Ab.lgG	ELISA	In-house*	EL.U/mL	5	GSK Biologicals§
Serum	Bordetella pertussis.Filamentous Hemaglutinin Ab.lgG	ELISA	In-house*	EL.U/mL	5	GSK Biologicals§
Serum	Bordetella pertussis.Pertactin Ab.lgG	ELISA	In-house*	EL.U/mL	5	GSK Biologicals§
Serum	Corynebacterium diphtheriae.Diphtheria Toxoid Ab.lgG	ELISA	In-house*	IU/mL	0.1	GSK Biologicals§
Serum	Clostridium tetani.Tetanus Toxoid Ab.lgG	ELISA	In-house*	IU/mL	0.1	GSK Biologicals§
Serum	Hepatitis B Virus.Surface Ab	CLIA	Centaur (Siemens Healthcare)	mIU/mL	6.2	GSK Biologicals§
Serum	Poliovirus Sabin Types 1, 2 and 3	NEUTRA	In-house*	ED ₅₀	8	GSK Biologicals§
Serum	Haemophilus influenzae type b.Polyribosyl Ribitol Phosphate Ab ‡	ELISA	In-house*	µg/mL	0.15	GSK Biologicals§

^{*}In-house refers to assays developed internally by GSK which can be performed at GSK Biologicals' laboratories or external laboratory designated by GSK

§GSK Biologicals laboratory refers to the Global Vaccines Clinical Laboratories (GVCL) in Rixensart, Belgium; Wavre, † †Due to ongoing re-validation of all assays, the cut-offs may be subject to change.

‡For anti-PRP post-dose 3, the assay is not yet qualified or validated.

Belgium and Laval, Canada.

ELISA = Enzyme-Linked Immunosorbent Assay

NEUTRA = Neutralization Assay

CLIA = ChemiLuminescence ImmunoAssay

The GSK Biologicals' clinical laboratories have established a Quality System supported by procedures. The activities of GSK Biologicals' clinical laboratories are audited regularly for quality assessment by an internal (sponsor-dependent) but laboratory-independent Quality Department.

^{**}Refer to APPENDIX A for the laboratory addresses.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

5.7.4. Biological samples evaluation

5.7.4.1. Immunological read-outs

The immunological read-outs are presented in Table 8.

Table 8 Immunological read-outs

Blood sampling ti	me point	No. of	
Type of contact and time point	Sampling time point	subjects	Components and priority rank
Visit 4 (Month 5)	Post-Pri	585 (All)	PRN, FHA, PT PRP, D, T, HBs, Poliovirus type 1,
			Poliovirus type 2, Poliovirus type 3
Visit 5 (Month 13-16)	Pre-Bst	585 (All)	PRN, FHA, PT PRP, D, T, HBs, Poliovirus type 1,
			Poliovirus type 2, Poliovirus type 3
Visit 6 (Month 14-17)	Post-Bst	585 (All)	PRN, FHA, PT, PRP, D, T

Post-Pri = blood sample collected from subjects, one month after the administration of the third dose in the Epoch 001
Pre-Bst = blood sample collected from subjects, before the administration of the booster dose in the Epoch 002
Post-Bst = blood sample collected from subjects, one month after the administration of booster dose in the Epoch 002

In case of insufficient blood sample volume to perform assays for all antibodies, the samples will be analysed according to priority ranking provided in Table 8.

5.7.5. Immunological correlates of protection

The following cut-offs are accepted as immunological correlates of protection:

- Specific antibodies against diphtheria toxoid (anti-diphtheria) and tetanus toxoid (anti-tetanus) will be measured by enzyme-linked immunosorbent assay (ELISA). The assay cut-off of ELISA is set at 0.1 International Units per ml (IU/ml), which provides a conservative estimate of the percentage of subjects deemed to be protected [Camargo, 1984; Melville-Smith, 1983].
- Antibodies to the hepatitis B surface antigen (anti-HBs) will be measured using CLIA. The cut-off of the test is set at 6.2 mIU/ml. An antibody concentration ≥10 mIU/ml defines seroprotection [CDC, 1991; WHO, 1988].
- Antibodies against poliovirus types 1, 2 and 3 will be determined by a virus micro-neutralization test adapted from the World Health Organization Guidelines for WHO/EPI Collaborative Studies on Poliomyelitis [WHO, 1993]. The lowest dilution at which serum samples will be tested is 1:8, from which a test will be considered positive. Titers will be expressed in terms of the reciprocal of the dilution resulting in 50% inhibition. Antibody titers greater than or equal to this value are considered as protective.
- Data from subjects given unconjugated Hib vaccine suggest that, in the absence of induction of immunological memory, a concentration of 0.15 μg/mL is indicative of short-term protection, with 1 μg/mL considered indicative of long-term protection [Käyhty, 1983; Anderson, 1984].
- No serological correlate of protection against pertussis has been established [Granström, 1987; Karpinsky, 1987]. Antibodies against the pertussis components

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

s PT, FHA and PRN will be measured by ELISA. The seropositivity cut-off for all three pertussis antibodies in ELISA is 5 EL.U/ml. Subjects with antibody concentration below the cut-off will be considered seronegative.

For the purpose of identification of sub-optimal responders and communication to the investigators, anti-HBs and anti-poliovirus types 1, 2 and 3 assessment of the protection level will be done for each subject on samples taken approximately 4 weeks after the 3rd dose of the primary vaccination. For PRP, D and T antigens, the assessment of the protection level will be done for each subject on samples taken approximately 4 weeks after the administration of the booster dose. In addition a listing of subjects who did not seroconvert to anti-PT, anti-FHA and anti-PRN will be provided.

The immunological assay results will be communicated to the investigator within one year following the last subject visit for the relevant time point (Visit 4 for HBV and poliovirus; Visit 6 for PRP, D, T and pertussis antigens).

The investigator is encouraged to share the immunological assay results for non-responders with the study subjects' parent(s)/LAR(s).

For the study subjects identified as non-responders, it remains the responsibility of the study investigator in charge of the subject's clinical management to determine the medical need for re-vaccination and to re-vaccinate the subjects as per local/regional practices.

6. STUDY VACCINES AND ADMINISTRATION

6.1. Description of study vaccines

All candidate vaccines to be used have been developed and manufactured by GSK Biologicals.

The Quality Control Standards and Requirements for each candidate vaccine are described in separate Quality Assurance documents (e.g. release protocols, certificate of analysis) and the required approvals have been obtained.

The vaccines are labeled and packed according to applicable regulatory requirements.

Commercial vaccines are assumed to comply with the specifications given in the manufacturer's Summary of Product Characteristics.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Table 9 Study vaccines

(Amendment 2: 17 April 2015)

Treatment name	Vaccine/ Product name	Formulation	Presentation	Volume	Number of doses
Infanrix	DTPa-HBV- IPV	DT>=30IU; TT>=40IU; PT=25μg; FHA=25μg; PRN=8μg; HBsAg=10μg; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; Aluminium=700μg Al3+	The DTPa-HBV-IPV component is presented as a turbid white suspension in a pre-filled syringe.	full	3
hexa	Hib	PRP=10µG; TT~=25µG Aluminum as salts = 0.12 mg	The lyophilized Hib component is presented as a white pellet in a glass vial; it must be reconstituted before use with the DTPa-HBV-IPV component.	volume^	
Pediarix	DTPa-HBV- IPV	DT>=30IU; TT>=40IU; PT=25µg; FHA=25µg; PRN=8µg; HBsAg=10µg; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; Aluminium=700µg Al3+	The DTPa-HBV-IPV component is presented as a turbid white suspension in a pre-filled syringe.	0.5 mL	3
ActHIB ActHIB		Hib=10μg TT, TT=24μg	White lyophilized pellet in a single dose vial, it must be reconstituted before use with sterile 0.4% saline solution	0.5 mL*	4
	NaCl	NaCI=60mM	Sterile 0.4% saline solution		
Pentacel	PT=20µg; FHA=20µg; FIM=5µg; PRN=3µg; DT=15Lf; TT=5Lf; Inactivated Poliovirus type 1 DTaP-IPV (Mahoney strain)=40DU; Inactivated		Suspension for injection (0.5-mL dose) supplied as a liquid vaccine component in a single dose vial. The lyophilized Hib component is presented as a white pellet in a separate glass vial. It must be reconstituted with the liquid DTaP-IPV component before use.	0.5 mL*	4
Engerix-B	HBV	HBsAg=10μg; Al(OH) ₃ =250μg Al3+	Suspension pre-filled syringe	0.5 mL	2 or 3**

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Treatment name	Vaccine/ Product name	Formulation	Presentation	Volume	Number of doses
Infanrix	DTPa	DT>=30IU; TT>=40IU; PT=25μg; FHA=25μg; PRN=8μg; AIPO₄=500μg Al3+	Homogeneous, turbid, white suspension in a pre-filled syringe	0.5 mL	1
Hiberix	Hib	PRP=10μG; TT~=25μG	The lyophilized Hib component is presented as a white pellet in a glass vial; it must be reconstituted before use with sterile 0.9% saline solution.		1
	NaCl	NaCI=150mM	Sterile 0.9% saline solution		
Prevnar13	Prevenar 13	PS1=2.2µg CRM197; PS3=2.2µg CRM197; PS4=2.2µg CRM197; PS6A=2.2µg CRM197; PS5=2.2µg CRM197; PS6B=4.4µg CRM197; PS7F=2.2µg CRM197; PS9V=2.2µg CRM197; PS14=2.2µg CRM197; PS18C=2.2µg CRM197; PS19A=2.2µg CRM197; PS19F=2.2µg CRM197; PS19F=2.2µg CRM197; PS23F=2.2µg CRM197; AIPO ₄ =125µg AI3+	Suspension for injection in a pre-filled syringe.	0.5 mL	3
Rotarix	HRV CaCO ₃	HRV RIX4144=10 ⁶ · O CCID ₅₀ CaCO ₃ =60µg	Lyophilized vaccine in a monodose glass vial to be reconstituted with the calcium carbonate buffer diluent) Diluent (calcium carbonate liquid buffer)	1.0 mL*	2
			supplied separately in prefilled syringe		

CCID₅₀ = median Cell Culture Infective Dose; DMEM = Dulbecco's Modified Eagle Medium

6.2. Storage and handling of study vaccines

The study vaccines must be stored at the respective label storage temperature conditions in a safe and locked place. Access to the storage space should be limited to authorized study personnel. The storage conditions will be assessed during pre-study activities under the responsibility of the sponsor study contact. The storage temperature should be continuously monitored with calibrated (if not validated) temperature monitoring device(s) and recorded. Refer to the Module on Clinical Trial Supplies in the SPM for more details on storage of the study vaccines.

Temperature excursions must be reported in degree Celsius.

Any temperature excursion outside the range of 0.0 to +8.0°C (for +2 to +8°C/+36 to +46°F label storage condition) impacting investigational medicinal products (IMPs) must

^{*} After reconstitution

^{**} Subjects in the Penta Group who receive a birth dose of hepatitis B vaccine should not receive Engerix-B at the Month 4 visit (Visit 2)

[^] Full volume after reconstitution (approximately 0.5 mL) to be administered

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

be reported in the appropriate (electronic) temperature excursion decision form ([e]TDF). The impacted IMPs must not be used and must be stored in quarantine at label temperature conditions until usage approval has been obtained from the sponsor.

In case of temperature excursion below $\pm 2.0^{\circ}$ C down to 0.0° C impacting IMP(s) there is no need to report in (e)TDF, but adequate actions must be taken to restore the ± 2 to $\pm 8^{\circ}$ C/ ± 36 to $\pm 46^{\circ}$ F label storage temperature conditions. The impacted IMP(s) may still be administered, but the site should avoid re-occurrence of such temperature excursion. Refer to the Module on Clinical Trial Supplies in the SPM for more details on actions to take.

Refer to the Module on Clinical Trial Supplies in the SPM for details and instructions on the temperature excursion reporting and usage decision process, packaging and accountability of the study vaccines.

6.3. Dosage and administration of study vaccines

The injectable vaccines must be administered intramuscularly, at a 90-degree angle into the anterolateral side of the thigh [CDC, 2002] on the side stated in Table 10. The buttock should not be used.

In order to ensure proper intramuscular injection of the vaccines, a needle of at least 1 inch (2.54 cm) length, 25 gauge will be used [Diggle, 2006; Zuckerman, 2000].

For reconstitution of *Infanrix hexa* vaccine, an appropriate needle should be attached to the prefilled syringe containing the DTPa-HBV-IPV liquid vaccine and inserted into the vial containing the lyophilized Hib vaccine. The entire contents of the syringe should be transferred to the vial. With needle still inserted, the vial should be vigorously shaken. After reconstitution, the full volume of the vial (approximately 0.5 mL) is then withdrawn using the same syringe. A new needle should then be affixed to the syringe for administration of the vaccine.

NOTE: After reconstitution, *Infanrix hexa* should be injected immediately. However the vaccine may be kept for up to 8 hours at room temperature (21°C).

The vaccinees will be observed closely for at least 30 minutes following the administration of vaccines, with appropriate medical treatment readily available in case of a rare anaphylactic reaction.

Rotarix must be exclusively administered orally. DO NOT INJECT.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Table 10 Dosage and administration

Visit	Study Group	Treatment name	Route ¹	Site ²	Side ³
		Epoch 001			
1, 2, 3	Hexa Group	Infanrix hexa	IM	Т	R
		(lot A, lot B or lot C)			
1, 2, 3		Prevnar13	IM	T	LoL
1, 2		Rotarix	0	-	-
1, 2, 3	Pedia Group	Pediarix	IM	T	R
1, 2, 3		ActHIB	IM	Τ	UpL
1, 2, 3		Prevnar13	IM	Т	LoL
1, 2		Rotarix	0	,	=
1, 2, 3	Penta Group	Pentacel	IM	Τ	R
1, 2, 3		Engerix-B [†]	IM	Τ	UpL
1, 2, 3		Prevnar13	IM	T	LoL
1, 2		Rotarix	0	-	-
		Epoch 002*			
5	Hexa Group	Infanrix	IM	Τ	R
		Hiberix	IM	T	Ĺ
5	Pedia Group	Infanrix	IM	T	R
		ActHIB	IM	Τ	L
5	Penta Group	Pentacel	IM	T	R

¹Oral (O), Intramuscular (IM); ²Thigh (T), ³Left (L), Right (R), Upper Left (UpL), Lower Left (LoL)

6.4. Replacement of unusable vaccine doses

In addition to the vaccine doses provided for the planned number of subjects (including over-randomization when applicable), at least 60% additional vaccine doses will be supplied to replace those that are unusable.

6.5. Contraindications to subsequent vaccination

6.5.1. Absolute contraindications:

The following events constitute absolute contraindications to further administration of the study and co-administration vaccines. If any of these events occur during the study, the subject must not receive additional doses of vaccine but may continue other study procedures at the discretion of the investigator.

- Anaphylaxis following the administration of vaccine(s).
- Other hypersensitivity reaction to any component of the vaccine(s) and any excipients in the formulation, including yeast.
- Hypersensitivity to latex.

Note: Vaccination can be performed in the opposite side in case of medical indication preventing vaccination in the side stated in the table, as judged by the investigator

[†]Subjects in the Penta Group who receive a birth dose of hepatitis B vaccine should not receive *Engerix-B* at the Month 4 visit (Visit 2).

^{*}Toddlers (12 Months through 2 Years): For toddlers, the vastus lateralis muscle in the anterolateral thigh is preferred. The needle should be at least 1-inch long. The deltoid muscle can be used if the muscle mass is adequate.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- Contraindication for pertussis-containing vaccines:
 - Encephalopathy of unknown etiology, defined as an acute, severe central
 nervous system disorder, occurring within 7 days following previous vaccination
 with pertussis-containing vaccine and generally consisting of major alterations
 in consciousness, unresponsiveness, generalised or focal seizures that persist
 more than a few hours, with failure to recover within 24 hours.
 - Individuals with progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy should not receive a pertussis-containing vaccine until a treatment regimen has been established and the condition has stabilized.
- Contraindications to *Rotarix*:
 - Subjects with uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract that would predispose for intussusceptions.
 - History of intussusception or history of SCID.

6.5.2. Temporary contraindications:

The following events constitute contraindications to administration of the study and coadministration vaccines at that point in time; if any of these events occur at the time scheduled for vaccination, the subject may be vaccinated at a later date, within the time window specified in the protocol, or withdrawn at the discretion of the investigator.

- Acute disease and/or fever at the time of vaccination.
 - Fever is defined as temperature ≥ 38.0°C/100.4°F by any route. The preferred route for recording temperature in this study will be rectal for Epoch 001 and axillary for Epoch 002.
 - Subjects with a minor illness (such as mild upper respiratory infection) without fever can be administered all vaccines
- Acute diarrhea or vomiting is a contra-indication to the administration of *Rotarix* at that point in time.

6.6. Warnings and precautions

The information below presents, in addition to the contraindications in Section 6.5, warnings and precautions to administration of *Infanrix hexa*.

- As with other vaccines, administration of *Infanrix hexa* should be postponed in subjects suffering from acute severe febrile illness. The presence of a minor infection is not a contra-indication.
- Vaccination should be preceded by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable events) and a clinical examination.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- If any of the following events are known to have occurred in temporal relation to receipt of pertussis-containing vaccine, the decision to give further doses of pertussis-containing vaccines should be carefully considered:
 - Temperature of $\geq 40.0^{\circ}$ C within 48 hours, not due to another identifiable cause.
 - Collapse or shock-like state (hypotonic-hyporesponsiveness episode) within 48 hours of vaccination.
 - Persistent, inconsolable crying lasting ≥ 3 hours, occurring within 48 hours of vaccination.
 - Convulsions with or without fever, occurring within 3 days of vaccination.
- As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.
- Infanrix hexa should be administered with caution to subjects with thrombocytopenia
 or a bleeding disorder since bleeding may occur following an intramuscular
 administration to these subjects.
- *Infanrix hexa* should under no circumstances be administered intravascularly or intradermally.
- A protective immune response may not be elicited in all vaccinees.
- A history of febrile convulsions, a family history of convulsions or Sudden Infant Death Syndrome (SIDS) do not constitute contraindications for the use of *Infanrix hexa*. Vaccinees with a history of febrile convulsions should be closely followed up as such adverse events may occur within 2 to 3 days post vaccination.
- Since the Hib capsular polysaccharide antigen is excreted in the urine a positive urine test can be observed within 1-2 weeks following vaccination. Other tests should be performed in order to confirm Hib infection during this period.
- Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from faints.

Refer to the approved product label/package insert for warnings and precautions for the use of *Pediarix*, *ActHIB*, *Pentacel*, *Engerix-B*, *Prevnar13*, *Rotarix*, *Hiberix* and *Infanrix* vaccines.

6.7. Concomitant medication/product and concomitant vaccination

At each study visit/contact, the investigator should question the subject's parent(s)/LAR(s) about any medication/product taken and vaccination received by the subject.

63

534

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

6.7.1. Recording of concomitant medications/products and concomitant vaccination

The following concomitant medications/products/vaccines must be recorded in the eCRF if administered during the indicated recording period:

- All concomitant medications/products, except vitamins and dietary supplements, administered within 30 days following each dose of study vaccine.
- Any concomitant vaccination administered since birth and ending 30 days after the booster dose (Visit 6). Vaccinations listed prior to the first dose of study vaccine are to be recorded as vaccination history. The fourth dose of *Prevnar 13* will be recorded as concomitant vaccination.
- Prophylactic medication (i.e. medication administered in the absence of ANY symptom and in anticipation of a reaction to the vaccination).
 - E.g. an anti-pyretic is considered to be prophylactic when it is given in the absence of fever and any other symptom, to prevent fever from occurring [fever is defined as temperature $\geq 38.0^{\circ}\text{C}/100.4^{\circ}\text{F}$ by any route].
- Any concomitant medications/products/vaccines listed in Section 6.7.2.
- Any concomitant medication/product/vaccine relevant to a SAE* or administered at any time during the study period for the treatment of a SAE*.
 - * Refer to those SAEs that are required to be reported per protocol.

6.7.2. Concomitant medications/products/vaccines that may lead to the elimination of a subject from ATP analyses

The use of the following concomitant medications/products/vaccines will not require withdrawal of the subject from the study but may determine a subject's evaluability in the ATP analysis. See Section 10.4 for study cohorts/ data sets to be analysed.

- Any investigational or non-registered product (drug or vaccine) other than the study vaccines used during the study period (starting from Visit 1 and ending at Visit 6).
- Immunosuppressants or other immune-modifying drugs administered chronically (i.e. more than 14 days) during the study period until the final blood sample (Visit 6).
 For corticosteroids, this will mean prednisone ≥ 0.5 mg/kg/day, or equivalent.
 Inhaled and topical steroids are allowed.
- A vaccine not foreseen by the study protocol administered during the period starting from 30 days before the first vaccination until Post-Pri blood sampling i.e. approximately 30 days after Dose 3 (Epoch 001) and from 30 days before Pre-Bst until Post-Bst blood sampling i.e. approximately 30 days after Dose 4 (Epoch 002). Thus, routine administration(s) of measles-mumps-rubella, varicella and pneumococcal vaccines are allowed from 30 days after the last dose of primary vaccination (after Post-Pri blood sampling) until 30 days before the booster dose and from 30 days after the booster dose (after Post-Bst blood sampling), as well as according to the recommended immunization schedule in the US.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- Exceptions:
 - Inactivated influenza vaccine and hepatitis A vaccines are allowed throughout the study.

In case an emergency mass vaccination for an unforeseen public health threat (e.g.: a pandemic) is organized by the public health authorities, outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine provided it is licensed and used according to its SPC or PI and according to the local governmental recommendations and provided a written approval of the Sponsor is obtained.

• Immunoglobulins and/or any blood products administered during the study period until the final blood sample (Visit 6).

6.8. Intercurrent medical conditions that may lead to elimination of a subject from ATP analyses

At each study visit subsequent to the first vaccination visit, it must be verified if the subject has experienced or is experiencing any intercurrent medical condition. If it is the case, the condition(s) must be recorded in the eCRF.

- Subjects may be eliminated from the ATP cohort for immunogenicity if they incur a condition that has the capability of altering their immune response or are confirmed to have an immunodeficiency condition.
- Subjects will be eliminated from the ATP cohort for immunogenicity if they
 experience intercurrent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B
 and/or Hib prior to the post-dose 3 blood draw and diphtheria, tetanus, pertussis
 and/or Hib post-dose 4 blood draw.

7. HEALTH ECONOMICS

Not applicable.

8. SAFETY

The investigator or site staff is/are responsible for the detection, documentation and reporting of events meeting the criteria and definition of an adverse event (AE) or serious adverse event (SAE) as provided in this protocol.

Each subject's parent(s)/LAR(s) will be instructed to contact the investigator immediately should the subject manifest any signs or symptoms they perceive as serious.

8.1. Safety definitions

8.1.1. Definition of an adverse event

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse.

Examples of an AE include:

- Significant or unexpected worsening or exacerbation of the condition/indication under study.
- New conditions detected or diagnosed after investigational vaccines administration even though they may have been present prior to the start of the study.
- Signs, symptoms, or the clinical sequelae of a suspected interaction.
- Signs, symptoms, or the clinical sequelae of a suspected overdose of either investigational vaccines or a concurrent medication (overdose per se should not be reported as an AE/SAE).
- Signs, symptoms temporally associated with vaccine administration.
- Significant failure of expected pharmacological or biological action.
- Pre- or post-treatment events that occur as a result of protocol-mandated procedures (i.e. invasive procedures, modification of subject's previous therapeutic regimen).

AEs to be recorded as endpoints (solicited AEs) are described in Section 8.1.3. All other AEs will be recorded as UNSOLICITED AEs.

Examples of an AE DO NOT include:

- Medical or surgical procedures (e.g. endoscopy, appendectomy); the condition that leads to the procedure is an AE/SAE.
- Situations where an untoward medical occurrence did not occur (e.g. social and/or convenience admission to a hospital, admission for routine examination).
- Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen.
- Pre-existing conditions or signs and/or symptoms present in a subject prior to the first study vaccination. These events will be recorded in the medical history section of the eCRF.

8.1.2. Definition of a serious adverse event

A serious adverse event is any untoward medical occurrence that:

- Results in death,
- b. Is life-threatening,

Note: The term 'life-threatening' in the definition of 'serious' refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, had it been more severe.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

c. Requires hospitalisation or prolongation of existing hospitalisation,

Note: In general, hospitalisation signifies that the subject has been admitted at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician's office or in an out-patient setting. Complications that occur during hospitalisation are also considered AEs. If a complication prolongs hospitalisation or fulfils any other serious criteria, the event will also be considered serious. When in doubt as to whether 'hospitalisation' occurred or was necessary, the AE should be considered serious.

Hospitalisation for elective treatment of a pre-existing condition (known or diagnosed prior to informed consent signature) that did not worsen from baseline is NOT considered an AE.

d. Results in disability/incapacity,

Note: The term disability means a substantial disruption of a person's ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza like illness, and accidental trauma (e.g. sprained ankle) which may interfere or prevent everyday life functions but do not constitute a substantial disruption.

Medical or scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation.

8.1.3. Solicited adverse events

A 4-day follow-up (Day 0-Day 3) of solicited local (at each injection site) and general AEs will be performed after administration of the vaccine. Data concerning the following AEs will be solicited using diary cards provided by the sponsor.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

8.1.3.1. Solicited local (injection-site) adverse events

The following local (injection-site) AEs will be solicited (Table 11):

Table 11 Solicited local adverse events

Pain at injection site
Redness at injection site
Swelling at injection site
Post-dose 4 measurements of
circumference of limbs (arm or leg
according to where vaccine was
administered)

N.B. If parent(s) /LAR(s) of infants observe any large injection site reaction (defined as swelling with a diameter > 50 mm, noticeable diffuse swelling or noticeable increase of limb circumference) after the booster dose at Visit 5, they are to contact study personnel and to visit the investigator's office for evaluation as soon as possible and bring the diary card with them. The investigator will record detailed information describing the AE on a specific large injection site reaction form in the eCRF. In addition to the diameter of the swelling and the circumference of the limb that are reported as solicited symptoms the parent(s)/LAR(s) will need to record additional symptoms/characteristics as mentioned in Section 5.6.2.13.

Note: local AEs will not be solicited for co-administered vaccines like *Prevnar 13*.

8.1.3.2. Solicited general adverse events

The following general AEs will be solicited (Table 12):

Table 12 Solicited general adverse events

Drowsiness				
Fever				
Irritability/Fussiness				
Loss of appetite				

Note: Temperature will be recorded in the evening. Should additional temperature measurements be performed at other times of day, the highest temperature will be recorded. Fever is defined as temperature $\geq 38.0^{\circ}\text{C}/100.4^{\circ}\text{F}$ by any route. The preferred route for recording temperature in this study will be rectal for Epoch 001 and axillary for Epoch 002.

8.1.4. Clinical laboratory parameters and other abnormal assessments qualifying as adverse events or serious adverse events

In absence of diagnosis, abnormal laboratory findings (e.g. clinical chemistry, haematology, urinalysis) or other abnormal assessments (e.g. vital signs etc.) that are judged by the investigator to be clinically significant will be recorded as AE or SAE if they meet the definition of an AE or SAE (refer to Sections 8.1.1 and 8.1.2). Clinically significant abnormal laboratory findings or other abnormal assessments that are present at

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

baseline and significantly worsen following the start of the study will also be reported as AEs or SAEs. However, clinically significant abnormal laboratory findings or other abnormal assessments that are associated with the disease being studied, unless judged by the investigator as more severe than expected for the subject's condition, or that are present or detected at the start of the study and do not worsen, will not be reported as AEs or SAEs.

The investigator will exercise his or her medical and scientific judgement in deciding whether an abnormal laboratory finding or other abnormal assessment is clinically significant.

8.1.5. Adverse events of specific interest

Adverse events of specific interest (i.e. NOCDs such as autoimmune disorders, asthma, type I diabetes and allergies) will be recorded from Day 0 up to 6 months after the last primary vaccination (Epoch 001) and from booster dose up to one month after booster vaccination (Epoch 002). NOCDs will be reported as either AEs or SAEs, as appropriate in the eCRF.

8.2. Events or outcomes not qualifying as adverse events or serious adverse events

Not applicable.

8.3. Detecting and recording adverse events and serious adverse events

8.3.1. Time period for detecting and recording adverse events and serious adverse events

All AEs starting within 30 days following administration of each dose of study vaccine/comparator must be recorded into the appropriate section of the eCRF, irrespective of intensity or whether or not they are considered vaccination-related.

The time period for collecting and recording SAEs and AEs of specific interest will begin at the first receipt of study vaccine/comparator and will end 180 days following administration of the last dose of study vaccine/comparator of the primary vaccination course for each subject and 30 days following administration of the booster dose. See Section 8.4 for instructions on reporting of SAEs.

All AEs/SAEs leading to withdrawal from the study will be collected and recorded from the time of the first receipt of study vaccine/comparator.

In addition to the above-mentioned reporting requirements and in order to fulfil international reporting obligations, SAEs that are related to study participation (i.e. protocol-mandated procedures, invasive tests, a change from existing therapy) or are related to a concurrent GSK medication/vaccine will be collected and recorded from the time the subject consents to participate in the study until she/he is discharged from the study.

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Note: With the exception of AEs/SAEs leading to withdrawal, study participation and concurrent GSK medications or vaccines, there is no reporting of SAEs from the time of the Epoch 1 ESFU phone contact and administration of dose 4 (approximately three months).

An overview of the protocol-required reporting periods for AEs and SAEs is given in Table 13.

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Table 13 Reporting periods for adverse events and serious adverse events

Study activity	C.O	V1	4-days post vac	31-days post- vac	V2	4-days post vac	31-days post-vac	V3	4-days post- vac	31-days post-vac	Phone call 6 months post-V3	V5	4-days post- vac	31-days post-vac
Age of subject		2 months			4 months			6 months		7 months	12 months	15-18 months		16-19 months
Solicited local and general AEs														
Large injection site reactions														
Unsolicited AEs														
AEs/SAEs leading to withdrawal from the study														
NOCDs														
SAEs														
SAEs related to study participation or concurrent GSK medication/vaccine														

NOCD: New Onset of Chronic Diseases; C.O. consent obtained; V. Visit; Post-V. Post-Visit; vac. vaccination

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

8.3.2. Post-Study adverse events and serious adverse events

A post-study AE/SAE is defined as any event that occurs outside of the AE/SAE reporting period defined in Table 13. Investigators are not obligated to actively seek AEs or SAEs in former study participants. However, if the investigator learns of any SAE at any time after a subject has been discharged from the study, and he/she considers the event reasonably related to the investigational vaccine/product, the investigator will promptly notify the Study Contact for Reporting SAEs.

8.3.3. Evaluation of adverse events and serious adverse events

8.3.3.1. Active questioning to detect adverse events and serious adverse events

As a consistent method of collecting AEs, the subject's parent(s)/LAR(s) should be asked a non-leading question such as:

'Has your child acted differently or felt different in any way since receiving the vaccine or since the last visit?'

When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (e.g. hospital progress notes, laboratory and diagnostics reports) relative to the event. The investigator will then record all relevant information regarding an AE/SAE in the eCRF. The investigator is not allowed to send photocopies of the subject's medical records to GSK Biologicals instead of appropriately completing the eCRF. However, there may be instances when copies of medical records for certain cases are requested by GSK Biologicals. In this instance, all subject identifiers will be blinded on the copies of the medical records prior to submission to GSK Biologicals.

The investigator will attempt to establish a diagnosis pertaining to the event based on signs, symptoms, and/or other clinical information. In such cases, the diagnosis should be documented as the AE/SAE and not the individual signs/symptoms.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

8.3.3.2. Assessment of adverse events

8.3.3.2.1. Assessment of intensity

The intensity of the following solicited AEs will be assessed as described:

Table 14 Intensity scales for solicited symptoms in infants/toddlers

	Infant/Toddler (15–24 months)					
Adverse Event	Intensity grade	Parameter				
Pain at injection site	0	None				
	1	Mild: Minor reaction to touch				
	2	Moderate: Cries/protests on touch				
	3	Severe: Cries when limb is moved/spontaneously painful				
Redness at injection	on site	Record greatest surface diameter in mm				
Swelling at injection		Record greatest surface diameter in mm				
Increase in limb circumference		Record the limb circumference at the level of the injection site				
or leg according to where						
administered)					
Fever*		Record temperature in °C/°F				
Irritability/Fussiness	0	Behaviour as usual				
	1	Mild: Crying more than usual/no effect on normal activity				
	2	Moderate: Crying more than usual/interferes with normal activity				
	3	Severe: Crying that cannot be comforted/prevents normal				
		activity				
Drowsiness	0	Behaviour as usual				
	1	Mild: Drowsiness easily tolerated				
	2	Moderate: Drowsiness that interferes with normal activity				
	3	Severe: Drowsiness that prevents normal activity				
Loss of appetite	0	Appetite as usual				
	1	Mild: Eating less than usual/no effect on normal activity				
	2	Moderate: Eating less than usual/interferes with normal activity				
	3	Severe: Not eating at all				

^{*} Fever is defined as temperature ≥38.0°C /100.4°F by any route. The preferred route for recording temperature in this study will be rectal for Epoch 001 and axillary for Epoch 002.

The maximum intensity of local injection site redness/swelling/fever will be scored at GSK Biologicals as follows:

 $\begin{array}{ccc} 0 & : & Absent \\ 1 & : & \leq 5 \ mm \end{array}$

2 : $> 5 \text{ mm and} \le 20 \text{ mm}$

3 : > 20 mm

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

The maximum intensity of fever will be scored at GSK Biologicals as follows:

0	=	<100.4°F	<38.0°C
1	=	≥100.4°F to ≤102.2°F	≥38.0°C to ≤39.0°C
2	=	>102.2°F to ≤104.0°F	>39.0°C to ≤40.0°C
3	=	> 104.0°F	> 40.0°C

Following each vaccination (3 doses during the primary vaccination course and one booster dose) during the 4 days after the vaccine dose has been administered (day of vaccination and subsequent 3 days), the child's temperature will be screened each evening, at bedtime, for signs of fever by means of the rectal/axillary thermometer. Children < 15 months will have their temperature taken rectally and children \geq 15 months will have their temperature taken by the axillary route. Rectal/axillary temperatures will be recorded on the diary card. Temperature measured by any route will be presented in 0.5°C increments starting at 38°C/100.4°F.

Prior to analysis, the increase in limb circumference of each limb as compared to the baseline pre-vaccination measurement will be scored for each subject at GSK Biologicals' as follows:

Grade $0 = \text{Increase in limb circumference } \le 5 \text{ mm}$

1 = Increase in limb circumference >5 mm but ≤20 mm

2 = Increase in limb circumference >20 mm but ≤40 mm

3 = Increase in limb circumference >40 mm

The investigator will assess the maximum intensity that occurred over the duration of the event for all unsolicited AEs (including SAEs) recorded during the study. The assessment will be based on the investigator's clinical judgement.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

For unsolicited symptoms and adverse events associated with large injection site reactions (e.g. pruritus, induration and functional impairment, the intensity should be assigned to one of the following categories:

1 (mild)	= An AE which is easily tolerated by the subject, causing minimal
	discomfort and not interfering with everyday activities

2 (moderate) = An AE which is sufficiently discomforting to interfere with normal everyday activities.

3 (severe) = An AE which prevents normal, everyday activities. In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care center and would cause the parent(s)/LAR(s) to seek medical advice.

An AE that is assessed as Grade 3 (severe) should not be confused with a SAE. Grade 3 is a category used for rating the intensity of an event; and both AEs and SAEs can be assessed as Grade 3. An event is defined as 'serious' when it meets one of the predefined outcomes as described in Section 8.1.2.

8.3.3.2.2. Assessment of causality

The investigator is obligated to assess the relationship between investigational vaccines and the occurrence of each AE/SAE. The investigator will use clinical judgement to determine the relationship. Alternative plausible causes, such as natural history of the underlying diseases, concomitant therapy, other risk factors, and the temporal relationship of the event to the investigational vaccines will be considered and investigated. The investigator will also consult the IB and/or PI for marketed products to determine his/her assessment. Investigational vaccines include vaccines such as *Infanrix hexa*, *Pediarix*, *Pentacel*, *ActHIB*, *Engerix-B*, *Rotarix*, *Prevnar 13*, *Infanrix* and *Hiberix*.

There may be situations when a SAE has occurred and the investigator has minimal information to include in the initial report to GSK Biologicals. However, it is very important that the investigator always makes an assessment of causality for every event prior to submission of the SAE report to GSK Biologicals. The investigator may change his/her opinion of causality in light of follow-up information and update the SAE information accordingly. The causality assessment is one of the criteria used when determining regulatory reporting requirements.

In case of concomitant administration of multiple vaccines, it may not be possible to determine the causal relationship of general AEs to the individual vaccines administered. The investigator should, therefore, assess whether the AE could be causally related to vaccination rather than to the individual vaccines.

All solicited local (injection site) reactions will be considered causally related to vaccination. Causality of all other AEs should be assessed by the investigator using the following question:

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Is there a reasonable possibility that the AE may have been caused by the investigational vaccines?

YES : There is a reasonable possibility that the vaccines contributed to the

AE.

NO : There is no reasonable possibility that the AE is causally related to

the administration of the study vaccine(s). There are other, more likely causes and administration of the study vaccine(s) is not

suspected to have contributed to the AE.

If an event meets the criteria to be determined as 'serious' (see Section 8.1.2), additional examinations/tests will be performed by the investigator in order to determine ALL possible contributing factors for each SAE.

Possible contributing factors include:

- Medical history.
- Other medication.
- Protocol required procedure.
- Other procedure not required by the protocol.
- Lack of efficacy of the vaccines, if applicable.
- Erroneous administration.
- Other cause (specify).

8.3.3.3. Assessment of outcomes

The investigator will assess the outcome of all unsolicited AEs (including SAEs) recorded during the study as:

- Recovered/resolved.
- Recovering/resolving.
- Not recovered/not resolved.
- Recovered with sequelae/resolved with sequelae.
- Fatal (SAEs only).

8.3.3.4. Medically attended visits

For each solicited and unsolicited symptom the subject experiences, the subject's parent(s)/LAR(s) will be asked if the subject received medical attention defined as hospitalisation, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. This information will be recorded in the eCRF.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

8.4. Reporting of serious adverse events and other events

8.4.1. Prompt reporting of serious adverse events and other events to GSK Biologicals


SAEs that occur in the time period defined in Section 8.3 will be reported promptly to GSK within the timeframes described in Table 15, once the investigator determines that the event meets the protocol definition of a SAE.

Table 15 Timeframes for submitting serious adverse event and other events reports to GSK Biologicals

Type of Event	ı	nitial Reports	Follow-up of Relevant Information on a Previous Report		
	Timeframe	Documents	Timeframe	Documents	
SAEs	24 hours*	electronic SAE report	24 hours*	electronic SAE report	

^{*} Timeframe allowed after receipt or awareness of the information.

8.4.2. Contact information for reporting serious adverse events and other events to GSK Biologicals



8.4.3. Completion and transmission of SAE reports to GSK Biologicals

Once an investigator becomes aware that a SAE has occurred in a study subject, the investigator (or designate) must complete the information in the electronic SAE report WITHIN 24 HOURS. The SAE report will always be completed as thoroughly as possible with all available details of the event. Even if the investigator does not have all information regarding a SAE, the report should still be completed within 24 hours. Once additional relevant information is received, the report should be updated WITHIN 24 HOURS.

The investigator will always provide an assessment of causality at the time of the initial report.

8.4.3.1. Back-up system in case the electronic SAE reporting system does not work

If the electronic SAE reporting system does not work, the investigator (or designate) must complete, then date and sign a paper SAE report and fax it to the GSK Biologicals Clinical Safety and Pharmacovigilance department within 24 hours. Please refer to the Study Procedure Manual for the dedicated US Fax Machine number.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

This back-up system should only be used if the electronic SAE reporting system is not working and NOT if the system is slow. As soon as the electronic SAE reporting system is working again, the investigator (or designate) must complete the electronic SAE report within 24 hours. The final valid information for regulatory reporting will be the information reported through the electronic SAE reporting system.

8.4.4. Updating of SAE information after freezing of the subject's eCRF

When additional SAE information is received after freezing of the subject's eCRF, new or updated information should be recorded on a paper report, with all changes signed and dated by the investigator. The updated report should be faxed to the GSK Biologicals Clinical Safety and Pharmacovigilance department or to the Study Contact for Reporting SAEs (refer to the Sponsor Information Sheet) within the designated reporting time frames specified in Table 15.

8.4.5. Regulatory reporting requirements for serious adverse events

The investigator will promptly report all SAEs to GSK in accordance with the procedures detailed in Section 8.4.1. GSK Biologicals has a legal responsibility to promptly notify, as appropriate, both the local regulatory authority and other regulatory agencies about the safety of a product under clinical investigation. Prompt notification of SAEs by the investigator to the Study Contact for Reporting SAEs is essential so that legal obligations and ethical responsibilities towards the safety of other subjects are met.

Investigator safety reports are prepared according to the current GSK policy and are forwarded to investigators as necessary. An investigator safety report is prepared for a SAE(s) that is both attributable to the investigational vaccine/product and unexpected. The purpose of the report is to fulfil specific regulatory and GCP requirements, regarding the product under investigation.

8.5. Follow-up of adverse events and serious adverse events

8.5.1. Follow-up during the study

After the initial AE/SAE report, the investigator is required to proactively follow each subject and provide additional relevant information on the subject's condition to GSK Biologicals (within 24 hours for SAEs; refer to Table 15).

All SAEs documented at a previous visit/contact and designated as not recovered/not resolved or recovering/resolving will be reviewed at subsequent visits/contacts until the end of the study.

All AEs documented at a previous visit/contact and designated as not recovered/not resolved or recovering/resolving will be reviewed at subsequent visits/contacts until 30 days after the last vaccination.

New onset of chronic diseases (such as autoimmune disorders, asthma, type I diabetes and allergies) documented at a previous visit/contact and designated as not recovered/not

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

resolved or recovering/resolving will be reviewed at subsequent visits/contacts until end of the study.

8.5.2. Follow-up after the subject is discharged from the study

The investigator will follow subjects:

- with SAEs, or subjects withdrawn from the study as a result of an AE, until the event has resolved, subsided, stabilized, disappeared, or until the event is otherwise explained, or the subject is lost to follow-up.
- with other non-serious AEs of specific interest, i.e. NOCDs, such as autoimmune disorders, asthma, type I diabetes and allergies, until the end of the study period or they are lost to follow-up.

If the investigator receives additional relevant information on a previously reported SAE, he/she will provide this information to GSK Biologicals using a paper SAE form.

GSK Biologicals may request that the investigator performs or arranges the conduct of additional clinical examinations/tests and/or evaluations to elucidate as fully as possible the nature and/or causality of the AE or SAE. The investigator is obliged to assist. If a subject dies during participation in the study or during a recognized follow-up period, GSK Biologicals will be provided with any available post-mortem findings, including histopathology.

8.6. Treatment of adverse events

Treatment of any AE is at the sole discretion of the investigator and according to current good medical practice. Any medication administered for the treatment of an AE should be recorded in the subject's eCRF (refer to Section 6.7).

8.7. Subject card

Study subjects' parent(s)/LAR(s) must be provided with the address and telephone number of the main contact for information about the clinical study.

The investigator (or designate) must therefore provide a "subject card" to each subject's parent(s)/LAR(s). In an emergency situation this card serves to inform the responsible attending physician that the subject is in a clinical study and that relevant information may be obtained by contacting the investigator.

Subjects' parent(s)/LAR(s) must be instructed to keep subject cards in their possession at all times.

9. SUBJECT COMPLETION AND WITHDRAWAL

9.1. Subject completion

A subject who returns for the concluding visit/is available for the concluding contact foreseen in the protocol is considered to have completed the study.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

9.2. Subject withdrawal

Withdrawals will not be replaced.

9.2.1. Subject withdrawal from the study

From an analysis perspective, a 'withdrawal' from the study refers to any subject who did not come back for the concluding visit/was not available for the concluding contact foreseen in the protocol.

All data collected until the date of withdrawal/last contact of the subject will be used for the analysis.

A subject is considered a 'withdrawal' from the study when no study procedure has occurred, no follow-up has been performed and no further information has been collected for this subject from the date of withdrawal/last contact.

Investigators will make an attempt to contact those subjects who do not return for scheduled visits or follow-up.

Information relative to the withdrawal will be documented in the eCRF. The investigator will document whether the decision to withdraw a subject from the study was made by the subject's parent(s) or LAR(s), or by the investigator, as well as which of the following possible reasons was responsible for withdrawal:

- Serious adverse event.
- Non-serious adverse event.
- Protocol violation (specify).
- Consent withdrawal, not due to an adverse event*.
- Moved from the study area.
- Lost to follow-up.
- Other (specify).

*In case a subject is withdrawn from the study because the subject's parent(s) has withdrawn consent, the investigator will document the reason for withdrawal of consent, if specified by the subject, in the eCRF.

Subjects who are withdrawn from the study because of SAEs/AEs must be clearly distinguished from subjects who are withdrawn for other reasons. Investigators will follow subjects who are withdrawn from the study as result of a SAE/AE until resolution of the event (see Section 8.5.2).

9.2.2. Subject withdrawal from investigational vaccine

A 'withdrawal' from the investigational vaccine refers to any subject who does not receive the complete treatment, i.e. when no further planned dose is administered from

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

the date of withdrawal. A subject withdrawn from the investigational vaccine may not necessarily be withdrawn from the study as further study procedures or follow-up may be performed (safety or immunogenicity) if planned in the study protocol.

Information relative to premature discontinuation of the investigational vaccine will be documented on the Vaccine Administration screen of the eCRF. The investigator will document whether the decision to discontinue further vaccination/treatment was made by the subject's parent(s) or LAR(s), or by the investigator, as well as which of the following possible reasons was responsible for withdrawal:

- Serious adverse event.
- Non-serious adverse event.
- Other (specify).

10. STATISTICAL METHODS

10.1. Primary endpoint

10.1.1. Epoch 001 (Primary vaccination)

- Immunogenicity with respect to pertussis components of the study vaccines Infanrix hexa and Pediarix.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination.

10.2. Secondary endpoints

10.2.1. Epoch 001 (Primary vaccination)

- Immunogenicity (other parameters) with respect to the pertussis component of the study vaccines *Infanrix hexa*, *Pentacel* and *Pediarix*.
 - Anti-PT, anti-FHA, anti-PRN seropositivity status, one month after the third dose of the primary vaccination.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination (for *Pentacel* only).
- Immunogenicity with respect to the other components of the study vaccines *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B*.
 - Anti-D, anti-T, anti-HBs, anti-poliovirus types 1, 2 and 3 and anti-PRP seroprotection status, anti-PRP antibody concentrations ≥1.0 μg/mL and antibody concentrations/titers, one month after the third dose of the primary vaccination.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0 Day 3) after each vaccination (*Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0 Day 3) after each vaccination.
- Unsolicited adverse events.
 - Occurrence of unsolicited AEs within 31 days (Day 0 Day 30) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.
- Specific adverse events.
 - Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies) from Day 0 up to six months post primary vaccination.
- Serious adverse events.
 - Occurrence of serious adverse events from Day 0 up to six months post primary vaccination.

10.2.2. Epoch 002 (Booster vaccination)

- Immunogenicity with respect to all study vaccines.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-HBs, anti-PRP and anti-poliovirus 1, 2, 3 seroprotection/ seropositivity status, anti-PRP antibody concentrations ≥1 μg/mL and antibody concentrations/ titers before the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccine *Pentacel*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-PRP seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
 - Anti-PRP antibody concentrations $\geq 1~\mu g/mL$ one month after the booster dose (Dose 4).
 - Anti-D and anti-T antibody concentrations ≥1 IU/mL one month after the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccine *Infanrix*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
- Anti-D and anti-T antibody concentrations ≥1 IU/mL one month after the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccines *ActHIB* and *Hiberix*.
 - Anti-PRP seroprotection status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PRP antibody concentrations ≥1 µg/mL one month after the booster dose (Dose 4)
- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0 Day 3) after booster vaccination (*Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0 Day 3) after booster vaccination.
- Unsolicited adverse events.
 - Occurrence of unsolicited AEs within 31 days (Day 0 Day 30) after booster vaccination, according to the MedDRA classification.
- Specific adverse events.
 - Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies) from the booster dose up to one month after the booster vaccination.
- Serious adverse events.
 - Occurrence of serious adverse events from the booster dose up to one month after the booster vaccination.

10.3. Determination of sample size

Target enrolment will be 585 subjects. Assuming 65% of the subjects will be evaluable post-dose 3, this will provide approximately 378 subjects (126 subjects in each group) evaluable for immunogenicity in the Epoch 001.

The sample size has been estimated in order to obtain at least 94% power to demonstrate the primary inferential objective (i.e. non-inferiority of the response to the pertussis antigens). The power associated to the target sample size for the conclusion on the inferential primary objective of this study is detailed in the next section.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

10.3.1. Control on type I error

A 2.5% nominal type I error will be used for each pertussis non-inferiority (NI) evaluation. Since NI has to be met simultaneously for the 3 pertussis antigens, the global type I error will be below 2.5%.

10.3.2. References for sample size

References were chosen based on observed standard deviations observed in studies Hib-MenCY-TT-005 (101858) and Hib-MenCY-TT-009 (103813) one month post-dose 3 from the subjects that receive *ActHIB* co-administered with *Pediarix* and *Prevnar*, and from study DTPa-HBV-IPV-027 (217744/027) one month post-dose 3 from the DTPa-HBV-IPV/Hib pooled groups. All these studies enrolled subjects in the US.

The standard deviation for log₁₀ transformed concentrations post vaccination for pertussis antigens is presented in Table 16.

Table 16 Standard deviation for log₁₀ transformed concentration post vaccination

Study	Antigen						
	PT		FHA		PRN		
	N	SD	N	SD	N	SD	
Hib-MenCY-TT-005-US	215	0.274	213	0.312	217	0.392	
Hib-MenCY-TT-009 - US	100	0.258	97	0.252	101	0.482	
cohort							
DTPa-HBV-IPV-027-US	865	0.274	802	0.254	869	0.376	
Reference taken		0.274		0.307		0.392	

N: Number of subjects; SD: standard deviation

10.3.3. Power computation

Out of the 585 subjects enrolled, 65% (126 in each pooled group) are expected to be evaluable post-Dose 3.

The individual type II error for each pertussis antigen was obtained using PASS 2005, one-sided non-inferiority test for 2 means from normal data with common variance between groups, under the alternative of equal means and alpha=2.5% (Table 17).

To account for the multiplicity of comparisons, the global type II error was conservatively estimated as the sum of individual type II errors, ensuring a global power for the study of 94.02% as presented in Table 17.

Table 17 Power for pertussis NI post-Dose 3

Antigen	Margin	SD on log₁₀ transformed titer	Type I error	N evaluable per pooled group	Type II error			
PT	1.5	0.274	2.5%	126	0.08%			
FHA	1.5	0.307	2.5%	126	0.48%			
PRN	1.5	0.392	2.5%	126	5.42%			
Global Power = 100-(0.08+0.48+5.42) % = 94.02%								

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

10.4. Study cohorts/ data sets to be analysed

Six cohorts are defined for the purpose of the analysis:

- Primary Total Vaccinated cohort
- Primary ATP cohort for analysis of safety
- Primary ATP cohort for analysis of immunogenicity
- Booster Total Vaccinated cohort
- Booster ATP cohort for analysis of safety
- Booster ATP cohort for analysis of immunogenicity

10.4.1. Primary Total vaccinated cohort

The Primary Total Vaccinated cohort (TVC) will include all vaccinated subjects for whom data are available.

- A safety analysis based on the Primary TVC will include all subjects with at least one vaccine administration documented.
- An immunogenicity analysis based on the Primary TVC will include all vaccinated subjects for whom data concerning at least one immunogenicity endpoint measure is available.

10.4.2. Primary ATP cohort for analysis of safety

The Primary ATP cohort for safety will consist of all subjects from the Primary TVC who complied with the protocol up to the end of Epoch 001, namely all subjects:

- who meet all inclusion criteria and no exclusion criteria for the study
- who have received all planned study vaccines for each completed vaccination visit in Epoch 001;
- for whom administration site of study vaccines is known and is according to protocol;
- who did not receive a product before the blood sampling at Visit 4 (Month 5) leading to elimination from an ATP analysis as listed in Section 6.7.2.

Note that for the purpose of ATP cohort definition, the Epoch 001 ends at Visit 4.

Adherence to the interval related to ESFU phone contact will not be taken into account for inclusion in ATP cohort for safety.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

10.4.3. Primary ATP cohort for analysis of immunogenicity

The Primary ATP cohort for immunogenicity will consist of all subjects from the Primary ATP cohort for safety who complied with eligibility criteria and study procedures (see Table 5 for the definition of the intervals) up to the post-dose 3 blood sample and had immunogenicity results for the post-dose 3 blood sample. The analysis will be performed per treatment (first dose) actually administered.

More specifically, the analysis post-dose 3 based on the ATP cohort for immunogenicity will include all eligible subjects:

- who receive all the study vaccines up to dose 3 as per the vaccination schedule;
- for whom administration site and route of study vaccines up to dose 3 is as per protocol;
- who did not receive a medication/product before the blood sampling at Visit 4 (Month 5) leading to elimination from an ATP analysis as listed in Section 6.7.2
- who did not present with a medical condition before the blood sampling at Visit 4 (Month 5) leading to elimination from an ATP analysis as listed in Section 6.8.
- who comply with the post-dose 3 blood sample schedule, i.e. 21-48 days post-dose 3.
- who were not administered a vaccine not foreseen by the study protocol before the corresponding post-vaccination blood sample.
- who have immunogenicity results post-dose 3.

10.4.4. Booster Total vaccinated cohort

The Booster TVC will include all subjects from primary TVC that received the booster vaccine dose.

- For the Booster-TVC analysis of safety, this will include all subjects with booster vaccine administration documented.
- For the Booster-TVC analysis of immunogenicity, this will include vaccinated subjects for whom data concerning immunogenicity endpoint measures are available.

10.4.5. Booster ATP cohort for analysis of safety

The Booster ATP cohort for safety will consist of all subjects from the Booster TVC who complied with the protocol up to the end of Epoch 002, namely all subjects:

- who meet all inclusion criteria and no exclusion criteria for the study
- who have received the planned booster dose at 15-18 months of age;
- who received 3 doses in Epoch 001;
- for whom administration site of study vaccines is known and is according to protocol;

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

• who did not receive a product before the blood sampling at Visit 6 (Months 14-17) leading to elimination from an ATP analysis as listed in Section 6.7.2.

10.4.6. Booster ATP cohort for analysis of immunogenicity

The Booster ATP cohort for immunogenicity will consist of all subjects from the Booster ATP cohort for safety who complied with eligibility criteria and study procedures (see Table 5 for the definition of the intervals) up to the post-dose 4 blood sample and had immunogenicity results for the post-dose 4 blood sample.

More specifically, the analysis pre- and post-dose 4 based on the Booster ATP cohort for immunogenicity will include all eligible subjects:

- who receive all the study vaccines up to dose 4 as per the vaccination schedule;
- for whom administration site and route of the study vaccines up to dose 4 is as per protocol;
- who did not receive a medication/product before the blood sampling at Visit 6 (Months 14-17) leading to elimination from an ATP analysis (see Section 6.7.2);
- who did not present with a medical condition before the blood sampling at Visit 6 (Months 14-17) leading to elimination from an ATP analysis (see Section 6.8);
- who comply with the booster vaccination schedule at 15-18 months of age and with the post-dose 4 blood sample schedule i.e. 21-48 days for post-dose 4;
- who have immunogenicity results post-dose 4.

10.5. Derived and transformed data

- A seronegative subject is a subject whose antibody concentration/titer is below the assay cut-off.
- A seropositive subject is a subject whose antibody concentration/titer is greater than or equal to the assay cut-off defined in Table 7.
 - Note: Due to ongoing re-validation of all assays, these cut-offs may be subject to change.
- A seroprotected subject is a subject whose antibody concentration/titer is greater than
 or equal to the level defining clinical protection. The following seroprotection
 thresholds are applicable:
 - Anti-diphtheria antibody concentrations $\geq 0.1 \text{ IU/mL}$.
 - Anti-tetanus antibody concentrations $\geq 0.1 \text{ IU/mL}$.
 - Anti-HBs antibody concentrations ≥ 10 mIU/mL.
 - Anti-poliovirus types 1, 2 and 3 antibody titers ≥ 8 .
 - − Anti-PRP antibody concentrations $\ge 0.15 \mu g/mL$.
- Other cut-offs to be considered:
 - Anti-PRP antibody concentrations $\geq 1.0 \,\mu \text{g/mL}$.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- Anti-diphtheria and anti-tetanus antibody concentrations ≥ 1.0 IU/mL
- Booster responses for anti-PT, anti-FHA and anti-PRN antibodies are defined as:
 - initially seronegative subjects (pre-booster antibody concentration below cutoff: < 5 ELISA EL.U/mL) with an increase of at least four times the cut-off one
 month after vaccination (post-booster antibody concentration ≥20 EL.U/mL),
 and
 - initially seropositive subjects with pre-booster antibody concentration
 ≥ 5 EL.U./mL and < 20 EL.U/mL with an increase of at least four times the pre-booster antibody concentration one month after vaccination, and,
 - For initially seropositive subjects with pre-booster antibody concentration
 ≥ 20 EL.U/mL with an increase of at least two times the pre-booster antibody concentration, one month after vaccination.

Note: Due to ongoing re-validation of pertussis assays, the definition of booster responses may be subject to change.

• The GMC/GMT calculations will be performed by taking the anti-log of the mean of the log₁₀ titer/ concentration transformations. Antibody titers/concentrations below the cut-off of the assay will be given an arbitrary value of half the cut-off for the purpose of GMC/GMT calculation.

Handling of missing data:

Immunogenicity:

• For a given subject and a given immunogenicity measurement, missing or non-evaluable measurements will not be replaced.

Safety/reactogenicity:

- For a given subject and the analysis of solicited symptom within 4 days post-vaccination, missing or non-evaluable measurements will not be replaced. Therefore the analysis of the solicited symptoms based on the Total Vaccinated cohort will include only vaccinated subjects and doses with documented safety data (i.e. symptom screen completed).
- For analysis of unsolicited adverse events, such as serious adverse events or adverse
 events by primary MedDRA term, and for the analysis of concomitant medications,
 all vaccinated subjects will be considered. Subjects who did not report the event or
 the concomitant medication will be considered as subjects without the event or the
 concomitant medication respectively.
- For summaries reporting both solicited and unsolicited adverse events, all vaccinated subjects will be considered. Subjects for whom the event will not be reported will be considered as subjects without the event.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

10.6. Final analysis of the Epoch 001

10.6.1. Analysis of demographics

Demographic characteristics (age [weeks], gender, geographical ancestry, height in length [cm], weight [kg] at first dose, Hep B vaccination history, vaccination history of mother with respect to administration of Tdap vaccine during pregnancy) and withdrawal status will be summarised by group using descriptive statistics:

- Frequency tables will be generated for categorical variables such as center;
- Mean, median and standard error will be provided for continuous data such as age.

The distribution of subjects enrolled among the study sites will be tabulated as a whole and per group.

10.6.2. Analysis of immunogenicity

The primary analysis will be based on the primary ATP cohort for immunogenicity. An analysis on the primary Total Vaccinated cohort will be performed only if, in any vaccine group and at any time point, more than 5% of the vaccinated subjects with immunological data post-dose 3 are excluded from the primary ATP cohort for immunogenicity.

The following section describes the analyses that will be performed.

10.6.2.1. Within group assessment

For each group, one month post-dose 3 and for each assay for which a serological result is available:

- Seropositivity and seroprotection rates with exact 95% CIs will be calculated.
- GMCs/GMTs with 95% CIs will be tabulated.
- For D,T and pertussis antigens, additional summaries will be provided according to the Tdap vaccination history of mother during pregnancy.

For each antigen, antibody concentration or titer distribution one month post-vaccination will be tabulated and displayed using reverse cumulative curves (RCCs).

10.6.2.2. Between group assessment

At one month post-dose 3,

- The asymptotic standardized 95% CI for the group difference in the seropositivity/ seroprotection rates will be computed for each antigen.
- The 95% CI for each group GMC/GMT ratio will be computed using an Analysis of Variance (ANOVA) model on the logarithm-transformed concentrations/titers. The ANOVA model will include the vaccine group as fixed effect and the DTP vaccination of the mother during pregnancy as regressor leading to an Analysis of

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Co-variance (ANCOVA) model. For hepatitis B antigen, the hepatitis b at birth vaccine dose status will also be used as regressor.

10.6.2.3. Interpretation of analyses

Except for analyses addressing criteria specified in the primary objective, comparative analyses will be descriptive/ exploratory with the aim to characterise the difference between groups in immunogenicity. These descriptive/exploratory analyses should not be interpreted for formal conclusions since there is no adjustment for multiplicity of endpoints.

10.6.3. Analysis of safety

The primary analysis will be based on the primary Total Vaccinated cohort. If, in any vaccine group and at any time point of the Epoch 001, the percentage of vaccinated subjects excluded from the primary ATP cohort for safety is more than 5%, a second analysis based on the primary ATP cohort for safety will be performed to complement the primary Total Vaccinated cohort analysis.

- The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) or 31-day (Days 0-30) follow-up period will be tabulated after each vaccine dose and overall (for the Epoch 001) with exact 95% CI.
- The percentage of doses followed by at least one local AE (solicited and unsolicited), by at least one general AE (solicited and unsolicited) and by any AE during the 4-day or 31-day follow-up period will be tabulated over the primary vaccination period, with exact 95% CI.
- The percentage of subjects/doses with local AEs (solicited and unsolicited) will be calculated at each injection site for *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel and Engerix-B* vaccines, as well as overall (all sites considered).
- The percentage of subjects/doses reporting each individual solicited local and general AE during the 4-day follow-up period will be tabulated for each group as follows:
 - Over the primary doses, the percentage of subjects with the symptom and its exact 95% CI.
 - Over the primary doses, the percentage of doses with the symptom and its exact 95% CI.
 - At each study dose, the percentage of subjects with the symptom and its exact 95% CI.

The exact 95% CIs will be calculated assuming independence between doses.

 All computations mentioned above will be done for Grade ≥2 (solicited symptoms only) and Grade 3 symptoms, for symptoms considered related to vaccination (general symptoms only), for Grade 3 symptoms considered related to vaccination (general symptoms only) and for symptoms that resulted in a medically-attended visit.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- For fever, analyses will be performed by 0.5°C increments.
- The percentage of subjects/doses with concomitant medication, antipyretic medication and prophylactic antipyretic medication during the 4-day and 31-day follow-up period post-vaccination will be tabulated after each dose and over the Epoch 001.
- The verbatim reports of unsolicited AEs will be reviewed by a clinical development manager and the signs and symptoms will be coded according to MedDRA. Every verbatim term will be matched with the appropriate Preferred Term. The percentage of subjects/doses with unsolicited AEs occurring within 31 days with exact 95% CI will be tabulated by Preferred Term. Similar tabulations will be done for Grade 3 unsolicited AEs, for unsolicited AEs considered related to vaccination and for Grade 3 unsolicited AEs considered related to vaccination.
- Subjects who experienced AEs of specific interest (i.e. new onset of chronic disease such as autoimmune disorders, asthma, type I diabetes and allergies) from Day 0 up to 6 months after the last primary vaccination will be tabulated by Preferred Term.
- Subjects who experienced at least one SAE reported before the database lock for the Epoch 001 analysis with an onset date in the Epoch 001 will be reported and the SAE will be described in detail.

10.7. Final analysis of the Epoch 002

10.7.1. Analysis of demographics/baseline characteristics

Demographic characteristics (age in months at Visit 5) and withdrawal status will be summarized by group using descriptive statistics:

- Frequency tables will be generated for categorical variables such as race/ethnicity;
- Mean, median and standard error will be provided for continuous data such as age.

The distribution of subjects vaccinated at Visit 5 among the study sites will be tabulated as a whole and per group.

For enrolled subjects that do not participate in the Epoch 002, the reason for not participating will be summarized.

10.7.2. Analysis of immunogenicity

The primary analysis will be based on the booster ATP cohort for immunogenicity. An analysis on the booster Total Vaccinated cohort will be performed only if, in any vaccine group and at any time point of the Epoch 002, more than 5% of the vaccinated subjects with immunological data are excluded from the booster ATP cohort for immunogenicity.

The following section describes the analyses that will be performed.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

10.7.2.1. Within group assessment

For each group, prior to the booster dose and one month post-booster dose and for each assay for which a serological result is available:

- Seropositivity and seroprotection rates and booster response rates for pertussis with exact 95% CIs will be calculated.
- GMCs/GMTs with 95% CIs will be tabulated.

For D,T and pertussis antigens, additional summaries will be provided according to the Tdap vaccination history of mother during pregnancy.

For each antigen, antibody concentration or titer distribution before and one month Postbooster (when available) will be tabulated and displayed using RCCs.

10.7.2.2. Between group assessment

At pre-booster and at one month post-booster,

- The asymptotic standardized 95% CI for the group difference in the seroprotection/ seropositivity rates will be computed for each antigen.
- The 95% CI for each group GMC/GMT ratio will be computed using an ANOVA model on the logarithm-transformed concentrations/titers. The ANOVA model will include the vaccine group as fixed effect and the DTP vaccination of the mother during pregnancy as regressor leading to an Analysis of Co-variance (ANCOVA) model. For hepatitis B antigen, the hepatitis B at birth vaccine dose status will also be used as regressor.

10.7.2.3. Interpretation of analyses

In Epoch 002, all comparative analyses will be descriptive/ exploratory with the aim to characterise the difference between groups in immunogenicity. These descriptive/exploratory analyses should not be interpreted for formal conclusions since there is no adjustment for multiplicity of endpoints.

10.7.3. Analysis of safety

The primary analysis for the Epoch 002 will be based on the booster Total Vaccinated cohort and will only look at the booster dose. If, in any vaccine group, the percentage of vaccinated subjects excluded from the booster ATP cohort for safety is more than 5%, a second analysis based on the booster ATP cohort for safety will be performed to complement the booster Total Vaccinated cohort analysis.

• The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) and 31-day (Days 0-30) follow-up period after the booster dose, will be tabulated with exact 95% CI for each group.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

- The incidence of local AEs (solicited and unsolicited) will be calculated at each injection site as well as overall (all sites considered) for each group.
- The percentage of subjects reporting each individual solicited local and general AE during the 4-day follow-up period will be tabulated with its exact 95% CI for each group.
- All computations mentioned above will be done for Grade ≥2 (solicited symptoms only) and Grade 3 symptoms, for symptoms considered related to vaccination (general symptoms only), for Grade 3 symptoms considered related to vaccination (general symptoms only) and for symptoms that resulted in a medically-attended visit.
- For fever, analyses will be performed by 0.5°C increments.
- The percentage of subjects with concomitant medication, antipyretic medication and prophylactic antipyretic medication during the 4-day and 31-day follow-up period post-vaccination will be tabulated for each group.
- The verbatim reports of unsolicited AEs will be reviewed by a clinical development manager and the signs and symptoms will be coded according to MedDRA. Every verbatim term will be matched with the appropriate Preferred Term. The percentage of subjects with unsolicited AEs occurring within 31 days following the booster dose with its exact 95% CI will be tabulated by Preferred Term. Similar tabulations will be done for Grade 3 unsolicited AEs, for unsolicited AEs considered related to vaccination and for Grade 3 unsolicited AEs considered related to vaccination.

Additionally,

- Any large injection site reaction (defined as a swelling with a diameter > 50 mm, noticeable diffuse swelling or noticeable increase in limb circumference) reported within 4 days (Days 0-3) following the booster dose will be described in detail.
- Subjects who experienced AEs of specific interest (i.e. new onset of chronic disease such as autoimmune disorders, asthma, type I diabetes and allergies) from booster dose up to one month after booster vaccination will be tabulated by Preferred Term.
- Subjects who experienced at least one SAE from the booster dose to study end will be reported and the SAEs will be described in detail.

10.8. Statistical methods

- The exact CIs for a proportion within a group will be calculated from Proc StatXact [Clopper, 1934].
- The standardized asymptotic CI for the group difference in proportion is the method implemented in Proc StatXact 7.0. It corresponds to method 6 in the Newcombe paper [Newcombe, 1998].
- The CI for GMTs/GMCs will be obtained within each group separately. The CI for the mean of log-transformed titer/concentration will be first obtained assuming that log-transformed values were normally distributed with unknown variance. The CI for

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

the GMTs/GMCs will then be obtained by exponential-transformation of the CI for the mean of log-transformed titer/concentration.

• The GMT/GMC group ratio will be obtained using an ANOVA model on the logarithm-transformed concentrations/titers. The ANOVA model will include the vaccine group as fixed effect and the DTP vaccination of the mother during pregnancy as regressor leading to an Analysis of Co-variance (ANCOVA) model. For hepatitis B antigen, the hepatitis B status at birth vaccine dose will also be used as regressor. The GMC/GMT group ratio and its CI will be derived as exponential-transformation of the corresponding group contrast in the model.

10.9. Conduct of analyses

Any deviation(s) or change(s) from the original statistical plan outlined in this protocol will be described and justified in the final study report.

10.9.1. Sequence of analyses

(Amendment 2: 17 April 2015)

The analyses will be performed *stepwise*:

- 1. A partial analysis of Epoch 001 up to one month after the third primary vaccine dose will be conducted. This analysis will include the final analysis of anti-PRP, solicited and unsolicited symptoms on data as clean as possible. This analysis will be displayed on GSK clinical trial registry as soon as possible.
- 2. The final data analysis of the study covering both the epochs will be conducted at the end of the study. All these analyses will be presented in a final clinical study report.

10.9.2. Statistical considerations for interim analyses

All analyses will be conducted on final data and therefore no statistical adjustment for interim analyses is required.

11. ADMINISTRATIVE MATTERS

To comply with ICH GCP administrative obligations relating to data collection, monitoring, archiving data, audits, confidentiality and publications must be fulfilled.

11.1. Remote Data Entry instructions

RDE, a validated computer application, will be used as the method for data collection.

In all cases, subject initials will not be collected nor transmitted to GSK. Subject data necessary for analysis and reporting will be entered/transmitted into a validated database or data system. Clinical data management will be performed in accordance with applicable GSK standards and data cleaning procedures.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

While completed eCRFs are reviewed by a GSK Biologicals' Site Monitor at the study site, omissions or inconsistencies detected by subsequent eCRF review may necessitate clarification or correction of omissions or inconsistencies with documentation and approval by the investigator or appropriately qualified designee. In all cases, the investigator remains accountable for the study data.

The investigator will be provided with a CD-ROM of the final version of the data generated at the investigational site once the database is archived and the study report is complete and approved by all parties.

11.2. Study Monitoring by GSK Biologicals

GSK will monitor the study to verify that, amongst others, the:

- Data are authentic, accurate, and complete.
- Safety and rights of subjects are being protected.
- Study is conducted in accordance with the currently approved protocol, any other study agreements, GCP and all applicable regulatory requirements.

The investigator and the head of the medical institution (where applicable) agrees to allow the monitor direct access to all relevant documents.

The investigator must ensure provision of reasonable time, space and qualified personnel for monitoring visits.

Direct access to all study-site related and source data is mandatory for the purpose of monitoring review. The monitor will perform a RDE review and a Source Document Verification (SDV). By SDV we understand verifying RDE entries by comparing them with the source data that will be made available by the investigator for this purpose.

The Source Documentation Agreement Form describes the source data for the different data in the RDE. This document should be completed and signed by the site monitor and investigator and should be filed in the monitor's and investigator's study file. Any data item for which the RDE will serve as the source must be identified, agreed and documented in the source documentation agreement form.

For RDE, the monitor will mark completed and approved screens at each visit.

Upon completion or premature discontinuation of the study, the monitor will conduct site closure activities with the investigator or site staff, as appropriate, in accordance with applicable regulations, GCP, and GSK procedures.

11.3. Record retention

Following closure of the study, the investigator must maintain all site study records (except for those required by local regulations to be maintained elsewhere) in a safe and secure location. The records must be easily accessible, when needed (e.g. audit or inspection), and must be available for review in conjunction with assessment of the facility, supporting systems, and staff. Where permitted by applicable laws/regulations or

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

institutional policy, some or all of these records can be maintained in a validated format other than hard copy (e.g. microfiche, scanned, electronic); however, caution needs to be exercised before such action is taken. The investigator must ensure that all reproductions are legible and are a true and accurate copy of the original and meet accessibility and retrieval standards, including re-generating a hard copy, if required. Furthermore, the investigator must ensure that an acceptable back-up of the reproductions exists and that there is an acceptable quality control procedure in place for making these reproductions.

GSK will inform the investigator/institution of the time period for retaining these records to comply with all applicable regulatory requirements. However, the investigator/institution should seek the written approval of the sponsor before proceeding with the disposal of these records. The minimum retention time will meet the strictest standard applicable to a particular site, as dictated by ICH GCP, any institutional requirements, applicable laws or regulations, or GSK standards/procedures; otherwise, the minimum retention period will default to 15 years.

The investigator/institution must notify GSK of any changes in the archival arrangements, including, but not limited to archival at an off-site facility, transfer of ownership of the records in the event the investigator leaves the site.

11.4. Quality assurance

To ensure compliance with GCP and all applicable regulatory requirements, GSK may conduct a quality assurance audit. Regulatory agencies may also conduct a regulatory inspection of this study. Such audits/inspections can occur at any time during or after completion of the study. If an audit or inspection occurs, the investigator and institution agree to allow the auditor/inspector direct access to all relevant documents and to allocate his/her time and the time of his/her staff to the auditor/inspector to discuss findings and any relevant issues.

11.5. Posting of information on publicly available clinical trial registers and publication policy

Study information from this protocol will be posted on publicly available clinical trial registers before enrolment of subjects begins.

Summaries of the results of GSK interventional studies (phase I-IV) are posted on publicly available results registers within 12 months of the primary completion date for studies of authorized vaccines and 18 months for studies of non-authorized vaccines.

GSK also aims to publish the results of these studies in the searchable, peer reviewed scientific literature. Manuscripts are submitted for publication within 24 months of the last subject's last visit.

11.6. Provision of study results to investigators

Where required by applicable regulatory requirements, an investigator signatory will be identified for the approval of the study report. The investigator will be provided reasonable access to statistical tables, figures, and relevant reports and will have the

96

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

opportunity to review the complete study results at a GSK site or other mutuallyagreeable location.

GSK Biologicals will also provide the investigator with the full summary of the study results. The investigator is encouraged to share the summary results with the study subjects, as appropriate.

COUNTRY SPECIFIC REQUIREMENTS 12.

Not applicable.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

13. REFERENCES

Anderson P. The protective levels of serum antibodies to the capsular polysaccharide of *Haemophilus influenzae* type b. *J Infect Dis* 1984;149:1034-1035.

Camargo ME, et al. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. *J Clin Microbiol* 1984;20(4):772-4.

Centers for Disease Control and Prevention (CDC). Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States Through Universal Childhood Vaccination: Recommendations of the Immunisation Practices Advisory Committee (ACIP). *MMWR* 1991; 40(RR-13): 1-19.

Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunisation Practices (ACIP) and the American Academy of Family Physicians (AAFP). *MMWR* 2002, 51(RR02); 1-36.

Clopper C J, Pearson E S. The Use Of Confidence Or Fiducial Limits Illustrated In The Case Of The Binomial. *Biometrika* 1934;26(4):404-13.

Dhillon S. DTPa-HBV-IPV/Hib Vaccine (*Infanrix hexa*TM): A Review of its Use as Primary and Booster Vaccination. *Drugs* 2010; 70(8): 1021-58

Diggle L, Deeks JJ, Pollard AJ. Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomized controlled trial. *BMJ* 2006;333 (7568):571.

General recommendations on immunization—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Surveill Summ, 60 (2011), pp. 1–64. http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf. Accessed on 26 September 2013.

Granström M, Thoren M, Sato Y et al. Acellular Pertussis Vaccine in Adults: Adverse Reactions and Immune Response. *Eur J Clin Microbiol* 1987;6 (1):18-21.

Kalies H, Grote V, Verstraeten T, et al. The Use of Combination Vaccines Has Improved Timeliness of Vaccination in Children. *Pediatr Infect Dis J* 2006;25(6):507-12.

Karpinsky KF, Hayward S and Tryphonas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). *J Immunol Methods* 1987;103:189-94.

Käyhty H, Peltola H, Karanko V and Makela PH. The protective level of serum antibodies to the capsular polysaccharide of *Haemophilus influenzae* type b. *J Infect Dis* 1983;147:1100.

Kohl KS, Walop W, Gidudu J, et al. Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data. *Vaccine*. 2007; 25(31):5858-74.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralisation test in mice as a method for the estimation of tetanus antitoxin in human sera. *J Biol Stand* 1983;11:137-44.

Newcombe R G. Two-sided confidence intervals for the single proportion: Comparison of seven methods. *Statistics in Medicine* 1998;17(8):857–72.

World Health Organization (WHO). Progress in the control of viral hepatitis: memorandum for a WHO meeting. *Bull WHO* 1988;66:443-45.

World Health Organisation (WHO). Standard Procedure for Determining Immunity to Poliovirus using the Microneutralisation Test (*WHO*/EPI/GEN 93.9) 1993.

Zepp F, Schmitt HJ, Cleerbout J et al. Review of 8 years of experience with *Infanrix hexa*[™] (DTPa-HBV-IPV/Hib hexavalent vaccine). *Expert Rev Vaccines* 2009;8(6):663-78.

Zinke M, Disselhoff J, Gartner B et al. Immunological persistence in 4–6 and 7–9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib. Human *vaccines* 2010;6(2):1-5.

Zuckerman JN. The importance of injecting vaccines into muscles. BMJ 2000;321:1.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

APPENDIX A CLINICAL LABORATORIES

Table 18 GSK Biologicals' laboratories

Laboratory	Address
GSK Biologicals Global Vaccine	Biospecimen Reception - B7/44
Clinical Laboratory, Rixensart	Rue de l'Institut, 89 - B-1330 Rixensart - Belgium
GSK Biologicals Global Vaccine	Biospecimen Reception - Clinical Serology
Clinical Laboratory, North America-	525 Cartier blvd West - Laval - Quebec - Canada -
Laval	H7V 3S8
GSK Biologicals Global Vaccine	Avenue Fleming, 20 - B-1300 Wavre - Belgium
Clinical Laboratory, Wavre-Nord	
Noir Epine	

Table 19 Outsourced laboratories

Laboratory	Address
Quest Diagnostics Clinical Trials	27027 Tourney Road, Suite 2E
(US)	Valencia, CA 91355
	USA
Quest Diagnostics Clinical Trials	27027 Tourney Road, Suite 2E
(Biomarkers)	Valencia, CA 91355
	USA
Quest Diagnostics Nichols Institute	33608 Ortega Highway
	San Juan Capistrano,
	CA 92675-2042
	USA
Quest Diagnostics, Inc.	1 Malcolm Way
	Teterboro, NJ 07608
	USA
Quest Diagnostics Nichols Institute	14225 Newbrook Drive
	Chantilly, VA 20153
	USA

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

APPENDIX B AMENDMENTS AND ADMINISTRATIVE CHANGES TO THE PROTOCOL

GlaxoSmithKline Biologicals							
Cli	Clinical Research & Development						
	Protocol Ame	endment 1					
eTrack study number	117119 (DTPA-	HBV-IPV-135)					
and Abbreviated Title							
IND number	BB-IND 006687						
EudraCT number	1draCT number 2013-004304-19						
Amendment number:	Amendment 1						
Amendment date:	Final: 18 September 2014						
Co-ordinating author:	PPD Scientific Writer						

Rationale/background for changes:

- Clarification has been provided that large injection site reactions and measurement
 of the injected limb should be collected as a solicited symptom. Specific
 instructions regarding measurement of limb circumference and clinical details of
 large injection site reactions have been added.
- Additional minor clarifications of study procedures and data analyses have been made throughout the document.
- Instructions regarding interval between preparation and administration of vaccine has been aligned with the stability data described in the current Investigator Brochure.
- Due to ongoing re-validation of serological assays for antibodies to diphtheria and tetanus toxoids, pertussis antigens, poliovirus, hepatitis B surface antigen and polyribosyl ribitol phosphate, the cut-offs for these assays could potentially change and hence a note has been added in the protocol regarding this. The definition of booster response to pertussis antigens could also potentially be revised.
- Sequence of reporting the results has been clarified.
- The contributing authors and sponsor signatory were updated to reflect changes in the study team.

Amended text has been included in *bold italics* and deleted text in strikethrough in the following sections:

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Primary study vaccine and number	GlaxoSmithKline (GSK) Biologicals' Combined Diphtheria-Tetanus-acellular Pertussis (DTaP), Hepatitis B, Poliovirus and <i>Haemophilus influenzae</i> type b vaccine (DTPa-HBV-IPV/Hib) (GSK SB217744, Infanrix hexa TM).
----------------------------------	--

Section 1.2.1 Rationale for the study

More than 73 100 million doses have been distributed to date and the benefit/risk profile remains favorable.

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Section 5.5 Outline of study procedures

Table 4 List of study procedures

		EPOCH 001 (PRIMARY VACCINATION)					EPOCH 002 (BOOSTER VACCINATION)	
Age	2 Months	4 Months	6 Months	7 Months	12 Months	15-18 Months	16-19 Months	
Visit	VISIT 1	VISIT 2	VISIT 3†	VISIT 4	ESFU CONTACT (PHONE)	VISIT 5	VISIT 6	
Time point	Day 0	Month 2	Month 4	Month 5	Month 10	Month 13 -16	Month 14 - 17	
Sampling time point				Post-Pri		Pre-Bst	Post-Bst	
Informed consent	•							
Check inclusion/exclusion criteria	•							
Medical history	•							
Collect demography data	•							
Vaccination history including HepB vaccination history	•							
Informed consent for Tdap vaccination history of mother ^a	•							
Last Tdap vaccination history of mother ^β	•							
History directed physical examination including length and weight	•					•		
Study group and treatment number allocation (Randomization)	0							
Treatment number allocation for subsequent doses		0	0			0		
Recording of administered treatment number	•	•	•			•		
Pre-vaccination body temperature	•	•	•			•		
Blood sampling				•		•	•	
Check warnings and precautions	0	0	0			0		
Check contraindications to subsequent vaccination		•	•			•		
Pre-vaccination measurement of limb length and circumference of						_		
limb(s) at site of injection by investigator ⁸						•		
Vaccination	•	• **	•			•		
Distribution of thermometer	0							
Distribution of measuring device	0					0		
Distribution of diary cards	0	0	0			0		

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135)

Protocol Amendment 2 Final Version 02 **EPOCH 001 (PRIMARY VACCINATION) EPOCH 002** (BOOSTER VACCINATION) 2 Months 4 Months 6 Months 7 Months 12 Months 15-18 MONTHS 16-19 MONTHS Age Visit VISIT 1 VISIT 2 VISIT 3 † VISIT 4 ESFU VISIT 5 VISIT 6 CONTACT (PHONE) Time point Month 13 -16 Month 14 - 17 Day 0 Month 2 Month 4 Month 5 Month 10 Sampling time point Post-Pri Pre-Bst Post-Bst Daily post-vaccination recording of solicited adverse events during the 4day (Day 0-3) follow-up period, recorded by the subjects' parent(s)/LAR(s) in diary card Recording of non-serious (unsolicited) adverse events during the 31-day (Day 0-30) follow-up period, recorded by the subjects' parent(s)/LAR(s) in diary card Recording of any large injection site reactions in the eCRF by the investigator* Return of diary cards and transcription by the investigator • • Record any concomitant medication and vaccination § • • Record any intercurrent medical conditions • Recording of serious adverse events including related to study participation • Investigator sign-off 0 Analysis of the Epoch 001 # 0 0 Analysis of the Epoch 002 # 0 Study Conclusion •

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

a Child can still continue in the study if the mother does not wish to provide consent to record her Tdap vaccination history.

⁶ Only the Tdap vaccination history (during the pregnancy of the enrolled child) from mothers who have given consent to provide this information will be obtained and recorded in the eCRF..

⁸ For the Penta group, which receives only one vaccine at Visit 5, baseline measurement of only the limb receiving the vaccine is required

^{*} Refer to Section 8.1.3.1 and 5.6.2.9 for detailed explanation on the reporting of large injection site reaction

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Section 5.6.2.4 Vaccination history

The Tdap vaccination history of the mother during pregnancy will also be collected and recorded in the eCRF (provided that the mother has consented to provide this information).

Note: Maternal vaccination is requested in order to be able to summarize the responses of the subjects to pertussis antigens according to whether or not the mothers received a pertussis vaccine during their pregnancy. This information will aid in understanding the effect of transplacentally transferred antibodies on the childs' immune response to vaccination.

Section 5.6.2.9.1 Blood sampling for immune response assessments

• A volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) should be drawn from all subjects for the analysis of humoral immune response at Visits 4 and 5. At least 3.5 mL of whole blood (to provide atleast approximately 1.2 mL of serum) should be drawn from all subjects for the analysis of humoral immune response at Visit 6. After centrifugation, serum samples should be kept at -20°C/-4°F or below until shipment. Refer to the SPM for more details on sample storage conditions.

Section 5.6.2.11 Baseline measurement of limb length and circumference after booster vaccination at visit 5

During Epoch 002, baseline measurement of length of limb(s) and circumference (arms or legs according to where the vaccine was administered) at the level of the injection site should be obtained. For the Penta group, baseline measurement is only required for the limb that will be vaccinated. Clothing should be removed so as not to interfere with the measurement of the length of the limb and the circumference. Upper arm length will be determined from the acromion process of the scapula to the tip of the elbow and thigh length will be determined from the midpoint of the abdomen thigh flexure crease and the proximal end of the patella. For measuring upper arm circumference, the measurement will be performed while the arm is held parallel to the trunk and the elbow is flexed in front at 90° (as if the subject is carrying a tray) [Kohl, 2007]. For measuring leg circumference the child should be standing or lying flat, as appropriate, as long as the leg is straight.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Section 5.6.2.13 Recording of AEs, SAEs and NOCDs

- During Epoch 002, following the fourth dose vaccination, the parents/LAR(s) should be provided with a measurement device for recording circumference of injected limbs (arms or legs according to where vaccine was administered) at the level of the injection site on the day of vaccination and during the next three days on a diary card. The parents/LAR(s) should be instructed on how and where to perform the measurement of the circumference of the vaccinated limb. Daily measurements should be performed in the same manner preferably by the same person and at the same time of day during the 4-day follow-up (Day 0-Day3) period.
- During Epoch 002, iIf the parent(s) /LAR(s) of infants observe any large injection site reaction (defined as swelling with a diameter > 50 mm, noticeable diffuse swelling or noticeable increase of arm limb circumference) during the 4-day follow-up (Day 0-Day 3) period, they will be asked are to contact study personnel and to visit the investigator's office for evaluation as soon as possible and to bring the diary card with them. The investigator will record detailed information describing the AE on a specific large injection site reaction in the eCRF.
- In addition to the diameter of the swelling and the circumference of the limb that are reported as solicited symptoms, the parents(s)/LAR(s) will record the following additional symptoms/characteristics that may be associated with large injection site swelling reactions on the diary card:
 - Type of swelling (local swelling only around the injection site, diffuse swelling not involving the elbow or knee joint, swelling involving the elbow or knee joint)
 - Whether or not the diameter of the swelling involves more than 50% of the limb (baseline measurement of the length of the limb taken by study personnel at the vaccination visit will be provided on the diary cards)
 - Induration at injection site (largest diameter)
 - Pruritis at the injection site (intensity scale provided)
 - Functional impairment (intensity scale and description provided)
- The study personnel's evaluation will be recorded in the medical chart. In case the diary card score is not in line with the medical chart score, the medical chart will indicate what is the most intense score. The largest or most intense score for a given day will be recorded in the eCRF at the level of the solicited symptoms and at the level of the large swelling report form.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Section 5.7.3 Laboratory assays

At Visits 4, 5 and 6, blood will be collected for measurement of immune response. Total blood volume to be taken from each subject over the study period is approximately 13.5 mL (approximately 5.0 mL of whole blood *to provide approximately 1.7 mL of serum* at Visits 4 and 5 and at least 3.5 mL of whole blood *to provide approximately 1.2 mL of serum* at Visit 6).

Table 7 Humoral Immunity (Antibody determination)

System	Component	Method	Test kit/	Unit	Cut-off†	Laboratory**
			Manufacturer			
Serum	Bordetella pertussis.Pertussis Toxin Ab.IgG	ELISA	In-house*	EL.U/m L	5	GSK Biologicals§
Serum	Bordetella pertussis.Filamentous Hemaglutinin Ab.lgG	ELISA	In-house*	EL.U/m L	5	GSK Biologicals§
Serum	Bordetella pertussis.Pertactin Ab.IgG	ELISA	In-house*	EL.U/m L	5	GSK Biologicals§
Serum	Corynebacterium diphtheriae.Diphtheria Toxoid Ab.IgG	ELISA	In-house*	IU/mL	0.1	GSK Biologicals§
Serum	Clostridium tetani.Tetanus Toxoid Ab.IgG	ELISA	In-house*	IU/mL	0.1	GSK Biologicals§
Serum	Hepatitis B Virus.Surface Ab	CLIA	Centaur (Siemens Healthcare)	mIU/mL	6.2	GSK Biologicals§
Serum	Poliovirus Sabin Types 1, 2 and 3	NEUTRA	In-house*	ED50	8	GSK Biologicals§
Serum	Haemophilus influenzae type b.Polyribosyl Ribitol Phosphate Ab	ELISA	In-house*	µg/mL	0.15	GSK Biologicals§

^{*}In-house refers to assays developed internally by GSK which can be performed at GSK Biologicals' laboratories or external laboratory designated by GSK

^{**}Refer to APPENDIX A for the laboratory addresses.

[§]GSK Biologicals laboratory refers to the Global Vaccines Clinical Laboratories (GVCL) in Rixensart, Belgium; Wavre,

[†]Due to ongoing re-validation of all assays, the cut-offs may be subject to change.

Belgium and Laval, Canada.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Section 6.1 Description of study vaccines

Table 9 Study vaccines

Treatment name	Vaccine/ Product name	Formulation	Presentation	Volume	Number of doses
Pentacel	DTaP-IPV (Sanofi Pasteur)	PT=20µg; FHA=20µg; FIM=5µg; PRN=3µg; DT=15Lf; TT=5Lf; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; PRP=10µg TT,TT=24µg; AIPO ₄ =330µg AI3+	Suspension for injection (0.5-mL dose) supplied as a liquid vaccine component in a single dose vial	0.5 mL*	4
, chaodi	ActHIB Hib	Hib=10μg TT, TT=24μg PRP=10μG; TT~=25μG	White lyophilized pellet in a single dose vial, it must be reconstituted before use with the liquid DTaP-IPV component. The lyophilized Hib component is presented as a white pellet in a glass vial; it must be reconstituted with the liquid DTaP-IPV component before use		

Section 6.3 Dosage and administration of study vaccines

NOTE: After reconstitution, *Infanrix hexa* should be administered promptly or stored refrigerated between 2° and 8°C and administered within 24 hours. If the vaccine is not administered promptly, shake the solution vigorously again before injection injected immediately. However the vaccine may be kept for up to 8 hours at room temperature (21°C).

Section 6.7.1 Recording of concomitant medications/products and concomitant vaccination

Any concomitant vaccination administered since birth in the period starting 30 days before the first dose of the study vaccine and ending 30 days after the booster dose (Visit 6). Notes: 1). Vaccinations listed prior to the first dose of study vaccine are to be recorded as vaccination history. 2) The fourth dose of Prevnar 13 will be recorded as concomitant vaccination.

* *Refer to those* SAEs that are required to be reported per protocol.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Section 8.1.3.1 Solicited local (injection-site) adverse events

Table 11 Solicited local adverse events

Pain at injection site

Redness at injection site

Swelling at injection site

Post-dose 4 measurements of circumference of limbs (arm or leg according to where vaccine was administered)

N.B. If parent(s) /LAR(s) of infants observe any large injection site reaction (defined as swelling with a diameter > 50 mm, noticeable diffuse swelling or noticeable increase of arm limb circumference) after the booster dose at Visit 5, they will be asked are to contact study personnel and to visit the investigator's office for evaluation as soon as possible and bring the diary card with them. The investigator will record detailed information describing the AE on a specific large injection site reaction form in the eCRF. In addition to the diameter of the swelling and the circumference of the limb that are reported as solicited symptoms the parent(s)/LAR(s) will need to record additional symptoms/characteristics as mentioned in Section 5.6.2.13.

Note: local AEs will not be eollected solicited for co-administered vaccines like *Prevnar 13* and *Rotarix*.

Section 8.3.1 Time period for detecting and recording adverse events and serious adverse events

Note: With the exception of AEs/SAEs leading to withdrawal, study participation and concurrent GSK medications or vaccines, there is no reporting of SAEs from the time of the Epoch 1 ESFU phone contact and administration of dose 4 (approximately three months).

Section 8.3.3.2.1 Assessment of intensity

Table 14 Intensity scales for solicited symptoms in infants/toddlers

Infant/Toddler (15-24 months)					
Adverse Event	Intensity grade	Parameter			
Pain at injection site	0	None			
	1	Mild: Minor reaction to touch			
	2	Moderate: Cries/protests on touch			
	3	Severe: Cries when limb is moved/spontaneously painful			
Redness at injection site		Record greatest surface diameter in mm			
Swelling at injection site		Record greatest surface diameter in mm			
		Record the limb circumference at the level of the injection			
or leg according to where vaccine was		site			
administered)					

The maximum intensity of fever was will be scored at GSK Biologicals as follows:

0	= <100.4°F	<38.0°C
1	$=$ ≥ 100.4 °F to ≤ 102.2 °F	≥38.0°C to ≤39.0°C
2	$= >102.2$ °F to ≤ 104.0 °F	>39.0°C to ≤40.0°C
3	= > 104.0°F	> 40.0°C

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Prior to analysis, the increase in limb circumference of each limb as compared to the baseline pre-vaccination measurement will be scored for each subject at GSK Biologicals' as follows:

Grade θ = Increase in limb circumference \leq 5 mm

- 1 = Increase in limb circumference >5 mm but ≤20 mm
- 2 = Increase in limb circumference >20 mm but ≤40 mm
- 3 = Increase in limb circumference >40 mm

For unsolicited symptoms and adverse events associated with large injection site reactions (e.g. pruritus, induration and functional impairment, the intensity should be assigned to one of the following categories:

Section 10.4.2 Primary ATP cohort for analysis of safety

 who have received all planned study vaccines as planned for each completed vaccination visit in up to the end of Epoch 001;

Section 10.4.5 Booster ATP cohort for analysis of safety

• who have received the *planned* booster dose at 15-18 months of age;

Section 10.5 Derived and transformed data

- A seropositive subject is a subject whose antibody concentration/titer is greater than or equal to the assay cut-off defined in Table 7.
 - Note: Due to ongoing re-validation of all assays, these cut-offs may be subject to change.
- Booster responses for anti-PT, anti-FHA and anti-PRN antibodies are defined as:
 - For initially seropositive subjects with pre-booster antibody concentration
 ≥ 20 EL.U/mL with an increase of at least two times the pre-booster antibody concentration, one month after vaccination.

Note: Due to ongoing re-validation of pertussis assays, the definition of booster responses may be subject to change.

Section 10.6.2.2 Between group assessment

• The 95% CI for each group GMC/GMT ratio will be computed using an Analysis of Variance (ANOVA) model on the logarithm-transformed concentrations/titers. The ANOVA model will include the vaccine group as fixed effect and the DTP vaccination of the mother during pregnancy as regressor leading to an Analysis of Co-variance (ANCOVA) model. For hepatitis B antigen, the hepatitis b at birth vaccine dose status will also be used as regressor leading to an Analysis of Co-variance (ANCOVA) model.

Section 10.7.2.2 Between group assessments

• The 95% CI for each group GMC/GMT ratio will be computed using an ANOVA model on the logarithm-transformed concentrations/titers. The ANOVA model will include the vaccine group as fixed effect and the DTP vaccination of the mother during pregnancy as regressor leading to an Analysis of Co-variance (ANCOVA) model. For hepatitis B antigen, the hepatitis B at birth vaccine dose status will also be used as regressor leading to an ANCOVA model.

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Section 10.8 Statistical methods

• The GMT/GMC group ratio will be obtained using an ANOVA model on the logarithm-transformed concentrations/titers. The ANOVA model will include the vaccine group as fixed effect and the DTP vaccination of the mother during pregnancy as regressor leading to an Analysis of Co-variance (ANCOVA) model. For hepatitis B antigen, the hepatitis B status at birth vaccine dose will also be used as regressor leading to an Analysis of Co-variance (ANCOVA) model.

Section 10.9.1 Sequence of analyses

- I. The final data analysis of Epoch 001 including all as clean as possible data, up to one month after the third primary vaccine dose, and some partial data from the ESFU contact will be conducted as soon as possible. This analysis will include the final analysis of immunogenicity and the final analysis of solicited symptoms for the primary vaccination course. All analyses will be presented in Clinical Study Report (CSR). The CSR will be shared with the investigators.
- 2. All these analyses will be presented in an Epoch 002 specific *final* CSR. The final CSR will be shared with the investigators.

Section 13 References

Kohl KS, Walop W, Gidudu J, et al. Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine. 2007; 25(31):5858-74.

Appendix A Clinical laboratories

Table 19 Outsourced laboratories

Laboratory	Address
BARC USA Inc	5, Delaware Drive
	Lake Success
	NY 11042-1114
	USA

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Gla	GlaxoSmithKline Biologicals						
Cli	Clinical Research & Development						
	Protocol Amo	endment 2					
eTrack study number	117119 (DTPA-	HBV-IPV-135)					
and Abbreviated Title							
IND number	BB-IND 006687						
EudraCT number	2013-004304-19)					
Amendment number:	Amendment 2						
Amendment date:	Final Version 02: 17 April 2015						
Co-ordinating author:	PPD	Scientific Writer					

Rationale/background for changes:

The amendment 2 has been implemented to amend the following sections of the protocol:

- The assay for testing antibodies against polyribosyl ribitol phosphate (anti-PRP)
 has been re-developed but is not yet qualified or validated for testing the one
 month post dose-3 samples. This has been clarified in the protocol in Table 7
 Humoral immunity (antibody determination) and Section 5.7.3 Laboratory assays.
- Investigator sign-off on the patient identification (PIDS) will be done after Visit 4 instead of extended safety follow-up (ESFU). In Table 4 List of study procedures, the bullets pertaining to investigator sign-off and analysis of Epoch 001 has been removed from the ESFU visit and retained at Visit 4 to reflect this change.
- The collection of baseline measurement of limb length has been removed since it will not be used in analysis; only limb circumference will be used in analysis. Accordingly, text related to this has been amended in Table 4 List of study procedures, Sections 5.6.2.11, Baseline measurement of limb circumference after booster vaccination at visit 5 and 5.6.2.13 Recording of AEs, SAEs and NOCDs.
- Errors in the vaccines dictionary of Study Master Repository (SMR) have been rectified for *Infanrix hexa*, *Pediarix* and *Pentacel* vaccines. The corresponding correction has been made in Table 9 Study vaccines.
- The sequence of analysis in Section 10.9.1 Sequence of analyses, has been amended to reflect that there will first be an analysis of immunogencity for anti-PRP and safety for Epoch 001, followed by a final analysis covering both Epochs at the end of the study.

Amended text has been included in *bold italics* and deleted text in strikethrough in the following sections:

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Section 5.5 Outline of study procedures: Table 4 List of study procedures

	EPOCH 001 (PRIMARY VACCINATION)					EPOCH 002 (BOOSTER VACCINATION)	
Age	2 Months	4 Months	6 Months	7 Months	12 Months	15-18 Months	16-19 Months
Visit	VISIT 1	VISIT 2	Visit 3 †	VISIT 4	ESFU	VISIT 5	VISIT 6
					CONTACT		
					(PHONE)		
Time point	Day 0	Month 2	Month 4	Month 5	Month 10	Month 13 -16	Month 14 - 17
Sampling time point				Post-Pri		Pre-Bst	Post-Bst
Pre-vaccination measurement of limb length and circumference of limb(s) at						_	
site of injection by investigator $^{\delta}$						•	
Investigator sign-off				•	•		•
Analysis of the Epoch 001 #				0	0		

17-APR-2015 6a799184c9b15497796cc43497dd0e1b0c61d882

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

In Section 5.6.2.11 Baseline measurement of limb circumference after booster vaccination at visit 5

In Section 5.6.2.11 Baseline measurement of limb length and circumference after booster vaccination at visit 5

During Epoch 002, baseline measurement of length of limb(s) and circumference (arms or legs according to where the vaccine was administered) at the level of the injection site should be obtained. For the Penta group, baseline measurement is only required for the limb that will be vaccinated. Clothing should be removed so as not to interfere with the measurement of the length of the limb and the circumference. Upper arm length will be determined from the acromion process of the scapula to the tip of the elbow and thigh length will be determined from the midpoint of the abdomen thigh flexure crease and the proximal end of the patella.

In Section 5.6.2.13 Recording of AEs, SAEs and NOCDs:

Whether or not the diameter of the swelling involves more than 50% of the limb (baseline measurement of the length of the limb taken by study personnel at the vaccination visit will be provided on the diary cards).

In Section 5.7.3 Laboratory assays

All serology will be determined in GSK Biologicals' laboratories, or in a laboratory designated by GSK, using standardized validated procedures with adequate controls. All serology for primary endpoints will be determined in GSK Biologicals' laboratories, or in a laboratory designated by GSK, using standardized, validated procedures with adequate controls.

Table 7 Humoral immunity (antibody determination)

System	Component	Method	Test kit/ Manufacturer	Unit	Cut-off [†]	Laboratory**
Serum	Haemophilus influenzae type b.Polyribosyl Ribitol Phosphate Ab ‡	ELISA	In-house*	μg/mL	0.15	GSK Biologicals§

‡For anti-PRP post-dose 3, the assay is not yet qualified or validated.

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Section 6.1 Description of study vaccines

Table 9 Study vaccines

Treatment name	Vaccine/ Product name	Formulation	Presentation	Volume	Number of doses
Infanrix hexa	DTPa- HBV-IPV	DT>=30IU; TT>=40IU; PT=25µg; FHA=25µg; PRN=8µg; HBsAg=10µg; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; Aluminium=700µg Al3+	The DTPa-HBV-IPV component is presented as a turbid white suspension in a pre-filled syringe.	full volume^	3
Pediarix	DTPa- HBV-IPV	DT>=30IU; TT>=40IU; PT=25µg; FHA=25µg; PRN=8µg; HBsAg=10µg; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; Aluminium=700µg Al3+	The DTPa-HBV-IPV component is presented as a turbid white suspension in a pre-filled syringe.	0.5 mL	3
Pentacel	DTaP-IPV (Sanofi Pasteur)	PT=20µg; FHA=20µg; FIM=5µg; PRN=3µg; DT=15Lf; TT=5Lf; Inactivated Poliovirus type 1 (Mahoney strain)=40DU; Inactivated Poliovirus type 2 (MEF-1 strain)=8DU; Inactivated Poliovirus type 3 (Saukett strain)=32DU; PRP=10µg TT,TT=24µg; AIPO ₄ =330µg AI3+	Suspension for injection (0.5-mL dose) supplied as a liquid vaccine component in a single dose vial. The lyophilized Hib component is presented as a white pellet in a separate glass vial. It must be reconstituted with the liquid DTaP-IPV component before use.	0.5 mL*	4
	Hib	PRP=10µG; TT~=25µG			

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Section 10.9.1 Sequence of analyses

The analyses will be performed *stepwise* in 2 steps:

- 1. The final data analysis of Epoch 001 including all as clean as possible data, up to one month after the third primary vaccine dose, and some partial data from the ESFU contact will be conducted as soon as possible. This analysis will include the final analysis of immunogenicity and the final analysis of solicited symptoms for the primary vaccination course. A partial analysis of Epoch 001 up to one month after the third primary vaccine dose will be conducted. This analysis will include the final analysis of anti-PRP, solicited and unsolicited symptoms on data as clean as possible. This analysis will be displayed on GSK clinical trial registry as soon as possible.
- 2. The final data analysis of Epoch 002 will be conducted subsequently. This analysis will include final analysis of the ESFU from Epoch 001 and the final analysis of immunogenicity and safety from Epoch 002. All these analyses will be presented in a final CSR. The final data analysis of the study covering both the epochs will be conducted at the end of the study. All these analyses will be presented in a final clinical study report.

117119 (DTPA-HBV-IPV-135) Protocol Final Version 01

Protocol Sponsor Signatory Approval

eTrack study number and

Abbreviated Title

117119 (DTPA-HBV-IPV-135)

IND number

BB-IND 006687

EudraCT number:

2013-004304-19

Date of protocol

Final Version 01: 18 October 2013

Detailed Title

A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexaTM vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar[®] and RotarixTM with a booster dose of GSK Biologicals' Infanrix[®] and HiberixTM vaccines at 15-18 months of age.

Sponsor signatory

Jacqueline Miller, MD,

Senior Director and Head, Portfolio Head CRDL,

DTP/Polio/Meningococcal/Rotavirus/

Travellers' Vaccines

Late Clinical Development, Vaccine Discovery and Development, GlaxoSmithKline Biologicals.

Signature

PPD

Date

29 October 2013

For internal use only

18-OCT-2013

3

9ec4fb051440e8a47d4c37738037a452e6ff4873

117119 (DTPA-HBV-IPV-135) Protocol Amendment 1 Final

Protocol Amendment 1 Sponsor Signatory Approval

eTrack study number and **Abbreviated Title**

117119 (DTPA-HBV-IPV-135)

IND number

BB-IND 006687

EudraCT number:

2013-004304-19

Date of protocol amendment

Amendment 1 Final: 18 September 2014

Detailed Title

A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa[™] vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar[®] and Rotarix[™] with a booster dose of GSK Biologicals' Infanrix® and Hiberix $^{\text{TM}}$ vaccines at 15-18 months of age.

Sponsor signatory

Narcisa Elena Mesaros

Project level CRDL, DTP/Polio Vaccines

Late Clinical Development, Vaccine Discovery and Development, GlaxoSmithKline Biologicals.

Signature

Date

10-001-2014

For internal use only

b0b56746a8f7057ebcdaac2119d7f5a88430ea76

117119 (DTPA-HBV-IPV-135) Protocol Amendment 2 Final Version 02

Protocol Amendment 2 Sponsor Signatory Approval

eTrack study number and

117119 (DTPA-HBV-IPV-135)

Abbreviated Title

BB-IND 006687

EudraCT number:

2013-004304-19

Date of protocol amendment

Amendment 2 Final Version 02: 17 April 2015

Detailed Title

IND number

A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa[™] vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar[®] and Rotarix[™] with a booster dose of GSK Biologicals' Infanrix[®] and Hiberix[™] vaccines at 15-18 months of age.

Sponsor signatory

Narcisa Elena Mesaros

Project level CRDL, DTP/Polio Vaccines

Late Clinical Development, Vaccine Discovery and PPD ent, GlaxoSmithKline Biologicals.

PPD

Signature

Date

b. 04. 2015

For internal use only

117119 (DTPA-HBV-IPV-135) Report Final

Sample Case Report Form

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 1 of 150

Annotated Study Book for Study Design: DTPA-HBV-IPV-135 (117119)

Study Design Version: 1.0

Sponsor: GlaxoSmithKline Vaccines

Protocol: DTPA-HBV-IPV-135 (117119)

Generic Drug Name: DTPA-HBV-IPV Vaccine

Trade Drug Name: Infanrix Hexa

A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa™ vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, coadministered with Prevnar® and Rotarix™ with a booster dose of GSK Biologicals' Infanrix® and Hiberix™ vaccines at 15-18 months of age.

Generated by Central Designer TM

June 8, 2015 1:31

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 2 of 150

DTPA-HBV-IPV-135 (117119): SCREENING (Screening)			
SC	SCREENING		
1.*	Please tick box to confirm CRF creation:	[CRF_FLG] [A:Y]	
N	Key: [*] = Item is required [✔] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 3 of 150

DTPA-HBV-IPV-135 (117119): ENROLLMENT (Enrollment)			
E	ENROLLMENT		
1.	* Subject Number: [Subj Nr]	[PID] N9	
	Key: [*] = Item is required [✓] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 4 of 150

DTPA-HBV-IPV-135 (117119): SUBJECT IDENTIFICATION (Subj ID)			
SU	SUBJECT IDENTIFICATION		
1.*	Subject Number: [Subj Nr]	[PID] N9	
	Key: [*] = Item is required [✓] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 5 of 150

DTPA-HBV-IPV-135 (117119): DEMOGRAPHICS (Demog)			
DEMOGRAPHICS			
1.*	Date of birth: [DOB]	[DOB_RAW] Req/Unk	
2.*	Gender: [Gender]	[A:M]	
3.* •	Ethnicity: [Ethnicity]	[A:1] American Hispanic or Latino [A:2] Not American Hispanic or Latino	
4.*	Geographic Ancestry: [Geographic Ancestry]	[RACE] [A:1]	
5.* •	Please specify subject group: [Please specify subject group:]	[SUBSET] [A:1]	
N	Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 6 of 150

DTPA-HBV-IPV-135 (117119): INFORMED CONSENT (IC)		
DATE OF VISIT		
1.* Date of visit: [DOV]	[ACTRDATE] Req / Req (2013-2018)	
INFORMED CONSENT		
I certify that Informed Consent has been obtained price	or to any study procedure.	
2.* Informed Consent Date: [IC date]	[CONS_DAT] Req / Req (2013-2018)	
3.* Did the subjects' parent(s)/Legally Acceptable Representative(s) agree that subjects' biological sample(s) may be used by GSK Biologicals for future research? (Type 4 tests) [Did the subject's parent(s)/Legally Acceptable Representative(s) agree that subject's biological sample(s) may be used by GSK Biologicals for future research? (Type 4 tests)]	[CONS_LAB_Q4] [A:Y]	
Key: [*] = Item is required [♥] = Source verification required Note: Hidden Items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

PPD

Page 7 of 150

	DTPA-HBV-IPV-135 (117119): GENERAL MEDICAL HISTORY / EXAMINATION (Gen med hist) ENERAL MEDICAL HISTORY / EXAMINATION				
✓ S S [S	are you aware of any pre-existing conditions, igns or symptoms having started before first tudy vaccination? Are you aware of any pre-existing conditions, igns or symptoms having started before first tudy vaccination?	ED_COND] :NJ ○ No :YJ ○ Yes -> Please give diagnosis and tick appropriate Past/Current box in the table below			
\perp	MedDRA S	SYSTEM ORGAN CLASS	Diagnosis	Past / Current?	
2. •					
DIAG	SNOSIS Entry				
Pleas	e report medication(s) as specified in the protoc	col and fill in the medication section.			
2.1*	MedDRA SYSTEM ORGAN CLASS: [MedDRA SYSTEM ORGAN CLASS]	[DIAGTERM]			
	Diagnosis: [Diagnosis]	[DIAGNOSI] A80			
2.3*	9* Past / Current? [DIAGSTAT] [Past / Current?] [A:P] Past [A:C] Current				

Codelist Data Type	Label	Code	Codelist Item	Data Variable
String	Skin and subcutaneous tissue	1	SKINANDSUBCUTANEOUSTISSUE	DIAGTERM
	Musculoskeletal and connective tissue	2	MUSCULOSKELETALANDCONNECTIVETISSUE	
	Cardiac	3	CARDIAC	
	Vascular	4	VASCULAR	
	Respiratory, thoracic and mediastinal	5	RESPIRATORYTHORACICANDMEDIASTINAL	
	Gastrointestinal	6	GASTROINTESTINAL	
	Hepatobiliary	7	HEPATOBILIARY	
	Renal and urinary	8	RENALANDURINARY	
	Nervous system	9	NERVOUSSYSTEM	
	Eye	10	EYE	
	Ear and labyrinth	11	EARANDLABYRINTH	
	Endocrine	12	ENDOCRINE	
	String	Musculoskeletal and connective tissue Cardiac Vascular Respiratory, thoracic and mediastinal Gastrointestinal Hepatobiliary Renal and urinary Nervous system Eye Ear and labyrinth	Musculoskeletal and connective tissue 2 Cardiac 3 Vascular 4 Respiratory, thoracic and mediastinal 5 Gastrointestinal 6 Hepatobiliary 7 Renal and urinary 8 Nervous system 9 Eye 10 Ear and labyrinth 11	Musculoskeletal and connective tissue 2 MUSCULOSKELETALANDCONNECTIVETISSUE Cardiac 3 CARDIAC Vascular 4 VASCULAR Respiratory, thoracic and mediastinal 5 RESPIRATORYTHORACICANDMEDIASTINAL Gastrointestinal 6 GASTROINTESTINAL Hepatobiliary 7 HEPATOBILIARY Renal and urinary 8 RENALANDURINARY Nervous system 9 NERVOUSSYSTEM Eye 10 EYE Ear and labyrinth 11 EARANDLABYRINTH

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 8 of 150

Metabolism and nutrition	13	METABOLISMANDNUTRITION
Blood and lymphatic system	14	BLOODLYMPHATICSYSTEM
Immune system	15	IMMUNESYSTEM
Infections and infestations	16	INFECTIONSINFESTATIONS
Neoplasm benign, malignant and unspecified	17	NEOPLASMBENIGNMALIGNANTANDUNSPECIFIED
Surgical and medical procedures	18	SURGICALANDMEDICALPROCEDURES
Other	99	OTHER_99

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 9 of 150

DT	OTPA-HBV-IPV-135 (117119): DISEASE HISTORY (Dis Hist)			
DIS	EASE HISTORY			
Plea	se note that If disease history is answered Yes, the	en exclı	usion criteria 12 needs to be ticked.	
1.* Has the subject had history of Hib, diphtheria, tetanus, pertussis, pneumococcal, rotavirus, poliovirus and/or hepatitis B diseases? [DTP-Hib-Pn-Rot-Pol-HB disease history?] [DTP-Hib-Vn-Rot-Pol-HB disease history?]		[A:Y] [A:N]	Yes -> Please complete table below with appropriate information No	
\Box	Disease		Date(s) of diagnosis	
2.				
DIS	EASE DETAILS Entry			
2.1*	Disease: [Disease] [Disease] [Disease] [A:DT]			
2.2*	2* Date(s) of diagnosis [HIST_DAT] Req/Unk			
	(ey: [*] = Item is required [▼] = Source verification required Vote: Source verification critical settings made in InForm will override any settings made in Central Designer.			

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 10 of 150

D.	OTPA-HBV-IPV-135 (117119): MOTHERS INFORMED CONSENT (Mot Inf Cons)		
М	MOTHERS INFORMED CONSENT		
1.	Did the Mother give her consent to collect the Tdap Vaccination History Information ? [Did the Mother give her consent to collect the Tdap Vaccination History Information ?]	[MOTH_INF_CONS_Q] [A:NJ ○ NO [A:Y] ○ Yes	
2. •	Mother's Informed Consent date : [Mother's Informed Consent date :]	[MOTHERS INFORMED CONSENT DATE] NReq	
	Key: [▼] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

PPD

Page 11 of 150

DT	DTPA-HBV-IPV-135 (117119): MOTHER'S TDAP VACCINATION HISTORY (Mot Tdap hist)				
мо	HERS VACCINATION HISTORY FLAG				
•	Has the mother of the subject received Tdap vaccination during pregnancy before enrolment? [Has the mother of the subject received Tdap vaccination during pregnancy before enrolment?]	[A:Y] Yes [A:N] No [A:U] Unknown, no in	nformation available		
Ш	Vaccine name	Route	Dose number	Date	e of administration
2.					
VAC	CINATION HISTORY DETAILS Entry				
2.1*	Vaccine name: (Trade name is preferred) [Vaccine name]	[CVACC_TRADNAME] A60			
2.2*	Route: [Route]	[CVACC_ROUTE] [MEDROUT_CVACC]			
2.3 [*]	* Dose number: [NB_DOSE] N10 N10				
2.4*	Date of administration: [Date of administration]	[CVACC_RDAT] Req/Unk / Req/Unk (2013-2018)			
No	Note: Hidden items are not displayed. Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.				

Codelist Valu	ies Tables: MO1	HER'S TD	AP VA	CCINATIO	N HISTORY
Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
MEDROUT_CVACC	String	Inhalation	IH	Inhalation	CVACC_ROUTE
		Intradermal	ID	Intradermal	
		Intramuscular	IM	Intramuscular	
		Intranasal	IN	Intranasal	
		Intravenous	IV	Intravenous	
		Oral	PO	Oral	
		Parenteral	PE	Parenteral	
		Subcutaneous	SC	Subcutaneous	
		Sublingual	SL	Sublingual	
		Transdermal	TD	Transdermal	
		Other	ОТН	OTHER_OTH	
		Unknown	UNK	Unknown	

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 12 of 150

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 13 of 150

DT	PA-HBV-IPV-135 (117119): HEPA	TITIS B VACCI	NATION HISTORY (HepB Hist)		
~	Has the subject received any vaccination against Hepatitis B before enrolment? [Has the subject received any vaccination against Hepatitis B before enrolment?]		se complete the following table		
\sqcup	Vaccine name	Route	Dose number	Date	of administration
2.					
2.1*	Vaccine name: (Trade name is preferred) [Vaccine name]	[CVACC_TRADNAME] A60			
2.2*	Route: [Route]	[CVACC_ROUTE] [MEDROUT_CVACC]	[CVACC_ROUTE] [MEDROUT_CVACC]		
2.3*	Dose number: [Dose number]	[NB_DOSE]			
2.4* •	* Date of administration: [CVACC_RDAT] [Date of administration] Req/Unk / Req/Unk (2013-2018)				
No	Key: [*] = Item is required [✔] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.				

Codelist Valu	Codelist Values Tables: HEPATITIS B VACCINATION HISTORY						
Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable		
MEDROUT_CVACC	String	Inhalation	IH	Inhalation	CVACC_ROUTE		
		Intradermal	ID	Intradermal			
		Intramuscular	IM	Intramuscular			
		Intranasal	IN	Intranasal			
		Intravenous	IV	Intravenous			
		Oral	PO	Oral			
		Parenteral	PE	Parenteral			
		Subcutaneous	SC	Subcutaneous			
		Sublingual	SL	Sublingual			
		Transdermal	TD	Transdermal			
		Other	ОТН	OTHER_OTH			
		Unknown	UNK	Unknown			

PPD

Page 14 of 150

DT	DTPA-HBV-IPV-135 (117119): OTHER VACCINATION HISTORY (Oth Hist)					
VAC	ACCINATION HISTORY FLAG					
•	Has the subject received any other vaccination before enrolment? [Has the subject received any other vaccination before enrolment?]	[A:Y] OYes [A:N] No [A:U] OUnknown, no	information available			
Ш	Vaccine name	Route	Dose number	Date	e of administration	
2.						
2.1*	Vaccine name: (Trade name is preferred) [Vaccine name]	[CVACC_TRADNAME] A60				
2.2*	Route: [Route]	[CVACC_ROUTE] [MEDROUT_CVACC]	[CVACC_ROUTE] [MEDROUT_CVACC]			
2.3*	Dose number: [NB_DOSE] [Dose number] N10					
2.4*	Date of administration: [Date of administration]					
No	Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.					

Codelist Valu	ies Tables: OTH	ER VACCI	ITA	ON HISTOR	Υ
Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
MEDROUT_CVACC	String	Inhalation	IH	Inhalation	CVACC_ROUTE
		Intradermal	ID	Intradermal	
		Intramuscular	IM	Intramuscular	
		Intranasal	IN	Intranasal	
		Intravenous	IV	Intravenous	
		Oral	PO	Oral	
		Parenteral	PE	Parenteral	
		Subcutaneous	SC	Subcutaneous	
		Sublingual	SL	Sublingual	
		Transdermal	TD	Transdermal	
		Other	ОТН	OTHER_OTH	
		Unknown	UNK	Unknown	

PPD

Page 15 of 150

D	OTPA-HBV-IPV-135 (117119): PHYSICAL EXAMINATION / VITAL SIGNS (VS)		
HE	IGHT / WEIGHT		
1.*	Height: [Height]	[HEIGHT_US] [FEET] [INCHES] [N2] feet xxx. inches	
2.*	Weight: [Weight]	[WEIGHT] [POUNDS] [OUNCES] N3 pounds N2 ounces	
N	Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
VSORRESU	String	beats per minute	ВРМ	ВРМ	FEET_UNI,
		breaths per minute	BRTH	BRTH	INCHES_UNI, POUNDS UNI,
		Celsius	CE	CE	OUNCES_UNI
		Fahrenheit	FA	FAR	
		feet	FT	FT	
		inches	IN	INCH	
		kg	KG	KG	
		ounces	OZ	OZ	
		pounds	LB	LB	
		cm	СМ	СМ	
		mmHg	MMHG	MMHG	
		grams	G	GRAM	
VSTESTCD	String	DIABP	DBP	DBP	VSTESTCD
		HEART RATE	HR	HR	
		HEIGHT	HE	HEI	
		MUAC	MUAC	MAUC2	
		RESP RATE	RR	RESPR	
		SYSBP	SBP	SBP	
		TEMP	TE	TEMP	
		WEIGHT	WE	WEIGHT2	
		CRANIAL PERIMETER	CRP	CRP	
		APGAR SCORE	APGAR	APGAR	
VSTEST	String				VSTEST

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 16 of 150

Diastolic Blood F	ressure DIASTOLIC BI	LOOD PRESSURE DIASTOLIC	BLOOD PRESSURE
Heart Rate	HEART RATE	HEART RAT	E
Height	HEIGHT	HEIGHT	
Mid Upper Arm (Circumference MUAC	MUAC	
Respiratory Rate	RESPIRATORY	Y RATE RESPIRATO	RY RATE
Systolic Blood Pr	essure SYSTOLIC BLO	OOD PRESSURE SYSTOLIC E	BLOOD PRESSURE
Temperature	TEMPERATUR	E TEMPERATU	JRE
Weight	WEIGHT	WEIGHT	
Cranial Perimete	r CRANIAL PER	IMETER CRANIAL PE	RIMETER
Apgar Score	APGAR SCORE	E APGAR SCC	DRE

Page 17 of 150

D	ГРА-НВV-IPV-135 (117119): ELI	GIBILITY CHECK (Elig	gibility)	
EL:	IGIBILITY CHECK			
1.*	Did the subject meet all the entry criteria? [Eligible]	[ELIGIBIL] [A:Y] Yes [A:N] [INCL_EXCL_CRIT No -> Tick all box		violations of any inclusion/exclusion criteria.
		Do not enter the s	subject into the stud	dy if he/she failed any of the inclusion or exclusion criteria below.
		[A:1]		1.Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
		[A:2]		2. A male or female between, and including, 6 and 12 weeks of age at the time of first vaccination.
		[A:3]		3. Born full-term (i.e. after a gestation period of 37 weeks to less than 42 completed weeks [259 to 293 days]).
		[A:4]		Written informed consent obtained from the parent(s)/LAR(s) of the subject
		[A:5]		Healthy subjects as established by medical history and clinical examination before entering into the study.
		[A:6]		6. Infants who have not received a previous dose of hepatitis B vaccine or those who have received only 1 dose of hepatitis B vaccine administered at least 30 days prior to enrolment.
		[EXCL_CRITERIA]		
			rresponding to any o eria that disqualified	
		[A:7]		7. Child in care
		[A:8]		Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccines, or planned use during the study period
		[A:9]		 Chronic administration (defined as more than 14 days in total) of immunosupp. or other immune-modifying drugs since birth. (For corticosteroids, this will mean prednisone > or = 0.5 mg/kg/day, or equivalent). Inhaled and topical steroids are allowed.
		[A:10]		10. Planed adm/adm of vac not forseen by prot 30d before dose1 till 30d after dose3 & 30d before/after booster. Inactiv. flu & HepA vac allowed. Rout.admin. of MMR, varicella, pneumo vac allowed 30d after last pri vacc till 30d before Bst&post-bst sampling
		[A:11]		aniowed Sou arter last, in vact can solve be sexposed as annipping 11. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
		[A:12]		 History of Hib, diphtheria, tetanus, pertussis, pneumococcal, rotavirus, poliovirus and hepatitis B diseases.
		[A:13]		13. Previous vaccination against Hib, diphtheria, tetanus, pertussis, pneumococcus, rotavirus and/or poliovirus; more than one previous dose of hepatitis B vaccine.
		[A:14]		 Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
		[A:15]		15. Family history of congenital or hereditary immunodeficiency.
		[A:16]		16. History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines (including yeast).
		[A:17]		17. Hypersensitivity to latex.

117119 (DTPA-HBV-IPV-135) Report Final

Page 18 of 150

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

	[A:18] [A:19]		18. Major congenital defects or serious chronic illness.19. History of any neurological disorders including seizures.
	[A:20]		 Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
	[A:21]		 History of intussusception or of any uncorrected congenital malformation of the gastrointestinal tract that would predispose the infant to intussusception.
	[A:22]		22. History of Severe Combined Immunodeficiency Disease (SCID).
	[A:23]		23. Acute disease and/or fever at time of enrol. – Fever: temp>or=38.0°C /100.4°F by any rout. Pref route: rectal for pri & axilary for bst. Sub. with minor illnes (eg: mild diar, mild uper resp.infection) with no fever may be enrol. at discretion of INV
Key: [*] = Item is required [✔] = Source verificat Note: Hidden items are not displayed. Note: Source verification critical settings made in Inf	·	n Central Designer.	

Page 19 of 150

	CINE ADMINISTRATION - DOSE 1 (HEXA GROUP) (vac adm hexa-dose1)
PRE-VACC TEMPERATURE	
1.* Pre-vaccination temperature: [Pre-vacc temp]	[RE_TEMP] [PRE_TEMP] Temperature (°F)
Infanrix Hexa Vaccine	
2.* Has Infanrix Hexa Vaccine been administered?	[V_ADM_HEXA] [A:Y]
Prevnar13 Vaccine	
3.* Has Prevnar13 Vaccine been administered? [Vaccinated]	[V_ADM_PREVNAR13] [A:Y]

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 20 of 150

	Route: [A:IM]
	[A:N] No
Rotarix Vaccine	
4.* Has Rotarix Vaccine been administered? [Vaccinated]	[V_ADM_ROTARIX] [A:Y] [VACC_DET_3VACC_ROTARIX] Yes - [V_TR_ROTARIX] Administered treatment number: N10 [P_AP_ROTARIX] [A:Y] [A:Y] [A:X] [A:
	[A:N]
VACCINATION DETAILS	
5. Date of administration:	[VACCRDAT] If at least one vaccine administered [VACCRDAT] Req ▼ / Req ▼ / Req ▼ (2013-2018) [SAME_DATE] Or tick box if date is the same as visit date [A:Y] □
6. If at least one vaccination not done: [Reason for non-admin]	[VACC_REAS] [VACC_REAS] [VACC_REAS] [VACC_REAS] [VACC_REAS] Please select the major reason for non administration: [A:SAE] [SAE_CASE] Serious Adverse Event-> Please complete a SAE Report and specify SAE Report No. N2 [A:AEX] [AE_NB] Non-Serious Adverse Event -> Please complete Non-Serious Adverse Event section and specify AE No. N2 [A:OTH] [V_OTH] Other, please specify (e.g.: consent withdrawal, Protocol violation,) A100 [DECISION] Please select who made the decision: [A:I] [Investigator [A:P] [Osubject's parents / Legally Acceptable Representatives
Key: [*] = Item is required [✓] = Source verification in Note: Hidden items are not displayed.	

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 21 of 150

Note: Source verification critical settings made in InForm will override any settings made in Central Designer.

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
VSORRESU	String	beats per minute	ВРМ	ВРМ	TEMP_UNIT_HID
		breaths per minute	BRTH	BRTH	
		Celsius	CE	CE	
		Fahrenheit	FA	FAR	
		feet	FT	FT	1
		inches	IN	INCH	1
		kg	KG	KG	1
		ounces	OZ	OZ	
		pounds	LB	LB	
		cm	СМ	СМ	
		mmHg	MMHG	MMHG	
		grams	G	GRAM	
VSTEST	String	Diastolic Blood Pressure	DIASTOLIC BLOOD PRESSURE	DIASTOLIC BLOOD PRESSURE	VSTEST
		Heart Rate	HEART RATE	HEART RATE	
		Height	HEIGHT	HEIGHT	
		Mid Upper Arm Circumference	MUAC	MUAC	
		Respiratory Rate	RESPIRATORY RATE	RESPIRATORY RATE	
		Systolic Blood Pressure	SYSTOLIC BLOOD PRESSURE	SYSTOLIC BLOOD PRESSURE	
		Temperature	TEMPERATURE	TEMPERATURE	
		Weight	WEIGHT	WEIGHT	
		Cranial Perimeter	CRANIAL PERIMETER	CRANIAL PERIMETER	
		Apgar Score	APGAR SCORE	APGAR SCORE	
VSTESTCD	String	DIABP	DBP	DBP	VSTESTCD
		HEART RATE	HR	HR	
		HEIGHT	HE	HEI	
		MUAC	MUAC	MAUC2	
		RESP RATE	RR	RESPR	1
		SYSBP	SBP	SBP	
		TEMP	TE	TEMP	
		WEIGHT	WE	WEIGHT2	
		CRANIAL PERIMETER	CRP	CRP	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 22 of 150

		APGAR SCORE	APGAR	APGAR	
VACCSITE	String	Deltoid	1	Deltoid	P_SITE_HEXA,
		Thigh	3	Thigh	P_SITE_PREVNAR13
		Buttock	6	Buttock	
VACCSIDE	String	Left	L	LEFT	P_SIDE_HEXA,
		Right	R	RIGHT	P_SIDE_PREVNAR13
		Upper Left	UL	UPPER LEFT	
		Lower Left	LL	LOWER LEFT	
		Upper Right	UR	UPPER RIGHT	
		Lower Right	LR	LOWER RIGHT	
MEDROUT_VACC	String	Intramuscular	IM	Intramuscular	P_ROUTE_HEXA,
		Subcutaneous	SC	Subcutaneous	P_ROUTE_PREVNAR13
PRODNAMES	String	Infanrix Hexa	158	Infanrix Hexa	P_CODE_HEXA,
		Prevnar 13	406	Prevnar 13	P_CODE_PREVNAR13,
		Pediarix	198	Pediarix	P_CODE_ROTARIX
		Acthib	3	Acthib	
		Pentacel	404	Pentacel	
		Rotarix	270	Rotarix	
		Engerix-B	5	Engerix-B	
		Infanrix	9	Infanrix	
		Hiberix	95	Hiberix	
MEDROUT_CVACC	String	Inhalation	IH	Inhalation	P_ROUTE_ROTARIX
		Intradermal	ID	Intradermal	
		Intramuscular	IM	Intramuscular	
		Intranasal	IN	Intranasal	
		Intravenous	IV	Intravenous	
		Oral	PO	Oral	
		Parenteral	PE	Parenteral	
		Subcutaneous	SC	Subcutaneous	
		Sublingual	SL	Sublingual	
		Transdermal	TD	Transdermal	
		Other	ОТН	OTHER_OTH	
		Unknown	UNK	Unknown	

Page 23 of 150

DTPA-HBV-	IPV-135 (117119): VAC	CINE ADMINISTRATION - DOSE 1 (PENTA GROUP) (vac adm penta-dose1)
PRE-VACC TEM	PERATURE	
1.* Pre-vaccinat	on temperature: mp]	[PRE_TEMP] [PRE_TEMP] Temperature (°F) XXX.X [TEMP_ROUTE] Route: [A:A] Axillary [A:O] Oral [A:R] Rectal (Preferred) [A:T] Tympanic
Pentacel Vaccine		
2.* Has Pentace [Vaccinated]	Vaccine been administered?	[V_ADM_PENTACEL] [A:Y]
		[A:N] ONO
Engerix-B Vaccin 3.* Has Engerix- [Vaccinated]	B Vaccine been administered?	[V_ADM_ENGERIX_B] [A:Y]

Page 24 of 150

		NADM COM ENGERTY RI
		[VADM_COM_ENGERIX_B] If relevant, comment on administration: A200
		[A:N]
Pre	vnar13 Vaccine	
4.*	Has Prevnar13 Vaccine been administered? [Vaccinated]	[VADM_PREVNAR13] [A:Y] \(\begin{array}{l} \text{[VACC_DET_3VACC_PREVNAR13]} \\ Yes \(\begin{array}{l} \text{[VATF_PREVNAR13]} \\ Yes \(\begin{array}{l} \text{[VATF_PREVNAR13]} \\ Yes \(\begin{array}{l} \text{[VATF_PREVNAR13]} \\ Injection \text{Site} \(\text{Side} \text{Route:} \\ [A:Y] \(\begin{array}{l} \text{[P_AP_PREVNAR13]} \\ Yes \(\text{[P_AP] DET_PREVNAR13]} \\ Yot according \(\begin{array}{l} \text{[P_APSIDE_PREVNAR13]} \\ Yes \(\text{[P_APSIDE_PREVNAR13]} \\ Yes \(\text{[P_APSIDE_PREVNAR13]} \\ Yes \(\text{[P_APROUTE_PREVNAR13]} \\ You \(\text{[P_APROUTE_PREVNAR13]} \\ You \(\text{[P_APROUTE_PREVNAR13]} \\ Yes \
Rot	arix Vaccine	
5.*	Has Rotarix Vaccine been administered? [Vaccinated]	[V_ADM_ROTARIX] [A:Y]
VA	CCINATION DETAILS	
6.	Date of administration:	[VACCRDAT] If at least one vaccine administered

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 25 of 150

		[VACCRDAT] Req
7.	If at least one vaccination not done: [Reason for non-admin]	[VACC_REAS] [VACC_REAS] [VACC_REAS] Please select the major reason for non administration: [A:SAE]
N	ey: [*] = Item is required [✔] = Source verification re ote: Hidden items are not displayed. ote: Source verification critical settings made in InForm v	

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
VSORRESU	String	beats per minute	ВРМ	ВРМ	TEMP_UNIT_HID
		breaths per minute	BRTH	BRTH	
		Celsius	CE	CE	
		Fahrenheit	FA	FAR	
		feet	FT	FT	
		inches	IN	INCH	
		kg	KG	KG	
		ounces	OZ	OZ	
		pounds	LB	LB	
		cm	СМ	СМ	
		mmHg	MMHG	MMHG	
		grams	G	GRAM	
VSTEST	String	Diastolic Blood Pressure	DIASTOLIC BLOOD PRESSURE	DIASTOLIC BLOOD PRESSURE	VSTEST
		Heart Rate	HEART RATE	HEART RATE]
		Height	HEIGHT	HEIGHT	
		Mid Upper Arm Circumference	MUAC	MUAC	

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 26 of 150

		Respiratory Rate	RESPIRATORY RATE	RESPIRATORY RATE	
		Systolic Blood Pressure	SYSTOLIC BLOOD PRESSURE	SYSTOLIC BLOOD PRESSURE	1
		Temperature	TEMPERATURE	TEMPERATURE	1
		Weight	WEIGHT	WEIGHT	
		Cranial Perimeter	CRANIAL PERIMETER	CRANIAL PERIMETER	
		Apgar Score	APGAR SCORE	APGAR SCORE	
VSTESTCD	String	DIABP	DBP	DBP	VSTESTCD
		HEART RATE	HR	HR	1
		HEIGHT	HE	HEI	1
		MUAC	MUAC	MAUC2	1
		RESP RATE	RR	RESPR	1
		SYSBP	SBP	SBP]
		TEMP	TE	TEMP	
		WEIGHT	WE	WEIGHT2	
		CRANIAL PERIMETER	CRP	CRP	
		APGAR SCORE	APGAR	APGAR	
/ACCSITE	String	Deltoid	1	Deltoid	P_SITE_PENTACEL, P_SITE_ENGERIX_B, P_SITE_PREVNAR13
		Thigh	3	Thigh	
		Buttock	6	Buttock	1 = -
VACCSIDE	String	Left	L	LEFT	P_SIDE_PENTACEL,
		Right	R	RIGHT	P_SIDE_ENGERIX_B, P_SIDE_PREVNAR13
		Upper Left	UL	UPPER LEFT	1 ======
		Lower Left	LL	LOWER LEFT	
		Upper Right	UR	UPPER RIGHT	
		Lower Right	LR	LOWER RIGHT	
MEDROUT_VACC	String	Intramuscular	IM	Intramuscular	P_ROUTE_PENTACEL,
		Subcutaneous	SC	Subcutaneous	P_ROUTE_ENGERIX_E P_ROUTE_PREVNAR13
PRODNAMES	String	Infanrix Hexa	158	Infanrix Hexa	P_CODE_PENTACEL,
		Prevnar 13	406	Prevnar 13	P_CODE_ENGERIX_B, P_CODE_PREVNAR13,
		Pediarix	198	Pediarix	P_CODE_ROTARIX
		Acthib	3	Acthib	1
		Pentacel	404	Pentacel	1
		Rotarix	270	Rotarix	1
		Engerix-B	5	Engerix-B	1

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 27 of 150

		Infanrix	9	Infanrix	
		Hiberix	95	Hiberix	
MEDROUT_CVACC	String	Inhalation	IH	Inhalation	P_ROUTE_ROTARIX
		Intradermal	ID	Intradermal	
		Intramuscular	IM	Intramuscular	
		Intranasal	IN	Intranasal	
		Intravenous	IV	Intravenous	
		Oral	PO	Oral	
		Parenteral	PE	Parenteral	
		Subcutaneous	SC	Subcutaneous	
		Sublingual	SL	Sublingual	
		Transdermal	TD	Transdermal	
		Other	OTH	OTHER_OTH	
		Unknown	UNK	Unknown	

Page 28 of 150

	ACCINE ADMINISTRATION - DOSE 1 (PEDIA GROUP) (vac adm pedia-dose1)
PRE-VACC TEMPERATURE	
1.* Pre-vaccination temperature: [Pre-vacc temp]	[PRE_TEMP] [PRE_TEMP] Temperature (°F) XXX.X TEMP_ROUTE] Route: [A:A]
Pediarix Vaccine	
2.* [Vaccinated]	[V_ADM_PEDIARIX] [A:Y]
ActHib Vaccine	12
3.* Has ActHib Vaccine been administered? [Vaccinated]	[V_ADM_ACTHIB] [A:Y]

Page 29 of 150

		DIADM CON ACTURE	
		[VADM_COM_ACTHIB] If relevant, comment on administration: A200	
		[A:N]	
Pre	vnar13 Vaccine		
4.*	Has Prevnar13 Vaccine been administered? [Vaccinated]	[V_ADM_PREVNAR13] [A:Y] [VACC_DET_SVACC_PREVNAR13] -> Administered treatment number: N10 [P_AP_PREVNAR13] Injection Site/Side/Route: [A:Y] According to protocol (Thigh - Lower Left - IM) [A:N] [P_AP_DET_PREVNAR13] Not according [P_APSITE_PREVNAR13] to protocol -> Site: [A:I] Deltoid [A:3] Thigh [A:6] Buttock [P_APSIDE_PREVNAR13] Side: [A:L] Left [A:R] Right [A:UL] Upper [A:LL] Lower [A:UR] Upper [A:LR] Left [P_APROUTE_PREVNAR13] Route: [A:IM] Intramuscular [A:SC] Subcutaneous [VADM_COM_PREVNAR13] If relevant, comment on administration: [A:N] No	
Rot	arix Vaccine		_
5.*	Has Rotarix Vaccine been administered? [Vaccinated]	[V_ADM_ROTARIX] /A:Y] [VACC_DET_SVACC_ROTARIX] /Yes - [V_TRT_ROTARIX] > Administered treatment number: N10 [P_AP_ROTARIX] [A:Y] According to protocol (Oral) [A:N] No taccording to protocol [VADM_COM_ROTARIX] If relevant, comment on administration: [A:N] No	
VA	CCINATION DETAILS		_
6.	Date of administration:	[VACCRDAT] If at least one vaccine administered	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 30 of 150

		[VACCRDAT] Req
7.	If at least one vaccination not done: [Reason for non-admin]	[VACC_REAS] [VACC_REAS] [VACC_REAS] Please select the major reason for non administration: [A:SAE]
N	oy: [*] = Item is required [

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
VSORRESU	String	beats per minute	ВРМ	ВРМ	TEMP_UNIT_HID
		breaths per minute	BRTH	BRTH	
		Celsius	CE	CE	
		Fahrenheit	FA	FAR	
		feet	FT	FT	
		inches	IN	INCH	
		kg	KG	KG	
		ounces	OZ	OZ	
		pounds	LB	LB	
		cm	СМ	СМ	
		mmHg	MMHG	MMHG	
		grams	G	GRAM	
VSTEST	String	Diastolic Blood Pressure	DIASTOLIC BLOOD PRESSURE	DIASTOLIC BLOOD PRESSURE	VSTEST
		Heart Rate	HEART RATE	HEART RATE	
		Height	HEIGHT	HEIGHT	
		Mid Upper Arm Circumference	MUAC	MUAC	

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 31 of 150

		Respiratory Rate	RESPIRATORY RATE	RESPIRATORY RATE	
		Systolic Blood Pressure	SYSTOLIC BLOOD PRESSURE	SYSTOLIC BLOOD PRESSURE	
		Temperature	TEMPERATURE	TEMPERATURE	
		Weight	WEIGHT	WEIGHT	
		Cranial Perimeter	CRANIAL PERIMETER	CRANIAL PERIMETER	
		Apgar Score	APGAR SCORE	APGAR SCORE	
VSTESTCD	String	DIABP	DBP	DBP	VSTESTCD
		HEART RATE	HR	HR	
		HEIGHT	HE	HEI	
		MUAC	MUAC	MAUC2	
		RESP RATE	RR	RESPR	
		SYSBP	SBP	SBP	
		TEMP	TE	TEMP	
		WEIGHT	WE	WEIGHT2	
		CRANIAL PERIMETER	CRP	CRP	
		APGAR SCORE	APGAR	APGAR	
VACCSITE	String	Deltoid	1	Deltoid	P_SITE_PEDIARIX,
		Thigh	3	Thigh	P_SITE_ACTHIB, P_SITE_PREVNAR13
		Buttock	6	Buttock	
VACCSIDE	String	Left	L	LEFT	P_SIDE_PEDIARIX,
		Right	R	RIGHT	P_SIDE_ACTHIB, P_SIDE_PREVNAR13
		Upper Left	UL	UPPER LEFT	
		Lower Left	LL	LOWER LEFT	
		Upper Right	UR	UPPER RIGHT	
		Lower Right	LR	LOWER RIGHT	
MEDROUT_VACC	String	Intramuscular	IM	Intramuscular	P_ROUTE_PEDIARIX,
		Subcutaneous	SC	Subcutaneous	P_ROUTE_ACTHIB, P_ROUTE_PREVNAR13
PRODNAMES	String	Infanrix Hexa	158	Infanrix Hexa	P_CODE_PEDIARIX,
		Prevnar 13	406	Prevnar 13	P_CODE_ACTHIB, P_CODE_PREVNAR13,
		Pediarix	198	Pediarix	
		Acthib	3	Acthib	P_CODE_ROTARIX
		Pentacel	404	Pentacel	
		Rotarix	270	Rotarix	
		Engerix-B	5	Engerix-B	
		Infanrix	9	Infanrix	1

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 32 of 150

		Hiberix	95	Hiberix	
MEDROUT_CVACC	String	Inhalation	IH	Inhalation	P_ROUTE_ROTARIX
		Intradermal	ID	Intradermal	
		Intramuscular	IM	Intramuscular	
		Intranasal	IN	Intranasal	
		Intravenous	IV	Intravenous	
		Oral	PO	Oral	
		Parenteral	PE	Parenteral	
		Subcutaneous	SC	Subcutaneous	
		Sublingual	SL	Sublingual	
		Transdermal	TD	Transdermal	
		Other	OTH	OTHER_OTH	
		Unknown	UNK	Unknown	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 33 of 150

DTPA-HBV-IPV-135 (117119): LOCAL SIGNS/SYMPTOMS FLAG - HEXA (Loc symp fig Hexa)					
LO	CAL SIGNS/SYMPTOMS FLAG - HEXA				
	Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [Local Symp flag for Infanrix Hexa]	[LOCSOL_YN_HEXA] [A:Y] ○ Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary [A:N] ○ No [A:U] ○ Unknown, no information available			
N	ey: $[*]$ = Item is required $[\checkmark]$ = Source verification re ote: Hidden items are not displayed. ote: Source verification critical settings made in InForm v				

Page 34 of 150

DTPA-HBV-IPV-135 (117119): SOLICITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (INFANRIX HEXA) (Loc symp-Hexa)
Infanrix Hexa vaccine injection site. If any of these adverse events meets the o	definition of serious, complete a Serious Adverse Event Report.
REDNESS	
1.* Occurred?	[RE_YN] [A:V] ○ NO [A:V] ○ [SYMP_VAL_MM] Yes -> [SYMP_VAL_MM_D0] [SYMP_VAL_MM_D1] [SYMP_VAL_MM_D2] [SYM_VAL_MM_D3] Size (mm): Day 0: Day 1: Day 2: Day 3: N5 N5 N5 N5 [RE_ONG] After Day 3: Ongoing? [A:N] ○ NO [A:Y] ○ [SYMP_ONG_MM] Yes -> [SYMP_ONG_MM] Yes -> [SYMP_MAX_SIZE] Maximum size: N5 [ERDAT] Date of last day of sign/symptom: Req/Unk ✓ / Req/Unk ✓ / Req/Unk ✓ (2013-2018) [CONT_END] Continuing at the end of the study? [A:Y] □ [MED_TYPE] Medically attended visit: [A:ER] ○ Emergency Room [A:HO] ○ Mospitalisation [A:MD] ○ Medical Personnel [A:NO] ○ None
SWELLING	
2.* Occurred?	[SW_YN] [A:A
PAIN	
3.* Occurred?	[PA_YN] [A:V] No [A:Y] SYMP_VAL_INTEN] Yes -> [SYMP_VAL_INTEN_D0] [SYMP_VAL_D1] [SYMP_VAL_INTEN_D2] [SYMP_VAL_INTEN_D3]

Page 35 of 150

	Intensity: Day 0: Day 1: Day 2: Day 3: [INTENSITYSOL] [INTENSITYSOL] [INTENSITYSOL]
	[PA_ONG]
	After Day 3: Ongoing? [A:N] ○ No
	[A:Y] O[SYMP_ONG_INTEN]
	Yes -> [SYMP_MAX_INTEN]
	Maximum intensity: [INTENSITYSOLMAX] V
	[ERDAT]
	Date of last day of sign/symptom: Req/Unk / Req/Unk / Req/Unk (2013-2018)
	[CONT_END]
	Continuing at the end of the study? [A:Y]
	[MED_TYPE]
	Medically attended visit: [A:ER] Emergency Room [A:HO] Hospitalisation [A:MD] Medical Personnel [A:NO] None
1	Key: [*] = Item is required [✔] = Source verification required Note: Hidden Items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD_HID, SYMP_COD_HID, SYMP_COD_HID
		Fever	FE	FE	
		Loss Of Appetite	LO	LO	
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	
SYMPUNITS	String	Celsius	CE	CE	SYMP_UNI, SYMP_UNI
		Coded	со	CODED	
		Fahrenheit	FA	FAR	
		inches	IN	INCH	
		Millimeters	MM	MM	
		Occurence	oc	ос	
		Score	SC	SCORE	
INTENSITYSOL	String	0	0	0	SYMP_VAL_INTEN_D0,
		1	1	1	SYMP_VAL_D1, SYMP_VAL_INTEN_D2, SYMP_VAL_INTEN_D3
		2	2	2	
		3	3	3	
INTENSITYSOLMAX	String	1	1	1	SYMP_MAX_INTEN
		2	2	2	
					1

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119) Page 36 of 150

3 3 3

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 37 of 150

LOCAL SIGNS/SYMPTOMS FLAG - PEDIARIX		
1.*	Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [Local Symp flag for Pediarix]	[LOCSOL_YN_PEDIARIX] [A:Y] ○ Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary [A:N] ○ No [A:U] ○ Unknown, no information available
Key: [*] = Item is required [✓] = Source verification required Note: Hidden Items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

Page 38 of 150

Pediarix vaccine injection site.	(119): SOLICITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (PEDIARIX) (Loc symp-Pediarix) s the definition of serious, complete a Serious Adverse Event Report.
REDNESS	s the definition of Serious, complete a Serious Adverse Event Report.
1.* Occurred?	[RE_YN] [A:N]
SWELLING	
2.* Occurred?	[SW_YN] [A:N]
PAIN	
3.* Occurred?	[PA_YN] [A:N] NO [A:Y] [SYMP_VAL_INTEN] Yes -> [SYMP_VAL_INTEN_D0] [SYMP_VAL_D1] [SYMP_VAL_INTEN_D2] [SYMP_VAL_INTEN_D3]

Page 39 of 150

	Intensity: Day 0: Day 1: Day 2: Day 3: [INTENSITYSOL]
	[PA_ONG]
	After Day 3: Ongoing? [A:N] ONo
	[A:Y] (SYMP_ONG_INTEN]
	Yes -> [SYMP_MAX_INTEN] Maximum intensity: [INTENSITYSOLMAX]
	[ERDAT] Date of last day of sign/symptom: Req/Unk ▼ / Req/Unk ▼ / Req/Unk ▼ (2013-2018)
	[CONT_END] Continuing at the end of the study? [A:Y]
	[MED_TYPE] Medically attended visit: [A:ER] Emergency Room [A:HO] Hospitalisation [A:MD] Medical Personnel [A:NO] None
Key: [*] = Item is required [v] = Source verification require Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will o	

Codelist Values Tables: SOLICITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (PEDIARIX					
Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD_HID, SYMP_COD_HID, SYMP_COD_HID
		Fever	FE	FE	
		Loss Of Appetite	LO	LO	
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	
SYMPUNITS	String	Celsius	CE	CE	SYMP_UNI, SYMP_UNI
		Coded	СО	CODED	
		Fahrenheit	FA	FAR	
		inches	IN	INCH	
		Millimeters	MM	MM	
		Occurence	ос	ос	
		Score	SC	SCORE	
INTENSITYSOL	String	0	0	0	SYMP_VAL_INTEN_D0, SYMP_VAL_D1, SYMP_VAL_INTEN_D2, SYMP_VAL_INTEN_D3
		1	1	1	
		2	2	2	
		3	3	3	
INTENSITYSOLMAX	String	1	1	1	SYMP_MAX_INTEN
		2	2	2	
	1			1	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119) Page 40 of 150

3 3 3

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 41 of 150

LOCSYMPTOMS_FLG_ACTHIB		
	Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [Local Symp flag for ActHib]	[LOCSOL_YN_ACTHIB] [A:Y]
Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.		

PPD

Page 42 of 150

ActHib vaccine injection site.	7119): SOLICITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (ACTHIB) (Loc symp-ActHib)
	s the definition of serious, complete a Serious Adverse Event Report.
REDNESS	
1.* Occurred?	[RE_YN] [A:N]
SWELLING	
2.* Occurred?	[SW_YN] (A:N)
PAIN	
3.* Occurred?	[PA_YN] [A:N]

PPD

Page 43 of 150

	Intensity: Day 0: Day 1: Day 2: Day 3: [INTENSITYSOL] [INTENSITYSOL] [INTENSITYSOL] [INTENSITYSOL]
	[PA_ONG]
	After Day 3: Ongoing? [A:N] ○ No
	[A:Y] ○ [SYMP_ONG_INTEN]
	Yes -> [SYMP_MAX_INTEN]
	Maximum intensity: [INTENSITYSOLMAX] ~
	[ERDAT]
	Date of last day of sign/symptom: Req/Unk / Req/Unk / Req/Unk (2013-2018)
	[CONT_END]
	Continuing at the end of the study? [A:Y]
	[MED_TYPE] Medically attended visit: [A:ER]
1	

Codelist Values	s Tables: SOLICITE	D ADVERSE EVENT	S - LO	CAL SIGNS/S	YMPTOMS (ACTH
Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD_HID, SYMP_COD_HID, SYMP_COD_HID
		Fever	FE	FE	
		Loss Of Appetite	LO	LO	
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	
SYMPUNITS	String	Celsius	CE	CE	SYMP_UNI, SYMP_UNI
		Coded	со	CODED	
		Fahrenheit	FA	FAR	
		inches	IN	INCH	
		Millimeters	ММ	мм	
		Occurence	ос	ос	
		Score	SC	SCORE	
INTENSITYSOL	String	0	0	0	SYMP_VAL_INTEN_D0,
		1	1	1	SYMP_VAL_D1, SYMP_VAL_INTEN_D2
		2	2	2	SYMP_VAL_INTEN_D3
		3	3	3	
INTENSITYSOLMAX	String	1	1	1	SYMP_MAX_INTEN
		2	2	2	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119) Page 44 of 150

3 3

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 45 of 150

LOCAL SIGNS/SYMPTOMS FLAG - P	ENTACEL		
L.* Has the subject experienced any of Solicited signs/symptoms between Day 3? [Local Symp flag for Pentacel]			
Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed.			

PPD

06-JUL-2018 812f4fb003c07b74cae10f81cf90c72c48e48cbd

Page 46 of 150

Pentacel vaccine injection site.	119): SOLICITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (PENTACEL) (Loc symp-Pentacel) the definition of serious, complete a Serious Adverse Event Report.
REDNESS	
1.* Occurred?	[RE_YN] [A:N] ○ NO [A:N] ○ [SYMP_VAL_MM] Yes -> [SYMP_VAL_MM_D0] [SYMP_VAL_MM_D1] [SYMP_VAL_MM_D2] [SYM_VAL_MM_D3] Size (mm): Day 0: Day 1: Day 2: Day 3: N5 N5 N5 N5 [RE_ONG] After Day 3: Ongoing? [A:N] ○ NO [A:Y] ○ [SYMP_ONG_MM] Yes -> [SYMP_MAX_SIZE] Maximum size: N5 [ERDAT] Date of last day of sign/symptom: Req/Unk ▼ / Req/Unk ▼ / Req/Unk ▼ (2013-2018) [CONT_END] Continuing at the end of the study? [A:Y] □ [MED_TYPE] Medically attended visit: [A:ER] ○ Emergency Room [A:HO] ○ Hospitalisation [A:MD] ○ Medical Personnel [A:NO] ○ None
SWELLING	
2.* Occurred?	[SW_YN] [A:N]
PAIN	
3.* Occurred?	[PA_YN] [A:N]

Page 47 of 150

Intensity: Day 0: Day 1: Day 2: Day 3: [INTENSITYSOL] [INTENSITYSOL] [INTENSITYSOL]
[PA_ONG]
After Day 3: Ongoing? [A:N] No
$[A:Y] \bigcirc [SYMP_ONG_INTEN]$
Yes -> [SYMP_MAX_INTEN]
Maximum intensity: [INTENSITYSOLMAX] V
[ERDAT]
Date of last day of sign/symptom: Req/Unk / Req/Unk / Req/Unk (2013-2018)
[CONT_END]
Continuing at the end of the study? [A:Y]
[MED_TYPE] Medically attended visit: [A:ER]
Key: [*] = Item is required [✔] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.

Codelist Values Tables: SOLICITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (PENTACEL)					
Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD_HID,
		Fever	FE	FE	SYMP_COD_HID, SYMP COD HID
		Loss Of Appetite	LO	LO	
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	
SYMPUNITS	String	Celsius	CE	CE	SYMP_UNI,
		Coded	СО	CODED	SYMP_UNI
		Fahrenheit	FA	FAR	
		inches	IN	INCH	
		Millimeters	MM	мм	
		Occurence	ОС	ос	
		Score	SC	SCORE	
INTENSITYSOL	String	0	0	0	SYMP_VAL_INTEN_D0,
		1	1	1	SYMP_VAL_D1, SYMP_VAL_INTEN_D2,
		2	2	2	SYMP_VAL_INTEN_D3
		3	3	3	
INTENSITYSOLMAX	String	1	1	1	SYMP_MAX_INTEN
		2	2	2	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119) Page 48 of 150

3 3 3

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 49 of 150

LO	CAL SIGNS/SYMPTOMS FLAG - ENGERIX B		
1.* Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [Local Symp flag for Engerix-B] [LOCSOL_YN_ENGERIX_B] [A:Y] Yes -> Please tick No/Yes for each sign/symptom and complete further as necessal [A:N] No [A:U] Unknown, no information available		[A:Y]	
Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.			

Page 50 of 150

Engerix-B vaccine injection site.	(119): SOLICITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (ENGERIX-B) (Loc symp-Engerix-B) s the definition of serious, complete a Serious Adverse Event Report.
REDNESS	
1.* Occurred?	[RE_YN] [A:N]
SWELLING	
2.* Occurred?	[SW_YN] [A:N]
PAIN	
3.* Occurred?	[PA_YN] [A:N] NO [A:Y] [SYMP_VAL_INTEN] Yes -> [SYMP_VAL_INTEN_D0] [SYMP_VAL_D1] [SYMP_VAL_INTEN_D2] [SYMP_VAL_INTEN_D3]

PPD

06-JUL-2018 812f4fb003c07b74cae10f81cf90c72c48e48cbd

Page 51 of 150

	Intensity: Day 0: Day 1: Day 2: Day 3: [INTENSITYSOL] [INTENSITYSOL] [INTENSITYSOL] [INTENSITYSOL]
	After Day 3: Ongoing? [A:N] No
	[A:Y] [SYMP_ONG_INTEN]
	Yes -> [SYMP_MAX_INTEN] Maximum intensity: [INTENSITYSOLMAX]
	[ERDAT] Date of last day of sign/symptom: Req/Unk ✓ / Req/Unk ✓ / Req/Unk ✓ (2013-2018)
	[CONT_END] Continuing at the end of the study? [A:Y]
	[MED_TYPE] Medically attended visit: [A:ER]
1	Key: [*] = Item is required [✔] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.

Codelist	Codelist Data Type	Label	Code	Codelist Item	1PTOMS (ENGERIX-B Data Variable
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD_HID,
		Fever	FE	FE	SYMP_COD_HID, SYMP COD HID
		Loss Of Appetite	LO	LO	
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	
SYMPUNITS	String	Celsius	CE	CE	SYMP_UNI,
		Coded	СО	CODED	SYMP_UNI
		Fahrenheit	FA	FAR	
		inches	IN	INCH	
		Millimeters	ММ	мм	
		Occurence	ос	ос	
		Score	SC	SCORE	
INTENSITYSOL	String	0	0	0	SYMP_VAL_INTEN_D0,
		1	1	1	SYMP_VAL_D1, SYMP VAL INTEN D2,
		2	2	2	SYMP_VAL_INTEN_D3
		3	3	3	
INTENSITYSOLMAX	String	1	1	1	SYMP_MAX_INTEN
		2	2	2	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119) Page 52 of 150

3 3 3

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)


Page 53 of 150

Dī	DTPA-HBV-IPV-135 (117119): GENERAL SIGNS/SYMPTOMS FLAG (Gen symp flg)					
GE	GENERAL SIGNS/SYMPTOMS FLAG					
1.*	Has the subject experienced any of the General Solicited signs/symptoms between Day 0 and Day 3?	[GENSOL_YN] [A:Y] ○ Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary [A:N] ○ No [A:U] ○ Unknown, no information available				
N	Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.					

PPD

06-JUL-2018 812f4fb003c07b74cae10f81cf90c72c48e48cbd

Page 54 of 150



Page 55 of 150

		[CONT_END] Continuing at the end of the study? [A:Y] [CAUSAL] Is there a reasonable possibility that the AE may have been caused by the investigational product? [A:N] \(\) No \([A:Y] \) Yes [MED_TYPE] Medically attended visit: [A:ER] \(\) Emergency Room \([A:HO] \) \(\) Hospitalisation \([A:MD] \) \(\) Medical Personnel \([A:NO] \) \(\) None
3.** v	RITABILITY/FUSSINESS Occurred?	[IF_VN] [A:N]
LO	SS OF APPETITE	
4.**	Occurred?	[LO_NN] [A:N] ○ No [A:N] ○ [SYMP_VAL_INTEN] Yes -> [SYMP_VAL_INTEN_D0] [SYMP_VAL_D1] [SYMP_VAL_INTEN_D2] [SYMP_VAL_INTEN_D3] Intensity: Day 0: Day 1: Day 2: Day 3: [INTENSITYSOL] ▼ [INTENSITYSOL] ▼ [INTENSITYSOL] ▼ [INTENSITYSOL] ▼ [LO_ONG] After Day 3: Ongoing? [A:N] ○ No [A:Y] ○ [SYMP_ONG_INTEN] Yes -> [SYMP_MAX_INTEN] Maximum intensity: [INTENSITYSOLMAX] ▼ [ERDAT] Date of last day of sign/symptom: Req/Unk ▼ / Req

117119 (DTPA-HBV-IPV-135) Report Final


Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 56 of 150

		Is there a reasonable possibility that the AE may have been caused by the investigational product? [A:N] \(\cap \) No [A:Y] \(\cap \) Yes					
		[MED_TYPE] Medically attended visit: [A:ER] Emergency Room [A:HO] Hospitalisation [A:MD] Medical Personnel [A:NO] None					
1	Key: [*] = Item is required [v] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in Inform will override any settings made in Central Designer.						

Codelist Value	s Tables: SOLICI	TED ADVERSE EV	ENTS	- GENERAL	SIGNS/SYMPTOMS
Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD_HID,
		Fever	FE	FE	SYMP_COD_HID, SYMP COD HID,
		Loss Of Appetite	LO	LO	SYMP_COD_HID
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	
SYMPUNITS	String	Celsius	CE	CE	SYMP_UNI
		Coded	СО	CODED	
		Fahrenheit	FA	FAR	
		inches	IN	INCH	
		Millimeters	MM	ММ	
		Occurence	ОС	ос	
		Score	SC	SCORE	
INTENSITYSOL	String	0	0	0	SYMP_VAL_INTEN_D0, SYMP_VAL_D1, SYMP_VAL_INTEN_D2,
		1	1	1	SYMP_VAL_INTEN_D3, SYMP_VAL_INTEN_D0, SYMP_VAL_D1,
		2	2	2	SYMP_VAL_INTEN_D2, SYMP_VAL_INTEN_D3, SYMP_VAL_INTEN_D0,
		3	3	3	SYMP_VAL_D1, SYMP_VAL_INTEN_D2, SYMP_VAL_INTEN_D3
INTENSITYSOLMAX	String	1	1	1	SYMP_MAX_INTEN,
		2	2	2	SYMP_MAX_INTEN, SYMP_MAX_INTEN
		3	3	3]

Page 57 of 150



117119 (DTPA-HBV-IPV-135) Report Final

Annotated S	tudv Book -	DTPA-HBV-	-IPV-135	(117119

Page 58 of 150

☐ In this case, terminate the CRF: Complete Medication, Concomitant Vaccination, (S)AE sections and Study Conclusion.	
Key: [*] = Item is required [▼] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.	

Codelist Values Tables: CHECK FOR STUDY CONTINUATION							
Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable		
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD		
		Fever	FE	FE			
		Loss Of Appetite	LO	LO			
		Pain	PA	PA			
		Redness	RE	RE			
		Swelling	SW	sw			
		Irritability / Fussiness	IF	IF			

Page 59 of 150

DT	PA-HBV-IPV-135 (117119): VAC	CINE ADMINISTRATION - DOSE 2 (HEXA GROUP) (vac adm hexa-dose2)			
PRE	-VACC TEMPERATURE				
1.*	Pre-vaccination temperature: [Pre-vacc temp]	[PRE_TEMP] [PRE_TEMP] Temperature (°F) XXX.X [TEMP_ROUTE] Route: [A:A]			
Infa	nrix Hexa Vaccine				
2.*	Has Infanrix Hexa Vaccine been administered? [Vaccinated]	[V_ADM_HEXA] [A:Y]			
Prev	rnar13 Vaccine				
3.*	Has Prevant13 Vaccine been administered? [Vaccinated]	[V_ADM_PREVNAR13] [A:Y]			

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 60 of 150

		[VADM_COM_PREVNAR13] If relevant, comment on administration: [A:N] No		
Rot	arix Vaccine			
4.*	Has Rotarix Vaccine been administered? [Vaccinated]	[V_ADM_ROTARIX] [A:Y]		
VA	CCINATION DETAILS	<u> </u>		
5.	Date of administration:	[VACCRDAT] If at least one vaccine administered [VACCRDAT] Req		
6.	If at least one vaccination not done: [Reason for non-admin]	[VACC_REAS] [VACC_REAS] Please select the major reason for non administration: [A:SAE] ○ [SAE_CASE] Serious Adverse Event-> Please complete a SAE Report and specify SAE Report No. N2 [A:AEX] ○ [AE_NB] Non-Serious Adverse Event [AE_NB] -> Please complete Non-Serious Adverse Event section and specify AE No. N2 [SYMP_COD] or Solicited AE code: [SYMPCODE] ▼ [A:OTH] ○ [V_OTH] Other, please specify (e.g.: consent withdrawal, Protocol violation,) A100 [DECISION] Please select who made the decision: [A:I] ○ Investigator [A:P] ○ Subject's parents / Legally Acceptable Representatives		

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 61 of 150

Key: [*] = Item is required [✓] = Source verification required

Note: Hidden items are not displayed.

Note: Source verification critical settings made in InForm will override any settings made in Central Designer.

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
VSORRESU	String	beats per minute	ВРМ	ВРМ	TEMP_UNIT_HID
		breaths per minute	BRTH	BRTH	
		Celsius	CE	CE	
		Fahrenheit	FA	FAR	
		feet	FT	FT	1
		inches	IN	INCH	1
		kg	KG	KG	
		ounces	OZ	OZ	
		pounds	LB	LB	
		cm	СМ	СМ	1
		mmHg	MMHG	MMHG	
		grams	G	GRAM	
VSTEST	String	Diastolic Blood Pressure	DIASTOLIC BLOOD PRESSURE	DIASTOLIC BLOOD PRESSURE	RE VSTEST
		Heart Rate	HEART RATE	HEART RATE	
		Height	HEIGHT	HEIGHT	
		Mid Upper Arm Circumference	MUAC	MUAC	1
		Respiratory Rate	RESPIRATORY RATE	RESPIRATORY RATE	
		Systolic Blood Pressure	SYSTOLIC BLOOD PRESSURE	SYSTOLIC BLOOD PRESSURE	
		Temperature	TEMPERATURE	TEMPERATURE	
		Weight	WEIGHT	WEIGHT	1
		Cranial Perimeter	CRANIAL PERIMETER	CRANIAL PERIMETER	1
		Apgar Score	APGAR SCORE	APGAR SCORE	1
VSTESTCD	String	DIABP	DBP	DBP	VSTESTCD
		HEART RATE	HR	HR	1
		HEIGHT	HE	HEI	1
		MUAC	MUAC	MAUC2	1
		RESP RATE	RR	RESPR	1
		SYSBP	SBP	SBP]
		TEMP	TE	TEMP	
		WEIGHT	WE	WEIGHT2]

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 62 of 150

		CRANIAL PERIMETER	CRP	CRP	
		APGAR SCORE	APGAR	APGAR	
VACCSITE	String	Deltoid	1	Deltoid	P_SITE_HEXA,
		Thigh	3	Thigh	P_SITE_PREVNAR13
		Buttock	6	Buttock	
VACCSIDE	String	Left	L	LEFT	P_SIDE_HEXA,
		Right	R	RIGHT	P_SIDE_PREVNAR13
		Upper Left	UL	UPPER LEFT	
		Lower Left	LL	LOWER LEFT	
		Upper Right	UR	UPPER RIGHT	
		Lower Right	LR	LOWER RIGHT	
MEDROUT_VACC	String	Intramuscular	IM	Intramuscular	P_ROUTE_HEXA,
		Subcutaneous	SC	Subcutaneous	P_ROUTE_PREVNAR1
PRODNAMES	String	Infanrix Hexa	158	Infanrix Hexa	P_CODE_HEXA,
		Prevnar 13	406	Prevnar 13	P_CODE_PREVNAR13
		Pediarix	198	Pediarix	P_CODE_ROTARIX
		Acthib	3	Acthib	
		Pentacel	404	Pentacel	
		Rotarix	270	Rotarix	
		Engerix-B	5	Engerix-B	
		Infanrix	9	Infanrix	
		Hiberix	95	Hiberix	
MEDROUT_CVACC	String	Inhalation	IH	Inhalation	P_ROUTE_ROTARIX
		Intradermal	ID	Intradermal	
		Intramuscular	IM	Intramuscular	
		Intranasal	IN	Intranasal	
		Intravenous	IV	Intravenous	
		Oral	PO	Oral	
		Parenteral	PE	Parenteral	
		Subcutaneous	SC	Subcutaneous	
		Sublingual	SL	Sublingual	
		Transdermal	TD	Transdermal	
		Other	ОТН	OTHER_OTH	
		Unknown	UNK	Unknown	
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 63 of 150

Fever	FE	FE	
Loss Of Appetite	LO	LO	
Pain	PA	PA	
Redness	RE	RE	
Swelling	SW	SW	
Irritability / Fussiness	IF	IF	

Page 64 of 150

DTPA-HBV-IPV-135 (117119): V	ACCINE ADMINISTRATION - DOSE 2 (PEDIA GROUP) (vac adm pedia-dose2)
PRE-VACC TEMPERATURE	
1.* Pre-vaccination temperature: [Pre-vacc temp]	[PRE_TEMP] [PRE_TEMP] Temperature (°F) XXX.X [TEMP_ROUTE] Route: [A:A] Axillary [A:O] Oral [A:R] Rectal (Preferred) [A:T] OTympanic
Pediarix Vaccine	
2.* Has Pediarix Vaccine been administered? [Vaccinated]	[V_ADM_PEDIARIX] [A:Y]
	[A:N] (NO
actHib Vaccine 3.* Has ActHib Vaccine been administered? [Vaccinated]	[V_ADM_ACTHIB] [A:Y] [VACC_DET_4VACC_ACTHIB] Yes [V_TRT_ACTHIB] -> Administered treatment number: N10 [P_AP_ACTHIB] Injection Site/Side/Route: [A:Y] (According to protocol (Thigh - Upper Left - IM) [A:N] (P_AP_DET_ACTHIB] Not according [P_APSITE_ACTHIB] Not according [P_APSITE_ACTHIB] to protocol -> Site: [A:I] (Deltoid [A:3] (Thigh [A:6] (Buttock) [P_APSIDE_ACTHIB] Side: [A:L] (Left [A:R] (Right [A:UL] (Lower [A:UR] (Upper [A:LL] (Lower Right (IP_APROUTE_ACTHIB)) [P_APROUTE_ACTHIB] Route: [A:IM] (Intramuscular [A:SC) (Subcutaneous)

Page 65 of 150

	1	DIADM CON ACTURE
		[VADM_COM_ACTHIB] If relevant, comment on administration: A200
		[A:N]
Pre	vnar13 Vaccine	
4.*	Has Prevnar13 Vaccine been administered? [Vaccinated]	[V_ADM_PREVNAR13] [A:Y] [VACC_DET_SVACC_PREVNAR13] -> Administered treatment number: N10 [P_AP_PREVNAR13] Injection Site/Side/Route: [A:Y] According to protocol (Thigh - Lower Left - IM) [A:N] [P_AP_DET_PREVNAR13] Not according [P_APSITE_PREVNAR13] to protocol -> Site: [A:I] Deltoid [A:3] Thigh [A:6] Buttock [P_APSIDE_PREVNAR13] Side: [A:L] Cleft [A:R] Right [A:LL] Clower [A:LR] Clower Right [P_APROUTE_PREVNAR13] Route: [A:IM] Intramuscular [A:SC] Subcutaneous [VADM_COM_PREVNAR13] If relevant, comment on administration: [A:N] No
Rot	arix Vaccine	
5.*	Has Rotarix Vaccine been administered? [Vaccinated]	[V_ADM_ROTARIX] /A:Y] [VACC_DET_SVACC_ROTARIX] /Yes - [V_TRT_ROTARIX] > Administered treatment number: N10 [P_AP_ROTARIX] [A:Y] According to protocol (Oral) [A:N] No No according to protocol [VADM_COM_ROTARIX] If relevant, comment on administration: [A:N] No
VA	CCINATION DETAILS	
6.	Date of administration:	[VACCRDAT] If at least one vaccine administered

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 66 of 150

		[VACCRDAT] Req ♥ / Req ♥ (2013-2018) [SAME_DATE] Or tick box if date is the same as visit date [A:Y] □			
	If at least one vaccination not done: [Reason for non-admin]	VACC_REAS] VACC_REAS] lease select the major reason for non administration: (A:SAE] ○ [SAE_CASE] Serious Adverse Event-> Please complete a SAE Report and specify SAE Report No. N2			
		[A:AEX] [AE_NB] Non-Serious Adverse Event [AE_NB] -> Please complete Non-Serious Adverse Event section and specify AE No. N2 [SYMP_COD] Or Solicited AE code: [SYMPCODE]			
		[A:OTH] [V_OTH] Other, please specify A100 [DECISION] Please select who made the decision: [A:I] Investigator [A:P] Subject's parents / Legally Acceptable Representatives			
No.	Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.				

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
VSORRESU	String	beats per minute	ВРМ	ВРМ	TEMP_UNIT_HID
		breaths per minute	BRTH	BRTH	
		Celsius	CE	CE	
		Fahrenheit	FA	FAR	
		feet	FT	FT	
		inches	IN	INCH	
		kg	KG	KG	
		ounces	OZ	OZ	
		pounds	LB	LB	
		cm	CM	СМ	
		mmHg	MMHG	MMHG	
		grams	G	GRAM	
VSTEST	String	Diastolic Blood Pressure	DIASTOLIC BLOOD PRESSURE	DIASTOLIC BLOOD PRESSURE	VSTEST
		Heart Rate	HEART RATE	HEART RATE	

PPD

06-JUL-2018 812f4fb003c07b74cae10f81cf90c72c48e48cbd

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 67 of 150

		Height	HEIGHT	HEIGHT	
		Mid Upper Arm Circumference	MUAC	MUAC	
		Respiratory Rate	RESPIRATORY RATE	RESPIRATORY RATE	
		Systolic Blood Pressure	SYSTOLIC BLOOD PRESSURE	SYSTOLIC BLOOD PRESSURE	
		Temperature	TEMPERATURE	TEMPERATURE	
		Weight	WEIGHT	WEIGHT	
		Cranial Perimeter	CRANIAL PERIMETER	CRANIAL PERIMETER	
		Apgar Score	APGAR SCORE	APGAR SCORE	
VSTESTCD	String	DIABP	DBP	DBP	VSTESTCD
		HEART RATE	HR	HR	
		HEIGHT	HE	HEI	
		MUAC	MUAC	MAUC2	
		RESP RATE	RR	RESPR	
		SYSBP	SBP	SBP	
		TEMP	TE	TEMP	
		WEIGHT	WE	WEIGHT2	
		CRANIAL PERIMETER	CRP	CRP	
		APGAR SCORE	APGAR	APGAR	
VACCSITE	String	Deltoid	1	Deltoid	P_SITE_PEDIARIX,
		Thigh	3	Thigh	P_SITE_ACTHIB, P_SITE_PREVNAR13
		Buttock	6	Buttock	
VACCSIDE	String	Left	L	LEFT	P_SIDE_PEDIARIX,
		Right	R	RIGHT	P_SIDE_ACTHIB, P_SIDE_PREVNAR13
		Upper Left	UL	UPPER LEFT	
		Lower Left	LL	LOWER LEFT	
		Upper Right	UR	UPPER RIGHT	
		Lower Right	LR	LOWER RIGHT	
MEDROUT_VACC	String	Intramuscular	IM	Intramuscular	P_ROUTE_PEDIARIX,
		Subcutaneous	SC	Subcutaneous	P_ROUTE_ACTHIB, P ROUTE PREVNAR1
PRODNAMES	String	Infanrix Hexa	158	Infanrix Hexa	P_CODE_PEDIARIX,
		Prevnar 13	406	Prevnar 13	P_CODE_ACTHIB, P_CODE_PREVNAR13,
		Pediarix	198	Pediarix	
		Acthib	3	Acthib	P_CODE_ROTARIX
		Pentacel	404	Pentacel	
		Rotarix	270	Rotarix	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 68 of 150

		Engerix-B	5	Engerix-B	
		Infanrix	9	Infanrix	
		Hiberix	95	Hiberix	
MEDROUT_CVACC	String	Inhalation	IH	Inhalation	P_ROUTE_ROTARIX
		Intradermal	ID	Intradermal	
		Intramuscular	IM	Intramuscular	
		Intranasal	IN	Intranasal	
		Intravenous	IV	Intravenous	
		Oral	PO	Oral	
		Parenteral	PE	Parenteral	
		Subcutaneous	SC	Subcutaneous	
		Sublingual	SL	Sublingual	
		Transdermal	TD	Transdermal	
		Other	ОТН	OTHER_OTH	
		Unknown	UNK	Unknown	
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD
		Fever	FE	FE	
		Loss Of Appetite	LO	LO	
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	

Page 69 of 150

DTPA-HBV-IPV-135 (117119): VA	PA-HBV-IPV-135 (117119): VACCINE ADMINISTRATION - DOSE 2 (PENTA GROUP) (vac adm penta-dose2)					
PRE-VACC TEMPERATURE						
1.* Pre-vaccination temperature: [Pre-vacc temp]	[PRE_TEMP] [PRE_TEMP] Temperature (°F) XXX.X [TEMP_ROUTE] Route: [A:A] Axillary [A:O] Oral [A:R] Rectal (Preferred) [A:T] Tympanic					
Pentacel Vaccine						
2.* Has Pentacel Vaccine been administered? [Vaccinated]	[V_ADM_PENTACEL] [A:Y] [VACC_DET_4VACC_PENTACEL] Yes [V_TRT_PENTACEL] -> Administered treatment number: N10 [P_AP_PENTACEL] Injection Site/Side/Route: [A:Y]					
	[A:N]					
Engerix-B Vaccine (should not be given at Month 2	(4 months of age) if a dose of Hepatitis B vaccine was given at birth up to 30 days prior to study dose 1)					
3.* Has Engerix-B Vaccine been administered? [Vaccinated]	[V_ADM_ENGERIX_B] [A:Y]					

Page 70 of 150

		TUADH CON ENGERTY RI
		[VADM_COM_ENGERIX_B] If relevant, comment on administration: A200
		[A:N]
Pre	vnar13 Vaccine	
4.*	Has Prevnar13 Vaccine been administered? [Vaccinated]	[VADM_PREVNAR13] [A:Y] \(\begin{array}{l} \text{[VACC_DET_3VACC_PREVNAR13]} \\ Yes \(\begin{array}{l} \text{[VATF_PREVNAR13]} \\ Yes \(\begin{array}{l} \text{[VATF_PREVNAR13]} \\ Yes \(\begin{array}{l} \text{[VATF_PREVNAR13]} \\ Injection \text{Site} \(\text{Side} \text{Route:} \\ [A:Y] \(\begin{array}{l} \text{[P_AP_PREVNAR13]} \\ Yes \(\text{[P_AP] DET_PREVNAR13]} \\ Yot according \(\begin{array}{l} \text{[P_APSIDE_PREVNAR13]} \\ Yes \(\text{[P_APSIDE_PREVNAR13]} \\ Yes \(\text{[P_APSIDE_PREVNAR13]} \\ Yes \(\text{[P_APROUTE_PREVNAR13]} \\ You \(\text{[P_APROUTE_PREVNAR13]} \\ You \(\text{[P_APROUTE_PREVNAR13]} \\ Yes \
Rot	arix Vaccine	-
5.*	Has Rotarix Vaccine been administered? [Vaccinated]	[V_ADM_ROTARIX] [A:Y]
VA	CCINATION DETAILS	
6.	Date of administration:	[VACCRDAT] If at least one vaccine administered

Page 71 of 150

		[VACCRDAT] Req			
7.	If at least one vaccination not done: [Reason for non-admin]	[VACC_REAS] [VACC_REAS] [VACC_REAS] Please select the major reason for non administration: [A:SAE]			
N	Key: [*] = Item is required [•] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.				

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
VSORRESU	String	beats per minute	ВРМ	ВРМ	TEMP_UNIT_HID
		breaths per minute	BRTH	BRTH	1
		Celsius	CE	CE	
		Fahrenheit	FA	FAR	
		feet	FT	FT	
		inches	IN	INCH	
		kg	KG	KG	
		ounces	OZ	OZ	
		pounds	LB	LB	
		cm	CM	СМ	
		mmHg	MMHG	MMHG	
		grams	G	GRAM	
VSTEST	String	Diastolic Blood Pressure	DIASTOLIC BLOOD PRESSURE	DIASTOLIC BLOOD PRESSURE	VSTEST
		Heart Rate	HEART RATE	HEART RATE	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 72 of 150

		Height	HEIGHT	HEIGHT	
		Mid Upper Arm Circumference	MUAC	MUAC	
		Respiratory Rate	RESPIRATORY RATE	RESPIRATORY RATE	
		Systolic Blood Pressure	SYSTOLIC BLOOD PRESSURE	SYSTOLIC BLOOD PRESSURE	
		Temperature	TEMPERATURE	TEMPERATURE	
		Weight	WEIGHT	WEIGHT	
		Cranial Perimeter	CRANIAL PERIMETER	CRANIAL PERIMETER	
		Apgar Score	APGAR SCORE	APGAR SCORE	
/STESTCD	String	DIABP	DBP	DBP	VSTESTCD
		HEART RATE	HR	HR	
		HEIGHT	HE	HEI	
		MUAC	MUAC	MAUC2	
		RESP RATE	RR	RESPR	
		SYSBP	SBP	SBP	
		TEMP	TE	TEMP	
		WEIGHT	WE	WEIGHT2	
		CRANIAL PERIMETER	CRP	CRP	
		APGAR SCORE	APGAR	APGAR	
VACCSITE	String	Deltoid	1	Deltoid	P_SITE_PENTACEL,
		Thigh	3	Thigh	P_SITE_ENGERIX_B, P_SITE_PREVNAR13
		Buttock	6	Buttock	
/ACCSIDE	String	Left	L	LEFT	P_SIDE_PENTACEL,
		Right	R	RIGHT	P_SIDE_ENGERIX_B, P_SIDE_PREVNAR13
		Upper Left	UL	UPPER LEFT	
		Lower Left	LL	LOWER LEFT	
		Upper Right	UR	UPPER RIGHT	
		Lower Right	LR	LOWER RIGHT	
MEDROUT_VACC	String	Intramuscular	IM	Intramuscular	P_ROUTE_PENTACEL,
		Subcutaneous	sc	Subcutaneous	P_ROUTE_ENGERIX_E P_ROUTE_PREVNAR13
PRODNAMES	String	Infanrix Hexa	158	Infanrix Hexa	P_CODE_PENTACEL,
		Prevnar 13	406	Prevnar 13	P_CODE_ENGERIX_B, P_CODE_PREVNAR13
		Pediarix	198	Pediarix	P_CODE_ROTARIX
		Acthib	3	Acthib	
		Pentacel	404	Pentacel	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 73 of 150

		Rotarix	270	Rotarix	
		Engerix-B	5	Engerix-B	1
		Infanrix	9	Infanrix	1
		Hiberix	95	Hiberix	1
MEDROUT_CVACC	String	Inhalation	IH	Inhalation	P_ROUTE_ROTARIX
		Intradermal	ID	Intradermal	1
		Intramuscular	IM	Intramuscular	
		Intranasal	IN	Intranasal	
		Intravenous	IV	Intravenous	
		Oral	PO	Oral	
		Parenteral	PE	Parenteral	
		Subcutaneous	SC	Subcutaneous]
		Sublingual	SL	Sublingual	
		Transdermal	TD	Transdermal	
		Other	OTH	OTHER_OTH	
		Unknown	UNK	Unknown	
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD
		Fever	FE	FE]
		Loss Of Appetite	LO	LO	
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 74 of 150

C	DTPA-HBV-IPV-135 (117119): LOCAL SIGNS/SYMPTOMS FLAG - ACTHIB (Loc symp flg ActHib)					
1	* Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [Local Symp flag for ActHib]	[IOCSOL_YN_ACTHIB] [A:Y]				
Key: [*] = Item is required [✔] = Source verifi Note: Hidden items are not displayed. Note: Source verification critical settings made in		quired will override any settings made in Central Designer.				

PPD

06-JUL-2018 812f4fb003c07b74cae10f81cf90c72c48e48cbd

Page 75 of 150

DTPA-HBV-IPV-135 (1	TPA-HBV-IPV-135 (117119): VACCINE ADMINISTRATION - DOSE 3 (HEXA GROUP) (vac adm hexa-dose3)				
PRE-VACC TEMPERATURE					
1.* Pre-vaccination temperature	e: [PRE_TEMP] [PRE_TEMP] [PRE_TEMP] Temperature (°F) XXX.X [TEMP_ROUTE] Route: [A:A]	7 ⊙ Tympanic			
Infanrix Hexa					
2.* Has Infanrix Hexa Vaccine b	[A:Y]	ht [A:UL] OUpper [A:LL] OLower [A:UR] OUpper [A:LR] OLower Right			
	[A:N] No				
Prevnar13 Vaccine 3.* Has Prevnar13 Vaccine beer [Vaccinated]	[A:Y]	ht [A:UL] OUpper [A:LL] OLower [A:UR] OUpper [A:LR] OLower Right			

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 76 of 150

		[VADM_COM_PREVNAR13] If relevant, comment on administration:	A200			
		[A:N] ONO				
VA	CCINATION DETAILS					
4.	Date of administration:	[VACCRDAT] If at least one vaccine administered [VACCRDAT] Req				
5.	If at least one vaccination not done: [Reason for non-admin]	: [VACC_REAS] [VACC_REAS] [VACC_REAS] Please select the major reason for non administration: [A:SAE]				
		[SYMP_COD] or Solicited AE code: [SYMPCODE] [A:OTH]				
			=			
N	Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.					

Codelist Values Tables: VACCINE ADMINISTRATION - DOSE 3 (HEXA GROUP)					
Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
VSORRESU	String	beats per minute	BPM	ВРМ	TEMP_UNIT_HID
		breaths per minute	BRTH	BRTH	
		Celsius	CE	CE	
		Fahrenheit	FA	FAR	
		feet	FT	FT	
		inches	IN	INCH	

PPD

06-JUL-2018 812f4fb003c07b74cae10f81cf90c72c48e48cbd

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 77 of 150

		kg	KG	KG	
		ounces	OZ	OZ	
		pounds	LB	LB	
		cm	СМ	СМ	
		mmHg	MMHG	MMHG	
		grams	G	GRAM	
VSTEST	String	Diastolic Blood Pressure	DIASTOLIC BLOOD PRESSURE	DIASTOLIC BLOOD PRESSURE	VSTEST
		Heart Rate	HEART RATE	HEART RATE	
		Height	HEIGHT	HEIGHT	
		Mid Upper Arm Circumference	MUAC	MUAC	
		Respiratory Rate	RESPIRATORY RATE	RESPIRATORY RATE	
		Systolic Blood Pressure	SYSTOLIC BLOOD PRESSURE	SYSTOLIC BLOOD PRESSURE	
		Temperature	TEMPERATURE	TEMPERATURE	
		Weight	WEIGHT	WEIGHT	
		Cranial Perimeter	CRANIAL PERIMETER	CRANIAL PERIMETER	
		Apgar Score	APGAR SCORE	APGAR SCORE	
/STESTCD	String	DIABP	DBP	DBP	VSTESTCD
		HEART RATE	HR	HR	
		HEIGHT	HE	HEI	
		MUAC	MUAC	MAUC2	
	RESP RATE	RR	RESPR		
		SYSBP	SBP	SBP	
		TEMP	TE	TEMP	
	WEIGHT	WE	WEIGHT2		
	CRANIAL PERIMETER	CRP	CRP		
		APGAR SCORE	APGAR	APGAR	
VACCSITE	String	Deltoid	1	Deltoid	P_SITE_HEXA, P_SITE_PREVNAR13
		Thigh	3	Thigh	
		Buttock	6	Buttock	
VACCSIDE	String	Left	L	LEFT	P_SIDE_HEXA, P_SIDE_PREVNAR13
		Right	R	RIGHT	
		Upper Left	UL	UPPER LEFT	
		Lower Left	Ш	LOWER LEFT	
		Upper Right	UR	UPPER RIGHT	
		Lower Right	LR	LOWER RIGHT	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 78 of 150

MEDROUT_VACC	String	Intramuscular	IM	Intramuscular	P_ROUTE_HEXA, P_ROUTE_PREVNAR13
		Subcutaneous	SC	Subcutaneous	
PRODNAMES	String	Infanrix Hexa	158	Infanrix Hexa	P_CODE_HEXA, P_CODE_PREVNAR13
		Prevnar 13	406	Prevnar 13	
		Pediarix	198	Pediarix	
		Acthib	3	Acthib	
		Pentacel	404	Pentacel	
		Rotarix	270	Rotarix	
		Engerix-B	5	Engerix-B	
		Infanrix	9	Infanrix	
		Hiberix	95	Hiberix	
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD
		Fever	FE	FE	
		Loss Of Appetite	LO	LO	
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	

Page 79 of 150

D.	TPA-HBV-IPV-135 (117119): VAC	CCINE ADMINISTRATION - DOSE 3 (PEDIA GROUP) (vac adm pedia-dose3)
PF	E-VACC TEMPERATURE	
1.	Pre-vaccination temperature: [Pre-vacc temp]	[PRE_TEMP] [PRE_TEMP] Temperature (°F) xxx.x [TEMP_ROUTE] Route: [A:A] Axillary [A:O] Oral [A:R] Rectal (Preferred) [A:T] Tympanic
VA	CCINE ADMINISTRATION - PEDIARIX	
2.''	Has Pediarix Vaccine been administered? [Vaccinated]	[V_ADM_PEDIARIX] [A:Y] [VACC_DET_4VACC_PEDIARIX] Yes [V_TRT_PEDIARIX] -> Administered treatment number: N10 [P_AP_PEDIARIX] Injection Site/Side/Route: [A:Y] According to protocol (Thigh - Right - IM) [A:N] [P_AP_DET_PEDIARIX] Not according [P_APSITE_PEDIARIX] to protocol -> Site: [A:1] Deltoid [A:3] Thigh [A:6] Buttock [P_APSIDE_PEDIARIX] Side: [A:L] Lower [A:LL] Lower [A:LL] Lower [A:LR] Lower Right [P_APROUTE_PEDIARIX] Route: [A:LM] Intramuscular [A:SC] Subcutaneous [VADM_COM_PEDIARIX] If relevant, comment on administration:
		[A:N] No
3.°	Hib Vaccine Has ActHib Vaccine been administered? [Vaccinated]	[V_ADM_ACTHIB] [A:Y]

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 80 of 150

		[VADM_COM_ACTHIB]
		If relevant, comment on administration:
		[A:N]
Pre	vnar13 Vaccine	
4.*	Has Prevnar13 Vaccine been administered? [Vaccinated]	[V_ADM_PREVNAR13] [A:Y]
VA	CCINATION DETAILS	[A:N] O No
\vdash	Date of administration:	[VACCRDAT]
5.	Date of administration:	[YACCRDAT] If at least one vaccine administered Req
6.	If at least one vaccination not done: [Reason for non-admin]	[VACC_REAS] [VACC_REAS] [VACC_REAS] [Please select the major reason for non administration: [A:SAE] ○ [SAE_CASE] Serious Adverse Event-> Please complete a SAE Report and specify SAE Report No. N2 [A:AEX] ○ [AE_NB] Non-Serious Adverse Event [AE_NB] -> Please complete Non-Serious Adverse Event section and specify AE No. N2 [SYMP_COD] Solicited AE code: [SYMPCODE] ▼

Page 81 of 150

	[A:OTH] Other, please specify A100 [DECISION] Please select who made the decision: [A:I] Investigator [A:P] Subject's parents / Legally Acceptable Representatives
Key: [*] = Item is required [✔] = Source verification re Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm v	

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
VSORRESU	String	beats per minute	ВРМ	ВРМ	TEMP_UNIT_HID
		breaths per minute	BRTH	BRTH	
		Celsius	CE	CE	
		Fahrenheit	FA	FAR	
		feet	FT	FT	
		inches	IN	INCH	
		kg	KG	KG	
		ounces	OZ	OZ	
		pounds	LB	LB	
		cm	СМ	СМ	
		mmHg	MMHG	MMHG	
		grams	G	GRAM	
/STEST	String	Diastolic Blood Pressure	DIASTOLIC BLOOD PRESSURE	DIASTOLIC BLOOD PRESSURE	VSTEST
		Heart Rate	HEART RATE	HEART RATE	
		Height	HEIGHT	HEIGHT	
		Mid Upper Arm Circumference	MUAC	MUAC	
		Respiratory Rate	RESPIRATORY RATE	RESPIRATORY RATE	
		Systolic Blood Pressure	SYSTOLIC BLOOD PRESSURE	SYSTOLIC BLOOD PRESSURE	
		Temperature	TEMPERATURE	TEMPERATURE	
		Weight	WEIGHT	WEIGHT	
		Cranial Perimeter	CRANIAL PERIMETER	CRANIAL PERIMETER	
		Apgar Score	APGAR SCORE	APGAR SCORE	
VSTESTCD	String	DIABP	DBP	DBP	VSTESTCD
		HEART RATE	HR	HR	
		HEIGHT	HE	HEI	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 82 of 150

		MUAC	MUAC	MAUC2	
		RESP RATE	RR	RESPR	
		SYSBP	SBP	SBP	
		TEMP	TE	TEMP	
		WEIGHT	WE	WEIGHT2	
		CRANIAL PERIMETER	CRP	CRP	
		APGAR SCORE	APGAR	APGAR	
VACCSITE	String	Deltoid	1	Deltoid	P_SITE_PEDIARIX,
		Thigh	3	Thigh	P_SITE_ACTHIB, P_SITE_PREVNAR13
		Buttock	6	Buttock	
VACCSIDE	String	Left	L	LEFT	P_SIDE_PEDIARIX,
		Right	R	RIGHT	P_SIDE_ACTHIB, P_SIDE_PREVNAR13
		Upper Left	UL	UPPER LEFT	
		Lower Left	LL	LOWER LEFT	
		Upper Right	UR	UPPER RIGHT	
		Lower Right	LR	LOWER RIGHT	
MEDROUT_VACC	String	Intramuscular	IM	Intramuscular	P_ROUTE_PEDIARIX,
		Subcutaneous	SC	Subcutaneous	P_ROUTE_ACTHIB, P_ROUTE_PREVNAR13
PRODNAMES	String	Infanrix Hexa	158	Infanrix Hexa	P_CODE_PEDIARIX,
		Prevnar 13	406	Prevnar 13	P_CODE_ACTHIB, P_CODE_PREVNAR13
		Pediarix	198	Pediarix]
		Acthib	3	Acthib	
		Pentacel	404	Pentacel	
		Rotarix	270	Rotarix	
		Engerix-B	5	Engerix-B	
		Infanrix	9	Infanrix	
		Hiberix	95	Hiberix	
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD
		Fever	FE	FE	
		Loss Of Appetite	LO	LO	
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	

Page 83 of 150

DTPA-HBV-IPV-135 (117119): VA	CCINE ADMINISTRATION - DOSE 3 (PENTA GROUP) (vac adm penta-dose3)				
PRE-VACC TEMPERATURE					
1.* Pre-vaccination temperature: [Pre-vacc temp]	[RE_TEMP] [PRE_TEMP] Temperature (°F)				
Pentacel Vaccine					
2.* Has Pentacel Vaccine been administered? [Vaccinated]	[V_ADM_PENTACEL] [A:Y]				
Facerity B.Vessins	panj Oro				
Engerix-B Vaccine 3.* Has Engerix-B Vaccine been administered? [Vaccinated]	[V_ADM_ENGERIX_B] [A:Y]				

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 84 of 150

		[VADM_COM_ENGERIX_B]				
		If relevant, comment on administration:				
		[A:N]				
Pre	vnar13 Vaccine been administered?					
4.*	Has Prevnar13 Vaccine been administered? [Vaccinated]	[V_ADM_PREVNAR13] [A:Y] [VACC_DET_3VACC_PREVNAR13] -> Administered treatment number: N10 [P_AP_PREVNAR13] Injection Site/Side/Route: [A:Y] According to protocol (Thigh - Lower Left - IM) [A:N] [P_AP_DET_PREVNAR13] Not according [P_AP_DET_PREVNAR13] Not according to protocol -> Site: [A:1] Deltoid [A:3] Thigh [A:6] Buttock [P_APSIDE_PREVNAR13] Side: [A:L] Cleft [A:R] Right [A:UL] Upper [A:LL] Clower [A:UR] Upper Right [P_APROUTE_PREVNAR13] [P_APROUTE_PREVNAR13] Route: [A:IM] Intramuscular [A:SC] Subcutaneous [VADM_COM_PREVNAR13] If relevant, comment on administration:				
VA	CCINATION DETAILS	[A:N] No				
5.	Date of administration:	[VACCRDAT]				
5.	pare or auministration.	[VACCRDAT] If at least one vaccine administered Req				
6.	If at least one vaccination not done: [Reason for non-admin]	[VACC_REAS] [VACC_REAS] [VACC_REAS] [VACC_REAS] [Please select the major reason for non administration: [A:SAE]				

Page 85 of 150

	[A:OTH] Other, please specify A100 [DECISION] Please select who made the decision: [A:I] OInvestigator [A:P] OSubject's parents / Legally Acceptable Representatives	
Key: [*] = Item is required [✔] = Source verification req Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm w		

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
VSORRESU	String	beats per minute	ВРМ	ВРМ	TEMP_UNIT_HID
		breaths per minute	BRTH	BRTH	
		Celsius	CE	CE	
		Fahrenheit	FA	FAR	
		feet	FT	FT	
		inches	IN	INCH	
		kg	KG	KG	
		ounces	OZ	OZ	
		pounds	LB	LB	
		cm	СМ	СМ	
		mmHg	MMHG	MMHG	
		grams	G	GRAM	
VSTEST	String	Diastolic Blood Pressure	DIASTOLIC BLOOD PRESSURE	DIASTOLIC BLOOD PRESSURE	VSTEST
		Heart Rate	HEART RATE	HEART RATE	
		Height	HEIGHT	HEIGHT	
		Mid Upper Arm Circumference	MUAC	MUAC	
		Respiratory Rate	RESPIRATORY RATE	RESPIRATORY RATE	
		Systolic Blood Pressure	SYSTOLIC BLOOD PRESSURE	SYSTOLIC BLOOD PRESSURE	
		Temperature	TEMPERATURE	TEMPERATURE	
		Weight	WEIGHT	WEIGHT	
		Cranial Perimeter	CRANIAL PERIMETER	CRANIAL PERIMETER	
		Apgar Score	APGAR SCORE	APGAR SCORE	
VSTESTCD	String	DIABP	DBP	DBP	VSTESTCD
		HEART RATE	HR	HR	
		HEIGHT	HE	HEI	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 86 of 150

		MUAC	MUAC	MAUC2	
		RESP RATE	RR	RESPR	
		SYSBP	SBP	SBP	
		TEMP	TE	TEMP	
		WEIGHT	WE	WEIGHT2	
		CRANIAL PERIMETER	CRP	CRP	
		APGAR SCORE	APGAR	APGAR	
VACCSITE	String	Deltoid	1	Deltoid	P_SITE_PENTACEL,
		Thigh	3	Thigh	P_SITE_ENGERIX_B, P_SITE_PREVNAR13
		Buttock	6	Buttock	
VACCSIDE	String	Left	L	LEFT	P_SIDE_PENTACEL,
		Right	R	RIGHT	P_SIDE_ENGERIX_B, P_SIDE_PREVNAR13
		Upper Left	UL	UPPER LEFT] =
		Lower Left	LL	LOWER LEFT	
		Upper Right	UR	UPPER RIGHT	
		Lower Right	LR	LOWER RIGHT	
MEDROUT_VACC	String	Intramuscular	IM	Intramuscular	P_ROUTE_PENTACEL,
		Subcutaneous	sc	Subcutaneous	P_ROUTE_ENGERIX_B, P_ROUTE_PREVNAR13
PRODNAMES	String	Infanrix Hexa	158	Infanrix Hexa	P_CODE_PENTACEL,
		Prevnar 13	406	Prevnar 13	P_CODE_ENGERIX_B, P CODE PREVNAR13
		Pediarix	198	Pediarix	
		Acthib	3	Acthib	
		Pentacel	404	Pentacel	
		Rotarix	270	Rotarix	
		Engerix-B	5	Engerix-B	
		Infanrix	9	Infanrix	
		Hiberix	95	Hiberix	
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD
		Fever	FE	FE	
		Loss Of Appetite	LO	LO	
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	


117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 87 of 150

_	DTPA-HBV-IPV-135 (117119): LOCAL SIGNS/SYMPTOMS FLAG - ACTHIB (Loc symp flg ActHib) LOCSYMPTOMS FLG ACTHIB					
1.*	Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [Local Symp flag for ActHib]	[LOCSOL_YN_ACTHIB] [A:Y]				
N-	quired vill override any settings made in Central Designer.					

Page 88 of 150



Codelist	Codelist Values Tables: LABORATORY TESTS								
Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable				
SYSTEMCD	String	Peripheral blood mononuclear cells	РВМС	PBMC	EVENTTYP_HID				
		Serum	SER	SER					
		Serum 1	SER01	SER01					
		Serum 2	SER02	SER02					
		Pregnancy test	PRG	PRG					
		Urine	URI	URI					
		Whole blood	WHB	WHB					

117119 (DTPA-HBV-IPV-135) Report Final


Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 89 of 150

D.	DTPA-HBV-IPV-135 (117119): INVESTIGATOR SIGNATURE (Inv sign)				
IN	INVESTIGATOR SIGNATURE				
	Is this casebook ready to sign? If not, click on the RETURN button below	[INVSIGN] [A:Y] Ready to sign			
1	Key: [*] = Item is required [♥] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.				

PPD

Page 90 of 150



 PPC

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 91 of 150

•	-> [DISCNT] [A:Y]	
	Key: [*] = Item is required [✓] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.	

Codelist	Codelist Values Tables: ESFU CONTACT (M10)					
Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable	
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD	
		Fever	FE	FE		
		Loss Of Appetite	LO	LO		
		Pain	PA	PA		
		Redness	RE	RE		
		Swelling	SW	SW		
		Irritability / Fussiness	IF	IF		

Page 92 of 150

	DTPA-HBV-IPV-135 (117119): CHECK FOR STUDY CONTINUATION (BOOSTER EPOCH) (Study Cont)				
CHE	ECK FOR STUDY CONTINUATION (BOOSTER E	EPOCH)			
1.* •	Did the subject return for the booster epoch?	[VIS_FLG_EPOCH] [A:7] ○ [ACTRDATE] Yes -> Date of visit: Req			
		[A:N] [VIS_REAS_EPOCH] No [VIS_REAS_EPOCH] -> Please select the major reason:			
		[A:SAE1]			
		[FATAL] -> Tick box if SAE is fatal: [A:Y]			
		[A:AEX1] O [AE_NB] Non-Serious Adverse Event in the course or after previous study epoch leading to withdrawal from the study, please specify: [AE_NB] [SYMP_COD] AE No. N2 Solicited AE code: [SYMPCODE]			
		[A:PTV] PTV_SP] Protocol violation, please specify: AS0			
		[A:CWS1] Consent Withdrawal / not willing to participate, not due to a (S)AE ->Please specify the reason (only if the Subject's parents / Legally Acceptable Representatives has / have spontaneously explained it): [CWS_SP]			
		A50 [CWS_NA]			
		Or tick box if reason not provided [A:N]			
		[A:MIG] Migrated / moved from the study area			
		[A:LFU] OLOST to follow-up			
		[A:DED]			
		[A:SST] Sponsor study termination			
		[A:07H] [V_OTH]			
		Other, please specify:			
		A100			
		[DECISION]			
		Please select who made the decision: [A:I] Investigator			
		[A:P] Subject's parents / Legally Acceptable Representatives			
PER	RMANENT DISCONTINUATION				
2.	Study discontinuation:	[DISCNT]			

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 93 of 150

•		[DISCNT] [A:Y] Tick box only if permanent discontinuation, i.e. if the subject definitively withdraws from the study If Yes, please sign off booster epoch
	Key: [*] = Item is required [✓] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.	

Codelist	Codelist Values Tables: CHECK FOR STUDY CONTINUATION (BOOSTER EPOCH)						
Codelist	Codelist Codelist Data Type Label Code Codelist Item Data Variable						
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD		
		Fever	FE	FE			
		Loss Of Appetite	LO	LO			
		Pain	PA	PA			
		Redness	RE	RE			
		Swelling	SW	SW			
		Irritability / Fussiness	IF	IF			

Page 94 of 150

Dī	[PA-HBV-IPV-135 (117119): VAC	CINE ADMINISTRATION - DOSE 4 (HEXA GROUP) (vac adm hexa-dose4)
\vdash	E-VACC TEMPERATURE	, (, (, ()
1.*	Pre-vaccination temperature: [Pre-vacc temp]	[PRE_TEMP] [PRE_TEMP] Temperature (°F) XXX.X
Inf	anrix Vaccine	
2.*	Pre vaccination Limb Circumference measurement (Infanrix):	[PRE_VACC_LIMB_INF] [INT_LIMB] [CIRC_LIMB] Not taken Circumference of [A:Y]
3.*	Has Infanrix Vaccine been administered? [Vaccinated]	[V_ADM_INFANRIX] [A:Y]
Hib	erix Vaccine	
4.*	Pre vaccination Limb Circumference measurement (Hiberix):	[PRE_VACC_LIMB_HIB] [NT_LIMB] [CIRC_LIMB] Not taken Circumference of Injected Limb (in mm) N10 N10
5.* •	Has Hiberix Vaccine been administered? [Vaccinated]	[V_ADM_HIBERIX] [A:Y]

PPD

Page 95 of 150

		[A:N] P_AP_DET_HIBERI Not according IP_J to protocol -> Site IP_J Side		
		Rout [VADM_COM_HIBERIX] If relevant, comment on	e: [A:IM] OIntramuscular [A:SC] OSubcutaneous A200	
		administration:	AZUU	
		[A:N] No		
VA	CCINATION DETAILS			
6.	Date of administration:	[VACCRDAT] If at least one vaccine administered [VACCRDAT] Req	[A:Y] [
7.	If at least one vaccination not done: [Reason for non-admin]	[A:AEX] [AE_NB] Non-Serious Adverse Event [AE> P or S [A:OTH] [V_OTH] Other, please specify (e.g.: cons A100 [DECISION] Please select who made the decision: [A:I]	complete a SAE Report and specify SAE Report No. N2 NB] lease complete Non-Serious Adverse Event section and specify AE No. N2 [SYMP_COD] olicited AE code: [SYMPCODE]	
N-	Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.			

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 96 of 150

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
VSORRESU	SU String	beats per minute	ВРМ	ВРМ	TEMP_UNIT_HID
		breaths per minute	BRTH	BRTH	
		Celsius	CE	CE	
		Fahrenheit	FA	FAR	
		feet	FT	FT	
		inches	IN	INCH	
		kg	KG	KG	
		ounces	OZ	OZ	
		pounds	LB	LB	
		cm	СМ	СМ	
		mmHg	MMHG	MMHG	
		grams	G	GRAM	
/STEST	String	Diastolic Blood Pressure	DIASTOLIC BLOOD PRESSURE	DIASTOLIC BLOOD PRESSURE	VSTEST
		Heart Rate	HEART RATE	HEART RATE	
		Height	HEIGHT	HEIGHT	
		Mid Upper Arm Circumference	MUAC	MUAC	
		Respiratory Rate	RESPIRATORY RATE	RESPIRATORY RATE	
		Systolic Blood Pressure	SYSTOLIC BLOOD PRESSURE	SYSTOLIC BLOOD PRESSURE	
		Temperature	TEMPERATURE	TEMPERATURE	
		Weight	WEIGHT	WEIGHT	
		Cranial Perimeter	CRANIAL PERIMETER	CRANIAL PERIMETER	
		Apgar Score	APGAR SCORE	APGAR SCORE	
/STESTCD	String	DIABP	DBP	DBP	VSTESTCD
		HEART RATE	HR	HR	
		HEIGHT	HE	HEI	
		MUAC	MUAC	MAUC2	
		RESP RATE	RR	RESPR	
		SYSBP	SBP	SBP	
		TEMP	TE	TEMP	
		WEIGHT	WE	WEIGHT2	
		CRANIAL PERIMETER	CRP	CRP	
		APGAR SCORE	APGAR	APGAR	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 97 of 150

VACCSIDE	String	Left	L	LEFT	P_SIDE_INFANRIX,
		Right	R	RIGHT	P_SIDE_HIBERIX
		Upper Left	UL	UPPER LEFT	
		Lower Left	LL	LOWER LEFT	
		Upper Right	UR	UPPER RIGHT	
		Lower Right	LR	LOWER RIGHT	
MEDROUT_VACC	String	Intramuscular	IM	Intramuscular	P_ROUTE_INFANRIX,
		Subcutaneous	SC	Subcutaneous	P_ROUTE_HIBERIX
PRODNAMES	String	Infanrix Hexa	158	Infanrix Hexa	P_CODE_INFANRIX,
		Prevnar 13	406	Prevnar 13	P_CODE_HIBERIX
		Pediarix	198	Pediarix	
		Acthib	3	Acthib	
		Pentacel	404	Pentacel	
		Rotarix	270	Rotarix	
		Engerix-B	5	Engerix-B	
		Infanrix	9	Infanrix	
		Hiberix	95	Hiberix	
VACCSITE	String	Deltoid	1	Deltoid	P_SITE_HIBERIX
		Thigh	3	Thigh	
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD
		Fever	FE	FE	
		Loss Of Appetite	LO	LO	
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	

Page 98 of 150

DI	DTPA-HBV-IPV-135 (117119): VACCINE ADMINISTRATION - DOSE 4 (PEDIA GROUP) (vac adm pedia-dose4)				
PR	E-VACC TEMPERATURE				
1.*	Pre-vaccination temperature: [Pre-vacc temp]	[PRE_TEMP] [PRE_TEMP] Temperature (°F) [TEMP_ROUTE] Route: [A:A] Axillary (Preferred) [A:O] Oral [A:R] Rectal [A:T] Tympanic			
Infa	anrix Vaccine				
2.*	Pre vaccination Limb Circumference measurement (Infanrix):	[PRE_VACC_LIMB_INF] [INT_LIMB] [CIRC_LIMB] Not taken [A:Y]			
3.*	Has Infanrix Vaccine been administered? [Vaccinated]	[V_ADM_INFANRIX] [A:Y] [VACC_DET_SVACC_INFANRIX] Yes [V_TRT_INFANRIX] -> Administered treatment number: N10 [P_AP_INFANRIX] Injection Site/Side/Route: [A:Y] [P_STE_INFANRIX] According to protocol: (Deltoid/Thigh - Right - IM) [A:1] Deltoid [A:3] Thigh [A:N] [P_AP_DET_INFANRIX] Not according [P_APSITE_INFANRIX] Side: [A:1] Deltoid [A:3] Thigh [A:6] Buttock [P_APSIDE_INFANRIX] Side: [A:L] Deltoid [A:R] Right [A:UL] Upper [A:LL] Lower [A:UR] Upper Right Right [P_APROUTE_INFANRIX] Route: [A:IM] Intramuscular [A:SC] Subcutaneous [VADM_COM_INFANRIX] If relevant, comment on administration: [A:N] No			
Act	Hib Vaccine				
4.*	Pre vaccination Limb Circumference measurement (ActHib):	[PRE_VACC_LIMB_ACT] [INT_LIMB] [CIRC_LIMB] Not taken [A:Y] Note Note			
5.*	Has ActHib Vaccine been administered? [Vaccinated]	[V_ADM_ACTHIB] [A:Y] O [VACC_DET_4VACC_ACTHIB] Yes [V_TRT_ACTHIB] -> Administered treatment number:			

PPD

Page 99 of 150

		[P_AP_ACTHIB] Injection Site/Side/Route: [A:Y]		
		If relevant, comment on administration:		
		[A:N]		
VA	CCINATION DETAILS			
6.	Date of administration:	[YACCRDAT] If at least one vaccine administered [YACCRDAT] Req		
7.	If at least one vaccination not done: [Reason for non-admin]	[VACC_REAS] [VACC_REAS] [VACC_REAS] Please select the major reason for non administration: [A:SAE]		
N	Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.			

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 100 of 150

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
/SORRESU String		beats per minute	ВРМ	ВРМ	TEMP_UNIT_HID
		breaths per minute	BRTH	BRTH	
		Celsius	CE	CE	
		Fahrenheit	FA	FAR	
		feet	FT	FT	
		inches	IN	INCH	
		kg	KG	KG	
		ounces	OZ	OZ	
		pounds	LB	LB	
		cm	СМ	СМ	
		mmHg	MMHG	MMHG	
		grams	G	GRAM	
VSTEST	String	Diastolic Blood Pressure	DIASTOLIC BLOOD PRESSURE	DIASTOLIC BLOOD PRESSURE	VSTEST
		Heart Rate	HEART RATE	HEART RATE	
		Height	HEIGHT	HEIGHT	
		Mid Upper Arm Circumference	MUAC	MUAC	
		Respiratory Rate	RESPIRATORY RATE	RESPIRATORY RATE	
		Systolic Blood Pressure	SYSTOLIC BLOOD PRESSURE	SYSTOLIC BLOOD PRESSURE	
		Temperature	TEMPERATURE	TEMPERATURE	
		Weight	WEIGHT	WEIGHT	
		Cranial Perimeter	CRANIAL PERIMETER	CRANIAL PERIMETER	
		Apgar Score	APGAR SCORE	APGAR SCORE	
VSTESTCD	String	DIABP	DBP	DBP	VSTESTCD
		HEART RATE	HR	HR	
		HEIGHT	HE	HEI	
		MUAC	MUAC	MAUC2	
		RESP RATE	RR	RESPR	
		SYSBP	SBP	SBP	
		TEMP	TE	TEMP	
		WEIGHT	WE	WEIGHT2	
		CRANIAL PERIMETER	CRP	CRP	
		APGAR SCORE	APGAR	APGAR	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 101 of 150

VACCSIDE	String	Left	L	LEFT	P_SIDE_INFANRIX,
		Right	R	RIGHT	P_SIDE_ACTHIB
		Upper Left	UL	UPPER LEFT	
		Lower Left	LL	LOWER LEFT	
		Upper Right	UR	UPPER RIGHT	
		Lower Right	LR	LOWER RIGHT	
MEDROUT_VACC	String	Intramuscular	IM	Intramuscular	P_ROUTE_INFANRIX,
		Subcutaneous	SC	Subcutaneous	P_ROUTE_ACTHIB
PRODNAMES	String	Infanrix Hexa	158	Infanrix Hexa	P_CODE_INFANRIX,
		Prevnar 13	406	Prevnar 13	P_CODE_ACTHIB
		Pediarix	198	Pediarix	
		Acthib	3	Acthib	
		Pentacel	404	Pentacel	
		Rotarix	270	Rotarix	
		Engerix-B	5	Engerix-B	
		Infanrix	9	Infanrix	
		Hiberix	95	Hiberix	
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD
		Fever	FE	FE	
		Loss Of Appetite	LO	LO	
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	

Page 102 of 150

D.	PA-HBV-IPV-135 (117119): VAC	CCINE ADMINISTRATION - DOSE 4 (PENTA GROUP) (vac adm penta-dose4)
PR	E-VACC TEMPERATURE	
1.*	Pre-vaccination temperature: [Pre-vacc temp]	[PRE_TEMP] [PRE_TEMP] Temperature (°F) xxx.x [TEMP_ROUTE] Route: [A:A] Axillary (Preferred) [A:O] Oral [A:R] Rectal [A:T] Tympanic
Pei	tacel Vaccine	
2.*	Pre vaccination Limb Circumference measurement (Pentacel):	[PRE_VACC_LIMB_PENTA] [NT_LIMB] [CIRC_LIMB] Not Taken Circumference of [A:Y]
3.*	Has Pentacel Vaccine been administered? [Vaccinated]	[V_ADM_PENTACEL] (A:Y)

Page 103 of 150

	Non-Serious Adverse Event [AE_NB] -> Please complete Non-Serious Adverse Event section and specify AE No. $_{ m N2}$
	[SYMP_COD] or Solicited AE code: [SYMPCODE]
	[A:OTH] (V_OTH) Other, please specify (e.g.: consent withdrawal, Protocol violation,)
	A100
	[DECISION]
	Please select who made the decision: [A:I] OInvestigator
	[A:P] Subject's parents / Legally Acceptable Representatives
Key: [*] = Item is required [✔] = Source verification red Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm w	

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable	
/SORRESU	String	beats per minute	ВРМ	ВРМ	TEMP_UNIT_HID	
		breaths per minute	BRTH	BRTH		
		Celsius	CE	CE		
		Fahrenheit	FA	FAR		
		feet	FT	FT		
		inches	IN	INCH		
			kg	KG	KG	
		ounces	OZ	OZ		
		pounds	LB	LB		
		cm	СМ	СМ		
		mmHg	MMHG	MMHG		
		grams	G	GRAM		
/STEST	String	Diastolic Blood Pressure	DIASTOLIC BLOOD PRESSURE	DIASTOLIC BLOOD PRESSURE	VSTEST	
		Heart Rate	HEART RATE	HEART RATE		
		Height	HEIGHT	HEIGHT		
		Mid Upper Arm Circumference	MUAC	MUAC		
		Respiratory Rate	RESPIRATORY RATE	RESPIRATORY RATE		
		Systolic Blood Pressure	SYSTOLIC BLOOD PRESSURE	SYSTOLIC BLOOD PRESSURE		
		Temperature	TEMPERATURE	TEMPERATURE		
		Weight	WEIGHT	WEIGHT		
		Cranial Perimeter	CRANIAL PERIMETER	CRANIAL PERIMETER		

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 104 of 150

		Apgar Score	APGAR SCORE	APGAR SCORE	
VSTESTCD	String	DIABP	DBP	DBP	VSTESTCD
		HEART RATE	HR	HR	
		HEIGHT	HE	HEI	
		MUAC	MUAC	MAUC2	
		RESP RATE	RR	RESPR	
		SYSBP	SBP	SBP	
		TEMP	TE	TEMP	
		WEIGHT	WE	WEIGHT2	
		CRANIAL PERIMETER	CRP	CRP	
		APGAR SCORE	APGAR	APGAR	
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD
		Fever	FE	FE	
		Loss Of Appetite	LO	LO	
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	
VACCSIDE	String	Left	L	LEFT	P_SIDE_PENTACEL
		Right	R	RIGHT	
		Upper Left	UL	UPPER LEFT	
		Lower Left	LL	LOWER LEFT	
		Upper Right	UR	UPPER RIGHT	
		Lower Right	LR	LOWER RIGHT	
MEDROUT_VACC	String	Intramuscular	IM	Intramuscular	P_ROUTE_PENTACE
		Subcutaneous	SC	Subcutaneous	
PRODNAMES	String	Infanrix Hexa	158	Infanrix Hexa	P_CODE_PENTACEL
		Prevnar 13	406	Prevnar 13	
		Pediarix	198	Pediarix	
		Acthib	3	Acthib	
		Pentacel	404	Pentacel	
		Rotarix	270	Rotarix	
		Engerix-B	5	Engerix-B	
		Infanrix	9	Infanrix	
		Hiberix	95	Hiberix	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 105 of 150

LOCAL SIGNS/SYMPTOMS FLAG - INFANRIX				
* Has the subject experienced any of the Loc Solicited signs/symptoms between Day 0 a Day 3? [Local Symp flag for Infanrix]				
Key: [*] = Item is required [✓] = Source verification. Note: Hidden items are not displayed.	cion required			

PPD

Page 106 of 150

D٦	PA-HBV-IPV-135 (117119): SOLI	CITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (INFANRIX) (Loc symp-Infanrix)
	anrix vaccine injection site. ny of these adverse events meets the definition of	serious, complete a Serious Adverse Event Report.
RE	DNESS	
1.*	Occurred?	[RE_YN] [A:Y] ONO [A:Y] OSYMP_VAL_MM] [Yes -> SYMP_VAL_MM_D0] [SYMP_VAL_MM_D1] [SYMP_VAL_MM_D2] [SYM_VAL_MM_D3] Size (mm): Day 0: Day 1: Day 2: Day 3: N5 N5 N5 [RE_ONG] After Day 3: Ongoing? [A:N] ONO [A:Y] OSYMP_ONG_MM] Yes -> [SYMP_MAX_SIZE] Maximum size: N5 [ERDAT] Date of last day of sign/symptom: Req/Unk V / Req/Unk V / Req/Unk V (2013-2018) [CONT_END] Continuing at the end of the study? [A:Y] [MED_TYPE] Medically attended visit: [A:ER] OF Emergency Room [A:HO] OF Hospitalisation [A:MD] Medical Personnel [A:NO] OF None
sw	ELLING	
In	case of large swelling reaction at the injection limb	, please fill in ALSO the large Swelling Reaction form
2.**	Occurred?	[SW_YN] [A:X]
PA	IN	
3.* •	Occurred?	[PA_YN] [A:N] ○ No [A:Y] ○ [SYMP_VAL_INTEN]

Page 107 of 150

	Yes -> [SYMP_VAL_INTEN_D0] [SYMP_VAL_D1] [SYMP_VAL_INTEN_D2] [SYMP_VAL_INTEN_D3] Intensity: Day 0: Day 1: Day 2: Day 3: [INTENSITYSOL] [INTENSITYSOL] [INTENSITYSOL] [INTENSITYSOL]
	After Day 3: Ongoing? [A:N] ○ No
	[A:Y] SYMP_ONG_INTEN]
	Yes -> [SYMP_MAX_INTEN] Maximum intensity: [INTENSITYSOLMAX]
	[ERDAT] Date of last day of sign/symptom: Req/Unk ▼ / Req/Unk ▼ / Req/Unk ▼ (2013-2018)
	[CONT_END] Continuing at the end of the study? [A:Y]
	[MED_TYPE] Medically attended visit: [A:ER] Emergency Room [A:HO] Hospitalisation [A:MD] Medical Personnel [A:NO] None
Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will over	rride any settings made in Central Designer.

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD_HID,
		Fever	FE	FE	SYMP_COD_HID, SYMP COD HID
		Loss Of Appetite	LO	LO	
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	
SYMPUNITS	String	Celsius	CE	CE	SYMP_UNI,
		Coded	СО	CODED	SYMP_UNI
		Fahrenheit	FA	FAR	
		inches	IN	INCH	
		Millimeters	MM	ММ	
		Occurence	ос	ОС	
		Score	SC	SCORE	
INTENSITYSOL	String	0	0	0	SYMP_VAL_INTEN_D0,
		1	1	1	SYMP_VAL_D1, SYMP VAL INTEN D2,
		2	2	2	SYMP_VAL_INTEN_D3
		3	3	3	
INTENSITYSOLMAX	String	1	1	1	SYMP_MAX_INTEN

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 108 of 150

	2	2	2
	3	3	3

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 109 of 150

LO	CAL SIGNS/SYMPTOMS FLAG - HIBERIX		
1.* •	Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [Local Symp flag for Hiberix]	[LOCSOL_YN_HIBERIX] [A:Y] ○ Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary [A:N] ○ No [A:U] ○ Unknown, no information available	
	(ey: $[*]$ = Item is required $[\checkmark]$ = Source verification relate: Hidden items are not displayed.	quired vill override any settings made in Central Designer.	

PPD

Page 110 of 150

D٦	PA-HBV-IPV-135 (117119): SOLI	CITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (HIBERIX) (Loc symp-Hiberix)
	erix vaccine injection site. ny of these adverse events meets the definition of	serious, complete a Serious Adverse Event Report.
RE	DNESS	### STATE OF THE PROPERTY OF T
1.*	Occurred?	[A:N] No [A:Y] Symp_val_mm] Yes -> [SYMP_val_mm_do] [SYMP_val_mm_do] [SYMP_val_mm_do] Size (mm): Day 0: Day 1: Day 2: Day 3: N5 N5 N5 [RE_ONG] After Day 3: Ongoing? [A:N] No [A:Y] Symp_ong_mm] Yes -> [SYMP_MAX_SIZE] Maximum size: N5 [ERDAT] Date of last day of sign/symptom: Req/Unk /
sw	ELLING	
In	case of large swelling reaction at the injection limb	, please fill in ALSO the large Swelling Reaction form
2.*	Occurred?	[A:N] No [A:Y] Symp_val_mm] Yes -> [SYMP_val_mm_bo] [SYMP_val_mm_bl] [SYMP_val_mm_bl] [SYMP_val_mm_bl] Size (mm): Day 0: Day 1: Day 2: Day 3: N5 N5 N5 [SW_ONG] After Day 3: Ongoing? [A:N] No [A:Y] Symp_ong_mm] Yes -> [SYMP_MAX_SIZE] Maximum size: NS [ERDAT] Date of last day of sign/symptom: Req/Unk / Req/Unk (2013-2018) [CONT_END]
PA	IN	
3.* •	Occurred?	[PA_YN] [A:N] ○ No [A:Y] ○ [SYMP_VAL_INTEN]

PPD

Page 111 of 150

	Yes -> [SYMP_VAL_INTEN_D0] [SYMP_VAL_D1] [SYMP_VAL_INTEN_D2] [SYMP_VAL_INTEN_D3] Intensity: Day 0: Day 1: Day 2: Day 3: [INTENSITYSOL] [INTENSITYSOL] [INTENSITYSOL] [INTENSITYSOL]
	[PA_ONG]
	After Day 3: Ongoing? [A:N] O No
	[A:Y] SYMP_ONG_INTEN]
	Yes -> [SYMP_MAX_INTEN] Maximum intensity: [INTENSITYSOLMAX]
	[ERDAT] Date of last day of sign/symptom: Req/Unk ▼ / Req/Unk ▼ / Req/Unk ▼ (2013-2018)
	[CONT_END] Continuing at the end of the study? [A:Y]
	[MED_TYPE] Medically attended visit: [A:ER] Emergency Room [A:HO] Hospitalisation [A:MD] Medical Personnel [A:NO] None
Key: [*] = Item is required [✔] Note: Hidden items are not display Note: Source verification critical se	

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD_HID, SYMP_COD_HID, SYMP_COD_HID
		Fever	FE	FE	
		Loss Of Appetite	LO	LO	
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	
SYMPUNITS String	String	Celsius	CE	CE	SYMP_UNI, SYMP_UNI
		Coded	СО	CODED	
		Fahrenheit	FA	FAR	
		inches	IN	INCH	
		Millimeters	MM	MM	
		Occurence	ОС	ос	
		Score	SC	SCORE	
INTENSITYSOL	String	0	0	0	SYMP_VAL_INTEN_D0,
		1	1	1	SYMP_VAL_D1, SYMP VAL INTEN D2,
		2	2	2	SYMP_VAL_INTEN_D3
		3	3	3	
INTENSITYSOLMAX	String	1	1	1	SYMP_MAX_INTEN

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 112 of 150

	2	2	2
	3	3	3

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 113 of 150

LO	LOCSYMPTOMS_FLG_ACTHIB		
1.*	Has the subject experienced any of the Local Solicited signs/symptoms between Day 0 and Day 3? [Local Symp flag for ActHib]	[LOCSOL_YN_ACTHIB] [A:Y] ○ Yes -> Please tick No/Yes for each sign/symptom and complete further as necessary [A:N] ○ No [A:U] ○ Unknown, no information available	
	ley: $[*]$ = Item is required $[\checkmark]$ = Source verification relote: Hidden items are not displayed.	quired	

Page 114 of 150

DTPA-HBV-IPV-135 (117119)	SOLICITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (ACTHIB) (Loc symp-ActHib)
ActHib vaccine injection site. If any of these adverse events meets the de	finition of serious, complete a Serious Adverse Event Report.
REDNESS	A CONTROL OF THE CONT
1.* Occurred?	[RE_YN] [A:N]
SWELLING	
In case of large swelling reaction at the injection	tion limb, please fill in ALSO the large Swelling Reaction form
2.* Occurred?	[SW_YN] [A:N]
PAIN	
3.* Occurred?	[PA_YN] [A:N] ○ No [A:Y] ○ [SYMP_VAL_INTEN]

PPD

Page 115 of 150

Yes -> [SYMP_VAL_INTEN_D0] [SYMP_VAL_D1] [SYMP_VAL_INTEN_D2] [SYMP_VAL_INTEN_D3] Intensity: Day 0: Day 2: Day 3: [INTENSITYSOL]
[PA_ONG]
After Day 3: Ongoing? [A:N] ○ No
$[A:Y] \cap [SYMP_ONG_INTEN]$
Yes -> [SYMP_MAX_INTEN]
Maximum intensity: [INTENSITYSOLMAX]
[ERDAT]
Date of last day of sign/symptom: Req/Unk / Req/Unk / Req/Unk (2013-2018)
[CONT_END]
Continuing at the end of the study? [A:Y]
[MED_TYPE] Medically attended visit: [A:ER]
Acy: [*] = Item is required [🗸] = Source verification required **Note: Hidden items are not displayed. **Note: Source verification critical settings made in InForm will override any settings made in Central Designer.

Codelist Values Tables: SOLICITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (ACTHIB) Codelist Codelist Data Type Codelist Item Data Variable Label Code SYMP_COD_HID, SYMP_COD_HID, SYMP_COD_HID SYMPCODE String DR DR Drowsiness FE Fever FE Loss Of Appetite LO LO PA PA Pain Redness RE RE Swelling SW SW Irritability / Fussiness IF IF Celsius SYMP_UNI, SYMP_UNI SYMPUNITS String CE CE СО CODED Coded Fahrenheit FA FAR inches IN INCH Millimeters ММ ММ Occurence ОС ОС Score SC SCORE SYMP_VAL_INTEN_D0, SYMP_VAL_D1, SYMP_VAL_INTEN_D2, SYMP_VAL_INTEN_D3 INTENSITYSOL String 0 2 3 3 INTENSITYSOLMAX String SYMP_MAX_INTEN

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 116 of 150

2	2	2	
3	3	3	

Page 117 of 150

DTPA-HBV-IPV-135 (1171:	19): SOLICITED ADVERSE EVENTS - LOCAL SIGNS/SYMPTOMS (PENTACEL) (Loc symp-Pentacel)
Pentacel vaccine injection site. If any of these adverse events meets the	ne definition of serious, complete a Serious Adverse Event Report.
REDNESS	
1.* Occurred?	[RE_YN] [A:N] ○ No [A:Y] ○ [SYMP_VAL_MM] Yes -> [SYMP_VAL_MM_D0] [SYMP_VAL_MM_D1] [SYMP_VAL_MM_D2] [SYM_VAL_MM_D3] Size (mm): Day 0: Day 1: Day 2: Day 3: N5 N5 N5 N5 [RE_ONG] After Day 3: Ongoing? [A:N] ○ No [A:Y] ○ [SYMP_ONG_MM] Yes -> [SYMP_MAX_SIZE] Maximum size: N5 [ERDAT] Date of last day of sign/symptom: Req/Unk ✓ / Req/Unk ✓ / Req/Unk ✓ (2013-2018) [CONT_END] Continuing at the end of the study? [A:Y] □ [MED_TYPE] Medically attended visit: [A:ER] ○ Emergency Room [A:HO] ○ Hospitalisation [A:MO] ○ Medical Personnel [A:NO] ○ None
SWELLING	
In case of large swelling reaction at the	injection limb, please fill in ALSO the large Swelling Reaction form
2.* Occurred?	ISW_YN] (A:N) No No (A:Y) (SYMP_VAL_MM] (A:Y) (SYMP_VAL_MM_D0] (SYMP_VAL_MM_D1] (SYMP_VAL_MM_D2] (SYM_VAL_MM_D3] (A:Y) (SYMP_VAL_MM_D1] (SYMP_VAL_MM_D2] (SYM_VAL_MM_D3] (SYM_VAL_
PAIN	
3.* Occurred?	[PA_YN] [A:N]

PPD

Page 118 of 150

	Yes -> [SYMP_VAL_INTEN_D0] [SYMP_VAL_D1] [SYMP_VAL_INTEN_D2] [SYMP_VAL_INTEN_D3] Intensity: Day 0: Day 1: Day 2: Day 3: [INTENSITYSOL] [INTENSITYSOL] [INTENSITYSOL]
	[PA_ONG] After Day 3: Ongoing? [A:N] \(\cap \) No
	Arter bay 3. Origining: [A.Y] Original [A.Y] Origin
	Yes -> [SYMP_MAX_INTEN] Maximum intensity: [INTENSITYSOLMAX]
	[ERDAT] Date of last day of sign/symptom: Req/Unk ▼ / Req/Unk ▼ / Req/Unk ▼ (2013-2018)
	[CONT_END] Continuing at the end of the study? [A:Y]
	[MED_TYPE] Medically attended visit: [A:ER] Emergency Room [A:HO] Hospitalisation [A:MD] Medical Personnel [A:NO] None
Key: [*] = Item is required [✔] = Source verification Note: Hidden items are not displayed. Note: Source verification critical settings made in InFor	

Codelist Data Type		Label	Code	Codelist Item	Data Variable		
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD_HID, SYMP_COD_HID, SYMP_COD_HID		
		Fever	FE	FE			
		Loss Of Appetite	LO	LO			
		Pain	PA	PA			
		Redness	RE	RE			
		Swelling	SW	SW			
		Irritability / Fussiness	IF	IF			
SYMPUNITS	String	Celsius	CE	CE	SYMP_UNI,		
		Coded	СО	CODED	SYMP_UNI		
		Fahrenheit	FA	FAR			
		inches	IN	INCH			
		Millimeters	MM	ММ			
		Occurence	ос	ОС			
		Score	SC	SCORE			
INTENSITYSOL	String	0	0	0	SYMP_VAL_INTEN_D0,		
		1	1	1	SYMP_VAL_D1, SYMP_VAL_INTEN_D2,		
		2	2	2	SYMP_VAL_INTEN_D3		
		3	3	3			
INTENSITYSOLMAX	String	1	1	1	SYMP_MAX_INTEN		

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 119 of 150

2	2	2
3	3	3

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 120 of 150

1.* Is a large swelling reaction as defined above present? [LARGESWELLING_FLAG] [Large swelling reaction] [LARGESWELLING_FLAG] [A:Y]			

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 121 of 150

# V	accine	Date of physical examination	Start date of swelling	Size of swelling		Circumference	Temperature	Redness	Induration	Pruritis	Pain		Case description	Last date when the swelling was still considered to be a large swelling reaction:	Outcome of the large swelling reaction	Is there an alternative explanation fo the swelling?
1																
If h	ospitalis	ation is require	d, please al	lso complet	e a Seriou	is Adverse Event	Report.									
	CINE															
1.* •	Vaccir [Vacc				17.7	_CODE] RODNAMES]										
2.*	Date of physical examination: [Date of physical examination] [PHYSICAL EXAMDATE] [PHYSDAT] NReq / NReq / NReq (2013-2018) [Examination performed] Was the examination performed by a member of study personnel during the large swelling reaction period? [A:N] No [A:Y] Yes															
3.* •					[SI	[FIRST SWELLING DATE] [SWFDAT] NReq										
4.* •		of swelling: of swelling]				ZE OF SWELLING asurement of the		eter: mm	N10							
Please specify in the case description section [Type of swelling] [A:1] [A:2]					[TYPE OF SWELLING] [A:1] OLocal swelling around injection site, not involving adjacent joint [A:2] Oliffuse swelling, not involving adjacent joint [A:3] Swelling, involving adjacent joint											
6.* •	[Circumference]					[CIRCUMFERENCE] [CIRCUMFERENCE SWOLLEN LIMB] Circumference of swollen limb (at the site of maximum swelling): mm N10										
ASS	OCIAT	ED SIGNS														
		s, Induration, P velling, please s					elect the Yes/N	o box for e	each symptoi	n occurri	ng du	iring the large	swelling react	ion period. If other	symptoms are	associated with
7.* •	Temperature: Please record the temperature. If temperature has been taken more than once a day please report the highest value. [Temperature] Temperature (*F)															
8.*						EDNESS] :NJ No :YJ [DIAMETEI Yes -> Lar	R for REDNESS: gest diameter:									

PPD

Page 122 of 150

9.* •	Induration [Induration]	[INDURATION] [(A:N) ○ No [A:Y] ○ [DIAMETER for INDURATION] Yes -> Largest diameter: mm N10
10.*	Pruritis [Pruritis]	[RA:N] No [A:Y] [INTENSITY PRURITIS] Yes -> [A:1] Grade 1(An AE which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.) [A:2] Grade 2 (An AE which is sufficiently discomforting to interfere with normal everyday activities.) [A:3] Grade 3 (An AE which prevents normal, everyday activities. In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care center and would cause the parent(s)/LAR(s) to seek medical advice)
11.*	Pain (at administration site): [Pain]	[PAIN AT ADMINISTRATION SITE] [A:N] ○ No [A:Y] ○ [INSTENSITY FOR PAIN] Yes -> Intensity [A:1] ○ Grade 1 (Minor reaction to touch) [A:2] ○ Grade 2 (Cries / protests on touch) [A:3] ○ Grade 3 (Cries when limb is moved / spontaneously painful)
12.*	Functional impairment: [Functional impairment]	[FUNCTIONAL IMPAIRMENT] [A:N]
CLI	NICAL CASE DESCRIPTION	
13.**	Case description [Case description]	[CASE DESCRIPTION] Please give a clinical description of the observed swelling reaction, including a description of the joint involved and specific associated symptoms. Please mention also eventual diagnostic(s) procedures and therapeutic interventions. AS00
14.	Last date when the swelling was still considered to be a large swelling reaction: [Last date when the swelling was still considered to be a large swelling reaction:]	[LAST SWELLING DATE] [SWLDAT] NReq
15.*	Outcome of the large swelling reaction: [Outcome of the large swelling reaction]	[OUTCOME_SW]

PPD

117119 (DTPA-HBV-IPV-135) Report Final


Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 123 of 150

•		[A:1]				
16.*	Is there an alternative explanation for the swelling? (e.g.: allergy, infection, trauma, underlying conditions) [Is there an alternative explanation for the swelling?]	[SWELLING ALTERNATIVE] [A:Y] ○ No [A:Y] ○ [SWELLING EXPLANAT: Yes -> Please specify:	ION] A500			
No	Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.					

Codelist '	Codelist Values Tables: LARGE SWELLING REACTION							
Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable			
PRODNAMES	String	Acthib	3	Acthib	P_CODE			
		Pentacel	404	Pentacel				
		Infanrix	9	Infanrix				
		Hiberix	95	Hiberix				
SYMPUNITS	String	Celsius	CE	CE	SIZE OF SWELLING_UNI,			
		Coded	со	CODED	CIRCUMFERENCE SWOLLEN LIMB_UNI_HD,			
		Fahrenheit	FA	FAR	CIRCUMFERENCE OPPOSITE LIMB_UNI			
		inches	IN	INCH				
		Millimeters	ММ	мм				
		Occurence	ос	ос				
		Score	SC	SCORE				

Page 124 of 150



Page 125 of 150

IRRITABILITY/FUSSINESS	[CONT_END] Continuing at the end of the study? [A:Y] [CAUSAL] Is there a reasonable possibility that the AE may have been caused by the investigational product? [A:N] [A:Y] No [A:Y] [MED_TYPE] Medically attended visit: [A:ER] Emergency Room [A:HO] Hospitalisation [A:MD] Medical Personnel [A:NO] None
3.* Occurred?	[IF_VN] [A:N] ○ NO [A:Y] ○ [SYMP_VAL_INTEN_D0] [SYMP_VAL_D1] [SYMP_VAL_INTEN_D2] [SYMP_VAL_INTEN_D3] Intensity: Day 0: Day 1: Day 2: Day 3: [INTENSITYSOL] ▼ [INTENSITYSOL] ▼ [INTENSITYSOL] ▼ [INTENSITYSOL] ▼ [IF_ONG] After Day 3: Ongoing? [A:N] ○ No [A:Y] ○ [SYMP_ONG_INTEN] Yes -> Maximum intensity: [INTENSITYSOLMAX] ▼ [ERDAT] Date of last day of sign/symptom: Req/Unk ▼ / Req
LOSS OF APPETITE	
4.* Occurred?	[LO_YN] [A:N]

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 126 of 150

	Is there a reasonable possibility that the AE may have been caused by the investigational product	? [A:N]				
	[MED_TYPE] Medically attended visit: [A:ER]	l Personnel [A:NO] None				
Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.						

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD_HID,
		Fever	FE	FE	SYMP_COD_HID, SYMP COD HID,
		Loss Of Appetite	LO	LO	SYMP_COD_HID
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	
SYMPUNITS	String	Celsius	CE	CE	SYMP_UNI
		Coded	СО	CODED	
		Fahrenheit	FA	FAR	
		inches	IN	INCH	
		Millimeters	MM	мм	
		Occurence	ОС	ос	
		Score	SC	SCORE	
INTENSITYSOL	String	0	0	0	SYMP_VAL_INTEN_D0, SYMP_VAL_D1, SYMP_VAL_INTEN_D2,
		1	1	1	SYMP_VAL_INTEN_D3, SYMP_VAL_INTEN_D0, SYMP_VAL_D1,
		2	2	2	SYMP_VAL_INTEN_D2, SYMP_VAL_INTEN_D3, SYMP_VAL_INTEN_D0,
		3	3	3	SYMP_VAL_D1, SYMP_VAL_INTEN_D2, SYMP_VAL_INTEN_D3
INTENSITYSOLMAX	String	1	1	1	SYMP_MAX_INTEN,
		2	2	2	SYMP_MAX_INTEN, SYMP MAX INTEN
		3	3	3	1

Page 127 of 150

	ECK FOR STUDY CONTINUATION	
*	Did the subject return for this visit?	[VIS_FLG] [A:Y] [ACTRDATE]
		Yes -> Date of visit: Req ▼ / Req ▼ / Req ▼ (2013-2018)
		[A:N] [VIS_REAS] No [VIS_REAS]
		-> Please select the major reason:
		[A:SAE] [SAE_CASE]
		Serious Adverse Event [SAE_CASE]
		-> Please complete a SAE Report and specify SAE Report No. N2
		[FATAL]
		-> Tick box if SAE is fatal: [A:Y]
		[A:AEX] [AE_NB] Non-Serious Adverse Event [AE_NB]
		-> Please complete Non-Serious Adverse Event section and specify AE No. N2
		[SYMP_COD]
		or Solicited AE code: SYMPCODE
		[A:PTV] [PTV_SP]
		Protocol violation, please specify:
		A50
		[A:CWS] CCWS]
		Consent Withdrawal not due to an adverse event
		->Please specify the reason (only if the Subject's parents / Legally Acceptable Representative has / have spontaneously explained it):
		[CWS_SP]
		A50
		[CWS_NA]
		Or tick box if reason not provided [A:N]
		[A:MIG] Migrated / moved from the study area
		[A:LFU]
		[A:SST] Sponsor study termination
		[A:OTH] [V_OTH]
		Other, please specify
		A100
		[DECISION] -> For serious (except death), non-serious adverse events and Other reasons only:
		-> rot serious (except deatif), non-serious adverse events and Other reasons only: Please select who made the decision:
		[A:I] Nestigator
		[A:P] Subject's parents / Legally Acceptable Representatives
-	The State of the second section of the section of the second section of the second section of the second section of the section of the second section of the	
	(ey: [*] = Item is required [✓] = Source verification critical cottings made in Item.	ation required Iform will override any settings made in Central Designer.

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 128 of 150

Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable
SYMPCODE	String	Drowsiness	DR	DR	SYMP_COD
		Fever	FE	FE	
		Loss Of Appetite	LO	LO	
		Pain	PA	PA	
		Redness	RE	RE	
		Swelling	SW	SW	
		Irritability / Fussiness	IF	IF	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 129 of 150

DI	DTPA-HBV-IPV-135 (117119): LOG STATUS (Log status)				
со	NCOMITANT VACCINATION				
1.*	Have any vaccines required to be reported as per protocol other than the study vaccine(s) been administered?	[CV_FLAG] [A:Y] Ores -> Please complete the following page [A:N] No			
ME	DICATION				
2.*	Have any medications that are required to be reported per protocol been administered?	[MD_FLAG] [A:Y] ○ Yes -> Please complete the following page [A:N] ○ No			
NO	N-SERIOUS ADVERSE EVENTS AND INTERCUR	RENT MEDICAL CONDITIONS			
Plea	se report serious adverse events only in the Serio	us Adverse Events Report, not here.			
3.* Have any non-serious adverse events that are required to be reported per protocol occurred? [A:Y]					
	Key: [*] = Item is required [✔] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.				

PPD

Page 130 of 150

D.	DTPA-HBV-IPV-135 (117119): CONCOMITANT VACCINATION (Conc vacc) - Repeating Form						
#	Vaccine name		Route	Date of adminis	tration		
1							
CO	CONCOMITANT VACCINATION						
	Please record any concomitant vaccination according to the protocol reporting requirements. Vaccination admistered prior to the first dose of study vaccine are to be recorded in vaccination history section						
	Vaccine name: (Trade name is preferred) [Vaccine name]	A60	ONAME]				
2.*	Route:						
3.*	3,* Date of administration: [CVACC_RDAT] [Date of administration] Req/Unk (2013-2018)						
l N	Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.						

Codelist Values Tables: CONCOMITANT VACCINATION						
Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable	
MEDROUT_CVACC	String	Inhalation	IH	Inhalation	CVACC_ROUTE	
		Intradermal	ID	Intradermal		
		Intramuscular	IM	Intramuscular		
		Intranasal	IN	Intranasal		
		Intravenous	IV	Intravenous		
		Oral	PO	Oral		
		Parenteral	PE	Parenteral		
		Subcutaneous	SC	Subcutaneous		
		Sublingual	SL	Sublingual		
		Transdermal	TD	Transdermal		
		Other	отн	OTHER_OTH		
		Unknown	UNK	Unknown		

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 131 of 150

DT	DTPA-HBV-IPV-135 (117119): MEDICATION (Medic) - Repeating Form							
#	Drug Name	Medical indication:	Total daily dose	Route	Start date	End date		
1								
ME	DICATION							
Plea	se record any concomitant medication a	according to the protocol reporting requireme	ents.					
	Drug name:	[CMTERM]						
~	[Drug Name]	A100						
2.*	Medical indication:	[MEDINDIC] [MEDINDIC] A80						
		[PROPH_CK] In anticipation of study vaccine in [CHRON_CK] Chronic use [A:Y]	In anticipation of study vaccine reaction [A:Y] [
	Total daily dose: [Total daily dose]	[MED_DOSE] Dose: A20 [MED_UNIT] Unit: A20						
	Route: [Route]	[MED_ROUT] [MEDROUT_MED]						
	Start date: [Start date]	[SRDAT] Req/Unk	[SRDAT] Req/Unk / Req/Unk / Req/Unk (2013-2018)					
6.* End date: or tick box if continuing at the end of the study [End date] [End date] [MEDERDAT] [ERDAT] [Req/Unk / Req/Unk / R								
No	Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.							

Codelist Values Tables: MEDICATION						
Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable	
MEDROUT_MED	String	Inhalation	IH	Inhalation	MED_ROUT	
		Intraarticular	IR	Intraarticular		
		Intradermal	ID	Intradermal		
		Intramuscular	IM	Intramuscular		

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 132 of 150

Intran	asal	IN	Intranasal
Intrave	enous	IV	Intravenous
Oral		PO	Oral
Parent	eral	PE	Parenteral
Rectal		PR	Rectal
Subcu	taneous	SC	Subcutaneous
Subline	gual	SL	Sublingual
Topica	ı	то	Topical
Transc	Iermal	TD	Transdermal
Vagina	ıl	VA	Vaginal
Other		OTH	OTHER_OTH
Unkno	wn	UNK	Unknown

Page 133 of 150

	PA-	A-HBV-IPV-135 (117119): NON-SERIOUS ADVERSE EVENTS AND INTERCURRENT MEDICAL CONDITIONS (Non-Ser AE) - Repeating										
#	AE No.	Event		Start late:	Outcome	End date	Maximum intensity	Is there a reasonable possibility that the AE may have been caused by the investigational product?	Medically attended visit			
1												
NC	N-SEF	RIOUS	ADVERS	E EVEN	ITS AND IN	NTERCUE	RENT MEDICAL CO	INDITIONS				
Ple	ase red	se record any non-serious AEs to the protocol reporting requirements.										
1.	AE N	o. [read	-only]				[AE_NO]					
L	-						N3					
2.*		nosis on sympto	ly (if kno m	wn), ot	herwise		A100					
3.*												
4.* Start date: [AE_SRDAT] [SRDAT] [Req/Unk / Req/Unk / Req/Unk (2013-2018) [AEPOSTVC] 30 minutes immediate post-vaccination [A:Y]												
5.* •					[OUTCOME_NSAE] [A:1]							
6.	End o	date: date]	[ERDAT] Req/Unk									
7.*						[AE_INTEN] [A:1]						
8.*	* Is there a reasonable possibility that the AE may have been caused by the investigational product? * [CAUSAL] [A:N] \[\text{No.} \] [A:Y] \[\text{Yes}											
9.*							[A:MD] Medical	isation				

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 134 of 150

	[A:NO] None			
Key: [*] = Item is required [✔] = Source verification required Note: Hidden items are not displayed.				
Note: Source verification critical settings made in InForm will override any settings made in Central Designer.				

Codelist Values Tables: NON-SERIOUS ADVERSE EVENTS AND INTERCURRENT MEDICAL CONDITIONS								
Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable			
PRODNAMES	String	Infanrix Hexa	158	Infanrix Hexa	P_CODE			
		Prevnar 13	406	Prevnar 13				
		Pediarix	198	Pediarix				
		Acthib	3	Acthib				
		Pentacel	404	Pentacel				
		Rotarix	270	Rotarix				
		Engerix-B	5	Engerix-B				
		Infanrix	9	Infanrix				
		Hiberix	95	Hiberix				
AFTER / BEFORE	String	After vaccination	A	After	AE_VACC			
		Before vaccination	В	Before				

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 135 of 150

DI	DTPA-HBV-IPV-135 (117119): OCCURRENCE OF SERIOUS ADVERSE EVENTS (SAE Flg)					
ОС	OCCURRENCE OF SERIOUS ADVERSE EVENTS					
1.*	Did the subject experience any Serious Adverse Events that are required to be reported per protocol?	[SAE_FLG] [A:Y] ○ Yes -> Please remember to complete a SAE Report [A:N] ○ No				
	Key: [*] = Item is required [✓] = Source verification required Note: Source verification critical settings made in InForm will override any settings made in Central Designer.					

Page 136 of 150

_				•				(SAE) - Repeatir	-	DELEVANT	Delevent diamentia	Camanal
#	SAE Repo No.	ort	initiation	occur after of study cation?	SERIOUS ADVERSE EVENT	Seriousness		OMITANT/TREATMENT S/VACCINATIONS	RELEVANT MEDICAL CONDITIONS/RISK FACTORS	RELEVANT DIAGNOSTIC RESULTS	Relevant diagnostic results not noted on the left columns	General narrative comments
1												
If y	es, re ot cli	ecord nically	the details or tempo	below using rally related,	the 'Add Entry'	button in this AE form for th	form. is subject by clicking	ally related to an SAE pr on the 'New' button at t	eviously entered on this form. the top of the page.			
SA	E REF	PORT	NO.									
1. •			rt No. [rea ort No.]	ad-only]		[SAE_NB]						
TY	PE OF	FREP	ORT									
RA	NDO	MIZA	TION									
2.*	inve [Did	stigat	ional prod occur afte	after initiation uct(s)? r initiation of		[A:N] ON	0					
	No. I	Event	Start date and time	Outcome / date and ti	End Maximu me Intensi	y investig	on taken with ational product(s) sult of the event	Did the subject withdraw from study due to this event?	Is there a reasonable poss that the event may have caused by the investigati product(s)?	been relate	e AE caused by activities d to study participation er than investigational product?	Medically attended visit
3.												
SE	RIOU	S AD	VERSE EV	/ENT Entry								
Us	e the '	'Add E	ntry' butt	on to enter de	etails of the SA SAE. Enter ON			cally or temporally relate	ed (e.g., SAEs that occur during	the same hospital	zation) use the 'Add Entry' b	utton to create
3.1		o. [re	ad-only]			[AESEQ]						
3.2	3.2* Event: Diagnosis only (if known), otherwise sign/symptom			Diagnosis only (if known), otherwise A100								
3.3	3.3* Start date and time Hr:Min (00:00-23:59) [Start date and time]			[AESTDTTM] Reg/Unk / Req (2013-2018) NReq : NReq 24-hour clock								
3.4	H	r:Min	(00:23-59	ate and time 9) date and time	1	[A:2]	AEENDTTM1] Recovered/resolved, p					

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 137 of 150

		[A:4] [AEENDTTM2] Recovered/resolved with sequelae, provide End date and time Req/Unk / Req/Unk / Req/Unk (2013-2018) NReq NReq 24-hour clock [A:5] [AEENDTTM3] Fatal, record Date and time of Death Req/Unk / Req/Unk / Req/Unk (2013-2018) NReq NReq 24-hour clock
3.5*	Maximum Intensity Record maximum intensity throughout duration of event [Maximum Intensity]	[A:2] ○ Mild [A:3] ○ Severe [A:X] ○ Not applicable
3.6*	Action taken with investigational product(s) as a result of the event: [Action taken with investigational product(s) as a result of the event]	[AEACTRCD] [A:1] ○ Investigational product(s) withdrawn [A:4] ○ Dose not changed [A:5] ○ Dose delayed [A:X] ○ Not applicable
3.7*	Did the subject withdraw from study due to this event?	[A:Y] ○ Yes [A:N] ○ No
3.8*	Is there a reasonable possibility that the event may have been caused by the investigational product(s)? **Use best judgment at initial entry. May be amended when additional information becomes available. **Is there a reasonable possibility that the event may have been caused by the investigational product(s)?	[A:N] ○ No [A:Y] ○ Yes
3.9*	Was the AE caused by activities related to study participation other than investigational product? [Was the AE caused by activities related to study participation other than investigational product?]	[rdcAESREL] [A:Y] ○ Yes [A:N] ○ No
3.10*	Medically attended visit: [Medically attended visit]	[MED_TYPE] [A:HO]
SERI	DUSNESS	
	pecify the reason for considering this event as AE.	[chkAESER] [A:A]
	Fick all that apply)	[A:A] Tesuits in death

PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 138 of 150

	[Seriousness]		[A:C] Requir	es hospitalisation s in disability/inca nital anomaly/birt	ect was at risk of death or prolongation of hos pacity (substantial / pe th defect (in offspring o neral narrative comme	oitalisation (Provide admis ermanent) f subject)	ssion and discharge date(s) in narrative		
Н	Drug Name	Total daily	dose	Route	Start Date	End date	Medical Indication	Drug type	
5. •									
REL	EVANT CONCOMITANT/TI	REATMENT MEDICAT	TIONS/VACCINA	ATIONS Entry					
	the 'Add Entry' button to en ication recorded in this secti						used to treat the SAE. Ensure each cor	comitant vaccination or	
5.1*	Drug name:		[CMTERM]						
~	[Drug Name]		(Trade name is	preferred)					
			AIUU						
5.2	Total daily dose:		[SAECMDOS]						
~	[Total daily dose]		Dose: XXXXXXX	[txtsAECMDOS]					
				[pdcMUNIT]					
			Unit: [clCMUNI						
5.3*			[pdcCMROUTCD	_					
	[Route]		[MEDROUT_MEDSAE]						
5.4*	Start Date [Start Date]		[dtmSAECMSTD] NReq/Unk v / NReq/Unk v / NReq/Unk v (2002-2018)						
5.5	End date: or tick box if continuing at		[SAECMEND] [dtmSAECMEND]						
*	[End date]	the end of the study	NReq/Unk v / NReq/Unk v / NReq/Unk v (2002-2018)						
			[rdcSAECMONG]						
			_	e end of the stud	y [A:Y]				
5.6	Medical indication Enter a medical diagnosis	not description	[txtCMIND] A50						
	[Medical Indication]	, , , , , , , , , , , , , , , , , , ,							
5.7*	Drug type: [Drug type]	[pdcCMDRGTYP] [cdRugTYP] [cdRugTYP]							
	Condition		Start da	te		Cor	ntinuing at time of SAE?		
6.									
\vdash	EVANT MEDICAL CONDIT	IONS/RISK FACTOR	S Entry						
-				er, allergy or surg	gery that may be RELEV	'ANT to the SAE. Enter a d	diagnosis, not description. Relevant fam	ily or social history shoud be	
desc							ion is also recorded in the General Medi		
	l l l l l l l l l l l l l l l l l l l								

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 139 of 150

6.1*	1* Condition Enter a medical diagnosis not description. [Condition]		[txtSAEMHTRM] A100				
6.2*	2* Start date: [Start date]		[dtmMHSTDTM] Req/Unk	Req/Unk (2002-2018)			
6.3*	Continuing at time of SAE [Continuing at time of SAE	.E?]	Req/Unk / Req/	te or date of last occurrence Unk (2002-mation available	2018)		
-	Test name	Test date	Test result	Test units	Normal low range	Normal high range	
7.							
REL	EVANT DIAGNOSTIC RES	SULTS Entry					
Use	the 'Add Entry' button to e	nter details of relevant	tests or procedures carried ou	it to diagnose or confirm th	e SAE or rule out other diagnoses		
7.1*	Test name [Test name]		[pdcLBTST]				
7.2*	Test date [Test date]		[dtmLABDTM] Req/Unk				
7.3*	Test result [Test result]		[txtLABRES] A12				
7.4*	Test units [Test units]		[txtLABUNIT] A12				
7.5*	Normal low range [Normal low range]		[txtLABNLR] xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx				
7.6*	Normal high range [Normal high range]		[txtLABNHR] xxxxxxxxxxxxxx				
8.	Enter here only the diagno not be entered in the abov		[cmpLABTEXT] [txtLABTEXT]				
	procedure such as ECG, X rays, etc and tests on stool, CSF etc. Also provide dates. [Relevant diagnostic results not noted on the left columns]		A1000				
			[txtLABTEXT1]				
			A1000				

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 140 of 150

GENE	RAL NARRATIVE COMMENTS		
- Asso - Clini - Non- - Othe - Rele - Poss - Ratio	ciated signs and symptoms cal evolution (hospitalisation, outcome, descripti- drug treatment such as surgery ir information useful for the medical assessment vant additional risk factors including family or so ible cause(s) of the event	of the case (e.g. reason for diagnosis if not obvious or if diagnosis changed) ocial history (negative sentence can also be helpful) ed to study product, concomitant product or study procedure, etc.	uding:
_	eneral narrative comments	[cmpNARRATIVE]	
ا , ا	choral harrative comments	[txtSAECOMM]	
		[txtSAECOMM1] A1000	
		[txtSAECOMM2]	
		A1000	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 141 of 150

I I		
	[txtSAECOMM3]	
	A1000	
NON CLINICAL		
Key: [*] = Item is required [✓] = Source verification re	quired	
Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm v	vill override any settings made in Central Designer.	

Codelist Values Tables: SERIOUS ADVERSE EVENTS								
Codelist	Codelist Data Type	Label	Code	Codelist Item	Data Variable			
clCMUNITSAE	String	ACTU	ACTU	clCMUNIT_ACTU	pdcCMUNIT			
		AMP	AMP	clCMUNIT_AMP				
		application(s)	AP	clCMUNIT_AP				
		BT	ВТ	clCMUNIT_BT				
		capsule	CAP	clCMUNIT_CAP				
		Cubic centimeter	СС	clCMUNIT_CC				
		MBecquerel	16	citmCMUNIT_MBQ				
		Variable dose	VA	citmCMUNIT_VA				
		blister	BLS	citmCMUNIT_BLS				
		caplet(s)	CAPL	citmCMUNIT_CAPL				
		cg	CG	citmCMUNIT_CG	7			
					7			

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 142 of 150

drop(s)	31	citmCMUNIT_DROP
elisa unit	EU	citmCMUNIT_EU
g/L	GML	citmCMUNIT_GM/L
g/M2	GM/M2	citmCMUNIT_GM/M2
g/kg	GM/KG	citmCMUNIT_GM/KG
grain	GR	citmCMUNIT_GR
gram(s)	2	citmCMUNIT_G
inch	INCH	citmCMUNIT_INCH
injection	INJ	citmCMUNIT_INJ
iu	25	citmCMUNIT_IU
iu x 10**3	26	citmCMUNIT_IU3
iu x 10**6	27	citmCMUNIT_IU6
liter	11	citmCMUNIT_L
lozenge	LOZ	citmCMUNIT_LOZ
mCi	19	citmCMUNIT_MCI
mEq	29	citmCMUNIT_MEQ
mcg	4	citmCMUNIT_MCG
mcg/mg	MCG/MG	citmCMUNIT_MCG/M
Megaunits (million units)	MEGU	citmCMUNIT_MEGU
mg	3	citmCMUNIT_MG
mg/kg	7	citmCMUNIT_MGK
mg/m2	9	citmCMUNIT_MGM2
mg/min	MGM	citmCMUNIT_MGM
mg/ml	MGML	citmCMUNIT_MGML
micro unit	MCRU	citmCMUNIT_MCU
ml	12	citmCMUNIT_ML
ml/hr	MLH	citmCMUNIT_MLH
mm	ММ	citmCMUNIT_MM
mmol	23	citmCMUNIT_MMOL
nebule(s)	NEB	citmCMUNIT_NEB
ng	5	citmCMUNIT_NG
ng/kg	NGK	citmCMUNIT_NGK
ounce	OZ	citmCMUNIT_OZ
patch	PAT	citmCMUNIT_PAT
percent	30	citmCMUNIT_PCT

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 143 of 150

			PUFF	citmCMUNIT_PUFF	
		sachet	SAC	citmCMUNIT_SAC	1
		spray	SPR	citmCMUNIT_SPR	1
		suppository	SUP	citmCMUNIT_SUP	1
		tablespoon	TBS	citmCMUNIT_TBS	1
		tablet	TAB	citmCMUNIT_TAB	1
		teaspoon	TSP	citmCMUNIT_TSP	1
		uBecquerel	14	citmCMUNIT_UBQ	1
		ugk	8	citmCMUNIT_UGK	1
		umol	24	citmCMUNIT_UMOL	1
		unit	UNT	citmCMUNIT_UNT	1
		unknown	U	citmCMUNIT_U	1
		vial(s)	VIA	citmCMUNIT_VIA	1
ISAECMFRQ	String	2 times per week	2W	clSAECMFRQ_2W	pdcSAECMFRQ
		3 times per week	3W	clSAECMFRQ_3W	1
		4 times per week	4W	clSAECMFRQ_4W	1
		5 times per day	5D	clSAECMFRQ_5D	1
		5 times per week	5W	clSAECMFRQ_5W	1
		AC	AC	clSAECMFRQ_AC	1
		BID	2D	clSAECMFRQ_2D	
		Continuous infusion	СО	clSAECMFRQ_CO	
		Every 2 weeks	FO	clSAECMFRQ_FO	
		Every 3 weeks	Q3W	clSAECMFRQ_Q3W	
		Every 3 months	Q3M	clSAECMFRQ_Q3M	
		Every other day	AD	clSAECMFRQ_AD	1
		Once a month	МО	clSAECMFRQ_MO	
		Once a week	WE	clSAECMFRQ_WE	
		Once daily	1D	clSAECMFRQ_1D	
		Once only	1S	clSAECMFRQ_1S	1
		PC	PC	clSAECMFRQ_PC	
		PRN	PRN	clSAECMFRQ_PRN	
		Q2H	12D	clSAECMFRQ_Q2H	1
		Q3D	Q3D	clSAECMFRQ_Q3D	1
		Q4D	Q4D	clSAECMFRQ_Q4D	1
		Q4H	6D	clSAECMFRQ_Q4H	

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 144 of 150

		QAM	1M	clSAECMFRQ_QAM	
		QH	24D	cISAECMFRQ_QH	
		QID	4D	clSAECMFRQ_QID	
		QPM	1N	cISAECMFRQ_QPM	
		TID	3D	clSAECMFRQ_TID	1
MEDROUT_MEDSAE	String	Inhalation	055	Inhalation	pdcCMROUTCD
		Intraarticular	014	Intraarticular	
		Intradermal	023	Intradermal]
		Intramuscular	030	Intramuscular	1
		Intranasal	045	Intranasal	1
		Intravenous	042	Intravenous	1
		Oral	048	Oral]
		Parenteral	051	Parenteral	
		Rectal	054	Rectal	
		Subcutaneous	058	Subcutaneous]
		Sublingual	060	Sublingual	1
		Topical	061	Topical	1
		Transdermal	062	Transdermal	1
		Vaginal	067	Vaginal	
		Other	050	Other	
		Unknown	065	Unknown	
cIDRUGTYP	String	Concomitant	2	cIDRUGTYP_01	pdcCMDRGTYP
		Treatment	Т	cIDRUGTYP_02	1
		Cause of AE	1	cIDRUGTYP_03	1
cISAELBTST	String	Activated partial thromboplastin time	Activated partial thromboplastin time	SAELBTST01	pdcLBTST
		Alanine aminotransferase	Alanine Amino Transferase	SAELBTST79	
		Albumin	Albumin	SAELBTST02	
		Alkaline phosphatase	Alkaline phosphatase	SAELBTST03	
		Amylase	Amylase	SAELBTST04	
		Aspartate Amino Transferase	Aspartate Amino Transferase	SAELBTST80	
		Band Neutrophil count	Band Neutrophil count	SAELBTST81	
		Base Excess	Base Excess	SAELBTST82	
		Basophils	Basophils	SAELBTST05	
		Bicarbonate	Bicarbonate	SAELBTST06	1
		Bilirubin	Bilirubin	SAELBTST07	1

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 145 of 150

Bilirubin direct	Bilirubin direct	SAELBTST08
Bilirubin total	Bilirubin total	SAELBTST09
Blood glucose	Blood glucose	SAELBTST83
Blood myoglobin	Blood myoglobin	SAELBTST10
Blood pH	Blood pH	SAELBTST11
Blood pressure	Blood pressure	SAELBTST12
Blood urea nitrogen	Blood urea nitrogen	SAELBTST13
Body temperature	Body temperature	SAELBTST14
Calcium	Calcium	SAELBTST15
Carbone dioxide	Carbone dioxide	SAELBTST84
CD4 lymphocytes	CD4 lymphocytes	SAELBTST16
CD8 lymphocytes	CD8 lymphocytes	SAELBTST17
Chloride	Chloride	SAELBTST18
Cholesterol total	Cholesterol total	SAELBTST19
C-reactive protein	C-reactive protein	SAELBTST20
Creatine	Creatine	SAELBTST21
Creatine phosphokinase	Creatine phosphokinase	SAELBTST22
Creatine phosphokinase MB	Creatine phosphokinase MB	SAELBTST23
Creatinine	Creatinine	SAELBTST24
Creatinine clearance	Creatinine clearance	SAELBTST25
Diastolic blood pressure	Diastolic blood pressure	SAELBTST26
Eosinophils	Eosinophils	SAELBTST27
Erythrocyte sedimentation rate	Erythrocyte sedimentation rate	SAELBTST28
Fasting blood glucose	Fasting blood glucose	SAELBTST29
FEV 1	FEV 1	SAELBTST30
Gamma-glutamyltransferase	Gamma-glutamyltransferase	SAELBTST31
Granulocyte count	Granulocyte count	SAELBTST85
HbA1c	HbA1c	SAELBTST34
HBV-DNA decreased	HBV-DNA decreased	SAELBTST35
HBV-DNA increased	HBV-DNA increased	SAELBTST36
Heart rate	Heart rate	SAELBTST37
Hematocrit	Hematocrit	SAELBTST38
Hemoglobin	Hemoglobin	SAELBTST39
High density lipoprotein	High density lipoprotein	SAELBTST40
HIV viral load	HIV viral load	SAELBTST41
INR		

 PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 146 of 150

tional normalized ratio dehydrogenase SAELBTST88 SAELBTST44 SAELBTST44 sity lipoprotein SAELBTST45 socytes SAELBTST46 sium SAELBTST47 sell hemoglobin concentration spruscular hemoglobin SAELBTST49 sprupscular volume SAELBTST59 latelet Volume SAELBTST89 tes SAELBTST51
SAELBTST44
nsity lipoprotein SAELBTST45 bcytes SAELBTST46 ium SAELBTST47 ell hemoglobin concentration SAELBTST48 orpuscular hemoglobin SAELBTST49 orpuscular volume SAELBTST50 latelet Volume SAELBTST89
SAELBTST46
ium SAELBTST47 ell hemoglobin concentration SAELBTST48 orpuscular hemoglobin SAELBTST49 orpuscular volume SAELBTST50 latelet Volume SAELBTST89
ell hemoglobin concentration SAELBTST48 orpuscular hemoglobin SAELBTST49 orpuscular volume SAELBTST50 latelet Volume SAELBTST89
orpuscular hemoglobin SAELBTST49 orpuscular volume SAELBTST50 latelet Volume SAELBTST89
orpuscular volume SAELBTST50 latelet Volume SAELBTST89
latelet Volume SAELBTST89
tes SAFLBTST51
oin urine SAELBTST90
ohils SAELBTST52
saturation SAELBTST53
SAELBTST54
SAELBTST55
e SAELBTST91
ate SAELBTST56
count SAELBTST57
SAELBTST58
rase Chain Reaction SAELBTST92
rphonuclear Count SAELBTST93
ım SAELBTST59
total SAELBTST60
mbin time SAELBTST61
od cell count SAELBTST62
l Distribution Width SAELBTST94
tory rate SAELBTST63
cyte count SAELBTST64
nted Neutrophil Count SAELBTST95
glucose SAELBTST65
3
uric acid SAELBTST66
uric acid SAELBTST66 SAELBTST67
1

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 147 of 150

		Thrombin time	SAELBTST69
Tota	al lung capacity	Total lung capacity	SAELBTST70
Trig	glycerides	Triglycerides	SAELBTST71
Trop	ponin	Troponin	SAELBTST72
Trop	ponin I	Troponin I	SAELBTST73
Trop	ponin T	Troponin T	SAELBTST74
Urin	ne myoglobin	Urine myoglobin	SAELBTST75
Urin	ne pH	Urine pH	SAELBTST76
Vita	al capacity	Vital capacity	SAELBTST77
Whi	ite blood cell count	White blood cell count	SAELBTST78

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 148 of 150

DTPA-HBV-IPV-135 (117119): STUDY CONCLUSION (Conclusion)				
STUDY CONCLUSION				
1.* Date of subject completion or withdrawal (or date of death if applicable):	[LC_RDAT] Req ☑ / Req ☑ (2013-2018)			
Key: [*] = Item is required [✓] = Source verification required Note: Hidden items are not displayed. Note: Source verification critical settings made in InForm will override any settings made in Central Designer.				

PPD

06-JUL-2018 812f4fb003c07b74cae10f81cf90c72c48e48cbd 838

Page 149 of 150

	TPA-HBV-IPV-135 (117119): USE OF HUMAN SAMPLES (UHS) - Repeating Form Text Text Text Please check GSK Biologicals sample storage period specified in the ICF in use at If new version of UHS: Date at which the new ICF version was first signed			ow ICE version was first signed by			
#	3A	Text 3B	4	FIEASE CHECK USK BIOIOG	your centre.	If new version of UHS: Date at which the new ICF version was first signed by a Subject :	
1							
In a	ddition	to the t	ests de	scribed in the study protocol	, please check what may also be done with the subject samples a	as per the Informed Consent Form (ICF) in use a	t your center.
TYP	E 3A	TESTS					
	1.* Use of samples to improve tests and develop new tests linked to study vaccine(s)/product(s) or the disease under study. These tests will never include tests related to genes' hereditary characteristics. [Text 3A]		udy vaccine(s)/product(s) study. These tests will	[CONS_YN_3A] [A:Y] ○ Yes (A:N] ○ No			
TYP	E 3B	TESTS					
2.*	Comm sampl linked diseas includ	es to imple to study to study to e under to tests reteristics	nstitution prove to vaccin study.	sion of independent Ethics onal Review Board: Use of ests and develop new tests e(s)/product(s) or the These tests will never o genes' hereditary	[CONS_YN_3B] [A:Y] ○ Yes [A:N] ○ No		
TYP	E 4 TE	STS					
3.*	paren GSK n sampl collect	ts / Lega nay perfo es. Any i ted will b val for th	lly Acce orm futo research e perfo	sion of the Subject's ptable Representatives: ure research on collected n undertaken with samples rmed after obtaining urch by an IRB/IEC.	[CONS_YN_4] [A:Y] ○ Yes [A:N] ○ No		
SAN	SAMPLE STORAGE PERIOD						
4.*	period [Pleas	specifie e check	d in the GSK Bid	ogicals sample storage I.CF in use at your centre. Jogicals sample storage I.CF in use at your centre.]	[PERIOD] [A:20]		
IF N	IF NEW VERSION OF UHS FORM						
Com	Complete and submit a new Use of Human Samples by GSK form for each change in the ICF that affects the use of samples.						
	signed [If new	l by a Su w version	bject :	v ICF version was first S: Date at which the new signed by a Subject :]	t which the new NReq V / NReq V (2013-2018)		
	Key: [▼] = Source verification required Note: Hidden items are not displayed.						


PPD

117119 (DTPA-HBV-IPV-135) Report Final

Annotated Study Book - DTPA-HBV-IPV-135 (117119)

Page 150 of 150

 $Note: Source\ verification\ critical\ settings\ made\ in\ InForm\ will\ override\ any\ settings\ made\ in\ Central\ Designer.$



General Instructions

Thank you for your child's participation in this clinical trial.

During your child's last study visit, you received a "Diary Card" to fill in every day for a defined period, so that your child's study doctor or the study staff will know your child's general health status after the vaccination.

Here below you will find general instructions on how to complete the "Diary Card". There are also other specific instructions relative to each part of the "Diary Card" that you will need to fill in.

► INSTRUCTIONS TO COMPLETE THE "DIARY CARD"

- Write in clearly, use a pen (never pencil).
- The grey areas are dedicated to the investigator or delegate only. Do not write in these areas.

Illness/Sign/Symptom ☑ if at vaccine injection site ↓	Worst Intensity 1/2/3	Start Date	End Date Tick box if still engoing	Did you receive medical attention?	Type of medical attention To be completed by the investigator or delegate	Relationship to inv. Product To be completed by the investigator or delegate
Tendinitis 🗆	5	04-FEB-2012	08-F6B-2012 U	□ No ⊠ Yes		∐No ∐Yes

► How to correct mistakes?

- · Cross out the mistake with a single line.
- Don't hide the mistake. Don't use correction fluid or don't make inkblots.
- Write the correct response close to the mistaken one.
- If the correct response is written outside of the box, circle it and point to it with an arrow towards the box.
- Put your initials near the correction.
- Date the correction



Who to contact in case of questions?

If you have any questions, please contact your child's study doctor or the study staff on the following phone number:

[insert phone n° of the study doctor or study staff]



Please contact your child's study doctor or the study staff immediately if your child has any symptoms you think are serious.

Instructions to complete: Local and general symptoms




- If your child experience(s) any other symptoms than those listed in the local symptoms or general symptoms pages, please write these symptoms down in the Adverse Event section.
- If a symptom appears only after day 3, please write this symptom down in the Adverse Event section.
- ► How to complete Diary Card for any SYMPTOM "After day 3"?
- In the columns "After day 3", if the symptom is still ongoing* after day 3, tick "Yes". Otherwise, tick "No".
 - * The symptom is ongoing if after day 3:
 - ➤ The intensity of the symptom is 1 or higher
 - > The oral (in the mouth), axillary (under the armpit), tympanic (in the ear) or rectal (in the anus) temperature is higher or equal to 100.4°F.
 - If Yes,
 - o Please write the worst intensity for pain, the highest temperature or the greatest measurement of Redness or swelling recorded for the respective symptom during this follow-up period, after day 3.
 - And note the date when the symptom has disappeared or tick the box "still ongoing".
 - If No, then leave empty the columns "Worst intensity/ greatest size/ highest temperature" and "End Date".
 - ► BOX "STILL ONGOING" IN COLUMN "END DATE" WHEN TO TICK IT?
- Tick the box "Still ongoing" if the illness /sign /symptom is still present at the time you return the diary card to the site

						After [Day 3	Did you	Type of
	Day 0	Day 1	Day 2	Day 3	Ongoing	Worst Intensity/ Greatest size	End Date		
						Size	Tick box if still ongoing ↓	?	investigator or delegate
Injection site	mm	mm	mm	mm	□ No	mm		□ No	HOERMD
Redness → size (mm)	10	8	5	3	⊠ Yes →	2	⊠	Yes	

DID YOUR CHILD RECEIVE ANY MEDICAL ATTENTION? HOW TO COMPLETE THIS QUESTION?

- Medical attention means hospitalisation, an emergency room visit or a visit to or from medical personnel.
- Tick the box "No" if your child did not visit medical personnel or was not visited by medical personnel or did not go to the hospital or an emergency room for the symptom.
- Tick the box "Yes" if your child went to the hospital, an emergency room, if your child visited medical personnel or was visited by medical personnel for the symptom.


Keep the type of medical attention (grey column) empty. It will be completed by the study doctor or study staff.



Instructions to complete: Local symptoms

- If your child receive(s) more than one vaccine, you will have to fill in one section for each administered vaccine.
- Redness, swelling and pain may appear around the area where your child received the vaccine (administration site(s)). These are called LOCAL symptoms.
- If similar symptoms appear on another part of your child's body than this/those corresponding to the administration site(s), please report them in the Adverse Event section.

[The study doctor or study staff should show in the drawing where is/are the administration site(s).]





For Infanrix

For Hiberix

• Write down the size of the redness and swelling in millimetres (mm) only. Use the ruler given to you by the site staff.

Please note that in case a swelling greater than 50 mm is observed please describe the swelling on the page titled the Large Swelling Reaction

- ► How to complete the daily value?
- Write down a value for each symptom and each day (measure or intensity). Don't leave any field empty.
- If there is no symptom, please write "0".



Daily measurement of circumference: Every day, using the tape provided to you, please measure around the vaccinated arm or leg.

INTENSITY DEFINITIONS

Redness and swelling:

Measure and record the greatest surface diameter in millimetres (mm).

- Pain:
 - 0: Absent
 - 1: Minor reaction to touch
 - 2: Cries/protests on touch
 - 3: Cries when limb is moved / spontaneously painful

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

LOCAL SYMPTOMS (HEXA GROUP-Booster)

Infanrix									
To be completed by the investigator or delegate:									
Date of vaccination = Day 0: Injection Site: Side: Baseline Circumference of injected limb (ln mm) =									
						Afte	er Day 3		
	Day 0	Day 1	Day 2	Day 3	Ongoing	Worst Intensity/ Greatest size	End Date Tick box if still ongoing ψ	Did your child receive any medical attention ?	Type of medical attention To be completed by the investigator or delegate
Injection site Redness → size (mm)					□ No □ Yes →			□ No □ Yes	HO/ERMD
Injection site Swelling → size (mm)					□ No □ Yes →			□ No □ Yes	HO/ERMD
Injection site Pain → intensity (0/1/2/3)					□ No □ Yes →			□ No □ Yes	HO/ERMD

06-JUL-2018 848

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk _{GlaxoSmithKline}	Vaccine Dose Number 4	To be completed by the investigator or delegate

Daily Circumferential measurement- Infanrix

* Please measure the circumference using the tape provided to you, around the vaccinated arm or leg.

			Day 2	Day 3	After Day 3			
	Day 0	Day 1			Is large swelling reaction ongoing	If Yes then please enter the maximum circumference observed	End Date Tick box if still ongoing ✔	
Daily measurement of Injection site Circumference→ size (mm)					□ No □ Yes →		TICK BOX II SUII OTIGOTING	

Clarification(s) for Investigator or delegate only:	



LARGE SWELLING REACTION

- A large swelling reaction is a swelling at the place where your child received the vaccination that has a diameter greater than 50 mm,
 or a large swelling that is very spread out and cannot be measured or a noticeable swelling of the vaccinated arm or thigh
 circumference.
- If your child has a large swelling please call the study doctor immediately.
- Please fill in the data in the large swelling reaction section. In the section below, please enter the day, month and year when the large swelling reaction was first observed.

DESCRIBE THE TYPE OF SWELLING.

- If the swelling occurred only around the place where the vaccination shot was given and did not spread to the adjacent joint, check the first box. Adjacent joint means the shoulder or elbow (in cases where the vaccination was given in the arm) or the knee or hip joint(in cases where the vaccination was given in the thigh)
- If the swelling was spread out over a large area, but did not spread to adjacent joint, check the middle box.
- · If the swelling spread to the adjacent joint



INDURATION

• If the large swelling is hard to the touch, measure and record daily the greatest surface diameter in millimetres (mm) of the hard area.

If the swelling is not hard, check the "No" box.

PRURITIS MEANS ITCHING

• If you notice your child has itching at the large injection site (e.g. your child is scratching or vigorously rubbing the swelling), please check "Yes" and the type of Grade it is. If there is no itch check the "No" box

FUNCTIONAL IMPAIRMENT

• If the large swelling changes the way your child moves or uses the swollen arm or leg as they normally would, please check "Yes" and the type of Grade it is. If there is no change to your child's use of the swollen arm or leg, check the "No" box.



Large Swelling Reaction (HEXA GROUP-Booster)

Infanrix

Date when the swelling was first considered to be a large swelling reaction*:	day month year Please enter the date in DD/MMM/YYYY format Was the examination performed by a member of study personnel during the large swelling reaction period?
*:To be completed by the investigator or delegate	No Yes
Type of swelling and Location of swelling	 □ Local swelling only around the injection site, not involving adjacent joint □ Diffuse swelling, not involving adjacent joint □ Swelling involving adjacent joint
Induration at injection site (in mm)	No Yes → If Yes then, Day 0 Day 1 Day 2 Day 3 Image: Description of the control of the

06-JUL-2018 852

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number		
GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate		

Pruritis at injection site	 No Yes -> If yes then: Grade 1 (An AE which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.) Grade 2 (An AE which is sufficiently discomforting to interfere with normal everyday activities.) Grade 3 (An AE which prevents normal, everyday activities. In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care center and would cause the parent(s)/LAR(s) to seek medical advice)
	Has the swelling episode resulted in functional impairment?
Functional impairment	□ No □ Yes -> If yes then: □ Grade 1 (An AE which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.) □ Grade 2 (An AE which is sufficiently discomforting to interfere with normal everyday activities.) □ Grade 3 (An AE which prevents normal, everyday activities. In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care center and would cause the parent(s)/LAR(s) to seek medical advice)
Last date when the swelling was still considered a large swelling reaction *	L_ _ day month year
*:To be completed by the investigator or delegate	Please enter the date in DD/MMM/YYYY format
Outcome of the extensive swelling	Recovered / Resolved Recovering / Resolving Not Recovered / Not Resolved Recovered with ongoing events / Resolved with ongoing events

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

LOCAL SYMPTOMS (HEXA GROUP-Booster) Hiberix

To be completed by the investigator or delegate: Date of vaccination = Day 0: Injection Site: Side: Baseline Circumference of injected limb (In mm) =									
						Afte	er Day 3	Did your child receive any medical attention ?	
	Day 0	Day 1	Day 2	Day 3	Ongoing	Worst Intensity/ Greatest size	End Date Tick box if still ongoing √		Type of medical attention To be completed by the investigator or delegate
Injection site Redness → size (mm)					□ No □ Yes →			□ No □ Yes	HO/ERMD
Injection site Swelling → size (mm)					□ No □ Yes →			□ No □ Yes	HO/ERMD
Injection site Pain → intensity (0/1/2/3)					□ No □ Yes →			□ No □ Yes	HO/ERMD

06-JUL-2018 854

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

Daily Circumferential measurement- Hiberix

* Please measure the circumference using the tape provided to you, around the vaccinated arm or leg.

						Aft	er Day 3
	Day 0	Day 1	Day 2	Day 3	Is large swelling reaction ongoing	If Yes then please enter the maximum circumference observed	End Date
							Tick box if still ongoing ↓
Daily measurement of Injection site Circumference→ size (mm)					□ No □ Yes →		

Clarification(s) for Investigator or delegate only:											

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

Large Swelling Reaction (HEXA GROUP-Booster) **Hiberix**

Date when the swelling was first considered to be a large swelling reaction*:	day month year Please enter the date in DD/MMM/YYYY format
*:To be completed by the investigator or delegate	Was the examination performed by a member of study personnel during the large swelling reaction period? ☐ No ☐ Yes
Type of swelling and Location of swelling	□ Local swelling only around the injection site, not involving adjacent joint □ Diffuse swelling, not involving adjacent joint □ Swelling involving adjacent joint
Induration at injection site (in mm)	No Yes → If Yes then, Day 0 Day 1 Day 2 Day 3 Not Taken Not Taken Not Taken Not Taken Not Taken Not Taken Not Taken No Yes If Yes then please enter the Largest Diameter observed

06-JUL-2018 856

DTPA-HBV-IPV-135 117119	DIARY CARDS	Subject Number
GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

Develop at intention site	
Pruritis at injection site	□ No
	☐ Yes -> If yes then:
	Grade 1 (An AE which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.)
	Grade 2 (An AE which is sufficiently discomforting to interfere with normal everyday activities.)
	Grade 3 (An AE which prevents normal, everyday activities. In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care center and would cause the parent(s)/LAR(s) to seek medical advice)
	Has the swelling episode resulted in functional impairment?
Functional impairment	□ No
	☐ No ☐ Yes -> If yes then:
	Grade 1 (An AE which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday
	activities.)
	Grade 2 (An AE which is sufficiently discomforting to interfere with normal everyday activities.)
	Grade 3 (An AE which prevents normal, everyday activities. In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care center and would cause the parent(s)/LAR(s) to seek medical advice)
Last date when the swelling	
was still considered a large swelling reaction	day month year
*:To be completed by the investigator or delegate	Please enter the date in DD/MMM/YYYY format
Outcome of the extensive	
swelling	☐ Recovered / Resolved
	Recovering / Resolving Not Recovered / Not Resolved
	Recovered with ongoing events / Resolved with ongoing events



Instructions to complete:

General symptoms


► How to complete the daily value?

- Write down a value for each symptom and each day (measure or intensity). Don't leave any field empty.
- Write "0" if there is no increase in intensity compared to normal

	Day 0	Day 1	Day 2	Day 3	Ongoing	After Day 3 Worst Intensity End Date Tick box # 988 engoing ◆		Did you receive medical attention?*	Type of medical attention To be completed by the investigator or delegate	Relationship to inv. Product To be completed by the investigator or delegate
Drowsiness → Intensity(0/1/2/3)	0/1/2/5	0/1/2/3	0/1/2/3	0/1/2/3	□No □Yes →	1/2/3	_	□No □Yes	HOBINIO	□No □Yes

GENERAL SYMPTOMS: TEMPERATURE

- Please use the provided thermometer.
- Take your child's temperature each day from day of vaccination (day 0) until day 3, and write down the values.
- If you took more than once a day your child's temperature, then write down the highest one.
- The preferred route for recording temperature in this study will be Axillary for Booster vaccination.



• Please write down NT (Not Taken) if you did not take the temperature.

DTPA-HBV-IPV-135 117119					DIARY CARDS Vaccine Dose Number 4					Subject Number L L L L L L To be completed by the investigator or delegate					
											10 be 00	прев	eu by trie ii	rivesilgalor	or delegate
			Day 9	Day 1 D	ay 2 Day 3		ngoing °F by any	High	After Day 3	End C	hate	Dic child any r atte	l your receive medical ntion?	Type of medica attentic. To be comply the invest or delega	Relationship to inv. Product leted dyster for delegate
	Temper	ature →	98	99	01 100.5	□No □Yes	→		Ì		0	OY.) s	HORRAG	No No Yes
GENERAL S			egate: Dat	e of vaccir	ation = Day () :			_						
	Day 0	Day 1	Day 2	Day 3	Ongoi ≥100.4°F by		After Da Highest Temperatur		End Date Tick box if still on	ngoing	Did your ch receive an medical attention?	ild y	Type of atten To be com the inver	ntion inpleted by stigator	Relationship to inv. Product To be completed by the investigator or delegate
Temperature →					□ No □ Yes →						□ No □ Yes		HO/EF		□ No □ Yes
Temperature:				measureme route must b	nt: e used for all y	our meası	urements.)								
Clarification(s) for	Investigato	or deleç	gate only:												

> INTENSITY DEFINITIONS

- Drowsiness:
 - 0: Behaviour as usual
 - 1: Mild: Drowsiness easily tolerated
 - 2: Moderate: Drowsiness that interferes with normal activity
 - 3: Severe: Drowsiness that prevents normal activity
- Irritability/Fussiness:
 - 0: Behaviour as usual
 - 1: Mild: Crying more than usual/no effect on normal activity
 - 2: Moderate: Crying more than usual/interferes with normal activity
 - 3: Severe: Crying that cannot be comforted/prevents normal activity
- · Loss of appetite:
 - 0: Appetite as usual
 - 1: Mild: Eating less than usual/no effect on normal activity
 - 2: Moderate: Eating less than usual/interferes with normal activity
 - 3: Severe: Not eating at all

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

To be completed by the investigator or delegate: Date of vaccination = Day 0:										
						After Da	ay 3		Type of	Relationship
	Day 0	Day 1	Day 2	Day 3	Ongoing	Worst Intensity	End Date Tick box if still ongoing ↓	Did your child receive medical attention?*	medical attention To be completed by the investigator or delegate	to inv. Product To be completed by the investigate or delegate
Drowsiness → Intensity (0/1/2/3)					□ No □ Yes →			□ No □ Yes	HO/ERMD	□ No □ Yes
Irritability/Fussiness → intensity (0/1/2/3)					□ No □ Yes →			□ No □ Yes	HO/ER/MD L_L_J	□ No □ Yes
Loss of appetite → intensity (0/1/2/3)					□ No □ Yes →			□ No □ Yes	HO/ER/MD	□ No □ Yes
Clarification(s) for Inve	stigator o	r delegate	only:							

06-JUL-2018 861



Instructions to complete: Adverse Events

- If your child experience(s) any other symptoms than those listed in the local symptoms or general symptoms pages, please write these symptoms down in this section.
- If a symptom appears only after day 3, please write this symptom down in this section.
- If redness, swelling or pain appears on another area than area where your child received the vaccine, please report these symptoms in this section.

INTENSITY DEFINITIONS

- 1: Mild. An adverse event which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.
- 2: Moderate. An adverse event which is sufficiently discomforting to interfere with normal everyday activities.
- **3: Severe.** An adverse event which prevents normal, everyday activities. (In a young child, such an adverse event would, for example, prevent attendance at school/kindergarten/a day-care centre and would cause the parents/guardians to seek medical advice).

BOX "STILL ONGOING" IN THE COLUMN "END DATE" - WHEN TO TICK IT?

• Tick the box "Still ongoing" if the illness / sign / symptom is still present at the time you return the diary card to the site.

117119 (DTPA-HBV-IPV-135) Report Final



DID YOUR CHILD RECEIVE ANY MEDICAL ATTENTION? HOW TO COMPLETE THIS QUESTION?

- Medical attention means hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor).
- Tick the box "No" if your child did not visit a doctor or go to the hospital or an emergency room for the symptom.
- Tick the box "Yes" if your child went to the hospital, an emergency room or if your child visited a doctor for the symptom. Keep the type of medical attention (grey column) empty. It will be completed by the study doctor or study staff.

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

ADVERSE EVENTS - MULTIPLE INJECTIONS

Record any adverse event (= any illness, sign, symptom) other than the local and general symptoms listed on the previous pages, which may have started or any medical condition which may have worsened since the last study vaccination.

		ase of reaction at inistration site				Did your child	I ype of	Relationship to inv. Product
Illness/Sign/Symptom	Site	Side	Worst Intensity 1/2/3	Start Date	End Date Tick box if still ongoing	receive medical attention?	attention To be completed by the investigator or delegate	To be complete
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
Clarification(s) for Investigator or delega	te only:							

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

VACCINATION

Record any vaccination received since the last study vaccination

Vaccination	Date of administration	Route* To be completed by the investigator or delegate

^{*} Route codes = inhalation [IH], intradermal [ID], intramuscular [IM], intranasal [IN], intravenous [IV], oral [PO], parenteral [PE], subcutaneous [SC], sublingual [SL], transdermal [TD], other [OTH], unknown [UNK]

Clarification(s) for Investigator or delegate only:		

Instructions to complete: Medication

Dose, Unit and Frequency

• Write the amount of the medication your child took.

Dose, unit and frequency

200mg pill 3 times a day

2 coffee spoon 100mg once
per day

3 suppositories per day

Nasal drops 4 times per day

• Most of this information can be found on the label of the medication. You may want to bring the medication to your child's next visit with the study doctor or study staff. Then they can help you to fill in the required information.

BOX "STILL ONGOING" IN THE COLUMN "END DATE" – WHEN TO TICK IT?

• Tick the box "Still ongoing" if the medication is still taken at the time you return the diary card to the site.

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

MEDICATION

Record any medication taken since the last study vaccination.							
Medication	Reason	Dose, unit and frequency	Start Date	End Date Tick box if still ongoing↓	Route* To be completed by the investigator or delegate		
* Route codes = inhalation [IH], intraarticular [70.0	(1) (1) (1)		1.1.		

* Route codes = inhalation [IH], intraarticular [IR], intradermal [ID], intramuscular [IM], intranasal [IN], intravenous [IV], oral [PO], paenteral [PE], rectal [PR], subcutaneous [SC], sublingual [SL], topical [TO], transdermal [TD], vaginal [VA], other [OTH], unknown [UNK]


Clarification(s) for Investigator or delegate only:		

DTPA-HBV-IPV-135 117119	DIARY CARDS Vaccine Dose Number 4	Subject Number

NOTES	
-------	--

INVESTIGATOR'S OR DELEGATE'S SIGNATURE

Investigator's or delegate's signature:	 Date:	
Printed Investigator's or delegate's name:		



General Instructions

Thank you for your child's participation in this clinical trial.

During your child's last study visit, you received a "Diary Card" to fill in every day for a defined period, so that your child's study doctor or the study staff will know your child's general health status after the vaccination.

Here below you will find general instructions on how to complete the "Diary Card". There are also other specific instructions relative to each part of the "Diary Card" that you will need to fill in.


► INSTRUCTIONS TO COMPLETE THE "DIARY CARD"

- Write in clearly, use a pen (never pencil).
- The grey areas are dedicated to the investigator or delegate only. Do not write in these areas.

Illness/Sign/Symptom ☑ if at vaccine injection site ↓	Worst Intensity 1/2/3	Start Date	End Date Tick box if still engoing ↓	Did you receive medical attention?	Type of medical attention To be completed by the investigator or delegate	Relationship to inv. Product To be completed by the investigator or delegate
Tendinitis 🗆	S	04-FEB-2 <i>0</i> 12	08-FEB-2012 U	□ No ☑ Yes	HOERMD	∐No ∐Yes

► How to correct mistakes?

- · Cross out the mistake with a single line.
- Don't hide the mistake. Don't use correction fluid or don't make inkblots.
- Write the correct response close to the mistaken one.
- If the correct response is written outside of the box, circle it and point to it with an arrow towards the box.
- Put your initials near the correction.
- Date the correction



Who to contact in case of questions?

If you have any questions, please contact your child's study doctor or the study staff on the following phone number:

[insert phone n° of the study doctor or study staff]



Please contact your child's study doctor or the study staff immediately if your child has any symptoms you think are serious.

Instructions to complete: Local and general symptoms




- If your child experience(s) any other symptoms than those listed in the local symptoms or general symptoms pages, please write these symptoms down in the Adverse Event section.
- If a symptom appears only after day 3, please write this symptom down in the Adverse Event section.
- ► How to complete Diary Card for any SYMPTOM "After day 3"?
- In the columns "After day 3", if the symptom is still ongoing* after day 3, tick "Yes". Otherwise, tick "No".
 - * The symptom is ongoing if after day 3:
 - The intensity of the symptom is 1 or higher
 - > The oral (in the mouth), axillary (under the armpit), tympanic (in the ear) or rectal (in the anus) temperature is higher or equal to 100.4°F.
 - If Yes,
 - o Please write the worst intensity for pain, the highest temperature or the greatest measurement of Redness or swelling recorded for the respective symptom during this follow-up period, after day 3.
 - And note the date when the symptom has disappeared or tick the box "still ongoing".
 - If No, then leave empty the columns "Worst intensity/ greatest size/ highest temperature" and "End Date".
 - ► BOX "STILL ONGOING" IN COLUMN "END DATE" WHEN TO TICK IT?
- . Tick the box "Still ongoing" if the illness /sign /symptom is still present at the time you return the diary card to the site

	Day 0	Day 1	Day 2	Day 3	After Day 3			Did you	Type of
					Ongoing	Worst Intensity/ Greatest size	End Date Tick box if still ongoing ↓	receive any medical attention ?	medical attention To be completed by the investigator
							Tick box if sail ongoing ♥		or delegate
Injection site	mm	mm	mm	mm	□ No	mm		■ No	HOERMD
Redness → size (mm)	10	8	5	3	⊠ Yes →	2	⊠	Yes	

DID YOUR CHILD RECEIVE ANY MEDICAL ATTENTION? HOW TO COMPLETE THIS QUESTION?

- Medical attention means hospitalisation, an emergency room visit or a visit to or from medical personnel.
- Tick the box "No" if your child did not visit medical personnel or was not visited by medical personnel or did not go to the hospital or an emergency room for the symptom.
- Tick the box "Yes" if your child went to the hospital, an emergency room, if your child visited medical personnel or was visited by medical personnel for the symptom.


Keep the type of medical attention (grey column) empty. It will be completed by the study doctor or study staff.




Instructions to complete: Local symptoms

- If your child receive(s) more than one vaccine, you will have to fill in one section for each administered vaccine.
- Redness, swelling and pain may appear around the area where your child received the vaccine (administration site(s)). These are called LOCAL symptoms.
- If similar symptoms appear on another part of your child's body than this/those corresponding to the administration site(s), please report them in the Adverse Event section.

[The study doctor or study staff should show in the drawing where is/are the administration site(s).]





For Infanrix

For ActHib

• Write down the size of the redness and swelling in millimetres (mm) only. Use the ruler given to you by the site staff.

Please note that in case a swelling greater than 50 mm is observed please describe the swelling on the page titled the Large Swelling Reaction

- ► How to complete the daily value?
- Write down a value for each symptom and each day (measure or intensity). Don't leave any field empty.
- If there is no symptom, please write "0".



Daily measurement of circumference: Every day, using the tape provided to you, please measure around the vaccinated arm or leg.

INTENSITY DEFINITIONS

Redness and swelling:

Measure and record the greatest surface diameter in millimetres (mm).

- Pain:
 - 0: Absent
 - 1: Minor reaction to touch
 - 2: Cries/protests on touch
 - 3: Cries when limb is moved / spontaneously painful

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

LOCAL SYMPTOMS (PEDIA GROUP-Booster)

Infanris

Infanrix									
To be completed by the investigator or delegate:									
Date of vaccination = Day 0: Injection Site: Side: Baseline Circumference of injected limb (In mm) =									
					Afte		er Day 3	Did your child receive any medical attention ?	Type of medical attention To be completed by the investigator or delegate
Day 0		Day 1	Day 2	Day 3	Ongoing	Worst Intensity/ Greatest size	End Date Tick box if still ongoing Ψ		
							TICK DOX II SUII OTIGOTIIG ♥		
Injection site Redness → size (mm)					□ No □ Yes →			□ No □ Yes	HO/ERMD
Injection site Swelling → size (mm)					□ No □ Yes →			□ No □ Yes	HO/ERMD
Injection site Pain → intensity (0/1/2/3)					□ No □ Yes →			□ No □ Yes	HO/ERMD

06-JUL-2018 876

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
GlaxoSmithKline 117119	Vaccine Dose Number 4	To be completed by the investigator or delegate

Daily Circumferential measurement- Infanrix

* Please measure the circumference using the tape provided to you, around the vaccinated arm or leg.

					After Day 3		
	Day 0	Day 1	Day 2	Day 3	Is large swelling reaction ongoing	If Yes then please enter the maximum circumference observed	End Date Tick box if still ongoing ✓
Daily measurement of Injection site Circumference→ size (mm)					□ No □ Yes →		

Clarification(s) for Investigator or delegate only:	



➤ LARGE SWELLING REACTION

- A large swelling reaction is a swelling at the place where your child received the vaccination that has a diameter greater than 50 mm,
 or a large swelling that is very spread out and cannot be measured or a noticeable swelling of the vaccinated arm or thigh
 circumference.
- If your child has a large swelling please call the study doctor immediately.
- Please fill in the data in the large swelling reaction section. In the section below, please enter the day, month and year when the large swelling reaction was first observed.

DESCRIBE THE TYPE OF SWELLING.

- If the swelling occurred only around the place where the vaccination shot was given and did not spread to the adjacent joint, check the first box. Adjacent joint means the shoulder or elbow (in cases where the vaccination was given in the arm) or the knee or hip joint (in cases where the vaccination was given in the thigh)
- If the swelling was spread out over a large area, but did not spread to adjacent joint, check the middle box.
- · If the swelling spread to the adjacent joint



INDURATION

• If the large swelling is hard to the touch, measure and record daily the greatest surface diameter in millimetres (mm) of the hard area.

If the swelling is not hard, check the "No" box.

PRURITIS MEANS ITCHING

• If you notice your child has itching at the large injection site (e.g. your child is scratching or vigorously rubbing the swelling), please check "Yes" and the type of Grade it is. If there is no itch check the "No" box

FUNCTIONAL IMPAIRMENT

• If the large swelling changes the way your child moves or uses the swollen arm or leg as they normally would, please check "Yes" and the type of Grade it is. If there is no change to your child's use of the swollen arm or leg, check the "No" box.



Large Swelling Reaction (*PEDIA GROUP-Booster*)

Infanrix

Date when the swelling was first considered to be a large swelling reaction*:	day month year Please enter the date in DD/MMM/YYYY format
*:To be completed by the investigator or delegate	Was the examination performed by a member of study personnel during the large swelling reaction period?
Type of swelling and Location of swelling	☐ Local swelling only around the injection site, not involving adjacent joint ☐ Diffuse swelling, not involving adjacent joint ☐ Swelling involving adjacent joint
Induration at injection site (in mm)	No Yes → If Yes then, Day 0 Day 1 Day 2 Day 3 Not Taken Not Taken Not Taken Not Taken Not Induration ongoing ? No Yes If Yes then please enter the Largest Diameter observed

880

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number	
GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate	

Pruritis at injection site	□ No □ Yes -> If yes then: □ Grade 1 (An AE which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.) □ Grade 2 (An AE which is sufficiently discomforting to interfere with normal everyday activities.) □ Grade 3 (An AE which prevents normal, everyday activities. In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care center and would cause the parent(s)/LAR(s) to seek medical advice)
Functional impairment	Has the swelling episode resulted in functional impairment? No Yes -> If yes then: Grade 1 (An AE which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.) Grade 2 (An AE which is sufficiently discomforting to interfere with normal everyday activities.) Grade 3 (An AE which prevents normal, everyday activities. In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care center and would cause the parent(s)/LAR(s) to seek medical advice)
Last date when the swelling was still considered a large swelling reaction * *:To be completed by the investigator or delegate	
Outcome of the extensive swelling	Recovered / Resolved Recovering / Resolving Not Recovered / Not Resolved Recovered with ongoing events / Resolved with ongoing events

881

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

LOCAL SYMPTOMS (PEDIA GROUP-Booster) ActHib

To be completed by the ir Date of vaccination = Baseline Circumferer	Day 0: _				on Site:		Side:		
						Afte	er Day 3		
	Day 0	Day 1	Day 2	Day 3	Ongoing	Worst Intensity/ Greatest size	End Date Tick box if still ongoing √	Did your child receive any medical attention ?	Type of medical attention To be completed by the investigator or delegate
Injection site Redness → size (mm)					□ No □ Yes →			□ No □ Yes	HO/ER/MD
Injection site Swelling → size (mm)					□ No □ Yes →			□ No □ Yes	HO/ERMD
Injection site Pain → intensity (0/1/2/3)					□ No □ Yes →			□ No □ Yes	HO/ERMD

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

Daily Circumferential measurement- ActHib

* Please measure the circumference using the tape provided to you, around the vaccinated arm or leg.

					After Day 3		
	Day 0	Day 1	Day 2	Day 3	Is large swelling reaction ongoing	If Yes then please enter the maximum circumference observed	End Date
							Tick box if still ongoing ↓
Daily measurement of Injection site Circumference→ size (mm)					□ No □ Yes →		

Clarification(s) for Investigator or delegate only:		



Large Swelling Reaction (PEDIA GROUP-Booster) ActHib

Date when the swelling was first considered to be a large swelling reaction*:	day month year Please enter the date in DD/MMM/YYYY format
*:To be completed by the investigator or delegate	Was the examination performed by a member of study personnel during the large swelling reaction period? ☐ No ☐ Yes
Type of swelling and Location of swelling	 □ Local swelling only around the injection site, not involving adjacent joint □ Diffuse swelling, not involving adjacent joint □ Swelling involving adjacent joint
Induration at injection site (in mm)	□ No □ Yes → If Yes then, Day 0 Day 1 Day 2 Day 3 □ □ □ □ □ □ Is Induration ongoing? □ No □ Yes . If Yes then please enter the Largest Diameter observed □ □ □ □

06-JUL-2018 884

$\sigma_{\rm SV}$ 11/119	DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
To be completed by the investigator or delegate	gsk GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

□ No
☐ Yes -> If yes then :
Grade 1 (An AE which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday
activities.) Grade 2 (An AE which is sufficiently discomforting to interfere with normal everyday activities.)
Grade 3 (An AE which prevents normal, everyday activities. In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care center and would cause the parent(s)/LAR(s) to seek medical advice)
Has the swelling episode resulted in functional impairment?
□ No □ Yes -> If yes then:
Grade 1 (An AE which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.)
Grade 2 (An AE which is sufficiently discomforting to interfere with normal everyday activities.)
Grade 3 (An AE which prevents normal, everyday activities. In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care center and would cause the parent(s)/LAR(s) to seek medical advice)
day month year
Please enter the date in DD/MMM/YYYY format
Recovered / Resolved Recovering / Resolving Not Recovered / Not Resolved Recovered with ongoing events / Resolved with ongoing events



Instructions to complete:

General symptoms


➢ How to complete the daily value?

- Write down a value for each symptom and each day (measure or intensity). Don't leave any field empty.
- Write "0" if there is no increase in intensity compared to normal

	Day 0	Day 1	Day 2	Day 3	Ongoing	Worst Intensity	ter Day 3 End Date Tick box if still ongoing	Did you receive medical attention?*	Type of medical attention To be completed by the investigator or delegate	Relationship to inv. Product To be completed by the investigator or delegate
Drowsiness → Intensity(0/1/2/3)	0/1/2/5	0/1/2/3	0/1/2/3	0/1/2/3	□No □Yes →	1/2/3	_	□No □Yes	HOBINIO	□No □Yes

GENERAL SYMPTOMS: TEMPERATURE

- Please use the provided thermometer.
- Take your child's temperature each day from day of vaccination (day 0) until day 3, and write down the values.
- If you took more than once a day your child's temperature, then write down the highest one.
- The preferred route for recording temperature in this study will be Axillary for Booster vaccination.



• Please write down NT (Not Taken) if you did not take the temperature.

gsk GlaxoSmithKlin	117119	-HBV-IP)	V-135			DIARY CARDS Vaccine Dose Number 4				Subject Number L L L To be completed by the investigator or delegate				
			Day 0	Day 1	Day 2	Day 3	Ongoing ≥100.4°F by any route	Hig Temp	After D	End C	Nate .	Did your child recei any medic attention	Type of medical attentical To be comp by the invest of delega	Signator by the investigator
	Temper	ature →	98	99 I	101	100.5	□No □Yes →				0	□No □Yes	HORNAG	° No Yes
GENERAL SYMPTOMS To be completed by the investigator or delegate: Date of vaccination = Day 0:														
	Day 0	Day 1	Day 2	Day	≥1	Ongoin 100.4°F by oute	ng Highes			ind Date box if still ongoing	Did your ch receive an medical attention?	ild a To be the	e of medical ttention e completed by investigator or delegate	Relationship to inv. Product To be completed by the investigator or delegate
Temperature →] No] Yes →					□ No □ Yes	Н	HO/ER/MD	□ No □ Yes
Temperature: Route of measurement: (The same route must be used for all your measurements.)														
Clarification(s) for	Investigato	or or deleg	jate only:											

> INTENSITY DEFINITIONS

- Drowsiness:
 - 0: Behaviour as usual
 - 1: Mild: Drowsiness easily tolerated
 - 2: Moderate: Drowsiness that interferes with normal activity
 - 3: Severe: Drowsiness that prevents normal activity
- Irritability/Fussiness:
 - 0: Behaviour as usual
 - 1: Mild: Crying more than usual/no effect on normal activity
 - 2: Moderate: Crying more than usual/interferes with normal activity
 - 3: Severe: Crying that cannot be comforted/prevents normal activity
- · Loss of appetite:
 - 0: Appetite as usual
 - 1: Mild: Eating less than usual/no effect on normal activity
 - 2: Moderate: Eating less than usual/interferes with normal activity
 - 3: Severe: Not eating at all

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

GENERAL SYMPTOMS										
To be completed by the investigator or delegate: Date of vaccination = Day 0:										
	Day 0	Day 1	Day 2	Day 3	Ongoing	After E Worst Intensity	Day 3 End Date Tick box if still ongoing ₩	Did your child receive medical attention?*	Type of medical attention To be completed by the investigator or delegate	Relationship to inv. Product To be completed by the investigator or delegate
Drowsiness → Intensity (0/1/2/3)					□ No □ Yes →			□ No □ Yes	HO/ERMD	□ No □ Yes
Irritability/Fussiness → intensity (0/1/2/3)					□ No □ Yes →			□ No □ Yes	HO/ER/MD	□ No □ Yes
Loss of appetite → intensity (0/1/2/3)					□ No □ Yes →			□ No □ Yes	HO/ER/MD	□ No □ Yes
Clarification(s) for Inve	estigator or	delegate	only:							

889



Instructions to complete: Adverse Events

- If your child experience(s) any other symptoms than those listed in the local symptoms or general symptoms pages, please write these symptoms down in this section.
- If a symptom appears only after day 3, please write this symptom down in this section.
- If redness, swelling or pain appears on another area than area where your child received the vaccine, please report these symptoms in this section.

INTENSITY DEFINITIONS

- 1: Mild. An adverse event which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.
- '2: Moderate. An adverse event which is sufficiently discomforting to interfere with normal everyday activities.
- **3: Severe.** An adverse event which prevents normal, everyday activities. (In a young child, such an adverse event would, for example, prevent attendance at school/kindergarten/a day-care centre and would cause the parents/guardians to seek medical advice).

BOX "STILL ONGOING" IN THE COLUMN "END DATE" - WHEN TO TICK IT?

• Tick the box "Still ongoing" if the illness / sign / symptom is still present at the time you return the diary card to the site.

117119 (DTPA-HBV-IPV-135) Report Final



DID YOUR CHILD RECEIVE ANY MEDICAL ATTENTION? HOW TO COMPLETE THIS QUESTION?

- Medical attention means hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor).
- Tick the box "No" if your child did not visit a doctor or go to the hospital or an emergency room for the symptom.
- Tick the box "Yes" if your child went to the hospital, an emergency room or if your child visited a doctor for the symptom. Keep the type of medical attention (grey column) empty. It will be completed by the study doctor or study staff.

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

ADVERSE EVENTS - MULTIPLE INJECTIONS

Record any adverse event (= any illness, sign, symptom) other than the local and general symptoms listed on the previous pages, which may have started or any medical condition which may have worsened since the last study vaccination.

		ase of reaction at inistration site				Did your child	I ype of	Relationship to inv. Product
Illness/Sign/Symptom	Site	Side	Worst Intensity 1/2/3			receive medical attention?	attention To be completed by the investigator or delegate	To be complete
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
Clarification(s) for Investigator or delega	te only:							

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk _{GlaxoSmithKline}	Vaccine Dose Number 4	To be completed by the investigator or delegate

VACCINATION

Record any vaccination received since the last study vaccination

Vaccination	Date of administration	Route* To be completed by the investigator or delegate

^{*} Route codes = inhalation [IH], intradermal [ID], intramuscular [IM], intranasal [IN], intravenous [IV], oral [PO], parenteral [PE], subcutaneous [SC], sublingual [SL], transdermal [TD], other [OTH], unknown [UNK]

Clarification(s) for Investigator or delegate only:		

Instructions to complete: Medication

Dose, UNIT AND FREQUENCY

• Write the amount of the medication your child took.

Dose, unit and frequency

200mg pill 3 times a day

2 coffeespoon 100mg once
per day

3 suppositories per day

Nasal drops 4 times per day

• Most of this information can be found on the label of the medication. You may want to bring the medication to your child's next visit with the study doctor or study staff. Then they can help you to fill in the required information.

BOX "STILL ONGOING" IN THE COLUMN "END DATE" – WHEN TO TICK IT?

• Tick the box "Still ongoing" if the medication is still taken at the time you return the diary card to the site.

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk _{GlaxoSmithKline}	Vaccine Dose Number 4	To be completed by the investigator or delegate

MEDICATION

Record any medication taken since the last study vaccination.						
Medication	Reason	Dose, unit and frequency	Start Date	End Date Tick box if still ongoing↓	Route* To be completed by the investigator or delegate	
	_		_			
	_	_	_			
* Route codes = inhalation [IH], intraarticular [II transdermal [TD], vaginal [VA], other [OTH], unl		ır [IM], intranasal [IN], intrave	enous [IV], oral [PO], palenteral [PE], rectal	[PR], subcutaneous [SC], sublingual [S	L], topical [TO],	

Clarification(s) for Investigator or delegate only:

DTPA-HBV-IPV-135 117119	DIARY CARDS Vaccine Dose Number 4	Subject Number L L L L L L To be completed by the investigator or delegate
----------------------------	------------------------------------	--

NOTES		

INVESTIGATOR'S OR DELEGATE'S SIGNATURE

Investigator's or delegate's signature:	 Date:	
Printed Investigator's or delegate's name:		



General Instructions

Thank you for your child's participation in this clinical trial.

During your child's last study visit, you received a "Diary Card" to fill in every day for a defined period, so that your child's study doctor or the study staff will know your child's general health status after the vaccination.

Here below you will find general instructions on how to complete the "Diary Card". There are also other specific instructions relative to each part of the "Diary Card" that you will need to fill in.

► INSTRUCTIONS TO COMPLETE THE "DIARY CARD"

- Write in clearly, use a pen (never pencil).
- The grey areas are dedicated to the investigator or delegate only. Do not write in these areas.

Illness/Sign/Symptom ☑ if at vaccine injection site ↓	Worst Intensity 1/2/3	Start Date	End Date Tick box if still engoing ↓	Did you receive medical attention?	Type of medical attention To be completed by the investigator or delegate	Relationship to inv. Product To be completed by the investigator or delegate
Tendinitis 🗆	2	04-FEB-2012	08-FEB-2012 LI	□ No ☑ Yes	HOERMD	∐No ∐Yes

► How to correct mistakes?

- · Cross out the mistake with a single line.
- Don't hide the mistake. Don't use correction fluid or don't make inkblots.
- Write the correct response close to the mistaken one.
- If the correct response is written outside of the box, circle it and point to it with an arrow towards the box.
- Put your initials near the correction.
- Date the correction



Who to contact in case of questions?

If you have any questions, please contact your child's study doctor or the study staff on the following phone number:

[insert phone n° of the study doctor or study staff]



Please contact your child's study doctor or the study staff immediately if your child has any symptoms you think are serious.

Instructions to complete: Local and general symptoms




- If your child experience(s) any other symptoms than those listed in the local symptoms or general symptoms pages, please write these symptoms down in the Adverse Event section.
- If a symptom appears only after day 3, please write this symptom down in the Adverse Event section.
- ► How to complete Diary Card for any SYMPTOM "After day 3"?
- In the columns "After day 3", if the symptom is still ongoing* after day 3, tick "Yes". Otherwise, tick "No".
 - * The symptom is ongoing if after day 3:
 - > The intensity of the symptom is 1 or higher
 - > The oral (in the mouth), axillary (under the armpit), tympanic (in the ear) or rectal (in the anus) temperature is higher or equal to 100.4°F.
 - If Yes,
 - Please write the worst intensity for pain, the highest temperature or the greatest measurement of Redness or swelling recorded for the respective symptom during this follow-up period, after day 3.
 - And note the date when the symptom has disappeared or tick the box "still ongoing".
 - If No, then leave empty the columns "Worst intensity/ greatest size/ highest temperature" and "End Date".
 - Box "Still ongoing" in column "End date" When to tick it?
- . Tick the box "Still ongoing" if the illness /sign /symptom is still present at the time you return the diary card to the site

						After [Day 3	Did you	Type of medical
	Day 0	Day 1	Day 2	Day 3	Ongoing	Worst Intensity/ Greatest	End Date	receive any medical	attention To be completed
						size	Tick box if still ongoing ↓	attention ?	by the investigator or delegate
Injection site Redness → size (mm)	mm 10	mm 2	mm 5	mm 3	□ No ⊠ Yes →	mm 2		□ No ⊠ Yes	HOERMD

DID YOUR CHILD RECEIVE ANY MEDICAL ATTENTION? HOW TO COMPLETE THIS QUESTION?

- Medical attention means hospitalisation, an emergency room visit or a visit to or from medical personnel.
- Tick the box "No" if your child did not visit medical personnel or was not visited by medical personnel or did not go to the hospital or an emergency room for the symptom.
- Tick the box "Yes" if your child went to the hospital, an emergency room, if your child visited medical personnel or was visited by medical personnel for the symptom.

Keep the type of medical attention (grey column) empty. It will be completed by the study doctor or study staff.



Instructions to complete: Local symptoms

- If your child receive(s) more than one vaccine, you will have to fill in one section for each administered vaccine.
- Redness, swelling and pain may appear around the area where your child received the vaccine (administration site(s)). These are called LOCAL symptoms.
- If similar symptoms appear on another part of your child's body than this/those corresponding to the administration site(s), please report them in the Adverse Event section.

[The study doctor or study staff should show in the drawing where is/are the administration site(s).]



For Pentacel

• Write down the size of the redness and swelling in millimetres (mm) only. Use the ruler given to you by the site staff.

Please note that in case a swelling greater than 50 mm is observed please describe the swelling on the page titled the Large Swelling Reaction

- ► How to complete the daily value?
- Write down a value for each symptom and each day (measure or intensity). Don't leave any field empty.
- If there is no symptom, please write "0".



Daily measurement of circumference: Every day, using the tape provided to you, please measure around the vaccinated arm or leg.

INTENSITY DEFINITIONS

Redness and swelling:

Measure and record the greatest surface diameter in millimetres (mm).

- Pain:
 - 0: Absent
 - 1: Minor reaction to touch
 - 2: Cries/protests on touch
 - 3: Cries when limb is moved / spontaneously painful

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
GlaxoSmithKline 117119	Vaccine Dose Number 4	To be completed by the investigator or delegate

LOCAL SYMPTOMS (PENTA GROUP-Booster)

Pentacel									
To be completed by the in	nvestigator	or delegate	:						
Date of vaccination = Day 0: Injection Site: Side: Baseline Circumference of injected limb (ln mm) =									
						Aft	er Day 3		
	Day 0	Day 1	Day 2	Day 3	Ongoing	Worst Intensity/ Greatest size	End Date Tick box if still ongoing √	Did your child receive any medical attention ?	Type of medical attention To be completed by the investigator or delegate
Injection site Redness → size (mm)					□ No □ Yes →			□ No □ Yes	HO/ERMD
Injection site Swelling → size (mm)					□ No □ Yes →			□ No □ Yes	HO/ERMD
Injection site Pain → intensity (0/1/2/3)					□ No □ Yes →			□ No □ Yes	HO/ERMD

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

Daily Circumferential measurement- Pentacel

* Please measure the circumference using the tape provided to you, around the vaccinated arm or leg.

						Afte	r Day 3
	Day 0	Day 1	Day 2	Day 3	Is large swelling reaction ongoing	If Yes then please enter the maximum circumference observed	End Date Tick box if still ongoing ✔
Daily measurement of Injection site Circumference→ size (mm)					□ No □ Yes →		

Clarification(s) for Investigator or delegate only:		



➤ LARGE SWELLING REACTION

- A large swelling reaction is a swelling at the place where your child received the vaccination that has a diameter greater than 50 mm,
 or a large swelling that is very spread out and cannot be measured or a noticeable swelling of the vaccinated arm or thigh
 circumference.
- If your child has a large swelling please call the study doctor immediately.
- Please fill in the data in the large swelling reaction section. In the section below, please enter the day, month and year when the large swelling reaction was first observed.

DESCRIBE THE TYPE OF SWELLING.

- If the swelling occurred only around the place where the vaccination shot was given and did not spread to the adjacent joint, check the first box. Adjacent joint means the shoulder or elbow (in cases where the vaccination was given in the arm) or the knee or hip joint (in cases where the vaccination was given in the thigh)
- If the swelling was spread out over a large area, but did not spread to adjacent joint, check the middle box.
- · If the swelling spread to the adjacent joint



INDURATION

• If the large swelling is hard to the touch, measure and record daily the greatest surface diameter in millimetres (mm) of the hard area.

If the swelling is not hard, check the "No" box.

PRURITIS MEANS ITCHING

• If you notice your child has itching at the large injection site (e.g. your child is scratching or vigorously rubbing the swelling), please check "Yes" and the type of Grade it is. If there is no itch check the "No" box

FUNCTIONAL IMPAIRMENT

• If the large swelling changes the way your child moves or uses the swollen arm or leg as they normally would, please check "Yes" and the type of Grade it is. If there is no change to your child's use of the swollen arm or leg, check the "No" box.



Large Swelling Reaction (*PENTA GROUP-Booster*)

Pentacel

Date when the swelling was first considered to be a large swelling reaction*:	day month year Please enter the date in DD/MMM/YYYY format
*:To be completed by the investigator or delegate	Was the examination performed by a member of study personnel during the large swelling reaction period?
Type of swelling and Location of swelling	☐ Local swelling only around the injection site, not involving adjacent joint ☐ Diffuse swelling, not involving adjacent joint ☐ Swelling involving adjacent joint
Induration at injection site (in mm)	No Yes → If Yes then, Day 0 Day 1 Day 2 Day 3 Not Taken Not Taken Not Taken Not Taken Not Induration ongoing ? No Yes If Yes then please enter the Largest Diameter observed

908

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number		
GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate		

Pruritis at injection site	□ No □ Yes -> If yes then: □ Grade 1 (An AE which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.) □ Grade 2 (An AE which is sufficiently discomforting to interfere with normal everyday activities.) □ Grade 3 (An AE which prevents normal, everyday activities. In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care center and would cause the parent(s)/LAR(s) to seek medical advice)
Functional impairment	Has the swelling episode resulted in functional impairment? No Yes -> If yes then: Grade 1 (An AE which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.) Grade 2 (An AE which is sufficiently discomforting to interfere with normal everyday activities.) Grade 3 (An AE which prevents normal, everyday activities. In a young child, such an AE would, for example, prevent attendance at school/kindergarten/a day-care center and would cause the parent(s)/LAR(s) to seek medical advice)
Last date when the swelling was still considered a large swelling reaction * *:To be completed by the investigator or delegate	
Outcome of the extensive swelling	Recovered / Resolved Recovering / Resolving Not Recovered / Not Resolved Recovered with ongoing events / Resolved with ongoing events

06-JUL-2018 909



Instructions to complete:

General symptoms

► How to complete the daily value?

- Write down a value for each symptom and each day (measure or intensity). Don't leave any field empty.
- Write "0" if there is no increase in intensity compared to normal

	Day 0	Day 1	Day 2	Day 3	Ongoing	Worst Intensity	ter Day 3 End Date Tick box if still ongoing ◆	Did you receive medical attention?*	Type of medical attention To be completed by the investigator or delegate	Relationship to inv. Product To be completed by the investigator or delegate
Drowsiness → Intensity(0/1/2/3)	0/1/2/3	0/1/2/3	0/1/2/3	0/1/2/3	□No □Yes →	1/2/3		□No □Yes	HOERMO	□No □Yes

GENERAL SYMPTOMS: TEMPERATURE

- Please use the provided thermometer.
- Take your child's temperature each day from day of vaccination (day 0) until day 3, and write down the values.
- If you took more than once a day your child's temperature, then write down the highest one.
- The preferred route for recording temperature in this study will be Axillary for Booster vaccination.

Example: if on Day 0

• At 8 am: 98.8°F

• At 1 pm: 99.3°F

At 7 pm: 99.7°F

} —

99.7°F is to be recorded in for Day 0

Please write down NT (Not Taken) if you did not take the temperature.

	Day 9	Day 1	Day 2		Ongoing ≥100.4°F by any route	After C	End Date	Did your child receive any medical attention?	Type of medical attention To be completed by the investigator or delegate	Relationship to inv. Product To be completed by the investigator or delegate
Temperature →	98	99 I	101	100.5	□No □Yes →		0	□No □Yes	HOMMO	□No Yes

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

GENERAL SYMPTOMS										
To be completed by the investigator or delegate: Date of vaccination = Day 0:										
		T			After Day 3		; 			
	Day 0	Day 1	Day 2	Day 3	Ongoing ≥100.4°F by any route	Highest Temperature	End Date	Did your child receive any medical attention?	Type of medical attention To be completed by the investigator or delegate	Relationship to inv. Product To be completed by the investigator or delegate
							Tick box if still ongoing			
Temperature →					□ No □ Yes →			□ No □ Yes	HO/ER/MD	□ No □ Yes
Temperature:			Route of me		nt: e used for all your meas	usurements.)				
☐ Fahrenheit										
Clarification(s) for	Investigato	r or delega	ate only:							

> INTENSITY DEFINITIONS

- Drowsiness:
 - 0: Behaviour as usual
 - 1: Mild: Drowsiness easily tolerated
 - 2: Moderate: Drowsiness that interferes with normal activity
 - 3: Severe: Drowsiness that prevents normal activity
- Irritability/Fussiness:
 - 0: Behaviour as usual
 - 1: Mild: Crying more than usual/no effect on normal activity
 - 2: Moderate: Crying more than usual/interferes with normal activity
 - 3: Severe: Crying that cannot be comforted/prevents normal activity
- · Loss of appetite:
 - 0: Appetite as usual
 - 1: Mild: Eating less than usual/no effect on normal activity
 - 2: Moderate: Eating less than usual/interferes with normal activity
 - 3: Severe: Not eating at all

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

GENERAL SYMPTOMS										
To be completed by the investigator or delegate: Date of vaccination = Day 0:										
	Day 0	Day 1	Day 2	Day 3	Ongoing	After I Worst Intensity	Day 3 End Date Tick box if still ongoing ₩	Did your child receive medical attention?*	Type of medical attention To be completed by the investigator or delegate	Relationship to inv. Product To be completed by the investigator or delegate
Drowsiness → Intensity (0/1/2/3)					□ No □ Yes →			□ No □ Yes	HO/ERMD	□ No □ Yes
Irritability/Fussiness → intensity (0/1/2/3)					□ No □ Yes →			□ No □ Yes	HO/ERMD	□ No □ Yes
Loss of appetite → intensity (0/1/2/3)					□ No □ Yes →			□ No □ Yes	HO/ERMD	□ No □ Yes
Clarification(s) for Inve	estigator oi	r delegate	only:							

06-JUL-2018 913



Instructions to complete: Adverse Events

- If your child experience(s) any other symptoms than those listed in the local symptoms or general symptoms pages, please write these symptoms down in this section.
- If a symptom appears only after day 3, please write this symptom down in this section.
- If redness, swelling or pain appears on another area than area where your child received the vaccine, please report these symptoms in this section.

INTENSITY DEFINITIONS

- 1: Mild. An adverse event which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.
- 2: Moderate. An adverse event which is sufficiently discomforting to interfere with normal everyday activities.
- **3: Severe.** An adverse event which prevents normal, everyday activities. (In a young child, such an adverse event would, for example, prevent attendance at school/kindergarten/a day-care centre and would cause the parents/guardians to seek medical advice).

BOX "STILL ONGOING" IN THE COLUMN "END DATE" - WHEN TO TICK IT?

• Tick the box "Still ongoing" if the illness / sign / symptom is still present at the time you return the diary card to the site.

117119 (DTPA-HBV-IPV-135) Report Final



DID YOUR CHILD RECEIVE ANY MEDICAL ATTENTION? HOW TO COMPLETE THIS QUESTION?

- Medical attention means hospitalisation, an emergency room visit or a visit to or from medical personnel (medical doctor).
- Tick the box "No" if your child did not visit a doctor or go to the hospital or an emergency room for the symptom.
- Tick the box "Yes" if your child went to the hospital, an emergency room or if your child visited a doctor for the symptom. Keep the type of medical attention (grey column) empty. It will be completed by the study doctor or study staff.

DTPA-HBV-IPV-135 117119	DIARY CARDS	Subject Number
GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

ADVERSE EVENTS - MULTIPLE INJECTIONS

Record any adverse event (= any illness, sign, symptom) other than the local and general symptoms listed on the previous pages, which may have started or any medical condition which may have worsened since the last study vaccination.

		ase of reaction at inistration site				Did your child	Type of	Relationship to inv.
Illness/Sign/Symptom	Site	Side	Worst Intensity 1/2/3	Start Date	End Date Tick box if still ongoing	receive medical attention?	medical attention To be completed by the investigator or delegate	To be completed by the investigator or delegate
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
	☐ Thigh ☐ Deltoid	Left Right				□ No □ Yes	HO/ER/MD	□ No □ Yes
Clarification(s) for Investigator or delega	te only:							

06-JUL-2018 812f4fb003c07b74cae10f81cf90c72c48e48cbd

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk GlaxoSmithKline	Vaccine Dose Number 4	To be completed by the investigator or delegate

VACCINATION

Record any vaccination received since the last study vaccination

Vaccination	Date of administration	Route* To be completed by the investigator or delegate

^{*} Route codes = inhalation [IH], intradermal [ID], intramuscular [IM], intranasal [IN], intravenous [IV], oral [PO], parenteral [PE], subcutaneous [SC], sublingual [SL], transdermal [TD], other [OTH], unknown [UNK]

Clarification(s) for Investigator or delegate only:		

06-JUL-2018 812f4fb003c07b74cae10f81cf90c72c48e48cbd

Instructions to complete: Medication

Dose, unit and frequency

• Write the amount of the medication your child took.

Dose, unit and frequency

200mg pill 3 times a day

2 coffee spoon 100mg once
per day

3 suppositories per day

Nasal drops 4 times per day

• Most of this information can be found on the label of the medication. You may want to bring the medication to your child's next visit with the study doctor or study staff. Then they can help you to fill in the required information.

BOX "STILL ONGOING" IN THE COLUMN "END DATE" – WHEN TO TICK IT?

• Tick the box "Still ongoing" if the medication is still taken at the time you return the diary card to the site.

DTPA-HBV-IPV-135	DIARY CARDS	Subject Number
gsk _{GlaxoSmithKline}	Vaccine Dose Number 4	To be completed by the investigator or delegate

MEDICATION

Record any medication taken since the	ne last study vaccination.				
Medication	Reason	Dose, unit and frequency	Start Date	End Date Tick box if still ongoing ↓	Route* To be completed by the investigator or delegate

*Route codes = inhalation [IH], intraarticular [IR], intradermal [ID], intramuscular [IM], intranasal [IN], intravenous [IV], oral [PO], paenteral [PE], rectal [PR], subcutaneous [SC], sublingual [SL], topical [TO], transdermal [TD], vaginal [VA], other [OTH], unknown [UNK]

Clarification(s) for Investigator or delegate only:	

06-JUL-2018 812f4fb003c07b74cae10f81cf90c72c48e48cbd

Subject Number

UTFA-HBV-IFV-15S 117119	Vaccine Dose Number 4	To be completed by the investigator or delegate
NOTES		

INVESTIGATOR'S OR DELEGATE'S SIGNATURE

Investigator's or delegate's signature:	 Date:	
Printed Investigator's or delegate's name:		
ucicyale s name.		

06-JUL-2018 812f4fb003c07b74cae10f81cf90c72c48e48cbd

List of investigators, IEC/IRB and distribution of subjects

Investigator	Sub-Investigator	Center no	Description of Research Facility, Hospital/ Institution, and Address	Name of IEC/IRB Committee, Address	Number of Subjects	% of Subjects
United States					585	100
Aguilar, Richard	Charlesworth, Cynthia Cihigoyenetche, Jennie Crook, Teresa Earl, Lisa Rose, Vicki	PPD	Saltzer Medical Group, 215 E Hawaii Ave,Nampa,Idaho,United States,83686	St. Luke's Health System Institutional Review Board, 190 E. Bannock Street Boise, ID 83712 St. Luke's Health System Institutional Review Board, 3000 S. Denver Way Boise, ID 83705	11	1.9
Andrews, Wilson	Anderson, Dana Bien, Richard Chernik, Christine Fearing, Donna Fernandez, Carole Fleming, Debra Hassel, Stephanie King, Deborah King, Stephen Morgan, Bakari Nevius, Patricia Nix, Tamara Royal, Dina Scheffer, Elizabeth Smail, Nicole Turlapaty, Neelima Worly, Julia		Pediatric and Adolescent Medicine PA, 2155 Post Oak Tritt Road, Marietta, Georgia, United States,30062	Quorum Review IRB, 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	10	1.7

117119 (DTPA-HBV-IPV-135)

Investigator	Sub-Investigator	Center no.	Description of Research Facility, Hospital/ Institution, and Address	Name of IEC/IRB Committee, Address	Number of Subjects	% of Subjects
Andrews, Wilson	Anderson, Dana Bien, Richard Chernik, Christine Fearing, Donna Fernandez, Carole Fleming, Debra Hassel, Stephanie King, Deborah King, Stephen Morgan, Bakari Nevius, Patricia Nix, Tamara Royal, Dina Scheffer, Elizabeth Smail, Nicole Turlapaty, Neelima	PPD	Pediatrics and Adolescent Medicine, 120 Stonebridge Parkway, Woodstock, Georgia, United States,30189	Quorum Review IRB, 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	11	1.9
Concannon, Kevin	Worly, Julia Davis, Eileen McHorney, David Patton, Robert Typlin, Bonnie Valdes de-la-Cruz, Monica		Cholla Pediatrics, 2167 West Orange Grove Rd,Tucson,Arizona,United States,85741	Quorum Review IRB, 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	14	2.4
Daly, Wendy	Becherer, Rebecca Cornett, Denver III Heustis, Renee		Bluegrass Clinical Research, INC, 5512 Bardstown Road, Louisville, Kentucky, United States, 40291	Quorum Review IRB, 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	5	0.9

Investigator	Sub-Investigator	Center no.	Description of Research Facility, Hospital/ Institution, and Address	Name of IEC/IRB Committee, Address	Number of Subjects	% of Subjects
Garscadden, Alan	Burke, Charles	PPD	Colorado Springs Heath Partner - East,	Quorum Review IRB, 1501 Fourth	11	1.9
	Finck, Lani		6340 Barnes Road, Colorado Springs,	Avenue, Suite 800 Seattle, WA 98101		
	Freson, Brandon		Colorado,United States,80922			
	Hill, Stephanie					
Karaboitis, Krisoula Lundy, Samantha Nevarez, Max Pink, Cyndi Southern, Patryce	· '					
	=					
	· ·					
	•					
	· ·					
	Weiss, Sarah					
Haney, Byron	Beachy, Ryan		Family Health Care of Ellensburg,107	Quorum Review IRB, 1501 Fourth	7	1.2
	Bowman, Diane		East Mountain View Ave, Ellensburg,	Avenue, Suite 800 Seattle, WA		
	Brower, Stephanie		Washington, United States, 98926	98101		
	Izzi, Tami					
	Kelly, Kate					
	Long, Aaron					
	McHargue, Jenny					
	Miller, Heidi					
	Mongrain, Chad					
	Sackett, Stephanie					
	Vaughan, Rick					
	Walters, John					
Harris, JoAnn	Cabrilo, Nadia		Cotton O'Neill Research Center, 4100	Quorum Review IRB, 1501 Fourth	12	2.1
	Cotter, Michael		SW 15th St,Topeka,Kansas,United	Avenue, Suite 800 Seattle, WA		
	Noruzian, Masoud		States,66604	98101		
	Parr, Harold					
	Schumacher, Randall					

Investigator	Sub-Investigator	Center no.	Description of Research Facility, Hospital/ Institution, and Address	Name of IEC/IRB Committee, Address	Number of Subjects	% of Subjects
Harrison, Christopher	Buford, Terry Hobbs, Kristie Pahud, Barbara Seybert, Missy Weltmer, Kristen	PPD	Children's Mercy Hospitals and Clinics - Pediatric Clinical Pharmacology & Medical Toxicology, 2401 Gillham Road,Kansas City, Missouri, United States,64108	Children's Mercy Hospitals Pediatric Institutional Review Board 2401 Gillham Road Kansas City, MO 64108	6	1.0
Hartvickson, Robyn	Allen, Michele Barnes, Adriene Craig, Abigail Holdeman, Troy King, Jeri Lindholm, Gerald Oubre, Sarah Phillips, Justin Shuman, Bobbie Slechta, Stacy Thomas, Shannon Thompson, Jackie Watts, Hannah Wiens, Terra		Heartland Research Associates,700 Medical Center Drive, Newton, Kansas,United States,67114	Quorum Review IRB, 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	10	1.7
Heise, John	Backus, Kathryn Bays, Anna Lewis, Donald Reinhardt, Diana Ress, Diane Shook, Josh Smith, Ashley Sturm, Donna Taylor, Peggy		Holston Medical Group, 2033 Meadowview Lane, Kingsport, Tennessee, United States,37660	Quorum Review IRB, 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	3	0.5

117119 (DTPA-HBV-IPV-135)

Investigator	Sub-Investigator	Center n	o. Description of Research Facility, Hospital/ Institution, and Address	Name of IEC/IRB Committee, Address	Number of Subjects	% of Subjects
Klein, Nicola	Baxter, Roger Hempstead, Kenneth Rossi, LaVonne	PPD	Kaiser Permanente Roseville 1840 Sierra Gardens Dr RosevilleOakland, California, United States,95661	Kaiser Permanente Northern California (KPNC) Institutional Review Board (IRB). 1800 Harrison Street Oakland, CA 94612	45	7.7
Klein, Nicola	Bailon, Eileen Baxter, Roger Pelliccione, Linda Purdy, Kenneth Upadhyaya, Sally		Kaiser Permanente - Santa Clara, 186 710 Expressway, Santa Clara, California, United States, 95051	Kaiser Permanente Northern California (KPNC) Institutional Review Board (IRB). 1800 Harrison Street Oakland, CA 94612	34	5.8
Klein, Nicola	Baxter, Roger Huynh, Tuan Mullen, Shannon		Kaiser Permanente - San Jose,Unit B1 276 International Circle,San Jose, California,United States,95119	Kaiser Permanente Northern California (KPNC) Institutional Review Board (IRB). 1800 Harrison Street Oakland, CA 94612	42	7.2
Klein, Nicola	Baguinguito, Michelle Baxter, Roger Enochian, Karen Latimer, Manya Lepejian, Garine		Kaiser Permanente Fresno 4785 North First Street Fresno, California, United States, 93726	Kaiser Permanente Northern California (KPNC) Institutional Review Board (IRB). 1800 Harrison Street Oakland, CA 94612	18	3.1
Klein, Nicola	Backs, Julia Baires, Janelle Baxter, Roger Chan-Werner, Siew	_	Kaiser Permanente Oakland, 3505 Broadway,Oakland,California,United States,94611	Kaiser Permanente Northern California (KPNC) Institutional Review Board (IRB). 1800 Harrison Street Oakland, CA 94612	29	5.0
Klein, Nicola	Anand, Lei Baxter, Roger Duenas-Fernandez, Therese Kaneko, Jennifer		Kaiser Permanente Clinic - Pleasanton, 2nd Floor 7601 Stoneridge Mall Road, Pleasanton, California, United States,94588	Kaiser Permanente Northern California (KPNC) Institutional Review Board (IRB). 1800 Harrison Street Oakland, CA 94612	8	1.4

117119 (DTPA-HBV-IPV-135)

Investigator	Sub-Investigator	Center	no.	Description of Research Facility, Hospital/ Institution, and Address	Name of IEC/IRB Committee, Address	Number of Subjects	% of Subjects
Lee, Sa Minetto Owen,	Baxter, Roger Lee, Sandra Minetto, Margaret Owen, Susie Takahashi, Irene	PPD		Kaiser Permanente Daly City 395 Hickey Blvd,Daly City, California, United States,94015	Kaiser Permanente Northern California (KPNC) Institutional Review Board (IRB). 1800 Harrison Street Oakland, CA 94612	48	8.2
Klein, Nicola	Baxter, Roger Carlson, Linda Chan, Eva Duenas-Fernandez, Therese Phelan, Michael Tichenor, Thorston			Kaiser Permanente Hayward, 27303 Sleepy Hollow Ave, Hayward, California, United States,94545	Kaiser Permanente Northern California (KPNC) Institutional Review Board (IRB). 1800 Harrison Street Oakland, CA 94612	20	3.4
Klein, Nicola	Baxter, Roger Cook, Gail Cooper, David Hansen, Gabriel Henson, Linda			Kaiser Permanente Sacramento, 1650 Response Road, Sacramento, California, United States, 95815	Kaiser Permanente Northern California (KPNC) Institutional Review Board (IRB). 1800 Harrison Street Oakland, CA 94612	23	3.9
Klein, Nicola	Baxter, Roger Burun, Latisha Hansen, Gabriel Jordan, Weldon Theisen, Susan			Kaiser Permanente South Sacramento, 6600 Bruceville Rd,Sacramento, California, United States,95823	Kaiser Permanente Northern California (KPNC) Institutional Review Board (IRB). 1800 Harrison Street Oakland, CA 94612	13	2.2
Klein, Nicola	Angel, Valerie Baxter, Roger Bergen, Randy Encarnacion, Jolynne			Kaiser Permanente Walnut Creek, 1425 South Main Street, Walnut Creek, California, United States, 94596	Kaiser Permanente Northern California (KPNC) Institutional Review Board (IRB). 1800 Harrison Street Oakland, CA 94612	11	1.9

117119 (DTPA-HBV-IPV-135)

Investigator	Sub-Investigator	Center no.	Description of Research Facility, Hospital/ Institution, and Address	Name of IEC/IRB Committee, Address	Number of Subjects	% of Subjects
Kratz, Richard	Bartholomew, Susan	PPD	Pennridge Pediatric Associates, 711	Quorum Review IRB 1501 Fourth	7	1.2
	Bolanowski, Deborah		Lawn Ave, Sellersville, Pennsylvania, United States, 18960	Avenue, Suite 800 Seattle, WA 98101		
	Couper, Rebecca		Officed States, 10300	90101		
	Dickinson, Normajean					
	Dolha, Anuta					
	Faccenda, Deborah					
	Flaherty, Betty Jo					
	Hipp, Thomas					
	Kivela, Ursula					
	Lamberth, Erik					
	Leatherman, Tammy					
	Moretski, Kelly					
	Moyer, Margery					
	Ozeck, Deborah					
	Pforter, Bonnie					
	Schafer, Katelyn					
	Sims, Audrey					
	Souder, Ronald					
	Velasquez, Ivania					
	Vogl, Jeffery					
Landis, Miles	Alber, Thomas		Miles M. Landis, MD 2505 Junior Street		2	0.3
	Hillock, Karen		Orange City Florida United States	Avenue, Suite 800 Seattle, WA		
	Kornegay, Jill		32763	98101		
	Roque, Mark					
	Walker, Cynthia					

Investigator	Sub-Investigator	Center no.	Description of Research Facility, Hospital/ Institution, and Address	Name of IEC/IRB Committee, Address	Number of Subjects	% of Subjects
Livingston, Sean	Ball, Charles Benafield, Laureen Davis, Orrin Denton, Meredith Furlow, Stacy Grear, Tim Jackson, Charles Koehler, Andrew Mahan, Meredith McCord, Virginia Park, Josephine Payton, Terry Rasmussen, Daniel Robinson, Joe Silvey, Brentley Simmons, John Swindle, James	PPD	Northwest Arkansas Pediatric, 3383 N. MANA Court, Fayetteville, Arkansas, United States,72703	Quorum Review IRB 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	19	3.3
Marshall, Gary	Bryant, Kristina Carothers, Becky Chaney, Elizabeth Espinosa, Claudia Franck, Emily Franco, Sofia Frazier, Erin Jones, Veronnie Kurbasic, Mirzada Nota, Maria Fernanda Pasquenza, Natalie		University of Louisville Hospital, 555 South Floyd Street, Louisville, Kentucky, United States,40202	University of Louisville Human Subjects Protection Program Office MedCenter One – Suite 200 501 E. Broadway Louisville, KY 40202- 1798	15	2.6

Investigator	Sub-Investigator	Center no.	Description of Research Facility, Hospital/ Institution, and Address	Name of IEC/IRB Committee, Address	Number of Subjects	% of Subjects
	Patel, Pradip					
	Pendleton, Amber					
	Sayat, Gena					
	Sayat, Jonathan					
	Scott, Penny					
	Smith, Michael					
	Statler, Victoria					
	Theriot, Judith					
	Thompson, Jennifer					
	Woods, Charles					
	Wortham, Laura					
Mehta, Praful	Duncan, Sheri	PPD	Heartland Research Associates, LLC,	Quorum Review IRB 1501 Fourth	9	1.5
	Entriken, Leslie		3730 N Ridge Road, Wichita, Kansas,	Avenue, Suite 800 Seattle, WA		
	Goering, Tana		United States, 67205	98101		
	Hardy, Chelsey					
	Hastings, Amber					
	Hook, Kristen					
	Koehler, Timothy					
	Neuberger, Cari					
	Reheis, Jordan					
	Schmidt, Holli					
	Thomas, Shannon					
	Zinkovsky, Sophia					

Investigator	Sub-Investigator	Center no.	Description of Research Facility, Hospital/ Institution, and Address	Name of IEC/IRB Committee, Address	Number of Subjects	% of Subjects
Miller, Garron	Goodrich, Diane Hellyer, Jeanie Lauritzen, Benjamin Murphy, Annette Peterson, Jonathan Yacolca, Ischia	PPD	Utah Valley Pediatrics - Payson, 15 S 1000 East, Payson, Utah, United States,84651	Quorum Review IRB 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	20	3.4
Moore, Susan	Zomcik, Anne		Childrens Health Care - West, 2501 West 12th Street, Erie, Pennsylvania, United States,16505	Quorum Review IRB 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	21	3.6
Peterson, James	Clark, Alexander Clyde, Jennifer Eborn, Shana Edwards, Susan Henry, Dan Iwasaki, Pamela Ann Jackson, Heather John, Whitney Kelty, Gerald Lewis, Janet C Mickelson, Christopher Pace, Laura Rohrer, Jacqueline Taylor, Jack Wagner, Gintare Wilkerson, Jeanna		J. Lewis Research, Inc., Foothill Family Clinic, 2295 Foothill Drive, Salt Lake City, Utah, United States, 84109	Quorum Review IRB 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	3	0.5
Ramsey, Keith			Jordan Ridge Kids and Teens, 8822 S Redwood Road,West Jordan, Utah, United States,84088	Quorum Review IRB 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	6	1.0
Rausch, Michael	Allen, Michele		Heartland Research Associates, LLC,	Quorum Review IRB 1501 Fourth	3	0.5

	<u> </u>			I		eport Fin
Investigator	Sub-Investigator	Center n	Description of Research Facility, Hospital/ Institution, and Address	Name of IEC/IRB Committee, Address	Number of Subjects	% of Subjects
Naccarato, Teran (FPI)	Babb, Andrea Cerullo, Janis Cowgill, Stephanie Hiebert, Jill Phan, Linda Phillips, Justin Regehr, Emily Stackhouse, Johnny Warman, Elizabeth Wilson, Dorothy		1601 State Street, Augusta, Kansas, United States,67010	Avenue, Suite 800 Seattle, WA 98101		
Reyes, Elizabeth	Reyes, Antonio	PPD	Emmaus Research Center Inc, 408 South Beach Blvd, Anaheim, California, United States,92804	Quorum Review IRB 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	10	1.7
Shepard, Julie	Byers, Matthew Goodfellow, Jessica Mergler, Kristin		Ohio Pediatric Research Association, 7200 Poe Avenue, Dayton, Ohio, United States, 45414	Quorum Review IRB 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	11	1.9
Sigg, Laurent	Cook, Kimberly Downs, Kandy Hunt, Vickie Silas, Peter		Wee Care Pediatrics II, 934 South Main Street, Layton, Utah, United States,84041	Quorum Review IRB 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	2	0.3
Simon, Michael	Hippe, Sandra Rush, Carol Sutherland, Teresa Wilson, Erin		Michael W Simon MD, 610 East Brannon Road, Nicholasville, Kentucky, United States, 40356	Quorum Review IRB 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	2	0.3
Strahlman, R Scott	Kari, Manjula Zapata, Graciela		Columbia Medical Practice, 5450 Knoll Drive North, Columbia, Maryland, United States,21045	Quorum Review IRB 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	2	0.3

Investigator	Sub-Investigator	Center no.	Description of Research Facility, Hospital/ Institution, and Address	Name of IEC/IRB Committee, Address	Number of Subjects	% of Subjects
Tipton, Mary	Andrews, Curtis Cook, Kimberly Cottle, Kevin Garcia, Kathy Goodrich, Diane Hellyer, Jeanie Hollingsworth, Martin Hunt, Vickie Nakata, Thanh Perkins, Janene Thur, Vilate	PPD	Copperview Medical Center, 3556 West 9800 South, South Jordon,U tah, United States,84095	Quorum Review IRB 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	7	1.2
Twiggs, Jerry	Lee, Russell McMullin, Karl		Dixie Pediatrics, 1240 East 100 South, #14,St. George, Utah, United States,84790	Quorum Review IRB 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	14	2.4
Weiner, Leonard	Butler, Maureen Ferguson, Lori Fluno, Kristen Halczyn, Jodi Joseph, Kristine Losito, Vito Massa, Tracy Odin, Rosalind O'Malley, Sean Potter, Rebecca Remillard, Phillip Shaw, Jana Sisskind, Jaclyn Skeval, Sandra Stoeckel, Kathleen		SUNY Upstate Medical University, 750 E. Adams Street, Syracuse, New York, United States, 13210	Upstate Medical University Institutional Review Board for the Protection of Human Subjects SUNY Upstate Medical University Institutional Review Board 750 East Adams Street, WSK Hall Syracuse NY USA 13210	11	1.9

117119 (DTPA-HBV-IPV-135)

Investigator	Sub-Investigator	Center no.	Description of Research Facility,	Description of Research Facility, Name of IEC/IRB Committee,		
vooligatoi	ous invocagator	Contor no.	Hospital/ Institution, and Address	Address	Number of Subjects	% of Subjects
Wisman, Paul	Aderholt, Christie Armengol, Carlos Bouber, Gemilla Brown, Alaina Davis, Sheila Harper, Lorna Knight, Sarah Perriello, L. Paige Sauer, Paul Wisman, Claudia	PPD	Pediatric Associates of Charlottesville LLC, 1011 East Jefferson Street, Charlottesville, Virginia, United States,22902	Quorum Review IRB 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	9	1.5
Zissman, Edward	Belton, Janet Candelori, Jaime Harris, Brian Mullen, Kerry Powell, Kristin Soven, Wayne		Advanced Investigation Research, 475 Osceola Street, Altamonte Springs, Florida, United States,32701	Quorum Review IRB 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	10	1.7
Zollo, Kenneth	Fuller, Joshua Goodrich, Diane Meyer, Marie Murphy, Annette Wright, Aubrey Yacolca, Ischia		Pediatric Care, 1675 North Freedom Boulevard, Provo, Utah, United States, 84604	Quorum Review IRB 1501 Fourth Avenue, Suite 800 Seattle, WA 98101	11	1.9

117119 (DTPA-HBV-IPV-135) Report Final

Representative written information for patient and sample consent forms

Instructions for Local ICF development

The LOC should ensure that all local legal regulatory requirements are satisfied before finalizing the Local ICF. It is strongly recommended to align the content of the Local ICF with the content of the Model ICF and this template.

When developing a Local ICF, all changes to the content that affect the meaning of the Model ICF should be justified and documented locally. Any **black bold** text in the final Model ICF is GSK Vaccines' **mandatory** wording and should be retained, any alterations or additions to this text must be communicated to the central team prior to the finalization of the local ICF.

Refer to Appendix A Best Practices document for the development of the Local ICF.

Significant changes in the local ICF compared to the model ICF related to the processing and use of human biological samples and data need to be tracked in the Informed Consent Significant Changes Tracking Form. For example changes in the sample use and/or future research; sample retention period; what happens to samples or data if a subject withdraws consent; any restriction in sharing samples or data with other researchers; any changes to what data can be collected. These changes are tracked to ensure that GSK and other third parties collecting and using samples and data from GSK clinical trials are informed of and can comply with what was agreed to by the subject in the informed consent he/she signed.

Note: In the final Local ICF all text should be in the same format i.e. any bold text must be in normal font and red hidden text must not be retained.

Refer to SOP_54823, GUI_51905 and GUI-BIO-CLIN-0014 for more information. (Delete the instructions above from the Final Local ICF).

117119 (DTPA-HBV-IPV-135) Report Final

Informed Consent Form

CONFIDENTIAL

Study Identification 117119 (DTPA-HBV-IPV-135)

INFORMED CONSENT FORM

Study Identification: 117119 (DTPA-HBV-IPV-135)

Study Title: Immunogenicity and safety study of GSK Biologicals' Infanrix

hexa[™] at 2, 4 and 6 months of age in healthy infants.

Model ICF Version Number: Final Version 03 (replace with Version of Local

ICF)

Date: 08/APR/2014 (replace with Date of Local ICF)

Company Name: GlaxoSmithKline (GSK) Biologicals S.A.

Subject Identification: _____

Insert subject ID here

What is consent?

Consent means that you allow your child/ward to take part in this research study. You can decide if you want your child/ward to take part in this study or not. Please take time to read the following information and ask us if you have any questions. You can talk in confidence with your family and family doctor to help you make a decision. You must sign the consent pages at the end of this form if you decide to let your child/ward join this research study. You will receive a copy of this form.

Why is this study being done?

This research study is looking at the safety and effectiveness of *Infanrix hexa* in infants in the United States of America (USA). *Infanrix hexa* is a combination vaccine (a vaccine against more than one disease combined into one shot) that protects children against the following six diseases in a single injection: diphtheria, tetanus, pertussis, poliomyelitis, *Haemophilus influenzae* type b (Hib) and hepatitis B. Some of the effects of these diseases are explained below:

- Diphtheria is an infection of the throat. Children with diphtheria may stop breathing, have permanent damage to the heart and brain, or even die.
- Tetanus is an infection of the blood. It causes strong cramps that prevent breathing and can lead to death.
- Pertussis (whooping cough) is a highly infectious disease which causes severe coughing during which children are unable to breathe. The disease can lead to death. Recently there have been outbreaks of pertussis in several states in the US.
- Poliomyelitis is a severe disease that is highly contagious amongst children and can cause paralysis (loss or inability to move a body part) and death.
- Hib causes bacterial meningitis (an infection of the fluid and cover surrounding the brain) and infections of the blood, lungs, joints or bones. Most cases occur in children less than five years old. About a quarter of the children who survive Hib

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version Number 03, Dated: 08/APR/2014

(Page 1 of 15) [Template Edition 6.2]

CONFIDENTIAL

Study Identification 117119 (DTPA-HBV-IPV-135)

meningitis suffer permanent damage to the brain and/or nerves ranging from mild hearing loss to mental retardation.

 Hepatitis B is a viral infection that attacks the liver and can causes life threatening liver infection. It is also a major cause of liver cancer worldwide.

In the USA, vaccination against all of these diseases is routinely recommended.

Combination vaccines are easier and more cost-effective to administer as they reduce the number of injections needed to vaccinate a child. *Infanrix hexa* is licensed in more than 98 countries around the world, including the European Union, but not in the USA. This vaccine is an investigational vaccine in the USA, which means it is still being tested and it is not approved by the government for sale.

Vaccines work by causing the body to make substances in the blood called antibodies that protect against disease. The present study will compare how *Infanrix hexa* causes the body to produce antibodies as compared to vaccines that are already approved by the government in the USA.

How is GSK involved?

GlaxoSmithKline (GSK) is a company that studies and makes vaccines, medicines and other health products. GSK planned and organized this study. GSK pays the study doctor and the institution to run this study.

GSK will be the owner of the study results. GSK plans to use the information from this study to get patents, sell the vaccine in the future or make profits in other ways. You will not be paid for any part of this.

The information and materials we give you about this study are confidential and belong to GSK. We ask that you keep it private. You can share this information with your doctor, family or friends when discussing about your child's/ward's participation in this study and your child's/ward's healthcare.

Who can join this study?

Your child/ ward can only be in this study if:

- He/she is between, and including, 6 and 12 weeks of age at the time of the first vaccination,
- He/she is healthy,
- He/she has not had a history of diphtheria, tetanus, pertussis, pneumococcal, rotavirus, poliovirus, hepatitis B and Hib disease.
- He/she has not had previous vaccinations against diphtheria, tetanus, pertussis, poliomyelitis, pneumococcal, rotavirus and Hib diseases; and has received no more than one previous dose of hepatitis B vaccine,

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version Number 03, Dated: 08/APR/2014

(Page 2 of 15) [Template Edition 6.2]

CONFIDENTIAL

Study Identification 117119 (DTPA-HBV-IPV-135)

 You, as the parent(s)/legally acceptable representative [LAR(s)] of the child/ward provide written informed consent for your child/ward to participate in this study.

The study doctor will also check details about your child's/ward's medical history before your child/ ward can join this study. If the mother agrees by signing a separate informed consent, the study doctor will ask if the mother received vaccination against pertussis during her pregnancy. However, even if the mother does not sign the separate informed consent, the child can still be allowed to enroll and to participate in this study if he/she is eligible.

You can ask your study doctor for more details.

What does this study involve?

About 585 children will take part in this study. When we have enough children taking part in this study, we will not allow any more to join.

The study will be done in multiple locations in the USA.

Your doctor will evaluate whether your child/ward can take part in this study by asking you questions about your child's/ward's health and doing a physical examination.

The children participating in this study will be divided into three vaccination groups (the Hexa group, the Pedia group and the Penta group). Upon your consent to have your child/ward participate in the study, a computer will be used to place the children into groups. Your child/ward has a one in three chance of being placed in any one group. Neither you nor the study doctor can choose a group. You will know what vaccines your child/ward will be receiving.

All children in the study will receive vaccines at four visits. Children who are not assigned to receive the *Infanrix Hexa* vaccine will instead receive two other vaccination regimens that are standard of care in the USA. All the children will be vaccinated against the same diseases in this study.

At the first three visits (at approximately 2, 4 and 6 months of age), the following vaccines will be given by injection into the thigh muscle:

- **Hexa Group:** Children in this group will receive a single dose of *Infanrix hexa* at each of the first three visits.
- **Pedia Group:** Children in this group will receive a single dose of *Pediarix* and a single dose of *ActHib* at each of the first three visits.
- **Penta Group**: Children in this group will receive a single dose of *Pentacel* at each of the first three visits and a single dose of *Engerix-B* at either two or three visits, depending on whether your child/ward has been vaccinated against hepatitis B in the past.

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version Number 03, Dated: 08/APR/2014

(Page 3 of 15) [Template Edition 6.2]

CONFIDENTIAL

Study Identification 117119 (DTPA-HBV-IPV-135)

In addition, all the children will receive a dose of *Prevnar13* at approximately 2, 4, and 6 months of age by injection into the thigh muscle and a dose of *Rotarix* vaccine at approximately 2 and 4 months of age orally as per US national recommendations.

At the fourth vaccination visit (at approximately 15 to 18 months of age), the following vaccines will be given by injection into the thigh or arm muscle:

- **Hexa Group**: Children in this group will receive a dose of *Infanrix* and *Hiberix* vaccines.
- **Pedia Group**: Children in this group will receive a dose of *Infanrix* and *ActHIB* vaccines.
- **Penta Group**: Children in this group will receive a dose of *Pentacel* vaccine.

Besides the vaccines given in this study, your child could receive the influenza, measles, mumps, rubella, varicella, hepatitis A, and a fourth dose of pneumococcal vaccine (*Prevnar 13*) as per US national recommendations. Talk to your doctor for more information about these.

If your child/ward is sick on the day of vaccination visit, the visit will be rescheduled during the period permitted by the study.

After each vaccination, you and your child/ward will have to stay at the study center for at least 30 minutes to make sure your child/ward does not have any immediate adverse reactions to any of the vaccinations before going home.

After your child/ward receives the vaccines, the study staff will give you a card (called a diary card) to write down information about how your child/ward feels on the day of each vaccination and for the following three days (for a total of four days). You will need to write down:

- if there was any pain, redness or swelling and the size of any redness and/or swelling
 where the vaccines were given. The doctor will instruct you how to measure the
 redness and swelling,
- any drowsiness, irritability, or loss of appetite that your child/ward experiences.
- your child's/ward's temperature and how you measured it.

You will also be asked to write down any changes in your child's/ward's health and any medications and vaccines your child/ward got besides those that are part of the study for a month after each vaccination visit.

Information about the effect of the vaccines on your child's/ward's body and health will be collected by taking a blood sample and asking you questions. Approximately 5 mL (for Visit 4 and 5) and 3.5 mL (for Visit 6) of blood will be taken from your child/ward at three separate visits to measure the amount of antibodies your child's/ ward's body made to the vaccines which were given. At the end of the study, the study doctor will be informed of your child's/ward's response to the vaccinations.

The study will last for a period of about 14-17 months. Your child/ward will need to visit the study site six times.

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version Number 03, Dated: 08/APR/2014 (Page 4 of 15) [Template Edition 6.2]

CONFIDENTIAL

Study Identification 117119 (DTPA-HBV-IPV-135)

If you allow your child/ward to take part in this study then it is important that you follow all study activities as described here:

Day	What will happen at this visit			
	First phase of the study			
Day 0 (Visit 1) – your child/ward is 6 to 12 weeks of age	You will have the study purpose and procedures explained to you and you will be asked to sign the informed consent form.			
	The doctor will ask you about your child's/ward's medical history.			
	Your child/ward will undergo:			
	 Physical examination 			
	 Measurement of body temperature 			
	 Administration of vaccines according to the group your child/ward is in. 			
	You will receive a diary card for Visit 1 and will be asked to use it to write down any symptom/illness your child/ward may get and medications or vaccines your child/ward may receive for a month after the study vaccination.			
Month 2 (Visit 2) – your child/ward is about 4 months of age	You will return the completed diary card from Visit 1 and the study doctor will review it with you.			
	Your child/ward will undergo:			
	 Measurement of body temperature 			
	 Administration of vaccines according to the group your child/ward is in 			
	You will receive a diary card for Visit 2 and will be asked to write down any symptom/illness your child/ward may get and medications or vaccines your child/ward may receive for a month after the study vaccination.			
Month 4 (Visit 3) – your child/ward is about 6 months of age	You will return the completed diary card from Visit 2 and the study doctor will review it with you.			
	Your child/ward will undergo:			
	 Measurement of body temperature 			
	 Administration of vaccines according to the group your child/ward is in 			
	You will receive a diary card for Visit 3 and will be asked to write down any symptom/illness your child/ward may get and medications or vaccines your child/ward may receive for a month after the study vaccination.			
Month 5 (Visit 4) – your child/ward is about 7 months of age	You will return the completed diary card for Visit 3 and the study doctor will review it with you.			
	Your child/ward will undergo:			
	Blood sampling (approximately 1 teaspoon of blood)			
Month 10 (Phone-contact)- your child/ward is about 12 months of age	You will receive a phone call by the study staff asking about your child's/ward's health and about any other vaccines or medicines given during Month 5 to Month 10 of the study period.			
Important non study activity: A fourth dose of <i>Prevnar13</i> is required at 12-15 months of age as part of your child's/ward's routine health care, but only the first three doses are given as part of this study. Your primary health care provider will provide the fourth dose of <i>Prevnar13</i> vaccine at 12-15 months of age. Please make sure you schedule an appointment with your primary health receive <i>Prevnar13</i> and any other non-study vaccines as per US national recommendation at least 30 days before and/or after your child receives a study				

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version Number 03, Dated: 08/APR/2014

(Page 5 of 15) [Template Edition 6.2]

vaccine. The study doctor will ask you about the other vaccines your child might have received as per the US

CONFIDENTIAL

Study Identification 117119 (DTPA-HBV-IPV-135)

Day	What will happen at this visit				
national recommendation.					
Second phase of the study					
Month 13-16 (Visit 5) – your child/ward is about 15 to 18 months	Your child/ward will undergo:				
of age	 Physical examination 				
	 Measurement of body temperature 				
	 Blood sampling (approximately 1 teaspoon of blood) 				
	Administration of vaccines according to the group your child is in. You will receive a diary card for Visit 5 and will be asked to use it to write down any symptom/illness your child/ward may get and medications or vaccines your child/ward may receive for a month after the study vaccination.				
Month 14-17 (Visit 6) – your child/ward is about 16 to 19 months of age	You will return the completed diary card for Visit 5 and the study doctor will review it with you.				
or age	Your child/ward will undergo:				
	 Blood sampling (approximately 1 teaspoon of blood) 				
	The study will then be completed.				

Throughout the study, you will be asked to contact the study doctor immediately if your child/ward has any reactions or changes to his/her health, went to emergency care for a medical condition or has to be hospitalized.

You will receive a card with study contact information. Keep this card with you at all times during the study. Show this card to the medical staff if your child/ ward needs emergency care during the study. The medical staff can then contact your study doctor if needed to ask about the vaccine or product your child/ ward received.

What will happen to samples taken in this study?

The content of this section needs to be aligned with the Use of Human Samples form. Any request to changes in this section must be discussed with the central study team and the GSK Biologicals' ICF taskforce prior to finalization of the ICF.

As part of the study, samples of your child's/ward's blood will be collected. Your child's/ward's blood samples may be sent to GSK or other laboratories working with GSK including those outside the United States to:

- measure how your child's/ward's body reacts to the study vaccines,
- ensure the quality of the tests used for the study vaccines and/ or diseases,
- improve tests and develop new tests linked to the study vaccines and/or diseases. These tests will never include testing related to your child's/ward's genes or hereditary characteristics.

Your child's/ward's samples will be given a code so that it does not directly identify to your child/ward.

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version Number 03, Dated: 08/APR/2014

(Page 6 of 15) [Template Edition 6.2]

CONFIDENTIAL

Study Identification 117119 (DTPA-HBV-IPV-135)

Your child's/ward's samples will be kept for a maximum of 20 years from the end of the study. Any sample remaining at that time will be destroyed.

Optional tests on your samples:

If you agree, your child's/ward's sample(s) may also be used for future research. GSK will always ask permission for this research to an independent ethics committee or independent review board.

You can choose not to allow these optional tests and your child/ward will still be in the study.

What side effects or risks can you expect in this study?

If your child/ward is allergic to latex, he/she should not receive the vaccines. The study staff will ask you about this.

Most children who receive vaccines remain healthy. There are some common reactions that might be observed after vaccination with *Infanrix hexa*, which can be divided into local (at the place where shot was given) and general (not local) reactions, and are described below. These reactions are usually seen within three days following vaccination.

- Local side effects (at the place where shot was given):
 - very common (reported in more than 1 in 10 children): pain, redness, swelling smaller than 50 mm (about 2 inches);
 - common (reported in more than 1 in 100 children): swelling larger than 50 mm, hard lump where the injection was given;
 - uncommon (reported in more than 1 in 1000 children): large swelling of the vaccinated limb;
 - very rare (reported in less than 1 in 10,000 children): swelling of the whole injected limb and blister where the injection was given;
- General (not local) side effects after vaccination are:
 - very common (reported in more than 1 in 10 children): fever of 100.4°F or more, loss of appetite, tiredness, irritability, restlessness and abnormal crying.
 - common (reported in more than 1 in 100 children): nervousness, vomiting, diarrhea, itching, fever of 103.1°F or more.
 - uncommon (reported in more than 1 in 1,000 children): infection of the nose, throat or windpipe, cough and feeling sleepy.
 - rare (reported in more than 1 in 10,000 children): bronchitis and rash.
 - very rare (reported in less than 1 in 10,000 children): uncontrollable shaking of the body with or without fever, skin rash (also known as hives which is an outbreak of swollen, pale red bumps, patches on the skin that appear suddenly),

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version Number 03, Dated: 08/APR/2014

(Page 7 of 15) [Template Edition 6.2]

CONFIDENTIAL

Study Identification 117119 (DTPA-HBV-IPV-135)

swollen glands in the neck, armpit or groin, bleeding or bruising more easily than normal, temporarily stopping breathing, in babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2-3 days after vaccination, swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing, allergic reactions including anaphylactic (extreme sensitivity) reactions. These extreme sensitivity reactions can be recognized by symptoms such as an itchy rash of the hands and feet, swelling of the eyes and face, difficulty in breathing or swallowing, a sudden drop in blood pressure and loss of consciousness.

When *Infanrix hexa* and *Prevnar* are administered on the same day, higher incidence of fever > 103.1°F (1.7%) was reported as compared *to Infanrix hexa* given alone (0.6%).

It has been noted that when *Infanrix hexa* was given with *Prevnar 13* compared to *Infanrix hexa* given alone, the following events were reported more often:

Fits (with or without fever), collapse (sudden onset of muscle floppiness), periods of unconsciousness or lack of awareness and paleness or bluish skin discoloration were observed. However, all events were still rare.

Hepatitis B vaccine is included in the *Infanrix hexa*, *Pediarix*, and *Engerix-B* vaccines. During the routine use of hepatitis B vaccines, very rare events (reported in less than 1 in 10,000 children) were reported which included loss of skin sensitivity to pain or touch, swelling or infection of the brain (meningitis), numbness or weakness of the arms and legs, inflammation of nerves, blood vessels or joints; low blood pressure (hypotension) paralysis, convulsions, fits or seizures and severe allergic reactions like itchy rash of the hands and feet, swelling of eyes and feet and difficulty in breathing or swallowing.

After your child receives *Infanrix hexa*, contact the study doctor right away if your child has any of the following serious side effects:

- collapse,
- times when they lose consciousness or have a lack of awareness,
- fits this may be when they have a fever.

These side effects have happened very rarely with other vaccines against whooping cough. They usually happen within 2 to 3 days after vaccination.

After your child/ward has received *Rotarix*, contact the study doctor right away if your child/ward has the following:

- severe stomach pain,
- keeps on vomiting,
- has blood in his or her stools,
- has a swollen belly, or
- high fever.

These signs may show that your child/ward has a blockage or twisting of part of his or her intestine.

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version Number 03, Dated: 08/APR/2014

(Page 8 of 15) [Template Edition 6.2]

CONFIDENTIAL

Study Identification 117119 (DTPA-HBV-IPV-135)

GSK found in one study that this blockage or twisting happened more often, although still very rarely, in the first week after the first dose.

Pieces from a virus that is commonly seen in animals (called "PCV-1") were found in *Rotarix* vaccine. This virus does not make animals or people sick.

Please refer to the vaccines information sheet for the side effects/risks expected due to administration of the other vaccines used in this study-*Prevnar13*, *Pediarix*, *ActHIB*, *Pentacel*, *Engerix-B*, *Infanrix and Hiberix* vaccines. The study doctor can provide you with more information.

When a blood sample is taken from your child/ward there is the possibility that some temporary bruising and infection may occur at the site where the blood was drawn.

The vaccines in this study may not protect all children who get them. In some cases, tests may show that your child's/ward's response to the vaccination was not strong enough to protect against the diseases. If the study doctor believes your child/ward would benefit from another vaccination, he or she will contact you.

What benefits can you expect in this study?

This study may be beneficial/ useful in the following ways:

- The potential to protect your child/ward against the following major diseases: diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, Hib, pneumococcal and rotavirus diseases. However, there is no guarantee your child/ward will be protected against these diseases.
- Your child/ward will be closely watched and followed-up by the physician and his staff. Also, tests will be done on the blood samples taken from your child/ward to assess if your child/ward is protected. Such tests are not done during routine vaccination and are a benefit of study participation.
- Information from this study may help to learn more about the vaccine or disease. This will help to make new vaccines to protect people against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Hib diseases.

Are there other products or treatment?

This section should be completed locally using the most current information regarding the vaccines that are available in the country and their important potential benefits and risks. State if there are no alternate treatments.

There are other vaccines approved in the US that provide protection against the same diseases (although you may need to receive two shots instead of one at each visit). Your doctor can provide you with more information.

In addition, *Pedarix, ActHIB, Hiberix, Infanrix, Pentacel, Prevnar-13* and *Rotarix* are all approved in the US and your child/ward can get them from your doctor without having to participate in this study.

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version Number 03, Dated: 08/APR/2014

(Page 9 of 15) [Template Edition 6.2]

CONFIDENTIAL

Study Identification 117119 (DTPA-HBV-IPV-135)

Talk with your doctor about your child's/ ward's options, before you decide if your child/ward should take part in this study. The study doctor can advise you if you need more information.

Does your child/ward have to stay in the study?

You may choose to withdraw your child/ward from the study at any time, without giving a reason. If you do give a reason, then it may be recorded. Your choice will not change the medical care or other benefits the child/ward will receive outside of this study.

We will share with you as soon as possible any new information that may change your choice to let your child/ward stay in the study.

Tell the study doctor if you no longer want your child/ward to take part in this study.

GSK may choose to stop the study or the study doctor may choose to stop your child's/ward's participation in the study at any time. We will then tell you why. We may ask you to withdraw your child/ward from the study if:

- Test results show that this study is not right for your child/ward
- You do not follow study instructions
- The study doctor thinks it is in your child/ward's best interest to stop, e.g. if your child/ward develops specific health problems.

What happens if your child/ward leaves the study?

Check local regulations and seek local legal advice for the use of data after subject withdrawal. If any changes are made to this section in the Local ICF compared to the Model ICF, in response to a request from any source, these should be discussed with the central study team and GSK Vaccines' ICF taskforce for alignment prior to the finalization of the local ICF, so that the impact for database collection can be taken into account. Significant changes to this section must be documented in the Tracking Form.

You may choose to stop your child/ward from being in this study at any time, without giving a reason. We will keep and use the data and samples collected before your child/ward left the study. The study doctor may find out information about your child's/ward's health after your child/ward has left the study. The study doctor will send this information to GSK if it involves the safety profile of the vaccine.

What about your personal and medical information?

If changes are made to this text it needs to be checked with the local Legal team that this is aligned with local rules and regulations. These changes must be discussed with the central study team and GSK Vaccines' ICF taskforce for alignment prior to the finalization of the local ICF, so that the impact for data sharing can be taken into account. Significant changes to this section must be documented in the Tracking Form.

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version Number 03, Dated: 08/APR/2014

(Page 10 of 15) [Template Edition 6.2]

CONFIDENTIAL

Study Identification 117119 (DTPA-HBV-IPV-135)

It is very important that your child's/ward's personal and medical information stay confidential and secure. Your child's/ward's personal and medical information will be protected in accordance with current law.

When you sign this consent form you agree that your child/ward's personal and medical information can be used as described here.

- Your child's/ward's personal and medical information may be checked by GSK and others [like agencies that approve and monitor studies, for example the Food and Drug administration (FDA)]. This is to make sure that the study is being run properly.
- Besides that, only the researchers at this study site can use information that identifies your child/ward (such as name and address) and only for the purpose of the study.
- Your child's/ward's information collected during the study will be labelled with a code number (for example, PPD It will not include your child/ward's name or address. The study doctor will have the link between your child/ward's name and the code number.
- The link between your child's/ward's name and the code number will not be shared. Only the code number and coded information will be sent to GSK.
- GSK will use your child's/ward's coded information for research only, including research looking at improving the quality and efficiency in conducting clinical research trials in general.
- GSK may do the following with your child's/ward's coded study information:
 - keep it electronically, and analyze it by computer to find out what the study is telling us. This may be done by GSK or a third party, in which case GSK will ensure that the third party is required to keep your data secure.
 - share it with regulatory agencies that approve new vaccines and medicines,
 - share it with people who check that the study is done properly (like the independent ethics committee or review boards),
 - combine it with results from other studies to learn more about the vaccine and other vaccines and this disease and related diseases. This may help us to assess the risks and benefits of GSK (or other) vaccines or medicines, or to improve disease understanding,
 - publish study results in medical journals, for meetings and on the internet for other researchers to use. Your child's/ward's name will not appear in any publication.
 - share coded information with other companies, organizations or universities to carry out research, including research looking at improving the quality and efficiency in conducting clinical research trials in general.

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version Number 03, Dated: 08/APR/2014

(Page 11 of 15) [Template Edition 6.2]

CONFIDENTIAL

Study Identification 117119 (DTPA-HBV-IPV-135)

Personal and medical data collected during the trial may be moved to, stored and used in the country where you live or another country where GSK or those working with GSK work

Use of this information may take place in countries with lower data protection rules than the country where you live. GSK will make sure that if your child/ward's data are moved to another country, it will still be treated as stated in this Informed Consent Form.

A description of this clinical trial will be available on the GSK Clinical Study Register http://www.gsk-clinicalstudyregister.com/ and may also appear in clinical trial registries in countries in which the clinical study is conducted.

A description of this clinical trial will be available on http://www.clinicaltrials.gov, as required by U.S. Law. This web site will not include information that can identify your child/ward. At most, the web site will include a summary of the results. You can search this web site at any time.

If you withdraw your consent for us to use your child's/ward's personal information your child/ward will no longer be able to continue in the study.

At any time, you may ask to see your child's/ward's personal information and correct it if necessary.

In some circumstances you may not be able to access your child/ward's study information while the study is ongoing. However the study doctor will share any important medical information if it is relevant to your child/ward's health during the course of the study.

You should know that once identifiable medical information about your child/ward is given to someone that is not a health care provider, it is not protected by the US federal privacy rules called the HIPAA Privacy Regulations.

06-JUL-2018

CONFIDENTIAL

Study Identification 117119 (DTPA-HBV-IPV-135)

What happens if your child/ward gets hurt while taking part in this study?

GSK will help pay for your child/ward's care if your child/ward is hurt by the study vaccines or a procedure done to your child/ward as part of the study. GSK will pay for reasonable and necessary care for the injury that is not covered by the National Vaccine Injury Compensation Fund. GSK will not pay for any other expenses. To pay these medical expenses, GSK will need to know some information about your child/ward like your child/ward's name, date of birth, and social security number or Medicare Health Insurance Claim Number. This is because GSK has to check to see if your child/ward receives Medicare and if your child/ward does, report the payment it makes to Medicare. GSK will not use this information for any other purpose.

Signing this consent form does not change any legal rights your child/ward may have.

Will you be paid for your child/ward being in the study?

This section should be completed locally.

You will be paid for the cost of travelling to your child's/ward's study visits. You may receive up to [amount] for travel / per visit.

Do you have to pay anything to allow your child/ward to be in the study?

Authors note that this section is optional. This section should be completed locally.

Your child/ward will get all the study vaccines and study tests and procedures for free [or indicate if there is a cost].

Who should you contact if you have questions?

Identify who the legally acceptable representative should contact for information about the study, the subject's rights or study-related injuries. This section may be completed at Country Level.

Person to contact for any questions: name, address, telephone number.

Person to contact about your rights: name, address, telephone number.

Person to contact in case of injury: name, address, telephone number.

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version Number 03, Dated: 08/APR/2014

(Page 13 of 15) [Template Edition 6.2]

117119 (DTPA-HBV-IPV-135) Report Final

nformed Consent Forr		Subject ID	
	CONFIDE Study Identification 11711		
	Consent st	tatement	
I,			
Parent/ Legally acceptable representative of	(Printed name of	Parent/ Legally acceptable representative)	
		Subject's name	
me) for study 11? Pages (to be upd	7119 (DTPA-HBV-IPV-1	nation (or have had the information read to 35) Final Version 03 08/APR/2014 15 dy procedures have been explained to me for this study.	
	ve had the chance to ask of and explanations that have	questions about this study and I am satisfied we been given.	
understand that I in this information		child/ward to authorized persons described	
I know what will	happen to my child's/war	rd's blood samples.	
understand that by signing this form any of my child's/ward's identifiable medical information given to someone that is not a health care provider is not protected by the US federal privacy rules called the HIPAA Privacy Regulations.			
have been given time and opportunity to consider allowing my child/ward to take part in this study.			
Tick as appropriate (study):	this decision will not affe	ct your child's/ward's <u>ability</u> to enter the	
agree that the study study.	doctor tells my family do	octor of my child/ward taking part in the	
Yes	No No	NA	
Tick as appropriat	e		
research. GSK will committee or inde	l always ask approval fo	mple(s) may be used for future r this research to an independent ethics understand that if I select "No", my	
Yes	No		

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version Number 03, Dated: 08/APR/2014

(Page 14 of 15) [Template Edition 6.] [Template Edition 6.2]

117119 (DTPA-HBV-IPV-135) Report Final

Informed Consent Form		Subject ID
Study Id	CONFIDENTIAL Ientification 117119 (DTPA-HBV-IPV-1	35)
I agree to let my child/ward to		,
Relationship of legally acceptable representative to subject		
Signature of legally acceptable representative	Dat	e: day/ month/ year
I confirm that I have conductegulations.	ted the consent process according to	o applicable
Printed name of person conducting consent		
Signature of person conducting consent	Dat	e: day/ month/ year
-	lent of the study, that I attended the the written information for the stud	
*Printed name of Witness		
Signature of Witness		
	Dat	e: day/ month/ year
* Witness is only required if t	the subject/ legally acceptable repre	sentative is unable to

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version Number 03, Dated: 08/APR/2014 (Page 15 of 15) [Template Edition 6.2]

read.



Delete the following Appendix in the Final local ICF.

Appendix A GlaxoSmithKline Vaccines Best Practices Document for the Development of the Local ICF

Introduction

The local informed consent form (ICF) is created based on the GSK Vaccines internally approved model ICF and is adapted according to country or local requirements.

The model ICF is the recommended content and structure which contains all ICH and GSK required elements and is aligned with the study protocol.

The content of the local ICF should be aligned with the Model ICF and any local specifications and regulations included.

The local GSK approved version should be submitted for ethical/regulatory approval and should be presented to the subject/patient and/or their legally acceptable representative.

It is essential that the version of the local ICF is accurately tracked, with a unique version number, date and reference to the model ICF on which it is based, to ensure that the correct version of the ICF is used and can be identified if needed.

It is strongly recommended to have a final local ICF, back-translated in English, available in the Investigator's study file to ensure site readiness in case of audits and/or inspections.

Objective

These best practices are intended to give adequate support and to ensure consistency while developing the local ICF from the model ICF.

It is a tool to know what changes are not permitted and what changes can be justified and/or are required per local regulations and site specific information.

The development of the accurate and complete local ICF is a local responsibility and alignment with the model ICF is essential to study conduct.

Any changes made to the local ICF from the model ICF must be documented at local level.

Human Sample Management

The collection of human tissue samples, the intended use, and secondary use, if retained, and how the subject's confidentiality would be maintained for the retained samples, must be reported in the ICF.

The content of this section must be fully aligned with the Use of Human Samples form. This form allows the central project team to track the actual testing at GSK (or laboratories used for GSK-sponsored studies) with the individual subject's consent and

951

GlaxoSmithKline

Best Practices Document for the Development of the Local ICF local regulations. To avoid ethical and legal implications and invalidating the study data, any changes made to this section must be discussed with the central study team and GSK Vaccines' central ICF taskforce for alignment prior to the finalization of the local ICF.

Significant changes to this section must be documented in the Tracking Form.

Subject/patient data after withdrawal

The retention of samples collected and data recorded before withdrawal and the continued collection of safety information after withdrawal must be reported in the ICF. Check local regulations and seek local legal advice for the use of data after subject/patient withdrawal. If any changes are made to this section in response to a request from any source, these changes must be discussed with the central study team and GSK Vaccines' central ICF taskforce for alignment prior to the finalization of the local ICF, so that the impact for database collection and sample destruction can be taken into account.

Significant changes to this section must be documented in the Tracking Form.

What about your personal and medical information?

The content of this section is required by ICH-GCP and must be included in the ICF so that the subject is well informed before consenting to participation. Omitting this information would be violating the confidentiality and the data privacy of the subject/patient and could have legal implications. If any changes are made to this section in response to a request from any source, these changes must be discussed with the central study team and GSK Vaccines' central ICF taskforce for alignment prior to the finalization of the local ICF, so that the impact for data sharing can be taken into account.

Significant changes to this section must be documented in the Tracking Form.

Type of changes

Changes to the local ICF can be classified into 3 categories:

'Not permitted' changes

BOLD BLACK mandatory text in the model ICF should not be changed.

'Required' changes

Required changes must be made in the local ICF to add country-specific or center-specific information. (Indicated as **BOLD RED** text in the model ICF e.g. investigator details).



'Justified' changes

Justified changes may be necessary in some countries to comply with local requirements / regulations or to comply with a specific template e.g. country specific compensation guidance text.

In addition, some text can be clarified / simplified, provided the meaning remains the same as in the model ICF and does not contradict or change the intended meaning of the model ICF.

Changes that require a specific rationale or justification, that may be necessary in specific situations e.g. storage duration of samples, or changes required by the relevant Ethics Committees, can also be justified.

Best Practices per ICF Section

This table describes the type of changes (not permitted, required or justified) for each ICF section of the local ICF compared to the model ICF.

ICF section	Type of changes	Rationale/Impact
Study Identification		
Check if study identification is identical to Model ICF.	Not permitted	The study identification and study number allows us to link the document to the study protocol, the corresponding IRB/IEC approvals, all relevant study documentation and ensures that the subject/patient is linked to the correct study.
Study Title		
Check if study title is identical to Model ICF.	Not permitted	The study title allows us to link the document to the study protocol, the corresponding IRB/IEC approvals, all relevant study documentation and ensures that the subject/patient is linked to the correct study.



Best Practices Document for the Development of the Local ICF			
ICF section	Type of	Rationale/Impact	
	changes		
ICF Version Number and Date			
Update with version and date of Local ICF and check if reference to the Model ICF version and date is included. Specify country and subset if applicable.	Required	It is mandatory to include an ICF version number, the date of the final version, the page number and the total number of pages (for the Local and Model ICF). Each ICF type has to be uniquely identified and must include a reference to the source. The version of the local ICF allows us to link the ICF to the corresponding approval documents. If the version is omitted in the local ICF, the subject may not receive the most up to date ICF and thus may not receive the complete information required to make an informed consent.	
Company Name			
Check if company name is GlaxoSmithKline (GSK) Biologicals S.A. or the local	Justified	A change to this section is permitted if it is justified by local regulations.	
GSK affiliate if this is required by local regulations.		For some countries, the local GSK affiliate should be indicated as Company Name.	
Subject/Patient Identification			
Check whether there is space foreseen to insert the subject ID.	Required	The subject/patient ID should be mentioned on the ICF to be able to link the subject/patient ID with the corresponding source documents and RDE entries.	
Header			
Check if study identification in header is identical to Model ICF.	Not permitted	The study identification and study number allows us to link the document to the study protocol, the corresponding IRB/IEC approvals, all relevant study documentation and ensures that the subject/patient is linked to the correct study.	



ICF section	or the Development of the Local ICF	
icr section	Type of	Rationale/Impact
	changes	
Footer		
Indicate version of Local ICF and check if reference to the Model ICF version is included. Specify country and subset if applicable.	Required	It is mandatory to include an ICF version number, the date of the final version, the page number and the total number of pages (for the Local and Model ICF).
		Each ICF type has to be uniquely identified and must include a reference to the source. The version of the local ICF allows us to link the ICF to the corresponding approval documents.
		If the version is omitted in the local ICF, the subject/patient may not receive the most up to date ICF and thus may not receive the complete information required to make an informed consent.
What is consent?		
Explain the consent process and check if the meaning of the text is not changed compared to the Model ICF (Text can be simplified if necessary).	Justified	Freely given and written informed consent must be obtained from each subject/patient/LAR prior to study participation. Informed consent involves an education and information exchange that takes place between the researcher and the potential subject/patient. How the process of consenting looks like, needs to be explained in the ICF. The text can be simplified, if necessary.
Why is this study being done?		
Describe the study aim and check if the meaning of the text is not changed compared to the Model ICF (Text can be simplified if necessary).	Justified	The content of this section is required by ICH-GCP. If any of this information is omitted in the local ICF, the subject/patient may not receive the complete information required to make an informed consent. Text can be simplified if necessary.



Best Practices Document for the Development of the Local ICF			
ICF section	Type of	Rationale/Impact	
	changes		
How is GSK involved?			
Check if the meaning of the text is not changed compared to the Model ICF (Text can be simplified if necessary).	Justified	The role of the sponsor should be explained in this section. The text can be simplified if necessary.	
Who can join this study?			
Summarize the main inclusion and exclusion criteria. Check if the meaning of the text is not changed compared to the Model ICF (Text can be simplified if necessary).	Justified	If any of this information is omitted in the local ICF, the subject/patient may not receive the complete information required to make an informed consent. Text can be simplified if necessary.	
What does this study involve?			
Explain the approximate number of subjects/patients involved in the study, the study design and groups, the study procedures and check if the meaning of the text is not changed compared to the Model ICF (Text can be simplified if necessary).	Justified	The content of this section is required by ICH-GCP. If any of this information is omitted in the local ICF, the subject/patient may not receive the complete information required to make an informed consent. Text can be simplified if necessary	
If subject cards are used, check if the text is identical to the Model ICF.	Not permitted	Subject cards provide information about the study which can be used in the event of a medical emergency. Provision of this information in the ICF ensures that the subject/patient is aware of the use of the subject card. This information will also indicate to the ethics committee that it is provided to the subject/patient.	
What about pregnancy and breastfeeding?			
Check if the meaning of the text is not changed compared to the Model ICF (Text can be simplified if necessary).	Justified	If any of this information is omitted in the local ICF, the subject/patient may not receive the complete information required to make an informed consent. Text can be simplified if necessary.	



Best Practices Document for the Development of the Local ICF			
ICF section	Type of	Rationale/Impact	
	changes		
	8		
What will happen to samples taken in this study?			
Check if all mandatory wording from the Model ICF is present in the Local ICF.	Not permitted	If this text is changed, there is a risk to use human samples outside the subject's/patient's consent. This has major ethical implications and can lead to a loss of company reputation, lack of confidence, invalid study data etc Significant changes to this section must be documented in the Tracking Form	
Check if the QA (Quality Assurance), test improvement and new test method development in the scope of the study protocol is reported in the Local ICF.	Not permitted	This testing will be done at <u>all</u> <u>times</u> , assuming it is allowed as per individual subject's/patient's consent. If this testing is not mentioned in the ICF, there is a risk that GSK will be unable to perform the protocol tests and therefore this type of testing cannot be omitted. Also refer to the Clarification Paper on the future use of biospecimens.	
Check Local regulations regarding storage duration. Check if the wording "for a maximum of 20 years" is not changed into "for 20 years". [If there are concerns regarding this text then this should be discussed with the central project team and GSK Vaccines' central ICF taskforce for alignment prior to the finalization of the local ICF]	Justified	It is necessary to put a defined storage period in the ICF. As a standard, GSK proposes to store samples for "for a maximum of"20 years. Attention should be paid to the used wording "for a maximum of" 20 years. This wording allows GSK to cover different situations (e.g. to keep samples for maximum 20 years, to destroy samples when GSK no longer wants to store them or no longer is interested in testing, when physical integrity of some type of samples does not permit such long storage, etc). Any changes to this section should be captured in the Sample Retention Period Form. This will allow the laboratory to take the appropriate measures for sample storage, "for a maximum of 20"	



Best Practices Document for the Development of the Local ICF			
ICF section	Type of	Rationale/Impact	
	changes		
	8		
		years or as defined in the ICF and	
		documented in the section called	
		"other".	
		Significant changes to this section	
		must be documented in the	
		Tracking Form	
Check local regulations	Justified	A change to this section is justified,	
regarding future research.		since depending on local	
[If there are concerns		regulations, this type of testing is	
regarding this text then this		allowed or not. However, the	
should be discussed with the		wording of the text itself, should	
central study team and GSK		not be changed and nothing should	
Vaccines' central ICF		be added! We capture this info in	
taskforce for alignment prior to		the CRF/eCRF, which contains	
the finalization of the local		standard wording so if the wording	
ICF]		in the ICF is changed, this will not	
		be matching. This form allows the	
		central study team to track the	
		actual testing at GSK (or	
		laboratories used for GSK-	
		sponsored studies) with the individual subject's/patient's	
		consent and local regulations. If	
		this text is changed, there is a risk	
		to use human samples outside the	
		subject's consent.	
		This has major ethical and legal	
		implications and can lead to a loss	
		of company reputation, lack of	
		confidence, invalid study data,	
		etc	
		Also refer to the Clarification Paper	
		on the future use of biospecimens.	



Best Practices Document for the Development of the Local ICF			
ICF section	Type of	Rationale/Impact	
	changes		
	vges		
What side effects or risks can			
you expect in the study?			
Check if the meaning of the text is not changed compared to the Model ICF (Text can be simplified if necessary).	Justified	The content of this section is required by ICH-GCP. The reasonably foreseeable risks or inconveniences to the subject should be mentioned in the ICF. If any of this information is omitted in the local ICF, the subject may not receive the complete information required to make an informed consent. Text can be simplified if necessary. Refer to the GSK Position Paper on 'Communication of Individual Immunological Assay Results to Study Sites' for additional information.	
Check if the text on autoimmune diseases (applicable if product/vaccine contains an adjuvant) is identical to the Model ICF.	Not permitted	The text on autoimmune diseases has been approved by GSK upper management following feedback from Authorities. The AID wording should remain consistent in all projects and countries. There is a reputational risk associated to the fact that GSK might seem to be sharing different information with Subjects/Patients/Externally on AID.	
Check if the text on Rotarix, if applicable, is identical to the Model ICF.	Not permitted	This text has been approved by GSK upper management following feedback from Authorities.	



Best Practices Document for the Development of the Local ICF		
ICF section	Type of	Rationale/Impact
	changes	
What benefits can you expect in the study?		
Check if the meaning of the text is not changed compared to the Model ICF (Text can be simplified if necessary).	Justified	The content of this section is required by ICH-GCP. The reasonably expected benefits or indirect benefits or if there is no direct clinical benefit for the subjects/patients must be included in the local ICF. Text can be simplified if necessary
Are there other products or		
treatment?		
Check if the meaning of the text is not changed compared to the Model ICF (Text can be simplified if necessary).	Justified	It is an ICH-GCP requirement to provide to the subject information on alternative procedures or treatment that may be available and their important potential benefits and risks. Omitting any of this information would be violating the rights of the subject/patient to freely participate to the study and would be putting the company reputation at risk. Text can be simplified if necessary.
Add currently available local alternatives, if applicable.	Required	This information must be added locally to the ICF using the most current information regarding the treatments that are available in the country.
Do you have to stay in the study?		
Explain voluntary participation and check if the meaning of the text is not changed compared to the Model ICF (Text can be simplified if necessary).	Justified	The content of this section is required by ICH-GCP. Omitting any of this information would be violating the rights of the subject/patient to freely participate to the study and would be putting the company reputation at risk. Text can be simplified if necessary.



Best Practices Document for the Development of the Local ICF		
ICF section	Type of	Rationale/Impact
	changes	
What happens if you leave the study?		
Check if the text on the use of data after subject/patient withdrawal is identical to the Model ICF. [Check local regulations and seek local legal advice] [If the text needs to be changed it should be discussed with the central project team and GSK Vaccines' central ICF taskforce for alignment prior to the finalization of the local ICF].	Justified	The bold text in this section has been approved by Medical Governance. Changes to this section in response to a request from any source, can have an impact for database collection and sample handling and should therefore be discussed with the central teams for alignment. Also refer to the Clarification Paper on the Handling of Data after Subject Withdrawal. Significant changes to this section must be documented in the Tracking Form.
What about your personal and medical information?		
Check if the meaning of the text is not changed compared to the Model ICF (Text can be simplified if necessary). [If the text needs to be changed, it should be reviewed by the local legal team]. [If the text needs to be changed it should be discussed with the central study team and GSK Vaccines' central ICF taskforce for alignment prior to the finalization of the local ICF].	Justified	The content of this section is required by ICH-GCP and must be included in the ICF so that the subject is well informed before consenting to participation. Omitting this information would be violating the confidentiality and the data privacy of the subject/patient and could have legal implications. Text can be simplified if necessary. Significant changes to this section must be documented in the Tracking Form.



Best Practices Document for the Development of the Local ICF			
ICF section	Type of	Rationale/Impact	
	changes		
What happens if you get hurt			
while taking part in this			
study?			
- For UK, US and countries	Justified	The content of this section is	
without special local		required by ICH-GCP. In the UK	
regulations, check if		and in countries where there is no	
compensation section is not		local scheme, GSK will apply the	
changed compared to the		Clinical Trial Compensation	
section in the Model ICF.		guidelines set down by the UK	
[If changes are made, the		Association of British	
CMD (Country Medical		Pharmaceutical Industry (ABPI) to	
Department) should ensure that		compensate subjects/patients for	
all local legal regulatory		GSK sponsored clinical study	
requirements are satisfied.]		related injury	
- For other countries where	Justified	The content of this section is	
there is compensation for		required by ICH-GCP and must be	
injury, the CMD (Country		completed so that the	
Medical Department) should		subject/patient is well informed	
ensure that the rules and		before consenting to participation.	
conventions required locally			
are applied.			
Will you be paid for being in			
the study?			
Information related to this	Required	The content of this section is	
section is added at a regional		required by ICH-GCP and must be	
or country level.		included in the ICF so that the	
		subject/patient is well informed	
		before consenting to participation.	
		The anticipated prorated payment	
		or other financial benefit, if any, to	
		the subject for participating in the	
		study should be mentioned in the	
		ICF.	
		Explain if expenses incurred by	
		subjects for clinical visits made	
		because of their participation in the	
		study will be reimbursed or not.	



		or the Development of the Local ICF				
ICF section	Type of	Rationale/Impact				
	changes					
Do you have to now envithing						
Do you have to pay anything to be in the study?						
This section is optional. Information related to this section is added at a regional or country level when it is appropriate for a study and/or is required by local practice.	Justified	If appropriate for a study, include here information on cost/expenses that subject/patient will have to bear for taking part in the study i.e., whether the subject/patient or the subject's/patient's insurance will be charged for any study item or procedure. According to ICH-GCP, the anticipated expenses, if any, to the subject/patient for participating in the study should be mentioned.				
Who should you contact if		in the study should be mentioned.				
you have questions?						
Add local contact details.	Required	The content of this section is required by ICH-GCP. The subject/patient must have a contact person for further information regarding the study, his rights and who to contact in the event of trial-related injury.				
Consent statement						
Check if the meaning of the text is not changed compared to the Model ICF (Text can be simplified if necessary).	Justified	The consent statement should be aligned with ICH-GCP requirements. Omitting any of the information can have legal implications				
Check local regulations regarding future research (type 4 testing). Check if the wording is identical to the wording in the body of the ICF. [If there are concerns regarding this text then this should be discussed with the central project team and GSK Vaccines' central ICF taskforce for alignment prior to the finalization of the local ICF]	Justified	A change to this section is justified, since depending on local regulations, this type of testing is allowed or not. This type of testing is optional for the subject/patient, meaning that if this testing is mentioned in the body of the ICF, a tick box should be available in the consent statement. The wording of the text itself, should not be changed and nothing should be added! We capture this info in the CRF/eCRF by using the UHSF, which contains standard wording so if the wording in the ICF is				



ICF section	Type of changes	Rationale/Impact
		changed, this will not be matching with the UHSF.
Check local regulations for the legal of age of consent, the use of LARs, witnesses and any documentation requirements.	Justified	An additional line can be added if two LARs or two witnesses are needed as per local law.
		Refer to SOP_54823 and local regulations.

References

SOP_54823, Development and implementation of Informed Consent Forms for R&D and GSK Vaccines-Sponsored Studies.

GUI_51905, Guidance for Informed Consent documents.

GUI-BIO-CLIN-0014, Guidance for the development of Informed Consent-related documents.

GSK's Position Paper on Communication of Individual Immunological Assay Results To Study Sites.

GSK's Clarification Paper on Handling Data after Subject withdrawal.

GSK's Clarification Paper on Future Use of Biospecimens.

Addendum 1 to the Informed Consent Form

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135)

ADDENDUM 1 TO THE INFORMED CONSENT FORM FOR THE SUBJECT'S MOTHER

[Country to be inserted]

Study Identification: 117119 (DTPA-HBV-IPV-135)

Study Title: Immunogenicity and safety study of GSK Biologicals' Infanrix

hexa™ at 2, 4 and 6 months of age in healthy infants.

Version and Date: Addendum 1 to the Model ICF Version 03 16/APR/2014

Company Name: GlaxoSmithKline (GSK) Biologicals S.A.

Subject Identification: _____

This document should be presented to the subject's mother in full; no pages or sections should be omitted. The document contents should be explained verbally to the subject's mother.

Purpose of this document

You have already signed an informed consent form to allow your child's participation in a research study of the safety and effectiveness of GSK Biologicals' *Infanrix hexa* vaccine in infants in the United States of America (USA).

One of the diseases that the vaccines in the study will vaccinate the infants against is pertussis (whooping cough). There have been recent outbreaks of pertussis in the US, and infants too young to be fully vaccinated against pertussis are at greatest risk for severe disease and even death due to pertussis. In order to protect newborns, the Advisory Committee on Immunization Practices (the group that sets the immunization schedule for the USA) recommended in October 2012 that all women receive a vaccine against pertussis in their third trimester of pregnancy, so that antibodies (what the body makes to protect against disease) transferred from their blood into their infants blood during pregnancy would protect both mothers and their infants. The pertussis vaccine that will be given to the mother is a tetanus, diphtheria toxoid and pertussis vaccine called Tdap.

Since the recommendation to vaccinate the mothers is quite recent, not all mothers of the children in this study will have been vaccinated with Tdap during pregnancy. It is not known whether the mother's antibodies in their infant's bloodstream will affect the infants' ability to make their own antibodies to the study vaccines, so we want to study the responses of the infants enrolled in this study based on whether their mothers received the Tdap vaccine during pregnancy.

This document is intended to obtain your consent in order to collect information about any Tdap vaccination that you might have received during your pregnancy.

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version 3 Addendum 1, Dated: 16/APR/2014 (Page 1 of 5)

Addendum 1 to the Informed Consent Form

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135)

What about your personal and medical information?

It is very important that your personal and medical information stay confidential and secure. Your personal and medical information will be protected in accordance with current law.

When you sign this consent form you agree that your personal and medical information can be used as described here.

- Your personal and medical information may be checked by GSK and others [like agencies that approve and monitor studies, for example the Food and Drug administration (FDA)]. This is to make sure that the study is being run properly.
- Besides that, only the researchers at this study site can use information that identifies you (such as name and address) and only for the purpose of the study.
- Your information collected during the study will be labelled with a code number (for example, PPD It will not include your name or address. The study doctor will have the link between your/your child's name and the code number. The code number assigned to you will be your child's code number.
- The link between your/your child's name and the code number will not be shared. Only the code number and coded information will be sent to GSK.
- GSK will use your/your child's coded information for research only, including research looking at improving the quality and efficiency in conducting clinical research trials in general.
- GSK may do the following with your/your child's coded study information:
 - keep it electronically, and analyze it by computer to find out what the study is telling us. This may be done by GSK or a third party, in which case GSK will ensure that the third party is required to keep your data secure.
 - share it with regulatory agencies that approve new vaccines and medicines,
 - share it with people who check that the study is done properly (like the independent ethics committee or review boards),
 - combine it with results from other studies to learn more about the vaccine and other vaccines and this disease and related diseases. This may help us to assess the risks and benefits of GSK (or other) vaccines or medicines, or to improve disease understanding,
 - publish study results in medical journals, for meetings and on the internet for other researchers to use. Your name will not appear in any publication.
 - share coded information with other companies, organizations or universities to carry out research, including research looking at improving the quality and efficiency in conducting clinical research trials in general.

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version 3 Addendum 1, Dated: 16/APR/2014 (Page 2 of 5)

117119 (DTPA-HBV-IPV-135) Report Final

Addendum 1 to the Informed Consent Form

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135)

Personal and medical data collected during the trial may be moved to, stored and used in the country where you live or another country where GSK or those working with GSK work.

Use of this information may take place in countries with lower data protection rules than the country where you live. GSK will make sure that if your data are moved to another country, it will still be treated as stated in this Informed Consent Form.

A description of this clinical trial will be available on the GSK Clinical Study Register http://www.gsk-clinicalstudyregister.com/ and may also appear in clinical trial registries in countries in which the clinical study is conducted.

A description of this clinical trial will be available on http://www.clinicaltrials.gov, as required by U.S. Law. This web site will not include information that can identify you. At most, the web site will include a summary of the results. You can search this web site at any time.

At any time, you may ask to see your personal information and correct it if necessary.

In some circumstances you may not be able to access your study information while the study is ongoing. However the study doctor will share any important medical information if it is relevant to your health during the course of the study.

You should know that once identifiable medical information about you is given to someone that is not a health care provider, it is not protected by the US federal privacy rules called the HIPAA Privacy Regulations.

Your consent is voluntary. Refusal will involve no penalty or loss of benefits or attention that your child is otherwise entitled to receive from your healthcare provider. Refusal will also not hamper your child's participation in this study.

You should not sign this document unless you have received satisfactory answers to all of your questions. You will receive a signed copy of this form to take home.

Do you agree that we will collect your Tdap vaccination history during pregnancy?

Yes

No

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version 3 Addendum 1, Dated: 16/APR/2014 (Page 3 of 5)

117119 (DTPA-HBV-IPV-135) Report Final

Addendum 1 to the Info			Subject ID
		NFIDENTIAL TPA-HBV-IPV-135)	
		ent statement	
T			
I,			
the mother of		Printe	d name of Subject's mother
			Subject's name
			Subject's name
me) for 117119 (dated 16 April 20	DTPA-HBV-IPV-12 014, pages 1-5 <mark>[to b</mark> e	35) Addendum 1 to	had the information read to the Model ICF Version 03, and the changes have been a for this study.
		ity to ask questions a been provided were s	about this addendum and the atisfactory.
• have been given participating in the	1.1	unity to consider allo	owing my child to continue
I agree to let the stud	dv doctor collect my	Tdap vaccination h	istory including collecting
medical history by n			
			_
Signature of subject	's mother	Date: dd/mmm/y	ууу
D: 4 1 C 1	· 42 41		<u>—</u>
Printed name of sub	ject's mother		
I confirm that I have	e conducted the cons	sent process accordin	g to applicable regulations
Signature of person	explaining the	Date: dd/mmm/	['] уууу
addendum			
Printed name of pers	son explaining the a	ddendum	_
Timou mano or por	you empressing the w		
Indicate version: i.e. Loca DD/MMM/YYYY, based or	n Model ICF Version 3 A		ersion Number <mark>NN</mark> , Dated: APR/2014

06-JUL-2018 968 51abb6bd72601dfecb7d29e02b309073e769d8e3

117119 (DTPA-HBV-IPV-135) Report Final

	Subject ID DENTIAL A-HBV-IPV-135)
If the mother of the subject is illiterate, a form	an impartial witness must also sign this
I confirm that I am independent of the student process and that I have read the written info	-
Signature of Witness	Date: dd/mmm/yyyy
Printed name of Witness	

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version 3 Addendum 1, Dated: 16/APR/2014 (Page 5 of 5)

Addendum 2 to the Informed Consent Form

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135)

ADDENDUM 2 TO THE INFORMED CONSENT FORM

[Country to be inserted]

Study Identification: 117119 (DTPA-HBV-IPV-135)

Study Title: Immunogenicity and safety study of GSK Biologicals' Infanrix

hexa[™] at 2, 4 and 6 months of age in healthy infants.

Version and Date: Addendum 2 to the Model ICF Version 03 28/OCT/2014

Company Name: GlaxoSmithKline (GSK) Biologicals S.A.

Sub	ject l	dentification:					

This document should be presented to the subject's parent(s)/legally acceptable representative(s) [LAR(s)] in full; no pages or sections should be omitted. The document contents should be explained verbally to the subject's parent(s)/LAR(s).

Purpose of this document

You have already signed an informed consent form to allow your child's/ward's participation in a research study of the safety and effectiveness of GSK Biologicals' *Infanrix hexa* vaccine in infants in the United States of America (USA).

By means of this document, we would like to provide you with some new information regarding the collection of information on any injection site swelling that your child/ward may experience after vaccination and new information that recently became available about GSK Biologicals' rotavirus vaccine, *Rotarix* which is one of the vaccines that is given in the study your child/ward is taking part.

Please note that your child/ward would have already received the first and second dose of the *Rotarix* vaccine in this study and intussusceptions (twisting or blockage of a part of the intestine) is more often seen during seven days after the first dose and to a lesser extent after the second dose of *Rotarix* vaccine. The updated text regarding intussusceptions provided below is for your information.

The following section of the informed consent which you signed at the start of the study has been updated and the new text is indicated in *bold italics*.

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version 3 Addendum 2, Dated: 28/OCT/2014 (Page 1 of 5)

Addendum 2 to the Informed Consent Form

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135)

What does this study involve?

The informed consent that you have signed mentioned the following:

After your child/ward receives the vaccines, the study staff will give you a card (called a diary card) to write down information about how your child/ward feels on the day of each vaccination and for the following three days (for a total of four days). You will need to write down:

- if there was any pain, redness or swelling and the size of any redness and/or swelling where the vaccines were given. The doctor will instruct you how to measure the redness and swelling.
- any drowsiness, irritability, or loss of appetite that your child/ward experiences.
- your child's/ward's temperature and how you measured it.

Please read carefully the following new information:

After your child/ward receives the vaccines, the study staff will give you a card (called a diary card) to write down information about how your child/ward feels on the day of each vaccination and for the following three days (for a total of four days). You will need to write down:

- if there was any pain, redness or swelling and the size of any redness and/or swelling where the vaccines were given. The doctor will instruct you how to measure the redness and swelling.
- any drowsiness, irritability, or loss of appetite that your child/ward experiences.
- your child's/ward's temperature and how you measured it.
- After the fourth vaccination, when your child/ward is 15-18 months of age, you will also have to measure the circumference (length around) the arm or leg where your child/ward received a vaccine. The doctor will instruct you how to measure this length.
- If after the fourth vaccination, the swelling where the vaccine was given is greater than 50 mm and/or you feel the swelling is quite noticeable, you will also have to write down additional symptoms such as itching, hardness and whether the swelling interferes with the use of the injected arm or leg. You will also have to call the study doctor and come in right away for examination of the swelling.

What side effects or risks can you expect in this study?

The informed consent that you have signed mentioned the following:

After your child/ward has received *Rotarix*, contact the study doctor right away if your child/ward has the following:

- severe stomach pain,
- keeps on vomiting,

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version 3 Addendum 2, Dated: 28/OCT/2014 (Page 2 of 5)

117119 (DTPA-HBV-IPV-135) Report Final

Addendum 2 to the Informed Consent Form

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135)

- has blood in his or her stools,
- has a swollen belly, or
- high fever.

These signs may show that your child/ward has a blockage or twisting of part of his or her intestine.

GSK found in one study that this blockage or twisting happened more often, although still very rarely, in the first week after the first dose.

Pieces from a virus that is commonly seen in animals (called "PCV-1") were found in *Rotarix* vaccine. This virus does not make animals or people sick.

Please read carefully the following new information:

After your child/ward has received *Rotarix*, contact the study doctor right away if your child/ward has the following:

- severe stomach pain,
- keeps on vomiting,
- has blood in his or her stools,
- has a swollen belly, or
- high fever.

These signs may show that your child/ward has a blockage or twisting of part of his or her intestine.

Large post-marketing safety studies indicate a transient increased incidence of intussusception after vaccination, mostly within 7 days of the first dose and, to a lesser extent, the second dose.

The overall incidence of intussusception remains rare.

Pieces from a virus that is commonly seen in animals (called "PCV-1") were found in *Rotarix* vaccine. This virus does not make animals or people sick.

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version 3 Addendum 2, Dated: 28/OCT/2014 (Page 3 of 5)

117119 (DTPA-HBV-IPV-135) Report Final

Addendum 2 to the Informed Consent Form CONFIDEN 117119 (DTPA-HE	-
Your consent is voluntary. Refusal will involve that your child/ward is otherwise entitled to rece	
You should not sign this document unless you h your questions. You will receive a signed copy of	
Consent sta	tement
I,	
the Parent/ Legally acceptable representative of	Printed name of Subject's parent/LAR
	Subject's name
 confirm that I have read the written information me) for 117119 (DTPA-HBV-IPV-135) Add dated 28 October 2014, pages 1-5 to be up been explained to me by study staff during the staf	dendum 2 to the Model ICF Version 03, dated locally]), and the changes have
 confirm that I have had the opportunity to a answers and explanations that have been pre- 	
• have been given the time and opportunity to continue participating in this study.	consider allowing my child/ward to
agree to let my child/ward continue to particular	cipate in the study
I confirm that I have conducted the consent pro	ocess according to applicable regulations

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version 3 Addendum 2, Dated: 28/OCT/2014 (Page 4 of 5)

Signature of person explaining the

Printed name of person explaining the addendum

addendum

Date: dd/mmm/yyyy

117119 (DTPA-HBV-IPV-135) Report Final

Addendum 2 to the Informed Consent Form CONFID 117119 (DTPA	Subject IDPENTIAL -HBV-IPV-135)
If the Parent/ Legally acceptable represent impartial witness must also sign this form	•
I confirm that I am independent of the study process and that I have read the written info	<u> </u>
Signature of Witness	Date: dd/mmm/yyyy
Printed name of Witness	

Indicate version: i.e. Local (specify country and subset if applicable) ICF Version Number NN, Dated: DD/MMM/YYYY, based on Model ICF Version 3 Addendum 2, Dated: 28/OCT/2014 (Page 5 of 5)

117119 (DTPA-HBV-IPV-135) Report Final

Investigator CVs or equivalent summaries of training and experience relevant to the performance of the clinical study

Page(s) removed - Out of Scope of phase 1 of Policy 0070 – Investigator CVs

Signature of principal or coordinating investigator

GlaxoSmithKline Biologicals Vaccines R&D Investigator Approval Page

STUDY TITLE: A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age.

Study: 117119 (DTPA-HBV-IPV-135) Development Phase: III

I have read this report and confirm that to the best of my knowledge it accurately describes the conduct and results of the study.

Name of Investigator:	Dr. Nicola Klein
Affiliation /investigational centre:	Kaiser Permanente Oakland, One Kaiser Plaza, Oakland, CA, USA
Signature of Investigator:	
Date:	

For internal use only

-----!Ver.!Created On - -1d409104a7b9515b0ffe9e529e32508fdf3000b3 1.0 7/12/2018 1:54:15 PM - a1433090e9c94e485de5d60db92b1e31d0ccda72 1.0 7/12/2018 1:54:19 PM - -13de9131962684a03d6ff328df4cc9746fa9eb10 1.0 7/12/2018 1:54:33 PM - ea0faebd1d956d107e7e0d85f4695a06669aab1b 1.0 7/12/2018 1:54:41 PM -66963771677c17e9a20f64573b32717a1b1e2ac4 1.0 7/12/2018 1:54:37 PM - -51abb6bd72601dfecb7d29e02b309073e769d8e3 1.0 7/12/2018 1:55:07 PM - -55f1c72f6bafb82a4cd207420835613347227bfd 1.0 7/12/2018 1:55:17 PM - ac342ae2501721bd94637bff166bca886cd8c674 1.0 7/12/2018 1:55:03 PM - -9e87e824d35ce3848b99267f52394dca3a57c57a 1.0 7/12/2018 1:54:23 PM - e425c4a7b748c0dbb1b8028e9b153ce0e704e939 1.0 7/12/2018 1:54:59 PM - b746277d27dc86537be04d8768738edd61b7ab2b 1.0 7/12/2018 1:54:54 PM - -622d4ec61abc0524d85a0f1af3968a4c1306b198 1.0 7/12/2018 1:55:22 PM - -812f4fb003c07b74cae10f81cf90c72c48e48cbd 1.0 7/12/2018 1:55:13 PM - a8a4e5fa618ebcf2c407631e910df440ec16f0fd 1.0 7/13/2018 12:38:12 PM - -4138e5e7efd1f15bf35572227c1d9fd9bd7066e8 1.0 7/12/2018 1:53:54 PM -7e8612f798705c5d24886d296f5433e26004cc03 1.0 7/12/2018 1:54:10 PM - -8a04772baf20207a79a8e4e358c424c80f00eab7 1.0 7/13/2018 4:34:50 PM - -

117119 (DTPA-HBV-IPV-135) Report Final

GlaxoSmithKline Biologicals Vaccines R&D

Sponsor Signatory Approval Page

Please note that by signing this page, you take responsibility for the content of the Study Report, including appendices

STUDY TITLE: A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age.

Study: 117119 (DTPA-HBV-IPV-135) Development Phase: III

I have read this report and confirm that to the best of my knowledge it accurately describes the conduct and results of the study.

Name of Sponsor Signatory: Narcisa Elena Mesaros

Title of Sponsor Signatory: MD, Clinical and Epidemiology R&D Project Leader, DTP, Polio and Hib containing vaccines – R&D Centre Belgium, GlaxoSmithKline Biologicals

Signature: Date:

-----!Ver.!Created On - -1d409104a7b9515b0ffe9e529e32508fdf3000b3 1.0 7/12/2018 1:54:15 PM - a1433090e9c94e485de5d60db92b1e31d0ccda72 1.0 7/12/2018 1:54:19 PM - -13de9131962684a03d6ff328df4cc9746fa9eb10 1.0 7/12/2018 1:54:33 PM - ea0faebd1d956d107e7e0d85f4695a06669aab1b 1.0 7/12/2018 1:54:41 PM -66963771677c17e9a20f64573b32717a1b1e2ac4 1.0 7/12/2018 1:54:37 PM - -51abb6bd72601dfecb7d29e02b309073e769d8e3 1.0 7/12/2018 1:55:07 PM - -55f1c72f6bafb82a4cd207420835613347227bfd 1.0 7/12/2018 1:55:17 PM - ac342ae2501721bd94637bff166bca886cd8c674 1.0 7/12/2018 1:55:03 PM -9e87e824d35ce3848b99267f52394dca3a57c57a 1.0 7/12/2018 1:54:23 PM - e425c4a7b748c0dbb1b8028e9b153ce0e704e939 1.0 7/12/2018 1:54:59 PM - b746277d27dc86537be04d8768738edd61b7ab2b 1.0 7/12/2018 1:54:54 PM - -622d4ec61abc0524d85a0f1af3968a4c1306b198 1.0 7/12/2018 1:55:22 PM - -812f4fb003c07b74cae10f81cf90c72c48e48cbd 1.0 7/12/2018 1:55:13 PM - a8a4e5fa618ebcf2c407631e910df440ec16f0fd 1.0 7/13/2018 12:38:12 PM - -4138e5e7efd1f15bf35572227c1d9fd9bd7066e8 1.0 7/12/2018 1:53:54 PM -7e8612f798705c5d24886d296f5433e26004cc03 1.0 7/12/2018 1:54:10 PM - -8a04772baf20207a79a8e4e358c424c80f00eab7 1.0 7/13/2018 4:34:50 PM - -

06-JUL-2018 55f1c72f6bafb82a4cd207420835613347227bfd

For internal use only

Listings of patients receiving test drug(s) /investigational product(s) from specific batches, where more than one batch was used

Batch (Lot) number	Treatement group
DLOCA102AY@DLOCA102AZ@	Penta
AD05VA833A@AROTVA291D@	Rotarix
DLOCA107A@	Prevnar 13
AHBVC253A@	Engerix B
DLOCA144AY@DLOCA144AZ@	Pentacel
AHIBC950C@	Hexa_1
AC14B195A@	Infanrix
AHIBC875A@DEXTA517AZ@	Hiberix
DLOCA106AY@DLOCA106AZ@	ActHIB
AC21VB448C@	Pedia
DLOCA150AY@DLOCA150AZ@	ActHIB-Epoch2
AC21B514A@AHIBC907D@	Hexa_2
DLOCA108AY@DLOCA108AZ@	Penta
AC21B510B@AHIBC954A@	Hexa_3

117119 (DTPA-HBV-IPV-135) Report Final

Randomisation list

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	N	. Bl. o nb	Trt. No	nb	Trt. I	nb	Trt. I	nb	Trt. I	nb	Trt. B No n	nb
PPD 1 2 3 3 4 5 5 6 6 7 7 8 8 9 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 2	PPD	9 nb 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73	No	nb 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114	No 1	nb	No 1	nb 165	No 1	nb 206 207 208 209 210 211 212 213 214 215 216 217 218 229 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237	No n	nb 247 248 249 250 251 252 253 254 255 256 267 268 269 271 272 273 274 275 278
32 33 34 35 36 37 38 39 40 41		73 74 75 76 77 78 79 80 81		114 115 116 117 118 119 120 121 122 123		155 156 157 158 159 160 161 162 163 164		196 197 198 199 200 201 202 203 204 205		237 238 239 240 241 242 243 244 245 246		278 279 280 281 282 283 284 285 286 287

117119 (DTPA-HBV-IPV-135) Report Final

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	No nb No nb		Trt. Bl. No nb									
No nb	No	nb	No	nb	No	nb	No	nb 	No 1	nb	No	nb
324 325 326 327 328		365 366 367 368 369		406 407 408 409 410		447 448 449 450 451		488 489 490 491 492		529 530 531 532 533		570 571 572 573 574

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. I	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb
PPD	575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 615	PPD		PPD		PPD		PPD		PPD	780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 709 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820	PPD	821 822 823 824 825 826 827 828 831 832 833 835 836 837 838 841 842 843 844 845 846 847 851 852 853 855 856 858 859 861

Randomisation list

SD4\0\INFORM

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	
PPD	

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41	PPD 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 78 79 80 81 82	PPD 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123	PPD 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164	PPD 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 201 202 203 204 205	PPD 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246	PPD 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286

DTPA-HBV-IPV-135 (A.15MAR2018)

289 330 371 412 453 494 53 290 331 372 413 454 495 53 291 332 373 414 455 496 53 292 333 374 415 456 497 53 293 334 375 416 457 498 53 294 335 376 417 458 499 54 295 336 377 418 459 500 54 296 337 378 419 460 501 54 297 338 379 420 461 502 54 298 339 380 421 462 503 54 299 340 381 422 463 504 54 300 341 382 423 464 505 55 301 342 383 424 465 506 54 302 343 384 425 466 507 54 303 344 385 426 467 508 54 304 345	Trt. No	nb												
289	PPD	288	PPD	329	PPD	370	PPD	411	PPD	452	PPD	493	PPD	534
290 331 372 413 454 495 53 291 332 373 414 455 496 53 292 333 374 415 456 497 53 293 334 375 416 457 498 53 294 335 376 417 458 499 54 295 336 377 419 459 500 54 296 337 378 419 460 501 54 297 338 379 420 461 502 54 298 339 380 421 462 503 504 54 300 341 382 422 463 504 54 301 342 383 424 465 506 54 302 343 384 425 466 507 54 303 344 385 426 467 508 54 304 345 386 427 468 509 55 306 347 388 429 470 511 55 307 348 389 430 471 512 55 308 349 390 431 472 513 55 308 349 390 431 472 513 55 301 351 352 393 434 475 516 55 311 352 393 434 435 55 311 352 393 434 435 55 311 352 393 434 435 55 311 352 393 434 435 55 311 352 393 434 435 55 311 352 393 434 435 55 311 352 393 434 435 55 311 352 393 434 435 55 311 352 393 434 435 55 311 352 393 434 435 55 311 352 393 434 435 576 516 55 311 352 393 434 435 576 516 55 311 352 393 434 435 577 556 313 354 399 430 471 512 55 311 352 393 434 435 576 516 55 311 352 393 434 435 476 517 556 312 353 394 435 436 477 518 55 313 354 399 430 441 482 525 56 313 354 399 430 471 512 55 311 352 393 434 475 516 55 311 352 393 434 435 476 517 556 313 354 399 430 441 472 513 55 311 352 353 394 435 476 517 556 313 354 399 430 441 482 525 56 313 354 399 430 441 482 525 56 313 354 399 430 441 482 525 56 314 355 396 437 478 519 56 315 356 397 438 449 439 440 481 522 56 316 357 339 440 441 482 523 56 317 358 399 440 441 482 523 56 318 359 400 441 482 525 56 322 363 404 405 446 485 526 56 322 363 404 405 446 485 526 56 323 366 407 448 489 489 550 57 326 367 408 449 449 449 449 552 56 326 367 408 449 449 449 449 552 56 326 367 408 449 449 449 449 449 552 56 326 367 408 449 449 449 449 449 552 56 327 368 409 449 449 449 449 449 449 449 449 449														535
291 332 373 414 455 496 53 292 333 374 415 456 497 53 293 334 375 416 457 498 53 294 335 376 417 458 499 54 295 336 377 418 459 500 54 296 337 378 418 459 500 54 297 338 379 420 461 502 54 298 339 380 420 461 502 54 299 340 381 422 463 504 54 300 341 382 422 463 504 54 301 342 383 424 465 555 56 302 343 384 425 466 557 58 303 344 385 386 427 468 509 510 55 306 347 388 428 429 470 511 55 307 348 389 430 471 512 55 308 349 390 411 512 55 308 349 390 411 512 55 308 349 390 411 512 55 309 350 391 422 513 55 301 351 392 433 447 55 311 352 393 444 55 311 352 393 444 55 311 352 393 441 55 311 352 393 441 55 311 352 393 441 55 311 352 393 441 55 311 352 393 441 55 311 352 393 441 55 311 352 393 441 55 311 352 393 441 52 477 518 55 311 352 393 441 52 477 518 55 311 352 393 441 52 477 518 55 311 352 393 441 52 477 518 55 311 352 393 441 52 477 518 55 311 352 393 441 52 477 518 55 311 352 393 441 52 477 518 55 311 352 393 441 52 477 518 55 311 352 393 441 52 477 518 55 311 352 393 441 52 477 518 55 311 352 393 441 52 55 311 352 393 441 52 477 518 55 311 352 393 441 477 518 55 311 352 393 441 477 518 55 311 352 393 444 475 516 55 312 353 394 435 476 517 55 313 354 399 440 441 482 52 53 314 355 356 397 438 479 520 56 316 357 398 439 440 521 56 317 358 399 440 441 482 523 56 318 359 400 441 482 523 56 319 360 401 442 483 524 56 322 363 404 405 445 486 527 56 323 366 407 448 489 520 57 326 367 408 449 499 530 57 327 368 409 449 449 449 50 511 57 327 368 409 449 449 449 449 552 57 326 366 407 448 449 449 449 552 57 326 366 407 448 449 449 449 552 57 327 368 409 459 459 449 449 449 552 57 327 368 409 459 459 449 449 449 449 552 57 326 366 407 448 449 449 449 449 552 57 327 368 409 459 449 449 449 449 552 57 327 368 409 449 449 449 449 449 449 449 449 449														536
292 333 334 375 416 457 498 53 294 335 376 417 458 499 54 295 336 377 418 459 500 54 296 337 379 419 460 501 54 297 338 379 420 461 502 54 298 339 380 379 420 461 502 53 344 300 341 382 423 463 504 55 300 341 382 423 463 504 55 301 342 383 424 465 505 507 54 302 343 384 425 466 507 54 303 344 385 426 467 508 57 304 345 386 427 468 509 55 306 347 388 429 470 511 55 307 348 389 430 471 512 55 308 349 390 431 472 513 308 349 390 431 472 513 308 349 390 431 472 513 308 349 390 431 472 513 308 349 390 431 472 513 308 349 390 431 472 513 308 349 390 431 472 513 309 350 391 432 473 514 55 310 351 392 433 474 515 516 55 311 352 393 434 435 477 518 55 312 353 394 435 477 518 55 313 354 394 435 477 518 55 314 355 399 430 477 518 55 315 336 377 488 499 470 511 55 316 357 595 436 55 317 359 400 441 482 52 52 56 318 359 400 441 482 52 52 56 318 359 400 441 482 52 52 56 318 359 400 441 482 52 52 56 318 359 400 441 482 52 52 56 318 359 400 441 482 522 523 56 319 360 401 442 488 529 57 318 359 400 441 482 523 56 319 360 401 442 488 529 57 324 365 406 447 488 529 57 325 366 407 448 489 530 57 326 367 408 449 449 490 531 57 327 368 409 449 449 490 531 57 327 368 409 449 449 490 531 57														537
294 335 376 417 458 499 54 295 336 377 418 459 500 54 296 337 378 419 460 501 54 297 338 379 420 461 502 54 298 339 380 421 462 503 54 299 340 381 422 463 504 54 300 341 382 423 464 55 506 54 301 342 383 424 465 505 56 302 343 384 425 466 577 58 303 344 385 426 467 508 57 304 345 388 429 470 511 55 305 346 387 428 469 510 55 306 347 388 429 470 511 55 307 348 389 430 471 512 55 308 349 390 431 472 513 55 309 350 391 432 473 514 55 311 352 393 474 55 311 352 393 474 55 311 352 393 474 55 311 352 393 474 55 311 352 393 474 55 311 352 393 474 55 311 352 393 474 55 311 352 393 474 55 311 352 393 474 55 312 353 394 435 476 517 518 55 313 354 355 396 437 478 519 56 316 357 398 439 430 471 512 55 311 352 393 434 475 516 55 311 352 393 474 515 55 311 352 393 474 515 55 311 352 393 474 55 312 353 394 435 476 517 518 55 313 354 335 433 444 485 525 56 315 356 397 438 439 440 481 522 523 56 316 357 398 440 440 481 522 523 56 317 358 399 440 441 482 522 56 318 359 400 441 442 483 524 56 322 363 404 405 444 488 525 56 323 366 407 448 488 529 57 326 367 408 449 490 531 57 327 368 409 409 450 491 532 57														538
294 335 376 417 458 499 54 295 336 377 418 459 500 54 296 337 378 419 460 501 54 297 338 379 420 461 502 54 288 339 380 421 462 503 54 299 340 381 422 463 503 504 300 341 382 423 464 505 506 54 301 342 383 424 465 506 577 54 303 344 385 426 467 508 59 304 343 384 425 466 570 508 54 303 344 385 426 467 508 59 306 347 388 429 470 511 552 307 348 389 430 471 512 55 307 348 389 430 471 512 55 308 349 390 431 472 513 55 309 350 391 432 433 474 515 55 311 352 393 434 435 475 516 55 311 352 393 434 435 57 314 355 366 477 518 55 315 356 394 435 436 477 518 55 311 352 393 434 435 56 314 355 366 477 518 55 315 356 397 438 479 520 566 557 316 357 388 479 550 566 557 317 358 399 430 471 512 55 319 350 551 556 551														539
296 337 378 419 460 501 54 297 338 379 420 461 502 54 298 339 380 421 462 503 54 299 340 381 422 463 504 54 300 341 382 423 464 505 54 301 342 383 424 465 506 54 302 343 384 425 466 507 54 303 344 385 426 467 508 54 304 345 386 427 468 509 55 305 346 387 428 469 510 55 306 347 388 429 470 511 55 307 348 389 430 471 512 55 308 349 390 431 472 513 55 309 350 391 432 473 514 55 310 351 392 433 474 515 55 311 352 393 434 475 516 55 312 353 394 475 516 55 313 355 366 377 438 479 520 56 315 316 337 398 439 477 518 55 316 357 398 379 448 479 519 56 317 358 399 440 481 522 56 318 359 400 441 482 55 319 350 391 56 311 352 393 434 475 516 55 312 353 394 435 476 517 55 313 355 366 397 438 479 520 56 315 316 357 398 439 480 521 56 317 358 399 440 481 522 56 319 360 401 442 483 524 56 319 360 401 442 483 524 56 321 362 403 444 485 526 56 322 366 407 448 489 500 57 325 366 407 448 489 500 57 327 368 409 455 491 552 591 552														540
297 338 339 380 421 462 503 54 299 340 381 422 463 504 54 300 341 382 423 464 505 54 301 342 383 424 465 506 54 302 343 384 425 466 507 54 303 344 385 426 467 508 54 304 345 386 427 468 509 55 305 346 387 428 469 510 55 306 347 388 429 470 511 55 307 348 389 430 471 512 55 308 349 390 431 472 513 55 309 350 391 432 473 514 55 311 352 393 434 475 516 55 311 352 393 434 475 516 55 312 353 394 435 476 517 55 313 354 395 436 477 518 55 314 355 396 477 518 55 315 316 357 398 439 430 471 512 55 317 353 394 435 476 517 55 318 359 366 377 438 479 520 56 319 350 391 432 473 514 55 310 351 392 433 474 515 55 311 352 393 434 475 516 55 312 353 394 435 476 517 55 313 354 395 436 477 518 55 314 355 396 437 478 519 56 315 356 397 438 479 520 56 316 357 398 439 440 481 522 56 319 360 401 442 483 524 56 321 362 403 444 485 526 56 322 363 404 445 486 527 56 323 364 405 446 487 528 56 324 365 406 447 488 529 57 325 366 367 408 449 499 490 531 57 326 367 408 449 449 490 531 57 327 368 409 4550 491 532 57		295		336		377		418		459		500		541
298 339 380 421 462 503 54 299 340 381 422 463 504 54 300 341 382 423 464 505 54 301 342 383 424 465 506 54 302 343 384 425 466 507 54 303 344 385 426 467 508 54 304 345 386 427 468 509 55 305 346 387 428 469 510 55 307 348 389 429 470 511 55 307 348 389 430 471 512 55 308 349 390 431 472 513 55 309 350 391 432 473 514 55 310 351 392 433 474 515 55 311 352 393 434 475 516 55 312 353 394 435 476 517 55 313 354		296		337		378		419		460		501		542
299 340 381 422 463 504 54 300 341 382 423 464 505 54 301 342 383 424 465 506 54 302 343 384 425 466 507 54 304 345 385 426 467 508 54 305 346 387 428 469 509 55 306 347 388 429 470 511 55 307 348 389 430 471 512 55 308 349 390 431 472 513 55 309 350 391 432 473 514 55 311 352 393 434 475 516 55 311 352 393 434 475 516 55 313 354 395 436 477 518 55 314 355 396 437 478 519 56 314 355 396 437 478 519 56 315 356		297		338		379		420		461		502		543
300 341 382 423 464 505 54 34 301 342 383 424 465 506 54 34 302 343 384 425 466 507 54 303 344 385 426 467 508 54 303 344 385 426 467 508 54 303 344 385 386 427 468 509 55 305 305 346 387 428 469 510 551 55 306 347 388 429 470 511 552 308 349 390 431 472 513 55 308 349 390 431 472 513 55 311 352 331 354 352 393 434 475 516 557 312 353 394 435 476 517 558 314 355 396 397 438 477 518 557 314 355 356 397 438 477 518 557 314 355 356 397 438 477 518 557 314 355 356 397 438 477 518 557 314 355 356 397 438 477 518 557 314 355 356 357 398 439 440 481 522 56 316 357 358 399 440 441 482 523 523 56 319 360 401 442 483 524 56 322 366 367 408 409 445 488 529 577 326 326 367 408 449 449 489 530 577 326 327 368 409 449 449 489 530 577 326 327 368 409 449 449 449 551 577 327 327 368 409 450 449 450 531 532 577 368 409 450 449 450 531 577 327 368 409 449 449 449 551 532 577 327 368 409 450 449 450 591 532 577 327 368 409 450 449 450 531 532 577 368 327 368 409 450 450 491 532 577 327 368		298		339		380		421		462		503		544
301 342 383 424 465 506 54 302 343 384 425 466 507 54 303 344 385 426 467 508 54 304 345 386 427 468 509 55 305 346 387 428 469 510 55 306 347 388 429 470 511 55 307 348 389 430 471 512 55 308 349 390 431 472 513 55 309 350 391 432 473 514 55 310 351 392 433 474 515 55 311 352 393 434 475 516 55 312 353 394 435 476 517 55 313 354 395 436 477 518 55 314 355 396 437 478 519 56 315 356 397 438 479 520 56 316 357 398 439 480 521 56 317 358 399 440 481 522 56 318 359 400 441 482 483 524 56 320 361 402 443 484 525 56 321 362 363 404 445 486 527 56 322 366 367 408 449 490 531 57 326 367 408 449 490 531 57 327 368 409 445 449 490 531 57		299		340		381		422		463		504		545
302 343 384 425 466 507 54 303 344 385 426 467 508 54 304 345 386 427 468 509 55 305 346 387 428 469 510 55 306 347 388 429 470 511 55 307 348 389 430 471 512 55 308 349 390 431 472 513 55 310 351 392 433 474 515 516 55 311 352 393 424 475 516 55 312 353 394 435 476 517 55 313 354 395 436 477 518 55 314 355 366 397 438 479 520 56 315 356 397 438 479 520 56 316 357 398 439 480 521 56 317 358 399 440 481 522 56 318 359 400 441 482 523 56 319 360 401 442 483 524 56 320 361 402 443 485 526 56 321 362 363 404 405 446 487 528 56 322 366 367 408 449 490 531 57 326 367 408 449 490 531 57 327 368 409 400 441 488 489 530 57 327 368 409 409 450 491 532 57		300		341		382		423		464		505		546
303		301		342		383		424		465		506		547
304 345 346 386 427 468 509 555 305 346 387 428 469 510 555 306 347 388 429 470 511 552 307 348 389 430 471 512 555 308 349 390 431 472 513 555 310 351 392 433 474 515 516 555 311 352 393 434 475 516 555 312 353 394 435 476 517 555 313 355 314 355 396 437 478 519 56 314 355 336 397 438 479 520 56 316 357 398 439 439 480 521 56 317 358 399 440 481 522 56 319 360 401 442 483 524 56 322 363 361 402 443 484 525 56 322 363 364 404 445 486 527 566 324 365 406 447 488 529 57 325 366 367 408 409 450 491 532 57		302		343		384				466				548
305 346 387 428 469 510 55 306 347 388 429 470 511 55 307 348 389 430 471 512 55 308 349 390 431 472 513 55 309 350 391 432 473 514 55 310 351 392 433 474 515 55 311 352 393 434 475 516 55 312 353 394 435 476 517 55 313 354 395 436 477 518 55 314 355 396 437 478 519 56 315 356 397 438 479 520 56 317 358 399 440 481 522 56 317 358 399 440 481 522 56 319 360 401 442 483 524 56 320 361 402 443 484 525 56 322 363		303		344		385		426		467		508		549
306 347 388 429 470 511 55 307 348 389 430 471 512 55 308 349 390 431 472 513 55 309 350 391 432 473 514 55 310 351 392 433 474 515 55 311 352 393 434 475 516 55 312 353 394 435 476 517 55 313 354 395 436 477 518 55 314 355 396 437 478 519 56 315 356 397 438 479 520 56 316 357 398 439 480 521 56 318 359 400 441 482 523 56 319 360 401 442 483 524 56 321 362 403 444 485 526 56 322 363 404 445 486 527 56 322 363				345				427		468				550
307 348 389 430 471 512 55 308 349 390 431 472 513 55 309 350 391 432 473 514 55 310 351 392 433 474 515 55 311 352 393 434 475 516 55 312 353 394 435 476 517 55 313 354 395 436 477 518 55 314 355 396 437 478 519 56 315 356 397 438 479 520 56 316 357 398 439 480 521 56 318 359 400 441 482 523 56 318 359 400 441 482 523 56 319 360 401 442 483 524 56 321 362 403 444 485 526 56 322 363 404 445 486 527 56 323 364				346										551
308 349 390 431 472 513 55 309 350 391 432 473 514 55 310 351 392 433 474 515 55 311 352 393 434 475 516 55 312 353 394 435 476 517 55 313 354 395 436 477 518 55 314 355 396 437 478 519 56 315 356 397 438 479 520 56 316 357 398 439 480 521 56 318 359 400 441 482 523 56 319 360 401 442 483 524 56 320 361 402 443 484 525 56 321 362 403 444 485 526 56 322 363 404 445 486 527 56 322 363 404 445 486 527 56 324 365														552
309 350 391 432 473 514 55 310 351 392 433 474 515 55 311 352 393 434 475 516 55 312 353 394 435 476 517 55 313 354 395 436 477 518 55 314 355 396 437 478 519 56 315 356 397 438 479 520 56 316 357 398 439 480 521 56 317 358 399 440 481 522 56 318 359 400 441 482 523 56 319 360 401 442 483 524 56 320 361 402 443 484 525 56 321 362 403 444 485 526 56 322 363 404														553
310 351 392 433 474 515 55 311 352 393 434 475 516 55 312 353 394 435 476 517 55 313 354 395 436 477 518 55 314 355 396 437 478 519 56 315 356 397 438 479 520 56 316 357 398 439 480 521 56 317 358 399 440 481 522 56 318 359 400 441 482 523 56 319 360 401 442 483 524 56 320 361 402 443 484 525 56 321 362 403 444 485 526 56 322 363 404 445 486 527 56 323 364 405 446 487 528 56 324 365 406 447 488 529 57 325 366														554
311 352 393 434 475 516 55 312 353 394 435 476 517 55 313 354 395 436 477 518 55 314 355 396 437 478 519 56 315 356 397 438 479 520 56 316 357 398 439 480 521 56 317 358 399 440 481 522 56 318 359 400 441 482 523 56 319 360 401 442 483 524 56 320 361 402 443 484 525 56 321 362 403 444 485 526 56 322 363 404 445 486 527 56 323 364 405 446 487 528 56 324 365 406 447 488 529 57 325 366 407 448 489 530 57 326 367														555
312 353 394 435 476 517 55 313 354 395 436 477 518 55 314 355 396 437 478 519 56 315 356 397 438 479 520 56 316 357 398 439 480 521 56 317 358 399 440 481 522 56 318 359 400 441 482 523 56 319 360 401 442 483 524 56 320 361 402 443 484 525 56 321 362 403 444 485 526 56 322 363 404 445 486 527 56 323 364 405 446 487 528 56 324 365 406 447 488 529 57 325 366 407 448 489 530 57 326 367 408 449 490 531 57 327 368														556
313 354 395 436 477 518 55 314 355 396 437 478 519 56 315 356 397 438 479 520 56 316 357 398 439 480 521 56 317 358 399 440 481 522 56 318 359 400 441 482 523 56 319 360 401 442 483 524 56 320 361 402 443 484 525 56 321 362 403 444 485 526 56 322 363 404 445 486 527 56 323 364 405 446 487 528 56 324 365 406 447 488 529 57 325 366 407 448 489 530 57 326 367 408 449 490 531 57 327 368 409 450 491 532 57														557
314 355 396 437 478 519 56 315 356 397 438 479 520 56 316 357 398 439 480 521 56 317 358 399 440 481 522 56 318 359 400 441 482 523 56 319 360 401 442 483 524 56 320 361 402 443 484 525 56 321 362 403 444 485 526 56 322 363 404 445 486 527 56 323 364 405 446 487 528 56 324 365 406 447 488 529 57 325 366 407 448 489 530 57 326 367 408 449 490 531 57 327 368 409 450 491 532 57														558
315 356 397 438 479 520 56 316 357 398 439 480 521 56 317 358 399 440 481 522 56 318 359 400 441 482 523 56 319 360 401 442 483 524 56 320 361 402 443 484 525 56 321 362 403 444 485 526 56 322 363 404 445 486 527 56 323 364 405 446 487 528 56 324 365 406 447 488 529 57 325 366 407 448 489 530 57 326 367 408 449 490 531 57 327 368 409 450 491 532 57														559
316 357 398 439 480 521 56 317 358 399 440 481 522 56 318 359 400 441 482 523 56 319 360 401 442 483 524 56 320 361 402 443 484 525 56 321 362 403 444 485 526 56 322 363 404 445 486 527 56 323 364 405 446 487 528 56 324 365 406 447 488 529 57 325 366 407 448 489 530 57 326 367 408 449 490 531 57 327 368 409 450 491 532 57														560
317 358 399 440 481 522 56 318 359 400 441 482 523 56 319 360 401 442 483 524 56 320 361 402 443 484 525 56 321 362 403 444 485 526 56 322 363 404 445 486 527 56 323 364 405 446 487 528 56 324 365 406 447 488 529 57 325 366 407 448 489 530 57 326 367 408 449 490 531 57 327 368 409 450 491 532 57														561
318 359 400 441 482 523 56 319 360 401 442 483 524 56 320 361 402 443 484 525 56 321 362 403 444 485 526 56 322 363 404 445 486 527 56 323 364 405 446 487 528 56 324 365 406 447 488 529 57 325 366 407 448 489 530 57 326 367 408 449 490 531 57 327 368 409 450 491 532 57														562
319 360 401 442 483 524 56 320 361 402 443 484 525 56 321 362 403 444 485 526 56 322 363 404 445 486 527 56 323 364 405 446 487 528 56 324 365 406 447 488 529 57 325 366 407 448 489 530 57 326 367 408 449 490 531 57 327 368 409 450 491 532 57														563
320 361 402 443 484 525 56 321 362 403 444 485 526 56 322 363 404 445 486 527 56 323 364 405 446 487 528 56 324 365 406 447 488 529 57 325 366 407 448 489 530 57 326 367 408 449 490 531 57 327 368 409 450 491 532 57														564
321 362 403 444 485 526 56 322 363 404 445 486 527 56 323 364 405 446 487 528 56 324 365 406 447 488 529 57 325 366 407 448 489 530 57 326 367 408 449 490 531 57 327 368 409 450 491 532 57														565
322 363 404 445 486 527 56 323 364 405 446 487 528 56 324 365 406 447 488 529 57 325 366 407 448 489 530 57 326 367 408 449 490 531 57 327 368 409 450 491 532 57														
323 364 405 446 487 528 56 324 365 406 447 488 529 57 325 366 407 448 489 530 57 326 367 408 449 490 531 57 327 368 409 450 491 532 57														
324 365 406 447 488 529 57 325 366 407 448 489 530 57 326 367 408 449 490 531 57 327 368 409 450 491 532 57														
325 366 407 448 489 530 57 326 367 408 449 490 531 57 327 368 409 450 491 532 57														
326 367 408 449 490 531 57 327 368 409 450 491 532 57														
327 368 409 450 491 532 57														
328 309 410 451 492 533 57														
		328		369		410		451		492		533		5/4
		_												

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
PPD 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613	PPD 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653	PPD 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694	PPD 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736	PPD 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 775 775	PPD 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 811 812 813 814 815 816 817 818	PPD 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854
614 615	655 656	696 697	737 738	778 779	819 820	860 861

SD4\0\INFORM

Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. F		Trt. I	
	901 902		

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

PPD 1 PPD 42 PPD 83 PPD 124 PPD 165 PPD 247 2 43 44 85 126 166 207 248 4 44 85 126 166 207 248 4 45 86 127 168 209 250 5 46 87 128 169 210 251 6 47 88 129 170 211 212 252 8 49 90 131 130 171 212 213 8 49 90 131 172 213 254 9 50 91 132 173 214 255 10 51 92 133 174 215 256 11 52 93 134 175 216 257 12 53 94 135 176 217 218 259 13 54 95 136 177 218 259 14 55 96 137 178 219 260 15 56 97 138 179 220 261 16 57 98 139 180 221 17 58 99 100 141 182 222 263 18 59 100 141 182 222 263 18 59 100 141 182 222 263 18 59 100 141 182 222 263 18 59 100 141 182 222 263 18 59 100 141 182 222 263 18 59 100 141 182 222 263 18 59 100 141 182 222 263 18 59 100 141 185 222 263 18 59 100 141 182 222 263 264 19 60 101 142 183 224 265 27 68 109 100 141 182 222 263 28 69 110 144 185 188 229 270 266 27 68 109 159 140 181 222 263 27 68 109 159 140 181 222 263 28 69 110 191 22 143 184 225 266 29 66 107 148 189 299 270 25 66 107 148 189 299 270 25 66 177 288 299 270 25 66 177 188 299 270 26 27 68 109 150 191 232 233 264 27 68 29 70 111 155 199 230 271 26 67 108 149 190 231 272 27 68 109 150 191 232 233 274 28 69 110 151 192 233 234 274 29 70 111 155 199 230 231 272 28 69 110 151 199 230 231 272 28 69 110 151 199 230 231 272 28 69 110 151 199 230 231 272 28 69 110 151 199 230 231 272 28 69 110 151 199 230 231 274 29 70 111 155 156 196 237 238 234 274 33 74 115 155 156 197 238 239 280 33 77 118 159 199 240 281 36 77 118 159 200 241 282 38 79 120 161 200 201 242 283 38 79 120 161 200 201 242 283 38 79 120 161 200 201 242 283 38 79 120 161 200 201 242 283 38 39 80 121 166 200 201 244 288	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
	No nb	No nb	No nb	No nb	No nb	No nb	No nb
40 81 122 163 204 245 286 41 82 123 164 205 246 287	PPD 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40	PPD 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 78 79 80 81	PPD 83 84 85 86 87 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121	PPD 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163	PPD 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204	PPD 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245	PPD 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
No nb	No nb	No nb	No nb	No nb	No nb	PPD 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb
PPD	575 576	PPD	616 617	PPD	657 658	PPD	698 699	PPD	739 740	PPD	780 781	PPD	821 822
	577		618		659		700		741		782		823
	578		619		660		701		742		783		824
	579		620		661		702		743		784		825
	580		621		662		703		744		785		826
	581		622		663		704		745		786		827
	582		623		664		705		746		787		828
	583		624		665		706		747		788		829
	584		625		666		707		748		789		830
	585		626		667		707		749		790		831
	586		627		668		709		750		791		832
	587		628		669		710		751		792		833
	588		629		670		711		752		793		834
	589		630		671		712		753		794		835
	590		631		672		713		754		795		836
	591		632		673		714		755		796		837
	592		633		674		715		756		797		838
	593		634		675		716		757		798		839
	594		635		676		717		758		799		840
	595		636		677		718		759		800		841
	596		637		678		719		760		801		842
	597		638		679		720		761		802		843
	598		639		680		721		762		803		844
	599		640		681		722		763		804		845
	600		641		682		723		764		805		846
	601		642		683		724		765		806		847
	602		643		684		725		766		807		848
	603		644		685		726		767		808		849
	604		645		686		727		768		809		850
	605		646		687		728		769		810		851
	606		647		688		729		770		811		852
	607		648		689		730		771		812		853
	608		649		690		731		772		813		854
	609		650		691		732		773		814		855
	610		651		692		733		774		815		856
	611		652		693		734		775		816		857
	612		653		694		735		776		817		858
	613		654		695		736		777		818		859
	614		655		696		737		778		819		860
	615		656		697		738		779		820		861
	010		300				. 55				-20		001

SD4\0\INFORM

DTPA-HBV-IPV-135 (A.15MAR2018)

Randomisation list

Trt. No	Bl. nb	Trt.	Bl.
PPD	862 863 864 865 866 867 868 871 872 873 874 875 877 878 881 882 883 884 885 886 887 889 891 892 893 894 895 897 899 900 900 900	PPD	903 904 905 906

DTPA-HBV-IPV-135 (A.15MAR2018)

No nb No	. Bl. Trt. o nb No	nb No	nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
PPD 1 1 2 2 2 2 2 2 3 3 3 3 4 4 4 4 4 4 5 5 5 5 5 5 6 6 6 6 6 6 7 7 7 7 7 8 8 8 8 8 9 9 9 9 9 10 10 10 10 11 11 11 11 11 11 11 11 11	14 PPD 15 15 15 16 16 16 16 17 17 17 18 18 18 18 19 19 20 20 20 20 20 21 21 21 21 22 22 22 23 23 23 24 24 24 24 25 25 25 26 26 26 26 27 27 27 27 28	28 PPD 28 29 29 29 30 30 30 31 31 31 31 32 32 32 32 33 33 33 33 34 34 34 35 35 35 35 36 36 36 36 36 36 37 37 37 37 38 38 38 38 39 39 39 40 40 40 41 41 41 41 41	42 42 43 43 43 44 44 44 45 45 45 45 46 46 46 47 47 47 48 48 48 49 49 49 50 50 50 50 51 51 51 52 52 52 53 53 54 54 54 55 55 55		PPD 69 69 70 70 70 71 71 71 71 72 72 72 72 73 73 73 74 74 74 75 75 75 76 76 76 76 76 77 77 77 77 78 88 78 79 79 80 80 80 81 81 81 81 82 82 82	PPD 83 83 83 83 84 84 84 84 85 85 86 86 86 87 87 87 88 88 88 89 89 90 90 90 91 91 91 91 91 91 91 91 91 91 91 91 91

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD 96 97 97 98 98 98 98 99 99 99 99 100 100 100 101 101 101 102 102 102 102	No nb	No nb	No nb	No nb	PPD 165 165 165 165 166 166 166 166 167 167 168 168 169 169 170 170 170 170 171 171 171 172 172 172 172 172 172 173 173 173 173 173 173 173 173 173 173	No nb
109	123	137	150	164	178	191
110	123	137	151	164	178	192

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
No nb	No nb	PPD 219 220 220 220 221 221 221 221 222 222 222	PPD 233 234 234 234 234 235 235 235 236 236 237 237 237 237 238 238 238 239 239 240 240 241 241 241 241 242 242 242 242 242 242	No nb	No nb	No nb
203 203 203 204 204 204 205 205 205	216 217 217 217 218 218 218 219 219	230 230 231 231 231 232 232 232 232 233	244 244 245 245 245 245 246 246 246	257 258 258 258 259 259 259 260 260	271 271 272 272 272 273 273 273 274	285 285 285 286 286 286 287 287 287

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD 288 288 288 289 289 289 290 290 291 291 291 291 291 292 292 292 293 293 293 294 294 294 294 295 295 295 295 295 296 296 296 296 297 297 297 298 298 298 298 299 299 300 300 300 300 300	No nb	PPD 315 315 316 316 316 317 317 317 318 318 319 319 319 319 320 320 320 320 320 320 320 320 320 321 321 321 321 321 321 321 321 321 321	PPD 329 329 329 329 330 330 330 331 331 331 331 332 332 332 332 333 333	PPD 342 343 344 344 344 344 345 345 345 346 346 346 347 347 347 347 348 348 349 349 350 350 351 351 351 351 351 351 351 351 351 351	PPD 356 356 357 357 357 357 357 358 358 359 360 360 360 361 361 361 361 362 362 362 362 363 363 363 363 363 364 364 364 364 365 365 365 365 366 366 367 367 367 368 368 368 368 369	PPD 370 370 370 370 370 371 371 371 371 372 372 372 373 373 373 374 374 374 375 375 376 376 376 376 377 377 377 377 377 377
301	314	328	342	355	369	383
301	315	328	342	356	369	383

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
No nb	No nb	No nb	No nb	No nb	No nb	No nb

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	nb No nb	
No nb	No nb	No nb	No nb	No nb	No nb	PPD 561 562 562 562 563 563 563 564 564 564 565 565 565 565 566 566 566
487 487 487 488 488 488 489 489 490 490 490 491 491 491 492 492	500 501 501 501 502 502 502 503 503 503 504 504 504 505 505 505 506	514 514 515 515 515 516 516 516 517 517 517 517 518 518 518 519 519 519	528 528 528 529 529 529 530 530 531 531 531 531 532 532 532 532 533 533	541 542 542 542 543 543 544 544 544 545 545 545	555 555 556 556 556 557 557 557 557 558 558 558 559 559 559 559 560 560 560	569 569 569 570 570 571 571 571 572 572 572 573 573 573 574 574

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
No nb	No nb	PPD 602 602 603 603 603 604 604 604 605 605 605 605 606 606 606 607 607	No nb	PPD 629 630 630 630 631 631 631 632 632 632 632 633 633 633 634 634 634	No nb	PPD 657 657 658 658 658 659 659 660 660 660 661 661 661 662 662
580 580 581 581 581 582 582 582 583 583 583 584 584 584 585 585 585 586 586 586 586 587 587 587	594 594 594 595 595 595 596 596 596 597 597 597 598 598 598 599 599 600 600 600 601 601 601	607 608 608 608 609 609 609 610 610 611 611 611 612 612 612 612 613 613 613 613 614 614 614 615 615	621 622 622 622 623 623 623 623 624 624 624 625 625 625 625 625 625 627 627 627 627 627 628 628 628 629 629	635 635 635 636 636 636 637 637 637 638 638 638 639 639 640 640 640 641 641 641 641 642 642 642	648 649 649 650 650 650 651 651 651 652 652 652 653 653 653 654 654 654 655 655 655	662 663 663 663 664 664 664 665 665 665 666 666 667 667 667 667 668 668 668 668

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. Trt. Bl. Trt. Bl. No nb No nb No nb			Trt. Bl. No nb
PPD 670 671 671 672 672 672 673 673 673 674 674 674 675 675 675 676 676 676 677 677 677 678 678 678 679 679 680 680 680 681 681 681 681 682	No nb	No nb	No nb	No nb	PPD 739 739 739 739 739 740 740 740 741 741 741 741 742 742 742 743 743 744 744 745 745 746 746 746 747 747 747 748 748 748 749 749 750 750	PPD 752 753 753 753 754 754 754 755 755 755 756 756 756 756 756 756 757 757
682 682 682 683 683 683 684	695 696 696 696 697 697	709 709 710 710 710 711 711	723 723 723 724 724 724 725	736 737 737 737 738 738 738	750 750 751 751 751 752 752	764 764 765 765 765 766

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
No nb	No nb	No nb	No nb	No nb	No nb	No nb

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb
	PPD 875 876 876 876 877 877 877 877 878 878 879 879 879 880 880 880 881 881 881 881 882 882 882 882 882 883 883 883 884 884 884 884 885 885 885 886 886 886 887 887 887 888 888 888 888	PPD 889 889 890 890 890 890 891 891 891 891 892 892 892 892 893 893 893 894 894 894 895 895 895 896 896 896 897 897 897 897 897 897 897 897 897 898 898	PPD 903 903 903 904 904 905 905 905 906 906

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD 1 1 1 1 2 2 2 2 3 3 3 3 4 4 4 4 4 5 5 5 5 6 6 6 6 6 7 7 7 7 8 8 8 8 8 9 9 9 9 10 10 10 10 10 11 11 11 11 11 11 11 11	No nb	No nb	PPD 42 42 42 43 43 43 43 44 44 44 45 45 45 45 46 46 46 46 47 47 47 48 48 49 49 49 50 50 50 50 50 51 51 51 51 52 52 52 52 53 53 53 53 53 54 54 54	PPD 55 56 56 56 56 57 57 57 58 58 58 58 59 59 60 60 60 61 61 61 61 62 62 62 62 63 63 63 64 64 64 65 65 65 66 66 66 66 67 67 67 67 68	PPD 69 69 70 70 70 71 71 71 71 72 72 72 72 73 73 73 74 74 74 74 75 75 75 75 75 76 76 76 76 76 76 76 76 77 77 77 77 77	PPD 83 83 83 83 83 84 84 84 85 85 86 86 86 87 87 87 88 88 88 88 89 90 90 90 91 91 91 91 91 92 92 92 92 92 92 92 92 93 93 93 93 93 94
13	27	41	54	68	82	95
14	27	41	55	68	82	96
14	28	41	55	69	82	96

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	o nb No nb No nb		Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb			No nb	No nb	No nb	No nb
No nb	No nb	No nb	No nb	No nb	No nb	No nb
109	123	137	150	164	178	191
	123	137	151	164	178	192

DTPA-HBV-IPV-135 (A.15MAR2018)

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
PPD 383 384 384 384 385 385 385 385 386 386 386 387 387 387 387 387 387 387 387 387 387	PPD 397 397 398 398 398 398 399 399 400 400 400 400 401 401 401 401 402 402 402 402 403	PPD 411 411 411 412 412 412 413 413 413 414 414 414 415 415 415 416 416	PPD 424 425 425 425 426 426 426 427 427 427 428 428 428 429 429 430 430	PPD 438 438 439 439 439 440 440 441 441 441 441 441 442 442 442 442 443 443 443	PPD 452 452 452 453 453 453 454 454 454 455 455 455 455	PPD 465 466 466 466 467 467 467 468 468 469 469 470 470 470 471
389 389 390 390 390 391 391 391 392 392 392 393 393 393 393 394 394 394 395 395 396 396 396 396 397	403 403 404 404 404 405 405 405 406 406 406 407 407 407 408 408 408 408 409 409 410 410	416 417 417 417 418 418 418 419 419 419 420 420 420 421 421 421 421 422 422 422 422 422 423 423 423 424	430 430 431 431 431 432 432 433 433 433 433 434 434	444 444 444 445 445 445 445 446 446 446	457 458 458 458 459 459 459 460 460 461 461 461 461 462 462 462 462 463 463 463 463 464 464 464	471 471 472 472 472 473 473 473 474 474 474 475 475 475 476 476 476 477 477 477 477 477

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl No nb		Trt. Bl. No nb		Trt. H	nb	Trt. E No r	nb	Trt. No	nb	Trt. E No r	nb	Trt. No	nb
PPD	479 479 480 480 480 481 481 481 481 482 483 484 482 483 484 485 485 485 485 485 485 485 485 486 486 487 487 487 488 489 489 490 490 490 490 490	No	nb 493 493 493 494 494 494 494 495 495 495 496 496 497 497 497 497 498 498 499 499 499 500 500 500 501 501 501 501 501 502 502 502 502 502 503 503 503 504 504 504	No r	506 507 507 508 508 508 509 509 509 510 510 511 511 511 511 512 512 512 513 513 514 514 515 515 516 516 516 516 517 517 517 518	No r	520 520 520 521 521 521 521 522 522 522 523 523 523 524 524 524 524 525 525 525 525	No	nb 534 534 534 534 535 535 535 535 536 536 536 537 537 537 537 538 538 539 539 540 540 540 540 541 541 541 541 542 542 542 542 542 542 542 544 544 545 545	No r	10 547 548 548 549 549 549 550 550 550 551 551 551 552 552 552 553 554 555 555 555 556 556 557 557 557	No	nb 561 562 562 563 563 563 564 564 565 565 566 566 567 567 567 568 569 570 570 571 571 571 572 572 572 572 573
	491 491 491 492 492 492		504 505 505 505 506 506		518 518 519 519 519 520		532 532 532 533 533 533		545 546 546 546 547 547		559 559 560 560 560 561		573 573 573 574 574 574

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
No nb	PPD 588 589 589 589 590 590 590 591 591 591 591 592 592 592 593 593 593 593 594	PPD 602 602 603 603 604 604 605 605 605 606 606 607 607 607	PPD 616 616 616 617 617 618 618 619 619 620 620 620 621 621	PPD 629 630 630 630 631 631 631 632 632 632 633 633 634 634 634 635	No nb	PPD 657 657 658 658 658 659 659 660 660 660 661 661 661 662 662
580 580 581 581 581 582 582 582 583 583 583 584 584 584 584 585 585 585 585 586 586 586 586 587 587	594 594 594 595 595 595 596 596 596 597 597 597 598 598 598 599 599 600 600 600 601 601 601 601	607 608 608 609 609 609 610 610 611 611 611 612 612 612 613 613 613 614 614 614 615 615	621 621 622 622 622 623 623 623 624 624 624 625 625 625 625 625 626 626 626 627 627 627 627 627 628 628 629 629	635 635 635 636 636 636 637 637 637 638 638 639 639 640 640 640 641 641 641 641 642 642	648 649 649 649 650 650 651 651 651 652 652 652 653 653 653 654 654 654 655 655 655	662 662 663 663 664 664 664 665 665 666 666 666 667 667 667 668 668 668 669 669

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
PPD 670 671 671 671 672 672 672 673 673 673 674 674 674 675 675 675 675 676 676 676 677 677 677	No nb	No nb	No nb	No nb	PPD 739 739 739 739 740 740 740 741 741 741 741 742 742 742 742 743 743 743 744 744 745 745 745 746 746 746 747 747 747 748 748 748 749 749 750 750	PPD 752 753 753 753 754 754 754 755 755 755 756 756 756 756 756 756 757 757
682 682 682 683 683 683 684	695 696 696 696 697 697	709 709 710 710 710 711 711	723 723 723 724 724 724 725	736 737 737 737 738 738 738	750 750 751 751 751 752 752	764 764 764 765 765 765 766

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
No nb	No nb	No nb	No nb	No nb	PPD 834 835 835 835 836 836 836 836 837 837 837 837 838 838 838 839 839 839 840 840 841 841 841 841 841 842 842 842 842 842 842 842 842 842 842	PPD 848 848 848 849 849 849 850 850 851 851 851 851 852 852 852 852 853 853 853 853 854 854 854 855 855 856 856 856 857 857 857 857 857 858 858 858 858 859 859 859

DTPA-HBV-IPV-135 (A.15MAR2018)

No nb	rt. Bl.	Trt. Bl.	Trt. Bl.
	No nb	No nb	No nb
PPD 862 862 862 862 863 863 863 864 864 864 865 865 865 866 866 866 867 867 867 867 867 867 869 869 869 870 871 871 871 871 871 871 871 871 871 871	875 876 876 876 877 877 877 878 878	889 889 889 889 8890 890 890 890 891 891 891 891 892 892 892 893 893 893 894 894 894 895 895 895 896 896 896 896 897 897 897 897 897 897 897 897 897 897	PPD 903 903 903 904 904 905 905 905 906 906

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Tr	. Bl.	Trt	. Bl.		Trt. Bl	1.
No	nb	No	nb	No	nb	No	nb	1	lo nb	No	o nb		No nh	b
PPD	70907	PPD	70948	PPD	70989	PPD	71030	PPD	71071	PPD	71112	PI	PD 71	1153
	70908		70949		70990		71031		71072		71113			1154
	70909		70950		70991		71032		71073		71114			1155
	70910		70951		70992		71033		71074		71115			1156
	70911		70952		70993		71034		71075		71116			1157
	70912		70953		70994		71035		71076		71117			1158
	70913		70954		70995		71036		71077		71118		7.	1159
	70914		70955		70996		71037		71078		71119		7.	1160
	70915		70956		70997		71038		71079		71120		7.5	1161
	70916		70957		70998		71039		71080		71121		7:	1162
	70917		70958		70999		71040		71081		71122		7.	1163
	70918		70959		71000		71041		71082		71123		7:	1164
	70919		70960		71001		71042		71083		71124			1165
	70920		70961		71002		71043		71084		71125		7:	1166
	70921		70962		71003		71044		71085		71126		7:	1167
	70922		70963		71004		71045		71086		71127		7.1	1168
	70923		70964		71005		71046		71087		71128			1169
	70924		70965		71006		71047		71088		71129			1170
	70925		70966		71007		71048		71089		71130			1171
	70926		70967		71008		71049		71090		71131			1172
	70927		70968		71009		71050		71091		71132			1173
	70928		70969		71010		71051		71092		71133			1174
	70929		70970		71011		71052		71093		71134			1175
	70930		70971		71012		71053		71094		71135			1176
	70931		70972		71013		71054		71095		71136			1177
	70932		70973		71014		71055		71096		71137			1178
	70933		70974		71015		71056		71097		71138			1179
	70934		70975		71016		71057		71098		71139			1180
	70935		70976		71017		71058		71099		71140			1181
	70936 70937		70977 70978		71018 71019		71059 71060		71100		71141			1182
	70937		70978		71019		71060		71101 71102		71142 71143			1183
	70938		70979		71020		71061		71102		71143			1184
	70939		70981		71021		71062		71103		71144			1186
	70940		70982		71022		71063		71104		71145			1187
	70941		70983		71023		71064		71105		71146			1188
	70942		70984		71024		71065		71106		71147			1189
	70943		70985		71025		71066		71107		71146			1190
	70944		70986		71026		71067		71108		71149			1190
	70945		70987		71027		71068		71109		71150			1191
	70947		70988		71028		71009		71111		71151			1193
	1021		70300		11029		71070		/1111		11132		/ ·	1193
			l											

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl.						
	No nb						
No nb	No nb	No nb	No nb	No nb	No nb		
71230	71271	71312	71353	71394	71435	71476	
71231	71272	71313	71354	71395	71436	71477	
71232	71273	71314	71355	71396	71437	71478	
71233	71274	71315	71356	71397	71438	71479	
71234	71275	71316	71357	71398	71439	71480	

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.	Trt. 1		Trt.		Trt.			Bl.	Trt.	
NO	nb	No nb	No i	no 	NO	nb	NO	nb	NO	nb	NO	nb
									DDD			
PPD	71481	PPD 71522	PPD	71563	PPD	71604	PPD	71645	PPD	71686	PPD	71727
	71482	71523		71564		71605		71646		71687		71728
	71483	71524		71565		71606		71647		71688		71729
	71484	71525		71566		71607		71648		71689		71730
	71485	71526		71567		71608		71649		71690		71731
	71486	71527		71568		71609		71650		71691		71732
	71487	71528		71569		71610		71651		71692		71733
	71488	71529		71570		71611		71652		71693		71734
	71489	71530		71571		71612		71653		71694		71735
	71490	71531		71572		71613		71654		71695		71736
	71491	71532		71573		71614		71655		71696		71737
	71492	71533		71574		71615		71656		71697		71738
	71493	71534		71575		71616		71657		71698		71739
	71494	71535		71576		71617		71658		71699		71740
	71495	71536		71577		71618		71659		71700		71741
	71496	71537		71578		71619		71660		71701		71742
	71497	71538		71579		71620		71661		71702		71743
	71498	71539		71580		71621		71662		71703		71744
	71499	71540		71581		71622		71663		71704		71745
	71500	71541		71582		71623		71664		71705		71746
	71501	71542		71583		71624		71665		71706		71747
	71502	71543		71584		71625		71666		71707		71748
	71503	71544		71585		71626		71667		71708		71749
	71504	71545		71586		71627		71668		71709		71750
	71505	71546		71587		71628		71669		71710		71751
	71506	71547		71588		71629		71670		71711		71752
	71507	71548		71589		71630		71671		71712		71753
	71508	71549		71590		71631		71672		71713		71754
	71509	71550		71591		71632		71673		71714		71755
	71510	71551		71592		71633		71674		71715		71756
	71511	71552		71593		71634		71675		71716		71757
	71512	71553		71594		71635		71676		71717		71758
	71513	71554		71595		71636		71677		71718		71759
	71514	71555		71596		71637		71678		71719		71760
	71515	71556		71597		71638		71679		71720		71761
	71516	71557		71598		71639		71680		71721		71762
	71517	71558		71599		71640		71681		71722		71763
	71518	71559		71600		71641		71682		71723		71764
	71519	71560		71601		71642		71683		71724		71765
	71520	71561		71602		71643		71684		71725		71766
	71521	71562		71603		71644		71685		71726		71767

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl. nb	Trt. No		Trt. No		Trt.	Bl. nb	Trt.	Bl. nb		Bl.	Trt.	Bl. nb
NO		NO	nb 	NO		NO	11D 	NO		NO		NO	
						DDD				PPD			
PPD	7 = 7 0 0	PPD	12003	PPD		PPD		PPD	71932		71973	PPD	72014
	71769		71810		71851		71892		71933		71974		72015
	71770		71811		71852		71893		71934		71975		72016
	71771		71812		71853		71894		71935		71976		72017
	71772		71813		71854		71895		71936		71977		72018
	71773		71814		71855		71896		71937		71978		72019
	71774		71815		71856		71897		71938		71979		72020
	71775		71816		71857		71898		71939		71980		72021
	71776		71817		71858		71899		71940		71981		72022
	71777		71818		71859		71900		71941		71982		72023
	71778		71819		71860		71901		71942		71983		72024
	71779		71820		71861		71902		71943		71984		72025
	71780		71821		71862		71903		71944		71985		72026
	71781		71822		71863		71904		71945		71986		72027
	71782		71823		71864		71905		71946		71987		72028
	71783		71824		71865		71906		71947		71988		72029
	71784		71825		71866		71907		71948		71989		72030
	71785		71826		71867		71908		71949		71990		72031
	71786		71827		71868		71909		71950		71991		72032
	71787		71828		71869		71910		71951		71992		72033
	71788		71829		71870		71911		71952		71993		72034
	71789		71830		71871		71912		71953		71994		72035
	71790		71831		71872		71913		71954		71995		72036
	71791		71832		71873		71914		71955		71996		72037
	71792		71833		71874		71915		71956		71997		72038
	71793		71834		71875		71916		71957		71998		72039
	71794		71835		71876		71917		71958		71999		72040
	71795		71836		71877		71918		71959		72000		72041
	71796		71837		71878		71919		71960		72001		72042
	71797		71838		71879		71920		71961		72002		72043
	71798		71839		71880		71921		71962		72003		72044
	71799		71840		71881		71922		71963		72004		72045
	71800		71841		71882		71923		71964		72005		72046
	71801		71842		71883		71924		71965		72006		72047
	71802		71843		71884		71925		71966		72007		72048
	71803		71844		71885		71926		71967		72008		72049
	71804		71845		71886		71927		71968		72009		72050
	71805		71846		71887		71928		71969		72010		72051
	71806		71847		71888		71929		71970		72011		72052
	71807		71848		71889		71930		71971		72012		72053
	71808		71849		71890		71931		71972		72013		72054

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.		Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	72055	PPD	72096	PPD	72137	PPD	72178	PPD	72219	PPD	72260	PPD	72301
FFD	72056	110	72097		72137	110	72179	FFD	72220		72261	110	72301
	72057		72098		72130		72180		72221		72262		72302
	72058		72099		72140		72181		72222		72263		72303
	72059		72100		72140		72182		72223		72264		72304
	72060		72100		72141		72183		72224		72265		72305
	72060		72101		72142		72184		72224		72266		72300
	72062		72102		72143		72185		72226		72267		72307
	72062		72103		72144		72186		72227		72268		72300
	72063		72104		72145		72187		72228		72269		72310
	72065		72105		72140		72188		72229		72270		72310
	72066		72100		72148		72189		72230		72271		72311
	72067		72107		72149		72190		72230		72272		72312
	72068		72100		72145		72191		72232		72273		72313
	72069		72103		72150		72192		72232		72274		72314
	72070		72110		72151		72193		72234		72275		72316
	72071		72111		72152		72194		72235		72276		72317
	72072		72113		72153		72195		72236		72277		72317
	72073		72114		72155		72196		72237		72278		72319
	72073		72115		72156		72197		72237		72279		72320
	72075		72116		72157		72198		72239		72280		72321
	72076		72117		72158		72199		72240		72281		72322
	72077		72118		72159		72200		72241		72282		72323
	72078		72119		72160		72201		72242		72283		72324
	72079		72120		72161		72202		72243		72284		72325
	72080		72121		72162		72203		72244		72285		72326
	72081		72122		72163		72204		72245		72286		72327
	72082		72123		72164		72205		72246		72287		72328
	72083		72124		72165		72206		72247		72288		72329
	72084		72125		72166		72207		72248		72289		72330
	72085		72126		72167		72208		72249		72290		72331
	72086		72127		72168		72209		72250		72291		72332
	72087		72128		72169		72210		72251		72292		72333
	72088		72129		72170		72211		72252		72293		72334
	72089		72130		72171		72212		72253		72294		72335
	72090		72131		72172		72213		72254		72295		72336
	72091		72132		72173		72214		72255		72296		72337
	72092		72133		72174		72215		72256		72297		72338
	72093		72134		72175		72216		72257		72298		72339
	72094		72135		72176		72217		72258		72299		72340
	72095		72136		72177		72218		72259		72300		72341
	-										l e		

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
PPD 72342 72343 72344 72345 72346 72347 72348 72349 72350 72351 72352 72353 72354 72355 72356 72357 72358 72359 72360 72361	No nb	No nb	No nb	No nb	No nb	PPD 72588 72589 72590 72591 72592 72593 72594 72595 72596 72597 72598 72599 72600 72601 72602 72603 72604 72605 72606 72607
72361 72362 72363 72364 72365 72366 72367 72368 72369 72370 72371 72372 72373 72374 72375 72376 72376 72377 72378 72379 72379 72380 72381 72382	72402 72403 72404 72405 72406 72407 72408 72409 72410 72411 72412 72413 72414 72415 72416 72417 72418 72419 72420 72420 72422 72423	72443 72444 72445 72446 72447 72448 72449 72450 72451 72451 72452 72453 72454 72455 72456 72457 72458 72459 72460 72461 72462 72463 72463	72484 72485 72486 72487 72488 72489 72490 72491 72492 72493 72494 72495 72498 72498 72499 72500 72501 72502 72503 72504 72505	72525 72526 72527 72528 72529 72530 72531 72532 72533 72534 72535 72536 72537 72538 72539 72540 72541 72542 72542 72543 72545	72566 72567 72568 72569 72570 72571 72572 72573 72574 72575 72576 72577 72578 72579 72580 72580 72581 72582 72583 72584 72585 72586 72586	72607 72608 72609 72610 72611 72612 72613 72614 72615 72616 72617 72618 72619 72620 72621 72622 72623 72624 72625 72624 72627 72626 72627

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.			Bl.		Bl.	Trt.		Trt.		Trt.		Trt.	
No	nb	No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	72629	PPD	72670	PPD	72711	PPD	72752	PPD	72793	PPD	72834	PPD	72875
	72630		72671		72712		72753		72794		72835		72876
	72631		72672		72713		72754		72795		72836		72877
	72632		72673		72714		72755		72796		72837		72878
	72633		72674		72715		72756		72797		72838		72879
	72634		72675		72716		72757		72798		72839		72880
	72635		72676		72717		72758		72799		72840		72881
	72636		72677		72718		72759		72800		72841		72882
	72637		72678		72719		72760		72801		72842		72883
	72638		72679		72720		72761		72802		72843		72884
	72639		72680		72721		72762		72803		72844		72885
	72640		72681		72722		72763		72804		72845		72886
	72641		72682		72723		72764		72805		72846		72887
	72642		72683		72724		72765		72806		72847		72888
	72643		72684		72725		72766		72807		72848		72889
	72644		72685		72726		72767		72808		72849		72890
	72645		72686		72727		72768		72809		72850		72891
	72646		72687		72728		72769		72810		72851		72892
	72647		72688		72729		72770		72811		72852		72893
	72648		72689		72730		72771		72812		72853		72894
	72649		72690		72731		72772		72813		72854		72895
	72650		72691		72732		72773		72814		72855		72896
	72651		72692		72733		72774		72815		72856		72897
	72652		72693		72734		72775		72816		72857		72898
	72653		72694		72735		72776		72817		72858		72899
	72654		72695		72736		72777		72818		72859		72900
	72655		72696		72737		72778		72819		72860		72901
	72656		72697		72738		72779		72820		72861		72902
	72657		72698		72739		72780		72821		72862		72903
	72658		72699		72740		72781		72822		72863		72904
	72659		72700		72741		72782		72823		72864		72905
	72660		72701		72742		72783		72824		72865		72906
	72661		72702		72743		72784		72825		72866		72907
	72662		72703		72744		72785		72826		72867		72908
	72663		72704		72745		72786		72827		72868		72909
	72664		72705		72746		72787		72828		72869		72910
	72665		72706		72747		72788		72829		72870		72911
	72666		72707		72748		72789		72830		72871		72912
	72667		72708		72749		72790		72831		72872		72913
	72668		72709		72750		72791		72832		72873		72914
	72669		72710		72751		72792		72833		72874		72915

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt.		Trt.		Trt.		Trt.		Trt.		Trt.	
No	nb	No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	72916	PPD	72957	PPD	72998	PPD	73039	PPD	73080	PPD	73121	PPD	73162
FFD	72917	110	72958		72999	110	73040	FFD	73081		73122		73162
	72918		72959		73000		73041		73082		73123		73163
	72919		72960		73000		73042		73083		73124		73165
	72920		72961		73001		73043		73084		73125		73166
	72921		72962		73002		73043		73085		73126		73166
	72922		72963		73003		73045		73086		73127		73167
	72923		72964		73005		73046		73087		73127		73169
	72924		72965		73005		73047		73088		73129		73170
	72925		72966		73007		73048		73089		73130		73170
	72926		72967		73007		73049		73090		73131		73171
	72927		72968		73009		73050		73091		73132		73172
	72928		72969		73010		73051		73092		73133		73174
	72929		72970		73011		73052		73093		73134		73175
	72930		72971		73012		73053		73094		73135		73176
	72931		72972		73012		73054		73095		73136		73177
	72932		72973		73014		73055		73096		73137		73178
	72933		72974		73015		73056		73097		73137		73179
	72934		72975		73016		73057		73098		73139		73180
	72935		72976		73017		73058		73099		73140		73181
	72936		72977		73018		73059		73100		73141		73182
	72937		72978		73019		73060		73101		73142		73183
	72938		72979		73020		73061		73102		73143		73184
	72939		72980		73021		73062		73103		73144		73185
	72940		72981		73022		73063		73104		73145		73186
	72941		72982		73023		73064		73105		73146		73187
	72942		72983		73024		73065		73106		73147		73188
	72943		72984		73025		73066		73107		73148		73189
	72944		72985		73026		73067		73108		73149		73190
	72945		72986		73027		73068		73109		73150		73191
	72946		72987		73028		73069		73110		73151		73192
	72947		72988		73029		73070		73111		73152		73193
	72948		72989		73030		73071		73112		73153		73194
	72949		72990		73031		73072		73113		73154		73195
	72950		72991		73032		73073		73114		73155		73196
	72951		72992		73033		73074		73115		73156		73197
	72952		72993		73034		73075		73116		73157		73198
	72953		72994		73035		73076		73117		73158		73199
	72954		72995		73036		73077		73118		73159		73200
	72955		72996		73037		73078		73119		73160		73201
	72956		72997		73038		73079		73120		73161		73202

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl. No nb	Trt. Bl.				
No nb		No nb				
PPD 73203 73204 73205 73206 73207 73208 73209 73210 73211 73212 73213 73214 73215 73216 73217 73218 73219 73220 73221 73222 73223 73224 73225 73226 73227 73228 73229 73227 73228 73229 73230 73231 73232 73233 73234 73235 73236 73237	PPD 73244 73245 73246 73247 73248 73249 73250 73251 73252 73253 73254 73255 73256 73256 73257 73258 73259 73260 73261 73262 73263 73264 73263 73264 73265 73266 73267 73268 73266 73267 73268 73270 73271 73272 73271 73272 73273 73274 73275 73276 73277 73277	No nb	No nb	No nb	No nb	PPD 73449 73450 73451 73452 73453 73454 73455 73456 73457 73458 73459 73460 73461 73462 73463 73464 73465 73466 73477 73478 73471 73472 73473 73474 73475 73478 73479 73480 73481
73238	73279	73320	73361	73402	73443	73484
73239	73280	73321	73362	73403	73444	73485
73240	73281	73322	73363	73404	73445	73486
73241	73282	73323	73364	73405	73446	73487
73242	73283	73324	73365	73406	73447	73488
73243	73284	73325	73366	73407	73448	73489

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl. nb	Trt. Bl. No nb					
NO	nb 	NO IID	NO IID	QII ON	NO IID		00 IID
						PPD	
PPD	73490	PPD 73531	PPD 73572	PPD 73613	PPD 73654	73695	PPD 73736
	73491	73532	73573	73614	73655	73696	73737
	73492	73533	73574	73615	73656	73697	73738
	73493	73534	73575	73616	73657	73698	73739
	73494	73535	73576	73617	73658	73699	73740
	73495	73536	73577	73618	73659	73700	73741
	73496	73537	73578	73619	73660	73701	73742
	73497	73538	73579	73620	73661	73702	73743
	73498	73539	73580	73621	73662	73703	73744
	73499	73540	73581	73622	73663	73704	73745
	73500	73541	73582	73623	73664	73705	73746
	73501	73542	73583	73624	73665	73706	73747
	73502	73543	73584	73625	73666	73707	73748
	73503	73544	73585	73626	73667	73708	73749
	73504	73545	73586	73627	73668	73709	73750
	73505	73546	73587	73628	73669	73710	73751
	73506	73547	73588	73629	73670	73711	73752
	73507	73548	73589	73630	73671	73712	73753
	73508	73549	73590	73631	73672	73713	73754
	73509	73550	73591	73632	73673	73714	73755
	73510	73551	73592	73633	73674	73715	73756
	73511	73552	73593	73634	73675	73716	73757
	73512	73553	73594	73635	73676	73717	73758
	73513	73554	73595	73636	73677	73718	73759
	73514	73555	73596	73637	73678	73719	73760
	73515	73556	73597	73638	73679	73720	73761
	73516	73557	73598	73639	73680	73721	73762
	73517	73558	73599	73640	73681	73722	73763
	73518	73559	73600	73641	73682	73723	73764
	73519	73560	73601	73642	73683	73724	73765
	73520	73561	73602	73643	73684	73725	73766
	73521	73562	73603	73644	73685	73726	73767
	73522	73563	73604	73645	73686	73727	73768
	73523	73564	73605	73646	73687	73728	73769
	73524	73565	73606	73647	73688	73729	73770
	73525	73566	73607	73648	73689	73730	73771
	73526	73567	73608	73649	73690	73731	73772
	73527	73568	73609	73650	73691	73732	73773
	73528	73569	73610	73651	73692	73733	73774
	73529	73570	73611	73652	73693	73734	73775
	73530	73571	73612	73653	73694	73735	73776

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt	. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	o nb	No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	73777	PPD	73818	PPD	73859	PPD	73900	PPD	73941	PPD	73982	PPD	74023
FFD	73778		73819		73860	110	73901	FFD	73942		73983	110	74023
	73779		73820		73861		73902		73943		73984		74025
	73780		73821		73862		73903		73944		73985		74025
	73781		73822		73863		73904		73945		73986		74027
	73782		73823		73864		73905		73946		73987		74027
	73783		73824		73865		73906		73947		73988		74028
	73784		73825		73866		73907		73948		73989		74029
	73785		73826		73867		73908		73949		73990		74030
	73786		73827		73868		73909		73950		73991		74031
	73787		73828		73869		73910		73951		73992		74032
	73788		73829		73870		73911		73952		73993		74034
	73789		73830		73871		73912		73953		73994		74035
	73790		73831		73872		73913		73954		73995		74035
	73791		73832		73873		73914		73955		73996		74037
	73792		73833		73874		73915		73956		73997		74038
	73793		73834		73875		73916		73957		73998		74039
	73794		73835		73876		73917		73958		73999		74040
	73795		73836		73877		73918		73959		74000		74041
	73796		73837		73878		73919		73960		74001		74042
	73797		73838		73879		73920		73961		74002		74043
	73798		73839		73880		73921		73962		74003		74044
	73799		73840		73881		73922		73963		74004		74045
	73800		73841		73882		73923		73964		74005		74046
	73801		73842		73883		73924		73965		74006		74047
	73802		73843		73884		73925		73966		74007		74048
	73803		73844		73885		73926		73967		74008		74049
	73804		73845		73886		73927		73968		74009		74050
	73805		73846		73887		73928		73969		74010		74051
	73806		73847		73888		73929		73970		74011		74052
	73807		73848		73889		73930		73971		74012		74053
	73808		73849		73890		73931		73972		74013		74054
	73809		73850		73891		73932		73973		74014		74055
	73810		73851		73892		73933		73974		74015		74056
	73811		73852		73893		73934		73975		74016		74057
	73812		73853		73894		73935		73976		74017		74058
	73813		73854		73895		73936		73977		74018		74059
	73814		73855		73896		73937		73978		74019		74060
	73815		73856		73897		73938		73979		74020		74061
	73816		73857		73898		73939		73980		74021		74062
	73817		73858		73899		73940		73981		74022		74063

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
No nb	No nb	No nb	No nb	No nb	No nb	
74101 74101 74102 74103 74104	74141 74142 74143 74144 74145	74183 74184 74185 74186	74224 74225 74226 74227	74265 74265 74266 74267 74268	74306 74307 74308 74309	74347 74348 74349 74350

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No	nb	No			nb	No	nb	No	nb	No	nb
PPD	74351	PPD	74392	PPD	74433	PPD	74474	PPD	74515	PPD	74556	PPD	74597
FFD	74351		74393		74433	יוו	74475	FFD	74516		74557		74598
	74352		74394		74435		74476		74517		74558		74599
	74354		74395		74436		74477		74517		74559		74600
	74355		74396		74437		74478		74519		74560		74601
	74355		74397		74438		74479		74520		74561		74601
	74350		74397		74439		74480		74521		74562		74602
	74357		74399		74440		74481		74522		74563		74603
	74359		74400		74441		74482		74523		74564		74604
	74360		74401		74442		74483		74524		74565		74605
	74360		74402		74443		74484		74525		74566		74607
	74362		74403		74444		74485		74526		74567		74608
	74362		74404		74445		74486		74527		74568		74608
	74364		74405		74446		74487		74528		74569		74610
	74365		74406		74447		74488		74529		74570		74611
	74366		74407		74448		74489		74530		74571		74611
	74367		74408		74449		74490		74531		74572		74612
	74368		74409		74450		74491		74532		74573		74613
	74369		74410		74451		74492		74533		74574		74614
	74370		74411		74452		74493		74534		74575		74616
	74370		74412		74453		74494		74535		74576		74617
	74371		74413		74454		74495		74536		74577		74617
	74373		74414		74455		74496		74537		74578		74619
	74374		74415		74456		74497		74537		74579		74620
	74375		74416		74457		74498		74539		74580		74621
	74376		74417		74458		74499		74540		74581		74622
	74377		74418		74459		74500		74541		74582		74623
	74378		74419		74460		74500		74542		74583		74624
	74379		74420		74461		74502		74543		74584		74625
	74375		74421		74462		74503		74544		74585		74626
	74381		74422		74463		74504		74545		74586		74627
	74382		74423		74464		74505		74546		74587		74628
	74383		74424		74465		74506		74547		74588		74629
	74384		74425		74466		74507		74548		74589		74630
	74385		74426		74467		74508		74549		74590		74631
	74386		74427		74468		74509		74550		74591		74632
	74387		74428		74469		74510		74551		74592		74633
	74388		74429		74470		74511		74552		74593		74634
	74389		74430		74471		74512		74553		74594		74635
	74390		74431		74472		74512		74554		74595		74636
	74391		74432		74473		74514		74555		74596		74637
	. 1331						. 1911		. 1000		. 1000		. 1037
											l		

DTPA-HBV-IPV-135 (A.15MAR2018)

	Bl. o nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb
PPD	74638 74639 74640 74641 74642 74643 74644 74644	PPD	74679 74680 74681 74682 74683 74684 74685 74686	PPD	74720 74721 74722 74723 74724 74725 74726 74727	PPD	74761 74762 74763 74764 74765 74766 74767 74768	PPD	74802 74803 74804 74805 74806 74807 74808 74809	PPD	74843 74844 74845 74846 74847 74848 74849 74850		74884 74885 74886 74887 74888 74889 74890 74891
	74646 74647 74648 74649 74650 74651 74652		74687 74688 74689 74690 74691 74692 74693		74728 74729 74730 74731 74732 74733 74734		74769 74770 74771 74772 74773 74774 74775		74810 74811 74812 74813 74814 74815 74816		74851 74852 74853 74854 74855 74856 74857		74892 74893 74894 74895 74896 74897 74898
	74653 74654 74655 74656 74657 74658 74659 74660		74694 74695 74696 74697 74698 74700 74700		74735 74736 74737 74738 74739 74740 74741 74742		74776 74777 74778 74779 74780 74781 74782 74783		74817 74818 74819 74820 74821 74822 74823 74824		74858 74859 74860 74861 74862 74863 74864 74865		74899 74900 74901 74902 74903 74904 74905 74906
	74661 74662 74663 74664 74665 74666		74701 74702 74703 74704 74705 74706 74707 74708		74742 74743 74744 74745 74746 74747 74748 74749		74784 74785 74786 74787 74788 74789 74790		74824 74825 74826 74827 74828 74829 74830 74831		74865 74866 74868 74869 74870 74871 74872		74906 74907 74908 74909 74910 74911 74912 74913
	74668 74669 74670 74671 74672 74673 74674		74708 74709 74710 74711 74712 74713 74714 74715		74749 74750 74751 74752 74753 74754 74755 74756		74791 74792 74793 74794 74795 74796 74797		74831 74832 74833 74834 74835 74836 74837 74838		74872 74874 74875 74876 74877 74878		74913 74914 74915 74916 74917 74918 74919 74920
	74675 74676 74677 74678		74716 74717 74718 74719		74757 74758 74759 74760		74798 74799 74800 74801		74839 74840 74841 74842		74880 74881 74882 74883		74921 74922 74923 74924

DTPA-HBV-IPV-135 (A.15MAR2018)

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No	nb	No			nb	No	nb		nb	No	nb
PPD	75212	PPD	75253	PPD	75294	PPD	75335	PPD	75376	PPD	75417	PPD	75458
FFD	75212	110	75254	110	75294	110	75336	FFD	75377		75417	110	75459
	75213		75255		75296		75337		75377		75419		75460
	75214		75256		75297		75337		75379		75420		75461
	75216		75257		75298		75339		75380		75421		75462
	75217		75258		75299		75340		75381		75422		75463
	75217		75259		75300		75341		75382		75423		75464
	75218		75260		75300		75342		75383		75424		75465
	75220		75261		75302		75342		75384		75425		75466
	75221		75262		75302		75344		75385		75426		75467
	75221		75263		75304		75345		75386		75427		75468
	75222		75264		75305		75346		75387		75428		75469
	75223		75265		75306		75347		75388		75429		75470
	75224		75266		75307		75347		75389		75430		75471
	75226		75267		75308		75349		75390		75431		75472
	75227		75268		75309		75350		75391		75432		75473
	75227		75269		75310		75350		75392		75433		75474
	75229		75270		75310		75351		75392		75434		75475
	75230		75271		75312		75352		75394		75435		75476
	75230		75272		75312		75354		75395		75436		75477
	75232		75273		75314		75355		75396		75437		75478
	75233		75274		75315		75356		75397		75438		75479
	75234		75275		75316		75357		75398		75439		75480
	75235		75276		75317		75358		75399		75440		75481
	75236		75277		75318		75359		75400		75441		75482
	75237		75278		75319		75360		75401		75442		75483
	75238		75279		75320		75361		75402		75443		75484
	75239		75280		75321		75362		75403		75444		75485
	75240		75281		75322		75363		75404		75445		75486
	75241		75282		75323		75364		75405		75446		75487
	75242		75283		75324		75365		75406		75447		75488
	75243		75284		75325		75366		75407		75448		75489
	75244		75285		75326		75367		75408		75449		75490
	75245		75286		75327		75368		75409		75450		75491
	75246		75287		75328		75369		75410		75451		75492
	75247		75288		75329		75370		75411		75452		75493
	75248		75289		75330		75371		75412		75453		75494
	75249		75290		75331		75372		75413		75454		75495
	75250		75291		75332		75373		75414		75455		75496
	75251		75292		75333		75374		75415		75456		75497
	75252		75293		75334		75375		75416		75457		75498
	•										l		

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.					
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	75499	PPD 75540	PPD 75581	PPD 75622	PPD 75663	PPD 75704	PPD 75745
	75500	75541	75582	75623	75664	75705	75746
	75501	75542	75583	75624	75665	75706	75747
	75502	75543	75584	75625	75666	75707	75748
	75503	75544	75585	75626	75667	75708	75749
	75504	75545	75586	75627	75668	75709	75750
	75505	75546	75587	75628	75669	75710	75751
	75506	75547	75588	75629	75670	75711	75752
	75507	75548	75589	75630	75671	75712	75753
	75508	75549	75590	75631	75672	75713	75754
	75509	75550	75591	75632	75673	75714	75755
	75510	75551	75592	75633	75674	75715	75756
	75511	75552	75593	75634	75675	75716	75757
	75512	75553	75594	75635	75676	75717	75758
	75513	75554	75595	75636	75677	75718	75759
	75514	75555	75596	75637	75678	75719	75760
	75515	75556	75597	75638	75679	75720	75761
	75516	75557	75598	75639	75680	75721	75762
	75517	75558	75599	75640	75681	75722	75763
	75518	75559	75600	75641	75682	75723	75764
	75519	75560	75601	75642	75683	75724	75765
	75520	75561	75602	75643	75684	75725	75766
	75521	75562	75603	75644	75685	75726	75767
	75522	75563	75604	75645	75686	75727	75768
	75523	75564	75605	75646	75687	75728	75769
	75524	75565	75606	75647	75688	75729	75770
	75525	75566	75607	75648	75689	75730	75771
	75526	75567	75608	75649	75690	75731	75772
	75527	75568	75609	75650	75691	75732	75773
	75528	75569	75610	75651	75692	75733	75774
	75529	75570	75611	75652	75693	75734	75775
	75530	75571	75612	75653	75694	75735	75776
	75531	75572	75613	75654	75695	75736	75777
	75532	75573	75614	75655	75696	75737	75778
	75533	75574	75615	75656	75697	75738	75779
	75534	75575	75616	75657	75698	75739	75780
	75535	75576	75617	75658	75699	75740	75781
	75536	75577	75618	75659	75700	75741	75782
	75537	75578	75619	75660	75701	75742	75783
	75538	75579	75620	75661	75702	75743	75784
	75539	75580	75621	75662	75703	75744	75785

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl.					
	No nb					
PPD 75786 75787 75788 75788 75789 75790 75791 75792 75793 75794 75795 75796 75797 75798 75796 75797 75800 75801 75802 75803 75804 75805 75806 75806 75807 75808 75809 75811 75812 75812 75813 75814 75815 75816 75816 75817 75818 75819 75820 75820	No nb	PPD 76032 76033 76034 76035 76036 76037 76038 76040 76041 76042 76043 76044 76045 76047 76048 76049 76051 76052 76053 76056 76057 76058 76059 76050 76051 76056 76060 76061 76062 76063 76064 76065 76066				
75822	75863	75904	75945	75986	76027	76068
75823	75864	75905	75946	75987	76028	76069
75824	75865	75906	75947	75988	76029	76070
75825	75866	75907	75948	75989	76030	76071
75826	75867	75908	75949	75990	76031	76072

DTPA-HBV-IPV-135 (A.15MAR2018)

76087 76128 76169 76210 76251 76292 76333 76088 76129 76170 76211 76252 76293 76334 76089 76130 76171 76212 76253 76294 76335 76090 76131 76172 76213 76254 76295 76336 76091 76132 76173 76214 76255 76296 76337 76092 76133 76174 76215 76256 76297 76338 76093 76134 76175 76216 76257 76298 76339 76094 76135 76176 76217 76218 76299 76340 76095 76136 76177 76218 76259 76300 76341 76096 76137 76178 76219 76260 76301 76342 76097 76138 76179 76220 76261 76302 76343 76098 76140 <	Trt.	Bl.	Trt. Bl.	Trt.			Bl.	Trt.			. Bl.		. Bl.
Process	No	nb	No nb	No	nb	No	nb	No	nb	No	nb	No	nb
Process													
76074	PPD	76073	PPD 76114	PPD	76155	PPD	76196	PPD	76237	PPD	76278	PPD	76319
76075	110							110				–	
76076 76118 76159 76240 76281 76322 76077 76118 76159 76200 76241 76282 76323 76078 76119 76160 76201 76242 76283 76324 76079 76120 76161 76202 76243 76284 76325 76080 76121 76162 76203 76244 76285 76326 76081 76122 76163 76204 76245 76286 76327 76082 76123 76164 76205 76246 76287 76328 76083 76124 76165 76206 76247 76288 76329 76084 76125 76166 76207 76248 76289 76230 76085 76126 76167 76208 76249 76290 76331 76086 76127 76168 76209 76251 76291 7633 76087 76128 76129 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>													
76077 76118 76159 76200 76241 76282 76323 76078 76119 76160 76201 76201 76242 76283 76324 76079 76120 76161 76202 76243 76284 76285 76326 76080 76121 76162 76203 76244 76285 76326 76081 76122 76163 76204 76245 76286 76327 76082 76123 76164 76205 76206 76246 76287 76328 76082 76123 76166 76207 76206 76246 76287 76328 76083 76124 76165 76206 76247 76288 76329 76084 76125 76166 76207 76248 76289 76330 76084 76125 76166 76207 76248 76289 76330 76085 76126 76127 76168 76209 76249 76290 76331 76086 76127 76168 76209 76211 76252 76291 76332 76087 76128 76100 76211 76252 76293 76334 76088 76129 76170 76211 76252 76293 76334 76089 76130 76171 76212 76253 76294 76333 76099 76130 76171 76212 76253 76294 76333 76091 76132 76170 76211 76252 76293 76334 76090 76131 76172 76213 76254 76295 76336 76091 76132 76173 76214 76255 76296 76337 76092 76133 76174 76215 76255 76296 76337 76092 76133 76174 76215 76255 76296 76337 76092 76133 76174 76215 76255 76296 76337 76092 76133 76174 76215 76255 76296 76337 76092 76133 76174 76215 76255 76296 76337 76092 76133 76174 76215 76255 76296 76337 76092 76133 76174 76215 76255 76296 76337 76094 76135 76176 76177 76218 76257 76298 76330 76344 76175 76216 76257 76298 76330 76344 76155 76176 76217 76258 76296 76337 76094 76135 76176 76177 76218 76257 76298 76300 76341 76096 76137 76138 76179 76220 76261 76262 76303 76344 76195 76180 76220 76261 76300 76341 76190 76141 76182 76220 76261 76300 76341 76190 76141 76182 76220 76266 76307 76300 76341 76100 76141 76182 76220 76266 76307 76300 76341 76100 76141 76185 76166 76227 76268 76300 76311 76322 76100 76141 76185 76166 76227 76268 76300 76311 76322 76100 76144 76185 76166 76227 76268 76300 76311 76320 76100 76141 76188 76229 76266 76307 76311 76312 76350 76100 76144 76185 76186 76227 76268 76300 76311 76312 76100 76144 76185 76186 76227 76266 76307 76311 76312 76350 76100 76144 76185 76186 76227 76266 76307 76311 76312 76350 76100 76144 76188 76229 76231 76266 76307 76311 76312 76350 76100 76149 76149 76190 76231 76231 76231 76231 76231 76331													
76078 76119 76110 76161 76202 76242 76283 76328 76329 76079 76120 76161 76202 76243 76284 76285 76326 76080 76121 76162 76203 76244 76285 76326 76381 76122 76163 76204 76245 76285 76286 76327 76082 76123 76164 76205 76246 76287 76328 76328 76083 76124 76165 76206 76247 76288 76328 76084 76125 76166 76207 76248 76289 76330 76085 76126 76126 76167 76208 76247 76288 76330 76085 76126 76127 76168 76209 76249 76290 76331 76085 76126 76127 76168 76209 76250 76241 76292 76333 76086 76127 76168 76169 76210 76251 76292 76333 76088 76129 76170 76211 76252 76293 76330 76089 76130 76111 76212 76253 76294 76335 76090 76131 76127 76187 76212 76253 76294 76335 76090 76131 76127 76128 76170 76211 76252 76293 76334 76090 76131 76122 76173 76214 76255 76296 76337 76091 76132 76174 76215 76215 76256 76297 76338 76091 76132 76173 76214 76255 76296 76337 76094 76135 76176 76175 76216 76257 76299 76300 76311 76175 76176 76217 76228 76297 76338 76094 76135 76176 76177 76218 76259 76300 76311 76175 76176 76217 76258 76299 76300 76311 76095 76136 76177 76218 76259 76300 76311 76324 76097 76138 76175 76176 76217 76258 76299 76300 76311 76324 76097 76138 76177 76218 76259 76300 76311 76324 76099 76130 76131 76175 76176 76217 76258 76299 76300 76311 76324 76099 76130 76131 76175 76176 76217 76258 76299 76300 76311 76342 76097 76138 76179 76220 76261 76302 76337 76099 76140 76181 76182 76222 76263 76304 76304 76345 76099 76140 76181 76222 76266 76307 76344 76190 76241 76262 76266 76307 76344 76190 76241 76262 76266 76307 76344 76190 76241 76262 76266 76307 76344 76190 76241 76262 76266 76307 76344 76190 76241 76262 76266 76307 76344 76190 76241 76262 76266 76307 76344 76190 76241 76262 76266 76307 76344 76190 76241 76262 76266 76307 76344 76190 76241 76262 76266 76307 76344 76190 76141 76182 76222 76266 76307 76344 76190 76141 76182 76188 76229 76266 76307 76344 76190 76141 76188 76229 76266 76307 76311 76332 76100 76144 76145 76188 76229 76260 76261 76309 76311 76332 76100 76144 76148 76189 76229 76270 76311 76312 76335 76100 76144 76148													
76079 76120 76161 76202 76243 76284 76325 76080 76121 76162 76203 76244 76285 76325 76081 76122 76163 76204 76245 76286 76327 76082 76123 76164 76205 76246 76287 76328 76083 76124 76165 76206 76247 76288 76328 76084 76125 76166 76207 76248 76289 76330 76085 76126 76167 76208 76249 76289 76330 76086 76127 76168 76209 76250 76291 76333 76087 76128 76129 76170 76211 76250 76291 76333 76087 76128 76129 76170 76211 76250 76291 76333 76087 76128 76170 76211 76253 76293 76334 <													
76080 76121 76162 76203 76244 76285 76326 76081 76122 76163 76204 76245 76286 76327 76082 76123 76164 76205 76246 76287 76328 76083 76124 76165 76206 76247 76288 76329 76084 76125 76166 76207 76248 76289 76333 76085 76126 76167 76208 76249 76290 76331 76086 76127 76168 76209 76250 76291 76331 76087 76128 76169 76210 76251 76292 76333 76088 76129 76170 76211 76252 76293 76334 76099 76130 76172 76213 76254 76295 76336 76090 76131 76172 76213 76254 76295 76336 76091 76133 <													
76081 76122 76163 76204 76245 76286 76327 76082 76123 76164 76205 76246 76287 76388 76083 76124 76155 76206 76247 76288 76329 76084 76125 76166 76207 76248 76289 76330 76085 76126 76167 76208 76249 76290 76331 76086 76127 76168 76209 76250 76291 76332 76087 76128 76169 76210 76251 76292 76333 76088 76129 76170 76211 76252 76293 76334 76089 76130 76171 76212 76253 76294 76325 76091 76132 76173 76214 76255 76295 76337 76091 76133 76174 76215 76256 76297 76338 76092 76133 <													
76082 76123 76164 76205 76246 76287 76388 76329 76083 76124 76165 76206 76247 76288 76329 76084 76125 76166 76207 76248 76289 76330 76085 76126 76167 76208 76249 76290 76331 76086 76127 76168 76209 76250 76291 76393 76087 76128 76169 76210 76251 76292 76333 76088 76129 76130 76171 76211 76252 76293 76333 76089 76130 76171 76212 76253 76294 76393 76090 76131 76172 76213 76254 76295 76336 76091 76132 76133 76174 76215 76256 76297 76338 76092 76133 76174 76215 76256 76297 76338 76093 76134 76175 76216 76257 76298 76339 76094 76135 76176 76217 76218 76259 76300 76341 76095 76136 76177 76218 76259 76300 76341 76096 76137 76138 76179 76220 76261 76302 76341 76099 76138 76199 76220 76261 76302 76341 76099 76139 76130 76180 76221 76222 76263 76300 76341 76099 76130 76180 76217 76220 76261 76302 76342 76099 76130 76131 76180 76221 76220 76261 76302 76342 76099 76130 76180 76181 76222 76263 76304 76342 76099 76140 76181 76222 76263 76304 76345 76100 76141 76142 76183 76224 76266 76307 76346 76101 76142 76183 76224 76266 76307 76346 76100 76141 76142 76183 76224 76266 76307 76346 76101 76142 76183 76224 76263 76304 76346 76100 76141 76142 76183 76224 76266 76307 76346 76101 76144 76185 76226 76266 76307 76346 76102 76143 76184 76225 76266 76307 76348 76104 76145 76186 76227 76268 76309 76311 76352 76106 76147 76188 76229 76260 76311 76312 76335 76107 76148 76189 76230 76271 76312 76312 76335													
76083 76124 76165 76206 76247 76288 76329 76084 76125 76166 76207 76248 76289 76330 76085 76126 76167 76208 76249 76290 76331 76086 76127 76168 76209 76250 76291 76332 76087 76128 76169 76210 76251 76292 76332 76088 76129 76170 76211 76252 76293 76334 76089 76130 76171 76212 76253 76294 76335 76091 76132 76173 76214 76255 76296 76337 76091 76132 76173 76214 76255 76296 76337 76092 76133 76174 76215 76256 76297 76338 76093 76134 76175 76216 76257 76298 76339 76094 76135 <													
76084 76125 76166 76207 76248 76289 76330 76085 76126 76167 76208 76249 76290 76331 76086 76127 76168 76209 76250 76291 76332 76087 76128 76169 76210 76251 76292 76333 76088 76129 76170 76211 76252 76293 76334 76089 76130 76171 76212 76253 76294 76335 76090 76131 76172 76213 76254 76295 76336 76091 76132 76173 76214 76255 76296 76337 76092 76133 76174 76215 76256 76297 76338 76093 76134 76175 76216 76257 76298 76339 76094 76135 76176 77217 76218 76259 76300 76343 76095 <													
76085 76126 76167 76208 76249 76290 76331 76086 76127 76168 76209 76250 76291 76332 76087 76128 76169 76210 76251 76292 76333 76088 76129 76170 76211 76252 76293 76334 76089 76130 76171 76212 76253 76294 76335 76090 76131 76172 76213 76254 76295 76336 76091 76132 76173 76214 76255 76296 76337 76092 76133 76174 76215 76256 76297 76338 76093 76134 76175 76216 76257 76298 76339 76094 76135 76176 76217 76218 76259 76300 76341 76095 76136 76177 76218 76259 76300 76342 76097 <													
76086 76127 76168 76209 76250 76291 76332 76087 76128 76169 76210 76251 76292 76333 76088 76129 76170 76211 76252 76293 76333 76089 76130 76171 76212 76253 76294 76335 76090 76131 76172 76213 76254 76295 76336 76091 76132 76173 76214 76255 76296 76337 76092 76133 76174 76215 76256 76297 76338 76093 76134 76175 76216 76257 76298 76339 76094 76135 76176 76217 76218 76259 76300 76341 76095 76136 76177 76218 76259 76300 76341 76097 76138 76179 76219 76260 76301 76342 76097 <													
76087 76128 76169 76210 76251 76292 76333 76088 76129 76170 76211 76252 76293 76334 76089 76130 76171 76212 76253 76294 76335 76090 76131 76172 76213 76254 76295 76336 76091 76132 76173 76214 76255 76296 76337 76092 76133 76174 76215 76256 76297 76338 76093 76134 76175 76216 76257 76298 76339 76094 76135 76176 76217 76218 76299 76340 76095 76136 76177 76218 76259 76300 76341 76096 76137 76178 76219 76260 76301 76342 76097 76138 76179 76220 76261 76302 76343 76098 76140 <		76086			76168				76250		76291		76332
76088 76129 76170 76211 76252 76293 76334 76089 76130 76171 76212 76253 76294 76335 76090 76131 76172 76213 76254 76295 76336 76091 76132 76173 76214 76255 76296 76337 76092 76133 76174 76215 76256 76297 76338 76093 76134 76175 76216 76257 76298 76339 76094 76135 76176 76217 76258 76299 76340 76095 76136 76177 76218 76259 76300 76341 76096 76137 76178 76219 76260 76301 76342 76098 76139 76180 76220 76261 76302 76343 76099 76140 76181 76222 76263 76303 76344 76100 76141 <													76333
76089 76130 76171 76212 76253 76294 76335 76090 76131 76172 76213 76254 76295 76336 76091 76132 76173 76214 76255 76296 76337 76092 76133 76174 76215 76256 76297 76338 76093 76134 76175 76216 76257 76298 76339 76094 76135 76176 76217 76258 76299 76340 76095 76136 76177 76218 76259 76300 76341 76096 76137 76178 76219 76260 76301 76342 76097 76138 76179 76220 76261 76302 76343 76098 76139 76180 76221 76262 76303 76344 76099 76140 76181 76222 76263 76304 76345 76100 76141 <													76334
76090 76131 76172 76213 76254 76295 76336 76091 76132 76173 76214 76255 76296 76337 76092 76133 76174 76215 76256 76297 76338 76093 76134 76175 76216 76257 76298 76338 76094 76135 76176 76217 76258 76299 76300 76095 76136 76177 76218 76259 76300 76341 76096 76137 76178 76219 76260 76301 76342 76097 76138 76179 76220 76261 76302 76343 76098 76139 76180 76221 76262 76303 76344 76100 76141 76182 76222 76263 76304 76345 76100 76141 76182 76223 76264 76305 76346 76102 76143 <		76089											76335
76091 76132 76173 76214 76255 76296 76337 76092 76133 76174 76215 76256 76297 76338 76093 76134 76175 76216 76257 76298 76338 76094 76135 76176 76217 76258 76299 76340 76095 76136 76177 76218 76259 76300 76341 76096 76137 76178 76219 76260 76301 76342 76097 76138 76179 76220 76261 76302 76343 76098 76139 76180 76221 76262 76303 76344 76099 76140 76181 76222 76263 76304 76345 76100 76141 76182 76223 76264 76305 76346 76101 76142 76183 76224 76265 76306 76347 76102 76143 <		76090											76336
76093 76134 76175 76216 76257 76298 76339 76094 76135 76176 76217 76258 76299 76340 76095 76136 76177 76218 76259 76300 76341 76096 76137 76178 76219 76260 76301 76342 76097 76138 76179 76220 76261 76302 76343 76098 76139 76180 76221 76262 76303 76344 76099 76140 76181 76222 76263 76304 76345 76100 76141 76182 76223 76264 76305 76346 76101 76142 76183 76224 76265 76306 76347 76102 76143 76184 76225 76266 76307 76348 76103 76144 76185 76226 76267 76308 76349 76104 76145 <		76091	76132		76173		76214		76255		76296		76337
76094 76135 76176 76217 76258 76299 76340 76095 76136 76177 76218 76259 76300 76341 76096 76137 76178 76219 76260 76301 76342 76097 76138 76179 76220 76261 76302 76343 76098 76139 76180 76221 76262 76303 76344 76099 76140 76181 76222 76263 76304 76345 76100 76141 76182 76223 76264 76305 76346 76101 76142 76183 76224 76265 76306 76347 76102 76143 76184 76225 76266 76307 76348 76103 76144 76185 76226 76267 76308 76349 76104 76145 76186 76227 76268 76310 76311 76352 76106 <		76092	76133		76174		76215		76256		76297		76338
76095 76136 76177 76218 76259 76300 76341 76096 76137 76178 76219 76260 76301 76342 76097 76138 76179 76220 76261 76302 76343 76098 76139 76180 76221 76262 76303 76344 76099 76140 76181 76222 76263 76304 76345 76100 76141 76182 76223 76264 76305 76346 76101 76142 76183 76224 76265 76306 76347 76102 76143 76184 76225 76266 76307 76348 76103 76144 76185 76226 76267 76308 76349 76104 76145 76186 76227 76268 76300 76310 76351 76105 76146 76187 76228 76270 76311 76352 76107 <		76093	76134		76175		76216		76257		76298		76339
76096 76137 76178 76219 76260 76301 76342 76097 76138 76179 76220 76261 76302 76343 76098 76139 76180 76221 76262 76303 76344 76099 76140 76181 76222 76263 76304 76345 76100 76141 76182 76223 76264 76305 76346 76101 76142 76183 76224 76265 76306 76347 76102 76143 76184 76225 76266 76307 76348 76103 76144 76185 76226 76267 76308 76349 76104 76145 76186 76227 76268 76309 76350 76105 76146 76187 76228 76269 76310 76351 76107 76148 76189 76230 76271 76312 76352 76108 76149 <		76094	76135		76176		76217		76258		76299		76340
76097 76138 76179 76220 76261 76302 76343 76098 76139 76180 76221 76262 76303 76344 76099 76140 76181 76222 76263 76304 76345 76100 76141 76182 76223 76264 76305 76346 76101 76142 76183 76224 76265 76306 76347 76102 76143 76184 76225 76266 76307 76348 76103 76144 76185 76226 76267 76308 76349 76104 76145 76186 76227 76268 76309 76350 76105 76146 76187 76228 76269 76310 76351 76107 76148 76189 76230 76271 76311 76352 76108 76149 76190 76231 76272 76313 76354		76095	76136		76177		76218		76259		76300		76341
76098 76139 76180 76221 76262 76303 76344 76099 76140 76181 76222 76263 76304 76345 76100 76141 76182 76223 76264 76305 76346 76101 76142 76183 76224 76265 76306 76347 76102 76143 76184 76225 76266 76307 76348 76103 76144 76185 76226 76267 76308 76349 76104 76145 76186 76227 76268 76309 76310 76105 76146 76187 76228 76269 76310 76351 76106 76147 76188 76229 76270 76311 76352 76108 76149 76190 76231 76272 76312 76353		76096	76137		76178		76219		76260		76301		76342
76099 76140 76181 76222 76263 76304 76345 76100 76141 76182 76223 76264 76305 76346 76101 76142 76183 76224 76265 76306 76347 76102 76143 76184 76225 76266 76307 76348 76103 76144 76185 76226 76267 76308 76349 76104 76145 76186 76227 76268 76309 76350 76105 76146 76187 76228 76269 76310 76351 76107 76148 76189 76230 76271 76312 76352 76108 76149 76190 76231 76272 76313 76354		76097	76138		76179		76220		76261		76302		76343
76100 76141 76182 76223 76264 76305 76346 76101 76142 76183 76224 76265 76306 76347 76102 76143 76184 76225 76266 76307 76348 76103 76144 76185 76226 76267 76308 76388 76104 76145 76186 76227 76268 76309 76350 76105 76146 76187 76228 76269 76310 76351 76106 76147 76188 76229 76270 76311 76352 76107 76148 76189 76230 76271 76312 76354 76108 76149 76190 76231 76272 76313 76354			76139										76344
76101 76142 76183 76224 76265 76306 76347 76102 76143 76184 76225 76266 76307 76348 76103 76144 76185 76226 76267 76308 76349 76104 76145 76186 76227 76268 76309 76350 76105 76146 76187 76228 76269 76310 76351 76106 76147 76188 76229 76270 76311 76352 76107 76148 76189 76230 76271 76312 76354 76108 76149 76190 76231 76272 76313 76354		76099	76140		76181		76222		76263		76304		76345
76102 76143 76184 76225 76266 76307 76348 76103 76144 76185 76226 76267 76308 76349 76104 76145 76186 76227 76268 76309 76350 76105 76146 76187 76228 76269 76310 76351 76106 76147 76188 76229 76270 76311 76352 76107 76148 76189 76230 76271 76312 76353 76108 76149 76190 76231 76272 76313 76354		76100	76141										76346
76103 76144 76185 76226 76267 76308 76349 76104 76145 76186 76227 76268 76309 76350 76105 76146 76187 76228 76269 76310 76351 76106 76147 76188 76229 76270 76311 76352 76107 76148 76189 76230 76271 76312 76354 76108 76149 76190 76231 76272 76313 76354		76101	76142		76183		76224		76265		76306		76347
76104 76145 76186 76227 76268 76309 76350 76105 76146 76187 76228 76269 76310 76351 76106 76147 76188 76229 76270 76311 76352 76107 76148 76189 76230 76271 76312 76354 76108 76149 76190 76231 76272 76313 76354		76102	76143		76184		76225		76266		76307		76348
76105 76146 76187 76228 76269 76310 76351 76106 76147 76188 76229 76270 76311 76352 76107 76148 76189 76230 76271 76312 76353 76108 76149 76190 76231 76272 76313 76354													76349
76106 76147 76188 76229 76270 76311 76352 76107 76148 76189 76230 76271 76312 76353 76108 76149 76190 76231 76272 76313 76354													
76107 76148 76189 76230 76271 76312 76353 76108 76149 76190 76231 76272 76313 76354													76351
76108 76149 76190 76231 76272 76313 76354													
													76353
76109 76150 76191 76232 76273 76314 76355													
		76109	76150		76191				76273		76314		76355
													76356
													76357
													76358
76113 76154 76195 76236 76277 76318 76359		76113	76154		76195		76236		76277		76318		76359

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl. nb	Trt. Bl. No nb	Trt. No		Trt.	Bl. nb	Trt.	Bl. nb	Trt.	Bl. nb	Trt.	Bl. nb
NO		NO IID	NO		NO				NO		NO	
			222			_			PPD		-	
PPD	, 0000	PPD 76401		76442	PPD	76483	PPD	76524	110	76565	PPD	76606
	76361	76402		76443		76484		76525		76566		76607
	76362	76403		76444		76485		76526		76567		76608
	76363	76404		76445		76486		76527		76568		76609
	76364	76405		76446		76487		76528		76569		76610
	76365	76406		76447		76488		76529		76570		76611
	76366	76407		76448		76489		76530		76571		76612
	76367	76408		76449		76490		76531		76572		76613
	76368	76409		76450		76491		76532		76573		76614
	76369	76410		76451		76492		76533		76574		76615
	76370	76411		76452		76493		76534		76575		76616
	76371	76412		76453		76494		76535		76576		76617
	76372	76413		76454		76495		76536		76577		76618
	76373	76414		76455		76496		76537		76578		76619
	76374	76415		76456		76497		76538		76579		76620
	76375	76416		76457		76498		76539		76580		76621
	76376	76417		76458		76499		76540		76581		76622
	76377	76418		76459		76500		76541		76582		76623
	76378	76419		76460		76501		76542		76583		76624
	76379	76420		76461		76502		76543		76584		76625
	76380	76421		76462		76503		76544		76585		76626
	76381	76422		76463		76504		76545		76586		76627
	76382	76423		76464		76505		76546		76587		76628
	76383	76424		76465		76506		76547		76588		76629
	76384	76425		76466		76507		76548		76589		76630
	76385	76426		76467		76508		76549		76590		76631
	76386	76427		76468		76509		76550		76591		76632
	76387	76428		76469		76510		76551		76592		76633
	76388	76429		76470		76511		76552		76593		76634
	76389	76430		76471		76512		76553		76594		76635
	76390	76431		76472		76513		76554		76595		76636
	76391	76432		76473		76514		76555		76596		76637
	76392	76433		76474		76515		76556		76597		76638
	76393	76434		76475		76516		76557		76598		76639
	76394	76435		76476		76517		76558		76599		76640
	76395	76436		76477		76518		76559		76600		76641
	76396	76437		76478		76519		76560		76601		76642
	76397	76438		76479		76520		76561		76602		76643
	76398	76439		76480		76521		76562		76603		76644
	76399	76440		76481		76522		76563		76604		76645
	76400	76441		76482		76523		76564		76605		76646

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl. nb	Trt. Bl. No nb					
NO		NO 110	NO IID	NO IID	NO ND	NO IID	NO 11D
						PPD	
PPD	76647	PPD 76688	PPD 76729	PPD 76770	PPD 76811	76852	PPD 76893
	76648	76689	76730	76771	76812	76853	76894
	76649	76690	76731	76772	76813	76854	76895
	76650	76691	76732	76773	76814	76855	76896
	76651	76692	76733	76774	76815	76856	76897
	76652	76693	76734	76775	76816	76857	76898
	76653	76694	76735	76776	76817	76858	76899
	76654	76695	76736	76777	76818	76859	76900
	76655	76696	76737	76778	76819	76860	76901
	76656	76697	76738	76779	76820	76861	76902
	76657	76698	76739	76780	76821	76862	76903
	76658	76699	76740	76781	76822	76863	76904
	76659	76700	76741	76782	76823	76864	76905
	76660	76701	76742	76783	76824	76865	76906
	76661	76702	76743	76784	76825	76866	76907
	76662	76703	76744	76785	76826	76867	76908
	76663	76704	76745	76786	76827	76868	76909
	76664	76705	76746	76787	76828	76869	76910
	76665	76706	76747	76788	76829	76870	76911
	76666	76707	76748	76789	76830	76871	76912
	76667	76708	76749	76790	76831	76872	76913
	76668	76709	76750	76791	76832	76873	76914
	76669	76710	76751	76792	76833	76874	76915
	76670	76711	76752	76793	76834	76875	76916
	76671	76712	76753	76794	76835	76876	76917
	76672	76713	76754	76795	76836	76877	76918
	76673	76714	76755	76796	76837	76878	76919
	76674	76715	76756	76797	76838	76879	76920
	76675	76716	76757	76798	76839	76880	76921
	76676	76717	76758	76799	76840	76881	76922
	76677	76718	76759	76800	76841	76882	76923
	76678	76719	76760	76801	76842	76883	76924
	76679	76720	76761	76802	76843	76884	76925
	76680	76721	76762	76803	76844	76885	76926
	76681	76722	76763	76804	76845	76886	76927
	76682	76723	76764	76805	76846	76887	76928
	76683	76724	76765	76806	76847	76888	76929
	76684	76725	76766	76807	76848	76889	76930
	76685	76726	76767	76808	76849	76890	76931
	76686	76727	76768	76809	76850	76891	76932
	76687	76728	76769	76810	76851	76892	76933

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
				NO 11D	NO 11D	
PPD 76934	PPD 76975	PPD 77016	PPD 77057	PPD 77098	PPD 77139	PPD 77180
76935	76976	77017	77058	77099	77140	77181
76936	76977	77018	77059	77100	77141	77182
76937	76978	77019	77060	77101	77142	77183
76938	76979	77020	77061	77102	77143	77184
76939	76980	77021	77062	77103	77144	77184
76940 76941 76942 76943 76944 76945 76946	76981 76982 76983 76984 76985 76986	77022 77022 77023 77024 77025 77026 77027	77063 77064 77065 77066 77067 77068	77104 77105 77106 77107 77108 77109 77110	77145 77146 77147 77148 77149 77150	77186 77187 77188 77189 77190 77191
76947 76948 76949 76950 76951 76952 76953	76988 76989 76990 76991 76992 76993 76994	77029 77030 77031 77032 77033 77034 77035	77070 77071 77072 77073 77074 77075	77111 77112 77113 77114 77115 77116 77117	77152 77153 77154 77155 77156 77157 77158	77193 77194 77195 77196 77197 77198
76954	76995	77036	77077	77118	77159	77200
76955	76996	77037	77078	77119	77160	77201
76956	76997	77038	77079	77120	77161	77202
76957	76998	77039	77080	77121	77162	77203
76958	76999	77040	77081	77122	77163	77204
76959	77000	77041	77082	77123	77164	77205
76960	77001	77042	77083	77124	77165	77206
76961	77002	77043	77084	77125	77166	77207
76962	77003	77044	77085	77126	77167	77208
76963	77004	77045	77086	77127	77168	77209
76964	77005	77046	77087	77128	77169	77210
76965	77006	77047	77088	77129	77170	77211
76966	77007	77048	77089	77130	77171	77212
76967 76968 76969 76970 76971 76972 76973	77008 77009 77010 77011 77012 77013 77014 77015	77049 77050 77051 77052 77053 77054 77055 77056	77090 77091 77092 77093 77094 77095 77096 77097	77131 77132 77133 77134 77135 77136 77137 77138	77172 77173 77174 77175 77176 77177 77178 77179	77213 77214 77215 77216 77217 77218 77219 77220

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl. nb	Trt. Bl No nb		Trt. No		Trt. No		Trt.	Bl. nb	Trt.	Bl. nb	Trt.	Bl. nb
PPD	77221					PPD		PPD	77385	PPD	77426	PPD	77467
	77222	77:	263		77304		77345		77386		77427		77468
	77223	77:	264		77305		77346		77387		77428		77469
	77224		265		77306		77347		77388		77429		77470
	77225	77:	266		77307		77348		77389		77430		77471
	77226	77:	267		77308		77349		77390		77431		77472
	77227	77:	268		77309		77350		77391		77432		77473
	77228	77:	269		77310		77351		77392		77433		77474
	77229	77:	270		77311		77352		77393		77434		77475
	77230	77:	271		77312		77353		77394		77435		77476
	77231		272		77313		77354		77395		77436		77477
	77232	77:	273		77314		77355		77396		77437		77478
	77233		274		77315		77356		77397		77438		77479
	77234		275		77316		77357		77398		77439		77480
	77235	77:	276		77317		77358		77399		77440		77481
	77236		277		77318		77359		77400		77441		77482
	77237		278		77319		77360		77401		77442		77483
	77238		279		77320		77361		77402		77443		77484
	77239		280		77321		77362		77403		77444		77485
	77240		281		77322		77363		77404		77445		77486
	77241		282		77323		77364		77405		77446		77487
	77242		283		77324		77365		77406		77447		77488
	77243		284		77325		77366		77407		77448		77489
	77244		285		77326		77367		77408		77449		77490
	77245		286		77327		77368		77409		77450		77491
	77246		287		77328		77369		77410		77451		77492
	77247		288		77329		77370		77411		77452		77493
	77248		289		77330		77371		77412		77453		77494
	77249		290		77331		77372		77413		77454		77495
	77250		291		77332		77373		77414		77455		77496
	77251		292		77333		77374		77415		77456		77497
	77252		293		77334		77375		77416		77457		77498
	77253		294		77335		77376		77417		77458		77499
	77254		295		77336		77377		77418		77459		77500
	77255		296		77337		77378		77419		77460		77501
	77256		297		77338		77379		77420		77461		77502
	77257		298		77339		77380		77421		77462		77503
	77258		299		77340		77381		77422		77463		77504
	77259		300		77341		77382		77423		77464		77505
	77260		301		77342		77383		77424		77465		77506
	77261	77:	302		77343		77384		77425		77466		77507

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt.		Trt.		Trt.		Trt.		Trt.		Trt.	
No	nb	No	nb	No			nb		nb		nb	No	nb
PPD	77508	PPD	77549	PPD	77590	PPD	77631	PPD	77672	PPD	77713	PPD	77754
PPD		FFD	77550	יוו	77591	FFU	77632	PPD	77673		77714	110	77755
	77509						77632						
	77510		77551		77592				77674		77715	1	77756
	77511		77552		77593		77634		77675		77716		77757
	77512		77553		77594		77635		77676		77717	1	77758
	77513		77554		77595		77636		77677		77718	1	77759
	77514		77555		77596		77637		77678		77719	1	77760
	77515		77556		77597		77638		77679		77720	1	77761
	77516		77557		77598		77639		77680		77721	1	77762
	77517		77558		77599		77640		77681		77722	1	77763
	77518		77559		77600		77641		77682		77723	1	77764
	77519		77560		77601		77642		77683		77724	1	77765
	77520		77561		77602		77643		77684		77725	1	77766
	77521		77562		77603		77644		77685		77726	1	77767
	77522		77563		77604		77645		77686		77727	1	77768
	77523		77564		77605		77646		77687		77728		77769
	77524		77565		77606		77647		77688		77729	1	77770
	77525		77566		77607		77648		77689		77730	1	77771
	77526		77567		77608		77649		77690		77731	1	77772
	77527		77568		77609		77650		77691		77732	1	77773
	77528		77569		77610		77651		77692		77733	1	77774
	77529		77570		77611		77652		77693		77734	1	77775
	77530		77571		77612		77653		77694		77735	1	77776
	77531		77572		77613		77654		77695		77736	1	77777
	77532		77573		77614		77655		77696		77737	1	77778
	77533		77574		77615		77656		77697		77738	1	77779
	77534		77575		77616		77657		77698		77739	1	77780
	77535		77576		77617		77658		77699		77740	1	77781
	77536		77577		77618		77659		77700		77741	1	77782
	77537		77578		77619		77660		77701		77742		77783
	77538		77579		77620		77661		77702		77743		77784
	77539		77580		77621		77662		77703		77744	1	77785
	77540		77581		77622		77663		77704		77745	1	77786
	77541		77582		77623		77664		77705		77746	1	77787
	77542		77583		77624		77665		77706		77747	1	77788
	77543		77584		77625		77666		77707		77748	1	77789
	77544		77585		77626		77667		77708		77749		77790
	77545		77586		77627		77668		77709		77750		77791
	77546		77587		77628		77669		77710		77751		77792
	77547		77588		77628		77670		77711		77752		77793
	77548		77589		77629		77671		77712		77753		77794
	11348		11389		11030		//0/1		11112		11153		11194

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
No nb	No nb	No nb	No nb	No nb	No nb	PPD 78041 78042 78043 78044 78045 78046 78047 78048 78050 78051 78052 78053 78054 78055 78056 78057 78058 78059 78060 78061 78062 78063 78064 78065 78066 78067 78068 78069 78070 78071 78072 78073

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
No nb	No nb	No nb	No nb	No nb	PPD 78287 78288 78289 78290 78291 78292 78293 78294 78295 78296 78297 78298 78299 78300 78301 78302 78303	PPD 78328 78329 78330 78331 78332 78333 78334 78335 78336 78337 78338 78339 78340 78341 78342 78343
78099 78100 78101 78102 78103 78104 78105 78106 78107 78108 78109 78110 78111 78112 78113 78114 78115 78116 78117 78118 78119 78120 78121 78122	78140 78141 78142 78143 78144 78145 78146 78147 78148 78149 78150 78151 78152 78153 78154 78155 78156 78157 78158 78159 78160 78161 78162 78163	78181 78182 78183 78184 78185 78186 78187 78188 78189 78190 78191 78192 78193 78194 78195 78196 78197 78198 78199 78200 78201 78202 78203 78204	78222 78223 78224 78224 78225 78226 78226 78227 78228 78229 78230 78231 78232 78233 78234 78235 78236 78237 78238 78239 78240 78241 78242 78243 78244 78245	78263 78264 78265 78266 78267 78268 78269 78270 78271 78272 78273 78274 78275 78276 78277 78278 78278 78278 78278 78280 78281 78282 78283 78284 78285 78286	78304 78305 78306 78307 78308 78309 78310 78311 78312 78313 78314 78315 78316 78317 78318 78319 78320 78321 78322 78323 78324 78325 78326 78327	78345 78346 78347 78348 78349 78350 78351 78352 78353 78354 78355 78356 78357 78358 78359 78360 78361 78362 78363 78364 78365 78366 78367 78368

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	B1.	Trt.	B1.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
				PPD		DDD				PPD			
PPD		PPD	78410	PPD		PPD	78492	PPD	78533		78574	PPD	78615
	78370		78411		78452		78493		78534		78575		78616
	78371		78412		78453		78494		78535		78576		78617
	78372		78413		78454		78495		78536		78577		78618
	78373		78414		78455		78496		78537		78578		78619
	78374		78415		78456		78497		78538		78579		78620
	78375		78416		78457		78498		78539		78580		78621
	78376		78417		78458		78499		78540		78581		78622
	78377		78418		78459		78500		78541		78582		78623
	78378		78419		78460		78501		78542		78583		78624
	78379		78420		78461		78502		78543		78584		78625
	78380		78421		78462		78503		78544		78585		78626
	78381		78422		78463		78504		78545		78586		78627
	78382		78423		78464		78505		78546		78587		78628
	78383		78424		78465		78506		78547		78588		78629
	78384		78425		78466		78507		78548		78589		78630
	78385		78426		78467		78508		78549		78590		78631
	78386		78427		78468		78509		78550		78591		78632
	78387		78428		78469		78510		78551		78592		78633
	78388		78429		78470		78511		78552		78593		78634
	78389		78430		78471		78512		78553		78594		78635
	78390		78431		78472		78513		78554		78595		78636
	78391		78432		78473		78514		78555		78596		78637
	78392		78433		78474		78515		78556		78597		78638
	78393		78434		78475		78516		78557		78598		78639
	78394		78435		78476		78517		78558		78599		78640
	78395		78436		78477		78518		78559		78600		78641
	78396		78437		78478		78519		78560		78601		78642
	78397		78438		78479		78520		78561		78602		78643
	78398		78439		78480		78521		78562		78603		78644
	78399		78440		78481		78522		78563		78604		78645
	78400		78441		78482		78523		78564		78605		78646
	78401		78442		78483		78524		78565		78606		78647
	78402		78443		78484		78525		78566		78607		78648
	78403		78444		78485		78526		78567		78608		78649
	78404		78445		78486		78527		78568		78609		78650
	78405		78446		78487		78528		78569		78610		78651
	78406		78447		78488		78529		78570		78611		78652
	78407		78448		78489		78530		78571		78612		78653
	78408		78449		78490		78531		78572		78613		78654
	78409		78450		78491		78532		78573		78614		78655
	,0405		,0450		,0101		,0332		,0010		,0014		,0000
					ı								

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt.		Trt.		Trt.		Trt.		Trt.		Trt.	
No	nb	No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	78656	PPD	78697	PPD	78738	PPD	78779	PPD	78820	PPD	78861	PPD	78902
FFD	78657	110	78698		78739	110	78780	FFD	78821		78862	110	78903
	78658		78699		78740		78781		78822		78863		78904
	78659		78700		78741		78782		78823		78864		78905
	78660		78701		78742		78783		78824		78865		78906
	78661		78702		78743		78784		78825		78866		78907
	78662		78703		78744		78785		78826		78867		78908
	78663		78704		78745		78786		78827		78868		78909
	78664		78705		78746		78787		78828		78869		78910
	78665		78706		78747		78788		78829		78870		78911
	78666		78707		78748		78789		78830		78871		78912
	78667		78708		78749		78790		78831		78872		78913
	78668		78709		78750		78791		78832		78873		78914
	78669		78710		78751		78792		78833		78874		78915
	78670		78711		78752		78793		78834		78875		78916
	78671		78712		78753		78794		78835		78876		78917
	78672		78713		78754		78795		78836		78877		78918
	78673		78714		78755		78796		78837		78878		78919
	78674		78715		78756		78797		78838		78879		78920
	78675		78716		78757		78798		78839		78880		78921
	78676		78717		78758		78799		78840		78881		78922
	78677		78718		78759		78800		78841		78882		78923
	78678		78719		78760		78801		78842		78883		78924
	78679		78720		78761		78802		78843		78884		78925
	78680		78721		78762		78803		78844		78885		78926
	78681		78722		78763		78804		78845		78886		78927
	78682		78723		78764		78805		78846		78887		78928
	78683		78724		78765		78806		78847		78888		78929
	78684		78725		78766		78807		78848		78889		78930
	78685		78726		78767		78808		78849		78890		78931
	78686		78727		78768		78809		78850		78891		78932
	78687		78728		78769		78810		78851		78892		78933
	78688		78729		78770		78811		78852		78893		78934
	78689		78730		78771		78812		78853		78894		78935
	78690		78731		78772		78813		78854		78895		78936
	78691		78732		78773		78814		78855		78896		78937
	78692		78733		78774		78815		78856		78897		78938
	78693		78734		78775		78816		78857		78898		78939
	78694		78735		78776		78817		78858		78899		78940
	78695		78736		78777		78818		78859		78900		78941
	78696		78737		78778		78819		78860		78901		78942

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.					
NO.	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	78943	PPD 78984	PPD 79025	PPD 79066	PPD 79107	PPD 79148	PPD 79189
	78944	78985	79026	79067	79108	79149	79190
	78945	78986	79027	79068	79109	79150	79191
	78946	78987	79028	79069	79110	79151	79192
	78947	78988	79029	79070	79111	79152	79193
	78948	78989	79030	79071	79112	79153	79194
	78949	78990	79031	79072	79113	79154	79195
	78950	78991	79032	79073	79114	79155	79196
	78951	78992	79033	79074	79115	79156	79197
	78952	78993	79034	79075	79116	79157	79198
	78953	78994	79035	79076	79117	79158	79199
	78954	78995	79036	79077	79118	79159	79200
	78955	78996	79037	79078	79119	79160	79201
	78956	78997	79038	79079	79120	79161	79202
	78957	78998	79039	79080	79121	79162	79203
	78958	78999	79040	79081	79122	79163	79204
	78959	79000	79041	79082	79123	79164	79205
	78960	79001	79042	79083	79124	79165	79206
	78961	79002	79043	79084	79125	79166	79207
	78962	79003	79044	79085	79126	79167	79208
	78963	79004	79045	79086	79127	79168	79209
	78964	79005	79046	79087	79128	79169	79210
	78965	79006	79047	79088	79129	79170	79211
	78966	79007	79048	79089	79130	79171	79212
	78967	79008	79049	79090	79131	79172	79213
	78968	79009	79050	79091	79132	79173	79214
	78969	79010	79051	79092	79133	79174	79215
	78970	79011	79052	79093	79134	79175	79216
	78971	79012	79053	79094	79135	79176	79217
	78972	79013	79054	79095	79136	79177	79218
	78973	79014	79055	79096	79137	79178	79219
	78974	79015	79056	79097	79138	79179	79220
	78975	79016	79057	79098	79139	79180	79221
	78976	79017	79058	79099	79140	79181	79222
	78977	79018	79059	79100	79141	79182	79223
	78978	79019	79060	79101	79142	79183	79224
	78979	79020	79061	79102	79143	79184	79225
	78980	79021	79062	79103	79144	79185	79226
	78981	79022	79063	79104	79145	79186	79227
	78982	79023	79064	79105	79146	79187	79228
	78983	79024	79065	79106	79147	79188	79229

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. E		Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No r	np 	No nb	No nb	No nb	No nb	No nb	No nb
						PPD	
PPD	79230	PPD 79271	PPD 79312	PPD 79353	PPD 79394	79435	PPD 79476
	79231	79272	79313	79354	79395	79436	79477
	79232	79273	79314	79355	79396	79437	79478
	79233	79274	79315	79356	79397	79438	79479
	79234	79275	79316	79357	79398	79439	79480
7	79235	79276	79317	79358	79399	79440	79481
7	79236	79277	79318	79359	79400	79441	79482
7	79237	79278	79319	79360	79401	79442	79483
	79238	79279	79320	79361	79402	79443	79484
7	79239	79280	79321	79362	79403	79444	79485
	79240	79281	79322	79363	79404	79445	79486
	79241	79282	79323	79364	79405	79446	79487
	79242	79283	79324	79365	79406	79447	79488
	79243	79284	79325	79366	79407	79448	79489
	79244	79285	79326	79367	79408	79449	79490
7	79245	79286	79327	79368	79409	79450	79491
7	79246	79287	79328	79369	79410	79451	79492
	79247	79288	79329	79370	79411	79452	79493
7	79248	79289	79330	79371	79412	79453	79494
	79249	79290	79331	79372	79413	79454	79495
7	79250	79291	79332	79373	79414	79455	79496
	79251	79292	79333	79374	79415	79456	79497
	79252	79293	79334	79375	79416	79457	79498
	79253	79294	79335	79376	79417	79458	79499
	79254	79295	79336	79377	79418	79459	79500
	79255	79296	79337	79378	79419	79460	79501
	79256	79297	79338	79379	79420	79461	79502
	79257	79298	79339	79380	79421	79462	79503
	79258	79299	79340	79381	79422	79463	79504
	79259	79300	79341	79382	79423	79464	79505
7	79260	79301	79342	79383	79424	79465	79506
7	79261	79302	79343	79384	79425	79466	79507
7	79262	79303	79344	79385	79426	79467	79508
7	79263	79304	79345	79386	79427	79468	79509
7	79264	79305	79346	79387	79428	79469	79510
7	79265	79306	79347	79388	79429	79470	79511
	79266	79307	79348	79389	79430	79471	79512
	79267	79308	79349	79390	79431	79472	79513
	79268	79309	79350	79391	79432	79473	79514
	79269	79310	79351	79392	79433	79474	79515
	79270	79311	79352	79393	79434	79475	79516

DTPA-HBV-IPV-135 (A.15MAR2018)

	. Bl. o nb	Trt. No	Bl. nb	Trt. No	Bl. nb		Bl. nb		Bl.		Bl.		Trt. Bl. No nb
PPD	79517	PPD	79558	PPD	79599	PPD	79640	PPD	79681	PPD	79722	PP	D 79763
	79518		79559		79600		79641		79682		79723		79764
	79519		79560		79601		79642		79683		79724		79765
	79520		79561		79602		79643		79684		79725		79766
	79521		79562		79603		79644		79685		79726		79767
	79522		79563		79604		79645		79686		79727		79768
	79523		79564		79605		79646		79687		79728		79769
	79524		79565		79606		79647		79688		79729		79770
	79525		79566		79607		79648		79689		79730		79771
	79526		79567		79608		79649		79690		79731		79772
	79527		79568		79609		79650		79691		79732		79773
	79528		79569		79610		79651		79692		79733		79774
	79529		79570		79611		79652		79693		79734		79775
	79530		79571		79612		79653		79694		79735		79776
	79531		79572		79613		79654		79695		79736		79777
	79532		79573		79614		79655		79696		79737		79778
	79533		79574		79615		79656		79697		79738		79779
	79534		79575		79616		79657		79698		79739		79780
	79535		79576		79617		79658		79699		79740		79781
	79536		79577		79618		79659		79700		79741		79782
	79537		79578		79619		79660		79701		79742		79783
	79538		79579		79620		79661		79702		79743		79784
	79539		79580		79621		79662		79703		79744		79785
	79540 79541		79581		79622		79663		79704		79745		79786
			79582		79623		79664		79705		79746		79787
	79542 79543		79583 79584		79624 79625		79665 79666		79706		79747		79788
									79707		79748		79789
	79544 79545		79585		79626 79627		79667 79668		79708 79709		79749 79750		79790
	79546		79586 79587		79628		79669		79709		79751		79791 79792
	79546		79587		79628		79670		79710		79751		79792
	79548		79589		79630		79671		79711		79753		79794
	79549		79590		79631		79672		79712		79754		79795
	79550		79591		79632		79673		79714		79755		79796
	79551		79592		79633		79674		79715		79756		79797
	79552		79593		79634		79675		79716		79757		79798
	79553		79594		79635		79676		79717		79758		79799
	79554		79595		79636		79677		79718		79759		79800
	79555		79596		79637		79678		79719		79760		79801
	79556		79597		79638		79679		79720		79761		79802
	79557		79598		79639		79680		79721		79762		79803

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	B1.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	B1.	Trt.	Bl.	Trt.	Bl.
No	nb	No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
222		DDD		PPD				DDD		PPD		PPD	
PPD	79804	PPD	79845	PPD		PPD	79927	PPD	79968		80009	PPU	80050
	79805		79846		79887		79928		79969		80010		80051
	79806		79847		79888		79929		79970		80011		80052
	79807		79848		79889		79930		79971		80012		80053
	79808		79849		79890		79931		79972		80013		80054
	79809		79850		79891		79932		79973		80014		80055
	79810		79851		79892		79933		79974		80015		80056
	79811		79852		79893		79934		79975		80016		80057
	79812		79853		79894		79935		79976		80017		80058
	79813		79854		79895		79936		79977		80018		80059
	79814		79855		79896		79937		79978		80019		80060
	79815		79856		79897		79938		79979		80020		80061
	79816		79857		79898		79939		79980		80021		80062
	79817		79858		79899		79940		79981		80022		80063
	79818		79859		79900		79941		79982		80023		80064
	79819		79860		79901		79942		79983		80024		80065
	79820		79861		79902		79943		79984		80025		80066
	79821		79862		79903		79944		79985		80026		80067
	79822		79863		79904		79945		79986		80027		80068
	79823		79864		79905		79946		79987		80028		80069
	79824		79865		79906		79947		79988		80029		80070
	79825		79866		79907		79948		79989		80030		80071
	79826		79867		79908		79949		79990		80031		80072
	79827		79868		79909		79950		79991		80032		80073
	79828		79869		79910		79951		79992		80033		80074
	79829		79870		79911		79952		79993		80034		80075
	79830		79871		79912		79953		79994		80035		80076
	79831		79872		79913		79954		79995		80036		80077
	79832		79873		79914		79955		79996		80037		80078
	79833		79874		79915		79956		79997		80038		80079
	79834		79875		79916		79957		79998		80039		80080
	79835		79876		79917		79958		79999		80040		80081
	79836		79877		79918		79959		80000		80041		80082
	79837		79878		79919		79960		80001		80042		80083
	79838		79879		79920		79961		80002		80043		80084
	79839		79880		79921		79962		80003		80044		80085
	79840		79881		79922		79963		80004		80045		80086
	79841		79882		79923		79964		80005		80046		80087
	79842		79883		79924		79965		80006		80047		88008
	79843		79884		79925		79966		80007		80048		80089
	79844		79885		79926		79967		80008		80049		80090
	_												

DTPA-HBV-IPV-135 (A.15MAR2018)

80092 80133 80174 80215 80257 80298 8030 80093 80134 80175 80176 80217 80258 80299 803 80094 80135 80176 80217 80258 80299 803 80095 80136 80177 80218 80219 80260 80301 803 80096 80137 80138 80179 80220 80261 80301 803 80097 80138 80139 80180 80221 80262 80303 8039 80099 80140 80181 80222 80263 80303 803 80100 80141 80182 80223 80264 80305 80301 803 80101 80142 80183 80224 80265 80306 80301 803 80103 80104 80144 80185 80226 80266 80307 803 80105 80107 80148 80189 80227 80268 80309 80368 8039 80369 8	Trt.	. Bl.	Trt	. Bl.	Trt	. Bl.	Trt.	. Bl.	Trt	. Bl.	Trt.	. Bl.	Trt	. Bl.
80092 80133 80174 80215 80216 80225 80225 80297 80298 80303 80134 80175 80216 80227 80228 80299 80303 80094 80135 80176 80217 80218 80229 80300 80095 80136 80177 80218 80229 80200 80006 80137 80178 80218 80229 80200 80006 80137 80178 80219 80220 80261 80300 80097 80138 80179 80220 80261 803002 80098 80139 80180 80221 80262 80303 80099 80140 80181 80222 80263 80304 80304 80309 80110 80141 80182 80223 80264 80305 80301 80300 80110 80141 80182 80223 80264 80305 80301 80100 80141 80182 80222 80263 803004 80301 80100 80141 80182 80223 80266 80307 80308 80100 80144 80185 80226 80267 80308 80309 80100 80144 80185 80226 80267 80308 80309 80100 80144 80185 80226 80267 80308 80309 80100 80144 80145 80188 80227 80268 80309 80308 80309 80100 80144 80145 80188 80227 80268 80309 80308 80309 80104 80145 80186 80227 80268 80309 80308 80309 80104 80145 80186 80227 80268 80309 80308 80309 80301 80308 80104 80146 80147 80188 80229 80270 80311 80308 80309 80301 80308 80106 80147 80188 80229 80270 80311 80302 80301 80308 80108 80109 80150 80149 80190 80231 80272 80313 80314 80308 80108 80149 80190 80231 80272 80313 80314 80302 80110 80151 80192 80233 80274 80315 80316 80311 80372 80311 80372 80311 80312 80318 80311 80312 80311 80312 80311 80312 80311 80312 80311 80312 80311 80312 80311 80311 80312 80311 80311 80312 80311 8031	No	nb	No	o nb	N	o nb	No	o nb	N	o nb	No	nb	1	Io nb
80092 80133 80174 80215 80216 80225 80225 80297 80298 80303 80134 80175 80216 80227 80228 80299 80303 80094 80135 80176 80217 80218 80229 80300 80095 80136 80177 80218 80229 80200 80006 80137 80178 80218 80229 80200 80006 80137 80178 80219 80220 80261 80300 80097 80138 80179 80220 80261 803002 80098 80139 80180 80221 80262 80303 80099 80140 80181 80222 80263 80304 80304 80309 80110 80141 80182 80223 80264 80305 80301 80300 80110 80141 80182 80223 80264 80305 80301 80100 80141 80182 80222 80263 803004 80301 80100 80141 80182 80223 80266 80307 80308 80100 80144 80185 80226 80267 80308 80309 80100 80144 80185 80226 80267 80308 80309 80100 80144 80185 80226 80267 80308 80309 80100 80144 80145 80188 80227 80268 80309 80308 80309 80100 80144 80145 80188 80227 80268 80309 80308 80309 80104 80145 80186 80227 80268 80309 80308 80309 80104 80145 80186 80227 80268 80309 80308 80309 80301 80308 80104 80146 80147 80188 80229 80270 80311 80308 80309 80301 80308 80106 80147 80188 80229 80270 80311 80302 80301 80308 80108 80109 80150 80149 80190 80231 80272 80313 80314 80308 80108 80149 80190 80231 80272 80313 80314 80302 80110 80151 80192 80233 80274 80315 80316 80311 80372 80311 80372 80311 80312 80318 80311 80312 80311 80312 80311 80312 80311 80312 80311 80312 80311 80312 80311 80311 80312 80311 80311 80312 80311 8031											DDD			
80093	PPD	80091	PPD	80132	PPD	80173	PPD	80214	PPD	80255	PPD	80296	PPD	80337
80094 80135 80176 80217 80258 80299 8030 80095 80136 80177 8018 80219 80260 80301 803 80096 80137 80180 80219 80260 80301 803 80098 80139 80180 80221 80262 80303 803 80100 80141 80182 80223 80264 80305 803 80101 80141 80182 80223 80264 80305 803 80101 80141 80182 80223 80264 80305 803 80101 80143 80184 80225 80266 80307 803 80102 80143 80184 80225 80266 80307 803 80103 80144 80185 80226 80266 80307 803 80104 80145 80186 80227 80268 80309 803 80105 80148		80092		80133		80174		80215		80256		80297		80338
80094 80135 80176 80217 80258 80299 8030 80095 80136 80177 8018 80219 80260 80301 803 80096 80137 80180 80219 80260 80301 803 80098 80139 80180 80221 80262 80303 803 80100 80141 80182 80223 80264 80305 803 80101 80141 80182 80223 80264 80305 803 80101 80141 80182 80223 80264 80305 803 80101 80143 80184 80225 80266 80307 803 80102 80143 80184 80225 80266 80307 803 80103 80144 80185 80226 80266 80307 803 80104 80145 80186 80227 80268 80309 803 80105 80148		80093		80134		80175		80216		80257		80298		80339
80096		80094		80135		80176		80217		80258		80299		80340
80096 80137 80138 80179 80220 80261 80302 80283 80199 80140 80181 80221 80262 80303 80304 80309 80140 80181 80222 80263 80304 80335 80301 80141 80182 80223 80264 80305 80306 80311 80142 80183 80224 80265 80306 80307 80308 80102 80143 80184 80225 80266 80307 80308 80103 80144 80185 80226 80267 80308 80309 80300 80144 80185 80226 80267 80308 80309 80300 80144 80185 80226 80267 80308 80309 80308 80309 8030		80095		80136		80177		80218		80259		80300		80341
80098 80139 80180 80221 80262 80303 802 80100 80141 80182 80223 80264 80305 803 80101 80142 80183 80224 80265 80306 803 80102 80143 80184 80225 80266 80307 803 80103 80144 80185 80226 80267 80308 803 80104 80145 80186 80227 80266 80309 803 80105 80146 80187 80288 80269 80310 803 80106 80147 80188 80229 80270 80311 803 80107 80148 80189 80230 80271 80312 803 80109 80150 80191 80232 80273 80314 803 80111 80152 80193 80234 80275 80316 80 80111 80155 80196 <		80096		80137		80178				80260		80301		80342
80099		80097		80138		80179		80220		80261		80302		80343
80100 80141 80182 80223 80264 80305 8020 80101 80142 80183 80224 80265 80306 803 80307 80308 80102 801143 801185 80226 80266 80307 80308 80104 801145 801186 80227 80268 80309 80308 80308 80309 80308 80309 80308 80309 80308 80309 80308 80309 80308 80309 80308 80309 80308 80309 80308 80309 80308 80309 80308 80309 80308 80309 80308 80309 80308 80309 80308 80309 803		80098		80139		80180		80221		80262		80303		80344
80101		80099		80140		80181		80222		80263		80304		80345
80102		80100		80141		80182		80223		80264		80305		80346
80103 80144 80185 80226 80267 80308 803 80104 80145 80186 80227 80268 80309 803 80105 80146 80187 80228 80269 80310 803 80106 80147 80188 80229 80270 80311 803 80107 80148 80189 80230 80271 80312 80312 80108 80149 80190 80231 80272 80313 80 80110 80151 80191 80232 80273 80314 80 80111 80152 80193 80233 80274 80315 80 80111 80152 80193 80234 80275 80316 80 80112 80153 80194 80235 80276 80317 80 80113 80154 80195 80236 80277 80318 80 80114 80155 80196		80101		80142		80183		80224		80265		80306		80347
80104 80145 80186 80227 80268 80309 802 80105 80146 80187 80228 80269 80310 803 80106 80147 80188 80229 80270 80311 803 80107 80148 80189 80230 80271 80312 803 80108 80149 80190 80231 80272 80313 803 801109 80150 80191 80232 80273 80314 803 80111 80152 80193 80234 80275 80316 803 80111 80152 80193 80234 80275 80316 803 80112 80153 80194 80235 80276 80317 803 80113 80154 80195 80236 80277 80318 803 80114 80155 80196 80237 80278 80319 80320 803 80115 80156 80197 80238 80279 80320 803 80117 8018		80102		80143		80184		80225		80266		80307		80348
80105 80146 80187 80228 80269 80310 802 80106 80147 80188 80229 80270 80311 803 80107 80148 80189 80230 80271 80312 803 80108 80149 80190 80231 80272 80313 803 80110 80151 80192 80233 80274 80315 803 80111 80152 80193 80234 80275 80316 803 80112 80153 80194 80235 80276 80317 803 80113 80154 80195 80236 80277 80318 803 80114 80155 80196 80237 80278 80319 80 80115 80156 80197 80238 80279 80320 80 80116 80157 80198 80239 80280 80321 80 80117 80158 80199 80240 80281 80322 80 80118 80159 80200 80241 80282 80323 80 80119 80160 80201 80242 80283 80324 80		80103		80144		80185		80226		80267		80308		80349
80106 80147 80188 80229 80270 80311 803 80107 80148 80189 80230 80271 80312 803 80108 80149 80190 80231 80272 80313 803 80110 80150 80191 80232 80273 80314 803 80111 80152 80193 80234 80275 80316 803 80112 80153 80194 80235 80276 80317 803 80113 80154 80195 80236 80277 80318 803 80114 80155 80196 80237 80278 80319 803 80115 80156 80197 80238 80279 80320 803 80116 80157 80188 80239 80280 80321 803 80117 80158 80199 80240 80281 80322 803 80118 80159 80200		80104		80145		80186		80227		80268		80309		80350
80107 80148 80189 80230 80271 80312 8032 80108 80149 80190 80231 80272 80313 803 80110 80151 80192 80233 80274 80315 803 80111 80152 80193 80234 80275 80316 803 80112 80153 80194 80235 80276 80317 803 80113 80154 80195 80236 80277 80318 803 80114 80155 80196 80237 80278 80319 803 80115 80156 80197 80238 80279 80320 803 80116 80157 80198 80239 80280 80321 80 80118 80159 80200 80241 80282 80323 80 80119 80160 80201 80242 80283 80324 80 80119 80160 80201 80242 80283 80324 80 80121 80162 80203 <td></td> <td>80105</td> <td></td> <td>80146</td> <td></td> <td>80187</td> <td></td> <td>80228</td> <td></td> <td>80269</td> <td></td> <td>80310</td> <td></td> <td>80351</td>		80105		80146		80187		80228		80269		80310		80351
80108 80149 80190 80231 80272 80313 802 80110 80150 80191 80232 80273 80314 803 80110 80151 80192 80233 80274 80315 803 80111 80152 80193 80234 80275 80316 803 80112 80153 80194 80235 80276 80317 803 80113 80154 80195 80236 80277 80318 803 80114 80155 80196 80237 80278 80319 803 80115 80156 80197 80238 80279 80320 803 80116 80157 80198 80239 80280 80321 803 80117 80158 80199 80240 80281 80322 803 80118 80159 80200 80241 80282 80333 803 80119 80160 80201 80242 80283 80324 803 80120 80161 80202		80106		80147		80188		80229		80270		80311		80352
80109 80150 80191 80232 80273 80314 803 80110 80151 80192 80233 80274 80315 803 80111 80152 80193 80234 80275 80316 803 80112 80153 80194 80235 80276 80317 803 80113 80154 80195 80236 80277 80318 803 80114 80155 80196 80237 80278 80319 803 80115 80156 80197 80238 80279 80320 803 80116 80157 80198 80239 80280 80321 803 80117 80158 80199 80240 80281 80322 803 80118 80159 80200 80241 80282 80323 803 80119 80160 80201 80242 80283 80324 803 80121 80162 80203 80244 80285 80326 803 80122 80163 80204		80107		80148		80189		80230		80271		80312		80353
80110 80151 80192 80233 80274 80315 803 80111 80152 80193 80234 80275 80316 803 80112 80153 80194 80235 80276 80317 803 80113 80154 80195 80236 80277 80318 803 80114 80155 80196 80237 80278 80319 803 80115 80156 80197 80238 80279 80320 803 80116 80157 80188 80239 80280 80321 803 80117 80158 80199 80240 80281 80322 803 80118 80159 80200 80241 80282 80323 803 80119 80160 80201 80242 80283 80324 803 80120 80161 80202 80243 80284 80325 803 80121 80162 80203 80244 80285 80326 803 80123 80163 80264		80108		80149		80190		80231		80272		80313		80354
80111 80152 80193 80234 80275 80316 803 80112 80153 80194 80235 80276 80317 803 80113 80154 80195 80236 80277 80318 803 80114 80155 80196 80237 80278 80319 803 80115 80156 80197 80238 80279 80320 803 80116 80157 80198 80239 80280 80321 803 80117 80158 80199 80240 80281 80322 803 80118 80159 80200 80241 80282 80323 803 80119 80160 80201 80242 80283 80324 803 80120 80161 80202 80243 80284 80325 803 80121 80162 80203 80244 80285 80326 803 80122 80163 80204 80245 80286 80327 803 80123 80164 80205		80109		80150		80191		80232		80273		80314		80355
80112 80153 80194 80235 80276 80317 803 80113 80154 80195 80236 80277 80318 803 80114 80155 80196 80237 80278 80319 803 80115 80156 80197 80238 80279 80320 803 80116 80157 80198 80239 80280 80321 803 80117 80158 80199 80240 80281 80322 803 80118 80159 80200 80241 80282 80323 803 80119 80160 80201 80242 80283 80324 803 80120 80161 80202 80243 80284 80325 803 80121 80162 80203 80244 80285 80326 803 80121 80163 80204 80245 80286 80327 803 80123 80164 80205 80246 80287 803 803 80124 80165 80206 </td <td></td> <td>80110</td> <td></td> <td>80151</td> <td></td> <td>80192</td> <td></td> <td>80233</td> <td></td> <td>80274</td> <td></td> <td>80315</td> <td></td> <td>80356</td>		80110		80151		80192		80233		80274		80315		80356
80113 80154 80195 80236 80277 80318 8038 80114 80155 80196 80237 80278 80319 803 80115 80156 80197 80238 80279 80320 803 80116 80157 80198 80239 80280 80321 803 80117 80158 80199 80240 80281 80322 803 80118 80159 80200 80241 80282 80323 803 80119 80160 80201 80242 80283 80324 803 80120 80161 80202 80243 80284 80325 803 80121 80162 80203 80244 80285 80326 803 80121 80163 80204 80245 80286 80327 803 80123 80163 80204 80245 80286 80327 803 80124 80165 80206 80247 80288 80329 803 80125 80166 8020		80111		80152		80193		80234		80275		80316		80357
80114 80155 80196 80237 80278 80319 80320 80115 80156 80197 80238 80279 80320 803 80116 80157 80198 80239 80280 80321 803 80117 80158 80199 80240 80281 80322 803 80118 80159 80200 80241 80282 80323 803 80119 80160 80201 80242 80283 80324 803 80120 80161 80202 80243 80284 80325 803 80121 80162 80203 80244 80285 80326 803 80122 80163 80204 80245 80286 80327 803 80123 80164 80205 80246 80287 80328 803 80124 80165 80206 80247 80288 80329 803 80125 80166 80207 80248 80289 80330 803 80126 80167 802		80112		80153		80194		80235		80276		80317		80358
80115 80156 80197 80238 80279 80320 8032 80116 80157 80198 80239 80280 80321 803 80117 80158 80199 80240 80281 80322 803 80118 80159 80200 80241 80282 80323 803 80119 80160 80201 80242 80283 80324 803 80120 80161 80202 80243 80284 80325 803 80121 80162 80203 80244 80285 80326 803 80122 80163 80204 80245 80286 80327 803 80123 80164 80205 80246 80287 80328 803 80124 80165 80206 80247 80288 80329 803 80125 80166 80207 80248 80289 80330 803 80126 80167 80208		80113		80154		80195		80236		80277		80318		80359
80116 80157 80198 80239 80280 80321 803 80117 80158 80199 80240 80281 80322 803 80118 80159 80200 80241 80282 80323 803 80119 80160 80201 80242 80283 80324 803 80120 80161 80202 80243 80284 80325 803 80121 80162 80203 80244 80285 80326 803 80122 80163 80204 80245 80286 80327 803 80123 80164 80205 80246 80287 80328 803 80124 80165 80206 80247 80288 80329 803 80125 80166 80207 80248 80289 80330 803 80126 80167 80208 80249 80290 80331 803 80128 80169 80210 80251 80292 80333 803 80129 80170 80211 80252 80293 80334 803 80130 80171 80212 80253 80294 80335 803		80114		80155		80196		80237		80278		80319		80360
80117 80158 80199 80240 80281 80322 803 80118 80159 80200 80241 80282 80323 803 80119 80160 80201 80242 80283 80324 803 80120 80161 80202 80243 80284 80325 803 80121 80162 80203 80244 80285 80326 803 80122 80163 80204 80245 80286 80327 803 80123 80164 80205 80246 80287 80328 803 80124 80165 80206 80247 80288 80329 803 80125 80166 80207 80248 80289 80330 803 80125 80166 80207 80248 80290 80331 803 80127 80168 80209 80250 80291 80332 803 80128 80169 80210		80115		80156		80197		80238		80279		80320		80361
80118 80159 80200 80241 80282 80323 803 80119 80160 80201 80242 80283 80324 803 80120 80161 80202 80243 80284 80325 803 80121 80162 80203 80244 80285 80326 803 80122 80163 80204 80245 80286 80327 803 80123 80164 80205 80246 80287 80328 803 80124 80165 80206 80247 80288 80329 803 80125 80166 80207 80248 80289 80330 803 80126 80167 80208 80249 80290 80331 803 80127 80168 80209 80250 80291 80332 803 80128 80169 80210 80251 80292 80333 803 80129 80170 80211		80116		80157		80198		80239		80280		80321		80362
80119 80160 80201 80242 80283 80324 803 80120 80161 80202 80243 80284 80325 803 80121 80162 80203 80244 80285 80326 803 80122 80163 80204 80245 80286 80327 803 80123 80164 80205 80246 80287 80328 803 80124 80165 80206 80247 80288 80329 803 80125 80166 80207 80248 80289 80330 803 80126 80167 80208 80249 80290 80331 803 80127 80168 80209 80250 80291 80332 803 80128 80169 80210 80251 80292 80333 803 80129 80170 80211 80252 80293 80334 803 80130 80171 80212 80253 80294 80335 803		80117		80158		80199		80240		80281		80322		80363
80120 80161 80202 80243 80284 80325 803 80121 80162 80203 80244 80285 80326 803 80122 80163 80204 80245 80286 80327 803 80123 80164 80205 80246 80287 80328 803 80124 80165 80206 80247 80288 80329 803 80125 80166 80207 80248 80289 80330 803 80126 80167 80208 80249 80290 80331 803 80127 80168 80209 80250 80291 80332 803 80128 80169 80210 80251 80292 80333 803 80129 80170 80211 80252 80293 80334 803 80130 80171 80212 80253 80294 80335 803		80118		80159		80200		80241		80282		80323		80364
80121 80162 80203 80244 80285 80326 803 80122 80163 80204 80245 80286 80327 803 80123 80164 80205 80246 80287 80328 803 80124 80165 80206 80247 80288 80329 803 80125 80166 80207 80248 80289 80330 803 80126 80167 80208 80249 80290 80331 803 80127 80168 80209 80250 80291 80332 803 80128 80169 80210 80251 80292 80333 803 80129 80170 80211 80252 80293 80334 803 80130 80171 80212 80253 80294 80335 803		80119		80160		80201		80242		80283		80324		80365
80122 80163 80204 80245 80286 80327 803 80123 80164 80205 80246 80287 80328 803 80124 80165 80206 80247 80288 80329 803 80125 80166 80207 80248 80289 80330 803 80126 80167 80208 80249 80290 80331 803 80127 80168 80209 80250 80291 80332 803 80128 80169 80210 80251 80292 80333 803 80129 80170 80211 80252 80293 80334 803 80130 80171 80212 80253 80294 80335 803				80161										80366
80123 80164 80205 80246 80287 80328 803 80124 80165 80206 80247 80288 80329 803 80125 80166 80207 80248 80289 80330 803 80126 80167 80208 80249 80290 80331 803 80127 80168 80209 80250 80291 80332 803 80128 80169 80210 80251 80292 80333 803 80129 80170 80211 80252 80293 80334 803 80130 80171 80212 80253 80294 80335 803		80121								80285				80367
80124 80165 80206 80247 80288 80329 803 80125 80166 80207 80248 80289 80330 803 80126 80167 80208 80249 80290 80331 803 80127 80168 80209 80250 80291 80332 803 80128 80169 80210 80251 80292 80333 803 80129 80170 80211 80252 80293 80334 803 80130 80171 80212 80253 80294 80335 803														80368
80125 80166 80207 80248 80289 80330 803 80126 80167 80208 80249 80290 80331 803 80127 80168 80209 80250 80291 80332 803 80128 80169 80210 80251 80292 80333 803 80129 80170 80211 80252 80293 80334 803 80130 80171 80212 80253 80294 80335 803														80369
80126 80167 80208 80249 80290 80331 803 80127 80168 80209 80250 80291 80332 803 80128 80169 80210 80251 80292 80333 803 80129 80170 80211 80252 80293 80334 803 80130 80171 80212 80253 80294 80335 803														80370
80127 80168 80209 80250 80291 80332 803 80128 80169 80210 80251 80292 80333 803 80129 80170 80211 80252 80293 80334 803 80130 80171 80212 80253 80294 80335 803				80166										80371
80128 80169 80210 80251 80292 80333 803 80129 80170 80211 80252 80293 80334 803 80130 80171 80212 80253 80294 80335 803														80372
80129 80170 80211 80252 80293 80334 803 80130 80171 80212 80253 80294 80335 803														80373
80130 80171 80212 80253 80294 80335 803														80374
														80375
80131 80172 80213 80254 80295 80336 803														80376
		80131		80172		80213		80254		80295		80336		80377

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	80378	PPD	80419	PPD	80460	PPD	80501	PPD	80542	PPD	80583	PPD	80624
יוו	80379		80420		80461		80502	110	80543		80584		80625
	80379		80421		80462		80503		80544		80585		80626
	80381		80422		80463		80504		80545		80586		80627
	80382		80423		80464		80505		80546		80587		80628
	80383		80424		80465		80506		80547		80588		80629
	80384		80425		80466		80507		80548		80589		80630
	80385		80426		80467		80508		80549		80590		80631
	80386		80427		80468		80509		80550		80591		80632
	80387		80428		80469		80510		80551		80592		80633
	80388		80429		80470		80511		80552		80593		80634
	80389		80430		80471		80512		80553		80594		80635
	80390		80431		80472		80513		80554		80595		80636
	80391		80432		80473		80514		80555		80596		80637
	80392		80433		80474		80515		80556		80597		80638
	80393		80434		80475		80516		80557		80598		80639
	80394		80435		80476		80517		80558		80599		80640
	80395		80436		80477		80518		80559		80600		80641
	80396		80437		80478		80519		80560		80601		80642
	80397		80438		80479		80520		80561		80602		80643
	80398		80439		80480		80521		80562		80603		80644
	80399		80440		80481		80522		80563		80604		80645
	80400		80441		80482		80523		80564		80605		80646
	80401		80442		80483		80524		80565		80606		80647
	80402		80443		80484		80525		80566		80607		80648
	80403		80444		80485		80526		80567		80608		80649
	80404		80445		80486		80527		80568		80609		80650
	80405		80446		80487		80528		80569		80610		80651
	80406		80447		80488		80529		80570		80611		80652
	80407		80448		80489		80530		80571		80612		80653
	80408		80449		80490		80531		80572		80613		80654
	80409		80450		80491		80532		80573		80614		80655
	80410		80451		80492		80533		80574		80615		80656
	80411		80452		80493		80534		80575		80616		80657
	80412		80453		80494		80535		80576		80617		80658
	80413		80454		80495		80536		80577		80618		80659
	80414		80455		80496		80537		80578		80619		80660
	80415		80456		80497		80538		80579		80620		80661
	80416		80457		80498		80539		80580		80621		80662
	80417		80458		80499		80540		80581		80622		80663
	80418		80459		80500		80541		80582		80623		80664
							-				•		•

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt	. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No nb	N	lo nb	No	nb	No	nb	No	nb	No	nb
PPD 806	65 PPD	80706	PPD	80747	PPD	80788	PPD	80829	PPD	80870
806		80707		80748		80789	110	80830		80871
806		80708		80749		80790		80831		80872
806		80709		80750		80791		80832		80873
806		80710		80751		80792		80833		80874
806		80711		80752		80793		80834		80875
806		80712		80753		80794		80835		80876
806		80713		80754		80795		80836		80877
806		80714		80755		80796		80837		80878
806		80715		80756		80797		80838		80879
806		80716		80757		80798		80839		80880
806		80717		80758		80799		80840		80881
806		80718		80759		80800		80841		80882
806		80719		80760		80801		80842		80883
806		80720		80761		80802		80843		80884
806		80721		80762		80803		80844		80885
806		80722		80763		80804		80845		80886
806		80723		80764		80805		80846		80887
806		80724		80765		80806		80847		80888
806		80725		80766		80807		80848		80889
806		80726		80767		80808		80849		80890
806		80727		80768		80809		80850		80891
806		80728		80769		80810		80851		80892
806		80729		80770		80811		80852		80893
806		80730		80771		80812		80853		80894
806		80731		80772		80813		80854		80895
806		80732		80773		80814		80855		80896
806		80733		80774		80815		80856		80897
806		80734		80775		80816		80857		80898
806		80735		80776		80817		80858		80899
806		80736		80777		80818		80859		80900
806		80737		80778		80819		80860		80901
806		80738		80779		80820		80861		80902
806		80739		80780		80821		80862		80903
806		80740		80781		80822		80863		80904
807		80741		80782		80823		80864		80905
807		80742		80783		80824		80865		80906
807		80743		80784		80825		80866		
807		80744		80785		80826		80867		
807		80745		80786		80827		80868		
807		80746		80787		80828		80869		

DTPA-HBV-IPV-135 (A.15MAR2018)

	Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	10907	PPD 10948	PPD 10989	PPD 11030	PPD 11071	PPD 11112	PPD 11153
110	10908	10949	10990	11031	11072	11113	11154
	10909	10950	10991	11032	11073	11114	11155
	10910	10951	10992	11032	11074	11115	11156
	10911	10952	10993	11033	11075	11116	11157
	10912	10953	10994	11035	11076	11117	11158
	10913	10954	10995	11036	11077	11118	11159
	10914	10955	10996	11037	11078	11119	11160
	10915	10956	10997	11037	11079	11120	11161
	10916	10957	10998	11039	11080	11121	11162
	10917	10958	10999	11040	11081	11122	11163
	10918	10959	11000	11041	11082	11123	11164
	10919	10960	11001	11042	11083	11124	11165
	10920	10961	11002	11043	11084	11125	11166
	10921	10962	11003	11044	11085	11126	11167
	10922	10963	11004	11045	11086	11127	11168
	10923	10964	11005	11046	11087	11128	11169
	10924	10965	11006	11047	11088	11129	11170
	10925	10966	11007	11048	11089	11130	11171
	10926	10967	11008	11049	11090	11131	11172
	10927	10968	11009	11050	11091	11132	11173
	10928	10969	11010	11051	11092	11133	11174
	10929	10970	11011	11052	11093	11134	11175
	10930	10971	11012	11053	11094	11135	11176
	10931	10972	11013	11054	11095	11136	11177
	10932	10973	11014	11055	11096	11137	11178
	10933	10974	11015	11056	11097	11138	11179
	10934	10975	11016	11057	11098	11139	11180
	10935	10976	11017	11058	11099	11140	11181
	10936	10977	11018	11059	11100	11141	11182
	10937	10978	11019	11060	11101	11142	11183
	10938	10979	11020	11061	11102	11143	11184
	10939	10980	11021	11062	11103	11144	11185
	10940	10981	11022	11063	11104	11145	11186
	10941	10982	11023	11064	11105	11146	11187
	10942	10983	11024	11065	11106	11147	11188
	10943	10984	11025	11066	11107	11148	11189
	10944	10985	11026	11067	11108	11149	11190
	10945	10986	11027	11068	11109	11150	11191
	10946	10987	11028	11069	11110	11151	11192
	10947	10988	11029	11070	11111	11152	11193

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD 11194	PPD 11235	PPD 11276	PPD 11317	PPD 11358	PPD 11399	PPD 11440
11195	11236	11277	11318	11359	11400	11441
11196	11237	11278	11319	11360	11401	11442
11197	11238	11279	11320	11361	11402	11443
11198	11239	11280	11321	11362	11403	11444
11199	11240	11281	11322	11363	11404	11445
11200	11241	11282	11323	11364	11405	11446
11201	11242	11283	11324	11365	11406	11447
11202	11243	11284	11325	11366	11407	11448
11203	11244	11285	11326	11367	11408	11449
11204	11245	11286	11327	11368	11409	11450
11205	11246	11287	11328	11369	11410	11451
11206	11247	11288	11329	11370	11411	11452
11207	11248	11289	11330	11371	11412	11453
11208	11249	11290	11331	11372	11413	11454
11209	11250	11291	11332	11373	11414	11455
11210	11251	11292	11333	11374	11415	11456
11211	11252	11293	11334	11375	11416	11457
11212	11253	11294	11335	11376	11417	11458
11213	11254	11295	11336	11377	11418	11459
11214	11255	11296	11337	11378	11419	11460
11215	11256	11297	11338	11379	11420	11461
11216	11257	11298	11339	11380	11421	11462
11217	11258	11299	11340	11381	11422	11463
11218	11259	11300	11341	11382	11423	11464
11219	11260	11301	11342	11383	11424	11465
11220	11261	11302	11343	11384	11425	11466
11221	11262	11303	11344	11385	11426	11467
11222	11263	11304	11345	11386	11427	11468
11223	11264	11305	11346	11387	11428	11469
11224	11265	11306	11347	11388	11429	11470
11225	11266	11307	11348	11389	11430	11471
11226	11267	11308	11349	11390	11431	11472
11227	11268	11309	11350	11391	11432	11473
11228	11269	11310	11351	11392	11433	11474
11229	11270	11311	11352	11393	11434	11475
11230	11271	11312	11353	11394	11435	11476
11231	11272	11313	11354	11395	11436	11477
11232	11273	11314	11355	11396	11437	11478
11233	11274	11315	11356	11397	11438	11479
11234	11275	11316	11357	11398	11439	11480

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Treatment number associated to material : Prevnar 13

Trt. No	Bl. nb		nb	nb	Trt. No	nb		nb	Trt. No	Bl. nb	Trt. No	Bl. nb
									PPD			
PPD	11481	PPD	11522		PPD	11604	PPD	11645	PPU	11686	PPD	11727
	11482		11523	11564		11605		11646		11687		11728
	11483		11524	11565		11606		11647		11688		11729
	11484		11525	11566		11607		11648		11689		11730
	11485		11526	11567		11608		11649		11690		11731
	11486		11527	11568		11609		11650		11691		11732
	11487		11528	11569		11610		11651		11692		11733
	11488		11529	11570		11611		11652		11693		11734
	11489		11530	11571		11612		11653		11694		11735
	11490		11531	11572		11613		11654		11695		11736
	11491		11532	11573		11614		11655		11696		11737
	11492		11533	11574		11615		11656		11697		11738
	11493		11534	11575		11616		11657		11698		11739
	11494		11535	11576		11617		11658		11699		11740
	11495		11536	11577		11618		11659		11700		11741
	11496		11537	11578		11619		11660		11701		11742
	11497		11538	11579		11620		11661		11702		11743
	11498		11539	11580		11621		11662		11703		11744
	11499		11540	11581		11622		11663		11704		11745
	11500		11541	11582		11623		11664		11705		11746
	11501		11542	11583		11624		11665		11706		11747
	11502		11543	11584		11625		11666		11707		11748
	11503		11544	11585		11626		11667		11708		11749
	11504		11545	11586		11627		11668		11709		11750
	11505		11546	11587		11628		11669		11710		11751
	11506		11547	11588		11629		11670		11711		11752
	11507		11548	11589		11630		11671		11712		11753
	11508		11549	11590		11631		11672		11713		11754
	11509		11550	11591		11632		11673		11714		11755
	11510		11551	11592		11633		11674		11715		11756
	11511		11552	11593		11634		11675		11716		11757
	11512		11553	11594		11635		11676		11717		11758
	11513		11554	11595		11636		11677		11718		11759
	11514		11555	11596		11637		11678		11719		11760
	11515		11556	11597		11638		11679		11720		11761
	11516		11557	11598		11639		11680		11721		11762
	11517		11558	11599		11640		11681		11722		11763
	11518		11559	11600		11641		11682		11723		11764
	11519		11560	11601		11642		11683		11724		11765
	11520		11561	11602		11643		11684		11725		11766
	11521		11562	11603		11644		11685		11726		11767
	l		l									

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
PPD	12055	PPD 12096	PPD 12137	PPD 12178	PPD 12219	PPD 12260	PPD 12301
	12056	12097	12138	12179	12220	12261	12302
	12057	12098	12139	12180	12221	12262	12303
	12058	12099	12140	12181	12222	12263	12304
	12059	12100	12141	12182	12223	12264	12305
	12060	12101	12142	12183	12224	12265	12306
	12061	12102	12143	12184	12225	12266	12307
	12062	12103	12144	12185	12226	12267	12308
	12063	12104	12145	12186	12227	12268	12309
	12064	12105	12146	12187	12228	12269	12310
	12065	12106	12147	12188	12229	12270	12311
	12066	12107	12148	12189	12230	12271	12312
	12067	12108	12149	12190	12231	12272	12313
	12068	12109	12150	12191	12232	12273	12314
	12069	12110	12151	12192	12233	12274	12315
	12070	12111	12152	12193	12234	12275	12316
	12071	12112	12153	12194	12235	12276	12317
	12072	12113	12154	12195	12236	12277	12318
	12073	12114	12155	12196	12237	12278	12319
	12074	12115	12156	12197	12238	12279	12320
	12075	12116	12157	12198	12239	12280	12321
	12076	12117	12158	12199	12240	12281	12322
	12077	12118	12159	12200	12241	12282	12323
	12078	12119	12160	12201	12242	12283	12324
	12079	12120	12161	12202	12243	12284	12325
	12080	12121	12162	12203	12244	12285	12326
	12081	12122	12163	12204	12245	12286	12327
	12082	12123	12164	12205	12246	12287	12328
	12083	12124	12165	12206	12247	12288	12329
	12084	12125	12166	12207	12248	12289	12330
	12085	12126	12167	12208	12249	12290	12331
	12086	12127	12168	12209	12250	12291	12332
	12087	12128	12169	12210	12251	12292	12333
	12088	12129	12170	12211	12252	12293	12334
	12089	12130	12171	12212	12253	12294	12335
	12090	12131	12172	12213	12254	12295	12336
	12091	12132	12173	12214	12255	12296	12337
	12092	12133	12174	12215	12256	12297	12338
	12093	12134	12175	12216	12257	12298	12339
	12094	12135	12176	12217	12258	12299	12340
	12095	12136	12177	12218	12259	12300	12341
	l						

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. No	nb	Trt. No	nb	Trt. No	nb		Bl. nb		Bl. nb	Trt. No	Bl. nb
DDD		PPD		PPD		PPD				PPD		PPD	
PPD	12342 12343	PPD	12383 12384	FFD	12424 12425	PPD	12465 12466	PPD	12506 12507		12547 12548	FFD	12588 12589
									12507		1 1		12589
	12344 12345		12385 12386		12426 12427		12467 12468		12508		12549 12550		12590
	12345		12387		12427		12469		12510		12551		12591
	12346		12387		12428		12469		12510		12551		12592
	12347		12388		12429		12470		12511		12552		12593
	12349		12399		12430		12471		12512		12554		12594
	12350		12390		12431		12472		12513		12555		12596
	12351		12391		12432		12474		12514		12556		12597
	12351		12392		12433		12474		12515		12557		12597
	12352		12394		12435		12475		12517		12558		12599
	12354		12394		12436		12477		12517		12559		12600
	12354		12396		12437		12477		12519		12560		12601
	12356		12397		12438		12479		12520		12561		12602
	12357		12397		12439		12479		12521		12562		12602
	12357		12399		12440		12481		12521		12563		12603
	12359		12400		12441		12482		12523		12564		12604
	12360		12401		12442		12483		12524		12565		12606
	12361		12402		12443		12484		12525		12566		12607
	12362		12403		12444		12485		12526		12567		12608
	12363		12404		12445		12486		12527		12568		12609
	12364		12405		12446		12487		12528		12569		12610
	12365		12406		12447		12488		12529		12570		12611
	12366		12407		12448		12489		12530		12571		12612
	12367		12408		12449		12490		12531		12572		12613
	12368		12409		12450		12491		12532		12573		12614
	12369		12410		12451		12492		12533		12574		12615
	12370		12411		12452		12493		12534		12575		12616
	12371		12412		12453		12494		12535		12576		12617
	12372		12413		12454		12495		12536		12577		12618
	12373		12414		12455		12496		12537		12578		12619
	12374		12415		12456		12497		12538		12579		12620
	12375		12416		12457		12498		12539		12580		12621
	12376		12417		12458		12499		12540		12581		12622
	12377		12418		12459		12500		12541		12582		12623
	12378		12419		12460		12501		12542		12583		12624
	12379		12420		12461		12502		12543		12584		12625
	12380		12421		12462		12503		12544		12585		12626
	12381		12422		12463		12504		12545		12586		12627
	12382		12423		12464		12505		12546		12587		12628

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. No		Trt. No		Trt. No	nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	
PPD	12629	PPD	12670	PPD	12711	PPD	12752	PPD	12793	PPD	12834	PPD	12875
	12630	–	12671	_	12712		12753		12794		12835		12876
	12631		12672		12713		12754		12795		12836		12877
	12632		12673		12714		12755		12796		12837		12878
	12633		12674		12715		12756		12797		12838		12879
	12634		12675		12716		12757		12798		12839		12880
	12635		12676		12717		12758		12799		12840		12881
	12636		12677		12718		12759		12800		12841		12882
	12637		12678		12719		12760		12801		12842		12883
	12638		12679		12720		12761		12802		12843		12884
	12639		12680		12721		12762		12803		12844		12885
	12640		12681		12722		12763		12804		12845		12886
	12641		12682		12723		12764		12805		12846		12887
	12642		12683		12724		12765		12806		12847		12888
	12643		12684		12725		12766		12807		12848		12889
	12644		12685		12726		12767		12808		12849		12890
	12645		12686		12727		12768		12809		12850		12891
	12645		12687		12728		12769		12810		12850		12891
	12647		12688		12729		12770		12811		12852		12893
	12647		12689		12729		12771		12811		12852		12893
	12648		12689		12731		12771		12812		12853		12894
					12731		12773		12813		12854		
	12650		12691		12733								12896
	12651		12692				12774		12815		12856		12897
	12652		12693		12734		12775		12816		12857		12898
	12653		12694		12735		12776		12817		12858		12899
	12654		12695		12736		12777		12818		12859		12900
	12655		12696		12737		12778		12819		12860		12901
	12656		12697		12738		12779		12820		12861		12902
	12657		12698		12739		12780		12821		12862		12903
	12658		12699		12740		12781		12822		12863		12904
	12659		12700		12741		12782		12823		12864		12905
	12660		12701		12742		12783		12824		12865		12906
	12661		12702		12743		12784		12825		12866		12907
	12662		12703		12744		12785		12826		12867		12908
	12663		12704		12745		12786		12827		12868		12909
	12664		12705		12746		12787		12828		12869		12910
	12665		12706		12747		12788		12829		12870		12911
	12666		12707		12748		12789		12830		12871		12912
	12667		12708		12749		12790		12831		12872		12913
	12668		12709		12750		12791		12832		12873		12914
	12669		12710		12751		12792		12833		12874		12915

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	. Bl.	Trt. Bl. No nb	Trt.	Bl. nb		Bl.		Bl.		Bl.		Bl.
PPD	12916	PPD 12957	PPD	12998	PPD	13039	PPD	13080	PPD	13121	PPD	13162
	12917	12958		12999		13040		13081		13122		13163
	12918	12959		13000		13041		13082		13123		13164
	12919	12960		13001		13042		13083		13124		13165
	12920	12961		13002		13043		13084		13125		13166
	12921	12962		13003		13044		13085		13126		13167
	12922	12963		13004		13045		13086		13127		13168
	12923	12964		13005		13046		13087		13128		13169
	12924	12965		13006		13047		13088		13129		13170
	12925	12966		13007		13048		13089		13130		13171
	12926	12967		13008		13049		13090		13131		13172
	12927	12968		13009		13050		13091		13132		13173
	12928	12969		13010		13051		13092		13133		13174
	12929	12970		13011		13052		13093		13134		13175
	12930	12971		13012		13053		13094		13135		13176
	12931	12972		13013		13054		13095		13136		13177
	12932	12973		13014		13055		13096		13137		13178
	12933	12974		13015		13056		13097		13138		13179
	12934	12975		13016		13057		13098		13139		13180
	12935	12976		13017		13058		13099		13140		13181
	12936	12977		13018		13059		13100		13141		13182
	12937	12978		13019		13060		13101		13142		13183
	12938	12979		13020		13061		13102		13143		13184
	12939	12980		13021		13062		13103		13144		13185
	12940	12981		13022		13063		13104		13145		13186
	12941	12982		13023		13064		13105		13146		13187
	12942	12983		13024		13065		13106		13147		13188
	12943	12984		13025		13066		13107		13148		13189
	12944	12985		13026		13067		13108		13149		13190
	12945	12986		13027		13068		13109		13150		13191
	12946	12987 12988		13028 13029		13069		13110		13151		13192
	12947 12948	12988		13029		13070 13071		13111 13112		13152 13153		13193 13194
	12948	12989		13030		13071		13112		13153		13194
	12949	12990		13031		13072		13113		13154		13195
	12950	12991		13032		13073		13114		13155		13196
	12951	12992		13034		13074		13116		13156		13197
	12952	12993		13035		13075		13117		13157		13196
	12954	12994		13036		13076		13117		13150		13200
	12955	12996		13036		13077		13110		13160		13200
	12956	12997		13037		13078		13120		13161		13201
	12,550	12331		10000		130,3		13120		10101		13202

DTPA-HBV-IPV-135 (A.15MAR2018)

Treatment number associated to material : Prevnar 13

Trt.	Bl.	Trt. Bl.	Trt	. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No nb	N	o nb	No	nb	No	nb	No	nb	No	nb
PPD	12002	PPD 13244	PPD	13285	PPD	12206	PPD	1226	PPD	12400	PPD	13449
PPD	13203 13204	13245		13285	FFD	13326 13327	PPU	13367 13368		13408 13409		13449
	13204	13243		13286		13327		13368		13409		13450
	13205	13247		13287		13328		13370				
										13411		13452
	13207	13248		13289		13330		13371		13412		13453
	13208	13249		13290		13331		13372		13413		13454
	13209	13250		13291		13332		13373		13414		13455
	13210	13251		13292		13333		13374		13415		13456
	13211	13252		13293		13334		13375		13416		13457
	13212	13253		13294		13335		13376		13417		13458
	13213	13254		13295		13336		13377		13418		13459
	13214	13255		13296		13337		13378		13419		13460
	13215	13256		13297		13338		13379		13420		13461
	13216	13257		13298		13339		13380		13421		13462
	13217	13258		13299		13340		13381		13422		13463
	13218	13259		13300		13341		13382		13423		13464
	13219	13260		13301		13342		13383		13424		13465
	13220	13261		13302		13343		13384		13425		13466
	13221	13262		13303		13344		13385		13426		13467
	13222	13263	3	13304		13345		13386		13427		13468
	13223	13264		13305		13346		13387		13428		13469
	13224	13265		13306		13347		13388		13429		13470
	13225	13266		13307		13348		13389		13430		13471
	13226	13267		13308		13349		13390		13431		13472
	13227	13268	3	13309		13350		13391		13432		13473
	13228	13269		13310		13351		13392		13433		13474
	13229	13270)	13311		13352		13393		13434		13475
	13230	13271		13312		13353		13394		13435		13476
	13231	13272		13313		13354		13395		13436		13477
	13232	13273	3	13314		13355		13396		13437		13478
	13233	13274		13315		13356		13397		13438		13479
	13234	13275	i i	13316		13357		13398		13439		13480
	13235	13276	i i	13317		13358		13399		13440		13481
	13236	13277		13318		13359		13400		13441		13482
	13237	13278	3	13319		13360		13401		13442		13483
	13238	13279		13320		13361		13402		13443		13484
	13239	13280		13321		13362		13403		13444		13485
	13240	13281		13322		13363		13404		13445		13486
	13241	13282		13323		13364		13405		13446		13487
	13242	13283		13324		13365		13406		13447		13488
	13243	13284		13325		13366		13407		13448		13489
		, ,										

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl. nb	Trt. No	Bl. nb	Trt. No		Trt. No	nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	
DDD		PPD		PPD				DDD		PPD	 	PPD	
PPD		PPD	10001	FFU		PPD		PPD	13654	–	13695		13736
	13491		13532		13573		13614		13655		13696		13737
	13492		13533		13574		13615		13656		13697	1	13738
	13493		13534		13575		13616		13657		13698	1	13739
	13494		13535		13576		13617		13658		13699	1	13740
	13495		13536		13577		13618		13659		13700		13741
	13496		13537		13578		13619		13660		13701	1	13742
	13497		13538		13579		13620		13661		13702	1	13743
	13498		13539		13580		13621		13662		13703		13744
	13499		13540		13581		13622		13663		13704		13745
	13500		13541		13582		13623		13664		13705		13746
	13501		13542		13583		13624		13665		13706	1	13747
	13502		13543		13584		13625		13666		13707	1	13748
	13503		13544		13585		13626		13667		13708		13749
	13504		13545		13586		13627		13668		13709	1	13750
	13505		13546		13587		13628		13669		13710	1	13751
	13506		13547		13588		13629		13670		13711	1	13752
	13507		13548		13589		13630		13671		13712	1	13753
	13508		13549		13590		13631		13672		13713	1	13754
	13509		13550		13591		13632		13673		13714		13755
	13510		13551		13592		13633		13674		13715		13756
	13511		13552		13593		13634		13675		13716	1	13757
	13512		13553		13594		13635		13676		13717	1	13758
	13513		13554		13595		13636		13677		13718	1	13759
	13514		13555		13596		13637		13678		13719	1	13760
	13515		13556		13597		13638		13679		13720	1	13761
	13516		13557		13598		13639		13680		13721		13762
	13517		13558		13599		13640		13681		13722		13763
	13518		13559		13600		13641		13682		13723	1	13764
	13519		13560		13601		13642		13683		13724	1	13765
	13520		13561		13602		13643		13684		13725		13766
	13521		13562		13603		13644		13685		13726		13767
	13522		13563		13604		13645		13686		13727		13768
	13523		13564		13605		13646		13687		13728		13769
	13524		13565		13606		13647		13688		13729	1	13770
	13525		13566		13607		13648		13689		13730	1	13771
	13526		13567		13608		13649		13690		13731		13771
	13527		13568		13609		13650		13691		13732		13773
	13527		13569		13610				13691		13733		13774
	13528		13569				13651		13692		13734		
					13611		13652						13775
	13530		13571		13612		13653		13694		13735		13776
	l												

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	B1.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	13777	PPD 13818	PPD 13859	PPD 13900	PPD 13941	PPD 13982	PPD 14023
FFD	13778	13819	13860	13901	13942	13983	14024
	13779	13820	13861	13902	13942	13984	14025
	13780	13821	13862	13902	13943	13985	14025
	13781	13822	13863	13904	13944	13986	14027
	13782	13823	13864	13904	13945	13987	14027
	13783	13824	13865	13906	13946	13988	14029
	13784	13825	13866	13906	13947	13989	14029
	13784	13825	13867	13907	13948	13989	14030
	13786	13827	13868			13990	
	13787	13827	13869	13909 13910	13950 13951	13991	14032 14033
	13788	13829	13870	13910	13952	13992	14033
	13789	13829	13870	13911	13952	13993	14034
	13789	13831	13871	13912	13953	13994	14035
	13791	13832	13873	13914	13955	13996	14037
	13792	13833	13874	13915	13956	13997	14038
	13793	13834	13875	13916	13957	13998	14039
	13794	13835	13876	13917	13958	13999	14040
	13795	13836	13877	13918	13959	14000	14041
	13796	13837	13878	13919	13960	14001	14042
	13797	13838	13879	13920	13961	14002	14043
	13798	13839	13880	13921	13962	14003	14044
	13799	13840	13881	13922	13963	14004	14045
	13800	13841	13882	13923	13964	14005	14046
	13801	13842	13883	13924	13965	14006	14047
	13802	13843	13884	13925	13966	14007	14048
	13803	13844	13885	13926	13967	14008	14049
	13804	13845	13886	13927	13968	14009	14050
	13805	13846	13887	13928	13969	14010	14051
	13806	13847	13888	13929	13970	14011	14052
	13807	13848	13889	13930	13971	14012	14053
	13808	13849	13890	13931	13972	14013	14054
	13809	13850	13891	13932	13973	14014	14055
	13810	13851	13892	13933	13974	14015	14056
	13811	13852	13893	13934	13975	14016	14057
	13812	13853	13894	13935	13976	14017	14058
	13813	13854	13895	13936	13977	14018	14059
	13814	13855	13896	13937	13978	14019	14060
	13815	13856	13897	13938	13979	14020	14061
	13816	13857	13898	13939	13980	14021	14062
	13817	13858	13899	13940	13981	14022	14063

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
No nb	No nb	No nb	No nb	No nb	No nb	No nb
14100	14141	14182	14223	14264	14305	14346
14101	14142	14183	14224	14265	14306	14347
14102	14143	14184	14225	14266	14307	14348
14103	14144	14185	14226	14267	14308	14349
14104	14145	14186	14227	14268	14309	14350

DTPA-HBV-IPV-135 (A.15MAR2018)

Treatment number associated to material : Prevnar 13

Trt. Bl. No nb	•	Trt. Bl. No nb	Trt.	Bl. nb	Trt.	Bl. nb	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
PPD 143	351 PP	D 14392	PPD	14433	PPD	14474	PPD	14515	PPD	14556	PPD	14597
	351	14392	יוו	14433	FFD	14474	PPD	14515		14556	ווט	14597
	352	14393		14434		14475		14516		14557		14598
	354	14394		14435		14476		14517		14558		14599
	355	14395		14437		14477		14516		14559		14600
	356	14396		14437		14479		14519		14561		14601
	357	14397		14430		14479		14521		14562		14602
	358	14399		14440		14481		14522		14563		14604
143		14400		14441		14482		14523		14564		14605
	360	14401		14442		14483		14524		14565		14606
	361	14402		14443		14484		14525		14566		14607
143		14403		14444		14485		14526		14567		14608
	363	14404		14445		14486		14527		14568		14609
	364	14405		14446		14487		14528		14569		14610
	365	14406		14447		14488		14529		14570		14611
	366	14407		14448		14489		14530		14571		14612
	367	14408		14449		14490		14531		14572		14613
	368	14409		14450		14491		14532		14573		14614
	369	14410		14451		14492		14533		14574		14615
143		14411		14452		14493		14534		14575		14616
	371	14412		14453		14494		14535		14576		14617
143		14413		14454		14495		14536		14577		14618
143		14414		14455		14496		14537		14578		14619
	374	14415		14456		14497		14538		14579		14620
	375	14416		14457		14498		14539		14580		14621
143	376	14417		14458		14499		14540		14581		14622
143	377	14418		14459		14500		14541		14582		14623
143	378	14419		14460		14501		14542		14583		14624
143	379	14420		14461		14502		14543		14584		14625
143	380	14421		14462		14503		14544		14585		14626
143	381	14422		14463		14504		14545		14586		14627
143	382	14423		14464		14505		14546		14587		14628
143	383	14424		14465		14506		14547		14588		14629
143	384	14425		14466		14507		14548		14589		14630
143	385	14426		14467		14508		14549		14590		14631
143	386	14427		14468		14509		14550		14591		14632
143	387	14428		14469		14510		14551		14592		14633
143	388	14429		14470		14511		14552		14593		14634
143	389	14430		14471		14512		14553		14594		14635
143	390	14431		14472		14513		14554		14595		14636
143	391	14432		14473		14514		14555		14596		14637

DTPA-HBV-IPV-135 (A.15MAR2018)

	Trt. No	Bl. nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	Bl. nb	Trt. No	
	DDD										PPD		PPD	
- 1	PPD		PPU	11075	FFD				PPD	14802		11010		14884
		14639		14680		14721		14762		14803		14844		14885
		14640		14681		14722		14763		14804		14845		14886
		14641		14682		14723		14764		14805		14846		14887
		14642		14683		14724		14765		14806		14847		14888
		14643		14684		14725		14766		14807		14848		14889
		14644		14685		14726		14767		14808		14849		14890
		14645		14686		14727		14768		14809		14850		14891
		14646		14687		14728		14769		14810		14851		14892
		14647		14688		14729		14770		14811		14852		14893
		14648		14689		14730		14771		14812		14853		14894
		14649		14690		14731		14772		14813		14854		14895
		14650		14691		14732		14773		14814		14855		14896
		14651		14692		14733		14774		14815		14856		14897
		14652		14693		14734		14775		14816		14857		14898
		14653		14694		14735		14776		14817		14858		14899
		14654		14695		14736		14777		14818		14859		14900
		14655		14696		14737		14778		14819		14860		14901
		14656		14697		14738		14779		14820		14861		14902
		14657		14698		14739		14780		14821		14862		14903
		14658		14699		14740		14781		14822		14863		14904
		14659		14700		14741		14782		14823		14864		14905
		14660		14701		14742		14783		14824		14865		14906
		14661		14702		14743		14784		14825		14866		14907
		14662		14703		14744		14785		14826		14867		14908
		14663		14704		14745		14786		14827		14868		14909
		14664		14705		14746		14787		14828		14869		14910
		14665		14706		14747		14788		14829		14870		14911
		14666		14707		14748		14789		14830		14871		14911
		14667		14708		14749		14790		14831		14872		14913
		14668		14709		14749		14791		14832		14873		14913
		14669		14709		14751		14791		14832		14874		14914
		14670		14711		14751		14793		14833		14874		14915
		14671		14712		14753		14794		14835		14876		14917
		14672		14713		14754		14795		14836		14877		14918
		14673		14714		14755		14796		14837		14878		14919
		14674		14715		14756		14797		14838		14879		14920
		14675		14716		14757		14798		14839		14880		14921
		14676		14717		14758		14799		14840		14881		14922
		14677		14718		14759		14800		14841		14882		14923
		14678		14719		14760		14801		14842		14883		14924

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb		nb		nb		nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	
PPD	14925	PPD	14966	PPD	15007	PPD	15048	PPD	15089	PPD	15130	PPD	15171
FFD	14926	110	14967		15007	110	15049	FFD	15099		15131		15171
	14927		14968		15009		15049		15090		15131		15172
	14928		14969		15010		15050		15091		15132		15173
	14929		14970		15010		15052		15092		15134		15174
	14930		14971		15012		15052		15094		15135		15176
	14931		14972		15012		15054		15095		15136		15177
	14932		14973		15013		15055		15096		15137		15177
	14933		14974		15014		15056		15096		15137		15176
	14934		14975		15016		15057		15097		15139		15179
	14935		14976		15017		15057		15099		15140		15181
	14936		14977		15018		15059		15100		15141		15182
	14937		14978		15019		15060		15100		15141		15183
	14938		14979		15020		15061		15102		15142		15184
	14939		14980		15020		15062		15102		15143		15185
	14940		14981		15021		15062		15103		15144		15186
	14941		14982		15022		15063		15104		15145		15187
	14941		14983		15023		15065		15105		15146		15188
	14943		14984		15024		15065		15106		15147		15189
	14943		14985		15025		15067		15107		15149		15109
	14945		14986		15027		15067		15100		15149		15190
	14945		14986		15027		15068		15110		15150		15191
	14947		14988		15029		15070		15111		15151		15192
	14948		14989		15029		15070		15111		15152		15193
	14948		14989		15030		15071		15112		15153		15194
	14950		14991		15031		15072		15114		15154		15195
	14951		14991		15032		15074		15114		15156		15196
	14951		14992		15033		15074		15115		15156		15197
	14952		14993		15034		15076		15116		15157		15198
	14953		14994		15035		15076		15117		15158		15199
	14954		14995		15036		15077		15118		15160		15200
	14956		14997		15037		15079		15119		15161		15201
	14956		14997		15039		15079		15121		15162		15202
	14958		14999		15040		15081		15121		15162		15203
	14959		15000		15040		15082		15122		15164		15204
	14960 14961		15001 15002		15042 15043		15083 15084		15124 15125		15165 15166		15206 15207
	14961		15002		15043		15084		15125		15166		15207
	14963 14964		15004 15005		15045 15046		15086 15087		15127 15128		15168		15209 15210
	14964		15005		15046		15087		15128		15169 15170		15210
	14900		13000		1504/		12088		13129		131/0		15211
	l												

DTPA-HBV-IPV-135 (A.15MAR2018)

Treatment number associated to material : Prevnar 13

Trt. No	Bl.	Trt. No	Bl. nb	Trt. No		Trt. No	Bl. nb	Trt.	Bl. nb	Trt. No	Bl. nb	Trt. No	
PPD	15212	PPD	15253	PPD	15294	PPD	15335	PPD	15376	PPD	15417	PPD	15458
	15213		15254		15295		15336		15377		15418		15459
	15214		15255		15296		15337		15378		15419		15460
	15215		15256		15297		15338		15379		15420		15461
	15216		15257		15298		15339		15380		15421		15462
	15217		15258		15299		15340		15381		15422		15463
	15218		15259		15300		15341		15382		15423		15464
	15219		15260		15301		15342		15383		15424		15465
	15220		15261		15302		15343		15384		15425		15466
	15221		15262		15303		15344		15385		15426		15467
	15222		15263		15304		15345		15386		15427		15468
	15223		15264		15305		15346		15387		15428		15469
	15224		15265		15306		15347		15388		15429		15470
	15225		15266		15307		15348		15389		15430		15471
	15226		15267		15308		15349		15390		15431		15472
	15227		15268		15309		15350		15391		15432		15473
	15228		15269		15310		15351		15392		15433		15474
	15229		15270		15311		15352		15393		15434		15475
	15230		15271		15312		15353		15394		15435		15476
	15231		15272		15313		15354		15395		15436		15477
	15232		15273		15314		15355		15396		15437		15478
	15233		15274		15315		15356		15397		15438		15479
	15234		15275		15316		15357		15398		15439		15480
	15235		15276		15317		15358		15399		15440		15481
	15236		15277		15318		15359		15400		15441		15482
	15237		15278		15319		15360		15401		15442		15483
	15238		15279		15320		15361		15402		15443		15484
	15239		15280		15321		15362		15403		15444		15485
	15240		15281		15322		15363		15404		15445		15486
	15241		15282		15323		15364		15405		15446		15487
	15242		15283		15324		15365		15406		15447		15488
	15243		15284		15325		15366		15407		15448		15489
	15244		15285		15326		15367		15408		15449		15490
	15245		15286		15327		15368		15409		15450		15491
	15246		15287		15328		15369		15410		15451		15492
	15247		15288		15329		15370		15411		15452		15493
	15248		15289		15330		15371		15412		15453		15494
	15249		15290		15331		15372		15413		15454		15495
	15250		15291		15332		15373		15414		15455		15496
	15251		15292		15333		15374		15415		15456		15497
	15252		15293		15334		15375		15416		15457		15498
	l												

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. E	31.	Trt. Bl.		Bl.	Trt.	Bl.	Trt.		Trt.	Bl.	Trt.	. Bl.
No r	nb	No nb		nb		nb		nb	No	nb	No	nb
PPD 1	15499	PPD 15540	PPD	15581	PPD	15622	PPD	15663	PPD	15704	PPD	15745
	15500	15541		15582	110	15623	FFD	15664		15705		15746
	15501	15542		15583		15624		15665		15706		15747
	15502	15542		15584		15625		15666		15707		15747
	15503	15544		15585		15626		15667		15708		15749
	15504	15545		15586		15627		15668		15709		15750
	15504	15545		15586		15627		15669		15709		15751
	15506	15547		15588		15629		15670		15711		15752
	15506	15547		15588		15630		15670		15711		15752
		15549		15590								15754
	15508 15509	15549		15590		15631 15632		15672 15673		15713 15714		15754
	15510	15551		15591		15633		15674		15714		15756
	15510	15551		15592		15634		15675		15716		15757
	15511	15552		15593		15635		15676		15716		15757
	15513	15554		15595		15636		15677		15718		15759
	15514	15555		15596		15637		15678		15719		15760
	15515	15556		15597		15638		15679		15720		15761
	15516	15557		15598		15639		15680		15721		15762
	15517	15558		15599		15640		15681		15722		15763
	15518	15559		15600		15641		15682		15723		15764
	15519	15560		15601		15642		15683		15724		15765
	15520	15561		15602		15643		15684		15725		15766
	15521	15562		15603		15644		15685		15726		15767
	15522	15563		15604		15645		15686		15727		15768
	15523	15564		15605		15646		15687		15728		15769
	15524	15565		15606		15647		15688		15729		15770
	15525	15566		15607		15648		15689		15730		15771
	15526	15567		15608		15649		15690		15731		15772
	15527	15568		15609		15650		15691		15732		15773
	15528	15569		15610		15651		15692		15733		15774
	15529	15570		15611		15652		15693		15734		15775
	15530	15571		15612		15653		15694		15735		15776
	15531	15572		15613		15654		15695		15736		15777
	15532	15573		15614		15655		15696		15737		15778
	15533	15574		15615		15656		15697		15738		15779
	15534	15575		15616		15657		15698		15739		15780
	15535	15576		15617		15658		15699		15740		15781
	15536	15577		15618		15659		15700		15741		15782
	15537	15578		15619		15660		15701		15742		15783
	15538	15579		15620		15661		15702		15743		15784
1	15539	15580		15621		15662		15703		15744		15785

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
	45506	PPD	4.5005	PPD	4.50.00				45050	PPD		PPD	
PPD	15786		1001	FFU		PPD	15909	PPD	15950	–	15991	FFD	16032
	15787		15828		15869		15910		15951		15992		16033
	15788		15829		15870		15911		15952		15993		16034
	15789		15830		15871		15912		15953		15994		16035
	15790		15831		15872		15913		15954		15995		16036
	15791		15832		15873		15914		15955		15996		16037
	15792		15833		15874		15915		15956		15997		16038
	15793		15834		15875		15916		15957		15998		16039
	15794		15835		15876		15917		15958		15999		16040
	15795		15836		15877		15918		15959		16000		16041
	15796		15837		15878		15919		15960		16001		16042
	15797		15838		15879		15920		15961		16002		16043
	15798		15839		15880		15921		15962		16003		16044
	15799		15840		15881		15922		15963		16004		16045
	15800		15841		15882		15923		15964		16005		16046
	15801		15842		15883		15924		15965		16006		16047
	15802		15843		15884		15925		15966		16007		16048
	15803		15844		15885		15926		15967		16008		16049
	15804		15845		15886		15927		15968		16009		16050
	15805		15846		15887		15928		15969		16010		16051
	15806		15847		15888		15929		15970		16011		16052
	15807		15848		15889		15930		15971		16012		16053
	15808		15849		15890		15931		15972		16013		16054
	15809		15850		15891		15932		15973		16014		16055
	15810		15851		15892		15933		15974		16015		16056
	15811		15852		15893		15934		15975		16016		16057
	15812		15853		15894		15935		15976		16017		16058
	15813		15854		15895		15936		15977		16018		16059
	15814		15855		15896		15937		15978		16019		16060
	15815		15856		15897		15938		15979		16020		16061
	15816		15857		15898		15939		15980		16021		16062
	15817		15858		15899		15940		15981		16022		16063
	15818		15859		15900		15941		15982		16023		16064
	15819		15860		15901		15942		15983		16024		16065
	15820		15861		15902		15943		15984		16025		16066
	15821		15862		15903		15944		15985		16026		16067
	15822		15863		15904		15945		15986		16027		16068
	15823		15864		15905		15946		15987		16028		16069
	15824		15865		15906		15947		15988		16029		16070
	15825		15866		15907		15948		15989		16030		16071
	15826		15867		15908		15949		15990		16031		16072
	•												I .

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Treatment number associated to material : Prevnar 13

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
PPD 16073	PPD 16114	PPD 16155	PPD 16196	PPD 16237	PPD	PPD 16319
		10100			16278 16279	16319 16320
16074		16156	16197	16238		
16075		16157	16198	16239	16280	16321
16076	_	16158	16199	16240	16281	16322
16077		16159	16200	16241	16282	16323
16078		16160	16201	16242	16283	16324
16079		16161	16202	16243	16284	16325
16080	_	16162	16203	16244	16285	16326
16081		16163	16204	16245	16286	16327
16082		16164	16205	16246	16287	16328
16083		16165	16206	16247	16288	16329
16084		16166	16207	16248	16289	16330
16085		16167	16208	16249	16290	16331
16086	_	16168	16209	16250	16291	16332
16087		16169	16210	16251	16292	16333
16088		16170	16211	16252	16293	16334
16089		16171	16212	16253	16294	16335
16090		16172	16213	16254	16295	16336
16091		16173	16214	16255	16296	16337
16092		16174	16215	16256	16297	16338
16093		16175	16216	16257	16298	16339
16094		16176	16217	16258	16299	16340
16095		16177	16218	16259	16300	16341
16096		16178	16219	16260	16301	16342
16097		16179	16220	16261	16302	16343
16098		16180	16221	16262	16303	16344
16099		16181	16222	16263	16304	16345
16100	_	16182	16223	16264	16305	16346
16101		16183	16224	16265	16306	16347
16102		16184	16225	16266	16307	16348
16103	_	16185	16226	16267	16308	16349
16104		16186	16227	16268	16309	16350
16105		16187	16228	16269	16310	16351
16106	16147	16188	16229	16270	16311	16352
16107	16148	16189	16230	16271	16312	16353
16108		16190	16231	16272	16313	16354
16109	16150	16191	16232	16273	16314	16355
16110		16192	16233	16274	16315	16356
16111	16152	16193	16234	16275	16316	16357
16112	16153	16194	16235	16276	16317	16358
16113	16154	16195	16236	16277	16318	16359

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

16361	Trt	. Bl.	T	rt. Bl.										
PPD														
16361														
16362	PPD	16360	PPD	16401	PPD	16442	PPD	16483	PPD	16524	PPD	16565	PPE	16606
16363		16361		16402		16443		16484	–	16525		16566		16607
16363		16362		16403		16444		16485		16526		16567		16608
16365		16363		16404		16445		16486		16527		16568		16609
16366		16364		16405		16446		16487		16528		16569		16610
16367		16365		16406		16447		16488		16529		16570		16611
16368		16366		16407		16448		16489		16530		16571		16612
16369		16367		16408		16449		16490		16531		16572		16613
16370		16368		16409		16450		16491		16532		16573		16614
16371		16369		16410		16451		16492		16533		16574		16615
16372		16370		16411		16452		16493		16534		16575		16616
16373 16414 16455 16496 16537 16578 166 16374 16415 16456 16497 16538 16579 166 16375 16416 16457 16498 16539 16580 166 16376 16417 16458 16499 16540 16581 166 16377 16418 16459 16500 16541 16582 166 16378 16419 16460 16501 16542 16583 166 16379 16420 16461 16502 16543 16584 166 16380 16421 16462 16503 16544 16585 166 16381 16422 16463 16504 16545 16586 166 16382 16423 16464 16505 16546 16587 16586 166 16383 16424 16465 16506 16547 16588 166 16384 16425 16466 16507 16548 16589 166 16385 16426		16371		16412		16453		16494		16535		16576		16617
16374 16415 16456 16497 16538 16579 166 16375 16416 16457 16498 16539 16580 166 16376 16417 16488 16499 16540 16581 166 16377 16418 16459 16500 16541 16582 166 16378 16419 16460 16501 16542 16583 166 16379 16420 16461 16502 16543 16584 166 16380 16421 16462 16503 16544 16585 166 16381 16422 16463 16504 16545 16586 166 16382 16423 16464 16505 16546 16587 166 16383 16424 16465 16507 16548 16589 166 16384 16425 16467 16508 16549 16590 166 16385 16426 16467 16508 16549 16590 166 16386 16427 16468		16372		16413		16454		16495		16536		16577		16618
16375 16416 16457 16498 16539 16580 1668 16376 16417 16458 16499 16540 16581 1666 16377 16418 16459 16500 16541 16582 166 16378 16419 16460 16501 16542 16583 166 16379 16420 16461 16502 16543 16584 166 16380 16421 16462 16503 16544 16585 166 16381 16422 16463 16504 16545 16586 166 16382 16423 16464 16505 16546 16587 166 16383 16424 16465 16506 16547 16588 166 16384 16425 16466 16507 16548 16589 166 16385 16426 16467 16508 16549 16590 166 16386 16427 16468		16373		16414		16455		16496		16537		16578		16619
16376 16417 16458 16499 16540 16581 16681 16377 16418 16459 16500 16541 16582 166 16378 16419 16460 16501 16542 16583 166 16379 16420 16461 16502 16543 16584 166 16380 16421 16462 16503 16544 16585 166 16381 16422 16463 16504 16545 16586 166 16382 16423 16464 16505 16546 16587 166 16384 16424 16465 16506 16547 16588 166 16385 16424 16466 16507 16548 16589 166 16386 16427 16468 16509 16550 16591 166 16387 16428 16469 16510 16551 16591 166 16388 16429 16470 16511 16552 16593 166 16389 16430 164		16374		16415		16456		16497		16538		16579		16620
16377 16418 16459 16500 16541 16582 166 16378 16419 16460 16501 16542 16583 166 16379 16420 16461 16502 16543 16584 166 16380 16421 16462 16503 16544 16585 166 16381 16422 16463 16504 16545 16586 166 16382 16423 16464 16505 16546 16587 166 16383 16424 16465 16506 16547 16588 166 16384 16425 16466 16507 16548 16589 166 16385 16426 16467 16508 16549 16590 166 16386 16427 16468 16509 16550 16591 166 16387 16428 16469 16510 16551 16592 166 16388 16427 16468 16509 16551 16591 166 16389 16430 16471 16511 16551 16592 166 16390 16431 16472 16513 16554 16594 166		16375		16416		16457		16498		16539		16580		16621
16378 16419 16460 16501 16542 16583 166 16379 16420 16461 16502 16543 16584 166 16380 16421 16462 16503 16544 16585 166 16381 16422 16463 16504 16545 16586 166 16382 16423 16464 16505 16546 16587 166 16383 16424 16465 16506 16547 16588 166 16384 16425 16466 16507 16548 16589 166 16385 16426 16467 16508 16549 16590 166 16386 16427 16468 16509 16550 16590 166 16388 16429 16470 16511 16552 16593 166 16389 16430 16471 16512 16553 16594 166 16391 16432 16473 16514 16554 16595 166 16392 16433 16474		16376		16417		16458		16499		16540		16581		16622
16379 16420 16461 16502 16543 16584 1668 16380 16421 16462 16503 16544 16585 1666 16381 16422 16463 16504 16545 16586 1666 16382 16423 16464 16505 16546 16587 166 16383 16424 16465 16506 16547 16588 166 16384 16425 16466 16507 16548 16589 166 16385 16426 16467 16508 16549 16589 166 16386 16427 16468 16509 16550 16591 166 16387 16428 16469 16510 16551 16592 166 16388 16429 16470 16511 16552 16593 166 16389 16430 16471 16512 16553 16594 166 16391 16430 16471 16513 16554 16595 166 16391 16432 16		16377		16418		16459		16500		16541		16582		16623
16380 16421 16462 16503 16544 16585 166 16381 16422 16463 16504 16545 16586 166 16382 16423 16464 16505 16546 16587 166 16383 16424 16465 16506 16547 16588 166 16384 16425 16466 16507 16548 16589 166 16385 16426 16467 16508 16549 16590 166 16386 16427 16468 16509 16550 16591 166 16387 16428 16469 16510 16551 16592 166 16388 16429 16470 16511 16552 16593 166 16389 16430 16471 16512 16553 16594 166 16390 16431 16472 16513 16554 16595 166 16391 16432 16473 16514 16555 16596 166 16393 16434 16475		16378		16419		16460		16501		16542		16583		16624
16381 16422 16463 16504 16545 16586 166 16382 16423 16464 16505 16546 16587 166 16383 16424 16465 16506 16547 16588 166 16384 16425 16466 16507 16548 16589 166 16385 16426 16467 16508 16549 16590 166 16386 16427 16468 16509 16550 16591 166 16387 16428 16469 16510 16551 16592 166 16388 16429 16470 16511 16552 16593 166 16389 16430 16471 16512 16553 16594 166 16390 16431 16472 16513 16554 16595 166 16391 16432 16473 16513 16554 16595 166 16392 16433 16474 16515 16556 16597 166 16393 16434 16475		16379		16420		16461		16502		16543		16584		16625
16382 16423 16464 16505 16546 16587 166 16383 16424 16465 16506 16547 16588 166 16384 16425 16466 16507 16548 16589 166 16385 16426 16467 16508 16549 16590 166 16386 16427 16468 16509 16550 16591 166 16387 16428 16469 16510 16551 16592 166 16388 16429 16470 16511 16552 16593 166 16389 16430 16471 16512 16553 16594 166 16390 16431 16472 16513 16554 16595 166 16391 16432 16473 16514 16555 16596 166 16392 16433 16474 16515 16556 16597 166 16393 16434 16475 16516 16557 16598 166 16394 16435 16476														16626
16383 16424 16465 16506 16547 16588 166 16384 16425 16466 16507 16548 16589 166 16385 16426 16467 16508 16549 16590 166 16386 16427 16468 16509 16550 16591 166 16387 16428 16469 16510 16551 16592 166 16388 16429 16470 16511 16552 16593 166 16389 16430 16471 16512 16553 16594 166 16390 16431 16472 16513 16554 16595 166 16391 16432 16473 16514 16555 16596 166 16392 16433 16474 16515 16556 16597 166 16393 16434 16475 16516 16557 16598 166 16394 16435 16476 16517 16558 16599 166 16396 16437 16478		16381		16422		16463		16504		16545		16586		16627
16384 16425 16466 16507 16548 16589 166 16385 16426 16467 16508 16549 16590 166 16386 16427 16468 16509 16550 16591 166 16387 16428 16469 16510 16551 16592 166 16388 16429 16470 16511 16552 16593 166 16389 16430 16471 16512 16553 16594 166 16390 16431 16472 16513 16554 16595 166 16391 16432 16473 16514 16555 16596 166 16392 16433 16474 16515 16556 16597 166 16393 16434 16475 16516 16557 16598 166 16394 16435 16476 16517 16558 16599 166 16395 16436 16477 16518 16559 16600 166 16396 16437 16478		16382		16423		16464		16505				16587		16628
16385 16426 16467 16508 16549 16590 166 16386 16427 16468 16509 16550 16591 166 16387 16428 16469 16510 16551 16592 166 16388 16429 16470 16511 16552 16593 166 16389 16430 16471 16512 16553 16594 166 16390 16431 16472 16513 16554 16595 166 16391 16432 16473 16514 16555 16596 166 16392 16433 16474 16515 16556 16597 166 16393 16434 16475 16516 16557 16598 166 16394 16435 16476 16517 16558 16599 166 16395 16436 16477 16518 16559 16600 166 16396 16437 16478 16519 16560 16601 166 16398 16439 16480 16520 16561 16602 166 16399 16440 16481 16522 16563 16604 1660				16424		16465		16506		16547		16588		16629
16386 16427 16468 16509 16550 16591 166 16387 16428 16469 16510 16551 16592 166 16388 16429 16470 16511 16552 16593 166 16389 16430 16471 16512 16553 16594 166 16390 16431 16472 16513 16554 16595 166 16391 16432 16473 16514 16555 16596 166 16392 16433 16474 16515 16556 16597 166 16393 16434 16475 16516 16557 16598 166 16394 16435 16476 16517 16558 16599 166 16395 16436 16477 16518 16559 16600 166 16396 16437 16478 16519 16560 16601 166 16397 16438 16479 16520 16561 16602 166 16398 16440 16480 16521 16562 16603 166 16399 16440 16481 16522 16563 16604 16604 <td></td> <td>16384</td> <td></td> <td>16425</td> <td></td> <td>16466</td> <td></td> <td>16507</td> <td></td> <td>16548</td> <td></td> <td>16589</td> <td></td> <td>16630</td>		16384		16425		16466		16507		16548		16589		16630
16387 16428 16469 16510 16551 16592 166 16388 16429 16470 16511 16552 16593 166 16389 16430 16471 16512 16553 16594 166 16390 16431 16472 16513 16554 16595 166 16391 16432 16473 16514 16555 16596 166 16392 16433 16474 16515 16556 16597 166 16393 16434 16475 16516 16557 16598 166 16394 16435 16476 16516 16558 16599 166 16395 16436 16477 16518 16559 16600 166 16396 16437 16478 16519 16560 16601 166 16397 16438 16479 16520 16561 16602 166 16398 16439 16480 16521 16562 16603 166 16399 16440 16481 16522 16563 16604 166								16508		16549				16631
16388 16429 16470 16511 16552 16593 166 16389 16430 16471 16512 16553 16594 166 16390 16431 16472 16513 16554 16595 166 16391 16432 16473 16514 16555 16596 166 16392 16433 16474 16515 16556 16597 166 16393 16434 16475 16516 16557 16598 166 16394 16435 16476 16517 16558 16599 166 16395 16436 16477 16518 16559 16600 166 16396 16437 16478 16519 16560 16601 166 16397 16438 16479 16520 16561 16602 166 16398 16439 16480 16521 16562 16603 166 16399 16640 16481 16522 16563 16604 166				16427		16468		16509		16550				16632
16389 16430 16471 16512 16553 16594 166 16390 16431 16472 16513 16554 16595 166 16391 16432 16473 16514 16555 16596 166 16392 16433 16474 16515 16556 16597 166 16393 16434 16475 16516 16557 16598 166 16394 16435 16476 16517 16558 16599 166 16395 16436 16477 16518 16559 16600 166 16396 16437 16478 16519 16560 16601 166 16397 16438 16479 16520 16561 16602 166 16398 16439 16480 16521 16562 16603 166 16399 16440 16481 16522 16563 16604 1660		16387		16428		16469		16510		16551		16592		16633
16390 16431 16472 16513 16554 16595 166 16391 16432 16473 16514 16555 16596 166 16392 16433 16474 16515 16556 16597 166 16393 16434 16475 16516 16557 16598 166 16394 16435 16476 16517 16558 16599 166 16395 16436 16477 16518 16559 16600 166 16396 16437 16478 16519 16560 16601 166 16397 16438 16479 16520 16561 16602 166 16398 16439 16480 16521 16562 16603 166 16399 16440 16481 16522 16563 16604 166		16388		16429		16470		16511		16552		16593		16634
16391 16432 16473 16514 16555 16596 166 16392 16433 16474 16515 16556 16597 166 16393 16434 16475 16516 16557 16598 166 16394 16435 16476 16517 16558 16599 166 16395 16436 16477 16518 16559 16600 166 16396 16437 16478 16519 16560 16601 166 16397 16438 16479 16520 16561 16602 166 16398 16439 16480 16521 16562 16603 166 16399 16440 16481 16522 16563 16604 166														16635
16392 16433 16474 16515 16556 16597 166 16393 16434 16475 16516 16557 16598 166 16394 16435 16476 16517 16558 16599 166 16395 16436 16477 16518 16559 16600 166 16396 16437 16478 16519 16560 16601 166 16397 16438 16479 16520 16561 16602 166 16398 16439 16480 16521 16562 16603 166 16399 16440 16481 16522 16563 16604 166														16636
16393 16434 16475 16516 16557 16598 166 16394 16435 16476 16517 16558 16599 166 16395 16436 16477 16518 16559 16600 166 16396 16437 16478 16519 16560 16601 166 16397 16438 16479 16520 16561 16602 166 16398 16439 16480 16521 16562 16603 166 16399 16440 16481 16522 16563 16604 166														16637
16394 16435 16476 16517 16558 16599 166 16395 16436 16477 16518 16559 16600 166 16396 16437 16478 16519 16560 16601 166 16397 16438 16479 16520 16561 16602 166 16398 16439 16480 16521 16562 16603 166 16399 16440 16481 16522 16563 16604 166								16515						16638
16395 16436 16477 16518 16559 16600 166 16396 16437 16478 16519 16560 16601 166 16397 16438 16479 16520 16561 16602 166 16398 16439 16480 16521 16562 16603 166 16399 16440 16481 16522 16563 16604 166										16557				16639
16396 16437 16478 16519 16560 16601 166 16397 16438 16479 16520 16561 16602 166 16398 16439 16480 16521 16562 16603 166 16399 16440 16481 16522 16563 16604 166														16640
16397 16438 16479 16520 16561 16602 166 16398 16439 16480 16521 16562 16603 166 16399 16440 16481 16522 16563 16604 166														16641
16398 16439 16480 16521 16562 16603 166 16399 16440 16481 16522 16563 16604 166														16642
16399 16440 16481 16522 16563 16604 166														16643
														16644
16400 16441 16482 16523 16564 16605 16605 16605														16645
		16400		16441		16482		16523		16564		16605		16646

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt	. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No nb		lo nb	No	nb	No	nb		nb	No	nb
PPD	16647	PPD 1668	R8 PPD	16729	PPD	16770	PPD	16811	PPD	16852	PPD	16893
יוו	16648	1668	, ,	16730	110	16771	יוו	16812		16853		16894
	16649	1669		16731		16772		16813		16854		16895
	16650	1669		16732		16773		16814		16855		16896
	16651	1669		16733		16774		16815		16856		16897
	16652	1669		16734		16775		16816		16857		16898
	16653	1669		16735		16776		16817		16858		16899
	16654	1669		16736		16777		16818		16859		16900
	16655	1669		16737		16778		16819		16860		16901
	16656	1669		16738		16779		16820		16861		16902
	16657	1669		16739		16780		16821		16862		16903
	16658	1669		16740		16781		16822		16863		16904
	16659	1670		16741		16782		16823		16864		16905
	16660	1670		16742		16783		16824		16865		16906
	16661	1670		16743		16784		16825		16866		16907
	16662	1670		16744		16785		16826		16867		16908
	16663	1670		16745		16786		16827		16868		16909
	16664	1670		16746		16787		16828		16869		16910
	16665	1670		16747		16788		16829		16870		16911
	16666	1670		16748		16789		16830		16871		16911
	16667	1670		16749		16790		16831		16872		16913
	16668	1670		16750		16791		16832		16873		16913
	16669	1671		16751		16792		16833		16874		16915
	16670	1671		16752		16793		16834		16875		16916
	16671	1671		16753		16794		16835		16876		16917
	16672	1671		16754		16795		16836		16877		16918
	16673	1671		16755		16796		16837		16878		16919
	16674	1671		16756		16797		16838		16879		16920
	16675	1671		16757		16798		16839		16880		16920
	16676	1671		16758		16799		16840		16881		16922
	16677	1671		16759		16800		16841		16882		16923
	16678	1671		16760		16801		16842		16883		16924
	16679	1672		16761		16802		16843		16884		16925
	16680	1672		16762		16803		16844		16885		16926
	16681	1672		16763		16804		16845		16886		16927
	16682	1672		16764		16805		16846		16887		16928
	16683	1672		16765		16806		16847		16888		16929
	16684	1672		16766		16807		16848		16889		16930
	16685	1672		16767		16808		16849		16890		16931
	16686	1672		16768		16809		16850		16891		16932
	16687	1672		16769		16810		16851		16892		16933
	1000/	10/2		10,00		10010		10001		10072		10733
	ı											

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	. Bl. o nb	Trt. No	Bl. nb	Trt. No	Bl. nb		nb		Bl. nb	No	Bl. nb		Trt. Bl. No nb
PPD	16934	PPD	16975	PPD	17016	PPD	17057	PPD	17098	PPD	17139	PP	PD 17180
	16935		16976		17017		17058		17099		17140		17181
	16936		16977		17018		17059		17100		17141		17182
	16937		16978		17019		17060		17101		17142		17183
	16938		16979		17020		17061		17102		17143		17184
	16939		16980		17021		17062		17103		17144		17185
	16940		16981		17022		17063		17104		17145		17186
	16941		16982		17023		17064		17105		17146		17187
	16942		16983		17024		17065		17106		17147		17188
	16943		16984		17025		17066		17107		17148		17189
	16944		16985		17026		17067		17108		17149		17190
	16945		16986		17027		17068		17109		17150		17191
	16946		16987		17028		17069		17110		17151		17192
	16947		16988		17029		17070		17111		17152		17193
	16948		16989		17030		17071		17112		17153		17194
	16949		16990		17031		17072		17113		17154		17195
	16950		16991		17032		17073		17114		17155		17196
	16951		16992		17033		17074		17115		17156		17197
	16952		16993		17034		17075		17116		17157		17198
	16953		16994		17035		17076		17117		17158		17199
	16954		16995		17036		17077		17118		17159		17200
	16955		16996		17037		17078		17119		17160		17201
	16956		16997		17038		17079		17120		17161		17202
	16957		16998		17039		17080		17121		17162		17203
	16958		16999		17040		17081		17122		17163		17204
	16959		17000		17041		17082		17123		17164		17205
	16960		17001		17042		17083		17124		17165		17206
	16961		17002		17043		17084		17125		17166		17207
	16962		17003		17044		17085		17126		17167		17208
	16963		17004		17045		17086		17127		17168		17209
	16964		17005		17046		17087		17128		17169		17210
	16965		17006		17047		17088		17129		17170		17211
	16966		17007		17048		17089		17130		17171		17212
	16967		17008		17049		17090		17131		17172		17213
	16968		17009		17050		17091		17132		17173		17214
	16969 16970		17010		17051 17052		17092		17133		17174		17215
			17011				17093		17134		17175		17216
	16971		17012		17053		17094		17135		17176		17217
	16972 16973		17013 17014		17054 17055		17095 17096		17136		17177 17178		17218
	16973		17014		17055		17096		17137 17138		17178		17219 17220
	109/4		1/012		1/026		1/09/		1/138		1/1/9		1/220
					ı								

DTPA-HBV-IPV-135 (A.15MAR2018)

Treatment number associated to material : Prevnar 13

110 1/221 1/2 1/202 1/2 1/011 1/010	PPD 17467 17468
17222 17263 17304 17345 17386 17427	
17223 17264 17305 17346 17387 17428 17224 17265 17306 17347 17388 17429	17469 17470
17225 17266 17307 17348 17389 17430 17226 17267 17308 17349 17390 17431 17227 17268 17309 17350 17391 17432	17471 17472 17473
17227 17269 17309 17351 17392 17432 17228 17269 17310 17351 17392 17433 17229 17270 17311 17352 17393 17434	17473 17474 17475
17230 17271 17312 17353 17394 17435 17231 17272 17313 17354 17395 17436	17476 17477
17232 17273 17314 17355 17396 17437 17233 17274 17315 17356 17397 17438 17234 17275 17316 17357 17398 17439	17478 17479 17480
17235 17276 17318 17359 17440 17441	17481 17482
17237 17278 17319 17360 17401 17442 17238 17279 17320 17361 17402 17443	17483 17484
17239 17280 17321 17362 17403 17444 17240 17281 17322 17363 17404 17445 17241 17282 17323 17364 17405 17446	17485 17486 17487
17242 17283 17365 17406 17447 17243 17244 17325 17366 17407 17448	17487 17488 17489
17244 17285 17326 17367 17408 17449 17245 17286 17327 17368 17409 17450	17490 17491
17246 17287 17328 17369 17410 17451 17247 17288 17329 17370 17411 17452 17288 17309 17411 17452	17492 17493
17248 17289 17330 17371 17412 17453 17249 17290 17331 17372 17413 17454 17250 17291 17332 17373 17414 17455	17494 17495 17496
17251 17292 17333 17374 17415 17456 17252 17293 17334 17375 17416 17457	17497 17498
17253 17294 17335 17376 17417 17458 17254 17295 17336 17377 17418 17459 17255 17296 17337 17378 17419 17460	17499 17500 17501
17256 17297 17338 17379 17420 17461 17257 17298 17339 17380 17421 17462	17501 17502 17503
17258 17299 17340 17381 17422 17463 17259 17300 17341 17382 17423 17464 17259 17300 17341 17382 17423 17464	17504 17505
17260 17301 17342 17383 17424 17465 17361 17302 17343 17384 17425 17466	17506 17507

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. No	nb	Trt. No		Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	
No	nb 17508 17509 17510 17511 17512 17513 17514 17515 17516 17517 17518 17519 17520 17520 17521 17522 17523 17524 17525 17526 17527 17528 17529 17530 17531 17532 17533 17534 17535 17536 17537 17538 17537	PPD	7549 17550 17551 17552 17553 17554 17555 17556 17557 17558 17558 17560 17561 17562 17563 17564 17564 17565 17568 17567 17568 17567 17570 17571 17572 17573 17574 17575 17578 17578 17578 17578 17579 17580	PPD	nb 17590 17591 17592 17593 17594 17595 17596 17597 17598 17599 17600 17601 17602 17603 17604 17605 17608 17609 17611 17612 17613 17614 17615 17616 17617 17618 17616 17617 17618 17619 17619 17619 17620 17621 17620 17621 17620 17621 17622 17621 17620 17621 17622 17621 17622 1	PPD	nb 17631 17632 17633 17634 17635 17636 17637 17638 17639 17640 17641 17642 17643 17644 17645 17646 17647 17650 17650 17651 17652 17653 17655 17656 17657 17658 17658 17659 176601 17661	No	nb 17672 17673 17674 17675 17676 17677 17678 17679 17680 17681 17682 17683 17684 17685 17686 17687 17688 17689 17690 17691 17692 17693 17694 17695 17696 17697 17698 177699 17700 17701 17701 17702 17703	No	nb 17713 17714 17715 17716 17717 17718 17719 17720 17721 17722 17723 17724 17725 17726 17727 17728 17728 17729 17730 17731 17732 17733 17734 17735 17736 17737 17738 17738 17739 17741 17742 17742 17743 17744	PPD	17754 17755 17756 17756 17757 17758 17759 17760 17761 17762 17763 17764 17765 17766 17767 17768 17770 17771 17772 17773 17771 17772 17773 17776 17777 17778 17778 17779 17780 17779 17781 17778
	17540 17541 17542 17543 17544 17545 17546 17546 17547		17581 17582 17583 17584 17585 17586 17587 17588 17589		17622 17623 17624 17625 17626 17627 17628 17629 17630		17663 17664 17665 17666 17667 17668 17669 17670		17704 17705 17706 17707 17708 17709 17710 17711 17712		17745 17746 17747 17748 17749 17750 17751 17752 17753		17786 17787 17788 17789 17790 17791 17792 17793 17794

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
	No nb	No nb	No nb	No nb	No nb	No nb
PPD 17795 17796 17797 17798 17799 17800 17801 17802 17803 17804 17805 17806 17807 17808 17809 17810 17811 17812 17812 17813 17814 17815 17816 17817 17818 17819 17819 17820 17821 17822 17823 17824 17825 17826 17827 17828 17829 17830 17830 17830	PPD 17836 17837 17838 17839 17840 17840 17841 17842 17843 17844 17845 17846 17847 17848 17849 17850 17851 17852 17853 17854 17855 17856 17857 17858 17859 17859 17860 17861 17862 17863 17864 17865 17866 17867 17868 17868 17869 17868	PPD 17877 17878 17878 17879 17880 17881 17882 17883 17884 17885 17886 17887 17888 17890 17891 17892 17893 17894 17895 17896 17897 17898 17899 17900 17901 17902 17903 17904 17905 17906 17907 17908 17909 17909 17909 17909 17910 17911	PPD 17918 17919 17920 17921 17922 17923 17924 17925 17926 17927 17928 17929 17930 17931 17932 17933 17934 17935 17936 17937 17938 17939 17940 17941 17942 17943 17944 17945 17946 17947 17948 17949 17950 17951 17952	PPD 17959 17960 17961 17962 17963 17964 17965 17966 17967 17968 17969 17970 17971 17972 17973 17974 17975 17978 17977 17988 17979 17980 17981 17982 17983 17984 17985 17986 17987 17988 17989 17980 17981 17982 17983 17984 17985 17986 17987 17988 17999 17990 17991 17992 17993	PPD 18000 18001 18002 18003 18004 18005 18006 18007 18008 18009 18010 18011 18012 18013 18014 18015 18016 18017 18018 18019 18020 18021 18022 18023 18024 18025 18026 18027 18028 18029 18030 18031 18032 18033 18034 18035 18036	PPD 18041 18042 18043 18044 18045 18046 18047 18050 18051 18052 18053 18054 18055 18055 18056 18057 18056 18057 18060 18061 18062 18063 18064 18062 18063 18064 18064 18065 18067 18066 18067 18068 18067 18079
17832	17873	17914	17955	17996	18037	18078
17833	17874	17915	17956	17997	18038	18079
17834	17875	17916	17957	17998	18039	18080
17835	17876	17917	17958	17999	18040	18081

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt	. Bl.	Trt	. Bl.	Trt	. Bl.	Trt	. Bl.	Trt	. Bl.	Trt.	. Bl.	Trt	. Bl.
No	o nb		o nb		o nb		o nb	N	o nb		nb	1	lo nb
PPD	18082	PPD	18123	PPD	18164	PPD	18205	PPD	18246	PPD	18287	PPD	18328
	18083		18124		18165		18206		18247		18288		18329
	18084		18125		18166		18207		18248		18289		18330
	18085		18126		18167		18208		18249		18290		18331
	18086		18127		18168		18209		18250		18291		18332
	18087		18128		18169		18210		18251		18292		18333
	18088		18129		18170		18211		18252		18293		18334
	18089		18130		18171		18212		18253		18294		18335
	18090		18131		18172		18213		18254		18295		18336
	18091		18132		18173		18214		18255		18296		18337
	18092		18133		18174		18215		18256		18297		18338
	18093		18134		18175		18216		18257		18298		18339
	18094		18135		18176		18217		18258		18299		18340
	18095		18136		18177		18218		18259		18300		18341
	18096		18137		18178		18219		18260		18301		18342
	18097		18138		18179		18220		18261		18302		18343
	18098		18139		18180		18221		18262		18303		18344
	18099		18140		18181		18222		18263		18304		18345
	18100		18141		18182		18223		18264		18305		18346
	18101		18142		18183		18224		18265		18306		18347
	18102		18143		18184		18225		18266		18307		18348
	18103		18144		18185		18226		18267		18308		18349
	18104		18145		18186		18227		18268		18309		18350
	18105		18146		18187		18228		18269		18310		18351
	18106		18147		18188		18229		18270		18311		18352
	18107		18148		18189		18230		18271		18312		18353
	18108		18149		18190		18231		18272		18313		18354
	18109		18150		18191		18232		18273		18314		18355
	18110		18151		18192		18233		18274		18315		18356
	18111		18152		18193		18234		18275		18316		18357
	18112		18153		18194		18235		18276		18317		18358
	18113		18154		18195		18236		18277		18318		18359
	18114		18155		18196		18237		18278		18319		18360
	18115		18156		18197		18238		18279		18320		18361
	18116		18157		18198		18239		18280		18321		18362
	18117		18158		18199		18240		18281		18322		18363
	18118		18159		18200		18241		18282		18323		18364
	18119		18160		18201		18242		18283		18324		18365
	18120		18161		18202		18243		18284		18325		18366
	18121		18162		18203		18244		18285		18326		18367
	18122		18163		18204		18245		18286		18327		18368
											_		

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb		nb	Trt. No	nb		nb		nb	Trt. No	Bl. nb	Trt. No	
PPD	18369	PPD	18410	PPD	18451	PPD	18492	PPD	18533	PPD	18574	PPD	18615
PPD	18370	110	18411	110	18452	FFD	18493	FFD	18534		18575		18616
	18371		18412		18453		18494		18535		18576		18617
	18371		18412		18453		18494		18535		18576		18617
	18372				18454		18495				18578		18618
			18414						18537				
	18374		18415		18456		18497		18538		18579		18620
	18375		18416		18457		18498		18539		18580		18621
	18376		18417		18458		18499		18540		18581		18622
	18377		18418		18459		18500		18541		18582		18623
	18378		18419		18460		18501		18542		18583		18624
	18379		18420		18461		18502		18543		18584		18625
	18380		18421		18462		18503		18544		18585		18626
	18381		18422		18463		18504		18545		18586		18627
	18382		18423		18464		18505		18546		18587		18628
	18383		18424		18465		18506		18547		18588		18629
	18384		18425		18466		18507		18548		18589		18630
	18385		18426		18467		18508		18549		18590		18631
	18386		18427		18468		18509		18550		18591		18632
	18387		18428		18469		18510		18551		18592		18633
	18388		18429		18470		18511		18552		18593		18634
	18389		18430		18471		18512		18553		18594		18635
	18390		18431		18472		18513		18554		18595		18636
	18391		18432		18473		18514		18555		18596		18637
	18392		18433		18474		18515		18556		18597		18638
	18393		18434		18475		18516		18557		18598		18639
	18394		18435		18476		18517		18558		18599		18640
	18395		18436		18477		18518		18559		18600		18641
	18396		18437		18478		18519		18560		18601		18642
	18397		18438		18479		18520		18561		18602		18643
	18398		18439		18480		18521		18562		18603		18644
	18399		18440		18481		18522		18563		18604		18645
	18400		18441		18482		18523		18564		18605		18646
	18401		18442		18483		18524		18565		18606		18647
	18402		18443		18484		18525		18566		18607		18648
	18403		18444		18485		18526		18567		18608		18649
	18404		18445		18486 18487		18527 18528		18568		18609		18650
	18405		18446						18569		18610		18651
	18406		18447		18488		18529		18570		18611		18652
	18407		18448		18489		18530		18571		18612		18653
	18408		18449		18490		18531		18572		18613		18654
	18409		18450		18491		18532		18573		18614		18655
	l												

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. No	nb	Trt. No	Bl. nb	Trt. No	nb	Trt. No	nb	Trt. No	Bl. nb	Trt. No	
No	nb	No	nb		nb	PPD	nb	No	nb			PPD	
	18677 18678 18679 18680 18681 18682 18683 18684 18685 18686 18687 18689 18690 18691 18692 18693 18694 18695 18696		18718 18719 18720 18721 18722 18723 18724 18725 18726 18727 18728 18729 18730 18731 18732 18733 18734 18735 18735		18759 18760 18761 18762 18763 18764 18765 18766 18767 18768 18769 18770 18771 18772 18773 18774 18775 18776		18800 18801 18802 18803 18804 18805 18806 18807 18808 18809 18810 18811 18812 18813 18814 18815 18816 18817 18818		18841 18842 18843 18844 18845 18846 18847 18848 18850 18851 18852 18853 18854 18855 18856 18857 18858 18858 18859 18860		18882 18883 18884 18885 18886 18887 18888 18889 18890 18891 18892 18893 18894 18895 18896 18897 18898 18899 18900 18901		18923 18924 18925 18926 18927 18928 18930 18931 18932 18933 18934 18935 18938 18939 18940 18941 18942

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	18943	PPD 18984	PPD 19025	PPD 19066	PPD 19107	PPD 19148	PPD 19189
FFD	18944	18985	19026	19067	19108	19149	19199
	18945	18986	19027	19068	19109	19149	19190
	18946	18987	19027	19069	19110	19151	19191
	18947	18988	19029	19070	19111	19151	19193
	18948	18989	19029	19070	19111	19152	19193
	18949	18990	19030	19071	19112	19153	19194
	18950	18991	19031	19072	19113	19154	19195
	18951	18992	19032	19073	19114	19156	19197
	18952	18993	19033	19074	19115	19157	19197
	18953	18994	19034	19076	19117	19157	19199
	18954	18995	19035	19076	19117	19159	19200
	18955	18996	19036	19077	19110	19160	19200
	18955	18996	19037	19078	19119	19161	19201
	18957	18998	19030	19079	19121	19162	19202
	18958	18999	19039	19080	19121	19162	19203
	18958	18999	19040	19081	19122	19163	19204
	18959	19000	19041	19082	19123	19164	19205
		19001	19042		19124		
	18961		19043	19084		19166	19207
	18962 18963	19003 19004	19044	19085 19086	19126 19127	19167 19168	19208 19209
	18964	19004	19045	19086	19127	19168	19209
	18964	19005	19046	19087	19128	19169	19210
	18965	19006	19047	19088	19129	19170	19211
	18967	19007	19048	19089	19130	19171	19212
	18968	19008	19050	19090	19131	19172	19213
	18968	19009	19050	19091	19132	19173	
							19215
	18970	19011	19052 19053	19093	19134	19175	19216 19217
	18971	19012	19053	19094 19095	19135 19136	19176 19177	
	18972 18973	19013 19014	19054	19095	19136	19177	19218 19219
	18974	19014	19056	19096	19137	19179	19219
	18974	19015	19056	19097	19138	19179	19220
	18976	19016	19057	19098	19139	19181	19222
	18977	19017	19059	19100	19141	19182	19223
	18978	19018	19059	19100	19141	19183	19223
	18978	19019	19060	19101	19142	19183	19224
	18980					19184	
		19021 19022	19062 19063	19103	19144		19226
	18981 18982	19022	19063	19104	19145	19186 19187	19227
				19105	19146		19228
	18983	19024	19065	19106	19147	19188	19229
	I						

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt.		Trt.		Trt.		Trt.		Trt.		Trt.	
No nb		nb	No		No	nb	No	nb	No	nb	No	nb
PPD 1923	o PPD	19271	PPD	19312	PPD	19353	PPD	19394	PPD	19435	PPD	19476
1923		19272		19313		19354		19395		19436		19477
1923		19273		19314		19355		19396		19437		19478
1923		19274		19315		19356		19397		19438		19479
1923		19275		19316		19357		19398		19439		19480
1923		19276		19317		19358		19399		19440		19481
1923		19277		19318		19359		19400		19441		19482
1923	7	19278		19319		19360		19401		19442		19483
1923		19279		19320		19361		19402		19443		19484
1923		19280		19321		19362		19403		19444		19485
1924		19281		19322		19363		19404		19445		19486
1924	1	19282		19323		19364		19405		19446		19487
1924	2	19283		19324		19365		19406		19447		19488
1924	3	19284		19325		19366		19407		19448		19489
1924	4	19285		19326		19367		19408		19449		19490
1924	5	19286		19327		19368		19409		19450		19491
1924	6	19287		19328		19369		19410		19451		19492
1924	7	19288		19329		19370		19411		19452		19493
1924	8	19289		19330		19371		19412		19453		19494
1924	9	19290		19331		19372		19413		19454		19495
1925	0	19291		19332		19373		19414		19455		19496
1925	1	19292		19333		19374		19415		19456		19497
1925	2	19293		19334		19375		19416		19457		19498
1925	3	19294		19335		19376		19417		19458		19499
1925	4	19295		19336		19377		19418		19459		19500
1925		19296		19337		19378		19419		19460		19501
1925		19297		19338		19379		19420		19461		19502
1925	7	19298		19339		19380		19421		19462		19503
1925		19299		19340		19381		19422		19463		19504
1925		19300		19341		19382		19423		19464		19505
1926		19301		19342		19383		19424		19465		19506
1926		19302		19343		19384		19425		19466		19507
1926		19303		19344		19385		19426		19467		19508
1926		19304		19345		19386		19427		19468		19509
1926		19305		19346		19387		19428		19469		19510
1926		19306		19347		19388		19429		19470		19511
1926		19307		19348		19389		19430		19471		19512
1926		19308		19349		19390		19431		19472		19513
1926		19309		19350		19391		19432		19473		19514
1926		19310		19351		19392		19433		19474		19515
1927	0	19311		19352		19393		19434		19475		19516

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. No	Bl. nb		nb	Trt. No		Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb
										PPD			
PPD	1001	PPD	19558	PPD		PPD	19640	PPD	19681	PPD	19722	PPD	19763
	19518		19559		19600		19641		19682		19723		19764
	19519		19560		19601		19642		19683		19724		19765
	19520		19561		19602		19643		19684		19725	1	19766
	19521		19562		19603		19644		19685		19726	1	19767
	19522		19563		19604		19645		19686		19727		19768
	19523		19564		19605		19646		19687		19728	1	19769
	19524		19565		19606		19647		19688		19729	1	19770
	19525		19566		19607		19648		19689		19730	1	19771
	19526		19567		19608		19649		19690		19731		19772
	19527		19568		19609		19650		19691		19732	1	19773
	19528		19569		19610		19651		19692		19733		19774
	19529		19570		19611		19652		19693		19734		19775
	19530		19571		19612		19653		19694		19735	1	19776
	19531		19572		19613		19654		19695		19736	1	19777
	19532		19573		19614		19655		19696		19737		19778
	19533		19574		19615		19656		19697		19738		19779
	19534		19575		19616		19657		19698		19739		19780
	19535		19576		19617		19658		19699		19740		19781
	19536		19577		19618		19659		19700		19741	1	19782
	19537		19578		19619		19660		19701		19742	1	19783
	19538		19579		19620		19661		19702		19743		19784
	19539		19580		19621		19662		19703		19744		19785
	19540		19581		19622		19663		19704		19745		19786
	19541		19582		19623		19664		19705		19746		19787
	19542		19583		19624		19665		19706		19747	1	19788
	19543		19584		19625		19666		19707		19748	1	19789
	19544		19585		19626		19667		19708		19749		19790
	19545		19586		19627		19668		19709		19750		19791
	19546		19587		19628		19669		19710		19751		19792
	19547		19588		19629		19670		19711		19752		19793
	19548		19589		19630		19671		19712		19753		19794
	19549		19590		19631		19672		19713		19754		19795
	19550		19591		19632		19673		19714		19755		19796
	19551		19592		19633		19674		19715		19756		19797
	19552		19593		19634		19675		19716		19757		19798
	19553		19594		19635		19676		19717		19758		19799
	19554		19595		19636		19677		19718		19759		19800
	19555		19596		19637		19678		19719		19760		19801
	19556		19597		19638		19679		19720		19761		19802
	19557		19598		19639		19680		19721		19762		19803

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No		Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	
PPD		PPD	13010	PPD		PPD		PPD	19968	PPD	20009	PPD	20050
	19805		19846		19887		19928		19969		20010		20051
	19806		19847		19888		19929		19970		20011		20052
	19807		19848		19889		19930		19971		20012		20053
	19808		19849		19890		19931		19972		20013		20054
	19809		19850		19891		19932		19973		20014		20055
	19810		19851		19892		19933		19974		20015		20056
	19811		19852		19893		19934		19975		20016		20057
	19812		19853		19894		19935		19976		20017		20058
	19813		19854		19895		19936		19977		20018		20059
	19814		19855		19896		19937		19978		20019		20060
	19815		19856		19897		19938		19979		20020		20061
	19816		19857		19898		19939		19980		20021		20062
	19817		19858		19899		19940		19981		20022		20063
	19818		19859		19900		19941		19982		20023		20064
	19819		19860		19901		19942		19983		20024		20065
	19820		19861		19902		19943		19984		20025		20066
	19821		19862		19903		19944		19985		20026		20067
	19822		19863		19904		19945		19986		20027		20068
	19823		19864		19905		19946		19987		20028		20069
	19824		19865		19906		19947		19988		20029		20070
	19825		19866		19907		19948		19989		20030		20071
	19826		19867		19908		19949		19990		20031		20072
	19827		19868		19909		19950		19991		20032		20073
	19828		19869		19910		19951		19992		20033		20074
	19829		19870		19911		19952		19993		20034		20075
	19830		19871		19912		19953		19994		20035		20076
	19831		19872		19913		19954		19995		20036		20077
	19832		19873		19914		19955		19996		20037		20078
	19833		19874		19915		19956		19997		20038		20079
	19834		19875		19916		19957		19998		20039		20080
	19835		19876		19917		19958		19999		20040		20081
	19836		19877		19918		19959		20000		20041		20082
	19837		19878		19919		19960		20001		20042		20083
	19838		19879		19920		19961		20002		20043		20084
	19839		19880		19921		19962		20003		20044		20085
	19840		19881		19922		19963		20004		20045		20086
	19841		19882		19923		19964		20005		20046		20087
	19842		19883		19924		19965		20006		20047		20088
	19843		19884		19925		19966		20007		20048		20089
	19844		19885		19926		19967		20008		20049		20090

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.					
No.	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	20091	PPD 20132	PPD 20173	PPD 20214	PPD 20255	PPD 20296	PPD 20337
	20092	20133	20174	20215	20256	20297	20338
	20093	20134	20175	20216	20257	20298	20339
	20094	20135	20176	20217	20258	20299	20340
	20095	20136	20177	20218	20259	20300	20341
	20096	20137	20178	20219	20260	20301	20342
	20097	20138	20179	20220	20261	20302	20343
	20098	20139	20180	20221	20262	20303	20344
	20099	20140	20181	20222	20263	20304	20345
	20100	20141	20182	20223	20264	20305	20346
	20101	20142	20183	20224	20265	20306	20347
	20102	20143	20184	20225	20266	20307	20348
	20103	20144	20185	20226	20267	20308	20349
	20104	20145	20186	20227	20268	20309	20350
	20105	20146	20187	20228	20269	20310	20351
	20106	20147	20188	20229	20270	20311	20352
	20107	20148	20189	20230	20271	20312	20353
	20108	20149	20190	20231	20272	20313	20354
	20109	20150	20191	20232	20273	20314	20355
	20110 20111	20151 20152	20192 20193	20233 20234	20274 20275	20315 20316	20356 20357
	20111	20152	20193	20234	20275	20316	20358
	20112	20153	20194	20235	20276	20317	20359
	20113	20154	20195	20236	20277	20319	20360
	20114	20156	20197	20237	20279	20319	20360
	20116	20157	20198	20230	20280	20320	20362
	20117	20158	20199	20240	20281	20321	20362
	20118	20159	20200	20241	20282	20323	20364
	20119	20160	20201	20242	20283	20324	20365
	20120	20161	20202	20243	20284	20325	20366
	20121	20162	20203	20244	20285	20326	20367
	20122	20163	20204	20245	20286	20327	20368
	20123	20164	20205	20246	20287	20328	20369
	20124	20165	20206	20247	20288	20329	20370
	20125	20166	20207	20248	20289	20330	20371
	20126	20167	20208	20249	20290	20331	20372
	20127	20168	20209	20250	20291	20332	20373
	20128	20169	20210	20251	20292	20333	20374
	20129	20170	20211	20252	20293	20334	20375
	20130	20171	20212	20253	20294	20335	20376
	20131	20172	20213	20254	20295	20336	20377

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	B1.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	20378	PPD 20419	PPD 20460	PPD 20501	PPD 20542	PPD 20583	PPD 20624
FFD	20378	20419	20461	20502	20543	20584	20625
	20379	20420	20462	20502	20543	20585	20626
	20381	20421	20463	20504	20545	20586	20627
	20382	20422	20464	20505	20546	20587	20628
	20382	20423	20465	20506	20547	20588	20629
	20384	20424	20465	20507	20547	20589	20630
	20385	20426	20467	20508	20549	20590	20631
	20386	20427	20467	20509	20550	20591	20632
	20387	20427	20469	20510	20551	20592	20633
	20388	20429	20470	20511	20552	20593	20634
	20389	20430	20471	20512	20553	20594	20635
	20390	20431	20472	20512	20554	20595	20636
	20391	20432	20473	20514	20555	20596	20637
	20392	20433	20474	20515	20556	20597	20638
	20393	20434	20475	20516	20557	20598	20639
	20394	20435	20476	20517	20558	20599	20640
	20395	20436	20477	20518	20559	20600	20641
	20396	20437	20478	20519	20560	20601	20642
	20397	20438	20479	20520	20561	20602	20643
	20398	20439	20480	20521	20562	20603	20644
	20399	20440	20481	20522	20563	20604	20645
	20400	20441	20482	20523	20564	20605	20646
	20401	20442	20483	20524	20565	20606	20647
	20402	20443	20484	20525	20566	20607	20648
	20403	20444	20485	20526	20567	20608	20649
	20404	20445	20486	20527	20568	20609	20650
	20405	20446	20487	20528	20569	20610	20651
	20406	20447	20488	20529	20570	20611	20652
	20407	20448	20489	20530	20571	20612	20653
	20408	20449	20490	20531	20572	20613	20654
	20409	20450	20491	20532	20573	20614	20655
	20410	20451	20492	20533	20574	20615	20656
	20411	20452	20493	20534	20575	20616	20657
	20412	20453	20494	20535	20576	20617	20658
	20413	20454	20495	20536	20577	20618	20659
	20414	20455	20496	20537	20578	20619	20660
	20415	20456	20497	20538	20579	20620	20661
	20416	20457	20498	20539	20580	20621	20662
	20417	20458	20499	20540	20581	20622	20663
	20418	20459	20500	20541	20582	20623	20664
	_						

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.	B1.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	20665	PPD	20706	PPD	20747	PPD	20788	PPD	20829	PPD	20870
PPD	20666	110	20707	110	20748	110	20789		20830		20870
	20667		20707		20749		20790		20831		20871
	20668		20709		20750		20791		20832		20872
	20669		20710		20751		20792		20833		20874
	20670		20710		20752		20793		20834		20875
	20671		20712		20753		20794		20835		20876
	20672		20713		20754		20795		20836		20877
	20673		20714		20755		20796		20837		20878
	20674		20715		20756		20797		20838		20879
	20675		20716		20757		20798		20839		20880
	20676		20717		20758		20799		20840		20881
	20677		20718		20759		20800		20841		20882
	20678		20719		20760		20801		20842		20883
	20679		20720		20761		20802		20843		20884
	20680		20721		20762		20803		20844		20885
	20681		20722		20763		20804		20845		20886
	20682		20723		20764		20805		20846		20887
	20683		20724		20765		20806		20847		20888
	20684		20725		20766		20807		20848		20889
	20685		20726		20767		20808		20849		20890
	20686		20727		20768		20809		20850		20891
	20687		20728		20769		20810		20851		20892
	20688		20729		20770		20811		20852		20893
	20689		20730		20771		20812		20853		20894
	20690		20731		20772		20813		20854		20895
	20691		20732		20773		20814		20855		20896
	20692		20733		20774		20815		20856		20897
	20693		20734		20775		20816		20857		20898
	20694		20735		20776		20817		20858		20899
	20695		20736		20777		20818		20859		20900
	20696		20737		20778		20819		20860		20901
	20697		20738		20779		20820		20861		20902
	20698		20739		20780		20821		20862		20903
	20699		20740		20781		20822		20863		20904
	20700		20741		20782		20823		20864		20905
	20701		20742		20783		20824		20865		20906
	20702		20743		20784		20825		20866		
	20703		20744		20785		20826		20867		
	20704		20745		20786		20827		20868		
	20705		20746		20787		20828		20869		
			ı								

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
No nb	No nb	No nb	No nb	No nb	No nb	No nb
1231	1272	1313	1354	1395	1436	1477
1232	1273	1314	1355	1396	1437	1478
1233	1274	1315	1356	1397	1438	1479
1234	1275	1316	1357	1398	1439	1480

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	nb	Trt. No		Trt. No	nb	Trt. Bl. No nb		Trt. Bl. No nb		Trt. No	nb	Trt. No	nb
No	nb	No	nb	No	nb 	No	nb	No	nb 	No	nb	No	nb
	1517 1518 1519 1520 1521		1558 1559 1560 1561 1562		1599 1600 1601 1602 1603		1640 1641 1642 1643 1644		1681 1682 1683 1684 1685		1722 1723 1724 1725 1726		1763 1764 1765 1766 1767

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
	No nb					
1807	1848	1889	1930	1971	2012	2053
1808	1849	1890	1931	1972	2013	2054

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb		nb	Trt. No	nb	Trt. No	nb
PPD	2055	PPD	2096	PPD	2137	PPD	2178	PPD	2219	PPD	2260	PPD	2301
	2056		2097		2138		2179		2220		2261		2302
	2057		2098		2139		2180		2221		2262		2303
	2058		2099		2140		2181		2222		2263		2304
	2059		2100		2141		2182		2223		2264		2305
	2060		2101		2142		2183		2224		2265		2306
	2061		2102		2143		2184		2225		2266		2307
	2062		2103		2144		2185		2226		2267		2308
	2063		2104		2145		2186		2227		2268		2309
	2064		2105		2146		2187		2228		2269		2310
	2065		2106		2147		2188		2229		2270		2311
	2066		2107		2148		2189		2230		2271		2312
	2067		2108		2149		2190		2231		2272		2313
	2068		2109		2150		2191		2232		2273		2314
	2069		2110		2151		2192		2233		2274		2315
	2070		2111		2152		2193		2234		2275		2316
	2071		2112		2153		2194		2235		2276		2317
	2072		2113		2154		2195		2236		2277		2318
	2073		2114		2155		2196		2237		2278		2319
	2074		2115		2156		2197		2238		2279		2320
	2075		2116		2157		2198		2239		2280		2321
	2076		2117		2158		2199		2240		2281		2322
	2077		2118		2159		2200		2241		2282		2323
	2078		2119		2160		2201		2242		2283		2324
	2079		2120		2161		2202		2243		2284		2325
	2080		2121		2162		2203		2244		2285		2326
	2081		2122		2163		2204		2245		2286		2327
	2082		2123		2164		2205		2246		2287		2328
	2083		2124		2165		2206		2247		2288		2329
	2084		2125		2166		2207		2248		2289		2330
	2085		2126		2167		2208		2249		2290		2331
	2086		2127		2168		2209		2250		2291		2332
	2087		2128		2169		2210		2251		2292		2333
	2088		2129		2170		2211		2252		2293		2334
	2089		2130		2171		2212		2253		2294		2335
	2090		2131		2172		2213		2254		2295		2336
	2091		2132		2173		2214		2255		2296		2337
	2092		2133		2174		2215		2256		2297		2338
	2093		2134		2175		2216		2257		2298		2339
	2094		2135		2176		2217		2258		2299		2340
	2095		2136		2177		2218		2259		2300		2341

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD 2342	PPD 2383	PPD 2424	PPD 2465	PPD 2506	PPD 2547	PPD 2588
2343	2384	2425	2466	2507	2548	2589
2344	2385	2426	2467	2508	2549	2590
2345	2386	2427	2468	2509	2550	2591
2346	2387	2428	2469	2510	2551	2592
2347	2388	2429	2470	2511	2552	2593
2348	2388	2430	2471	2512	2553	2594
2349	2390	2431	2472	2513	2554	2595
2350	2391	2432	2473	2514	2555	2596
2351	2392	2433	2474	2515	2556	2597
2352	2393	2434	2475	2516	2557	2598
2353	2394	2435	2476	2517	2558	2599
2354	2395	2436	2477	2518	2559	2600
2355	2396	2437	2478	2519	2560	2601
2356	2397	2438	2479	2520	2561	2602
2357	2398	2439	2480	2521	2562	2603
2358 2359 2360 2361 2362 2363 2364 2365	2399 2400 2401 2402 2403 2404 2405 2406	2440 2441 2442 2443 2444 2445 2446 2447	2481 2482 2483 2484 2485 2486 2487 2488	2522 2523 2524 2525 2526 2527 2528 2529	2563 2564 2565 2566 2567 2568 2569 2570	2604 2605 2606 2607 2608 2609 2610
2366	2407	2448	2489	2530	2571	2612
2367	2408	2449	2490	2531	2572	2613
2368	2409	2450	2491	2532	2573	2614
2369	2410	2451	2492	2533	2574	2615
2370	2411	2452	2493	2534	2575	2616
2371	2412	2453	2494	2535	2576	2617
2372	2413	2454	2495	2536	2577	2618
2373	2414	2454	2496	2537	2578	2619
2374	2415	2456	2497	2538	2579	2620
2375	2416	2457	2498	2539	2580	2621
2376	2417	2458	2499	2540	2581	2622
2377	2418	2459	2500	2541	2582	2623
2378	2419	2460	2501	2542	2583	2624
2379	2420	2461	2502	2543	2584	2625
2380	2421	2462	2503	2544	2585	2626
2381	2422	2463	2504	2545	2586	2627
2382	2422	2464	2505	2546	2587	2628

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
2669	2710	2751	2792	2833	2874	2915

DTPA-HBV-IPV-135 (A.15MAR2018)

PPD 2916 PPD 2957 PPD 2998 PPD 3039 PPD 3081 3121 PPD 2917 2958 2999 3040 3081 3122 3123 3121 2918 2919 2960 3000 3041 3082 3123 3124 2929 2920 2961 3002 3043 3084 3125 3126 2921 2962 3003 3044 3085 3126 3126 2922 2963 3004 3045 3086 3127 3128 2922 2963 3004 3045 3086 3127 3128 2924 2965 3006 3047 3088 3129 3223 2964 3005 3046 3047 3088 3129 2922 2966 3007 3048 3089 3110 3126 2927 2968 3008 3049 3090 3131 322 2928 2966 3007 3048 3049 3090 3131 322 2928 2969 3010 3051 3092 3133 3134 2930 2911 3012 3053 3093 3134 2930 2911 3012 3053 3093 3134 2930 2911 3012 3053 3094 3135 2931 2972 3013 3054 3094 3094 3135 2931 2972 3013 3054 3094 3095 3136 3136 2933 2973 3014 3055 3094 3135 2933 2974 3015 3056 3096 3097 3138 2934 2975 3016 3057 3098 3099 3141 2032 2933 2977 3018 3017 3058 3096 3077 3188 2934 2977 3018 3017 3059 3099 3141 2032 2935 2977 3018 3017 3059 3099 3141 2032 2933 2977 3018 3017 3059 3099 3141 2032 2933 2977 3018 3017 3059 3099 3141 2032 2933 2977 3018 3017 3059 3099 3141 2032 2935 2977 3018 3017 3059 3099 3141 2032 2935 2977 3018 3019 3009 3009 3141 2033 2934 2977 3018 3019 3009 3009 3141 2033 2934 2977 3018 3019 3009 3009 3141 2033 3099 3141 2032 2934 2977 3018 3019 3009 3009 3141 2033 3099 3141 2033 3099 3141 2032 2934 2977 3018 3009 3009 3141 2033 3099 3141 2033 3099 3141 2033 3099 3141 2033 3099 3141 2033 3099 3141 2033 3099 3141 3059 3099 3099 3099 3099 3099 3099 3099	Trt. No	nb	No nb		Trt. No	nb								
Pro														
2918 2999 3000 3041 3082 3123 2919 2960 3001 3042 3083 3124 2920 2961 3002 3043 3084 3125 2921 2962 3003 3044 3085 3126 2922 2963 3004 3045 3086 3127 2923 2964 3005 3046 3087 3128 2924 2965 3006 3047 3088 3129 2925 2966 3007 3048 3089 3130 2927 2968 3009 3050 3091 3131 2927 2968 3009 3050 3091 3133 2927 2968 3009 3051 3092 3133 2929 2970 3011 3052 3093 3134 2929 2970 3011 3052 3093 3135 2931 2972 3013	PPD	2916	PPD	2957	PPD	2998	PPD	3039	PPD	3080	PPD	3121	PPD	3162
2919 2960 3001 3042 3083 3124 2920 2961 3002 3043 3084 3125 2921 2962 3003 3044 3085 3126 2922 2963 3004 3045 3086 3127 2923 2964 3005 3046 3087 3128 2924 2965 3006 3047 3088 3129 2925 2966 3007 3048 3089 3130 2926 2967 3008 3049 3090 3131 2927 2968 3009 3051 3092 3133 2928 2969 3010 3051 3092 3133 2929 2970 3011 3052 3093 3134 2930 2971 3012 3053 3094 3135 2931 2972 3013 3054 3095 3136 2932 2973 3014		2917		2958		2999		3040		3081		3122		3163
2920 2961 3002 3043 3084 3125 2921 2962 3003 3044 3085 3126 2922 2963 3004 3045 3086 3127 2924 2965 3006 3047 3088 3129 2925 2966 3007 3048 3089 3130 2926 2967 3008 3049 3090 3131 2927 2968 3009 3051 3091 3132 2928 2969 3010 3051 3092 3133 2929 2970 3011 3052 3093 3134 2930 2971 3012 3053 3094 3135 2931 2972 3013 3054 3095 3136 2931 2972 3013 3054 3095 3136 2931 2972 3013 3054 3095 3133 2931 2972 3013		2918		2959		3000		3041		3082		3123		3164
2921 2962 3003 3044 3085 3126 2922 2963 3004 3045 3086 3127 2923 2964 3005 3046 3087 3128 2924 2965 3006 3047 3088 3129 2925 2966 3007 3048 3089 3130 2926 2967 3008 3049 3050 3131 2927 2968 3009 3050 3091 3132 2928 2969 3010 3051 3092 3133 2929 2970 3011 3052 3093 3134 2930 2971 3012 3053 3094 3135 2931 2972 3013 3054 3095 3136 2932 2973 3014 3055 3096 3137 2933 2974 3015 3056 3097 3138 2934 2975 3016		2919		2960		3001		3042		3083				3165
2922 2963 3004 3045 3086 3127 2923 2964 3005 3046 3087 3128 2924 2965 3006 3047 3088 3129 2926 2966 3007 3048 3089 3130 2927 2968 3009 3050 3091 3131 2927 2968 3009 3051 3092 3133 2929 2970 3011 3052 3093 3134 2930 2971 3012 3053 3094 3135 2931 2972 3013 3054 3095 3136 2931 2972 3013 3054 3095 3136 2931 2972 3013 3054 3095 3136 2932 2973 3014 3055 3096 3137 2933 2974 3015 3056 3097 3138 2934 2975 3016		2920		2961		3002		3043		3084		3125		3166
2923 2964 3005 3046 3087 3128 2924 2965 3006 3047 3088 3129 2926 2967 3008 3049 3090 3131 2927 2968 3009 3050 3091 3132 2928 2969 3010 3051 3092 3133 2929 2970 3011 3052 3093 3134 2930 2971 3012 3053 3094 3135 2931 2972 3013 3054 3095 3136 2932 2973 3014 3055 3096 3137 2933 2974 3015 3056 3097 3138 2934 2975 3016 3057 3098 3139 2934 2975 3016 3057 3098 3139 2935 2976 3017 3058 3099 3140 2937 2978 3019		2921		2962		3003		3044		3085		3126		3167
2924 2965 3006 3047 3088 3129 2925 2966 3007 3048 3099 3130 2926 2967 3008 3049 3090 3131 2927 2968 3009 3050 3091 3132 2928 2969 3010 3051 3092 3133 2929 2970 3011 3052 3093 3134 2930 2971 3012 3053 3094 3135 2931 2972 3013 3054 3095 3136 2931 2972 3014 3055 3096 3137 2932 2973 3014 3055 3096 3137 2932 2975 3016 3057 3098 3139 2934 2975 3016 3057 3098 3139 2935 2976 3017 3058 3099 3140 2937 2978 3019		2922		2963		3004		3045		3086		3127		3168
2925 2966 3007 3048 3089 3130 2926 2967 3008 3049 3090 3131 2927 2968 3009 3050 3091 3132 2928 2969 3010 3051 3092 3133 2929 2970 3011 3052 3093 3134 2930 2971 3012 3053 3094 3135 2931 2972 3013 3054 3095 3136 2932 2973 3014 3055 3096 3137 2933 2974 3015 3056 3097 3138 2934 2975 3016 3057 3098 3139 2935 2976 3017 3058 3099 3140 2936 2977 3018 3059 3100 3141 2937 2978 3019 3060 3101 3142 2938 2979 3020 3061 3102 3143 2939 2980 3021 3062		2923		2964		3005		3046		3087		3128		3169
2926 2967 3008 3049 3090 3131 2927 2968 3009 3050 3091 3132 2928 2969 3010 3051 3092 3133 2929 2970 3011 3052 3093 3134 2930 2971 3013 3053 3094 3135 2931 2972 3013 3054 3095 3136 2932 2973 3014 3055 3096 3137 2933 2974 3015 3056 3097 3138 2934 2975 3016 3057 3098 3139 2935 2976 3017 3058 3099 3140 2936 2977 3018 3059 3100 3141 2937 2978 3019 3060 3101 3142 2938 2979 3020 3061 3102 3143 2939 2980 3021 3062 3103 3144 2940 2981 3023 3063		2924		2965		3006		3047		3088		3129		3170
2927 2968 3009 3050 3091 3132 2928 2969 3010 3051 3092 3133 2929 2970 3011 3052 3093 3134 2930 2971 3012 3053 3094 3135 2931 2972 3013 3054 3095 3136 2932 2973 3014 3055 3096 3137 2933 2974 3015 3056 3097 3138 2934 2975 3016 3057 3098 3139 2935 2976 3017 3058 3099 3140 2936 2977 3018 3059 3100 3141 2937 2978 3019 3060 3101 3142 2938 2979 3020 3061 3102 3143 2939 2980 3021 3062 3103 3144 2940 2981 3022 3063 3104 3145 2941 2982 3023 3064		2925		2966		3007		3048		3089		3130		3171
2928 2969 3010 3051 3092 3133 2929 2970 3011 3052 3093 3134 2930 2971 3012 3053 3094 3135 2931 2972 3013 3054 3095 3136 2932 2973 3014 3055 3096 3137 2933 2974 3015 3056 3097 3138 2934 2975 3016 3057 3098 3139 2935 2976 3017 3058 3099 3140 2936 2977 3018 3059 3100 3141 2937 2978 3019 3060 3101 3142 2938 2979 3020 3061 3102 3143 2939 2980 3021 3062 3103 3144 2940 2981 3022 3063 3104 3145 2941 2982 3023 3064 3105 3146 2942 2983 3026 3066		2926		2967		3008		3049		3090		3131		3172
2929 2970 3011 3052 3093 3134 2930 2971 3012 3053 3094 3135 2931 2972 3013 3054 3095 3136 2932 2973 3014 3055 3096 3137 2933 2974 3015 3056 3097 3138 2934 2975 3016 3057 3098 3139 2935 2976 3017 3058 3099 3140 2936 2977 3018 3059 3100 3141 2937 2978 3019 3060 3101 3142 2938 2979 3020 3061 3102 3143 2939 2980 3021 3062 3103 3144 2940 2981 3022 3063 3104 3145 2941 2982 3023 3064 3105 3146 2942 2983 3024 3065 3106 3147 2943 2984 3025 3066		2927		2968		3009		3050		3091		3132		3173
2930 2971 3012 3053 3094 3135 2931 2972 3013 3054 3095 3136 2932 2973 3014 3055 3096 3137 2933 2974 3015 3056 3097 3138 2934 2975 3016 3057 3098 3139 2935 2976 3017 3058 3099 3140 2936 2977 3018 3059 3100 3141 2937 2978 3019 3060 3101 3142 2938 2979 3020 3061 3102 3143 2939 2980 3021 3062 3103 3144 2940 2981 3022 3063 3104 3145 2941 2982 3023 3064 3105 3146 2942 2983 3024 3065 3106 3147 2943 2984 3025 3066 3107 3148 2944 2985 3026 3067				2969		3010				3092				3174
2931 2972 3013 3055 3096 3137 2932 2973 3014 3055 3096 3137 2933 2974 3015 3056 3097 3138 2934 2975 3016 3057 3098 3139 2935 2976 3017 3058 3099 3140 2936 2977 3018 3059 3100 3141 2937 2978 3019 3060 3101 3142 2938 2979 3020 3061 3102 3143 2939 2980 3021 3062 3103 3144 2940 2981 3022 3063 3104 3145 2941 2982 3023 3064 3105 3146 2942 2983 3024 3065 3106 3147 2943 2984 3025 3066 3107 3148 2944 2985 3026 3067 3108 3149 2945 2986 3027 3068				2970								3134		3175
2932 2974 3015 3056 3097 3138 2933 2974 3015 3056 3097 3138 2934 2975 3016 3057 3098 3139 2935 2976 3017 3058 3099 3140 2936 2977 3018 3059 3100 3141 2937 2978 3019 3060 3101 3142 2938 2979 3020 3061 3102 3143 2939 2980 3021 3062 3103 3144 2940 2981 3022 3063 3104 3145 2941 2982 3023 3064 3105 3146 2942 2983 3024 3065 3106 3147 2943 2984 3025 3066 3107 3148 2944 2985 3026 3067 3108 3149 2945 2986 3027 3068 3109 3150 2947 2988 3029 3070						3012				3094				3176
2933 2974 3015 3056 3097 3138 2934 2975 3016 3057 3098 3139 2935 2976 3017 3058 3099 3140 2936 2977 3018 3059 3100 3141 2937 2978 3019 3060 3101 3142 2938 2979 3020 3061 3102 3143 2939 2980 3021 3062 3103 3144 2940 2981 3022 3063 3104 3145 2941 2982 3023 3064 3105 3146 2942 2983 3024 3065 3106 3147 2943 2984 3025 3066 3107 3148 2944 2985 3026 3067 3108 3149 2946 2987 3028 3069 3110 3150 2947 2988 3029 3070 3111 3152 2949 2990 3031 3072										3095				3177
2934 2975 3016 3057 3098 3139 2935 2976 3017 3058 3099 3140 2936 2977 3018 3059 3100 3141 2937 2978 3019 3060 3101 3142 2938 2979 3020 3061 3102 3143 2939 2980 3021 3062 3103 3144 2940 2981 3022 3063 3104 3145 2941 2982 3023 3064 3105 3146 2942 2983 3024 3065 3106 3147 2943 2984 3025 3066 3107 3148 2944 2985 3026 3067 3108 3149 2945 2986 3027 3068 3109 3150 2946 2987 3028 3069 3110 3151 2947 2988 3029 3070 3111 3152 2948 2989 3030 3071														3178
2935 2976 3017 3058 3099 3140 2936 2977 3018 3059 3100 3141 2937 2978 3019 3060 3101 3142 2938 2979 3020 3061 3102 3143 2939 2980 3021 3062 3103 3144 2940 2981 3022 3063 3104 3145 2941 2982 3023 3064 3105 3146 2942 2983 3024 3065 3106 3147 2943 2984 3025 3066 3107 3148 2944 2985 3026 3067 3108 3149 2945 2986 3027 3068 3109 3150 2946 2987 3028 3069 3110 3151 2948 2989 3030 3071 3112 3153 2949 2990 3031 3072 3113 3154 2950 2991 3032 3073														3179
2936 2977 3018 3059 3100 3141 2937 2978 3019 3060 3101 3142 2938 2979 3020 3061 3102 3143 2939 2980 3021 3062 3103 3144 2940 2981 3022 3063 3104 3145 2941 2982 3023 3064 3105 3146 2942 2983 3024 3065 3106 3147 2943 2984 3025 3066 3107 3148 2944 2985 3026 3067 3108 3149 2945 2986 3027 3068 3109 3150 2946 2987 3028 3069 3110 3151 2947 2988 3029 3070 3111 3152 2948 2989 3030 3071 3112 3153 2949 2990 3031 3072 3113 3154 2950 2991 3032 3073														3180
2937 2978 3019 3060 3101 3142 2938 2979 3020 3061 3102 3143 2939 2980 3021 3062 3103 3144 2940 2981 3022 3063 3104 3145 2941 2982 3023 3064 3105 3146 2942 2983 3024 3065 3106 3147 2943 2984 3025 3066 3107 3148 2944 2985 3026 3067 3108 3149 2945 2986 3027 3068 3109 3150 2946 2987 3028 3069 3110 3151 2947 2988 3029 3070 3111 3152 2948 2989 3030 3071 3112 3153 2949 2990 3031 3072 3113 3154 2950 2991 3032 3073 3114 3155 2951 2992 3033 3074														3181
2938 2979 3020 3061 3102 3143 2939 2980 3021 3062 3103 3144 2940 2981 3022 3063 3104 3145 2941 2982 3023 3064 3105 3146 2942 2983 3024 3065 3106 3147 2943 2984 3025 3066 3107 3148 2944 2985 3026 3067 3108 3149 2945 2986 3027 3068 3109 3150 2946 2987 3028 3069 3110 3151 2947 2988 3029 3070 3111 3152 2948 2989 3030 3071 3112 3153 2949 2990 3031 3072 3113 3154 2950 2991 3032 3073 3114 3155 2951 2992 3033 3074 3115 3156 2952 2993 3034 3075 3116 3157 2953 2994 3035 3076 3117 3158 2954 2995 3036 3077 <td></td> <td>3182</td>														3182
2939 2980 3021 3062 3103 3144 2940 2981 3022 3063 3104 3145 2941 2982 3023 3064 3105 3146 2942 2983 3024 3065 3106 3147 2943 2984 3025 3066 3107 3148 2944 2985 3026 3067 3108 3149 2945 2986 3027 3068 3109 3150 2946 2987 3028 3069 3110 3151 2947 2988 3029 3070 3111 3152 2948 2989 3030 3071 3112 3153 2949 2990 3031 3072 3113 3154 2950 2991 3032 3073 3114 3155 2951 2992 3033 3074 3115 3156 2952 2993 3034 3075 3116 3157 2953 2994 3035 3076 3117 3158 2954 2995 3036 3077 3118 3159 2955 2996 3037 3078 <th></th> <th>3183</th>														3183
2940 2981 3022 3063 3104 3145 2941 2982 3023 3064 3105 3146 2942 2983 3024 3065 3106 3147 2943 2984 3025 3066 3107 3148 2944 2985 3026 3067 3108 3149 2945 2986 3027 3068 3109 3150 2946 2987 3028 3069 3110 3151 2947 2988 3029 3070 3111 3152 2948 2989 3030 3071 3112 3153 2949 2990 3031 3072 3113 3154 2950 2991 3032 3073 3114 3155 2951 2992 3033 3074 3115 3156 2952 2993 3034 3075 3116 3157 2953 2994 3035 3076 3117 3158 2954 2995 3036 3077 3118 3159 2955 2996 3037 3078 3119 3160														3184
2941 2982 3023 3064 3105 3146 2942 2983 3024 3065 3106 3147 2943 2984 3025 3066 3107 3148 2944 2985 3026 3067 3108 3149 2945 2986 3027 3068 3109 3150 2946 2987 3028 3069 3110 3151 2947 2988 3029 3070 3111 3152 2948 2989 3030 3071 3112 3153 2949 2990 3031 3072 3113 3154 2950 2991 3032 3073 3114 3155 2951 2992 3033 3074 3115 3156 2952 2993 3034 3075 3116 3157 2953 2994 3035 3076 3117 3158 2954 2995 3036 3077 3118 3159 2955 2996 3037 3078 3119 3160														3185
2942 2983 3024 3065 3106 3147 2943 2984 3025 3066 3107 3148 2944 2985 3026 3067 3108 3149 2945 2986 3027 3068 3109 3150 2946 2987 3028 3069 3110 3151 2947 2988 3029 3070 3111 3152 2948 2989 3030 3071 3112 3153 2949 2990 3031 3072 3113 3154 2950 2991 3032 3073 3114 3155 2951 2992 3033 3074 3115 3156 2952 2993 3034 3075 3116 3157 2953 2994 3035 3076 3117 3158 2954 2995 3036 3077 3118 3159 2955 2996 3037 3078 3119 3160														3186
2943 2984 3025 3066 3107 3148 2944 2985 3026 3067 3108 3149 2945 2986 3027 3068 3109 3150 2946 2987 3028 3069 3110 3151 2947 2988 3029 3070 3111 3152 2948 2989 3030 3071 3112 3153 2949 2990 3031 3072 3113 3154 2950 2991 3032 3073 3114 3155 2951 2992 3033 3074 3115 3156 2952 2993 3034 3075 3116 3157 2953 2994 3035 3076 3117 3158 2954 2995 3036 3077 3118 3159 2955 2996 3037 3078 3119 3160														3187
2944 2985 3026 3067 3108 3149 2945 2986 3027 3068 3109 3150 2946 2987 3028 3069 3110 3151 2947 2988 3029 3070 3111 3152 2948 2989 3030 3071 3112 3153 2949 2990 3031 3072 3113 3154 2950 2991 3032 3073 3114 3155 2951 2992 3033 3074 3115 3156 2952 2993 3034 3075 3116 3157 2953 2994 3035 3076 3117 3158 2954 2995 3036 3077 3118 3159 2955 2996 3037 3078 3119 3160														3188
2945 2986 3027 3068 3109 3150 2946 2987 3028 3069 3110 3151 2947 2988 3029 3070 3111 3152 2948 2989 3030 3071 3112 3153 2949 2990 3031 3072 3113 3154 2950 2991 3032 3073 3114 3155 2951 2992 3033 3074 3115 3156 2952 2993 3034 3075 3116 3157 2953 2994 3035 3076 3117 3158 2954 2995 3036 3077 3118 3159 2955 2996 3037 3078 3119 3160														3189 3190
2946 2987 3028 3069 3110 3151 2947 2988 3029 3070 3111 3152 2948 2989 3030 3071 3112 3153 2949 2990 3031 3072 3113 3154 2950 2991 3032 3073 3114 3155 2951 2992 3033 3074 3115 3156 2952 2993 3034 3075 3116 3157 2953 2994 3035 3076 3117 3158 2954 2995 3036 3077 3118 3159 2955 2996 3037 3078 3119 3160														3190
2947 2988 3029 3070 3111 3152 2948 2989 3030 3071 3112 3153 2949 2990 3031 3072 3113 3154 2950 2991 3032 3073 3114 3155 2951 2992 3033 3074 3115 3156 2952 2993 3034 3075 3116 3157 2953 2994 3035 3076 3117 3158 2954 2995 3036 3077 3118 3159 2955 2996 3037 3078 3119 3160														3191
2948 2989 3030 3071 3112 3153 2949 2990 3031 3072 3113 3154 2950 2991 3032 3073 3114 3155 2951 2992 3033 3074 3115 3156 2952 2993 3034 3075 3116 3157 2953 2994 3035 3076 3117 3158 2954 2995 3036 3077 3118 3159 2955 2996 3037 3078 3119 3160														3192
2949 2990 3031 3072 3113 3154 2950 2991 3032 3073 3114 3155 2951 2992 3033 3074 3115 3156 2952 2993 3034 3075 3116 3157 2953 2994 3035 3076 3117 3158 2954 2995 3036 3077 3118 3159 2955 2996 3037 3078 3119 3160														3194
2950 2991 3032 3073 3114 3155 2951 2992 3033 3074 3115 3156 2952 2993 3034 3075 3116 3157 2953 2994 3035 3076 3117 3158 2954 2995 3036 3077 3118 3159 2955 2996 3037 3078 3119 3160														3195
2951 2992 3033 3074 3115 3156 2952 2993 3034 3075 3116 3157 2953 2994 3035 3076 3117 3158 2954 2995 3036 3077 3118 3159 2955 2996 3037 3078 3119 3160														3196
2952 2993 3034 3075 3116 3157 2953 2994 3035 3076 3117 3158 2954 2995 3036 3077 3118 3159 2955 2996 3037 3078 3119 3160														3197
2953 2994 3035 3076 3117 3158 2954 2995 3036 3077 3118 3159 2955 2996 3037 3078 3119 3160														3198
2954 2995 3036 3077 3118 3159 2955 2996 3037 3078 3119 3160														3199
2955 2996 3037 3078 3119 3160														3200
														3201
														3202

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	nb	Trt. Bl. No nb		No nb		Trt. No	nb	Trt. Bl. No nb		No	Trt. Bl. No nb		Bl. nb
PPD		PPD		PPD		PPD		PPD		PPD	3408 3409 3410 3411 3412 3413 3414 3415 3416 3417 3418 3419 3420 3421 3422 3423 3424 3425 3426 3427 3428 3424 3435 3436 3437 3438 3434 3435 3434 3435 3434 3435 3434 3435 3434 3435 3436 3437 3438 3439 3441 3442 3443 3444 3445 3446 3447	PPD	3449 3450 3451 3452 3453 3454 3455 3456 3457 3461 3462 3463 3463 3464 3465 3466 3467 3473 3474 3473 3474 3477 3478 3477 3478 3477 3478 3477 3478 3477 3478 3477 3478 3478

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD 3490	PPD 3531	PPD 3572	PPD 3613	PPD 3654	PPD 3695	PPD 3736
3491	3532	3573	3614	3655	3696	3737
3492	3533	3574	3615	3656	3697	3738
3493	3534	3575	3616	3657	3698	3739
3494	3535	3576	3617	3658	3699	3740
3495	3536	3577	3618	3659	3700	3741
3496	3537	3578	3619	3660	3701	3742
3497	3538	3579	3620	3661	3702	3743
3498	3539	3580	3621	3662	3703	3744
3499	3540	3581	3622	3663	3704	3745
3500	3541	3582	3623	3664	3705	3746
3501	3542	3583	3624	3665	3706	3747
3502	3543	3584	3625	3666	3707	3748
3503 3504 3505 3506 3507 3508 3509	3544 3545 3546 3547 3548 3549 3550	3585 3586 3587 3588 3589 3590	3626 3627 3628 3629 3630 3631 3632	3667 3668 3669 3670 3671 3672 3673	3708 3709 3710 3711 3712 3713 3714	3749 3750 3751 3752 3753 3754 3755
3510	3551	3592	3633	3674	3715	3756
3511	3552	3593	3634	3675	3716	3757
3512	3553	3594	3635	3676	3717	3758
3513	3554	3595	3636	3677	3718	3759
3514	3555	3596	3637	3678	3719	3760
3515	3556	3597	3638	3679	3720	3761
3516	3556	3598	3639	3680	3721	3762
3517 3518 3519 3520 3521 3522 3523	3558 3559 3560 3561 3562 3563 3564	3599 3600 3601 3602 3603 3604 3605	3640 3641 3642 3643 3644 3645	3681 3682 3683 3684 3685 3686 3687	3722 3723 3724 3725 3726 3727 3728	3763 3764 3765 3766 3767 3768
3524	3565	3606	3647	3688	3729	3770
3525	3566	3607	3648	3689	3730	3771
3526	3567	3608	3649	3690	3731	3772
3527	3568	3609	3650	3691	3732	3773
3528	3569	3610	3651	3692	3733	3774
3529	3570	3611	3652	3693	3734	3775
3530	3571	3612	3653	3694	3735	3776

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb
PPD	3777 3778 3779 3780 3781 3782 3783 3784 3785 3786 3787 3788 3789 3790 3791 3792 3793 3794 3795 3796 3797 3800 3801 3802 3803 3804 3805 3804 3805 3807 3808 3809 3810 3811 3812 3813 3814 3815 3816 3817	PPD	3818 3819 3820 3821 3822 3823 3824 3825 3826 3827 3828 3829 3830 3831 3832 3833 3834 3835 3836 3837 3838 3834 3845 3847 3848 3849 3841 3845 3846 3847 3848 3849 3850 3851 3852 3853 3856 3857 3858	PPD		PPD		PPD		PPD	3982 3983 3984 3985 3986 3987 3988 3990 3991 3992 3993 3994 3995 3996 3997 3998 3999 4000 4001 4002 4003 4004 4005 4006 4007 4008 4009 4010 4010 4011 4012 4013 4014 4015 4016 4017 4018 4019 4020 4021 4022 4021 4022	PPD	4023 4024 4025 4026 4027 4028 4029 4030 4031 4032 4033 4033 4033 4034 4035 4036 4037 4038 4039 4040 4041 4042 4043 4044 4045 4046 4047 4048 4049 4050 4051 4051 4051 4051 4051 4051 4051

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
4103	4144	4185	4226	4267	4308	4349
4104	4145	4186	4227	4268	4309	4350

DTPA-HBV-IPV-135 (A.15MAR2018)

N	. Bl. No nb	Trt. Bl. No nb						
PPD	4351	PPD 4392	PPD 4433	PPD 4474	PPD 4515	PPD 4556	PPD 4597	
	4352	4393	4434	4475	4516	4557	4598	
	4353	4394	4435	4476	4517	4558	4599	
	4354	4395	4436	4477	4518	4559	4600	
	4355	4396	4437	4478	4519	4560	4601	
	4356	4397	4438	4479	4520	4561	4602	
	4357	4398	4439	4480	4521	4562	4603	
	4358	4399	4440	4481	4522	4563	4604	
	4359	4400	4441	4482	4523	4564	4605	
	4360	4401	4442	4483	4524	4565	4606	
	4361	4402	4443	4484	4525	4566	4607	
	4362	4403	4444	4485	4526	4567	4608	
	4363	4404	4445	4486	4527	4568	4609	
	4364	4405	4446	4487	4528	4569	4610	
	4365	4406	4447	4488	4529	4570	4611	
	4366	4407	4448	4489	4530	4571	4612	
	4367	4408	4449	4490	4531	4572	4613	
	4368 4369	4409	4450	4491	4532	4573 4574	4614	
	4369	4410 4411	4451 4452	4492 4493	4533 4534	4574 4575	4615 4616	
	4370	4411	4452	4493	4534	4576 4576	4617	
	4371	4412	4454	4494	4536	4577	4618	
	4373	4414	4455	4496	4537	4578	4619	
	4374	4415	4456	4497	4538	4579	4620	
	4375	4416	4457	4498	4539	4580	4621	
	4376	4417	4458	4499	4540	4581	4622	
	4377	4418	4459	4500	4541	4582	4623	
	4378	4419	4460	4501	4542	4583	4624	
	4379	4420	4461	4502	4543	4584	4625	
	4380	4421	4462	4503	4544	4585	4626	
	4381	4422	4463	4504	4545	4586	4627	
	4382	4423	4464	4505	4546	4587	4628	
	4383	4424	4465	4506	4547	4588	4629	
	4384	4425	4466	4507	4548	4589	4630	
	4385	4426	4467	4508	4549	4590	4631	
	4386	4427	4468	4509	4550	4591	4632	
	4387	4428	4469	4510	4551	4592	4633	
	4388	4429	4470	4511	4552	4593	4634	
	4389	4430	4471	4512	4553	4594	4635	
	4390	4431	4472	4513	4554	4595	4636	
	4391	4432	4473	4514	4555	4596	4637	

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. No		Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb
PPD 4638 4633 4644 4644 4644 4644 4644 4644	PPD 8 PPD 1 1 2 2 3 4 4 5 5 6 6 7 7 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	4679 4680 4681 4682 4683 4684 4685 4686 4687 4690 4691 4692 4693 4694 4695 4696 4697 4698 4699	No	nb 4720 4721 4722 4723 4724 4725 4726 4727 4728 4730 4731 4733 4734 4735 4737 4738 4737 4738 4739 4740	No	nb 4761 4762 4763 4764 4765 4766 4767 4768 4770 4771 4772 4773 4777 4778 4779 4780 4781	No	nb 4802 4803 4804 4805 4806 4807 4808 4809 4810 4811 4812 4813 4814 4815 4816 4817 4818 4819 4820 4821 4822	No	nb 4843 4844 4845 4846 4847 4848 4849 4850 4851 4852 4853 4854 4855 4856 4857 4858 4859 4860 4861 4862	No	nb 4884 4885 4886 4887 4888 4889 4891 4891 4893 4894 4895 4896 4897 4898 4899 4890 4901 4902 4903 4904
465 466 466 466 466 466 466 466 467 467 467	9 0 1 1 2 2 3 3 4 4 5 5 6 6 7 7	4700 4701 4702 4703 4704 4705 4706 4707 4708 4709 4710 4711 4712 4713 4714 4715 4716 4717 4718		4741 4742 4743 4744 4745 4746 4747 4748 4749 4750 4751 4752 4753 4754 4755 4755 4756 4757 4758 4759 4760		4782 4783 4784 4785 4786 4787 4788 4790 4791 4792 4793 4794 4795 4796 4797 4798 4799 4800 4801		4823 4824 4825 4826 4827 4828 4829 4830 4831 4832 4833 4834 4835 4836 4837 4838 4839 4840 4841 4842		4864 4865 4866 4867 4868 4869 4870 4871 4872 4873 4874 4875 4876 4877 4878 4879 4880 4881 4882 4883		4905 4906 4907 4908 4909 4910 4911 4912 4913 4914 4916 4917 4918 4919 4920 4921 4922 4923 4924

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	nb	Trt. Bl. No nb	Trt.	nb	Trt. No	nb	Trt. No	nb		Bl. nb	Trt. No	Bl. nb
No	nb 4925 4926 4927 4928 4929 4930 4931 4932 4933 4934 4935 4936 4937 4938 4939 4940 4941 4942 4943 4940 4941 4942 4943 4945 4946 4947 4948	No nb	No	nb 5007 5008 5009 5010 5011 5012 5013 5014 5015 5016 5017 5018 5019 5020 5020 5021 5022 5023 5024 5025 5026 5027 5028 5029 5030	No	nb 5048 5049 5050 5051 5052 5053 5054 5055 5056 5057 5058 5060 5061 5062 5063 5064 5065 5066 5067 5068 5069 5071	No	nb 5089 5090 5091 5092 5093 5094 5095 5096 5097 5098 5099 5100 5101 5102 5103 5104 5105 5106 5107 5108 5109 5110 5111 5112	No	nb 5130 5131 5132 5133 5134 5135 5136 5137 5138 5139 5140 5141 5142 5143 5144 5145 5146 5147 5148 5149 5150 5151 5152 5153		nb 5171 5172 5173 5174 5175 5176 5177 5180 5181 5182 5183 5184 5185 5186 5187 5188 5189 5191 5192 5193
	4948 4949 4950 4951 4952 4953 4954 4955 4956 4957 4958 4959 4960 4961 4962 4963 4964 4965	4989 4990 4991 4992 4993 4994 4995 4996 4997 4998 4999 5000 5001 5002 5003 5004 5005		5030 5031 5032 5033 5034 5035 5036 5037 5038 5039 5040 5041 5042 5042 5043 5044 5045 5047		5071 5072 5073 5074 5075 5076 5077 5078 5079 5080 5081 5082 5083 5084 5085 5086 5087		5112 5113 5114 5115 5116 5117 5118 5119 5120 5121 5122 5123 5124 5125 5126 5127 5128 5129		\$153 \$154 \$155 \$156 \$157 \$158 \$159 \$160 \$161 \$162 \$163 \$164 \$165 \$166 \$167 \$168 \$169 \$170		5194 5195 5196 5197 5198 5199 5200 5201 5202 5203 5204 5205 5206 5207 5208 5209 5211

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb		Trt. Bl. No nb	No r	Trt. Bl. No nb		Trt. Bl. No nb		Trt. Bl. No nb		Bl. nb	Trt. Bl. No nb	
		PPD 5253 5254 5255 5256 5257 5258 5259 5260							PPD		PPD	5458 5459 5460 5461 5462 5463 5464 5465
	5220 5221 5222 5223 5224 5225 5226 5227 5228	5261 5262 5263 5264 5265 5266 5267 5268		5301 5302 5303 5304 5305 5306 5307 5308 5309 5310		5343 5344 5345 5346 5347 5348 5349 5350 5351		5384 5385 5386 5387 5388 5389 5390 5391 5392		5425 5426 5427 5428 5429 5430 5431 5432 5433		5466 5467 5468 5469 5470 5471 5472 5473
	5229 5230 5231 5232 5233 5234 5235 5236	5270 5271 5272 5273 5274 5275 5276 5277		5311 5312 5313 5314 5315 5316 5317 5318		5352 5353 5354 5355 5356 5357 5358 5359		5393 5394 5395 5396 5397 5398 5399 5400		5434 5435 5436 5437 5438 5439 5440 5441		5475 5476 5477 5478 5479 5480 5481 5482
	5237 5238 5239 5240 5241 5242 5243 5244 5245	5278 5279 5280 5281 5282 5283 5284 5285 5285		5319 5320 5321 5322 5323 5324 5325 5326 5327		5360 5361 5362 5363 5364 5365 5366 5367 5368		5401 5402 5403 5404 5405 5406 5407 5408 5409		5442 5443 5444 5445 5446 5447 5448 5449 5450		5483 5484 5485 5486 5487 5488 5489 5490 5491
	5246 5247 5248 5249 5250 5251 5252	5287 5288 5289 5290 5291 5292 5293		5328 5329 5330 5331 5332 5333 5334		5369 5370 5371 5372 5373 5374 5375		5410 5411 5412 5413 5414 5415 5416		5451 5452 5453 5454 5455 5456 5457		5492 5493 5494 5495 5496 5497 5498

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
No nb	No nb	No nb	No nb	No nb	No nb	PPD 5745 5746 5747 5748 5749 5750 5751 5752 5753 5754 5755 5756 5757 5758 5759 5760 5761 5762 5763 5764
5514	5555	5596	5637	5678	5719	5760
5515	5556	5597	5638	5679	5720	5761
5516	5557	5598	5639	5680	5721	5762
5517	5558	5599	5640	5681	5722	5763
5518	5559	5600	5641	5682	5723	5764
5537	5578	5619	5660	5701	5742	5783
5538	5579	5620	5661	5702	5743	5784
5539	5580	5621	5662	5703	5744	5785

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	786 787	PPD			No nb No nb		No nb		Trt. Bl. No nb		Trt. Bl. No nb		
	787	PPD											
			5827	PPD	5868	PPD	5909	PPD	5950	PPD	5991	PPD	6032
5			5828		5869		5910		5951		5992		6033
5	788		5829		5870		5911		5952		5993		6034
5	789		5830		5871		5912		5953		5994		6035
5	790		5831		5872		5913		5954		5995		6036
5	791		5832		5873		5914		5955		5996		6037
5	792		5833		5874		5915		5956		5997		6038
5	793		5834		5875		5916		5957		5998		6039
5	794		5835		5876		5917		5958		5999		6040
5	795		5836		5877		5918		5959		6000		6041
5	796		5837		5878		5919		5960		6001		6042
5	797		5838		5879		5920		5961		6002		6043
5	798		5839		5880		5921		5962		6003		6044
5	799		5840		5881		5922		5963		6004		6045
5	800		5841		5882		5923		5964		6005		6046
5	801		5842		5883		5924		5965		6006		6047
5	802		5843		5884		5925		5966		6007		6048
5	803		5844		5885		5926		5967		6008		6049
5	804		5845		5886		5927		5968		6009		6050
5	805		5846		5887		5928		5969		6010		6051
5	806		5847		5888		5929		5970		6011		6052
5	807		5848		5889		5930		5971		6012		6053
5	808		5849		5890		5931		5972		6013		6054
	809		5850		5891		5932		5973		6014		6055
5	810		5851		5892		5933		5974		6015		6056
	811		5852		5893		5934		5975		6016		6057
	812		5853		5894		5935		5976		6017		6058
	813		5854		5895		5936		5977		6018		6059
	814		5855		5896		5937		5978		6019		6060
	815		5856		5897		5938		5979		6020		6061
	816		5857		5898		5939		5980		6021		6062
	817		5858		5899		5940		5981		6022		6063
	818		5859		5900		5941		5982		6023		6064
	819		5860		5901		5942		5983		6024		6065
	820		5861		5902		5943		5984		6025		6066
	821		5862		5903		5944		5985		6026		6067
	822		5863		5904		5945		5986		6027		6068
	823		5864		5905		5946		5987		6028		6069
	824		5865		5906		5947		5988		6029		6070
	825		5866		5907		5948		5989		6030		6071
5	826		5867		5908		5949		5990		6031		6072

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
No nb	No nb	No nb	No nb	No nb	PPD 6278 6279 6280 6281 6282 6283 6284 6285 6286 6287 6288 6289 6290 6291 6292 6293 6294 6295 6296 6297 6298	PPD 6319 6320 6321 6322 6323 6324 6325 6326 6327 6328 6329 6330 6331 6332 6333 6334 6335 6336 6337 6338
6093 6094 6095 6096 6097 6098 6099 6100 6101 6102 6103 6104 6105 6106 6107 6108 6109 6110 6111 6112	6134 6135 6136 6137 6138 6139 6140 6141 6142 6143 6144 6145 6146 6147 6148 6149 6150 6151 6152 6153	6175 6176 6177 6178 6179 6180 6181 6182 6183 6184 6185 6186 6187 6188 6189 6190 6191 6192 6193 6194 6195	6216 6217 6218 6219 6220 6221 6222 6223 6224 6225 6226 6227 6228 6229 6230 6231 6232 6233 6234 6234	6257 6258 6259 6260 6261 6262 6263 6264 6265 6266 6267 6268 6269 6270 6271 6272 6273 6274 6275 6276	6298 6299 6300 6301 6302 6303 6304 6305 6306 6307 6308 6309 6310 6311 6312 6313 6314 6315 6316 6317	6339 6340 6341 6342 6343 6344 6345 6346 6347 6348 6349 6350 6351 6352 6353 6354 6355 6355

DTPA-HBV-IPV-135 (A.15MAR2018)

N	. Bl. o nb	Trt. E No n	nb	Trt. No	nb	Trt. No	nb	Trt. Bl. No nb		Trt. Bl. No nb		Trt. Bl. No nb	
PPD	6360	PPD	6401	PPD	6442	PPD	6483	PPD	6524	PPD	6565	PPD	6606
	6361		6402		6443		6484		6525		6566		6607
	6362		6403		6444		6485		6526		6567		6608
	6363		6404		6445		6486		6527		6568		6609
	6364		6405		6446		6487		6528		6569		6610
	6365		6406		6447		6488		6529		6570		6611
	6366		6407		6448		6489		6530		6571		6612
	6367		6408		6449		6490		6531		6572		6613
	6368		6409		6450		6491		6532		6573		6614
	6369		6410		6451		6492		6533		6574		6615
	6370		6411		6452		6493		6534		6575		6616
	6371		6412		6453		6494		6535		6576		6617
	6372		6413		6454		6495		6536		6577		6618
	6373		6414		6455		6496		6537		6578		6619
	6374		6415		6456		6497		6538		6579		6620
	6375		6416		6457		6498		6539		6580		6621
	6376		6417		6458		6499		6540		6581		6622
	6377		6418		6459		6500		6541		6582		6623
	6378		6419		6460		6501		6542		6583		6624
	6379		6420		6461		6502		6543		6584		6625
	6380		6421		6462		6503		6544		6585		6626
	6381		6422		6463		6504		6545		6586		6627
	6382		6423		6464		6505		6546		6587		6628
	6383		6424		6465		6506		6547		6588		6629
	6384		6425		6466		6507		6548		6589		6630
	6385		6426		6467		6508		6549		6590		6631
	6386		6427		6468		6509		6550		6591		6632
	6387		6428		6469		6510		6551		6592		6633
	6388		6429		6470		6511		6552		6593		6634
	6389		6430		6471		6512		6553		6594		6635
	6390		6431		6472		6513		6554		6595		6636
	6391		6432		6473		6514		6555		6596		6637
	6392		6433		6474		6515		6556		6597		6638
	6393		6434		6475		6516		6557		6598		6639
	6394		6435		6476		6517		6558		6599		6640
	6395		6436		6477		6518		6559		6600		6641
	6396		6437		6478		6519		6560		6601		6642
	6397		6438		6479		6520		6561		6602		6643
	6398		6439		6480		6521		6562		6603		6644
	6399		6440		6481		6522		6563		6604		6645
	6400		6441		6482		6523		6564		6605		6646

DTPA-HBV-IPV-135 (A.15MAR2018)

1	E. Bl. No nb	Trt. Bl. No nb	No nb					
PPD	6647	PPD 6688	PPD 6729	PPD 6770	PPD 6811	PPD 6852	PPD 6893	
–	6648	6689	6730	6771	6812	6853	6894	
	6649	6690	6731	6772	6813	6854	6895	
	6650	6691	6732	6773	6814	6855	6896	
	6651	6692	6733	6774	6815	6856	6897	
	6652	6693	6734	6775	6816	6857	6898	
	6653	6694	6735	6776	6817	6858	6899	
	6654	6695	6736	6777	6818	6859	6900	
	6655	6696	6737	6778	6819	6860	6901	
	6656	6697	6738	6779	6820	6861	6902	
	6657	6698	6739	6780	6821	6862	6903	
	6658	6699	6740	6781	6822	6863	6904	
	6659	6700	6741	6782	6823	6864	6905	
	6660	6701	6742	6783	6824	6865	6906	
	6661	6702	6743	6784	6825	6866	6907	
	6662	6703	6744	6785	6826	6867	6908	
	6663	6704	6745	6786	6827	6868	6909	
	6664	6705	6746	6787	6828	6869	6910	
	6665	6706	6747	6788	6829	6870	6911	
	6666	6707	6748	6789	6830	6871	6912	
	6667	6708	6749	6790	6831	6872	6913	
	6668	6709	6750	6791	6832	6873	6914	
	6669	6710	6751	6792	6833	6874	6915	
	6670	6711	6752	6793	6834	6875	6916	
	6671	6712	6753	6794	6835	6876	6917	
	6672	6713	6754	6795	6836	6877	6918	
	6673	6714	6755	6796	6837	6878	6919	
	6674	6715	6756	6797	6838	6879	6920	
	6675	6716	6757	6798	6839	6880	6921	
	6676	6717	6758	6799	6840	6881	6922	
	6677	6718	6759	6800	6841	6882	6923	
	6678	6719	6760	6801	6842	6883	6924	
	6679	6720	6761	6802	6843	6884	6925	
	6680	6721	6762	6803	6844	6885	6926	
	6681	6722	6763	6804	6845	6886	6927	
	6682	6723	6764	6805	6846	6887	6928	
	6683	6724	6765	6806	6847	6888	6929	
	6684	6725	6766	6807	6848	6889	6930	
	6685	6726	6767	6808	6849	6890	6931	
	6686	6727	6768	6809	6850	6891	6932	
	6687	6728	6769	6810	6851	6892	6933	

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
No nb	No nb	No nb	No nb	No nb	No nb	PPD 7180 7181 7182 7183 7184 7185 7186 7187 7188 7190 7191 7192 7193 7194 7195 7196 7197 7198 7199 7200 7201 7202 7203 7204 7205 7206 7207 7208 7209 7210 7211
6965 6966 6967 6968 6969 6970 6971 6972	7006 7007 7008 7009 7010 7011 7012 7013 7014	7047 7048 7049 7050 7051 7052 7053 7054 7055	7088 7089 7090 7091 7092 7093 7094 7095 7096	7129 7130 7131 7132 7133 7134 7135 7136 7137	7170 7171 7172 7173 7174 7175 7176 7177 7178	7211 7212 7213 7214 7215 7216 7217 7218 7219
6974	7015	7056	7097	7138	7179	7220

DTPA-HBV-IPV-135 (A.15MAR2018)

	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb		nb	Trt. No	nb		nb
PPD	7221	PPD	7262	PPD	7303	PPD	7344	PPD	7385	PPD	7426	PPD	7467
	7222		7263		7304		7345		7386		7427		7468
	7223		7264		7305		7346		7387		7428		7469
	7224		7265		7306		7347		7388		7429		7470
	7225		7266		7307		7348		7389		7430		7471
	7226		7267		7308		7349		7390		7431		7472
	7227		7268		7309		7350		7391		7432		7473
	7228		7269		7310		7351		7392		7433		7474
	7229		7270		7311		7352		7393		7434		7475
	7230		7271		7312		7353		7394		7435		7476
	7231		7272		7313		7354		7395		7436		7477
	7232		7273		7314		7355		7396		7437		7478
	7233		7274		7315		7356		7397		7438		7479
	7234		7275		7316		7357		7398		7439		7480
	7235		7276		7317		7358		7399		7440		7481
	7236		7277		7318		7359		7400		7441		7482
	7237		7278		7319		7360		7401		7442		7483
	7238		7279		7320		7361		7402		7443		7484
	7239		7280		7321		7362		7403		7444		7485
	7240		7281		7322		7363		7404		7445		7486
	7241		7282		7323		7364		7405		7446		7487
	7242		7283		7324		7365		7406		7447		7488
	7243		7284		7325		7366		7407		7448		7489
	7244		7285		7326		7367		7408		7449		7490
	7245		7286		7327		7368		7409		7450		7491
	7246		7287		7328		7369		7410		7451		7492
	7247		7288		7329		7370		7411		7452		7493
	7248		7289		7330		7371		7412		7453		7494
	7249		7290		7331		7372		7413		7454		7495
	7250		7291		7332		7373		7414		7455		7496
	7251		7292		7333		7374		7415		7456		7497
	7252		7293		7334		7375		7416		7457		7498
	7253 7254		7294 7295		7335 7336		7376 7377		7417		7458 7459		7499 7500
	7254				7336		7378		7418		7459		7500
	7256		7296 7297		7337		7378		7419 7420		7460		7501
	7256		7298		7338 7339		7379		7420		7461		7502
	7257		7298		7339		7380		7421		7462		7503
	7258		7300		7341		7381		7422		7463		7504
	7259 7260		7300		7341		7382 7383		7423		7464		7505
	7260		7301		7342		7384		7424		7465		7506
	1701		1302		1343		1304		1423		/400		/30/
	ı				ı								

DTPA-HBV-IPV-135 (A.15MAR2018)

	Bl. nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb		Bl. nb	Trt. No	nb
		PPD		PPD						PPD		PPD	
PPD	7508	PPD	7549	PPD		PPD	7631	PPD	7672		7713	PPU	7754
	7509		7550		7591 7592		7632 7633		7673		7714		7755 7756
	7510 7511		7551 7552		7592 7593		7634		7674 7675		7715 7716		7757
	7511		7553		7594		7635		7676		7717		7758
	7512		7554		7594		7636		7677		7718		7759
	7514		7555		7596		7637		7678		7719		7760
	7514		7556		7597		7638		7679		7720		7761
	7516		7557		7598		7639		7680		7721		7762
	7517		7558		7599		7640		7681		7722		7763
	7518		7559		7600		7641		7682		7723		7764
	7519		7560		7601		7642		7683		7724		7765
	7520		7561		7602		7643		7684		7725		7766
	7521		7562		7603		7644		7685		7726		7767
	7522		7563		7604		7645		7686		7727		7768
	7523		7564		7605		7646		7687		7728		7769
	7524		7565		7606		7647		7688		7729		7770
	7525		7566		7607		7648		7689		7730		7771
	7526		7567		7608		7649		7690		7731		7772
	7527		7568		7609		7650		7691		7732		7773
	7528		7569		7610		7651		7692		7733		7774
	7529		7570		7611		7652		7693		7734		7775
	7530		7571		7612		7653		7694		7735		7776
	7531		7572		7613		7654		7695		7736		7777
	7532		7573		7614		7655		7696		7737		7778
	7533		7574		7615		7656		7697		7738		7779
	7534		7575		7616		7657		7698		7739		7780
	7535		7576		7617		7658		7699		7740		7781
	7536		7577		7618		7659		7700		7741		7782
	7537		7578		7619		7660		7701		7742		7783
	7538		7579		7620		7661		7702		7743		7784
	7539		7580		7621		7662		7703		7744		7785
	7540		7581		7622		7663		7704		7745		7786
	7541		7582		7623		7664		7705		7746		7787
	7542		7583		7624		7665		7706		7747		7788
	7543 7544		7584 7585		7625 7626		7666 7667		7707		7748 7749		7789 7790
	7544 7545		7585 7586		7627		7668		7708 7709		7749		7790
	7545 7546		7586 7587		7628		7669		7709		7750 7751		7791
	7546		7587 7588		7628 7629		7670		7711		7752		7793
	7547		7589		7629		7671		7712		7753		7794
	1340		1303		1030		/ U / I		1112		1133		1194

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl No nk		Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb
PPD PPD	7795 7796 77979 77798 77798 77798 77799 7800 7801 7802 7803 7804 7805 7806 7807 7808 7808 7808 7808 7808 7810 7811 7811	No	nb 7836 7837 7838 7839 7840 7841 7842 7843 7844 7845 7846 7847 7848 7849 7850 7851 7855 7856 7857 7858 7859 7860 7861 7862 7863 7864 7865 7866 7867 7868 7869 7870	No	nb 7877 7878 7879 7880 7881 7882 7883 7884 7885 7886 7887 7888 7890 7891 7892 7893 7894 7895 7896 7897 7898 7899 7900 7901 7902 7903 7904 7905 7906 7907 7908 7909 7910 7911	No	nb 7918 7919 7920 7921 7922 7923 7924 7925 7926 7927 7928 7929 7930 7931 7932 7933 7934 7935 7936 7937 7938 7939 7940 7941 7942 7943 7944 7945 7946 7947 7948 7949 7950 7951 7952	No	nb 7959 7960 7961 7962 7963 7964 7965 7966 7967 7969 7970 7971 7972 7973 7974 7975 7976 7977 7978 7979 7980 7981 7982 7983 7984 7985 7986 7987 7988 7989 7990 7991 7992 7993	No	nb 8000 8001 8002 8003 8004 8005 8006 8007 8008 8009 8010 8011 8012 8013 8014 8015 8016 8017 8018 8019 8020 8021 8022 8023 8024 8025 8026 8027 8028 8029 8030 8031 8032 8033 8034 8035	No	nb 8041 8042 8043 8044 8045 8046 8047 8051 8052 8053 8054 8055 8056 8057 8058 8069 8061 8062 8063 8064 8067 8068 8067 8068 8067 8068 8070 8071 8072 8073 8074 8075 8076
	7831 7832 7833 7834 7835		7872 7873 7874 7875 7876		7913 7914 7915 7916 7917		7954 7955 7956 7957 7958		7995 7996 7997 7998 7999		8036 8037 8038 8039 8040		8077 8078 8079 8080 8081

DTPA-HBV-IPV-135 (A.15MAR2018)

No	nb	Trt. No	nb										
PPD	8082	PPD	8123	PPD	8164	PPD	8205	PPD	8246	PPD	8287	PPD	8328
	8083		8124		8165		8206	110	8247		8288	· -	8329
	8084		8125		8166		8207		8248		8289		8330
	8085		8126		8167		8208		8249		8290		8331
	8086		8127		8168		8209		8250		8291		8332
	8087		8128		8169		8210		8251		8292		8333
	8088		8129		8170		8211		8252		8293		8334
	8089		8130		8171		8212		8253		8294		8335
	8090		8131		8172		8213		8254		8295		8336
	8091		8132		8173		8214		8255		8296		8337
	8092		8133		8174		8215		8256		8297		8338
	8093		8134		8175		8216		8257		8298		8339
	8094		8135		8176		8217		8258		8299		8340
	8095		8136		8177		8218		8259		8300		8341
	8096		8137		8178		8219		8260		8301		8342
	8097		8138		8179		8220		8261		8302		8343
	8098		8139		8180		8221		8262		8303		8344
	8099		8140		8181		8222		8263		8304		8345
	8100		8141		8182		8223		8264		8305		8346
	8101		8142		8183		8224		8265		8306		8347
	8102		8143		8184		8225		8266		8307		8348
	8103 8104		8144 8145		8185 8186		8226 8227		8267 8268		8308 8309		8349 8350
	8104		8145		8187		8227		8268 8269		8310		8350
	8105		8146		8188		8228		8269 8270		8310		8351
	8107		8148		8189		8230		8271		8312		8353
	8108		8149		8190		8231		8272		8313		8354
	8109		8150		8191		8232		8273		8314		8355
	8110		8151		8192		8233		8274		8315		8356
	8111		8152		8193		8234		8275		8316		8357
	8112		8153		8194		8235		8276		8317		8358
	8113		8154		8195		8236		8277		8318		8359
	8114		8155		8196		8237		8278		8319		8360
	8115		8156		8197		8238		8279		8320		8361
	8116		8157		8198		8239		8280		8321		8362
	8117		8158		8199		8240		8281		8322		8363
	8118		8159		8200		8241		8282		8323		8364
	8119		8160		8201		8242		8283		8324		8365
	8120		8161		8202		8243		8284		8325		8366
	8121		8162		8203		8244		8285		8326		8367
	8122		8163		8204		8245		8286		8327		8368

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
No nb	No nb	No nb	PPD 8492 8493 8494 8495 8496 8497 8498 8499 8500 8501 8502 8503 8504 8505 8506 8507 8508 8509 8511 8512 8513 8514 8515 8516 8517 8518 8519 8522 8523 8524	PPD 8533 8534 8535 8536 8537 8538 8539 8540 8541 8542 8543 8544 8545 8546 8547 8548 8549 8550 8551 8552 8553 8554 8555 8556 8557 8558 8556 8557 8558 8566 8561 8562	PPD 8574 8575 8576 8577 8578 8579 8589 8581 8582 8883 8584 8585 8586 8887 8588 8589 8590 8591 8592 8593 8594 8595 8596 8597 8598 8599 8600 8601 8601 8602 8603 8604	PPD 8615 8616 8617 8618 8619 8620 8621 8622 8623 8624 8625 8626 8627 8628 8629 8630 8631 8631 8632 8633 8634 8635 8636 8637 8638 8639 8639 8631 8634 8635 8636 8637 8638 8639 8639 8630 8631 8631 8632 8633 8634 8635 8636 8636 8637 8638 8639 8639 8639 8630 8631 8631 8632 8633 8634 8635 8636 8636 8637 8638 8639 8639 8639 8639 8630 8631 8631 8632 8633 8634 8635 8636 8636 8637 8638 8639 8638 8639 8639 8639 8639 8630 8631 8631 8632 8633 8634 8635 8636 8636 8637 8638 8638 8639 8639 8639 8639 8639 8639
	2 844 844 4 844 5 844 5 844 7 844	3 8484 4 8485 5 8486 6 8487 7 8488 8 8489 9 8490				

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	No	Bl. onb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	
PPD 8656 8655 8655 8656 8666 8666 8666 8666	PPD 7 8 9 10 11 12 13 14 15 16 17 18 18 18 18 18 18 18 18 18	8697 8698 8699 8700 8701 8702 8703 8704 8705 8706 8707 8708 8709 8711 8712 8713 8714 8715 8716 8717 8718 8719 8711 8712 8713 8714 8715 8716 8717 8718 8719 8719 8720 8721	No	nb 8738 8739 8740 8741 8742 8743 8744 8745 8746 8747 8748 8749 8750 8751 8752 8753 8754 8755 8756 8757 8758 8759 8760 8761 8762 8763 8764 8765	No	nb 8779 8780 8781 8782 8783 8784 8785 8786 8787 8788 8789 8790 8791 8792 8793 8794 8795 8796 8797 8798 8800 8801 8802 8803 8804 8805	No	nb 8820 8821 8822 8823 8824 8825 8826 8827 8828 8829 8830 8831 8832 8833 8834 8835 8836 8837 8838 8839 8841 8842 8844 8844 8844 8844 8844 8844 8844 8844 8844 8844 8844 8844 8844 8844 8845 8846 8847 8846 8847	No	nb		8902 8903 8904 8905 8906 8907 8908 8910 8911 8912 8913 8914 8915 8916 8917 8916 8917 8918 8920 8921 8922 8923 8924 8925 8927 8928
868 868 868 868 868 868 869 869 869 869	1	8725 8726 8727 8728 8729 8730 8731 8732 8733 8734 8735 8735		8766 8767 8768 8769 8770 8771 8772 8773 8774 8775 8776 8777		8807 8808 8809 8810 8811 8812 8813 8814 8815 8816 8817 8818 8819		8848 8849 8850 8851 8852 8853 8854 8855 8856 8857 8858 8859 8860		8889 8890 8891 8892 8893 8894 8895 8896 8897 8898 8899 8900 8901		8930 8931 8932 8933 8934 8935 8936 8937 8938 8939 8940 8941 8942

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	
												PPD	nb 9189 9190 9191 9192 9193 9194 9195 9196 9197 9198 9199
	8955 8956 8957 8958 8959 8960 8961 8962 8963 8964 8965		8996 8997 8998 8999 9000 9001 9002 9003 9004 9005 9006		9037 9038 9039 9040 9041 9042 9043 9044 9045 9046 9047 9048		9078 9079 9080 9081 9082 9083 9084 9085 9086 9087 9088		9119 9119 9120 9121 9122 9123 9124 9125 9126 9127 9128 9129 9130		9160 9161 9162 9163 9164 9165 9166 9167 9168 9169 9170		9201 9202 9203 9204 9205 9206 9207 9208 9209 9210 9211 9212
	8967 8968 8969 8970 8971 8972 8973 8974 8975 8976		9008 9009 9010 9011 9012 9013 9014 9015 9016 9017		9049 9050 9051 9052 9053 9054 9055 9056 9057 9058		9090 9091 9092 9093 9094 9095 9096 9097 9098 9099		9131 9132 9133 9134 9135 9136 9137 9138 9139 9140		9172 9173 9174 9175 9176 9177 9178 9179 9180 9181 9182		9213 9214 9215 9216 9217 9218 9219 9220 9221 9222 9223
	8977 8978 8979 8980 8981 8982 8983		9018 9019 9020 9021 9022 9023 9024		9059 9060 9061 9062 9063 9064 9065		9100 9101 9102 9103 9104 9105 9106		9141 9142 9143 9144 9145 9146 9147		9182 9183 9184 9185 9186 9187 9188		9223 9224 9225 9226 9227 9228 9229

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
9268	9309	9350	9391	9432	9473	9514
9269	9310	9351	9392	9433	9474	9515
9270	9311	9352	9393	9434	9475	9516

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. Bl No nb		Trt.		Trt. No		Trt. No	Bl. nb	Trt. No		Trt. No	
PPD	9517 9518 9519 9520 9521 9522 9523	9. 9. 9. 9.	558 559 560 561 562 563	PPD	9599 9600 9601 9602 9603 9604 9605	PPD	9640 9641 9642 9643 9644 9645	PPD	9681 9682 9683 9684 9685 9686 9687	PPD	9722 9723 9724 9725 9726 9727 9728	PPD	9763 9764 9765 9766 9767 9768 9769
	9524 9525 9526 9527 9528 9529 9530	9. 9. 9. 9. 9.	565 565 566 567 568 569 570		9606 9607 9608 9609 9610 9611 9612		9647 9648 9649 9650 9651 9652 9653		9688 9689 9690 9691 9692 9693 9694		9729 9730 9731 9732 9733 9734 9735		9770 9771 9772 9773 9774 9775
	9531 9532 9533 9534 9535 9536 9537	9 9 9 9	572 573 574 575 576 577 578		9613 9614 9615 9616 9617 9618 9619		9654 9655 9656 9657 9658 9659		9695 9696 9697 9698 9699 9700		9736 9737 9738 9739 9740 9741 9742		9777 9778 9779 9780 9781 9782 9783
	9538 9539 9540 9541 9542 9543	9 9 9 9 9	579 580 581 582 583		9620 9621 9622 9623 9624 9625		9661 9662 9663 9664 9665 9666		9702 9703 9704 9705 9706 9707		9743 9744 9745 9746 9747 9748		9784 9785 9786 9787 9788 9789
	9544 9545 9546 9547 9548 9549	9 9 9 9 9	585 586 587 588 589 590		9626 9627 9628 9629 9630 9631 9632		9667 9668 9669 9670 9671 9672 9673		9708 9709 9710 9711 9712 9713 9714		9749 9750 9751 9752 9753 9754 9755		9790 9791 9792 9793 9794 9795
	9551 9552 9553 9554 9555 9556 9557	9. 9. 9. 9.	592 593 594 595 596 597		9633 9634 9635 9636 9637 9638 9639		9674 9675 9676 9677 9678 9679 9680		9715 9716 9717 9718 9719 9720 9721		9756 9757 9758 9759 9760 9761 9762		9797 9798 9799 9800 9801 9802 9803

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
		No nb		No nb		
9820	9861	9902	9943	9984	10025	10066
9821	9862	9903	9944	9985	10026	10067
9822	9863	9904	9945	9986	10027	10068
9823	9864	9905	9946	9987	10028	10069
9843	9884	9925	9966	10007	10048	10089
9844	9885	9926	9967	10008		10090

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl.					
	No nb					
No nb						
10128	10109	10210	10251	10292	10333	10374
10129	10170	10211	10252	10293	10334	10375
10130	10171	10212	10253	10294	10335	10376
10131	10172	10213	10254	10295	10336	10377

DTPA-HBV-IPV-135 (A.15MAR2018)

PPD 10378 PPD 10419 PPD 10460 PPD 10501 PPD 10543 10583 PPD 10 10379 10420 10461 10502 10503 10544 10585 10 10381 10422 10463 10503 10544 10585 10 10382 10423 10464 10505 10546 10587 10 10383 10424 10465 10565 10546 10587 10 10384 10425 10466 10507 10548 10589 10 10385 10426 10467 10508 10549 10589 10 10386 10427 10468 10509 10550 10591 10590 10387 10488 10388 10429 10468 10590 10550 10591 10 10388 10428 10429 10470 10511 10552 10593 10 10389 10430 10471 10512 10553 10554 10594 10390 10390 10391 10491 10390 10391 10492 10593 10391 10492 10473 10514 10555 10556 10594 10399 10399 10399 10399 10399 10491 10492 10470 10511 10552 10593 10 10390 10431 10472 10513 10554 10596 10596 10391 10391 10492 10493 10494 10555 10556 10597 10399 10399 10399 10493 10493 10474 10515 10556 10596 10399 10399 10399 10493 10493 10475 10516 10556 10597 10399 10399 10399 10493 10474 10515 10556 10597 10399 10399 10399 10493 10493 10475 10516 10557 10558 10599 10399 10399 10399 10493 10493 10476 10517 10558 10599 10600 10399 10399 10494 10475 10518 10559 10560 10599 10399 10399 10399 10493 10493 10478 10515 10556 10597 10600 10399 10399 10494 10478 10515 10566 10557 10599 10600 10399 10399 10440 10481 10522 10563 10599 10600 10399 10494 10498 10499 10500 10560 10601 10602 10400 10441 10482 10523 10564 10605 10601 10602 10444 10485 10488 10529 10566 10607 10601 10442 10488 10499 10550 10566 10607 10601 10444 10485 10488 10529 10570 10611 10612 10600 10444 10485 10488 10529 10570 10611 10612 10600 10444 10485 10488 10529 10570 10611 10612 10449	Trt. Bl.	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl.	Trt. Bl.	Trt. Bl. No nb
10379	NO ND	on on		NO ND		NO ND	NO ND
10379						DDD	
10380	PPD 10378	PPD 10419	PPD 10460	PPD 10501	PPD 10542	10583	PPD 10624
10381	10379	10420	10461	10502	10543	10584	10625
10382	10380	10421	10462	10503	10544	10585	10626
10383	10381	10422	10463	10504	10545	10586	10627
10384 10425 10466 10507 10548 10589 10 10385 10426 10467 10508 10549 10590 10 10386 10427 10468 10509 10550 10591 10 10387 10428 10469 10510 10551 10592 10 10388 10429 10470 10511 10552 10593 10 10399 10430 10471 10512 10553 10594 10 10391 10432 10473 10514 10555 10596 10 10391 10432 10473 10514 10555 10596 10 10392 10433 10474 10515 10556 10597 10 10392 10433 10474 10515 10556 10597 10 10393 10434 10475 10516 10557 10598 10 10394 10435 10476 10517 10558 10599 10 10395 10436 10477 10518 10559 10600 10 10396 10437 10478 10519 10550 10601 10 10397 10438 10479 10520 10561 10602 10 10398 10439 10480 10521 10562 10603 10 10399 10440 10481 10522 10563 10604 10 10400 10441 10482 10523 10564 10605 10 10401 10442 10483 10524 10566 10607 10 10402 10443 10484 10525 10566 10607 10 10403 10444 10485 10528 10569 10610 10 10404 10445 10486 10527 10568 10609 10 10406 10447 10488 10529 10571 10612 10 10407 10448 10485 10528 10569 10610 10 10408 10449 10490 10531 10572 10613 10614 10 10409 10446 10447 10488 10529 10570 10611 10 10400 10441 10485 10486 10527 10568 10607 10618 10407 10448 10485 10528 10573 10614 10615 10 10401 10445 10446 10487 10528 10573 10614 10615 10 10401 10445 10496 10533 10574 10615 10616 10417 10418 10495 10533 10577 10618 10619 10411 10455 10496 10533 10577 10618 10610 10611 10611 10612 10411 10455 10496 10533 10577 10618 10610 10611 10615 10411 10455 10496 10533 10534 10575 10616 10617 10414 10455 10496 10533 10534 10575 10616 10621 10411 10458 10496 10533 10539 10580 10621 10411	10382	10423	10464	10505	10546	10587	10628
10385	10383	10424	10465	10506	10547	10588	10629
10386	10384	10425	10466	10507	10548	10589	10630
10387	10385	10426	10467	10508	10549	10590	10631
10388	10386	10427	10468	10509	10550	10591	10632
10389	10387	10428	10469	10510	10551	10592	10633
10390	10388	10429	10470	10511	10552	10593	10634
10391	10389	10430	10471	10512	10553	10594	10635
10392	10390	10431	10472	10513	10554	10595	10636
10393 10434 10475 10516 10557 10598 10 10394 10435 10476 10517 10558 10599 10 10395 10436 10477 10518 10559 10600 10 10396 10437 10478 10519 10560 10601 10 10397 10438 10479 10520 10561 10602 10 10398 10439 10480 10521 10562 10603 10 10399 10440 10481 10522 10563 10604 10 10400 10441 10482 10523 10564 10605 10 10401 10442 10483 10524 10565 10606 10 10402 10443 10484 10525 10566 10607 10 10403 10444 10485 10526 10567 10608 10 10404 10445 10486 10527 </td <td>10391</td> <td>10432</td> <td>10473</td> <td>10514</td> <td>10555</td> <td>10596</td> <td>10637</td>	10391	10432	10473	10514	10555	10596	10637
10394	10392	10433	10474	10515	10556	10597	10638
10395	10393	10434	10475	10516	10557	10598	10639
10396	10394	10435	10476	10517	10558	10599	10640
10397	10395	10436	10477	10518	10559	10600	10641
10398 10439 10480 10521 10562 10603 10 10399 10440 10481 10522 10563 10604 10 10400 10441 10482 10523 10564 10605 10 10401 10442 10483 10524 10565 10606 10 10402 10443 10484 10525 10566 10607 10 10403 10444 10485 10526 10567 10608 10 10404 10445 10486 10527 10568 10609 10 10405 10446 10487 10528 10569 10610 10 10406 10447 10488 10529 10570 10611 10 10407 10448 10489 10530 10571 10612 10 10408 10449 10490 10531 10572 10613 10 10409 10450 10491 10532 10573 10614 10 10410 10451 10492	10396	10437	10478	10519	10560	10601	10642
10399 10440 10481 10522 10563 10604 10 10400 10441 10482 10523 10564 10605 10 10401 10442 10483 10524 10565 10606 10 10402 10443 10484 10525 10566 10607 10 10403 10444 10485 10526 10567 10608 10 10404 10445 10486 10527 10568 10609 10 10405 10446 10487 10528 10569 10610 10 10406 10447 10488 10529 10570 10611 10 10407 10448 10489 10530 10571 10612 10 10408 10449 10490 10531 10572 10613 10 10409 10450 10491 10532 10573 10614 10 10410 10450 10491 10532 10573 10615 10 10411 10452 10493	10397	10438	10479	10520	10561	10602	10643
10400 10441 10482 10523 10564 10605 10 10401 10442 10483 10524 10565 10606 10 10402 10443 10484 10525 10566 10607 10 10403 10444 10485 10526 10567 10608 10 10404 10445 10486 10527 10568 10609 10 10405 10446 10487 10528 10569 10610 10 10406 10447 10488 10529 10570 10611 10 10407 10448 10489 10530 10571 10612 10 10408 10449 10490 10531 10572 10613 10 10409 10450 10491 10532 10573 10614 10 10410 10451 10492 10533 10574 10615 10 10411 10452 10493 10534 10575 10616 10 10412 10453 10494 10535 10576 10617 10 10413 10454 10495 10536 10577 10618 10 <td< td=""><td>10398</td><td>10439</td><td>10480</td><td>10521</td><td>10562</td><td>10603</td><td>10644</td></td<>	10398	10439	10480	10521	10562	10603	10644
10401 10442 10483 10524 10565 10606 10 10402 10443 10484 10525 10566 10607 10 10403 10444 10485 10526 10567 10608 10 10404 10445 10486 10527 10568 10609 10 10405 10446 10487 10528 10569 10610 10 10406 10447 10488 10529 10570 10611 10 10407 10448 10489 10530 10571 10612 10 10408 10449 10490 10531 10572 10613 10 10409 10450 10491 10532 10573 10614 10 10410 10451 10492 10533 10574 10615 10 10411 10452 10493 10534 10575 10616 10 10412 10453 10494 10535 10576 10617 10 10413 10454 10495 10536 10577 10618 10 10415 10456 10497 10538 10579 10620 10 <td< td=""><td>10399</td><td>10440</td><td>10481</td><td>10522</td><td>10563</td><td>10604</td><td>10645</td></td<>	10399	10440	10481	10522	10563	10604	10645
10402 10443 10484 10525 10566 10607 10 10403 10444 10485 10526 10567 10608 10 10404 10445 10486 10527 10568 10609 10 10405 10446 10487 10528 10569 10610 10 10406 10447 10488 10529 10570 10611 10 10407 10448 10489 10530 10571 10612 10 10408 10449 10490 10531 10572 10613 10 10409 10450 10491 10532 10573 10614 10 10410 10451 10492 10533 10574 10615 10 10411 10452 10493 10534 10575 10616 10 10412 10453 10494 10535 10576 10617 10 10413 10454 10495 10536 10577 10618 10 10414 10455 10496 10537 10578 10619 10 10415 10456 10497 10538 10579 10620 10 <td< td=""><td>10400</td><td>10441</td><td>10482</td><td>10523</td><td>10564</td><td>10605</td><td>10646</td></td<>	10400	10441	10482	10523	10564	10605	10646
10403 10444 10485 10526 10567 10608 10 10404 10445 10486 10527 10568 10609 10 10405 10446 10487 10528 10569 10610 10 10406 10447 10488 10529 10570 10611 10 10407 10448 10489 10530 10571 10612 10 10408 10449 10490 10531 10572 10613 10 10409 10450 10491 10532 10573 10614 10 10410 10451 10492 10533 10574 10615 10 10411 10452 10493 10534 10575 10616 10 10412 10453 10494 10535 10576 10617 10 10413 10454 10495 10536 10577 10618 10 10414 10455 10496 10537 10578 10619 10 10415 10456 10497 10538 10579 10620 10 10416 10457 10498 10539 10580 10621 10 <td< td=""><td>10401</td><td>10442</td><td>10483</td><td>10524</td><td>10565</td><td>10606</td><td>10647</td></td<>	10401	10442	10483	10524	10565	10606	10647
10404 10445 10486 10527 10568 10609 10 10405 10446 10487 10528 10569 10610 10 10406 10447 10488 10529 10570 10611 10 10407 10448 10489 10530 10571 10612 10 10408 10449 10490 10531 10572 10613 10 10409 10450 10491 10532 10573 10614 10 10410 10451 10492 10533 10574 10615 10 10411 10452 10493 10534 10575 10616 10 10412 10453 10494 10535 10576 10617 10 10413 10454 10495 10536 10577 10618 10 10414 10455 10496 10537 10578 10619 10 10415 10456 10497 10538 10579 10620 10 10416 10457 10498 10539 10580 10621 10 10417 10458 10499 10540 10581 10622 10	10402	10443	10484	10525	10566	10607	10648
10405 10446 10487 10528 10569 10610 10611 10406 10447 10488 10529 10570 10611 10 10407 10448 10489 10530 10571 10612 10 10408 10449 10490 10531 10572 10613 10 10409 10450 10491 10532 10573 10614 10 10410 10451 10492 10533 10574 10615 10 10411 10452 10493 10534 10575 10616 10 10412 10453 10494 10535 10576 10617 10 10413 10454 10495 10536 10577 10618 10 10414 10455 10496 10537 10578 10619 10 10415 10456 10497 10538 10579 10620 10 10416 10457 10498 10539 10580 10621 10 10417 10458 10499 10540 10581 10622 10	10403	10444	10485	10526	10567	10608	10649
10406 10447 10488 10529 10570 10611 10 10407 10448 10489 10530 10571 10612 10 10408 10449 10490 10531 10572 10613 10 10409 10450 10491 10532 10573 10614 10 10410 10451 10492 10533 10574 10615 10 10411 10452 10493 10534 10575 10616 10 10412 10453 10494 10535 10576 10617 10 10413 10454 10495 10536 10577 10618 10 10414 10455 10496 10537 10578 10619 10 10415 10456 10497 10538 10579 10620 10 10416 10457 10498 10539 10580 10621 10 10417 10458 10499 10540 10581 10622 10	10404	10445	10486	10527	10568	10609	10650
10407 10448 10489 10530 10571 10612 10 10408 10449 10490 10531 10572 10613 10 10409 10450 10491 10532 10573 10614 10 10410 10451 10492 10533 10574 10615 10 10411 10452 10493 10534 10575 10616 10 10412 10453 10494 10535 10576 10617 10 10413 10454 10495 10536 10577 10618 10 10414 10455 10496 10537 10578 10619 10 10415 10456 10497 10538 10579 10620 10 10416 10457 10498 10539 10580 10621 10 10417 10458 10499 10540 10581 10622 10	10405	10446	10487	10528	10569	10610	10651
10408 10449 10490 10531 10572 10613 10 10409 10450 10491 10532 10573 10614 10 10410 10451 10492 10533 10574 10615 10 10411 10452 10493 10534 10575 10616 10 10412 10453 10494 10535 10576 10617 10 10413 10454 10495 10536 10577 10618 10 10414 10455 10496 10537 10578 10619 10 10415 10456 10497 10538 10579 10620 10 10416 10457 10498 10539 10580 10621 10 10417 10458 10499 10540 10581 10622 10	10406	10447	10488	10529	10570	10611	10652
10409 10450 10491 10532 10573 10614 10 10410 10451 10492 10533 10574 10615 10 10411 10452 10493 10534 10575 10616 10 10412 10453 10494 10535 10576 10617 10 10413 10454 10495 10536 10577 10618 10 10414 10455 10496 10537 10578 10619 10 10415 10456 10497 10538 10579 10620 10 10416 10457 10498 10539 10580 10621 10 10417 10458 10499 10540 10581 10622 10	10407	10448	10489	10530	10571	10612	10653
10410 10451 10492 10533 10574 10615 10 10411 10452 10493 10534 10575 10616 10 10412 10453 10494 10535 10576 10617 10 10413 10454 10495 10536 10577 10618 10 10414 10455 10496 10537 10578 10619 10 10415 10456 10497 10538 10579 10620 10 10416 10457 10498 10539 10580 10621 10 10417 10458 10499 10540 10581 10622 10	10408	10449	10490	10531	10572	10613	10654
10411 10452 10493 10534 10575 10616 10 10412 10453 10494 10535 10576 10617 10 10413 10454 10495 10536 10577 10618 10 10414 10455 10496 10537 10578 10619 10 10415 10456 10497 10538 10579 10620 10 10416 10457 10498 10539 10580 10621 10 10417 10458 10499 10540 10581 10622 10	10409	10450	10491	10532	10573	10614	10655
10412 10453 10494 10535 10576 10617 10 10413 10454 10495 10536 10577 10618 10 10414 10455 10496 10537 10578 10619 10 10415 10456 10497 10538 10579 10620 10 10416 10457 10498 10539 10580 10621 10 10417 10458 10499 10540 10581 10622 10	10410	10451	10492	10533	10574	10615	10656
10413 10454 10495 10536 10577 10618 10 10414 10455 10496 10537 10578 10619 10 10415 10456 10497 10538 10579 10620 10 10416 10457 10498 10539 10580 10621 10 10417 10458 10499 10540 10581 10622 10	10411	10452	10493	10534	10575	10616	10657
10414 10455 10496 10537 10578 10619 10 10415 10456 10497 10538 10579 10620 10 10416 10457 10498 10539 10580 10621 10 10417 10458 10499 10540 10581 10622 10	10412	10453	10494	10535	10576	10617	10658
10415 10456 10497 10538 10579 10620 10 10416 10457 10498 10539 10580 10621 10 10417 10458 10499 10540 10581 10622 10	10413	10454	10495	10536	10577	10618	10659
10416 10457 10498 10539 10580 10621 10 10417 10458 10499 10540 10581 10622 10	10414	10455	10496	10537	10578		10660
10417 10458 10499 10540 10581 10622 10	10415		10497	10538			10661
	10416	10457					10662
10418 10459 10500 10541 10582 10623 10	10417	10458	10499	10540	10581	10622	10663
	10418	10459	10500	10541	10582	10623	10664

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	No	. Bl. o nb	No	. Bl. o nb	No	Bl. nb	No	Bl. nb		Bl. nb
PPD 10665	PPD	10706	PPD	10747	PPD	10788	PPD	10829	PPD	10870
10666		10707		10748		10789		10830		10871
10667		10708		10749		10790		10831		10872
10668		10709		10750		10791		10832		10873
10669		10710		10751		10792		10833		10874
10670		10711		10752		10793		10834		10875
10671		10712		10753		10794		10835		10876
10672		10713		10754		10795		10836		10877
10673		10714		10755		10796		10837		10878
10674		10715		10756		10797		10838		10879
10675		10716		10757		10798		10839		10880
10676		10717		10758		10799		10840		10881
10677		10718		10759		10800		10841		10882
10678		10719		10760		10801		10842		10883
10679		10720		10761		10802		10843		10884
10680		10721		10762		10803		10844		10885
10681		10722		10763		10804		10845		10886
10682		10723		10764		10805		10846		10887
10683		10724		10765		10806		10847		10888
10684		10725		10766		10807		10848		10889
10685		10726		10767		10808		10849		10890
10686		10727		10768		10809		10850		10891
10687		10728		10769		10810		10851		10892
10688		10729		10770		10811		10852		10893
10689		10730		10771		10812		10853		10894
10690		10731		10772		10813		10854		10895
10691		10732		10773		10814		10855		10896
10692		10733		10774		10815		10856		10897
10693		10734		10775		10816		10857		10898
10694		10735		10776		10817		10858		10899
10695		10736		10777		10818		10859		10900
10696		10737		10778		10819		10860		10901
10697		10738		10779		10820		10861		10902
10698		10739		10780		10821		10862		10903
10699		10740		10781		10822		10863		10904
10700		10741		10782		10823		10864		10905
10701		10742		10783		10824		10865		10906
10702		10743		10784		10825		10866		
10703		10744		10785		10826		10867		
10704		10745		10786		10827		10868		
10705		10746		10787		10828		10869		

DTPA-HBV-IPV-135 (A.15MAR2018)

No nb No nb <th< th=""><th>3 21154 4 21155 5 21156</th></th<>	3 21154 4 21155 5 21156
20907 FFD 20948 FFD 20949 21030 FFD 21071 FF 2111 20908 20949 20990 21031 21072 2111 20909 20950 20991 21032 21073 2111	3 21154 4 21155 5 21156
20907 FFD 20948 FFD 20949 21030 FFD 21071 FF 2111 20908 20949 20990 21031 21072 2111 20909 20950 20991 21032 21073 2111	3 21154 4 21155 5 21156
20908 20949 20990 21031 21072 2111 20909 20950 20991 21032 21073 2111	3 21154 4 21155 5 21156
20909 20950 20991 21032 21073 2111	4 21155 5 21156
	5 21156
20910 20951 20992 21033 21074 2111	
20910 20951 20992 21033 21074 2111 20911 20952 20993 21034 21075 2111	
20911 20953 20993 21034 21075 2111 20912 20953 20994 21035 21076 2111	
20912 20953 20994 21035 21076 2111 20913 20954 20995 21036 21077 2111	
20916 20957 20998 21039 21080 2112 20917 20958 20999 21040 21081 2112	
20917 20958 20999 21040 21081 2112 20918 20959 21000 21041 21082 2112	
20919 20960 21001 21042 21083 2112 20920 20961 21002 21043 21084 2112	
20921 20962 21003 21044 21085 2112	
20922 20963 21004 21045 21086 2112	
20923 20964 21005 21046 21087 2112	
20924 20965 21006 21047 21088 2112	
20925 20966 21007 21048 21089 2113 00007 210000 2100000 21000 21000 21000 21000 21000 21000 21000 21000 21000 21000 21000 21000 21000 21000 21000 21000 21000 21000 210000 210000 21000000 210000 210000 21000 210000 21000 21000 21000 21000 21000 21	
20926 20967 21008 21049 21090 2113	
20927 20968 21009 21050 21091 2113	
20928 20969 21010 21051 21092 2113	
20929 20970 21011 21052 21093 2113	
20930 20971 21012 21053 21094 2113	
20931 20972 21013 21054 21095 2113	
20932 20973 21014 21055 21096 2113	
20933 20974 21015 21056 21097 2113	
20934 20975 21016 21057 21098 2113	
20935 20976 21017 21058 21099 2114	
20936 20977 21018 21059 21100 2114	
20937 20978 21019 21060 21101 2114	
20938 20979 21020 21061 21102 2114	
20939 20980 21021 21062 21103 2114	
20940 20981 21022 21063 21104 2114	
20941 20982 21023 21064 21105 2114	
20942 20983 21024 21065 21106 2114	
20943 20984 21025 21066 21107 2114	
20944 20985 21026 21067 21108 2114	
20945 20986 21027 21068 21109 2115	
20946 20987 21028 21069 21110 2115	
20947 20988 21029 21070 21111 2115.	2 21193

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD 21194	PPD 21235	PPD 21276	PPD 21317	PPD 21358	PPD 21399	PPD 21440
21195	21236	21277	21317	21359	21400	21441
21196	21237	21278	21319	21360	21401	21442
21197	21237	21279	21320	21361	21402	21443
21198	21239	21280	21321	21362	21403	21444
21190	21240	21281	21321	21363	21403	21445
21200	21240	21282	21323	21364	21404	21446
21200	21242	21283	21323	21365	21406	21447
21201	21242	21284	21325	21366	21407	21448
21202	21244	21285	21326	21367	21407	21449
21203	21244	21286	21327	21368	21400	21450
21205	21246	21287	21328	21369	21410	21451
21206	21247	21288	21329	21370	21411	21452
21207	21247	21289	21330	21370	21412	21453
21208	21249	21290	21331	21372	21413	21454
21200	21250	21291	21331	21372	21413	21455
21210	21251	21292	21332	21373	21415	21456
21210	21252	21293	21333	21374	21416	21457
21211	21253	21294	21334	21376	21417	21457
21212	21254	21295	21336	21377	21417	21459
21213	21255	21296	21337	21377	21419	21460
21214	21256	21297	21338	21379	21420	21461
21216	21257	21298	21339	21380	21421	21462
21217	21258	21299	21340	21381	21422	21463
21218	21259	21300	21341	21382	21423	21464
21219	21260	21301	21342	21383	21424	21465
21220	21261	21302	21343	21384	21425	21466
21221	21262	21302	21344	21385	21426	21467
21222	21263	21304	21345	21386	21427	21468
21223	21264	21305	21346	21387	21428	21469
21224	21265	21306	21347	21388	21429	21470
21225	21266	21307	21348	21389	21430	21471
21226	21267	21308	21349	21390	21431	21472
21227	21268	21309	21350	21391	21432	21473
21228	21269	21310	21351	21392	21433	21474
21229	21270	21311	21352	21393	21434	21475
21230	21271	21312	21353	21394	21435	21476
21231	21272	21313	21354	21395	21436	21477
21232	21273	21314	21355	21396	21437	21478
21233	21274	21315	21356	21397	21438	21479
21234	21275	21316	21357	21398	21439	21480
	===:0					100

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	21481	PPD 21522	PPD 21563	PPD 21604	PPD 21645	PPD 21686	PPD 21727
FFD	21482	21523	21564	21605	21646	21687	21728
	21483	21523	21565	21606	21647	21688	21729
	21483	21524	21565	21607	21647	21689	21729
	21485	21526	21567	21608	21649	21690	21731
	21486	21526	21567	21609	21650	21691	21731
	21487	21527	21569	21610	21651	21692	21732
	21487	21520	21570	21611	21651	21693	21734
	21489	21529	21570	21612	21652	21694	21734
	21409	21530	21571	21613	21654	21695	21736
	21490	21531	21572	21614	21655	21695	21737
	21491	21532	21573	21615	21656	21697	21737
	21492	21533	21574	21616	21657	21698	21739
	21493	21534	21576	21617	21658	21699	21740
		21535	21576		21659		21740
	21495 21496	21536	21577	21618 21619	21660	21700 21701	21742
	21496	21537	21578	21620	21660	21701	21742
	21497	21538	21579	21620	21662	21702	21743
	21499 21500	21540 21541	21581 21582	21622 21623	21663 21664	21704 21705	21745 21746
	21500	21541	21582	21624	21665	21706	21747
	21501	21542	21584	21625	21666	21707	21747
	21502	21543	21585	21626	21667	21707	21749
	21503	21544	21586	21627	21668	21709	21750
	21504	21545	21587	21628	21669	21710	21751
	21505	21547	21588	21629	21670	21711	21752
	21506	21547	21589	21630	21670	21711	21752
	21507	21549	21599	21631	21672	21712	21754
	21508	21549	21590	21632	21672	21713	21754
	21510	21551	21591	21633	21673	21714	21756
	21510	21552	21592	21634	21674	21716	21757
	21511	21553	21594	21635	21676	21717	21758
	21512	21554	21595	21636	21677	21717	21759
	21514	21555	21596	21637	21678	21719	21760
	21514	21556	21597	21638	21679	21720	21761
	21516	21557	21598	21639	21680	21721	21762
	21517	21558	21599	21640	21681	21722	21763
	21517	21559	21600	21641	21682	21723	21764
	21518	21560	21600	21642	21683	21724	21765
	21520	21561	21602	21643	21684	21725	21766
	21521	21562	21602	21644	21685	21725	21767
	21721	21302	21003	21011	21003	21/20	21/0/

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. Trt. Bl. No nb No nb		Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
PPD 21768 21769 21770 21771 21772 21773 21774 21775 21776 21777 21778 21779						
21780 21781 21782 21783 21784 21785 21786 21787 21788 21789 21790 21790 21791	21821 21822 21822 21823 21824 21825 21826 21827 21828 21829 21830 21831 21832 21832	21862 21863 21864 21865 21866 21867 21868 21869 21870 21871 21872 21873 21873	21903 21904 21905 21906 21907 21908 21910 21911 21912 21913 21914 21915	21944 21945 21946 21947 21948 21949 21950 21951 21952 21953 21954 21955 21955	21985 21985 21986 21987 21988 21989 21990 21991 21992 21993 21994 21995 21996 21997	22026 22027 22028 22029 22030 22031 22032 22033 22034 22035 22036 22037 22038
21793 21794 21795 21796 21797 21798 21799 21800 21801 21802 21803 21804 21805 21806 21807 21807	21834 21835 21836 21837 21838 21839 21840 21841 21842 21843 21844 21845 21846 21847 21848	21875 21876 21877 21877 21878 21879 21880 21881 21882 21883 21884 21885 21886 21887 21888 21889	21916 21917 21918 21919 21920 21921 21922 21923 21924 21925 21926 21927 21928 21929 21930	21957 21958 21959 21960 21961 21962 21963 21964 21965 21966 21967 21968 21969 21970 21971	21998 21999 22000 22001 22002 22003 22004 22005 22006 22007 22008 22009 22010 22011 22012	22039 22040 22041 22042 22043 22044 22045 22046 22047 22048 22049 22050 22051 22052 22053

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. E	31.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No n	nb	No	nb	No	nb	No	nb	No	nb	No	nb
000		PPD 2		PPD	00405			000		PPD		PPD	
PPD	22055		2000	–		PPD		PPD	22219		22260	FFD	22301
	22056		2097		22138		22179		22220		22261		22302
	22057		2098		22139		22180		22221		22262		22303
	22058		2099		22140		22181		22222		22263		22304
	22059		22100		22141		22182		22223		22264		22305
	22060		22101		22142		22183		22224		22265		22306
	22061	2	2102		22143		22184		22225		22266		22307
	22062	2	2103		22144		22185		22226		22267		22308
	22063	2	2104		22145		22186		22227		22268		22309
	22064	2	2105		22146		22187		22228		22269		22310
	22065	2	2106		22147		22188		22229		22270		22311
	22066	2	22107		22148		22189		22230		22271		22312
	22067	2	2108		22149		22190		22231		22272		22313
	22068	2	2109		22150		22191		22232		22273		22314
	22069	2	2110		22151		22192		22233		22274		22315
	22070		2111		22152		22193		22234		22275		22316
	22071		2112		22153		22194		22235		22276		22317
	22072		2113		22154		22195		22236		22277		22318
	22073		2114		22155		22196		22237		22278		22319
	22074		2115		22156		22197		22238		22279		22320
	22075		2116		22157		22198		22239		22280		22321
	22076		2117		22158		22199		22240		22281		22322
	22077		2118		22159		22200		22241		22282		22323
	22078		2119		22160		22201		22242		22283		22324
	22079		2120		22161		22202		22243		22284		22325
	22080		2121		22162		22203		22244		22285		22326
	22081		2122		22163		22204		22245		22286		22327
	22082		2123		22164		22205		22246		22287		22327
	22083		2124		22165		22206		22247		22288		22329
	22084		2125		22166		22207		22248		22289		22323
	22085		2126		22167		22207		22249		22290		22331
	22085		2127		22168		22209		22249		22291		22331
	22087		2128		22169		22210		22251		22292		22333
	22087		2129		22109		22210		22252		22293		22333
	22089		2129		22170		22211		22253		22294		22334
							22212		22254				
	22090		2131 2132		22172 22173		22213		22254		22295 22296		22336 22337
	22091												
	22092		22133		22174		22215		22256		22297		22338
	22093		22134		22175		22216		22257		22298		22339
	22094		22135		22176		22217		22258		22299		22340
	22095	2	22136		22177		22218		22259		22300		22341
	l												

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. No	nb	Trt. No									
	nb 22342 22343 22344 22345 22346 22347 22348 22350 22351 22352 22353 22354 22355 22356 22357 22358 22356 22361 22362 22363 22364 22365 22366 22367 22368 22369 22371 22372 22373 22374 22375	No	nb	No	nb	No	nb	No	nb	No	22547 22548 22549 22550 22551 22552 22553 22554 22555 22556 22556 22556 22560 22561 22562 22563 22564 22562 22563 22564 22565 22566 22567 22570 22571 22572 22573 22574 22575 22576 22577 22578 22578 22579 22580	PPD	22588 22589 22590 22591 22591 22592 22595 22596 22596 22599 22600 22601 22602 22603 22604 22607 22608 22609 22610 22611 22612 22613 22614 22615 22614 22615 22616

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	B1.	Trt. Bl.	Trt	. Bl.	Trt.	Bl.	Trt	. Bl.	Trt	. Bl.	Trt	. Bl.
No	nb	No nb	No	o nb	No	nb	N	o nb	No	o nb	N	lo nb
PPD	22629	PPD 22670	PPD	22711	PPD	22752	PPD	22793	PPD	22834	PPD	22875
FFD	22629	22671	110	22712	FFD	22753	PPD	22793		22835	110	22876
	22631	22672		22712		22754		22795		22836		22877
	22632	22673		22714		22755		22796		22837		22878
	22632	22674		22715		22756		22797		22838		22879
	22633	22675		22715		22757		22798		22838		22879
	22634	22676		22716		22758		22798		22839		22880
	22636	22677		22718		22759		22800		22841		22882
	22637	22678		22719		22760		22801		22842		22883
	22638	22679		22720 22721		22761 22762		22802		22843 22844		22884 22885
	22639	22680						22803				
	22640	22681		22722		22763		22804		22845		22886
	22641	22682		22723		22764		22805		22846		22887
	22642	22683		22724		22765		22806		22847		22888
	22643	22684		22725		22766		22807		22848		22889
	22644	22685		22726		22767		22808		22849		22890
	22645	22686		22727		22768		22809		22850		22891
	22646	22687		22728		22769		22810		22851		22892
	22647	22688		22729		22770		22811		22852		22893
	22648	22689		22730		22771		22812		22853		22894
	22649	22690		22731		22772		22813		22854		22895
	22650	22691		22732		22773		22814		22855		22896
	22651	22692		22733		22774		22815		22856		22897
	22652	22693		22734		22775		22816		22857		22898
	22653	22694		22735		22776		22817		22858		22899
	22654	22695		22736		22777		22818		22859		22900
	22655	22696		22737		22778		22819		22860		22901
	22656	22697		22738		22779		22820		22861		22902
	22657	22698		22739		22780		22821		22862		22903
	22658	22699		22740		22781		22822		22863		22904
	22659	22700		22741		22782		22823		22864		22905
	22660	22701		22742		22783		22824		22865		22906
	22661	22702		22743		22784		22825		22866		22907
	22662	22703		22744		22785		22826		22867		22908
	22663	22704		22745		22786		22827		22868		22909
	22664	22705		22746		22787		22828		22869		22910
	22665	22706		22747		22788		22829		22870		22911
	22666	22707		22748		22789		22830		22871		22912
	22667	22708		22749		22790		22831		22872		22913
	22668	22709		22750		22791		22832		22873		22914
	22669	22710		22751		22792		22833		22874		22915
						_		_		_		

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. E	31.	Trt.	Bl.								
No	nb	No r	nb	No		No	nb		nb	No	nb	No	nb
PPD	22916	PPD 2	22957	PPD	22998	PPD	23039	PPD	23080	PPD	23121	PPD	23162
FFD	22917		22958		22990	FFD	23040	FFD	23081		23121		23162
	22918		22959		23000		23040		23082		23122		23163
	22919		22960		23000		23041		23082		23123		23165
	22920		22961		23001		23042		23084		23124		23166
	22921		22962		23002		23043		23085		23125		23166
	22921		22963		23003		23045		23086		23126		23167
	22923		22964		23004		23046		23087		23127		23169
	22924		22965		23005		23047		23088		23120		23170
	22925		22966		23007		23048		23089		23129		23170
	22925		22967		23007		23049		23099		23131		23171
	22927		22968		23008		23050		23090		23131		23172
	22928		22969		23010		23050		23092		23132		23173
	22929		22970		23010		23052		23092		23133		23174
	22930		22971		23011		23052		23093		23134		23175
	22931		22972		23012		23054		23094		23133		23176
	22932		22973		23013		23055		23095		23137		23177
	22932		22974		23014		23056		23096		23137		23176
	22934		22975		23015		23057		23097		23130		23179
	22935		22976		23017		23058		23099		23140		23180
	22936		22977		23017		23059		23100		23140		23181
	22937		22978		23019		23060		23100		23141		23182
	22938		22979		23020		23061		23101		23142		23184
	22939		22980		23021		23062		23102		23143		23185
	22940		22981		23021		23063		23103		23145		23186
	22941		22982		23023		23064		23105		23146		23187
	22942		22983		23023		23065		23106		23147		23188
	22943		22984		23025		23066		23100		23147		23189
	22944		22985		23026		23067		23107		23149		23190
	22945		22986		23027		23068		23109		23150		23191
	22946		22987		23028		23069		23110		23151		23192
	22947		22988		23029		23070		23111		23152		23193
	22948		22989		23030		23071		23112		23153		23194
	22949		22990		23031		23072		23113		23154		23195
	22950		22991		23032		23073		23114		23155		23196
	22951		22992		23033		23074		23115		23156		23197
	22952		22993		23034		23075		23116		23157		23198
	22953		22994		23035		23076		23117		23158		23199
	22954		22995		23036		23077		23118		23159		23200
	22955		22996		23037		23078		23119		23160		23201
	22956		22997		23038		23079		23120		23161		23202

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

PPD 23203 PPD 23244 PPD 23285 PPD 23326 PPD 23367 23408 23409 23445 23204 23245 23204 23245 23286 23247 23288 23329 23369 23410 23452 23206 23247 23288 23289 23300 23371 23412 23452 23208 23249 23250 23291 23332 23371 23412 23452 23209 23250 23251 23292 23333 23374 23414 23452 23210 23251 23252 23293 23334 23375 23414 23452 23211 23252 23253 23293 23334 23375 23416 23452 23211 23253 23294 23393 23334 23375 23416 23452 23213 23254 23253 23294 23335 23376 23416 23452 23213 23254 23255 23294 23335 23376 23418 23454 23215 23215 23255 23294 23335 23376 23418 23454 23454 23214 23255 23256 23294 23335 23376 23418 23454 23215 23215 23256 23296 23398 23338 23378 23418 23452 23217 23258 23298 23339 23380 23379 23418 23452 23217 23258 23298 23399 23390 23319 23420 23462 23217 23258 23299 23300 23341 23382 23325 2342 23462 23219 23250 23301 23342 23380 23318 23259 23250 23301 23342 23380 23318 23259 23250 23301 23342 23380 23318 23424 23465 23219 23250 23301 23342 23382 23423 23462 23219 23250 23361 23362 23394 23382 23423 23462 23221 23256 23301 23342 23382 23380 23421 23462 23260 23201 23362 23301 23342 23382 23423 23462 23221 23256 23303 23344 23382 23389 23424 23452 23463 23221 23256 23303 23344 23382 23423 23462 23221 23256 23303 23344 23382 23389 23424 23453 23462 23221 23256 23303 23344 23382 23389 23424 23453 23462 23222 23266 23301 23342 23383 23344 23455 23462 23222 23266 23306 23301 23342 23389 23349 23349 23340 23427 23468 23222 23256 23306 23304 23345 23386 23347 23348 23429 234426 23222 23266 23306 23301 23342 23389 23349 23349 23429 234426 23223 23266 23306 23307 23344 23385 23389 23429 23429 23426 23223 23266 23306 23307 23344 23385 23389 23429 23429 23426 23223 23266 23306 23307 23344 23385 23389 23429 23429 23429 23426 23223 23266 23306 23307 23344 23385 23389 23439 23429 234426 23223 23266 23307 23366 23307 23348 23399 23431 23422 23468 23222 23266 23306 23307 23318 23399 23440 23428 23429 23442 23222 23226 23266 23307 23308 23309 23341 23342 23348 23349 23349 23349 23349 23349 23349 23349 23349 23349 23	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
PPD 23203 PPD 23244 PPD 23266 2337 23368 23408 23408 23205 23246 23286 2337 23368 23400 23411 23451 23206 23247 23288 23329 23370 23411 23452 23208 23248 23289 23331 23372 23413 23452 23209 23251 23291 23333 23374 23413 23452 23210 23251 23292 23333 23374 23415 23453 23211 23253 23294 23333 23374 23416 23457 23212 23253 23294 23335 23376 23417 23416 23212 23253 23294 23335 23376 23417 23418 23213 23254 23295 23336 23377 23418 23452 23214 23255 23296 23337 23378 23419 2	No nb	No nb	No nb	No nb	No nb	No nb	No nb
23204							
23204 23245 23286 23377 23368 22410 23451 23206 23247 23288 23329 23370 22411 2365 23207 23248 23289 23330 23371 22412 2365 23208 23249 23330 23371 22413 2365 23209 23250 23291 23332 23373 2414 2365 23210 23251 23292 23333 23374 24145 2325 23211 23252 23293 23334 23375 24146 2265 23212 23253 23294 23336 23377 23417 2245 23213 23254 22255 23296 23377 2378 23419 2346 23214 23255 23296 23377 23378 23419 2346 23215 23266 23277 23388 23379 2342 2346 23216 23277 23288	DDD 23203	PPD 23244	PPD 23285	23326	DDD 23367	PPD 23408	PPD 23/// 9
23205 23246 23287 23328 23499 23410 23451 23207 23248 23289 23330 23371 23412 23452 23208 23249 23290 23331 2371 23412 23452 23209 23250 23291 23332 23373 23414 23452 23210 23252 23293 23334 23375 23416 23452 23211 23252 23293 23334 23375 23416 23457 23212 23253 23295 23336 23377 23418 23457 23214 23255 23295 23336 23377 23418 23457 23214 23255 23295 23336 23377 23418 23452 23215 23256 23297 23388 23379 23418 23452 23216 23258 23299 23340 23361 23422 23462 23218 23259 <t< th=""><th></th><th></th><th></th><th></th><th></th><th></th><th>23113</th></t<>							23113
23206 23247 23288 23329 23371 23411 23452 23208 23248 23289 23310 23371 23412 23452 23208 23249 23290 23331 23372 23414 23452 23210 23251 23292 23333 23374 23415 23452 23211 23252 23293 23334 23375 23416 23457 23212 23253 23294 23335 23376 23417 23418 23213 23254 23295 23336 23377 23418 23457 23214 23255 23296 23377 2378 23418 23457 23216 23257 23298 23379 23419 23400 23461 23217 23258 23299 23340 23381 23422 2346 23218 23259 23300 2341 23382 23423 2346 23219 23260 2							
22207 22248 22289 23330 23371 23412 23452							
22208 23249 23290 23331 23372 23413 2345 23210 23251 23291 23332 23374 23415 2345 23211 23252 23293 23334 23375 23416 23457 23212 23253 23244 23355 23376 23417 23457 23214 23255 23336 23377 23418 23451 23214 23255 23296 23337 23378 23419 23461 23215 23256 23297 23338 23379 23400 23462 23216 23257 23298 23399 23340 23381 23422 23462 23217 23258 23299 23340 23381 23422 23462 23218 23259 23300 23411 23382 23422 23462 23219 23260 23011 23342 23384 23422 23462 23216 23221 <td< td=""><td></td><td>_</td><td></td><td></td><td></td><td></td><td></td></td<>		_					
23209 23250 23291 23332 23373 23414 23451 23210 23251 23292 23333 23374 23416 23451 23211 23252 23293 23334 23375 23416 23451 23212 23253 23294 23335 23377 23418 23451 23214 23255 23296 23337 23378 23419 23461 23215 23256 23297 23388 23379 23420 23461 23216 23257 23288 23339 23800 23421 23462 23217 23258 23299 23404 23381 23422 23461 23218 23259 23300 2341 23486 23219 23260 23311 23482 23423 2346 23219 23260 23301 23341 23382 23423 2346 23221 23261 23302 23343 23384 23427							
23210 23251 23292 23333 2374 23415 23457 23211 23252 23293 23334 23376 23417 23458 23212 23254 23295 23336 23377 23418 23457 23214 23255 23296 23337 23378 23419 23460 23215 23256 23297 23338 23379 23420 23461 23216 23257 23298 23339 23380 23421 23462 23217 23258 23299 23340 23381 23422 23462 23218 23259 23300 23441 23382 23423 23462 23219 23260 23301 23342 23383 23424 23463 23221 23262 23303 23344 23382 23423 23466 23221 2362 23303 23444 23385 23426 23461 23221 2362							
23211 22252 23293 23334 23375 23416 23457 23212 23253 23294 23335 23377 23418 23451 23214 23255 23296 23337 23378 23419 23461 23215 23266 23297 23338 23379 23420 23461 23216 23257 23298 23339 23360 23421 23462 23217 23288 23299 23340 23381 23422 23462 23218 23259 23300 23411 23382 23423 23462 23219 23260 23301 23341 23382 23423 23462 23221 23262 23302 23343 23384 23424 23465 23221 23262 23303 23444 23485 23426 23427 2346 23222 23263 23304 23345 23386 23427 2346 23223 23264 23305 23346 23387 23428 2346 23223							
23212 22253 23294 23335 2376 23417 2345 23213 23254 23295 23377 23418 23459 23215 23255 23296 23377 23378 23419 23460 23216 23257 23298 23339 23360 23421 23462 23217 23258 23299 23400 23381 23422 23463 23218 23259 23300 23411 23382 23424 23466 23219 22260 2301 23424 23483 23424 23466 23221 23261 23302 23343 23384 23424 23466 23221 23262 23303 23344 23385 23426 23427 23222 23263 23304 23345 23386 23427 2346 23222 23263 23304 23345 23386 23427 2346 23223 23264 23305 23346 23387 23428 23429 23224 23265 23306 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
23213 23254 23295 23336 23377 23418 23451 23214 23255 23296 23337 23378 23419 23461 23216 23257 23298 23339 23380 23421 23462 23217 23258 23299 23340 23381 23422 23462 23218 23259 23300 23341 23382 23423 2346 23219 23260 23301 23342 23383 23424 23466 23220 23261 23302 23343 23384 23425 2346 23221 23262 23303 23344 23385 23426 23466 23222 2363 2304 23345 23386 23427 2346 23223 23264 23305 23346 23387 23428 2346 23224 23265 23306 23347 23388 23429 2347 23225 23266 23307 23348 23389 23430 2347 23226 23266							
23214 23255 23296 23337 23378 23419 23461 23215 23256 23297 23338 23379 23420 23461 23217 23258 23299 23340 23381 23422 23462 23218 23259 23300 23341 23382 23423 23462 23219 23260 23301 23342 23383 23424 23462 23221 23262 23303 23344 23385 23425 23466 23221 23262 23303 23344 23385 23426 23466 23222 23263 23304 23345 23386 23477 2346 23223 23264 23305 23346 23387 23428 2346 23224 23265 23306 23347 23388 23427 2348 23224 23265 23306 23347 23388 23429 2347 23226 23267 23308 23349 23399 23430 2341 23227 23268 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
23215 23256 23297 23388 23379 23420 23461 23216 23257 23298 23339 23380 23421 23462 23218 23259 23300 2341 23382 23423 2346 23219 23260 23301 23342 23383 23424 2346 23220 23261 23302 23343 23384 23425 2346 23221 23262 23303 23344 23385 23426 2346 23222 23263 23304 23345 23386 23427 2346 23223 23264 23305 23346 23387 23428 2346 23224 23265 23306 23347 23388 23429 2347 23225 23266 23307 2348 23399 23430 2347 23226 23266 23307 2348 23399 23431 2347 23227 23268 23309 23350 23391 23431 2347 23228 23269 23310 23351 23392 23433 2347 23229 23270 23311 23352 23393 23434 2347<							
23216 23257 23298 23390 23810 23421 23462 23217 23258 23299 23340 2381 23422 2346 23218 23259 23300 23341 23382 23423 2346 23219 23260 23301 23342 23383 23424 2346 23221 23262 23303 23344 23385 23426 2346 23222 23263 23304 23345 23386 23427 2346 23223 23264 23305 23346 23387 23428 23429 23224 23265 23306 23347 23388 23429 2347 23225 23266 23307 23348 23389 23430 2347 23226 23267 23308 23349 23390 23431 2347 23227 23268 23309 23350 23391 23432 2347 23228 23269 23310 23351 23392 23433 2347 23229 2370 23311 2355 23394 23432 2347 23231 23271 23312 2355 23394 23433 2347 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
23217 23258 23299 23340 23381 23422 23461 23219 23260 23301 23342 23383 23424 23461 23220 23261 23302 23343 23384 23425 2346 23221 23262 23303 23344 23385 23426 2346 23222 23263 23304 23345 23386 23427 2346 23223 23264 23305 23346 23387 23428 2346 23224 23265 23306 23347 23388 23429 2347 23225 23266 23307 23348 23389 23430 2347 23226 23267 23308 23349 23390 23431 2347 23227 23268 23307 2348 23389 23430 2347 23228 23269 23310 2351 23391 23432 2347 23228 23269 23310 2351 23392 23433 2347 23228 23270							
23218 23259 23300 23341 23382 23423 23464 23219 23260 23301 23342 23383 23424 23465 23221 23262 23303 23344 23385 23426 23467 23222 23263 23304 23345 23386 23427 23467 23223 23264 23305 23346 23387 23428 23468 23224 23265 23306 23347 23388 23429 23470 23225 23266 23307 23348 23389 23430 2347 23226 23267 23308 23349 23390 23431 2347 23227 23268 23309 23550 23391 23432 2347 23228 23269 23310 23351 23392 23433 2347 23229 23270 23311 23352 23393 23434 2347 23231 23271 23312 23353 23394 23435 2347 23233 23271 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
23219 23260 23301 23342 23383 23424 23465 23220 23261 23302 23344 23385 23426 23467 23221 23262 23303 23344 23385 23426 23467 23222 23263 23304 23345 23386 23427 23468 23223 23264 23305 23346 23387 23428 23467 23224 23265 23306 23347 23388 23429 23470 23225 23266 23307 23348 23389 23430 2347 23226 23267 23308 23349 23390 23431 2347 23227 23268 23309 2350 23391 23432 2347 23228 23269 23310 23351 23392 23433 2347 23230 23271 23312 23352 23394 23434 2347 23231 23272 23313 2354 23395 23436 2347 23232 23273							
23220 2361 23302 23343 23384 23425 23466 23221 23262 23303 23344 23385 23426 23467 23222 23263 23304 23345 23386 23427 23466 23223 23264 23305 23346 23387 23428 23462 23224 23265 23306 23347 23388 23429 23470 23225 23266 23307 23348 23389 23430 23471 23226 23267 23308 23349 23390 23431 23472 23227 23268 23309 23350 23391 23432 23473 23229 23270 23310 23351 23392 23433 23474 23230 23271 23311 23352 23393 23434 23473 23231 23271 23312 23353 23394 23436 2347 23232 23273 23314 23355 23396 23437 23478 23233 2327							
23221 23262 23303 23344 23385 23426 23467 23222 23263 23304 23345 23386 23427 23468 23223 23264 23305 23346 23387 23428 23468 23224 23265 23306 23347 23388 23429 2347 23225 23266 23307 23348 23389 23430 2347 23227 23268 23309 23350 23391 23431 2347 23228 23269 23310 23351 23392 23433 2347 23229 23270 23311 23352 23393 23434 2347 23230 23271 23312 23353 23394 23433 2347 23231 23272 23313 23352 23393 23434 2347 23233 23271 23312 23353 23394 23435 2347 23234 23275 23313 23354 23395 23436 2347 23233 23274							
23222 23263 23304 23345 23386 23427 23466 23223 23264 23305 23346 23387 23428 23461 23224 23265 23306 23347 23388 23429 23471 23225 23266 23307 23348 23389 23430 23472 23226 23267 23308 23349 23390 23431 23472 23227 23268 23309 23350 23391 23432 23473 23228 23269 23310 23351 23392 23433 23474 23229 23270 23311 23352 23393 23434 23475 23231 23271 23312 23353 23394 23435 23476 23231 23272 23313 23354 23395 23436 23477 23231 23271 23312 23355 23396 23437 23476 23233 23274 23315 23356 23397 23438 23477 23234 23							
23223 23264 23305 23346 23387 23428 23466 23224 23265 23306 23347 23388 23429 23470 23225 23266 23307 23348 23399 23430 23472 23226 23267 23308 23349 23390 23431 23472 23227 23268 23309 23350 23391 23432 23473 23229 23270 23311 23352 23393 23434 23473 23230 23271 23312 23353 23394 23435 23474 23231 23272 23313 23354 23395 23436 23473 23231 23271 23312 23353 23394 23435 23476 23232 23271 23314 23355 23396 23437 23476 23233 23273 23314 23355 23396 23437 23476 23234 23275 23316 23357 23398 23439 23448 23235 23							
23224 23265 23306 23347 23388 23429 23470 23225 23266 23307 23348 23389 23430 23471 23226 23267 23308 23349 23390 23431 23472 23227 23268 23309 23350 23391 23432 23473 23228 23269 23310 23351 23392 23433 23474 23229 23270 23311 23352 23393 23434 23475 23230 23271 23312 23353 23394 23435 23476 23231 23272 23313 2354 23395 23436 2347 23232 23273 23314 23355 23396 23437 23476 23233 23274 23315 23356 23397 23438 23477 23234 23275 23316 23357 23398 23439 23440 23236 23277 23318 23359 23400 23441 23482 23238 2327							
23225 23266 23307 23348 23389 23430 23472 23226 23267 23308 23349 23390 23431 23472 23227 23268 23309 23350 23391 23432 23472 23228 23269 23310 23351 23392 23433 23474 23229 23270 23311 23352 23393 23434 23473 23231 23271 23312 23353 23394 23435 23476 23231 23272 23313 23354 23395 23436 23477 23232 23273 2314 23355 23396 23437 23478 23233 23274 23315 23356 23397 23438 23479 23234 23275 23316 23357 23398 23439 23488 23235 23276 23317 23358 23399 23440 2348 23237 23318 23359 23400 23411 2342 23238 23279 23319							
23226 23267 23308 23349 23390 23431 23472 23227 23268 23309 23350 23391 23432 23473 23228 23269 23310 23351 23392 23433 23474 23229 23270 23311 23352 23393 23434 23475 23230 23271 23312 23353 23394 23435 23476 23231 23272 23313 23354 23395 23436 23477 23232 23273 23314 23355 23396 23437 23478 23233 23274 23315 23356 23397 23438 23477 23234 23275 23316 23357 23398 23439 23480 23235 23276 23317 23358 23399 23440 23486 23237 23218 23319 23360 23401 23441 23486 23237 23278 23319 23360 23401 23442 23486 23238 23							
23227 23268 23309 23350 23391 23432 23472 23228 23269 23310 23351 23392 23433 23474 23229 23270 23311 23352 23393 23434 23475 23230 23271 23312 23353 23394 23435 23476 23231 23272 23313 23354 23395 23436 23477 23232 23273 23314 23355 23396 23437 23478 23233 23274 23315 23356 23397 23438 23479 23234 23275 23316 23357 23398 23439 2348 23235 23276 23317 23358 23399 23440 2348 23236 23277 23318 23359 23400 23441 2348 23237 23278 23319 23360 23401 23442 2348 23238 23279 23320 23361 23402 23443 2348 23239 23280 2321 23362 23403 23444 2348 23241 23282 23323 23364 23404 23445 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>							
23228 23269 23310 23351 23392 23433 23474 23229 23270 23311 23352 23393 23434 23475 23230 23271 23312 23353 23394 23435 23476 23231 23272 23313 23354 23395 23436 2347 23232 23273 23314 23355 23396 23437 23478 23233 23274 23315 23356 23397 23438 23479 23234 23275 23316 23357 23398 23439 2348 23235 23276 23317 23358 23399 23440 2348 23236 23277 23318 23359 23400 23441 2348 23237 23278 23319 23360 23401 23442 2348 23238 23279 23220 23361 23402 23443 2348 23240 23281 2322 23363 23404 23445 2348 23241 23282							
23229 23270 23311 23352 23393 23434 23475 23230 23271 23312 23353 23394 23435 23476 23231 23272 23313 23354 23395 23436 23477 23232 23273 23314 23355 23396 23437 23478 23233 23274 23315 23356 23397 23438 23479 23234 23275 23316 23357 23398 23439 23480 23235 23276 23317 23358 23399 23440 23481 23236 23277 23318 23359 23400 23441 23482 23237 23278 23319 23360 23401 23442 23482 23238 23279 23320 23361 23402 23443 23482 23239 23280 23321 23362 23403 23444 23488 23240 23281 23322 23363 23404 23445 23486 23241 23282 23323 23364 23405 23446 23486 23242 23283 23324 23365 23406 23447							
23230 23271 23312 23353 23394 23435 23476 23231 23272 23313 23354 23395 23436 2347 23232 23273 23314 23355 23396 23437 23478 23233 23274 23315 23356 23397 23438 23479 23234 23275 23316 23357 23398 23439 23480 23235 23276 23317 23358 23399 23440 23481 23236 23277 23318 23359 23400 23441 23482 23237 23278 23319 23360 23401 23442 23481 23239 2320 23321 23361 23402 23443 23484 23239 23280 2321 23362 23403 23444 2348 23240 23281 2322 23363 23404 23445 2348 23241 23282 23323 23364 23406 23447 2348 23242 23283 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
23231 23272 23313 23354 23395 23436 23477 23232 23273 23314 23355 23396 23437 23478 23233 23274 23315 23356 23397 23438 23475 23234 23275 23316 23357 23398 23439 23489 23235 23276 23317 23358 23399 23440 23481 23236 23277 23318 23359 23400 23441 23482 23237 23278 23319 23360 23401 23442 23482 23238 23279 23320 23361 23402 23443 2348 23239 23280 2321 23362 23403 23444 2348 23240 23281 23322 23363 23404 23445 2348 23241 23282 23233 23364 23405 23446 2348 23242 23283 23324 23365 23406 23447 2348							
23232 23273 23314 23355 23396 23437 23478 23233 23274 23315 23356 23397 23438 23478 23234 23275 23316 2357 23398 23439 2348 23235 23276 23317 23358 23399 23440 2348 23236 23277 23318 23359 23400 23441 2348 23237 23278 23319 23360 23401 23442 2348 23238 23279 23320 23361 23402 23443 2348 23239 23280 23321 23362 23403 23444 2348 23240 23281 23322 23363 23404 23445 2348 23241 23282 23323 23364 23405 23446 2348 23242 23283 23324 23365 23406 23447 2348							
23233 23274 23315 23356 23397 23438 23475 23234 23275 23316 23357 23398 23439 23480 23235 23276 23317 23358 23399 23440 23348 23236 23277 23318 23359 23400 23441 23482 23237 23278 23319 23360 23401 23442 23483 23238 23279 23320 23361 23402 23443 23484 23239 23280 23321 23362 23403 23444 23488 23240 23281 23322 23363 23404 23445 23486 23241 23282 23323 23364 23405 23446 2348 23242 23283 23324 23365 23406 23447 23486							
23234 23275 23316 23357 23398 23439 23480 23235 23276 23317 23358 23399 23440 23482 23236 23277 23318 23359 23400 23441 233482 23237 23278 23319 23360 23401 23442 23482 23238 23279 23320 23361 23402 23443 23484 23239 23280 23321 23362 23403 23444 23488 23240 23281 23322 23363 23404 23445 23486 23241 23282 23323 23364 23405 23446 23486 23242 23283 23324 23365 23406 23447 23486							
23235 23276 23317 23358 23399 23440 23481 23236 23277 23318 23359 23400 23441 23482 23237 23278 23319 23360 23401 23442 23348 23238 23279 23320 23361 23402 23443 23482 23239 23280 23321 23362 23403 23444 23485 23240 23281 23322 23363 23404 23445 23486 23241 23282 23323 23364 23405 23446 2348 23242 23283 23324 23365 23406 23447 2348							
23236 23277 23318 23359 23400 23441 23482 23237 23278 23319 23360 23401 23442 23483 23238 23279 23320 23361 23402 23443 23483 23239 23280 23321 23362 23403 23444 23485 23240 23281 23322 23363 23404 23445 23485 23241 23282 23323 23364 23405 23446 23487 23242 23283 23324 23365 23406 23447 23488							
23237 23278 23319 23360 23401 23442 23483 23238 23279 23320 23361 23402 23443 2348 23239 23280 23321 23362 23403 23444 2348 23240 23281 23322 23363 23404 23445 23465 23241 23282 23323 23364 23405 23446 2348 23242 23283 23324 23365 23406 23447 2348							
23238 23279 23320 23361 23402 23443 23484 23239 23280 23321 23362 23403 23444 2348 23240 23281 23322 23363 23404 23445 2348 23241 23282 23323 23364 23405 23446 2348 23242 23283 23324 23365 23406 23447 2348							
23239 23280 23321 23362 23403 23444 23485 23240 23281 23322 23363 23404 23445 23485 23241 23282 23323 23364 23405 23446 23486 23242 23283 23324 23365 23406 23447 23488							
23240 23281 23322 23363 23404 23445 23486 23241 23282 23323 23364 23405 23446 23486 23242 23283 23324 23365 23406 23447 23488							
23241 23282 23323 23364 23405 23446 23487 23242 23242 23324 23365 23406 23447 23488							
23242 23283 23324 23365 23406 23447 23488							23486
							23487
23243 23284 23325 23366 23407 23448 23488							23488
	23243	23284	23325	23366	23407	23448	23489

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	t. Bl. Trt. Bl. No nb No nb			Trt. Bl. No nb		Trt. Bl. No nb		Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb
PPD	20170	PPD	20001	PPD		PPD		PPD	23654	PPD	23695	PPD	23736
	23491		23532		23573		23614		23655		23696		23737
	23492		23533		23574		23615		23656		23697		23738
	23493		23534		23575		23616		23657		23698		23739
	23494		23535		23576		23617		23658		23699		23740
	23495		23536		23577		23618		23659		23700		23741
	23496		23537		23578		23619		23660		23701		23742
	23497		23538		23579		23620		23661		23702		23743
	23498		23539		23580		23621		23662		23703		23744
	23499		23540		23581		23622		23663		23704		23745
	23500		23541		23582		23623		23664		23705		23746
	23501		23542		23583		23624		23665		23706		23747
	23502		23543		23584		23625		23666		23707		23748
	23503		23544		23585		23626		23667		23708		23749
	23504		23545		23586		23627		23668		23709		23750
	23505		23546		23587		23628		23669		23710		23751
	23506		23547		23588		23629		23670		23711		23752
	23507		23548		23589		23630		23671		23712		23753
	23508		23549		23590		23631		23672		23713		23754
	23509		23550		23591		23632		23673		23714		23755
	23510		23551		23592		23633		23674		23715		23756
	23511		23552		23593		23634		23675		23716		23757
	23512		23553		23594		23635		23676		23717		23758
	23513		23554		23595		23636		23677		23718		23759
	23514		23555		23596		23637		23678		23719		23760
	23515		23556		23597		23638		23679		23720		23761
	23516		23557		23598		23639		23680		23721		23762
	23517		23558		23599		23640		23681		23722		23763
	23518		23559		23600		23641		23682		23723		23764
	23519		23560		23601		23642		23683		23724		23765
	23520		23561		23602		23643		23684		23725		23766
	23521		23562		23603		23644		23685		23726		23767
	23522		23563		23604		23645		23686		23727		23768
	23523		23564		23605		23646		23687		23728		23769
	23524		23565		23606		23647		23688		23729		23770
	23525		23566		23607		23648		23689		23730		23771
	23526		23567		23608		23649		23690		23731		23772
	23527		23568		23609		23650		23691		23732		23773
	23528		23569		23610		23651		23692		23733		23774
	23529		23570		23611		23652		23693		23734		23775
	23530		23571		23612		23653		23694		23735		23776
	•		l				l				l		

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No :	nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	23777	PPD	23818	PPD	23859	PPD	23900	PPD	23941	PPD	23982	PPD	24023
PPD	23778		23818	110	23860	FFU	23900	PPU	23941		23982	110	24023
	23779		23819		23860		23901		23942		23983		24024
	23779		23820 23821		23862		23902		23943		23984		24025
	23781		23822		23863		23904		23945		23986		24027
	23782		23823		23864		23905		23946		23987		24028
	23783		23824		23865		23906		23947		23988		24029
	23784		23825		23866		23907		23948		23989		24030
	23785		23826		23867		23908		23949		23990		24031
	23786		23827		23868		23909		23950		23991		24032
	23787		23828		23869		23910		23951		23992		24033
	23788		23829		23870		23911		23952		23993		24034
	23789		23830		23871		23912		23953		23994		24035
	23790		23831		23872		23913		23954		23995		24036
	23791		23832		23873		23914		23955		23996		24037
	23792		23833		23874		23915		23956		23997		24038
	23793		23834		23875		23916		23957		23998		24039
	23794		23835		23876		23917		23958		23999		24040
	23795		23836		23877		23918		23959		24000		24041
	23796		23837		23878		23919		23960		24001		24042
	23797		23838		23879		23920		23961		24002		24043
	23798		23839		23880		23921		23962		24003		24044
	23799		23840		23881		23922		23963		24004		24045
	23800		23841		23882		23923		23964		24005		24046
	23801		23842		23883		23924		23965		24006		24047
	23802		23843		23884		23925		23966		24007		24048
	23803		23844		23885		23926		23967		24008		24049
	23804		23845		23886		23927		23968		24009		24050
	23805		23846		23887		23928		23969		24010		24051
	23806		23847		23888		23929		23970		24011		24052
	23807		23848		23889		23930		23971		24012		24053
	23808		23849		23890		23931		23972		24013		24054
	23809		23850		23891		23932		23973		24014		24055
	23810		23851		23892		23933		23974		24015		24056
	23811		23852		23893		23934		23975		24016		24057
	23812		23853		23894		23935		23976		24017		24058
	23813		23854		23895		23936		23977		24018		24059
	23814		23855		23896		23937		23978		24019		24060
	23815		23856		23897		23938		23979		24020		24061
	23816		23857		23898		23939		23980		24021		24062
	23817		23858		23899		23940		23981		24022		24063
											l		

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No		Trt. Bl. No nb					
PPD	24064	PPD 24105	PPD 24146	PPD 24187	PPD 24228	PPD 24269	PPD 24310
	24065	24106	24147	24188	24229	24270	24311
	24066	24107	24148	24189	24230	24271	24312
	24067	24108	24149	24190	24231	24272	24313
	24068	24109	24150	24191	24232	24273	24314
	24069	24110	24151	24192	24233	24274	24315
	24070	24111	24152	24193	24234	24275	24316
	24071	24112	24153	24194	24235	24276	24317
	24072	24113	24154	24195	24236	24277	24318
	24073	24114	24155	24196	24237	24278	24319
	24074	24115	24156	24197	24238	24279	24320
	24075	24116	24157	24198	24239	24280	24321
	24076	24117	24158	24199	24240	24281	24322
	24077	24118	24159	24200	24241	24282	24323
	24078	24119	24160	24201	24242	24283	24324
	24079	24120	24161	24202	24243	24284	24325
	24080	24121	24162	24203	24244	24285	24326
	24081	24122	24163	24204	24245	24286	24327
	24082	24123	24164	24205	24246	24287	24328
	24083	24124	24165	24206	24247	24288	24329
	24084	24125	24166	24207	24248	24289	24330
	24085	24126	24167	24208	24249	24290	24331
	24086	24127	24168	24209	24250	24291	24332
	24087	24128	24169	24210	24251	24292	24333
	24088	24129	24170	24211	24252	24293	24334
	24089	24130	24171	24212	24253	24294	24335
	24090	24131	24172	24213	24254	24295	24336
	24091	24132	24173	24214	24255	24296	24337
	24092	24133	24174	24215	24256	24297	24338
	24093	24134	24175	24216	24257	24298	24339
	24094	24135	24176	24217	24258	24299	24340
	24095	24136	24177	24218	24259	24300	24341
	24096	24137	24178	24219	24260	24301	24342
	24097	24138	24179	24220	24261	24302	24343
	24098	24139	24180	24221	24262	24303	24344
	24099	24140	24181	24222	24263	24304	24345
	24100	24141	24182	24223	24264	24305	24346
	24101	24142	24183	24224	24265	24306	24347
	24102	24143	24184	24225	24266	24307	24348
	24103	24144	24185	24226	24267	24308	24349
	24104	24145	24186	24227	24268	24309	24350

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	. Bl. o nb	Trt. No		Trt. No		Trt. No	nb	Trt. No	nb		Bl. nb	Trt. No	nb
PPD	24351	PPD	24392	PPD	24433	PPD	24474	PPD	24515	PPD	24556	PPD	24597
110	24352	110	24393		24434	110	24475	110	24516		24557		24598
	24353		24393		24434		24476		24517		24558		24599
	24353		24394		24435		24477		24518		24559		24599
	24355		24395		24437		24478		24519		24560		24600
	24355		24396		24437		24479		24520		24561		24601
	24356		24397		24438		24479		24520		24562		24602
	24358		24399		24440		24481		24522		24563		24604
	24359		24400		24441		24482		24523		24564		24605
	24360		24401		24442		24483		24524		24565		24606
	24361		24402		24443		24484		24525		24566		24607
	24362		24403		24444		24485		24526		24567		24608
	24363		24404		24445		24486		24527		24568		24609
	24364		24405		24446		24487		24528		24569		24610
	24365		24406		24447		24488		24529		24570		24611
	24366		24407		24448		24489		24530		24571		24612
	24367		24408		24449		24490		24531		24572		24613
	24368		24409		24450		24491		24532		24573		24614
	24369		24410		24451		24492		24533		24574		24615
	24370		24411		24452		24493		24534		24575		24616
	24371		24412		24453		24494		24535		24576		24617
	24372		24413		24454		24495		24536		24577		24618
	24373		24414		24455		24496		24537		24578		24619
	24374		24415		24456		24497		24538		24579		24620
	24375		24416		24457		24498		24539		24580		24621
	24376		24417		24458		24499		24540		24581		24622
	24377		24418		24459		24500		24541		24582		24623
	24378		24419		24460		24501		24542		24583		24624
	24379		24420		24461		24502		24543		24584		24625
	24380		24421		24462		24503		24544		24585		24626
	24381		24422		24463		24504		24545		24586		24627
	24382		24423		24464		24505		24546		24587		24628
	24383		24424		24465		24506		24547		24588		24629
	24384		24425		24466		24507		24548		24589		24630
	24385		24426		24467		24508		24549		24590		24631
	24386		24427		24468		24509		24550		24591		24632
	24387		24428		24469		24510		24551		24592		24633
	24388		24429		24470		24511		24552		24593		24634
	24389		24429		24471		24511		24553		24594		24634
	24389		24430		24471		24512		24553		24594		24635
	24390		24431		24472		24513		24554		24595		24636
	24391		24432		244/3		24014		24333		24396		2403/

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	Bl. nb	Trt. No		Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb
PPD	24638	PPD	24679	PPD	24720	PPD	24761	PPD	24802	PPD	24843	PPD	24884
110	24639		24680		24721		24762	110	24803		24844		24885
	24640		24681		24722		24763		24804		24845		24886
	24641		24682		24723		24764		24805		24846		24887
	24642		24683		24724		24765		24806		24847		24888
	24643		24684		24725		24766		24807		24848		24889
	24644		24685		24726		24767		24808		24849		24890
	24645		24686		24727		24768		24809		24850		24891
	24646		24687		24728		24769		24810		24851		24891
	24647		24688		24729		24770		24811		24852		24893
	24647		24689		24730				24811		24852		24893
	24648		24689		24730		24771 24772		24812		24853		24894
	24650		24691		24732		24773		24814		24855		24896
	24651		24692		24733		24774		24815		24856		24897
	24652		24693		24734		24775		24816		24857		24898
	24653		24694		24735		24776		24817		24858		24899
	24654		24695		24736		24777		24818		24859		24900
	24655		24696		24737		24778		24819		24860		24901
	24656		24697		24738		24779		24820		24861		24902
	24657		24698		24739		24780		24821		24862		24903
	24658		24699		24740		24781		24822		24863		24904
	24659		24700		24741		24782		24823		24864		24905
	24660		24701		24742		24783		24824		24865		24906
	24661		24702		24743		24784		24825		24866		24907
	24662		24703		24744		24785		24826		24867		24908
	24663		24704		24745		24786		24827		24868		24909
	24664		24705		24746		24787		24828		24869		24910
	24665		24706		24747		24788		24829		24870		24911
	24666		24707		24748		24789		24830		24871		24912
	24667		24708		24749		24790		24831		24872		24913
	24668		24709		24750		24791		24832		24873		24914
	24669		24710		24751		24792		24833		24874		24915
	24670		24711		24752		24793		24834		24875		24916
	24671		24712		24753		24794		24835		24876		24917
	24672		24713		24754		24795		24836		24877		24918
	24673		24714		24755		24796		24837		24878		24919
	24674		24715		24756		24797		24838		24879		24920
	24675		24716		24757		24798		24839		24880		24921
	24676		24717		24758		24799		24840		24881		24921
	24677		24717		24759		24800		24841		24882		24922
	24678		24710		24760		24801		24842		24883		24923
	240/0		24/13		24/0U		7400T		24042		24000		24924
					l								

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.		Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No	nb	No		No	nb	No	nb	No	nb	No	nb
PPD	24925	PPD	24966	PPD	25007	PPD	25048	PPD	25089	PPD	25130	PPD	25171
FFD	24926		24967		25007	110	25049	FFD	25099		25130	110	25171
	24927		24968		25000		25050		25090		25131		25172
	24928		24969		25010		25050		25092		25132		25173
	24929		24970		25010		25051		25092		25133		25174
	24930		24971		25011		25052		25093		25134		25176
	24931		24972		25012		25053		25095		25136		25170
	24932		24973		25013		25054		25096		25130		25177
	24933		24974		25014		25056		25097		25137		25178
	24934		24975		25016		25057		25097		25138		25179
	24935		24976		25017		25057		25098		25140		25180
	24936		24977		25017		25059		25100		25140		25182
	24937		24978		25010		25060		25100		25141		25183
	24938		24979		25020		25061		25101		25142		25184
	24939		24980		25020		25062		25102		25143		25185
	24940		24981		25022		25063		25103		25144		25186
	24941		24982		25022		25064		25104		25146		25187
	24942		24983		25023		25065		25105		25140		25187
	24943		24984		25025		25066		25100		25147		25189
	24944		24985		25026		25067		25107		25149		25190
	24945		24986		25027		25068		25100		25149		25190
	24946		24987		25027		25069		25110		25150		25191
	24947		24988		25029		25070		25111		25151		25192
	24948		24989		25030		25071		25112		25152		25194
	24949		24990		25031		25072		25113		25154		25195
	24950		24991		25032		25072		25114		25151		25196
	24951		24992		25032		25074		25115		25156		25197
	24952		24993		25033		25075		25116		25157		25198
	24953		24994		25035		25076		25117		25157		25199
	24954		24995		25036		25077		25118		25159		25200
	24955		24996		25037		25078		25119		25160		25201
	24956		24997		25038		25079		25120		25161		25202
	24957		24998		25039		25080		25121		25162		25203
	24958		24999		25040		25081		25122		25163		25204
	24959		25000		25041		25082		25123		25164		25205
	24960		25001		25042		25083		25124		25165		25206
	24961		25002		25043		25084		25125		25166		25207
	24962		25003		25044		25085		25126		25167		25208
	24963		25004		25045		25086		25127		25168		25209
	24964		25005		25046		25087		25128		25169		25210
	24965		25006		25047		25088		25129		25170		25211
					* *								
	•												

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.					
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	25212	PPD 25253	PPD 25294	PPD 25335	PPD 25376	PPD 25417	PPD 25458
	25212	25254	25294	25336	25377	25417	25459
	25214	25255	25296	25337	25377	25419	25460
	25214	25256	25296	25338	25376	25419	25461
	25215	25257	25297	25339	25380	25420	25462
	25216	25257	25290	25340	25381	25421	25463
	25217	25258	25299	25340	25381	25422	25463
	25210	25260	25300	25341	25383	25424	25465
	25219	25260	25301	25342	25383	25424	25466
	25221	25261	25302	25343	25385	25425	25467
	25221	25262	25303	25344	25385	25426	25467
	25223	25263	25304	25345	25387	25427	25469
	25223	25264	25305	25346	25387	25428	25469
	25224	25265	25306	25347	25388	25429	25470
					25389		
	25226	25267	25308	25349		25431	25472
	25227	25268	25309	25350	25391	25432	25473
	25228	25269	25310	25351	25392	25433	25474
	25229	25270	25311	25352	25393	25434	25475
	25230	25271	25312	25353	25394	25435	25476
	25231	25272	25313	25354	25395	25436	25477
	25232	25273	25314	25355	25396	25437	25478
	25233	25274	25315	25356	25397	25438	25479
	25234	25275	25316	25357	25398	25439	25480
	25235	25276	25317	25358	25399	25440	25481
	25236	25277	25318	25359	25400	25441	25482
	25237	25278	25319	25360	25401	25442	25483
	25238	25279	25320	25361	25402	25443	25484
	25239	25280	25321	25362	25403	25444	25485
	25240	25281	25322	25363	25404	25445	25486
	25241	25282	25323	25364	25405	25446	25487
	25242	25283	25324	25365	25406	25447	25488
	25243	25284	25325	25366	25407	25448	25489
	25244	25285	25326	25367	25408	25449	25490
	25245	25286	25327	25368	25409	25450	25491
	25246	25287	25328	25369	25410	25451	25492
	25247	25288	25329	25370	25411	25452	25493
	25248	25289	25330	25371	25412	25453	25494
	25249	25290	25331	25372	25413	25454	25495
	25250	25291	25332	25373	25414	25455	25496
	25251	25292	25333	25374	25415	25456	25497
	25252	25293	25334	25375	25416	25457	25498

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No nb	No nb		nb		nb	No	nb	No	nb
PPD	25499	PPD 25540	PPD 255	R1 PPD	25622	PPD	25663	PPD	25704	PPD	25745
110	25500	25541	255		25623	110	25664		25705		25746
	25501	25542	255		25624		25665		25706		25747
	25502	25543	255		25625		25666		25707		25748
	25503	25544	255		25626		25667		25708		25749
	25504	25545	255		25627		25668		25700		25750
	25505	25546	255		25628		25669		25710		25751
	25506	25547	255		25629		25670		25711		25752
	25507	25548	255		25630		25671		25712		25753
	25508	25549	255		25631		25672		25713		25754
	25509	25550	255		25632		25673		25714		25755
	25510	25551	255	92	25633		25674		25715		25756
	25511	25552	255	9.3	25634		25675		25716		25757
	25512	25553	255	94	25635		25676		25717		25758
	25513	25554	255	95	25636		25677		25718		25759
	25514	25555	255	96	25637		25678		25719		25760
	25515	25556	255	97	25638		25679		25720		25761
	25516	25557	255	98	25639		25680		25721		25762
	25517	25558	255	99	25640		25681		25722		25763
	25518	25559	256	00	25641		25682		25723		25764
	25519	25560	256)1	25642		25683		25724		25765
	25520	25561	256)2	25643		25684		25725		25766
	25521	25562	256)3	25644		25685		25726		25767
	25522	25563	256)4	25645		25686		25727		25768
	25523	25564	256)5	25646		25687		25728		25769
	25524	25565	256		25647		25688		25729		25770
	25525	25566	256	7	25648		25689		25730		25771
	25526	25567	256		25649		25690		25731		25772
	25527	25568	256		25650		25691		25732		25773
	25528	25569	256		25651		25692		25733		25774
	25529	25570	256		25652		25693		25734		25775
	25530	25571	256		25653		25694		25735		25776
	25531	25572	256		25654		25695		25736		25777
	25532	25573	256		25655		25696		25737		25778
	25533	25574	256		25656		25697		25738		25779
	25534	25575	256		25657		25698		25739		25780
	25535	25576	256		25658		25699		25740		25781
	25536	25577	256		25659		25700		25741		25782
	25537	25578	256		25660		25701		25742		25783
	25538	25579	256		25661		25702		25743		25784
	25539	25580	256	21	25662		25703		25744		25785

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No nb		nb	No	nb	No	nb	No	nb	No	nb
PPD	25786	PPD 25827	PPD	25868	PPD	25909	PPD	25950	PPD	25991	PPD	26032
PPD	25787	25827 25828	110	25869	PPD	25909	PPD	25950		25991	יוו	26032
	25788	25828		25869		25910		25951		25992		26033
	25789			25870		25911		25952		25993		26034
		25830										
	25790	25831		25872		25913		25954		25995		26036
	25791	25832		25873		25914		25955		25996		26037
	25792	25833		25874		25915		25956		25997		26038
	25793	25834		25875		25916		25957		25998		26039
	25794	25835		25876		25917		25958		25999		26040
	25795	25836		25877		25918		25959		26000		26041
	25796	25837		25878		25919		25960		26001		26042
	25797	25838		25879		25920		25961		26002		26043
	25798	25839		25880		25921		25962		26003		26044
	25799	25840		25881		25922		25963		26004		26045
	25800	25841		25882		25923		25964		26005		26046
	25801	25842		25883		25924		25965		26006		26047
	25802	25843		25884		25925		25966		26007		26048
	25803	25844		25885		25926		25967		26008		26049
	25804	25845		25886		25927		25968		26009		26050
	25805	25846		25887		25928		25969		26010		26051
	25806	25847		25888		25929		25970		26011		26052
	25807	25848		25889		25930		25971		26012		26053
	25808	25849		25890		25931		25972		26013		26054
	25809	25850		25891		25932		25973		26014		26055
	25810	25851		25892		25933		25974		26015		26056
	25811	25852		25893		25934		25975		26016		26057
	25812	25853		25894		25935		25976		26017		26058
	25813	25854		25895		25936		25977		26018		26059
	25814	25855		25896		25937		25978		26019		26060
	25815	25856		25897		25938		25979		26020		26061
	25816	25857		25898		25939		25980		26021		26062
	25817	25858		25899		25940		25981		26022		26063
	25818	25859		25900		25941		25982		26023		26064
	25819	25860		25901		25942		25983		26024		26065
	25820	25861		25902		25943		25984		26025		26066
	25821	25862		25903		25944		25985		26026		26067
	25822	25863		25904		25945		25986		26027		26068
	25823	25864		25905		25946		25987		26028		26069
	25824	25865		25906		25947		25988		26029		26070
	25825	25866		25907		25948		25989		26030		26071
	25826	25867		25908		25949		25990		26031		26072
	20020	23007		23300		20010		20000		20001		20072

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.	Trt.		Trt.			. Bl.	Trt.		Trt.	
No	nb	No nb	No		No	nb		o nb	No	nb	No	nb
PPD	26073	PPD 26114	PPD	26155	PPD	26196	PPD	26237	PPD	26278	PPD	26319
	26074	26115		26156		26197		26238		26279		26320
	26075	26116		26157		26198		26239		26280		26321
	26076	26117		26158		26199		26240		26281		26322
	26077	26118		26159		26200		26241		26282		26323
	26078	26119		26160		26201		26242		26283		26324
	26079	26120		26161		26202		26243		26284		26325
	26080	26121		26162		26203		26244		26285		26326
	26081	26122		26163		26204		26245		26286		26327
	26082	26123		26164		26205		26246		26287		26328
	26083	26124		26165		26206		26247		26288		26329
	26084	26125		26166		26207		26248		26289		26330
	26085	26126		26167		26208		26249		26290		26331
	26086	26127		26168		26209		26250		26291		26332
	26087	26128		26169		26210		26251		26292		26333
	26088	26129		26170		26211		26252		26293		26334
	26089	26130		26171		26212		26253		26294		26335
	26090	26131		26172		26213		26254		26295		26336
	26091	26132		26173		26214		26255		26296		26337
	26092	26133		26174		26215		26256		26297		26338
	26093	26134		26175		26216		26257		26298		26339
	26094	26135		26176		26217		26258		26299		26340
	26095	26136		26177		26218		26259		26300		26341
	26096	26137		26178		26219		26260		26301		26342
	26097	26138		26179		26220		26261		26302		26343
	26098	26139		26180		26221		26262		26303		26344
	26099	26140		26181		26222		26263		26304		26345
	26100	26141		26182		26223		26264		26305		26346
	26101	26142		26183		26224		26265		26306		26347
	26102	26143		26184		26225		26266		26307		26348
	26103	26144		26185		26226		26267		26308		26349
	26104	26145		26186		26227		26268		26309		26350
	26105	26146		26187		26228		26269		26310		26351
	26106	26147		26188		26229		26270		26311		26352
	26107	26148		26189		26230		26271		26312		26353
	26108	26149		26190		26231		26272		26313		26354
	26109	26150		26191		26232		26273		26314		26355
	26110	26151		26192		26233		26274		26315		26356
	26111	26152		26193		26234		26275		26316		26357
	26112	26153		26194		26235		26276		26317		26358
	26113	26154		26195		26236		26277		26318		26359

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	
No	26360 26361 26362 26363 26364 26365 26366 26367 26368 26370 26371 26372 26373 26374 26375 26375 26377 26378 26377 26378 26379 26380 26381 26382 26381 26382 26384 26385 26386	No	nb 26401 26402 26403 26406 26406 26407 26411 26412 26413 26414 26415 26416 26417 26418 26419 26420 26421 26423 26424 26425 26428 26427 26428	No	nb 26442 26443 26444 26445 26446 26447 26448 26449 26450 26451 26452 26453 26454 26455 26456 26466 26466 26466 26466 26466 26466 26466 26466 26466	No	nb 26483 26484 26485 26486 26487 26488 26489 26490 26491 26492 26493 26494 26495 26497 26498 26499 26500 26501 26500 26501 26500 26501 26500 26501	No	nb	No	nb 26565 26566 26567 26568 26569 26570 26572 26573 26574 26575 26576 26576 26576 26578 26578 26578 26580 26580 26581 26582 26583 26584 26585 26586 26587 26588		26606 26607 26608 26609 26610 26611 26612 26613 26614 26615 26616 26617 26618 26620 26620 26621 26622 26623 26624 26625 26627 26628 26629 26630 26631 26633 26633
	26388 26389 26390 26391 26392 26393 26394 26395 26396 26397 26398 26399 26400		26429 26430 26431 26432 26433 26434 26435 26436 26437 26438 26438 26439 26440		26470 26471 26472 26473 26474 26475 26476 26477 26478 26479 26480 26481 26482		26511 26512 26513 26514 26515 26516 26517 26518 26519 26520 26521 26522 26523		26552 26553 26554 26555 26556 26557 26558 26559 26560 26561 26562 26563 26564		26593 26594 26595 26596 26597 26598 26599 26600 26601 26602 26603 26603 26604		26634 26635 26636 26637 26638 26639 26640 26641 26642 26644 26645 26646

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.	Trt. Bl.	Trt.		Trt.			Bl.	Trt.	
No	nb	No nb	No nb	No	nb	No	nb	No	nb	No	nb
PPD	26647	PPD 26688	PPD 26729	PPD	26770	PPD	26811	PPD	26852	PPD	26893
110	26648	26689	26730		26771	110	26812		26853		26894
	26649	26690	2673		26772		26813		26854		26895
	26650	26691	26732		26773		26814		26855		26896
	26651	26692	26733		26774		26815		26856		26897
	26652	26693	26734		26775		26816		26857		26898
	26653	26694	26735		26776		26817		26858		26899
	26654	26695	26736	5	26777		26818		26859		26900
	26655	26696	2673	1	26778		26819		26860		26901
	26656	26697	26738	3	26779		26820		26861		26902
	26657	26698	26739	9	26780		26821		26862		26903
	26658	26699	26740)	26781		26822		26863		26904
	26659	26700	26743	-	26782		26823		26864		26905
	26660	26701	26742	2	26783		26824		26865		26906
	26661	26702	26743	3	26784		26825		26866		26907
	26662	26703	2674		26785		26826		26867		26908
	26663	26704	26745	5	26786		26827		26868		26909
	26664	26705	2674	5	26787		26828		26869		26910
	26665	26706	2674	7	26788		26829		26870		26911
	26666	26707	26748		26789		26830		26871		26912
	26667	26708	26749		26790		26831		26872		26913
	26668	26709	26750		26791		26832		26873		26914
	26669	26710	2675		26792		26833		26874		26915
	26670	26711	26752		26793		26834		26875		26916
	26671	26712	26753		26794		26835		26876		26917
	26672	26713	26754		26795		26836		26877		26918
	26673	26714	26755		26796		26837		26878		26919
	26674	26715	26756		26797		26838		26879		26920
	26675	26716	2675		26798		26839		26880		26921
	26676	26717	26758		26799		26840		26881		26922
	26677	26718	26759		26800		26841		26882		26923
	26678 26679	26719 26720	26760 26761		26801 26802		26842 26843		26883 26884		26924 26925
	26680	26721	2676		26802		26843		26885		26925
	26681	26721	26762		26803		26845		26886		26926
	26682	26723	26764		26805		26846		26887		26927
	26683	26724	26765		26806		26847		26888		26929
	26684	26725	2676		26807		26848		26889		26929
	26685	26726	2676		26808		26849		26890		26930
	26686	26727	26768		26809		26850		26891		26931
	26687	26728	26769		26810		26851		26892		26933
	20001	20720	2070	·	20010		20001		20072		20,00

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	Trt. Bl. Trt. Bl. No nb No nb		nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	Bl. nb	Trt. No	Bl. nb
PPD	27221	PPD	27262	PPD		PPD		PPD	27385	PPD	27426	PPD	27467
FFD	27222	110	27263	110	27304	FFD	27344	FFD	27386		27427	יוו	27467
	27223		27264		27305		27346		27387		27428		27469
	27224		27265		27306		27347		27388		27429		27470
	27225		27266		27307		27348		27389		27430		27470
	27226		27267		27308		27349		27399		27431		27471
	27227		27268		27309		27350		27390		27431		27472
	27228		27269		27310		27351		27391		27433		27473
	27229		27270		27311		27352		27393		27434		27474
	27230		27271		27312		27353		27393		27435		27476
	27231		27272		27313		27354		27394		27436		27477
	27232		27273		27314		27355		27396		27437		27478
	27233		27274		27315		27356		27397		27438		27479
	27234		27275		27316		27357		27398		27439		27480
	27235		27276		27317		27358		27399		27440		27481
	27236		27277		27318		27359		27400		27441		27482
	27237		27278		27319		27360		27401		27442		27483
	27238		27279		27320		27361		27402		27443		27484
	27239		27280		27321		27362		27403		27444		27485
	27240		27281		27322		27363		27404		27445		27486
	27241		27282		27323		27364		27405		27446		27487
	27242		27283		27324		27365		27406		27447		27488
	27243		27284		27325		27366		27407		27448		27489
	27244		27285		27326		27367		27408		27449		27490
	27245		27286		27327		27368		27409		27450		27491
	27246		27287		27328		27369		27410		27451		27492
	27247		27288		27329		27370		27411		27452		27493
	27248		27289		27330		27371		27412		27453		27494
	27249		27290		27331		27372		27413		27454		27495
	27250		27291		27332		27373		27414		27455		27496
	27251		27292		27333		27374		27415		27456		27497
	27252		27293		27334		27375		27416		27457		27498
	27253		27294		27335		27376		27417		27458		27499
	27254		27295		27336		27377		27418		27459		27500
	27255		27296		27337		27378		27419		27460		27501
	27256		27297		27338		27379		27420		27461		27502
	27257		27298		27339		27380		27421		27462		27503
	27258		27299		27340		27381		27422		27463		27504
	27259		27300		27341		27382		27423		27464		27505
	27260		27301		27342		27383		27424		27465		27506
	27261		27302		27343		27384		27425		27466		27507

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl.					
	No nb					
		No nb			No nb	PPD 27754 27755 27756 27757 27758 27759 27760 27761 27762 27763 27764 27765 27768 27769 27777 27778 27779 27771 27772 27773 27774 27775 27777 27778 27777 27778 27779 27778 27779 27786 27777 27778 27777 27778 27778 27779 27786 27777 27778 27778 27779 27786 27777 27778 27778 27779 27786 27777 27778 27778 27779 27786 27777 27778 27778 27778 27778 27778 27778 27778 27778 27778 27778
27547	27588	27629	27670	27711	27752	27793
27548	27589	27630	27671	27712	27753	27794

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl		Trt.		Trt.		Trt.		Trt.		Trt.	
No	nb	No nh)	No	nb								
PPD	27795	PPD 27	7836 F	PPD	27877	PPD	27918	PPD	27959	PPD	28000	PPD	28041
	27796		1837		27878		27919		27960		28001		28042
	27797		7838		27879		27920		27961		28002		28043
	27798		7839		27880		27921		27962		28003		28044
	27799	27	7840		27881		27922		27963		28004		28045
	27800	27	7841		27882		27923		27964		28005		28046
	27801	27	7842		27883		27924		27965		28006		28047
	27802	27	7843		27884		27925		27966		28007		28048
	27803	27	7844		27885		27926		27967		28008		28049
	27804	27	7845		27886		27927		27968		28009		28050
	27805	27	7846		27887		27928		27969		28010		28051
	27806	27	7847		27888		27929		27970		28011		28052
	27807	27	7848		27889		27930		27971		28012		28053
	27808	27	7849		27890		27931		27972		28013		28054
	27809	27	7850		27891		27932		27973		28014		28055
	27810	27	7851		27892		27933		27974		28015		28056
	27811	27	7852		27893		27934		27975		28016		28057
	27812	27	7853		27894		27935		27976		28017		28058
	27813	27	7854		27895		27936		27977		28018		28059
	27814		7855		27896		27937		27978		28019		28060
	27815	27	7856		27897		27938		27979		28020		28061
	27816	27	7857		27898		27939		27980		28021		28062
	27817	27	7858		27899		27940		27981		28022		28063
	27818	27	7859		27900		27941		27982		28023		28064
	27819	27	7860		27901		27942		27983		28024		28065
	27820	27	7861		27902		27943		27984		28025		28066
	27821	27	7862		27903		27944		27985		28026		28067
	27822	27	7863		27904		27945		27986		28027		28068
	27823	27	7864		27905		27946		27987		28028		28069
	27824	27	7865		27906		27947		27988		28029		28070
	27825	27	7866		27907		27948		27989		28030		28071
	27826	27	1867		27908		27949		27990		28031		28072
	27827	27	7868		27909		27950		27991		28032		28073
	27828	27	7869		27910		27951		27992		28033		28074
	27829	27	7870		27911		27952		27993		28034		28075
	27830	27	7871		27912		27953		27994		28035		28076
	27831	27	1872		27913		27954		27995		28036		28077
	27832	27	1873		27914		27955		27996		28037		28078
	27833	27	7874		27915		27956		27997		28038		28079
	27834	27	7875		27916		27957		27998		28039		28080
	27835	27	7876		27917		27958		27999		28040		28081

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. B	31.	Trt. H	Bl.	Trt.		Trt.	Bl.	Trt.		Trt.	Bl.	Trt.	Bl.
No nl	ıb	No 1	nb	No		No	nb		nb	No	nb	No	nb
PPD 28	8082	PPD :	28123	PPD	28164	PPD	28205	PPD	28246	PPD	28287	PPD	28328
	18083		28124	–	28165	יוו	28206	יוו	28247		28288		28329
	8084		28125		28166		28207		28248		28289		28330
	28085		28126		28167		28208		28249		28290		28331
	18086		28127		28168		28209		28250		28291		28332
	8087		28128		28169		28210		28251		28292		28333
	28088		28129		28170		28211		28252		28293		28334
	8089		28130		28171		28212		28253		28294		28335
	28090		28131		28172		28213		28254		28295		28336
	8091		28132		28173		28214		28255		28296		28337
	18091		28133		28174		28215		28256		28297		28338
	18093		28134		28175		28216		28257		28298		28339
	8094		28135		28176		28217		28258		28299		28340
	28095		28136		28177		28218		28259		28300		28341
	18096		28137		28178		28219		28260		28301		28342
	8097		28138		28179		28220		28261		28302		28343
	18097		28139		28180		28221		28262		28303		28344
	28099		28140		28181		28222		28263		28304		28345
	8100		28141		28182		28223		28264		28305		28346
	8101		28142		28183		28224		28265		28306		28347
	8102		28143		28184		28225		28266		28307		28348
	28103		28144		28185		28226		28267		28308		28349
	28104		28145		28186		28227		28268		28309		28350
	8105		28146		28187		28228		28269		28310		28351
	8106		28147		28188		28229		28270		28311		28352
	8107		28148		28189		28230		28271		28312		28353
	8108		28149		28190		28231		28272		28313		28354
	8109		28150		28191		28232		28273		28314		28355
	8110		28151		28192		28233		28274		28315		28356
	8111		28152		28193		28234		28275		28316		28357
	8112		28153		28194		28235		28276		28317		28358
	8113		28154		28195		28236		28277		28318		28359
	8114		28155		28196		28237		28278		28319		28360
	8115		28156		28197		28238		28279		28320		28361
	8116		28157		28198		28239		28280		28321		28362
	28117		28158		28199		28240		28281		28322		28363
	8118		28159		28200		28241		28282		28323		28364
	8119		28160		28201		28242		28283		28324		28365
	8120		28161		28202		28243		28284		28325		28366
	8121		28162		28203		28244		28285		28326		28367
	8122		28163		28204		28245		28286		28327		28368
	· ·=												
							l						

DTPA-HBV-IPV-135 (A.15MAR2018)

	. Bl. o nb	Trt.		Trt. No	nb								
PPD	28369	PPD	28410	PPD	28451	PPD	28492	PPD	28533	PPD	28574	PPD	28615
110	28370	110	28411		28452	110	28493	110	28534		28575		28616
	28371		28412		28453		28494		28535		28576		28617
	28372		28413		28454		28495		28536		28577		28618
	28373		28414		28455		28496		28537		28578		28619
	28374		28415		28456		28497		28538		28579		28620
	28374		28415		28456		28497		28538		28580		28620
	28376		28417		28458		28499		28540		28581		28622
	28377		28418		28459		28500		28541		28582		28623
	28378		28419		28460		28501		28542		28583		28624
	28379		28420		28461		28502		28543		28584		28625
	28380		28421		28462		28503		28544		28585		28626
	28381		28422		28463		28504		28545		28586		28627
	28382		28423		28464		28505		28546		28587		28628
	28383		28424		28465		28506		28547		28588		28629
	28384		28425		28466		28507		28548		28589		28630
	28385		28426		28467		28508		28549		28590		28631
	28386		28427		28468		28509		28550		28591		28632
	28387		28428		28469		28510		28551		28592		28633
	28388		28429		28470		28511		28552		28593		28634
	28389		28430		28471		28512		28553		28594		28635
	28390		28431		28472		28513		28554		28595		28636
	28391		28432		28473		28514		28555		28596		28637
	28392		28433		28474		28515		28556		28597		28638
	28393		28434		28475		28516		28557		28598		28639
	28394		28435		28476		28517		28558		28599		28640
	28395		28436		28477		28518		28559		28600		28641
	28396		28437		28478		28519		28560		28601		28642
	28397		28438		28479		28520		28561		28602		28643
	28398		28439		28480		28521		28562		28603		28644
	28399		28440		28481		28522		28563		28604		28645
	28400		28441		28482		28523		28564		28605		28646
	28401		28442		28483		28524		28565		28606		28647
	28402		28443		28484		28525		28566		28607		28648
	28403		28444		28485		28526		28567		28608		28649
	28403		28444		28485		28526		28568		28608		28650
	28405		28446		28487		28528		28569		28610		28651
	28406		28447		28488		28529		28570		28611		28652
	28407		28448		28489		28530		28571		28612		28653
	28408		28449		28490		28531		28572		28613		28654
	28409		28450		28491		28532		28573		28614		28655

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	
PPD	28656 28657 28658 28659 28660 28661 28662 28663 28664 28665 28666	PPD		PPD		PPD		PPD		PPD	28861 28862 28863 28864 28865 28866 28867 28868 28869 28870		28902 28903 28904 28905 28906 28907 28908 28909 28910 28911 28912
	28667 28668 28669 28670 28671 28672 28673 28674 28675 28676 28677		28708 28709 28710 28711 28712 28713 28714 28715 28716 28717 28718		28749 28750 28751 28752 28753 28754 28755 28756 28757 28758 28758 28759		28790 28791 28792 28793 28794 28795 28796 28797 28798 28799 28799		28831 28833 28833 28834 28835 28836 28837 28838 28839 28840 28841		28872 28873 28874 28875 28876 28877 28878 28879 28880 28880 28881		28913 28914 28915 28916 28917 28918 28919 28920 28921 28922 28923
	28678 28679 28680 28681 28682 28683 28684 28685 28685 28686		28719 28720 28721 28722 28723 28724 28725 28726 28727 28728		28760 28761 28762 28763 28764 28765 28766 28767 28768 28769		28801 28802 28803 28804 28805 28806 28807 28808 28809 28810		28842 28843 28844 28845 28846 28847 28848 28849 28850 28851		28883 28884 28885 28886 28887 28888 28889 28890 28891 28892		28924 28925 28926 28927 28928 28929 28930 28931 28932 28933
	28687 28688 28689 28690 28691 28692 28693 28694 28695 28696		287/28 28729 28730 28731 28732 28733 28734 28735 28736 28737		28770 28771 28772 28773 28774 28775 28776 28777 28778		28810 28811 28812 28813 28814 28815 28816 28817 28818 28819		28851 28852 28853 28854 28855 28856 28857 28858 28859 28860		28893 28893 28894 28895 28896 28897 28898 28899 28900 28901		28933 28934 28935 28936 28937 28938 28939 28940 28941 28942

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb
PPD	28943	PPD	28984	PPD	29025	PPD	29066	PPD	29107	PPD	29148	PPD	29189
	28944	–	28985		29026		29067		29108		29149		29190
	28945		28986		29027		29068		29109		29150		29191
	28946		28987		29028		29069		29110		29151		29192
	28947		28988		29029		29070		29111		29152		29193
	28948		28989		29030		29071		29112		29153		29194
	28949		28990		29031		29072		29113		29154		29195
	28950		28991		29032		29073		29114		29155		29196
	28951		28992		29033		29074		29115		29156		29197
	28952		28993		29034		29075		29116		29157		29198
	28953		28994		29035		29076		29117		29158		29199
	28954		28995		29036		29077		29118		29159		29200
	28955		28996		29037		29078		29119		29160		29201
	28956		28997		29038		29079		29120		29161		29202
	28957		28998		29039		29080		29121		29162		29203
	28958		28999		29040		29081		29122		29163		29204
	28959		29000		29041		29082		29123		29164		29205
	28960		29001		29042		29083		29124		29165		29206
	28961		29002		29043		29084		29125		29166		29207
	28962		29003		29044		29085		29126		29167		29208
	28963		29004		29045		29086		29127		29168		29209
	28964		29005		29046		29087		29128		29169		29210
	28965		29006		29047		29088		29129		29170		29211
	28966		29007		29048		29089		29130		29171		29212
	28967		29008		29049		29090		29131		29172		29213
	28968		29009		29050		29091		29132		29173		29214
	28969		29010		29051		29092		29133		29174		29215
	28970		29011		29052		29093		29134		29175		29216
	28971		29012		29053		29094		29135		29176		29217
	28972		29013		29054		29095		29136		29177		29218
	28973		29014		29055		29096		29137		29178		29219
	28974		29015		29056		29097		29138		29179		29220
	28975		29016		29057		29098		29139		29180		29221
	28976		29017		29058		29099		29140		29181		29222
	28977		29018		29059		29100		29141		29182		29223
	28978		29019		29060		29101		29142		29183		29224
	28979		29020		29061		29102		29143		29184		29225
	28980		29021		29062		29103		29144		29185		29226
	28981		29022		29063		29104		29145		29186		29227
	28982		29023		29064		29105		29146		29187		29228
	28983		29024		29065		29106		29147		29188		29229

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD 29230	PPD 29271	PPD 29312	PPD 29353	PPD 29394	PPD 29435	PPD 29476
29231	29272	29312	29354	29395	29436	29477
29232	29273	29314	29355	29396	29437	29478
29233	29274	29315	29356	29397	29438	29479
29234	29275	29316	29357	29398	29439	29480
29235	29276	29317	29358	29399	29440	29481
29236	29277	29318	29359	29400	29441	29482
29237	29278	29319	29360	29401	29442	29483
29238	29279	29320	29361	29402	29443	29484
29239	29280	29321	29362	29403	29444	29485
29240	29281	29322	29363	29404	29445	29486
29241	29282	29323	29364	29405	29446	29487
29242	29283	29324	29365	29406	29447	29488
29243	29284	29325	29366	29407	29448	29489
29244	29285	29326	29367	29408	29449	29490
29245	29286	29327	29368	29409	29450	29491
29246	29287	29328	29369	29410	29451	29492
29247	29288	29329	29370	29411	29452	29493
29248	29289	29330	29371	29412	29453	29494
29249	29290	29331	29372	29413	29454	29495
29250	29291	29332	29373	29414	29455	29496
29251	29292	29333	29374	29415	29456	29497
29252	29293	29334	29375	29416	29457	29498
29253	29294	29335	29376	29417	29458	29499
29254	29295	29336	29377	29418	29459	29500
29255	29296	29337	29378	29419	29460	29501
29256	29297	29338	29379	29420	29461	29502
29257	29298	29339	29380	29421	29462	29503
29258	29299	29340	29381	29422	29463	29504
29259	29300	29341	29382	29423	29464	29505
29260	29301	29342	29383	29424	29465	29506
29261	29302	29343	29384	29425	29466	29507
29262	29303	29344	29385	29426	29467	29508
29263	29304	29345	29386	29427	29468	29509
29264	29305	29346	29387	29428	29469	29510
29265	29306	29347	29388	29429	29470	29511
29266	29307	29348	29389	29430	29471	29512
29267	29308	29349	29390	29431	29472	29513
29268	29309	29350	29391	29432	29473	29514
29269	29310	29351	29392	29433	29474	29515
29270	29311	29352	29393	29434	29475	29516

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No nb		nb	No	nb	No	nb	No	nb	No	nb
PPD	29517	PPD 29558	PPD	29599	PPD	29640	PPD	29681	PPD	29722	PPD	29763
	29518	29559		29600	110	29641	FFD	29682		29723		29764
	29519	29560		29601		29642		29683		29724		29765
	29520	29561		29602		29643		29684		29725		29766
	29521	29562		29603		29644		29685		29726		29767
	29522	29563		29603		29645		29686		29727		29768
	29523	29564		29605		29646		29687		29728		29769
	29524	29565		29606		29647		29688		29729		29770
	29525	29566		29607		29648		29689		29730		29771
	29526	29567		29607		29649		29690		29731		29772
	29527	29568		29609		29650		29691		29732		29773
	29528	29569		29610		29651		29692		29733		29774
	29529	29570		29611		29652		29693		29734		29775
	29530	29571		29612		29653		29694		29735		29776
	29531	29572		29613		29654		29695		29736		29777
	29532	29573		29614		29655		29696		29737		29778
	29533	29574		29615		29656		29697		29738		29779
	29534	29575		29616		29657		29698		29739		29780
	29535	29576		29617		29658		29699		29740		29781
	29536	29577		29618		29659		29700		29741		29782
	29537	29578		29619		29660		29701		29742		29783
	29538	29579		29620		29661		29702		29743		29784
	29539	29580		29621		29662		29703		29744		29785
	29540	29581		29622		29663		29704		29745		29786
	29541	29582		29623		29664		29705		29746		29787
	29542	29583		29624		29665		29706		29747		29788
	29543	29584		29625		29666		29707		29748		29789
	29544	29585		29626		29667		29708		29749		29790
	29545	29586		29627		29668		29709		29750		29791
	29546	29587		29628		29669		29710		29751		29792
	29547	29588		29629		29670		29711		29752		29793
	29548	29589		29630		29671		29712		29753		29794
	29549	29590		29631		29672		29713		29754		29795
	29550	29591		29632		29673		29714		29755		29796
	29551	29592		29633		29674		29715		29756		29797
	29552	29593		29634		29675		29716		29757		29798
	29553	29594		29635		29676		29717		29758		29799
	29554	29595		29636		29677		29718		29759		29800
	29555	29596		29637		29678		29719		29760		29801
	29556	29597		29638		29679		29720		29761		29802
	29557	29598		29639		29680		29721		29762		29803
	· · · ·											

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD 29804 29805 29806 29806 29807 29808 29809 29810 29811 29812 29813 29814 29815 29816 29817 29818 29819 29820 29821 29821 29822 29823 29824 29825 29826 29827 29826 29827 29828 29829 29830 29831 29832 29833 29834 29835 29836 29837 29836 29837 29836 29837 29838	PPD 29845 29846 29847 29848 29849 29850 29851 29852 29853 29854 29855 29856 29857 29860 29861 29862 29863 29864 29865 29866 29877 29868 29870 29871 29872 29873 29874 29875 29876 29877 29878	PPD 29886 29887 29888 29889 29890 29891 29892 29893 29894 29895 29896 29897 29898 29899 29900 29901 29902 29903 29904 29905 29906 29907 29908 29909 29910 29911 29902 29911 29912 29913 29914 29915 29916 29917 29918 29917 29918 29919	PPD 29927 29928 29929 29930 29931 29932 29933 29934 29935 29936 29937 29938 29939 29940 29941 29942 29943 29944 29945 29946 29947 29948 29949 29950 29951 29952 29953 29956 29957 29958 29956 29957 29958 29959 29960 29961 29962 29963	PPD 29968 29969 29970 29971 29975 29976 29977 29978 29978 29979 29980 29981 29982 29983 29986 29987 29986 29987 29988 29999 29991 29992 29993 29994 29995 29995 29996 29997 29998 29997 29998 29999 30000 30001 30002 30003 30004	PPD 30009 30010 30011 30012 30013 30014 30015 30016 30017 30018 30019 30020 30021 30022 30023 30024 30025 30026 30027 30028 30027 30028 30029 30030 30031 30032 30031 30032 30033 30034 30035 30036 30037 30038 30039 30040 30041 30042 30043 30044 30045	PPD 30050 30051 30052 30053 30054 30055 30056 30057 30058 30059 30060 30061 30062 30063 30064 30065 30066 30067 30068 30069 30070 30071 30072 30073 30074 30075 30076 30077 30078 30079 30080 30081 30082 30083 30084 30085 30086
29841	29882	29923	29964	30005	30046	30087
29842	29883	29924	29965	30006	30047	30088
29843	29884	29925	29966	30007	30048	30089
29844	29885	29926	29967	30008	30049	30090

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No		Trt. No		Trt. No	Bl. nb	Trt. No		Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	
PPD PPD	nb 30091 30092 30093 30093 30094 30095 30096 30097 30098 30100 30101 30102 30103 30104 30105 30110 30112 30113 30114 30115 30116 30117 30118 30119 30112 30113 30114 30115 30116 30117 30118 30119 30120 30121 30122 30123 30124 30125 30126	PPD	nb 30132 30133 30134 30135 30136 30137 30138 30139 30140 30141 30142 30143 30144 30145 30146 30147 30148 30149 30150 30151 30152 30153 30154 30155 30156 30157 30158 30157 30158 30159 30160 30161 30162 30163 30164 30165 30166 30167		nb 30173 30174 30175 30176 30177 30178 30179 30180 30181 30182 30183 30184 30185 30186 30187 30188 30199 30191 30192 30193 30191 30195 30196 30197 30198 30199 30199 30199 30199 30190 30202 30203 30204 30205 30206 30207 30208		nb 30214 30215 30216 30217 30218 30219 30220 30221 30222 30223 30224 30225 30226 30227 30228 30227 30228 30230 30231 30232 30233 30234 30235 30236 30237 30238 30239 30240 30240 30241 30242 30243 30244 30245 30246 30247 30248 30249 3		nb		nb	PPD	nb 30337 30338 30339 30340 30341 30342 30345 30346 30355 30356 30357 30356 30357 30366 30367 30368 30369 30370 30371 30372
	30126 30127 30128 30129 30130 30131		30167 30168 30169 30170 30171 30172		30208 30209 30210 30211 30212 30213		30249 30250 30251 30252 30253 30254		30290 30291 30292 30293 30294 30295		30331 30332 30333 30334 30335 30336		30372 30373 30374 30375 30376 30377

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
		PPD 30460 30461 30462 30463 30464 30465 30466 30467 30468 30470 30471 30472 30473 30474 30475 30476 30477 30478 30479 30480 30481 30482 30483 30484 30485 30486 30487 30488 30489 30490 30491 30492 30493 30496 30497 30498				PPD 30624 30625 30627 30628 30627 30628 30630 30631 30632 30633 30634 30635 30636 30637 30638 30639 30640 30641 30642 30643 30644 30645 30646 30647 30648 30649 30650 30651 30650 30651 30655 30655 30655 30656 30657 30658
30417	30458	30499	30540	30581	30622	30663
30418	30459	30500	30541	30582	30623	30664

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No	nb	No	nb		nb	No	nb	No	nb
PPD	30665	PPD	30706	PPD	30747	PPD	30788	PPD	30829	PPD	30870
	30666	–	30707		30748		30789		30830		30871
	30667		30708		30749		30790		30831		30872
	30668		30709		30750		30791		30832		30873
	30669		30710		30751		30792		30833		30874
	30670		30711		30752		30793		30834		30875
	30671		30712		30753		30794		30835		30876
	30672		30713		30754		30795		30836		30877
	30673		30714		30755		30796		30837		30878
	30674		30715		30756		30797		30838		30879
	30675		30716		30757		30798		30839		30880
	30676		30717		30758		30799		30840		30881
	30677		30718		30759		30800		30841		30882
	30678		30719		30760		30801		30842		30883
	30679		30720		30761		30802		30843		30884
	30680		30721		30762		30803		30844		30885
	30681		30722		30763		30804		30845		30886
	30682		30723		30764		30805		30846		30887
	30683		30724		30765		30806		30847		30888
	30684		30725		30766		30807		30848		30889
	30685		30726		30767		30808		30849		30890
	30686		30727		30768		30809		30850		30891
	30687		30727		30769		30810		30851		30892
	30688		30729		30770		30811		30852		30893
	30689		30730		30771		30812		30853		30894
	30690		30731		30772		30813		30854		30895
	30691		30732		30773		30814		30855		30896
	30692		30733		30774		30815		30856		30897
	30693		30734		30775		30816		30857		30898
	30694		30735		30776		30817		30858		30899
	30695		30736		30777		30818		30859		30900
	30696		30737		30778		30819		30860		30901
	30697		30738		30779		30820		30861		30902
	30698		30739		30780		30821		30862		30903
	30699		30740		30781		30822		30863		30904
	30700		30741		30782		30823		30864		30905
	30701		30742		30783		30824		30865		30906
	30702		30743		30784		30825		30866		20200
	30702		30743		30785		30826		30867		
	30704		30745		30786		30827		30868		
	30704		30746		30787		30828		30869		
	30703		30/40		30101		JU020		20003		
			l								

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	. Bl.	Trt. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt	. Bl.	Trt.	. Bl.
No	nb	No nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	30907	PPD 30948	PPD	30989	PPD	31030	PPD	31071	PPD	31112	PPD	31153
FFD	30908	30949		30990	110	31030	FFD	31072		31112		31154
	30909	30950		30991		31032		31072		31114		31155
	30910	30951		30992		31032		31073		31115		31156
	30911	30952		30993		31033		31075		31116		31157
	30912	30953		30994		31034		31076		31117		31157
	30913	30954		30995		31035		31077		31117		31150
	30914	30955		30996		31036		31077		31119		31160
	30915	30956		30997		31037		31078		31120		31161
	30916	30957		30998		31030		31080		31121		31162
	30917	30958		30999		31040		31081		31122		31163
	30918	30959		31000		31041		31082		31123		31164
	30919	30960		31000		31042		31083		31124		31165
	30920	30961		31002		31043		31084		31125		31166
	30921	30962		31002		31044		31085		31126		31167
	30922	30963		31003		31045		31086		31127		31168
	30923	30964		31005		31046		31087		31128		31169
	30924	30965		31006		31047		31088		31129		31170
	30925	30966		31007		31048		31089		31130		31171
	30926	30967		31008		31049		31090		31131		31172
	30927	30968		31009		31050		31091		31132		31173
	30928	30969		31010		31051		31092		31133		31174
	30929	30970		31011		31052		31093		31134		31175
	30930	30971		31012		31053		31094		31135		31176
	30931	30972		31013		31054		31095		31136		31177
	30932	30973		31014		31055		31096		31137		31178
	30933	30974		31015		31056		31097		31138		31179
	30934	30975		31016		31057		31098		31139		31180
	30935	30976		31017		31058		31099		31140		31181
	30936	30977		31018		31059		31100		31141		31182
	30937	30978		31019		31060		31101		31142		31183
	30938	30979		31020		31061		31102		31143		31184
	30939	30980		31021		31062		31103		31144		31185
	30940	30981		31022		31063		31104		31145		31186
	30941	30982		31023		31064		31105		31146		31187
	30942	30983		31024		31065		31106		31147		31188
	30943	30984		31025		31066		31107		31148		31189
	30944	30985		31026		31067		31108		31149		31190
	30945	30986		31027		31068		31109		31150		31191
	30946	30987		31028		31069		31110		31151		31192
	30947	30988		31029		31070		31111		31152		31193
						-				_		

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	Bl.	Trt. Bl.		Bl.	Trt.		Trt.		Trt.		Trt.	
No	nb	No nb		nb	No	nb	No	nb	No	nb	No	nb
PPD	31194	PPD 3123	5 PPD	31276	PPD	31317	PPD	31358	PPD	31399	PPD	31440
110	31195	3123		31277		31318	110	31359		31400		31441
	31196	3123		31278		31319		31360		31401		31442
	31197	3123		31279		31320		31361		31402		31443
	31198	3123		31280		31321		31362		31403		31444
	31199	3124		31281		31322		31363		31404		31445
	31200	3124		31282		31323		31364		31405		31446
	31201	3124	2	31283		31324		31365		31406		31447
	31202	3124	3	31284		31325		31366		31407		31448
	31203	3124	4	31285		31326		31367		31408		31449
	31204	3124	5	31286		31327		31368		31409		31450
	31205	3124	6	31287		31328		31369		31410		31451
	31206	3124	7	31288		31329		31370		31411		31452
	31207	3124	8	31289		31330		31371		31412		31453
	31208	3124	9	31290		31331		31372		31413		31454
	31209	3125	0	31291		31332		31373		31414		31455
	31210	3125	1	31292		31333		31374		31415		31456
	31211	3125		31293		31334		31375		31416		31457
	31212	3125		31294		31335		31376		31417		31458
	31213	3125		31295		31336		31377		31418		31459
	31214	3125		31296		31337		31378		31419		31460
	31215	3125		31297		31338		31379		31420		31461
	31216	3125		31298		31339		31380		31421		31462
	31217	3125		31299		31340		31381		31422		31463
	31218	3125		31300		31341		31382		31423		31464
	31219	3126		31301		31342		31383		31424		31465
	31220	3126		31302		31343		31384		31425		31466
	31221	3126		31303		31344		31385		31426		31467
	31222	3126		31304		31345		31386		31427		31468
	31223	3126		31305		31346		31387		31428		31469
	31224	3126		31306		31347		31388		31429		31470
	31225 31226	3126 3126		31307 31308		31348 31349		31389 31390		31430 31431		31471 31472
	31226	3126		31308		31349		31390		31431		31472
	31227	3126		31309		31350		31391		31432		31473
	31229	3126		31311		31352		31393		31434		31474
	31230	3127		31311		31353		31394		31435		31475
	31231	3127		31312		31354		31395		31436		31470
	31231	3127		31313		31355		31396		31437		31477
	31232	3127		31314		31356		31396		31438		31476
	31233	3127		31316		31357		31397		31439		31480
	31231	3127		31310		31337		31330		31133		31 100
												I and

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

N	. Bl. o nb	Trt. Bl. No nb	Trt. Bl. No nb	No	. Bl. o nb	Trt. No	Bl. nb		Bl. nb	Trt. No	Bl. nb
	_				_			PPD		DDD	
PPD	31481	PPD 31522			31604	PPD	31645		31686	PPD	31727
	31482	31523			31605		31646		31687		31728
	31483	31524			31606		31647		31688		31729
	31484	31525			31607		31648		31689		31730
	31485	31526			31608		31649		31690		31731
	31486	31527			31609		31650		31691		31732
	31487	31528			31610		31651		31692		31733
	31488	31529			31611		31652		31693		31734
	31489	31530			31612		31653		31694		31735
	31490	31531			31613		31654		31695		31736
	31491	31532			31614		31655		31696		31737
	31492 31493	31533			31615		31656		31697		31738
	31493	31534 31535			31616 31617		31657 31658		31698 31699		31739 31740
	31495	31536			31618		31659		31700		31741
	31496	31537			31619 31620		31660		31701 31702		31742
	31497 31498	31538 31539			31620		31661 31662		31702		31743 31744
	31499	31540			31622		31663		31704		31744
	31499	31540			31623		31664		31704		31745
	31500	31542			31624		31665		31706		31747
	31502	31542			31625		31666		31707		31748
	31502	31544			31626		31667		31707		31749
	31504	31545			31627		31668		31700		31750
	31505	31546			31628		31669		31710		31751
	31506	31547			31629		31670		31711		31752
	31507	31548			31630		31671		31712		31753
	31508	31549			31631		31672		31713		31754
	31509	31550			31632		31673		31714		31755
	31510	31551			31633		31674		31715		31756
	31511	31552			31634		31675		31716		31757
	31512	31553			31635		31676		31717		31758
	31513	31554			31636		31677		31718		31759
	31514	31555	3159	6	31637		31678		31719		31760
	31515	31556			31638		31679		31720		31761
	31516	31557			31639		31680		31721		31762
	31517	31558			31640		31681		31722		31763
	31518	31559			31641		31682		31723		31764
	31519	31560			31642		31683		31724		31765
	31520	31561			31643		31684		31725		31766
	31521	31562			31644		31685		31726		31767
		21002	3100								. =
	_										

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	31768	PPD 31809	PPD 31850	PPD 31891	PPD 31932	PPD 31973	PPD 32014
FFD	31769	31810	31851	31892	31933	31974	32015
	31770	31811	31852	31893	31933	31975	32016
	31771	31812	31853	31894	31934	31976	32016
	31772	31813	31854	31895	31936	31977	32018
	31773	31814	31855	31896	31937	31978	32010
	31774	31814	31855	31897	31937	31978	32019
	31774	31816	31857	31898	31930	31980	32020
	31776	31816	31857	31898	31939	31980	32021
	31777		31859			31982	
	31777	31818 31819	31859	31900 31901	31941 31942	31982	32023 32024
	31779	31820	31861	31902	31942	31984	32024
	31779	31821	31862	31902	31943	31985	32025
	31780	31821	31862		31944	31985	32026
	31781	31822	31864	31904	31945	31986	32027
				31905			
	31783	31824	31865	31906	31947	31988 31989	32029
	31784	31825	31866	31907	31948		32030
	31785	31826	31867	31908	31949	31990	32031
	31786	31827	31868	31909	31950	31991	32032
	31787	31828	31869	31910	31951	31992	32033
	31788 31789	31829 31830	31870 31871	31911 31912	31952 31953	31993 31994	32034 32035
	31789	31830	31871	31912	31953	31994	32035
	31791	31832	31873 31874	31914	31955	31996 31997	32037
	31792	31833		31915	31956		32038
	31793	31834	31875	31916	31957	31998	32039
	31794	31835	31876	31917	31958	31999	32040
	31795	31836	31877	31918	31959	32000	32041
	31796	31837	31878	31919	31960	32001	32042
	31797	31838	31879	31920	31961	32002	32043
	31798	31839	31880	31921	31962	32003	32044
	31799	31840	31881	31922	31963	32004	32045
	31800	31841	31882	31923	31964	32005	32046
	31801	31842	31883	31924	31965	32006	32047
	31802	31843	31884	31925	31966	32007	32048
	31803	31844	31885	31926	31967	32008	32049
	31804	31845	31886	31927	31968	32009	32050
	31805	31846	31887	31928	31969	32010	32051
	31806	31847	31888	31929	31970	32011	32052
	31807	31848	31889	31930	31971	32012	32053
	31808	31849	31890	31931	31972	32013	32054

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt.		Trt.		Trt.		Trt.			Bl.	Trt.	
No	nb	No	nb	No		No	nb	No	nb	No	nb	No	nb
PPD	32055	PPD	32096	PPD	32137	PPD	32178	PPD	32219	PPD	32260	PPD	32301
110	32056		32097		32138		32179	110	32220		32261		32302
	32057		32098		32139		32180		32221		32262		32302
	32058		32099		32140		32181		32222		32263		32304
	32059		32100		32141		32182		32223		32264		32305
	32060		32101		32142		32183		32224		32265		32306
	32061		32102		32143		32184		32225		32266		32300
	32062		32102		32144		32185		32226		32267		32308
	32063		32104		32145		32186		32227		32268		32309
	32064		32105		32146		32187		32228		32269		32310
	32065		32106		32147		32188		32229		32270		32311
	32066		32107		32148		32189		32230		32271		32312
	32067		32108		32149		32190		32231		32272		32312
	32068		32100		32150		32191		32232		32273		32314
	32069		32110		32151		32192		32233		32274		32315
	32070		32111		32152		32193		32234		32275		32316
	32071		32112		32153		32194		32235		32276		32317
	32072		32113		32154		32195		32236		32277		32317
	32073		32114		32155		32196		32237		32278		32319
	32074		32115		32156		32197		32238		32279		32320
	32075		32116		32157		32198		32239		32280		32321
	32076		32117		32158		32199		32240		32281		32322
	32077		32118		32159		32200		32241		32282		32323
	32078		32119		32160		32201		32242		32283		32324
	32079		32120		32161		32202		32243		32284		32325
	32080		32121		32162		32203		32244		32285		32326
	32081		32122		32163		32204		32245		32286		32327
	32082		32123		32164		32205		32246		32287		32328
	32083		32124		32165		32206		32247		32288		32329
	32084		32125		32166		32207		32248		32289		32330
	32085		32126		32167		32208		32249		32290		32331
	32086		32127		32168		32209		32250		32291		32332
	32087		32128		32169		32210		32251		32292		32333
	32088		32129		32170		32211		32252		32293		32334
	32089		32130		32171		32212		32253		32294		32335
	32090		32131		32172		32213		32254		32295		32336
	32091		32132		32173		32214		32255		32296		32337
	32092		32133		32174		32215		32256		32297		32338
	32093		32134		32175		32216		32257		32298		32339
	32094		32135		32176		32217		32258		32299		32340
	32095		32136		32177		32218		32259		32300		32341

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. Bl.	Tr	t. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No nb	No nb]	No nb	No	nb	No	nb	No	nb
PPD	20240	PPD 32383	PPD 324	24 PPD	20465	PPD	20506	PPD	20545	PPD	32588
PPD	32342 32343	32383	324		32465 32466	PPD	32506 32507		32547 32548	ווט	32588
	32343	32384	324		32466		32507		32548		32589
	1 1	32385	324				32508		32549		32590
	32345		324		32468						
	32346	32387			32469		32510		32551		32592
	32347	32388	324		32470		32511		32552		32593
	32348	32389	324		32471		32512		32553		32594
	32349	32390	324		32472		32513		32554		32595
	32350	32391	324		32473		32514		32555		32596
	32351	32392	324		32474		32515		32556		32597
	32352	32393	324		32475		32516		32557		32598
	32353	32394	324		32476		32517		32558		32599
	32354	32395	324		32477		32518		32559		32600
	32355	32396	324		32478		32519		32560		32601
	32356	32397	324		32479		32520		32561		32602
	32357	32398	324		32480		32521		32562		32603
	32358	32399	324		32481		32522		32563		32604
	32359	32400	324		32482		32523		32564		32605
	32360	32401	324		32483		32524		32565		32606
	32361	32402	324		32484		32525		32566		32607
	32362	32403	324		32485		32526		32567		32608
	32363	32404	324		32486		32527		32568		32609
	32364	32405	324		32487		32528		32569		32610
	32365	32406	324		32488		32529		32570		32611
	32366	32407	324	48	32489		32530		32571		32612
	32367	32408	324		32490		32531		32572		32613
	32368	32409	324	50	32491		32532		32573		32614
	32369	32410	324	51	32492		32533		32574		32615
	32370	32411	324	52	32493		32534		32575		32616
	32371	32412	324	53	32494		32535		32576		32617
	32372	32413	324	54	32495		32536		32577		32618
	32373	32414	324	55	32496		32537		32578		32619
	32374	32415	324	56	32497		32538		32579		32620
	32375	32416	324	57	32498		32539		32580		32621
	32376	32417	324	58	32499		32540		32581		32622
	32377	32418	324	59	32500		32541		32582		32623
	32378	32419	324	60	32501		32542		32583		32624
	32379	32420	324	61	32502		32543		32584		32625
	32380	32421	324		32503		32544		32585		32626
	32381	32422	324		32504		32545		32586		32627
	32382	32423	324		32505		32546		32587		32628
			,						1.1		
	•										

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. Bl		Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No nb	No nb)	No	nb	No	nb	No	nb	No	nb
PPD	32629	PPD 32670	PPD 32	711	PPD	32752	PPD	32793	PPD	32834	PPD	32875
FFD	32630	32671		712	110	32753	FFD	32794		32835	110	32876
	32631	32672		1713		32754		32795		32836		32877
	32632	32673		1714		32755		32796		32837		32878
	32633	32674		1715		32756		32797		32838		32879
	32634	32674		1716		32757		32798		32839		32880
	32635	32676		716		32758		32798		32839		32880
	32636	32677		1718		32759		32800		32841		32882
	32637	32678		1718		32760		32800		32841		32882
		32679		1720						32843		
	32638 32639	32679		1720		32761 32762		32802 32803		32843		32884 32885
	32640	32681		1722		32763		32804		32845		32886
	32641 32642	32682 32683		.723 .724		32764		32805 32806		32846 32847		32887 32888
						32765						
	32643	32684		1725		32766		32807		32848		32889
	32644	32685		726		32767		32808		32849		32890
	32645	32686		1727		32768		32809		32850		32891
	32646	32687		1728		32769		32810		32851		32892
	32647	32688		729		32770		32811		32852		32893
	32648	32689		1730		32771		32812		32853		32894
	32649	32690		731		32772		32813		32854		32895
	32650	32691		732		32773		32814		32855		32896
	32651	32692		1733		32774		32815		32856		32897
	32652	32693		1734		32775		32816		32857		32898
	32653	32694		1735		32776		32817		32858		32899
	32654	32695		1736		32777		32818		32859		32900
	32655	32696		1737		32778		32819		32860		32901
	32656	32697		1738		32779		32820		32861		32902
	32657	32698		1739		32780		32821		32862		32903
	32658	32699		740		32781		32822		32863		32904
	32659	32700		741		32782		32823		32864		32905
	32660	32701		1742		32783		32824		32865		32906
	32661	32702		1743		32784		32825		32866		32907
	32662	32703		744		32785		32826		32867		32908
	32663	32704		745		32786		32827		32868		32909
	32664	32705	32	1746		32787		32828		32869		32910
	32665	32706	32	1747		32788		32829		32870		32911
	32666	32707	32	1748		32789		32830		32871		32912
	32667	32708		749		32790		32831		32872		32913
	32668	32709	32	750		32791		32832		32873		32914
	32669	32710	32	751		32792		32833		32874		32915
								ı		•		

DTPA-HBV-IPV-135 (A.15MAR2018)

	. Bl. o nb	Trt. No		Trt.	Bl. nb		Bl.		. Bl. o nb		. Bl.	Т	rt. Bl. No nb
PPD	32916	PPD	32957	PPD	32998	PPD	33039	PPD	33080	PPD	33121	PPI	D 33162
	32917		32958		32999		33040		33081		33122		33163
	32918		32959		33000		33041		33082		33123		33164
	32919		32960		33001		33042		33083		33124		33165
	32920		32961		33002		33043		33084		33125		33166
	32921		32962		33003		33044		33085		33126		33167
	32922		32963		33004		33045		33086		33127		33168
	32923		32964		33005		33046		33087		33128		33169
	32924		32965		33006		33047		33088		33129		33170
	32925		32966		33007		33048		33089		33130		33171
	32926		32967		33008		33049		33090		33131		33172
	32927		32968		33009		33050		33091		33132		33173
	32928		32969		33010		33051		33092		33133		33174
	32929		32970		33011		33052		33093		33134		33175
	32930		32971		33012		33053		33094		33135		33176
	32931		32972		33013		33054		33095		33136		33177
	32932		32973		33014		33055		33096		33137		33178
	32933		32974		33015		33056		33097		33138		33179
	32934		32975		33016		33057		33098		33139		33180
	32935		32976		33017		33058		33099		33140		33181
	32936		32977		33018		33059		33100		33141		33182
	32937		32978		33019		33060		33101		33142		33183
	32938		32979		33020		33061		33102		33143		33184
	32939		32980		33021		33062		33103		33144		33185
	32940		32981		33022		33063		33104		33145		33186
	32941 32942		32982 32983		33023 33024		33064 33065		33105 33106		33146 33147		33187
													33188
	32943 32944		32984 32985		33025 33026		33066 33067		33107 33108		33148 33149		33189 33190
	32944		32986		33026		33068		33100		33150		33190
	32945		32987		33027		33069		33110		33150		33191
	32947		32988		33029		33070		33111		33151		33192
	32948		32989		33030		33070		33112		33152		33194
	32949		32990		33031		33072		33112		33154		33195
	32950		32991		33032		33072		33114		33155		33196
	32951		32992		33033		33074		33115		33156		33197
	32952		32993		33034		33075		33116		33157		33198
	32953		32994		33035		33076		33117		33158		33199
	32954		32995		33036		33077		33118		33159		33200
	32955		32996		33037		33078		33119		33160		33201
	32956		32997		33038		33079		33120		33161		33202

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.	Trt.									
No	nb	No nb	No			nb		nb	No	nb	No	nb
PPD	33203	PPD 33244	PPD	33285	PPD	33326	PPD	33367	PPD	33408	PPD	33449
110	33204	33245		33286		33327	110	33368		33409		33450
	33205	33246		33287		33328		33369		33410		33451
	33206	33247		33288		33329		33370		33411		33452
	33207	33248		33289		33330		33371		33412		33453
	33208	33249		33290		33331		33372		33413		33454
	33200	33250		33291		33332		33373		33414		33455
	33210	33251		33292		33333		33374		33415		33456
	33211	33252		33293		33334		33375		33416		33457
	33212	33253		33294		33335		33376		33417		33458
	33213	33254		33295		33336		33377		33418		33459
	33214	33255		33296		33337		33378		33419		33460
	33215	33256		33297		33338		33379		33420		33461
	33216	33257		33298		33339		33380		33421		33462
	33217	33258		33299		33340		33381		33422		33463
	33218	33259		33300		33341		33382		33423		33464
	33219	33260		33301		33342		33383		33424		33465
	33220	33261		33302		33343		33384		33425		33466
	33221	33262		33303		33344		33385		33426		33467
	33222	33263		33304		33345		33386		33427		33468
	33223	33264		33305		33346		33387		33428		33469
	33224	33265		33306		33347		33388		33429		33470
	33225	33266		33307		33348		33389		33430		33471
	33226	33267		33308		33349		33390		33431		33472
	33227	33268		33309		33350		33391		33432		33473
	33228	33269		33310		33351		33392		33433		33474
	33229	33270		33311		33352		33393		33434		33475
	33230	33271		33312		33353		33394		33435		33476
	33231	33272		33313		33354		33395		33436		33477
	33232	33273		33314		33355		33396		33437		33478
	33233	33274		33315		33356		33397		33438		33479
	33234	33275		33316		33357		33398		33439		33480
	33235	33276		33317		33358		33399		33440		33481
	33236	33277		33318		33359		33400		33441		33482
	33237	33278		33319		33360		33401		33442		33483
	33238	33279		33320		33361		33402		33443		33484
	33239	33280		33321		33362		33403		33444		33485
	33240	33281		33322		33363		33404		33445		33486
	33241	33282		33323		33364		33405		33446		33487
	33242	33283		33324		33365		33406		33447		33488
	33243	33284		33325		33366		33407		33448		33489
				l								

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb
PPD	33490	PPD	33531	PPD	33572	PPD	33613	PPD	33654	PPD	33695	PPD	33736
	33491		33532		33573		33614		33655		33696		33737
	33492		33533		33574		33615		33656		33697		33738
	33493		33534		33575		33616		33657		33698		33739
	33494		33535		33576		33617		33658		33699		33740
	33495		33536		33577		33618		33659		33700		33741
	33496		33537		33578		33619		33660		33701		33742
	33497		33538		33579		33620		33661		33702		33743
	33498		33539		33580		33621		33662		33703		33744
	33499		33540		33581		33622		33663		33704		33745
	33500		33541		33582		33623		33664		33705		33746
	33501		33542		33583		33624		33665		33706		33747
	33502		33543		33584		33625		33666		33707		33748
	33503		33544		33585		33626		33667		33708		33749
	33504		33545		33586		33627		33668		33709		33750
	33505		33546		33587		33628		33669		33710		33751
	33506		33547		33588		33629		33670		33711		33752
	33507		33548		33589		33630		33671		33712		33753
	33508		33549		33590		33631		33672		33713		33754
	33509		33550		33591		33632		33673		33714		33755
	33510		33551		33592		33633		33674		33715		33756
	33511		33552		33593		33634		33675		33716		33757
	33512		33553		33594		33635		33676		33717		33758
	33513		33554		33595		33636		33677		33718		33759
	33514		33555		33596		33637		33678		33719		33760
	33515		33556		33597		33638		33679		33720		33761
	33516		33557		33598		33639		33680		33721		33762
	33517		33558		33599		33640		33681		33722		33763
	33518		33559		33600		33641		33682		33723		33764
	33519		33560		33601		33642		33683		33724		33765
	33520		33561		33602		33643		33684		33725		33766
	33521		33562		33603		33644		33685		33726		33767
	33522		33563		33604		33645		33686		33727		33768
	33523		33564		33605		33646		33687		33728		33769
	33524		33565		33606		33647		33688		33729		33770
	33525		33566		33607		33648		33689		33730		33771
	33526		33567		33608		33649		33690		33731		33772
	33527		33568		33609		33650		33691		33732		33773
	33528		33569		33610		33651		33692		33733		33774
	33529		33570		33611		33652		33693		33734		33775
	33530		33571		33612		33653		33694		33735		33776
			l										

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt	. Bl.	Trt	. Bl.	Trt	. Bl.	Trt	. Bl.	Trt	. Bl.	Trt	. Bl.	Tr	rt. Bl.
N	o nb	No		No			o nb	N	o nb		o nb		No nb
PPD	33777	PPD	33818	PPD	33859	PPD	33900	PPD	33941	PPD	33982	PPD	34023
	33778		33819		33860		33901		33942		33983		34024
	33779		33820		33861		33902		33943		33984		34025
	33780		33821		33862		33903		33944		33985		34026
	33781		33822		33863		33904		33945		33986		34027
	33782		33823		33864		33905		33946		33987		34028
	33783		33824		33865		33906		33947		33988		34029
	33784		33825		33866		33907		33948		33989		34030
	33785		33826		33867		33908		33949		33990		34031
	33786		33827		33868		33909		33950		33991		34032
	33787		33828		33869		33910		33951		33992		34033
	33788		33829		33870		33911		33952		33993		34034
	33789		33830		33871		33912		33953		33994		34035
	33790		33831		33872		33913		33954		33995		34036
	33791		33832		33873		33914		33955		33996		34037
	33792		33833		33874		33915		33956		33997		34038
	33793		33834		33875		33916		33957		33998		34039
	33794		33835		33876		33917		33958		33999		34040
	33795		33836		33877		33918		33959		34000		34041
	33796		33837		33878		33919		33960		34001		34042
	33797		33838		33879		33920		33961		34002		34043
	33798		33839		33880		33921		33962		34003		34044
	33799		33840		33881		33922		33963		34004		34045
	33800		33841		33882		33923		33964		34005		34046
	33801		33842		33883		33924		33965		34006		34047
	33802		33843		33884		33925		33966		34007		34048
	33803		33844		33885		33926		33967		34008		34049
	33804		33845		33886		33927		33968		34009		34050
	33805		33846		33887		33928		33969		34010		34051
	33806		33847		33888		33929		33970		34011		34052
	33807		33848		33889		33930		33971		34012		34053
	33808		33849		33890		33931		33972		34013		34054
	33809		33850		33891		33932		33973		34014		34055
	33810		33851		33892		33933		33974		34015		34056
	33811		33852		33893		33934		33975		34016		34057
	33812		33853		33894		33935		33976		34017		34058
	33813		33854		33895		33936		33977		34018		34059
	33814		33855		33896		33937		33978		34019		34060
	33815		33856		33897		33938		33979		34020		34061
	33816		33857		33898		33939		33980		34021		34062
	33817		33858		33899		33940		33981		34022		34063

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No		Trt. Bl. No nb	No	Bl. nb	Trt. No	Bl. nb	No	Bl. nb	No	Bl. nb		Bl. nb
PPD	34064	PPD 34105	PPD	34146	PPD	34187	PPD	34228	PPD	34269	PPD	34310
	34065	34106		34147		34188		34229		34270		34311
	34066	34107		34148		34189		34230		34271		34312
	34067	34108		34149		34190		34231		34272		34313
	34068	34109		34150		34191		34232		34273		34314
	34069	34110		34151		34192		34233		34274		34315
	34070	34111		34152		34193		34234		34275		34316
	34071	34112		34153		34194		34235		34276		34317
	34072	34113		34154		34195		34236		34277		34318
	34073	34114		34155		34196		34237		34278		34319
	34074	34115		34156		34197		34238		34279		34320
	34075	34116		34157		34198		34239		34280		34321
	34076	34117		34158		34199		34240		34281		34322
	34077	34118		34159		34200		34241		34282		34323
	34078	34119		34160		34201		34242		34283		34324
	34079	34120		34161		34202		34243		34284		34325
	34080	34121		34162		34203		34244		34285		34326
	34081	34122		34163		34204		34245		34286		34327
	34082	34123		34164		34205		34246		34287		34328
	34083	34124		34165		34206		34247		34288		34329
	34084	34125		34166		34207		34248		34289		34330
	34085	34126		34167		34208		34249		34290		34331
	34086	34127		34168		34209		34250		34291		34332
	34087	34128		34169		34210		34251		34292		34333
	34088	34129		34170		34211		34252		34293		34334
	34089	34130		34171		34212		34253		34294		34335
	34090	34131		34172		34213		34254		34295		34336
	34091	34132		34173		34214		34255		34296		34337
	34092	34133		34174		34215		34256		34297		34338
	34093	34134		34175		34216		34257		34298		34339
	34094	34135		34176		34217		34258		34299		34340
	34095	34136		34177		34218		34259		34300		34341
	34096	34137		34178		34219		34260		34301		34342
	34097	34138		34179		34220		34261		34302		34343
	34098	34139		34180		34221		34262		34303		34344
	34099	34140		34181		34222		34263		34304		34345
	34100	34141		34182		34223		34264		34305		34346
	34101	34142		34183		34224		34265		34306		34347
	34102	34143		34184		34225		34266		34307		34348
	34103	34144		34185		34226		34267		34308		34349
	34104	34145		34186		34227		34268		34309		34350

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.					
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	34351	PPD 34392	PPD 34433	PPD 34474	PPD 34515	PPD 34556	PPD 34597
	34352	34393	34434	34475	34516	34557	34598
	34353	34394	34435	34476	34517	34558	34599
	34354	34395	34436	34477	34518	34559	34600
	34355	34396	34437	34478	34519	34560	34601
	34356	34397	34438	34479	34520	34561	34602
	34357	34398	34439	34480	34521	34562	34603
	34358	34399	34440	34481	34522	34563	34604
	34359	34400	34441	34482	34523	34564	34605
	34360	34401	34442	34483	34524	34565	34606
	34361	34402	34443	34484	34525	34566	34607
	34362	34403	34444	34485	34526	34567	34608
	34363	34404	34445	34486	34527	34568	34609
	34364	34405	34446	34487	34528	34569	34610
	34365	34406	34447	34488	34529	34570	34611
	34366	34407	34448	34489	34530	34571	34612
	34367	34408	34449	34490	34531	34572	34613
	34368	34409	34450	34491	34532	34573	34614
	34369	34410	34451	34492	34533	34574	34615
	34370	34411	34452	34493	34534	34575	34616
	34371	34412	34453	34494	34535	34576	34617
	34372	34413	34454	34495	34536	34577	34618
	34373	34414	34455	34496	34537	34578	34619
	34374	34415	34456	34497	34538	34579	34620
	34375	34416	34457	34498	34539	34580	34621
	34376	34417	34458	34499	34540	34581	34622
	34377	34418	34459	34500	34541	34582	34623
	34378	34419	34460	34501	34542	34583	34624
	34379	34420	34461	34502	34543	34584	34625
	34380	34421	34462	34503	34544	34585	34626
	34381	34422	34463	34504	34545	34586	34627
	34382	34423	34464	34505	34546	34587	34628
	34383	34424	34465	34506	34547	34588	34629
	34384	34425	34466	34507	34548	34589	34630
	34385	34426	34467	34508	34549	34590	34631
	34386	34427	34468	34509	34550	34591	34632
	34387	34428	34469	34510	34551	34592	34633
	34388	34429	34470	34511	34552	34593	34634
	34389	34430	34471	34512	34553	34594	34635
	34390	34431	34472	34513	34554	34595	34636
	34391	34432	34473	34514	34555	34596	34637
	l						

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl.	Trt. Bl.	Trt. Bl.
				NO 11D			NO 11D
PPD	34638	PPD 34679	PPD 34720	PPD 34761	PPD 34802	PPD 34843	PPD 34884
FFD	34639	34680	34721	34762	34803	34844	34885
	34640	34681	34722	34763	34804	34845	34886
	34641	34682	34723	34764	34805	34846	34887
	34642	34683	34724	34765	34806	34847	34888
	34643	34684	34725	34766	34807	34848	34889
	34644	34685	34726	34767	34808	34849	34890
	34645	34686	34727	34768	34809	34850	34891
	34646	34687	34728	34769	34810	34851	34892
	34647	34688	34729	34770	34811	34852	34893
	34648	34689	34730	34771	34812	34853	34894
	34649	34690	34731	34772	34813	34854	34895
	34650	34691	34732	34773	34814	34855	34896
	34651	34692	34733	34774	34815	34856	34897
	34652	34693	34734	34775	34816	34857	34898
	34653	34694	34735	34776	34817	34858	34899
	34654	34695	34736	34777	34818	34859	34900
	34655	34696	34737	34778	34819	34860	34901
	34656	34697	34738	34779	34820	34861	34902
	34657	34698	34739	34780	34821	34862	34903
	34658	34699	34740	34781	34822	34863	34904
	34659	34700	34741	34782	34823	34864	34905
	34660	34701	34742	34783	34824	34865	34906
	34661	34702	34743	34784	34825	34866	34907
	34662 34663	34703 34704	34744 34745	34785 34786	34826 34827	34867 34868	34908 34909
	34664	34704	34745	34786	34827	34869	34909
	34665	34706	34747	34787	34828	34869	34910
	34666	34707	34747	34789	34829	34871	34911
	34667	34707	34749	34790	34831	34872	34913
	34668	34709	34750	34791	34832	34873	34914
	34669	34710	34751	34792	34833	34874	34915
	34670	34711	34752	34793	34834	34875	34916
	34671	34712	34753	34794	34835	34876	34917
	34672	34713	34754	34795	34836	34877	34918
	34673	34714	34755	34796	34837	34878	34919
	34674	34715	34756	34797	34838	34879	34920
	34675	34716	34757	34798	34839	34880	34921
	34676	34717	34758	34799	34840	34881	34922
	34677	34718	34759	34800	34841	34882	34923
	34678	34719	34760	34801	34842	34883	34924
	l						

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.		. Bl.	Trt.			Bl.		Bl.		. Bl.
No	nb	No nb	No	o nb	No	nb	No	nb	No	nb	No	nb
PPD	34925	PPD 34966	PPD	35007	PPD	35048	PPD	35089	PPD	35130	PPD	35171
110	34926	34967		35007	110	35049	110	35090		35131		35171
	34927	34968		35009		35050		35091		35132		35172
	34928	34969		35010		35051		35092		35132		35173
	34929	34970		35010		35052		35093		35133		35175
	34930	34971		35012		35052		35094		35135		35176
	34931	34972		35012		35054		35095		35136		35177
	34932	34973		35013		35055		35096		35137		35178
	34933	34974		35011		35056		35097		35137		35179
	34934	34975		35016		35057		35098		35139		35180
	34935	34976		35017		35058		35099		35140		35181
	34936	34977		35018		35059		35100		35141		35182
	34937	34978		35019		35060		35101		35142		35183
	34938	34979		35020		35061		35102		35143		35184
	34939	34980		35021		35062		35103		35144		35185
	34940	34981		35022		35063		35104		35145		35186
	34941	34982		35023		35064		35105		35146		35187
	34942	34983		35024		35065		35106		35147		35188
	34943	34984		35025		35066		35107		35148		35189
	34944	34985		35026		35067		35108		35149		35190
	34945	34986		35027		35068		35109		35150		35191
	34946	34987		35028		35069		35110		35151		35192
	34947	34988		35029		35070		35111		35152		35193
	34948	34989		35030		35071		35112		35153		35194
	34949	34990		35031		35072		35113		35154		35195
	34950	34991		35032		35073		35114		35155		35196
	34951	34992		35033		35074		35115		35156		35197
	34952	34993		35034		35075		35116		35157		35198
	34953	34994		35035		35076		35117		35158		35199
	34954	34995		35036		35077		35118		35159		35200
	34955	34996		35037		35078		35119		35160		35201
	34956	34997		35038		35079		35120		35161		35202
	34957	34998		35039		35080		35121		35162		35203
	34958	34999		35040		35081		35122		35163		35204
	34959	35000		35041		35082		35123		35164		35205
	34960	35001		35042		35083		35124		35165		35206
	34961	35002		35043		35084		35125		35166		35207
	34962	35003		35044		35085		35126		35167		35208
	34963	35004		35045		35086		35127		35168		35209
	34964	35005		35046		35087		35128		35169		35210
	34965	35006		35047		35088		35129		35170		35211

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt	. Bl.	Trt	. Bl.	Trt	. Bl.	Trt	. Bl.	Trt	. Bl.	Trt	. Bl.
No	nb		o nb	No	o nb		o nb		o nb	No	nb	P	lo nb
PPD	35212	PPD	35253	PPD	35294	PPD	35335	PPD	35376	PPD	35417	PPD	35458
–	35213		35254		35295	–	35336		35377		35418		35459
	35214		35255		35296		35337		35378		35419		35460
	35215		35256		35297		35338		35379		35420		35461
	35216		35257		35298		35339		35380		35421		35462
	35217		35258		35299		35340		35381		35422		35463
	35218		35259		35300		35341		35382		35423		35464
	35219		35260		35301		35342		35383		35424		35465
	35220		35261		35302		35343		35384		35425		35466
	35221		35262		35303		35344		35385		35426		35467
	35222		35263		35304		35345		35386		35427		35468
	35223		35264		35305		35346		35387		35428		35469
	35224		35265		35306		35347		35388		35429		35470
	35225		35266		35307		35348		35389		35430		35471
	35226		35267		35308		35349		35390		35431		35472
	35227		35268		35309		35350		35391		35432		35473
	35228		35269		35310		35351		35392		35433		35474
	35229		35270		35311		35352		35393		35434		35475
	35230		35271		35312		35353		35394		35435		35476
	35231		35272		35313		35354		35395		35436		35477
	35232		35273		35314		35355		35396		35437		35478
	35233		35274		35315		35356		35397		35438		35479
	35234		35275		35316		35357		35398		35439		35480
	35235		35276		35317		35358		35399		35440		35481
	35236		35277		35318		35359		35400		35441		35482
	35237		35278		35319		35360		35401		35442		35483
	35238		35279		35320		35361		35402		35443		35484
	35239		35280		35321		35362		35403		35444		35485
	35240		35281		35322		35363		35404		35445		35486
	35241		35282		35323		35364		35405		35446		35487
	35242		35283		35324		35365		35406		35447		35488
	35243		35284		35325		35366		35407		35448		35489
	35244		35285		35326		35367		35408		35449		35490
	35245		35286		35327		35368		35409		35450		35491
	35246		35287		35328		35369		35410		35451		35492
	35247		35288		35329		35370		35411		35452		35493
	35248		35289		35330		35371		35412		35453		35494
	35249		35290		35331		35372		35413		35454		35495
	35250		35291		35332		35373		35414		35455		35496
	35251		35292		35333		35374		35415		35456		35497
	35252		35293		35334		35375		35416		35457		35498

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	
	nb 35499 35500 35501 35502 35503 35504 35506 35507 35508 35509 35510 35511 35512 35512 35513 35514 35515 35516 35517 35518 35519 35520 35521 35522 35523 35524 35525 35526 35527	No	75540 35541 35542 35543 35544 35545 35546 35546 35547 35548 35549 35550 35551 35552 35553 35555 35556 35556 35556 35556 35556 35556 35560 35561 35562 35563 35563 35563 35564 35563 35563 35563 35566	No	nb 35581 35582 35583 35584 35585 35586 35588 35589 35590 35591 35592 35593 35594 35595 35596 35597 35598 35599 35600 35601 35602 35603 35604 35605 35606 35607 35608	No	nb 35622 35623 35624 35625 35626 35627 35628 35629 35630 35631 35632 35633 35633 35634 35635 35636 35636 35637 35638 35636 35637 35644 35645 35640 35641 35644 35645 35644 35645 35646 35647 35648 35649 35650	No	nb 35663 35664 35665 35666 35667 35668 35670 35671 35672 35673 35674 35675 35677 35678 35677 35678 35679 35680 35681 35682 35684 35685 35688 35688 35688 35688 35689 35689	No	nb 35704 35705 35706 35706 35707 35708 35709 35711 35712 35713 35714 35715 35716 35716 35716 35716 35721 35722 35723 35724 35725 35724 35725 35726 35727 35728 35729 35730 35731	PPD	35745 35746 35747 35749 35750 35751 35752 35753 35755 35756 35756 35756 35760 35762 35763 357763 357763 357763 357763 357763 357763 357763 357763 357763 357763 357763 357763 357763 357763 357763 357763 357763 357763 357773
	35528 35529 35530 35531 35532 35533 35534 35535 35536 35537 35538 35538		35569 35570 35571 35572 35572 35573 35574 35576 35576 35577 35578 35578 35579		35610 35611 35612 35613 35614 35615 35616 35616 35617 35618 35619 35620 35621		35651 35652 35653 35654 35655 35656 35657 35658 35659 35660 35661 35662		35692 35693 35694 35695 35696 35697 35698 35699 35700 35701 35702 35703		35733 35733 35735 35736 35737 35738 35739 35740 35741 35742 35742 35743 35744		35774 35775 35776 35777 35778 35778 35779 35780 35781 35781 35782 35783 35784 35785

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb		. Bl. o nb		Bl. nb		Trt. E	
												-		
PPD	35786	PPD	35827	PPD	35868	PPD	35909	PPD	35950	PPD	35991	P	PD 3	36032
	35787		35828		35869		35910		35951		35992		3	36033
	35788		35829		35870		35911		35952		35993		3	36034
	35789		35830		35871		35912		35953		35994		3	36035
	35790		35831		35872		35913		35954		35995		3	36036
	35791		35832		35873		35914		35955		35996		3	36037
	35792		35833		35874		35915		35956		35997		3	36038
	35793		35834		35875		35916		35957		35998		3	36039
	35794		35835		35876		35917		35958		35999		3	36040
	35795		35836		35877		35918		35959		36000		3	36041
	35796		35837		35878		35919		35960		36001		3	36042
	35797		35838		35879		35920		35961		36002		3	36043
	35798		35839		35880		35921		35962		36003		3	36044
	35799		35840		35881		35922		35963		36004		3	36045
	35800		35841		35882		35923		35964		36005		3	36046
	35801		35842		35883		35924		35965		36006		3	36047
	35802		35843		35884		35925		35966		36007		3	36048
	35803		35844		35885		35926		35967		36008		3	36049
	35804		35845		35886		35927		35968		36009		3	36050
	35805		35846		35887		35928		35969		36010		3	36051
	35806		35847		35888		35929		35970		36011		3	36052
	35807		35848		35889		35930		35971		36012		-	36053
	35808		35849		35890		35931		35972		36013		3	36054
	35809		35850		35891		35932		35973		36014			36055
	35810		35851		35892		35933		35974		36015		-	36056
	35811		35852		35893		35934		35975		36016			36057
	35812		35853		35894		35935		35976		36017		-	36058
	35813		35854		35895		35936		35977		36018		3	36059
	35814		35855		35896		35937		35978		36019		3	36060
	35815		35856		35897		35938		35979		36020			36061
	35816		35857		35898		35939		35980		36021		-	36062
	35817		35858		35899		35940		35981		36022			36063
	35818		35859		35900		35941		35982		36023		-	36064
	35819		35860		35901		35942		35983		36024		-	36065
	35820		35861		35902		35943		35984		36025			36066
	35821		35862		35903		35944		35985		36026			36067
	35822		35863		35904		35945		35986		36027			36068
	35823		35864		35905		35946		35987		36028			36069
	35824		35865		35906		35947		35988		36029		-	36070
	35825		35866		35907		35948		35989		36030		-	36071
	35826		35867		35908		35949		35990		36031		3	36072

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.		. Bl.		Bl.		. Bl.		Bl.	Trt.	
No	nb	No nb		nb	No	nb		o nb	No	nb	No	nb
PPD	36073	PPD 36114	PPD	36155	PPD	36196	PPD	36237	PPD	36278	PPD	36319
	36074	36115		36156		36197		36238		36279		36320
	36075	36116		36157		36198		36239		36280		36321
	36076	36117		36158		36199		36240		36281		36322
	36077	36118		36159		36200		36241		36282		36323
	36078	36119		36160		36201		36242		36283		36324
	36079	36120		36161		36202		36243		36284		36325
	36080	36121		36162		36203		36244		36285		36326
	36081	36122		36163		36204		36245		36286		36327
	36082	36123		36164		36205		36246		36287		36328
	36083	36124		36165		36206		36247		36288		36329
	36084	36125		36166		36207		36248		36289		36330
	36085	36126		36167		36208		36249		36290		36331
	36086	36127		36168		36209		36250		36291		36332
	36087	36128		36169		36210		36251		36292		36333
	36088	36129		36170		36211		36252		36293		36334
	36089	36130		36171		36212		36253		36294		36335
	36090	36131		36172		36213		36254		36295		36336
	36091	36132		36173		36214		36255		36296		36337
	36092	36133		36174		36215		36256		36297		36338
	36093	36134		36175		36216		36257		36298		36339
	36094	36135		36176		36217		36258		36299		36340
	36095	36136		36177		36218		36259		36300		36341
	36096	36137		36178		36219		36260		36301		36342
	36097	36138		36179		36220		36261		36302		36343
	36098	36139		36180		36221		36262		36303		36344
	36099	36140		36181		36222		36263		36304		36345
	36100	36141		36182		36223		36264		36305		36346
	36101	36142		36183		36224		36265		36306		36347
	36102	36143		36184		36225		36266		36307		36348
	36103	36144		36185		36226		36267		36308		36349
	36104	36145		36186		36227		36268		36309		36350
	36105	36146		36187		36228		36269		36310		36351
	36106	36147		36188		36229		36270		36311		36352
	36107	36148		36189		36230		36271		36312		36353
	36108	36149		36190		36231		36272		36313		36354
	36109	36150		36191		36232		36273		36314		36355
	36110	36151		36192		36233		36274		36315		36356
	36111	36152		36193		36234		36275		36316		36357
	36112	36153		36194		36235		36276		36317		36358
	36113	36154		36195		36236		36277		36318		36359

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Trt. Bl.	Trt	. Bl.	Trt.	. Bl.	Trt	. Bl.						
No	nb	N	o nb	No	o nb	No	nb	N	o nb	No	nb	N	lo nb
PPD	36360	PPD	36401	PPD	36442	PPD	36483	PPD	36524	PPD	36565	PPD	36606
	36361	–	36402		36443		36484		36525		36566		36607
	36362		36403		36444		36485		36526		36567		36608
	36363		36404		36445		36486		36527		36568		36609
	36364		36405		36446		36487		36528		36569		36610
	36365		36406		36447		36488		36529		36570		36611
	36366		36407		36448		36489		36530		36571		36612
	36367		36408		36449		36490		36531		36572		36613
	36368		36409		36450		36491		36532		36573		36614
	36369		36410		36451		36492		36533		36574		36615
	36370		36411		36452		36493		36534		36575		36616
	36371		36412		36453		36494		36535		36576		36617
	36372		36413		36454		36495		36536		36577		36618
	36373		36414		36455		36496		36537		36578		36619
	36374		36415		36456		36497		36538		36579		36620
	36375		36416		36457		36498		36539		36580		36621
	36376		36417		36458		36499		36540		36581		36622
	36377		36418		36459		36500		36541		36582		36623
	36378		36419		36460		36501		36542		36583		36624
	36379		36420		36461		36502		36543		36584		36625
	36380		36421		36462		36503		36544		36585		36626
	36381		36422		36463		36504		36545		36586		36627
	36382		36423		36464		36505		36546		36587		36628
	36383		36424		36465		36506		36547		36588		36629
	36384		36425		36466		36507		36548		36589		36630
	36385		36426		36467		36508		36549		36590		36631
	36386		36427		36468		36509		36550		36591		36632
	36387		36428		36469		36510		36551		36592		36633
	36388		36429		36470		36511		36552		36593		36634
	36389		36430		36471		36512		36553		36594		36635
	36390		36431		36472		36513		36554		36595		36636
	36391		36432		36473		36514		36555		36596		36637
	36392		36433		36474		36515		36556		36597		36638
	36393		36434		36475		36516		36557		36598		36639
	36394		36435		36476		36517		36558		36599		36640
	36395		36436		36477		36518		36559		36600		36641
	36396		36437		36478		36519		36560		36601		36642
	36397		36438		36479		36520		36561		36602		36643
	36398		36439		36480		36521		36562		36603		36644
	36399		36440		36481		36522		36563		36604		36645
	36400		36441		36482		36523		36564		36605		36646

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	36647	PPD 36688	PPD 36729	PPD 36770	PPD 36811	PPD 36852	PPD 36893
FFD	36648	36689	36730	36771	36812	36853	36894
	36649	36690	36731	36772	36813	36854	36895
	36650	36691	36732	36773	36814	36855	36896
	36651	36692	36733	36774	36815	36856	36897
	36652	36693	36734	36775	36816	36857	36898
	36653	36694	36735	36776	36817	36857	36899
	36654	36695	36736	36777	36818	36859	36900
	36655	36696	36737	36778	36818	36859	36900
		36697	36738				
	36656 36657	36698	36739	36779 36780	36820 36821	36861 36862	36902 36903
	36658	36699	36740	36781	36822	36863	36904
	36659	36700	36741	36782	36823	36864	36905
	36660	36700	36742		36823	36865	36905
		36702	36743	36783 36784	36825	36866	36907
	36661						
	36662	36703	36744 36745	36785	36826	36867 36868	36908
	36663	36704		36786	36827		36909
	36664	36705	36746	36787	36828	36869	36910
	36665	36706	36747	36788	36829	36870	36911
	36666	36707	36748	36789	36830	36871	36912
	36667	36708	36749	36790	36831	36872	36913
	36668	36709	36750	36791	36832	36873	36914
	36669	36710	36751	36792	36833	36874	36915
	36670 36671	36711	36752	36793	36834	36875 36876	36916
		36712	36753	36794	36835		36917
	36672	36713	36754	36795	36836	36877	36918
	36673	36714	36755	36796	36837	36878	36919
	36674	36715	36756	36797	36838	36879	36920
	36675	36716	36757	36798	36839	36880	36921
	36676	36717	36758	36799	36840	36881	36922
	36677	36718	36759	36800	36841	36882	36923
	36678	36719	36760	36801	36842	36883	36924
	36679	36720	36761	36802	36843	36884	36925
	36680	36721	36762	36803	36844	36885	36926
	36681	36722	36763	36804	36845	36886	36927
	36682	36723	36764	36805	36846	36887	36928
	36683	36724	36765	36806	36847	36888	36929
	36684	36725	36766	36807	36848	36889	36930
	36685	36726	36767	36808	36849	36890	36931
	36686	36727	36768	36809	36850	36891	36932
	36687	36728	36769	36810	36851	36892	36933

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl. nb	Trt. E		Trt. No		Trt. No		Trt.	Bl. nb		Bl.	Trt. No	
		DDD					ı			PPD		PPD	
PPD	00001		,0,,0			PPD		PPD	37098	110	37139		37180
	36935		36976		37017		37058		37099		37140		37181
	36936		36977		37018		37059		37100		37141		37182
	36937		36978		37019		37060		37101		37142		37183
	36938		36979		37020		37061		37102		37143		37184
	36939	3	36980		37021		37062		37103		37144		37185
	36940	3	36981		37022		37063		37104		37145		37186
	36941	3	36982		37023		37064		37105		37146		37187
	36942	3	36983		37024		37065		37106		37147		37188
	36943	3	36984		37025		37066		37107		37148		37189
	36944	3	36985		37026		37067		37108		37149		37190
	36945	3	36986		37027		37068		37109		37150		37191
	36946	3	36987		37028		37069		37110		37151		37192
	36947	3	36988		37029		37070		37111		37152		37193
	36948	3	36989		37030		37071		37112		37153		37194
	36949		36990		37031		37072		37113		37154		37195
	36950		36991		37032		37073		37114		37155		37196
	36951		36992		37033		37074		37115		37156		37197
	36952		36993		37034		37075		37116		37157		37198
	36953		36994		37035		37076		37117		37158		37199
	36954		86995		37036		37077		37118		37159		37200
	36955		36996		37037		37078		37119		37160		37201
	36956		36997		37038		37079		37120		37161		37202
	36957		36998		37039		37080		37121		37162		37202
	36958		36999		37040		37081		37122		37163		37204
	36959		37000		37040		37082		37123		37164		37205
	36960		37000		37042		37083		37124		37165		37205
	36961		37001		37042		37084		37125		37166		37200
	36962		37002		37043		37085		37126		37166		37207
	36963		37003		37044		37086		37127		37168		37208
	36964		37004		37045		37087		37128		37166		37210
	36965		37005		37046		37088		37129		37170		37210
	36966		37006		37047		37088		37129		37170		37211
					37048				37130		37171		37212
	36967		37008				37090						
	36968		37009		37050		37091		37132		37173		37214
	36969		37010		37051		37092		37133		37174		37215
	36970		37011		37052		37093		37134		37175		37216
	36971		37012		37053		37094		37135		37176		37217
	36972		37013		37054		37095		37136		37177		37218
	36973		37014		37055		37096		37137		37178		37219
	36974	3	37015		37056		37097		37138		37179		37220

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. No	nb	Trt. No	Bl. nb	Trt. No	nb	Trt. No	nb	Trt. No	Bl. nb	Trt. No	Bl. nb
PPD	nb 37221 37222 37223 37224 37225 37226 37227 37228 37228 37229 37230 37231 37232 37233 37234 37235 37236 37237 37238 37237 37238 37237 37238 37240 37241 37245 37240 37241 37245 37249 37244 37245 37249 37249 37249 37249 37249 37250 37251	No	nb 37262 37263 37264 37265 37266 37267 37276 37271 37271 37271 37272 37273 37274 37275 37277 37278 37277 37278 37278 37279 37280 37281 37282 37283 37284 37285 37286 37287 37288 37288 37288 37289 37290 37291 37292		nb 37303 37304 37305 37306 37307 37308 37309 37310 37311 37312 37313 37314 37315 37316 37317 37318 37319 37320 37321 37322 37322 37322 37322 37322 37322 37322 37322 37322 37323 37324 37325 37326 37327 37328 37329 37330 37331 37332	No	nb 37344 37345 37346 37347 37348 37349 37350 37351 37352 37353 37354 37355 37356 37356 37360 37361 37362 37363 37364 37365 37366 37367 37368 37367 37368 37370 37371 37372 37373	No	nb 37385 37386 37387 37388 37389 37390 37391 37392 37393 37394 37395 37396 37397 37398 37390 37400 37401 37402 37403 37404 37405 37406 37407 37408 37409 37410 37411 37412 37411		nb 37426 37427 37428 37429 37430 37431 37432 37433 37434 37435 37436 37437 37438 37443 37444 37445 37446 37447 37448 37446 37447 37448 37449 37450 37450 37451 37452 37453 37456	PPD	nb 37467 37468 37479 37471 37471 37477 37477 37477 37478 37479 37481 37482 37483 37484 37486 37486 37487 37488 37489 37489 37491 37492 37491 37492 37494 37495 37497
					37333 37334 37335 37336 37337 37338 37339 37340 37341 37342 37343				37415 37416 37417 37418 37419 37420 37421 37422 37422 37423 37424 37425				
	J/201		37302		37343		37304		51425		3/400		37307

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	t. Bl.		. Bl.		. Bl.		Bl.		Bl.		Bl.	Trt.	
	No nb	N	o nb	No	nb	NC	nb	No.	nb	No	nb	No	nb
PPD	37508	PPD	37549	PPD	37590	PPD	37631	PPD	37672	PPD	37713	PPD	37754
–	37509		37550		37591		37632	–	37673		37714		37755
	37510		37551		37592		37633		37674		37715		37756
	37511		37552		37593		37634		37675		37716		37757
	37512		37553		37594		37635		37676		37717		37758
	37513		37554		37595		37636		37677		37718		37759
	37514		37555		37596		37637		37678		37719		37760
	37515		37556		37597		37638		37679		37720		37761
	37516		37557		37598		37639		37680		37721		37762
	37517		37558		37599		37640		37681		37722		37763
	37518		37559		37600		37641		37682		37723		37764
	37519		37560		37601		37642		37683		37724		37765
	37520		37561		37602		37643		37684		37725		37766
	37521		37562		37603		37644		37685		37726		37767
	37522		37563		37604		37645		37686		37727		37768
	37523		37564		37605		37646		37687		37728		37769
	37524		37565		37606		37647		37688		37729		37770
	37525		37566		37607		37648		37689		37730		37771
	37526		37567		37608		37649		37690		37731		37772
	37527		37568		37609		37650		37691		37732		37773
	37528		37569		37610		37651		37692		37733		37774
	37529		37570		37611		37652		37693		37734		37775
	37530		37571		37612		37653		37694		37735		37776
	37531		37572		37613		37654		37695		37736		37777
	37532		37573		37614		37655		37696		37737		37778
	37533		37574		37615		37656		37697		37738		37779
	37534		37575		37616		37657		37698		37739		37780
	37535		37576		37617		37658		37699		37740		37781
	37536		37577		37618		37659		37700		37741		37782
	37537		37578		37619		37660		37701		37742		37783
	37538		37579		37620		37661		37702		37743		37784
	37539		37580		37621		37662		37703		37744		37785
	37540		37581		37622		37663		37704		37745		37786
	37541		37582		37623		37664		37705		37746		37787
	37542		37583		37624		37665		37706		37747		37788
	37543		37584		37625		37666		37707		37748		37789
	37544		37585		37626		37667		37708		37749		37790
	37545		37586		37627		37668		37709		37750		37791
	37546		37587		37628		37669		37710		37751		37792
	37547		37588		37629		37670		37711		37752		37793
	37548		37589		37630		37671		37712		37753		37794

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.		Bl.		Bl.		Bl.		Bl.		Bl.
No	nb	No nb	NC	nb	NC	nb	NC	nb	NC	nb	NC	nb
						_			PPD			_
PPD	37795	PPD 37836	PPD	37877	PPD	37918	PPD	37959	PPD	38000	PPD	38041
	37796	37837		37878		37919		37960		38001		38042
	37797	37838		37879		37920		37961		38002		38043
	37798	37839		37880		37921		37962		38003		38044
	37799	37840		37881		37922		37963		38004		38045
	37800	37841		37882		37923		37964		38005		38046
	37801	37842		37883		37924		37965		38006		38047
	37802	37843		37884		37925		37966		38007		38048
	37803	37844		37885		37926		37967		38008		38049
	37804	37845		37886		37927		37968		38009		38050
	37805	37846		37887		37928		37969		38010		38051
	37806	37847		37888		37929		37970		38011		38052
	37807	37848		37889		37930		37971		38012		38053
	37808	37849		37890		37931		37972		38013		38054
	37809	37850		37891		37932		37973		38014		38055
	37810	37851		37892		37933		37974		38015		38056
	37811	37852		37893		37934		37975		38016		38057
	37812	37853		37894		37935		37976		38017		38058
	37813	37854		37895		37936		37977		38018		38059
	37814	37855		37896		37937		37978		38019		38060
	37815	37856		37897		37938		37979		38020		38061
	37816	37857		37898		37939		37980		38021		38062
	37817	37858		37899		37940		37981		38022		38063
	37818	37859		37900		37941		37982		38023		38064
	37819	37860		37901		37942		37983		38024		38065
	37820	37861		37902		37943		37984		38025		38066
	37821	37862		37903		37944		37985		38026		38067
	37822	37863		37904		37945		37986		38027		38068
	37823	37864		37905		37946		37987		38028		38069
	37824	37865		37906		37947		37988		38029		38070
	37825	37866		37907		37948		37989		38030		38071
	37826	37867		37908		37949		37990		38031		38072
	37827	37868		37909		37950		37991		38032		38073
	37828	37869		37910		37951		37992		38033		38074
	37829	37870		37911		37952		37993		38034		38075
	37830	37871		37912		37953		37994		38035		38076
	37831	37872		37913		37954		37995		38036		38077
	37832	37873		37914		37955		37996		38037		38078
	37833	37874		37915		37956		37997		38038		38079
	37834	37875		37916		37957		37998		38039		38080
	37835	37876		37917		37958		37999		38040		38081

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.		. Bl.	Trt.			. Bl.		Bl.	Trt.	
NO.	nb	No nb		nb	No	nb		o nb	NC 	nb	NO	nb
									222	•		
PPD	38082	PPD 38123	PPD	38164	PPD	38205	PPD	38246	PPD	38287	PPD	38328
	38083	38124		38165		38206		38247		38288		38329
	38084	38125		38166		38207		38248		38289		38330
	38085	38126		38167		38208		38249		38290		38331
	38086	38127		38168		38209		38250		38291		38332
	38087	38128		38169		38210		38251		38292		38333
	38088	38129		38170		38211		38252		38293		38334
	38089	38130		38171		38212		38253		38294		38335
	38090	38131		38172		38213		38254		38295		38336
	38091	38132		38173		38214		38255		38296		38337
	38092	38133		38174		38215		38256		38297		38338
	38093	38134		38175		38216		38257		38298		38339
	38094	38135		38176		38217		38258		38299		38340
	38095	38136		38177		38218		38259		38300		38341
	38096	38137		38178		38219		38260		38301		38342
	38097	38138		38179		38220		38261		38302		38343
	38098	38139		38180		38221		38262		38303		38344
	38099	38140		38181		38222		38263		38304		38345
	38100	38141		38182		38223		38264		38305		38346
	38101	38142		38183		38224		38265		38306		38347
	38102	38143		38184		38225		38266		38307		38348
	38103	38144		38185		38226		38267		38308		38349
	38104	38145		38186		38227		38268		38309		38350
	38105	38146		38187		38228		38269		38310		38351
	38106	38147		38188		38229		38270		38311		38352
	38107	38148		38189		38230		38271		38312		38353
	38108	38149		38190		38231		38272		38313		38354
	38109	38150		38191		38232		38273		38314		38355
	38110	38151		38192		38233		38274		38315		38356
	38111	38152		38193		38234		38275		38316		38357
	38112	38153		38194		38235		38276		38317		38358
	38113	38154		38195		38236		38277		38318		38359
	38114	38155		38196		38237		38278		38319		38360
	38115	38156		38197		38238		38279		38320		38361
	38116	38157		38198		38239		38280		38321		38362
	38117	38158		38199		38240		38281		38322		38363
	38118	38159		38200		38241		38282		38323		38364
	38119	38160		38201		38242		38283		38324		38365
	38120	38161		38202		38243		38284		38325		38366
	38121	38162		38203		38244		38285		38326		38367
	38122	38163		38204		38245		38286		38327		38368

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt	. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	38369	PPD 38410	PPD 38451	PPD 38492	2 PPD 38533	PPD	3574 PPD 38615
PPD	38370	38410 38411	38451		• • -		3574 11D 38615 3575 38616
	38371 38372	38412	38453				38617 3577 38618
		38413	38454				
	38373	38414	38455				38619
	38374	38415	38456				38620
	38375	38416	38457				38621
	38376	38417	38458				38622
	38377	38418	38459				38623
	38378	38419	38460				38624
	38379	38420	38461				38625
	38380	38421	38462				38626
	38381	38422	38463				38627
	38382	38423	38464				38628
	38383	38424	38465				38629
	38384	38425	38466				38630
	38385	38426	38467				38631
	38386	38427	38468				38632
	38387	38428	38469				38633
	38388	38429	38470				38634
	38389	38430	38471				38635
	38390	38431	38472				38636
	38391	38432	38473				38637
	38392	38433	38474				38638
	38393	38434	38475				38639
	38394	38435	38476				38640
	38395	38436	38477				38641
	38396	38437	38478				38642
	38397	38438	38479				38643
	38398	38439	38480				38644
	38399	38440	38481				38645
	38400	38441	38482				38646
	38401	38442	38483				38647
	38402	38443	38484				38648
	38403	38444	38485				38649
	38404	38445	38486				38650
	38405	38446	38487				38651
	38406	38447	38488	3852	9 38570	38	38652
	38407	38448	38489				38653
	38408	38449	38490				38654
	38409	38450	38491	3853	2 38573	38	38655

DTPA-HBV-IPV-135 (A.15MAR2018)

No nb	Trt.	Bl.	Trt. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	B1.	Trt.	Bl.
38657 38698 38739 3878	No	nb	No nb	No	nb	No	nb	No	nb	No	nb	No	nb
38657 38698 38739 3878													
38657 38698 38730 38780 38821 38862 38903 38904 38658 38699 38740 38782 38823 38844 38905 38660 38701 38742 38783 38824 38865 38905 38661 38702 38743 38744 38785 38825 38866 38907 38662 38703 38744 38785 38826 38867 38908 38663 38704 38745 38786 38827 38868 38909 38664 38705 38744 38785 38826 38867 38908 38665 38704 38745 38786 38827 38868 38909 38665 38706 38747 38788 38829 38870 38911 38912 38666 38707 38748 38789 38830 38871 38912 38666 38707 38748 38789 38830 38871 38912 38669 38710 38751 38792 38833 38874 38914 38669 38710 38751 38792 38833 38874 38915 38671 38712 38753 38794 38835 38876 38914 38673 38714 38755 38796 38876 38914 38673 38714 38755 38796 38877 38918 38673 38714 38755 38796 38877 38918 38673 38716 38757 38796 38879 38830 38871 38912 38673 38716 38757 38798 38839 38890 38871 38912 38673 38716 38759 38890 38871 38918 38979 38676 38717 38718 38759 38890 38811 38922 38673 38916 38771 38718 38759 38890 38811 38892 38879 38900 38671 38718 38759 38890 38814 38892 38890 38919 38679 38750 38766 38717 38718 38759 38890 38810 38919 38669 38716 38757 38718 38759 38890 38810 38922 38673 38718 38759 38890 38810 38922 38673 38718 38752 38756 38799 38890 38810 38922 38673 38718 38752 38756 38799 38890 38890 38919 38669 38717 38718 38750 38800 38811 38922 38673 38718 38750 38766 38777 38718 38756 38766 38807 38890 38810 38922 38673 38754 38766 38777 38718 38766 38807 38890 38890 38922 38666 38727 38766 38777 38768 38800 38811 38922 38668 38729 38770 38810 38893 38893 38893 38893 38893 38893 38893 38893 3889	DDD	20656	PPD 20607	PPD	20720	חסס	20770	DDD	20020	PPD	20061	PPD	20002
38658 38699 38700 38741 38782 38823 38864 38905 38669 38700 38741 38782 38823 38864 38905 38660 38701 38742 38783 38824 38855 38866 38906 38661 38702 38743 38784 38825 38866 38907 38662 38703 38744 38785 38826 38827 38868 38909 38663 38704 38745 38786 38827 38868 38909 38664 38705 38746 38787 38828 38829 38800 38801 38827 38866 38909 38666 38707 38748 38788 38829 38870 38911 38666 38707 38748 38789 38830 38871 38912 38668 38709 38750 38749 38790 38831 38872 38913 38669 38710 38751 38792 38833 38874 38915 38670 38711 38752 38793 38834 38875 38916 38671 38712 38753 38794 38835 38876 38917 38677 38718 38755 38796 38837 38818 38877 38918 38672 38713 38755 38796 38837 38877 38918 38677 38718 38755 38796 38837 38877 38918 38677 38718 38755 38796 38837 38877 38918 38677 38918 38677 38718 38755 38796 38837 38878 38919 38677 38718 38755 38796 38837 38887 38919 38677 38718 38755 38796 38837 38887 38919 38677 38718 38755 38796 38837 38887 38919 38677 38718 38755 38796 38837 38887 38919 38677 38718 38755 38796 38837 38887 38919 38677 38718 38755 38796 38837 38887 38919 38677 38718 38755 38796 38837 38887 38919 38677 38718 38755 38766 38777 38718 38755 38766 38777 38718 38755 38766 38767 38886 38927 38886 38927 38686 38929 38930 38881 38929 38930 38886 38929 38930 38886 38929 38930 3888	FFD		00037			110		FFD					
38659 38700 38741 38782 38823 38864 33905 38660 38701 38742 33783 38824 38825 38866 33907 38661 38702 38744 38755 38826 38827 38866 33907 38662 38704 38744 38755 38826 38827 38868 38909 38663 38704 38746 38707 38828 38829 38870 38810 38665 38706 38747 38788 38829 38870 38811 38827 38866 38706 38747 38788 38829 38870 38811 38827 38866 38706 38747 38788 38829 38870 38811 38812 38871 38912 38667 38708 38749 38730 38831 38872 38913 38669 38710 38751 38752 38733 38814 38872 38813 38874 38915 38670 38711 38752 38793 38834 38875 38916 38671 38712 38753 38744 38935 38876 38917 38672 38713 38754 38755 38796 38837 38877 38918 38673 38714 38755 38796 38837 38878 38919 38673 38716 38757 38759 38836 38877 38919 38675 38716 38757 38759 38836 38877 38919 38675 38716 38757 38758 38799 38830 38811 38920 38871 38875 38916 38757 38758 38799 38830 38871 38878 38919 38677 38718 38759 38830 38841 38920 38871 38759 38836 38877 38918 38677 38718 38759 38800 38811 38920 38871 38759 38800 38811 38920 38871 38759 38800 38811 38920 38679 38720 38761 38802 38830 38844 38885 38920 38679 38720 38761 38802 38830 38844 38885 38920 38611 38722 38768 38800 38841 38822 38923 38668 38927 38668 38927 38668 38927 38668 38927 38668 38927 38668 38927 38668 38927 38668 38927 38668 38927 38668 38927 38668 38927 38669 38731 38766 38807 38800 38841 38922 38669 38731 38766 38807 38808 38899 38930 38811 38922 38669 38724 38766 38807 38808 38899 38930 38930 38669 38731 38772 38813 38855 38896 38930 38931 38669 38731 38772 38813 38855 38896 38937 38938 3893													
38600 38701 38702 38743 38784 38825 38866 38907 38661 38702 38733 38744 38755 38826 38867 38908 38663 38704 38745 38746 38755 38826 38867 38908 38664 38705 38746 38747 38788 38829 38869 38910 38911 38666 38707 38748 38748 38769 38830 38871 38872 38912 38666 38707 38748 38748 38749 38830 38871 38872 38912 38666 38707 38748 38750 38791 38831 38872 38913 38668 38709 38750 38791 38832 38873 38914 38669 38711 38752 38791 38832 38873 38914 38670 38711 38752 38793 38834 38875 38916 38711 38752 38793 38834 38875 38916 38711 38752 38793 38834 38875 38916 38711 38752 38793 38834 38875 38916 38917 38672 38713 38754 38755 38796 38837 38838 38878 38919 38674 38715 38756 38796 38837 38838 38879 38910 38756 38777 38838 38879 38910 38674 38755 38796 38837 38838 38879 38910 38674 38755 38796 38797 38838 38889 38919 38674 38757 38758 38799 38830 38887 38888 38919 38674 38759 38836 38877 38888 38919 38676 38717 38758 38759 38830 38841 38882 38924 38679 38720 38756 38759 38800 38841 38882 38924 38679 38720 38761 38876 38877 38888 38924 38679 38720 38761 38876 38801 38887 38886 38927 38660 38721 38762 38763 38804 38881 38887 38926 38661 38727 38768 38800 38841 38882 38924 38669 38720 38761 38806 38841 38882 38924 38669 38721 38763 38864 38865 38926 38927 38668 38727 38766 38807 38888 38899 38920 38669 38720 38761 38800 38841 38882 38924 38669 38721 38763 38804 38861 38882 38924 38669 38721 38763 38804 38864 38887 38928 38668 38927 38668 38727 38766 38800 38841 38882 38924 38669 38720 38761 38800 38841 38886 38927 38668 38727 38766 38800 38841 38886 38927 38668 38727 38766 38800 38841 38886 38927 38668 38727 38768 38800 38841 38886 38927 38668 38727 38768 38800 38841 38886 38927 38668 38727 38768 38800 38841 38886 38927 38668 38727 38768 38800 38841 38886 38929 38669 38733 38769 38800 38841 38889 38929 38669 38733 38769 38770 38811 38852 38893 38934 38669 38733 38774 38769 38811 38855 38896 38933 38934 38669 38733 38774 38815 38855 38896 38933 38934 38934 38935 38934 38935 38934 38935 38936 38933 38934 38934 38935 38936 38933 38934													
38661 38702 38143 38785 38866 38907 38662 38703 38744 38785 38826 38667 38908 38663 38705 38746 38787 38828 38869 38910 38665 38706 38747 38788 38829 38870 38911 38666 38707 38748 38799 38830 38871 38912 38667 38708 38749 38790 38831 38872 38913 38668 38709 38750 38791 38832 38873 38914 38670 38711 38752 38792 38833 38873 3891 38671 38711 38752 38793 38834 38875 3891 38671 38714 38753 38794 38835 38876 3891 38672 38714 38755 38793 38834 38875 3891 38672 38714 38755 38796 38837 38878 3891 38673 38714 38757 </td <td></td>													
38662 38703 38744 38785 38826 38867 38908 38663 38705 38746 38787 38828 38869 38909 38664 38705 38746 38787 38828 38829 38870 38910 38666 38707 38748 38799 38830 38871 38912 38667 38708 38749 38790 38831 38872 38913 38668 38709 38750 38791 38832 38874 38913 38669 38710 38751 38792 38833 38874 38913 38670 38711 38752 38793 38834 38875 38916 38671 38712 38753 38794 38835 38876 38917 38672 38713 38754 38793 38834 38875 38918 38672 38713 38754 38795 38836 38877 38918 38673 38714 38755 38796 38837 38876 38919 38													
38663 38704 38745 38786 38827 38868 38909 38664 38705 38746 38787 3828 38699 38910 38665 38706 38747 38788 38829 38870 38911 38666 33707 33748 38789 38830 38871 38912 38667 38708 38749 38790 38831 38872 38913 38668 38709 38750 38791 38832 38873 38914 38670 38711 38752 38793 38834 38875 38916 38671 38711 38752 38793 38834 38875 38916 38672 38713 38754 38794 38835 38876 38917 38673 38714 38755 38796 38837 38878 38918 38673 38714 38755 38797 38838 38879 38918 38674 38715 38756 38797 38838 38879 38920 38674 387													
38664 38705 38746 38787 38828 38869 38910 38665 38706 38747 38788 38829 38870 38911 38667 38708 38749 38790 38831 38872 38913 38668 38709 38750 38791 38832 38873 38914 38669 38710 38751 38792 38833 38874 38915 38671 38712 38752 38793 38833 38874 38915 38671 38712 38752 38793 38833 38876 38916 38671 38712 38753 38794 38835 38876 38917 38673 38714 38755 38795 38836 38877 38918 38674 38715 38756 38796 38837 38878 38919 38675 38717 38758 38798 38839 38880 38920 38675 38717 38758 38799 38840 38881 38922 38679 38													
38665 38706 38747 38788 38829 38870 38911 38666 38707 38748 38790 38830 38871 38912 38667 38708 38749 38790 38831 38872 38913 38668 38709 38750 38791 38832 38873 38914 38669 38710 38711 38752 38792 38833 38874 38915 38671 38712 38753 38794 38835 38876 38916 38672 38713 38754 38795 38836 38877 38918 38673 38714 38755 38796 38837 38878 38919 38674 38715 38756 38797 38838 38879 38920 38675 38716 38757 38798 38839 38800 38921 38676 38717 38758 38799 38840 38811 38922 38678 38719 38760 38801 38842 38883 38822 38679 38720 38761 38802 38841 38882 38923 38680 38721 38762 38803 38844													
38666 38707 38748 38790 38831 38871 38912 38667 38708 38749 38790 38831 38872 38913 38668 38709 38750 38791 38832 38873 38914 38670 38711 38752 38792 38833 38874 38915 38671 38712 38753 38794 38835 38876 38917 38672 38713 38754 38795 38836 38877 38918 38673 38714 38755 38796 38837 38878 38919 38674 38715 38756 38797 38838 38879 38920 38675 38716 38757 38798 38839 38800 38819 38676 38717 38758 38799 38840 38881 38892 38677 38718 38759 38800 38841 38892 38924 38679 38721 38760 38801 38842 38882 38924 38680 38													
38667 38708 38749 38790 38831 38872 38913 38668 38709 38750 38791 38832 38873 38914 38670 38711 38752 38793 38834 38875 38916 38671 38712 38752 38793 38834 38875 38916 38672 38713 38754 38795 38836 38877 38918 38673 38714 38755 38796 38837 38878 38919 38673 38714 38755 38796 38837 38878 38919 38674 38715 38756 38797 38838 38879 38919 38675 38716 38757 38798 38839 38880 38921 38676 38717 38758 38799 38840 3881 38922 38678 38719 38760 38801 38842 38881 38922 38679 38720 38761 38802 38844 38883 38924 38691 38721 38762 38803 38844 38885 38926 38682 38723 38764 38805 38844 38885													
38668 38709 38750 38791 38832 38873 38914 38670 38711 38752 38793 38834 38875 38916 38671 38712 38753 38794 38835 38876 38917 38672 38713 38754 38795 38836 38877 38918 38673 38714 38755 38796 38837 38878 38919 38674 38715 38756 38797 38838 38879 38920 38675 38716 38757 38798 38839 38880 38920 38676 38717 38758 38799 38840 38811 38922 38677 38718 38759 38800 38841 38822 38923 38678 38719 38760 38801 38842 38883 38923 38679 38720 38761 38802 38843 38844 38825 38681 38722 38763 38804 38844 38885 38927 38682 38													
38669 38710 38751 38792 38833 38874 38915 38670 38711 38752 38793 38834 38875 38916 38671 38712 38753 38794 38835 38876 38917 38672 38713 38754 38795 38836 38877 38918 38673 38714 38755 38796 38837 38878 38918 38674 38715 38756 38797 38838 38879 38890 38675 38716 38757 38798 38839 38880 38912 38676 38717 38758 38799 38840 38811 38922 38677 38718 38759 38800 38841 38822 38923 38678 38719 38760 38801 38841 38882 38923 38679 38720 38761 38802 38843 38884 38924 38680 38721 38762 38803 38844 38885 38927 38681 38													
38670 38711 38752 38793 38834 38875 38916 38671 38712 38753 38794 38835 38876 38917 38672 38713 38754 38795 38836 38877 38917 38673 38714 38755 38796 38837 38878 38919 38674 38715 38756 38797 38838 38879 38920 38675 38716 38757 38798 38839 38880 38922 38676 38717 38758 38799 38840 38881 38922 38677 38718 38759 38800 38841 38882 38923 38678 38719 38760 38801 38842 3883 38923 38679 38720 38761 38802 38843 38884 38923 38680 38721 38762 38803 38844 38885 38925 38681 38722 38763 38804 38845 38886 38927 38682 387													
38671 38712 38753 38794 38835 38876 38917 38672 38713 38754 38795 38836 38877 38918 38673 38714 38755 38796 38837 38878 38918 38674 38715 38756 38797 38838 38879 38920 38675 38716 38757 38798 38839 38880 38921 38676 38717 38758 38799 38840 38881 38922 38677 38718 38759 38800 38841 38882 38923 38678 38719 38760 38801 38842 38883 38923 38679 38720 38761 38802 38843 38884 38924 38680 38721 38762 38803 38844 38885 38926 38681 38722 38763 38804 38845 38886 38927 38682 38723 38764 38805 38846 3887 38988 38683 387													
38672 38713 38754 38795 38836 38877 38918 38673 38714 38755 38796 38837 38878 38919 38674 38715 38756 38797 38838 38879 38920 38675 38716 38757 38798 38839 3880 38921 38676 38717 38758 38799 38840 38881 38922 38677 38718 38759 38800 3841 38822 38923 38678 38719 38760 38801 38842 38883 38924 38679 38720 38761 38802 38843 38884 38925 38680 38721 38762 38803 38844 38885 38926 38681 38722 38763 38804 38845 38886 38927 38682 38723 38764 38805 38846 38887 38928 38683 38724 38765 38806 38847 38888 38929 38684 3872													
38673 38714 38755 38796 38837 38878 38919 38674 38715 38756 38797 38838 38879 38920 38675 38716 38757 38798 38839 38880 38921 38676 38717 38758 38799 38840 38881 38922 38677 38718 38759 38800 38841 38882 38923 38678 38719 38760 38801 38842 38883 38923 38679 38720 38761 38802 38843 38884 38925 38680 38721 38762 38803 38844 38885 38926 38681 38722 38763 38804 38845 38886 38927 38682 38723 38764 38805 38846 38887 38929 38683 38724 38765 38806 38847 38888 38929 38684 38727 38768 38909 38849 38890 38931 38686 38													
38674 38715 38756 38797 38838 38879 38920 38675 38716 38757 38788 38839 38880 38921 38676 38717 38758 38799 38840 38881 38922 38677 38718 38759 38800 38841 38882 38923 38678 38719 38760 38801 38842 38883 38924 38679 38720 38761 38802 38843 38884 38925 38680 38721 38762 38803 38844 38855 38926 38681 38722 38763 38804 38845 38886 38927 38682 38723 38764 38805 38846 38887 38928 38683 38724 38765 38806 38847 38888 38929 38684 38725 38766 38807 38848 38899 38930 38685 38727 38768 38809 38850 38891 38932 38686 38727 38768 38809 38850 38891 38932 38688 38729 38771 38811 38852 38893													
38675 38716 38757 38798 38839 38880 38921 38676 38717 38758 38799 38840 38881 38922 38677 38718 38759 38800 38841 38822 38923 38678 38719 38760 38801 38842 38883 38924 38679 38720 38761 38802 38843 38884 38925 38680 38721 38762 38803 38844 38885 38926 38681 38722 38762 38804 38845 38885 38926 38682 38723 38764 38805 38846 38887 38928 38683 38724 38765 38806 38847 38888 38929 38684 38725 38766 38807 38848 38899 38930 38685 38726 38768 38809 38850 38891 38932 38686 38727 38768 38809 38851 38992 38933 38688 38729 38770 38811 38852 38893 38934 38699 38731 38772 38813 38854 38895													
38676 38717 38758 38799 38840 38881 38922 38677 38718 38759 38800 38841 38882 38923 38678 38719 38760 38801 38842 38883 38924 38679 38720 38761 38802 38843 38884 38925 38680 38721 38762 38803 38844 38885 38926 38681 38722 38763 38804 38845 38886 38927 38682 38723 38764 38805 38846 38887 38928 38683 38724 38765 38806 38847 38888 38929 38684 38725 38766 38807 38848 38899 38930 38685 38726 38767 38808 38849 38890 38931 38686 38727 38768 38809 38850 38891 38932 38687 38728 38769 38810 38851 38892 38933 38688 38729 38770 38811 38852 38893 38934 38690 38731 38772 38813 38854 38895													
38677 38718 38759 38800 38841 38882 38923 38678 38719 38760 38801 38842 38883 38924 38679 38720 38761 38802 38843 38884 38925 38680 38721 38762 38803 38844 38885 38926 38681 38722 38763 38804 38845 38886 38927 38682 38723 38764 38805 38846 38887 38928 38683 38724 38765 38806 38847 38888 38929 38684 38725 38766 38807 38848 38899 3830 38685 38726 38767 38808 38849 38890 38931 38686 38727 38768 38809 38850 38891 38932 38687 38728 38770 38811 38852 38893 38934 38699 38730 38771 38812 38853 38894 38935 38691 387													
38678 38719 38760 38801 38842 38883 38924 38679 38720 38761 38802 38843 38884 38925 38680 38721 38762 38803 38844 38885 38926 38681 38722 38763 38804 38845 38886 38927 38682 38723 38764 38805 38846 38887 38928 38683 38724 38765 38806 38847 38888 38929 38684 38725 38766 38807 38848 38899 38930 38685 38726 38767 38808 38849 38890 38931 38686 38727 38768 38809 38850 3891 38932 38687 38728 38769 38810 38851 3892 38933 38688 38729 38770 38811 38852 38893 38934 38690 38731 38772 38813 38854 38895 38936 38691 38732 38773 38814 38855 38896 38937 38692 38733 38774 38815 38856 38897													
38679 38720 38761 38802 38843 38884 38925 38680 38721 38762 38803 38844 38855 38926 38681 38722 38763 38804 38845 38886 38927 38682 38723 38764 38805 38846 38887 38928 38683 38724 38765 38806 38847 38888 38929 38684 38725 38766 38807 38848 38889 38930 38685 38726 38767 38808 38849 38890 38931 38686 38727 38768 38809 38850 38891 38932 38687 38728 38769 38810 38851 38922 38933 38688 38729 38770 38811 38852 38993 38934 38690 38731 38772 38813 38854 38995 38936 38691 38732 38773 38814 38855 38996 38937 38692 38733 38774 38815 38856 38997 38938													
38680 38721 38762 38803 38844 38885 38926 38681 38722 38763 38804 38845 38886 38927 38682 38723 38764 38805 38846 38887 38928 38683 38724 38765 38806 38847 38888 38929 38684 38725 38766 38807 38848 38889 38930 38685 38726 38767 38808 38849 38890 38931 38686 38727 38768 38099 38850 3891 38932 38687 38728 38769 38810 38851 38892 38933 38688 38729 38770 38811 38852 38893 38934 38699 38730 38771 38812 38853 38894 38935 38691 38732 38773 38814 38855 38996 38936 38691 38732 38773 38814 38856 38897 38938													
38681 38722 38763 38804 38845 38886 38927 38682 38723 38764 38805 38846 38887 38928 38683 38724 38765 38806 38847 38888 38929 38684 38725 38766 38807 38848 38889 38930 38685 38726 38767 38808 38849 38890 38931 38686 38727 38768 38809 38850 38891 38932 38687 38728 38769 38810 38851 38892 38933 38688 38729 38770 38811 38852 38893 38934 38699 38730 38771 38812 38853 38894 38935 38691 38732 38772 38813 38854 38895 38936 38691 38732 38773 38814 38855 38896 38937 38692 38733 38774 38815 38856 38897 38938													
38682 38723 38764 38805 38846 38887 38928 38683 38724 38765 38806 38847 38888 38929 38684 38725 38766 38807 38848 38889 38930 38685 38726 38767 38808 38849 38900 38931 38686 38727 38768 38809 38850 38891 38932 38687 38728 38769 38810 38851 38892 38933 38688 38729 38770 38811 38852 38893 38934 38690 38731 38772 38813 38854 38995 38936 38691 38732 38773 38814 38855 38896 38937 38692 38733 38774 38815 38856 38897 38938													
38683 38724 38765 38806 38847 38888 38929 38684 38725 38766 38807 38848 38899 38930 38685 38726 38767 38808 38849 38890 38931 38686 38727 38768 38809 38850 38891 38931 38687 38728 38769 38810 38851 38992 38933 38688 38729 38770 38811 38852 38893 38934 38689 38730 38771 38812 38853 38894 38935 38690 38731 38772 38813 38854 38995 38936 38691 38732 38773 38814 38855 38996 38937 38692 38733 38774 38815 38856 38997 38938													
38694 38725 38766 38807 38848 38889 38930 38685 38726 38767 38808 38849 38890 38931 38686 38727 38768 38099 38850 38891 38932 38687 38728 38769 38810 38851 38892 38933 38688 38729 38770 38811 38852 38893 38934 38689 38730 38771 38812 38853 38894 38935 38690 38731 38772 38813 38854 38955 38996 38937 38691 38732 38773 38814 38855 38896 38937 38938 38692 38733 38774 38815 38856 38897 38938													
38685 38726 38767 38808 38849 38890 38931 38686 38727 38768 38809 38850 38891 38932 38687 38728 38769 38810 38851 3892 38933 38688 38729 38770 38811 38852 38893 38934 38689 38730 38771 38812 38853 38894 38935 38690 38731 38772 38813 38854 38895 38936 38691 38732 38773 38814 38855 38896 38937 38692 38733 38774 38815 38856 38897 38938													
38686 38727 38768 38809 38850 38891 38932 38687 38728 38769 38810 38851 38892 38933 38688 38729 38770 38811 38852 38893 38934 38689 38730 38771 38812 38853 38894 38935 38690 38731 38772 38813 38854 38895 3895 38691 38732 38773 38814 38855 38966 38937 38692 38733 38774 38815 38856 38897 38938													
38687 38728 38769 38810 38851 38892 38933 38688 38729 38770 38811 38852 38893 38934 38689 38730 38771 38812 38853 38894 38935 38690 38731 38772 38813 38854 38955 38936 38691 38732 38773 38814 38855 38966 38937 38692 38733 38774 38815 38856 38897 38938													
38688 38729 38770 38811 38852 38893 38934 38689 38730 38771 38812 38853 38894 38935 38690 38731 38772 38813 38854 3895 38936 38691 38732 38773 38814 38855 38966 38937 38692 38733 38774 38815 38856 38997 38938													
38689 38730 38771 38812 38853 38894 38935 38690 38731 38772 38813 38854 38895 38936 38691 38732 38773 38814 38855 38896 38937 38692 38733 38774 38815 38856 38897 38938													
38690 38731 38772 38813 38854 38895 38936 38691 38732 38773 38814 38855 38896 38937 38692 38733 38774 38815 38856 38897 38938													
38691 38732 38773 38814 38855 38896 38937 38692 38733 38774 38815 38856 38897 38938													
38692 38733 38774 38815 38856 38897 38938													
38693 38734 38775 38816 38857 38898 38939													
38694 38735 38776 38817 38858 38899 38940													
													38941
38696 38737 38778 38819 38860 38901 38942		38696	38737		38778		38819		38860		38901		38942

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	. Bl. o nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt.	Bl.		. Bl.		Bl.		Trt.	
												-		
PPD	38943	PPD	38984	PPD	39025	PPD	39066	PPD	39107	PPD	39148	Р	PD	39189
· · -	38944		38985		39026		39067	–	39108		39149			39190
	38945		38986		39027		39068		39109		39150			39191
	38946		38987		39028		39069		39110		39151			39192
	38947		38988		39029		39070		39111		39152			39193
	38948		38989		39030		39071		39112		39153			39194
	38949		38990		39031		39072		39113		39154			39195
	38950		38991		39032		39073		39114		39155			39196
	38951		38992		39033		39074		39115		39156			39197
	38952		38993		39034		39075		39116		39157			39198
	38953		38994		39035		39076		39117		39158			39199
	38954		38995		39036		39077		39118		39159			39200
	38955		38996		39037		39078		39119		39160			39201
	38956		38997		39038		39079		39120		39161			39202
	38957		38998		39039		39080		39121		39162			39203
	38958		38999		39040		39081		39122		39163			39204
	38959		39000		39041		39082		39123		39164			39205
	38960		39001		39042		39083		39124		39165			39206
	38961		39002		39043		39084		39125		39166			39207
	38962		39003		39044		39085		39126		39167			39208
	38963		39004		39045		39086		39127		39168			39209
	38964		39005		39046		39087		39128		39169			39210
	38965		39006		39047		39088		39129		39170			39211
	38966		39007		39048		39089		39130		39171			39212
	38967		39008		39049		39090		39131		39172			39213
	38968		39009		39050		39091		39132		39173			39214
	38969		39010		39051		39092		39133		39174			39215
	38970		39011		39052		39093		39134		39175			39216
	38971		39012		39053		39094		39135		39176			39217
	38972		39013		39054		39095		39136		39177			39218
	38973		39014		39055		39096		39137		39178			39219
	38974		39015		39056		39097		39138		39179			39220
	38975		39016		39057		39098		39139		39180			39221
	38976		39017		39058		39099		39140		39181			39222
	38977		39018		39059		39100		39141		39182			39223
	38978		39019		39060		39101		39142		39183			39224
	38979		39020		39061		39102		39143		39184			39225
	38980		39021		39062		39103		39144		39185			39226
	38981		39022		39063		39104		39145		39186			39227
	38982		39023		39064		39105		39146		39187			39228
	38983		39024		39065		39106		39147		39188			39229

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.	Trt.		Trt.			. Bl.		. Bl.		. Bl.
No	nb	No nb	No	nb	No	nb	N ₁	o nb	No	nb	No	o nb
PPD	39230	PPD 39271	PPD	39312	PPD	39353	PPD	39394	PPD	39435	PPD	39476
	39231	39272		39313		39354	110	39395		39436		39477
	39232	39273		39314		39355		39396		39437		39478
	39233	39274		39315		39356		39397		39438		39479
	39234	39275		39316		39357		39398		39439		39480
	39235	39276		39317		39358		39399		39440		39481
	39236	39277		39318		39359		39400		39441		39482
	39237	39278		39319		39360		39401		39442		39483
	39238	39279		39320		39361		39402		39443		39484
	39239	39280		39321		39362		39403		39444		39485
	39240	39281		39322		39363		39404		39445		39486
	39241	39282		39323		39364		39405		39446		39487
	39242	39283		39324		39365		39406		39447		39488
	39243	39284		39325		39366		39407		39448		39489
	39244	39285		39326		39367		39408		39449		39490
	39245	39286		39327		39368		39409		39450		39491
	39246	39287		39328		39369		39410		39451		39492
	39247	39288		39329		39370		39411		39452		39493
	39248	39289		39330		39371		39412		39453		39494
	39249	39290		39331		39372		39413		39454		39495
	39250	39291		39332		39373		39414		39455		39496
	39251	39292		39333		39374		39415		39456		39497
	39252	39293		39334		39375		39416		39457		39498
	39253	39294		39335		39376		39417		39458		39499
	39254	39295		39336		39377		39418		39459		39500
	39255	39296		39337		39378		39419		39460		39501
	39256	39297		39338		39379		39420		39461		39502
	39257	39298		39339		39380		39421		39462		39503
	39258	39299		39340		39381		39422		39463		39504
	39259	39300		39341		39382		39423		39464		39505
	39260	39301		39342		39383		39424		39465		39506
	39261	39302		39343		39384		39425		39466		39507
	39262	39303		39344		39385		39426		39467		39508
	39263	39304		39345		39386		39427		39468		39509
	39264	39305		39346		39387		39428		39469		39510
	39265	39306		39347		39388		39429		39470		39511
	39266	39307		39348		39389		39430		39471		39512
	39267	39308		39349		39390		39431		39472		39513
	39268	39309		39350		39391		39432		39473		39514
	39269	39310		39351		39392		39433		39474		39515
	39270	39311		39352		39393		39434		39475		39516

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.		Bl.	Trt.			Bl.		Bl.	Trt.	
No	nb	No nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	39517	PPD 39558	PPD	39599	PPD	39640	PPD	39681	PPD	39722	PPD	39763
110	39518	39559		39600	110	39641	יוו	39682		39723		39764
	39519	39560		39601		39642		39683		39724		39765
	39520	39561		39602		39643		39684		39725		39766
	39521	39562		39603		39644		39685		39726		39767
	39522	39563		39604		39645		39686		39727		39768
	39523	39564		39605		39646		39687		39728		39769
	39524	39565		39606		39647		39688		39729		39770
	39525	39566		39607		39648		39689		39730		39771
	39526	39567		39608		39649		39690		39731		39772
	39527	39568		39609		39650		39691		39732		39773
	39528	39569		39610		39651		39692		39733		39774
	39529	39570		39611		39652		39693		39734		39775
	39530	39571		39612		39653		39694		39735		39776
	39531	39572		39613		39654		39695		39736		39777
	39532	39573		39614		39655		39696		39737		39778
	39533	39574		39615		39656		39697		39738		39779
	39534	39575		39616		39657		39698		39739		39780
	39535	39576		39617		39658		39699		39740		39781
	39536	39577		39618		39659		39700		39741		39782
	39537	39578		39619		39660		39701		39742		39783
	39538	39579		39620		39661		39702		39743		39784
	39539	39580		39621		39662		39703		39744		39785
	39540	39581		39622		39663		39704		39745		39786
	39541	39582		39623		39664		39705		39746		39787
	39542	39583		39624		39665		39706		39747		39788
	39543	39584		39625		39666		39707		39748		39789
	39544	39585		39626		39667		39708		39749		39790
	39545	39586		39627		39668		39709		39750		39791
	39546	39587		39628		39669		39710		39751		39792
	39547	39588		39629		39670		39711		39752		39793
	39548	39589		39630		39671		39712		39753		39794
	39549	39590		39631		39672		39713		39754		39795
	39550	39591		39632		39673		39714		39755		39796
	39551	39592		39633		39674		39715		39756		39797
	39552	39593		39634		39675		39716		39757		39798
	39553	39594		39635		39676		39717		39758		39799
	39554	39595		39636		39677		39718		39759		39800
	39555	39596		39637		39678		39719		39760		39801
	39556	39597		39638		39679		39720		39761		39802
	39557	39598		39639		39680		39721		39762		39803

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb
PPD	39804	PPD	39845	PPD	39886	PPD	39927	PPD	39968	PPD	40009	PPD	40050
	39805		39846		39887		39928		39969		40010		40051
	39806		39847		39888		39929		39970		40011		40052
	39807		39848		39889		39930		39971		40012		40053
	39808		39849		39890		39931		39972		40013		40054
	39809		39850		39891		39932		39973		40014		40055
	39810		39851		39892		39933		39974		40015		40056
	39811		39852		39893		39934		39975		40016		40057
	39812		39853		39894		39935		39976		40017		40058
	39813		39854		39895		39936		39977		40018		40059
	39814		39855		39896		39937		39978		40019		40060
	39815		39856		39897		39938		39979		40020		40061
	39816		39857		39898		39939		39980		40021		40062
	39817		39858		39899		39940		39981		40022		40063
	39818		39859		39900		39941		39982		40023		40064
	39819		39860		39901		39942		39983		40024		40065
	39820		39861		39902		39943		39984		40025		40066
	39821		39862		39903		39944		39985		40026		40067
	39822		39863		39904		39945		39986		40027		40068
	39823		39864		39905		39946		39987		40028		40069
	39824		39865		39906		39947		39988		40029		40070
	39825		39866		39907		39948		39989		40030		40071
	39826		39867		39908		39949		39990		40031		40072
	39827		39868		39909		39950		39991		40032		40073
	39828		39869		39910		39951		39992		40033		40074
	39829		39870		39911		39952		39993		40034		40075
	39830		39871		39912		39953		39994		40035		40076
	39831		39872		39913		39954		39995		40036		40077
	39832		39873		39914		39955		39996		40037		40078
	39833		39874		39915		39956		39997		40038		40079
	39834		39875		39916		39957		39998		40039		40080
	39835		39876		39917		39958		39999		40040		40081
	39836		39877		39918		39959		40000		40041		40082
	39837		39878		39919		39960		40001		40042		40083
	39838		39879		39920		39961		40002		40043		40084
	39839		39880		39921		39962		40003		40044		40085
	39840		39881		39922		39963		40004		40045		40086
	39841		39882		39923		39964		40005		40046		40087
	39842		39883		39924		39965		40006		40047		40088
	39843		39884		39925		39966		40007		40048		40089
	39844		39885		39926		39967		40008		40049		40090
	l		l		l								

DTPA-HBV-IPV-135 (A.15MAR2018)

	. Bl.		Bl.		Bl.		Bl.		Bl.		Bl.	Trt.	
No	nb		nb		nb		nb		nb	No	nb	No	nb
										DDD			
PPD	40091	PPD	40132	PPD	40173	PPD	40214	PPD	40255	PPD	40296	PPD	40337
	40092		40133		40174		40215		40256		40297		40338
	40093		40134		40175		40216		40257		40298		40339
	40094		40135		40176		40217		40258		40299		40340
	40095		40136		40177		40218		40259		40300		40341
	40096		40137		40178		40219		40260		40301		40342
	40097		40138		40179		40220		40261		40302		40343
	40098		40139		40180		40221		40262		40303		40344
	40099		40140		40181		40222		40263		40304		40345
	40100		40141		40182		40223		40264		40305		40346
	40101		40142		40183		40224		40265		40306		40347
	40102		40143		40184		40225		40266		40307		40348
	40103		40144		40185		40226		40267		40308		40349
	40104		40145		40186		40227		40268		40309		40350
	40105		40146		40187		40228		40269		40310		40351
	40106		40147		40188		40229		40270		40311		40352
	40107		40148		40189		40230		40271		40312		40353
	40108		40149		40190		40231		40272		40313		40354
	40109		40150		40191		40232		40273		40314		40355
	40110		40151		40192		40233		40274		40315		40356
	40111		40152		40193		40234		40275		40316		40357
	40112		40153		40194		40235		40276		40317		40358
	40113		40154		40195		40236		40277		40318		40359
	40114		40155		40196		40237		40278		40319		40360
	40115		40156		40197		40238		40279		40320		40361
	40116		40157		40198		40239		40280		40321		40362
	40117		40158		40199		40240		40281		40322		40363
	40118		40159		40200		40241		40282		40323		40364
	40119		40160		40201		40242		40283		40324		40365
	40120		40161		40202		40243		40284		40325		40366
	40121		40162		40203		40244		40285		40326		40367
	40122		40163		40204		40245		40286		40327		40368
	40123		40164		40205		40246		40287		40328		40369
	40124		40165		40206		40247		40288		40329		40370
	40125		40166		40207		40248		40289		40330		40371
	40126		40167		40208		40249		40290		40331		40372
	40127		40168		40209		40250		40291		40332		40373
	40128		40169		40210		40251		40292		40333		40374
	40129		40170		40211		40252		40293		40334		40375
	40130		40171		40212		40253		40294		40335		40376
	40131		40172		40213		40254		40295		40336		40377
			· -										

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. E	31.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No nb	No r		No	nb	No	nb	No	nb	No	nb
PPD	40378	PPD 40419	PPD 4	10460	PPD	40501	PPD	40542	PPD	40583	PPD	40624
110	40370	40420		10461	110	40502	110	40543		40584		40625
	40373	40420		10462		40503		40544		40585		40626
	40381	40422		10463		40504		40545		40586		40627
	40382	40423		10464		40505		40546		40587		40628
	40383	40423		10465		40506		40547		40588		40628
	40383	40424		10466		40507		40547		40589		40629
	40385	40425		10467		40508		40549		40590		40630
	40386	40420		10468		40509		40550		40591		40631
	40387	40427		10469		40510		40551		40592		40632
	40387	40428		10470		40510		40551		40593		40633
	40389	40423		10470		40512		40553		40594		40635
	40309	40430		10471		40512		40554		40595		40635
	40390	40431		10472		40514		40555		40596		40637
	40391	40432		10474		40515		40556		40597		40637
	40392	40433		10474		40516		40557		40598		40638
	40393	40434		10476		40517		40558		40599		40639
	40394	40433		10477		40518		40559		40600		40641
	40393	40436		10477		40519		40560		40601		40642
	40390	40437		10479		40520		40561		40602		40642
	40397	40438		10479		40521		40562		40603		40643
	40398	40439		10481		40522		40563		40603		40645
	40400	40441		10482		40523		40564		40605		40646
	40400	40442		10483		40524		40565		40606		40647
	40401	40443		10484		40525		40566		40607		40648
	40403	40444		10485		40526		40567		40608		40649
	40403	40445		10486		40527		40568		40609		40650
	40405	40446		10487		40528		40569		40610		40651
	40405	40447		10488		40529		40570		40611		40651
	40400	40448		10489		40530		40571		40612		40653
	40407	40449		10490		40531		40572		40613		40654
	40400	40450		10491		40532		40573		40614		40655
	40410	40451		10492		40533		40574		40615		40656
	40410	40451		10493		40534		40575		40616		40657
	40411	40453		10494		40535		40576		40617		40658
	40413	40454		10495		40536		40577		40618		40659
	40414	40455		10496		40537		40578		40619		40660
	40415	40456		10497		40538		40579		40620		40661
	40416	40457		10498		40539		40575		40621		40662
	40417	40457		10499		40540		40581		40622		40663
	40417	40459		10500		40541		40582		40623		40664
	10110	10100				10011		10002		10020		10001
						l						

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	B1.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	40665	PPD	40706	PPD	40747	PPD	40788	PPD	40829	PPD	40870
110	40666		40707		40748		40789		40830		40871
	40667		40708		40749		40790		40831		40872
	40668		40709		40750		40791		40832		40873
	40669		40710		40751		40792		40833		40874
	40670		40711		40752		40793		40834		40875
	40671		40712		40753		40794		40835		40876
	40672		40713		40754		40795		40836		40877
	40673		40714		40755		40796		40837		40878
	40674		40715		40756		40797		40838		40879
	40675		40716		40757		40798		40839		40880
	40676		40717		40758		40799		40840		40881
	40677		40718		40759		40800		40841		40882
	40678		40719		40760		40801		40842		40883
	40679		40720		40761		40802		40843		40884
	40680		40721		40762		40803		40844		40885
	40681		40722		40763		40804		40845		40886
	40682		40723		40764		40805		40846		40887
	40683		40724		40765		40806		40847		40888
	40684 40685		40725 40726		40766 40767		40807 40808		40848		40889
	40685		40726		40768		40808		40849		40890
	40686		40727		40769		40809		40850		40891
	40688		40729		40770		40810		40852		40892
	40689		40730		40771		40812		40853		40894
	40690		40731		40772		40813		40854		40895
	40691		40732		40773		40814		40855		40896
	40692		40733		40774		40815		40856		40897
	40693		40734		40775		40816		40857		40898
	40694		40735		40776		40817		40858		40899
	40695		40736		40777		40818		40859		40900
	40696		40737		40778		40819		40860		40901
	40697		40738		40779		40820		40861		40902
	40698		40739		40780		40821		40862		40903
	40699		40740		40781		40822		40863		40904
	40700		40741		40782		40823		40864		40905
	40701		40742		40783		40824		40865		40906
	40702		40743		40784		40825		40866		
	40703		40744		40785		40826		40867		
	40704		40745		40786		40827		40868		
	40705		40746		40787		40828		40869		
									•		

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	60907	PPD 60948	PPD 60989	PPD 61030	PPD 61071	PPD 61112	PPD 61153
FFD	60908	60949	60990	61030	61072	61113	61154
	60909	60950	60991	61032	61073	61114	61155
	60909	60951	60991	61032	61073	61115	61156
	60911	60952	60993	61034	61074	61116	61157
	60911	60952	60993	61034	61076	61117	61158
	60912	60954	60994	61036	61076	61117	
	60913	60955	60996	61036	61078	61119	61159 61160
	60914	60956	60996	61037	61078	61119	61161
	60916		60997				
	60916	60957 60958	60998	61039 61040	61080 61081	61121 61122	61162 61163
	60917	60959	61000	61041	61082	61123	61164
	60919	60959	61000	61042	61083	61123	61165
	60919	60961	61001	61042	61083	61124	61166
	60920	60962	61002	61043	61085	61126	
	60921	60962	61003	61045	61086	61127	61167 61168
	60922	60964	61004	61045	61086	61127	
	60923	60965	61005	61046	61087	61128	61169 61170
	60924		61007				
	60926	60966		61048	61089	61130	61171
	60926	60967 60968	61008	61049	61090	61131 61132	61172
	60927	60969	61009 61010	61050 61051	61091 61092	61133	61173
	60928	60970	61010	61051	61092	61133	61174
	60929	60971	61011	61052	61093	61134	61175 61176
	60930	60971	61012	61054	61094	61136	61177
	60932	60972	61013	61054	61095	61137	61178
	60932	60974		61056	61096	61137	
			61015	61057			61179
	60934	60975	61016		61098	61139	61180 61181
	60935 60936	60976 60977	61017	61058	61099	61140	
	60936	60977	61018 61019	61059 61060	61100 61101	61141 61142	61182 61183
	60938	60978	61020	61061	61101	61143	61184
	60939	60979	61020	61062	61102	61144	61185
	60940	60981	61021	61063	61103	61145	61186
	60940	60982	61022	61063	61104	61146	61187
	60942	60983	61023	61065	61105	61147	61188
	60942	60984	61024	61066	61107	61148	61189
	60943	60985	61025	61067	61107	61148	61189
		60986	61026				
	60945 60946	60987	61027	61068 61069	61109 61110	61150 61151	61191 61192
	60946	60988	61028	61070	61111	61151	61192
	00947	60988	61029	61070	61111	61152	61193
	ı						

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.					
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	61194	PPD 61235	PPD 61276	PPD 61317	PPD 61358	PPD 61399	PPD 61440
	61195	61236	61277	61318	61359	61400	61441
	61196	61237	61278	61319	61360	61401	61442
	61197	61238	61279	61320	61361	61402	61443
	61198	61239	61280	61321	61362	61403	61444
	61199	61240	61281	61322	61363	61404	61445
	61200	61241	61282	61323	61364	61405	61446
	61201	61242	61283	61324	61365	61406	61447
	61202	61243	61284	61325	61366	61407	61448
	61203	61244	61285	61326	61367	61408	61449
	61204	61245	61286	61327	61368	61409	61450
	61205	61246	61287	61328	61369	61410	61451
	61206	61247	61288	61329	61370	61411	61452
	61207	61248	61289	61330	61371	61412	61453
	61208	61249	61290	61331	61372	61413	61454
	61209	61250	61291	61332	61373	61414	61455
	61210	61251	61292	61333	61374	61415	61456
	61211	61252	61293	61334	61375	61416	61457
	61212	61253	61294	61335	61376	61417	61458
	61213	61254	61295	61336	61377	61418	61459
	61214	61255	61296	61337	61378	61419	61460
	61215	61256	61297	61338	61379	61420	61461
	61216	61257	61298	61339	61380	61421	61462
	61217	61258	61299	61340	61381	61422	61463
	61218	61259	61300	61341	61382	61423	61464
	61219	61260	61301	61342	61383	61424	61465
	61220	61261	61302	61343	61384	61425	61466
	61221	61262	61303	61344	61385	61426	61467
	61222	61263	61304	61345	61386	61427	61468
	61223	61264	61305	61346	61387	61428	61469
	61224	61265	61306	61347	61388	61429	61470
	61225	61266	61307	61348	61389	61430	61471
	61226	61267	61308	61349	61390	61431	61472
	61227	61268	61309	61350	61391	61432	61473
	61228	61269	61310	61351	61392	61433	61474
	61229	61270	61311	61352	61393	61434	61475
	61230	61271	61312	61353	61394	61435	61476
	61231	61272	61313	61354	61395	61436	61477
	61232	61273	61314	61355	61396	61437	61478
	61233	61274	61315	61356	61397	61438	61479
	61234	61275	61316	61357	61398	61439	61480

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

No	Bl. nb	Trt. No	nb	Trt. No	nb		Bl. nb	N	. Bl. o nb	No	Bl.		Trt. Bl. No nb
PPD		PPD	61522	PPD		PPD	_			PPD		PF	PD 61727
PPD	61481	PPD	61522	FFD	61563	PPD	61604	PPD	61645		61686	-	61727
	61482 61483		61523		61564 61565		61605 61606		61646 61647		61687 61688		61728
	61484		61524		61566		61607		61648		61689		61730
	61485		61526		61567		61608		61649		61690		61731
	61486		61527		61568		61609		61650		61691		61732
	61487		61528		61569		61610		61651		61692		61733
	61488		61529		61570		61611		61652		61693		61734
	61489		61530		61571		61612		61653		61694		61735
	61490		61531		61572		61613		61654		61695		61736
	61491		61532		61573		61614		61655		61696		61737
	61492		61533		61574		61615		61656		61697		61738
	61493		61534		61575		61616		61657		61698		61739
	61494		61535		61576		61617		61658		61699		61740
	61495		61536		61577		61618		61659		61700		61741
	61496		61537		61578		61619		61660		61701		61742
	61497		61538		61579		61620		61661		61702		61743
	61498		61539		61580		61621		61662		61703		61744
	61499		61540		61581		61622		61663		61704		61745
	61500		61541		61582		61623		61664		61705		61746
	61501		61542		61583		61624		61665		61706		61747
	61502		61543		61584		61625		61666		61707		61748
	61503		61544		61585		61626		61667		61708		61749
	61504		61545		61586		61627		61668		61709		61750
	61505		61546		61587		61628		61669		61710		61751
	61506		61547		61588		61629		61670		61711		61752
	61507		61548		61589		61630		61671		61712		61753
	61508		61549		61590		61631		61672		61713		61754
	61509		61550		61591		61632		61673		61714		61755
	61510		61551		61592		61633		61674		61715		61756
	61511		61552		61593		61634		61675		61716		61757
	61512		61553		61594		61635		61676		61717		61758
	61513		61554		61595		61636		61677		61718		61759
	61514		61555		61596		61637		61678		61719		61760
	61515		61556		61597		61638		61679		61720		61761
	61516		61557		61598		61639		61680		61721		61762
	61517		61558		61599		61640		61681		61722		61763
	61518		61559		61600		61641		61682		61723		61764
	61519		61560		61601		61642		61683		61724		61765
	61520		61561		61602		61643		61684		61725		61766
	61521		61562		61603		61644		61685		61726		61767

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	61760	PPD	61809	PPD	61850	PPD	61891	PPD	61932	PPD	61973	PPD	62014
PPD	61768 61769	FFD	61810	110	61851	FFD	61891	PPU	61932		61974	110	62014
													62015
	61770		61811		61852		61893		61934		61975		
	61771		61812		61853		61894		61935		61976		62017
	61772		61813		61854		61895		61936		61977		62018
	61773		61814		61855		61896		61937		61978		62019
	61774		61815		61856		61897		61938		61979		62020
	61775		61816		61857		61898		61939		61980		62021
	61776		61817		61858		61899		61940		61981		62022
	61777		61818		61859		61900		61941		61982		62023
	61778		61819		61860		61901		61942		61983		62024
	61779		61820		61861		61902		61943		61984		62025
	61780		61821		61862		61903		61944		61985		62026
	61781		61822		61863		61904		61945		61986		62027
	61782		61823		61864		61905		61946		61987		62028
	61783		61824		61865		61906		61947		61988		62029
	61784		61825		61866		61907		61948		61989		62030
	61785		61826		61867		61908		61949		61990		62031
	61786		61827		61868		61909		61950		61991		62032
	61787		61828		61869		61910		61951		61992		62033
	61788		61829		61870		61911		61952		61993		62034
	61789		61830		61871		61912		61953		61994		62035
	61790		61831		61872		61913		61954		61995		62036
	61791		61832		61873		61914		61955		61996		62037
	61792		61833		61874		61915		61956		61997		62038
	61793		61834		61875		61916		61957		61998		62039
	61794		61835		61876		61917		61958		61999		62040
	61795		61836		61877		61918		61959		62000		62041
	61796		61837		61878		61919		61960		62001		62042
	61797		61838		61879		61920		61961		62002		62043
	61798		61839		61880		61921		61962		62003		62044
	61799		61840		61881		61922		61963		62004		62045
	61800		61841		61882		61923		61964		62005		62046
	61801		61842		61883		61924		61965		62006		62047
	61802		61843		61884		61925		61966		62007		62048
	61803		61844		61885		61926		61967		62008		62049
	61804		61845		61886		61927		61968		62009		62050
	61805		61846		61887		61928		61969		62010		62051
	61806		61847		61888		61929		61970		62011		62052
	61807		61848		61889		61930		61971		62012		62053
	61808		61849		61890		61931		61972		62013		62054
											l		

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl. nb	Trt.	Bl. nb	Trt. No		Trt.		Trt.	Bl.		Bl.		Trt. B	
PPD	62055	PPD	62096	PPD	62137	PPD	62178	PPD	62219	PPD	62260	PF	PD 6	2301
	62056		62097		62138		62179		62220		62261			2302
	62057		62098		62139		62180		62221		62262			2303
	62058		62099		62140		62181		62222		62263			2304
	62059		62100		62141		62182		62223		62264		6.	2305
	62060		62101		62142		62183		62224		62265			2306
	62061		62102		62143		62184		62225		62266		6:	2307
	62062		62103		62144		62185		62226		62267		6:	2308
	62063		62104		62145		62186		62227		62268		6:	2309
	62064		62105		62146		62187		62228		62269		6:	2310
	62065		62106		62147		62188		62229		62270		6:	2311
	62066		62107		62148		62189		62230		62271		6.3	2312
	62067		62108		62149		62190		62231		62272		6:	2313
	62068		62109		62150		62191		62232		62273		6:	2314
	62069		62110		62151		62192		62233		62274		6.3	2315
	62070		62111		62152		62193		62234		62275		6:	2316
	62071		62112		62153		62194		62235		62276		6:	2317
	62072		62113		62154		62195		62236		62277		6.	2318
	62073		62114		62155		62196		62237		62278		6:	2319
	62074		62115		62156		62197		62238		62279		6:	2320
	62075		62116		62157		62198		62239		62280		6:	2321
	62076		62117		62158		62199		62240		62281		6:	2322
	62077		62118		62159		62200		62241		62282		6:	2323
	62078		62119		62160		62201		62242		62283		6:	2324
	62079		62120		62161		62202		62243		62284		6:	2325
	62080		62121		62162		62203		62244		62285		6:	2326
	62081		62122		62163		62204		62245		62286		6:	2327
	62082		62123		62164		62205		62246		62287		6:	2328
	62083		62124		62165		62206		62247		62288		6:	2329
	62084		62125		62166		62207		62248		62289		6:	2330
	62085		62126		62167		62208		62249		62290			2331
	62086		62127		62168		62209		62250		62291			2332
	62087		62128		62169		62210		62251		62292		6:	2333
	62088		62129		62170		62211		62252		62293		6:	2334
	62089		62130		62171		62212		62253		62294		63	2335
	62090		62131		62172		62213		62254		62295			2336
	62091		62132		62173		62214		62255		62296		6:	2337
	62092		62133		62174		62215		62256		62297		6:	2338
	62093		62134		62175		62216		62257		62298			2339
	62094		62135		62176		62217		62258		62299			2340
	62095		62136		62177		62218		62259		62300		6:	2341

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt	. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt	. Bl.	Trt	. Bl.	T	Trt. Bl.
N	o nb	No	nb	No	nb	No	nb	No	o nb	No	nb		No nb
PPD	62342	PPD	62383	PPD	62424	PPD	62465	PPD	62506	PPD	62547	PP	D 62588
	62343		62384		62425		62466		62507		62548		62589
	62344		62385		62426		62467		62508		62549		62590
	62345		62386		62427		62468		62509		62550		62591
	62346		62387		62428		62469		62510		62551		62592
	62347		62388		62429		62470		62511		62552		62593
	62348		62389		62430		62471		62512		62553		62594
	62349		62390		62431		62472		62513		62554		62595
	62350		62391		62432		62473		62514		62555		62596
	62351		62392		62433		62474		62515		62556		62597
	62352		62393		62434		62475		62516		62557		62598
	62353		62394		62435		62476		62517		62558		62599
	62354		62395		62436		62477		62518		62559		62600
	62355		62396		62437		62478		62519		62560		62601
	62356		62397		62438		62479		62520		62561		62602
	62357		62398		62439		62480		62521		62562		62603
	62358		62399		62440		62481		62522		62563		62604
	62359		62400		62441		62482		62523		62564		62605
	62360		62401		62442		62483		62524		62565		62606
	62361		62402		62443		62484		62525		62566		62607
	62362		62403 62404		62444		62485 62486		62526		62567 62568		62608
	62363 62364		62404		62445 62446		62486		62527 62528		62569		62609 62610
	62365		62405		62446		62488		62528		62570		62611
	62366		62406		62447		62488		62529		62570		62612
	62367		62408		62449		62490		62531		62572		62613
	62368		62409		62450		62491		62532		62573		62614
	62369		62410		62451		62492		62533		62574		62615
	62370		62411		62452		62493		62534		62575		62616
	62371		62412		62453		62494		62535		62576		62617
	62372		62413		62454		62495		62536		62577		62618
	62373		62414		62455		62496		62537		62578		62619
	62374		62415		62456		62497		62538		62579		62620
	62375		62416		62457		62498		62539		62580		62621
	62376		62417		62458		62499		62540		62581		62622
	62377		62418		62459		62500		62541		62582		62623
	62378		62419		62460		62501		62542		62583		62624
	62379		62420		62461		62502		62543		62584		62625
	62380		62421		62462		62503		62544		62585		62626
	62381		62422		62463		62504		62545		62586		62627
	62382		62423		62464		62505		62546		62587		62628
							_						

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
DDD	62620	PPD	60670	PPD	60711	PPD	60750	PPD	60702	PPD	62024	PPD	62875
PPD	62629	FFU	02070	FFD	62711 62712	PPD	62752	PPD	62793		62834	FFD	
	62630		62671				62753		62794		62835		62876
	62631		62672		62713		62754		62795		62836		62877
	62632		62673		62714		62755		62796		62837		62878
	62633		62674		62715		62756		62797		62838		62879
	62634		62675		62716		62757		62798		62839		62880
	62635		62676		62717		62758		62799		62840		62881
	62636		62677		62718		62759		62800		62841		62882
	62637		62678		62719		62760		62801		62842		62883
	62638		62679		62720		62761		62802		62843		62884
	62639		62680		62721		62762		62803		62844		62885
	62640		62681		62722		62763		62804		62845		62886
	62641		62682		62723		62764		62805		62846		62887
	62642		62683		62724		62765		62806		62847		62888
	62643		62684		62725		62766		62807		62848		62889
	62644		62685		62726		62767		62808		62849		62890
	62645		62686		62727		62768		62809		62850		62891
	62646		62687		62728		62769		62810		62851		62892
	62647		62688		62729		62770		62811		62852		62893
	62648		62689		62730		62771		62812		62853		62894
	62649		62690		62731		62772		62813		62854		62895
	62650		62691		62732		62773		62814		62855		62896
	62651		62692		62733		62774		62815		62856		62897
	62652		62693		62734		62775		62816		62857		62898
	62653		62694		62735		62776		62817		62858		62899
	62654		62695		62736		62777		62818		62859		62900
	62655		62696		62737		62778		62819		62860		62901
	62656		62697		62738		62779		62820		62861		62902
	62657		62698		62739		62780		62821		62862		62903
	62658		62699		62740		62781		62822		62863		62904
	62659		62700		62741		62782		62823		62864		62905
	62660		62701		62742		62783		62824		62865		62906
	62661		62702		62743		62784		62825		62866		62907
	62662		62703		62744		62785		62826		62867		62908
	62663		62704		62745		62786		62827		62868		62909
	62664		62705		62746		62787		62828		62869		62910
	62665		62706		62747		62788		62829		62870		62911
	62666		62707		62748		62789		62830		62871		62912
	62667		62708		62749		62790		62831		62872		62913
	62668		62709		62750		62791		62832		62873		62914
	62669		62710		62751		62792		62833		62874		62915
	02000		02/10		02 / 01		02172		02000		02017		02313
	ı						l				l		

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.		Trt.		Trt.		Trt.		Trt.	Bl.	Trt.	Bl.
No	nb	No	nb		nb	No	nb	No	nb	No	nb	No	nb
PPD	62916	PPD	62957	PPD	62998	PPD	63039	PPD	63080	PPD	63121	PPD	63162
FFD	62917	110	62958	110	62999	110	63040	FFD	63081		63122	110	63163
	62918		62959		63000		63041		63082		63123		63164
	62919		62960		63001		63042		63083		63124		63165
	62920		62961		63002		63043		63084		63125		63166
	62921		62962		63002		63044		63085		63126		63167
	62922		62963		63004		63045		63086		63127		63168
	62923		62964		63005		63046		63087		63128		63169
	62924		62965		63006		63047		63088		63129		63170
	62925		62966		63007		63048		63089		63130		63171
	62926		62967		63008		63049		63099		63131		63172
	62927		62968		63009		63050		63091		63132		63173
	62928		62969		63010		63051		63092		63133		63174
	62929		62970		63011		63052		63093		63134		63175
	62930		62971		63012		63053		63094		63135		63176
	62931		62972		63013		63054		63095		63136		63177
	62932		62973		63014		63055		63096		63137		63177
	62933		62974		63015		63056		63097		63138		63179
	62934		62975		63016		63057		63098		63139		63180
	62935		62976		63017		63058		63099		63140		63181
	62936		62977		63018		63059		63100		63141		63182
	62937		62978		63019		63060		63101		63142		63183
	62938		62979		63020		63061		63102		63143		63184
	62939		62980		63021		63062		63103		63144		63185
	62940		62981		63022		63063		63104		63145		63186
	62941		62982		63023		63064		63105		63146		63187
	62942		62983		63024		63065		63106		63147		63188
	62943		62984		63025		63066		63107		63148		63189
	62944		62985		63026		63067		63108		63149		63190
	62945		62986		63027		63068		63109		63150		63191
	62946		62987		63028		63069		63110		63151		63192
	62947		62988		63029		63070		63111		63152		63193
	62948		62989		63030		63071		63112		63153		63194
	62949		62990		63031		63072		63113		63154		63195
	62950		62991		63032		63073		63114		63155		63196
	62951		62992		63033		63074		63115		63156		63197
	62952		62993		63034		63075		63116		63157		63198
	62953		62994		63035		63076		63117		63158		63199
	62954		62995		63036		63077		63118		63159		63200
	62955		62996		63037		63078		63119		63160		63201
	62956		62997		63038		63079		63120		63161		63202
			·										
	•												

DTPA-HBV-IPV-135 (A.15MAR2018)

	Bl. nb		nb		nb	Trt. No	nb		nb		nb	Trt. No	Bl. nb
PPD	63203	PPD	63244	PPD	63285	PPD	63326	PPD	63367	PPD	63408	PPD	63449
	63204		63245		63286		63327		63368		63409		63450
	63205		63246		63287		63328		63369		63410		63451
	63206		63247		63288		63329		63370		63411		63452
	63207		63248		63289		63330		63371		63412		63453
	63208		63249		63290		63331		63372		63413		63454
	63209		63250		63291		63332		63373		63414		63455
	63210		63251		63292		63333		63374		63415		63456
	63211		63252		63293		63334		63375		63416		63457
	63212		63253		63294		63335		63376		63417		63458
	63213		63254		63295		63336		63377		63418		63459
	63214		63255		63296		63337		63378		63419		63460
	63215		63256		63297		63338		63379		63420		63461
	63216		63257		63298		63339		63380		63421		63462
	63217		63258		63299		63340		63381		63422		63463
	63218		63259		63300		63341		63382		63423		63464
	63219		63260		63301		63342		63383		63424		63465
	63220		63261		63302		63343		63384		63425		63466
	63221		63262		63303		63344		63385		63426		63467
	63222		63263		63304		63345		63386		63427		63468
	63223		63264		63305		63346		63387		63428		63469
	63224		63265		63306		63347		63388		63429		63470
	63225		63266		63307		63348		63389		63430		63471
	63226		63267		63308		63349		63390		63431		63472
	63227		63268		63309		63350		63391		63432		63473
	63228		63269		63310		63351		63392		63433		63474
	63229		63270		63311		63352		63393		63434		63475
	63230		63271		63312		63353		63394		63435		63476
	63231		63272		63313		63354		63395		63436		63477
	63232		63273		63314		63355		63396		63437		63478
	63233		63274		63315		63356		63397		63438		63479
	63234		63275		63316		63357		63398		63439		63480
	63235		63276		63317		63358		63399		63440		63481
	63236		63277		63318		63359		63400		63441		63482
	63237		63278		63319		63360		63401		63442		63483
	63238		63279		63320		63361		63402		63443		63484
	63239		63280		63321		63362		63403		63444		63485
	63240		63281		63322		63363		63404		63445		63486
	63241		63282		63323		63364		63405		63446		63487
	63242		63283		63324		63365		63406		63447		63488
	63243		63284		63325		63366		63407		63448		63489
	-				1								

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl. nb	Trt. Bl. No nb		Bl.		Bl.		Bl.		Bl.		. Bl.
NO	no 	NO ND		no	NC	o no	NC	o no	NC	o no	N	o no
				_		_		_	PPD			_
PPD	63490	PPD 63531	PPD	63572	PPD	63613	PPD	63654	FFD	63695	PPD	00700
	63491	63532		63573		63614		63655		63696		63737
	63492	63533		63574		63615		63656		63697		63738
	63493	63534		63575		63616		63657		63698		63739
	63494	63535		63576		63617		63658		63699		63740
	63495	63536		63577		63618		63659		63700		63741
	63496	63537		63578		63619		63660		63701		63742
	63497	63538		63579		63620		63661		63702		63743
	63498	63539		63580		63621		63662		63703		63744
	63499	63540		63581		63622		63663		63704		63745
	63500	63541		63582		63623		63664		63705		63746
	63501	63542		63583		63624		63665		63706		63747
	63502	63543		63584		63625		63666		63707		63748
	63503	63544		63585		63626		63667		63708		63749
	63504	63545		63586		63627		63668		63709		63750
	63505	63546		63587		63628		63669		63710		63751
	63506	63547		63588		63629		63670		63711		63752
	63507	63548		63589		63630		63671		63712		63753
	63508	63549		63590		63631		63672		63713		63754
	63509	63550		63591		63632		63673		63714		63755
	63510	63551		63592		63633		63674		63715		63756
	63511	63552		63593		63634		63675		63716		63757
	63512	63553		63594		63635		63676		63717		63758
	63513	63554		63595		63636		63677		63718		63759
	63514	63555		63596		63637		63678		63719		63760
	63515	63556		63597		63638		63679		63720		63761
	63516	63557		63598		63639		63680		63721		63762
	63517	63558		63599		63640		63681		63722		63763
	63518	63559		63600		63641		63682		63723		63764
	63519	63560		63601		63642		63683		63724		63765
	63520	63561		63602		63643		63684		63725		63766
	63521	63562		63603		63644		63685		63726		63767
	63522	63563		63604		63645		63686		63727		63768
	63523	63564		63605		63646		63687		63728		63769
	63524	63565		63606		63647		63688		63729		63770
	63525	63566		63607		63648		63689		63730		63771
	63526	63567		63608		63649		63690		63731		63772
	63527	63568		63609		63650		63691		63732		63773
	63528	63569		63610		63651		63692		63733		63774
	63529	63570		63611		63652		63693		63734		63775
	63530	63571		63612		63653		63694		63735		63776

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb		nb	Trt. No	nb	Trt. No	nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb
										PPD			
PPD	63777	PPD	63818	PPD	63859	PPD	63900	PPD	63941	PPD	63982	PPD	64023
	63778		63819		63860		63901		63942		63983		64024
	63779		63820		63861		63902		63943		63984		64025
	63780		63821		63862		63903		63944		63985		64026
	63781		63822		63863		63904		63945		63986		64027
	63782		63823		63864		63905		63946		63987		64028
	63783		63824		63865		63906		63947		63988		64029
	63784		63825		63866		63907		63948		63989		64030
	63785		63826		63867		63908		63949		63990		64031
	63786		63827		63868		63909		63950		63991		64032
	63787		63828		63869		63910		63951		63992		64033
	63788		63829		63870		63911		63952		63993		64034
	63789		63830		63871		63912		63953		63994		64035
	63790		63831		63872		63913		63954		63995		64036
	63791		63832		63873		63914		63955		63996		64037
	63792		63833		63874		63915		63956		63997		64038
	63793		63834		63875		63916		63957		63998		64039
	63794		63835		63876		63917		63958		63999		64040
	63795		63836		63877		63918		63959		64000		64041
	63796		63837		63878		63919		63960		64001		64042
	63797		63838		63879		63920		63961		64002		64043
	63798		63839		63880		63921		63962		64003		64044
	63799		63840		63881		63922		63963		64004		64045
	63800		63841		63882		63923		63964		64005		64046
	63801		63842		63883		63924		63965		64006		64047
	63802		63843		63884		63925		63966		64007		64048
	63803		63844		63885		63926		63967		64008		64049
	63804		63845		63886		63927		63968		64009		64050
	63805		63846		63887		63928		63969		64010		64051
	63806		63847		63888		63929		63970		64011		64052
	63807		63848		63889		63930		63971		64012		64053
	63808		63849		63890		63931		63972		64013		64054
	63809		63850		63891		63932		63973		64014		64055
	63810		63851		63892		63933		63974		64015		64056
	63811		63852		63893		63934		63975		64016		64057
	63812		63853		63894		63935		63976		64017		64058
	63813		63854		63895		63936		63977		64018		64059
	63814		63855		63896		63937		63978		64019		64060
	63815		63856		63897		63938		63979		64020		64061
	63816		63857		63898		63939		63980		64021		64062
	63817		63858		63899		63940		63981		64022		64063

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt	. Bl.	Trt	. Bl.	Trt	. Bl.	Trt	. Bl.	Trt	. Bl.	Trt	. Bl.	Trt	. Bl.
N	o nb		o nb		o nb		o nb		o nb	No	nb	N	lo nb
PPD	64064	PPD	64105	PPD	64146	PPD	64187	PPD	64228	PPD	64269	PPD	64310
	64065		64106		64147		64188		64229		64270		64311
	64066		64107		64148		64189		64230		64271		64312
	64067		64108		64149		64190		64231		64272		64313
	64068		64109		64150		64191		64232		64273		64314
	64069		64110		64151		64192		64233		64274		64315
	64070		64111		64152		64193		64234		64275		64316
	64071		64112		64153		64194		64235		64276		64317
	64072		64113		64154		64195		64236		64277		64318
	64073		64114		64155		64196		64237		64278		64319
	64074		64115		64156		64197		64238		64279		64320
	64075		64116		64157		64198		64239		64280		64321
	64076		64117		64158		64199		64240		64281		64322
	64077		64118		64159		64200		64241		64282		64323
	64078		64119		64160		64201		64242		64283		64324
	64079		64120		64161		64202		64243		64284		64325
	64080		64121		64162		64203		64244		64285		64326
	64081		64122		64163		64204		64245		64286		64327
	64082		64123		64164		64205		64246		64287		64328
	64083		64124		64165		64206		64247		64288		64329
	64084		64125		64166		64207		64248		64289		64330
	64085		64126		64167		64208		64249		64290		64331
	64086		64127		64168		64209		64250		64291		64332
	64087		64128		64169		64210		64251		64292		64333
	64088		64129		64170		64211		64252		64293		64334
	64089		64130		64171		64212		64253		64294		64335
	64090		64131		64172		64213		64254		64295		64336
	64091		64132		64173		64214		64255		64296		64337
	64092		64133		64174		64215		64256		64297		64338
	64093		64134		64175		64216		64257		64298		64339
	64094		64135		64176		64217		64258		64299		64340
	64095		64136		64177		64218		64259		64300		64341
	64096		64137		64178		64219		64260		64301		64342
	64097		64138		64179		64220		64261		64302		64343
	64098		64139		64180		64221		64262		64303		64344
	64099		64140		64181		64222		64263		64304		64345
	64100		64141		64182		64223		64264		64305		64346
	64101		64142		64183		64224		64265		64306		64347
	64102		64143		64184		64225		64266		64307		64348
	64103		64144		64185		64226		64267		64308		64349
	64104		64145		64186		64227		64268		64309		64350
										_	_		

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt	. Bl.	Trt. Bl.	Trt. Bl		Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No nb	No nb		No	nb	No	nb	No	nb	No	nb
		PPD 64392	PPD 64		PPD		000		PPD		PPD	
PPD	64351		0 1		PPD	64474	PPD	64515		64556	FFD	64597
	64352	64393		434		64475		64516		64557		64598
	64353	64394		435		64476		64517		64558		64599
	64354	64395		436		64477		64518		64559		64600
	64355	64396		437		64478		64519		64560		64601
	64356	64397		438		64479		64520		64561		64602
	64357	64398		439		64480		64521		64562		64603
	64358	64399		440		64481		64522		64563		64604
	64359	64400		441		64482		64523		64564		64605
	64360	64401		442		64483		64524		64565		64606
	64361	64402		443		64484		64525		64566		64607
	64362	64403		444		64485		64526		64567		64608
	64363	64404		445		64486		64527		64568		64609
	64364	64405		446		64487		64528		64569		64610
	64365	64406		447		64488		64529		64570		64611
	64366	64407	64	448		64489		64530		64571		64612
	64367	64408		449		64490		64531		64572		64613
	64368	64409	64	450		64491		64532		64573		64614
	64369	64410	64	451		64492		64533		64574		64615
	64370	64411	64	452		64493		64534		64575		64616
	64371	64412		453		64494		64535		64576		64617
	64372	64413	64	454		64495		64536		64577		64618
	64373	64414	64	455		64496		64537		64578		64619
	64374	64415	64	456		64497		64538		64579		64620
	64375	64416	64	457		64498		64539		64580		64621
	64376	64417	64	458		64499		64540		64581		64622
	64377	64418	64	459		64500		64541		64582		64623
	64378	64419	64	460		64501		64542		64583		64624
	64379	64420	64	461		64502		64543		64584		64625
	64380	64421	64	462		64503		64544		64585		64626
	64381	64422	64	463		64504		64545		64586		64627
	64382	64423	64	464		64505		64546		64587		64628
	64383	64424	64	465		64506		64547		64588		64629
	64384	64425	64	466		64507		64548		64589		64630
	64385	64426	64	467		64508		64549		64590		64631
	64386	64427	64	468		64509		64550		64591		64632
	64387	64428	64	469		64510		64551		64592		64633
	64388	64429	64	470		64511		64552		64593		64634
	64389	64430	64	471		64512		64553		64594		64635
	64390	64431	64	472		64513		64554		64595		64636
	64391	64432	64	473		64514		64555		64596		64637
												111
	•					l						

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt	. Bl.	Trt. B	1.	Trt.	Bl.								
N	o nb	No nl	b	No	nb								
DDD	64620	PPD 64	4670	PPD	64700	PPD	C47.61		64000	PPD	64040	PPD	64004
PPD			10,0			PPU		PPD	64802	–	64843	FFD	64884
	64639		4680		64721		64762		64803		64844		64885
	64640 64641	_	4681 4682		64722 64723		64763 64764		64804 64805		64845 64846		64886 64887
	64642		4683		64724		64765		64806		64847		64888
	64643		4684 4685		64725 64726		64766 64767		64807		64848		64889 64890
	64644 64645		4686		64727		64768		64808 64809		64849 64850		64890
	64646		4687		64728		64769		64810		64851		64891
	64647		4688		64729		64770		64811		64851		64892
	64648		4688		64730		64771		64812		64853		64893
	64649		4690		64731		64772		64813		64854		64895
	64650		4691		64732		64773		64814		64855		64896
	64651		4692		64733		64774		64815		64856		64897
	64652		4693		64734		64775		64816		64857		64898
	64653		4694		64735		64776		64817		64858		64899
	64654		4695		64736		64777		64818		64859		64900
	64655		4696		64737		64778		64819		64860		64900
	64656		4697		64738		64779		64820		64861		64902
	64657		4698		64739		64780		64821		64862		64902
	64658		4699		64740		64781		64822		64863		64904
	64659	_	4700		64741		64782		64823		64864		64905
	64660		4701		64742		64783		64824		64865		64906
	64661		4702		64743		64784		64825		64866		64907
	64662		4703		64744		64785		64826		64867		64908
	64663		4704		64745		64786		64827		64868		64909
	64664		4705		64746		64787		64828		64869		64910
	64665		4706		64747		64788		64829		64870		64911
	64666		4707		64748		64789		64830		64871		64912
	64667		4708		64749		64790		64831		64872		64913
	64668		4709		64750		64791		64832		64873		64914
	64669		4710		64751		64792		64833		64874		64915
	64670		4711		64752		64793		64834		64875		64916
	64671		4712		64753		64794		64835		64876		64917
	64672		4713		64754		64795		64836		64877		64918
	64673		4714		64755		64796		64837		64878		64919
	64674		4715		64756		64797		64838		64879		64920
	64675		4716		64757		64798		64839		64880		64921
	64676		4717		64758		64799		64840		64881		64922
	64677		4718		64759		64800		64841		64882		64923
	64678	64	4719		64760		64801		64842		64883		64924
					* *								
	_						l						

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	64925	PPD 64966	PPD 65007	PPD 65048	PPD 65089	PPD 65130	PPD 65171
110	64926	64967	65008	65049	65090	65131	65172
	64927	64968	65009	65050	65091	65132	65173
	64928	64969	65010	65051	65092	65133	65174
	64929	64970	65011	65052	65093	65134	65175
	64930	64971	65012	65053	65094	65135	65176
	64931	64972	65013	65054	65095	65136	65177
	64932	64973	65014	65055	65096	65137	65178
	64933	64974	65015	65056	65097	65138	65179
	64934	64975	65016	65057	65098	65139	65180
	64935	64976	65017	65058	65099	65140	65181
	64936	64977	65018	65059	65100	65141	65182
	64937	64978	65019	65060	65101	65142	65183
	64938	64979	65020	65061	65102	65143	65184
	64939	64980	65021	65062	65103	65144	65185
	64940	64981	65022	65063	65104	65145	65186
	64941	64982	65023	65064	65105	65146	65187
	64942	64983	65024	65065	65106	65147	65188
	64943	64984	65025	65066	65107	65148	65189
	64944	64985	65026	65067	65108	65149	65190
	64945	64986	65027	65068	65109	65150	65191
	64946	64987	65028	65069	65110	65151	65192
	64947	64988	65029	65070	65111	65152	65193
	64948	64989	65030	65071	65112	65153	65194
	64949	64990	65031	65072	65113	65154	65195
	64950	64991	65032	65073	65114	65155	65196
	64951	64992	65033	65074	65115	65156	65197
	64952	64993	65034	65075	65116	65157	65198
	64953	64994	65035	65076	65117	65158	65199
	64954	64995	65036	65077	65118	65159	65200
	64955	64996	65037	65078	65119	65160	65201
	64956	64997	65038	65079	65120	65161	65202
	64957	64998	65039	65080	65121	65162	65203 65204
	64958 64959	64999	65040	65081	65122	65163	
		65000	65041	65082	65123	65164	65205
	64960	65001 65002	65042	65083	65124	65165	65206 65207
	64961 64962	65002	65043 65044	65084	65125 65126	65166	65207
	64962	65003	65044	65085	65126	65167	65208
	64963	65004	65045	65086 65087	65127	65168 65169	65209
	64965	65005	65047	65087	65128	65170	65210
	04300	00000	63047	63000	03129	631/0	03211

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.	Trt.		Trt.		Trt.			Bl.	Trt.	
No	nb	No nb		nb		nb		nb	No	nb	No	nb
PPD	65212	PPD 65253	PPD	65294	PPD	65335	PPD	65376	PPD	65417	PPD	65458
FFD	65213	65254		65295	110	65336	FFD	65377		65418		65459
	65214	65255		65296		65337		65378		65419		65460
	65215	65256		65297		65338		65379		65420		65461
	65216	65257		65298		65339		65380		65421		65462
	65217	65258		65299		65340		65381		65422		65463
	65218	65259		65300		65341		65382		65423		65464
	65219	65260		65301		65342		65383		65424		65465
	65220	65261		65302		65343		65384		65425		65466
	65221	65262		65303		65344		65385		65426		65467
	65222	65263		65304		65345		65386		65427		65468
	65223	65264		65305		65346		65387		65428		65469
	65224	65265		65306		65347		65388		65429		65470
	65225	65266		65307		65348		65389		65430		65471
	65226	65267		65308		65349		65390		65431		65472
	65227	65268		65309		65350		65391		65432		65473
	65228	65269		65310		65351		65392		65433		65474
	65229	65270		65311		65352		65393		65434		65475
	65230	65271		65312		65353		65394		65435		65476
	65231	65272		65313		65354		65395		65436		65477
	65232	65273		65314		65355		65396		65437		65478
	65233	65274		65315		65356		65397		65438		65479
	65234	65275		65316		65357		65398		65439		65480
	65235	65276		65317		65358		65399		65440		65481
	65236	65277		65318		65359		65400		65441		65482
	65237	65278		65319		65360		65401		65442		65483
	65238	65279		65320		65361		65402		65443		65484
	65239	65280		65321		65362		65403		65444		65485
	65240	65281		65322		65363		65404		65445		65486
	65241	65282		65323		65364		65405		65446		65487
	65242	65283		65324		65365		65406		65447		65488
	65243	65284		65325		65366		65407		65448		65489
	65244	65285		65326		65367		65408		65449		65490
	65245	65286		65327		65368		65409		65450		65491
	65246	65287		65328		65369		65410		65451		65492
	65247	65288		65329		65370		65411		65452		65493
	65248	65289		65330		65371		65412		65453		65494
	65249	65290		65331		65372		65413		65454		65495
	65250	65291		65332		65373		65414		65455		65496
	65251	65292		65333		65374		65415		65456		65497
	65252	65293		65334		65375		65416		65457		65498
												4

DTPA-HBV-IPV-135 (A.15MAR2018)

	. Bl. o nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb		Bl. nb		Bl. nb		Trt. Bl. No nb
PPD	65499	PPD	65540	PPD	65581	PPD	65622	PPD	65663	PPD	65704	PI	PD 65745
	65500		65541		65582	_	65623		65664		65705		6574
	65501		65542		65583		65624		65665		65706		6574
	65502		65543		65584		65625		65666		65707		65748
	65503		65544		65585		65626		65667		65708		6574
	65504		65545		65586		65627		65668		65709		65750
	65505		65546		65587		65628		65669		65710		6575
	65506		65547		65588		65629		65670		65711		65752
	65507		65548		65589		65630		65671		65712		65753
	65508		65549		65590		65631		65672		65713		6575
	65509		65550		65591		65632		65673		65714		6575
	65510		65551		65592		65633		65674		65715		6575
	65511		65552		65593		65634		65675		65716		6575
	65512		65553		65594		65635		65676		65717		65758
	65513		65554		65595		65636		65677		65718		65759
	65514		65555		65596		65637		65678		65719		65760
	65515		65556		65597		65638		65679		65720		65763
	65516		65557		65598		65639		65680		65721		65762
	65517		65558		65599		65640		65681		65722		65763
	65518		65559		65600		65641		65682		65723		65764
	65519		65560		65601		65642		65683		65724		6576
	65520 65521		65561 65562		65602 65603		65643 65644		65684 65685		65725 65726		6576
	65522		65563		65604		65645		65686		65727		6576°
	65523		65564		65605		65646		65687		65728		65769
	65524		65565		65606		65647		65688		65729		65770
	65525		65566		65607		65648		65689		65730		6577
	65526		65567		65608		65649		65690		65731		65772
	65527		65568		65609		65650		65691		65732		65773
	65528		65569		65610		65651		65692		65733		6577
	65529		65570		65611		65652		65693		65734		6577
	65530		65571		65612		65653		65694		65735		6577
	65531		65572		65613		65654		65695		65736		6577
	65532		65573		65614		65655		65696		65737		65778
	65533		65574		65615		65656		65697		65738		65779
	65534		65575		65616		65657		65698		65739		65780
	65535		65576		65617		65658		65699		65740		65783
	65536		65577		65618		65659		65700		65741		65782
	65537		65578		65619		65660		65701		65742		65783
	65538		65579		65620		65661		65702		65743		65784
	65539		65580		65621		65662		65703		65744		6578

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt	. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	. Bl.	Trt.	Bl.	Trt.	Bl.	Trt	. Bl.
N	o nb	No	nb	No	nb	No	nb	No	nb	No	nb	N	o nb
	65706	PPD	65007	PPD	65060	PPD	65000	DDD	65050	PPD	65.001	PPD	66000
PPD	65786	PPD	65827	FFD	65868	PPD	65909	PPD	65950		65991	FFD	66032
	65787		65828		65869		65910		65951		65992		66033
	65788		65829		65870		65911		65952		65993		66034
	65789		65830		65871		65912		65953		65994		66035
	65790		65831		65872		65913		65954		65995		66036
	65791		65832		65873		65914		65955		65996		66037
	65792		65833		65874		65915		65956		65997		66038
	65793		65834		65875		65916		65957		65998		66039
	65794		65835		65876		65917		65958		65999		66040
	65795		65836		65877		65918		65959		66000		66041
	65796		65837		65878		65919		65960		66001		66042
	65797		65838		65879		65920		65961		66002		66043
	65798		65839		65880		65921		65962		66003		66044
	65799		65840		65881		65922		65963		66004		66045
	65800		65841		65882		65923		65964		66005		66046
	65801		65842		65883		65924		65965		66006		66047
	65802		65843		65884		65925		65966		66007		66048
	65803		65844		65885		65926		65967		66008		66049
	65804		65845		65886		65927		65968		66009		66050
	65805		65846		65887		65928		65969		66010		66051
	65806		65847		65888		65929		65970		66011		66052
	65807		65848		65889		65930		65971		66012		66053
	65808		65849		65890		65931		65972		66013		66054
	65809		65850		65891		65932		65973		66014		66055
	65810		65851		65892		65933		65974		66015		66056
	65811		65852		65893		65934		65975		66016		66057
	65812		65853		65894		65935		65976		66017		66058
	65813		65854		65895		65936		65977		66018		66059
	65814		65855		65896		65937		65978		66019		66060
	65815		65856		65897		65938		65979		66020		66061
	65816		65857		65898		65939		65980		66021		66062
	65817		65858		65899		65940		65981		66022		66063
	65818		65859		65900		65941		65982		66023		66064
	65819		65860		65901		65942		65983		66024		66065
	65820		65861		65902		65943		65984		66025		66066
					65902								
	65821		65862				65944		65985		66026		66067
	65822		65863		65904		65945		65986		66027		66068
	65823		65864		65905		65946		65987		66028		66069
	65824		65865		65906		65947		65988		66029		66070
	65825		65866		65907		65948		65989		66030		66071
	65826		65867		65908		65949		65990		66031		66072
									-		_		

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.		Bl.	Trt.		Trt.		Trt.		Trt.	
No	nb	No nb		nb	No	nb	No	nb	NO	nb 	NO	nb
				_					PPD			_
PPD	66073	PPD 6611	4 PPD	66155	PPD	66196	PPD	66237	PPD	66278	PPD	66319
	66074	6611	5	66156		66197		66238		66279		66320
	66075	6611	6	66157		66198		66239		66280		66321
	66076	6611	7	66158		66199		66240		66281		66322
	66077	6611	8	66159		66200		66241		66282		66323
	66078	6611	9	66160		66201		66242		66283		66324
	66079	6612	0	66161		66202		66243		66284		66325
	66080	6612	1	66162		66203		66244		66285		66326
	66081	6612	2	66163		66204		66245		66286		66327
	66082	6612	3	66164		66205		66246		66287		66328
	66083	6612	4	66165		66206		66247		66288		66329
	66084	6612	5	66166		66207		66248		66289		66330
	66085	6612	6	66167		66208		66249		66290		66331
	66086	6612	7	66168		66209		66250		66291		66332
	66087	6612	8	66169		66210		66251		66292		66333
	66088	6612	9	66170		66211		66252		66293		66334
	66089	6613	0	66171		66212		66253		66294		66335
	66090	6613	1	66172		66213		66254		66295		66336
	66091	6613	2	66173		66214		66255		66296		66337
	66092	6613	3	66174		66215		66256		66297		66338
	66093	6613	4	66175		66216		66257		66298		66339
	66094	6613	5	66176		66217		66258		66299		66340
	66095	6613	6	66177		66218		66259		66300		66341
	66096	6613	7	66178		66219		66260		66301		66342
	66097	6613	8	66179		66220		66261		66302		66343
	66098	6613	9	66180		66221		66262		66303		66344
	66099	6614	0	66181		66222		66263		66304		66345
	66100	6614	1	66182		66223		66264		66305		66346
	66101	6614	2	66183		66224		66265		66306		66347
	66102	6614	3	66184		66225		66266		66307		66348
	66103	6614	4	66185		66226		66267		66308		66349
	66104	6614	5	66186		66227		66268		66309		66350
	66105	6614	6	66187		66228		66269		66310		66351
	66106	6614	7	66188		66229		66270		66311		66352
	66107	6614	8	66189		66230		66271		66312		66353
	66108	6614		66190		66231		66272		66313		66354
	66109	6615	0	66191		66232		66273		66314		66355
	66110	6615		66192		66233		66274		66315		66356
	66111	6615		66193		66234		66275		66316		66357
	66112	6615	3	66194		66235		66276		66317		66358
	66113	6615	4	66195		66236		66277		66318		66359

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt.		Trt.		Trt.		Trt.			Bl.	Trt.	
No	nb	No	nb	No		No	nb	No	nb	No	nb	No	nb
											•		
PPD	66360	PPD	66401	PPD	66442	PPD	66483	PPD	66524	PPD	66565	PPD	66606
	66361		66402		66443		66484		66525		66566		66607
	66362		66403		66444		66485		66526		66567	1	66608
	66363		66404		66445		66486		66527		66568		66609
	66364		66405		66446		66487		66528		66569		66610
	66365		66406		66447		66488		66529		66570	1	66611
	66366		66407		66448		66489		66530		66571		66612
	66367		66408		66449		66490		66531		66572	1	66613
	66368		66409		66450		66491		66532		66573		66614
	66369		66410		66451		66492		66533		66574	1	66615
	66370		66411		66452		66493		66534		66575	1	66616
	66371		66412		66453		66494		66535		66576		66617
	66372		66413		66454		66495		66536		66577		66618
	66373		66414		66455		66496		66537		66578	1	66619
	66374		66415		66456		66497		66538		66579		66620
	66375		66416		66457		66498		66539		66580		66621
	66376		66417		66458		66499		66540		66581	1	66622
	66377		66418		66459		66500		66541		66582		66623
	66378		66419		66460		66501		66542		66583	1	66624
	66379		66420		66461		66502		66543		66584		66625
	66380		66421		66462		66503		66544		66585	1	66626
	66381		66422		66463		66504		66545		66586	1	66627
	66382		66423		66464		66505		66546		66587		66628
	66383		66424		66465		66506		66547		66588		66629
	66384		66425		66466		66507		66548		66589		66630
	66385		66426		66467		66508		66549		66590		66631
	66386		66427		66468		66509		66550		66591	1	66632
	66387		66428		66469		66510		66551		66592	1	66633
	66388		66429		66470		66511		66552		66593		66634
	66389		66430		66471		66512		66553		66594		66635
	66390		66431		66472		66513		66554		66595		66636
	66391		66432		66473		66514		66555		66596		66637
	66392		66433		66474		66515		66556		66597	1	66638
	66393		66434		66475		66516		66557		66598	1	66639
	66394		66435		66476		66517		66558		66599		66640
	66395		66436		66477		66518		66559		66600		66641
	66396		66437		66478		66519		66560		66601		66642
	66397		66438		66479		66520		66561		66602		66643
	66398		66439		66480		66521		66562		66603		66644
	66399		66440		66481		66522		66563		66604		66645
	66400		66441		66482		66523		66564		66605		66646

DTPA-HBV-IPV-135 (A.15MAR2018)

	. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
N	o nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	66647	PPD 66688	PPD 66729	PPD 66770	PPD 66811	PPD 66852	PPD 66893
	66648	66689	66730	66771	66812	66853	66894
	66649	66690	66731	66772	66813	66854	66895
	66650	66691	66732	66773	66814	66855	66896
	66651	66692	66733	66774	66815	66856	66897
	66652	66693	66734	66775	66816	66857	66898
	66653	66694	66735	66776	66817	66858	66899
	66654	66695	66736	66777	66818	66859	66900
	66655	66696	66737	66778	66819	66860	66901
	66656	66697	66738	66779	66820	66861	66902
	66657	66698	66739	66780	66821	66862	66903
	66658	66699	66740	66781	66822	66863	66904
	66659	66700	66741	66782	66823	66864	66905
	66660	66701	66742	66783	66824	66865	66906
	66661	66702	66743	66784	66825	66866	66907
	66662	66703	66744	66785	66826	66867	66908
	66663	66704	66745	66786	66827	66868	66909
	66664	66705	66746	66787	66828	66869	66910
	66665	66706	66747	66788	66829	66870	66911
	66666	66707	66748	66789	66830	66871	66912
	66667	66708	66749	66790	66831	66872	66913
	66668	66709	66750	66791	66832	66873	66914
	66669	66710	66751	66792	66833	66874	66915
	66670 66671	66711 66712	66752 66753	66793 66794	66834 66835	66875 66876	66916 66917
	66672	66713	66754	66795	66835	66876	66917
	66673	66714	66755	66796	66837	66878	66918
	66674	66715	66756	66797	66838	66879	66920
	66675	66716	66757	66798	66839	66880	66921
	66676	66717	66758	66799	66840	66881	66922
	66677	66718	66759	66800	66841	66882	66923
	66678	66719	66760	66801	66842	66883	66924
	66679	66720	66761	66802	66843	66884	66925
	66680	66721	66762	66803	66844	66885	66926
	66681	66722	66763	66804	66845	66886	66927
	66682	66723	66764	66805	66846	66887	66928
	66683	66724	66765	66806	66847	66888	66929
	66684	66725	66766	66807	66848	66889	66930
	66685	66726	66767	66808	66849	66890	66931
	66686	66727	66768	66809	66850	66891	66932
	66687	66728	66769	66810	66851	66892	66933

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

No nb	Trt. Bl.			. Bl.		. Bl.		Bl.		Bl.		. Bl.		Bl.
69935 66976 670117 67058 67059 671140 67181 66936 66937 66938 66997 67018 67059 67100 671141 67182 66937 66938 66999 67020 67061 67102 67143 67184 66938 66999 67021 67062 67061 67102 67143 67184 66939 66990 67021 67062 67063 67104 67145 67186 66939 66990 67021 67062 67063 67104 67145 67186 66941 66982 67023 67063 67104 67145 67186 66941 66982 67023 67063 67106 67106 67147 67188 66944 66983 66984 67025 67065 67106 67107 67148 67189 66944 66985 67025 67063 67106 67147 67188 66944 66985 67027 67066 67067 67108 67149 67190 66945 66986 67027 67068 67067 67108 67149 67190 66946 66987 66988 67029 67028 67069 67110 67151 67192 66947 66988 67029 67023 67070 67111 67152 67153 67194 66949 66990 67031 67071 67112 67153 67194 66949 66990 67031 67072 67073 67114 67155 67196 66951 66992 67033 67074 67114 67155 67196 66951 66992 67033 67074 67116 67157 67198 66953 66994 67035 67093 67074 67118 67159 67156 67157 67198 66955 66996 67037 67078 67079 67116 67157 67158 67196 66955 66996 67037 67078 67079 67116 67157 67158 67196 66955 66996 67037 67078 67116 67157 67158 67196 66955 66996 67037 67078 67116 67157 67158 67196 66955 66996 67037 67078 67116 67157 67158 67196 66955 66996 67037 67078 67116 67157 67158 67196 66955 66996 67037 67078 67116 67157 67158 67196 66957 66998 67039 67030 67071 67118 67152 67156 67157 67158 67196 66955 66996 67037 67078 67116 67157 67158 67196 66955 66996 67037 67078 67116 67157 67158 67196 66955 66996 67037 67078 67116 67157 67158 67200 66956 66996 67037 67080 67091 67122 67163 67220 66956 66996 67007 67044 67085 67097 67120 67161 67220 66956 66996 67007 67044 67085 67099 67120 67161 67220 67066 67007 67044 67085 67099 67120 67161 67122 67163 67220 66966 67007 67044 67085 67099 67120 67161 67122 67163 67220 66966 67007 67044 67085 67099 67120 67161 67122 67163 67220 66966 67007 67044 67085 67099 67120 67161 67157 67220 66966 67007 67044 67085 67099 67120 67130 67171 67212 66966 67007 67048 67089 67099 67130 67171 67212 66966 67007 67048 67089 67099 67130 67171 67212 66967 67000 67041 67085 67099 671	No.	o nb	No.	o nb	N-	o nb	No.	nb	No	nb	No.	nb	No	nb
69935 66976 670117 67058 67059 671140 67181 66936 66937 66938 66997 67018 67059 67100 671141 67182 66937 66938 66999 67020 67061 67102 67143 67184 66938 66999 67021 67062 67061 67102 67143 67184 66939 66990 67021 67062 67063 67104 67145 67186 66939 66990 67021 67062 67063 67104 67145 67186 66941 66982 67023 67063 67104 67145 67186 66941 66982 67023 67063 67106 67106 67147 67188 66944 66983 66984 67025 67065 67106 67107 67148 67189 66944 66985 67025 67063 67106 67147 67188 66944 66985 67027 67066 67067 67108 67149 67190 66945 66986 67027 67068 67067 67108 67149 67190 66946 66987 66988 67029 67028 67069 67110 67151 67192 66947 66988 67029 67023 67070 67111 67152 67153 67194 66949 66990 67031 67071 67112 67153 67194 66949 66990 67031 67072 67073 67114 67155 67196 66951 66992 67033 67074 67114 67155 67196 66951 66992 67033 67074 67116 67157 67198 66953 66994 67035 67093 67074 67118 67159 67156 67157 67198 66955 66996 67037 67078 67079 67116 67157 67158 67196 66955 66996 67037 67078 67079 67116 67157 67158 67196 66955 66996 67037 67078 67116 67157 67158 67196 66955 66996 67037 67078 67116 67157 67158 67196 66955 66996 67037 67078 67116 67157 67158 67196 66955 66996 67037 67078 67116 67157 67158 67196 66955 66996 67037 67078 67116 67157 67158 67196 66957 66998 67039 67030 67071 67118 67152 67156 67157 67158 67196 66955 66996 67037 67078 67116 67157 67158 67196 66955 66996 67037 67078 67116 67157 67158 67196 66955 66996 67037 67078 67116 67157 67158 67200 66956 66996 67037 67080 67091 67122 67163 67220 66956 66996 67007 67044 67085 67097 67120 67161 67220 66956 66996 67007 67044 67085 67099 67120 67161 67220 67066 67007 67044 67085 67099 67120 67161 67122 67163 67220 66966 67007 67044 67085 67099 67120 67161 67122 67163 67220 66966 67007 67044 67085 67099 67120 67161 67122 67163 67220 66966 67007 67044 67085 67099 67120 67161 67157 67220 66966 67007 67044 67085 67099 67120 67130 67171 67212 66966 67007 67048 67089 67099 67130 67171 67212 66966 67007 67048 67089 67099 67130 67171 67212 66967 67000 67041 67085 67099 671											DDD			
66936 66977 67018 67059 67100 67141 67182 67183 66937 66978 67010 67060 67101 67142 67183 66938 66939 66980 67021 67061 67102 67143 67184 67185 67890 67020 67061 67103 67144 67185 67186 66940 66981 67022 67063 67104 67145 67185 67186 66941 66982 67023 67064 67105 67146 67185 67186 66941 66982 67023 67064 67105 67146 67187 67187 66942 66983 67024 67065 67106 67147 67188 66943 66984 67025 67066 67107 67148 67189 66944 66985 67026 67067 67108 67149 67189 67189 66944 66985 67026 67067 67108 67149 67189 67199 66946 66987 67028 67069 67110 67151 67191 67191 66946 66987 67068 67027 67068 67100 67151 67192 67193 66948 66989 67020 67070 67111 67152 67193 67194 66949 66990 67051 67072 67113 67192 67153 67194 66949 66990 67051 67072 67113 67155 67196 66951 66991 67032 67073 67114 67155 67195 66951 66992 67033 67074 67115 67195 67195 66951 66992 67034 67075 67116 67117 67115 67195 67195 66951 66992 67034 67075 67116 67117 67115 67195 67195 66951 66995 67034 67075 67116 67157 67198 66955 66994 67034 67075 67116 67157 67198 66955 66994 67036 67034 67077 67118 67155 67196 66955 66994 67036 67037 67078 67116 67157 67198 66955 66996 67037 67078 67116 67157 67198 66955 66996 67037 67078 67116 67157 67198 66955 66996 67037 67078 67119 67160 67201 66955 66996 67037 67078 67119 67160 67201 66955 66996 67037 67078 67119 67160 67201 66955 66996 67037 67078 67119 67160 67201 66955 66996 67037 67078 67119 67160 67201 66955 66996 67003 67044 67055 67126 67121 67162 67203 66956 66996 67003 67044 67085 67122 67163 67204 66955 67006 67044 67085 67086 67121 67162 67203 66956 66996 67001 67042 67083 67124 67165 67206 66966 67007 67044 67085 67124 67165 67206 66966 67007 67044 67085 67124 67165 67206 66966 67007 67044 67085 67124 67165 67206 66966 67007 67044 67085 67124 67165 67206 66966 67007 67044 67085 67124 67165 67206 66966 67007 67044 67085 67124 67165 67207 66966 67007 67044 67085 67124 67165 67207 66966 67007 67044 67085 67124 67165 67207 67044 67085 67124 67165 67207 67044 67085 67124 67165 67207 67044 67085 67124 67125 67163 67207	PPD	66934	PPD	66975	PPD	67016	PPD	67057	PPD	67098	PPD	67139	PPD	67180
66937 66978 67019 67060 67101 67142 67183 66938 66979 67020 67061 67102 67143 67184 66939 66980 66980 67021 67062 67103 67144 67185 66940 66981 67022 67063 67104 67145 67186 66941 66982 67023 67064 67105 67146 67186 67186 66941 66982 67023 67064 67105 67146 67187 67188 66942 66983 67024 67065 67106 67147 67188 67189 66944 66985 67025 67066 67107 67148 67189 66944 66985 67025 67066 67107 67148 67189 66945 66986 67027 67068 67109 67150 67190 67190 66945 66986 67027 67068 67109 67150 67191 67192 67190 66946 66987 67029 67069 67110 67151 67192 67190 66946 66987 67029 67070 67111 67112 67152 67193 66948 66989 67029 67070 67111 67112 67152 67193 66949 66990 67021 67072 67111 67112 67153 67194 66949 66990 67021 67072 67111 67112 67153 67194 66949 66991 67031 67072 67114 67155 67196 66951 66992 67033 67074 67114 67155 67196 66951 66992 67033 67074 67116 67116 67157 67198 66951 66992 67033 67074 67116 67117 67118 67159 67197 66952 66993 67034 67035 67074 67111 67112 67155 67197 66952 66993 67034 67035 67075 67116 67117 67118 67159 67197 66955 66956 66997 67036 67037 67077 67118 67159 67150 67250 66955 66996 67037 67038 67077 67118 67119 67150 67201 66956 66997 67030 6704 67081 67117 67118 67129 67201 66956 66997 67030 6704 67081 67112 67153 67164 67202 66957 66998 67030 67040 67081 67112 67163 67201 66956 66999 67040 67081 67119 67160 67201 66956 66999 67040 67081 67121 67162 67203 66956 66999 67040 67081 67082 67123 67164 67205 66956 66999 67040 67081 67082 67123 67164 67205 66956 66999 67044 67085 67086 67127 67163 67206 66966 67007 67044 67085 67086 67127 67163 67207 66966 67007 67044 67085 67129 67161 67207 66966 67007 67044 67085 67086 67127 67163 67207 66966 67007 67048 67089 67129 67160 67207 66966 67007 67044 67085 67086 67129 67160 67207 66966 67007 67044 67085 67129 67160 67207 66966 67007 67044 67085 67086 67129 67160 67207 66966 67007 67044 67085 67086 67129 67100 67111 67112 67121 67161 67208 66966 67007 67044 67085 67086 67129 67100 67111 67122 67088 67199 67100 67011 67048 67089 67130 67111 67112 67121 67		66935		66976		67017		67058		67099		67140		67181
66937 66978 67019 67060 67101 67142 67183 66938 66979 67020 67061 67102 67143 67184 66939 66980 66980 67021 67062 67103 67144 67185 66940 66981 67022 67063 67104 67145 67186 66941 66982 67023 67064 67105 67146 67186 67186 66941 66982 67023 67064 67105 67146 67187 67188 66942 66983 67024 67065 67106 67147 67188 67189 66944 66985 67025 67066 67107 67148 67189 66944 66985 67025 67066 67107 67148 67189 66945 66986 67027 67068 67109 67150 67190 67190 66945 66986 67027 67068 67109 67150 67191 67192 67190 66946 66987 67029 67069 67110 67151 67192 67190 66946 66987 67029 67070 67111 67112 67152 67193 66948 66989 67029 67070 67111 67112 67152 67193 66949 66990 67021 67072 67111 67112 67153 67194 66949 66990 67021 67072 67111 67112 67153 67194 66949 66991 67031 67072 67114 67155 67196 66951 66992 67033 67074 67114 67155 67196 66951 66992 67033 67074 67116 67116 67157 67198 66951 66992 67033 67074 67116 67117 67118 67159 67197 66952 66993 67034 67035 67074 67111 67112 67155 67197 66952 66993 67034 67035 67075 67116 67117 67118 67159 67197 66955 66956 66997 67036 67037 67077 67118 67159 67150 67250 66955 66996 67037 67038 67077 67118 67119 67150 67201 66956 66997 67030 6704 67081 67117 67118 67129 67201 66956 66997 67030 6704 67081 67112 67153 67164 67202 66957 66998 67030 67040 67081 67112 67163 67201 66956 66999 67040 67081 67119 67160 67201 66956 66999 67040 67081 67121 67162 67203 66956 66999 67040 67081 67082 67123 67164 67205 66956 66999 67040 67081 67082 67123 67164 67205 66956 66999 67044 67085 67086 67127 67163 67206 66966 67007 67044 67085 67086 67127 67163 67207 66966 67007 67044 67085 67129 67161 67207 66966 67007 67044 67085 67086 67127 67163 67207 66966 67007 67048 67089 67129 67160 67207 66966 67007 67044 67085 67086 67129 67160 67207 66966 67007 67044 67085 67129 67160 67207 66966 67007 67044 67085 67086 67129 67160 67207 66966 67007 67044 67085 67086 67129 67100 67111 67112 67121 67161 67208 66966 67007 67044 67085 67086 67129 67100 67111 67122 67088 67199 67100 67011 67048 67089 67130 67111 67112 67121 67		66936		66977		67018		67059		67100		67141		67182
66939 66980 67021 67062 67103 67144 67185 66940 66981 67022 67063 67104 67145 67186 66941 66982 67023 67064 67105 67146 67147 67188 66942 66983 67024 67065 67106 67147 67148 67186 66942 66983 67024 67065 67106 67107 67148 67189 66944 66985 67026 67026 67067 67108 67149 67149 67190 66944 66985 67026 67067 67108 67149 67149 67190 66946 66987 67028 67069 67110 67151 67192 66947 66988 67029 67070 67111 67152 67193 66948 66989 67030 67071 67112 67153 67194 66949 66990 67030 67071 67112 67153 67194 66949 66990 67031 67072 67113 67154 67195 66950 66991 67032 67073 67114 67155 67196 66951 66992 67033 67074 67115 67156 67197 66952 66993 67034 67075 67116 67157 67198 66953 66994 66999 67034 67075 67116 67157 67198 66953 66994 67035 67034 67075 67116 67157 67198 66953 66994 67035 67036 67077 67118 67157 67198 66953 66994 67035 67036 67077 67118 67157 67198 66953 66994 67035 67036 67077 67118 67157 67198 66953 66994 67035 67036 67077 67118 67157 67198 66953 66994 67035 67036 67077 67118 67159 67159 67200 66955 66993 67037 67038 67077 67118 67159 67150 67201 66955 66996 67037 67038 67077 67118 67159 67160 67201 66955 66996 67037 67038 67077 67118 67159 67160 67201 66956 66999 67000 67041 67082 67127 67163 67200 66958 66999 67000 67041 67082 67122 67163 67200 66958 66999 67000 67041 67082 67123 67164 67202 66958 66999 67000 67041 67082 67123 67164 67202 67066 67001 67042 67083 67084 67122 67163 67204 66959 67003 67044 67085 67086 67127 67168 67207 67046 67047 67088 67129 67120 67161 67202 66966 67007 67044 67045 67086 67127 67168 67207 67046 67047 67088 67129 67120 671167 67208 66960 67001 67042 67088 67129 67120 671167 67208 66960 67001 67042 67088 67129 67120 671167 67208 66960 67001 67042 67088 67129 67120 671167 67208 66962 67003 67004 67045 67086 67127 67168 67127 67168 67207 67048 67099 67120 67110 67122 67123 67144 67125 67166 67007 67044 67045 67086 67127 67168 67127 67168 67207 67044 67045 67086 67124 67165 67207 67046 67047 67088 67129 67120 67110 67121 67122 67133 67114 67122 67203 66960 67001 67001 67005 67099 67		66937		66978		67019		67060		67101		67142		67183
66940 66981 67022 67063 67104 67145 67186 66941 66982 67023 67064 67105 67146 67187 67188 66942 66983 67024 67065 67106 67147 67188 66943 66984 67025 67025 67066 67107 67148 67189 66944 66985 67026 67027 67066 67107 67148 67189 66944 66985 67027 67086 67067 67109 67149 67190 66945 66986 67027 67088 67100 67140 67140 67190 66945 66986 67027 67088 67069 67110 67151 67192 66947 66988 67029 67070 67111 67152 67133 67194 66948 66989 67030 67071 67112 67152 67193 66948 66989 67030 67071 67112 67155 67196 66950 66991 67031 67072 67113 67154 67195 66950 66991 67032 67073 67144 67155 67196 66952 66993 67034 67074 67115 67156 67197 66952 66993 66994 67035 67076 67117 67158 67199 66954 66995 66994 67035 67076 67117 67158 67199 66954 66995 66994 67035 67036 67077 67118 67157 67198 66954 66995 66996 67037 67038 67076 67117 67158 67199 66954 66995 66996 67037 67038 67076 67117 67158 67199 66954 66995 66996 67037 67038 67077 67118 67159 67200 66955 66996 67037 67038 67079 67120 67161 67201 67060 67201 66956 66997 67030 67040 67080 67121 67160 67201 66958 66999 67000 67041 67082 67120 67161 67202 66958 66999 67000 67041 67082 67123 67164 67203 66958 66999 67000 67041 67082 67123 67164 67205 66958 66999 67000 67041 67082 67123 67164 67205 66958 66999 67000 67041 67082 67123 67164 67205 66958 66999 67000 67041 67082 67123 67164 67205 66958 66999 67000 67041 67082 67123 67164 67205 66958 66999 67000 67041 67082 67123 67164 67205 66958 66999 67000 67041 67082 67123 67164 67205 66968 67007 67048 67089 67120 67161 67202 67068 66960 67001 67044 67085 67125 67166 67127 67168 67204 66968 67007 67044 67089 67120 67161 67122 67163 67204 66968 67007 67044 67089 67120 67161 67122 67163 67204 66968 67007 67044 67089 67120 67161 67122 67163 67204 66968 67007 67044 67089 67120 67161 67122 67163 67204 66968 67007 67044 67089 67120 67161 67122 67163 67204 66968 67007 67044 67089 67120 67131 67122 67163 67171 67212 66967 67008 67004 67049 67099 67131 67122 67163 67171 67212 66967 67001 67044 67055 67096 67131 67174 67212 66972 67003 67004 67055		66938		66979		67020		67061		67102		67143		67184
66941 66982 67023 67064 67105 67146 67187 67188 66942 66983 67024 67065 67106 671147 67188 66943 66944 66985 67026 67026 67066 67107 67148 67189 66944 66985 67026 67027 67068 67109 67150 671191 66946 66946 66987 67028 67029 67070 67111 67151 67192 67028 67089 67100 67151 67192 67029 67070 67111 67152 67193 66948 66989 67030 67071 67012 670153 67194 66949 66990 67030 67071 67012 670155 67196 66951 66991 67032 67033 67074 67114 67155 67196 66951 66991 67032 67033 67074 67115 67155 67196 66951 66992 67033 67074 67115 67155 67196 66953 66994 67035 67036 67077 67116 67157 67188 67199 66953 66994 67035 67036 67077 67118 67159 67159 67159 66955 66996 67037 67037 67078 67110 67151 67152 67198 66955 66996 67037 67038 67077 67118 67159 67200 66955 66996 67037 67038 67077 67118 67159 67200 66955 66996 67037 67038 67077 67118 67159 67200 66955 66996 67037 67038 67079 67120 67160 67201 66956 66997 67030 67040 67080 67121 67152 67202 66957 66998 67030 67040 67080 67121 67162 67202 66958 66999 67000 67041 67082 67123 67164 67202 66958 66999 67000 67041 67082 67123 67164 67202 66958 66999 67000 67041 67082 67123 67164 67202 66958 66999 67000 67041 67082 67123 67164 67205 66960 67001 67042 67083 67124 67165 67207 66962 67003 67044 67085 67126 67167 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67096 67131 67117 67128 66970 67011 67052 67053 67096 67131 67117 67128 66971 67004 67		66939		66980		67021		67062		67103		67144		67185
66942 66983 66984 67025 67066 67107 67148 67189 66944 66985 67025 67026 67067 67108 67149 67190 66945 66986 67027 67068 67109 67150 67149 67190 66945 66986 67027 67068 67109 67150 67151 67192 66946 66987 67028 67028 67070 67111 67151 67192 67193 66948 66989 67030 67071 67111 67152 67194 66949 66990 67030 67071 67112 67153 67194 66991 66991 67030 67031 67072 67113 67154 67195 66991 66991 67032 67073 67114 67155 67196 66991 66992 67033 67074 67115 67155 67196 66991 66993 67033 67074 67115 67155 67196 66991 66992 67033 67074 67115 67156 67197 66992 66993 67034 67075 67116 67157 67198 66993 66994 66999 67035 67076 67117 67158 67199 66995 66995 66994 67035 67076 67117 67158 67199 66995 66995 66996 67037 67078 67117 67158 67199 66995 66995 66996 67037 67078 67119 67160 67201 66995 66997 67038 67079 67120 67161 67202 66997 67039 67040 67091 67120 67161 67202 66995 67000 67041 67082 67099 67120 67161 67202 66995 67000 67044 67081 67122 67163 67204 66999 67000 67041 67082 67122 67163 67204 67205 66995 67000 67044 67081 67122 67163 67204 66999 67000 67041 67082 67122 67163 67204 67205 66995 67000 67044 67081 67122 67163 67204 66999 67000 67044 67081 67122 67163 67204 67205 66995 67003 67044 67085 67124 67165 67207 67208 66999 67000 67044 67081 67122 67163 67204 67205 66995 67003 67044 67085 67086 67127 67168 67207 66962 67003 67044 67085 67086 67127 67168 67207 66962 67003 67004 67045 67085 67126 67167 67208 66963 67004 67004 67085 67086 67127 67168 67207 66962 67003 67004 67045 67085 67126 67167 67208 66963 67004 67005 67004 67085 67124 67125 67166 67207 67208 66963 67004 67005 67044 67085 67124 67125 67166 67207 67208 66963 67004 67005 67004 67085 67124 67125 67166 67207 67208 66966 67007 67044 67085 67124 67125 67166 67207 67208 66966 67007 67044 67085 67124 67125 67167 67208 66966 67007 67044 67085 67124 67125 67167 67208 66966 67007 67048 67004 67089 67130 67171 67212 66966 67007 67008 67004 67085 67094 67133 67174 67212 66971 67005 67004 67005 67005 67004 67005 67004 67005 67004 67005 67004 67005 67004 67005 67004		66940		66981		67022		67063		67104		67145		67186
66943 66984 67025 67066 67107 67148 67189 67190 66945 66986 67027 67068 67109 67150 67191 66946 66987 67028 67029 67070 67111 67152 67193 66948 66989 67030 67071 67112 67153 67194 66949 66949 66990 67030 67071 67112 67153 67195 66951 66996 67031 67029 67070 67111 67112 67153 67195 66952 66993 67030 67074 67115 67155 67166 67197 66952 66993 67033 67074 67115 67155 67156 67197 66952 66993 67034 67035 67074 67115 67158 67197 66953 66994 67033 67074 67115 67156 67157 67198 66953 66994 67033 67074 67115 67156 67157 67198 66953 66994 67035 67076 67117 67158 67156 67197 67198 66953 66994 67035 67076 67117 67158 67156 67197 67198 66955 66996 67037 67070 67111 67112 67158 67190 66954 66995 67036 67077 67118 67159 67200 66955 66996 67037 67078 67119 67160 67201 66956 66997 67038 67099 67120 67161 67122 67163 67204 66959 67090 67001 67001 67002 67001 67002 67001 67002 67003 67004 67112 67162 67203 66959 67000 67001 67004 67001 67002 67004 67002 67004 67002 67003 67004 67002 67003 67004 67002 67003 67004 67002 67003 67004 67002 67003 67004 67002 67003 67004 67002 67003 67004 67002 67003 67004 67002 67003 67104 67002 67003 67104 67002 67003 67104 67002 67003 67104 67002 67003 67104 67002 67003 67104 67002 67003 67104 67002 67003 67104 67002 67003 67104 67002 67003 67104 67002 67003 67104 67002 67003 67104 67002 67003 67104 67002 67003 67104 67002 67003 67104 67005 67104 67102 67103 67104 67102 67103 67104 67102 67103 67104 67102 67103 67104 67102 67103 67104 67102 67103 67104 67102 67103 67104 67102 67103 67104 67102 67103 67104 67102 67103 67104 67102 67103 67104 67102 67113 67112 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67114 67112 67113 67114 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67111 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67112 67113 67114 67112 67113 67112 67113 67114 67112 67113 67114 67112 67113 67114		66941		66982		67023		67064		67105		67146		67187
66944 66985 67027 67088 67109 67150 67191 66945 66946 66987 67027 67088 67109 67150 67191 66946 66947 66988 67029 67070 67111 67152 67193 66948 66989 67030 67011 67112 67153 67194 66948 66989 67030 67071 67111 67152 67193 66949 66990 67031 67072 67113 67154 67195 67196 66951 66991 67032 67033 67044 67115 67155 67196 66951 66992 67033 67044 67115 67155 67196 66952 66993 67034 67035 67075 67116 67157 67198 66953 66994 67035 67036 67077 67118 67157 67198 66953 66994 67035 67036 67077 67118 67157 67199 66955 66956 66995 67037 67038 67077 67118 67159 67120 67159 66955 66996 67037 67038 67077 67118 67159 67200 66955 66996 67037 67038 67077 67118 67159 67120 67161 67202 67039 67039 67039 67039 67020 67121 67162 67202 67039 67039 67039 67039 67020 67121 67162 67202 67039 67039 67040 67081 67122 67163 67204 66959 67000 67001 67042 67082 67123 67164 67204 66959 67000 67001 67042 67082 67123 67164 67204 66959 67003 67004 67081 67122 67163 67204 66959 67003 67004 67044 67085 67126 67127 67168 67204 66959 67000 67001 67042 67083 67084 67122 67163 67204 66959 67000 67001 67042 67083 67084 67125 67166 67207 66962 67003 67044 67085 67126 67127 67168 67204 66959 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66964 67005 67044 67085 67126 67127 67168 67207 66964 67005 67044 67085 67086 67127 67168 67207 66964 67005 67044 67085 67126 67127 67168 67207 66965 67006 67047 67088 67129 67130 67171 67211 66966 67007 67048 67049 67090 67131 67122 67170 67211 66966 67007 67048 67049 67090 67131 67122 67170 67211 66966 67007 67048 67049 67090 67131 67122 67170 67211 66967 67008 67044 67085 67126 67130 67171 67211 66967 67008 67044 67085 67090 67131 67172 67213 66970 67000 67011 67082 67090 67031 67132 67171 67211 66970 67011 67032 67033 67044 67085 67135 67136 67171 67213 66971 67012 67033 67044 67085 67135 67176 67217 67090 67011 67032 67093 67133 67174 67213 66970 67010 67011 67052 67053 67094 67135		66942		66983		67024		67065		67106		67147		67188
66945 66986 67027 67068 67109 67150 67191 66946 66947 66988 67028 67069 67070 67111 67152 67193 66948 66988 67029 67070 67071 67111 67152 67193 66948 66989 67030 67071 67072 67113 67154 67155 67194 66950 66950 66991 67032 67073 67074 67115 67155 67196 66951 66992 67034 67034 67074 67115 67155 67196 66951 66992 67034 67035 67074 67115 67156 67197 66953 66994 67035 67034 67075 67116 67157 67188 67199 66954 66995 67035 67036 67077 67118 67158 67199 66955 66996 67037 67038 67119 67120 67161 67202 66956 66997 67038 67039 67080 67121 67160 67201 67058 66999 67040 67041 67081 67122 67163 67204 66959 67000 67041 67082 67123 67164 67205 66960 67001 67042 67083 67124 67123 67164 67205 66961 67002 67044 67085 67084 67125 67166 67207 66962 67003 67044 67085 67123 67164 67205 66961 67002 67044 67085 67125 67123 67164 67205 66961 67001 67042 67083 67124 67165 67206 66961 67001 67042 67083 67124 67165 67206 66961 67001 67042 67083 67124 67165 67206 66961 67001 67042 67083 67124 67165 67206 66961 67002 67044 67085 67123 67164 67205 66962 67003 67044 67085 67123 67164 67205 66962 67003 67044 67085 67125 67166 67207 66962 67003 67044 67085 67125 67166 67207 66962 67003 67044 67085 67125 67126 67167 67208 66963 67004 67044 67085 67127 67168 67206 66963 67004 67044 67085 67125 67166 67107 67218 66965 67004 67044 67085 67127 67168 67209 66964 67005 67044 67085 67127 67168 67206 66966 67007 67048 67049 67088 67127 67168 67207 67218 66966 67007 67048 67049 67089 67130 67171 67211 66966 67007 67048 67059 67133 67114 67212 67213 66967 67008 67049 67050 67091 67132 67173 67214 66968 67007 67048 67050 67051 67059 67133 67174 67213 66972 67013 67054 67055 67094 67135 67135 67176 67217 67218 66973 67013 67054 67055 67094 67135 67135 67176 67217 67218 66973 67013 67054 67055 67096 67133 67174 67218 66973 67013 67054 67055 67096 67133 67174 67218 66973 67013 67054 67055 67096 67133 67174 67218 66973 67013 67054 67055 67096 67137 67138 67217 67218 66973 67013 67054 67055 67096 67137 67138 67217 67218 66973 67013 67054 67055 67096 67137 67138		66943		66984		67025		67066		67107		67148		67189
66946 66987 67028 67069 67110 67151 67152 67193 66947 66988 67029 67070 67111 67152 67193 66948 66949 66990 67031 67072 67113 67154 67155 67194 66950 66950 66991 67032 67073 67114 67115 67155 67196 66951 66992 67033 67074 67115 67115 67156 67197 66952 66993 67034 67075 67116 67115 67156 67197 66953 66994 67035 67076 67117 67158 67199 66955 66995 66994 67035 67076 67117 67158 67199 66955 66956 66995 67037 67076 67117 67158 67199 66955 66956 66997 67038 67079 67118 67159 67200 66957 66998 67039 67080 67081 67122 67163 67204 66958 66999 67000 67041 67082 67123 67164 67205 66958 66999 67000 67041 67082 67123 67164 67205 66960 67001 67002 67043 67084 67125 67166 67207 67206 66960 67001 67002 67044 67085 67124 67155 67166 67207 66966 67003 67004 67044 67082 67123 67164 67205 66961 67002 67043 67084 67125 67165 67166 67207 67206 66961 67002 67043 67084 67125 67166 67207 67206 66963 67004 67045 67044 67085 67124 67165 67206 66961 67002 67043 67084 67125 67166 67207 67206 66963 67004 67044 67085 67124 67165 67206 66964 67005 67044 67085 67186 67127 67168 67207 67206 66963 67004 67045 67046 67087 67128 67167 67208 66964 67005 67046 67087 67128 67169 67211 67212 67206 66966 67007 67048 67089 67120 67171 67212 66966 67007 67048 67089 67120 67171 67212 66966 67007 67048 67089 67130 67171 67212 66966 67007 67048 67089 67130 67171 67212 66966 67007 67048 67089 67130 67171 67212 66966 67007 67048 67089 67130 67171 67212 66968 67009 67000 67051 67092 67133 67174 67212 66969 67010 67051 67052 67093 67133 67174 67212 66971 67012 67053 67054 67095 67133 67174 67212 66971 67012 67053 67054 67095 67135 67175 67217 67218 66972 67013 67014 67055 67095 67133 67174 67212 66972 67013 67014 67055 67095 67133 67174 67212 66973 67014 67055 67055 67095 67133 67174 67212 66973 67013 67014 67055 67095 67095 67133 67174 67212 66973 67013 67014 67055 67095 67133 67174 67212 66973 67013 67014 67055 67095 67095 67133 67174 67217 66972 67013 67014 67055 67095 67133 67174 67217 66972 67013 67014 67055 67095 67133 67174 67217		66944		66985		67026		67067		67108		67149		67190
66947 66988 67029 67070 67111 67152 67193 66948 66949 66989 67030 67071 67072 67113 67153 67194 66949 66990 67031 67072 67113 671154 67155 67196 66951 66991 67032 67073 67114 67155 67196 66951 66992 67033 67074 67115 67155 67196 66952 66993 67034 67075 67116 67157 67198 66954 66995 66995 67036 67077 67118 67157 67198 67199 66954 66995 67036 67077 67078 67117 67158 67199 66955 66996 67037 67078 67119 67160 67201 66956 66957 66998 67039 67080 67121 67162 67203 66958 66998 67039 67080 67121 67162 67203 66959 67000 67041 67082 67123 67164 67205 66960 67001 67002 67041 67082 67123 67164 67205 66961 67002 67003 67044 67085 67124 67165 67206 66961 67003 67044 67085 67126 67126 67167 67208 66962 67003 67044 67085 67126 67126 67167 67208 66963 67004 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67127 67168 67207 66962 67003 67044 67085 67126 67167 67208 66963 67004 67005 67044 67085 67126 67167 67208 66963 67004 67005 67044 67085 67126 67167 67208 66964 67005 67046 67087 67088 67127 67168 67207 67208 66966 67007 67048 67089 67120 67113 67172 67211 66966 67007 67008 67049 67089 67130 67171 67212 66968 67009 67000 67051 67049 67089 67130 67171 67212 66968 67009 67000 67051 67052 67093 67131 67172 67211 66968 67009 67001 67053 67054 67089 67133 67174 67212 66969 67010 67051 67052 67093 67133 67174 67212 66969 67010 67051 67052 67093 67133 67174 67212 66969 67010 67051 67052 67093 67133 67174 67212 66972 67013 67014 67055 67094 67095 67133 67174 67212 66972 67013 67014 67055 67094 67095 67133 67174 67212 66972 67013 67014 67055 67094 67095 67133 67174 67212 66972 67013 67014 67055 67094 67095 67133 67174 67212 66972 67013 67014 67055 67094 67095 67133 67174 67212 66972 67013 67014 67055 67094 67095 67133 67174 67212 66972 67013 67014 67055 67094 67095 67133 67174 67212 66972 67013 67014 67055 67094 67095 67133 67174 67212 66973 67013 67014 67055 67095 67135 67176 67177 67218 66972 67013 67014 67055 67095 67135 67136 67177 67218 66973 67014 67055 67095 67095		66945		66986		67027		67068		67109		67150		67191
66948 66989 67030 67071 67112 67112 67153 67194 66949 66990 67031 67072 67113 67154 67195 66950 66991 67032 67073 67114 67155 67196 66951 66992 67033 67074 67115 67156 67197 66952 66993 67034 67075 67116 67157 67118 66953 66994 67035 67076 67117 67158 67159 66954 66995 67036 67077 67118 67159 67200 66955 66996 67037 67078 67119 67150 67150 66956 66997 67038 67099 67120 67161 67202 66957 66998 67039 67040 67081 67122 67163 67204 66959 67000 67041 67082 67123 67164 67205 66960 67001 67041 67082 67123 67164 67205 66960 67001 67044 67085 67124 67155 67166 66961 67002 67043 67084 67125 67166 67207 66962 67003 67044 67085 67126 67126 67166 67207 66963 67004 67045 67084 67125 67166 67207 66964 67005 67046 67045 67086 67127 67168 67208 66965 67006 67007 67048 67087 67128 67169 67210 66966 67007 67048 67089 67120 67111 67122 66967 67008 67009 67048 67089 67120 67111 67212 66968 67009 67000 6704 67085 67126 67127 67168 67200 66968 67000 67001 67045 67086 67127 67168 67200 66969 67000 67048 67089 67120 67111 67212 66969 67000 67049 67050 67091 67131 67172 67213 66968 67009 67001 67051 67089 67120 67117 67212 66969 67010 67051 67092 67133 67114 67212 66969 67011 67052 67093 67134 671175 67218 66970 67011 67053 67054 67095 67136 67177 67218 66971 67012 67053 67094 67135 67176 67217 66972 67013 67054 67055 67095 67136 67177 67218 66972 67013 67054 67055 67095 67136 67177 67218 66972 67013 67054 67055 67095 67136 67177 67218 66973 67014 67055 67095 67095 67136 67177 67218 66971 67012 67053 67054 67095 67136 67177 67218 66972 67013 67054 67055 67095 67136 67177 67218 66972 67013 67054 67055 67095 67136 67177 67218 66972 67013 67054 67055 67095 67136 67177 67218 66973 67014 67055 67095 67095 67136 67177 67218		66946		66987		67028		67069		67110		67151		67192
66949 66900 67031 67072 67113 67154 67195 66950 66991 67032 67073 67114 67155 67196 66951 66992 67033 67074 67115 67156 67197 66952 66993 67034 67075 67116 67157 67198 66954 66995 67035 67076 67117 67158 67199 66955 66996 67037 67078 67119 67160 67201 66956 66997 67038 67079 67120 67161 67202 66957 66998 67039 67080 67121 67162 67203 66958 66999 67040 67081 67122 67163 67204 66959 67000 67041 67082 67123 67164 67205 66950 67001 67042 67083 67124 67165 67206 66961 67002 <		66947		66988		67029		67070		67111		67152		67193
66950 66991 67032 67073 67114 67155 67196 66951 66992 67033 67074 67115 67115 67156 67197 67198 66952 66993 67034 67035 67076 67116 67117 67158 67198 67199 66953 66994 67035 67076 67117 67158 67199 67200 67055 67036 67077 67118 67159 67200 67201 67050 67095 67036 67077 67118 67159 67200 67201 670000		66948		66989		67030		67071		67112		67153		67194
66951 66992 67033 67074 67115 67156 67197 66952 66993 67034 67075 67116 67157 67198 66953 66994 67035 67076 67117 67158 67199 66954 66995 67036 67077 67118 67159 67200 66955 66996 67037 67078 67119 67160 67201 66956 66997 67038 67079 67120 67161 67202 66957 66998 67039 67080 67121 67162 67203 66958 66999 67040 67081 67122 67163 67204 66959 67000 67041 67082 67123 67164 67205 66960 67001 67042 67083 67124 67165 67206 66961 67003 67044 67085 67126 67167 67168 67220 66962 <		66949		66990		67031		67072		67113		67154		67195
66952 66993 67034 67075 67116 67157 67198 66953 66994 67035 67076 67117 67158 67199 66954 66995 67036 67077 67118 671159 67159 66955 66996 67037 67078 67119 67160 67201 66956 66997 67038 67079 67120 67161 67202 66957 66998 67039 67080 67121 67162 67202 66958 66999 67040 67081 67122 67163 67204 66959 67000 67041 67082 67123 67164 67205 66950 67001 67042 67083 67124 67165 67205 66961 67002 67043 67084 67125 67166 67207 66962 67003 67044 67085 67126 67167 67208 66963 67004		66950		66991		67032		67073		67114		67155		67196
66953 66994 67035 67076 67117 67158 67199 66954 66995 67036 67077 67118 67159 67200 66955 66996 67037 67078 67119 67160 67201 66956 66997 67038 67079 67120 67161 67202 66957 66998 67039 67080 67121 67162 67203 66958 66999 67040 67081 67122 67163 67204 66959 67000 67041 67082 67123 67164 67205 66960 67001 67042 67083 67124 67165 67206 66961 67002 67043 67084 67125 67166 67207 66962 67003 67044 67085 67126 67167 67208 66963 67004 67045 67086 67127 67168 67220 66964 67005 <		66951		66992		67033		67074		67115		67156		67197
66954 66995 67036 67077 67118 67159 67200 66955 66996 67037 67078 67119 67160 67201 66956 66997 67038 67079 67120 67161 67202 66957 66998 67039 67080 67121 67162 67203 66958 66999 67040 67081 67122 67163 67204 66959 67000 67041 67082 67123 67164 67205 66960 67001 67042 67083 67124 67165 67206 66961 67002 67043 67084 67125 67166 67207 66962 67003 67044 67085 67126 67167 67208 66963 67004 67045 67086 67127 67168 67209 66964 67005 67046 67087 67128 67169 67171 66965 67006 <		66952		66993		67034		67075		67116		67157		67198
66955 66996 67037 67078 67119 67160 67201 66956 66997 67038 67079 67120 67161 67202 66957 66998 67039 67080 67121 67162 67203 66958 66999 67040 67081 67122 67163 67204 66959 67000 67041 67082 67123 67164 67205 66960 67001 67042 67083 67124 67165 67206 66961 67002 67043 67084 67125 67166 67207 66962 67003 67044 67085 67126 67167 67208 66963 67004 67045 67086 67127 67168 67209 66964 67005 67046 67087 67128 67169 67110 66965 67006 67047 67088 67129 67170 67211 66966 67007 <		66953		66994		67035		67076		67117		67158		67199
66956 66997 67038 67079 67120 67161 67202 66957 66998 67039 67080 67121 67162 67203 66958 66999 67040 67081 67122 67163 67204 66959 67000 67041 67082 67123 67164 67205 66960 67001 67042 67083 67124 67165 67206 66961 67002 67043 67084 67125 67166 67207 66962 67003 67044 67085 67126 67167 67208 66963 67004 67045 67086 67127 67168 67209 66964 67005 67046 67087 67128 67169 67210 66965 67006 67047 67088 67129 67170 67211 66966 67007 67048 67089 67130 67171 67212 66967 67088 <		66954		66995		67036		67077		67118		67159		67200
66957 66998 67039 67080 67121 67162 67203 66958 66999 67040 67081 67122 67163 67204 66959 67000 67041 67082 67123 67164 67205 66960 67001 67042 67083 67124 67165 67206 66961 67002 67043 67084 67125 67166 67207 66962 67003 67044 67085 67126 67167 67208 66963 67004 67045 67086 67127 67168 67209 66964 67005 67046 67087 67128 67169 67210 66965 67006 67047 67088 67129 67170 67211 66966 67007 67048 67089 67130 67171 67212 66967 67008 67009 67131 67172 6713 67213 66968 67009 <t< td=""><td></td><td>66955</td><td></td><td>66996</td><td></td><td>67037</td><td></td><td>67078</td><td></td><td>67119</td><td></td><td>67160</td><td></td><td>67201</td></t<>		66955		66996		67037		67078		67119		67160		67201
66958 66999 67040 67081 67122 67163 67204 66959 67000 67041 67082 67123 67164 67205 66960 67001 67042 67083 67124 67165 67206 66961 67002 67043 67084 67125 67166 67207 66962 67003 67044 67085 67126 67167 67208 66963 67004 67045 67086 67127 67168 67209 66964 67005 67046 67087 67128 67169 67210 66965 67006 67047 67088 67129 67170 67211 66966 67007 67048 67089 67130 67171 67212 66967 67008 67049 67090 67131 67172 67213 66968 67009 67051 67092 67133 67174 67214 66970 67011 <		66956		66997		67038		67079		67120		67161		67202
66959 67000 67041 67082 67123 67164 67205 66960 67001 67042 67083 67124 67165 67206 66961 67002 67043 67084 67125 67166 67207 66962 67003 67044 67085 67126 67167 67208 66963 67004 67045 67086 67127 67168 67209 66964 67005 67046 67087 67128 67169 67210 66965 67006 67047 67088 67129 67170 67211 66966 67007 67048 67089 67130 67171 67212 66967 67008 67049 67090 67131 67172 67213 66968 67009 67051 67092 67133 67174 67215 66969 67010 67051 67092 67133 67174 67216 66971 67012 <		66957		66998		67039		67080		67121		67162		67203
66960 67001 67042 67083 67124 67165 67206 66961 67002 67043 67084 67125 67166 67207 66962 67003 67044 67085 67126 67167 67208 66963 67004 67045 67086 67127 67168 67209 66964 67005 67046 67087 67128 67169 67210 66965 67006 67047 67088 67129 67170 67211 66966 67007 67048 67089 67130 67171 67212 66967 67008 67049 67090 67131 67172 67213 66968 67009 67051 67091 67132 67173 67214 66969 67010 67051 67092 67133 67174 67215 66971 67011 67052 67093 67134 67175 67216 66971 67013 <		66958		66999		67040		67081		67122		67163		67204
66961 67002 67043 67084 67125 67166 67207 66962 67003 67044 67085 67126 67167 67208 66963 67004 67045 67086 67127 67168 67209 66964 67005 67046 67087 67128 67169 67210 66965 67006 67047 67088 67129 67170 67211 66966 67007 67048 67089 67130 67171 67212 66967 67008 67049 67090 67131 67172 67213 66968 67009 67050 67091 67132 67173 67214 66970 67011 67052 67093 67134 67175 67216 66971 67012 67053 67094 67135 67176 67217 66972 67013 67054 67095 67136 67177 67218 66973 67014 <		66959		67000		67041		67082		67123		67164		67205
66962 67003 67044 67085 67126 67167 67208 66963 67004 67045 67086 67127 67168 67209 66964 67005 67046 67087 67128 67169 67210 66965 67006 67047 67088 67129 67170 67211 66966 67007 67048 67089 67130 67171 67212 66967 67008 67049 67090 67131 67172 67213 66968 67009 67050 67091 67132 67173 67214 66969 67010 67051 67092 67133 67174 67215 66970 67011 67052 67093 67134 67175 67216 66971 67012 67053 67094 67135 67176 67217 66973 67014 67055 67095 67136 67177 67218 66973 67014 <		66960		67001		67042		67083		67124		67165		67206
66963 67004 67045 67086 67127 67168 67209 66964 67005 67046 67087 67128 67169 67210 66965 67006 67047 67088 67129 67170 67211 66966 67007 67048 67089 67130 67171 67212 66967 67008 67049 67090 67131 67172 67213 66968 67009 67050 67091 67132 67173 67214 66969 67010 67051 67092 67133 67174 67215 66970 67011 67052 67093 67134 67175 67216 66971 67012 67053 67094 67135 67176 67217 66972 67013 67054 67095 67136 67177 67218 66973 67014 67055 67096 67137 67178 67218		66961		67002		67043		67084		67125		67166		67207
66964 67005 67046 67087 67128 67169 67210 66965 67006 67047 67088 67129 67170 67211 66966 67007 67048 67089 67130 67171 67212 66967 67008 67049 67090 67131 67172 67213 66968 67009 67050 67091 67132 67173 67214 66969 67010 67051 67092 67133 67174 67215 66970 67011 67052 67093 67134 67175 67216 66971 67012 67053 67094 67135 67176 67217 66972 67013 67054 67095 67136 67177 67218 66973 67014 67055 67096 67137 67178 67219		66962		67003		67044		67085		67126		67167		67208
66965 67006 67047 67088 67129 67170 67211 66966 67007 67048 67089 67130 67171 67212 66967 67008 67049 67090 67131 67172 67213 66968 67009 67050 67091 67132 67173 67214 66969 67010 67051 67092 67133 67174 67215 66970 67011 67052 67093 67134 67175 67216 66971 67012 67053 67094 67135 67176 67217 66972 67013 67054 67095 67136 67177 67218 66973 67014 67055 67096 67137 67178 67219		66963				67045		67086						
66966 67007 67048 67089 67130 67171 67212 66967 67008 67049 67090 67131 67172 67213 66968 67009 67050 67091 67132 67173 67214 66969 67010 67051 67092 67133 67174 67215 66970 67011 67052 67093 67134 67175 67216 66971 67012 67053 67094 67135 67176 67217 66972 67013 67054 67095 67136 67177 67218 66973 67014 67055 67096 67137 67178 67219		66964		67005		67046		67087		67128		67169		67210
66967 67008 67049 67090 67131 67172 67213 66968 67009 67050 67091 67132 67173 67214 66969 67010 67051 67092 67133 67174 67215 66970 67011 67052 67093 67134 67175 67216 66971 67012 67053 67094 67135 67176 67217 66972 67013 67054 67095 67136 67177 67218 66973 67014 67055 67096 67137 67178 67219		66965		67006		67047				67129				
66968 67009 67050 67091 67132 67173 67214 66969 67010 67051 67092 67133 67174 67215 66970 67011 67052 67093 67134 67175 67216 66971 67012 67053 67094 67135 67176 67217 66972 67013 67054 67095 67136 67177 67218 66973 67014 67055 67096 67137 67178 67219														
66969 67010 67051 67092 67133 67174 67215 66970 67011 67052 67093 67134 67175 67216 66971 67012 67053 67094 67135 67176 67217 66972 67013 67054 67095 67136 67177 67218 66973 67014 67055 67096 67137 67178 67219		66967		67008		67049		67090		67131		67172		67213
66970 67011 67052 67093 67134 67175 67216 66971 67012 67053 67094 67135 67176 67217 66972 67013 67054 67095 67136 67177 67218 66973 67014 67055 67096 67137 67178 67219		66968												
66971 67012 67053 67094 67135 67176 67217 66972 67013 67054 67095 67136 67177 67218 66973 67014 67055 67096 67137 67178 67219														67215
66972 67013 67054 67095 67136 67177 67218 66973 67014 67055 67096 67137 67178 67219														
66973 67014 67055 67096 67137 67178 67219		66971		67012		67053		67094				67176		
		66972		67013		67054				67136		67177		67218
66974 67015 67056 67097 67138 67179 67220		66973								67137				67219
		66974		67015		67056		67097		67138		67179		67220

DTPA-HBV-IPV-135 (A.15MAR2018)

	Bl.	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt.	Bl. nb		. Bl. Io nb		Bl.		Trt. Bl. No nb
												-	
PPD	67221	PPD	67262	PPD	67303	PPD	67344	PPD	67385	PPD	67426	Р	PD 6746
–	67222		67263		67304		67345		67386		67427		6746
	67223		67264		67305		67346		67387		67428		6746
	67224		67265		67306		67347		67388		67429		6747
	67225		67266		67307		67348		67389		67430		6747
	67226		67267		67308		67349		67390		67431		6747
	67227		67268		67309		67350		67391		67432		6747
	67228		67269		67310		67351		67392		67433		6747
	67229		67270		67311		67352		67393		67434		6747
	67230		67271		67312		67353		67394		67435		6747
	67231		67272		67313		67354		67395		67436		6747
	67232		67273		67314		67355		67396		67437		6747
	67233		67274		67315		67356		67397		67438		6747
	67234		67275		67316		67357		67398		67439		6748
	67235		67276		67317		67358		67399		67440		6748
	67236		67277		67318		67359		67400		67441		6748
	67237		67278		67319		67360		67401		67442		6748
	67238		67279		67320		67361		67402		67443		6748
	67239		67280		67321		67362		67403		67444		6748
	67240		67281		67322		67363		67404		67445		6748
	67241		67282		67323		67364		67405		67446		6748
	67242		67283		67324		67365		67406		67447		6748
	67243		67284		67325		67366		67407		67448		6748
	67244		67285		67326		67367		67408		67449		6749
	67245		67286		67327		67368		67409		67450		6749
	67246		67287		67328		67369		67410		67451		6749
	67247		67288		67329		67370		67411		67452		6749
	67248		67289		67330		67371		67412		67453		6749
	67249		67290		67331		67372		67413		67454		6749
	67250		67291		67332		67373		67414		67455		6749
	67251		67292		67333		67374		67415		67456		6749
	67252		67293		67334		67375		67416		67457		6749
	67253		67294		67335		67376		67417		67458		6749
	67254		67295		67336		67377		67418		67459		6750
	67255		67296		67337		67378		67419		67460		6750
	67256		67297		67338		67379		67420		67461		6750
	67257		67298		67339		67380		67421		67462		6750
	67258		67299		67340		67381		67422		67463		6750
	67259		67300		67341		67382		67423		67464		6750
	67260		67301		67342		67383		67424		67465		6750
	67261		67302		67343		67384		67425		67466		6750
					l								

DTPA-HBV-IPV-135 (A.15MAR2018)

	. Bl.	Trt. Bl.	Trt.									
No	o nb	No nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	67508	PPD 6754	PPD	67590	PPD	67631	PPD	67672	PPD	67713	PPD	67754
	67509	67550		67591		67632		67673		67714		67755
	67510	6755		67592		67633		67674		67715		67756
	67511	6755		67593		67634		67675		67716		67757
	67512	6755		67594		67635		67676		67717		67758
	67513	6755	1	67595		67636		67677		67718		67759
	67514	6755	5	67596		67637		67678		67719		67760
	67515	6755	5	67597		67638		67679		67720		67761
	67516	6755	7	67598		67639		67680		67721		67762
	67517	6755	3	67599		67640		67681		67722		67763
	67518	6755		67600		67641		67682		67723		67764
	67519	6756		67601		67642		67683		67724		67765
	67520	6756		67602		67643		67684		67725		67766
	67521	6756		67603		67644		67685		67726		67767
	67522	6756		67604		67645		67686		67727		67768
	67523	6756		67605		67646		67687		67728		67769
	67524	6756		67606		67647		67688		67729		67770
	67525	6756		67607		67648		67689		67730		67771
	67526	6756		67608		67649		67690		67731		67772
	67527	6756		67609		67650		67691		67732		67773
	67528	6756		67610		67651		67692		67733		67774
	67529	6757		67611		67652		67693		67734		67775
	67530	6757		67612		67653		67694		67735		67776
	67531	6757		67613		67654		67695		67736		67777
	67532 67533	67573 6757		67614 67615		67655 67656		67696 67697		67737 67738		67778 67779
	67534	6757		67616		67657		67698		67739		67780
	67535	6757		67617		67658		67699		67740		67781
	67536	6757		67618		67659		67700		67741		67782
	67537	6757		67619		67660		67701		67742		67783
	67538	6757		67620		67661		67702		67743		67784
	67539	6758		67621		67662		67703		67744		67785
	67540	6758		67622		67663		67704		67745		67786
	67541	6758		67623		67664		67705		67746		67787
	67542	6758		67624		67665		67706		67747		67788
	67543	6758		67625		67666		67707		67748		67789
	67544	6758		67626		67667		67708		67749		67790
	67545	6758		67627		67668		67709		67750		67791
	67546	6758		67628		67669		67710		67751		67792
	67547	6758		67629		67670		67711		67752		67793
	67548	6758	9	67630		67671		67712		67753		67794
	_			-								I .

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl. Trt. Bl.					
NO	nb 	No nb No nb					
						PPD	
PPD	67795	PPD 67836	PPD 67877	PPD 67918	PPD 67959	68000	PPD 68041
	67796	67837	67878	67919	67960	68001	68042
	67797	67838	67879	67920	67961	68002	68043
	67798	67839	67880	67921	67962	68003	68044
	67799	67840	67881	67922	67963	68004	68045
	67800	67841	67882	67923	67964	68005	68046
	67801	67842	67883	67924	67965	68006	68047
	67802	67843	67884	67925	67966	68007	68048
	67803	67844	67885	67926	67967	68008	68049
	67804	67845	67886	67927	67968	68009	68050
	67805	67846	67887	67928	67969	68010	68051
	67806	67847	67888	67929	67970	68011	68052
	67807	67848	67889	67930	67971	68012	68053
	67808	67849	67890	67931	67972	68013	68054
	67809	67850	67891	67932	67973	68014	68055
	67810	67851	67892	67933	67974	68015	68056
	67811	67852	67893	67934	67975	68016	68057
	67812	67853	67894	67935	67976	68017	68058
	67813	67854	67895	67936	67977	68018	68059
	67814	67855	67896	67937	67978	68019	68060
	67815	67856	67897	67938	67979	68020	68061
	67816	67857	67898	67939	67980	68021	68062
	67817	67858	67899	67940	67981	68022	68063
	67818	67859	67900	67941	67982	68023	68064
	67819	67860	67901	67942	67983	68024	68065
	67820	67861	67902	67943	67984	68025	68066
	67821	67862	67903	67944	67985	68026	68067
	67822	67863	67904	67945	67986	68027	68068
	67823	67864	67905	67946	67987	68028	68069
	67824	67865	67906	67947	67988	68029	68070
	67825	67866	67907	67948	67989	68030	68071
	67826	67867	67908	67949	67990	68031	68072
	67827	67868	67909	67950	67991	68032	68073
	67828	67869	67910	67951	67992	68033	68074
	67829	67870	67911	67952	67993	68034	68075
	67830	67871	67912	67953	67994	68035	68076
	67831	67872	67913	67954	67995	68036	68077
	67832	67873	67914	67955	67996	68037	68078
	67833	67874	67915	67956	67997	68038	68079
	67834	67875	67916	67957	67998	68039	68080
	67835	67876	67917	67958	67999	68040	68081
			2.22				

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.					
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	68082	PPD 68123	PPD 68164	PPD 68205	PPD 68246	PPD 68287	PPD 68328
	68083	68124	68165	68206	68247	68288	68329
	68084	68125	68166	68207	68248	68289	68330
	68085	68126	68167	68208	68249	68290	68331
	68086	68127	68168	68209	68250	68291	68332
	68087	68128	68169	68210	68251	68292	68333
	68088	68129	68170	68211	68252	68293	68334
	68089	68130	68171	68212	68253	68294	68335
	68090	68131	68172	68213	68254	68295	68336
	68091	68132	68173	68214	68255	68296	68337
	68092	68133	68174	68215	68256	68297	68338
	68093	68134	68175	68216	68257	68298	68339
	68094	68135	68176	68217	68258	68299	68340
	68095	68136	68177	68218	68259	68300	68341
	68096	68137	68178	68219	68260	68301	68342
	68097	68138	68179	68220	68261	68302	68343
	68098	68139	68180	68221	68262	68303	68344
	68099	68140	68181	68222	68263	68304	68345
	68100	68141	68182	68223	68264	68305	68346
	68101	68142	68183	68224	68265	68306	68347
	68102	68143	68184	68225	68266	68307	68348
	68103	68144	68185	68226	68267	68308	68349
	68104	68145	68186	68227	68268	68309	68350
	68105	68146	68187	68228	68269	68310	68351
	68106	68147	68188	68229	68270	68311	68352
	68107	68148	68189	68230	68271	68312	68353
	68108	68149	68190	68231	68272	68313	68354
	68109	68150	68191	68232	68273	68314	68355
	68110	68151	68192	68233	68274	68315	68356
	68111	68152	68193	68234	68275	68316	68357
	68112	68153	68194	68235	68276	68317	68358
	68113	68154	68195	68236	68277	68318	68359
	68114	68155	68196	68237	68278	68319	68360
	68115	68156	68197	68238	68279	68320	68361
	68116	68157	68198	68239	68280	68321	68362
	68117	68158	68199	68240	68281	68322	68363
	68118	68159	68200	68241	68282	68323	68364
	68119	68160	68201	68242	68283	68324	68365
	68120	68161	68202	68243	68284	68325	68366
	68121	68162	68203	68244	68285	68326	68367
	68122	68163	68204	68245	68286	68327	68368

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb		nb		nb	Trt. No	nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	
PPD	68369	PPD	68410	PPD	68451	PPD	68492	PPD	68533	PPD	68574	PPD	68615
	68370		68411		68452		68493	–	68534		68575		68616
	68371		68412		68453		68494		68535		68576		68617
	68372		68413		68454		68495		68536		68577		68618
	68373		68414		68455		68496		68537		68578		68619
	68374		68415		68456		68497		68538		68579		68620
	68375		68416		68457		68498		68539		68580		68621
	68376		68417		68458		68499		68540		68581		68622
	68377		68418		68459		68500		68541		68582		68623
	68378		68419		68460		68501		68542		68583		68624
	68379		68420		68461		68502		68543		68584		68625
	68380		68421		68462		68503		68544		68585		68626
	68381		68422		68463		68504		68545		68586		68627
	68382		68423		68464		68505		68546		68587		68628
	68383		68424		68465		68506		68547		68588		68629
	68384		68425		68466		68507		68548		68589		68630
	68385		68426		68467		68508		68549		68590		68631
	68386		68427		68468		68509		68550		68591		68632
	68387		68428		68469		68510		68551		68592		68633
	68388		68429		68470		68511		68552		68593		68634
	68389		68430		68471		68512		68553		68594		68635
	68390		68431		68472		68513		68554		68595		68636
	68391		68432		68473		68514		68555		68596		68637
	68392		68433		68474		68515		68556		68597		68638
	68393		68434		68475		68516		68557		68598		68639
	68394		68435		68476		68517		68558		68599		68640
	68395		68436		68477		68518		68559		68600		68641
	68396		68437		68478		68519		68560		68601		68642
	68397		68438		68479		68520		68561		68602		68643
	68398		68439		68480		68521		68562		68603		68644
	68399		68440		68481		68522		68563		68604		68645
	68400		68441		68482		68523		68564		68605		68646
	68401		68442		68483		68524		68565		68606		68647
	68402		68443		68484		68525		68566		68607		68648
	68403		68444		68485		68526		68567		68608		68649
	68404		68445		68486		68527		68568		68609		68650
	68405		68446		68487		68528		68569		68610		68651
	68406		68447		68488		68529		68570		68611		68652
	68407		68448		68489		68530		68571		68612		68653
	68408		68449		68490		68531		68572		68613		68654
	68409		68450		68491		68532		68573		68614		68655
			l										

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	B1.	Trt. Bl.	Trt.			Bl.		. Bl.		Bl.	Trt.	
No	nb	No nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	68656	PPD 68697	PPD	68738	PPD	68779	PPD	68820	PPD	68861	PPD	68902
FFD	68657	68698		68739	110	68780	FFD	68821		68862		68903
	68658	68699		68740		68781		68822		68863		68904
	68659	68700		68741		68782		68823		68864		68905
	68660	68701		68742		68783		68824		68865		68906
	68661	68702		68743		68784		68825		68866		68907
	68662	68703		68744		68785		68826		68867		68908
	68663	68704		68745		68786		68827		68868		68909
	68664	68705		68746		68787		68828		68869		68910
	68665	68706		68747		68788		68829		68870		68911
	68666	68707		68748		68789		68830		68871		68912
	68667	68708		68749		68790		68831		68872		68913
	68668	68709		68750		68791		68832		68873		68914
	68669	68710		68751		68792		68833		68874		68915
	68670	68711		68752		68793		68834		68875		68916
	68671	68712		68753		68794		68835		68876		68917
	68672	68713		68754		68795		68836		68877		68918
	68673	68714		68755		68796		68837		68878		68919
	68674	68715		68756		68797		68838		68879		68920
	68675	68716		68757		68798		68839		68880		68921
	68676	68717		68758		68799		68840		68881		68922
	68677	68718		68759		68800		68841		68882		68923
	68678	68719		68760		68801		68842		68883		68924
	68679	68720		68761		68802		68843		68884		68925
	68680	68721		68762		68803		68844		68885		68926
	68681	68722		68763		68804		68845		68886		68927
	68682	68723		68764		68805		68846		68887		68928
	68683	68724		68765		68806		68847		68888		68929
	68684	68725		68766		68807		68848		68889		68930
	68685	68726		68767		68808		68849		68890		68931
	68686	68727		68768		68809		68850		68891		68932
	68687	68728		68769		68810		68851		68892		68933
	68688	68729		68770		68811		68852		68893		68934
	68689	68730		68771		68812		68853		68894		68935
	68690	68731		68772		68813		68854		68895		68936
	68691	68732		68773		68814		68855		68896		68937
	68692	68733		68774		68815		68856		68897		68938
	68693	68734		68775		68816		68857		68898		68939
	68694	68735		68776		68817		68858		68899		68940
	68695	68736		68777		68818		68859		68900		68941
	68696	68737		68778		68819		68860		68901		68942
	•											

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.	Bl. nb	Trt.	Bl.	Trt.	Bl. nb	Trt.	Bl.	Trt.	Bl. nb
PPD	68943	PPD	68984	PPD	69025	PPD	69066	PPD	69107	PPD	69148	PPD	69189
	68944		68985		69026		69067		69108		69149		69190
	68945		68986		69027		69068		69109		69150		69191
	68946		68987		69028		69069		69110		69151		69192
	68947		68988		69029		69070		69111		69152		69193
	68948		68989		69030		69071		69112		69153		69194
	68949		68990		69031		69072		69113		69154		69195
	68950		68991		69032		69073		69114		69155		69196
	68951		68992		69033		69074		69115		69156		69197
	68952		68993		69034		69075		69116		69157		69198
	68953		68994		69035		69076		69117		69158		69199
	68954		68995		69036		69077		69118		69159		69200
	68955		68996		69037		69078		69119		69160		69201
	68956		68997		69038		69079		69120		69161		69202
	68957		68998		69039		69080		69121		69162		69203
	68958		68999		69040		69081		69122		69163		69204
	68959		69000		69041		69082		69123		69164		69205
	68960		69001		69042		69083		69124		69165		69206
	68961		69002		69043		69084		69125		69166		69207
	68962		69003		69044		69085		69126		69167		69208
	68963		69004		69045		69086		69127		69168		69209
	68964		69005		69046		69087		69128		69169		69210
	68965		69006		69047		69088		69129		69170		69211
	68966		69007		69048		69089		69130		69171		69212
	68967		69008		69049		69090		69131		69172		69213
	68968		69009		69050		69091		69132		69173		69214
	68969		69010		69051		69092		69133		69174		69215
	68970		69011		69052		69093		69134		69175		69216
	68971		69012		69053		69094		69135		69176		69217
	68972		69013		69054		69095		69136		69177		69218
	68973		69014		69055		69096		69137		69178		69219
	68974		69015		69056		69097		69138		69179		69220
	68975		69016		69057		69098		69139		69180		69221
	68976		69017		69058		69099		69140		69181		69222
	68977		69018		69059		69100		69141		69182		69223
	68978		69019		69060		69101		69142		69183		69224
	68979		69020		69061		69102		69143		69184		69225
	68980		69021		69062		69103		69144		69185		69226
	68981		69022		69063		69104		69145		69186		69227
	68982		69023		69064		69105		69146		69187		69228
	68983		69024		69065		69106		69147		69188		69229
			l						l				

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. B		Trt.		Trt.		Trt.		Trt.			Bl.	Trt.	
No n	nb	No	nb	No		No	nb	No	nb	No	nb	No	nb
PPD 6	59230	PPD	69271	PPD	69312	PPD	69353	PPD	69394	PPD	69435	PPD	69476
	59231		69272		69313	יוו	69354	110	69395		69436	–	69477
	59232		69273		69314		69355		69396		69437		69478
	59233		69274		69315		69356		69397		69438		69479
	59234		69275		69316		69357		69398		69439		69480
	59235		69276		69317		69358		69399		69440		69481
	59236		69277		69318		69359		69400		69441		69482
	59237		69278		69319		69360		69401		69442		69483
	59238		69279		69320		69361		69402		69443		69484
	59239		69280		69321		69362		69403		69444		69485
	59240		69281		69322		69363		69404		69445		69486
	59241		69282		69323		69364		69405		69446		69487
	59242		69283		69324		69365		69406		69447		69488
	59243		69284		69325		69366		69407		69448		69489
	59244		69285		69326		69367		69408		69449		69490
	59245		69286		69327		69368		69409		69450		69491
	59246		69287		69328		69369		69410		69451		69492
	59247		69288		69329		69370		69411		69452		69493
	59248		69289		69330		69371		69412		69453		69494
	59249		69290		69331		69372		69413		69454		69495
	59250		69291		69332		69373		69414		69455		69496
	59251		69292		69333		69374		69415		69456		69497
	59252		69293		69334		69375		69416		69457		69498
	59253		69294		69335		69376		69417		69458		69499
	59254		69295		69336		69377		69418		69459		69500
	59255		69296		69337		69378		69419		69460		69501
	59256		69297		69338		69379		69420		69461		69502
	59257		69298		69339		69380		69421		69462		69503
	59258		69299		69340		69381		69422		69463		69504
	59259		69300		69341		69382		69423		69464		69505
	59260		69301		69342		69383		69424		69465		69506
	59261		69302		69343		69384		69425		69466		69507
	59262		69303		69344		69385		69426		69467		69508
6	59263		69304		69345		69386		69427		69468		69509
6	59264		69305		69346		69387		69428		69469		69510
6	59265		69306		69347		69388		69429		69470		69511
	59266		69307		69348		69389		69430		69471		69512
	59267		69308		69349		69390		69431		69472		69513
	59268		69309		69350		69391		69432		69473		69514
	59269		69310		69351		69392		69433		69474		69515
6	59270		69311		69352		69393		69434		69475		69516

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	69517	PPD 69558	PPD 69599	PPD 69640	PPD 69681	PPD 69722	PPD 69763
110	69518	69559	69600	69641	69682	69723	69764
	69519	69560	69601	69642	69683	69724	69765
	69520	69561	69602	69643	69684	69725	69766
	69521	69562	69603	69644	69685	69726	69767
	69522	69563	69604	69645	69686	69727	69768
	69523	69564	69605	69646	69687	69728	69769
	69524	69565	69606	69647	69688	69729	69770
	69525	69566	69607	69648	69689	69730	69771
	69526	69567	69608	69649	69690	69731	69772
	69527	69568	69609	69650	69691	69732	69773
	69528	69569	69610	69651	69692	69733	69774
	69529	69570	69611	69652	69693	69734	69775
	69530	69571	69612	69653	69694	69735	69776
	69531	69572	69613	69654	69695	69736	69777
	69532	69573	69614	69655	69696	69737	69778
	69533	69574	69615	69656	69697	69738	69779
	69534	69575	69616	69657	69698	69739	69780
	69535	69576	69617	69658	69699	69740	69781
	69536	69577	69618	69659	69700	69741	69782
	69537	69578	69619	69660	69701	69742	69783
	69538	69579	69620	69661	69702	69743	69784
	69539	69580	69621	69662	69703	69744	69785
	69540	69581	69622	69663	69704	69745	69786
	69541	69582	69623	69664	69705	69746	69787
	69542	69583	69624	69665	69706	69747	69788
	69543	69584	69625	69666	69707	69748	69789
	69544	69585	69626	69667	69708	69749	69790
	69545	69586	69627	69668	69709	69750	69791
	69546	69587	69628	69669	69710	69751	69792
	69547	69588	69629	69670	69711	69752	69793
	69548	69589	69630	69671	69712	69753	69794
	69549	69590	69631	69672	69713	69754	69795
	69550	69591	69632	69673	69714	69755	69796
	69551	69592	69633	69674	69715	69756	69797
	69552 69553	69593 69594	69634 69635	69675	69716	69757	69798 69799
				69676	69717	69758	
	69554	69595	69636	69677	69718	69759	69800
	69555 69556	69596 69597	69637 69638	69678 69679	69719 69720	69760	69801 69802
	69556	69597	69638			69761	
	1 5550	09398	09039	69680	69721	69762	69803

DTPA-HBV-IPV-135 (A.15MAR2018)

PPD 69804 PPD 69845 PPD 69886 PPD 69927 PPD 69968 69905 69805 69846 69888 69929 69929 69970 70010 70051 70052 69908 69909 6990	Trt	. Bl.	Trt. Bl.	Trt. Bl		Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
69805 69806 69807 69808 69907 69918 69909 69910 70011 70012 70013 69808 69809 69809 69911 69912 70013 70014 70015 70015 69809 69811 69917 70015 70015 70015 70015 69811 6981	No	o nb	No nb	No nb)	No	nb	No	nb	No	nb	No	nb
69805 69846 69886 69887 69988 69998 70009 70051 69805 69806 69847 69888 69999 69970 70011 70052 70053 69808 69849 69890 69931 69972 70013 70054 69809 69850 69851 69952 69933 69974 70015 70055 69811 69852 69863 69899 69955 69955 69956 69977 70016 70055 69811 69852 69893 69955 69976 70017 70055 69813 69854 69865 69866 69937 69814 69955 69966 69977 70018 70056 69815 69855 69866 69977 70018 70056 69816 69857 69868 69959 69940 69981 70021 70066 69817 69888 69899 69940 69981 69982 69988 70021 70066 69819 69860 69901 69942 69983 70024 70066 69822 69863 69904 69982 69986 69906 69941 69982 70023 70064 69822 69863 69904 69984 69985 69966 69907 69986 69900 69941 69982 70023 70064 69822 69863 69904 69982 69988 70025 70066 69821 69860 69901 69942 69983 69984 70025 70066 69822 69863 69904 69945 69986 70027 70066 69823 69866 69907 69944 69985 69986 70027 70066 69824 69865 69906 69947 69988 70029 70070 69824 69865 69906 69947 69988 70029 70070 69826 69867 69908 69949 69990 70031 70072 69826 69867 69908 69949 69990 70031 70072 69826 69867 69908 69949 69990 70031 70073 69826 69867 69910 69951 69992 70033 70044 69825 69866 69907 69948 69950 69991 69950 69991 69950 69991 70032 70073 69828 69869 69910 69951 69992 70033 70044 69826 69867 69918 69950 69991 69950 69991 70032 70073 69828 69869 69910 69951 69952 69933 69870 69911 69952 69933 69874 69915 69950 69991 70032 70073 69833 69874 69915 69950 69950 69991 70032 70073 69834 69875 69916 69957 69918 69950 70007 70048 69835 69876 69911 69952 69953 69996 70007 70048 69836 69877 6991													
69805 69846 69887 69988 69999 70010 70011 70052 69806 69807 69808 69809 69900 69911 70012 70053 69808 69809 69800 69911 69922 69931 70012 70053 69808 69809 69800 69911 69922 69933 70014 70055 69810 69810 69850 69991 69922 69933 69974 70013 70056 69810 69851 69823 69934 69935 699374 70016 70055 69811 69822 69933 69934 69935 69912 69833 69944 69955 69912 69933 699376 70018 70055 69812 69855 69866 69929 69939 69939 69940 69941 69982 70020 70061 69815 69815 69856 69897 69939 69939 69940 69941 69982 70023 70064 69818 69859 69860 69939 69940 69941 69982 70023 70064 69819 69860 69900 69941 69985 69986 70027 70066 69823 69864 69902 69940 69941 69985 70025 70066 69823 69866 69907 69940 69941 69982 70023 70066 69821 69860 69900 69941 69982 70023 70066 69821 69860 69900 69941 69982 70023 70066 69821 69860 69900 69941 69982 70023 70066 69821 69860 69900 69941 69982 70023 70066 69821 69860 69900 69941 69982 70023 70066 69821 69860 69900 69941 69982 70023 70066 69821 69860 69900 69941 69982 70023 70066 69821 69860 69900 69941 69982 70023 70066 69821 69860 69900 69941 69985 70025 70066 69822 69863 69900 69940 69940 69981 70025 70066 69822 69863 69900 69940 69940 69981 70025 70066 69822 69863 69900 69940 69940 69981 70025 70066 69822 69863 69900 69940 69940 69985 70026 70067 69822 69863 69900 69940 69940 69985 70026 70067 69822 69866 69900 69940 69940 69985 70026 70067 69823 69866 69900 69940 69940 69991 70025 70066 69823 69866 69900 69940 69940 69990 70031 70070 69826 69866 69900 69940 69940 69990 70031 70070 69826 69860 69900 69940 69991 70032 70073 69828 69869 69910 69951 69990 70031 70070 69826 69860 69900 69951 69990 70031 70070 69826 69860 69900 69951 69990 70031 70070 69830 69870 69911 69952 69993 70030 70071 69830 69870 69911 69952 69993 70030 70071 69830 69870 69911 69952 69993 70030 70071 69830 69870 69911 69952 69993 70030 70071 69830 69870 69911 69952 69993 70030 70071 69830 69870 69911 69952 69993 70030 70044 70045 69830 69870 69911 69952 69993 70030 70044 70045 69830 69870 69911 69952 69950 70000 70044 70045 6983	DDD	60004	DDD 60045	PPD 60	1006	DDD	60027	חחח	60060	PPD	70000	PPN	70050
69806 69847 69888 69929 69970 70011 70022 69807 69948 69889 69930 69911 69972 70013 70024 69808 69809 69850 69891 69931 69972 70013 70024 69809 69850 69851 69892 69933 69974 70015 70055 69810 69851 69852 69933 69974 70015 70056 69811 69852 69853 6984 69955 69976 70017 70058 69812 69853 69894 69955 69976 70017 70058 69813 69854 69855 69936 69977 70018 70059 69814 69855 69866 69937 69978 70019 70060 69815 69816 69857 69888 69939 69979 70021 70062 69818 69858 69859 69900 69941 69952 70023 70064 69818 69859 69900 69941 69982 70023 70064 69819 69860 69901 69941 69982 70023 70066 69820 69861 69902 69943 69984 70025 70066 69821 69862 69903 69944 69955 70026 69821 69862 69903 69944 69955 70026 69824 69862 69903 69944 69955 70026 69824 69862 69903 69944 69955 70026 69824 69862 69903 69944 69955 70026 69824 69862 69903 69944 69955 70026 69824 69862 69903 69944 69955 70026 69824 69862 69903 69944 69955 70026 69824 69862 69903 69944 69955 70026 69824 69862 69903 69944 69955 70026 69824 69862 69903 69944 69955 70026 69824 69862 69903 69944 69955 70026 69824 69862 69903 69944 69955 70026 69824 69862 69903 69944 69955 70026 69824 69865 69906 69904 69945 69986 70027 70066 69824 69865 69906 69907 69948 69995 70029 70070 69825 69868 69900 69911 69955 69946 69997 70031 70027 69826 69827 69868 69900 69910 69951 69999 70031 70027 69826 69827 69868 69900 69910 69951 69999 70031 70027 69827 69868 69900 69910 69951 69999 70031 70027 69829 69870 69911 69952 69993 70033 70074 69829 69870 69911 69952 69993 70034 70035 69834 69872 69873 69914 69955 69998 70030 70071 69832 69873 69914 69955 69998 70030 70071 69833 69874 69915 69955 69998 70030 70071 69833 69874 69915 69955 69998 70030 70071 69834 69955 69998 70030 70071 69834 69875 69918 69990 70031 70047 70088 69834 69875 69918 69990 70000 70041 70042 70088 69834 69875 69918 69990 70000 70041 70042 70088 69834 69875 69918 69920 69961 70000 70041 70042 70088 69834 69883 69979 69920 69961 70000 70041 70048 69843 69843 69984 69923 69964 69924 69965 70000 70001 70044 70088 69843 69984 69984 6	PPD		05010	0,		FFD		PPD				110	
69807 69848 69849 69800 69911 70012 70053 69808 698649 69850 69891 69932 69973 70014 70055 69810 69851 69852 69833 69974 70015 70056 69811 69852 69803 69934 69975 70016 70057 69812 69853 68894 69935 69976 70017 70058 69813 69854 69855 69936 69977 70018 70059 69814 69855 69869 69936 69977 70018 70059 69815 69856 69857 69938 69979 70010 70060 69815 69857 69858 69899 69940 69980 70021 70061 69818 69859 69900 69941 69982 70023 70064 69819 69800 69811 69982 69940 69881 70022 70064 69818 69859 69900 69941 69982 70023 70064 69819 69800 69861 69901 69942 69983 70024 70065 69810 69866 69807 69908 69940 69881 70025 70066 69820 69861 69900 69941 69982 70023 70064 69821 69866 69807 69900 69941 69982 70023 70066 69822 69863 69904 69944 69985 70025 70066 69823 69866 69907 69944 69985 70026 70067 69824 69865 69908 69940 69940 70021 70062 69825 69866 69909 69940 69980 70021 70068 69826 69827 69808 69990 69940 69981 70022 70066 69827 69868 69900 69941 69982 70023 70066 69828 69869 69900 69941 69982 70023 70066 69829 69866 69900 69941 69985 70025 70066 69821 69866 69900 69941 69985 70026 70067 69822 69863 69908 69948 69989 70030 70071 69825 69866 69907 69948 69989 70030 70071 69826 69867 69908 69908 69949 70030 70071 69827 69868 69908 69908 69909 70031 70072 69829 69870 69911 69912 69953 69999 70030 70071 69830 69871 69912 69953 69999 70030 70074 69831 69872 69973 69914 69995 70036 70077 69833 69974 69975 69918 69999 70000 70041 70082 69831 69872 69973 69914 69955 69996 70037 70074 69833 69874 69975 69918 69999 70000 70041 70042 69836 69877 69918 69990 70000 70041 70042 69836 69870 69911 69957 69998 70000 70041 70042 69836 69870 69971 69918 69999 70000 70041 70042 69836 69870 69981 69900 69901 70000 70044 69836 69870 69981 69902 69961 70000 70044 69836 69838 69999 69900 69901 70000 70044 69836 69838 69988 69992 69965 70006 70007 70048 69836 69838 69988 69924 69965 70006 70007 70048													
69808 69849 69849 69800 69911 69922 70013 70054 69809 69809 69850 69811 69922 69933 69974 70015 70055 69810 69811 69852 69893 69934 69975 70016 70057 69812 69833 69844 69955 69916 70017 70058 69813 69814 69855 69866 69935 69937 70018 70058 69814 69855 69866 69937 69918 70019 70019 70058 69814 69855 69866 69937 69918 70019 70020 70061 69816 69857 69888 69939 69940 69911 70022 70063 69818 69859 69900 69941 69962 70023 70044 70055 69820 69861 69902 69944 69982 69933 69944 70025 70066 69821 69862 69903 69944 69985 70026 70067 69822 69863 69904 69944 69985 70026 70067 69823 69864 69905 69946 69947 69988 70027 70068 69824 69865 69906 69910 69946 69987 70028 70067 69824 69866 69907 69948 69999 70029 70070 69825 69866 69907 69948 69999 70020 70067 69824 69865 69906 69910 69946 69987 70028 70069 69824 69866 69907 69948 69999 70027 70068 69824 69866 69907 69948 69999 70029 70070 69825 69866 69907 69948 69999 70029 70070 69825 69866 69907 69948 69999 70030 70071 69826 69827 69868 69908 69908 69940 69941 69999 70030 70071 69826 69827 69868 69909 69950 69941 69999 70030 70071 69826 69827 69868 69909 69950 69949 69999 70030 70071 69828 69869 69910 69910 69950 69991 70032 70073 69828 69869 69910 69910 69950 69991 70032 70073 69828 69869 69910 69910 69950 69991 70032 70073 69828 69870 69911 69952 69933 70034 70074 69829 69870 69911 69952 69933 70034 70075 69828 69870 69911 69952 69933 70034 70075 69828 69870 69911 69952 69933 70034 70075 69828 69870 69911 69952 69933 70034 70075 69828 69870 69911 69952 69933 70034 70075 69828 69870 69911 69952 69933 70034 70075 69828 69870 69911 69952 69933 70034 70075 69828 69870 69911 69952 69933 70034 70075 69828 69870 69911 69952 69933 70034 70075 69828 69870 69911 69952 69933 70034 70075 69828 69870 69911 69952 69933 70034 70075 69828 69970 69911 69952 69933 70034 70075 69828 69970 69911 69952 69933 70034 70075 69828 69970 69911 69952 69953 70030 70071 70086 69834 69975 69916 69957 69956 700077 70046 69834 69984 69985 69966 700077 70046 69834 69984 69985 69952 69966 700077 70046 69834 699													
69809 69850 69851 69892 69933 70014 70055 70056 69811 69852 69893 69934 69975 70016 70057 69812 69833 69894 69935 69976 70017 70058 69813 69854 69855 69865 69937 69913 69914 69855 69866 69937 69915 70018 70059 69915 69856 69897 69938 69997 70020 70061 69816 69857 69888 69939 69960 70021 70062 69817 69888 69899 69940 69911 70022 70063 69818 69859 69900 69941 69962 69819 69860 69901 69942 69983 70024 70056 69820 69861 69902 69943 69984 70025 70066 69821 69862 69903 69944 69985 70026 70066 69822 69864 69905 69944 69985 70027 70066 69824 69858 69906 69947 69988 70027 70066 69824 69858 69906 69947 69988 70027 70066 69824 69856 69907 69948 69987 70028 70070 69825 69866 69907 69948 69987 70028 70070 69825 69866 69907 69948 69989 70029 70070 69825 69866 69907 69948 69989 70029 70070 69825 69866 69907 69948 69989 70030 70071 69826 69869 69910 69911 69952 70033 70074 69827 69868 69907 69948 69989 70030 70071 69826 69867 69908 69907 69948 69999 70030 70071 69827 69869 69910 69911 69952 70033 70074 69828 69869 69910 69911 69952 69993 70034 70075 69830 69871 69912 69913 69954 69995 70036 70077 69831 69872 69914 69915 69955 69996 70037 70078 69831 69872 69914 69955 69960 70037 70078 69834 69875 69916 69917 69958 69999 70030 70071 69835 69876 69917 69918 69955 69996 70037 70078 69831 69873 69914 69955 69960 70037 70078 69831 69873 69914 69955 69960 70001 70044 70055 69831 69877 69918 69910 69910 69951 69952 69993 70040 70041 70042 69844 69844 69885 69977 69918 69950 70000 70044 70056 69844 69844 69883 69924 69955 69966 7000													
69810 69851 69892 69933 69974 70015 70056 69811 69852 69883 69934 69975 70016 70057 69812 69853 69854 69855 69936 69976 70017 70058 69813 69854 69855 69936 69977 70018 70059 69814 69855 69836 69937 69938 70019 70000 69815 69856 69897 69938 69939 70020 70061 69816 69817 69858 69899 69939 69930 70021 70062 69818 69859 69900 69941 69982 70023 70063 69818 69859 69900 69941 69982 70023 70064 69820 69861 69902 69943 69944 70055 69821 69862 69903 69944 69985 70026 70067 69822 69863 69904 69945 69986 70027 70068 69823 69864 69905 69944 69985 70026 70067 69823 69866 69907 69948 69987 70028 70069 69824 69865 69906 69907 69948 69989 70030 70011 69825 69866 69907 69948 69989 70030 70070 69826 69867 69908 69909 69950 69991 70032 70070 69827 69868 69909 69950 69949 69990 70031 70071 69828 69869 69910 69911 69952 69993 70030 70071 69829 69870 69911 69952 69993 70030 70071 69829 69870 69911 69952 69993 70030 70071 69829 69870 69911 69952 69993 70030 70071 69829 69870 69911 69952 69993 70030 70071 69829 69870 69911 69952 69993 70030 70071 69829 69870 69911 69952 69993 70034 70072 69829 69870 69911 69952 69993 70034 70072 69829 69870 69911 69952 69993 70034 70074 69829 69870 69911 69952 69993 70034 70075 69830 69871 69912 69955 69996 70037 70078 69831 69872 69913 69914 69955 69999 70030 70071 69832 69873 69914 69955 69999 70030 70071 69833 69874 69915 69955 69999 70030 70071 69834 69875 69916 69917 69955 69999 70030 70071 69836 69877 69918 69950 69991 70032 70073 69838 69879 69910 69951 69995 70036 70077 69839 69830 69871 69912 69955 69999 70030 70041 70082 69831 69878 69919 69950 69950 70040 70041 69836 69878 69919 69950 69950 70040 70041 69836 69878 69919 69950 69950 70000 70041 70082 69837 69838 69979 69900 69950 70000 70041 70082 69839 69840 69881 69925 69963 70000 70041 70042 69839 69840 69881 69925 69963 70000 70041 70088 69840 69841 69982 69923 69964 70005 70044 70085 69841 69884 69955 69966 70007 70041 70048 69841 69884 69925 69966 70007 70004 70048													
69812 69853 69844 69935 69976 70016 70057 69812 69853 69894 69935 69976 70017 70058 69813 69854 69855 69836 69977 70018 70059 69814 69855 69886 69937 69938 70019 70000 69815 69856 69857 69988 69938 69979 70020 70061 69816 69857 69988 69939 69980 70021 70062 69817 69858 69899 69940 69981 70022 70063 69818 69859 69900 69941 69982 70023 70064 69819 69860 69901 69942 69983 70024 70065 69820 69861 69902 69943 69984 70025 70066 69821 69862 69903 69944 69985 70026 70066 69822 69863 69904 69945 69986 70027 70068 69822 69863 69904 69945 69986 70027 70068 69823 69864 69905 69946 69987 70029 70070 69825 69866 69907 69948 69989 70030 70071 69826 69867 69908 69909 69950 69949 69990 70031 70072 69827 69868 69909 69950 69949 69990 70031 70072 69828 69869 69910 69911 69952 69993 70034 70072 69829 69870 69911 69952 69993 70034 70072 69828 69869 69910 69910 69955 69946 69999 70030 70071 69828 69869 69910 69910 69955 69949 70030 70071 69829 69870 69911 69952 69993 70034 70072 69829 69870 69911 69952 69993 70034 70072 69830 69871 69912 69953 69994 70035 70076 69831 69872 69913 69955 69996 70037 70078 69833 69874 69912 69953 69999 70030 70071 69834 69875 69914 69955 69996 70037 70078 69833 69874 69912 69953 69999 70030 70071 69834 69875 69914 69955 69996 70037 70078 69833 69874 69915 69955 69996 70037 70078 69833 69874 69915 69955 69996 70037 70078 69833 69874 69915 69955 69996 70037 70078 69834 69875 69916 69957 69998 70040 70081 69835 69876 69977 69918 69955 70006 70047 70088 69839 69880 69871 69918 69955 70004 70041 70082 69839 69880 69921 69965 70004 70044 70085 69840 69881 69922 69963 70004 70044 70085 69841 69882 69923 69964 70005 70004 70048 69842 69883 69924 69925 69966 70007 70048 70086													
69812 69853 69894 69955 69936 69977 70018 70058 69814 69855 6986 69937 69938 70019 70060 69814 69855 69866 69877 69938 69979 70020 70061 69816 69857 69858 69899 69940 69981 70022 70063 69818 69859 69900 69941 69982 70023 70064 69822 69864 69905 69944 69945 69986 70026 70066 69821 69864 69905 69944 69945 69988 70029 70066 69823 69864 69905 69944 69945 69988 70029 70066 69824 69966 69907 69946 69947 70066 69827 69866 69907 69948 69949 69990 70031 70067 69826 69867 69868 69909 69949 69949 69990 70031 70068 69824 69966 69967 69966 69907 69948 69999 70030 70071 69926 69867 69868 69907 69948 69999 70030 70071 69926 69867 69968 69907 69948 69999 70030 70071 69926 69868 69969 69910 69950 69950 70031 70072 69827 69828 69969 69910 69950 69950 70031 70072 69828 69869 69910 69950 69950 70031 70073 69828 69869 69910 69950 69950 70031 70073 69828 69869 69910 69950 69950 70031 70073 69828 69869 69910 69950 69950 70033 70074 69828 69869 69910 69950 69950 69991 70033 70074 69828 69869 69910 69950 69950 69991 70033 70074 69828 69869 69910 69950 69950 69991 70033 70074 69828 69869 69910 69951 69952 69993 70033 70074 69828 69870 69914 69952 69953 69994 70035 70076 69831 69872 69873 69914 69955 69994 70035 70076 69831 69872 69873 69914 69955 69995 70036 70077 69832 69873 69974 69913 69955 69995 70036 70037 70078 69832 69873 69914 69915 69955 69993 70030 70077 69832 69873 69874 69915 69955 69993 70030 70077 69832 69873 69874 69915 69955 69993 70030 70077 69832 69873 69874 69915 69955 69993 70030 70077 69833 69874 69915 69956 69957 69998 70030 70040 70078 69833 69874 69915 69956 69957 69999 70040 70088 69835 69876 69877 69918 69950 70000 70041 70082 69837 69878 69879 69910 69960 70001 70042 70083 69835 69879 69879 69910 69960 70001 70042 70088 69835 69879 69880 69919 69960 70001 70042 70083 69835 69879 69880 69919 69960 70001 70042 70083 69835 69879 69880 69919 69960 70001 70044 70085 69844 69882 69883 69999 69960 70001 70044 70085 69844 69844 69882 69923 69966 70007 70044 70045 69844 69844 69985 69966 70007 70044 70086 69844 69844 6													
69813 69854 69895 69936 69937 70018 70059 69814 69855 69866 69897 69938 69979 70020 70061 69815 69856 69857 69898 69939 69980 70021 70061 69816 69857 69888 69899 69940 69981 70022 70063 69818 69859 69900 69941 69982 70023 70064 69818 69859 69900 69941 69982 70023 70064 69819 69860 69901 69942 69983 70024 70065 69820 69861 69902 69943 69944 70025 70066 69821 69862 69903 69944 69985 70026 70067 69822 69863 69904 69944 69985 70026 70067 69823 69864 69905 69946 69947 69988 70028 70068 69824 69865 69906 69947 69988 70029 70070 69825 69866 69907 69948 69999 70030 70071 69825 69866 69907 69948 69999 70030 70071 69826 69827 69868 69909 69950 69991 70030 70071 69827 69868 69909 69950 69991 70030 70071 69828 69869 69910 69951 69992 70033 70074 69829 69870 69911 69952 69993 70033 70074 69829 69870 69911 69952 69993 70033 70074 69829 69870 69911 69952 69993 70033 70074 69830 69871 69912 69953 69944 70035 70076 69831 69872 69913 69914 69955 69996 70037 70078 69831 69872 69913 69914 69955 69996 70037 70078 69833 69874 69915 69956 69997 70030 70077 69833 69870 69911 69952 69993 70030 70077 69833 69870 69911 69952 69993 70030 70077 69833 69871 69912 69953 69994 70035 70076 69833 69870 69911 69952 69999 70037 70077 69833 69874 69915 69955 69996 70037 70078 69833 69876 69917 69918 69959 70000 70040 70081 69838 69879 69900 69910 69950 70000 70040 70081 69838 69879 69900 69910 69950 70000 70040 70081 69838 69879 69900 69960 70001 70042 70083 69838 69879 69900 69961 70000 70044 70085 69838 69879 69800 69911 69962 70003 70044 70085 69838 69879 69800 69911 69962 70003 70044 70085 69844 69884 69882 69923 69964 70005 70047 70088 69843 69884 69985 69993 69966 70007 70046 70087 69844 69884 69885 69993 69966 70007 70046 69844													
69814 69855 69866 69937 69938 70019 70060 69815 69856 69857 69898 69939 69940 70021 70062 70063 69817 69858 69859 69940 69981 70022 70063 69818 69819 69860 69901 69941 69982 70023 70064 69819 69860 69901 69942 69983 70024 70025 70066 69821 69862 69903 69943 69984 70025 70066 69821 69862 69903 69944 69985 70026 70066 69821 69862 69903 69944 69985 70026 70067 69822 69863 69904 69905 69945 69988 70027 70066 69823 69864 69905 69945 69988 70027 70066 69823 69864 69905 69946 69985 70027 70066 69823 69864 69905 69946 69987 70029 70070 69825 69866 69907 69948 69988 70029 70070 69825 69866 69907 69948 69999 70030 70071 69826 69865 69867 69908 69949 69900 70031 70072 69826 69867 69908 69909 69950 69991 70032 70073 69828 69869 69910 69951 69991 70032 70073 69828 69869 69910 69951 69991 70032 70073 69828 69869 69910 69951 69991 70032 70073 69828 69869 69910 69951 69991 70032 70073 69828 69869 69910 69951 69991 70032 70073 69828 69869 69910 69951 69991 70032 70073 69828 69869 69910 69951 69991 70032 70073 69828 69869 69910 69955 69993 70033 70074 69829 69870 69911 69952 69993 70034 70075 69830 69871 69912 69953 69994 70035 70076 69831 69972 69913 69954 69955 69999 70034 70075 69830 69871 69912 69955 69999 70034 70075 69830 69871 69912 69955 69999 70034 70075 69830 69871 69912 69955 69999 70034 70075 69831 69972 69913 69955 69999 70034 70075 69831 69972 69913 69955 69999 70040 70036 70077 69832 69877 69918 69955 69999 70040 70041 70072 69837 69838 69874 69915 69955 69999 70040 70041 70078 69838 69877 69918 69959 70000 70041 70042 70083 69836 69877 69918 69919 69960 70001 70044 70045 69838 69844 69883 69924 69965 70000 70044 70045 69834 69839 69800 69921 69960 70001 70044 70045 69834 69834 69834 69924 69965 70000 70044 70045 69834 69834 69834 69924 69965 70000 70044 70045 69834 69834 69883 69924 69965 70000 70044 70045 69834 69834 69883 69924 69966 70000 70004 70045 69834 69834 69883 69924 69966 70000 70004 70045 69834 69834 69883 69924 69966 70007 70004 70045 69834 69834 69925 69966 70007 70004 70044 69084													
69815 69856 69877 69888 69939 70020 70061 69816 69857 69888 69899 69940 69981 70021 70062 69817 69858 69859 69900 69941 69982 70023 70064 69818 69859 69900 69941 69982 70023 70064 69819 69860 69901 69942 69983 70024 70065 69820 69861 69902 69943 69984 70025 70066 69821 69862 69903 69944 69985 70026 70067 69822 69863 69904 69945 69985 70026 70067 69823 69864 69905 69946 69987 70028 70069 69824 69985 69864 69905 69946 69987 70028 70069 69825 69866 69907 69948 69989 70030 70071 69826 69866 69907 69948 69989 70030 70071 69827 69868 69909 69949 69990 70031 70072 69828 69869 69910 69951 69992 70033 70073 69829 69870 69911 69912 69953 69994 70035 70073 69830 69871 69912 69953 69994 70035 70073 69831 69872 69913 69914 69955 69996 70037 70074 69832 69873 69914 69955 69996 70037 70075 69833 69874 69915 69916 69957 69998 70030 70071 69833 69874 69917 69918 69957 69998 70030 70077 69833 69874 69917 69918 69957 69999 70034 70075 69833 69874 69917 69918 69957 69999 70036 70077 69833 69874 69917 69918 69957 69999 70037 70078 69833 69874 69917 69918 69958 69999 70037 70078 69833 69874 69915 69958 69999 70037 70078 69834 69875 69916 69957 69998 70000 70041 70082 69837 69878 69919 69960 70001 70041 70082 69838 69879 69919 69960 70001 70041 70082 69839 69880 69919 69960 70001 70042 70083 69838 69879 69920 69961 70002 70043 69839 69880 69919 69960 70001 70041 70082 69839 69830 69881 69929 69920 69961 70002 70043 69838 69879 69920 69961 70002 70044 69839 69839 69880 69921 69962 70003 70044 70085 69831 69842 69883 69924 69965 70007 70048 69842 69883 69884 69925 69966 70007 70048													
69816 69857 69888 69939 69940 69981 70021 70062 69817 69818 69858 69899 69940 69981 70022 70063 70064 69818 69859 69900 69941 69982 70023 70064 69819 69860 69901 69942 69983 70024 70065 69820 69861 69902 69943 69944 70025 70066 69821 69862 69903 69944 69985 70026 70067 69822 69963 69944 69985 70026 70067 69822 69963 69944 69985 70026 70067 69822 69963 69944 69985 70026 70067 69823 69864 69905 69946 69947 69988 70029 70070 69825 69866 69907 69948 69989 70030 70071 69826 69867 69966 69947 69988 70029 70070 69826 69867 69966 69947 69988 70029 70070 69826 69867 69966 69949 69990 70031 70072 69827 69868 69909 69950 69949 69990 70031 70072 69827 69868 69909 69950 69951 69992 70033 70074 69829 69870 69911 69952 69991 70032 70073 69828 69869 69910 69951 69951 69992 70033 70074 69829 69870 69911 69952 69993 70034 70075 69830 69871 69912 69953 69994 70035 70076 69831 69972 69913 69954 69955 70036 70077 69832 69873 69914 69955 69998 70036 70077 69833 69874 69915 69913 69956 69994 70035 70076 69831 69872 69913 69956 69999 70036 70077 69833 69874 69915 69956 69997 70038 70077 69833 69874 69915 69956 69997 70038 70078 69834 69875 69916 69957 69998 70039 70038 69834 69875 69916 69957 69958 69999 70040 70041 70042 69836 69877 69838 69919 69950 70000 70041 70042 70083 69839 69880 69879 69920 69960 70001 70042 70043 69838 69879 69920 69956 70000 70041 70042 70083 69839 69880 69879 69920 69960 70001 70044 70045 69836 69839 69880 69921 69962 70003 70044 70045 69836 69877 69881 69922 69963 70004 70041 70042 70083 69839 69880 69921 69962 70003 70044 70045 69841 69882 69923 69964 70005 70044 70045 69841 69882 69983 69924 69965 70007 70048 69844 69843 69884 69925 69966 70007 70048 69844 69843 69884 69925 69966 70007 70048 69844 69843 69884 69925 69966 70007 70048 69844 69843 69884 69925 69966 70007 70048 69844 69843 69884 69925 69966 70007 70048 69844 69883 69884 69925 69966 70007 70048 69844 69883 69884 69925 69966 70007 70048 69844 69883 69884 69925 69966 70007 70048 69844 69844 69883 69884 69925 69966 70007 70048 69844 69844 69883													
69817 69858 69899 69940 69981 70022 70063 69818 69859 69900 69941 69982 70023 70064 69819 69860 69901 69942 69983 70024 70065 69820 69861 69902 69943 69984 70025 70066 69821 69863 69904 69945 69986 70027 70068 69823 69864 69905 69946 69987 70028 70029 69824 69865 69906 69947 69988 70029 70070 69825 69866 69907 69948 69989 70030 70071 69827 69868 69907 69948 69999 70031 70072 69827 69868 69907 69948 69999 70031 70073 69828 69869 69910 69951 69992 70033 70074 69828 69870 <													
69818 69859 69900 69941 69822 70023 70064 69820 69861 69902 69943 69984 70025 70065 69821 69862 69903 69944 69985 70026 70067 69823 69864 69905 69946 69987 70028 70069 69824 69865 69906 69947 69988 70029 70070 69826 69867 69906 69947 69988 70029 70070 69826 69867 69908 69949 69990 70031 70072 69827 69868 69909 69950 69991 70030 70073 69829 69867 69908 69949 69990 70031 70072 69829 69869 69910 69950 69991 70033 70074 69829 69870 69811 69952 69993 70033 70074 69830 69870 <													
69819 69860 69901 69942 69983 70024 70065 69820 69861 69902 69943 69944 70025 70066 69821 69862 69903 69944 69985 70026 70067 69822 69863 69904 69945 69986 70027 70068 69823 69864 69905 69946 69987 70028 70069 69824 69865 69906 69947 69988 70029 70070 69825 69866 69907 69948 69989 70030 70071 69825 69866 69907 69948 69989 70030 70071 69826 69827 69868 69909 69950 69949 69990 70031 70072 69828 69869 69910 69951 69952 70033 70074 69829 69870 69911 69952 69993 70034 70075 69829 69870 69911 69952 69993 70034 70075 69830 69871 69912 69953 69944 70035 70076 69831 69872 69913 69954 69955 70036 70077 69832 69873 69914 69955 69966 70037 70078 69834 69875 69916 69956 69956 69998 70039 70039 70078 69834 69875 69916 69957 69958 69998 70039 70080 69837 69837 69916 69957 69958 69999 70040 70081 69837 69838 69877 69918 69958 69959 70000 70041 70082 69837 69838 69877 69918 69959 70000 70041 70082 69837 69838 69877 69918 69959 70000 70041 70082 69837 69838 69877 69918 69959 70000 70041 70082 69837 69838 69879 69916 69957 69958 69999 70040 70081 69837 69838 69879 69919 69960 70001 70042 70083 69839 69838 69879 69920 69961 70002 70043 70084 69839 69880 69879 69920 69961 70002 70043 70084 69839 69840 69881 69922 69963 70004 70045 70086 69841 69842 69983 69994 69920 69961 70004 70045 69841 69842 69984 69955 70004 70045 69841 69842 69984 69965 70004 70045 69841 69842 69984 69965 70004 70045 69841 69842 69984 69965 70004 70045 69844 69985 69844 69985 69889 69889 69889 69889 69889 69889 69889 69889 69889 69889 69889 69889 69889 69880 69921 69960 70001 70042 70083 69844 69985 69844 69985 70004 70045 70086 69841 69884 69985 69966 70007 70048 69884													
69820 69861 69902 69943 69984 70025 70066 69821 69982 69903 69944 69985 70026 70067 70068 69822 69903 69946 69945 69986 70027 70068 69823 69864 69905 69946 69987 70028 70069 69824 69825 69966 69947 69948 70029 70070 69825 69826 69826 69867 69907 69948 69989 70030 70071 69826 69827 69868 69909 69949 69990 70031 70072 69828 69827 69868 69909 69950 69951 70032 70073 69828 69829 69970 69910 69951 69952 69969 69970 69949 69990 70031 70072 69828 69829 69970 69911 69952 69993 70034 70075 69831 69871 69912 69953 69994 70035 70076 69831 69872 69913 69954 69955 70036 70077 69832 69873 69914 69955 69956 69995 70036 70077 69834 69875 69916 69915 69956 69997 70038 70079 69834 69875 69916 69957 69958 69999 70040 70081 69835 69836 69877 69918 69957 69958 69999 70040 70081 69835 69837 69878 69919 69950 70001 70042 70083 69837 69838 69879 69919 69950 70001 70042 70083 69838 69879 69919 69950 70000 70041 70082 69838 69839 69880 69919 69950 70000 70041 70082 69838 69879 69919 69960 70001 70042 70083 69838 69879 69919 69960 70001 70042 70083 69839 69840 69881 69922 69963 70004 70044 70085 69840 69881 69922 69963 70004 70045 70086 69841 69882 69923 69964 70005 70047 70088 69841 69882 69923 69964 70005 70047 70088 69841 69882 69923 69966 70007 70048 70048 69842 69883 69984 69925 69966 70007 70048 70048 69842 69883 69984 69925 69966 70007 70048 70048 69842 69883 69984 69925 69966 70007 70048 70088													
69821 69862 69903 69944 69985 70026 70067 69822 69863 69904 69945 69986 70027 7068 69823 69864 69905 69946 69987 70028 70068 69824 69865 69906 69947 69988 70029 70070 69825 69866 69907 69948 69989 70030 70071 69826 69827 69868 69909 69949 69990 70031 70072 69827 69868 69909 69950 69991 70032 70073 69828 69969 69910 69951 69992 70033 70074 69829 69870 69911 69952 69993 70034 70075 69830 69871 69912 69953 69994 70035 70076 69831 69872 69913 69954 69995 70036 70077 69832 69873 69914 69955 6996 70037 70078 69833 69874 69915 69955 69996 70037 70078 69833 69876 69916 69957 69998 70000 70041 70082 69836 69877 69918 69959 70000 70041 70082 69837 69838 69879 69910 69950 70000 70041 70082 69839 69878 69919 69960 70001 70042 70083 69839 69878 69919 69960 70001 70044 70085 69840 69881 69922 69963 70006 70007 70044 69842 69882 69923 69964 70005 70046 70087 69842 69884 69925 69965 70006 70047 70088 69842 69884 69925 69965 70006 70047 70088													
69822 69863 69904 69945 69986 70027 70068 69823 69864 69905 69946 69987 70029 70070 69824 69865 69906 69947 69988 70029 70070 69825 69866 69907 69948 69989 70030 70071 69826 69867 69908 69949 69990 70031 70072 69827 69868 69909 69950 69991 70032 70073 69828 69869 69910 69951 69992 70033 70074 69829 69870 69911 69952 69993 70034 70075 69830 69871 69912 69953 69993 70034 70075 69831 69872 69913 69954 69995 70035 70076 69832 69873 69913 69955 69996 70037 70038 70077 69833 <													
69823 69864 69905 69946 69987 70028 70069 69824 69865 69906 69947 69988 70029 70070 69825 69866 69907 69948 69989 70030 70071 69826 69867 69908 69949 69990 70031 70072 69827 69868 69909 69950 69991 70032 70073 69828 69869 69910 69951 69992 70033 70074 69829 69870 69911 69952 69993 70034 70075 69830 69871 69912 69953 69994 70035 70076 69831 69872 69913 69954 69955 70036 70077 69833 69873 69914 69955 69996 70037 70078 69834 69875 69916 69957 69998 70039 70080 69834 69876 <													
69824 69865 69906 69947 69988 70029 70070 69825 69866 69907 69948 69989 70030 70071 69826 69867 69908 69949 69990 70031 70072 69827 69868 69909 69950 69991 70032 70073 69828 69869 69910 69951 69992 70033 70074 69829 69870 69911 69952 69993 70034 70075 69830 69871 69912 69953 69994 70035 70076 69831 69872 69913 69954 69995 70036 70077 69832 69873 69914 69955 69996 70037 70078 69833 69874 69915 69955 69996 70037 70078 69834 69875 69916 69957 69988 70039 70080 69835 69876 <													
69825 69866 69907 69948 69989 70030 70071 69826 69867 69908 69949 69990 70031 70072 69827 69868 69909 69950 69991 70032 70073 69828 69869 69910 69951 69992 70033 70074 69829 69870 69911 69952 69993 70034 70075 69830 69871 69912 69953 69994 70035 70076 69831 69872 69913 69954 69995 70036 70077 69832 69873 69914 69955 6996 70037 70078 69833 69874 69915 69956 69997 70038 70079 69834 69875 69916 69957 69998 70039 70080 69836 69876 69917 69958 69999 70040 70041 70082 69837 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>													
69826 69867 69908 69949 69990 70031 70072 69827 69868 69909 69950 69991 70032 70073 69828 69869 69910 69951 69992 70033 70074 69829 69870 69911 69952 69993 70034 70075 69830 69871 69912 69953 69994 70035 70076 69831 69872 69913 69954 69995 70036 70077 69832 69873 69914 69955 69996 70037 70078 69833 69874 69915 69956 69997 70038 70079 69834 69875 69916 69957 69988 70039 70080 69835 69876 69917 69958 69999 70040 70081 69836 69877 69918 69959 70000 70041 70082 69837 69878 <													
69827 69868 69909 69950 69991 70032 70073 69828 69869 69910 69951 69992 70033 70074 69829 69870 69911 69952 69993 70034 70075 69830 69871 69912 69953 69994 70035 70076 69831 69872 69913 69954 69995 70036 70077 69832 69873 69914 69955 69996 70037 70078 69833 69874 69915 69956 69997 70038 70079 69834 69875 69916 69957 6998 70039 7008 69835 69876 69917 69958 69998 70040 70081 69836 69877 69918 69959 70000 70041 70082 69837 69878 69919 69960 70001 70042 70083 69838 69879 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>													
69828 69869 69910 69951 69992 70033 70074 69829 69870 69911 69952 69993 70034 70075 69830 69871 69912 69953 69994 70035 70076 69831 69872 69913 69954 69995 70036 70077 69832 69873 69914 69955 69996 70037 70078 69833 69874 69915 69956 69997 70038 70079 69834 69875 69916 69957 69998 70039 70080 69835 69876 69917 69958 69999 70040 70081 69836 69877 69918 69959 70000 70041 70082 69837 69878 69919 69960 70001 70042 70083 69838 69879 69910 70002 70043 70084 69840 69881 69921 <													
69829 69870 69911 69952 69993 70034 70075 69830 69871 69912 69953 69994 70035 70076 69831 69872 69913 69954 69995 70036 70077 69832 69873 69914 69955 69996 70037 70078 69833 69874 69915 69956 69997 70038 70079 69834 69875 69916 69957 69988 70039 70080 69835 69876 69917 69958 69999 70040 70081 69836 69877 69918 69959 70000 70041 70082 69837 69878 69919 69960 70001 70042 70083 69838 69879 69920 69961 70002 70043 70084 69840 69881 69922 69963 70004 70045 70086 69841 69982 <													
69830 69871 69912 69953 69994 70035 70076 69831 69872 69913 69954 69995 70036 70077 69832 69873 69914 69955 69996 70037 70078 69833 69874 69915 69956 69997 70038 70079 69834 69875 69916 69957 69988 70039 70080 69835 69876 69917 69958 69999 70040 70081 69836 69877 69918 69959 70000 70041 70082 69837 69878 69919 69960 70001 70042 70083 69838 69879 69920 69961 70002 70043 70044 69839 6980 69921 69962 70003 70044 70085 69840 69881 69922 69963 70004 70045 70086 69842 69883 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>													
69831 69872 69913 69954 69995 70036 70077 69832 69873 69914 69955 69996 70037 70078 69833 69874 69915 69956 69997 70038 70079 69834 69875 69916 69957 69998 70039 70080 69835 69876 69917 69958 69999 70040 70081 69836 69877 69918 69959 70000 70041 70082 69837 69878 69919 69960 70001 70042 70083 69838 69879 69920 69961 70002 70043 70084 69839 6980 69921 69962 70003 70044 70085 69840 69881 69922 69963 70004 70045 70086 69841 69982 69923 69964 70005 70046 70087 69842 69883 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>													
69832 69873 69914 69955 69996 70037 70078 69833 69874 69915 69956 69997 70038 70079 69834 69875 69916 69957 69998 70039 70080 69835 69876 69917 69958 69999 70040 70081 69836 69877 69918 69959 70000 70041 70082 69837 69878 69919 69960 70001 70042 70083 69838 69879 69920 69961 70002 70043 70084 69839 69880 69921 69962 70003 70044 70085 69840 69881 69922 69963 70004 70045 70086 69841 69882 69923 69964 70005 70046 70087 69842 69883 69984 69965 70006 70047 70088 69843 69844 <													
69833 69874 69915 69956 69997 70038 70079 69834 69875 69916 69957 69988 70039 70080 69835 69876 69917 69958 69999 70040 70081 69836 69877 69918 69959 70000 70041 70082 69837 69878 69919 69960 70001 70042 70083 69838 69879 69920 69961 70002 70043 70084 69839 69880 69921 69962 70003 70044 70085 69840 69881 69922 69963 70004 70045 70086 69841 69882 69923 69964 70005 70046 70087 69842 69883 69924 69965 70006 70047 70088 69843 69884 69925 69966 70007 70048 70089													
69834 69875 69916 69957 69998 70039 70080 69835 69876 69917 69958 69999 70040 70081 69836 69877 69918 69959 70000 70041 70082 69837 69878 69919 69960 70001 70042 70083 69838 69879 69920 69961 70002 70043 70084 69839 69880 69921 69962 70003 70044 70085 69840 69881 69922 69963 70004 70045 70086 69841 69882 69923 69964 70005 70046 70087 69842 69883 69924 69965 70006 70047 70089 69843 6984 69925 69966 70007 70048 70089													
69835 69876 69917 69958 69999 70040 70081 69836 69877 69918 69959 70000 70041 70082 69837 69878 69919 69960 70001 70042 70083 69838 69879 69920 69961 70002 70043 70084 69839 69880 69921 69962 70003 70044 70085 69840 69881 69922 69963 70004 70045 70086 69841 69882 69923 69964 70005 70046 70087 69842 69883 69924 69965 70006 70047 70088 69843 6984 69925 69966 70007 70048 70089													
69836 69877 69918 69959 70000 70041 70082 69837 69878 69919 69960 70001 70042 70083 69838 69879 69920 69961 70002 70043 70084 69839 69880 69921 69962 70003 70044 70085 69840 69881 69922 69963 70004 70045 70086 69841 69882 69923 69964 70005 70046 70087 69842 69883 69924 69965 70006 70047 70088 69843 69844 69925 69966 70007 70048 70089													
69837 69878 69919 69960 70001 70042 70083 69838 69879 69920 69961 70002 70043 70084 69839 69880 69921 69962 70003 70044 70085 69840 69881 69922 69963 70004 70045 70086 69841 69882 69923 69964 70005 70046 70087 69842 69883 69924 69965 70006 70047 70089 69843 6984 69925 69966 70007 70048 70089													
69838 69879 69920 69961 70002 70043 70084 69839 69880 69921 69962 70003 70044 70085 69840 69881 69922 69963 70004 70045 70086 69841 69882 69923 69964 70005 70046 70087 69842 69883 69924 69965 70006 70047 70089 69843 6984 69925 69966 70007 70048 70089													
69839 69880 69921 69962 70003 70044 70085 69840 69881 69922 69963 70004 70045 70086 69841 69882 69923 69964 70005 70046 70087 69842 69883 69924 69965 70006 70047 70089 69843 69844 69925 69966 70007 70048 70089													
69840 69881 69922 69963 70004 70045 70086 69841 69882 69923 69964 70005 70046 70087 69842 69883 69924 69965 70006 70047 70088 69843 69884 69925 69966 70007 70048 70089													
69841 69882 69923 69964 70005 70046 70087 69842 69883 69924 69965 70006 70047 70088 69843 6984 69925 69966 70007 70048 70089													
69842 69883 69924 69965 70006 70047 70088 69843 69844 69925 69966 70007 70048 70089													
69843 69884 69925 69966 70007 70048 70089													
69844 69885 69926 69967 70008 70049 70090													
		69844	69885	69	926		69967		70008		70049		70090

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb		Bl. nb		. Bl. o nb	No	Bl.		Trt. No	
		DDD		DDD						PPD		_	DD	
PPD	70091	PPD	70132	PPD	70173	PPD	70214	PPD	70255		70296	Р		70337
	70092		70133		70174		70215		70256		70297			70338
	70093		70134		70175		70216		70257		70298			70339
	70094		70135		70176		70217		70258		70299			70340
	70095		70136		70177		70218		70259		70300			70341
	70096		70137		70178		70219		70260		70301			70342
	70097		70138		70179		70220		70261		70302			70343
	70098		70139		70180		70221		70262		70303			70344
	70099		70140		70181		70222		70263		70304			70345
	70100		70141		70182		70223		70264		70305			70346
	70101		70142		70183		70224		70265		70306			70347
	70102		70143		70184		70225		70266		70307			70348
	70103		70144		70185		70226		70267		70308			70349
	70104		70145		70186		70227		70268		70309			70350
	70105		70146		70187		70228		70269		70310			70351
	70106		70147		70188		70229		70270		70311			70352
	70107		70148		70189		70230		70271		70312			70353
	70108		70149		70190		70231		70272		70313			70354
	70109		70150		70191		70232		70273		70314			70355
	70110		70151		70192		70233		70274		70315			70356
	70111		70152		70193		70234		70275		70316			70357
	70112		70153		70194		70235		70276		70317			70358
	70113		70154		70195		70236		70277		70318			70359
	70114		70155		70196		70237		70278		70319			70360
	70115		70156		70197		70238		70279		70320			70361
	70116		70157		70198		70239		70280		70321			70362
	70117		70158		70199		70240		70281		70322			70363
	70118		70159		70200		70241		70282		70323			70364
	70119		70160		70201		70242		70283		70324			70365
	70120		70161		70202		70243		70284		70325			70366
	70121		70162		70203		70244		70285		70326			70367
	70122 70123		70163		70204 70205		70245 70246		70286 70287		70327 70328			70368 70369
	70123		70164		70205						70328			
	70124		70165				70247		70288		70329			70370
			70166		70207		70248		70289					70371
	70126		70167		70208		70249		70290		70331			70372
	70127		70168		70209		70250		70291		70332			70373
	70128		70169		70210		70251		70292		70333			70374
	70129		70170		70211		70252		70293		70334			70375
	70130		70171		70212		70253		70294		70335			70376
	70131		70172		70213		70254		70295		70336			70377

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt	. Bl.	Trt.	. Bl.	Trt.	. Bl.	Trt.	. Bl.	Trt	. Bl.	Trt	. Bl.	Tr	t. Bl.
No	o nb		nb		o nb	No	nb	N	o nb		o nb	1	No nb
PPD	70378	PPD	70419	PPD	70460	PPD	70501	PPD	70542	PPD	70583	PPD	70624
	70379		70420		70461		70502		70543		70584		70625
	70380		70421		70462		70503		70544		70585		70626
	70381		70422		70463		70504		70545		70586		70627
	70382		70423		70464		70505		70546		70587		70628
	70383		70424		70465		70506		70547		70588		70629
	70384		70425		70466		70507		70548		70589		70630
	70385		70426		70467		70508		70549		70590		70631
	70386		70427		70468		70509		70550		70591		70632
	70387		70428		70469		70510		70551		70592		70633
	70388		70429		70470		70511		70552		70593		70634
	70389		70430		70471		70512		70553		70594		70635
	70390		70431		70472		70513		70554		70595		70636
	70391		70432		70473		70514		70555		70596		70637
	70392		70433		70474		70515		70556		70597		70638
	70393		70434		70475		70516		70557		70598		70639
	70394		70435		70476		70517		70558		70599		70640
	70395		70436		70477		70518		70559		70600		70641
	70396		70437		70478		70519		70560		70601		70642
	70397		70438		70479		70520		70561		70602		70643
	70398		70439		70480		70521		70562		70603		70644
	70399		70440		70481		70522		70563		70604		70645
	70400		70441		70482		70523		70564		70605		70646
	70401		70442		70483		70524		70565		70606		70647
	70402		70443		70484		70525		70566		70607		70648
	70403		70444		70485		70526		70567		70608		70649
	70404		70445		70486		70527		70568		70609		70650
	70405		70446		70487		70528		70569		70610		70651
	70406		70447		70488		70529		70570		70611		70652
	70407		70448		70489		70530		70571		70612		70653
	70408		70449		70490		70531		70572		70613		70654
	70409		70450		70491		70532		70573		70614		70655
	70410		70451		70492		70533		70574		70615		70656
	70411		70452		70493		70534		70575		70616		70657
	70412		70453		70494		70535		70576		70617		70658
	70413		70454		70495		70536		70577		70618		70659
	70414		70455		70496		70537		70578		70619		70660
	70415		70456		70497		70538		70579		70620		70661
	70416		70457 70458		70498 70499		70539		70580		70621		70662
	70417 70418						70540		70581		70622 70623		70663
	/0418		70459		70500		70541		70582		10023		70664

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	B1.	Trt.	B1.	Trt.	Bl.	Trt.	Bl.	Trt.	B1.	Trt.	Bl.
No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	70665	PPD	70706	PPD	70747	PPD	70788	PPD	70829	PPD	70870
	70666		70707		70748		70789		70830	–	70871
	70667		70708		70749		70790		70831		70872
	70668		70709		70750		70791		70832		70873
	70669		70710		70751		70792		70833		70874
	70670		70711		70752		70793		70834		70875
	70671		70712		70753		70794		70835		70876
	70672		70713		70754		70795		70836		70877
	70673		70714		70755		70796		70837		70878
	70674		70715		70756		70797		70838		70879
	70675		70716		70757		70798		70839		70880
	70676		70717		70758		70799		70840		70881
	70677		70718		70759		70800		70841		70882
	70678		70719		70760		70801		70842		70883
	70679		70720		70761		70802		70843		70884
	70680		70721		70762		70803		70844		70885
	70681		70722		70763		70804		70845		70886
	70682		70723		70764		70805		70846		70887
	70683		70724		70765		70806		70847		70888
	70684		70725		70766		70807		70848		70889
	70685		70726		70767		70808 70809		70849		70890 70891
	70686 70687		70727 70728		70768 70769		70810		70850 70851		70891
	70687		70729		70769		70810		70851		70892
	70688		70729		70770		70811		70852		70893
	70690		70731		70771		70812		70854		70895
	70691		70732		70773		70814		70855		70895
	70692		70733		70774		70815		70856		70897
	70693		70734		70775		70816		70857		70898
	70694		70735		70776		70817		70858		70899
	70695		70736		70777		70818		70859		70900
	70696		70737		70778		70819		70860		70901
	70697		70738		70779		70820		70861		70902
	70698		70739		70780		70821		70862		70903
	70699		70740		70781		70822		70863		70904
	70700		70741		70782		70823		70864		70905
	70701		70742		70783		70824		70865		70906
	70702		70743		70784		70825		70866		
	70703		70744		70785		70826		70867		
	70704		70745		70786		70827		70868		•
	70705		70746		70787		70828		70869		
			'		-						

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	40907	PPD 40948	PPD 40989	PPD 41030	PPD 41071	PPD 41112	PPD 41153
PPD	40907	40948 40949	40989	41030 41031	41071 41072	41112	41153
	40908	40949	40990	41031	41072	41113	41154
	40909	40950	40991	41032	41073	41114	41155
	40910	40951	40993	41033	41074	41116	41157
	40911	40952	40993	41034	41075	41116	41157
	40912	40953	40994	41035	41076	41117	41158
	40913	40954	40996	41036	41077	41110	41159
	40914	40955	40996	41037	41078	41119	41160
	40915	40956	40997	41036	41079	41120	41161
	40916	40957	40998	41039	41080	41121	41162
	40917	40958	41000	41040	41082	41123	41164
	40918	40959	41000	41041	41082	41123	41164
	40919	40960	41001	41042	41083	41124	41166
	40920	40961	41002	41043	41084	41126	41167
	40921	40962	41003	41044	41085	41126	41167
	40922	40963	41004	41045	41086	41127	
	40923	40964	41005	41046	41087	41128	41169 41170
	40924	40965	41006	41047	41088		41170
	40925	40966	41007	41048	41089	41130 41131	41171
	40926	40967	41008	41049	41090	41131	41172
	40927	40968	41009	41050	41091	41132	41174
	40928	40969	41010	41051	41092	41133	41174
	40929	40970	41011	41052	41093	41134	41176
	40930	40971	41012	41054	41094	41135	41177
	40931	40972	41013	41054	41095	41137	41177
	40932	40973	41014	41055	41096	41137	41179
	40933	40974	41015	41056	41097	41130	41179
	40934	40975	41016	41057	41098	41139	41180
	40936	40976	41017	41058	41100	41140	41182
	40936	40977	41018	41059	41100	41141	41183
	40937	40978	41019	41061	41101	41143	41184
	40936	40979	41020	41062	41102	41143	41185
	40939	40980	41021	41062	41103	41145	41186
	40940	40981	41022	41064	41104	41145	41187
	40941	40983	41023	41065	41105	41147	41188
	40942	40984	41024	41065	41106	41147	41189
	40943	40985	41025	41066	41107	41149	41109
	40944	40985	41026	41067	41108	41149	41190
	40945	40986	41027	41068	41109	41150	41191
	40946	40987	41028	41069	41110	41151	41192
	40947	40988	41029	41070	41111	41152	41193

DTPA-HBV-IPV-135 (A.15MAR2018)

	Bl.	Trt. Bl.	Trt. Bl.	Trt.		Trt.			Bl.		. Bl.
	nb	No nb	No nb	No			nb		nb	No	o nb
PPD	41194	PPD 41235	PPD 41276	PPD	41317	PPD	41358	PPD	41399	PPD	41440
FFD	41195	41236	41277	110	41317	FFD	41359		41400		41441
	41196	41237	41277		41319		41360		41401		41442
	41197	41237	41279		41320		41361		41402		41443
	41198	41239	41280		41321		41362		41403		41444
	41199	41240	41280		41321		41363		41404		41445
	41200	41240	41282		41323		41364		41405		41446
	41200	41242	41283		41324		41365		41406		41447
	41201	41243	41284		41325		41366		41407		41448
	41202	41243	41285		41326		41367		41407		41449
	41203	41244	41286		41327		41368		41409		41450
	41205	41246	41287		41328		41369		41410		41451
	41206	41247	41288		41329		41370		41411		41452
	41207	41248	41289		41330		41371		41412		41453
	41207	41249	41200		41331		41372		41413		41454
	41200	41250	41291		41332		41373		41414		41455
	41210	41251	41292		41333		41374		41415		41456
	41211	41252	41293		41334		41375		41416		41457
	41212	41253	41294		41335		41376		41417		41458
	41213	41254	41295		41336		41377		41418		41459
	41213	41255	41296		41337		41378		41419		41460
	41215	41256	41297		41338		41379		41420		41461
	41216	41257	41298		41339		41380		41421		41462
	41217	41258	41299		41340		41381		41422		41463
	41218	41259	41300		41341		41382		41423		41464
	41219	41260	41301		41342		41383		41424		41465
	41220	41261	41302		41343		41384		41425		41466
	41221	41262	41303		41344		41385		41426		41467
	41222	41263	41304		41345		41386		41427		41468
	41223	41264	41305		41346		41387		41428		41469
	41224	41265	41306		41347		41388		41429		41470
	41225	41266	41307		41348		41389		41430		41471
	41226	41267	41308		41349		41390		41431		41472
	41227	41268	41309		41350		41391		41432		41473
	41228	41269	41310		41351		41392		41433		41474
	41229	41270	41311		41352		41393		41434		41475
	41230	41271	41312		41353		41394		41435		41476
	41231	41272	41313		41354		41395		41436		41477
	41232	41273	41314		41355		41396		41437		41478
	41233	41274	41315		41356		41397		41438		41479
	41234	41275	41316		41357		41398		41439		41480
			-1010								
							l				

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.					
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	41481	PPD 41522	PPD 41563	PPD 41604	PPD 41645	PPD 41686	PPD 41727
	41482	41523	41564	41605	41646	41687	41728
	41483	41524	41565	41606	41647	41688	41729
	41484	41525	41566	41607	41648	41689	41730
	41485	41526	41567	41608	41649	41690	41731
	41486	41527	41568	41609	41650	41691	41732
	41487	41528	41569	41610	41651	41692	41733
	41488	41529	41570	41611	41652	41693	41734
	41489	41530	41571	41612	41653	41694	41735
	41490	41531	41572	41613	41654	41695	41736
	41491	41532	41573	41614	41655	41696	41737
	41492	41533	41574	41615	41656	41697	41738
	41493	41534	41575	41616	41657	41698	41739
	41494	41535	41576	41617	41658	41699	41740
	41495	41536	41577	41618	41659	41700	41741
	41496	41537	41578	41619	41660	41701	41742
	41497	41538	41579	41620	41661	41702	41743
	41498	41539	41580	41621	41662	41703	41744
	41499	41540	41581	41622	41663	41704	41745
	41500	41541	41582	41623	41664	41705	41746
	41501	41542	41583	41624	41665	41706	41747
	41502	41543	41584	41625	41666	41707	41748
	41503	41544	41585	41626	41667	41708	41749
	41504	41545	41586	41627	41668	41709	41750
	41505	41546	41587	41628	41669	41710	41751
	41506	41547	41588	41629	41670	41711	41752
	41507	41548	41589	41630	41671	41712	41753
	41508	41549	41590	41631	41672	41713	41754
	41509	41550	41591	41632	41673	41714	41755
	41510	41551	41592	41633	41674	41715	41756
	41511	41552	41593	41634	41675	41716	41757
	41512	41553	41594	41635	41676	41717	41758
	41513	41554	41595	41636	41677	41718	41759
	41514	41555	41596	41637	41678	41719	41760
	41515	41556	41597	41638	41679	41720	41761
	41516	41557	41598	41639	41680	41721	41762
	41517	41558	41599	41640	41681	41722	41763
	41518	41559	41600	41641	41682	41723	41764
	41519	41560	41601	41642	41683	41724	41765
	41520	41561	41602	41643	41684	41725	41766
	41521	41562	41603	41644	41685	41726	41767

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
	No nb					
41807	41848	41889	41930	41971	42012	42053
41808	41849	41890	41931	41972	42013	42054

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	B1.	Trt. Bl.	Trt. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No nb	No nb	No	nb	No	nb	No	nb	No	nb
PPD	42055	PPD 42096	PPD 42137	PPD	42178	PPD	42219	PPD	42260	PPD	42301
FFD	42055	42097	42137		42179	FFD	42219		42260	110	42301
	42056	42097	42130		42179		42220		42261		42302
	42057	42098	42139		42181		42221		42263		42303
	42050	42100	42140		42182		42223		42264		42304
									42264		
	42060 42061	42101 42102	42142 42143		42183		42224 42225		42265		42306 42307
	1 1				42184						
	42062	42103	42144		42185		42226		42267		42308
	42063	42104	42145		42186		42227		42268		42309
	42064	42105	42146 42147		42187		42228 42229		42269 42270		42310
	42065	42106			42188						42311
	42066	42107	42148		42189		42230		42271		42312
	42067	42108	42149		42190		42231		42272		42313
	42068	42109	42150		42191		42232		42273		42314
	42069	42110	42151		42192		42233		42274		42315
	42070	42111	42152		42193		42234		42275		42316
	42071	42112	42153		42194		42235		42276		42317
	42072	42113	42154		42195		42236		42277		42318
	42073	42114	42155		42196		42237		42278		42319
	42074	42115	42156		42197		42238		42279		42320
	42075	42116	42157		42198		42239		42280		42321
	42076	42117	42158		42199		42240		42281		42322
	42077	42118	42159		42200		42241		42282		42323
	42078	42119	42160		42201		42242		42283		42324
	42079	42120	42161		42202		42243		42284		42325
	42080	42121	42162		42203		42244		42285		42326
	42081	42122	42163		42204		42245		42286		42327
	42082	42123	42164		42205		42246		42287		42328
	42083	42124	42165		42206		42247		42288		42329
	42084	42125	42166		42207		42248		42289		42330
	42085	42126	42167		42208		42249		42290		42331
	42086	42127	42168		42209		42250		42291		42332
	42087	42128	42169		42210		42251		42292		42333
	42088	42129	42170		42211		42252		42293		42334
	42089	42130	42171		42212		42253		42294		42335
	42090	42131	42172		42213		42254		42295		42336
	42091	42132	42173		42214		42255		42296		42337
	42092	42133	42174		42215		42256		42297		42338
	42093	42134	42175		42216		42257		42298		42339
	42094	42135	42176		42217		42258		42299		42340
	42095	42136	42177		42218		42259		42300		42341
							ı		•		4

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No nb		nb		nb		nb		nb	No	nb
PPD	42342	PPD 42383	PPD	42424	PPD	42465	PPD	42506	PPD	42547	PPD	42588
FFD	42342	42384		42424	FFD	42466	PPD	42507		42548	110	42589
	42343	42385		42425		42467		42507		42549		42599
	42344	42386		42426		42467		42509		42550		42590
	42345	42387		42428		42469		42510		42551		42591
	42346	42388		42420		42470		42510		42552		42592
	42347	42389		42429		42470		42512		42553		42593
	42349	42390		42430		42471		42512		42554		42594
	42349	42390		42431		42472		42514		42555		42596
	42350	42391		42432		42474		42515		42556		42596
	42351	42392		42433		42474		42516		42557		42597
	42352	42393		42434		42476		42517		42558		42596
	42353	42394		42435		42476		42517		42559		42599
	42354	42393		42436		42477		42519		42560		42600
	42356	42396		42437		42479		42520		42561		42601
	42356	42397		42438		42479		42520		42561		42602
	42357	42398		42439		42480		42521		42562		42603
	42358	42399		42440		42481		42522		42563		42604
	42359	42400		42441				42523		42564		42605
	42360	42401		42442		42483 42484		42524		42566		42606
	42362	42402		42443		42485		42526		42567		42607
	42362	42403		42444		42486		42527		42568		42608
	42363	42404		42445		42487		42528		42569		42609
	42364	42403		42447		42488		42529		42570		42610
	42365	42406		42447		42489		42530		42571		42611
	42367	42407		42449		42490		42531		42572		42613
	42367	42400		42449		42490		42532		42573		42613
	42369	42409		42450		42491		42532		42574		42614
	42369	42410		42451		42492		42533		42575		42615
	42370	42411		42452		42493		42535		42576		42616
	42371	42412		42453		42494		42536		42577		42617
	42372	42413		42455		42496		42537		42578		42619
	42374	42415		42456		42497		42538		42579		42620
	42375	42416		42457		42498		42539		42580		42621
	42376	42410		42458		42499		42540		42581		42622
	42377	42417		42459		42500		42541		42582		42623
	42377	42419		42460		42501		42542		42583		42623
	42379	42413		42461		42502		42543		42584		42625
	42379	42420		42462		42503		42544		42585		42625
	42381	42421		42463		42504		42545		42586		42627
	42382	42422		42464		42505		42546		42587		42628
	12302	12423		12101		12303		12370		12307		12020
										l		

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt	. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
N	o nb	No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
-		PPD		PPD				DDD		PPD		PPD	
PPD		PPD	42670	PPD		PPD	42752	PPD	42793		42834	PPD	42875
	42630		42671		42712		42753		42794		42835		42876
	42631		42672		42713		42754		42795		42836		42877
	42632		42673		42714		42755		42796		42837		42878
	42633		42674		42715		42756		42797		42838		42879
	42634		42675		42716		42757		42798		42839		42880
	42635		42676		42717		42758		42799		42840		42881
	42636		42677		42718		42759		42800		42841		42882
	42637		42678		42719		42760		42801		42842		42883
	42638		42679		42720		42761		42802		42843		42884
	42639		42680		42721		42762		42803		42844		42885
	42640		42681		42722		42763		42804		42845		42886
	42641		42682		42723		42764		42805		42846		42887
	42642		42683		42724		42765		42806		42847		42888
	42643		42684		42725		42766		42807		42848		42889
	42644		42685		42726		42767		42808		42849		42890
	42645		42686		42727		42768		42809		42850		42891
	42646		42687		42728		42769		42810		42851		42892
	42647		42688		42729		42770		42811		42852		42893
	42648		42689		42730		42771		42812		42853		42894
	42649		42690		42731		42772		42813		42854		42895
	42650		42691		42732		42773		42814		42855		42896
	42651		42692		42733		42774		42815		42856		42897
	42652		42693		42734		42775		42816		42857		42898
	42653		42694		42735		42776		42817		42858		42899
	42654		42695		42736		42777		42818		42859		42900
	42655		42696		42737		42778		42819		42860		42901
	42656		42697		42738		42779		42820		42861		42901
	42657		42698		42739		42780		42821		42862		42902
	42658		42699		42740		42781		42822		42863		42903
	42658		42699		42740		42781		42822		42863		42904
	42660		42701		42742		42783		42824		42865		42905
			42701		42743				42824				42906
	42661						42784				42866		
	42662		42703		42744		42785		42826		42867		42908
	42663		42704		42745		42786		42827		42868		42909
	42664		42705		42746		42787		42828		42869		42910
	42665		42706		42747		42788		42829		42870		42911
	42666		42707		42748		42789		42830		42871		42912
	42667		42708		42749		42790		42831		42872		42913
	42668		42709		42750		42791		42832		42873		42914
	42669		42710		42751		42792		42833		42874		42915
					•						•		•

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	42916	PPD 42957	PPD 42998	PPD 43039	PPD 43080	PPD 43121	PPD 43162
110	42917	42958	42999	43040	43081	43122	43163
	42918	42959	43000	43041	43082	43123	43164
	42919	42960	43001	43042	43083	43124	43165
	42920	42961	43002	43043	43084	43125	43166
	42921	42962	43003	43044	43085	43126	43167
	42922	42963	43004	43045	43086	43127	43168
	42923	42964	43005	43046	43087	43128	43169
	42924	42965	43006	43047	43088	43129	43170
	42925	42966	43007	43048	43089	43130	43171
	42926	42967	43008	43049	43090	43131	43172
	42927	42968	43009	43050	43091	43132	43173
	42928	42969	43010	43051	43092	43133	43174
	42929	42970	43011	43052	43093	43134	43175
	42930	42971	43012	43053	43094	43135	43176
	42931	42972	43013	43054	43095	43136	43177
	42932	42973	43014	43055	43096	43137	43178
	42933	42974	43015	43056	43097	43138	43179
	42934	42975	43016	43057	43098	43139	43180
	42935	42976	43017	43058	43099	43140	43181
	42936	42977	43018	43059	43100	43141	43182
	42937	42978	43019	43060	43101	43142	43183
	42938	42979	43020	43061	43102	43143	43184
	42939	42980	43021	43062	43103	43144	43185
	42940	42981	43022	43063	43104	43145	43186
	42941	42982	43023	43064	43105	43146	43187
	42942	42983	43024	43065	43106	43147	43188
	42943	42984	43025	43066	43107	43148	43189
	42944	42985	43026	43067	43108	43149	43190
	42945	42986	43027	43068	43109	43150	43191
	42946	42987	43028	43069	43110	43151	43192
	42947	42988	43029	43070	43111	43152	43193
	42948	42989	43030	43071	43112	43153	43194
	42949	42990	43031	43072	43113	43154	43195
	42950	42991	43032	43073	43114	43155	43196
	42951	42992	43033	43074	43115	43156	43197
	42952	42993	43034	43075	43116	43157	43198
	42953	42994	43035	43076	43117	43158	43199
	42954	42995	43036	43077	43118	43159	43200
	42955	42996	43037	43078	43119	43160	43201
	42956	42997	43038	43079	43120	43161	43202
	l						

DTPA-HBV-IPV-135 (A.15MAR2018)

Bl. o nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb
nb	No	nb 	No	nb 	No	nb 	No	nb 	No	nb	PPD	nb
43231 43232 43233 43234 43235 43236 43237 43238 43239 43240 43241 43242 43243		43272 43272 43273 43274 43275 43276 43277 43278 43279 43280 43281 43282 43283 43284		43312 43313 43314 43315 43316 43317 43318 43319 43320 43321 43322 43322 43323 43324 43325		43353 43355 43355 43357 43358 43359 43360 43361 43362 43363 43363 43364 43365 43366		43394 43395 43396 43398 43399 43400 43401 43402 43403 43404 43405 43406 43407		43435 43436 43437 43438 43440 43441 43442 43443 43444 43445 43446 43446 43447 43448		43476 43477 43478 43479 43480 43481 43482 43483 43484 43485 43486 43487 43488 43489

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.					
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	43490	PPD 43531	PPD 43572	PPD 43613	PPD 43654	PPD 43695	PPD 43736
–	43491	43532	43573	43614	43655	43696	43737
	43492	43533	43574	43615	43656	43697	43738
	43493	43534	43575	43616	43657	43698	43739
	43494	43535	43576	43617	43658	43699	43740
	43495	43536	43577	43618	43659	43700	43741
	43496	43537	43578	43619	43660	43701	43742
	43497	43538	43579	43620	43661	43702	43743
	43498	43539	43580	43621	43662	43703	43744
	43499	43540	43581	43622	43663	43704	43745
	43500	43541	43582	43623	43664	43705	43746
	43501	43542	43583	43624	43665	43706	43747
	43502	43543	43584	43625	43666	43707	43748
	43503	43544	43585	43626	43667	43708	43749
	43504	43545	43586	43627	43668	43709	43750
	43505	43546	43587	43628	43669	43710	43751
	43506	43547	43588	43629	43670	43711	43752
	43507	43548	43589	43630	43671	43712	43753
	43508	43549	43590	43631	43672	43713	43754
	43509	43550	43591	43632	43673	43714	43755
	43510	43551	43592	43633	43674	43715	43756
	43511	43552	43593	43634	43675	43716	43757
	43512	43553	43594	43635	43676	43717	43758
	43513	43554	43595	43636	43677	43718	43759
	43514	43555	43596	43637	43678	43719	43760
	43515	43556	43597	43638	43679	43720	43761
	43516	43557	43598	43639	43680	43721	43762
	43517	43558	43599	43640	43681	43722	43763
	43518	43559	43600	43641	43682	43723	43764
	43519	43560	43601	43642	43683	43724	43765
	43520	43561	43602	43643	43684	43725	43766
	43521	43562	43603	43644	43685	43726	43767
	43522	43563	43604	43645	43686	43727	43768
	43523	43564	43605	43646	43687	43728	43769
	43524	43565	43606	43647	43688	43729	43770
	43525	43566	43607	43648	43689	43730	43771
	43526	43567	43608	43649	43690	43731	43772
	43527	43568	43609	43650	43691	43732	43773
	43528	43569	43610	43651	43692	43733	43774
	43529	43570	43611	43652	43693	43734	43775
	43530	43571	43612	43653	43694	43735	43776

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt	. Bl.	Trt. Bl.	Trt.	. Bl.	Trt	. Bl.	Trt.	Bl.	Trt.	. Bl.	Trt	. Bl.
No	nb	No nb		nb	No	o nb		nb	No	nb	N	Io nb
PPD	43777	PPD 43818	PPD	43859	PPD	43900	PPD	43941	PPD	43982	PPD	44023
110	43778	43819		43860	110	43901	110	43942		43983		44024
	43779	43820		43861		43902		43943		43984		44025
	43780	43821		43862		43903		43944		43985		44026
	43781	43822		43863		43904		43945		43986		44027
	43782	43823		43864		43905		43946		43987		44028
	43783	43824		43865		43906		43947		43988		44029
	43784	43825		43866		43907		43948		43989		44030
	43785	43826		43867		43908		43949		43990		44031
	43786	43827		43868		43909		43950		43991		44032
	43787	43828		43869		43910		43951		43992		44033
	43788	43829		43870		43911		43952		43993		44034
	43789	43830		43871		43912		43953		43994		44035
	43790	43831		43872		43913		43954		43995		44036
	43791	43832		43873		43914		43955		43996		44037
	43792	43833		43874		43915		43956		43997		44038
	43793	43834		43875		43916		43957		43998		44039
	43794	43835		43876		43917		43958		43999		44040
	43795	43836		43877		43918		43959		44000		44041
	43796	43837		43878		43919		43960		44001		44042
	43797	43838		43879		43920		43961		44002		44043
	43798	43839		43880		43921		43962		44003		44044
	43799	43840		43881		43922		43963		44004		44045
	43800	43841		43882		43923		43964		44005		44046
	43801	43842		43883		43924		43965		44006		44047
	43802	43843		43884		43925		43966		44007		44048
	43803	43844		43885		43926		43967		44008		44049
	43804	43845		43886 43887		43927		43968		44009		44050
	43805 43806	43846 43847		43888		43928 43929		43969 43970		44010		44051 44052
	43806	43847		43888		43929		43970		44011 44012		44052
	43808	43849		43890		43930		43971		44012		44053
	43809	43850		43891		43931		43973		44013		44054
	43810	43851		43892		43933		43974		44015		44056
	43811	43852		43893		43934		43975		44016		44057
	43812	43853		43894		43935		43976		44017		44058
	43813	43854		43895		43936		43977		44018		44059
	43814	43855		43896		43937		43978		44019		44060
	43815	43856		43897		43938		43979		44020		44061
	43816	43857		43898		43939		43980		44021		44062
	43817	43858		43899		43940		43981		44022		44063
	-											

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl. No nb	Trt. Bl.					
	No nb					
	No nb					
44097	44138	44179	44220	44261	44302	44343
44098	44139	44180	44221	44262	44303	44344
44099	44140	44181	44222	44263	44304	44345
44100	44141	44182	44223	44264	44305	44346
44101	44142	44183	44224	44265	44306	44347
44102	44143	44184	44225	44266	44307	44348
44103	44143	44185	44226	44267	44308	44349
44104	44144	44186	44227	44268	44309	44350

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. B	L.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No nb	No nl		No			nb		nb	No	nb
PPD	44351	PPD 44392	PPD 4	1433	PPD	44474	PPD	44515	PPD	44556	PPD	44597
FFD	44351	44392		1434	FFD	44475	PPD	44515		44556	110	44597
	44353	44394		1435		44476		44517		44558		44599
	44353	44394	_	1436		44477		44517		44559		44599
	44355	44396		1437		44478		44519		44560		44601
	44355	44396		1438		44479		44519		44560		44601
	44356	44397	_	1439		44479		44521		44562		44602
	44357	44399		1440		44481		44521		44562		44603
	44359	44400		1441		44482		44523		44564		44604
	44359	44400		1442		44483		44523		44564		44605
	44360	44401		1442		44463		44525		44566		44606
	44362	44402	_	1443		44485		44526		44567		44607
	44362	44403		1444		44486		44527		44567		44609
	44363	44404	_	1445		44487		44527		44569		44610
	44364	44405		1447		44488		44529		44569		44610
	44365	44407		1448		44489		44529		44570		44612
	44366	44407		1448		44489		44530		44571		44612
	44367	44408		1449 1450		44490		44531		44572		44613
	44368	44409		1450 1451				44532				
	44369	44410		1451		44492 44493		44533		44574 44575		44615 44616
	44370	44411		1453		44493		44534		44576		44617
	44371	44412	_	1454		44495		44536		44576		44617
	44372	44413		1455		44496		44536		44577		44619
	44373	44414	_	1456		44497		44537		44579		44619
	44374	44415		1457		44498		44539		44579		44620
	44376	44417		1458		44499		44539		44581		44621
	44376	44417		1459		44499		44540		44582		44622
	44377	44419		1460		44500		44541		44583		44623
	44378	44419		1461		44501		44542		44583		44624
	44379	44421		1462		44503		44543		44585		44625
	44381	44421		1463		44504		44545		44586		44627
	44382	44423		1464		44505		44546		44587		44628
	44383	44423		1465		44505		44547		44587		44629
	44384	44425		1466		44507		44548		44589		44630
	44385	44426		1467		44508		44549		44590		44631
	44386	44427		1468		44509		44549		44590		44631
	44387	44427		1469		44510		44551		44591		44632
	44387	44429		1470		44510		44551		44592		44634
	44389	44429		1471		44512		44552		44593		44634
	44389	44430		1472		44512		44553		44594		44635
	44390	44431		1473		44513		44554		44595		44636
	44321	44432	4	1713		44014		44000		44330		4403/
	1					l						

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.		t. Bl.	Trt.		Trt.	
No	nb	No nb	No nb	No nb		No nb		nb	No	nb
PPD	44638	PPD 44679	PPD 44720	PPD 44	761 PPD	44802	PPD	44843	PPD	44884
	44639	44680	44721	44		44803		44844	–	44885
	44640	44681	44722	44"		44804		44845		44886
	44641	44682	44723	44	764	44805		44846		44887
	44642	44683	44724	44	765	44806		44847		44888
	44643	44684	44725	44	766	44807		44848		44889
	44644	44685	44726	447	767	44808		44849		44890
	44645	44686	44727	447	768	44809		44850		44891
	44646	44687	44728	447	769	44810		44851		44892
	44647	44688	44729	447	770	44811		44852		44893
	44648	44689	44730	447	771	44812		44853		44894
	44649	44690	44731	447	772	44813		44854		44895
	44650	44691	44732	447	773	44814		44855		44896
	44651	44692	44733	44"	774	44815		44856		44897
	44652	44693	44734	447	775	44816		44857		44898
	44653	44694	44735	44"	776	44817		44858		44899
	44654	44695	44736	44"		44818		44859		44900
	44655	44696	44737	44"	778	44819		44860		44901
	44656	44697	44738	44"	779	44820		44861		44902
	44657	44698	44739	44"	780	44821		44862		44903
	44658	44699	44740	447		44822		44863		44904
	44659	44700	44741	447		44823		44864		44905
	44660	44701	44742	447		44824		44865		44906
	44661	44702	44743	447		44825		44866		44907
	44662	44703	44744	447		44826		44867		44908
	44663	44704	44745	447		44827		44868		44909
	44664	44705	44746	447		44828		44869		44910
	44665	44706	44747	447		44829		44870		44911
	44666	44707	44748	447		44830		44871		44912
	44667	44708	44749	447		44831		44872		44913
	44668	44709	44750	447		44832		44873		44914
	44669	44710	44751	447		44833		44874		44915
	44670	44711	44752	447		44834		44875		44916
	44671	44712	44753	447		44835		44876		44917
	44672	44713 44714	44754 44755	447		44836 44837		44877 44878		44918 44919
	44673 44674	44714	44756	44		44837		44878		44919
	44674	44715	44757	44		44838		44879		44920
		44716	44757			44839				
	44676 44677	44717	44759	447		44840		44881 44882		44922 44923
	44677	44718	44759	448		44841		44882		44923
	44010	44/19	44/60	448	001	44042		44000		44924

DTPA-HBV-IPV-135 (A.15MAR2018)

No nb	Trt. Bl.
PPD 44925 PPD 44966 PPD 45007 PPD 45048 PPD 45089 PPD 45130 44927 44968 44967 45008 45009 45001 45081 45081 45132 44928 44968 45010 45081 45082 45133 44928 44970 45011 45062 45083 45094 45135 45095 45136 45095 45136 45095 45136 45095 45136 45095 45136 45095 45136 45095 45136 45095 45136 45095 45136 45095 45136 45095 45136 45095 45130 45137 45018 45095 45100 45141 45095 45098 45130 44977 45018 45095 45100 45141 44937 44978 45019 45000 45101 45142 44938 44979 45020 45061 45007 45008 45101 45142 44938 44979 44980 45021 45062 45063 45104 45143 44940 44981 44982 45025 45063 45104 45145 44940 44981 44982 45022 45063 45104 45145 44942 44983 44994 44984 44985 45022 45063 45107 45148 44944 44985 44986 45022 45063 45107 45148 44944 44985 44986 45022 45063 45106 45107 45148 44944 44985 44986 45022 45066 45107 45148 44944 44985 44986 45027 45066 45107 45148 44944 44985 44986 45027 45066 45107 45148 44944 44985 44986 45027 45066 45107 45148 44944 44985 44986 45027 45066 45107 45148 44944 44985 44986 45022 45066 45107 45148 44944 44985 44986 45027 45066 45107 45148 44944 44985 44986 45027 45066 45107 45148 44944 44985 44986 45027 45066 45107 45148 44944 44985 44986 45027 45066 45107 45188 45189 44944 44986 44987 45028 45066 45107 45188 45189 44946 44987 44986 45027 45066 45107 45188 45159 45160 45151 45152 45153 45166 45157 45160 45151 45152 45153 45166 45157 45156 45156 45156 45156 45156 45156 45156 45167 45156	No nb
## 4926 ## 4956 ## 45008 ## 45049 ## 45089 ## 45130 ## 4926 ## 49466 ## 45009 ## 45050 ## 45091 ## 45131 ## 44926 ## 44969 ## 45010 ## 45051 ## 45092 ## 45133 ## 44929 ## 44970 ## 45011 ## 45052 ## 45093 ## 45134 ## 44930 ## 44971 ## 45012 ## 45053 ## 45095 ## 45135 ## 44931 ## 44972 ## 45013 ## 45055 ## 45095 ## 45135 ## 44931 ## 44972 ## 45013 ## 45055 ## 45095 ## 45136 ## 44933 ## 44974 ## 45015 ## 45055 ## 45096 ## 45137 ## 44933 ## 44974 ## 45015 ## 45056 ## 45097 ## 45138 ## 44934 ## 44975 ## 45015 ## 45016 ## 45057 ## 45088 ## 45139 ## 44935 ## 44976 ## 45017 ## 45018 ## 45058 ## 45099 ## 45140 ## 44936 ## 44977 ## 45018 ## 45059 ## 45100 ## 45141 ## 44936 ## 44977 ## 45018 ## 45059 ## 45100 ## 45142 ## 44938 ## 44979 ## 45020 ## 45060 ## 45100 ## 45142 ## 44940 ## 44981 ## 45022 ## 45062 ## 45062 ## 45103 ## 45144 ## 44940 ## 44981 ## 45022 ## 45062 ## 45064 ## 45104 ## 45145 ## 44940 ## 44981 ## 45022 ## 45062 ## 45064 ## 45104 ## 45145 ## 44940 ## 44981 ## 45022 ## 45065 ## 45106 ## 45146 ## 44944 ## 44983 ## 45023 ## 45066 ## 45106 ## 45146 ## 44944 ## 44983 ## 45023 ## 45066 ## 45106 ## 45146 ## 44944 ## 44988 ## 45023 ## 45066 ## 45106 ## 45146 ## 44944 ## 44988 ## 45025 ## 45066 ## 45106 ## 45146 ## 44944 ## 44988 ## 45025 ## 45066 ## 45100 ## 45146 ## 44944 ## 44986 ## 45025 ## 45066 ## 45100 ## 45146 ## 44947 ## 44988 ## 45026 ## 45066 ## 45100 ## 45116 ## 44947 ## 44988 ## 45026 ## 45066 ## 45100 ## 45116 ## 44947 ## 44988 ## 45026 ## 45066 ## 45100 ## 45116 ## 45153 ## 44947 ## 44988 ## 45026 ## 45066 ## 45100 ## 45116 ## 45153 ## 44949 ## 44989 ## 45026 ## 45066 ## 45100 ## 45110 ## 45151 ## 44949 ## 44988 ## 45026 ## 45066 ## 45100 ## 45151 ## 44949 ## 44988 ## 45026 ## 45066 ## 45100 ## 45151 ## 44947 ## 44988 ## 45026 ## 45066 ## 45100 ## 45151 ## 44949 ## 44988 ## 45028 ## 45066 ## 45100 ## 45151 ## 45153 ## 44949 ## 44988 ## 45028 ## 45066 ## 45100 ## 45155 ## 44949 ## 44989 ## 45033 ## 45073 ## 45073 ## 45116 ## 45155 ## 45166 ## 45000 ## 45000 ## 45000 ## 45000 ## 45000 ## 45000 ## 450	
44926 44967 45008 45049 45090 45131 44927 44968 45090 45050 45091 45132 44928 44969 45010 45051 45092 45133 44929 44970 45011 45052 45093 45134 44930 44971 45012 45053 45094 45135 44931 44972 45013 45054 45095 45136 44932 44973 45014 45055 45096 45137 44933 44974 45015 45056 45097 45138 44934 44975 45016 45057 45098 45139 44935 44976 45017 45058 45099 45140 44936 44977 45018 45059 45100 45141 44937 44938 44979 45020 45061 45102 45143 44939 44940 44981 45022 45063 45104 45145 44940 44981 45022 45062 45103 45144 44940 44981 45022 45063 45104 45145 44941 44982 45023 45064 45105 45146 44942 44983 45024 45065 45106 45147 44944 44985 45023 45066 45107 45148 44940 44981 45022 45063 45100 45141 44947 44988 45029 45063 45100 45146 44944 44986 44987 45023 45066 45107 45148 44949 44949 44981 45022 45063 45100 45146 44944 44985 45023 45066 45107 45148 44949 44989 45020 45066 45107 45148 44940 44981 45025 45066 45107 45148 44940 44981 45025 45063 45100 45114 44947 44988 45029 45066 45107 45148 44949 44989 45020 45066 45107 45148 44949 44989 45020 45066 45107 45148 44949 44989 45020 45066 45107 45148 44940 44986 44987 45025 45066 45107 45148 44949 44986 44987 45025 45066 45107 45148 44949 44986 44987 45025 45066 45107 45148 44940 44986 44987 45025 45066 45107 45148 44940 44986 44987 45025 45066 45107 45148 44940 44986 44989 45020 45067 45108 45150 44946 44989 45020 45067 45108 45110 45151 44946 44987 45025 45066 45067 45108 45110 45151 44946 44989 45020 45071 45112 45153 44949 44990 45031 45072 45118 45152 44949 44990 45031 45072 45118 45155 44950 44991 45032 45033 45074 45115 45153 44950 44991 45032 45033 45074 45115 45153 44986 44989 45030 45071 45112 45153 44986 44989 45030 45071 45112 45153 44986 44989 45030 45071 45112 45153 44989 44990 45031 45072 45118 45155 44986 44999 45033 45074 45115 45156 44950 44991 45032 45073 45088 45109 45150 44955 44993 45004 45082 45082 45083 45074 45155 45166 44950 44996 45007 45088 45099 45120 45161	PPD 45171
44927 44968 45009 45050 45091 45132 44928 44969 45010 45051 45092 45133 44929 44970 45011 45052 45093 45134 44930 44971 45012 45053 45094 45135 44931 44972 45013 45054 45095 45136 44932 44973 45014 45055 45096 45137 44933 44974 45015 45056 45097 45138 44934 44975 45016 45057 45098 45139 44935 44976 45017 45088 45099 45140 44936 44977 45018 45059 45100 45141 44937 44978 45019 45060 45101 45142 44938 44979 45020 45061 45101 45142 44938 44979 45020 45061 45101 45143 44940 44981 45022 45063 45103 45144	45172
44928 44969 45010 45051 45092 45133 44929 44970 45011 45052 45033 45134 44930 44971 45012 45053 45094 45135 44931 44972 45013 45055 45096 45137 44932 44973 45015 45056 45097 45138 44934 44975 45016 45057 45098 45139 44934 44975 45016 45057 45098 45139 44936 44977 45018 45059 45100 45140 49336 44977 45018 45059 45100 45141 4937 44978 45019 45060 45101 45142 4938 44979 45020 45061 45102 45143 4939 44980 45021 45062 45103 45144 49494 44981 45022 45063 45104 45145 <t< td=""><td>45173</td></t<>	45173
44929 44970 45011 45052 45093 45134 44930 44971 45012 45053 45094 45135 44931 44972 45013 45054 45095 45136 44932 44973 45014 45055 45096 45137 44933 44974 45015 45056 45097 45138 44934 44975 45016 45057 45098 45139 44935 44976 45017 45058 45099 45140 4936 44977 45018 45059 45100 45141 44937 44978 45019 45060 45101 45142 44938 44979 45020 45061 45102 45143 44939 44980 45021 45062 45103 45144 44940 44981 45022 45063 45104 45145 44941 44982 45023 45064 45105 45146	45174
44930 44971 45012 45053 45094 45135 44931 44972 45013 45055 45096 45136 44932 44973 45015 45055 45096 45137 44933 44974 45015 45056 45097 45138 44934 44975 45016 45057 45098 45139 44935 44976 45017 45088 45099 45140 44936 44977 45018 45059 45100 45141 44937 44978 45019 45060 45101 45142 44938 44979 45020 45061 45102 45143 44939 44980 45021 45062 45103 45144 44940 44981 45022 45063 45104 45145 44941 44982 45023 45064 45105 45146 44944 44983 45024 45065 45106 45147 4944 44985 45026 45066 45107 45148 <	45175
44931 44972 45013 45054 45095 45136 44932 44973 45014 45055 45096 45137 44933 44974 45015 45056 45097 45138 44934 44975 45016 45057 45098 45139 44935 44976 45018 45059 45100 45141 44936 44977 45018 45059 45100 45141 44937 44978 45019 45060 45101 45142 44938 44979 45020 45061 45102 45143 44938 44979 45021 45062 45103 45144 44940 44981 45021 45062 45103 45145 44941 44982 45023 45064 45105 45146 44942 44983 45024 45065 45106 45147 4943 44984 45025 45066 45107 45148 44943 44984 45027 45068 45109 45150 <	45176
44932 44973 45014 45055 45096 45137 44933 44974 45015 45056 45097 45138 44934 44976 45017 45058 45099 45140 44936 44977 45018 45059 45100 45141 44937 44978 45019 45060 45101 45142 44938 44979 45020 45061 45102 45143 44939 44980 45021 45062 45103 45144 44940 44981 45022 45063 45104 45145 44941 44982 45023 45064 45105 45146 44942 44983 45024 45065 45106 45147 44943 44984 45025 45066 45107 45148 44944 44985 45026 45067 45108 45149 44944 44985 45026 45067 45108 45149 44946 44987 45088 45009 45110 45151	45177
44933 44974 45015 45056 45097 45138 44934 44975 45016 45057 45098 45139 44935 44976 45018 45059 45100 45141 44936 44977 45018 45059 45100 45141 44938 44979 45020 45061 45102 45143 44939 44980 45021 45062 45103 45144 44940 44981 45022 45063 45104 45145 44941 44982 45023 45064 45105 45146 44942 44983 45025 45065 45106 45147 44943 44984 45025 45066 45107 45148 44944 44985 45026 45067 45108 45147 44943 44985 45026 45067 45108 45149 44944 44985 45026 45067 45108 45150 44945 44986 45027 45068 45100 45151	45178
44934 44975 45016 45057 45098 45139 44935 44976 45017 45058 45099 45140 44936 44977 45018 45059 45100 45141 44937 44978 45019 45060 45101 45142 44938 44979 45020 45061 45102 45143 44939 44980 45021 45062 45103 45144 44940 44981 45022 45063 45104 45145 44941 44982 45023 45064 45105 45146 44942 44983 45024 45065 45106 45147 44943 44984 45025 45066 45107 45148 44944 44985 45025 45066 45107 45148 44944 44985 45025 45068 45109 45150 44946 44987 45028 45069 45110 45151 44947 44988 45029 45070 45111 45152	45179
44935 44976 45017 45088 45099 45140 44936 44977 45018 45059 45100 45141 44937 44978 45019 45060 45101 45142 44938 44979 45020 45061 45102 45143 44940 44981 45022 45063 45104 45145 44941 44982 45023 45064 45105 45146 44942 44983 45024 45065 45106 45147 44943 44984 45025 45066 45107 45148 44944 44985 45025 45066 45107 45148 44944 44985 45026 45067 45108 45149 44945 44986 45027 45068 45109 45150 44946 44987 45028 45069 45111 45152 44948 44989 45030 45071 45113 45154 44949 44990 45031 45072 45113 45154	45180
44936 44977 45018 45059 45100 45141 44937 44978 45019 45060 45101 45142 44938 44979 45020 45061 45102 45143 44939 44980 45021 45062 45103 45144 44940 44981 45022 45063 45104 45145 44941 44982 45023 45064 45105 45146 44942 44983 45024 45065 45106 45147 44943 44984 45025 45066 45107 45148 44944 44985 45026 45067 45108 45149 44945 44986 45027 45068 45109 45151 44947 44988 45029 45070 45111 45152 44948 44989 45030 45071 45113 45154 44949 44990 45031 45072 45113 45154 4951 44949 44990 45031 45072 45113 45154	45181
44937 44978 45019 45060 45101 45142 44938 44979 45020 45061 45102 45143 44939 44980 45021 45062 45103 45144 44940 44981 45022 45063 45104 45145 44941 44982 45023 45064 45105 45146 44942 44983 45024 45065 45106 45147 44943 44984 45025 45066 45107 45148 44944 44985 45026 45067 45108 45149 44945 44986 45027 45068 45109 45150 44946 44987 45028 45069 45110 45151 44947 44988 45029 45070 45111 45152 44948 44990 45031 45071 45113 45154 44949 44990 45031 45071 45113 45154 4950 44991 45032 45073 45114 45155 <	45182
44938 44979 45020 45061 45102 45143 44939 44980 45021 45062 45103 45144 44940 44981 45022 45063 45104 45145 44941 44982 45023 45064 45105 45146 44942 44983 45024 45065 45106 45147 44943 44984 45025 45066 45107 45148 44944 44985 45026 45067 45108 45149 44945 44986 45027 45068 45109 45150 44946 44987 45028 45069 45110 45151 44947 44988 45029 45070 45111 45152 44948 44989 45030 45071 45112 45153 44949 44990 45031 45072 45113 45154 44951 44991 45032 45073 45114 45155	45183
44939 44980 45021 45062 45103 45144 44940 44981 45022 45063 45104 45145 44941 44982 45023 45064 45105 45146 44942 44983 45024 45065 45106 45147 44943 44984 45025 45066 45107 45148 44944 44985 45026 45067 45108 45149 44945 44986 45027 45068 45109 45150 44946 44987 45028 45069 45110 45151 44947 44988 45029 45070 45111 45152 44948 44989 45030 45071 45112 45153 44949 44990 45031 45072 45113 45154 44950 44991 45032 45073 45114 45155 44951 44992 45033 45074 45115 45156 44952 44993 45034 45075 45116 45157	45184
44940 44981 45022 45063 45104 45145 44941 44982 45023 45064 45105 45146 44942 44983 45024 45065 45106 45147 44943 44984 45025 45066 45107 45148 44944 44985 45026 45067 45108 45149 44945 44986 45027 45068 45109 45150 44947 44988 45029 45070 45111 45152 44948 44989 45030 45071 45112 45153 44949 44990 45031 45072 45113 45154 44950 44991 45032 45073 45114 45155 44951 44992 45033 45074 45115 45156 44952 44993 45034 45075 45116 45157 44951 44992 45033 45074 45115 45156 44952 44993 45035 45076 45117 45158	45185
44941 44982 45023 45064 45105 45146 44942 44983 45024 45065 45106 45147 44943 44984 45025 45066 45107 45148 44944 44985 45026 45067 45108 45149 44945 44986 45027 45068 45109 45150 44946 44987 45028 45069 45110 45151 44947 44988 45029 45070 45111 45152 44948 44989 45030 45071 45112 45153 44949 44990 45031 45072 45113 45154 44950 44991 45032 45073 45114 45155 44951 44992 45033 45074 45115 45156 44952 44993 45034 45075 45116 45157 44953 44994 45035 45076 45117 45158 44951 44995 45036 45077 4518 45166 <	45186
44942 44983 45024 45065 45106 45147 44943 44984 45025 45066 45107 45148 44944 44985 45026 45067 45108 45149 44945 44986 45027 45068 45109 45150 44946 44987 45028 45069 45110 45151 44947 44988 45029 45070 45111 45152 44948 44989 45030 45071 45112 45153 44949 44990 45031 45072 45113 45154 44950 44991 45032 45073 45114 45155 44951 44992 45033 45074 45115 45156 44952 44993 45033 45075 45116 45157 44953 44994 45035 45076 45117 45158 44953 44994 45035 45076 45117 45158 44953 44994 45037 4508 45109 45160 <	45187
44943 44984 45025 45066 45107 45148 44944 44985 45026 45067 45108 45149 44945 44986 45027 45068 45109 45150 44946 44987 45028 45069 45110 45151 44947 44988 45029 45070 45111 45152 44948 44989 45030 45071 45112 45153 44949 44990 45031 45072 45113 45154 44950 44991 45032 45073 45114 45155 44951 44992 45033 45074 45115 45156 44952 44993 45034 45075 45116 45157 44953 44994 45035 45076 45117 45158 44952 44993 45036 45077 45118 45157 44953 44994 45035 45077 45118 45159 44954 44995 45036 45077 45118 45160	45188
44944 44985 45026 45067 45108 45149 44945 44986 45027 45068 45109 45150 44946 44987 45028 45069 45110 45151 44947 44988 45029 45070 45111 45152 44948 44989 45030 45071 45112 45153 44949 44990 45031 45072 45113 45154 44950 44991 45032 45073 45114 45155 44951 44992 45033 45074 45115 45156 44952 44993 45034 45075 45116 45157 44953 44994 45035 45076 45117 45158 44954 44995 45036 45077 45118 45159 44954 44995 45036 45077 45118 45160 44955 44996 45037 45078 45119 45160 44956 44997 45038 45079 45120 45161	45189
44945 44986 45027 45068 45109 45150 44946 44987 45028 45069 45110 45151 44947 44988 45029 45070 45111 45152 44948 44989 45030 45071 45112 45153 44949 44990 45031 45072 45113 45154 44950 44991 45032 45073 45115 45155 44951 44992 45033 45074 45115 45156 44952 44993 45034 45075 45116 45157 44953 44994 45035 45076 45117 45158 44954 44995 45036 45077 45118 45159 44955 44996 45037 45078 45119 45160 44956 44997 45038 45079 45120 45161 44958 44999 45040 45081 45122 45163 44959 45000 45041 45082 45123 45164	45190
44947 44988 45029 45070 45111 45152 44948 44989 45030 45071 45112 45153 44949 44990 45031 45072 45113 45154 44950 44991 45032 45073 45114 45155 44951 44992 45033 45074 45115 45156 44952 44993 45034 45075 45116 45157 44953 44994 45035 45076 45117 45158 44954 44995 45036 45077 45118 45159 44955 44996 45037 45078 45119 45160 44956 44997 45038 45079 45120 45161 44957 44998 45039 45080 45121 45162 44958 44999 45040 45081 45122 45163 44959 45001 45041 45082 45123 45164 44960 45001 45042 45083 45124 45165 44961 45002 45043 45084 45125 45166	45191
44948 44989 45030 45071 45112 45153 44949 44990 45031 45072 45113 45154 44950 44991 45032 45073 45114 45155 44951 44992 45033 45074 45115 45156 44952 44993 45034 45075 45116 45157 44953 44994 45035 45076 45117 45158 44954 44995 45036 45077 45118 45159 44955 44996 45037 45078 45119 45160 44956 44997 45038 45079 45120 45161 44957 44998 45039 45080 45121 45162 44958 44999 45040 45081 45122 45163 44959 45000 45081 45123 45164 44960 45001 45042 45083 45124 45165 44961 45002 45043 45084 45125 45166	45192
44949 44990 45031 45072 45113 45154 44950 44991 45032 45073 45114 45155 44951 44992 45033 45074 45115 45156 44952 44993 45075 45116 45157 44953 44994 45035 45075 45117 45158 44954 44995 45036 45077 45118 45159 44955 44996 45037 45078 45119 45160 44956 44997 45038 45079 45120 45161 44957 44998 45039 45080 45121 45162 44958 44999 45040 45081 45122 45163 44959 45000 45041 45082 45123 45164 44960 45001 45042 45083 45124 45165 44961 45002 45043 45084 45125 45166	45193
44950 44991 45032 45073 45114 45155 44951 44992 45033 45074 45115 45156 44952 44993 45034 45075 45116 45157 44953 44994 45035 45076 45117 45158 44954 44995 45036 45077 45118 45159 44955 44996 45037 45078 45119 45160 44956 44997 45038 45079 45120 45161 44957 44998 45039 45080 45121 45162 44958 44999 45040 45081 45122 45163 44959 45000 45041 45082 45123 45164 44960 45001 45042 45083 45124 45165 44961 45002 45043 45084 45125 45166	45194
44951 44992 45033 45074 45115 45156 44952 44993 45034 45075 45116 45157 44953 44994 45035 45076 45117 45158 44954 44995 45036 45077 45118 45159 44955 44996 45037 45078 45119 45160 44956 44997 45038 45079 45120 45161 44957 44998 45039 45080 45121 45162 44958 44999 45040 45081 45122 45163 44959 45000 45041 45082 45123 45164 44960 45001 45042 45083 45124 45165 44961 45002 45043 45084 45125 45166	45195
44952 44993 45034 45075 45116 45157 44953 44994 45035 45076 45117 45158 44954 44995 45036 45077 45118 45159 44955 44996 45037 45078 45119 45160 44956 44997 45038 45079 45120 45161 44957 44998 45039 45080 45121 45162 44958 44999 45040 45081 45122 45163 44959 45000 45041 45082 45123 45164 44960 45001 45042 45083 45124 45165 44961 45002 45043 45084 45125 45166	45196
44953 44994 45035 45076 45117 45158 44954 44995 45036 45077 45118 45159 44955 44996 45037 45078 45119 45160 44956 44997 45038 45079 45120 45161 44957 44998 45039 45080 45121 45162 44958 44999 45040 45081 45122 45163 44959 45000 45041 45082 45123 45164 44960 45001 45042 45083 45124 45165 44961 45002 45043 45084 45125 45166	45197
44954 44995 45036 45077 45118 45159 44955 44996 45037 45078 45119 45160 44956 44997 45038 45079 45120 45161 44957 44998 45039 45080 45121 45162 44958 44999 45040 45081 45122 45163 44959 45000 45041 45082 45123 45164 44960 45001 45042 45083 45124 45165 44961 45002 45043 45084 45125 45166	45198
44955 44996 45037 45078 45119 45160 44956 44997 45038 45079 45120 45161 44957 44998 45039 45080 45121 45162 44958 44999 45040 45081 45122 45163 44959 45000 45041 45082 45123 45164 44960 45001 45042 45083 45124 45165 44961 45002 45043 45084 45125 45166	45199
44956 44997 45038 45079 45120 45161 44957 44998 45039 45080 45121 45162 44958 44999 45040 45081 45122 45163 44959 45000 45041 45082 45123 45164 44960 45001 45042 45083 45124 45165 44961 45002 45043 45084 45125 45166	45200
44957 44998 45039 45080 45121 45162 44958 44999 45040 45081 45122 45163 44959 45000 45041 45082 45123 45164 44960 45001 45042 45083 45124 45165 44961 45002 45043 45084 45125 45166	45201
44958 44999 45040 45081 45122 45163 44959 45000 45041 45082 45123 45164 44960 45001 45042 45083 45124 45165 44961 45002 45043 45084 45125 45166	45202
44959 45000 45041 45082 45123 45164 44960 45001 45042 45083 45124 45165 44961 45002 45043 45084 45125 45166	45203
44960 45001 45042 45083 45124 45165 44961 45002 45043 45084 45125 45166	45204
44961 45002 45043 45084 45125 45166	45205
	45206
44062 45002 45004 45005	45207
	45208
44963 45004 45045 45086 45127 45168	45209
44964 45005 45046 45087 45128 45169	45210
44965 45006 45047 45088 45129 45170	45211

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD 45212	PPD 45253	PPD 45294	PPD 45335	PPD 45376	PPD 45417	PPD 45458
45213	45254	45295	45336	45377	45418	45459
45214	45255	45296	45337	45378	45419	45460
45215	45256	45297	45338	45379	45420	45461
45216	45257	45298	45339	45380	45421	45462
45217	45258	45299	45340	45381	45422	45463
45218	45259	45300	45341	45382	45423	45464
45219	45260	45301	45342	45383	45424	45465
45220	45261	45302	45343	45384	45425	45466
45221	45262	45303	45344	45385	45426	45467
45222	45263	45304	45345	45386	45427	45468
45223	45264	45305	45346	45387	45428	45469
45224	45265	45306	45347	45388	45429	45470
45225	45266	45307	45348	45389	45430	45471
45226	45267	45308	45349	45390	45431	45472
45227	45268	45309	45350	45391	45432	45473
45228	45269	45310	45351	45392	45433	45474
45229	45270	45311	45352	45393	45434	45475
45230	45271	45312	45353	45394	45435	45476
45231	45272	45313	45354	45395	45436	45477
45232	45273	45314	45355	45396	45437	45478
45233	45274	45315	45356	45397	45438	45479
45234	45275	45316	45357	45398	45439	45480
45235	45276	45317	45358	45399	45440	45481
45236	45277	45318	45359	45400	45441	45482
45237	45278	45319	45360	45401	45442	45483
45238	45279	45320	45361	45402	45443	45484
45239	45280	45321	45362	45403	45444	45485
45240	45281	45322	45363	45404	45445	45486
45241	45282	45323	45364	45405	45446	45487
45242	45283	45324 45325	45365	45406 45407	45447 45448	45488 45489
45243 45244	45284 45285	45325 45326	45366 45367	45407 45408	45448 45449	45489 45490
45244	45286	45326	45368	45409	45450	45491
45245	45287	45327	45369	45410	45450	45491
45247	45288	45326	45370	45411	45451	45493
45247	45289	45329	45371	45412	45452	45494
45249	45299	45330	45372	45413	45454	45494
45249	45290	45331	45373	45414	45454	45496
45251	45291	45332	45374	45414	45456	45497
45252	45293	45333	45375	45416	45457	45498
45252	15255	40004	43373	13110	45457	42430

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

DTPA-HBV-IPV-135 (A.15MAR2018)

No nb	Trt.	Bl.	Trt. Bl		Trt.	Bl.								
PPD 45786 PPD 45827 PPD 45868 PPD 45909 PPD 45951 45991 45991 45991 45991 45991 45991 45991 45993 46033 46033 45871 45912 45952 45993 46033 45871 45912 45953 45994 46035 45995 46035 45995 46035 45995 46034 45972 45831 45872 45913 45995 45995 46037 45995 46037 45995 46037 45995 46037 45995 46037 45995 46037 45996 46037 45997 46038 45971 45995 46037 46038 45973 45916 45997 45996 46037 46033 45875 45916 45997 45998 46039 46039 46039 46034 45979 45917 45918 45999 46000 46011 46011 46001 46011 46001 46011 46001 46011 46001 <th>No</th> <th>nb</th> <th>No nb</th> <th>)</th> <th></th> <th></th> <th>No</th> <th>nb</th> <th></th> <th></th> <th>No</th> <th>nb</th> <th>No</th> <th>nb</th>	No	nb	No nb)			No	nb			No	nb	No	nb
45787 45828 45869 45810 45911 45982 45991 46032 45787 45828 45869 45910 45911 45982 45993 46034 45789 45830 45871 45912 45933 45994 46034 45789 45831 45872 45913 45954 45995 46036 46036 45971 45832 45833 45874 45915 45956 45957 46038 45793 45834 45875 45916 45957 45988 45997 46038 45793 45834 45875 45916 45957 45988 45999 46001 45911 45922 45933 45874 45915 45956 45957 45988 45999 46000 45911 45922 45938 45879 45920 45941 45955 45966 46037 45948 45959 46000 46041 45796 45881 45895 45888 45999 45800 45811 45882 45923 45964 46003 46044 45799 45881 45894 45883 45899 45800 45841 45882 45923 45964 46000 46041 45800 45841 45882 45893 45894 45966 46007 46048 45800 45841 45882 45893 45896 46000 46041 45800 45841 45882 45893 45896 46000 46046 45801 45842 45883 45899 45800 45841 45882 45923 45964 46000 46046 45801 45842 45883 45899 45800 45841 45882 45923 45964 46000 46046 45801 45842 45883 45899 45800 45841 45882 45923 45964 46000 46046 45801 45842 45883 45899 45800 45841 45882 45923 45964 46000 46046 45801 45842 45883 45899 45800 45841 45885 45926 45967 46000 46048 45801 45842 45883 45899 45800 45844 45885 45926 45967 46000 46048 45801 45842 45885 45926 45967 46000 46081 45800 45844 45885 45926 45967 46000 46081 45800 45844 45885 45926 45967 46000 46081 45800 45844 45885 45926 45967 46000 46081 45800 45844 45885 45926 45967 46000 46081 45800 45844 45885 45926 45967 46000 46081 45800 45844 45885 45929 45970 46011 46082 45800 45846 45887 45888 45929 45970 46011 46082 45800 45846 45887 45888 45929 45970 46011 46082 45800 45846 45887 45888 45929 45970 46011 46082 45800 45846 45887 45888 45929 45970 46011 46082 45800 45846 45887 45888 45929 45970 46011 46082 45800 45846 45887 45888 45929 45970 46011 46082 45800 45846 45887 45888 45929 45970 46011 46082 45800 45846 45887 45889 45899 45890 45891 45890 45891 45890 45891 45890 45891 45890 45891 45890 45890 45891 45890 45891 45890 45891 45890 45891 45890 45891 45890 45890 45891 45890 45891 45890 45890 45891 45890 45890 45891 45890 45891 45890 45890 45891 45890 45890 45891 45890														
45787 45828 45869 45910 45911 45952 45933 46034 45788 45829 45870 45911 45952 45993 46033 45789 45830 45871 45912 45953 45994 46035 45790 45831 45872 45913 45954 45955 45791 45832 45873 45914 45955 45966 46037 45792 45833 45874 45915 45955 45996 46037 45793 45834 45875 45916 45957 45988 46039 45794 45835 45876 45917 45918 45959 46000 46014 45795 45836 45877 45918 45959 46000 46014 45796 45837 45878 45919 45900 45911 46002 46024 45797 45838 45879 45920 45961 46002 46034 45798 45839 45880 45921 45963 46000 46004 45798 45839 45880 45921 45963 46000 46004 45799 45839 45880 45921 45963 46000 46004 45799 45839 45880 45921 45960 46001 46002 45799 45839 45880 45921 45960 46001 46002 45799 45839 45880 45921 45963 46000 46004 45799 45839 45880 45921 45963 46000 46004 45799 45841 45882 45923 45963 46000 46004 45799 45840 45883 45880 45921 45963 46000 46004 45800 45841 45882 45923 45960 46001 46002 45800 45841 45882 45923 45960 46000 46004 45801 45842 45883 45826 45967 46000 46004 45802 45843 45844 45925 45965 46000 46004 45803 45844 45885 45926 45967 46008 46047 45802 45843 45844 45825 45966 46007 46048 45803 45846 45887 45828 45926 45967 46008 46048 45801 45845 45846 45827 45968 46000 46001 45805 45847 45888 45929 45970 46011 46083 45806 45847 45888 45929 45970 46011 46083 45807 45848 45889 45830 45937 45968 46010 46081 45808 45849 45889 45830 45937 45968 46010 46081 45809 45849 45889 45839 45937 45018 46011 46082 45801 45846 45887 45888 45929 45970 46011 46083 45806 45847 45888 45929 45970 46011 46083 45806 45847 45888 45929 45970 46011 46083 45808 45849 45889 45839 45939 45900 46011 46083 45808 45849 45889 45839 45939 45900 46011 46083 45808 45849 45889 45839 45939 45900 46011 46083 45809 45850 45887 45886 45937 45988 46010 46086 45811 45852 45883 45939 45990 46010 46081 45811 45852 45889 45839 45939 45900 46011 46082 45811 45856 45887 45886 45937 45988 46020 46066 45811 45862 45980 45940 45941 45985 46026 45812 45866 45907 45946 45947 45988 46029 46006 45812 45866 45907 45946 45947 45988 46029 46001	PPD	45786	PPD 45	827	PPD	45868	PPD	45909	PPD	45950	PPD	45991	PPD	46032
45788 45829 45870 45911 45952 45993 46024 45915 45956 45997 46028 45919 46035 45791 45832 45873 45914 45955 45956 45997 46036 45792 45833 45874 45915 45956 45997 46038 45793 45834 45875 45916 45957 45988 45999 46030 45871 45792 45838 45876 45917 45958 45999 46030 45791 45792 45838 45876 45917 45958 45999 46030 45791 45792 45838 45876 45917 45958 45999 46030 45791 45796 45837 45888 45999 46000 46011 45796 45837 45888 45899 45900 45961 45000 46011 46042 45799 45888 45899 45900 45961 45000 46041 45798 45888 45889 45889 45880 45811 45882 45852 45863 46000 46041 45799 45840 45881 45922 45963 46000 46041 45881 45800 45841 45882 45923 45964 46005 46047 45800 45841 45882 45884 45925 45966 46007 46048 45801 45842 45885 45884 45925 45966 46007 46048 45800 45841 45882 45925 45966 46007 46048 45800 45841 45885 45884 45925 45966 46007 46048 45800 45841 45885 45884 45925 45966 46007 46048 45800 45841 45885 45926 45967 46000 46047 45800 45841 45885 45926 45967 46000 46047 45800 45841 45885 45926 45967 46000 46047 45800 45841 45885 45926 45967 46000 46047 45800 45841 45885 45926 45967 46000 46047 45800 45841 45885 45926 45967 46000 46047 45800 45841 45885 45926 45967 46000 46007 46048 45800 45841 45885 45926 45967 46000 46007 46048 45800 45841 45885 45926 45967 46000 46001 46001 45800 45800 45841 45885 45926 45967 46000 46001 46001 45800 45800 45841 45885 45926 45967 46000 46001 46001 45800 45800 45841 45885 45920 45970 45011 46002 45800 45800 45841 45885 45980 45970 45971 46011 46002 45800 45800 45850 45840 45885 45980 45970 45971 46012 46033 45800 45851 45860 45867 45980 45990 45971 46011 46002 45800 45850 45860 45867 45980 45990 45971 46012 46033 45800 45851 45880 45890					_								–	
45789 45830 45831 45871 45912 45953 45994 46035 45790 45831 45872 45913 45954 45995 46036 45791 45832 45873 45914 45955 45996 46037 45792 45833 45874 45915 45956 45997 46038 45793 45834 45875 45916 45957 45988 4603 45794 45835 45836 45877 45918 45959 46000 4601 45795 45836 45877 45918 45959 46000 4601 45796 45837 45878 45919 45950 46000 4601 45797 45838 45879 45920 45961 46002 4601 45799 45839 45830 45879 45920 45961 46002 4601 45799 45839 45830 45981 45922 45963 46004 4601 45799 45840 45881 45922 45963 46004 46014 4602 45800 45841 45882 45932 45963 46006 46014 4602 45800 45841 45882 45932 45966 46007 46046 45801 45862 45883 45884 45925 45966 46007 46046 45801 45862 45883 45883 45887 45966 46007 46048 45803 45864 45803 45884 45925 45966 46007 46048 45803 45884 45885 45866 45927 45968 46008 46047 45803 45804 45885 45866 45927 45968 46008 46047 45803 45804 45885 45866 45927 45968 46003 46044 45803 45803 45884 45825 45966 46007 46048 45803 45884 45885 45866 45927 45968 46008 46049 45804 45803 45884 45885 45866 45927 45968 46008 46049 45804 45805 45886 45887 45828 45969 46010 46051 45807 45808 45809 45800 45887 45828 45969 46010 46051 45803 45806 45847 45888 45829 45970 46011 46052 45808 45809 45807 45888 45829 45970 46011 46052 45809 45800 45881 45889 45830 45971 46012 46053 45809 45800 45851 45880 45899 45830 45971 46012 46053 45809 45850 45881 45892 45933 45977 46018 46059 45811 45852 45883 45934 45975 46013 46054 45809 45880 45889 45830 45971 46011 46055 45809 45850 45881 45892 45933 45977 46018 46059 45811 45852 45893 45999 45990 46010 46051 45809 45811 45852 45883 45999 45990 45910 46001 46051 45809 45850 45880 45899 45830 45971 46012 46052 45809 45811 45852 45883 45999 45990 45910 46001 46051 45809 45850 45899 45830 45971 46012 46052 45809 45810 45850 45899 45830 45971 46018 46059 45811 45852 45893 45999 45990 46010 46051 45809 45810 45850 45899 45990 45990 46010 46051 45809 45809 45850 45899 45990 45990 46010 46051 45809 45809 45800 45891 45990 45990 46000 45811 45802 45809 45890 45990 45990 45990 46000 458														
45790 45831 45872 45913 45955 45996 46036 45977 45791 45832 45873 45915 45955 45996 46037 45791 45792 45833 45874 45915 45956 45997 46038 45793 45834 45875 45917 45958 45999 46039 45794 45835 45836 45877 45918 45959 46000 46011 45796 45977 45938 45839 45839 45839 45839 45839 45839 45839 45839 45839 45839 45839 45839 45830 45879 45930 45939 45939 46040 45796 45837 45888 45899 45930 45940 45865 45866 45897 45930 45941 45865 45866 45897 45838 45899 46040 46045 45866 45897 45888 45899 46040 46045 45866 45897 45888 45899 46040 46045 45860 45841 45885 45866 45897 45866 45897 45888 45899 46040 46045 45860 45844 45865 45866 45897 45886 45897 45866 45897 45866 45897 45866 45897 45866 45897 45888 45889 45880 45881 45922 45963 46006 46047 45862 45883 45884 45825 45863 45800 45844 45865 45866 45867 46066 46047 45802 45843 45885 45926 45967 46008 46049 45803 45844 45865 45866 45897 45888 45899 46010 46051 45804 45845 45845 45866 45897 45888 45899 46010 46051 45806 45847 45888 45889 45930 45911 46012 46033 45847 45848 45895 45969 46010 46051 45806 45847 45848 45889 45930 45911 46012 46033 45849 45849 45889 45930 45911 46012 46033 45849 45849 45889 45930 45911 46012 46033 45849 45849 45889 45930 45911 46012 46033 45849 45889 45899 45930 45911 46012 46033 45849 45889 45899 45930 45911 46012 46035 45810 45859 45859 45899 45890 45891 45892 45893 45899 46010 46051 46055 45849 45889 45899 45930 45911 46012 46033 45849 45889 45899 45890 45891 45892 45893 45899 45890 45811 45852 45889 45899 45930 45911 46012 46033 45849 45889 45899 45890 45891 45892 45893 45899 45890 45891 45892 45893 45899 45890 45891 45892 45893 45899 45890 45891 45892 45893 45899 45890 45891 45892 45893 45899 45890 45891 45892 45893 45899 45890 45891 45892 45893 45899 45890 45891 45892 45893 45899 45890 45891 45892 45893 45899 45890 45891 45892 45893 45899 45890 45891 45892 45893 45899 45890 45891 45892 45893 45899 45890 45891 45892 45893 45899 45890 45891 45892 45893 45899 45890 45891 45892 45893 45899 45890 45891 45892 45893 45899 45890 45891 45892 45893 45899														
45791 45832 45833 45874 45915 45956 45997 46038 45792 45833 45874 45916 45957 45998 46039 45794 45835 45876 45917 45958 45999 46040 45795 45836 45877 45918 45959 46000 46041 45796 45837 45838 45879 45919 45960 46001 46042 45797 45838 45839 45880 45911 45962 46003 46044 45798 45838 45839 45880 45911 45962 46003 46044 45799 45840 45881 45982 45963 46004 46045 45800 45841 45882 45923 45964 46005 46046 45801 45842 45883 45884 45923 45964 46005 46046 45803 45844 45885 45886 45927 45966 46007 46048 45804 45845 45886 45927 45968 46009 46008 45805 45846 45887 45988 45999 45900 46011 46052 45807 45888 45889 45909 45910 46011 46088 45808 45844 45885 45886 45927 45968 46009 46050 45807 45846 45887 45988 45999 45910 46011 46052 45807 45848 45889 45930 45971 46012 46033 45808 45849 45889 45930 45971 46012 46033 45809 45850 45847 45889 45930 45971 46012 46033 45808 45849 45889 45939 45970 46011 46052 45807 45848 45889 45939 45970 46011 46052 45807 45848 45889 45939 45970 46010 46051 45808 45849 45889 45939 45970 46011 46052 45807 45848 45889 45939 45970 46010 46051 45808 45849 45889 45939 45970 46011 46052 45807 45848 45889 45939 45970 46011 46052 45807 45848 45889 45939 45970 46010 46051 45808 45849 45889 45939 45970 46011 46052 45807 45848 45889 45939 45970 46010 46051 45808 45849 45889 45939 45970 46010 46051 45808 45849 45889 45939 45970 46011 46052 45807 45848 45889 45939 45970 46010 46051 45808 45849 45889 45939 45970 46010 46051 45808 45849 45889 45939 45970 46010 46051 45808 45849 45889 45939 45970 46010 46051 45808 45849 45889 45939 45970 46010 46051 45808 45849 45889 45939 45970 46010 46051 45808 45849 45889 45939 45970 46010 46051 45808 45849 45889 45939 45939 45970 46010 46051 45811 45855 45898 45999 45990 46020 46061 45811 45855 45898 45999 45990 45991 46020 46061 45813 45855 45896 45997 45988 45999 45990 46020 46061 45813 45856 45897 45988 45999 45990 46020 46061 45818 45859 45866 45907 45948 45985 46029 46002														
45792 45833 45874 45915 45956 45997 46038 46031 45793 45884 45895 45916 45959 45999 46010 46011 45795 4598 45998 45999 45794 45885 45876 45917 45918 45959 46000 46001 46012 45795 45986 45877 45918 45959 46000 46001 46012 45796 45879 45880 45879 45919 45960 46001 46012 45796 45879 45880 45879 45919 45960 46001 46012 45797 45918 45959 45800 46001 46012 45797 45918 45959 45800 45801 45811 45822 45933 45964 46003 46014 45799 45880 45811 45922 45963 46004 46015 45801 45881 45922 45963 46006 46014 45801 45881 45922 45963 46006 46014 45801 45882 45923 45966 46006 46014 45801 45882 45923 45966 46006 46014 45802 45883 45884 45925 45966 46007 46008 46014 45802 45883 45884 45925 45966 46007 46008 46014 45803 45884 45885 45966 45807 46008 46014 45803 45884 45885 45926 45967 46008 46010 46051 45806 45887 45888 45929 45910 46010 46051 45806 45887 45888 45889 45910 45911 46012 46053 45806 45807 45888 45889 45910 45911 46012 46053 45806 45887 45889 45900 45911 46012 46053 45806 45887 45889 45900 45911 45912 46013 46014 46055 4580 45809 45800 45811 45892 45993 45910 45911 46012 46053 45808 45889 45890 45910 45911 46012 46053 45808 45889 45890 45910 45911 46012 46053 45811 45892 45893 45994 45997 46016 46057 45811 45892 45893 45994 45997 46016 46057 45811 45892 45893 45994 45990 45911 45912 45913 45914 45915 45996 46010 46051 45811 45892 45893 45994 45990 45911 45912 45913 45914 45915 45996 46010 46051 45811 45892 45893 45994 45990 45911 45912 46013 46054 45811 45895 45899 45990 45911 45912 46013 46054 45811 45895 45899 45990 45911 45912 45913 45914 45915 45996 46010 46051 45811 45895 45899 45990 45911 45912 46013 46054 45887 45899 45890 45990 45991 45993 45990 45991 45992 45993 45990 45991 45992 45993 45990 45991 45992 45993 45990 45991 45992 45993 45990 45991 45992 45993 45990 45991 45992 45993 45990 45991 45990 45991 45990 45991 45990 45991 45990 45991 45990 45991 45990 45991 45990 45991 45990 45991 45990 45991 45990 45991 45990 45991 45990 45990 45991 45990 45991 45990 45990 45991 45990 45990 45991 45990 45990 45990 45990 45														
45793														
45794 45835 45876 45917 45958 45999 46000 45795 45836 45877 45918 45959 46000 46011 45795 45836 45837 45878 45919 45960 46001 46042 45797 45838 45839 45880 45921 45962 46003 46044 45798 45840 45881 45922 45963 46004 46045 46045 45880 45811 45822 45963 46004 46045 46046 45801 45881 45922 45965 46006 46047 45881 45820 45881 45925 45965 46006 46047 45800 45841 45882 45923 45965 46006 46047 45800 45841 45882 45925 45965 46006 46047 45800 45841 45885 45925 45966 460006 46047 45800 45841 45885 45925 45966 46000 46048 45801 45842 45883 45924 45965 46000 46048 45801 45844 45885 45926 45967 46008 46049 45805 45806 45847 45888 45929 45967 46008 46049 45805 45806 45847 45888 45929 45970 46011 46052 45806 45847 45888 45929 45970 46011 46052 45807 45808 45849 45890 45931 45972 46013 46054 45807 45808 45849 45890 45931 45972 46013 46054 45809 45850 45861 45891 45932 45973 46014 46055 45809 45851 45869 45891 45932 45973 46014 46055 45809 45851 45852 45893 45974 46015 46053 45809 45851 45852 45893 45974 46015 46053 45811 45852 45893 45994 45977 45018 46055 45809 45851 45852 45893 45974 46015 46055 45811 45852 45893 45994 45977 45018 46055 45811 45852 45893 45994 45977 45018 46055 45811 45852 45893 45994 45977 46018 46055 45811 45852 45893 45994 45997 46011 46055 45811 45852 45893 45993 45977 46011 46055 45811 45852 45893 45993 45977 46011 46055 45811 45852 45893 45993 45977 46011 46055 45811 45852 45893 45993 45977 46018 46055 45811 45852 45893 45993 45997 46010 46051 46051 45811 45852 45893 45993 45997 46010 46051 46056 45811 45852 45893 45993 45997 46010 46051 46056 45811 45852 45893 45993 45997 46010 46051 46056 45811 45852 45893 45993 45997 46010 46051 46056 45811 45852 45893 45993 45997 46010 46051 46056 45811 45852 45893 45993 45990 45990 45991 45990 45990 45991 45990 45991 45990 45991 45990 45991 45990 45991 45990 45990 45991 45990 45991 45990 45991 45990 45991 45990 45991 45990 45990 45991 45990 45990 45991 45990 45990 45991 45990 45990 45990 45991 45990 45990 45990 45991 45990 45990 45990 45990 45990 45990 45990 45990														
45795														
45797										45959				
45798		45796	45	837		45878		45919		45960		46001		46042
45799		45797	4.5	838		45879		45920		45961		46002		46043
45800		45798	45	839		45880		45921		45962		46003		46044
45801 45842 45883 45924 45965 46006 46047 45802 45843 45884 45925 45966 46007 46048 45803 45844 45885 45926 45967 46008 46049 45804 45845 45886 45927 45968 46009 46050 45805 45846 45887 45928 45969 46010 46051 45806 45847 45888 45929 45970 46011 46052 45807 45848 45889 45930 45971 46012 46053 45808 45849 45889 45930 45971 46012 46053 45810 45850 45891 45932 45973 46014 46053 45810 45851 45892 45933 45974 46015 46056 45811 45852 45893 45934 45975 46016 46057 45812 45853 45894 45935 45976 46017 46088 45813 45		45799	45	840		45881		45922		45963		46004		46045
45802		45800	45	841		45882		45923		45964		46005		46046
45803		45801	45	842		45883		45924		45965		46006		46047
45804 45845 45886 45927 45968 46009 46050 45805 45846 45887 45928 45969 46010 46051 45806 45847 45888 45929 45970 46011 46052 45807 45848 45889 45930 45971 46012 46053 45808 45849 45890 45931 45972 46013 46054 45809 45850 45891 45932 45973 46014 46055 45810 45851 45892 45933 45974 46015 46056 45811 45852 45893 45934 45975 46016 46057 45812 45853 45894 45935 45976 46016 46057 45813 45854 45895 45936 45977 46018 46059 45814 45855 45896 45937 45978 46019 46060 45815 45856 45897 45938 45979 46020 4601 45816 458		45802	45	843		45884		45925		45966		46007		46048
45805 45846 45887 45928 45969 46010 46051 45806 45847 45888 45929 45970 46011 46052 45807 45848 45889 45930 45971 46012 46053 45808 45849 45890 45931 45972 46013 46054 45809 45850 45891 45932 45973 46014 46055 45810 45851 45892 45933 45974 46015 46056 45811 45852 45893 45934 45975 46016 46057 45812 45853 45894 45935 45976 46017 46058 45813 45854 45895 45936 45977 46018 46058 45814 45855 45896 45937 45978 46019 46060 45815 45856 45897 45938 45979 46019 46060 45817 45858 45899 45940 45981 46022 46063 45817 45		45803	45	844		45885		45926		45967		46008		46049
45806 45847 45888 45929 45970 46011 46052 45807 45848 45889 45930 45971 46012 46053 45808 45849 45890 45931 45972 46013 46054 45809 45850 45891 45932 45973 46014 46055 45810 45851 45892 45933 45974 46015 46056 45811 45852 45893 45935 45976 46016 46057 45812 45853 45894 45935 45976 46017 46058 45813 45854 45895 45936 45977 46018 46059 45813 45854 45895 45937 45978 46019 46060 45815 45856 45897 45938 45979 46019 46061 45816 45857 45898 45939 45980 46021 46062 45817 45858 45899 45940 45981 46022 46063 45818 45		45804	45	845		45886		45927		45968		46009		46050
45807 45848 45889 45930 45971 46012 46053 45808 45849 45890 45931 45972 46013 46054 45809 45850 45891 45932 45973 46014 46055 45810 45851 45882 45933 45974 46015 46056 45811 45852 45893 45934 45975 46016 46057 45812 45853 45884 45935 45976 46017 46058 45813 45854 45895 45936 45977 46018 46059 45814 45855 45896 45937 45978 46019 46069 45815 45856 45897 45938 45979 46020 46061 45816 45857 45898 45939 45980 46021 46062 45818 45859 45900 45941 45982 46023 46064 45818 45860 <		45805	45	846		45887		45928		45969		46010		46051
45808 45849 45890 45931 45972 46013 46054 45809 45850 45891 45932 45973 46014 46055 45810 45851 45892 45933 45974 46015 46056 45811 45852 45893 45934 45975 46016 46057 45812 45853 45894 45935 45976 46017 46058 45813 45854 45895 45936 45977 46018 46059 45814 45855 45896 45978 46019 46060 45815 45856 45897 45938 45979 46020 46061 45816 45857 45898 45939 45980 46021 46062 45817 45858 45899 45940 45981 46022 46063 45818 45859 45900 45941 45982 46023 46064 45819 45860 45901 45942 45983 46024 46065 45821 45862 45		45806	45	847		45888		45929		45970		46011		46052
45809 45850 45891 45932 45973 46014 46055 45810 45851 45892 45933 45974 46015 46056 45811 45852 45893 45934 45975 46016 46057 45812 45853 45894 45935 45976 46017 46058 45813 45854 45895 45936 45977 46018 46059 45814 45855 45896 45937 45978 46019 46060 45815 45856 45897 45938 45979 46020 46061 45815 45857 45888 45939 45980 46020 46061 45817 45858 45899 45940 45981 46022 46063 45818 45859 45900 45941 45982 46023 46064 45819 45860 45901 45942 45983 46024 46065 45821 45861 45902 45943 45985 46026 46066 45822 45		45807	45	848		45889		45930		45971		46012		46053
45810 45851 45892 45933 45974 46015 46056 45811 45852 45893 45934 45975 46016 46057 45812 45853 45894 45935 45976 46017 46058 45813 45854 45895 45936 45977 46018 46059 45814 45855 45896 45937 45978 46019 46060 45815 45856 45897 45938 45979 46020 46061 45816 45857 45898 45939 45980 46021 46062 45817 45858 45899 45940 45981 46022 46063 45818 45859 45900 45941 45982 46023 46064 45819 45860 45901 45942 45983 46024 46065 45821 45862 45903 45942 45983 46024 46065 45821 45862 45903 45944 45985 46026 46067 45822 45		45808	45	849		45890		45931		45972		46013		46054
45811 45852 45893 45934 45975 46016 46057 45812 45853 45894 45935 45976 46017 46058 45813 45854 45895 45936 45977 46018 46059 45814 45855 45886 45937 45978 46019 46060 45815 45856 45897 45938 45979 46020 46061 45816 45857 45888 45939 45980 46021 46062 45817 45858 45899 45940 45981 46022 45063 45818 45859 45900 45941 45982 46023 46064 45819 45860 45901 45942 45983 46024 46065 45820 45861 45902 45943 45984 46025 46066 45821 45862 45903 45944 45985 46026 46067 45822 45863 45904 45945 45986 46027 46068 45823 45		45809	45	850		45891		45932		45973		46014		46055
45812 45853 45894 45935 45976 46017 46058 45813 45854 45895 45936 45977 46018 46059 45814 45855 45896 45937 45978 46019 46060 45815 45856 45897 45938 45979 46020 46061 45816 45857 45898 45939 45980 46021 46062 45817 45858 45899 45940 45981 46022 46063 45818 45859 45900 45941 45982 46023 46064 45819 45860 45901 45942 45983 46024 46065 45820 45861 45902 45943 45984 46025 46066 45821 45862 45903 45944 45985 46026 46067 45822 45863 45904 45945 45986 46027 46068 45823 45864 45905 45946 45987 46028 46069 45824 45		45810	45	851		45892		45933		45974		46015		46056
45813 45854 45895 45936 45977 46018 46059 45814 45855 45896 45937 45978 46019 46060 45815 45856 45897 45938 45979 46020 46061 45816 45857 45888 45939 45980 46021 46062 45817 45858 45899 45940 45981 46022 46063 45818 45859 45900 45941 45982 46023 46064 45819 45860 45901 45942 45983 46024 46065 45820 45861 45902 45943 45984 46025 46066 45821 45862 45903 45944 45985 46026 46067 45822 45863 45904 45945 45986 46027 46068 45823 45864 45905 45946 45987 46028 46069 45824 45865 45906 45947 45988 46029 46070 45825 45		45811	45	852		45893		45934		45975		46016		46057
45814 45855 45896 45937 45978 46019 46060 45815 45856 45897 45938 45979 46020 46061 45816 45857 45898 45939 45980 46021 46062 45817 45858 45899 45940 45981 46022 46063 45818 45859 45900 45941 45982 46023 46064 45819 45860 45901 45942 45983 46024 46065 45820 45861 45902 45943 45984 46025 46066 45821 45862 45903 45944 45985 46026 46067 45822 45863 45904 45945 45986 46027 46068 45823 45864 45905 45946 45987 46028 46069 45824 45865 45906 45947 45988 46029 46071 45825 45866 45907 45948 45989 46030 46071		45812	45	853		45894		45935		45976		46017		46058
45815 45856 45897 45938 45979 46020 46061 45816 45857 45888 45939 45980 46021 46062 45817 45858 45899 45940 45981 46022 46063 45818 45859 45900 45941 45982 46023 46064 45819 45860 45901 45942 45983 46024 46065 45820 45861 45902 45943 45984 46025 46066 45821 45862 45903 45944 45985 46026 45067 45822 45863 45904 45945 45986 46027 46068 45823 45864 45905 45946 45987 46028 46069 45824 45865 45906 45947 45988 46029 46070 45825 45866 45907 45948 45989 46030 46071		45813	45	854				45936		45977		46018		46059
45816 45857 45898 45939 45980 46021 46062 45817 45858 45899 45940 45981 46022 46063 45818 45859 45900 45941 45982 46023 46064 45819 45860 45901 45942 45983 46024 45065 45820 45861 45902 45943 45984 46025 46066 45821 45862 45903 45944 45985 46026 46067 45822 45863 45904 45945 45986 46027 46068 45823 45864 45905 45946 45987 46028 46069 45824 45865 45906 45947 45988 46029 46071 45825 45866 45907 45948 45989 46030 46071		45814	4.5	855		45896				45978		46019		46060
45817 45858 45899 45940 45981 46022 46063 45818 45859 45900 45941 45982 46023 46064 45819 45860 45901 45942 45983 46024 46065 45820 45861 45902 45943 45984 46025 46066 45821 45862 45903 45944 45985 46026 46067 45822 45863 45904 45945 45986 46027 46068 45823 45864 45905 45946 45987 46028 46069 45824 45865 45906 45947 45988 46029 46071 45825 45866 45907 45948 45989 46030 46071		45815	45	856		45897						46020		46061
45818 45859 45900 45941 45982 46023 46064 45819 45860 45901 45942 45983 46024 46065 45820 45861 45902 45943 45984 46025 46066 45821 45862 45903 45944 45985 46026 45067 45822 45863 45904 45945 45986 46027 46068 45823 45864 45905 45946 45987 46028 46069 45824 45865 45906 45947 45988 46029 46071 45825 45866 45907 45948 45989 46030 46071												1.1		
45819 45860 45901 45942 45983 46024 46065 45820 45861 45902 45943 45984 46025 46066 45821 45862 45903 45944 45985 46026 46067 45822 45863 45904 45945 45986 46027 46068 45823 45864 45905 45946 45987 46028 46069 45824 45865 45906 45947 45988 46029 46070 45825 45866 45907 45948 45989 46030 46071														
45820 45861 45902 45943 45984 46025 46066 45821 45862 45903 45944 45985 46026 46067 45822 45863 45904 45945 45986 46027 46068 45823 45864 45905 45946 45987 46028 46069 45824 45865 45906 45947 45988 46029 46070 45825 45866 45907 45948 45989 46030 46071														
45821 45862 45903 45944 45985 46026 46067 45822 45863 45904 45945 45986 46027 46068 45823 45864 45905 45946 45987 46028 46069 45824 45865 45906 45947 45988 46029 46070 45825 45866 45907 45948 45989 46030 46071												1.1		
45822 45863 45904 45945 45986 46027 46068 45823 45864 45905 45946 45987 46028 46069 45824 45865 45906 45947 45988 46029 46070 45825 45866 45907 45948 45989 46030 46071														
45823 45864 45905 45946 45987 46028 46069 45824 45865 45906 45947 45988 46029 46070 45825 45866 45907 45948 45989 46030 46071														
45824 45865 45906 45947 45988 46029 46070 45825 45866 45907 45948 45989 46030 46071												1.1		
45825 45866 45907 45948 45989 46030 46071														
45826 45867 45908 45949 45990 46031 46072														
		45826	45	867		45908		45949		45990		46031		46072

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. B		Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nl	b	No nb	No nb	No nb	No nb	No nb	No nb
PPD 4	6073	PPD 46114	PPD 46155	PPD 46196	PPD 46237	PPD 46278	PPD 46319
	6074	46115	46156	46197	46238	46279	46320
	6075	46116	46157	46198	46239	46280	46321
_	6076	46117	46158	46199	46240	46281	46322
	6077	46118	46159	46200	46241	46282	46323
4	6078	46119	46160	46201	46242	46283	46324
4	6079	46120	46161	46202	46243	46284	46325
4	6080	46121	46162	46203	46244	46285	46326
4	6081	46122	46163	46204	46245	46286	46327
4	6082	46123	46164	46205	46246	46287	46328
4	6083	46124	46165	46206	46247	46288	46329
4	6084	46125	46166	46207	46248	46289	46330
4	6085	46126	46167	46208	46249	46290	46331
4	6086	46127	46168	46209	46250	46291	46332
4	6087	46128	46169	46210	46251	46292	46333
4	6088	46129	46170	46211	46252	46293	46334
4	6089	46130	46171	46212	46253	46294	46335
4	6090	46131	46172	46213	46254	46295	46336
	6091	46132	46173	46214	46255	46296	46337
	6092	46133	46174	46215	46256	46297	46338
	6093	46134	46175	46216	46257	46298	46339
	6094	46135	46176	46217	46258	46299	46340
	6095	46136	46177	46218	46259	46300	46341
_	6096	46137	46178	46219	46260	46301	46342
	6097	46138	46179	46220	46261	46302	46343
	6098	46139	46180	46221	46262	46303	46344
	6099	46140	46181	46222	46263	46304	46345
	6100	46141	46182	46223	46264	46305	46346
	6101	46142	46183	46224	46265	46306	46347
	6102	46143	46184	46225	46266	46307	46348
	6103	46144	46185	46226	46267	46308	46349
	6104	46145 46146	46186 46187	46227 46228	46268 46269	46309 46310	46350 46351
	6106	46146	46188	46228	46269	46310	46351
	6107	46147	46188	46229	46270	46311	46352
		46148	46189		46271		
	6108	46149	46190	46231 46232	46272	46313 46314	46354 46355
	6110	46150	46191	46232	46274	46314	46356
	6111	46151	46192	46233	46274	46316	46357
	6112	46152	46193	46234	46276	46317	46357
	6113	46154	46195	46235	46277	46317	46359
4	0113	40174	40193	40230	40211	40310	40339

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt	B1.	Trt.	Bl.	Trt.	Bl.	Trt	. Bl.	Trt	. Bl.
	nb	No nb		nb		nb	No	nb		nb	No	o nb
PPD	46360	PPD 46401	PPD	46442	PPD	46483	PPD	46524	PPD	46565	PPD	46606
FFD	46361	46402		46443	110	46484	FFD	46525		46566		46607
	46362	46403		46444		46485		46526		46567		46608
	46363	46404		46445		46486		46527		46568		46609
	46364	46405		46446		46487		46528		46569		46610
	46365	46406		46447		46488		46529		46570		46611
	46366	46407		46448		46489		46530		46571		46612
	46367	46408		46449		46490		46531		46572		46613
	46368	46409		46450		46491		46532		46573		46614
	46369	46410		46451		46492		46533		46574		46615
	46370	46411		46452		46493		46534		46575		46616
	46371	46412		46453		46494		46535		46576		46617
	46372	46413		46454		46495		46536		46577		46618
	46373	46414		46455		46496		46537		46578		46619
	46374	46415		46456		46497		46538		46579		46620
	46375	46416		46457		46498		46539		46580		46621
	46376	46417		46458		46499		46540		46581		46622
	46377	46418		46459		46500		46541		46582		46623
	46378	46419		46460		46501		46542		46583		46624
	46379	46420		46461		46502		46543		46584		46625
	46380	46421		46462		46503		46544		46585		46626
	46381	46422		46463		46504		46545		46586		46627
	46382	46423		46464		46505		46546		46587		46628
	46383	46424		46465		46506		46547		46588		46629
	46384	46425		46466		46507		46548		46589		46630
	46385	46426		46467		46508		46549		46590		46631
	46386	46427		46468		46509		46550		46591		46632
	46387	46428		46469		46510		46551		46592		46633
	46388	46429		46470		46511		46552		46593		46634
	46389	46430		46471		46512		46553		46594		46635
	46390	46431		46472		46513		46554		46595		46636
	46391	46432		46473		46514		46555		46596		46637
	46392	46433		46474		46515		46556		46597		46638
	46393	46434		46475		46516		46557		46598		46639
	46394	46435		46476		46517		46558		46599		46640
	46395	46436		46477		46518		46559		46600		46641
	46396	46437		46478		46519		46560		46601		46642
	46397	46438		46479		46520		46561		46602		46643
	46398	46439		46480		46521		46562		46603		46644
	46399	46440		46481		46522		46563		46604		46645
	46400	46441		46482		46523		46564		46605		46646
	10100	10111		10102		10020		10001		10000		10010

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	46647	PPD 46688	PPD 46729	PPD 46770	PPD 46811	PPD 46852	PPD 46893
FFD	46648	46689	46730	46771	46812	46853	46894
	46649	46690	46731	46772	46813	46854	46895
	46650	46691	46732	46773	46814	46855	46896
	46651	46692	46733	46774	46815	46856	46897
	46652	46693	46734	46775	46816	46857	46898
	46653	46694	46735	46776	46817	46857	46898
	46654	46695	46736	46777	46818	46859	46900
	46655	46696	46737	46778	46818	46859	46900
	46656	46697	46738	46779	46820	46861	
	46657	46698	46739	46780	46820	46861	46902 46903
	46658	46699	46740	46781	46822	46863	46904
	46659	46700	46741	46782	46823	46864	46905
	46660	46701	46741			46865	46905
		46701	46743	46783 46784	46824	46866	46907
	46661				46825		
	46662	46703	46744	46785	46826	46867	46908
	46663	46704	46745	46786	46827	46868	46909
	46664	46705	46746	46787	46828	46869	46910
	46665	46706	46747	46788	46829	46870	46911
	46666	46707	46748	46789	46830	46871	46912
	46667	46708	46749	46790	46831	46872	46913
	46668	46709	46750	46791	46832	46873	46914
	46669	46710	46751	46792	46833	46874	46915
	46670	46711	46752	46793	46834	46875	46916
	46671	46712	46753	46794	46835	46876	46917
	46672	46713	46754	46795	46836	46877	46918
	46673	46714	46755	46796	46837	46878	46919
	46674	46715	46756	46797	46838	46879	46920
	46675	46716	46757	46798	46839	46880	46921
	46676	46717	46758	46799	46840	46881	46922
	46677	46718	46759	46800	46841	46882	46923
	46678	46719	46760	46801	46842	46883	46924
	46679	46720	46761	46802	46843	46884	46925
	46680	46721	46762	46803	46844	46885	46926
	46681	46722	46763	46804	46845	46886	46927
	46682	46723	46764	46805	46846	46887	46928
	46683	46724	46765	46806	46847	46888	46929
	46684	46725	46766	46807	46848	46889	46930
	46685	46726	46767	46808	46849	46890	46931
	46686	46727	46768	46809	46850	46891	46932
	46687	46728	46769	46810	46851	46892	46933

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.					
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	46934	PPD 46975	PPD 47016	PPD 47057	PPD 47098	PPD 47139	PPD 47180
	46935	46976	47017	47058	47099	47140	47181
	46936	46977	47018	47059	47100	47141	47182
	46937	46978	47019	47060	47101	47142	47183
	46938	46979	47020	47061	47102	47143	47184
	46939	46980	47021	47062	47103	47144	47185
	46940	46981	47022	47063	47104	47145	47186
	46941	46982	47023	47064	47105	47146	47187
	46942	46983	47024	47065	47106	47147	47188
	46943	46984	47025	47066	47107	47148	47189
	46944	46985	47026	47067	47108	47149	47190
	46945	46986	47027	47068	47109	47150	47191
	46946	46987	47028	47069	47110	47151	47192
	46947	46988	47029	47070	47111	47152	47193
	46948	46989	47030	47071	47112	47153	47194
	46949	46990	47031	47072	47113	47154	47195
	46950	46991	47032	47073	47114	47155	47196
	46951	46992	47033	47074	47115	47156	47197
	46952	46993	47034	47075	47116	47157	47198
	46953	46994	47035	47076	47117	47158	47199
	46954	46995	47036	47077	47118	47159	47200
	46955	46996	47037	47078	47119	47160	47201
	46956	46997	47038	47079	47120	47161	47202
	46957	46998	47039	47080	47121	47162	47203
	46958	46999	47040	47081	47122	47163	47204
	46959	47000	47041	47082	47123	47164	47205
	46960	47001	47042	47083	47124	47165	47206
	46961	47002	47043	47084	47125	47166	47207
	46962	47003	47044	47085	47126	47167	47208
	46963	47004	47045	47086	47127	47168	47209
	46964	47005	47046	47087	47128	47169	47210
	46965	47006	47047	47088	47129	47170	47211
	46966	47007	47048	47089	47130	47171	47212
	46967	47008	47049	47090	47131	47172	47213
	46968	47009	47050	47091	47132	47173	47214
	46969	47010	47051	47092	47133	47174	47215
	46970	47011	47052	47093	47134	47175	47216
	46971	47012	47053	47094	47135	47176	47217
	46972	47013	47054	47095	47136	47177	47218
	46973	47014	47055	47096	47137	47178	47219
	46974	47015	47056	47097	47138	47179	47220

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl. No nb	Trt. Bl. No nb	Trt.	Bl. nb	Trt.	Bl. nb	Trt.	Bl. nb	Trt.	Bl. nb
PPD	47221	PPD 47262	PPD 4730	3 PPD	47344	PPD	47385	PPD	47426	PPD	47467
	47222	47263	4730	4	47345		47386		47427		47468
	47223	47264	4730	15	47346		47387		47428		47469
	47224	47265	4730	16	47347		47388		47429		47470
	47225	47266	4730	17	47348		47389		47430		47471
	47226	47267	4730	18	47349		47390		47431		47472
	47227	47268	4730	19	47350		47391		47432		47473
	47228	47269	4731	.0	47351		47392		47433		47474
	47229	47270	4731	.1	47352		47393		47434		47475
	47230	47271	4731	.2	47353		47394		47435		47476
	47231	47272	4731		47354		47395		47436		47477
	47232	47273	4731	.4	47355		47396		47437		47478
	47233	47274	4731		47356		47397		47438		47479
	47234	47275	4731		47357		47398		47439		47480
	47235	47276	4731		47358		47399		47440		47481
	47236	47277	4731		47359		47400		47441		47482
	47237	47278	4731		47360		47401		47442		47483
	47238	47279	4732		47361		47402		47443		47484
	47239	47280	4732		47362		47403		47444		47485
	47240	47281	4732		47363		47404		47445		47486
	47241	47282	4732		47364		47405		47446		47487
	47242	47283	4732		47365		47406		47447		47488
	47243	47284	4732		47366		47407		47448		47489
	47244 47245	47285 47286	4732 4732		47367 47368		47408 47409		47449 47450		47490 47491
	47245	47286	4732		47368		47409		47450		47491
	47246	47287	4732		47370		47410		47451		47492
	47248	47289	4733		47370		47411		47453		47493
	47249	47290	4733		47372		47413		47454		47494
	47250	47291	4733		47373		47414		47455		47496
	47251	47292	4733		47374		47415		47456		47497
	47252	47293	4733		47375		47416		47457		47498
	47253	47294	4733		47376		47417		47458		47499
	47254	47295	4733		47377		47418		47459		47500
	47255	47296	4733		47378		47419		47460		47501
	47256	47297	4733		47379		47420		47461		47502
	47257	47298	4733		47380		47421		47462		47503
	47258	47299	4734		47381		47422		47463		47504
	47259	47300	4734		47382		47423		47464		47505
	47260	47301	4734		47383		47424		47465		47506
	47261	47302	4734	3	47384		47425		47466		47507
	l										

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	47508	PPD 47549	PPD 47590	PPD 47631	PPD 47672	PPD 47713	PPD 47754
110	47509	47550	47591	47632	47673	47714	47755
	47510	47551	47592	47633	47674	47715	47756
	47511	47552	47593	47634	47675	47716	47757
	47512	47553	47594	47635	47676	47717	47758
	47513	47554	47595	47636	47677	47718	47759
	47514	47555	47596	47637	47678	47719	47760
	47515	47556	47597	47638	47679	47720	47761
	47516	47557	47598	47639	47680	47721	47762
	47517	47558	47599	47640	47681	47722	47763
	47518	47559	47600	47641	47682	47723	47764
	47519	47560	47601	47642	47683	47724	47765
	47520	47561	47602	47643	47684	47725	47766
	47521	47562	47603	47644	47685	47726	47767
	47522	47563	47604	47645	47686	47727	47768
	47523	47564	47605	47646	47687	47728	47769
	47524	47565	47606	47647	47688	47729	47770
	47525	47566	47607	47648	47689	47730	47771
	47526	47567	47608	47649	47690	47731	47772
	47527	47568	47609	47650	47691	47732	47773
	47528	47569	47610	47651	47692	47733	47774
	47529	47570	47611	47652	47693	47734	47775
	47530	47571	47612	47653	47694	47735	47776
	47531	47572	47613	47654	47695	47736	47777
	47532	47573	47614	47655	47696	47737	47778
	47533	47574	47615	47656	47697	47738	47779
	47534	47575	47616	47657	47698	47739	47780
	47535	47576	47617	47658	47699	47740	47781
	47536	47577	47618	47659	47700	47741	47782
	47537	47578	47619	47660	47701	47742	47783
	47538	47579	47620	47661	47702	47743	47784
	47539	47580	47621	47662	47703	47744	47785
	47540	47581	47622	47663	47704	47745	47786
	47541	47582	47623	47664	47705	47746	47787
	47542	47583	47624	47665	47706	47747	47788
	47543	47584	47625	47666	47707	47748	47789
	47544	47585	47626	47667	47708	47749	47790
	47545	47586	47627	47668	47709	47750	47791
	47546	47587	47628	47669	47710	47751	47792
	47547	47588	47629	47670	47711	47752	47793
	47548	47589	47630	47671	47712	47753	47794
	_						

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.	Trt.		Trt.		Trt.		Trt.		Trt.	
No	nb	No nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	47795	PPD 47836	PPD	47877	PPD	47918	PPD	47959	PPD	48000	PPD	48041
	47796	47837		47878		47919		47960		48001		48042
	47797	47838		47879		47920		47961		48002	l l	48043
	47798	47839		47880		47921		47962		48003	l l	48044
	47799	47840		47881		47922		47963		48004	l l	48045
	47800	47841		47882		47923		47964		48005	l l	48046
	47801	47842		47883		47924		47965		48006	l l	48047
	47802	47843		47884		47925		47966		48007	l l	48048
	47803	47844		47885		47926		47967		48008	l l	48049
	47804	47845		47886		47927		47968		48009	l l	48050
	47805	47846		47887		47928		47969		48010	l l	48051
	47806	47847		47888		47929		47970		48011	l l	48052
	47807	47848		47889		47930		47971		48012	l l	48053
	47808	47849		47890		47931		47972		48013	l l	48054
	47809	47850		47891		47932		47973		48014	l l	48055
	47810	47851		47892		47933		47974		48015	l l	48056
	47811	47852		47893		47934		47975		48016	l l	48057
	47812	47853		47894		47935		47976		48017	l l	48058
	47813	47854		47895		47936		47977		48018	l l	48059
	47814	47855		47896		47937		47978		48019	l l	48060
	47815	47856		47897		47938		47979		48020	l l	48061
	47816	47857		47898		47939		47980		48021	l l	48062
	47817	47858		47899		47940		47981		48022	l l	48063
	47818	47859		47900		47941		47982		48023	l l	48064
	47819	47860		47901		47942		47983		48024	l l	48065
	47820	47861		47902		47943		47984		48025	l l	48066
	47821	47862		47903		47944		47985		48026	l l	48067
	47822	47863		47904		47945		47986		48027	l l	48068
	47823	47864		47905		47946		47987		48028	l l	48069
	47824	47865		47906		47947		47988		48029	l l	48070
	47825	47866		47907		47948		47989		48030	l l	48071
	47826	47867		47908		47949		47990		48031	l l	48072
	47827	47868		47909		47950		47991		48032	l l	48073
	47828	47869		47910		47951		47992		48033	l l	48074
	47829	47870		47911		47952		47993		48034	l l	48075
	47830	47871		47912		47953		47994		48035		48076
	47831	47872		47913		47954		47995		48036		48077
	47832	47873		47914		47955		47996		48037		48078
	47833	47874		47915		47956		47997		48038		48079 48080
	47834	47875 47876		47916		47957		47998 47999		48039		
	47835	4/8/6		47917		47958		4/999		48040		48081
				l								

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	B1.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	48082	PPD 48123	PPD 48164	PPD 48205	PPD 48246	PPD 48287	PPD 48328
PPD	48082	48123 48124	48164	48205 48206	48246 48247	48287	48328
	48083	48124	48165	48206	48247	48288	48329
		48125	48166	48207	48248	48289	48330
	48085						
	48086	48127	48168	48209	48250	48291	48332
	48087	48128	48169	48210	48251	48292	48333
	48088	48129	48170	48211	48252	48293	48334
	48089	48130	48171	48212	48253	48294	48335
	48090	48131	48172	48213	48254	48295	48336
	48091	48132	48173	48214	48255	48296	48337
	48092	48133	48174	48215	48256	48297	48338
	48093	48134	48175	48216	48257	48298	48339
	48094	48135	48176	48217	48258	48299	48340
	48095	48136	48177	48218	48259	48300	48341
	48096	48137	48178	48219	48260	48301	48342
	48097	48138	48179	48220	48261	48302	48343
	48098	48139	48180	48221	48262	48303	48344
	48099	48140	48181	48222	48263	48304	48345
	48100	48141	48182	48223	48264	48305	48346
	48101	48142	48183	48224	48265	48306	48347
	48102	48143	48184	48225	48266	48307	48348
	48103	48144	48185	48226	48267	48308	48349
	48104	48145	48186	48227	48268	48309	48350
	48105	48146	48187	48228	48269	48310	48351
	48106	48147	48188	48229	48270	48311	48352
	48107	48148	48189	48230	48271	48312	48353
	48108	48149	48190	48231	48272	48313	48354
	48109	48150	48191	48232	48273	48314	48355
	48110	48151	48192	48233	48274	48315	48356
	48111	48152	48193	48234	48275	48316	48357
	48112	48153	48194	48235	48276	48317	48358
	48113	48154	48195	48236	48277	48318	48359
	48114	48155	48196	48237	48278	48319	48360
	48115	48156	48197	48238	48279	48320	48361
	48116	48157	48198	48239	48280	48321	48362
	48117	48158	48199	48240	48281	48322	48363
	48118	48159	48200	48241	48282	48323	48364
	48119	48160	48201	48242	48283	48324	48365
	48120	48161	48202	48243	48284	48325	48366
	48121	48162	48203	48244	48285	48326	48367
	48122	48163	48204	48245	48286	48327	48368
	-						

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.	Trt.			Bl.		. Bl.		Bl.		. Bl.
No	nb	No nb		nb	No	nb		nb	No	nb	No	o nb
PPD	48369	PPD 48410	PPD	48451	PPD	48492	PPD	48533	PPD	48574	PPD	48615
FFD	48370	48411		48452	110	48493	FFD	48534		48575		48616
	48371	48412		48453		48494		48535		48576		48617
	48372	48413		48454		48495		48536		48577		48618
	48373	48414		48455		48496		48537		48578		48619
	48374	48415		48456		48497		48538		48579		48620
	48375	48416		48457		48498		48539		48580		48621
	48376	48417		48458		48499		48540		48581		48622
	48376	48417		48458		48499		48540		48581		48622
	48378	48419		48460		48501		48542		48583		48624
	48378	48419		48460		48501		48542		48583		48624
	48380	48421		48462		48503		48544		48585		48626
	4838U 48381	48421		48462		48503		48544		48585		48626
	48381	48422		48463		48504		48545		48586		48627
	48383	48424		48465		48506		48547		48588		48629
	48384	48425		48466		48507		48548		48589		48630
	48385	48426		48467		48508		48549		48590		48631
	48386	48427		48468		48509		48550		48591		48632
	48387	48428		48469		48510		48551		48592		48633
	48388	48429		48470		48511		48552		48593		48634
	48389	48430		48471		48512		48553		48594		48635
	48390	48431		48472		48513		48554		48595		48636
	48391	48432		48473		48514		48555		48596		48637
	48392	48433		48474		48515		48556		48597		48638
	48393	48434		48475		48516		48557		48598		48639
	48394	48435		48476		48517		48558		48599		48640
	48395	48436		48477		48518		48559		48600		48641
	48396	48437		48478		48519		48560		48601		48642
	48397	48438		48479		48520		48561		48602		48643
	48398	48439		48480		48521		48562		48603		48644
	48399	48440		48481		48522		48563		48604		48645
	48400	48441		48482		48523		48564		48605		48646
	48401	48442		48483		48524		48565		48606		48647
	48402	48443		48484		48525		48566		48607		48648
	48403	48444		48485		48526		48567		48608		48649
	48404	48445		48486		48527		48568		48609		48650
	48405	48446		48487		48528		48569		48610		48651
	48406	48447		48488		48529		48570		48611		48652
	48407	48448		48489		48530		48571		48612		48653
	48408	48449		48490		48531		48572		48613		48654
	48409	48450		48491		48532		48573		48614		48655
	l											

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	48656	PPD 48697	PPD 48738	PPD 48779	PPD 48820	PPD 48861	PPD 48902
FFD	48657	48698	48739	48780	48821	48862	48903
	48658	48699	48740	48781	48822	48863	48904
	48659	48700	48741	48782	48823	48864	48905
	48660	48701	48742	48783	48824	48865	48906
	48661	48702	48743	48784	48825	48866	48907
	48662	48703	48744	48785	48826	48867	48908
	48663	48704	48745	48786	48827	48868	48909
	48664	48705	48746	48787	48828	48869	48910
	48665	48706	48747	48788	48829	48870	48911
	48666	48707	48748	48789	48830	48871	48912
	48667	48708	48749	48790	48831	48872	48913
	48668	48709	48750	48791	48832	48873	48914
	48669	48710	48751	48792	48833	48874	48915
	48670	48711	48752	48793	48834	48875	48916
	48671	48712	48753	48794	48835	48876	48917
	48672	48713	48754	48795	48836	48877	48918
	48673	48714	48755	48796	48837	48878	48919
	48674	48715	48756	48797	48838	48879	48920
	48675	48716	48757	48798	48839	48880	48921
	48676	48717	48758	48799	48840	48881	48922
	48677	48718	48759	48800	48841	48882	48923
	48678	48719	48760	48801	48842	48883	48924
	48679	48720	48761	48802	48843	48884	48925
	48680	48721	48762	48803	48844	48885	48926
	48681	48722	48763	48804	48845	48886	48927
	48682	48723	48764	48805	48846	48887	48928
	48683	48724	48765	48806	48847	48888	48929
	48684	48725	48766	48807	48848	48889	48930
	48685	48726	48767	48808	48849	48890	48931
	48686	48727	48768	48809	48850	48891	48932
	48687	48728	48769	48810	48851	48892	48933
	48688	48729	48770	48811	48852	48893	48934
	48689	48730	48771	48812	48853	48894	48935
	48690	48731	48772	48813	48854	48895	48936
	48691	48732	48773	48814	48855	48896	48937
	48692	48733	48774	48815	48856	48897	48938
	48693	48734	48775	48816	48857	48898	48939
	48694	48735	48776	48817	48858	48899	48940
	48695	48736	48777	48818	48859	48900	48941
	48696	48737	48778	48819	48860	48901	48942

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	. Bl.
No	nb	No nb	No nb		nb	No	nb	No	nb	No	nb
PPD	48943	PPD 48984	PPD 4902	5 PPD	49066	PPD	49107	PPD	49148	PPD	49189
110	48944	48985	4902		49067		49108		49149		49190
	48945	48986	4902		49068		49109		49150		49191
	48946	48987	4902		49069		49110		49151		49192
	48947	48988	4902	9	49070		49111		49152		49193
	48948	48989	4903	0	49071		49112		49153		49194
	48949	48990	4903	1	49072		49113		49154		49195
	48950	48991	4903	2	49073		49114		49155		49196
	48951	48992	4903	3	49074		49115		49156		49197
	48952	48993	4903	4	49075		49116		49157		49198
	48953	48994	4903	5	49076		49117		49158		49199
	48954	48995	4903	6	49077		49118		49159		49200
	48955	48996	4903	7	49078		49119		49160		49201
	48956	48997	4903	8	49079		49120		49161		49202
	48957	48998	4903	9	49080		49121		49162		49203
	48958	48999	4904	0	49081		49122		49163		49204
	48959	49000	4904	1	49082		49123		49164		49205
	48960	49001	4904	2	49083		49124		49165		49206
	48961	49002	4904	3	49084		49125		49166		49207
	48962	49003	4904	4	49085		49126		49167		49208
	48963	49004	4904	~	49086		49127		49168		49209
	48964	49005	4904		49087		49128		49169		49210
	48965	49006	4904		49088		49129		49170		49211
	48966	49007	4904	-	49089		49130		49171		49212
	48967	49008	4904		49090		49131		49172		49213
	48968	49009	4905		49091		49132		49173		49214
	48969	49010	4905		49092		49133		49174		49215
	48970	49011	4905		49093		49134		49175		49216
	48971	49012	4905		49094		49135		49176		49217
	48972	49013	4905		49095		49136		49177		49218
	48973	49014	4905		49096		49137		49178		49219
	48974	49015	4905	~	49097		49138		49179		49220
	48975	49016	4905		49098		49139		49180		49221
	48976	49017	4905		49099		49140		49181		49222
	48977	49018	4905		49100		49141		49182		49223
	48978	49019	4906		49101		49142		49183		49224
	48979	49020	4906		49102		49143		49184		49225
	48980	49021	4906		49103		49144		49185		49226
	48981	49022	4906		49104		49145		49186		49227
	48982	49023	4906		49105		49146		49187		49228
	48983	49024	4906	5	49106		49147		49188		49229
	l										

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. E		Trt.		Trt.		Trt.		Trt.			Bl.	Trt.	
No r	nb	No	nb	No		No	nb		nb	No	nb	No	nb
PPD 4	49230	PPD	49271	PPD	49312	PPD	49353	PPD	49394	PPD	49435	PPD	49476
	49231		49272		49313	110	49354	110	49395		49436		49477
	49232		49273		49314		49355		49396		49437		49478
	49233		49274		49315		49356		49397		49438		49479
	49234		49275		49316		49357		49398		49439		49480
	49235		49276		49317		49358		49399		49440		49481
	49236		49277		49318		49359		49400		49441		49482
	49237		49278		49319		49360		49401		49442		49483
	49238		49279		49320		49361		49402		49443		49484
	49239		49280		49321		49362		49403		49444		49485
	49240		49281		49322		49363		49404		49445		49486
	49241		49282		49323		49364		49405		49446		49487
	49242		49283		49324		49365		49406		49447		49488
	49243		49284		49325		49366		49407		49448		49489
	49244		49285		49326		49367		49408		49449		49490
	49245		49286		49327		49368		49409		49450		49491
	49246		49287		49328		49369		49410		49451		49491
	49247		49288		49329		49370		49411		49452		49493
	49248		49289		49330		49371		49412		49453		49494
	49249		49290		49331		49372		49413		49454		49495
	49250		49291		49332		49373		49414		49455		49496
	49251		49292		49333		49374		49415		49456		49497
	49252		49293		49334		49375		49416		49457		49498
	49253		49294		49335		49376		49417		49458		49499
	49254		49295		49336		49377		49418		49459		49500
	49255		49296		49337		49378		49419		49460		49501
	49256		49297		49338		49379		49420		49461		49502
	49257		49298		49339		49380		49421		49462		49503
	49258		49299		49340		49381		49422		49463		49504
	49259		49300		49341		49382		49423		49464		49505
	49260		49301		49342		49383		49424		49465		49506
	49261		49302		49343		49384		49425		49466		49507
	49262		49303		49344		49385		49426		49467		49508
	49263		49304		49345		49386		49427		49468		49509
	49264		49305		49346		49387		49428		49469		49510
	49265		49306		49347		49388		49429		49470		49511
	49266		49307		49348		49389		49430		49471		49512
	49267		49308		49349		49390		49431		49472		49513
	49268		49309		49350		49391		49432		49473		49514
	49269		49310		49351		49392		49433		49474		49515
	49270		49311		49352		49393		49434		49475		49516
	- * *		= =										
							l						

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	49517	PPD 49558	PPD 49599	PPD 49640	PPD 49681	PPD 49722	PPD 49763
FFD	49518	49559	49600	49641	49682	49723	49764
	49519	49560	49601	49642	49683	49724	49765
	49520	49561	49602	49642	49684	49724	49766
	49521	49562	49603	49644	49685	49726	49767
	49521	49563	49603	49644	49686	49727	49768
	49523	49564	49604	49645	49687	49727	49769
	49524	49565	49605	49647	49688	49729	49770
	49525	49566	49607	49648	49689	49729	49771
	49526	49567	49607	49649	49699	49731	49772
	49527	49568	49608	49649	49690	49731	49773
	49528	49569	49610	49651	49691	49733	49774
	49526	49570	49610	49652	49693	49733	49774
	49529	49571	49611	49652	49693	49735	49776
	49531	49572	49612	49654	49695	49736	49777
	49531	49572	49613	49654	49695	49737	49778
		49573					
	49533 49534	49574	49615 49616	49656 49657	49697 49698	49738 49739	49779 49780
	49535 49536	49576 49577	49617	49658	49699	49740	49781
	49536		49618 49619	49659 49660	49700	49741 49742	49782 49783
	49537	49578 49579	49619	49660	49701 49702	49742	49783
	49538	49579	49620	49661	49702	49743	49784
	49539	49580	49621	49662	49703	49744	49786
	49540	49581	49622	49663	49704	49745	49787
	49541	49582	49623	49665	49705	49747	49788
	49542	49583	49624	49665	49706	49747	49789
	49544 49545	49585 49586	49626 49627	49667 49668	49708 49709	49749	49790
	49545	49586	49627	49669	49709	49750	49791 49792
	49546	49587	49628	49670	49710	49751 49752	49793
	49547	49589	49630	49671	49711	49753	49793
	49548	49589	49630	49671	49712	49754	49794
	49550	49591	49632	49673	49713	49755	49796
	49551	49591	49632	49674	49714	49756	49797
	49552	49593	49634	49675	49716	49757	49797
	49552	49593	49634	49676	49716	49758	49799
	49553	49594	49635	49677	49717	49759	49799
	49554	49595	49636	49678	49718	49760	49800
	49555	49596 49597	49637	49678	49719	49760	49801
	49556	49597	49638	49679	49720	49762	49802
	49007	49598	49639	49680	49721	49762	49803

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt	. Bl.
No	nb	No nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	49804	PPD 49845	PPD	49886	PPD	49927	PPD	49968	PPD	50009	PPD	50050
PPD	49805	49846	110	49887	FFD	49927	PPD	49969		50009	110	50050
	49806	49847		49888		49929		49970		50010		50051
	49807	49848		49889		49929		49970		50011		50052
	49808	49849		49890		49931		49972		50012		50054
	49809	49850		49891		49931		49972		50013		50054
	49810	49851		49892		49933		49973		50014		50055
	49811	49851		49893		49933		49974		50015		50057
	49812	49853		49894		49935		49975		50016		50057
	49813	49854		49895		49936		49976		50017		50058
	49814	49855		49896		49937		49977		50018		50059
	49815	49856		49897		49937		49976		50019		50060
	49816	49857		49898		49939		49979		50020		50061
	49817	49858		49899		49940		49981		50021		50062
	49818	49859		49999		49941		49961		50022		50063
	49819	49860		49900		49941		49962		50023		50064
	49819	49860		49901		49942		49983		50024		50065
	49820	49861		49902		49943		49984		50025		50066
	49821	49862		49903				49985				50067
	49822	49863		49904		49945 49946		49986		50027 50028		50068
	49824	49865		49905		49946		49988		50028		50070
	49825	49866		49907		49947		49989		50029		50070
	49826	49867		49907		49949		49999		50030		50071
	49827	49868		49908		49949		49990		50031		50072
	49828	49869		49910		49951		49991		50032		50073
	49829	49870		49911		49952		49993		50033		50074
	49830	49871		49912		49953		49994		50034		50075
	49831	49872		49913		49954		49995		50035		50070
	49832	49873		49913		49955		49996		50036		50077
	49833	49874		49915		49956		49997		50037		50078
	49834	49875		49916		49957		49998		50038		50079
	49835	49876		49917		49958		49999		50040		50081
	49836	49877		49918		49959		50000		50040		50082
	49837	49878		49919		49960		50001		50042		50083
	49838	49879		49920		49961		50001		50042		50084
	49839	49880		49921		49962		50002		50043		50085
	49840	49881		49922		49963		50003		50045		50086
	49841	49882		49923		49964		50005		50045		50087
	49842	49883		49924		49965		50005		50047		50087
	49843	49884		49925		49966		50000		50047		50089
	49844	49885		49926		49967		50007		50048		50099
	17011	4,000		13320		1000		55000		55045		30030

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.					
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	50091	PPD 50132	PPD 50173	PPD 50214	PPD 50255	PPD 50296	PPD 50337
	50092	50133	50174	50215	50256	50297	50338
	50093	50134	50175	50216	50257	50298	50339
	50094	50135	50176	50217	50258	50299	50340
	50095	50136	50177	50218	50259	50300	50341
	50096	50137	50178	50219	50260	50301	50342
	50097	50138	50179	50220	50261	50302	50343
	50098	50139	50180	50221	50262	50303	50344
	50099	50140	50181	50222	50263	50304	50345
	50100	50141	50182	50223	50264	50305	50346
	50101	50142	50183	50224	50265	50306	50347
	50102	50143	50184	50225	50266	50307	50348
	50103	50144	50185	50226	50267	50308	50349
	50104	50145	50186	50227	50268	50309	50350
	50105	50146	50187	50228	50269	50310	50351
	50106	50147	50188	50229	50270	50311	50352
	50107	50148	50189	50230	50271	50312	50353
	50108	50149	50190	50231	50272	50313	50354
	50109	50150	50191	50232	50273	50314	50355
	50110	50151	50192	50233	50274	50315	50356
	50111	50152	50193	50234	50275	50316	50357
	50112	50153	50194	50235	50276	50317	50358
	50113	50154	50195	50236	50277	50318	50359
	50114	50155	50196	50237	50278	50319	50360
	50115	50156	50197	50238	50279	50320	50361
	50116	50157	50198	50239	50280	50321	50362
	50117	50158	50199	50240	50281	50322	50363
	50118	50159	50200	50241	50282	50323	50364
	50119	50160	50201	50242	50283	50324	50365
	50120	50161	50202	50243	50284	50325	50366
	50121	50162	50203	50244	50285	50326	50367
	50122	50163	50204	50245	50286	50327	50368
	50123	50164	50205	50246	50287	50328	50369
	50124	50165	50206	50247	50288	50329	50370
	50125	50166	50207	50248	50289	50330	50371
	50126	50167	50208	50249	50290	50331	50372
	50127	50168	50209	50250	50291	50332	50373
	50128	50169	50210	50251	50292	50333	50374
	50129	50170	50211	50252	50293	50334	50375
	50130	50171	50212	50253	50294	50335	50376
	50131	50172	50213	50254	50295	50336	50377

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
000				PPD	1	000		DDD		PPD		PPD	
PPD		PPD	50419	PPD		PPD	50501	PPD	50542		50583	PPD	50624
	50379		50420		50461		50502		50543		50584		50625
	50380		50421		50462		50503		50544		50585		50626
	50381		50422		50463		50504		50545		50586		50627
	50382		50423		50464		50505		50546		50587		50628
	50383		50424		50465		50506		50547		50588		50629
	50384		50425		50466		50507		50548		50589		50630
	50385		50426		50467		50508		50549		50590		50631
	50386		50427		50468		50509		50550		50591		50632
	50387		50428		50469		50510		50551		50592		50633
	50388		50429		50470		50511		50552		50593		50634
	50389		50430		50471		50512		50553		50594		50635
	50390		50431		50472		50513		50554		50595		50636
	50391		50432		50473		50514		50555		50596		50637
	50392		50433		50474		50515		50556		50597		50638
	50393		50434		50475		50516		50557		50598		50639
	50394		50435		50476		50517		50558		50599		50640
	50395		50436		50477		50518		50559		50600		50641
	50396		50437		50478		50519		50560		50601		50642
	50397		50438		50479		50520		50561		50602		50643
	50398		50439		50480		50521		50562		50603		50644
	50399		50440		50481		50522		50563		50604		50645
	50400		50441		50482		50523		50564		50605		50646
	50401		50442		50483		50524		50565		50606		50647
	50402		50443		50484		50525		50566		50607		50648
	50403		50444		50485		50526		50567		50608		50649
	50404		50445		50486		50527		50568		50609		50650
	50405		50446		50487		50528		50569		50610		50651
	50406		50447		50488		50529		50570		50611		50652
	50407		50448		50489		50530		50571		50612		50653
	50408		50449		50490		50531		50572		50613		50654
	50409		50450		50491		50532		50573		50614		50655
	50410		50451		50492		50533		50574		50615		50656
	50411		50452		50493		50534		50575		50616		50657
	50412		50453		50494		50535		50576		50617		50658
	50413		50454		50495		50536		50577		50618		50659
	50414		50455		50496		50537		50578		50619		50660
	50415		50456		50497		50538		50579		50620		50661
	50416		50457		50498		50539		50580		50621		50662
	50417		50458		50499		50540		50581		50622		50663
	50418		50459		50500		50541		50582		50623		50664
	1												

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	B1.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt	. Bl.
No	nb	No	nb	No	nb	No	nb	No	nb	N	nb
PPD	50665	PPD	50706	PPD	50747	PPD	50788	PPD	50829	PPD	50870
PPD	50666	110	50707		50747	110	50789		50830	110	50871
	50667		50708		50748		50790				50871
			50708		50749		50790		50831		50872
	50668								50832		
	50669		50710		50751		50792		50833		50874
	50670		50711		50752		50793		50834		50875
	50671		50712		50753		50794		50835		50876
	50672		50713		50754		50795		50836		50877
	50673		50714		50755		50796		50837		50878
	50674		50715		50756		50797		50838		50879
	50675		50716		50757		50798		50839		50880
	50676		50717		50758		50799		50840		50881
	50677		50718		50759		50800		50841		50882
	50678		50719		50760		50801		50842		50883
	50679		50720		50761		50802		50843		50884
	50680		50721		50762		50803		50844		50885
	50681		50722		50763		50804		50845		50886
	50682		50723		50764		50805		50846		50887
	50683		50724		50765		50806		50847		50888
	50684		50725		50766		50807		50848		50889
	50685		50726		50767		50808		50849		50890
	50686		50727		50768		50809		50850		50891
	50687		50728		50769		50810		50851		50892
	50688		50729		50770		50811		50852		50893
	50689		50730		50771		50812		50853		50894
	50690		50731		50772		50813		50854		50895
	50691		50732		50773		50814		50855		50896
	50692		50733		50774		50815		50856		50897
	50693		50734		50775		50816		50857		50898
	50694		50735		50776		50817		50858		50899
	50695		50736		50777		50818		50859		50900
	50696		50737		50778		50819		50860		50901
	50697		50738		50779		50820		50861		50902
	50698		50739		50780		50821		50862		50903
	50699		50740		50781		50822		50863		50904
	50700		50741		50782		50823		50864		50905
	50701		50742		50783		50824		50865		50906
	50702		50743		50784		50825		50866		
	50703		50744		50785		50826		50867		
	50704		50745		50786		50827		50868		
	50705		50746		50787		50828		50869		

DTPA-HBV-IPV-135 (A.15MAR2018)

No nb	51153 51154 51155 51156 51157 51158 51159 51160 51161
Solid	51154 51155 51156 51157 51158 51159 51160
Solid	51154 51155 51156 51157 51158 51159 51160
50908 50949 50990 51031 51072 51113 50909 50950 50991 51032 51073 51114 50910 50951 50992 51033 51074 51115 50911 50952 50993 51034 51075 51116 50912 50953 50994 51035 51076 51117 50913 50954 50995 51036 51077 51118 50914 50955 50996 51037 51078 51119 50915 50956 50997 51038 51079 51120 50916 50957 50998 51039 51080 51121 50917 50958 50999 51040 51081 51122 50918 50959 51000 51041 51082 51123 50919 50960 51001 51042 51083 51124 50920 50961 51002 51043 51084 51125	51154 51155 51156 51157 51158 51159 51160
50909 50950 50991 51032 51073 51114 50910 50951 50992 51033 51074 51115 50911 50952 50993 51034 51075 51116 50912 50953 50994 51035 51076 51117 50913 50954 50995 51036 51077 51118 50914 50955 50996 51037 51078 51119 50915 50956 50997 51038 51079 51120 50916 50957 50998 51039 51080 51121 50917 50958 50999 51040 51081 51122 50918 50959 51000 51041 51082 51123 50919 50960 51001 51042 51083 51124 50920 50961 51002 51043 51084 51125 50921 50962 51003 51044 51085 51126	51155 51156 51157 51158 51159 51160
50910 50951 50992 51033 51074 51115 50911 50952 50993 51034 51075 51116 50912 50953 50994 51035 51076 51117 50913 50954 50995 51036 51077 51118 50914 50955 50996 51037 51078 51119 50915 50956 50997 51038 51079 51120 50916 50957 50998 51039 51080 51121 50917 50958 50999 51040 51081 51122 50918 50959 51000 51041 51082 51123 50919 50960 51001 51042 51083 51124 50920 50961 51002 51043 51084 51125 50921 50962 51003 51044 51085 51126 50922 50963 51004 51045 51086 51127	51156 51157 51158 51159 51160
50911 50952 50993 51034 51075 51116 50912 50953 50994 51035 51076 51117 50913 50954 50995 51036 51077 51118 50914 50955 50996 51037 51078 51119 50915 50956 50997 51038 51079 51120 50916 50957 50998 51039 51080 51121 50917 50958 50999 51040 51081 51122 50918 50959 51000 51041 51082 51123 50919 50960 51001 51042 51083 51124 50920 50961 51002 51043 51084 51125 50921 50962 51003 51044 51085 51126 50922 50963 51004 51045 51086 51127 50923 50964 51005 51046 51087 51128	51157 51158 51159 51160
50912 50953 50994 51035 51076 51117 50913 50954 50995 51036 51077 51118 50914 50955 50996 51037 51078 51119 50915 50956 50997 51038 51079 51120 50916 50957 50998 51039 51080 51121 50917 50958 50999 51040 51081 51122 50918 50959 51000 51041 51082 51123 50919 50960 51001 51042 51083 51124 50920 50961 51002 51043 51084 51125 50921 50962 51003 51044 51085 51126 50922 50963 51004 51045 51086 51127 50923 50964 51005 51046 51087 51128 50924 50965 51006 51047 51088 51129	51158 51159 51160
50913 50954 50995 51036 51077 51118 50914 50955 50996 51037 51078 51119 50915 50956 50997 51038 51079 51120 50916 50957 50998 51039 51080 51121 50917 50958 50999 51040 51081 51122 50918 50959 51000 51041 51082 51123 50919 50960 51001 51042 51083 51124 50920 50961 51002 51043 51084 51125 50921 50962 51003 51044 51085 51126 50922 50963 51004 51045 51086 51127 50923 50964 51005 51046 51087 51128 50924 50965 51006 51047 51088 51129 50925 50966 51007 51048 51089 51130	51159 51160
50914 50955 50996 51037 51078 51119 50915 50956 50997 51038 51079 51120 50916 50957 50998 51039 51080 51121 50917 50958 50999 51040 51081 51122 50918 50959 51000 51041 51082 51123 50919 50960 51001 51042 51083 51124 50920 50961 51002 51043 51084 51125 50921 50962 51003 51044 51085 51126 50922 50963 51004 51045 51086 51127 50923 50964 51005 51046 51087 51128 50924 50965 51006 51047 51088 51129 50925 50966 51007 51048 51089 51130 50926 50967 51008 51049 51090 51131	51160
50915 50956 50997 51038 51079 51120 50916 50957 50998 51039 51080 51121 50917 50958 50999 51040 51081 51122 50918 50959 51000 51041 51082 51123 50919 50960 51001 51042 51083 51124 50920 50961 51002 51043 51084 51125 50921 50962 51003 51044 51085 51126 50922 50963 51004 51045 51086 51127 50923 50964 51005 51046 51087 5128 50924 50965 51006 51047 51088 51129 50925 50966 51007 51048 51089 51130 50927 50968 51009 51050 51091 51132 50928 50969 51010 51051 51092 51133	
50916 50957 50998 51039 51080 51121 50917 50958 50999 51040 51081 51122 50918 50959 51000 51041 51082 51123 50919 50960 51001 51042 51083 51124 50920 50961 51002 51043 51084 51125 50921 50962 51003 51044 51085 51126 50922 50963 51004 51045 51086 51127 50923 50964 51005 51046 51087 51128 50924 50965 51006 51047 51088 51129 50925 50966 51007 51048 51089 51130 50926 50967 51008 51049 51090 51131 50927 50968 51009 51050 51091 51132 50928 50969 51010 51051 51092 51133	
50917 50958 50999 51040 51081 51122 50918 50959 51000 51041 51082 51123 50919 50960 51001 51042 51083 51124 50920 50961 51002 51043 51084 51125 50921 50962 51003 51044 51085 51126 50922 50963 51004 51045 51086 51127 50923 50964 51005 51046 51087 51128 50924 50965 51006 51047 51088 51129 50925 50966 51007 51048 51089 51130 50926 50967 51008 51049 51090 51131 50927 50968 51009 51050 51091 51132 50928 50969 51010 51051 51092 51133 50929 50970 51011 51052 51093 51134	
50918 50959 51000 51041 51082 51123 50919 50960 51001 51042 51083 51124 50920 50961 51002 51043 51084 51125 50921 50962 51003 51044 51085 51126 50922 50963 51004 51045 51086 51127 50923 50964 51005 51046 51087 51128 50924 50965 51006 51047 51088 51129 50925 50966 51007 51048 51089 51130 50926 50967 51008 51049 51090 51131 50927 50968 51009 51050 51091 51132 50928 50969 51010 51051 51092 51133 50930 50971 51012 51053 51094 51135 50931 50972 51013 51054 51095 51136 <td>51162 51163</td>	51162 51163
50919 50960 51001 51042 51083 51124 50920 50961 51002 51043 51084 51125 50921 50962 51003 51044 51085 51126 50922 50963 51004 51045 51086 51127 50923 50964 51005 51046 51087 51128 50924 50965 51006 51047 51088 51129 50925 50966 51007 51048 51089 51130 50926 50967 51008 51049 51090 51131 50927 50968 51009 51050 51091 51132 50928 50969 51010 51051 51092 51133 50929 50970 51011 51052 51093 51134 50930 50971 51012 51053 51094 51135 50931 50972 51013 51054 51095 51136 <td>51163</td>	51163
50920 50961 51002 51043 51084 51125 50921 50962 51003 51044 51085 51126 50922 50963 51004 51045 51086 51127 50923 50964 51005 51046 51087 51128 50924 50965 51006 51047 51088 51129 50925 50966 51007 51048 51089 51130 50926 50967 51008 51049 51090 51131 50927 50968 51009 51050 51091 51132 50928 50969 51010 51051 51092 51133 50929 50970 51011 51052 51093 51134 50930 50971 51012 51053 51094 51135 50931 50972 51013 51054 51095 51136	51164
50921 50962 51003 51044 51085 51126 50922 50963 51004 51045 51086 51127 50923 50964 51005 51046 51087 51128 50924 50965 51006 51047 51088 51129 50925 50966 51007 51048 51089 51130 50926 50967 51008 51049 51090 51131 50927 50968 51009 51050 51091 51132 50928 50969 51010 51051 51092 51133 50929 50970 51011 51052 51093 51134 50931 50972 51013 51054 51095 51136	51165
50922 50963 51004 51045 51086 51127 50923 50964 51005 51046 51087 51128 50924 50965 51006 51047 51088 51129 50925 50966 51007 51048 51089 51130 50926 50967 51008 51049 51090 51131 50927 50968 51009 51050 51091 51132 50928 50969 51010 51051 51092 51133 50929 50970 51011 51052 51093 51134 50930 50971 51012 51053 51094 51135 50931 50972 51013 51054 51095 51136	
50923 50964 51005 51046 51087 51128 50924 50965 51006 51047 51088 51129 50925 50966 51007 51048 51089 51130 50926 50967 51008 51049 51090 51131 50927 50968 51009 51050 51091 51132 50928 50969 51010 51051 51092 51133 50929 50970 51011 51052 51093 51134 50930 50971 51012 51053 51094 51135 50931 50972 51013 51054 51095 51136	51167
50924 50965 51006 51047 51088 51129 50925 50966 51007 51048 51089 51130 50926 50967 51008 51049 51090 51131 50927 50968 51009 51050 51091 51132 50928 50969 51010 51051 51092 51133 50929 50970 51011 51052 51093 51134 50930 50971 51012 51053 51094 51135 50931 50972 51013 51054 51095 51136	51168
50925 50966 51007 51048 51089 51130 50926 50967 51008 51049 51090 51131 50927 50968 51009 51050 51091 51132 50928 50969 51010 51051 51092 51133 50929 50970 51011 51052 51093 51134 50930 50971 51012 51053 51094 51135 50931 50972 51013 51054 51095 51136	51169
50926 50967 51008 51049 51090 51131 50927 50968 51009 51050 51091 51132 50928 50969 51010 51051 51092 51133 50929 50970 51011 51052 51093 51134 50930 50971 51012 51053 51094 51135 50931 50972 51013 51054 51095 51136	51170
50927 50968 51009 51050 51091 51132 50928 50969 51010 51051 51092 51133 50929 50970 51011 51052 51093 51134 50930 50971 51012 51053 51094 51135 50931 50972 51013 51054 51095 51136	51171
50928 50969 51010 51051 51092 51133 50929 50970 51011 51052 51093 51134 50930 50971 51012 51053 51094 51135 50931 50972 51013 51054 51095 51136	51172
50929 50970 51011 51052 51093 51134 50930 50971 51012 51053 51094 51135 50931 50972 51013 51054 51095 51136	51173
50930 50971 51012 51053 51094 51135 50931 50972 51013 51054 51095 51136	51174
50931 50972 51013 51054 51095 51136	51175
	51176
50932 50973 51014 51055 51096 51137	51177
	51178
50933 50974 51015 51056 51097 51138	51179
50934 50975 51016 51057 51098 51139	51180
50935 50976 51017 51058 51099 51140	51181
50936 50977 51018 51059 51100 51141	51182
50937 50978 51019 51060 51101 51142	51183
50938 50979 51020 51061 51102 51143	51184
50939 50980 51021 51062 51103 51144	51185
50940 50981 51022 51063 51104 51145	51186
50941 50982 51023 51064 51105 51146	51187
50942 50983 51024 51065 51106 51147	51188
50943 50984 51025 51066 51107 51148	51189
50944 50985 51026 51067 51108 51149	51190
50945 50986 51027 51068 51109 51150	51191
50946 50987 51028 51069 51110 51151	51192
50947 50988 51029 51070 51111 51152	51193

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	. Bl.	Trt. Bl.		. Bl.		. Bl.		. Bl.		. Bl.		. Bl.
No	nb	No nb		nb	No	nb		o nb	No	nb	N	o nb
PPD	51194	PPD 51235	PPD	51276	PPD	51317	PPD	51358	PPD	51399	PPD	51440
	51195	51236		51277	–	51318		51359		51400	–	51441
	51196	51237		51278		51319		51360		51401		51442
	51197	51238		51279		51320		51361		51402		51443
	51198	51239		51280		51321		51362		51403		51444
	51199	51240		51281		51322		51363		51404		51445
	51200	51241		51282		51323		51364		51405		51446
	51200	51242		51283		51324		51365		51406		51447
	51202	51243		51284		51325		51366		51407		51448
	51202	51244		51285		51326		51367		51408		51449
	51203	51245		51286		51327		51368		51409		51450
	51205	51246		51287		51328		51369		51410		51451
	51206	51247		51288		51329		51370		51411		51452
	51207	51248		51289		51330		51371		51412		51453
	51208	51249		51290		51331		51372		51413		51454
	51200	51250		51291		51332		51372		51414		51455
	51210	51251		51292		51333		51374		51415		51456
	51210	51252		51293		51334		51375		51416		51457
	51212	51253		51294		51335		51376		51417		51458
	51212	51254		51295		51336		51377		51418		51459
	51214	51255		51296		51337		51378		51419		51460
	51215	51256		51297		51338		51379		51420		51461
	51216	51257		51298		51339		51380		51421		51462
	51217	51258		51299		51340		51381		51422		51463
	51218	51259		51300		51341		51382		51423		51464
	51219	51260		51301		51342		51383		51424		51465
	51220	51261		51302		51343		51384		51425		51466
	51221	51262		51303		51344		51385		51426		51467
	51222	51263		51304		51345		51386		51427		51468
	51223	51264		51305		51346		51387		51428		51469
	51224	51265		51306		51347		51388		51429		51470
	51225	51266		51307		51348		51389		51430		51471
	51226	51267		51308		51349		51390		51431		51472
	51227	51268		51309		51350		51391		51432		51473
	51228	51269		51310		51351		51392		51433		51474
	51229	51270		51311		51352		51393		51434		51475
	51230	51271		51312		51353		51394		51435		51476
	51231	51272		51313		51354		51395		51436		51477
	51232	51273		51314		51355		51396		51437		51478
	51233	51274		51315		51356		51397		51438		51479
	51234	51275		51316		51357		51398		51439		51480
				_								

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

No	. Bl. o nb		nb		nb		nb	N	. Bl. o nb	No	Bl. o nb		Trt. Bl. No nb
PPD	51481	PPD	51522	PPD	51563	PPD	51604	PPD	51645	PPD	51686	PF	PD 51727
	51482		51523		51564		51605		51646		51687		51728
	51483		51524		51565		51606		51647		51688		51729
	51484		51525		51566		51607		51648		51689		51730
	51485		51526		51567		51608		51649		51690		51731
	51486		51527		51568		51609		51650		51691		51732
	51487		51528		51569		51610		51651		51692		51733
	51488		51529		51570		51611		51652		51693		51734
	51489		51530		51571		51612		51653		51694		51735
	51490		51531		51572		51613		51654		51695		51736
	51491		51532		51573		51614		51655		51696		51737
	51492		51533		51574		51615		51656		51697		51738
	51493		51534		51575		51616		51657		51698		51739
	51494		51535		51576		51617		51658		51699		51740
	51495		51536		51577		51618		51659		51700		51741
	51496		51537		51578		51619		51660		51701		51742
	51497		51538		51579		51620		51661		51702		51743
	51498		51539		51580		51621		51662		51703		51744
	51499		51540		51581		51622		51663		51704		51745
	51500		51541		51582		51623		51664		51705		51746
	51501		51542		51583		51624		51665		51706		51747
	51502		51543		51584		51625		51666		51707		51748
	51503		51544		51585		51626		51667		51708		51749
	51504		51545		51586		51627		51668		51709		51750
	51505		51546		51587		51628		51669		51710		51751
	51506		51547		51588		51629		51670		51711		51752
	51507		51548		51589		51630		51671		51712		51753
	51508		51549		51590		51631		51672		51713		51754
	51509		51550		51591		51632		51673		51714		51755
	51510		51551		51592		51633		51674		51715		51756
	51511		51552		51593		51634		51675		51716		51757
	51512		51553		51594		51635		51676		51717		51758
	51513		51554		51595		51636		51677		51718		51759
	51514		51555		51596		51637		51678		51719		51760
	51515		51556		51597		51638		51679		51720		51761
	51516		51557		51598		51639		51680		51721		51762
	51517		51558		51599		51640		51681		51722		51763
	51518		51559		51600		51641		51682		51723		51764
	51519		51560		51601		51642		51683		51724		51765
	51520		51561		51602		51643		51684		51725		51766
	51521		51562		51603		51644		51685		51726		51767
					l								

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl. nb	Trt. No		Trt. No		Trt.	Bl. nb	Trt.	Bl. nb	Trt.	Bl. nb	Trt.	Bl. nb
NO.	no 	NO	np 	NO.		NO.	no 	NO		NC	no 	NO	no
		DDD		DDD						PPD			
PPD	01700	PPD	01003	PPD		PPD		PPD	51932	110	51973	PPD	52014
	51769		51810		51851		51892		51933		51974		52015
	51770		51811		51852		51893		51934		51975		52016
	51771		51812		51853		51894		51935		51976		52017
	51772		51813		51854		51895		51936		51977		52018
	51773		51814		51855		51896		51937		51978		52019
	51774		51815		51856		51897		51938		51979		52020
	51775		51816		51857		51898		51939		51980		52021
	51776		51817		51858		51899		51940		51981		52022
	51777		51818		51859		51900		51941		51982		52023
	51778		51819		51860		51901		51942		51983		52024
	51779		51820		51861		51902		51943		51984		52025
	51780		51821		51862		51903		51944		51985		52026
	51781		51822		51863		51904		51945		51986		52027
	51782		51823		51864		51905		51946		51987		52028
	51783		51824		51865		51906		51947		51988		52029
	51784		51825		51866		51907		51948		51989		52030
	51785		51826		51867		51908		51949		51990		52031
	51786		51827		51868		51909		51950		51991		52032
	51787		51828		51869		51910		51951		51992		52033
	51788		51829		51870		51911		51952		51993		52034
	51789		51830		51871		51912		51953		51994		52035
	51790		51831		51872		51913		51954		51995		52036
	51791		51832		51873		51914		51955		51996		52037
	51792		51833		51874		51915		51956		51997		52038
	51793		51834		51875		51916		51957		51998		52039
	51794		51835		51876		51917		51958		51999		52040
	51795		51836		51877		51918		51959		52000		52041
	51796		51837		51878		51919		51960		52001		52042
	51797		51838		51879		51920		51961		52002		52043
	51798		51839		51880		51921		51962		52003		52044
	51799		51840		51881		51922		51963		52004		52045
	51800		51841		51882		51923		51964		52005		52046
	51801		51842		51883		51924		51965		52006		52047
	51802		51843		51884		51925		51966		52007		52048
	51803		51844		51885		51926		51967		52008		52049
	51804		51845		51886		51927		51968		52009		52050
	51805		51846		51887		51928		51969		52010		52051
	51806		51847		51888		51929		51970		52010		52051
	51807		51848		51889		51930		51970		52011		52052
	51808		51849		51890		51931		51972		52012		52054
	21000		シェリサフ		J±030		21321		J1314		J2U1J		J2UJ4
							l						

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. B	1.	Trt.	Bl.								
No	nb	No nl	b	No	nb								
PPD	52055	PPD 5	2096	PPD	52137	PPD	52178	PPD	52219	PPD	52260	PPD	52301
PPD	52055		2096		52137	FFD	52178	PPU	52219		52260	יוו	52301
	52057		2098		52139		52180		52221		52262		52303
	52058		2099		52140		52181		52222		52263		52304
	52059		2100		52141		52182		52223		52264		52305
	52060		2101		52142		52183		52224		52265		52306
	52061		2102		52143		52184		52225		52266		52307
	52062		2103		52144		52185		52226		52267		52308
	52063		2104		52145		52186		52227		52268		52309
	52064		2105		52146		52187		52228		52269		52310
	52065		2106		52147		52188		52229		52270		52311
	52066		2107		52148		52189		52230		52271		52312
	52067		2108		52149		52190		52231		52272		52313
	52068		2109		52150		52191		52232		52273		52314
	52069		2110		52151		52192		52233		52274		52315
	52070		2111		52152		52193		52234		52275		52316
	52071		2112		52153		52194		52235		52276		52317
	52072		2113		52154		52195		52236		52277		52318
	52073		2114		52155		52196		52237		52278		52319
	52074	5:	2115		52156		52197		52238		52279		52320
	52075		2116		52157		52198		52239		52280		52321
	52076		2117		52158		52199		52240		52281		52322
	52077		2118		52159		52200		52241		52282		52323
	52078		2119		52160		52201		52242		52283		52324
	52079		2120		52161		52202		52243		52284		52325
	52080		2121		52162		52203		52244		52285		52326
	52081	5:	2122		52163		52204		52245		52286		52327
	52082	5:	2123		52164		52205		52246		52287		52328
	52083		2124		52165		52206		52247		52288		52329
	52084	5:	2125		52166		52207		52248		52289		52330
	52085		2126		52167		52208		52249		52290		52331
	52086	5:	2127		52168		52209		52250		52291		52332
	52087	5:	2128		52169		52210		52251		52292		52333
	52088	5:	2129		52170		52211		52252		52293		52334
	52089	5:	2130		52171		52212		52253		52294		52335
	52090	5:	2131		52172		52213		52254		52295		52336
	52091	5:	2132		52173		52214		52255		52296		52337
	52092	5:	2133		52174		52215		52256		52297		52338
	52093	5:	2134		52175		52216		52257		52298		52339
	52094	5:	2135		52176		52217		52258		52299		52340
	52095	5:	2136		52177		52218		52259		52300		52341

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No nb		nb		nb		nb		nb	No	nb
PPD	52342	PPD 52383	PPD	52424	PPD	52465	PPD	52506	PPD	52547	PPD	52588
110	52343	52384		52425	110	52466	110	52507		52547	–	52589
	52344	52385		52426		52467		52508		52549		52590
	52345	52386		52427		52468		52509		52550		52591
	52346	52387		52428		52469		52510		52551		52592
	52347	52388		52429		52470		52510		52552		52593
	52348	52389		52430		52471		52511		52553		52594
	52349	52390		52431		52472		52512		52554		52595
	52350	52391		52432		52473		52514		52555		52596
	52350	52392		52433		52474		52514		52556		52597
	52352	52393		52434		52475		52516		52557		52598
	52353	52394		52435		52476		52517		52558		52599
	52354	52395		52436		52477		52517		52559		52600
	52355	52396		52437		52478		52519		52560		52601
	52356	52397		52438		52479		52520		52561		52602
	52357	52398		52439		52480		52520		52562		52603
	52358	52399		52440		52481		52521		52563		52604
	52359	52400		52441		52482		52523		52564		52605
	52360	52400		52442		52483		52524		52565		52606
	52361	52401		52443		52484		52525		52566		52607
	52362	52402		52443		52485		52526		52567		52608
	52363	52403		52445		52486		52527		52568		52609
	52364	52405		52446		52487		52527		52569		52610
	52365	52406		52447		52488		52529		52570		52611
	52366	52407		52448		52489		52525		52570		52612
	52367	52408		52449		52490		52531		52572		52613
	52368	52409		52450		52491		52531		52572		52614
	52369	52410		52451		52492		52532		52574		52615
	52370	52411		52452		52493		52533		52575		52616
	52371	52412		52453		52494		52535		52576		52617
	52372	52413		52454		52495		52536		52577		52618
	52373	52414		52455		52496		52537		52578		52619
	52374	52415		52456		52497		52538		52579		52620
	52375	52416		52457		52498		52539		52580		52621
	52376	52417		52458		52499		52540		52581		52622
	52377	52418		52459		52500		52541		52582		52623
	52378	52419		52460		52501		52542		52583		52624
	52379	52420		52461		52502		52543		52584		52625
	52380	52421		52462		52503		52544		52585		52626
	52381	52422		52463		52504		52545		52586		52627
	52382	52423		52464		52505		52546		52587		52628
		32123				-2000						-2020

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt. Bl.	Trt.	Bl.	Trt.	Bl.	Trt	. Bl.	Trt	. Bl.	Trt.	Bl.
No	nb	No nb		nb	No	nb	No	nb	No	nb	No	nb
PPD	52629	PPD 52670	PPD	52711	PPD	52752	PPD	52793	PPD	52834	PPD	52875
PPD	52629	52670 52671	110	52711	FFD	52752	PPD	52793		52834	110	52875
	52630	52672		52712		52754		52794		52835		52876
						52755		52795		52837		52877
	52632	52673		52714								
	52633	52674		52715		52756		52797		52838		52879
	52634	52675		52716		52757		52798		52839		52880
	52635	52676		52717		52758		52799		52840		52881
	52636	52677		52718		52759		52800		52841		52882
	52637	52678		52719		52760		52801		52842		52883
	52638	52679		52720		52761		52802		52843		52884
	52639	52680		52721		52762		52803		52844		52885
	52640	52681		52722		52763		52804		52845		52886
	52641	52682		52723		52764		52805		52846		52887
	52642	52683		52724		52765		52806		52847		52888
	52643	52684		52725		52766		52807		52848		52889
	52644	52685		52726		52767		52808		52849		52890
	52645	52686		52727		52768		52809		52850		52891
	52646	52687		52728		52769		52810		52851		52892
	52647	52688		52729		52770		52811		52852		52893
	52648	52689		52730		52771		52812		52853		52894
	52649	52690		52731		52772		52813		52854		52895
	52650	52691		52732		52773		52814		52855		52896
	52651	52692		52733		52774		52815		52856		52897
	52652	52693		52734		52775		52816		52857		52898
	52653	52694		52735		52776		52817		52858		52899
	52654	52695		52736		52777		52818		52859		52900
	52655	52696		52737		52778		52819		52860		52901
	52656	52697		52738		52779		52820		52861		52902
	52657	52698		52739		52780		52821		52862		52903
	52658	52699		52740		52781		52822		52863		52904
	52659	52700		52741		52782		52823		52864		52905
	52660	52701		52742		52783		52824		52865		52906
	52661	52702		52743		52784		52825		52866		52907
	52662	52703		52744		52785		52826		52867		52908
	52663	52704		52745		52786		52827		52868		52909
	52664	52705		52746		52787		52828		52869		52910
	52665	52706		52747		52788		52829		52870		52911
	52666	52707		52748		52789		52830		52871		52912
	52667	52708		52749		52790		52831		52872		52913
	52668	52709		52750		52791		52832		52873		52914
	52669	52710		52751		52792		52833		52874		52915
		*****										/===

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb		nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb
PPD	52916	PPD	52957	PPD	52998	PPD	53039	PPD	53080	PPD	53121	PPD	53162
	52917		52958		52999		53040		53081		53122		53163
	52918		52959		53000		53041		53082		53123		53164
	52919		52960		53001		53042		53083		53124		53165
	52920		52961		53002		53043		53084		53125		53166
	52921		52962		53003		53044		53085		53126		53167
	52922		52963		53004		53045		53086		53127		53168
	52923		52964		53005		53046		53087		53128		53169
	52924		52965		53006		53047		53088		53129		53170
	52925		52966		53007		53048		53089		53130		53171
	52926		52967		53008		53049		53090		53131		53172
	52927		52968		53009		53050		53091		53132		53173
	52928		52969		53010		53051		53092		53133		53174
	52929		52970		53011		53052		53093		53134		53175
	52930		52971		53012		53053		53094		53135		53176
	52931		52972		53013		53054		53095		53136		53177
	52932		52973		53014		53055		53096		53137		53178
	52933		52974		53015		53056		53097		53138		53179
	52934		52975		53016		53057		53098		53139		53180
	52935		52976		53017		53058		53099		53140		53181
	52936		52977		53018		53059		53100		53141		53182
	52937		52978		53019		53060		53101		53142		53183
	52938		52979		53020		53061		53102		53143		53184
	52939		52980		53021		53062		53103		53144		53185
	52940		52981		53022		53063		53104		53145		53186
	52941		52982		53023		53064		53105		53146		53187
	52942		52983		53024		53065		53106		53147		53188
	52943		52984		53025		53066		53107		53148		53189
	52944		52985		53026		53067		53108		53149		53190
	52945		52986		53027		53068		53109		53150		53191
	52946		52987		53028		53069		53110		53151		53192
	52947		52988		53029		53070		53111		53152		53193
	52948		52989		53030		53071		53112		53153		53194
	52949		52990		53031		53072		53113		53154		53195
	52950		52991		53032		53073		53114		53155		53196
	52951		52992		53033		53074		53115		53156		53197
	52952		52993		53034		53075		53116		53157		53198
	52953		52994		53035		53076		53117		53158		53199
	52954		52995		53036		53077		53118		53159		53200
	52955		52996		53037		53078		53119		53160		53201
	52956		52997		53038		53079		53120		53161		53202
					l								ı

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl	•	Trt.		Trt.		Trt.			Bl.	Trt.	
No	nb	No nb		No		No		No			nb	No	nb
PPD	53203	PPD 53	244 F	PD	53285	PPD	53326	PPD	53367	PPD	53408	PPD	53449
110	53204		3245		53286		53327	110	53368		53409		53450
	53205		246		53287		53328		53369		53410		53451
	53206		247		53288		53329		53370		53411		53452
	53207		248		53289		53330		53371		53412		53453
	53208		249		53290		53331		53372		53413		53454
	53209		250		53291		53332		53373		53414		53455
	53210	53	251		53292		53333		53374		53415		53456
	53211	53	252		53293		53334		53375		53416		53457
	53212	53	253		53294		53335		53376		53417		53458
	53213	53	254		53295		53336		53377		53418		53459
	53214	53	255		53296		53337		53378		53419		53460
	53215	53	256		53297		53338		53379		53420		53461
	53216	53	1257		53298		53339		53380		53421		53462
	53217	53	1258		53299		53340		53381		53422		53463
	53218	53	1259		53300		53341		53382		53423		53464
	53219	53	260		53301		53342		53383		53424		53465
	53220	53	261		53302		53343		53384		53425		53466
	53221		262		53303		53344		53385		53426		53467
	53222		1263		53304		53345		53386		53427		53468
	53223		1264		53305		53346		53387		53428		53469
	53224		1265		53306		53347		53388		53429		53470
	53225		1266		53307		53348		53389		53430		53471
	53226		267		53308		53349		53390		53431		53472
	53227		268		53309		53350		53391		53432		53473
	53228		269		53310		53351		53392		53433		53474
	53229		1270		53311		53352		53393		53434		53475
	53230		271		53312		53353		53394		53435		53476
	53231		272		53313		53354		53395		53436		53477
	53232		273		53314		53355		53396		53437		53478
	53233 53234		274 275		53315 53316		53356		53397 53398		53438		53479 53480
	53234		1276		53316		53357 53358		53398		53439 53440		53480
	53235		3277		53317		53358		53399		53440		53481
	53236		1278		53318		53360		53400		53441		53482
	53238		1279		53320		53361		53401		53442		53484
	53239		1280		53321		53362		53402		53444		53485
	53240		281		53322		53363		53404		53444		53486
	53240		1282		53323		53364		53404		53445		53487
	53241		1283		53324		53365		53406		53446		53488
	53242		284		53325		53366		53407		53447		53489
	33273	- 33	.201		55525		33300		33407		55770		22403
													l e

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	B1.	Trt. Bl.					
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	53490	PPD 53531	PPD 53572	PPD 53613	PPD 53654	PPD 53695	PPD 53736
110	53491	53532	53572	53614	53655	53696	53737
	53492	53532	53574	53615	53656	53697	53738
	53493	53534	53575	53616	53657	53698	53739
	53494	53535	53576	53617	53658	53699	53740
	53495	53536	53577	53618	53659	53700	53741
	53496	53537	53578	53619	53660	53701	53742
	53497	53537	53579	53620	53661	53702	53743
	53498	53539	53580	53621	53662	53703	53744
	53499	53540	53581	53622	53663	53704	53745
	53500	53540	53582	53622	53664	53705	53746
	53500	53542	53583	53624	53665	53706	53747
	53501	53542	53584	53625	53666	53707	53748
	53502	53544	53585	53626	53667	53708	53749
	53504	53545	53586	53627	53668	53709	53750
	53505	53546	53587	53628	53669	53710	53751
	53506	53547	53588	53629	53670	53711	53752
	53507	53548	53589	53630	53671	53712	53753
	53507	53549	53590	53631	53672	53713	53754
	53500	53550	53591	53632	53673	53714	53755
	53510	53551	53592	53633	53674	53715	53756
	53510	53552	53592	53634	53675	53716	53757
	53512	53553	53594	53635	53676	53717	53758
	53513	53554	53595	53636	53677	53718	53759
	53514	53555	53596	53637	53678	53719	53760
	53515	53556	53597	53638	53679	53720	53761
	53516	53557	53598	53639	53680	53721	53762
	53517	53558	53599	53640	53681	53722	53763
	53518	53559	53600	53641	53682	53723	53764
	53519	53560	53601	53642	53683	53724	53765
	53520	53561	53602	53643	53684	53725	53766
	53521	53562	53603	53644	53685	53726	53767
	53522	53563	53604	53645	53686	53727	53768
	53523	53564	53605	53646	53687	53728	53769
	53524	53565	53606	53647	53688	53729	53770
	53525	53566	53607	53648	53689	53730	53771
	53526	53567	53608	53649	53690	53731	53772
	53527	53568	53609	53650	53691	53732	53773
	53528	53569	53610	53651	53692	53733	53774
	53529	53570	53611	53652	53693	53734	53775
	53530	53571	53612	53653	53694	53735	53776
	_						

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No	nb	No		No	nb	No	nb	No	nb	No	nb
PPD	53777	PPD	53818	PPD	53859	PPD	53900	PPD	53941	PPD	53982	PPD	54023
PPD	53778	110	53819	110	53860	FFD	53900	FFD	53941		53983	יוו	54023
	53779		53820		53861		53901		53942		53984		54024
	53780		53821		53862		53902		53943		53985		54025
	53781		53822		53863		53904		53945		53986		54027
	53782		53823		53864		53905		53945		53987		54027
	53783		53824		53865		53905		53947		53988		54028
	53784		53825		53866		53906		53947		53989		54029
	53785		53826		53867		53907		53949		53990		54030
	53786		53827		53868		53909		53949		53990		54031
	53787		53828		53869		53910		53951		53991		54032
	53788		53829		53870		53910		53951		53992		54033
	53789		53830		53871		53911		53952		53993		54034
	53790		53831		53872		53913		53954		53995		54035
	53791		53832		53873		53914		53955		53996		54036
	53791		53832		53874		53914		53955		53996		54037
	53792		53834		53874		53915		53956		53997		54038
	53794		53835		53876		53916		53957		53998		54039
	53794		53836		53877				53958		54000		54040
	53796		53837		53878		53918 53919		53959		54000		54041
	53797		53838		53879		53920		53961		54001		54042
	53798		53839		53880		53920		53962		54002		54043
	53799		53840		53881		53921		53963		54003		54044
	53800		53841		53882		53922		53964		54004		54045
	53801		53842		53883		53924		53965		54005		54046
	53802		53843		53884		53925		53966		54007		54047
	53803		53844		53885		53926		53967		54007		54049
	53804		53845		53886		53926		53968		54008		54049
	53805		53846		53887		53928		53969		54010		54050
	53806		53847		53888		53929		53970		54011		54051
	53807		53848		53889		53930		53970		54012		54052
	53808		53849		53890		53931		53972		54013		54054
	53809		53850		53891		53932		53973		54014		54055
	53810		53851		53892		53933		53974		54015		54056
	53811		53852		53893		53934		53975		54016		54057
	53812		53853		53894		53935		53976		54017		54058
	53813		53854		53895		53936		53977		54018		54059
	53814		53855		53896		53937		53978		54019		54060
	53815		53856		53897		53938		53979		54020		54061
	53816		53857		53898		53939		53980		54021		54062
	53817		53858		53899		53940		53981		54022		54062
	JJJ1/		55556		55055		33330		JJJ01		51022		24003

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD 54064 54065 54066 54066 54069 54070 54071 54072 54073 54074 54075 54076 54077 54078 54079 54080 54081 54082 54083 54084 54085 54086 54087 54088 54089 54090 54091 54092 54093 54094 54095 54096 54097 54098 54099 54099 54099 54099 54099 54099 54099	PPD 54105 54106 54107 54108 54109 54110 54111 54112 54113 54114 54115 54116 54117 54118 54119 54120 54121 54122 54123 54124 54125 54127 54128 54127 54128 54129 54130 54131 54130 54131 54132 54133 54134 54135 54136 54137 54138 54137 54138 54139 54130 54137 54138 54137 54138 54139 54140 54141	No nb	PPD 54187 54188 54189 54190 54191 54192 54193 54194 54195 54196 54197 54198 54199 54200 54201 54202 54203 54204 54205 54206 54207 54208 54207 54208 54209 54211 54212 54213 54214 54217 54218 54217 54218 54219 54220 54221	PPD 54228 54229 54230 54231 54232 54233 54234 54235 54236 54237 54238 54239 54240 54241 54242 54243 54244 54245 54246 54247 54248 54249 54250 54253 54250 54253 54253 54255 54256 54257 54258 54259 54260 54261 54262 54263 54264	PPD 54269 54270 54271 54272 54271 54272 54273 54274 54275 54276 54277 54278 54279 54280 54281 54282 54283 54284 54285 54288 54287 54288 54289 54290 54291 54292 54293 54294 54295 54296 54297 54298 54299 54300 554301 54302 54303 554304 554305	PPD 54310 54311 54312 54313 54314 54315 54316 54317 54318 54319 54320 54321 54322 54323 54324 54325 54326 54327 54328 54329 54330 54331 54332 54333 54334 54335 54336 54337 54338 54339 54339 54340 54341 54342 54345 54346
54101	54142	54183	54224	54265	54306	54347
54102	54143	54184	54225	54266	54307	54348
54103	54144	54185	54226	54267	54308	54349
54104	54145	54186	54227	54268	54309	54350

DTPA-HBV-IPV-135 (A.15MAR2018)

	Bl.	Trt. Bl.	Trt. Bl.	I	rt. Bl.	Trt.		Trt.		Trt.	
NC	nb	No nb	No nb		No nb	NO.	nb		nb	NO	nb
								PPD			
PPD	54351	PPD 54392	PPD 544	33 PP I	D 54474	PPD	54515	PPD	54556	PPD	54597
	54352	54393	544	34	54475		54516		54557		54598
	54353	54394	544	35	54476		54517		54558		54599
	54354	54395	544	36	54477		54518		54559		54600
	54355	54396	544	37	54478		54519		54560		54601
	54356	54397	544	38	54479		54520		54561		54602
	54357	54398	544	39	54480		54521		54562		54603
	54358	54399	544	40	54481		54522		54563		54604
	54359	54400	544	41	54482		54523		54564		54605
	54360	54401	544	42	54483		54524		54565		54606
	54361	54402	544	43	54484		54525		54566		54607
	54362	54403	544	44	54485		54526		54567		54608
	54363	54404	544	45	54486		54527		54568		54609
	54364	54405	544	46	54487		54528		54569		54610
	54365	54406	544	47	54488		54529		54570		54611
	54366	54407	544	48	54489		54530		54571		54612
	54367	54408	544		54490		54531		54572		54613
	54368	54409	544		54491		54532		54573		54614
	54369	54410	544		54492		54533		54574		54615
	54370	54411	544		54493		54534		54575		54616
	54371	54412	544		54494		54535		54576		54617
	54372	54413	544		54495		54536		54577		54618
	54373	54414	544	55	54496		54537		54578		54619
	54374	54415	544	56	54497		54538		54579		54620
	54375	54416	544	57	54498		54539		54580		54621
	54376	54417	544		54499		54540		54581		54622
	54377	54418	544		54500		54541		54582		54623
	54378	54419	544		54501		54542		54583		54624
	54379	54420	544		54502		54543		54584		54625
	54380	54421	544		54503		54544		54585		54626
	54381	54422	544		54504		54545		54586		54627
	54382	54423	544		54505		54546		54587		54628
	54383	54424	544		54506		54547		54588		54629
	54384	54425	544		54507		54548		54589		54630
	54385	54426	544		54508		54549		54590		54631
	54386	54427	544		54509		54550		54591		54632
	54387	54428	544		54510		54551		54592		54633
	54388	54429	544		54511		54552		54593		54634
	54389	54430	544		54512		54553		54594		54635
	54390	54431	544		54513		54554		54595		54636
	54391	54432	544		54514		54555		54596		54637
	- 1001	01102	311		0.01.						2.007

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	. Bl.	Trt. Bl.	Trt. Bl. No nb	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
		NO 110	NO 110		NO 11D		
	_	DDD	DDD	DDD		PPD	DDD
PPD	54638	PPD 54679	PPD 54720	PPD 54761	PPD 54802	54843	PPD 54884
	54639	54680	54721	54762	54803	54844	54885
	54640	54681	54722	54763	54804	54845	54886
	54641	54682	54723	54764	54805	54846	54887
	54642	54683	54724	54765	54806	54847	54888
	54643	54684	54725	54766	54807	54848	54889
	54644	54685	54726	54767	54808	54849	54890
	54645	54686	54727	54768	54809	54850	54891
	54646	54687	54728	54769	54810	54851	54892
	54647	54688	54729	54770	54811	54852	54893
	54648	54689	54730	54771	54812	54853	54894
	54649	54690	54731	54772	54813	54854	54895
	54650	54691	54732	54773	54814	54855	54896
	54651	54692	54733	54774	54815	54856	54897
	54652	54693	54734	54775	54816	54857	54898
	54653	54694	54735	54776	54817	54858	54899
	54654	54695	54736	54777	54818	54859	54900
	54655	54696	54737	54778	54819	54860	54901
	54656	54697	54738	54779	54820	54861	54902
	54657	54698	54739	54780	54821	54862	54903
	54658	54699	54740	54781	54822	54863	54904
	54659	54700	54741	54782	54823	54864	54905
	54660	54701	54742	54783	54824	54865	54906
	54661	54702	54743	54784	54825	54866	54907
	54662	54703	54744	54785	54826	54867	54908
	54663	54704	54745	54786	54827	54868	54909
	54664	54705	54746	54787	54828	54869	54910
	54665	54706	54747	54788	54829	54870	54911
	54666	54707	54748	54789	54830	54871	54912
	54667	54708	54749	54790	54831	54872	54913
	54668	54709	54750	54791	54832	54873	54914
	54669	54710	54751	54792	54833	54874	54915
	54670	54711	54752	54793	54834	54875	54916
	54671	54712	54753	54794	54835	54876	54917
	54672	54713	54754	54795	54836	54877	54918
	54673	54714	54755	54796	54837	54878	54919
	54674	54715	54756	54797	54838	54879	54920
	54675	54716	54757	54798	54839	54880	54921
	54676	54717	54758	54799	54840	54881	54922
	54677	54718	54759	54800	54841	54882	54923
	54678	54719	54760	54801	54842	54883	54924

DTPA-HBV-IPV-135 (A.15MAR2018)

Bl. nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb
nb 	No	nb	No	nb	No	nb	No	nb	No	nb	PPD	nb
54946 54947 54948 54949 54950 54951 54952 54953 54955 54956 54957 54958 54959 54960 54960 54962 54963 54963 54964 54965		54987 54988 54990 54991 54992 54993 54994 54995 54996 54997 54998 55000 55001 55002 55003 55004 55005 55006		55028 55029 55030 55031 55032 55033 55034 55035 55036 55037 55038 55039 55040 55041 55042 55042 55042 55044 55045 55046 55047		55069 55070 55071 55072 55073 55074 55075 55076 55077 55078 55079 55080 55081 55082 55083 55083 55084 55085 55086 55087 55088		55110 55111 55112 55113 55114 55115 55116 55117 55118 55120 55120 55121 55122 55123 55124 55124 55125 55126 55127 55128 55129		55151 55152 55153 55154 55155 55156 55157 55158 55159 55160 55161 55162 55163 55164 55165 55165 55165 55166 55167 55168 55169 55170		55192 55193 55194 55195 55196 55197 55198 55199 55200 55201 55202 55203 55204 55205 55206 55206 55209 55208 55209 55211

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No			nb	No	nb		nb		nb	No	nb
PPD	55212	PPD	55253	PPD	55294	PPD	55335	PPD	55376	PPD	55417	PPD	55458
110	55213	110	55254		55295	110	55336	יוו	55377		55418		55459
	55214		55255		55296		55337		55378		55419		55460
	55215		55256		55297		55338		55379		55420		55461
	55216		55257		55298		55339		55380		55421		55462
	55217		55258		55299		55340		55381		55422		55463
	55218		55259		55300		55341		55382		55423		55464
	55219		55260		55301		55342		55383		55424		55465
	55220		55261		55302		55343		55384		55425		55466
	55221		55262		55303		55344		55385		55426		55467
	55222		55263		55304		55345		55386		55427		55468
	55223		55264		55305		55346		55387		55428		55469
	55224		55265		55306		55347		55388		55429		55470
	55225		55266		55307		55348		55389		55430		55471
	55226		55267		55308		55349		55390		55431		55472
	55227		55268		55309		55350		55391		55432		55473
	55228		55269		55310		55351		55392		55433		55474
	55229		55270		55311		55352		55393		55434		55475
	55230		55271		55312		55353		55394		55435		55476
	55231		55272		55313		55354		55395		55436		55477
	55232		55273		55314		55355		55396		55437		55478
	55233		55274		55315		55356		55397		55438		55479
	55234		55275		55316		55357		55398		55439		55480
	55235		55276		55317		55358		55399		55440		55481
	55236		55277		55318		55359		55400		55441		55482
	55237		55278		55319		55360		55401		55442		55483
	55238		55279		55320		55361		55402		55443		55484
	55239		55280		55321		55362		55403		55444		55485
	55240		55281		55322		55363		55404		55445		55486
	55241		55282		55323		55364		55405		55446		55487
	55242		55283		55324		55365		55406		55447		55488
	55243		55284		55325		55366		55407		55448		55489
	55244		55285		55326		55367		55408		55449		55490
	55245		55286		55327		55368		55409		55450		55491
	55246		55287		55328		55369		55410		55451		55492
	55247		55288		55329		55370		55411		55452		55493
	55248		55289		55330		55371		55412		55453		55494
	55249		55290		55331		55372		55413		55454		55495
	55250		55291		55332		55373		55414		55455		55496
	55251		55292		55333		55374		55415		55456		55497
	55252		55293		55334		55375		55416		55457		55498
							•				•		

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD 55786 55787 55788 55789 55790 55791 55792 55793 55794 55795 55796 55797 55798 55796 55797 55788 55797 55788 55800 55801 55802 55803 55804 55805 55806 55807 55808 55809 55811 55812 55813 55814 55815 55816 55816 55817 55818 55819 55820 55820	PPD 55827 55828 55829 55830 55831 55832 55833 55834 55835 55836 55837 55838 55839 55840 55841 55842 55843 55844 55845 55846 55846 55850 55850 55850 55851 55852 55853 55852 55853 55855 55856 55857 55858 55859 55860 55861 55862	PPD	PPD 55909 55910 55911 55912 55913 55914 55915 55916 55917 55918 55919 55920 55921 55922 55923 55924 55925 55926 55927 55928 55927 55928 55929 55930 55931 55932 55931 55932 55933 55934 55935 55936 55937 55938 55937 55938 55939 55940 55941 55942 55943	No nb	PPD 55991 55992 55993 55994 55995 55996 55997 55998 55999 56000 56001 56002 56003 56006 56007 56008 56009 56010 56011 56012 56013 56014 56015 56016 56017 56018 56019 56020 56021 56020 56021 56022 56023 56024 56025	PPD 56032 56033 56033 56036 56037 56038 56039 56040 56041 56042 56043 56044 56045 56046 56047 56048 56050 56051 56050 56051 56055 56056 56057 56056 56057 56058 56059 56060 56061 56062 56063 56064 56065 56066 56066 56066
55822	55863	55904	55945	55986	56027	56068
55823	55864	55905	55946	55987	56028	56069
55824	55865	55906	55947	55988	56029	56070
55825	55866	55907	55948	55989	56030	56071
55826	55867	55908	55949	55990	56031	56072

DTPA-HBV-IPV-135 (A.15MAR2018)

	. Bl.	Trt. No	Bl. nb	Trt. No		Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	
PPD	56073	PPD	56114	PPD	56155	PPD	56196	PPD	56237	PPD	56278	PPD	56319
	56074		56115		56156		56197		56238		56279		56320
	56075		56116		56157		56198		56239		56280		56321
	56076		56117		56158		56199		56240		56281		56322
	56077		56118		56159		56200		56241		56282		56323
	56078		56119		56160		56201		56242		56283		56324
	56079		56120		56161		56202		56243		56284		56325
	56080		56121		56162		56203		56244		56285		56326
	56081		56122		56163		56204		56245		56286		56327
	56082		56123		56164		56205		56246		56287		56328
	56083		56124		56165		56206		56247		56288		56329
	56084		56125		56166		56207		56248		56289		56330
	56085		56126		56167		56208		56249		56290		56331
	56086		56127		56168		56209		56250		56291		56332
	56087		56128		56169		56210		56251		56292		56333
	56088		56129		56170		56211		56252		56293		56334
	56089		56130		56171		56212		56253		56294		56335
	56090		56131		56172		56213		56254		56295		56336
	56091		56132		56173		56214		56255		56296		56337
	56092		56133		56174		56215		56256		56297		56338
	56093		56134		56175		56216		56257		56298		56339
	56094		56135		56176		56217		56258		56299		56340
	56095		56136		56177		56218		56259		56300		56341
	56096		56137		56178		56219		56260		56301		56342
	56097		56138		56179		56220		56261		56302		56343
	56098		56139		56180		56221		56262		56303		56344
	56099		56140		56181		56222		56263		56304		56345
	56100		56141		56182		56223		56264		56305		56346
	56101		56142		56183		56224		56265		56306		56347
	56102		56143		56184		56225		56266		56307		56348
	56103		56144		56185		56226		56267		56308		56349
	56104		56145		56186		56227		56268		56309		56350
	56105		56146		56187		56228		56269		56310		56351
	56106		56147		56188		56229		56270		56311		56352
	56107		56148		56189		56230		56271		56312		56353
	56108		56149		56190		56231		56272		56313		56354
	56109		56150		56191		56232		56273		56314		56355
	56110		56151		56192		56233		56274		56315		56356
	56111		56152		56193		56234		56275		56316		56357
	56112		56153		56194		56235		56276		56317		56358
	56113		56154		56195		56236		56277		56318		56359
					-								

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.	Trt. Bl.
No nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD 56360 56361 56362 56363 56364 56365 56366 56367 56368 56369 56371 56372 56373 56374 56375 56376 56376 56376 56377 56388 56380 56381 56382 56383 56384 56385 56386 56387 56388 56389 56390 56391 56392 56393 56394	PPD 56401 56402 56403 56404 56405 56406 56407 56408 56409 56410 56411 56412 56413 56414 56415 56416 56417 56418 56419 56420 56421 56422 56423 56424 56425 56426 56427 56428 56429 56430 56431 56432 56433 56434 56435 56436	PPD 56442 56443 56444 56445 56446 56447 56448 56449 56450 56451 56452 56453 56454 56455 56456 56457 56458 56464 56462 56461 56462 56463 56464 56465 56466 56467 56468 56467 56468 56470 56471 56472 56473 56474 56475	PPD 56483 56484 56485 56486 56487 56488 56490 56491 56492 56493 56494 56495 56496 56497 56498 56497 56500 56501 56502 56500 56501 56502 56503 56504 56505 56506 56507 56508 56507 56508 56510 56511 56512 56513 56514 56515	PPD 56524 56525 56526 56527 56528 56529 56530 56531 56532 56533 56534 56535 56536 56537 56538 56539 56540 56541 56542 56543 56544 56545 56546 56547 56548 56549 56550 56551 56552 56553 56556 56555 56556 56557 56556	PPD 56565 56566 56567 56568 56569 56571 56572 56573 56574 56575 56576 56577 56578 56578 56578 56580 56581 56582 56583 56584 56585 56586 56587 56588 56589 56590 56591 56592 56593 56594 56597 56598	PPD 56606 56607 56608 56609 56610 56611 56612 56613 56614 56615 56616 56617 56618 56619 56620 56621 56622 56623 56624 56625 56628 56629 56630 56631 56632 56633 56634 56633 56634 56633
56396	56437	56478	56519	56560	56601	56642
56397	56438	56479	56520	56561	56602	56643
56398	56439	56480	56521	56562	56603	56644
56399	56440	56481	56522	56563	56604	56645
56400	56441	56482	56523	56564	56605	56646

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.	Trt.		Trt.			. Bl.		Bl.	Trt.	
No	nb	No nb	No		No	nb	No	nb	No	nb	No	nb
PPD	56647	PPD 56688	PPD	56729	PPD	56770	PPD	56811	PPD	56852	PPD	56893
	56648	56689		56730		56771		56812		56853		56894
	56649	56690		56731		56772		56813		56854		56895
	56650	56691		56732		56773		56814		56855		56896
	56651	56692		56733		56774		56815		56856		56897
	56652	56693		56734		56775		56816		56857		56898
	56653	56694		56735		56776		56817		56858		56899
	56654	56695		56736		56777		56818		56859		56900
	56655	56696		56737		56778		56819		56860		56901
	56656	56697		56738		56779		56820		56861		56902
	56657	56698		56739		56780		56821		56862		56903
	56658	56699		56740		56781		56822		56863		56904
	56659	56700		56741		56782		56823		56864		56905
	56660	56701		56742		56783		56824		56865		56906
	56661	56702		56743		56784		56825		56866		56907
	56662	56703		56744		56785		56826		56867		56908
	56663	56704		56745		56786		56827		56868		56909
	56664	56705		56746		56787		56828		56869		56910
	56665	56706		56747		56788		56829		56870		56911
	56666	56707		56748		56789		56830		56871		56912
	56667	56708		56749		56790		56831		56872		56913
	56668	56709		56750		56791		56832		56873		56914
	56669	56710		56751		56792		56833		56874		56915
	56670	56711		56752		56793		56834		56875		56916
	56671	56712		56753		56794		56835		56876		56917
	56672	56713		56754		56795		56836		56877		56918
	56673	56714		56755		56796		56837		56878		56919
	56674	56715		56756		56797		56838		56879		56920
	56675	56716		56757		56798		56839		56880		56921
	56676	56717		56758		56799		56840		56881		56922
	56677	56718		56759		56800		56841		56882		56923
	56678	56719		56760		56801		56842		56883		56924
	56679	56720		56761		56802		56843		56884		56925
	56680	56721		56762		56803		56844		56885		56926
	56681	56722		56763		56804		56845		56886		56927
	56682	56723		56764		56805		56846		56887		56928
	56683	56724		56765		56806		56847		56888		56929
	56684	56725		56766		56807		56848		56889		56930
	56685	56726		56767		56808		56849		56890		56931
	56686	56727		56768		56809		56850		56891		56932
	56687	56728		56769		56810		56851		56892		56933

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.					
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	57221	PPD 57262	PPD 57303	PPD 57344	PPD 57385	PPD 57426	PPD 57467
	57222	57263	57304	57345	57386	57427	57468
	57223	57264	57305	57346	57387	57428	57469
	57224	57265	57306	57347	57388	57429	57470
	57225	57266	57307	57348	57389	57430	57471
	57226	57267	57308	57349	57390	57431	57472
	57227	57268	57309	57350	57391	57432	57473
	57228	57269	57310	57351	57392	57433	57474
	57229	57270	57311	57352	57393	57434	57475
	57230	57271	57312	57353	57394	57435	57476
	57231	57272	57313	57354	57395	57436	57477
	57232	57273	57314	57355	57396	57437	57478
	57233	57274	57315	57356	57397	57438	57479
	57234	57275	57316	57357	57398	57439	57480
	57235	57276	57317	57358	57399	57440	57481
	57236	57277	57318	57359	57400	57441	57482
	57237	57278	57319	57360	57401	57442	57483
	57238	57279	57320	57361	57402	57443	57484
	57239	57280	57321	57362	57403	57444	57485
	57240	57281	57322	57363	57404	57445	57486
	57241	57282	57323	57364	57405	57446	57487
	57242	57283	57324	57365	57406	57447	57488
	57243	57284	57325	57366	57407	57448	57489
	57244	57285	57326	57367	57408	57449	57490
	57245	57286	57327	57368	57409	57450	57491
	57246	57287	57328	57369	57410	57451	57492
	57247	57288	57329	57370	57411	57452	57493
	57248	57289	57330	57371	57412	57453	57494
	57249	57290	57331	57372	57413	57454	57495
	57250	57291	57332	57373	57414	57455	57496
	57251	57292	57333	57374	57415	57456	57497
	57252	57293	57334	57375	57416	57457	57498
	57253	57294	57335	57376	57417	57458	57499
	57254	57295	57336	57377	57418	57459	57500
	57255	57296	57337	57378	57419	57460	57501
	57256	57297	57338	57379	57420	57461	57502
	57257	57298	57339	57380	57421	57462	57503
	57258	57299	57340	57381	57422	57463	57504
	57259	57300	57341	57382	57423	57464	57505
	57260	57301	57342	57383	57424	57465	57506
	57261	57302	57343	57384	57425	57466	57507
	ı						

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. No	Bl. nb	Trt. Bl No nb		Trt. No		Trt. No		Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	
		PPD 57 57 57 57 57 57 57 57 57 57 57 57 57		PD	nb		nb 				nb	PPD	
	57519 57520 57521 57522 57522 57523 57524 57525 57525 57526 57527 57528 57529	57 57 57 57 57 57 57 57 57	560 561 562 563 564 565 566 567 568 568 5570		57601 57602 57603 57604 57605 57606 57607 57608 57609 57610		57642 57643 57644 57645 57646 57647 57648 57649 57650 57651 57652		57684 57684 57685 57686 57687 57688 57689 57690 57691 57692 57693		57724 57725 57726 57727 57727 57728 57729 57730 57731 57732 57733 57734		57765 57765 57766 57767 57768 57769 57770 57771 57772 57772 57773
	57530 57531 57532 57533 57534 57535 57536 57537 57538 57539	57 57 57 57 57 57 57 57 57	571 572 573 574 575 576 577 577 579 580		57612 57613 57614 57615 57616 57617 57618 57619 57620 57620 57621		57653 57654 57655 57656 57657 57658 57659 57660 57661 57662		57694 57695 57696 57697 57698 57699 57700 57701 57702 57702		57735 57736 57737 57738 57739 57740 57741 57742 57743 57744		57776 57777 57778 57779 57780 57781 57782 57783 57784 57785
	57540 57541 57542 57543 57544 57545 57546 57546 57547 57548	57 57 57 57 57 57	581 582 583 584 585 586 587 588 589		57622 57623 57624 57625 57626 57627 57628 57629 57630		57663 57664 57665 57666 57667 57668 57669 57670 57671		57704 57705 57706 57707 57708 57709 57710 57711 57712		57745 57746 57747 57748 57749 57750 57751 57752 57753		57786 57787 57788 57789 57790 57791 57792 57793 57794

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. B No n		Trt. No	nb										
PPD 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	ıb	No	nb	No	nb 	No	nb 	No	nb 	No	nb	No	nb
5 5 5	37831 37832 37833 37834 37835		57872 57873 57874 57875 57876		57913 57914 57915 57916 57917		57954 57955 57956 57957 57958		57995 57996 57997 57998 57999		58036 58037 58038 58039 58040		58077 58078 58079 58080 58081

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.					
No	nb	No nb	No nb	No nb	No nb	No nb	No nb
PPD	58082	PPD 58123	PPD 58164	PPD 58205	PPD 58246	PPD 58287	PPD 58328
	58083	58124	58165	58206	58247	58288	58329
	58084	58125	58166	58207	58248	58289	58330
	58085	58126	58167	58208	58249	58290	58331
	58086	58127	58168	58209	58250	58291	58332
	58087	58128	58169	58210	58251	58292	58333
	58088	58129	58170	58211	58252	58293	58334
	58089	58130	58171	58212	58253	58294	58335
	58090	58131	58172	58213	58254	58295	58336
	58091	58132	58173	58214	58255	58296	58337
	58092	58133	58174	58215	58256	58297	58338
	58093	58134	58175	58216	58257	58298	58339
	58094	58135	58176	58217	58258	58299	58340
	58095	58136	58177	58218	58259	58300	58341
	58096	58137	58178	58219	58260	58301	58342
	58097	58138	58179	58220	58261	58302	58343
	58098	58139	58180	58221	58262	58303	58344
	58099	58140	58181	58222	58263	58304	58345
	58100	58141	58182	58223	58264	58305	58346
	58101	58142	58183	58224	58265	58306	58347
	58102	58143	58184	58225	58266	58307	58348
	58103	58144	58185	58226	58267	58308	58349
	58104	58145	58186	58227	58268	58309	58350
	58105	58146	58187	58228	58269	58310	58351
	58106	58147	58188	58229	58270	58311	58352
	58107	58148	58189	58230	58271	58312	58353
	58108	58149	58190	58231	58272	58313	58354
	58109	58150	58191	58232	58273	58314	58355
	58110	58151	58192	58233	58274	58315	58356
	58111	58152	58193	58234	58275	58316	58357
	58112	58153	58194	58235	58276	58317	58358
	58113	58154	58195	58236	58277	58318	58359
	58114	58155	58196	58237	58278	58319	58360
	58115	58156	58197	58238	58279	58320	58361
	58116	58157	58198	58239	58280	58321	58362
	58117	58158	58199	58240	58281	58322	58363
	58118	58159	58200	58241	58282	58323	58364
	58119	58160	58201	58242	58283	58324	58365
	58120	58161	58202	58243	58284	58325	58366
	58121	58162	58203	58244	58285	58326	58367
	58122	58163	58204	58245	58286	58327	58368

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt. Bl.		Bl.	Trt.		Trt.		Trt.		Trt.	
No	nb	No nb		nb	No	nb	No	nb	No	nb	No	nb
PPD	58369	PPD 5841	PPD	58451	PPD	58492	PPD	58533	PPD	58574	PPD	58615
FFD	58370	5841		58452	110	58493	FFD	58534		58575		58616
	58371	5841		58453		58494		58535		58576		58617
	58372	5841		58454		58495		58536		58577		58618
	58373	5841		58455		58496		58537		58578		58619
	58374	5841		58456		58497		58538		58579		58620
	58374	5841		58456		58497		58538		58579		58620
	58376	5841		58458		58499		58540		58581		58622
	58377	5841		58459		58500		58541		58582		58623
	58378 58379	5841 5842		58460 58461		58501 58502		58542 58543		58583 58584		58624 58625
	58379	5842		58462		58502		58544		58585		58625
				58462				58544				58625
	58381	5842				58504				58586		
	58382	5842		58464		58505		58546		58587		58628
	58383	5842		58465		58506		58547		58588		58629
	58384	5842		58466		58507		58548		58589		58630
	58385	5842		58467		58508		58549		58590		58631
	58386	5842		58468		58509		58550		58591		58632
	58387	5842		58469		58510		58551		58592		58633
	58388	5842		58470		58511		58552		58593		58634
	58389	5843		58471		58512		58553		58594		58635
	58390	5843		58472		58513		58554		58595		58636
	58391	5843		58473		58514		58555		58596		58637
	58392	5843		58474		58515		58556		58597		58638
	58393	5843		58475		58516		58557		58598		58639
	58394	5843		58476		58517		58558		58599		58640
	58395	5843		58477		58518		58559		58600		58641
	58396	5843		58478		58519		58560		58601		58642
	58397	5843		58479		58520		58561		58602		58643
	58398	5843		58480		58521		58562		58603		58644
	58399	5844		58481		58522		58563		58604		58645
	58400	5844		58482		58523		58564		58605		58646
	58401	5844		58483		58524		58565		58606		58647
	58402	5844		58484		58525		58566		58607		58648
	58403	5844		58485		58526		58567		58608		58649
	58404	5844		58486		58527		58568		58609		58650
	58405	5844		58487		58528		58569		58610		58651
	58406	5844		58488		58529		58570		58611		58652
	58407	5844		58489		58530		58571		58612		58653
	58408	5844		58490		58531		58572		58613		58654
	58409	5845	0	58491		58532		58573		58614		58655
	l											

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.		Trt.		Trt.		Trt.		Trt.			Bl.	Trt.	
No	nb	No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	58656	PPD	58697	PPD	58738	PPD	58779	PPD	58820	PPD	58861	PPD	58902
110	58657		58698		58739	110	58780	יוו	58821		58862		58903
	58658		58699		58740		58781		58822		58863		58904
	58659		58700		58741		58782		58823		58864		58905
	58660		58701		58742		58783		58824		58865		58906
	58661		58702		58743		58784		58825		58866		58907
	58662		58703		58744		58785		58826		58867		58908
	58663		58704		58745		58786		58827		58868		58909
	58664		58705		58746		58787		58828		58869		58910
	58665		58706		58747		58788		58829		58870		58911
	58666		58707		58748		58789		58830		58871		58912
	58667		58708		58749		58790		58831		58872		58913
	58668		58709		58750		58791		58832		58873		58914
	58669		58710		58751		58792		58833		58874		58915
	58670		58711		58752		58793		58834		58875		58916
	58671		58712		58753		58794		58835		58876		58917
	58672		58713		58754		58795		58836		58877		58918
	58673		58714		58755		58796		58837		58878		58919
	58674		58715		58756		58797		58838		58879		58920
	58675		58716		58757		58798		58839		58880		58921
	58676		58717		58758		58799		58840		58881		58922
	58677		58718		58759		58800		58841		58882		58923
	58678		58719		58760		58801		58842		58883		58924
	58679		58720		58761		58802		58843		58884		58925
	58680		58721		58762		58803		58844		58885		58926
	58681		58722		58763		58804		58845		58886		58927
	58682		58723		58764		58805		58846		58887		58928
	58683		58724		58765		58806		58847		58888		58929
	58684		58725		58766		58807		58848		58889		58930
	58685		58726		58767		58808		58849		58890		58931
	58686		58727		58768		58809		58850		58891		58932
	58687		58728		58769		58810		58851		58892		58933
	58688		58729		58770		58811		58852		58893		58934
	58689		58730		58771		58812		58853		58894		58935
	58690		58731		58772		58813		58854		58895		58936
	58691		58732		58773		58814		58855		58896		58937
	58692		58733		58774		58815		58856		58897		58938
	58693		58734		58775		58816		58857		58898		58939
	58694		58735		58776		58817		58858		58899		58940
	58695		58736		58777		58818		58859		58900		58941
	58696		58737		58778		58819		58860		58901		58942
	•												

DTPA-HBV-IPV-135 (A.15MAR2018)

	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb		nb	Trt. No	Bl. nb	Trt. No	Bl. nb	Trt. No	Bl. nb
										PPD	 I		
PPD	58943	PPD	58984	PPD	59025	PPD	59066	PPD	59107	FFD	59148	PPD	59189
	58944		58985		59026		59067		59108		59149		59190
	58945		58986		59027		59068		59109		59150		59191
	58946		58987		59028		59069		59110		59151		59192
	58947		58988		59029		59070		59111		59152		59193
	58948		58989		59030		59071		59112		59153		59194
	58949		58990		59031		59072		59113		59154		59195
	58950		58991		59032		59073		59114		59155		59196
	58951		58992		59033		59074		59115		59156		59197
	58952		58993		59034		59075		59116		59157		59198
	58953		58994		59035		59076		59117		59158		59199
	58954		58995		59036		59077		59118		59159		59200
	58955		58996		59037		59078		59119		59160		59201
	58956		58997		59038		59079		59120		59161		59202
	58957		58998		59039		59080		59121		59162		59203
	58958		58999		59040		59081		59122		59163		59204
	58959		59000		59041		59082		59123		59164		59205
	58960		59001		59042		59083		59124		59165		59206
	58961		59002		59043		59084		59125		59166		59207
	58962		59003		59044		59085		59126		59167		59208
	58963		59004		59045		59086		59127		59168		59209
	58964		59005		59046		59087		59128		59169		59210
	58965		59006		59047		59088		59129		59170		59211
	58966		59007		59048		59089		59130		59171		59212
	58967		59008		59049		59090		59131		59172		59213
	58968		59009		59050		59091		59132		59173		59214
	58969		59010		59051		59092		59133		59174		59215
	58970		59011		59052		59093		59134		59175		59216
	58971		59012		59053		59094		59135		59176		59217
	58972		59013		59054		59095		59136		59177		59218
	58973		59014		59055		59096		59137		59178		59219
	58974		59015		59056		59097		59138		59179		59220
	58975		59016		59057		59098		59139		59180		59221
	58976		59017		59058		59099		59140		59181		59222
	58977		59018		59059		59100		59141		59182		59223
	58978		59019		59060		59101		59142		59183		59224
	58979		59020		59061		59102		59143		59184		59225
	58980		59021		59062		59103		59144		59185		59226
	58981		59022		59063		59104		59145		59186		59227
	58982		59023		59064		59105		59146		59187		59228
	58983		59024		59065		59106		59147		59188		59229

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	. Bl. o nb	Trt. No		Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb	Trt. No	nb
PPD	59230 59231 59232 59233 59234 59235 59236 59237 59238 59239 59240 59241 59241 59242 59243 59244		59271 59272 59273 59274 59275 59276 59277 59278 59279 59280 59281 59282 59283 59284 59285				59353 59354 59355 59356 59357 59358 59359 59360 59361 59362 59363 59364 59365 59366 59367		59394 59395 59396 59397 59398 59399 59400 59401 59402 59403 59404 59405 59406 59407 59408		59435 59436 59437 59438 59439 59440 59441 59442 59443 59444 59445 59446 59447 59448 59449		59476 59477 59478 59479 59481 59482 59483 59484 59484 59486 59487 59488 59489 59490
	59245 59246 59247 59248 59249 59250 59251 59252 59253 59254 59255 59256 59257 59258		59286 59287 59288 59289 59290 59291 59292 59293 59294 59295 59296 59297 59298 59299		59328 59329 59330 59331 59332 59333 59334 59335 59336 59337 59338 59339 59340		59368 59369 59370 59371 59372 59373 59374 59376 59376 59377 59378 59379 59380 59381		59409 59410 59411 59412 59413 59414 59415 59416 59417 59418 59419 59420 59420 59421 59422		59450 59451 59452 59453 59454 59455 59456 59457 59459 59460 59461 59462 59463		59491 59492 59493 59494 59495 59496 59497 59498 59499 59500 59500 59501 59502 59503 59504
	59259 59260 59261 59262 59263 59264 59265 59265 59266 59267 59268 59269 59270		59300 59301 59302 59303 59304 59305 59306 59307 59308 59309 59310 59311		59341 59342 59343 59344 59345 59346 59347 59348 59349 59350 59351 59352		59382 59383 59384 59385 59386 59387 59388 59389 59390 59391 59392 59393		59423 59424 59425 59426 59427 59428 59429 59430 59431 59432 59433 59434		59464 59465 59466 59467 59468 59469 59470 59471 59472 59473 59475		59505 59506 59507 59508 59509 59510 59511 59512 59513 59514 59515 59516

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt. No		Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt. No	
PPD	59517	PPD	59558	PPD	59599	PPD	59640	PPD	59681	PPD	59722	PPD	59763
	59518	–	59559	–	59600		59641		59682		59723		59764
	59519		59560		59601		59642		59683		59724		59765
	59520		59561		59602		59643		59684		59725		59766
	59521		59562		59603		59644		59685		59726		59767
	59522		59563		59604		59645		59686		59727		59768
	59523		59564		59605		59646		59687		59728		59769
	59524		59565		59606		59647		59688		59729		59770
	59525		59566		59607		59648		59689		59730		59771
	59526		59567		59608		59649		59690		59731		59772
	59527		59568		59609		59650		59691		59732		59773
	59528		59569		59610		59651		59692		59733		59774
	59529		59570		59611		59652		59693		59734		59775
	59530		59571		59612		59653		59694		59735		59776
	59531		59572		59613		59654		59695		59736		59777
	59532		59573		59614		59655		59696		59737		59778
	59533		59574		59615		59656		59697		59738		59779
	59534		59575		59616		59657		59698		59739		59780
	59535		59576		59617		59658		59699		59740		59781
	59536		59577		59618		59659		59700		59741		59782
	59537		59578		59619		59660		59701		59742		59783
	59538		59579		59620		59661		59702		59743		59784
	59539		59580		59621		59662		59703		59744		59785
	59540		59581		59622		59663		59704		59745		59786
	59541		59582		59623		59664		59705		59746		59787
	59542		59583		59624		59665		59706		59747		59788
	59543		59584		59625		59666		59707		59748		59789
	59544		59585		59626		59667		59708		59749		59790
	59545		59586		59627		59668		59709		59750		59791
	59546		59587		59628		59669		59710		59751		59792
	59547		59588		59629		59670		59711		59752		59793
	59548		59589		59630		59671		59712		59753		59794
	59549		59590		59631		59672		59713		59754		59795
	59550		59591		59632		59673		59714		59755		59796
	59551		59592		59633		59674		59715		59756		59797
	59552		59593		59634		59675		59716		59757		59798
	59553		59594		59635		59676		59717		59758		59799
	59554		59595		59636		59677		59718		59759		59800
	59555		59596		59637		59678		59719		59760		59801
	59556		59597		59638		59679		59720		59761		59802
	59557		59598		59639		59680		59721		59762		59803
									==				
											l		

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No	nb	No	nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	59804	PPD	59845	PPD	59886	PPD	59927	PPD	59968	PPD	60009	PPD	60050
FFD	59805	110	59846		59887	110	59928	FFD	59969		60003	110	60050
	59806		59847		59888		59929		59970		60011		60051
	59807		59848		59889		59930		59971		60012		60052
	59808		59849		59890		59931		59972		60013		60053
	59809		59850		59891		59932		59973		60013		60055
	59810		59851		59892		59933		59974		60014		60055
	59811		59852		59893		59934		59975		60016		60057
	59812		59853		59894		59935		59976		60017		60057
	59813		59854		59895		59936		59977		60017		60059
	59814		59855		59896		59937		59978		60018		60060
	59815		59856		59897		59938		59979		60020		60061
	59816		59857		59898		59939		59980		60020		60062
	59817		59858		59899		59940		59981		60022		60063
	59818		59859		59900		59941		59982		60023		60064
	59819		59860		59901		59942		59983		60023		60065
	59820		59861		59902		59943		59984		60025		60066
	59821		59862		59903		59944		59985		60025		60067
	59822		59863		59904		59945		59986		60027		60068
	59823		59864		59905		59946		59987		60028		60069
	59824		59865		59906		59947		59988		60029		60070
	59825		59866		59907		59948		59989		60030		60071
	59826		59867		59908		59949		59990		60031		60072
	59827		59868		59909		59950		59991		60032		60073
	59828		59869		59910		59951		59992		60033		60074
	59829		59870		59911		59952		59993		60033		60075
	59830		59871		59912		59953		59994		60035		60076
	59831		59872		59913		59954		59995		60036		60077
	59832		59873		59914		59955		59996		60037		60078
	59833		59874		59915		59956		59997		60038		60079
	59834		59875		59916		59957		59998		60039		60080
	59835		59876		59917		59958		59999		60040		60081
	59836		59877		59918		59959		60000		60041		60082
	59837		59878		59919		59960		60001		60042		60083
	59838		59879		59920		59961		60002		60043		60084
	59839		59880		59921		59962		60003		60044		60085
	59840		59881		59922		59963		60004		60045		60086
	59841		59882		59923		59964		60005		60046		60087
	59842		59883		59924		59965		60006		60047		60088
	59843		59884		59925		59966		60007		60048		60089
	59844		59885		59926		59967		60008		60049		60090

DTPA-HBV-IPV-135 (A.15MAR2018)

60092 60133 60174 60215 60256 60297 60093 60134 60175 60216 60257 60298 60094 60135 60176 60217 60258 60299 60095 60136 60177 60218 60259 60300 60096 60137 60178 60219 60260 60301 60097 60138 60179 60220 60261 60302 60098 60139 60180 60221 60262 60303 60100 60140 60181 60222 60263 60304 60100 60141 60182 60223 60264 60305 60101 60142 60183 60224 60265 60306 60102 60143 60184 60225 60266 60307 60103 60144 60185 60226 60267 60308 60104 60145 60186 60227 60268 60309	No nb	Trt. Bl. No nb		No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb	Trt. Bl. No nb
60112 60153 60194 60235 60276 60317 60113 60154 60195 60236 60277 60318 60114 60155 60196 60237 60278 60319 60115 60156 60197 60238 60279 60320 60116 60157 60198 60239 60280 60321 60117 60158 60199 60240 60281 60322 60118 60159 60200 60241 60282 60323 60119 60160 60201 60242 60283 60324 60120 60161 60202 60243 60284 60325 60121 60162 60203 60244 60285 60326 60122 60163 60204 60244 60285 60326 60123 60164 60205 60246 60287 60328 60124 60165 60206 60247 60288 60329 60125 60166 60207 60248 60289 60330 60126 60167 60208 60249 60290 60331 60127 60168 60209 60250 60291 60332 60128 60169 60210 60251 60292 60333 60129 60170 60211 60252 60293 60334 60129 60170 60211 60255 60293 60334 60129 60170 60211 60255 60293 60334 60129 60170 60211 60255 60293 60334	60091 60092 60093 60093 60094 60095 60096 60097 60098 60099 60100 60101 60102 60103 60104 60105 60106 60107 60108 60109 60110 60111 60112 60113 60114 60115 60116 60117 60118 60119 60119 60120 60121 60121 60122 60123 60124 60125 60126 60127 60128 60129	PPD 6009 6009 6009 6009 6009 6009 6010 6010	PPD 60132 0091 PPD 60132 0092 60133 0093 60134 0094 60135 0095 60136 0096 60137 0097 60138 0099 60140 0100 60141 0101 60142 0102 60143 0103 60144 0104 60145 0106 60147 0107 60148 0108 60149 0109 60150 0110 60151 0111 60152 0111 60152 0111 60155 0116 60157 0117 60158 0118 60159 0119 60150 0110 60151 0111 60155 0116 60157 0117 60158 0118 60159 0119 60160 0110 60161 0111 60155 0116 60157 0117 60158 0118 60159 0110 60161 0121 60162 0122 60163 0123 60164 0124 60165 0125 60166 0127 60168 0128 60169 0129 60161	PPD 60173 F 60174 60175 60176 60177 60178 60179 60180 60181 60182 60183 60184 60185 60186 60187 60188 60189 60190 60191 60192 60193 60194 60195 60196 60197 60198 60199 60200 60201 60202 60203 60204 60205 60206 60207 60208 60209 60210 60211	60214 60215 60216 60217 60218 60219 60220 60221 60222 60223 60224 60225 60226 60227 60228 60227 60228 60229 60230 60231 60232 60233 60234 60235 60236 60237 60238 60239 60240 60241 60242 60242 60242 60243 60244 60245 60246 60247 60248 60249 60249 60250 60251 60252	PPD 60255 60256 60257 60258 60259 60260 60261 60262 60263 60264 60265 60266 60267 60268 60269 60270 60271 60272 60273 60274 60275 60276 60277 60278 60277 60278 60279 60280 60281 60282 60283 60284 60285 60286 60287 60288 60289 60290 60291 60292	PPD 60296 60297 60298 60299 60300 60301 60302 60303 60304 60305 60306 60307 60308 60309 60311 60312 60313 60314 60315 60316 60317 60318 60319 60320 60320 60321 60322 60323 60324 60325 60326 60327 60328 60327 60328 60329 60331 60331 60331	

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

	Bl.	Trt. Bl.		Bl.		Bl.	Trt.			Bl.	Trt.	
No	nb	No nb	No	nb	No	nb	No	nb	No	nb	No	nb
PPD	60378	PPD 60419	PPD	60460	PPD	60501	PPD	60542	PPD	60583	PPD	60624
	60379	60420		60461		60502		60543		60584		60625
	60380	60421		60462		60503		60544		60585		60626
	60381	60422		60463		60504		60545		60586		60627
	60382	60423		60464		60505		60546		60587		60628
	60383	60424		60465		60506		60547		60588		60629
	60384	60425		60466		60507		60548		60589		60630
	60385	60426		60467		60508		60549		60590		60631
	60386	60427		60468		60509		60550		60591		60632
	60387	60428		60469		60510		60551		60592		60633
	60388	60429		60470		60511		60552		60593		60634
	60389	60430		60471		60512		60553		60594		60635
	60390	60431		60472		60513		60554		60595		60636
	60391	60432		60473		60514		60555		60596		60637
	60392	60433		60474		60515		60556		60597		60638
	60393	60434		60475		60516		60557		60598		60639
	60394	60435		60476		60517		60558		60599		60640
	60395	60436		60477		60518		60559		60600		60641
	60396	60437		60478		60519		60560		60601		60642
	60397	60438		60479		60520		60561		60602		60643
	60398	60439		60480		60521		60562		60603		60644
	60399	60440		60481		60522		60563		60604		60645
	60400	60441		60482		60523		60564		60605		60646
	60401 60402	60442 60443		60483 60484		60524 60525		60565 60566		60606 60607		60647 60648
	60402	60443		60485		60526		60567		60607		60649
	60403	60444		60486		60527		60568		60609		60650
	60404	60445		60487		60527		60569		60610		60651
	60405	60447		60488		60528		60570		60611		60652
	60406	60448		60489		60529		60570		60612		60653
	60407	60449		60490		60531		60572		60613		60654
	60409	60450		60491		60532		60573		60614		60655
	60410	60451		60492		60533		60574		60615		60656
	60411	60452		60493		60534		60575		60616		60657
	60412	60453		60494		60535		60576		60617		60658
	60413	60454		60495		60536		60577		60618		60659
	60414	60455		60496		60537		60578		60619		60660
	60415	60456		60497		60538		60579		60620		60661
	60416	60457		60498		60539		60580		60621		60662
	60417	60458		60499		60540		60581		60622		60663
	60418	60459		60500		60541		60582		60623		60664
	-			-								

SD4\0\INFORM Randomisation list

DTPA-HBV-IPV-135 (A.15MAR2018)

Trt. Bl.	Trt.	Bl.	Tr	t. Bl.	Trt.	Bl.	Trt.	Bl.	Trt.	Bl.
No nb		nb		No nb		nb	No			nb
PPD 60665	PPD		PPD		PPD		PPD		PPD	
	110	60706	110	00/4/	PPD	60788	יוו	60829	110	60870
60666		60707		60748		60789		60830		60871
60667		60708		60749		60790		60831		60872
60668		60709		60750		60791		60832		60873
60669		60710		60751		60792		60833		60874
60670		60711		60752		60793		60834		60875
60671		60712		60753		60794		60835		60876
60672		60713		60754		60795		60836		60877
60673		60714		60755		60796		60837		60878
60674		60715		60756		60797		60838		60879
60675		60716		60757		60798		60839		60880
60676		60717		60758		60799		60840		60881
60677		60718		60759		60800		60841		60882
60678		60719		60760		60801		60842		60883
60679		60720		60761		60802		60843		60884
60680		60721		60762		60803		60844		60885
60681		60722		60763		60804		60845		60886
60682		60723		60764		60805		60846		60887
60683		60724		60765		60806		60847		60888
60684		60725		60766		60807		60848		60889
60685		60726		60767		60808		60849		60890
60686		60727		60768		60809		60850		60891
60687		60728		60769		60810		60851		60892
60688		60729		60770		60811		60852		60893
60689		60730		60771		60812		60853		60894
60690		60731		60772		60813		60854		60895
60691		60732		60773		60814		60855		60896
60692		60733		60774		60815		60856		60897
60693		60734		60775		60816		60857		60898
60694		60735		60776		60817		60858		60899
60695		60736		60777		60818		60859		60900
60696		60737		60778		60819		60860		60901
60697		60738		60779		60820		60861		60902
60698		60739		60780		60821		60862		60903
60699		60740		60781		60822		60863		60904
60700		60741		60782		60823		60864		60905
60701		60742		60783		60824		60865		60906
60702		60743		60784		60825		60866		
60703		60744		60785		60826		60867		
60704		60745		60786		60827		60868		
60705		60746		60787		60828		60869		
		_								

117119 (DTPA-HBV-IPV-135) Report Final

Audit Certificates

AUDIT CERTIFICATE

Study Number: 117119

Good Clinical Practice (GCP) is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety and well being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible.

Clinical studies are conducted by or on behalf of GlaxoSmithKline in accordance with Standard Operating Procedures, which conform to the requirements of international GCP guidelines (ICH Harmonised Tripartite Guidelines E6 for Good Clinical Practice, FDA 21CFR parts 50, 56 and 312).

During the conduct and reporting of this/these study(s), the following independent audits were performed by or on behalf of GlaxoSmithKline.

Study Number	Туре	Conducted by	Centre number	Country	Audit Date
117119	Investigator Site	GSK-CQA	PPD	USA	4-6 Nov 2014
117119	Investigator Site	GSK-CQA		USA	21-23 Oct 2014
117119	Investigator Site	GSK-CQA		USA	4-6 Nov 2014
117119	Investigator Site	GSK-CQA		USA	4-5 Nov 2014
117119	Investigator Site	GSK-CQA		USA	13-14 Oct 2014
117119	Investigator Site	GSK-CQA		USA	24-26 Aug 2015

1349

117119 (DTPA-HBV-IPV-135)

Report Final

Clinical Quality Assurance hereby confirm that the audits detailed above were carried out in accordance with appropriate regulatory requirements and guidelines in order to assess compliance with the study protocol, ICH GCP, FDA 21CFR parts 314.50 and 601.2, appropriate standard operating procedures and policies.

Name: PPD Date: 06 Mar 2018

Role: Senior Manager CQA Clinical Quality Assurance

GlaxoSmithKline Research and Development

06-JUL-2018 4138e5e7efd1f15bf35572227c1d9fd9bd7066e8

Documentation of statistical methods

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

gsk GlaxoSmithKline	Statistical Analysis Plan
Detailed Title:	A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa [™] vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, coadministered with Prevnar [®] and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age
eTrack study number and Abbreviated Title	117119 (DTPA-HBV-IPV-135)
Scope:	All data pertaining to the above study.
Date of Statistical Analysis Plan	29-Nov-2017 (Amendment 2)
Co-ordinating author:	(Lead statistician)
Other author:	PPD (statistician)
Adhoc reviewers for first version:	PPD (Regulatory representative), PPD (Safety representative)
Approved by:	R&D Project Leader), (Clinical and Epidemiology
	Clinical Research and Development Lead (CRDL),
	(Lead Statistician),
	PPD (Scientific Writer),
	(Lead statistical analyst)

APP 9000058193 Statistical Analysis Plan Template (Effective date: 14April 2017)

29-NOV-2017 Page 1 of 30

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

TABLE OF CONTENTS

			PAGE
LIS	T OF ABBRE	/IATIONS	4
1.	DOCUMENT	HISTORY	6
2.	STUDY DES	IGN	7
3.		S	
		ry objective	
	3.1.1. 3.2. Secon	Epoch 001 (Primary vaccination)ndary objectives	
	3.2. 3eco		10 10
	3.2.1.		
4.	FNDPOINTS		11
		ry endpoint	
	4.1.1.		
	4.2. Secon	ndary endpoints	
	4.2.1.	_p,,,	
	4.2.2.	Epoch 002 (Booster vaccination)	12
5.	STUDY POP	ULATION	14
	5.1.1.		
	5.1.2.		
	5.1.3.		
	5.1.4.		
	5.1.5.		
	5.1.6.	, , , , ,	
6.		L METHODS	
		analysis of the Epoch 001	
	6.1.1.		
	6.1.2.		17
		6.1.2.1. Within group assessment	
		6.1.2.2. Between group assessment	
	6.1.3.	6.1.2.3. Interpretation of analyses	
		analysis of the Epoch 002	
	6.2.1.		
	6.2.2.		
	0.2.2.	6.2.2.1. Within group assessment	
		6.2.2.2. Between group assessment	
		6.2.2.3. Interpretation of analyses	
	6.2.3.		
7.	STATISTICA	L CALCULATIONS	24
		ed and transformed data	
	7.1.1.		
	7.1.2.	Immunogenicity	24

29-NOV-2017

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

		OUN IDENTIAL	
			117119 (DTPA-HBV-IPV-135)
		Statistical A	Analysis Plan Amendment 2 Final
		7.1.3. Safety/reactogenicity:	25
	7.2.	Data presentation description	
	7.3.	Methodology for computing confidence interval	
8.	CONE	OUCT OF ANALYSES	28
	8.1.	Sequence of analyses	28
		Statistical considerations for interim analyses	
9.	MAJO	R CHANGES FROM PLANNED ANALYSES	29
10.	REFE	RENCE	30

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135)

Statistical Analysis Plan Amendment 2 Final

LIST OF ABBREVIATIONS

AE Adverse event

ANCOVA Analysis of Co-variance
ANOVA Analysis of Variance
ATP According-To-Protocol
CI Confidence Interval
CSR Clinical Study Report

D Diphtheria

EL.U/ml ELISA unit per milliliter

ELISA Enzyme-linked immunosorbent assay

Eli Type Internal GSK database code for type of elimination code

ESFU Extended Safety Follow-up FHA Filamentous hemagglutinin

GMC Geometric mean antibody concentration

GMT Geometric mean antibody titer

GSK GlaxoSmithKline

HBs Hepatitis B surface antigen

HHE Hypotonic Hyporesponsive Episode

Hib Haemophilus influenzae (H. influenzae) type b

IU/ml International units per milliliter

LL Lower Limit of the confidence interval

MedDRA Medical Dictionary for Regulatory Activities

NOCD New Onset of Chronic Disease

PRN Pertactin

PRP Polyribosyl-Ribitol-Phosphate: polysaccharide component of the Hib

1354

bacterium capsule

PT Pertussis toxoid: a secreted exotoxin of the *Bordetella pertussis*

bacterium

RCC Reverse Cumulative Curve

SAE Serious adverse event SAP Statistical Analysis Plan

SBIR GSK Biological's Internet Randomization System

SD Standard Deviation

29-NOV-2017 Page 4 of 30

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

SR Study Report
T Tetanus

TFL Tables Figures and Listing template annexed to SAP

TVC Total Vaccinated cohort

UL Upper Limit of the confidence interval

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

1. DOCUMENT HISTORY

The complete statistical analysis plan and results presentation is divided into 2 parts: the first part detailing the analyses to be performed (known as SAP, current document) and a second part, annex (-es) (called TFL) describing the flow and format of tables, figures and listings to be annexed to the SR. For this study, there is only one annex TFL.

The following table presents the history of the statistical analysis plan development:

Date	Description	Protocol Version
10-Mar-2015	Version 1	Protocol Amendment 1 - 18-SEP-2014
		10-3EF-2014
06-May-2015	Version 2 (Amendment 1). The SAP has been updated to incorporate the changes in the sequence of analysis as per the protocol amendment 2	Protocol Amendment 2 - 17-Apr-2015
29-Nov-2017	Amendment 2*	Protocol Amendment 2 - 17-Apr-2015


^{*} statistical analysis amendment 2 included the following changes:

- During the course of the study, the assays used to measure the anti-D, -T, -PT, -FHA and -PRN IgG concentrations were re-developed and re-validated and both assay units and assay cut-offs were adapted. The new ELISAs for PT, FHA and PRN were calibrated against the WHO International Standard (NIBSC 06/140). This allowed the expression of concentrations measured with the new ELISAs in International Units per milliliter (IU/mL) instead of the formerly used ELISA units per milliliter (EL.U/mL). The newly validated DTPa ELISA's have a lower assay cut-off as compared to the one described in the protocol. The current assay cut-off is 0.057 IU/mL for anti-D, 0.043 IU/mL for anti-T, 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA and 2.187 IU/mL for anti-PRN. Since for anti-D, anti-T a threshold of 0.1 IU/mL provided a conservative estimate of the percentage of subjects deemed to be protected, the anti-D, anti-T seroposivity endpoints initially defined by the previous assay cut-off of 0.1 IU/mL were replaced by seroprotection rate endpoints defined as the percentage of subjects with concentration above 0.1 IU/mL. In the absence of a correlate of protection for the *B. pertussis* antigens, the pertussis vaccine response endpoints were redefined based on the assay cut-off.
- 2. A descriptive summary per lot was added for anti-PRP post priming.
- 3. The ANCOVA model was revised to include the 3 study groups rather than the 2 groups compared. This allowed identical adjusted GMC estimate regardless of the groups involved in the comparison.
- 4. The DTPA-HBV-IPV-135 (117119) Abridged Interim Report Main (19-Oct-2015) included immunogenicity data against Polyribosyl-Ribitol-Phosphate (PRP) antigen at Visit 4 using an assay which was not fully validated. For the final analysis, the visit 4 samples were retested together with the samples pre- and post booster using a newly validated assay. In the final analysis, the results of both assays will be descriptively presented at visit 4.

29-NOV-2017

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

2. STUDY DESIGN



N = number of subjects in the study; n = number of subjects in each group; Mo = months

Visit 3 should be conducted at least 8 weeks after Visit 2, with subjects at least 24 weeks of age, in order to comply with US recommendations on hepatitis B dosing

Post-Pri = blood sample collected from subjects, one month after the administration of the third dose in the Epoch 001
Pre-Bst = blood sample collected from subjects, before the administration of the booster dose in the Epoch 002
Post-Bst = blood sample collected from subjects, one month after the administration of booster dose in the Epoch 002
* Engerix-B should not be given at Month 2 (4 months of age) if a dose of hepatitis B vaccine was given at birth up to
30 days prior to study dose 1 to the subject in the Penta Group
ESFU = Extended safety follow-up

- Experimental design: Phase III, open-label, randomized, controlled, multi-centric, single-country study with five parallel groups
- Duration of the study: The intended duration of the study per subject is approximately 14-17 months.
 - Epoch 001: Primary, starting at Visit 1 (Day 0) and ending at safety follow up contact (i.e. six months following the third dose, Month 10),
 - Epoch 002: Booster, starting at Visit 5 (Month 13-16) and ending at Visit 6 (Month 14-17).

29-NOV-2017

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

- Control: active controls.
 - Epoch 001: Pediarix + ActHIB and Pentacel + Engerix-B
 - Epoch 002: *Infanrix* + *ActHIB* and *Pentacel*.
- Vaccination schedules:

Epoch 001

- Hexa Group: Subjects in this group will receive three doses of *Infanrix hexa* (lot A, lot B or lot C as per the group allocation) co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
 - Hexa 1 Group: Subjects will receive lot A of *Infanrix hexa*,
 - Hexa 2 Group: Subjects will receive lot B of *Infanrix hexa*
 - Hexa 3 Group: Subjects will receive lot C of *Infanrix hexa*.
- Pedia Group: Subjects in this group will receive three doses of *Pediarix* and *ActHIB* co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
- Penta Group: Subjects in this group will receive three doses of *Pentacel* and *Engerix-B** co-administered with *Prevnar13* at 2, 4 and 6 months of age and *Rotarix* at 2 and 4 months of age.
 - *Subjects in the Penta Group who have received a dose of hepatitis B vaccine from birth up to 30 days prior to study vaccination should not receive Engerix-B at 4 months of age (Visit 2).

Epoch 002

- Hexa Group: Subjects will receive a booster dose of *Infanrix* and *Hiberix* vaccines at 15-18 months of age.
- Pedia Group: Subjects will receive a booster dose of *Infanrix* and *ActHIB* vaccines at 15-18 months of age.
- Penta Group: Subjects will receive a booster dose of *Pentacel* vaccine at 15-18 months of age.

The fourth dose of pneumococcal conjugate vaccine is recommended to be administered at approximately 12-15 months of age. Since the booster dose of the candidate vaccine/active controls will be given in this study at 15-18 months of age, the fourth dose of *Prevnar13* will not be administered as part of the study protocol. Subject's parent(s)/Legally Acceptable Representative(s) (LARs) will be reminded at Visit 3 and Visit 4 to consult their primary health care provider regarding the fourth dose of *Prevnar13* at 12-15 months for their child.

• As the analyses will be performed regardless of the lot of *Infanrix hexa* received, unless otherwise specified, the Hexa_1, Hexa_2 and Hexa_3 groups will be pooled together for the analysis and will be called the Hexa group.

29-NOV-2017 Page 8 of 30

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

- Treatment allocation: The subjects will be randomized at a [1:1:1]:3:3 ratio to Hexa_1, Hexa_2, Hexa_3, Pedia and Penta groups. This will be done at study entry using GSK Biologicals' central randomization system on internet (SBIR).
- Blinding: The study is open-label for both epochs due to the differences in the number of injections and the appearance of the vaccines administered. However, the laboratory in charge of the serology testing will be blinded to the treatment, and codes will be used to link the subject and study (without any link to the treatment attributed to the subject) to each sample.
- Sampling schedule: Blood samples will be drawn from all subjects at the following time points:
 - Post-Pri (Visit 4): One month after the third dose of primary vaccination, a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) will be collected.
 - Pre-Bst (Visit 5): Before the administration of the booster dose, a volume of approximately 5.0 mL of whole blood (to provide approximately 1.7 mL of serum) will be collected.
 - Post-Bst (Visit 6): One month after the booster vaccination, a volume of at least
 3.5 mL of whole blood (to provide at least 1.2 mL of serum) will be collected.
- Type of study: Self-contained.

The following group names will be used for the final statistical analyses:

Group order in tables	Group label in tables	Group definition for footnote	Pooled Groups label in tables	Pooled definition for footnote
1	Hexa_1 group	Subjects who received primary doses of Infanrix hexa from lot A and a booster dose of Infanrix and Hiberix vaccines	Hexa group	Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines
2	Hexa_2 group	Subjects who received primary doses of Infanrix hexa from lot B and a booster dose of Infanrix and Hiberix vaccines	Hexa group	Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines
3	Hexa_3 group	Subjects who received primary doses of Infanrix hexa from lot C and a booster dose of Infanrix and Hiberix vaccines	Hexa group	Subjects who received primary doses of Infanrix hexa and a booster dose of Infanrix and Hiberix vaccines
4	Pedia group	Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines	Pedia group	Subjects who received primary doses of Pediarix and ActHIB and a booster dose of Infanrix and ActHIB vaccines
5	Penta group	Subjects who received primary doses of Pentacel and Engerix-B and a booster dose of Pentacel vaccine	Penta group	Subjects who received primary doses of Pentacel and Engerix- B and a booster dose of Pentacel vaccine

29-NOV-2017

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

3. OBJECTIVES

3.1. Primary objective

3.1.1. Epoch 001 (Primary vaccination)

• To demonstrate the non-inferiority of *Infanrix hexa* to *Pediarix* co-administered with *ActHIB*, in terms of antibody geometric mean concentrations (GMCs) for pertussis antigens [pertussis toxoid (PT), filamentous hemagglutinin (FHA) and pertactin (PRN)] one month after the third dose of the primary vaccination.

Criteria for non-inferiority:

Non-inferiority in terms of immune response to pertussis antigens will be demonstrated if, for each of the three antigens, the upper limit of the 95% confidence interval (CI) on the GMC ratio [Pedia divided by Hexa] is ≤ 1.5 .

3.2. Secondary objectives

3.2.1. Epoch 001 (Primary vaccination)

- To assess the immune response to *Infanrix hexa, Pediarix, ActHIB, Pentacel* and *Engerix-B*, in terms of seroprotection status, seropositivity status and concentrations or titers of antibodies to D, T, HBs, pertussis, poliovirus types 1, 2 and 3 and PRP antigens, one month after the third dose of the primary vaccination.
- To assess the safety and reactogenicity of a 3-dose primary vaccination course of *Infanrix hexa*, of *Pentacel* co-administered with *Engerix-B*, and that of *Pediarix* co-administered with *ActHIB*, in terms of solicited local symptoms.
- To assess the safety and reactogenicity of all study vaccines in terms of solicited general events, unsolicited adverse events, new-onset chronic diseases (NOCDs) and serious adverse events.

3.2.2. Epoch 002 (Booster vaccination)

- To assess the immunogenicity of *Infanrix hexa, Pentacel, Engerix-B, Pediarix* and *ActHIB*, in terms of persistence of the antibodies to D, T, pertussis, HBs, poliovirus types 1, 2 and 3 and PRP antigens, before the booster dose.
- To assess the immune response to *Infanrix, Hiberix, ActHIB* and *Pentacel*, in terms of seroprotection status, seropositivity status and antibody concentrations or titers for D, T, pertussis and PRP antigens, and in terms of booster response for pertussis antigens following *Infanrix and Pentacel*, one month after the booster dose.
- To assess the safety and reactogenicity of booster doses of *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*.

29-NOV-2017

Page 10 of 30

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

4. ENDPOINTS

4.1. Primary endpoint

4.1.1. Epoch 001 (Primary vaccination)

- Immunogenicity with respect to pertussis components of the study vaccines Infanrix hexa and Pediarix.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination.

4.2. Secondary endpoints

4.2.1. Epoch 001 (Primary vaccination)

- Immunogenicity (other parameters) with respect to the pertussis component of the study vaccines *Infanrix hexa*, *Pentacel* and *Pediarix*.
 - Anti-PT, anti-FHA, anti-PRN seropositivity status, one month after the third dose of the primary vaccination.
 - Anti-PT, anti-FHA, anti-PRN antibody concentrations, one month after the third dose of the primary vaccination (for *Pentacel* only).
- Immunogenicity with respect to the other components of the study vaccines *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B*.
 - Anti-D, anti-T, anti-HBs, anti-poliovirus types 1, 2 and 3 and anti-PRP seroprotection status, anti-PRP antibody concentrations ≥1.0 μg/mL and antibody concentrations/titers, one month after the third dose of the primary vaccination.
- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0 Day 3) after each vaccination (*Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel* and *Engerix-B*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0 Day 3) after each vaccination.
- Unsolicited adverse events.
 - Occurrence of unsolicited AEs within 31 days (Day 0 Day 30) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.

29-NOV-2017

Page 11 of 30

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

- Specific adverse events.
 - Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies) from Day 0 up to six months post primary vaccination.
- Serious adverse events.
 - Occurrence of serious adverse events from Day 0 up to six months post primary vaccination.

4.2.2. Epoch 002 (Booster vaccination)

- Immunogenicity with respect to all study vaccines.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-HBs, anti-PRP and anti-poliovirus 1, 2, 3 seroprotection/ seropositivity status, anti-PRP antibody concentrations ≥1 μg/mL and antibody concentrations/ titers before the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccine *Pentacel*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN, anti-PRP seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
 - − Anti-PRP antibody concentrations ≥ 1 µg/mL one month after the booster dose (Dose 4).
 - Anti-D and anti-T antibody concentrations ≥1 IU/mL one month after the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccine *Infanrix*.
 - Anti-D, anti-T, anti-PT, anti-FHA and anti-PRN seroprotection/ seropositivity status and antibody concentrations, one month after the booster dose (Dose 4).
 - Anti-PT, anti-FHA and anti-PRN booster response one month after the booster dose (Dose 4).
 - Anti-D and anti-T antibody concentrations ≥1 IU/mL one month after the booster dose (Dose 4).
- Immunogenicity with respect to the study vaccines ActHIB and Hiberix.
 - Anti-PRP seroprotection status and antibody concentrations, one month after the booster dose (Dose 4).
 - − Anti-PRP antibody concentrations ≥ 1 µg/mL one month after the booster dose (Dose 4)

29-NOV-2017

Page 12 of 30

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

- Solicited local and general symptoms.
 - Occurrence of each solicited local symptom (any, ≥Grade 2, Grade 3 and symptoms requiring medical attention) within 4 days (Day 0 Day 3) after booster vaccination (*Infanrix*, *Hiberix*, *ActHIB* and *Pentacel*).
 - Occurrence of each solicited general symptom (any, ≥Grade 2, Grade 3, symptoms requiring medical attention, related and Grade 3 related) within 4 days (Day 0 Day 3) after booster vaccination.
- Unsolicited adverse events.
 - Occurrence of unsolicited AEs within 31 days (Day 0 Day 30) after booster vaccination, according to the MedDRA classification.
- Specific adverse events.
 - Occurrence of specific adverse events, i.e., new onset chronic diseases (e.g. autoimmune disorders, asthma, type I diabetes and allergies) from the booster dose up to one month after the booster vaccination.
- Serious adverse events.
 - Occurrence of serious adverse events from the booster dose up to one month after the booster vaccination.

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

5. STUDY POPULATION

Six cohorts are defined for the purpose of the analysis:

- Primary Total Vaccinated cohort
- Primary ATP cohort for analysis of safety
- Primary ATP cohort for analysis of immunogenicity
- Booster Total Vaccinated cohort
- Booster ATP cohort for analysis of safety
- Booster ATP cohort for analysis of immunogenicity

5.1.1. Primary Total vaccinated cohort

The Primary Total Vaccinated cohort (TVC) will include all vaccinated subjects for whom data are available.

- A safety analysis based on the Primary TVC will include all subjects with at least one vaccine administration documented.
- An immunogenicity analysis based on the Primary TVC will include all vaccinated subjects for whom data concerning at least one immunogenicity endpoint measure is available.

5.1.2. Primary ATP cohort for analysis of safety

The Primary ATP cohort for safety will consist of all subjects from the Primary TVC who complied with the protocol up to the end of Epoch 001, namely all subjects:

- who meet all inclusion criteria and no exclusion criteria for the study
- who have received all planned study vaccines for each completed vaccination visit in Epoch 001;
- for whom administration site of study vaccines is known and is according to protocol;
- who did not receive a product before the blood sampling at Visit 4 (Month 5) leading to elimination from an ATP analysis as listed in Section 6.7.2 of the protocol.

Note that for the purpose of ATP cohort definition, the Epoch 001 ends at Visit 4.

Adherence to the interval related to ESFU phone contact will not be taken into account for inclusion in ATP cohort for safety.

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

5.1.3. Primary ATP cohort for analysis of immunogenicity

The Primary ATP cohort for immunogenicity will consist of all subjects from the Primary ATP cohort for safety who complied with eligibility criteria and study procedures (see Table 5 of the protocol for the definition of the intervals) up to the post-dose 3 blood sample and had immunogenicity results for the post-dose 3 blood sample. The analysis will be performed per treatment (first dose) actually administered.

More specifically, the analysis post-dose 3 based on the ATP cohort for immunogenicity will include all eligible subjects:

- who receive all the study vaccines up to dose 3 as per the vaccination schedule;
- for whom administration site and route of study vaccines up to dose 3 is as per protocol;
- who did not receive a medication/product before the blood sampling at Visit 4
 (Month 5) leading to elimination from an ATP analysis as listed in Section 6.7.2 of
 the protocol
- who did not present with a medical condition before the blood sampling at Visit 4 (Month 5) leading to elimination from an ATP analysis as listed in Section 6.8 of the protocol.
- who comply with the post-dose 3 blood sample schedule, i.e. 21-48 days post-dose 3.
- who were not administered a vaccine not foreseen by the study protocol before the corresponding post-vaccination blood sample.
- who have immunogenicity results post-dose 3.

5.1.4. Booster Total vaccinated cohort

The Booster TVC will include all subjects from primary TVC that received the booster vaccine dose.

- For the Booster-TVC analysis of safety, this will include all subjects with booster vaccine administration documented.
- For the Booster-TVC analysis of immunogenicity, this will include vaccinated subjects for whom data concerning immunogenicity endpoint measures are available.

5.1.5. Booster ATP cohort for analysis of safety

The Booster ATP cohort for safety will consist of all subjects from the Booster TVC who complied with the protocol up to the end of Epoch 002, namely all subjects:

- who meet all inclusion criteria and no exclusion criteria for the study
- who have received the planned booster dose at 15-18 months of age;

29-NOV-2017

Page 15 of 30

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

- who received 3 doses in Epoch 001;
- for whom administration site of study vaccines is known and is according to protocol;
- who did not receive a product before the blood sampling at Visit 6 (Months 14-17) leading to elimination from an ATP analysis as listed in Section 6.7.2 of the protocol.

5.1.6. Booster ATP cohort for analysis of immunogenicity

The Booster ATP cohort for immunogenicity will consist of all subjects from the Booster ATP cohort for safety who complied with eligibility criteria and study procedures (see Table 5 of the protocol for the definition of the intervals) up to the post-dose 4 blood sample and had immunogenicity results for the post-dose 4 blood sample.

More specifically, the analysis pre- and post-dose 4 based on the Booster ATP cohort for immunogenicity will include all eligible subjects:

- who receive all the study vaccines up to dose 4 as per the vaccination schedule;
- for whom administration site and route of the study vaccines up to dose 4 is as per protocol;
- who did not receive a medication/product before the blood sampling at Visit 6
 (Months 14-17) leading to elimination from an ATP analysis (see Section 6.7.2 of
 the protocol);
- who did not present with a medical condition before the blood sampling at Visit 6 (Months 14-17) leading to elimination from an ATP analysis (see Section 6.8 of the protocol);
- who comply with the booster vaccination schedule at 15-18 months of age and with the post-dose 4 blood sample schedule i.e. 21-48 days for post-dose 4;
- who have immunogenicity results post-dose 4.

The list of applicable elimination codes for each cohort can be found in the study specific form FORM-BIO-CLIN-9004-05 Criteria for eliminating subjects from the analyses.

Cohort	Elimination codes	Eli Type
Primary ATP cohort for analysis for safety	1030-2100	PR
Primary ATP cohort for analysis for immunogenicity	1030-2100	PR
Booster ATP cohort for analysis for safety	1030-2100	ВО
Booster ATP cohort for analysis for immunogenicity	1030-2100	ВО

29-NOV-2017 Page 16 of 30

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

6. STATISTICAL METHODS

6.1. Final analysis of the Epoch 001

6.1.1. Analysis of demographics

Demographic characteristics (age [weeks], gender, geographical ancestry, height in length [cm], weight [kg] at first dose, Hep B vaccination history, vaccination history of mother with respect to administration of Tdap vaccine during pregnancy) and withdrawal status will be summarised by group using descriptive statistics:

- Frequency tables will be generated for categorical variables such as center;
- Mean, median and standard error will be provided for continuous data such as age.

The distribution of subjects enrolled among the study sites will be tabulated as a whole and per group.

6.1.2. Analysis of immunogenicity

The primary analysis will be based on the Primary ATP cohort for immunogenicity. An analysis on the Primary Total Vaccinated cohort will be performed only if, in any vaccine group and at any time point, more than 5% of the vaccinated subjects with immunological data post-dose 3 are excluded from the Primary ATP cohort for immunogenicity.

The following section describes the analyses that will be performed.

6.1.2.1. Within group assessment

For each group, one month post-dose 3 and for each assay for which a serological result is available:

- Seropositivity and seroprotection rates with exact 95% CIs will be calculated.
- GMCs/GMTs with 95% CIs will be tabulated.
- For each antigen, antibody concentration or titer distribution one month post-vaccination will be tabulated and displayed using reverse cumulative curves (RCCs).
- For anti-PRP post primary vaccinate at visit 4, seropositivity and seroprotection rates and GMCs will be calculated per *Infanrix hexa* lot.

All the above within group analysis for Epoch 001, except the reverse cumulative curves and the presentation per *Infanrix hexa* lot, will also be performed by gender, by geographical ancestry (the most frequent geographical ancestry versus all other geographical ancestries, namely White Caucasian versus any other geographical ancestry), by Tdap vaccination history of mothers during pregnancy and by Hepatitis B vaccination of the subjects at birth (for anti-HBs antigen).

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

6.1.2.2. Between group assessment

At one month post-dose 3,

• The asymptotic standardized 95% CI for the group difference (Pedia group minus Hexa group and Penta group minus Hexa group) in the seroprotection rates will be computed for each antigen.

• Antigen	• Threshold considered for protection
• Anti-D	• 0.1 IU/mL (short term protection)
	• 1 IU/mL (long term protection)
• Anti-T	• 0.1 IU/mL (short term protection)
	• 1 IU/mL (long term protection)
Anti-polio	• 8 dilution
Anti-PRP	• 0.15 μg/mL (short term protection)
	• 1 μg/mL (long term protection)
Anti-Hbs	• 10 mIU/mL

• The 95% CI for each group GMC/GMT ratio (Pedia group divided by Hexa group and Penta group divided by Hexa group) will be computed using an Analysis of Variance (ANOVA) model on the logarithm-transformed concentrations/titers except for GMC ratio (Penta group divided by Hexa group) for pertussis antigens. The ANOVA model will include the vaccine group as fixed effect and the Tdap vaccination of the mother during pregnancy as continuous regressor leading to an Analysis of Co-variance (ANCOVA) model. For hepatitis B antigen, the hepatitis B at birth vaccine dose status will also be used as regressor leading to an Analysis of Co-variance (ANCOVA) model. The model will include the data from the 3 groups compared. For analysis purpose, we will consider DTP vaccination of the mother during pregnancy and Hepatitis B at birth as continuous variables. More specifically 2 continuous indicator variables will be used for Tdap vaccination of mother during pregnancy (an indicator for no Tdap vaccination at birth and an indicator for unknown vaccination at birth) while one indicator of hepatitis B at birth will be used.

6.1.2.3. Interpretation of analyses

Except for analyses addressing criteria specified in the primary objective, comparative analyses will be descriptive/ exploratory with the aim to characterise the difference between groups in immunogenicity. These descriptive/exploratory analyses should not be interpreted for formal conclusions since there is no adjustment for multiplicity of endpoints.

6.1.3. Analysis of safety

The primary analysis will be based on the primary Total Vaccinated cohort. If, in any vaccine group and at any time point of the Epoch 001, the percentage of vaccinated subjects excluded from the primary ATP cohort for safety is more than 5%, a second

29-NOV-2017

Page 18 of 30

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

analysis based on the primary ATP cohort for safety will be performed to complement the primary Total Vaccinated cohort analysis.

- The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) or 31-day (Days 0-30) follow-up period will be tabulated after each vaccine dose and overall (for the Epoch 001) with exact 95% CI.
- The percentage of doses followed by at least one local AE (solicited and unsolicited), by at least one general AE (solicited and unsolicited) and by any AE during the 4-day or 31-day follow-up period will be tabulated over the primary vaccination period, with exact 95% CI.
- The percentage of subjects/doses with local AEs (solicited and unsolicited) will be calculated at each injection site for *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel and Engerix-B* vaccines, as well as overall (all sites considered) during the 4-day follow-up period will be tabulated over the primary vaccination period, with exact 95% CI.
- The percentage of subjects/doses reporting each individual solicited local and general AE during the 4-day follow-up period will be tabulated for each group as follows:
 - Over the primary doses, the percentage of subjects with the symptom and its exact 95% CI.
 - Over the primary doses, the percentage of doses with the symptom and its exact 95% CI.
 - At each study dose, the percentage of subjects with the symptom and its exact 95% CI.

The exact 95% CIs will be calculated assuming independence between doses.

- All computations mentioned above will be done for Grade ≥2 (solicited symptoms only) and Grade 3 symptoms, for symptoms considered related to vaccination (general symptoms only), for Grade 3 symptoms considered related to vaccination (general symptoms only) and for symptoms that resulted in a medically-attended visit. The percentage of subjects/doses reporting each individual solicited local (any grade, grade 2, grade 3, medical advice) during the 4-day follow-up period will also be tabulated at each injection site for *Infanrix hexa*, *Pediarix*, *ActHIB*, *Pentacel and Engerix-B* vaccines with exact 95% CI after each vaccine dose and overall where the same row on the table is used for all vaccines given at the same site across the three study groups (e.g. *Infanrix hexa*, *Pentacel* and *Pediarix* together are in one row and *ActHIB* and *Engerix-B* together are in one row). The percentage of subjects/doses reporting each individual general solicited symptom (any grade, Grade ≥2, Grade 3, causally related, Grade 3 causally related, medical advice) during the 4-day follow-up period will also be tabulated with exact 95% CI. For fever, analyses will also be performed by 0.5°C increments.
- The percentage of subjects/doses with concomitant medication, antipyretic medication and prophylactic antipyretic medication during the 4-day and 31-day follow-up period post-vaccination will be tabulated after each dose and over the Epoch 001.

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

- The verbatim reports of unsolicited AEs will be reviewed by a Clinical Research and Development Lead and the signs and symptoms will be coded according to MedDRA. Every verbatim term will be matched with the appropriate Preferred Term. The percentage of subjects/doses with unsolicited AEs occurring within 31 days with exact 95% CI will be tabulated by Preferred Term. Similar tabulations will be done for Grade 3 unsolicited AEs, for unsolicited AEs considered related to vaccination and for Grade 3 unsolicited AEs considered related to vaccination.
- Subjects who experienced AEs of specific interest (i.e. convulsions, Hypotonic Hyporesponsive Episode) during 31 days with exact 95% CI will be tabulated by Preferred Term. Similar tabulations will be done for AEs considered related to vaccination. Subjects who experienced AEs of specific interest will also be described in detail.
- Subjects who experienced AEs of specific interest (i.e. new onset of chronic disease such as autoimmune disorders, asthma, type I diabetes and allergies) from Day 0 up to 6 months after the last primary vaccination will be tabulated by Preferred Term.
- Subjects who experienced at least one SAE reported before the database lock for the Epoch 001 analysis with an onset date in the Epoch 001 will be tabulated with MedDRA primary preferred term.
- All the above safety and reactogenicity analysis for Epoch 001 will also be performed by gender and geographical ancestry (the most frequent geographical ancestry versus all other geographical ancestries, namely White Caucasian versus any other geographical ancestry) except the percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) and 31-day (Days 0-30) follow-up period.

6.2. Final analysis of the Epoch 002

6.2.1. Analysis of demographics/baseline characteristics

Demographic characteristics (age [months] at Visit 5, gender, geographical ancestry, Hep B vaccination history, vaccination history of mother with respect to administration of Tdap vaccine during pregnancy) and withdrawal status will be summarized by group using descriptive statistics:

- Frequency tables will be generated for categorical variables such as race/ethnicity;
- Mean, median and standard error will be provided for continuous data such as age.

The distribution of subjects vaccinated at Visit 5 among the study sites will be tabulated as a whole and per group.

For enrolled subjects that do not participate in the Epoch 002, the reason for not participating will be summarized.

29-NOV-2017

Page 20 of 30

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

6.2.2. Analysis of immunogenicity

The primary analysis will be based on the booster ATP cohort for immunogenicity. An analysis on the booster Total Vaccinated cohort will be performed only if, in any vaccine group and at any time point of the Epoch 002, more than 5% of the vaccinated subjects with immunological data are excluded from the booster ATP cohort for immunogenicity.

The following section describes the analyses that will be performed.

6.2.2.1. Within group assessment

For each group, prior to the booster dose and one month post-booster dose and for each assay, for which a serological result is available:

- Seropositivity and seroprotection rates and booster response rates for pertussis with exact 95% CIs will be calculated.
- GMCs/GMTs with 95% CIs will be tabulated.
- For each antigen, antibody concentration or titer distribution before and one month Post-booster (when available) will be tabulated and displayed using RCCs.

All the above within group analysis for Epoch 002 except the reverse cumulative curves will also be performed by gender, by geographical ancestry (the most frequent geographical ancestry versus all other geographical ancestries, namely White Caucasian versus any other geographical ancestry), by Tdap vaccination history of mothers during pregnancy and Hepatitis B vaccination of the subjects at birth (for anti-HBs antigen).

6.2.2.2. Between group assessment

At pre-booster and at one month post-booster,

• The asymptotic standardized 95% CI for the group difference (Pedia group minus Hexa group and Penta group minus Hexa group) in the seroprotection/ seropositivity rates will be computed for each antigen except for group difference (Penta group minus Hexa group) in the seroprotection/ seropositivity rates for pertussis antigens.

Antigen	Threshold considered for protection
Anti-D	• 0.1 IU/mL (short term protection)
	• 1 IU/mL (long term protection)
Anti-T	• 0.1 IU/mL (short term protection)
	• 1 IU/mL (long term protection)
Anti-polio	8 dilution
Anti-PRP	• 0.15 µg/mL (short term protection)
	• 1 μg/mL (long term protection)
Anti-Hbs	• 10 mIU/mL

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

The 95% CI for each group GMC/GMT ratio (Pedia group divided by Hexa group and Penta group divided by Hexa group) will be computed using an ANOVA model on the logarithm-transformed concentrations/titers except for GMC ratio (Penta group divided by Hexa group) for pertussis antigens. The ANOVA model will include the vaccine group as fixed effect and the Tdap vaccination of the mother during pregnancy as regressor leading to an Analysis of Co-variance (ANCOVA). For hepatitis B antigen, the hepatitis B at birth vaccine dose status will also be used as regressor leading to an ANCOVA model. The model will include the data from the 3 groups compared. For analysis purpose, we will consider DTP vaccination of the mother during pregnancy and Hepatitis B at birth as continuous variables. More specifically 2 continuous indicator variables will be used for Tdap vaccination of mother during pregnancy (an indicator for no Tdap vaccination at birth and an indicator for unknown vaccination at birth) while one indicator of hepatitis B at birth will be used.

6.2.2.3. Interpretation of analyses

In Epoch 002, all comparative analyses will be descriptive/ exploratory with the aim to characterise the difference between groups in immunogenicity. These descriptive/exploratory analyses should not be interpreted for formal conclusions since there is no adjustment for multiplicity of endpoints.

6.2.3. Analysis of safety

The primary analysis for the Epoch 002 will be based on the booster Total Vaccinated cohort and will only look at the booster dose. If, in any vaccine group, the percentage of vaccinated subjects excluded from the booster ATP cohort for safety is more than 5%, a second analysis based on the booster ATP cohort for safety will be performed to complement the booster Total Vaccinated cohort analysis.

- The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) and 31-day (Days 0-30) follow-up period after the booster dose, will be tabulated with exact 95% CI for each group.
- The incidence of local AEs (solicited and unsolicited) will be calculated at each injection site as well as overall (all sites considered) for each group during the 4-day (Days 0-3) follow-up period after the booster dose.
- The percentage of subjects reporting each individual solicited local and general AE during the 4-day follow-up period will be tabulated with its exact 95% CI for each group.
- All computations mentioned above will be done for Grade ≥2 (solicited symptoms only) and Grade 3 symptoms, for symptoms considered related to vaccination (general symptoms only), for Grade 3 symptoms considered related to vaccination (general symptoms only) and for symptoms that resulted in a medically-attended visit. The percentage of subjects reporting each individual solicited local symptoms (any grade, Grade ≥2, Grade 3, medical advice) during the 4-day follow-up period will

29-NOV-2017

Page 22 of 30

117119 (DTPA-HBV-IPV-135)

Statistical Analysis Plan Amendment 2 Final

also be tabulated at each injection site for *Infanrix*, *Hiberix*, *ActHIB* and *Pentacel* vaccines with exact 95% CI after each vaccine dose and overall where vaccination with same vaccine site is considered together (e.g. *Infanrix* and *Pentacel* together are on one row and *ActHIB* and *Hiberix* together are on one row). The percentage of subjects reporting each individual general solicited symptom (any grade, Grade ≥2, Grade 3, causally related, Grade 3 causally related, medical advice) during the 4-day follow-up period will also be tabulated with exact 95% CI. For fever, analyses will also be performed by 0.5°C increments.

- The percentage of subjects with concomitant medication, antipyretic medication and prophylactic antipyretic medication during the 4-day and 31-day follow-up period post-vaccination will be tabulated for each group.
- The verbatim reports of unsolicited AEs will be reviewed by a Clinical Research and Development Lead and the signs and symptoms will be coded according to MedDRA. Every verbatim term will be matched with the appropriate Preferred Term. The percentage of subjects with unsolicited AEs occurring within 31 days following the booster dose with its exact 95% CI will be tabulated by Preferred Term. Similar tabulations will be done for Grade 3 unsolicited AEs, for unsolicited AEs considered related to vaccination and for Grade 3 unsolicited AEs considered related to vaccination.

Additionally,

- Any large injection site reaction (defined as a swelling with a diameter > 50 mm, noticeable diffuse swelling or increase in limb circumference of greater than 50 mm) reported within 4 days (Days 0-3) following the booster dose will be tabulated.
- Subjects who experienced AEs of specific interest (i.e. new onset of chronic disease such as autoimmune disorders, asthma, type I diabetes and allergies) from booster dose up to one month after booster vaccination will be tabulated by Preferred Term.
- Subjects who experienced at least one SAE from the booster dose to study end will tabulated with MedDRA primary preferred term.

All the above safety and reactogenicity analysis for Epoch 002 will also be performed by gender and geographical ancestry (the most frequent geographical ancestry versus all other geographical ancestry, namely White Caucasian versus any other geographical ancestry) except percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) and 31-day (Days 0-30) follow-up period after the booster dose.

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

7. STATISTICAL CALCULATIONS

7.1. Derived and transformed data

7.1.1. Demography

For a given subject and a given demographic variable, missing measurement will not be replaced excepting for age.

Age will be calculated as the number of years between the date of birth and the date of vaccination.

To ensure that the collection of date of birth will not jeopardise the privacy of personally identifiable information, only a partial date of birth (MMYYYY) will be collected.

Therefore, the 15th of the month will be used to replace the missing date. In case the day and the months are missing, the date will be replaced by the June 30th of the year.

- **7.1.2. Immunogenicity**A seronegative subject is a subject whose antibody concentration/titer is below the assay cut-off.
- A seropositive subject is a subject whose antibody concentration/titer is greater than or equal to the assay cut-off.
- Note: Due to re-validation of all assays, the cut-offs presented in Table 7 of the protocol have changed as follows

• Antigen	Threshold for positivity
• Anti-PT	• 2.693 IU/mL
• Anti-FHA	• 2.046 IU/mL
Anti-PRN	• 2.187 IU/mL
• Anti-D	• 0.057 IU/mL
• Anti-T	• 0.043 IU/mL
• Anti-polio	• 8 dilution
Anti-PRP	• 0.15 μg/mL (assay not fully qualified)
	• 0.066 μg/mL (new validated assay)
• Anti-Hbs	• 6.2 mIU/mL

117119 (DTPA-HBV-IPV-135)

Statistical Analysis Plan Amendment 2 Final

- A seroprotected subject is a subject whose antibody concentration/titer is greater than
 or equal to the level defining clinical protection. The following seroprotection
 thresholds are applicable:
 - Anti-diphtheria antibody concentrations \ge 0.1 IU/mL.
 - Anti-tetanus antibody concentrations ≥ 0.1 IU/mL.
 - Anti-HBs antibody concentrations ≥ 10 mIU/mL.
 - Anti-poliovirus types 1, 2 and 3 antibody titers ≥ 8 .
 - Anti-PRP antibody concentrations $\geq 0.15 \,\mu g/mL$.
- Other cut-offs to be considered:
 - Anti-PRP antibody concentrations $\geq 1.0 \,\mu \text{g/mL}$.
 - Anti-diphtheria and anti-tetanus antibody concentrations ≥ 1.0 IU/mL
- Booster responses for anti-PT, anti-FHA and anti-PRN antibodies are defined as:
 - initially seronegative subjects (pre-booster antibody concentration below the assay cut-off) presenting an increase of at least four times the assay cut-off one month after vaccination.
 - initially seropositive subjects with antibody concentration < four times the assay cut-off presenting an increase of at least four times the pre-booster antibody concentration one month after vaccination
 - initially seropositive subjects with anti-body concentration ≥ four times the
 assay cut-off presenting an increase of at least two times the pre-booster
 antibody concentration one month after vaccination
- The GMC/GMT calculations will be performed by taking the anti-log of the mean of the log₁₀ titer/ concentration transformations. Antibody titers/concentrations below the cut-off of the assay will be given an arbitrary value of half the cut-off for the purpose of GMC/GMT calculation.
- Handling of missing data For a given subject and a given immunogenicity measurement, missing or non-evaluable measurements will not be replaced.

7.1.3. Safety/reactogenicity:

- For a given subject and the analysis of solicited symptom within 4 days post-vaccination, missing or non-evaluable measurements will not be replaced. Therefore the analysis of the solicited symptoms based on the Total Vaccinated cohort will include only vaccinated subjects and doses with documented safety data (i.e. symptom screen completed).
- For analysis of unsolicited adverse events, such as serious adverse events or adverse
 events by primary MedDRA term, and for the analysis of concomitant medications,
 all vaccinated subjects will be considered. Subjects who did not report the event or
 the concomitant medication will be considered as subjects without the event or the
 concomitant medication respectively.

29-NOV-2017

Page 25 of 30

117119 (DTPA-HBV-IPV-135)

Statistical Analysis Plan Amendment 2 Final

- For analysis of convulsion, the adverse event will be identified by using narrow standard MedDRA query.
- For analysis of Hypotonic Hyporesponsive Episode (HHE), the adverse event will be identified by using broad standard MedDRA query.
- For analysis of New Onset of Chronic Illness (NOCI), the adverse event will be identified by using narrow standard MedDRA query.
- For summaries reporting both solicited and unsolicited adverse events, all vaccinated subjects will be considered. Subjects for whom the event will not be reported will be considered as subjects without the event.
- Large injection site reactions are defined as either swelling with a diameter of >50 mm or a >50 mm increase in the circumference of any limb when compared to the baseline (pre-vaccination) measurement, or any diffuse swelling that interferes with or prevents everyday activities (for example, active playing, eating, sleeping).
- For the analysis, temperatures by any route will be coded as follows:

Grade	Temperature
0	<38.0°C
1	≥ 38.0°C - ≤ 39.0°C
2	> 39.0°C - ≤ 40.0°C
3	>40.0°C

• The way the percentage of subjects will be derived will depend on the event analysed (see table below for details). As a result, the N value will differ from one table to another.

Event	N used for deriving % per subject for Vaccination phase
Concomitant vaccination	All subjects with study vaccine administered
Solicited general symptom	All subjects with at least one solicited general symptom documented as either present or absent (i.e. symptom screen completed)
Solicited local symptom	All subjects with at least one solicited local symptom documented as either present or absent (i.e. symptom screen completed)
Unsolicited symptom	All subjects with study vaccine administered
Concomitant medication	All subjects with study vaccine administered

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

7.2. Data presentation description

The following decimal description from the decision rules will be used for the demography, immunogenicity and safety/ reactogenicity.

Display Table	Parameters	Number of decimal digits
Demographic characteristics	Mean, median age	1
Demographic	SD (age)	1
characteristics		
anti-T	GMC	3
anti-D	GMC	3
anti-PT	GMC	1
anti-PHA	GMC	1
anti-PRN	GMC	1
anti-HBs	GMC	1
anti-PRP	GMC	3
anti-Polio 1	GMT	1
anti-Polio 2	GMT	1
anti-Polio 3	GMT	1
Immunogenicity	Ratio of GMT/C	2
Reactogenicity	Mean, Min, Q1, Median, Q3, Max for duration	1
All summaries	% of count, including LL & UL of CI	1
All summaries	% of difference, including LL & UL of CI	2

7.3. Methodology for computing confidence intervals

- All CI computed will be two-sided 95% CI.
- The exact 95% CIs for a proportion within a group will be based on the method by Clopper [Clopper, 1934*].
- The standardised asymptotic 95% CI for the group difference in proportions will be based on the method 6 described in paper by Newcombe [R Newcombe, 1998, method six**].
- The 95% CI for geometric mean titers/concentrations (GMTs/GMCs) will be obtained within each group separately. The 95% CI for the mean of log-transformed titer/concentration will be first obtained assuming that log-transformed values were normally distributed with unknown variance. The 95% CI for the GMTs/GMCs will be then obtained by exponential-transformation of the 95% CI for the mean of log-transformed titer/concentration.

The GMC/GMT group ratio will be computed using an ANOVA model on the logarithm10 transformation of the concentrations/titers. The ANOVA model will include the vaccine group as fixed effect and the Tdap vaccination of the mother during pregnancy as regressor leading to an Analysis of Co-variance (ANCOVA) model. For hepatitis B antigen, the hepatitis B vaccination at birth vaccine dose status will also be used as regressor leading to an Analysis of Co-variance (ANCOVA) model.

29-NOV-2017

Page 27 of 30

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

8. CONDUCT OF ANALYSES

8.1. Sequence of analyses

The analyses will be performed stepwise:

- A partial analysis of Epoch 001 up to one month after the third primary vaccine dose
 will be conducted. This analysis will include the final analysis of anti-PRP, solicited
 and unsolicited symptoms on data as clean as possible. This analysis will be
 displayed on GSK clinical trial registry as soon as possible.
- 2. The final data analysis of the study covering both the epochs will be conducted at the end of the study. All these analyses will be presented in a final clinical study report.

Following analysis folder will be created in SDD and CARS with given analysis ID to perform analysis and archival of statistical reports

Description	Analysis ID (SDD & CARS sub-folder)	Disclosure	TFL reference
Primary Epoch - Anti-PRP and safety	E1_01	CTRS	From TFL Version 1 dated 10-Mar-2015, following tables will be generated for time point - one month post vaccination dose 3. Post-Text table section – Table-29, 34, 35, 38, 39. CTRS table sections – Table 1-5, 10, 12-15) Annex table section – Table 3 Please note that the tables from post text section will be generated with output destination 'ANNEX'.
Final	E1_02	CTRS, Clinical Study report, Publication	TFL Version 2 dated 17-Nov-2017

8.2. Statistical considerations for interim analyses

All analyses will be conducted on final data and therefore no statistical adjustment for interim analyses is required.

29-NOV-2017 Page 28 of 30

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

9. MAJOR CHANGES FROM PLANNED ANALYSES

The following are the changes in the SAP from the protocol:-

- The analysis of percentage of doses followed by at least one local AE (solicited and unsolicited), by at least one general AE (solicited and unsolicited) and by any AE during the 31-day (Days 0-30) follow-up period will not be tabulated over the primary vaccination period and also over booster vaccination period, with exact 95% CI. Also the same analysis by gender and geographical ancestry will not be performed.
- During the course of the study, the assays used to measure the anti-D, -T, -PT, -FHA and -PRN IgG concentrations were re-developed and re-validated and both assay units and assay cut-off were adapted. The new ELISAs for PT, FHA and PRN were calibrated against the WHO International Standard (NIBSC 06/140). This allowed the expression of concentrations measured with the new ELISAs in International Units per milliliter (IU/mL) instead of the formerly used ELISA units per milliliter (EL.U/mL). The newly validated DTPa ELISA's have a lower assay cut-offs as compared to the one described in the protocol. The current assay cut-off is 0.057 IU/mL for anti-D, 0.043 IU/mL for anti-T, 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA and 2.187 IU/mL for anti-PRN. Since for anti-D, anti-T a threshold of 0.1 IU/mL provided a conservative estimate of the percentage of subjects deemed to be protected, the anti-D, anti-T seroposivity endpoints initially defined by the previous assay cut-off of 0.1 IU/mL were replaced by seroprotection rate endpoints defined as the percentage of subjects with concentration above 0.1 IU/mL. In the absence of a correlate of protection for the B. pertussis antigens, the pertussis vaccine response endpoints were redefined based on the assay cut-off.
- A descriptive summary per lot was added for anti-PRP post priming.
- The ANCOVA model was revised to include the 3 study groups rather than the 2 groups compared. This allowed identical adjusted GMC estimate regardless of the groups involved in the comparison.
- The DTPA-HBV-IPV-135 (117119) Abridged Interim Report Main (19-Oct-2015) included immunogenicity data against Polyribosyl-Ribitol-Phosphate (PRP) antigen at Visit 4 using an assay which was not fully validated. For the final analysis, the visit 4 samples were retested together with the samples pre- and post booster using a newly validated assay. In the final analysis, the results of both assays will be descriptively presented at visit 4.

117119 (DTPA-HBV-IPV-135) Report Final

CONFIDENTIAL

117119 (DTPA-HBV-IPV-135) Statistical Analysis Plan Amendment 2 Final

10. REFERENCE

- * Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of binomial. *Biometrika*. 1934;26:404-413
- ** Robert G. Newcombe, interval estimation for the difference between independent proportions: comparison of eleven methods, Statist Med. 1998; 17, 873-890

117119 (DTPA-HBV-IPV-135) Report Final

Documentation of inter-laboratory standardization methods and quality assurance procedures

Not Applicable

117119 (DTPA-HBV-IPV-135) Report Final

Publications based on the study

Not Applicable

117119 (DTPA-HBV-IPV-135) Report Final

Important publications referenced in the report

Not Applicable

117119 (DTPA-HBV-IPV-135) Report Final

CRF /eCRFs for deaths, other SAEs and withdrawals due to adverse events

Page(s) removed - Out of Scope of phase 1 of Policy 0070 - CRF/eCRFs

Study Administrative Table

Clinical Trial Activity	Performed by	Responsibilities and scope of activities	Site address
Monitoring	Central Study Monitor (Central Study coordinator)	 co-ordinates operational aspects of running the study from preparation of study supplies and data capture tools, to study tracking has regular contacts with local monitors in order to review the study progress and any issue raised by the local monitor. In this way compliance with the protocol and GCP/ICH guidelines is ensured during preparation, active and cleaning phases of the study is responsible for maintaining and archiving a comprehensive study file. If required, transitioning of a study from one monitor to another is documented in the study file is responsible for reviewing and signing off of the clinical study report 	GlaxoSmithKline Biologicals Rue de l'Institut 89, 1330 Rixensart (Belgium)
Monitoring	Local Monitor	 Prior to study start: is responsible for the evaluation of the study site and ensures that the staff and facilities are trained and appropriate for running of the study according to protocol and GCP guidelines is involved in the preparation of study package for submission to Ethics Committee and/or Independent Review Board (EC/IRBs) and appropriate authorities 	GSK United States: GlaxoSmithKline Biologicals Slaoui Center for Vaccine Research, 14200 Shady Grove Road, Rockville MD 20850. Novella: 1700 Perimeter Park Dr, Morrisville, NC 27560

Clinical Trial Activity	Performed by	Responsibilities and scope of activities	Site address
		At study initiation:	
		conducts study specific training	
		While trial is ongoing:	
		discusses all aspects of the trial with the study staff	
		verifies source documents and Case Report Forms (CRFs)	
		conducts a 100% review of all Informed Consent documentation	
		checks accountability of investigational product and its storage conditions	
		checks the collection and storage of biological samples and transport to central laboratory	
		reviews each SAE report	
		All monitoring visits are documented via a monitoring visit report (MVR), which will be reviewed by the monitor's manager. These reports allow the identification of protocol violation, re-education of site staff and communication of significant issues (SAEs, quality, efficacy and GCP compliance) to the central organisation. In this way the Local Monitors oversee the progress of the clinical trial and ensure that it is conducted, recorded and reported in accordance with the protocol and current GCP/ICH guidelines.	
		The Local Monitor works in close partnership with the Local Medical Advisor and the Central Study Monitor.	

Clinical Trial Activity	Performed by	Responsibilities and scope of activities	Site address
Data Management	Data Manager	Responsibilities involve: the design of the Case Report Form (CRF) the creation of data entry application the collection and handling of study data the cleaning of study data (in conjunction with the Clinical Development Manager, Central Study and Local Monitors) in order to provide cleaned database for the statistical analysis	GlaxoSmithKline Biologicals Rue de l'Institut 89, 1330 Rixensart (Belgium)
Statistics	Statistician	 is involved in the study design and is responsible for calculating the sample size, preparation of the randomisation list, identification of appropriate statistical tests to analyse the data, conducting the statistical analysis on the data collected, issuing the statistical report and interpretation of the statistical findings reviews the final study report to ensure that all aspects of the statistical analysis and findings are accurately represented in the final report 	GlaxoSmithKline Biologicals Rue de l'Institut 89, 1330 Rixensart (Belgium)
Laboratory assessments	GlaxoSmithKline Biologicals, Global Vaccine Clinical Laboratory (GVCL) now known as Clinical Laboratories Sciences (CLS).	 Testing for the analysis of the immune response: SERUM: Corynebacterium diphtheria Diphtheria Toxoid Ab.IgG (ELISA) Clostridium tetani.Tetanus Toxoid Ab.IgG (ELISA) Bordetella pertussis.Pertussis Toxin Ab.IgG (ELISA) Bordetella pertussis.Filamentous Hemaglutinin Ab.IgG (ELISA) Bordetella pertussis.Pertactin Ab.IgG (ELISA) Hepatitis B Virus.Surface Ab (CLIA) Poliovirus Sabin Types 1, 2 and 3 (NEUTRA) Haemophilus influenzae type b.Polyribosyl Ribitol Phosphate Ab (ELISA) 	GlaxoSmithKline Biologicals, Global Vaccine Clinical Laboratory (GVCL)) now known as Clinical Laboratories Sciences (CLS) GSK Rixensart Rue de l'Institut, 89 B-1330 Rixensart – Belgium

Clinical Trial Activity	Performed by	Responsibilities and scope of activities	Site address
Randomization	Clinical Operations, Department of Biometrics	 computer-generated a randomisation list which was used to number the vaccines A randomisation blocking scheme was used to ensure that the balance between vaccine groups was maintained. The randomisation number uniquely identified the vaccine dose to be administered to any subject. A randomisation blocking scheme was used to ensure that the balance between vaccine groups was maintained. The randomisation number uniquely identified the vaccine dose to be administered to any subject. 	GlaxoSmithKline Biologicals Rue de l'Institut 89, 1330 Rixensart (Belgium) (using SAS macro)
Medical writing	Scientific Writer	 In collaboration with the study team, prepares study protocols, Subject Information Sheet (SIS) Informed Consent Forms (IC), protocol amendments and the Clinical Study Reports (CSR). Co-ordinates the review of the final study report with the study team (including the investigators) to ensure that the report is an accurate account of the study and findings. 	GlaxoSmithKline Biologicals Rue de l'Institut 89, 1330 Rixensart (Belgium)
Central Safety	Central Safety Department	During the conduct of pre-licensure clinical studies, the Central Safety Department is responsible for: centralising collection, review and follow-up of all reported SAEs the issue of Expedited Investigator Safety Reports to inform all investigators in the programme and IRBs of unexpected and related SAEs the preparation and review of consolidated safety reports related to investigational vaccines the analysis of safety issues and review of the safety content of the final study report.	GlaxoSmithKline Biologicals Rue de l'Institut 89, 1330 Rixensart (Belgium)

	Report Fil			
Clinical Trial Activity	Performed by	Responsibilities and scope of activities	Site address	
Other information				
Location of trial master file	Local Study Monitor	The Sponsor's Trial Master file is composed of the following: • The country monitoring study file. This part of the master file is located at the particular GSK	Slaoui Center for Vaccine	
		office involved in the study. The type of documents retained by the GSK office is given in Annex 1.	Research, 14200 Shady Grove Road, Rockville MD 20850	
	Central Study Monitor	The central study file. This part of the master file is located at the GSK offices in Rixensart. The type of documents retained by the GSK central office in Rixensart is given in Annex 2.	GlaxoSmithKline Biologicals Rue de l'Institut 89, 1330 Rixensart (Belgium)	
Site(s) of	GSK Biologicals	LOT_NUMBER_LIST		
manufacture		AC21VB448C (DTPa-HBV-IPV)		
		AHIBC950C (Hib)	GlaxoSmithKline Biologicals Rue de l'Institut 89, 1330 Rixensart (Belgium)	
		AC21B514A (DTPa-HBV-IPV)	GlaxoSmithKline Biologicals Rue de l'Institut 89, 1330 Rixensart (Belgium) GlaxoSmithKline Biologicals, SA, Avenue Fleming, 20, B-1300 Wavre (Belgium)	
		AHIBC907D (Hib)	GlaxoSmithKline Biologicals Rue de l'Institut 89, 1330 Rixensart (Belgium)	

Clinical Trial Activity	Performed by	Responsibilities and scope of activities	Site address
		AC21B510B (DTPa-HBV-IPV) AHIBC954A (Hib)	GlaxoSmithKline Biologicals Rue de l'Institut 89, 1330 Rixensart (Belgium) GlaxoSmithKline Biologicals, SA, Avenue Fleming, 20, B-1300 Wavre (Belgium)
		AC21VB448C (Pediarix)	GlaxoSmithKline Biologicals Rue de l'Institut 89, 1330 Rixensart (Belgium)
		DLOCA102AY (DTaP-IPV Sanofi) DLOCA102AZ (ActHib for Pentacel) DLOCA108AY DLOCA108AZ	Sanofi Pasteur Limited, Toronto Ontario Canada and Sanofi Pasteur Inc. Swiftwater PA, USA
		AC14B195A (DTPa=Infanrix)	GlaxoSmithKline Biologicals Rue de l'Institut 89, 1330 Rixensart (Belgium) GlaxoSmithKline Biologicals, SA, Avenue Fleming, 20, B-1300 Wavre (Belgium)
		AHIBC875A (Hib)	GlaxoSmithKline Biologicals Rue de l'Institut 89,

117119 (DTPA-HBV-IPV-135)

Clinical Trial Activity	Performed by	Responsibilities and scope of activities	Site address
			1330 Rixensart (Belgium)
		DEXTA517AZ (diluent NaCl) DLOCA150AY DLOCA150AZ	Secondary packaging: GlaxoSmithKline Biologicals, SA, Avenue Fleming, 20, B-1300 Wavre (Belgium) Manufacturer: Hollister-Stier
		DLOCA144AY DLOCA144AZ	Sanofi Pasteur Limited, Toronto Ontario Canada and Sanofi Pasteur Inc. Swiftwater PA, USA
			Sanofi Pasteur Limited, Toronto Ontario Canada and Sanofi Pasteur Inc. Swiftwater PA, USA
Site of release in Europe	GSK Biologicals	-	GlaxoSmithKline Biologicals Rue de l'Institut 89, 1330 Rixensart (Belgium)

Signature of principal or coordinating investigator

GlaxoSmithKline Biologicals Vaccines R&D Investigator Approval Page

STUDY TITLE: A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age.

Study: 117119 (DTPA-HBV-IPV-135) Development Phase: III

I have read this report and confirm that to the best of my knowledge it accurately describes the conduct and results of the study.

Name of Investigator:	Dr. Nicola Klein
Affiliation /investigational centre:	Kaiser Permanente Oakland, One Kaiser Plaza, Oakland, CA, USA
Signature of Investigator:	PPD _
Date:	110412018

For internal use only

-----Checksum-----!Ver.!Created On - -1d409104a7b9515b0ffe9e529e32508fdf3000b3 1.0 7/12/2018 1:54:15 PM - a1433090e9c94e485de5d60db92b1e31d0ccda72 1.0 7/12/2018 1:54:19 PM - -13de9131962684a03d6ff328df4cc9746fa9eb10 1.0 7/12/2018 1:54:33 PM - ea0faebd1d956d107e7e0d85f4695a06669aab1b 1.0 7/12/2018 1:54:41 PM -66963771677c17e9a20f64573b32717a1b1e2ac4 1.0 7/12/2018 1:54:37 PM -51abb6bd72601dfecb7d29e02b309073e769d8e3 1.0 7/12/2018 1:55:07 PM - -55f1c72f6bafb82a4cd207420835613347227bfd 1.0 7/12/2018 1:55:17 PM ac342ae2501721bd94637bff166bca886cd8c674 1.0 7/12/2018 1:55:03 PM - -9e87e824d35ce3848b99267t52394dca3a57c57a 1.0 7/12/2018 1:54:23 PM - e425c4a7b748c0dbb1b8028e9b153ce0e704e939 1.0 7/12/2018 1:54:59 PM b746277d27dc86537be04d8768738edd61b7ab2b 1.0 7/12/2018 1:54:54 PM - -622d4ec61abc0524d85a0f1af3968a4c1306b198 1.0 7/12/2018 1:55:22 PM - -812f4fb003c07b74cae10f81cf90c72c48e48cbd 1.0 7/12/2018 1:55:13 PM - a8a4e5fa618ebcf2c407631e910df440ec16f0fd 1.0 7/13/2018 12:38:12 PM - -4138e5e7efd1f15bf35572227c1d9fd9bd7066e8 1.0 7/12/2018 1:53:54 PM - -7e8612f798705c5d24886d296f5433e26004cc03 1.0 7/12/2018 1:54:10 PM - - -8a04772baf20207a79a8e4e358c424c80f00eab7 1.0 7/13/2018 4:34:50 PM - -

117119 (DTPA-HBV-IPV-135) Report Final

GlaxoSmithKline Biologicals Vaccines R&D Sponsor Signatory Approval Page

Please note that by signing this page, you take responsibility for the content of the Study Report, including appendices

STUDY TITLE: A Phase III, randomized, open-label, controlled, multicenter study to evaluate immunogenicity and safety of GSK Biologicals' Infanrix hexa vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co administered with Prevnar and Rotarix with a booster dose of GSK Biologicals' Infanrix and Hiberix vaccines at 15-18 months of age.

Study: 117119 (DTPA-HBV-IPV-135) Development Phase: III

I have read this report and confirm that to the best of my knowledge it accurately describes the conduct and results of the study.

Name of Sponsor Signatory: Narcisa Elena Mesaros

Title of Sponsor Signatory: MD, Clinical and Epidemiology R&D Project

Leader, DTP, Polio and Hib containing vaccines

- R&D Centre Belgium, GlaxoSmithKline

Biologicals

PPD				
	16	JUL	2018	

For internal use only

Date:

Signature:

-----Checksum-----!Ver.!Created On - -1d409104a7b9515b0ffe9e529e32508fdf3000b3 1.0 7/12/2018 1:54:15 PM a1433090e9c94e485de5d60db92b1e31d0ccda72 1.0 7/12/2018 1:54:19 PM e46417894ec97341d5012c5dda1ae8295247270f 1.0 7/12/2018 1:54:27 PM -13de9131962684a03d6ff328df4cc9746fa9eb10 1 0 7/12/2018 1:54:33 PM ea0faebd1d956d107e7e0d85f4695a06669aab1b 1.0 7/12/2018 1:54:41 PM -66963771677c17e9a20f64573b32717a1b1e2ac4 1.0 7/12/2018 1;54;37 PM -51abb6bd72601dfecb7d29e02b309073e769d8e3 1.0 7/12/2018 1:55:07 PM -55f1c72f6bafb82a4cd207420835613347227bfd 1.0 7/12/2018 1:55:17 PM ac342ae2501721bd94637bff166bca886cd8c674 1.0 7/12/2018 1:55:03 PM -9e87e824d35ce3848b99267f52394dca3a57c57a 1.0 7/12/2018 1:54:23 PM e425c4a7b748c0dbb1b8028e9b153ce0e704e939 1,0 7/12/2018 1:54:59 PM b746277d27dc86537be04d8768738edd61b7ab2b1_0 7/12/20181:54:54 PM -622d4ec61abc0524d85a0f1af3968a4c1306b198 1.0 7/12/2018 1:55:22 PM -812f4fb003c07b74cae10f81cf90c72c48e48cbd 1,0 7/12/2018 1:55:13 PM a8a4e5fa618ebcf2c407631e910df440ec16f0fd 1,0 7/13/2018 12:38;12 PM -4138e5e7efd1f15bf35572227c1d9fd9bd7066e8 1.0 7/12/2018 1:53:54 PM -7e8612f798705c5d24886d296f5433e26004cc03 1.0 7/12/2018 1:54:10 PM -8a04772baf20207a79a8e4e358c424c80f00eab7 1.0 7/13/2018 4:34:50 PM -